PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	de Galan, BE				de Galan, Bastiaan E.			Blood Pressure Control in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	de Galan, BE (corresponding author), Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	b.degalan@aig.umcn.nl	de Galan, Bastiaan E/H-3161-2015; Wetzels, Jack F.M./A-1720-2014; Krüger, Bernd/F-5781-2011	de Galan, Bastiaan E/0000-0002-1255-7741; Wetzels, Jack F.M./0000-0002-0650-6921; 				de Galan BE, 2002, DIABETES, V51, P790, DOI 10.2337/diabetes.51.3.790; Messerli FH, 2006, ANN INTERN MED, V144, P884, DOI 10.7326/0003-4819-144-12-200606200-00005	2	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					695	696						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20701534				2022-12-28	WOS:000280764600022
J	Knosalla, C; Dandel, M; Hetzer, R				Knosalla, Christoph; Dandel, Michael; Hetzer, Roland			Duration of Clopidogrel Therapy with Drug-Eluting Stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CORONARY INTERVENTION		[Knosalla, Christoph; Dandel, Michael; Hetzer, Roland] Deutsch Herzzentrum Berlin, Berlin, Germany	German Heart Center Berlin	Knosalla, C (corresponding author), Deutsch Herzzentrum Berlin, Berlin, Germany.	knosalla@dhzb.de	van Onzenoort, Hein AW/A-1730-2016; Schouwenberg, B.J.J.W./L-4637-2015; Rennings, Alexander/H-3541-2015	Knosalla, Christoph/0000-0002-8127-5019				Cheng TO, 1996, QJM-MON J ASSOC PHYS, V89, P557; Goto S, 2009, HAMOSTASEOLOGIE, V29, P321; King SB, 2008, CIRCULATION, V117, P261, DOI 10.1161/CIRCULATIONAHA.107.188208; Ross AM, 2001, AM HEART J, V142, P244, DOI 10.1067/mhj.2001.116963	4	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					489	490						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830830	Green Published			2022-12-28	WOS:000280411300020
J	Okura, H				Okura, Hiroyuki			Duration of Clopidogrel Therapy with Drug-Eluting Stents.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Kawasaki Med Sch Hosp, Kurashiki, Okayama, Japan	Kawasaki Medical School	Okura, H (corresponding author), Kawasaki Med Sch Hosp, Kurashiki, Okayama, Japan.	hokura@fides.dti.ne.jp	van Onzenoort, Hein AW/A-1730-2016; Schouwenberg, B.J.J.W./L-4637-2015; Rennings, Alexander/H-3541-2015	Knosalla, Christoph/0000-0002-8127-5019				Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Lee SW, 2010, AM HEART J, V159, DOI 10.1016/j.ahj.2009.11.014; Moreno R, 2005, J AM COLL CARDIOL, V45, P954, DOI 10.1016/j.jacc.2004.11.065; Park SJ, 2010, NEW ENGL J MED, V362, P1374, DOI 10.1056/NEJMoa1001266	5	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					488	488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830830	Green Published			2022-12-28	WOS:000280411300017
J	Garattini, S; Bertele', V				Garattini, Silvio; Bertele', Vittorio			Dutasteride and Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Garattini, Silvio; Bertele', Vittorio] Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, S (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	silvio.garattini@marionegri.it	Bertele, Vittorio/AAA-6461-2020; Garattini, Silvio/AAA-6390-2020; Kiemeney, Lambertus A./D-3357-2009	Bertele, Vittorio/0000-0002-0032-7033; Garattini, Silvio/0000-0003-0647-9297; Kiemeney, Lambertus A./0000-0002-2368-1326				Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Walsh PC, 2010, NEW ENGL J MED, V362, P1237, DOI 10.1056/NEJMe1001045	2	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					794	794						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20842790	Green Published			2022-12-28	WOS:000280996600021
J	Schrier, RW				Schrier, Robert W.			Blood Pressure Control in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Colorado Denver, Aurora, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Schrier, RW (corresponding author), Univ Colorado Denver, Aurora, CO USA.	robert.schrier@ucdenver.edu	de Galan, Bastiaan E/H-3161-2015; Wetzels, Jack F.M./A-1720-2014; Krüger, Bernd/F-5781-2011	de Galan, Bastiaan E/0000-0002-1255-7741; Wetzels, Jack F.M./0000-0002-0650-6921; 				Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Schrier RW, 2007, NAT CLIN PRACT NEPHR, V3, P428, DOI 10.1038/ncpneph0559; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x	3	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					696	697						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20701534				2022-12-28	WOS:000280764600024
J	Rennings, AJM; Schouwenberg, BJJW; van Onzenoort, HAW				Rennings, Alexander J. M.; Schouwenberg, Bas J. J. W.; van Onzenoort, Hein A. W.			Duration of Clopidogrel Therapy with Drug-Eluting Stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Rennings, Alexander J. M.; Schouwenberg, Bas J. J. W.; van Onzenoort, Hein A. W.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Rennings, AJM (corresponding author), Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	a.rennings@pharmtox.umcn.nl	van Onzenoort, Hein AW/A-1730-2016; Schouwenberg, B.J.J.W./L-4637-2015; Rennings, Alexander/H-3541-2015	Knosalla, Christoph/0000-0002-8127-5019				Harmsze A, 2010, PHARMACOGENET GENOM, V20, P18, DOI 10.1097/FPC.0b013e328333dafe; MAN M, 2010, J CLIN PHARM    0219; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171	3	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					489	489						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830830	Green Published			2022-12-28	WOS:000280411300019
J	Dunn, D; Lynn, T				Dunn, Dan; Lynn, Thomas			Physician Cost Profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Dunn, Dan; Lynn, Thomas] Ingenix Eden, Prairie, MN USA		Dunn, D (corresponding author), Ingenix Eden, Prairie, MN USA.							Adams JL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-57	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					491	491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2022-12-28	WOS:000280411300023
J	Kang, J; Salmon, R				Kang, Jeffrey; Salmon, Richard			Physician Cost Profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Kang, Jeffrey; Salmon, Richard] Cigna, Bloomfield, CT USA		Kang, J (corresponding author), Cigna, Bloomfield, CT USA.	dick.salmon@cigna.com							0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					492	492						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2022-12-28	WOS:000280411300025
J	Luft, HS; Eaton, LJ				Luft, Harold S.; Eaton, Laura J.			Physician Cost Profiling.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Luft, Harold S.; Eaton, Laura J.] Palo Alto Med Fdn Res Inst, Palo Alto, CA USA	Palo Alto Medical Foundation Research Institute	Luft, HS (corresponding author), Palo Alto Med Fdn Res Inst, Palo Alto, CA USA.	lufth@pamfri.org						Adams JL, 2010, NEW ENGL J MED, V362, P1014, DOI 10.1056/NEJMsa0906323	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					491	491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2022-12-28	WOS:000280411300022
J	Klotz, L				Klotz, Laurence			Dutasteride and Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							RISK		Univ Toronto, Toronto, ON, Canada	University of Toronto	Klotz, L (corresponding author), Univ Toronto, Toronto, ON, Canada.	laurence.klotz@sunnybrook.ca	Bertele, Vittorio/AAA-6461-2020; Garattini, Silvio/AAA-6390-2020; Kiemeney, Lambertus A./D-3357-2009	Bertele, Vittorio/0000-0002-0032-7033; Garattini, Silvio/0000-0003-0647-9297; Kiemeney, Lambertus A./0000-0002-2368-1326				Burnet KL, 2007, BJU INT, V100, P540, DOI 10.1111/j.1464-410X.2007.07009.x; Cooperberg MR, 2007, J UROLOGY, V178, pS14, DOI 10.1016/j.juro.2007.03.135; Fang F, 2010, JNCI-J NATL CANCER I, V102, P307, DOI 10.1093/jnci/djp537; Redman MW, 2008, CANCER PREV RES, V1, P174, DOI 10.1158/1940-6207.CAPR-08-0092	4	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					794	794						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20842790	Green Published			2022-12-28	WOS:000280996600022
J	Memtsoudis, SG; Sharrock, NE				Memtsoudis, Stavros G.; Sharrock, Nigel E.			Duration of Clopidogrel Therapy with Drug-Eluting Stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Memtsoudis, Stavros G.; Sharrock, Nigel E.] Hosp Special Surg, New York, NY 10021 USA		Memtsoudis, SG (corresponding author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.	memtsoudiss@hss.edu	van Onzenoort, Hein AW/A-1730-2016; Schouwenberg, B.J.J.W./L-4637-2015; Rennings, Alexander/H-3541-2015	Knosalla, Christoph/0000-0002-8127-5019				Sharrock NE, 2008, CLIN ORTHOP RELAT R, V466, P714, DOI 10.1007/s11999-007-0092-4	1	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					488	489						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830830	Green Published			2022-12-28	WOS:000280411300018
J	Mitchell, DL				Mitchell, Dolores L.			Physician Cost Profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Grp Insurance Commiss, Boston, MA USA		Mitchell, DL (corresponding author), Grp Insurance Commiss, Boston, MA USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					491	492						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2022-12-28	WOS:000280411300024
J	Benck, U; Kruger, B; Kramer, BK				Benck, Urs; Krueger, Bernd; Kraemer, Bernhard K.			Blood Pressure Control in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Benck, Urs; Kraemer, Bernhard K.] Mannheim Univ Hosp, Mannheim, Germany; [Krueger, Bernd] Ruhr Univ Bochum, Bochum, Germany	Ruprecht Karls University Heidelberg; Ruhr University Bochum	Benck, U (corresponding author), Mannheim Univ Hosp, Mannheim, Germany.	bernhard.kraemer@umm.de	de Galan, Bastiaan E/H-3161-2015; Wetzels, Jack F.M./A-1720-2014; Krüger, Bernd/F-5781-2011	de Galan, Bastiaan E/0000-0002-1255-7741; Wetzels, Jack F.M./0000-0002-0650-6921; 					0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					696	696						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20701534				2022-12-28	WOS:000280764600023
J	Wetzels, JFM				Wetzels, Jack F. M.			Blood Pressure Control in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							DISEASE		Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Wetzels, JFM (corresponding author), Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	j.wetzels@nier.umcn.nl	de Galan, Bastiaan E/H-3161-2015; Wetzels, Jack F.M./A-1720-2014; Krüger, Bernd/F-5781-2011	de Galan, Bastiaan E/0000-0002-1255-7741; Wetzels, Jack F.M./0000-0002-0650-6921; 				Bavry AA, 2010, HYPERTENSION, V55, P48, DOI 10.1161/HYPERTENSIONAHA.109.142240; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; Messerli FH, 2006, ANN INTERN MED, V144, P884, DOI 10.7326/0003-4819-144-12-200606200-00005; Protogerou AD, 2007, HYPERTENSION, V50, P172, DOI 10.1161/HYPERTENSIONAHA.107.089797	4	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					695	695						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20701534				2022-12-28	WOS:000280764600021
J	Kiemeney, LA; Bosland, MC				Kiemeney, Lambertus A.; Bosland, Maarten C.			Dutasteride and Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Bosland, Maarten C.] Univ Illinois, Coll Med, Chicago, IL USA	Radboud University Nijmegen; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kiemeney, LA (corresponding author), Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	b.kiemeney@ebh.umcn.nl	Bertele, Vittorio/AAA-6461-2020; Garattini, Silvio/AAA-6390-2020; Kiemeney, Lambertus A./D-3357-2009	Bertele, Vittorio/0000-0002-0032-7033; Garattini, Silvio/0000-0003-0647-9297; Kiemeney, Lambertus A./0000-0002-2368-1326				Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Schroder FH, 2010, EUR UROL, V57, P256, DOI 10.1016/j.eururo.2009.10.031; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660	3	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					793	793						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20842790	Green Published			2022-12-28	WOS:000280996600019
J	Schroder, FH; Roobol, MJ				Schroder, Fritz H.; Roobol, Monique J.			Dutasteride and Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Schroder, Fritz H.; Roobol, Monique J.] Erasmus MC, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Schroder, FH (corresponding author), Erasmus MC, Rotterdam, Netherlands.	secr.schroder@erasmusmc.nl	Bertele, Vittorio/AAA-6461-2020; Garattini, Silvio/AAA-6390-2020; Kiemeney, Lambertus A./D-3357-2009	Bertele, Vittorio/0000-0002-0032-7033; Garattini, Silvio/0000-0003-0647-9297; Kiemeney, Lambertus A./0000-0002-2368-1326					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					793	794						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20842790	Green Published			2022-12-28	WOS:000280996600020
J	Burbach, JPH				Burbach, J. Peter H.			Neuropsychiatric connections of ADHD genes	LANCET			English	Editorial Material							COPY NUMBER VARIATION; SPECTRUM		Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Burbach, JPH (corresponding author), Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands.	j.p.h.burbach@umcutrecht.nl						Burbach JPH, 2009, TRENDS NEUROSCI, V32, P69, DOI 10.1016/j.tins.2008.11.002; Cook EH, 2008, NATURE, V455, P919, DOI 10.1038/nature07458; de Kovel CGF, 2010, BRAIN, V133, P23, DOI 10.1093/brain/awp262; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; Heinzen EL, 2010, AM J HUM GENET, V86, P707, DOI 10.1016/j.ajhg.2010.03.018; Hennah W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004906; Mefford HC, 2009, GENOME RES, V19, P1579, DOI 10.1101/gr.094987.109; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Williams MA, 2010, J CARDIOPULM REHABIL, V30, P1	12	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2010	376	9750					1367	1368		10.1016/S0140-6736(10)61192-0	http://dx.doi.org/10.1016/S0140-6736(10)61192-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672ZO	20888039				2022-12-28	WOS:000283627500006
J	Corbett, EL; Bandason, T; Duong, T; Dauya, E; Makamure, B; Churchyard, GJ; Williams, BG; Munyati, SS; Butterworth, AE; Mason, PR; Mungofa, S; Hayes, RJ				Corbett, Elizabeth L.; Bandason, Tsitsi; Duong, Trinh; Dauya, Ethel; Makamure, Beauty; Churchyard, Gavin J.; Williams, Brian G.; Munyati, Shungu S.; Butterworth, Anthony E.; Mason, Peter R.; Mungofa, Stanley; Hayes, Richard J.			Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial	LANCET			English	Article							HIGH HIV PREVALENCE; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; BURDEN; ERA; TRANSMISSION; KAMPALA; PATIENT; IMPACT; RISK	Background Control of tuberculosis in settings with high HIV prevalence is a pressing public health priority. We tested two active case-finding strategies to target long periods of infectiousness before diagnosis, which is typical of HIV-negative tuberculosis and is a key driver of transmission. Methods Clusters of neighbourhoods in the high-density residential suburbs of Harare, Zimbabwe, were randomised to receive six rounds of active case finding at 6-monthly intervals by either mobile van or door-to-door visits. Randomisation was done by selection of discs of two colours from an opaque bag, with one disc to represent every cluster, and one colour allocated to each intervention group before selection began. In both groups, adult (>= 16 years) residents volunteering chronic cough (>= 2 weeks) had two sputum specimens collected for fluorescence microscopy. Community health workers and cluster residents were not masked to intervention allocation, but investigators and laboratory staff were masked to allocation until final analysis. The primary outcome was the cumulative yield of smear-positive tuberculosis per 1000 adult residents, compared between intervention groups; analysis was by intention to treat. The secondary outcome was change in prevalence of culture-positive tuberculosis from before intervention to before round six of intervention in 12% of randomly selected households from the two intervention groups combined; analysis was based on participants who provided sputum in the two prevalence surveys. This trial is registered, number ISRCTN84352452. Findings 46 study clusters were identified and randomly allocated equally between intervention groups, with 55 741 adults in the mobile van group and 54 691 in the door-to-door group at baseline. HIV prevalence was 21% (1916/9060) and in the 6 months before intervention the smear-positive case notification rate was 2.8 per 1000 adults per year. The trial was completed as planned with no adverse events. The mobile van detected 255 smear-positive patients from 5466 participants submitting sputum compared with 137 of 4711 participants identified through door-to-door visits (adjusted risk ratio 1.48, 95% CI 1.11-1.96, p=0.0087). The overall prevalence of culture-positive tuberculosis declined from 6.5 per 1000 adults (95% CI 5.1-8.3) to 3.7 per 1000 adults (2.6-5.0; adjusted risk ratio 059, 95% CI 0.40-0.89, p=0.0112). Interpretation Wide implementation of active case finding, particularly with a mobile van approach, could have rapid effects on tuberculosis transmission and disease.	[Corbett, Elizabeth L.; Butterworth, Anthony E.] London Sch Hyg & Trop Med, Clin Res Unit, London WC1, England; [Duong, Trinh; Hayes, Richard J.] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England; [Corbett, Elizabeth L.; Bandason, Tsitsi; Dauya, Ethel; Makamure, Beauty; Munyati, Shungu S.; Butterworth, Anthony E.; Mason, Peter R.] Biomed Res & Training Inst, Harare, Zimbabwe; [Churchyard, Gavin J.] Aurum Inst, Johannesburg, South Africa; [Williams, Brian G.] Univ Stellenbosch, S African Ctr Epidemiol & Math Anal, ZA-7600 Stellenbosch, South Africa; [Mason, Peter R.] Univ Zimbabwe, Coll Hlth Sci, Dept Med Lab Sci, Harare, Zimbabwe; [Mungofa, Stanley] Harare City Hlth Dept, Harare, Zimbabwe	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Biomedical Research Training Institute; Stellenbosch University; University of Zimbabwe	Corbett, EL (corresponding author), MLW Clin Res Programme, POB 30096, Blantyre, Malawi.	lizcorbett04@gmail.com	Trajman, Anete/C-7679-2016	Trajman, Anete/0000-0002-4000-4984; Churchyard, Gavin/0000-0002-4269-3699; Hayes, Richard/0000-0002-1729-9892; Williams, Brian/0000-0002-3174-4876; Corbett, Elizabeth/0000-0002-3552-3181	Wellcome Trust; Medical Research Council [G0700837] Funding Source: researchfish; MRC [G0700837] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by the Wellcome Trust. We thank all participants and our community advisers and trial steering committee members.	Ayles H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005602; Borgdorff MW, 2000, INT J TUBERC LUNG D, V4, P123; Corbett EL, 2009, INT J TUBERC LUNG D, V13, P1231; Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9; Corbett EL, 2007, PLOS MED, V4, P164, DOI 10.1371/journal.pmed.0040022; Corbett EL, 2010, B WORLD HEALTH ORGAN, V88, P13, DOI 10.2471/BLT.08.055467; Currie CSM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-130; Datiko DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005443; de Vries G, 2007, AM J RESP CRIT CARE, V176, P201, DOI 10.1164/rccm.200612-1877OC; den Boon S, 2006, INT J TUBERC LUNG D, V10, P876; Dimairo M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011849; Dye C, 2008, LANCET INFECT DIS, V8, P233, DOI 10.1016/S1473-3099(07)70291-8; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Glynn JR, 2005, J INFECT DIS, V192, P480, DOI 10.1086/431517; Golub JE, 2005, INT J TUBERC LUNG D, V9, P1183; GRZYBOWSKI S, 1976, TUBERCLE, V57, pS1, DOI 10.1016/0041-3879(76)90059-3; Guwatudde D, 2003, B WORLD HEALTH ORGAN, V81, P799; Hayes RJ, 2009, INTERD STAT, P3; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Karim SSA, 2009, LANCET, V374, P921, DOI 10.1016/S0140-6736(09)60916-8; Kemp JR, 2007, B WORLD HEALTH ORGAN, V85, P580, DOI 10.2471/BLT.06.033167; Khumalo-Sakutukwa G, 2008, JAIDS-J ACQ IMM DEF, V49, P422, DOI 10.1097/QAI.0b013e31818a6cb5; KRIVINKA R, 1974, B WORLD HEALTH ORGAN, V51, P59; Lewin SA, 2005, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD004015.PUB2; Lonnroth K, 2010, LANCET, V375, P1814, DOI 10.1016/S0140-6736(10)60483-7; Mavhu W, 2010, TROP MED INT HEALTH, V15, P574, DOI 10.1111/j.1365-3156.2010.02493.x; Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3; Needham DM, 2004, HEALTH POLICY, V67, P93, DOI 10.1016/S0168-8510(03)00065-4; Schuurman MWE, 1996, TUBERCLE LUNG DIS, V77, P549, DOI 10.1016/S0962-8479(96)90054-4; Sekandi JN, 2009, INT J TUBERC LUNG D, V13, P508; Shenoi SV, 2010, CLIN INFECT DIS, V50, pS231, DOI 10.1086/651496; Storla DG, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-15; SUNG CK, 1976, B INT UNION TUBERC, V51, P381; Uplekar M, 2007, B WORLD HEALTH ORGAN, V85, P413, DOI 10.2471/BLT.07.041756; Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9; WHO, 2009, WHOHTMTB2009411; Wood R, 2007, AM J RESP CRIT CARE, V175, P87, DOI 10.1164/rccm.200606-759OC; World Health Organization, 2008, UN ACC SCAL PRIOR HI	38	181	183	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	2010	376	9748					1244	1253		10.1016/S0140-6736(10)61425-0	http://dx.doi.org/10.1016/S0140-6736(10)61425-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZT	20923715	Green Accepted, Green Published			2022-12-28	WOS:000283003500034
J	Sridhar, D				Sridhar, Devi			Improving aid for maternal, newborn, and child health	LANCET			English	Editorial Material									Univ Oxford All Souls Coll, Oxford OX1 4AL, England	University of Oxford	Sridhar, D (corresponding author), Univ Oxford All Souls Coll, Oxford OX1 4AL, England.	devi.sridhar@all-souls.ox.ac.uk						OMASWA F, 2010, REPORT STRONG MINIST; *OXF GB, MIN G8 MAT HLTH IN S; Pitt C, 2010, LANCET, V376, P1485, DOI 10.1016/S0140-6736(10)61302-5; Schaferhoff M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000305; SRIDHAR D, 2010, CHINA BRAZIL INDIAS; SRIDHAR D, 2010, CHATHAM HOUSE WORLD, V66, P26; PARTNERSHIP MATERNAL	7	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1444	1446		10.1016/S0140-6736(10)61418-3	http://dx.doi.org/10.1016/S0140-6736(10)61418-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	20850870				2022-12-28	WOS:000284248500007
J	Mariner, WK; Annas, GJ				Mariner, Wendy K.; Annas, George J.			Health Insurance Politics in Federal Court.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mariner, Wendy K.; Annas, George J.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Mariner, WK (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Mariner, Wendy/0000-0001-5176-5917; Annas, George/0000-0001-5836-7831				Annas GJ, 2005, NEW ENGL J MED, V353, P2291, DOI 10.1056/NEJMlim053151; Rosenbaum S, 2010, NEW ENGL J MED, V363, P401, DOI 10.1056/NEJMp1005897	2	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1300	1301		10.1056/NEJMp1009054	http://dx.doi.org/10.1056/NEJMp1009054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655TD	20879877				2022-12-28	WOS:000282271500003
J	Tsao, H; Tanabe, KK; Lawrence, DP; Piris, A				Tsao, Hensin; Tanabe, Kenneth K.; Lawrence, Donald P.; Piris, Adriano			Case 30-2010: A 15-Year-Old Boy with a Recurrent Skin Lesion.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPH-NODE BIOPSY; MELANOCYTIC TUMORS; CUTANEOUS MELANOMA; EXCISION MARGINS; BRAF MUTATIONS; SPITZ TUMORS; II MELANOMA; STAGE-I; 2 CM; NEVI		[Tsao, Hensin] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; [Tanabe, Kenneth K.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Piris, Adriano] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Lawrence, Donald P.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Tanabe, Kenneth K.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Lawrence, Donald P.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Piris, Adriano] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Tsao, H (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.				Harvard Medical School Office of Continuing Education; SciBase; Quest Diagnostics; Genentech; Best Doctors; Morningside Technology Advisory; LEK Consulting; Medical Mutual Insurance Company of Maine; Norcal Mutual Insurance Company; ProMutual Group; Schering-Plough; Novaratis	Harvard Medical School Office of Continuing Education; SciBase; Quest Diagnostics; Genentech(Roche HoldingGenentech); Best Doctors; Morningside Technology Advisory; LEK Consulting; Medical Mutual Insurance Company of Maine; Norcal Mutual Insurance Company; ProMutual Group; Schering-Plough(Merck & CompanySchering Plough Corporation); Novaratis	This case was presented at the postgraduate course, Dermatopathology Update, September 25, 2009 (course directors: Drs. Lyn M. Duncan, Mai Hoang, Martin C. Mihm, Jr., George F. Murphy, and Steven R. Tahan), sponsored by the Harvard Medical School Office of Continuing Education.; Dr. Tsao reports receiving consulting fees from SciBase, Quest Diagnostics, and Genentech; Dr. Tanabe, consulting fees from Best Doctors, Morningside Technology Advisory, LEK Consulting, Medical Mutual Insurance Company of Maine, Norcal Mutual Insurance Company, and ProMutual Group; and Dr. Lawrence, consulting fees from Schering-Plough and Novaratis. No other potential conflict of interest relevant to this article was reported.	Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Balch CM, 2001, ANN SURG ONCOL, V8, P101, DOI 10.1007/s10434-001-0101-x; Barnhill RL, 2006, MODERN PATHOL, V19, pS21, DOI 10.1038/modpathol.3800519; Barnhill RL, 1999, HUM PATHOL, V30, P513, DOI 10.1016/S0046-8177(99)90193-4; Bastian BC, 2002, RECENT RES CANCER, V160, P92; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P1495, DOI 10.1002/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D; ELDER DE, 2009, BENIGN PIGMENTED LES; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; Gershenwald JE, 1999, J CLIN ONCOL, V17, P976, DOI 10.1200/JCO.1999.17.3.976; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hocker TL, 2008, J INVEST DERMATOL, V128, P2575, DOI 10.1038/jid.2008.226; Khayat D, 2003, CANCER-AM CANCER SOC, V97, P1941, DOI 10.1002/cncr.11272; Livestro DP, 2007, CANCER, V110, P614, DOI 10.1002/cncr.22818; Lohmann CM, 2002, AM J SURG PATHOL, V26, P47, DOI 10.1097/00000478-200201000-00005; Ludgate MW, 2009, CANCER-AM CANCER SOC, V115, P631, DOI 10.1002/cncr.24047; Morton DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMoa060992; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Saenz NC, 1999, CANCER-AM CANCER SOC, V85, P750, DOI 10.1002/(SICI)1097-0142(19990201)85:3<750::AID-CNCR26>3.0.CO;2-5; Spatz A, 1999, ARCH DERMATOL, V135, P282, DOI 10.1001/archderm.135.3.282; SPITZ S, 1948, AM J PATHOL, V24, P591; Strouse JJ, 2005, J CLIN ONCOL, V23, P4735, DOI 10.1200/JCO.2005.02.899; Thomas JM, 2004, NEW ENGL J MED, V350, P757, DOI 10.1056/NEJMoa030681; VERONESI U, 1991, NEW ENGL J MED, V325, P292; Wheatley K, 2003, CANCER TREAT REV, V29, P241, DOI 10.1016/S0305-7372(03)00074-4	27	0	0	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1352	1360		10.1056/NEJMcpc1003889	http://dx.doi.org/10.1056/NEJMcpc1003889			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879885				2022-12-28	WOS:000282271500012
J	Middleton, A; Niruban, A; Girling, G; Myint, PK				Middleton, Anna; Niruban, Alagaratnam; Girling, Gill; Myint, Phyo Kyaw			Practice Pointer Communicating in a healthcare setting with people who have hearing loss	BRITISH MEDICAL JOURNAL			English	Editorial Material							OLDER-ADULTS; DEAF; IMPAIRMENT		[Niruban, Alagaratnam; Myint, Phyo Kyaw] Norfolk & Norwich Univ Hosp, Acad Dept Med Elderly, Norwich NR4 7UY, Norfolk, England; [Middleton, Anna] Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; [Girling, Gill] Norfolk Deaf Assoc, Norwich NR3 4TL, Norfolk, England; [Myint, Phyo Kyaw] Univ E Anglia, Sch Med, Fac Hlth, Hlth & Social Sci Res Inst, Norwich NR4 7TJ, Norfolk, England; [Myint, Phyo Kyaw] Univ Cambridge, Sch Clin Med, Dept Public Hlth & Primary Care, Clin Gerontol Unit, Cambridge CB2 0QQ, England	Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Cardiff University; University of East Anglia; University of Cambridge	Myint, PK (corresponding author), Norfolk & Norwich Univ Hosp, Acad Dept Med Elderly, Norwich NR4 7UY, Norfolk, England.	Phyo.K.Myint@uea.ac.uk		Middleton, Anna/0000-0003-3103-8098				Baker Holly, 2007, Psychol Health Med, V12, P380, DOI 10.1080/13548500601133466; Barnett S, 2002, FAM MED, V34, P376; Brink P, 2007, GERONTOLOGIST, V47, P633, DOI 10.1093/geront/47.5.633; Dalton DS, 2003, GERONTOLOGIST, V43, P661, DOI 10.1093/geront/43.5.661; Davidhizar Ruth, 2008, J Pract Nurs, V58, P12; Department of Health, 2005, MENT HLTH DEAFN EQ A; FORTNUM H, 2006, EFFECTS GENETIC HEAR, P29; Harmer L, 1999, J Deaf Stud Deaf Educ, V4, P73, DOI 10.1093/deafed/4.2.73; Hickson Louise, 2007, Seminars in Speech and Language, V28, P283, DOI 10.1055/s-2007-986525; Hines J, 2000, Nurs Stand, V14, P33; Iezzoni LI, 2004, ANN INTERN MED, V140, P356, DOI 10.7326/0003-4819-140-5-200403020-00011; JONES B, 1998, EBM, V1, P131; Ladd P., 2003, MULTILINGUAL MATTERS; Mackenzie I, 2009, ANN TROP MED PARASIT, V103, P565, DOI 10.1179/000349809X12459740922372; Mann W J, 1994, Md Med J, V43, P509; Middleton A., 2010, WORKING DEAF PEOPLE; Middleton A, 2010, J EVAL CLIN PRACT, V16, P811, DOI 10.1111/j.1365-2753.2009.01207.x; Middleton A, 2010, SIGN LANG STUD, V10, P170, DOI 10.1353/sls.0.0038; NHS Quality Improvement Scotland, 2005, MAX COMM OLD PEOPL W; *ROYAL NAT I DEAF, 2004, SIMPL CUR; Royal National Institute for the Deaf, 2006, FACTS FIG DEAFN TINN; SAUNDERS GH, 2007, TRENDS AMPLIF, V11, P227; Slaven Antoinette, 2003, Nurs Stand, V18, P39; Steinberg AG, 2006, J GEN INTERN MED, V21, P260, DOI 10.1111/j.1525-1497.2006.00340.x; Steinberg AG, 2002, J WOMEN HEALTH GEN-B, V11, P729, DOI 10.1089/15409990260363689; Stephens D., 2005, IMPACT GENETIC HEARI, P54; Traynor Noel, 2004, Nurs Times, V100, P32; WHO, 2001, WHO INT CLASS FUNCT; WITTE TN, 2000, J AM BOARD FAM PRACT, V13, P81; Zazove P, 2006, J AM BOARD FAM MED, V19, P141, DOI 10.3122/jabfm.19.2.141	30	16	16	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 29	2010	341								c4672	10.1136/bmj.c4672	http://dx.doi.org/10.1136/bmj.c4672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659ND	20880905				2022-12-28	WOS:000282572400008
J	Hunt, DP; Thabet, A; Rosenberg, ES				Hunt, Daniel P.; Thabet, Ashraf; Rosenberg, Eric S.			A Woman with Fever and Abdominal Pain Acute Epstein-Barr viral infection (infectious mononucleosis)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPLENIC INFARCTION; ANTIPHOSPHOLIPID ANTIBODIES; HEREDITARY SPHEROCYTOSIS; VIRUS-INFECTION; PATIENT; COMPLICATIONS		[Hunt, Daniel P.; Rosenberg, Eric S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Thabet, Ashraf] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Rosenberg, Eric S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Rosenberg, Eric S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Thabet, Ashraf] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Hunt, Daniel P.; Rosenberg, Eric S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hunt, DP (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.		Hunt, Dan/AAL-3807-2021					Antopolsky M, 2009, AM J EMERG MED, V27, P262, DOI 10.1016/j.ajem.2008.02.014; Bell AT, 2006, J FAM PRACTICE, V55, P799; Breuer C, 2008, EUR J PEDIATR, V167, P1449, DOI 10.1007/s00431-008-0781-3; Bruu AL, 2000, CLIN DIAGN LAB IMMUN, V7, P451, DOI 10.1128/CDLI.7.3.451-456.2000; GOERG C, 1990, RADIOLOGY, V174, P803, DOI 10.1148/radiology.174.3.2406785; Gulley ML, 2008, J MOL DIAGN, V10, P279, DOI 10.2353/jmoldx.2008.080023; Jenson HB, 2000, CURR OPIN PEDIATR, V12, P263, DOI 10.1097/00008480-200006000-00016; Lameris W, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2431; Luzuriaga K, 2010, NEW ENGL J MED, V362, P1993, DOI 10.1056/NEJMcp1001116; Ng CS, 2002, BRIT MED J, V325, P1387, DOI 10.1136/bmj.325.7377.1387; Nores M, 1998, AM SURGEON, V64, P182; Sala E, 2007, CLIN RADIOL, V62, P961, DOI 10.1016/j.crad.2007.01.030; Silen W., 1979, COPES EARLY DIAGNOSI; Sorice M, 2000, CLIN EXP IMMUNOL, V120, P301, DOI 10.1046/j.1365-2249.2000.01206.x; Suzuki Y, 2007, INT J HEMATOL, V85, P380, DOI 10.1532/IJH97.07208; Symeonidis A, 2001, ACTA HAEMATOL-BASEL, V105, P53, DOI 10.1159/000046534; Trevenzoli M, 2001, SCAND J INFECT DIS, V33, P550, DOI 10.1080/00365540110026629; Van Hal S, 2005, J CLIN VIROL, V32, P245, DOI 10.1016/j.jcv.2004.07.013; Ventura KC, 2004, AM J HEMATOL, V76, P315, DOI 10.1002/ajh.20119; Wallach JB, 2007, INTERPRETATION DIAGN; Yamamoto W, 1997, J Epidemiol, V7, P27	21	13	13	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1266	1274		10.1056/NEJMcpc1007084	http://dx.doi.org/10.1056/NEJMcpc1007084			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860509				2022-12-28	WOS:000282050000012
J	Batton, B				Batton, Beau			Healing Hearts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												bbatton@siumed.edu							0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1303	1304		10.1001/jama.2010.1363	http://dx.doi.org/10.1001/jama.2010.1363			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858869				2022-12-28	WOS:000282007900001
J	Desser, AS; Gyrd-Hansen, D; Olsen, JA; Grepperud, S; Kristiansen, IS				Desser, Arna S.; Gyrd-Hansen, Dorte; Olsen, Jan Abel; Grepperud, Sverre; Kristiansen, Ivar Sonbo			Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67	BRITISH MEDICAL JOURNAL			English	Article							CHOICE	Objective To determine whether a general societal preference for prioritising treatment of rare diseases over common ones exists and could provide a justification for accepting higher cost effectiveness thresholds for orphan drugs. Design Cross sectional survey using a web based questionnaire. Setting Norway. Participants Random sample of 1547 Norwegians aged 40-67. Main outcome measure Choice between funding treatment for a rare disease versus a common disease and how funds should be allocated if it were not possible to treat all patients, for each of two scenarios: identical treatment costs per patient and higher costs for the rare disease. Respondents rated five statements concerning attitudes to equity on a five point Likert scale (5=completely agree). Results For the equal cost scenario, 11.2% (9.6% to 12.8%) of respondents favoured treating the rare disease, 24.9% (21.7% to 26.0%) the common disease, and 64.9% (62.6% to 67.3%) were indifferent. When the rare disease was four times more costly to treat, the results were, respectively, 7.4% (6.1% to 8.7%), 45.3% (42.8% to 47.8%), and 47.3% (44.8% to 49.8%). Rankings for attitude on a Likert scale indicated strong support for the statements "rare disease patients should have the right to treatment even if more expensive" (mean score 4.5, SD 0.86) and "resources should be used to provide the greatest possible health benefits" (3.9, 1.23). Conclusions Despite strong general support for statements expressing a desire for equal treatment rights for patients with rare diseases, there was little evidence that a societal preference for rarity exists if treatment of patients with rare diseases is at the expense of treatment of those with common diseases.	[Desser, Arna S.; Grepperud, Sverre; Kristiansen, Ivar Sonbo] Univ Oslo, Dept Hlth Mgmt & Hlth Econ, N-0317 Oslo, Norway; [Gyrd-Hansen, Dorte; Kristiansen, Ivar Sonbo] Univ So Denmark, Inst Publ Hlth, Odense, Denmark; [Olsen, Jan Abel] Univ Tromso, Dept Community Med, Tromso, Norway	University of Oslo; University of Southern Denmark; UiT The Arctic University of Tromso	Desser, AS (corresponding author), Univ Oslo, Dept Hlth Mgmt & Hlth Econ, PO Box 1089,Blindern, N-0317 Oslo, Norway.	a.s.desser@medisin.uio.no	Gyrd-Hansen, Dorte/A-3161-2011	Grepperud, Sverre Ole/0000-0002-8658-7345; Gyrd-Hansen, Dorte/0000-0003-1137-2304	Norwegian Research Council; University of Oslo	Norwegian Research Council(Research Council of NorwayEuropean Commission); University of Oslo	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and all authors want to declare (1) Financial support for the submitted work from the Norwegian Research Council and the Health Economics Research Programme (HERO) at the University of Oslo. ISK (2) has received gifts, travel funds, honorariums, consultancy fees or salary from a wide range of public institutions, not for profit organisations or for profit organisations that may have an interest in orphan drug issues. The other authors declare no interests under (2), and all authors declare that they have (3) No spouses, partners, or children with relationships with commercial entities that might have an interest in the submitted work; (4) No non-financial interests that may be relevant to the submitted work.	DENIS A, 2010, J MED EC; Drummond MF, 2007, INT J TECHNOL ASSESS, V23, P36, DOI 10.1017/S0266462307051550; *EUROQOL, 2010, EQ 5D; *HELS OG OMS, 1987, 198723 NOU HELS OG O; Hughes DA, 2005, QJM-INT J MED, V98, P829, DOI 10.1093/qjmed/hci128; McCabe C, 2006, QJM-INT J MED, V99, P341, DOI 10.1093/qjmed/hcl033; McCabe C, 2005, BRIT MED J, V331, P1016, DOI 10.1136/bmj.331.7523.1016; McCabe C, 2007, INT J TECHNOL ASSESS, V23, P397; McKie J, 2003, SOC SCI MED, V56, P2407, DOI 10.1016/S0277-9536(02)00244-7; National Institute for Clinical Excellence, 2004, CIT COUNC REP ULTR D CIT COUNC REP ULTR D; NORD E, 1995, SOC SCI MED, V41, P1429, DOI 10.1016/0277-9536(95)00121-M; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TVERSKY A, 1992, PSYCHOL SCI, V3, P358, DOI 10.1111/j.1467-9280.1992.tb00047.x; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807	14	67	67	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 22	2010	341								c4715	10.1136/bmj.c4715	http://dx.doi.org/10.1136/bmj.c4715			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655TK	20861122	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000282272200023
J	Lin, K; Sharangpani, R				Lin, Kenneth; Sharangpani, Ruta			Screening for Testicular Cancer: An Evidence Review for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							FOLLOW-UP; MICROLITHIASIS; MEN	Background: Testicular cancer is the most common type of cancer in men aged 15 to 34 years. Because treatment produces favorable outcomes even in advanced stages, the U. S. Preventive Services Task Force (USPSTF) concluded in 2004 that screening asymptomatic men for testicular cancer is unlikely to produce additional benefits over clinical detection. Purpose: To search for new evidence on the benefits and harms of screening for testicular cancer to assist the USPSTF in updating its 2004 recommendation. Data Sources: English-language articles indexed in PubMed and the Cochrane Library and published between 1 January 2001 and 11 November 2009. Study Selection: Randomized, controlled trials; meta-analyses; systematic reviews; cohort studies; and case-control studies were selected to determine the benefits of screening for testicular cancer. Randomized, controlled trials; meta-analyses; systematic reviews; cohort studies; case-control studies; and case series of large, multisite databases were selected to determine the harms of screening. Each author independently reviewed titles, abstracts, and full-text articles for possible inclusion. Data Extraction: One author abstracted information on the benefits and harms of screening for testicular cancer. Data Synthesis: No studies met the inclusion criteria. Three studies were considered for inclusion at the full-text stage of review. These inconclusive studies addressed testicular microlithiasis, XIST gene testing, and testis-sparing surgery. Limitation: The focused search strategy may have missed some smaller studies or studies published in languages other than English on the benefits or harms of testicular cancer screening. Conclusion: No new evidence was found on the benefits or harms of screening for testicular cancer that would affect the USPSTF's previous recommendation against screening.	[Lin, Kenneth] Agcy Healthcare Res & Qual, Ctr Primary Care Prevent & Clin Partnerships, Rockville, MD 20850 USA	Agency for Healthcare Research & Quality	Lin, K (corresponding author), Agcy Healthcare Res & Qual, Ctr Primary Care Prevent & Clin Partnerships, 540 Gaither Rd,RM 6107, Rockville, MD 20850 USA.	Kenneth.Lin@ahrq.hhs.gov			Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Primary Funding Source: Agency for Healthcare Research and Quality.	ALTEKRUSE SF, 1975, SEER CANC STAT REV; Bennett HF, 2001, RADIOLOGY, V218, P359, DOI 10.1148/radiology.218.2.r01fe25359; Carmignani L, 2003, J UROLOGY, V170, P1783, DOI 10.1097/01.ju.0000092066.01699.90; DeCastro BJ, 2008, J UROLOGY, V179, P1420, DOI 10.1016/j.juro.2007.11.080; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; McGlynn KA, 2003, CANCER, V97, P63, DOI 10.1002/cncr.11054; Peterson AC, 2001, J UROLOGY, V166, P2061, DOI 10.1016/S0022-5347(05)65506-1; U. S. Preventive Services Task Force, 2004, SCREEN TEST CANC REC; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P153; Walsh TJ, 2009, ARCH INTERN MED, V169, P351, DOI 10.1001/archinternmed.2008.562	10	45	45	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					396	399		10.7326/0003-4819-153-6-201009210-00007	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855803				2022-12-28	WOS:000282043100006
J	Kumar, V; Takahashi, JS				Kumar, Vivek; Takahashi, Joseph S.			PARP around the Clock	CELL			English	Editorial Material							SIRT1		[Kumar, Vivek; Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Neurosci, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Takahashi, JS (corresponding author), Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Neurosci, 5323 Harry Hines Blvd,NA4-118, Dallas, TX 75390 USA.	joseph.takahashi@utsouthwestern.edu	Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012; Kumar, Vivek/P-8749-2014	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Kumar, Vivek/0000-0001-6643-7465	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Asher G, 2010, CELL, V142, P943, DOI 10.1016/j.cell.2010.08.016; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Froy O, 2010, AGING-US, V2, P7, DOI 10.18632/aging.100116; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Kolthur-Seetharam U, 2006, CELL CYCLE, V5, P873, DOI 10.4161/cc.5.8.2690; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002	10	9	9	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					841	843		10.1016/j.cell.2010.08.037	http://dx.doi.org/10.1016/j.cell.2010.08.037			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850006	Green Accepted, Bronze			2022-12-28	WOS:000281855000006
J	Maiani, L				Maiani, Luciano			Nicola Cabibbo (1935-2010) OBITUARY	NATURE			English	Biographical-Item									[Maiani, Luciano] Univ Roma La Sapienza, Dept Phys, I-00185 Rome, Italy; [Maiani, Luciano] Italian Natl Res Council, I-00185 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)	Maiani, L (corresponding author), Univ Roma La Sapienza, Dept Phys, I-00185 Rome, Italy.	luciano.maiani@cnr.it							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					284	284		10.1038/467284a	http://dx.doi.org/10.1038/467284a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844530				2022-12-28	WOS:000281824900029
J	Sah, S; Loewenstein, G				Sah, Sunita; Loewenstein, George			Effect of Reminders of Personal Sacrifice and Suggested Rationalizations on Residents' Self-Reported Willingness to Accept Gifts A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-SURVEY; INDUSTRY; PHYSICIANS; REPRESENTATIVES; EXCHANGE; DOCTORS	Context Despite expanding research on the prevalence and consequences of conflicts of interest in medicine, little attention has been given to the psychological processes that enable physicians to rationalize the acceptance of gifts. Objective To determine whether reminding resident physicians of the sacrifices made to obtain training, as well as suggesting this as a potential rationalization, increases self-stated willingness to accept gifts from industry. Design, Setting, and Participants Three hundred one US resident physicians from 2 sample populations (pediatrics and family medicine) who were recruited during March-July 2009 participated in a survey presented as evaluating quality of life and values. Intervention Physicians were randomly assigned to receive 1 of 3 different online surveys. The sacrifice reminders survey (n=120) asked questions about sacrifices made in medical training, followed by questions regarding the acceptability of receiving gifts from industry. The suggested rationalization survey (n=121) presented the same sacrifice questions, followed by a suggested possible rationalization (based on sacrifices made in medical training) for acceptance of gifts, before the questions regarding the acceptability of gifts. The control survey (n=60) asked about the acceptability of gifts before asking questions about sacrifices or suggesting a rationalization. Main Outcome Measures Physician self-stated acceptability of receiving gifts from industry. Results Reminding physicians of sacrifices made in obtaining their education resulted in gifts being evaluated as more acceptable: 21.7% (13/60) in the control group vs 47.5% (57/120) in the sacrifice reminders group (odds ratio, 1.81; 95% confidence interval, 1.27-2.58; P=.001). Although most residents disagreed with the suggested rationalization, exposure to it further increased the perceived acceptability of gifts to 60.3% (73/121) in that group (odds ratio relative to sacrifice reminders group, 1.45; 95% confidence interval, 1.22-1.72; P<.001). Conclusions Providing resident physicians with reminders of sacrifices increased the perceived acceptability of industry-sponsored gifts. Including a rationalization statement further increased gift acceptability. JAMA. 2010;304(11):1204-1211 www.jama.com	[Sah, Sunita; Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Sah, S (corresponding author), Carnegie Mellon Univ, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.	sunitasah@cmu.edu	Sah, Sunita/J-4613-2014; Loewenstein, George/G-7616-2014	Sah, Sunita/0000-0003-1671-4414; Loewenstein, George/0000-0003-2790-0474	Carnegie Mellon's internal departmental research funds	Carnegie Mellon's internal departmental research funds	This study was supported by Carnegie Mellon's internal departmental research funds.	ADAMS JS, 1965, ADV EXP SOC PSYCHOL, V2, P267; Babcock L, 1995, AM ECON REV, V85, P1337; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Campbell EG, 2007, NEW ENGL J MED, V357, P1796, DOI 10.1056/NEJMp078141; Campbell EG, 2007, NEW ENGL J MED, V356, P1742, DOI 10.1056/NEJMsa064508; Chimonas S, 2007, J GEN INTERN MED, V22, P184, DOI 10.1007/s11606-006-0041-z; Cohen J., 1983, APPL MULTIPLE REGRES; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; Fugh-Berman A, 2007, PLOS MED, V4, P621, DOI 10.1371/journal.pmed.0040150; King-Casas B, 2005, SCIENCE, V308, P78, DOI 10.1126/science.1108062; Mazar N, 2008, J MARKETING RES, V45, P633, DOI 10.1509/jmkr.45.6.633; MONTAGUE R, 2007, SCI BASIS INFLUENCE; Sierles FS, 2005, JAMA-J AM MED ASSOC, V294, P1034, DOI 10.1001/jama.294.9.1034; Steinman MA, 2007, PLOS MED, V4, P743, DOI 10.1371/journal.pmed.0040134; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Zipkin DA, 2005, J GEN INTERN MED, V20, P777, DOI 10.1111/j.1525-1497.2005.0134.x	17	23	23	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1204	1211		10.1001/jama.2010.1310	http://dx.doi.org/10.1001/jama.2010.1310			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841534	Bronze			2022-12-28	WOS:000281770600013
J	Lee, K; Gallop, JL; Rambani, K; Kirschner, MW				Lee, Kwonmoo; Gallop, Jennifer L.; Rambani, Komal; Kirschner, Marc W.			Self-Assembly of Filopodia-Like Structures on Supported Lipid Bilayers	SCIENCE			English	Article							N-WASP; ARP2/3 COMPLEX; DENDRITIC NETWORK; BARBED END; ACTIN; PROTEINS; FORMIN; CELLS; MOTILITY; FAMILY	Filopodia are finger-like protrusive structures, containing actin bundles. By incubating frog egg extracts with supported lipid bilayers containing phosphatidylinositol 4,5 bisphosphate, we have reconstituted the assembly of filopodia-like structures (FLSs). The actin assembles into parallel bundles, and known filopodial components localize to the tip and shaft. The filopodia tip complexes self-organize-they are not templated by preexisting membrane microdomains. The F-BAR domain protein toca-1 recruits N-WASP, followed by the Arp2/3 complex and actin. Elongation proteins, Diaphanous-related formin, VASP, and fascin are recruited subsequently. Although the Arp2/3 complex is required for FLS initiation, it is not essential for elongation, which involves formins. We propose that filopodia form via clustering of Arp2/3 complex activators, self-assembly of filopodial tip complexes on the membrane, and outgrowth of actin bundles.	[Lee, Kwonmoo; Gallop, Jennifer L.; Rambani, Komal; Kirschner, Marc W.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Lee, Kwonmoo] MIT, Dept Phys, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	marc@hms.harvard.edu		Gallop, Jennifer Louise/0000-0002-9978-1382; Lee, Kwonmoo/0000-0001-6838-7094	Korea Science and Engineering Foundation (KOSEF); Harvard-MIT; European Molecular Biology Organization; NIH [GM26875]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026875, R37GM026875] Funding Source: NIH RePORTER	Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation); Harvard-MIT; European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	K. L. was the recipient of a Korea Science and Engineering Foundation (KOSEF) Scholarship and Harvard-MIT Health Sciences and Technology Fellowship. J.L.G was the recipient of an European Molecular Biology Organization Long-Term Fellowship. This work was funded by NIH grant GM26875. We thank G. Bokoch for the gift of the GST-RhoA-N19 plasmid, S. Field for the gift of the pEGFP GFP-PLC delta PH domain plasmid, Weiner for the RhoGDI plasmid, R. Tsien for the mCherry plasmid, A. Alberts for the mDia2 plasmid, and D. Vignjevic for the fascin plasmid. We thank A. Lebensohn for helping extract preparation and valuable discussions and M. Coughlin, T. Walz, and D. Kelly for help with EM. We thank J. Waters, W. Salmon, and Nikon Imaging Center at Harvard Medical School.	Arasada R, 2007, BBA-MOL CELL RES, V1773, P631, DOI 10.1016/j.bbamcr.2007.03.009; Brieher WM, 2004, J CELL BIOL, V165, P233, DOI 10.1083/jcb.200311040; Chan YHM, 2007, CURR OPIN CHEM BIOL, V11, P581, DOI 10.1016/j.cbpa.2007.09.020; Co C, 2007, CELL, V128, P901, DOI 10.1016/j.cell.2006.12.049; Crane JM, 2004, BIOPHYS J, V86, P2965, DOI 10.1016/S0006-3495(04)74347-7; DAVENPORT RW, 1993, NATURE, V361, P721, DOI 10.1038/361721a0; Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024; Faix J, 2009, INT J BIOCHEM CELL B, V41, P1656, DOI 10.1016/j.biocel.2009.02.012; GUPTON SL, 2007, SCI STKE, pRE5, DOI DOI 10.1126/STKE.4002007RE5; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Johnston SA, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-65; Korobova F, 2008, MOL BIOL CELL, V19, P1561, DOI 10.1091/mbc.E07-09-0964; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Liu AP, 2008, NAT PHYS, V4, P789, DOI 10.1038/nphys1071; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; Medalia O, 2007, CURR BIOL, V17, P79, DOI 10.1016/j.cub.2006.11.022; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MOOSEKER MS, 1982, J CELL BIOL, V95, P223, DOI 10.1083/jcb.95.1.223; Nicholson-Dykstra SM, 2008, CELL MOTIL CYTOSKEL, V65, P904, DOI 10.1002/cm.20312; Padrick SB, 2008, MOL CELL, V32, P426, DOI 10.1016/j.molcel.2008.10.012; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Schwille P, 2005, PROTEIN-LIPID INTERACTIONS: FROM MEMBRANE DOMAINS TO CELLULAR NETWORKS, P337; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Steffen A, 2006, MOL BIOL CELL, V17, P2581, DOI 10.1091/mbc.E05-11-1088; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Vignjevic D, 2003, J CELL BIOL, V160, P951, DOI 10.1083/jcb.200208059; Vignjevic D, 2006, J CELL BIOL, V174, P863, DOI 10.1083/jcb.200603013; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317	39	115	115	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1341	1345		10.1126/science.1191710	http://dx.doi.org/10.1126/science.1191710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829485	Green Published, Green Accepted			2022-12-28	WOS:000281657300038
J	Shah, AN; Saldana, M				Shah, Anish N.; Saldana, Manuel			Ocular Loiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Shah, Anish N.; Saldana, Manuel] St Thomas Hosp, London, England	Guy's & St Thomas' NHS Foundation Trust	Shah, AN (corresponding author), St Thomas Hosp, London, England.								0	7	7	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					E16	E16		10.1056/NEJMicm1002020	http://dx.doi.org/10.1056/NEJMicm1002020			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20848684				2022-12-28	WOS:000281609700010
J	Hong, CS; Atlas, SJ; Chang, YC; Subramanian, SV; Ashburner, JM; Barry, MJ; Grant, RW				Hong, Clemens S.; Atlas, Steven J.; Chang, Yuchiao; Subramanian, S. V.; Ashburner, Jeffrey M.; Barry, Michael J.; Grant, Richard W.			Relationship Between Patient Panel Characteristics and Primary Care Physician Clinical Performance Rankings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAY-FOR-PERFORMANCE; MEDICARE MANAGED CARE; CASE-MIX ADJUSTMENT; QUALITY-OF-CARE; HEALTH-CARE; REGIONAL-VARIATIONS; RACIAL DISPARITIES; UNITED-STATES; CONSEQUENCES; ASSOCIATIONS	Context Physicians have increasingly become the focus of clinical performance measurement. Objective To investigate the relationship between patient panel characteristics and relative physician clinical performance rankings within a large academic primary care network. Design, Setting, and Participants Cohort study using data from 125 303 adult patients who had visited any of the 9 hospital-affiliated practices or 4 community health centers between January 1, 2003, and December 31, 2005, (162 primary care physicians in 1 physician organization linked by a common electronic medical record system in Eastern Massachusetts) to determine changes in physician quality ranking based on an aggregate of Health Plan Employer and Data Information Set (HEDIS) measures after adjusting for practice site, visit frequency, and patient panel characteristics. Main Outcome Measures Composite physician clinical performance score based on 9 HEDIS quality measures (reported by percentile, with lower scores indicating higher quality). Results Patients of primary care physicians in the top quality performance tertile compared with patients of primary care physicians in the bottom quality tertile were older (51.1 years [95% confidence interval {CI}, 49.6-52.6 years] vs 46.6 years [95% CI, 43.8-49.5 years], respectively; P<.001), had a higher number of comorbidities (0.91 [95% CI, 0.83-0.98] vs 0.80 [95% CI, 0.66-0.95]; P=.008), and made more frequent primary care practice visits (71.0% [95% CI, 68.5%-73.5%] vs 61.8% [95% CI, 57.3%-66.3%] with >3 visits/year; P=.003). Top tertile primary care physicians compared with the bottom tertile physicians had fewer minority patients (13.7% [95% CI, 10.6%-16.7%] vs 25.6% [95% CI, 20.2%-31.1%], respectively; P<.001), non-English-speaking patients (3.2% [95% CI, 0.7%-5.6%] vs 10.2% [95% CI, 5.5%-14.9%]; P<.001), and patients with Medicaid coverage or without insurance (9.6% [95% CI, 7.5%-11.7%] vs 17.2% [95% CI, 13.5%-21.0%]; P<.001). After accounting for practice site and visit frequency differences, adjusting for patient panel factors resulted in a relative mean change in physician rankings of 7.6 percentiles (95% CI, 6.6-8.7 percentiles) per primary care physician, with more than one-third (36%) of primary care physicians (59/162) reclassified into different quality tertiles. Conclusion Among primary care physicians practicing within the same large academic primary care system, patient panels with greater proportions of underinsured, minority, and non-English-speaking patients were associated with lower quality rankings for primary care physicians. JAMA. 2010; 304(10): 1107-1113	[Hong, Clemens S.; Atlas, Steven J.; Chang, Yuchiao; Ashburner, Jeffrey M.; Barry, Michael J.; Grant, Richard W.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02115 USA; [Hong, Clemens S.; Atlas, Steven J.; Chang, Yuchiao; Barry, Michael J.; Grant, Richard W.] Harvard Univ, Sch Med, Boston, MA USA; [Subramanian, S. V.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Hong, CS (corresponding author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02115 USA.	cshong@partners.org		Grant, Richard/0000-0002-6164-8025	National Institutes of Health [T32 HP12706, NIDDK K23 DK067452, NHLBI K25 HL081275]; Agency for Healthcare Research and Quality [R18 HS018161]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS018161] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K25HL081275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK067452] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr Hong is supported by National Research Service Award grant T32 HP12706 from the National Institutes of Health. Dr Grant is supported by career development grant NIDDK K23 DK067452 from the National Institutes of Health. Dr Atlas is supported by grant R18 HS018161 from the Agency for Healthcare Research and Quality. Dr Subramanian is supported by career development grant NHLBI K25 HL081275 from the National Institutes of Health.	Atlas SJ, 2006, J GEN INTERN MED, V21, P973, DOI 10.1007/BF02743147; Atlas SJ, 2009, ANN INTERN MED, V150, P325, DOI 10.7326/0003-4819-150-5-200903030-00008; Casalino LP, 2007, HEALTH AFFAIR, V26, pW405, DOI 10.1377/hlthaff.26.3.w405; Chien AT, 2007, MED CARE RES REV, V64, p283S, DOI 10.1177/1077558707305426; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Fisher ES, 2006, NEW ENGL J MED, V355, P1845, DOI 10.1056/NEJMp068221; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Friedberg MW, 2009, ANN INTERN MED, V151, P456, DOI 10.7326/0003-4819-151-7-200910060-00006; Gandhi TK, 2002, MED CARE, V40, P155, DOI 10.1097/00005650-200202000-00010; GONZALEZ ML, 1997, SOCIOECONOMIC CHARAC; Greenfield S, 2002, ANN INTERN MED, V136, P111, DOI 10.7326/0003-4819-136-2-200201150-00008; Higashi T, 2007, NEW ENGL J MED, V356, P2496, DOI 10.1056/NEJMsa066253; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Kaplan SH, 2009, MED CARE, V47, P378, DOI 10.1097/MLR.0b013e31818dce07; Karve AM, 2008, AM HEART J, V155, P571, DOI 10.1016/j.ahj.2007.10.043; Martin LM, 1996, AM J PREV MED, V12, P82, DOI 10.1016/S0749-3797(18)30349-0; McBean AM, 2003, DIABETES CARE, V26, P3250, DOI 10.2337/diacare.26.12.3250; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mehta RH, 2008, JAMA-J AM MED ASSOC, V300, P1897, DOI 10.1001/jama.300.16.1897; Murphy SN, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P552; Pearlman DN, 1996, AM J PREV MED, V12, P327, DOI 10.1016/S0749-3797(18)30287-3; Poon EG, 2010, MED CARE, V48, P203, DOI 10.1097/MLR.0b013e3181c16203; Reeves D, 2007, MED CARE, V45, P489, DOI 10.1097/MLR.0b013e31803bb479; Rosenthal GE, 1997, AM J PUBLIC HEALTH, V87, P429, DOI 10.2105/AJPH.87.3.429; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Rosenthal MB, 2004, HEALTH AFFAIR, V23, P127, DOI 10.1377/hlthaff.23.2.127; Rosenthal MB, 2006, NEW ENGL J MED, V355, P1895, DOI 10.1056/NEJMsa063682; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; Schneider EC, 2001, JAMA-J AM MED ASSOC, V286, P1455, DOI 10.1001/jama.286.12.1455; Schneider EC, 2002, JAMA-J AM MED ASSOC, V287, P1288, DOI 10.1001/jama.287.10.1288; Virnig BA, 2002, HEALTH AFFAIR, V21, P224, DOI 10.1377/hlthaff.21.6.224; Werner RM, 2005, JAMA-J AM MED ASSOC, V293, P1239, DOI 10.1001/jama.293.10.1239; Wharam JF, 2009, J GEN INTERN MED, V24, P854, DOI 10.1007/s11606-009-0947-3; Wilson IB, 2007, BMJ-BRIT MED J, V335, P1085, DOI 10.1136/bmj.39364.520278.55; Zaslavsky AM, 2005, INT J QUAL HEALTH C, V17, P67, DOI 10.1093/intqhc/mzi005	36	82	82	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1107	1113		10.1001/jama.2010.1287	http://dx.doi.org/10.1001/jama.2010.1287			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646RM	20823437	Bronze			2022-12-28	WOS:000281559800021
J	Harper, JT; Bradford, JH; Humphrey, NF; Meierbachtol, TW				Harper, Joel T.; Bradford, John H.; Humphrey, Neil F.; Meierbachtol, Toby W.			Vertical extension of the subglacial drainage system into basal crevasses	NATURE			English	Article							GREENLAND ICE-SHEET; WATER-PRESSURE; VALLEY GLACIER; FLOW; STORGLACIAREN; VELOCITY	Water plays a first-order role in basal sliding of glaciers and ice sheets and is often a key constituent of accelerated glacier motion(1-4). Subglacial water is known to occupy systems of cavities and conduits at the interface between ice and the underlying bed surface, depending upon the history of water input and the characteristics of the substrate(5). Full understanding of the extent and configuration of basal water is lacking, however, because direct observation is difficult. This limits our ability to simulate ice dynamics and the subsequent impacts on sea-level rise realistically. Here we show that the subglacial hydrological system can have a large volume of water occupying basal crevasses that extend upward from the bed into the overlying ice. Radar and seismic imaging combined with in situ borehole measurements collected on Bench Glacier, Alaska, reveal numerous water-filled basal crevasses with highly transmissive connections to the bed. Some crevasses extend many tens of metres above the bed and together they hold a volume of water equivalent to at least a decimetre layer covering the bed. Our results demonstrate that the basal hydrologic system can extend high into the overlying ice mass, where basal crevasses increase water-storage capacity and could potentially modulate basal water pressure. Because basal crevasses can form under commonly observed glaciological conditions, our findings have implications for interpreting and modelling subglacial hydrologic processes and related sliding accelerations of glaciers and ice sheets.	[Harper, Joel T.; Meierbachtol, Toby W.] Univ Montana, Dept Geosci, Missoula, MT 59812 USA; [Bradford, John H.] Boise State Univ, Ctr Geophys Invest Shallow Subsurface, Boise, ID 83725 USA; [Humphrey, Neil F.] Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA	University of Montana System; University of Montana; Idaho; Boise State University; University of Wyoming	Harper, JT (corresponding author), Univ Montana, Dept Geosci, Missoula, MT 59812 USA.	joel@mso.umt.edu		humphrey, neil/0000-0002-5175-2080; Harper, Joel/0000-0002-2151-8509	US National Science Foundation Office; Arctic Natural Sciences	US National Science Foundation Office(National Science Foundation (NSF)); Arctic Natural Sciences	This work was funded by the US National Science Foundation Office of Polar Programs, Arctic Natural Sciences.	Anderson RS, 2004, J GEOPHYS RES-EARTH, V109, DOI 10.1029/2004JF000120; Boon S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018034; Brown J, 2009, EARTH SURF PROC LAND, V34, P1497, DOI 10.1002/esp.1835; Clarke TS, 2000, J GEOPHYS RES-SOL EA, V105, P13409, DOI 10.1029/2000JB900037; Das SB, 2008, SCIENCE, V320, P778, DOI 10.1126/science.1153360; ENGELHARDT H, 1990, SCIENCE, V248, P57, DOI 10.1126/science.248.4951.57; Ensminger SL, 2001, J GLACIOL, V47, P412, DOI 10.3189/172756501781832007; Fountain AG, 1998, REV GEOPHYS, V36, P299, DOI 10.1029/97RG03579; Fountain AG, 2005, NATURE, V433, P618, DOI 10.1038/nature03296; Harper JT, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030233; Harper JT, 2001, J GEOPHYS RES-SOL EA, V106, P8547, DOI 10.1029/2000JB900440; HARPER JT, 1995, GEOLOGY, V23, P901, DOI 10.1130/0091-7613(1995)023<0901:BVAOAT>2.3.CO;2; Hodge SM, 1976, J GLACIOL, V16, P205; HOOKE RL, 1994, J GLACIOL, V40, P140; IKEN A, 1986, J GLACIOL, V32, P101, DOI 10.3189/S0022143000006936; IKEN A, 1993, J GLACIOL, V39, P15, DOI 10.3189/S0022143000015689; IKEN A, 1974, J GLACIOL, V58, P53; JANSSON P, 1995, J GLACIOL, V41, P232, DOI 10.3189/S0022143000016130; Krawczynski MJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036765; Lappegard G, 2006, J GLACIOL, V52, P137, DOI 10.3189/172756506781828908; Ling P, 2003, NEW ELECTRON, V36, P14; POHJOLA VA, 1994, J GLACIOL, V40, P231; Sugiyama S, 2004, J GLACIOL, V50, P353, DOI 10.3189/172756504781829846; van de Wal RSW, 2008, SCIENCE, V321, P111, DOI 10.1126/science.1158540; van der Veen CJ, 1998, COLD REG SCI TECHNOL, V27, P213, DOI 10.1016/S0165-232X(98)00006-8; Walder J., 1979, J GLACIOL, V23, P335, DOI DOI 10.1017/S0022143000029944; Woodward J, 2002, J QUATERNARY SCI, V17, P201, DOI 10.1002/jqs.673; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	28	53	53	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					579	582		10.1038/nature09398	http://dx.doi.org/10.1038/nature09398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882014	Green Published			2022-12-28	WOS:000282273100036
J	Sacks, FM; Carey, VJ; Fruchart, JC				Sacks, Frank M.; Carey, Vincent J.; Fruchart, Jean-Charles			Combination Lipid Therapy in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							DISEASE RISK		[Sacks, Frank M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Carey, Vincent J.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Fruchart, Jean-Charles] Fdn Heart & Arteries, Paris, France	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Sacks, FM (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	fsacks@hsph.harvard.edu						DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; Schlesinger Z, 2000, CIRCULATION, V102, P21, DOI 10.1161/01.CIR.102.1.21; Scott R, 2009, DIABETES CARE, V32, P493, DOI 10.2337/dc08-1543	5	158	162	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					692	694						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20842772				2022-12-28	WOS:000280764600018
J	Bhargava, P; Maki, JH				Bhargava, Puneet; Maki, Jeffrey H.			"Cotton Wool" Appearance of Paget's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bhargava, Puneet; Maki, Jeffrey H.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Bhargava, P (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.	bhargp@u.washington.edu		Bhargava, Puneet/0000-0002-3849-9666					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					E9	E9		10.1056/NEJMicm0912945	http://dx.doi.org/10.1056/NEJMicm0912945			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20836245				2022-12-28	WOS:000280552700012
J	Gonzalez-Suarez, E; Jacob, AP; Jones, J; Miller, R; Roudier-Meyer, MP; Erwert, R; Pinkas, J; Branstetter, D; Dougall, WC				Gonzalez-Suarez, Eva; Jacob, Allison P.; Jones, Jon; Miller, Robert; Roudier-Meyer, Martine P.; Erwert, Ryan; Pinkas, Jan; Branstetter, Dan; Dougall, William C.			RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis	NATURE			English	Article							HORMONE REPLACEMENT THERAPY; HUMAN BREAST-TUMORS; GLAND DEVELOPMENT; TRANSGENIC MICE; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN-LIGAND; CELL FUNCTION; RECEPTOR; EXPRESSION	RANK ligand (RANKL), a TNF-related molecule, is essential for osteoclast formation, function and survival through interaction with its receptor RANK(1,2). Mammary glands of RANK-and RANKL-deficient mice develop normally during sexual maturation, but fail to form lobuloalveolar structures during pregnancy because of defective proliferation and increased apoptosis of mammary epithelium(3). It has been shown that RANKL is responsible for the major proliferative response of mouse mammary epithelium to progesterone during mammary lactational morphogenesis(4), and in mouse models, manipulated to induce activation of the RANK/RANKL pathway in the absence of strict hormonal control, inappropriate mammary proliferation is observed(5,6). However, there is no evidence so far of a functional contribution of RANKL to tumorigenesis. Here we show that RANK and RANKL are expressed within normal, pre-malignant and neoplastic mammary epithelium, and using complementary gain-of-function (mouse mammary tumour virus (MMTV)-RANK transgenic mice) and loss-of function (pharmacological inhibition of RANKL) approaches, define a direct contribution of this pathway in mammary tumorigenesis. Accelerated pre-neoplasias and increased mammary tumour formation were observed in MMTV-RANK transgenic mice after multiparity or treatment with carcinogen and hormone (progesterone). Reciprocally, selective pharmacological inhibition of RANKL attenuated mammary tumour development not only in hormone-and carcinogen-treated MMTV-RANK and wild-type mice, but also in the MMTV-neu transgenic spontaneous tumour model. The reduction in tumorigenesis upon RANKL inhibition was preceded by a reduction in pre-neoplasias as well as rapid and sustained reductions in hormone-and carcinogen-induced mammary epithelial proliferation and cyclin D1 levels. Collectively, our results indicate that RANKL inhibition is acting directly on hormone-induced mammary epithelium at early stages in tumorigenesis, and the permissive contribution of progesterone to increased mammary cancer incidence is due to RANKL-dependent proliferative changes in the mammary epithelium. The current study highlights a potential role for RANKL inhibition in the management of proliferative breast disease.	[Gonzalez-Suarez, Eva; Jacob, Allison P.; Jones, Jon; Miller, Robert; Erwert, Ryan; Dougall, William C.] Amgen Inc, Dept Hematol Oncol Res, Seattle, WA 98119 USA; [Roudier-Meyer, Martine P.; Branstetter, Dan] Amgen Inc, Dept Pathol, Seattle, WA 98119 USA; [Pinkas, Jan] Amgen Inc, Dept Hematol Oncol Res, Cambridge, MA 02139 USA	Amgen; Amgen; Amgen	Dougall, WC (corresponding author), Amgen Inc, Dept Hematol Oncol Res, Seattle, WA 98119 USA.	dougallw@amgen.com	Gonzalez-Suarez, Eva/L-6298-2014	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Dougall, William/0000-0001-9487-251X				Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Aupperlee Mark, 2005, Breast Dis, V24, P37; Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fernandez-Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019; Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06; Greendale GA, 2003, J NATL CANCER I, V95, P30, DOI 10.1093/jnci/95.1.30; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hewitt SC, 2002, CANCER RES, V62, P2798; Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559; Holmberg L, 2008, JNCI-J NATL CANCER I, V100, P475, DOI 10.1093/jnci/djn058; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Klijn JGM, 2000, STEROIDS, V65, P825, DOI 10.1016/S0039-128X(00)00195-1; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0	28	396	408	0	43	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					103	+		10.1038/nature09495	http://dx.doi.org/10.1038/nature09495			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	20881963				2022-12-28	WOS:000283786900044
J	Lopes, I; Silk, J				Lopes, Ilidio; Silk, Joseph			Neutrino Spectroscopy Can Probe the Dark Matter Content in the Sun	SCIENCE			English	Article									[Lopes, Ilidio] Univ Tecn Lisboa, Inst Super Tecn, Dept Fis, Ctr Multidisciplinar Astrofis, P-1049001 Lisbon, Portugal; [Lopes, Ilidio] Univ Evora, Dept Fis, P-7000671 Evora, Portugal; [Silk, Joseph] Univ Oxford, Dept Phys, Oxford OX1 3RH, England; [Silk, Joseph] Inst Astrophys, F-75014 Paris, France	Universidade de Lisboa; Instituto Superior Tecnico; University of Evora; University of Oxford; UDICE-French Research Universities; Sorbonne Universite	Lopes, I (corresponding author), Univ Tecn Lisboa, Inst Super Tecn, Dept Fis, Ctr Multidisciplinar Astrofis, P-1049001 Lisbon, Portugal.	ilidio.lopes@ist.utl.pt	Lopes, Ilidio P/B-4170-2014	Lopes, Ilidio P/0000-0002-5011-9195; silk, joe/0000-0002-1566-8148	Fundacao para a Ciencia e a Tecnologia; Fundacao Calouste Gulbenkian; STFC [ST/H002456/1] Funding Source: UKRI; Science and Technology Facilities Council [ST/H002456/1] Funding Source: researchfish	Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Fundacao Calouste Gulbenkian(European Commission); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	While preparing this work, we benefited from the advice of J. Guzik, S. West, and J. Dias de Deus. I.L. acknowledges the financial support of Fundacao para a Ciencia e a Tecnologia and Fundacao Calouste Gulbenkian.	Aharmim B, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.111301; Arpesella C, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.091302; Bahcall JN, 2005, ASTROPHYS J, V621, pL85, DOI 10.1086/428929; Bertone G, 2005, PHYS REP, V405, P279, DOI 10.1016/j.physrep.2004.08.031; DEARBORN D, 1991, ASTROPHYS J, V368, P626, DOI 10.1086/169729; Garcia RA, 2007, SCIENCE, V316, P1591, DOI 10.1126/science.1140598; GIRAUDHERAUD Y, 1990, SOL PHYS, V128, P21, DOI 10.1007/BF00154144; Guzik JA, 2010, ASTROPHYS J, V713, P1108, DOI 10.1088/0004-637X/713/2/1108; Jungman G, 1996, PHYS REP, V267, P195, DOI 10.1016/0370-1573(95)00058-5; KAPLAN J, 1991, ASTROPHYS J, V378, P315, DOI 10.1086/170433; Lopes IP, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.151303; Turck-Chieze S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.211102; Turck-Chieze S, 2004, ASTROPHYS J, V604, P455, DOI 10.1086/381743; Turck-Chieze S, 2010, ASTROPHYS J, V715, P1539, DOI 10.1088/0004-637X/715/2/1539	14	29	29	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2010	330	6003					462	462		10.1126/science.1196564	http://dx.doi.org/10.1126/science.1196564			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	669EL	20829450				2022-12-28	WOS:000283329100027
J	McCoy, SI; Watts, CH; Padian, NS				McCoy, Sandra I.; Watts, Charlotte H.; Padian, Nancy S.			Preventing HIV infection: turning the tide for young women	LANCET			English	Editorial Material									[McCoy, Sandra I.; Padian, Nancy S.] Univ Calif Berkeley, Inst Business & Econ Res, Berkeley, CA 94720 USA; [Watts, Charlotte H.] London Sch Hyg & Trop Med, London WC1, England; [Padian, Nancy S.] US Presidents Emergency Plan AIDS Relief, Off Global AIDS Coordinator, Washington, DC USA	University of California System; University of California Berkeley; University of London; London School of Hygiene & Tropical Medicine	McCoy, SI (corresponding author), Univ Calif Berkeley, Inst Business & Econ Res, Berkeley, CA 94720 USA.	smccoy@berkeley.edu						BAIRD S, 2010, 18 INT AIDS C VIENN; *CAPRISA, 2010, STUD MICR GEL SHOWS; Cates W, 2010, LANCET, V376, P495, DOI 10.1016/S0140-6736(10)61200-7; Cowan F, 2009, CURR OPIN HIV AIDS, V4, P288, DOI 10.1097/COH.0b013e32832c7d10; DEWALQUE D, 2010, 18 INT AIDS C VIENN; *JOINT UN PROGR HI, 2009, AIDS EP UPD; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SA, 2009, 16 C RETR OPP INF MO; KOHLER HP, 2009, FINANCIAL INCENTIVES; MAVEDZENGE SN, 2010, HIV PREVENTION YOUNG; McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0; Padian NS, 2010, AIDS, V24, P621, DOI 10.1097/QAD.0b013e328337798a; STIRLING M, 2008, ADDRESSING VULNERABI; *WORLD BANK, 2010, DAT RES MAL TANZ RES	14	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 16	2010	376	9749					1281	1282		10.1016/S0140-6736(10)61309-8	http://dx.doi.org/10.1016/S0140-6736(10)61309-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	671RX	20851461				2022-12-28	WOS:000283528600007
J	Dorff, TB; Quinn, DI				Dorff, Tanya B.; Quinn, David I.			Cabazitaxel in prostate cancer: stretching a string	LANCET			English	Editorial Material							MITOXANTRONE PLUS PREDNISONE; ABIRATERONE ACETATE; DOCETAXEL; IMMUNOTHERAPY; CHEMOTHERAPY; TRIAL		[Dorff, Tanya B.; Quinn, David I.] Univ So Calif, Kenneth J Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90033 USA	University of Southern California	Quinn, DI (corresponding author), Univ So Calif, Kenneth J Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90033 USA.	diquinn@usc.edu	Quinn, David/N-3730-2019; Quinn, David I/F-4343-2015	Quinn, David/0000-0002-1411-0417; Quinn, David I/0000-0002-1411-0417				Danila DC, 2010, J CLIN ONCOL, V28, P1496, DOI 10.1200/JCO.2009.25.9259; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Fong L, 2009, CANCER RES, V69, P609, DOI 10.1158/0008-5472.CAN-08-3529; James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464-410X.2010.09638.x; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Mita AC, 2009, CLIN CANCER RES, V15, P723, DOI 10.1158/1078-0432.CCR-08-0596; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Rosenberg JE, 2007, CANCER-AM CANCER SOC, V110, P556, DOI 10.1002/cncr.22811; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720	14	13	17	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2010	376	9747					1119	1120		10.1016/S0140-6736(10)61510-3	http://dx.doi.org/10.1016/S0140-6736(10)61510-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888974				2022-12-28	WOS:000282915700004
J	Pietra, S; Grebe, M				Pietra, Stefano; Grebe, Markus			Auxin Paves the Way for Planar Morphogenesis	CELL			English	Editorial Material							ARABIDOPSIS; POLARITY		[Pietra, Stefano; Grebe, Markus] Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, SE-90187 Umea, Sweden	Umea University	Grebe, M (corresponding author), Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, SE-90187 Umea, Sweden.	markus.grebe@plantphys.umu.se		Grebe, Markus/0000-0001-7571-0670; Pietra, Stefano/0000-0003-4417-8153				Fischer U, 2006, CURR BIOL, V16, P2143, DOI 10.1016/j.cub.2006.08.091; Fu Y, 2005, CELL, V120, P687, DOI 10.1016/j.cell.2004.12.026; Fu Y, 2009, CURR BIOL, V19, P1827, DOI 10.1016/j.cub.2009.08.052; Hazak O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000282; Kleine-Vehn J, 2008, ANNU REV CELL DEV BI, V24, P447, DOI 10.1146/annurev.cellbio.24.110707.175254; Mockaitis K, 2008, ANNU REV CELL DEV BI, V24, P55, DOI 10.1146/annurev.cellbio.23.090506.123214; Robert S, 2010, CELL, V143, P111, DOI 10.1016/j.cell.2010.09.027; Tromas A, 2010, TRENDS PLANT SCI, V15, P436, DOI 10.1016/j.tplants.2010.05.001; Xu TD, 2010, CELL, V143, P99, DOI 10.1016/j.cell.2010.09.003; Yang ZB, 2008, ANNU REV CELL DEV BI, V24, P551, DOI 10.1146/annurev.cellbio.23.090506.123233	10	4	5	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					29	31		10.1016/j.cell.2010.09.029	http://dx.doi.org/10.1016/j.cell.2010.09.029			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887889	Bronze			2022-12-28	WOS:000282362000010
J	Ghaffari, S; Pourafkari, L				Ghaffari, Samad; Pourafkari, Leili			Aortic Dissection during Diagnostic Aortography	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ghaffari, Samad; Pourafkari, Leili] TBZ Univ Med Sci, Tabriz, Iran		Ghaffari, S (corresponding author), TBZ Univ Med Sci, Tabriz, Iran.		pourafkari, leili/M-5760-2017	Ghaffari, Samad/0000-0001-6806-9387					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					E18	E18		10.1056/NEJMicm1002666	http://dx.doi.org/10.1056/NEJMicm1002666			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20872991				2022-12-28	WOS:000282050000011
J	Lansdorp-Vogelaar, I; Kuntz, KM; Knudsen, AB; Wilschut, JA; Zauber, AG; van Ballegooijen, M				Lansdorp-Vogelaar, Iris; Kuntz, Karen M.; Knudsen, Amy B.; Wilschut, Janneke A.; Zauber, Ann G.; van Ballegooijen, Marjolein			Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population A Cost-Effectiveness Analysis	ANNALS OF INTERNAL MEDICINE			English	Article							FECAL OCCULT-BLOOD; LARGE-INTESTINE; LARGE-BOWEL; COLONOSCOPY; POLYPS; SURVEILLANCE; GUIDELINES; SOCIETY; PATIENT; UPDATE	Background: The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees. Objective: To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services. Design: Comparative microsimulation modeling study using 2 independently developed models. Data Sources: Derived from literature. Target Population: A cohort of persons aged 65 years. A sensitivity analysis was also conducted, in which a cohort of persons aged 50 years was studied. Time Horizon: Lifetime. Perspective: Third-party payer. Intervention: Stool DNA test every 3 or 5 years in comparison with currently recommended colorectal cancer screening strategies. Outcome Measures: Life expectancy, lifetime costs, incremental cost-effectiveness ratios, and threshold costs. Results of Base-Case Analysis: Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies. Screening with the stool DNA test would be cost-effective at a per-test cost of $40 to $60 for stool DNA testing every 3 years, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing every 3 years would be cost-effective at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50% better than that with other screening tests. Results of Sensitivity Analysis: None of the results changed substantially when a cohort of persons aged 50 years was considered. Limitation: No pathways other than the traditional adenoma-carcinoma sequence were modeled. Conclusion: Stool DNA testing could be a cost-effective alternative for colorectal cancer screening if the cost of the test substantially decreased or if its availability would entice a large fraction of otherwise unscreened persons to receive screening.	[Lansdorp-Vogelaar, Iris; Wilschut, Janneke A.; van Ballegooijen, Marjolein] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Lansdorp-Vogelaar, I (corresponding author), Erasmus MC, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	i.vogelaar@erasmusmc.nl		Wilschut, Janneke/0000-0002-4921-227X	Agency for Healthcare Research and Quality [HHSP233200700123P, HHSP233200700196P, HHSP233200700350P]; National Cancer Institute [U01-CA-088204, U01-CA-097426, U01-CA-115953]; NATIONAL CANCER INSTITUTE [U01CA115953, P30CA008748, U01CA097426, U01CA088204] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	By the Agency for Healthcare Research and Quality (HHSP233200700123P, HHSP233200700196P, HHSP233200700350P) and the National Cancer Institute (U01-CA-088204, U01-CA-097426, and U01-CA-115953).	Ahlquist DA, 2008, ANN INTERN MED, V149, P441, DOI 10.7326/0003-4819-149-7-200810070-00004; Allison JE, 2007, JNCI-J NATL CANCER I, V99, P1462, DOI 10.1093/jnci/djm150; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; BOMBI JA, 1988, CANCER-AM CANCER SOC, V61, P1472, DOI 10.1002/1097-0142(19880401)61:7<1472::AID-CNCR2820610734>3.0.CO;2-E; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; Chung DC, 2008, ANN INTERN MED, V149, P509, DOI 10.7326/0003-4819-149-7-200810070-00013; CLARK JC, 1985, INT J CANCER, V36, P179, DOI 10.1002/ijc.2910360209; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; *EX SCI CORP, 2010, EX SCI CORP ANN REP; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; Gold MR, 1996, COST EFFECTIVENESS H; Imperiale TF, 2004, NEW ENGL J MED, V351, P2704, DOI 10.1056/NEJMoa033403; Itzkowitz S, 2008, AM J GASTROENTEROL, V103, P2862, DOI 10.1111/j.1572-0241.2008.02088.x; Itzkowitz SH, 2007, CLIN GASTROENTEROL H, V5, P111, DOI 10.1016/j.cgh.2006.10.006; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; JASS JR, 1992, GUT, V33, P1508, DOI 10.1136/gut.33.11.1508; JOHANNSEN LGK, 1989, SCAND J GASTROENTERO, V24, P799, DOI 10.3109/00365528909089217; KNUDSEN A, 2005, THESIS HARVARD U; Lansdorp-Vogelaar I, 2009, CANCER-AM CANCER SOC, V115, P2410, DOI 10.1002/cncr.24256; Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002; Levin TR, 2006, ANN INTERN MED, V145, P880, DOI 10.7326/0003-4819-145-12-200612190-00004; Levin TR, 2002, GASTROENTEROLOGY, V123, P1786, DOI 10.1053/gast.2002.37064; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Loeve F, 1999, COMPUT BIOMED RES, V32, P13, DOI 10.1006/cbmr.1998.1498; Loeve F, 2000, J NATL CANCER I, V92, P557, DOI 10.1093/jnci/92.7.557; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434; Mark DH, 2002, JAMA-J AM MED ASSOC, V287, P2428, DOI 10.1001/jama.287.18.2428; Morikawa T, 2005, GASTROENTEROLOGY, V129, P422, DOI 10.1053/j.gastro.2005.05.056; Morikawa T, 2007, AM J GASTROENTEROL, V102, P2259, DOI 10.1111/j.1572-0241.2007.01404.x; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; PERRONE M, 2007, GOVT OFFICIALS WILL; Pox C, 2007, ENDOSCOPY, V39, P168, DOI 10.1055/s-2007-966182; Regula J, 2006, NEW ENGL J MED, V355, P1863, DOI 10.1056/NEJMoa054967; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; Schroy PC, 2007, AM J MANAG CARE, V13, P393; Schroy PC, 2005, AM J PREV MED, V28, P208, DOI 10.1016/j.amepre.2004.10.008; Shapiro JA, 2008, CANCER EPIDEM BIOMAR, V17, P1623, DOI 10.1158/1055-9965.EPI-07-2838; Smith RA, 2006, CA-CANCER J CLIN, V56, P11, DOI 10.3322/canjclin.56.1.11; Song K, 2004, GASTROENTEROLOGY, V126, P1270, DOI 10.1053/j.gastro.2004.02.016; Syngal S, 2006, CANCER, V106, P277, DOI 10.1002/cncr.21558; Tagore Kuldeep S, 2003, Clin Colorectal Cancer, V3, P47, DOI 10.3816/CCC.2003.n.011; *US CENS BUR, 2010, US POP PROJ; *US PREV SERV TASK, 2008, ANN INT MED, V149; van Rijn JC, 2006, AM J GASTROENTEROL, V101, P343, DOI 10.1111/j.1572-0241.2006.00390.x; VANBALLEGOOIJEN M, 2008, REPORT AGENCY HEALTH; VATN MH, 1982, CANCER, V49, P819, DOI 10.1002/1097-0142(19820215)49:4<819::AID-CNCR2820490435>3.0.CO;2-D; Warren JL, 2009, ANN INTERN MED, V150, P849, DOI 10.7326/0003-4819-150-12-200906160-00008; Whitney D, 2004, J MOL DIAGN, V6, P386, DOI 10.1016/S1525-1578(10)60536-3; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Winawer SJ, 2006, GASTROENTEROLOGY, V130, P1872, DOI 10.1053/j.gastro.2006.03.012; Wu GHM, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-136; Yabroff KR, 2008, JNCI-J NATL CANCER I, V100, P630, DOI 10.1093/jnci/djn103; ZAUBER A, 2000, EFFECTIVENESS DNA ST; 2002, 59100 FED REG	57	58	58	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					368	377		10.7326/0003-4819-153-6-201009210-00004	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855801				2022-12-28	WOS:000282043100003
J	Peruzzo, A; Lobino, M; Matthews, JCF; Matsuda, N; Politi, A; Poulios, K; Zhou, XQ; Lahini, Y; Ismail, N; Worhoff, K; Bromberg, Y; Silberberg, Y; Thompson, MG; O'Brien, JL				Peruzzo, Alberto; Lobino, Mirko; Matthews, Jonathan C. F.; Matsuda, Nobuyuki; Politi, Alberto; Poulios, Konstantinos; Zhou, Xiao-Qi; Lahini, Yoav; Ismail, Nur; Worhoff, Kerstin; Bromberg, Yaron; Silberberg, Yaron; Thompson, Mark G.; O'Brien, Jeremy L.			Quantum Walks of Correlated Photons	SCIENCE			English	Article							EXPERIMENTAL REALIZATION	Quantum walks of correlated particles offer the possibility of studying large-scale quantum interference; simulating biological, chemical, and physical systems; and providing a route to universal quantum computation. We have demonstrated quantum walks of two identical photons in an array of 21 continuously evanescently coupled waveguides in a SiOxNy chip. We observed quantum correlations, violating a classical limit by 76 standard deviations, and found that the correlations depended critically on the input state of the quantum walk. These results present a powerful approach to achieving quantum walks with correlated particles to encode information in an exponentially larger state space.	[Peruzzo, Alberto; Lobino, Mirko; Matthews, Jonathan C. F.; Politi, Alberto; Poulios, Konstantinos; Zhou, Xiao-Qi; Thompson, Mark G.; O'Brien, Jeremy L.] Univ Bristol, HH Wills Phys Lab, Ctr Quantum Photon, Bristol BS8 1UB, Avon, England; [Peruzzo, Alberto; Lobino, Mirko; Matthews, Jonathan C. F.; Politi, Alberto; Poulios, Konstantinos; Zhou, Xiao-Qi; Thompson, Mark G.; O'Brien, Jeremy L.] Univ Bristol, Dept Elect & Elect Engn, Bristol BS8 1UB, Avon, England; [Matsuda, Nobuyuki] Tohoku Univ, Res Inst Elect Commun, Sendai, Miyagi 9808577, Japan; [Lahini, Yoav; Bromberg, Yaron; Silberberg, Yaron] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; [Ismail, Nur; Worhoff, Kerstin] Univ Twente, MESA Inst Nanotechnol, Integrated Opt Microsyst Grp, NL-7500 AE Enschede, Netherlands	University of Bristol; University of Bristol; Tohoku University; Weizmann Institute of Science; University of Twente	O'Brien, JL (corresponding author), Univ Bristol, HH Wills Phys Lab, Ctr Quantum Photon, Merchant Venturers Bldg,Woodland Rd, Bristol BS8 1UB, Avon, England.	jeremy.obrien@bristol.ac.uk	ismail, Nur/B-6121-2012; Matthews, Jonathan/D-7129-2011; Zhou, Xiaoqi/A-5471-2011; Lahini, Yoav/Q-9223-2017; SILBERBERG, YARON/K-1564-2012; Lobino, Mirko/C-6503-2008; Politi, Alberto/D-7134-2011; Bromberg, Yaron/L-5447-2019; Lahini, Yoav/G-3425-2011; O'Brien, Jeremy L/A-6290-2008; Bromberg, Yaron/F-6570-2010; Ismail, Nur/AAB-9203-2020; Poulios, Konstantinos/K-5105-2015; Peruzzo, Alberto/E-2113-2011; Matsuda, Nobuyuki/T-2724-2019	Matthews, Jonathan/0000-0001-6184-1813; Zhou, Xiaoqi/0000-0003-4534-0474; Lobino, Mirko/0000-0001-8091-8951; Politi, Alberto/0000-0002-3668-9474; Bromberg, Yaron/0000-0003-2565-7394; Bromberg, Yaron/0000-0003-2565-7394; Ismail, Nur/0000-0002-6981-2037; Poulios, Konstantinos/0000-0003-4102-0297; Peruzzo, Alberto/0000-0002-7953-3875; /0000-0002-1266-4678; Thompson, Mark/0000-0002-2865-9558; O'Brien, Jeremy/0000-0002-3576-8285; Lahini, Yoav/0000-0002-5952-7144; Matsuda, Nobuyuki/0000-0001-6014-3570	Engineering and Physical Sciences Research Council; European Research Council; EU; Leverhulme Trust; Centre for Nanoscience and Quantum Information; Japan Society for the Promotion of Science; Royal Society; EPSRC [EP/F008023/1, EP/F010524/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/F010524/1, EP/F008023/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); European Research Council(European Research Council (ERC)European Commission); EU(European Commission); Leverhulme Trust(Leverhulme Trust); Centre for Nanoscience and Quantum Information; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Royal Society(Royal Society of London); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We thank N. Brunner, A. Laing, T. Rudolph, and J. Twamley for helpful discussions. This work was supported by Engineering and Physical Sciences Research Council, European Research Council, EU-FP7 project "Quantum Integrated Photonics", Quantum Information Processing Interdisciplinary Research, Intelligence Advanced Research Projects Activity, the Leverhulme Trust, Centre for Nanoscience and Quantum Information, and the Japan Society for the Promotion of Science. J. L. OB. acknowledges a Royal Society Wolfson Merit Award.	AHARONOV Y, 1993, PHYS REV A, V48, P1687, DOI 10.1103/PhysRevA.48.1687; Bouwmeester D, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.013410; Bromberg Y, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.253904; Childs AM, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.022314; CHILDS AM, 2003, STOC 03, P59; Childs AM, 2010, COMMUN MATH PHYS, V294, P581, DOI 10.1007/s00220-009-0930-1; Childs AM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.180501; Do B, 2005, J OPT SOC AM B, V22, P499, DOI 10.1364/JOSAB.22.000499; ESTES LE, 1968, PHYS REV, V175, P286, DOI 10.1103/PhysRev.175.286; Farhi E, 1998, PHYS REV A, V58, P915, DOI 10.1103/PhysRevA.58.915; Gamble JK, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.052313; Karski M, 2009, SCIENCE, V325, P174, DOI 10.1126/science.1174436; Keating JP, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.012315; Kempe J, 2003, CONTEMP PHYS, V44, P307, DOI 10.1080/00107151031000110776; Knight PL, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.020301; Lahini Y, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.013906; Mackay TD, 2002, J PHYS A-MATH GEN, V35, P2745, DOI 10.1088/0305-4470/35/12/304; Marshall GD, 2009, OPT EXPRESS, V17, P12546, DOI 10.1364/OE.17.012546; Matthews JCF, 2009, NAT PHOTONICS, V3, P346, DOI 10.1038/NPHOTON.2009.93; MATTLE K, 1995, APPL PHYS B-LASERS O, V60, pS111; Mohseni M, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3002335; O'Brien JL, 2009, NAT PHOTONICS, V3, P687, DOI 10.1038/nphoton.2009.229; Omar Y, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.042304; Perets HB, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.170506; Plenio MB, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/11/113019; Politi A, 2008, SCIENCE, V320, P646, DOI 10.1126/science.1155441; Politi A, 2009, SCIENCE, V325, P1221, DOI 10.1126/science.1173731; RECK M, 1994, PHYS REV LETT, V73, P58, DOI 10.1103/PhysRevLett.73.58; Ryan CA, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.062317; Schmitz H, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.090504; Schreiber A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.050502; Smith BJ, 2006, PHYS REV A, V74, DOI [10.1103/PhysRevA.74.062104, 10.1103/PhysRevA.062104]; Zahringer F, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.100503	33	632	654	6	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1500	1503		10.1126/science.1193515	http://dx.doi.org/10.1126/science.1193515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847264	Green Published, Green Submitted			2022-12-28	WOS:000281869000034
J	Rossman, JS; Jing, XH; Leser, GP; Lamb, RA				Rossman, Jeremy S.; Jing, Xianghong; Leser, George P.; Lamb, Robert A.			Influenza Virus M2 Protein Mediates ESCRT-Independent Membrane Scission	CELL			English	Article							ION-CHANNEL PROTEIN; A-VIRUS; CYTOPLASMIC TAIL; PROTON CHANNEL; MATRIX PROTEIN; M1 PROTEIN; PLASMA-MEMBRANES; LIPID-BILAYERS; HEMAGGLUTININ; NEURAMINIDASE	Many viruses utilize host ESCRT proteins for budding; however, influenza virus budding is thought to be ESCRT-independent. In this study we have found a role for the influenza virus M2 proton-selective ion channel protein in mediating virus budding. We observed that a highly conserved amphipathic helix located within the M2 cytoplasmic tail mediates a cholesterol-dependent alteration in membrane curvature. The 17 amino acid amphipathic helix is sufficient for budding into giant unilamellar vesicles, and mutation of this sequence inhibited budding of transfected M2 protein in vivo. We show that M2 localizes to the neck of budding virions and that mutation of the M2 amphipathic helix results in failure of the virus to undergo membrane scission and virion release. These data suggest that M2 mediates the final steps of budding for influenza viruses, bypassing the need for host ESCRT proteins.	[Rossman, Jeremy S.; Jing, Xianghong; Leser, George P.; Lamb, Robert A.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; [Rossman, Jeremy S.; Lamb, Robert A.] Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University	Lamb, RA (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	ralamb@northwestern.edu		Rossman, Jeremy/0000-0001-6124-4103	National Institute of Allergy and Infectious Diseases [R01 AI-20201]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020201] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank members of the Lamb laboratory for helpful discussions and critical reading of the manuscript. The electron microscopy was performed in the Northwestern University Biological Imaging Facility. This research was supported in part by a grant R01 AI-20201 from the National Institute of Allergy and Infectious Diseases. J.S.R. is an Associate and R. A. L. is an Investigator of the Howard Hughes Medical Institute.	Allain JM, 2006, EUR PHYS J E, V20, P409, DOI 10.1140/epje/i2006-10030-4; Antonny B, 2006, CURR OPIN CELL BIOL, V18, P386, DOI 10.1016/j.ceb.2006.06.003; Barman S, 2004, J VIROL, V78, P5258, DOI 10.1128/JVI.78.10.5258-5269.2004; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bruce EA, 2010, J VIROL, V84, P5848, DOI 10.1128/JVI.00307-10; Bruce EA, 2009, VIROLOGY, V390, P268, DOI 10.1016/j.virol.2009.05.016; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; Carlton JG, 2009, BIOCHEM SOC T, V37, P195, DOI 10.1042/BST0370195; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; Chen BJ, 2008, J VIROL, V82, P10059, DOI 10.1128/JVI.01184-08; Chen BJ, 2008, VIROLOGY, V372, P221, DOI 10.1016/j.virol.2007.11.008; Chen BJ, 2007, J VIROL, V81, P7111, DOI 10.1128/JVI.00361-07; Chen BJ, 2005, J VIROL, V79, P13673, DOI 10.1128/JVI.79.21.13673-13684.2005; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Cheung TKW, 2005, J GEN VIROL, V86, P1447, DOI 10.1099/vir.0.80727-0; DE MEYER F, 2009, P NATL ACAD SCI USA, V106, P3654; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; Drin G, 2010, FEBS LETT, V584, P1840, DOI 10.1016/j.febslet.2009.10.022; Egashira M, 2002, BIOCHEMISTRY-US, V41, P4165, DOI 10.1021/bi011885+; Girard P, 2004, BIOPHYS J, V87, P419, DOI 10.1529/biophysj.104.040360; Iwatsuki-Horimoto K, 2006, J VIROL, V80, P5233, DOI 10.1128/JVI.00049-06; Jackson D, 2008, J GEN VIROL, V89, P3097, DOI 10.1099/vir.0.2008/004739-0; Jin H, 1997, EMBO J, V16, P1236, DOI 10.1093/emboj/16.6.1236; Kaiser HJ, 2009, P NATL ACAD SCI USA, V106, P16645, DOI 10.1073/pnas.0908987106; Keller H, 2009, CHEMPHYSCHEM, V10, P2805, DOI 10.1002/cphc.200900598; Lamaziere A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000201; Lamb R.F., 2005, CONT TOPICS INFLUENZ, P65; Lee MT, 2008, P NATL ACAD SCI USA, V105, P5087, DOI 10.1073/pnas.0710625105; Leser GP, 1996, MOL BIOL CELL, V7, P155, DOI 10.1091/mbc.7.1.155; Leser GP, 2005, VIROLOGY, V342, P215, DOI 10.1016/j.virol.2005.09.049; Lingwood D, 2008, P NATL ACAD SCI USA, V105, P10005, DOI 10.1073/pnas.0804374105; Liu J, 2006, P NATL ACAD SCI USA, V103, P10277, DOI 10.1073/pnas.0601045103; Ma CL, 2009, P NATL ACAD SCI USA, V106, P12283, DOI 10.1073/pnas.0905726106; McCown MF, 2006, J VIROL, V80, P8178, DOI 10.1128/JVI.00627-06; McCown MF, 2005, J VIROL, V79, P3595, DOI 10.1128/JVI.79.6.3595-3605.2005; Nguyen PA, 2008, BIOCHEMISTRY-US, V47, P9934, DOI 10.1021/bi801315m; Noton SL, 2007, J GEN VIROL, V88, P2280, DOI 10.1099/vir.0.82809-0; PATTNAIK AK, 1986, J VIROL, V60, P994, DOI 10.1128/JVI.60.3.994-1001.1986; Pinto LH, 2007, MOL BIOSYST, V3, P18, DOI 10.1039/b611613m; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; Romer W, 2010, CELL, V140, P540, DOI 10.1016/j.cell.2010.01.010; Rossman JS, 2010, J VIROL, V84, P5078, DOI 10.1128/JVI.00119-10; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Schnell JR, 2008, NATURE, V451, P591, DOI 10.1038/nature06531; Schroeder C, 2005, EUR BIOPHYS J BIOPHY, V34, P52, DOI 10.1007/s00249-004-0424-1; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Streicher P, 2009, BBA-BIOMEMBRANES, V1788, P2291, DOI 10.1016/j.bbamem.2009.07.025; Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.2235620100; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; VENKATACHALAPATHI, 1993, PROTEINS, V15, P349; Wollert T, 2009, NATURE, V458, P172, DOI 10.1038/nature07836; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; Zhang J, 1996, VIROLOGY, V225, P255, DOI 10.1006/viro.1996.0599	56	360	366	2	55	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					902	913		10.1016/j.cell.2010.08.029	http://dx.doi.org/10.1016/j.cell.2010.08.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850012	Green Accepted, Bronze			2022-12-28	WOS:000281855000013
J	Boyd, K; Murray, SA				Boyd, Kirsty; Murray, Scott A.			Spotlight: Palliative Care Beyond Cancer Recognising and managing key transitions in end of life care	BRITISH MEDICAL JOURNAL			English	Article							HEART-FAILURE; PREDICTION; DISEASE; INDEX		[Boyd, Kirsty; Murray, Scott A.] Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland	University of Edinburgh	Boyd, K (corresponding author), Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland.	Kirsty.Boyd@luht.scot.nhs.uk		Boyd, Kirsty/0000-0002-5526-1078				Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Department of Health, 2008, END LIF CAR STRAT AD; Fortin M, 2007, BMJ-BRIT MED J, V334, P1016, DOI 10.1136/bmj.39201.463819.2C; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Larson AM, 2006, JAMA-J AM MED ASSOC, V295, P2168, DOI 10.1001/jama.295.18.2168; Lau F, 2009, J PAIN SYMPTOM MANAG, V38, P134, DOI 10.1016/j.jpainsymman.2008.05.017; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Luhrs CA, 2005, J PAIN SYMPTOM MANAG, V29, P544, DOI 10.1016/j.jpainsymman.2005.02.010; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Munday D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2391; Murray SA, 2008, FAM PRACT, V25, P78, DOI 10.1093/fampra/cmn011; National Gold Standards Framework Centre, 2008, PROGN IND GUID PAP; NORTON SA, PROACTIVE PALLIATIVE; *ROYAL COLL PHYS, 2008, ADV CAR PLANN CONC E; *ROYAL COLL PHYS L, 2007, PALL CAR SERV M NEED; *SCOTT GOV HLTH DE, 2008, LIV DYING WELL NAT A; Selman L, 2007, HEART, V93, P963, DOI 10.1136/hrt.2006.106518; Shipman C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1720; Stone CA, 2008, J PAIN SYMPTOM MANAG, V35, P617, DOI 10.1016/j.jpainsymman.2007.07.006	21	126	127	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4863	10.1136/bmj.c4863	http://dx.doi.org/10.1136/bmj.c4863			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847023				2022-12-28	WOS:000282095800011
J	Kim, HJ; Verbinnen, B; Tang, XL; Lu, LR; Cantor, H				Kim, Hye-Jung; Verbinnen, Bert; Tang, Xiaolei; Lu, Linrong; Cantor, Harvey			Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance	NATURE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOIMMUNE-DISEASE; B-CELLS; SUPPRESSION; T-HELPER-2; GENERATION; EXPANSION; IL-15; IL-21; MICE	The ability to produce vigorous immune responses that spare self tissues and organs depends on the elimination of autoreactive T and B cells. However, purging of immature and mature self-reactive T and B cells is incomplete and may also require the involvement of cells programmed to suppress immune responses(1). Regulatory T cells (T-reg) belonging to the CD4(+) T-cell subset may have a role in preventing untoward inflammatory responses, but T-cell subsets programmed to inhibit the development of autoantibody formation and systemic-lupus-erythematosus-like disease have not yet been defined(2). Here we delineate a CD8(+) regulatory T-cell lineage that is essential for the maintenance of self tolerance and prevention of murine autoimmune disease. Genetic disruption of the inhibitory interaction between these CD8(+) T cells and their target Qa-1(+) follicular T-helper cells results in the development of a lethal systemic-lupus-erythematosus-like autoimmune disease. These findings define a sublineage of CD8 T cells programmed to suppress rather than activate immunity that represents an essential regulatory element of the immune response and a guarantor of self tolerance.	[Kim, Hye-Jung; Verbinnen, Bert; Tang, Xiaolei; Cantor, Harvey] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Kim, Hye-Jung; Verbinnen, Bert; Tang, Xiaolei; Cantor, Harvey] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Lu, Linrong] Zhejiang Univ, Sch Med, Inst Immunol, Hangzhou 310058, Zhejiang, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Zhejiang University	Cantor, H (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	Harvey_Cantor@dfci.harvard.edu	Lu, Linrong/A-1429-2013	Lu, Linrong/0000-0002-0171-4115; Tang, Xiaoren/0000-0002-2402-3659	NIH [AI 037562]; Lupus Research Institute; Schecter Research Foundation; National Research Service [DFCI/NCI T32 CA070083, HSPH/NCI T32 CA009382]; Belgian American Educational Foundation; NATIONAL CANCER INSTITUTE [T32CA070083, T32CA009382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037562] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lupus Research Institute; Schecter Research Foundation; National Research Service; Belgian American Educational Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank R. Bronson (DF/HCC Rodent Histopathology Core) for histology analysis, R. Gelman and J. Yang for help with statistical analyses, C. Daniel and T. Kreslavsky for cytometry support and critical discussions, M. Iannacone and U. von Andrian for LCMV, X. Wang for technical assistance, M. Call, D. A. Alvarez Arias, T. Kadakia and A. Angel for manuscript and figure preparation. This work was supported in part by NIH Research Grant AI 037562, the Lupus Research Institute and a gift from the Schecter Research Foundation to H.C.; National Research Service Award Fellowships (DFCI/NCI T32 CA070083) to H.-J.K. and (HSPH/NCI T32 CA009382) to X.T.; and a Belgian American Educational Foundation Fellowship to B.V.	Bubier JA, 2009, P NATL ACAD SCI USA, V106, P1518, DOI 10.1073/pnas.0807309106; Cantor H, 2004, NAT IMMUNOL, V5, P347, DOI 10.1038/ni0404-347; Cantor H, 2000, ADV IMMUNOL, V75, P209, DOI 10.1016/S0065-2776(00)75005-X; Chen WL, 2007, P NATL ACAD SCI USA, V104, P20472, DOI 10.1073/pnas.0709878104; Hao ZY, 2008, IMMUNITY, V29, P615, DOI 10.1016/j.immuni.2008.07.016; Hu D, 2004, NAT IMMUNOL, V5, P516, DOI 10.1038/ni1063; Hunziker L, 2003, NAT IMMUNOL, V4, P343, DOI 10.1038/ni911; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Lu LR, 2008, CELL MOL IMMUNOL, V5, P401, DOI 10.1038/cmi.2008.50; Lu LR, 2008, P NATL ACAD SCI USA, V105, P19420, DOI 10.1073/pnas.0810383105; Mitchell DM, 2010, J IMMUNOL, V184, P6719, DOI 10.4049/jimmunol.0904089; Noble A, 1998, J IMMUNOL, V160, P566; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Panoutsakopoulou V, 2001, IMMUNITY, V15, P137, DOI 10.1016/S1074-7613(01)00172-8; Ray SK, 1996, P NATL ACAD SCI USA, V93, P2019, DOI 10.1073/pnas.93.5.2019; Sangster MY, 2000, J IMMUNOL, V164, P1820, DOI 10.4049/jimmunol.164.4.1820; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Yurasov S, 2007, CURR OPIN RHEUMATOL, V19, P421, DOI 10.1097/BOR.0b013e328277ef3b; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057	23	254	280	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					328	U107		10.1038/nature09370	http://dx.doi.org/10.1038/nature09370			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844537	Green Accepted			2022-12-28	WOS:000281824900039
J	Brotherton, SE; Etzel, SI				Brotherton, Sarah E.; Etzel, Sylvia I.			Graduate Medical Education, 2009-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Brotherton, Sarah E.; Etzel, Sylvia I.] Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60654 USA	American Medical Association	Brotherton, SE (corresponding author), Amer Med Assoc, Div Grad Med Educ, 515 N State St, Chicago, IL 60654 USA.	sarah.brotherton@ama-assn.org	Deville, Curtiland/B-2819-2013	Deville, Curtiland/0000-0003-4846-6486					0	67	67	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1255	1270		10.1001/jama.2010.1273	http://dx.doi.org/10.1001/jama.2010.1273			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841543				2022-12-28	WOS:000281770600022
J	Barral, Y				Barral, Yves			Septins at the Nexus	SCIENCE			English	Editorial Material							PRIMARY CILIUM; CYTOSKELETON; BINDING; GTP		Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Barral, Y (corresponding author), Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.	yves.barral@bc.biol.ethz.ch		Barral, Yves/0000-0002-0989-3373				Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Caudron F, 2009, DEV CELL, V16, P493, DOI 10.1016/j.devcel.2009.04.003; Gerdes JM, 2009, CELL, V137, P32, DOI 10.1016/j.cell.2009.03.023; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Hu QC, 2010, SCIENCE, V329, P436, DOI 10.1126/science.1191054; Ihara M, 2005, DEV CELL, V8, P343, DOI 10.1016/j.devcel.2004.12.005; Kim SK, 2010, SCIENCE, V329, P1337, DOI 10.1126/science.1191184; Kissel H, 2005, DEV CELL, V8, P353, DOI 10.1016/j.devcel.2005.01.021; Tada T, 2007, CURR BIOL, V17, P1752, DOI 10.1016/j.cub.2007.09.039; Tanaka-Takiguchi Y, 2009, CURR BIOL, V19, P140, DOI 10.1016/j.cub.2008.12.030; Weirich CS, 2008, NAT REV MOL CELL BIO, V9, P478, DOI 10.1038/nrm2407; Xie YL, 2007, CURR BIOL, V17, P1746, DOI 10.1016/j.cub.2007.08.042; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3	13	8	8	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1289	1290		10.1126/science.1195445	http://dx.doi.org/10.1126/science.1195445			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829470				2022-12-28	WOS:000281657300019
J	Haurwitz, RE; Jinek, M; Wiedenheft, B; Zhou, KH; Doudna, JA				Haurwitz, Rachel E.; Jinek, Martin; Wiedenheft, Blake; Zhou, Kaihong; Doudna, Jennifer A.			Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease	SCIENCE			English	Article							IDENTIFICATION; DEFENSE; TRANSCRIPTION; RECOGNITION; SULFOLOBUS; COMPLEX	Many bacteria and archaea contain clustered regularly interspaced short palindromic repeats (CRISPRs) that confer resistance to invasive genetic elements. Central to this immune system is the production of CRISPR-derived RNAs (crRNAs) after transcription of the CRISPR locus. Here, we identify the endoribonuclease (Csy4) responsible for CRISPR transcript (pre-crRNA) processing in Pseudomonas aeruginosa. A 1.8 angstrom crystal structure of Csy4 bound to its cognate RNA reveals that Csy4 makes sequence-specific interactions in the major groove of the crRNA repeat stem-loop. Together with electrostatic contacts to the phosphate backbone, these enable Csy4 to bind selectively and cleave pre-crRNAs using phylogenetically conserved serine and histidine residues in the active site. The RNA recognition mechanism identified here explains sequence-and structure-specific processing by a large family of CRISPR-specific endoribonucleases.	[Haurwitz, Rachel E.; Jinek, Martin; Wiedenheft, Blake; Zhou, Kaihong; Doudna, Jennifer A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Wiedenheft, Blake; Zhou, Kaihong; Doudna, Jennifer A.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; [Doudna, Jennifer A.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Doudna, Jennifer A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Doudna, JA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	doudna@berkeley.edu	Jinek, Martin/E-6621-2011	Jinek, Martin/0000-0002-7601-210X	U.S. NIH [5 T32 GM08295]; Human Frontier Science Program; NSF; Bill and Melinda Gates Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008295] Funding Source: NIH RePORTER	U.S. NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier Science Program(Human Frontier Science Program); NSF(National Science Foundation (NSF)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank W. Westphal for help with purification of Csy4 constructs; J. van der Oost for discussion; J. Doudna Cate and members of the Doudna laboratory for critical reading of the manuscript; and C. Ralston and J. Holton (Beamlines 8.2.2 and 8.3.1, Advanced Light Source, Lawrence Berkeley National Laboratory) and S. Coyle for assistance with X-ray data collection. R.E.H. is supported by the U.S. NIH training grant 5 T32 GM08295. M.J. is supported by a Human Frontier Science Program Long-Term Fellowship. B. W. is a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation. This work was supported in part by grants from NSF and the Bill and Melinda Gates Foundation. J.A.D. is a Howard Hughes Medical Institute Investigator. Coordinates and structure factors for the Csy4-crRNA complex have been deposited in the Protein Data Bank under accession codes 2xli, 2xlj, and 2xlk. The authors have filed a related patent.	Anand K, 2008, NAT STRUCT MOL BIOL, V15, P1287, DOI 10.1038/nsmb.1513; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Brouns SJJ, 2008, SCIENCE, V321, P960, DOI 10.1126/science.1159689; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; Carte J, 2008, GENE DEV, V22, P3489, DOI 10.1101/gad.1742908; Ebihara A, 2006, PROTEIN SCI, V15, P1494, DOI 10.1110/ps.062131106; Grissa I, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-172; HAIT DH, 2005, PLOS COMPUT BIOL, V1, pE60; Hale CR, 2009, CELL, V139, P945, DOI 10.1016/j.cell.2009.07.040; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huppler A, 2002, NAT STRUCT BIOL, V9, P431, DOI 10.1038/nsb800; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; Kunin V, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r61; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; Lillestol Reidun K., 2006, Archaea, V2, P59, DOI 10.1155/2006/542818; Lillestol RK, 2009, MOL MICROBIOL, V72, P259, DOI 10.1111/j.1365-2958.2009.06641.x; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Marraffini LA, 2010, NAT REV GENET, V11, P181, DOI 10.1038/nrg2749; Marraffini LA, 2008, SCIENCE, V322, P1843, DOI 10.1126/science.1165771; Tang TH, 2005, MOL MICROBIOL, V55, P469, DOI 10.1111/j.1365-2958.2004.04428.x; Tang TH, 2002, P NATL ACAD SCI USA, V99, P7536, DOI 10.1073/pnas.112047299; van der Oost J, 2009, TRENDS BIOCHEM SCI, V34, P401, DOI 10.1016/j.tibs.2009.05.002; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026	23	459	559	10	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1355	1358		10.1126/science.1192272	http://dx.doi.org/10.1126/science.1192272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829488	Green Accepted			2022-12-28	WOS:000281657300042
J	Niles, PB; Boynton, WV; Hoffman, JH; Ming, DW; Hamara, D				Niles, Paul B.; Boynton, William V.; Hoffman, John H.; Ming, Douglas W.; Hamara, Dave			Stable Isotope Measurements of Martian Atmospheric CO2 at the Phoenix Landing Site	SCIENCE			English	Article							ALLAN HILLS 84001; SNC METEORITES; WEATHERING PRODUCTS; VOLATILE EVOLUTION; CALCIUM-CARBONATE; MARS; OXYGEN; EETA-79001; ALH84001; RATIOS	Carbon dioxide is a primary component of the martian atmosphere and reacts readily with water and silicate rocks. Thus, the stable isotopic composition of CO2 can reveal much about the history of volatiles on the planet. The Mars Phoenix spacecraft measurements of carbon isotopes [referenced to the Vienna Pee Dee belemnite (VPDB)] [delta C-13(VPDB) = -2.5 +/- 4.3 per mil (parts per thousand)] and oxygen isotopes [referenced to the Vienna standard mean ocean water (VSMOW)] (delta O-18(VSMOW) = 31.0 +/- 5.7 parts per thousand), reported here, indicate that CO2 is heavily influenced by modern volcanic degassing and equilibration with liquid water. When combined with data from the martian meteorites, a general model can be constructed that constrains the history of water, volcanism, atmospheric evolution, and weathering on Mars. This suggests that low-temperature water-rock interaction has been dominant throughout martian history, carbonate formation is active and ongoing, and recent volcanic degassing has played a substantial role in the composition of the modern atmosphere.	[Niles, Paul B.; Ming, Douglas W.] NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; [Boynton, William V.; Hamara, Dave] Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA; [Hoffman, John H.] Univ Texas Dallas, Dept Phys, Dallas, TX 75080 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of Arizona; University of Texas System; University of Texas Dallas	Niles, PB (corresponding author), NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA.	paul.b.niles@nasa.gov						Borg LE, 1999, SCIENCE, V286, P90, DOI 10.1126/science.286.5437.90; Boynton WV, 2009, SCIENCE, V325, P61, DOI 10.1126/science.1172768; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; Encrenaz T, 2005, ICARUS, V179, P43, DOI 10.1016/j.icarus.2005.06.022; Faure G., 1986, PRINCIPLES ISOTOPE G, V2nd; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; Hoffman JH, 2008, J AM SOC MASS SPECTR, V19, P1377, DOI 10.1016/j.jasms.2008.07.015; Holland G, 2005, GEOCHIM COSMOCHIM AC, V69, P1359, DOI 10.1016/j.gca.2004.08.023; HUNTEN DM, 1987, ICARUS, V69, P532, DOI 10.1016/0019-1035(87)90022-4; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; Jakosky BM, 1999, ORIGINS LIFE EVOL B, V29, P47, DOI 10.1023/A:1006586319129; Jull AJT, 2000, GEOCHIM COSMOCHIM AC, V64, P3763, DOI 10.1016/S0016-7037(00)00458-0; Jull AJT, 1998, SCIENCE, V279, P366, DOI 10.1126/science.279.5349.366; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Krasnopolsky VA, 1996, ICARUS, V124, P553, DOI 10.1006/icar.1996.0230; Krasnopolsky VA, 2007, ICARUS, V192, P396, DOI 10.1016/j.icarus.2007.08.013; NIER AO, 1976, SCIENCE, V194, P68, DOI 10.1126/science.194.4260.68; Niles PB, 2005, GEOCHIM COSMOCHIM AC, V69, P2931, DOI 10.1016/j.gca.2004.12.012; Nyquist LE, 2001, SPACE SCI REV, V96, P105, DOI 10.1023/A:1011993105172; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; Rao MN, 1999, GEOPHYS RES LETT, V26, P3265, DOI 10.1029/1999GL005388; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SCHREY U, 1986, ASTRON ASTROPHYS, V155, P200; Swindle TD, 2000, METEORIT PLANET SCI, V35, P107, DOI 10.1111/j.1945-5100.2000.tb01978.x; WALKER JCG, 1989, GEOPHYS RES LETT, V16, P323, DOI 10.1029/GL016i004p00323; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; WRIGHT IP, 1988, GEOCHIM COSMOCHIM AC, V52, P917, DOI 10.1016/0016-7037(88)90362-6; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W	30	49	51	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1334	1337		10.1126/science.1192863	http://dx.doi.org/10.1126/science.1192863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829484				2022-12-28	WOS:000281657300036
J	Gandhi, TK; Lee, TH				Gandhi, Tejal K.; Lee, Thomas H.			Patient Safety beyond the Hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gandhi, Tejal K.; Lee, Thomas H.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Gandhi, Tejal K.; Lee, Thomas H.] Partners Healthcare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Gandhi, TK (corresponding author), Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA.							Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; McKinsey and Company Global Institute, 2008, ACC COST US HEALTHC; National Center for Health Statistics, FASTSTATS A Z; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; Wachter RM, 2006, ANN INTERN MED, V145, P547, DOI 10.7326/0003-4819-145-7-200610030-00014	5	72	72	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1001	1003		10.1056/NEJMp1003294	http://dx.doi.org/10.1056/NEJMp1003294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647HS	20825311				2022-12-28	WOS:000281609700003
J	Kaveri, SV; Mouthon, L; Bayry, J				Kaveri, Srini V.; Mouthon, Luc; Bayry, Jagadeesh			Basophils and Nephritis in Lupus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ERYTHEMATOSUS		[Kaveri, Srini V.; Bayry, Jagadeesh] Univ Paris 06, INSERM, Ctr Rech Cordeliers, Paris, France; [Mouthon, Luc] Univ Paris 05, INSERM, Inst Cochin & Pole Med Interne, AP HP, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bayry, J (corresponding author), Univ Paris 06, INSERM, Ctr Rech Cordeliers, Paris, France.		Bayry, Jagadeesh/A-6589-2011	Bayry, Jagadeesh/0000-0003-0498-9808; Kaveri, Srini/0000-0002-0837-4053				Atta AM, 2010, INT ARCH ALLERGY IMM, V152, P401, DOI 10.1159/000288293; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Crispin JC, 2010, TRENDS MOL MED, V16, P47, DOI 10.1016/j.molmed.2009.12.005; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297	4	25	27	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1080	1082		10.1056/NEJMcibr1006936	http://dx.doi.org/10.1056/NEJMcibr1006936			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825323				2022-12-28	WOS:000281609700015
J	Dudzinski, DM; Hebert, PC; Foglia, MB; Gallagher, TH				Dudzinski, Denise M.; Hebert, Philip C.; Foglia, Mary Beth; Gallagher, Thomas H.			The Disclosure Dilemma - Large-Scale Adverse Events	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; TRANSMISSION; FAILURE; ERRORS; RISK		[Dudzinski, Denise M.] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA 98195 USA; [Foglia, Mary Beth] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Gallagher, Thomas H.] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA; [Dudzinski, Denise M.] Univ Washington, Med Ctr, Ethics Consultat Serv, Seattle, WA 98195 USA; [Hebert, Philip C.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Family & Community Med, Toronto, ON, Canada; [Hebert, Philip C.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Joint Ctr Bioeth, Toronto, ON, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Dudzinski, DM (corresponding author), Univ Washington, Sch Med, Dept Bioeth & Humanities, Box 357120, Seattle, WA 98195 USA.	dudzin@uw.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS016506] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALLEN M, 2008, LAS VEGAS SUN   0302; *AM SOC GASTR END, 2008, GASTROINTEST ENDOSC, V67, P780; APPELBY J, 2003, US TODAY        0102; Bails J., 2005, PITTSBURGH TRIB 0401; BOGDANICH W, 2009, NY TIMES        0620; CAMERON MA, 2009, REPORT COMMISSION IN; Caulfield T, 1997, CAN MED ASSOC J, V157, P1389; Chafe R, 2009, CAN MED ASSOC J, V180, P1125, DOI 10.1503/cmaj.081016; COLLINS LM, 2006, DESERET MORNING 0120; *CTR DIS CONTR PRE, CJD CREUTZF DIS CLAS; DAVIES P, 2004, WALL STREET J   1224; *DEP HLTH SOC SERV, 2005, REP IND REV END DEC; *DEP VET AFF, 2009, VA COUNTR NOT PROC V; *DEP VET AFF OFF I, 2009, HEALTHC INSP FOLL UP; *DISC WORK GROUP, 2008, CAN DISCL GUID EDM; DONNELLAN E, 2009, IRISH TIMES     1102; Gallagher TH, 2003, JAMA-J AM MED ASSOC, V289, P1001, DOI 10.1001/jama.289.8.1001; Gallagher TH, 2007, NEW ENGL J MED, V356, P2713, DOI 10.1056/NEJMra070568; Gamble HP, 2007, J HOSP INFECT, V67, P350, DOI 10.1016/j.jhin.2007.08.017; Gillespie J., 2006, Morbidity and Mortality Weekly Report, V55, P776; Gillespie JL, 2007, UROLOGY, V69, P912, DOI 10.1016/j.urology.2007.01.047; GILMOUR IJ, 1990, ANESTH ANALG, V71, P302; GOLDSMITH T, 2008, NEWS OBSERVER   0619; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; HEALY P, 2004, NY TIMES        0616; HUNTER N, 2007, IRISHHEALTH COM 0511; HWANG S, 2000, WALL STREET J   1027; Johnson IL, 2000, CAN MED ASSOC J, V162, P1127; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; *JOINT COMM INT CT, 2001, SENT EV AL EXP CREUT; Kimmey MB, 1993, GASTROINTEST ENDOSC, V39, P885, DOI DOI 10.1016/S0016-5107(93)70316-8; KING W, 2004, SEATTLE TIMES   0320; KLEIN A, 2005, WASHINGTON POST 1230, pA3; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Labus B., 2008, Morbidity and Mortality Weekly Report, V57, P513; Lewis V, 2002, LANCET NEUROL, V1, P470, DOI 10.1016/S1474-4422(02)00233-8; Lumley JS, 2008, ANN ROY COLL SURG, V90, P91, DOI 10.1308/003588408X261726; MANNING M, 2008, LAS VEGAS SUN   0229; Mello MM, 2010, NEW ENGL J MED, V362, P1353, DOI 10.1056/NEJMp1001603; Morris J, 2006, J HOSP INFECT, V63, P1, DOI 10.1016/j.jhin.2005.10.014; MUSCARELLA LF, MYENDOSITE HOME PAGE; NOLIN R, 2009, S FLORIDA SUN S 1006; Potash J, 2008, COMPLEX ETHICS CONSULTATIONS: CASES THAT HAUNT US, P205; Rutala WA, 2007, INFECT CONT HOSP EP, V28, P146, DOI 10.1086/511700; Sutton JM, 2006, CLIN INFECT DIS, V43, P757, DOI 10.1086/507030; *VET HLTH ADM, 2008, DISCL ADV EV PAT VHA; WELLS A, 2008, LAS VEGAS REV J 0228; WELLS A, 2008, LAS VEGAS REV J 0323; WELLS A, 2008, LAS VEGAS REV J 0319; WHO, 1999, WHO INF CONTR GUID T; WU AW, 2004, ACCOUNTABILITY PATIE, P135; YEN H, 2009, ASSOCIATED PRES 0114; 2008, CBC NEWS        0318; 2008, CBC NEWS        0722; 2008, CBC NEWS        0514; 2008, CASPER STAR TRI 0515	56	34	34	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					978	986		10.1056/NEJMhle1003134	http://dx.doi.org/10.1056/NEJMhle1003134			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645GW	20818911				2022-12-28	WOS:000281441500015
J	Gann, A; Witkowski, J				Gann, Alexander; Witkowski, Jan			The lost correspondence of Francis Crick	NATURE			English	Editorial Material									[Gann, Alexander] Cold Spring Harbor Lab Press, Cold Spring Harbor, NY 11724 USA; [Witkowski, Jan] Cold Spring Harbor Lab, Banbury Ctr, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory	Gann, A (corresponding author), Cold Spring Harbor Lab Press, Cold Spring Harbor, NY 11724 USA.	ganna@cshl.edu; witkowsk@cshl.edu	Witkowski, Jan/FHJ-8549-2022	Witkowski, Jan/0000-0002-8159-2874				Judson Horace F., 1996, 8 DAY CREATION MAKER, Vsecond; MADDOX B., 2002, R FRANKLIN DARK LADY; Olby R., 1974, PATH DOUBLE HELIX; Olby RC, 2009, F CRICK HUNTER LIFES; Watson J D, 1980, DOUBLE HELIX PERSONA; Wilkins M., 2003, 3 MAN DOUBLE HELIX A	6	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP	2010	467	7315					519	524		10.1038/467519a	http://dx.doi.org/10.1038/467519a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	655TT	20881989				2022-12-28	WOS:000282273100013
J	Feng, MY; Grice, DM; Faddy, HM; Nguyen, N; Leitch, S; Wang, YY; Muend, S; Kenny, PA; Sukumar, S; Roberts-Thomson, SJ; Monteith, GR; Rao, R				Feng, Mingye; Grice, Desma M.; Faddy, Helen M.; Nguyen, Nguyen; Leitch, Sharon; Wang, Yingyu; Muend, Sabina; Kenny, Paraic A.; Sukumar, Saraswati; Roberts-Thomson, Sarah J.; Monteith, Gregory R.; Rao, Rajini			Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors	CELL			English	Article							GENE-EXPRESSION SIGNATURE; YEAST SECRETORY PATHWAY; BREAST-CANCER; CELL-PROLIFERATION; PLASMA-MEMBRANE; CRAC CHANNEL; CALCIUM-TRANSPORT; ION SELECTIVITY; I-CRAC; CA2+	Ca(2+) is an essential and ubiquitous second messenger. Changes in cytosolic Ca(2+) trigger events critical for tumorigenesis, such as cellular motility, proliferation, and apoptosis. Weshow that an isoform of Secretory Pathway Ca(2+)-ATPase, SPCA2, is upregulated in breast cancer-derived cells and human breast tumors, and suppression of SPCA2 attenuates basal Ca(2+) levels and tumorigenicity. Contrary to its conventional role in Golgi Ca(2+) sequestration, expression of SPCA2 increased Ca(2+) influx by a mechanism dependent on the store-operated Ca(2+) channel Orai1. Unexpectedly, SPCA2-Orai1 signaling was independent of ER Ca(2+) stores or STIM1 and STIM2 sensors and uncoupled from Ca(2+)-ATPase activity of SPCA2. Binding of the SPCA2 amino terminus to Orai1 enabled access of its carboxyl terminus to Orai1 and activation of Ca(2+) influx. Our findings reveal a signaling pathway in which the Orai1-SPCA2 complex elicits constitutive store-independent Ca(2+) signaling that promotes tumorigenesis.	[Feng, Mingye; Leitch, Sharon; Muend, Sabina; Rao, Rajini] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; [Nguyen, Nguyen; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Grice, Desma M.; Faddy, Helen M.; Roberts-Thomson, Sarah J.; Monteith, Gregory R.] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; [Kenny, Paraic A.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; [Wang, Yingyu] Johns Hopkins Univ, Dept Mech Engn, Whiting Sch Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; University of Queensland; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	rrao@jhmi.edu	Grice, Desma M/A-7730-2011; Monteith, Gregory/B-1626-2008; Feng, Mingye/E-2302-2013; Faddy, Helen M/A-6541-2015; Roberts-Thomson, Sarah J/B-4282-2011; Roberts-Thomson, Sarah/W-5676-2019	Monteith, Gregory/0000-0002-4345-530X; Roberts-Thomson, Sarah J/0000-0001-8202-5786; Roberts-Thomson, Sarah/0000-0001-8202-5786; Faddy, Helen/0000-0002-3446-8248	National Institution of Health [GM62142]; National Health and Medical Research [569644]; Cancer Council Queensland; Department of Defense-Center of Excellence [W81XWH-04-1-0595]; Albert Einstein College of Medicine; American Heart Association [0815058E]; American Psychological Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062142] Funding Source: NIH RePORTER	National Institution of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health and Medical Research; Cancer Council Queensland(Cancer Council Queensland); Department of Defense-Center of Excellence(United States Department of Defense); Albert Einstein College of Medicine; American Heart Association(American Heart Association); American Psychological Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Paul Worley and Dr. Guo Huang (Johns Hopkins University) for kind gifts of plasmids expressing Orai1, STIM1, and NFAT. This work was supported by grant GM62142 from the National Institution of Health to R.R., 569644 from the National Health and Medical Research and Cancer Council Queensland to G.R.M. and S.J.R.-T., Department of Defense-Center of Excellence Grant W81XWH-04-1-0595 to S.S., laboratory startup funds from the Albert Einstein College of Medicine to P.A.K., American Heart Association Pre-doctoral fellowship 0815058E to M.F., and American Psychological Association scholarship to H.M.F. and D.M.	Abdullaev IF, 2008, CIRC RES, V103, P1289, DOI 10.1161/01.RES.0000338496.95579.56; Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOS JL, 1989, CANCER RES, V49, P4682; Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Cahalan MD, 2007, CELL CALCIUM, V42, P133, DOI 10.1016/j.ceca.2007.03.002; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Clementi E, 1996, CELL CALCIUM, V19, P269, DOI 10.1016/S0143-4160(96)90068-8; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Downward J, 1996, CANCER SURV, V27, P87; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Faddy HM, 2008, BIOCHEM BIOPH RES CO, V369, P977, DOI 10.1016/j.bbrc.2008.03.003; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; GARSIDE VC, 2010, EXP CELL RES, DOI DOI 10.10.106/J.YEXCR.2010.06.014; Gwack Y, 2007, CELL CALCIUM, V42, P145, DOI 10.1016/j.ceca.2007.03.007; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Lecchi S, 2005, BIOCHEMISTRY-US, V44, P16624, DOI 10.1021/bi051555f; Lee WJ, 2006, BBA-REV CANCER, V1765, P235, DOI 10.1016/j.bbcan.2005.12.001; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Mamillapalli R, 2008, J BIOL CHEM, V283, P24435, DOI 10.1074/jbc.M801738200; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Missiaen L, 2007, CELL CALCIUM, V41, P405, DOI 10.1016/j.ceca.2006.11.001; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Morgan MP, 2005, J MAMMARY GLAND BIOL, V10, P181, DOI 10.1007/s10911-005-5400-6; Muik M, 2008, J BIOL CHEM, V283, P8014, DOI 10.1074/jbc.M708898200; Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Park CY, 2009, CELL, V136, P876, DOI 10.1016/j.cell.2009.02.014; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Reinhardt TA, 2004, J BIOL CHEM, V279, P42369, DOI 10.1074/jbc.M407788200; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vanoevelen J, 2005, J BIOL CHEM, V280, P22800, DOI 10.1074/jbc.M501026200; Vig M, 2007, CELL CALCIUM, V42, P157, DOI 10.1016/j.ceca.2007.03.008; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Wu ST, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-17; Xiang MH, 2005, J BIOL CHEM, V280, P11608, DOI 10.1074/jbc.M413116200; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108	50	206	208	1	28	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					84	98		10.1016/j.cell.2010.08.040	http://dx.doi.org/10.1016/j.cell.2010.08.040			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887894	Bronze, Green Accepted			2022-12-28	WOS:000282362000016
J	Ong, KT; Perdu, J; De Backer, J; Bozec, E; Collignon, P; Emmerich, J; Fauret, AL; Fiessinger, JN; Germain, DP; Georgesco, G; Hulot, JS; De Paepe, A; Plauchu, H; Jeunemaitre, X; Laurent, S; Boutouyrie, P				Ong, Kim-Thanh; Perdu, Jerome; De Backer, Julie; Bozec, Erwan; Collignon, Patrick; Emmerich, Joseph; Fauret, Anne-Laure; Fiessinger, Jean-Noel; Germain, Dominique P.; Georgesco, Gabriella; Hulot, Jean-Sebastien; De Paepe, Anne; Plauchu, Henri; Jeunemaitre, Xavier; Laurent, Stephane; Boutouyrie, Pierre			Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial	LANCET			English	Article							GROWTH-FACTOR-BETA; SYNDROME TYPE-IV; MARFAN-SYNDROME; III PROCOLLAGEN; AORTIC-ANEURYSM; MESSENGER-RNAS; PULSE PRESSURE; COLLAGEN; ADRENOCEPTOR; COMPLICATIONS	Background Vascular Ehlers-Danlos syndrome is a rare severe disease that causes arterial dissections and ruptures that can lead to early death. No preventive treatment has yet been validated. Our aim was to assess the ability of celiprolol, a beta(1)-adrenoceptor antagonist with a beta(2)-adrenoceptor agonist action, to prevent arterial dissections and ruptures in vascular Ehlers-Danlos syndrome. Methods Our study was a multicentre, randomised, open trial with blinded assessment of clinical events in eight centres in France and one in Belgium. Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment. Randomisation was done from a centralised, previously established list of sealed envelopes with stratification by patients' age (<= 32 years or >32 years). 33 patients were positive for mutation of collagen 3A1 (COL3A1). Celiprolol was uptitrated every 6 months by steps of 100 mg to a maximum of 400 mg twice daily. The primary endpoints were arterial events (rupture or dissection, fatal or not). This study is registered with ClinicalTrials.gov, number NCT00190411. Findings 53 patients were randomly assigned to celiprolol (25 patients) or control groups (28). Mean duration of follow-up was 47 (SD 5) months, with the trial stopped early for treatment benefit. The primary endpoints were reached by five (20%) in the celiprolol group and by 14 (50%) controls (hazard ratio [HR] 0.36; 95% CI 0.15-0.88; p=0.040). Adverse events were severe fatigue in one patient after starting 100 mg celiprolol and mild fatigue in two patients related to dose uptitration. Interpretation We suggest that celiprolol might be the treatment of choice for physicians aiming to prevent major complications in patients with vascular Ehlers-Danlos syndrome. Whether patients with similar clinical presentations and no mutation are also protected remains to be established.	[Boutouyrie, Pierre] Hop Europeen Georges Pompidou, AP HP, Serv Pharmacol, F-75908 Paris, France; [Ong, Kim-Thanh; Bozec, Erwan; Fauret, Anne-Laure; Jeunemaitre, Xavier; Laurent, Stephane; Boutouyrie, Pierre] INSERM, U970, Paris, France; [Ong, Kim-Thanh; Emmerich, Joseph; Fiessinger, Jean-Noel; Jeunemaitre, Xavier; Laurent, Stephane; Boutouyrie, Pierre] Univ Paris, F-75252 Paris, France; [De Backer, Julie; De Paepe, Anne] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Collignon, Patrick] Assistance Publ Hop Marseille, Marseille, France; [Emmerich, Joseph] INSERM, U765, Paris, France; [Germain, Dominique P.] Hop Raymond Poincare, AP HP, Garches, France; [Germain, Dominique P.] Univ Versailles St Quentin En Yvelines, Versailles, France; [Georgesco, Gabriella] Hop Trousseau, Ctr Hosp Reg & Univ Tours, F-75571 Paris, France; [Hulot, Jean-Sebastien] Hop La Pitie Salpetriere, AP HP, Paris, France; [Hulot, Jean-Sebastien] INSERM, U621, Paris, France; [Plauchu, Henri] Hosp Civils Lyon, Lyon, France; [Plauchu, Henri] Univ Lyon 1, F-69365 Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Ghent University; Ghent University Hospital; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; CHU Tours; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Boutouyrie, P (corresponding author), Hop Europeen Georges Pompidou, AP HP, Serv Pharmacol, 20 Rue Leblanc, F-75908 Paris, France.	pierre.boutouyrie@egp.aphp.fr	boutouyrie, pierre/HGT-8201-2022; Laurent, Stephane/J-8624-2015; Pierre, Boutouyrie/J-8592-2015; GERMAIN, Dominique P./AAD-6747-2020; JEUNEMAITRE, Xavier/AAQ-4853-2021; De Backer, Julie/B-2897-2014; Hulot, Jean-Sébastien/A-2278-2016	boutouyrie, pierre/0000-0002-4375-3569; Pierre, Boutouyrie/0000-0002-4375-3569; JEUNEMAITRE, Xavier/0000-0001-5925-381X; De Backer, Julie/0000-0001-8878-1507; Hulot, Jean-Sébastien/0000-0001-5463-6117	French Ministry of Health; Soutien aux Technologies Innovantes, STIC	French Ministry of Health; Soutien aux Technologies Innovantes, STIC	We thank the Association Francaise des Syndromes d'Ehlers-Danlos, who actively supported this study; the AVENTIS laboratories, who unconditionally offered celiprolol; Agence generale des equipements et produits de sante, Christine Francannet, Isabelle Quere, Philippe Khau Van Kien (who did genetic testing in patients 10,12,13, and 21), Martine Le Merrer, Luc Van Bortel, Agnes Lillo-Lelouet, Eve Puzenat, Elisabeth Koenig Berard, Esma Djelloul-Costello, Florence Tapie de Celeyran, Brigitte Laloux, Dries Mahieu, and Patrick Segers for their help; and Kennedy Cruickshank for his help with the report. This study was done with support from the French Ministry of Health, Programme Hospitalier de Recherche Clinique 2001 grant and Soutien aux Technologies Innovantes, STIC 2006.	Ahimastos AA, 2007, JAMA-J AM MED ASSOC, V298, P1539, DOI 10.1001/jama.298.13.1539; Akutsu S, 2006, BRIT J PHARMACOL, V147, P412, DOI 10.1038/sj.bjp.0706625; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; Boutouyrie P, 2000, CIRCULATION, V101, P2601, DOI 10.1161/01.CIR.101.22.2601; Boutouyrie P, 2004, CIRCULATION, V109, P1530, DOI 10.1161/01.CIR.0000121741.50315.C2; Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585; CARUSO FS, 1985, BRIT J CLIN PRACT, V39, P12; CARUSO FS, 1986, J CLIN PHARMACOL, V26, P32, DOI 10.1002/j.1552-4604.1986.tb02899.x; Dai JP, 2005, CIRCULATION, V112, P1008, DOI 10.1161/CIRCULATIONAHA.104.523357; DEMEY C, 1993, EUR J CLIN PHARMACOL, V44, P341, DOI 10.1007/BF00316470; Dietz HC, 2010, J CLIN INVEST, V120, P403, DOI 10.1172/JCI42014; Dowton SB, 1996, CLIN GENET, V50, P510; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; Ferguson MWJ, 2009, LANCET, V373, P1264, DOI 10.1016/S0140-6736(09)60322-6; FROHLICH ED, 1991, CARDIO, V68, P509; Gohel MS, 2008, J VASC SURG, V48, P1272, DOI 10.1016/j.jvs.2008.06.042; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; HIRATA K, 1991, J AM COLL CARDIOL, V18, P57, DOI 10.1016/S0735-1097(10)80218-9; Jakubetz J, 1999, J CARDIOVASC PHARM, V33, P461, DOI 10.1097/00005344-199903000-00017; Jondeau G, 1999, CIRCULATION, V99, P2677, DOI 10.1161/01.CIR.99.20.2677; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695; Malfait F, 2007, HUM MUTAT, V28, P387, DOI 10.1002/humu.20455; Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981; O'Callaghan CJ, 2002, J HYPERTENS, V20, P287, DOI 10.1097/00004872-200202000-00019; Pepin M, 2000, NEW ENGL J MED, V342, P673, DOI 10.1056/NEJM200003093421001; Rosenkranz S, 2002, AM J PHYSIOL-HEART C, V283, pH1253, DOI 10.1152/ajpheart.00578.2001; Schoenhoff FS, 2009, CIRCULATION, V120, pS1048; Schwarze U, 2001, AM J HUM GENET, V69, P989, DOI 10.1086/324123; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SUPERTIFURGA A, 1988, J BIOL CHEM, V263, P6226; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VARGA J, 1986, BIOCHEM BIOPH RES CO, V138, P974, DOI 10.1016/S0006-291X(86)80591-5; Wang Y, 2010, J CLIN INVEST, V120, P422, DOI 10.1172/JCI38136; Whitehead J., 2001, BIOSTATISTICS CLIN T, P414	35	213	222	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2010	376	9751					1476	1484		10.1016/S0140-6736(10)60960-9	http://dx.doi.org/10.1016/S0140-6736(10)60960-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QC	20825986				2022-12-28	WOS:000284248500030
J	Greenhagen, BT; Lucey, PG; Wyatt, MB; Glotch, TD; Allen, CC; Arnold, JA; Bandfield, JL; Bowles, NE; Hanna, KLD; Hayne, PO; Song, E; Thomas, IR; Paige, DA				Greenhagen, Benjamin T.; Lucey, Paul G.; Wyatt, Michael B.; Glotch, Timothy D.; Allen, Carlton C.; Arnold, Jessica A.; Bandfield, Joshua L.; Bowles, Neil E.; Hanna, Kerri L. Donaldson; Hayne, Paul O.; Song, Eugenie; Thomas, Ian R.; Paige, David A.			Global Silicate Mineralogy of the Moon from the Diviner Lunar Radiometer	SCIENCE			English	Article							SURFACE; EMISSION; SPECTROSCOPY; FEATURES; CRUST	We obtained direct global measurements of the lunar surface using multispectral thermal emission mapping with the Lunar Reconnaissance Orbiter Diviner Lunar Radiometer Experiment. Most lunar terrains have spectral signatures that are consistent with known lunar anorthosite and basalt compositions. However, the data have also revealed the presence of highly evolved, silica-rich lunar soils in kilometer-scale and larger exposures, expanded the compositional range of the anorthosites that dominate the lunar crust, and shown that pristine lunar mantle is not exposed at the lunar surface at the kilometer scale. Together, these observations provide compelling evidence that the Moon is a complex body that has experienced a diverse set of igneous processes.	[Greenhagen, Benjamin T.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Lucey, Paul G.] Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; [Wyatt, Michael B.; Hanna, Kerri L. Donaldson] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Glotch, Timothy D.; Arnold, Jessica A.] SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; [Allen, Carlton C.] NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; [Bandfield, Joshua L.; Song, Eugenie] Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; [Bowles, Neil E.; Thomas, Ian R.] Univ Oxford, Dept Atmospher Ocean & Planetary Phys, Oxford OX1 3PU, England; [Hayne, Paul O.; Paige, David A.] Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System; Brown University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of Washington; University of Washington Seattle; University of Oxford; University of California System; University of California Los Angeles	Greenhagen, BT (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	benjamin.t.greenhagen@jpl.nasa.gov	Greenhagen, Benjamin T/C-3760-2016; Hanna, Kerri Donaldson/AAC-9941-2020	Greenhagen, Benjamin T/0000-0002-8252-9922; Bandfield, Joshua/0000-0003-3571-3716; Hayne, Paul/0000-0003-4399-0449; Thomas, Ian/0000-0003-3887-6668	NASA; Diviner science budget; Science and Technology Facilities Council [ST/H00243X/1] Funding Source: researchfish	NASA(National Aeronautics & Space Administration (NASA)); Diviner science budget; Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	This research was carried out in part at the Jet Propulsion Laboratory, California Institute of Technology, under a contract with NASA. This work was funded by the Diviner science budget and the NASA LRO Participating Scientist program.	Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; BRUNO BC, 1991, P LUNAR PLANET SCI, V21, P405; Christensen PR, 2004, SCIENCE, V306, P1733, DOI 10.1126/science.1104909; CONEL JE, 1969, J GEOPHYS RES, V74, P1614, DOI 10.1029/JB074i006p01614; Glotch TD, 2010, SCIENCE, V329, P1510, DOI 10.1126/science.1192148; GREENHAGEN BT, 2009, THESIS UCLA; Hagerty JJ, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002592; Hapke B, 2001, J GEOPHYS RES-PLANET, V106, P10039, DOI 10.1029/2000JE001338; HEAD JW, 1978, SCIENCE, V199, P1433, DOI 10.1126/science.199.4336.1436; Henderson BG, 1996, J GEOPHYS RES-PLANET, V101, P14969, DOI 10.1029/96JE01089; JOLLIFF BL, 2010, P LUNAR PLANET SCI C, V41, P2412; Lawrence DJ, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002050; Logan L.M., 1975, INFRARED RAMAN SPECT, P117, DOI [10.1016/b978-0-12-399950-4.50010-0, DOI 10.1016/B978-0%2D12-399950-4.50010-0]; LOGAN LM, 1973, J GEOPHYS RES, V78, P4983, DOI 10.1029/JB078i023p04983; LOGAN LM, 1972, P LUNAR PLANET SCI C, V3, P3191; Lucey PG, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019406; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P3701, DOI 10.1029/97JE03146; MURCRAY FH, 1970, J GEOPHYS RES, V75, P2662, DOI 10.1029/JB075i014p02662; NASH DB, 1993, J GEOPHYS RES-PLANET, V98, P23535, DOI 10.1029/93JE02604; Ohtake M, 2009, NATURE, V461, P236, DOI 10.1038/nature08317; Paige DA, 2010, SPACE SCI REV, V150, P125, DOI 10.1007/s11214-009-9529-2; PIETERS CM, 1986, REV GEOPHYS, V24, P557, DOI 10.1029/RG024i003p00557; Salisbury J. W, 1973, P LUNAR PLANET SCI C, V4, P3191; SALISBURY JW, 1989, J GEOPHYS RES-SOLID, V94, P9192, DOI 10.1029/JB094iB07p09192; Shearer CK, 1999, AM MINERAL, V84, P1469; Shervais JW, 1999, AM MINERAL, V84, P806, DOI 10.2138/am-1999-5-615; SONG E, 2010, P LUNAR PLANET SCI C, V41, P2578; SPRAGUE AL, 1992, ICARUS, V115, P181; Taylor LA, 2001, J GEOPHYS RES-PLANET, V106, P27985, DOI 10.1029/2000JE001402; Taylor LA, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2009JE003427; Thomas I. R., 2010, P LUNAR PLANET SCI C, V41, P1364; Tompkins S, 1999, METEORIT PLANET SCI, V34, P25, DOI 10.1111/j.1945-5100.1999.tb01729.x; WHITAKER EA, 1972, MOON, V4, P348, DOI DOI 10.1007/BF00562002; White W.B., 1975, INFRARED RAMAN SPECT, P325; Wieczorek MA, 2000, J GEOPHYS RES-PLANET, V105, P20417, DOI 10.1029/1999JE001092; Yamamoto S, 2010, NAT GEOSCI, V3, P533, DOI [10.1038/NGEO897, 10.1038/ngeo897]	36	104	105	5	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1507	1509		10.1126/science.1192196	http://dx.doi.org/10.1126/science.1192196			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847266				2022-12-28	WOS:000281869000036
J	Moyle, LC; Nakazato, T				Moyle, Leonie C.; Nakazato, Takuya			Hybrid Incompatibility "Snowballs" Between Solanum Species	SCIENCE			English	Article							MALE-STERILITY; GENETICS; EPISTASIS; EVOLUTION; DOMINANCE; LOCI	Among the reproductive barriers that can isolate species, hybrid sterility is frequently due to dysfunctional interactions between loci that accumulate between differentiating lineages. Theory describing the evolution of these incompatibilities has generated the prediction, still empirically untested, that loci underlying hybrid incompatibility should accumulate faster than linearly with time-the "snowball effect." We evaluated the accumulation of quantitative trait loci (QTL) between species in the plant group Solanum and found evidence for a faster-than-linear accumulation of hybrid seed sterility QTL, thus empirically evaluating and confirming this theoretical prediction. In comparison, loci underlying traits unrelated to hybrid sterility show no evidence for an accelerating rate of accumulation between species.	[Moyle, Leonie C.; Nakazato, Takuya] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; [Nakazato, Takuya] Univ Memphis, Memphis, TN 38152 USA	Indiana University System; Indiana University Bloomington; University of Memphis	Moyle, LC (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	lmoyle@indiana.edu			National Science Foundation [DEB-0532097, DEB-0849157]	National Science Foundation(National Science Foundation (NSF))	M. Fryska, E. Graham, E. Lines, and K. Wolt contributed to collection of the data. C. Muir drew Figure 1. M. Hahn, C. Muir, and M. Turelli provided comments on the manuscript. Supported by National Science Foundation grants DEB-0532097 and DEB-0849157 (LCM).	BURNHAM K.P., 2002, MODEL SELECTION MULT, V2nd, DOI DOI 10.1007/B97636; CABOT EL, 1994, GENETICS, V137, P175; Chang AS, 2010, EVOLUTION, V64, P253, DOI 10.1111/j.1558-5646.2009.00823.x; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Coyne J.A., 2004, SPECIATION; Dobzhansky T, 1936, GENETICS, V21, P113; Gourbiere S, 2010, EVOLUTION, V64, P1, DOI 10.1111/j.1558-5646.2009.00844.x; Johnson Norman A., 2006, P374; Kondrashov AS, 2003, EVOLUTION, V57, P151; Mackay TFC, 2009, NAT REV GENET, V10, P565, DOI 10.1038/nrg2612; Mendelson TC, 2004, EVOLUTION, V58, P1424; Moyle LC, 2006, MOL BIOL EVOL, V23, P973, DOI 10.1093/molbev/msj112; Moyle LC, 2005, GENETICS, V169, P355, DOI 10.1534/genetics.104.029546; Moyle LC, 2008, GENETICS, V179, P1437, DOI 10.1534/genetics.107.083618; Muller HJ, 1942, BIOL S, V6, P71; ORR HA, 1995, GENETICS, V139, P1805; Orr HA, 2001, EVOLUTION, V55, P1085; Presgraves DC, 2010, NAT REV GENET, V11, P175, DOI 10.1038/nrg2718; Tao Y, 2003, GENETICS, V164, P1399; Turelli M, 2000, GENETICS, V154, P1663; Turelli M, 2007, GENETICS, V176, P1059, DOI 10.1534/genetics.106.065979; UNCKLESS R, COMMUNICATION; ZAR J.H., 2009, BIOSTAT ANAL, V5th	23	147	148	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1521	1523		10.1126/science.1193063	http://dx.doi.org/10.1126/science.1193063			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847271				2022-12-28	WOS:000281869000041
J	Sjoberg, BM				Sjoberg, Britt-Marie			A Never-Ending Story	SCIENCE			English	Editorial Material							RIBONUCLEOTIDE REDUCTASE; CRYSTAL-STRUCTURE; AMMONIAGENES; COFACTOR; REVEALS		Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360				Boal AK, 2010, SCIENCE, V329, P1526, DOI 10.1126/science.1190187; Cotruvo JA, 2010, BIOCHEMISTRY-US, V49, P1297, DOI 10.1021/bi902106n; Cox N, 2010, J AM CHEM SOC, V132, P11197, DOI 10.1021/ja1036995; Fieschi F, 1998, J BIOL CHEM, V273, P4329, DOI 10.1074/jbc.273.8.4329; Hartig E, 2006, APPL ENVIRON MICROB, V72, P5260, DOI 10.1128/AEM.00599-06; Hogbom M, 2002, BIOCHEMISTRY-US, V41, P1381, DOI 10.1021/bi011429l; Johansson R, 2010, FEBS J, V277, P4265, DOI 10.1111/j.1742-4658.2010.07815.x; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; Lundin D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-589; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Reichard P, 2010, BIOCHEM BIOPH RES CO, V396, P19, DOI 10.1016/j.bbrc.2010.02.108; Roca I, 2008, J BACTERIOL, V190, P4849, DOI 10.1128/JB.00185-08; Rohr AK, 2010, ANGEW CHEM INT EDIT, V49, P2324, DOI 10.1002/anie.200907143; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x	16	12	12	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1475	1476		10.1126/science.1196347	http://dx.doi.org/10.1126/science.1196347			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847256				2022-12-28	WOS:000281869000026
J	Vermeulen, M; Eberl, HC; Matarese, F; Marks, H; Denissov, S; Butter, F; Lee, KK; Olsen, JV; Hyman, AA; Stunnenberg, HG; Mann, M				Vermeulen, Michiel; Eberl, H. Christian; Matarese, Filomena; Marks, Hendrik; Denissov, Sergei; Butter, Falk; Lee, Kenneth K.; Olsen, Jesper V.; Hyman, Anthony A.; Stunnenberg, Henk G.; Mann, Matthias			Quantitative Interaction Proteomics and Genome-wide Profiling of Epigenetic Histone Marks and Their Readers	CELL			English	Article							CHROMATIN MODIFICATIONS; BAC TRANSGENEOMICS; MOLECULAR-BASIS; TUDOR DOMAIN; PWWP DOMAIN; METHYLATION; H3; COMPLEXES; BINDING; LYSINE-4	Trimethyl-lysine (me3) modifications on histones are the most stable epigenetic marks and they control chromatin-mediated regulation of gene expression. Here, we determine proteins that bind these marks by high-accuracy, quantitative mass spectrometry. These chromatin "readers'' are assigned to complexes by interaction proteomics of full-length BAC-GFP-tagged proteins. ChIP-Seq profiling identifies their genomic binding sites, revealing functional properties. Among the main findings, the human SAGA complex binds to H3K4me3 via a double Tudor-domain in the C terminus of Sgf29, and the PWWP domain is identified as a putative H3K36me3 binding motif. The ORC complex, including LRWD1, binds to the three most prominent transcriptional repressive lysine methylation sites. Our data reveal a highly adapted interplay between chromatin marks and their associated protein complexes. Reading specific trimethyl-lysine sites by specialized complexes appears to be a widespread mechanism to mediate gene expression.	[Vermeulen, Michiel; Eberl, H. Christian; Butter, Falk; Olsen, Jesper V.; Mann, Matthias] Max Planck Inst Biochem, Dept Prote & Signal Transduct, D-82152 Martinsried, Germany; [Matarese, Filomena; Marks, Hendrik; Denissov, Sergei; Stunnenberg, Henk G.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Fac Sci, Dept Mol Biol, NL-6525 GA Nijmegen, Netherlands; [Lee, Kenneth K.] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Hyman, Anthony A.] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; [Olsen, Jesper V.] Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Prot Res, DK-2200 Copenhagen, Denmark	Max Planck Society; Radboud University Nijmegen; Stowers Institute for Medical Research; Max Planck Society; University of Copenhagen	Vermeulen, M (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Utrecht, Netherlands.	m.vermeulen-3@umcutrecht.nl; h.stunnenberg@ncmls.ru.nl; mmann@biochem.mpg.de	Vermeulen, Michiel/C-8883-2013; Olsen, Jesper/ABH-4638-2020; Hyman, Anthony A/B-3917-2017; Marks, Hendrik/E-2801-2012; Mann, Matthias/A-3454-2013; Hyman, Tony/F-1923-2011; Stunnenberg, Hendrik G./D-6875-2012	Vermeulen, Michiel/0000-0003-0836-6894; Olsen, Jesper/0000-0002-4747-4938; Hyman, Anthony A/0000-0003-3664-154X; Marks, Hendrik/0000-0002-4198-3731; Mann, Matthias/0000-0003-1292-4799; Stunnenberg, Hendrik G./0000-0002-0066-1576; Butter, Falk/0000-0002-7197-7279; Eberl, H. Christian/0000-0002-4159-5958	Max-Planck Society for the Advancement of Science, HEROIC; European Union [LSHG-CT-2005-018883]	Max-Planck Society for the Advancement of Science, HEROIC(Max Planck Society); European Union(European Commission)	Eva Janssen-Megens, Kees-Jan Francois, and Yan Tan helped with the sequencing, the MPI core facility expressed and purified recombinant proteins, and Dr. F. Tashiro kindly provided Sgf29 antibody. This work was supported by the Max-Planck Society for the Advancement of Science, HEROIC, an Integrated Project funded by the European Union under the 6th Framework Program (LSHG-CT-2005-018883) and by Interaction Proteome (LSHG-CT-2003-505520). M. V. received a fellowship of the Dutch Cancer Society (KWF/NKB) and a grant from the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research.	Butter F, 2010, EMBO REP, V11, P305, DOI 10.1038/embor.2010.6; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Denissov S, 2007, EMBO J, V26, P944, DOI 10.1038/sj.emboj.7601550; Fejes AP, 2008, BIOINFORMATICS, V24, P1729, DOI 10.1093/bioinformatics/btn305; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fischle W, 2008, J BIOL CHEM, V283, P19626, DOI 10.1074/jbc.M802655200; Franz H, 2009, J BIOL CHEM, V284, P35049, DOI 10.1074/jbc.M109.052332; Garcia BA, 2007, CURR OPIN CHEM BIOL, V11, P66, DOI 10.1016/j.cbpa.2006.11.022; Horton JR, 2010, NAT STRUCT MOL BIOL, V17, P38, DOI 10.1038/nsmb.1753; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Hubner NC, 2010, J CELL BIOL, V189, P739, DOI 10.1083/jcb.200911091; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Hurd PJ, 2009, J BIOL CHEM, V284, P16575, DOI 10.1074/jbc.M109.005421; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lee N, 2009, MOL CELL BIOL, V29, P1401, DOI 10.1128/MCB.01643-08; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Mandel S, 2007, DEV BIOL, V303, P814, DOI 10.1016/j.ydbio.2006.11.039; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Moshkin YM, 2009, MOL CELL, V35, P782, DOI 10.1016/j.molcel.2009.07.020; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nagy Z, 2010, CELL MOL LIFE SCI, V67, P611, DOI 10.1007/s00018-009-0199-8; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P608, DOI 10.1074/mcp.T400003-MCP200; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Poser I, 2008, NAT METHODS, V5, P409, DOI 10.1038/NMETH.1199; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; VAN OEVELEN C, 2008, MOL CELL, V32, P359; Vermeulen M, 2008, CURR OPIN BIOTECH, V19, P331, DOI 10.1016/j.copbio.2008.06.001; Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016; Vermeulen M, 2009, CURR OPIN CELL BIOL, V21, P761, DOI 10.1016/j.ceb.2009.09.003; Vezzoli A, 2010, NAT STRUCT MOL BIOL, V17, P617, DOI 10.1038/nsmb.1797; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang Y, 2009, MOL CELL, V33, P428, DOI 10.1016/j.molcel.2009.02.002; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Winter S, 2008, CELL CYCLE, V7, P1336, DOI 10.4161/cc.7.10.5946; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	56	553	578	2	88	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					967	980		10.1016/j.cell.2010.08.020	http://dx.doi.org/10.1016/j.cell.2010.08.020			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850016	Bronze			2022-12-28	WOS:000281855000018
J	Lee, HL				Lee, Hang Lak			Radiation Proctitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hanyang Univ Hosp, Seoul, South Korea	Hanyang University; Hanyang University Hospital	Lee, HL (corresponding author), Hanyang Univ Hosp, Seoul, South Korea.	alwayshang@hanyang.ac.kr							0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1163	1163		10.1056/NEJMicm0911437	http://dx.doi.org/10.1056/NEJMicm0911437			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843251				2022-12-28	WOS:000281795800011
J	Tugwell, P; Petticrew, M; Kristjansson, E; Welch, V; Ueffing, E; Waters, E; Bonnefoy, J; Morgan, A; Doohan, E; Kelly, MP				Tugwell, Peter; Petticrew, Mark; Kristjansson, Elizabeth; Welch, Vivian; Ueffing, Erin; Waters, Elizabeth; Bonnefoy, Josiane; Morgan, Antony; Doohan, Emma; Kelly, Michael P.			Assessing equity in systematic reviews: realising the recommendations of the Commission on Social Determinants of Health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INEQUALITIES; COCHRANE		[Tugwell, Peter] Univ Ottawa, Ottawa Hosp Res Inst, Dept Med, Ottawa, ON, Canada; [Tugwell, Peter; Welch, Vivian] Univ Ottawa, Ottawa Hosp Res Inst, Inst Populat Hlth, Ottawa, ON, Canada; [Petticrew, Mark] London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, Fac Publ Hlth & Policy, London, England; [Kristjansson, Elizabeth] Univ Ottawa, Sch Psychol, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada; [Ueffing, Erin] Univ Ottawa, Campbell & Cochrane Equ Methods Grp, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada; [Waters, Elizabeth] Univ Melbourne, McCaughey Ctr, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia; [Bonnefoy, Josiane] Univ Chile, Sch Publ Hlth, Fac Med, Santiago, Chile; [Morgan, Antony; Doohan, Emma; Kelly, Michael P.] Natl Inst Hlth & Clin Excellence, Ctr Publ Hlth Excellence, London, England	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of London; London School of Hygiene & Tropical Medicine; University of Ottawa; University of Ottawa; University of Melbourne; Universidad de Chile; National Institute for Health & Care Excellence	Tugwell, P (corresponding author), Univ Ottawa, Ottawa Hosp Res Inst, Dept Med, Ottawa, ON, Canada.	tugwellb@uottawa.ca	Petticrew, Mark/AAY-6274-2021; Welch, Vivian Andrea/AAD-9338-2020; Tugwell, Peter/AFD-8076-2022	Welch, Vivian Andrea/0000-0002-5238-7097; Tugwell, Peter/0000-0001-5062-0556	CIHR; Canadian Research Chair Tier 1 Award; Canadian Institutes of Health Research (CIHR)	CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair Tier 1 Award; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	PT and VW have support from the Canadian Agency for Drugs and Technology for Health (CADTH) for the submitted work; the Campbell and Cochrane Equity Methods Group is funded by the Canadian Institutes of Health Research (CIHR); PT is funded by a Canadian Research Chair Tier 1 Award. VW was supported by a CIHR doctoral award. None of the funders had input or influence on the content or conclusions of this paper; the final decision to publish rested with the authors and the guarantor, PT.	ARMSTRONG R, 2008, COCHRANE HDD SYSTEMA; Baxter S, 2010, PUBLIC HEALTH, V124, P99, DOI 10.1016/j.puhe.2010.01.002; Boers M, 1998, J RHEUMATOL, V25, P198; Carling CLL, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000134; *COMM SOC DET HLTH, 2008, FIN REP CLOS GAP GE; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; Davies P, 2001, BRIT MED J, V323, P294, DOI 10.1136/bmj.323.7308.294; Evans T., 2001, CHALLENGING INEQUITI; Evans Tim, 2003, Inj Control Saf Promot, V10, P11, DOI 10.1076/icsp.10.1.11.14117; Friedli L., 2009, MENTAL HLTH; Gwatkin DR, 2003, LANCET, V361, P540, DOI 10.1016/S0140-6736(03)12558-5; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HIGGINS JPT, 2008, COCHRANE HDD SYSTEMA; Jackson N, 2008, SYSTEMATIC REV HLTH; Kelly MP, 2007, SOCIAL DETERMINANTS; Korkeila J, 2003, SCAND J PUBLIC HEALT, V31, P451, DOI 10.1080/14034940210165208; Kristjansson EA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004676.pub2; Lagarde M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008137; Lassere MN, 2007, J RHEUMATOL, V34, P607; Leon DA, 2001, BMJ-BRIT MED J, V322, P591, DOI 10.1136/bmj.322.7286.591; Lewin SA, 2005, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD004015.PUB2; Moher D, 2007, PLOS MED, V4, P447, DOI 10.1371/journal.pmed.0040078; Ogilvie D, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-8; Oliver SKJ, 2008, HLTH PROMOTION INEQU; Petticrew M, 2003, J EPIDEMIOL COMMUN H, V57, P527, DOI 10.1136/jech.57.7.527; Solar O, 2007, CONCEPTUAL FRAMEWORK; Thomas S, 2008, TOB CONTROL, V17, DOI 10.1136/tc.2007.023911; Tugwell P, 2006, BMJ-BRIT MED J, V332, P358, DOI 10.1136/bmj.332.7537.358; Tugwell P, 2008, ARTHRIT RHEUM-ARTHR, V59, P1603, DOI 10.1002/art.24206; Tugwell P, 2011, CAN MED ASSOC J, V183, pE933, DOI 10.1503/cmaj.090289; WHITEHEAD M, 1992, INT J HEALTH SERV, V22, P429, DOI 10.2190/986L-LHQ6-2VTE-YRRN	31	99	98	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2010	341								c4739	10.1136/bmj.c4739	http://dx.doi.org/10.1136/bmj.c4739			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653KH	20837575	Green Accepted			2022-12-28	WOS:000282089500012
J	Dosenbach, NUF; Nardos, B; Cohen, AL; Fair, DA; Power, JD; Church, JA; Nelson, SM; Wig, GS; Vogel, AC; Lessov-Schlaggar, CN; Barnes, KA; Dubis, JW; Feczko, E; Coalson, RS; Pruett, JR; Barch, DM; Petersen, SE; Schlaggar, BL				Dosenbach, Nico U. F.; Nardos, Binyam; Cohen, Alexander L.; Fair, Damien A.; Power, Jonathan D.; Church, Jessica A.; Nelson, Steven M.; Wig, Gagan S.; Vogel, Alecia C.; Lessov-Schlaggar, Christina N.; Barnes, Kelly Anne; Dubis, Joseph W.; Feczko, Eric; Coalson, Rebecca S.; Pruett, John R., Jr.; Barch, Deanna M.; Petersen, Steven E.; Schlaggar, Bradley L.			Prediction of Individual Brain Maturity Using fMRI	SCIENCE			English	Article							RESTING HUMAN BRAIN; FUNCTIONAL CONNECTIVITY; COGNITIVE CONTROL; PATTERN-ANALYSIS; CHILDREN; CORTEX; REPRESENTATIONS; NETWORKS; ABILITY; HUMANS	Group functional connectivity magnetic resonance imaging (fcMRI) studies have documented reliable changes in human functional brain maturity over development. Here we show that support vector machine-based multivariate pattern analysis extracts sufficient information from fcMRI data to make accurate predictions about individuals' brain maturity across development. The use of only 5 minutes of resting-state fcMRI data from 238 scans of typically developing volunteers (ages 7 to 30 years) allowed prediction of individual brain maturity as a functional connectivity maturation index. The resultant functional maturation curve accounted for 55% of the sample variance and followed a nonlinear asymptotic growth curve shape. The greatest relative contribution to predicting individual brain maturity was made by the weakening of short-range functional connections between the adult brain's major functional networks.	[Dosenbach, Nico U. F.; Nardos, Binyam; Cohen, Alexander L.; Power, Jonathan D.; Church, Jessica A.; Nelson, Steven M.; Wig, Gagan S.; Vogel, Alecia C.; Barnes, Kelly Anne; Dubis, Joseph W.; Coalson, Rebecca S.; Petersen, Steven E.; Schlaggar, Bradley L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Fair, Damien A.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA; [Nelson, Steven M.; Barch, Deanna M.; Petersen, Steven E.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [Wig, Gagan S.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; [Wig, Gagan S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA; [Lessov-Schlaggar, Christina N.; Feczko, Eric; Pruett, John R., Jr.; Barch, Deanna M.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Coalson, Rebecca S.; Barch, Deanna M.; Petersen, Steven E.; Schlaggar, Bradley L.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Petersen, Steven E.; Schlaggar, Bradley L.] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Schlaggar, Bradley L.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Oregon Health & Science University; Washington University (WUSTL); Harvard University; Harvard University; Massachusetts General Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dosenbach, NUF (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	ndosenbach@wustl.edu; schlaggarb@neuro.wustl.edu	Barch, Deanna M/G-8638-2013; Kennedy, Kristen M/B-4699-2008; Petersen, Steve/ABF-1368-2020; Schlaggar, Bradley/AAZ-4153-2020; Church, Jessica/L-2659-2016; Cohen, Alexander Li/H-6594-2019; Cohen, Alexander/A-6865-2009; Nelson, Steven/C-1003-2009; Church, Jessica/E-2836-2010	Kennedy, Kristen M/0000-0001-5373-9026; Church, Jessica/0000-0003-1369-9116; Cohen, Alexander Li/0000-0001-6557-5866; Cohen, Alexander/0000-0001-6557-5866; Power, Jonathan/0000-0002-6922-100X	NIH [NS55582, NS053425, HD057076, NS00169011, NS51281, NS32979, NS41255, NS46424, DA027046]; John Merck Scholars Fund; Burroughs-Wellcome Fund; Dana Foundation; Ogle Family Fund; McDonnell Center; Simons Foundation; American Hearing Research Foundation; Diabetes Research Center at Washington University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057076] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [K12EY016336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P20MH062130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046424, K02NS053425, R01NS032979, R21NS041255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA027046] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); John Merck Scholars Fund; Burroughs-Wellcome Fund(Burroughs Wellcome Fund); Dana Foundation; Ogle Family Fund; McDonnell Center; Simons Foundation; American Hearing Research Foundation; Diabetes Research Center at Washington University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by NIH grants NS55582, NS053425, HD057076, and NS00169011 (B.L.S.); NS51281, NS32979, NS41255, and NS46424 (S.E.P.); DA027046 (C.N.L.-S.); EY16336 (J.R.P.); and MH62130 (D.M.B.) and by the John Merck Scholars Fund (B.L.S.), Burroughs-Wellcome Fund (B.L.S.), Dana Foundation (B.L.S.), Ogle Family Fund (B.L.S.), McDonnell Center (S.E.P. and B.L.S.), Simons Foundation (S.E.P.), American Hearing Research Foundation (J. E. C. Lieu), and Diabetes Research Center at Washington University (T. G. Hershey). We thank J. E. C. Lieu, C. E. Pizoli, and T. G. Hershey for providing data and F. M. Miezin, J. Harwell, A. Z. Snyder, and H. M. Lugar for help with data analysis.	Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; [Anonymous], 2009, PSYCHOL SCI, V20, P1364, DOI 10.1111/j.1467-9280.2009.02460.x; Ben-Hur A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000173; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; Crone EA, 2006, P NATL ACAD SCI USA, V103, P9315, DOI 10.1073/pnas.0510088103; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Fair DA, 2007, P NATL ACAD SCI USA, V104, P13507, DOI 10.1073/pnas.0705843104; Fair DA, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000381; Formisano E, 2008, SCIENCE, V322, P970, DOI 10.1126/science.1164318; Gong GL, 2009, J NEUROSCI, V29, P15684, DOI 10.1523/JNEUROSCI.2308-09.2009; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Johnson JD, 2009, NEURON, V63, P697, DOI 10.1016/j.neuron.2009.08.011; Johnson MH, 2001, NAT REV NEUROSCI, V2, P475, DOI 10.1038/35081509; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Mitchell TM, 2008, SCIENCE, V320, P1191, DOI 10.1126/science.1152876; Norman KA, 2006, TRENDS COGN SCI, V10, P424, DOI 10.1016/j.tics.2006.07.005; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; POLYN SM, 1963, SCIENCE, V310, P2005; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schlaggar BL, 2002, SCIENCE, V296, P1476, DOI 10.1126/science.1069464; Schurger A, 2010, SCIENCE, V327, P97, DOI 10.1126/science.1180029; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Somerville LH, 2010, CURR OPIN NEUROBIOL, V20, P236, DOI 10.1016/j.conb.2010.01.006; Soon CS, 2008, NAT NEUROSCI, V11, P543, DOI 10.1038/nn.2112; Supekar K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000157; Tomasi D, 2010, P NATL ACAD SCI USA, V107, P9885, DOI 10.1073/pnas.1001414107; Tsoularis A, 2002, MATH BIOSCI, V179, P21, DOI 10.1016/S0025-5564(02)00096-2; Velanova K, 2009, J NEUROSCI, V29, P12558, DOI 10.1523/JNEUROSCI.1579-09.2009; Zhang DY, 2010, NAT REV NEUROL, V6, P15, DOI 10.1038/nrneurol.2009.198	37	1354	1382	13	265	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1358	1361		10.1126/science.1194144	http://dx.doi.org/10.1126/science.1194144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829489	Green Accepted			2022-12-28	WOS:000281657300043
J	David, AS; Hotopf, M; Moran, P; Owen, G; Szmukler, G; Richardson, G				David, Anthony S.; Hotopf, Matthew; Moran, Paul; Owen, Gareth; Szmukler, George; Richardson, Genevra			Mentally disordered or lacking capacity? Lessons for management of serious deliberate self harm	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INPATIENTS		[David, Anthony S.; Hotopf, Matthew; Moran, Paul; Owen, Gareth; Szmukler, George] Kings Coll London, Inst Psychiat, London SE5 8AF, England; [Richardson, Genevra] Kings Coll London, Sch Law, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	David, AS (corresponding author), Kings Coll London, Inst Psychiat, London SE5 8AF, England.	anthony.david@kcl.ac.uk	David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011; Hotopf, Matthew/E-4971-2010; Moran, Paul A/B-1740-2010	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Moran, Paul A/0000-0002-9257-8699	National Institute for Health Research [NF-SI-0507-10088] Funding Source: researchfish; Wellcome Trust Funding Source: Medline; Department of Health Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); Department of Health		*BRIT PSYCH SOC, 2009, BORD PERS DIS NICE G; CRAIGIE J, 2009, BIOETHICS        DEC; Dawson J, 2006, BRIT J PSYCHIAT, V188, P504, DOI 10.1192/bjp.188.6.504; Fistein EC, 2009, INT J LAW PSYCHIAT, V32, P147, DOI 10.1016/j.ijlp.2009.02.006; Jacob R, 2005, EMERG MED J, V22, P799, DOI 10.1136/emj.2004.018671; McLean SAM, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4695; McLean SAM, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4112; Owen GS, 2009, BRIT J PSYCHIAT, V195, P257, DOI 10.1192/bjp.bp.108.059782; Ranjith G, 2004, J ROY SOC MED, V97, P480, DOI 10.1258/jrsm.97.10.480; Raymont V, 2004, LANCET, V364, P1421, DOI 10.1016/S0140-6736(04)17224-3; SZMUKLER G, J MED ETHICS, P647; Tan JOA, 2006, PHILOS PSYCHIATR PSY, V13, P267, DOI 10.1353/ppp.2007.0032; Winburn E, 2008, J MED ETHICS, V34, P715, DOI 10.1136/jme.2007.023341	13	22	22	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 7	2010	341								c4489	10.1136/bmj.c4489	http://dx.doi.org/10.1136/bmj.c4489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZI	20823014				2022-12-28	WOS:000281814900013
J	Ito, T; Yokoyama, S				Ito, Takuhiro; Yokoyama, Shigeyuki			Two enzymes bound to one transfer RNA assume alternative conformations for consecutive reactions	NATURE			English	Article							STRUCTURAL BASIS; SYNTHETASE; AMIDOTRANSFERASE; CRYSTALLOGRAPHY; RECRUITMENT; GLUTAMINE	In most bacteria and all archaea, glutamyl-tRNA synthetase (GluRS) glutamylates both tRNA(Glu) and tRNA(Gln), and then Glu-tRNA(Gln) is selectively converted to Gln-tRNA(Gln) by a tRNAdependent amidotransferase(1,2). The mechanisms by which the two enzymes recognize their substrate tRNA(s), and how they cooperate with each other in Gln-tRNA(Gln) synthesis, remain to be determined. Here we report the formation of the 'glutamine transamidosome' from the bacterium Thermotoga maritima, consisting of tRNA(Gln), GluRS and the heterotrimeric amidotransferase GatCAB, and its crystal structure at 3.35 angstrom resolution. The anticodon-binding body of GluRS recognizes the common features of tRNA(Gln) and tRNA(Glu), whereas the tail body of GatCAB recognizes the outer corner of the L-shaped tRNA(Gln) in a tRNA(Gln)-specific manner. GluRS is in the productive form, as its catalytic body binds to the amino-acid-acceptor arm of tRNA(Gln). In contrast, GatCAB is in the non-productive form: the catalytic body of GatCAB contacts that of GluRS and is located near the acceptor stem of tRNA(Gln), in an appropriate site to wait for the completion of Glu-tRNA(Gln) formation by GluRS. We identified the hinges between the catalytic and anticodon-binding bodies of GluRS and between the catalytic and tail bodies of GatCAB, which allow both GluRS and GatCAB to adopt the productive and non-productive forms. The catalytic bodies of the two enzymes compete for the acceptor arm of tRNA(Gln) and therefore cannot assume their productive forms simultaneously. The transition from the present glutamylation state, with the productive GluRS and the non-productive GatCAB, to the putative amidation state, with the nonproductive GluRS and the productive GatCAB, requires an intermediate state with the two enzymes in their non-productive forms, for steric reasons. The proposed mechanism explains how the transamidosome efficiently performs the two consecutive steps of Gln-tRNA(Gln) formation, with a low risk of releasing the unstable intermediate Glu-tRNA(Gln).	[Ito, Takuhiro; Yokoyama, Shigeyuki] Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; [Ito, Takuhiro; Yokoyama, Shigeyuki] Univ Tokyo, Grad Sch Sci, Struct Biol Lab, Bunkyo Ku, Tokyo 1130033, Japan; [Ito, Takuhiro; Yokoyama, Shigeyuki] RIKEN Syst & Struct Biol Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	University of Tokyo; University of Tokyo; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Ito, Takuhiro/N-6893-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Ito, Takuhiro/0000-0003-3704-5205	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT); Japan Society for the Promotion of Science	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank S. Sekine for discussions and help with data collection, S. Goto-Ito for reading the manuscript, and S. Takahashi, N. Kiyasu and R. Matsunaga for help with sample preparation. We are grateful to the staff of the beamline BL41XU in the SPring-8 and the beamline AR-NE3A in the Photon Factory for their support during data collection. This work was supported by the Targeted Proteins Research Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT), a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and MEXT, and the Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from MEXT.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailly M, 2007, MOL CELL, V28, P228, DOI 10.1016/j.molcel.2007.08.017; Bailly M, 2006, NUCLEIC ACIDS RES, V34, P6083, DOI 10.1093/nar/gkl622; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ito T, 2010, ACTA CRYSTALLOGR D, V66, P813, DOI 10.1107/S0907444910019086; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Nakamura A, 2010, NUCLEIC ACIDS RES, V38, P672, DOI 10.1093/nar/gkp955; Nakamura A, 2006, SCIENCE, V312, P1954, DOI 10.1126/science.1127156; Oshikane H, 2006, SCIENCE, V312, P1950, DOI 10.1126/science.1128470; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMPIAS T, NUCL ACIDS IN PRESS; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; Sekine S, 2001, NAT STRUCT BIOL, V8, P203, DOI 10.1038/84927; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; Wu J, 2009, J MOL BIOL, V391, P703, DOI 10.1016/j.jmb.2009.06.014	24	44	46	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					612	U143		10.1038/nature09411	http://dx.doi.org/10.1038/nature09411			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882017				2022-12-28	WOS:000282273100044
J	Weber, TS; Deutsch, C				Weber, Thomas S.; Deutsch, Curtis			Ocean nutrient ratios governed by plankton biogeography	NATURE			English	Article							ANTARCTIC CIRCUMPOLAR CURRENT; GLACIAL SOUTHERN-OCEAN; ELEMENTAL STOICHIOMETRY; MARINE-PHYTOPLANKTON; COMMUNITY STRUCTURE; NITROGEN-FIXATION; PACIFIC-OCEAN; CO2; DENITRIFICATION; PHOSPHORUS	The major nutrients nitrate and phosphate have one of the strongest correlations in the sea, with a slope similar to the average nitrogen (N) to phosphorus (P) content of plankton biomass (N/P = 16:1). The processes through which this global relationship emerges despite the wide range of N/P ratios at the organism level are not known. Here we use an ocean circulation model and observed nutrient distributions to show that the N/P ratio of biological nutrient removal varies across latitude in Southern Ocean surface waters, from 12: 1 in the polar ocean to 20: 1 in the sub-Antarctic zone. These variations are governed by regional differences in the species composition of the plankton community. The covariation of dissolved nitrate and phosphate is maintained by ocean circulation, which mixes the shallow subsurface nutrients between distinct biogeographic provinces. Climate-driven shifts in these marine biomes may alter the mean N/P ratio and the associated carbon export by Southern Ocean ecosystems.	[Weber, Thomas S.; Deutsch, Curtis] Univ Calif Los Angeles, Dept Atmospher & Ocean Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Weber, TS (corresponding author), Univ Calif Los Angeles, Dept Atmospher & Ocean Sci, Los Angeles, CA 90095 USA.	tweber@atmos.ucla.edu	Deutsch, Curtis A/D-1703-2011		National Science Foundation; Gordon and Betty Moore Foundation; UCLA	National Science Foundation(National Science Foundation (NSF)); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); UCLA	We thank S. Khatiwala for providing the transport matrix. This work was funded by grants from the National Science Foundation and the Gordon and Betty Moore Foundation. Additional support for T.S.W. was provided by a Pauley Fellowship from UCLA.	ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; Anderson RF, 2009, SCIENCE, V323, P1443, DOI 10.1126/science.1167441; Arrigo KR, 1999, SCIENCE, V283, P365, DOI 10.1126/science.283.5400.365; BROECKER WS, 1982, PROG OCEANOGR, V11, P151, DOI 10.1016/0079-6611(82)90007-6; Brzezinski MA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014349; CODISPOTI LA, 1985, MAR CHEM, V16, P277, DOI 10.1016/0304-4203(85)90051-9; CODISPOTI LA, 1989, LIFE SCI R, V44, P377; Dentener F, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002672; Elderfield H, 2000, NATURE, V405, P305, DOI 10.1038/35012507; Falkowski PG, 2000, J PHYCOL, V36, P3, DOI 10.1046/j.1529-8817.2000.99161.x; Finkel ZV, 2006, LIMNOL OCEANOGR, V51, P2690, DOI 10.4319/lo.2006.51.6.2690; Fu FX, 2007, J PHYCOL, V43, P485, DOI 10.1111/j.1529-8817.2007.00355.x; Garcia H. E., 2006, WORLD OCEAN ATLAS 20; Geider RJ, 2002, EUR J PHYCOL, V37, P1, DOI 10.1017/S0967026201003456; Green SE, 2006, DEEP-SEA RES PT II, V53, P620, DOI 10.1016/j.dsr2.2006.01.022; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; Jin X, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002532; Karl D, 1997, NATURE, V388, P533, DOI 10.1038/41474; KARL DM, 2001, ENCY OCEAN SCI, P1876; Khatiwala S, 2005, OCEAN MODEL, V9, P51, DOI 10.1016/j.ocemod.2004.04.002; Klausmeier CA, 2004, NATURE, V429, P171, DOI 10.1038/nature02454; KOPCZYNSKA EE, 1986, POLAR BIOL, V6, P161, DOI 10.1007/BF00274879; Le Quere C, 2007, SCIENCE, V316, P1735, DOI 10.1126/science.1136188; Longhurst A, 1995, PROG OCEANOGR, V36, P77, DOI 10.1016/0079-6611(95)00015-1; ORSI AH, 1995, DEEP-SEA RES PT I, V42, P641, DOI 10.1016/0967-0637(95)00021-W; Price NM, 2005, LIMNOL OCEANOGR, V50, P1159, DOI 10.4319/lo.2005.50.4.1159; Quigg A, 2003, NATURE, V425, P291, DOI 10.1038/nature01953; REDFIELD AC, 1958, AM SCI, V46, P205; Sarmiento JL, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002134; SARMIENTO JL, 1984, NATURE, V308, P621, DOI 10.1038/308621a0; Schlitzer R, 2002, DEEP-SEA RES PT II, V49, P1623, DOI 10.1016/S0967-0645(02)00004-8; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, P80; TAKAHASHI T, 1985, J GEOPHYS RES-OCEANS, V90, P6907, DOI 10.1029/JC090iC04p06907; Tyrrell T, 1999, NATURE, V400, P525, DOI 10.1038/22941; Wu JF, 2000, SCIENCE, V289, P759, DOI 10.1126/science.289.5480.759	35	192	198	5	164	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP	2010	467	7315					550	554		10.1038/nature09403	http://dx.doi.org/10.1038/nature09403			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882009				2022-12-28	WOS:000282273100030
J	Jones, S; Wang, TL; Shih, IM; Mao, TL; Nakayama, K; Roden, R; Glas, R; Slamon, D; Diaz, LA; Vogelstein, B; Kinzler, KW; Velculescu, VE; Papadopoulos, N				Jones, Sian; Wang, Tian-Li; Shih, Ie-Ming; Mao, Tsui-Lien; Nakayama, Kentaro; Roden, Richard; Glas, Ruth; Slamon, Dennis; Diaz, Luis A., Jr.; Vogelstein, Bert; Kinzler, Kenneth W.; Velculescu, Victor E.; Papadopoulos, Nickolas			Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma	SCIENCE			English	Article							PHOSPHATASE 2A; HUMAN BREAST; ENDOMETRIOSIS; PATHWAYS; PATTERNS; DISTINCT	Ovarian clear cell carcinoma (OCCC) is an aggressive human cancer that is generally resistant to therapy. To explore the genetic origin of OCCC, we determined the exomic sequences of eight tumors after immunoaffinity purification of cancer cells. Through comparative analyses of normal cells from the same patients, we identified four genes that were mutated in at least two tumors. PIK3CA, which encodes a subunit of phosphatidylinositol-3 kinase, and KRAS, which encodes a well-known oncoprotein, had previously been implicated in OCCC. The other two mutated genes were previously unknown to be involved in OCCC: PPP2R1A encodes a regulatory subunit of serine/threonine phosphatase 2, and ARID1A encodes adenine-thymine (AT)-rich interactive domain-containing protein 1A, which participates in chromatin remodeling. The nature and pattern of the mutations suggest that PPP2R1A functions as an oncogene and ARID1A as a tumor-suppressor gene. In a total of 42 OCCCs, 7% had mutations in PPP2R1A and 57% had mutations in ARID1A. These results suggest that aberrant chromatin remodeling contributes to the pathogenesis of OCCC.	[Jones, Sian; Diaz, Luis A., Jr.; Vogelstein, Bert; Kinzler, Kenneth W.; Velculescu, Victor E.; Papadopoulos, Nickolas] Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA; [Jones, Sian; Diaz, Luis A., Jr.; Vogelstein, Bert; Kinzler, Kenneth W.; Velculescu, Victor E.; Papadopoulos, Nickolas] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; [Wang, Tian-Li] Johns Hopkins Med Inst, Dept Gynecol & Obstet & Oncol, Baltimore, MD 21231 USA; [Shih, Ie-Ming; Roden, Richard] Johns Hopkins Med Inst, Dept Pathol Oncol Gynecol & Obstet, Baltimore, MD 21231 USA; [Mao, Tsui-Lien] Natl Taiwan Univ, Coll Med, Dept Pathol, Taipei 100, Taiwan; [Nakayama, Kentaro] Shimane Univ, Sch Med, Dept Obstet & Gynecol, Izumo, Shimane 6938501, Japan; [Glas, Ruth; Slamon, Dennis] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; National Taiwan University; Shimane University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kinzler, KW (corresponding author), Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.	kinzlke@jhmi.edu; velculescu@jhmi.edu; npapado1@jhmi.edu	Jones, Sian/A-5050-2012; sdsd, shihieih/ABE-6190-2020; Papadopoulos, Nickolas/K-7272-2012; Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X; Diaz, Luis/0000-0002-7079-8914	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; American Association for Cancer Research, The Virginia; U.S. Department of Defense [OC0400600]; NIH [CA121113, CA57345, CA129080, CA103937, CA122581]; NATIONAL CANCER INSTITUTE [R01CA122581, R01CA129080, R01CA103937, R37CA057345, R01CA121113, R01CA057345] Funding Source: NIH RePORTER	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; American Association for Cancer Research, The Virginia; U.S. Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Y. He for technical advice and M. Whalen, J. Ptak, and N. Silliman for expert technical assistance. Funded by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, American Association for Cancer Research Stand Up To Cancer-Dream Team Translational Cancer Research Grant, The Virginia and D. K. Ludwig Fund for Cancer Research, U.S. Department of Defense grant OC0400600 (T.-L. W.), and NIH grants CA121113, CA57345, CA129080, CA103937 (IMS), and CA122581 (R. R.). N. P., B. V., L. D., V. V., and K. W. K. are members of the Scientific Advisory Board of Inostics, a company that is developing technologies for the molecular diagnosis of cancer. N. P., B. V., L. D., V. V., and K. W. K. also own stock in Inostics. The authors are entitled to a share of the royalties received by the university on sales of products related to genes described in this manuscript. The terms of these arrangements are being managed by the university in accordance with their conflict of interest policies. V. V., B. V., K. W. K., and Johns Hopkins University also own stock in Genzyme and Exact Sciences, which are managed under similar arrangements.	Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Erzen M, 2001, GYNECOL ONCOL, V83, P100, DOI 10.1006/gyno.2001.6382; Fukunaga M, 1997, HISTOPATHOLOGY, V30, P249, DOI 10.1046/j.1365-2559.1997.d01-592.x; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kuo KT, 2010, CLIN CANCER RES, V16, P1997, DOI 10.1158/1078-0432.CCR-09-2105; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Marquez RT, 2005, CLIN CANCER RES, V11, P6116, DOI 10.1158/1078-0432.CCR-04-2509; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Sato N, 2000, CANCER RES, V60, P7052; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Veras E, 2009, AM J SURG PATHOL, V33, P844, DOI 10.1097/PAS.0b013e31819c4271; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu JI, 2009, CELL, V136, P200, DOI 10.1016/j.cell.2009.01.009	28	877	921	0	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	2010	330	6001					228	231		10.1126/science.1196333	http://dx.doi.org/10.1126/science.1196333			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LP	20826764	Green Accepted			2022-12-28	WOS:000282644600044
J	Daniels, JP; Khan, KS				Daniels, Jane P.; Khan, Khalid S.			Chronic pelvic pain in women	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PREVALENCE		[Daniels, Jane P.] Univ Birmingham, Reprod Genes & Develop & Clin Trials Unit, Birmingham B15 2TT, England; [Khan, Khalid S.] Barts & London Queen Marys Sch Med & Dent, London E1 2DD, England	University of Birmingham; University of London; Queen Mary University London	Daniels, JP (corresponding author), Univ Birmingham, Reprod Genes & Develop & Clin Trials Unit, Birmingham B15 2TT, England.	j.p.daniels@bham.ac.uk	Khan, Khalid S/AAT-8824-2020	Khan, Khalid S/0000-0001-5084-7312				ALSOM N, 2009, BJOG, V116, P1551; *AM COLL OBST GYN, 2004, ACOG PRACT B, V51; Ballard K, 2010, FERTIL STERIL, V94, P20, DOI 10.1016/j.fertnstert.2009.01.164; Cody RF, 2000, BEST PRACT RES CL OB, V14, P433, DOI 10.1053/beog.1999.0085; Daniels J, 2009, JAMA-J AM MED ASSOC, V302, P955, DOI 10.1001/jama.2009.1268; DANIELS JP, 2010, HUM REPROD UPDATE; Fall M, 2010, EUR UROL, V57, P35, DOI 10.1016/j.eururo.2009.08.020; Grace Victoria, 2006, Health Care Women Int, V27, P585, DOI 10.1080/07399330600803725; Grace VM, 2007, WOMEN HEALTH, V46, P81, DOI 10.1300/J013v46n04_05; Howard F M, 1993, Obstet Gynecol Surv, V48, P357, DOI 10.1097/00006254-199306000-00001; Howard FM, 2000, BEST PRACT RES CL OB, V14, P467, DOI 10.1053/beog.1999.0086; Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135; Latthe P, 2006, BMJ-BRIT MED J, V332, P749, DOI 10.1136/bmj.38748.697465.55; Latthe P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-177; PETERS AAW, 1991, OBSTET GYNECOL, V77, P740; *RCOG GUID AUD COM, 2006, 24 RCOG GUID AUD COM; *RCOG GUID AUT COM, 2005, 41 RCOG GUID AUD COM; Stones RW, 2002, J ROY SOC MED, V95, P531, DOI 10.1258/jrsm.95.11.531; STONES W, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000387; Wesselmann U, 2001, WORLD J UROL, V19, P180, DOI 10.1007/s003450100201; Williams RE, 2004, OBSTET GYNECOL, V103, P686, DOI 10.1097/01.AOG.0000115513.92318.b7; WONG CL, 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD002120.PUB3; Zondervan KT, 2001, BRIT J GEN PRACT, V51, P541; Zondervan KT, 1999, BRIT J OBSTET GYNAEC, V106, P1149, DOI 10.1111/j.1471-0528.1999.tb08140.x	24	59	63	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2010	341								c4834	10.1136/bmj.c4834	http://dx.doi.org/10.1136/bmj.c4834			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663JB	20923840				2022-12-28	WOS:000282879000005
J	Parrinello, S; Napoli, I; Ribeiro, S; Digby, PW; Fedorova, M; Parkinson, DB; Doddrell, RDS; Nakayama, M; Adams, RH; Lloyd, AC				Parrinello, Simona; Napoli, Ilaria; Ribeiro, Sara; Digby, Patrick Wingfield; Fedorova, Marina; Parkinson, David B.; Doddrell, Robin D. S.; Nakayama, Masanori; Adams, Ralf H.; Lloyd, Alison C.			EphB Signaling Directs Peripheral Nerve Regeneration through Sox2-Dependent Schwann Cell Sorting	CELL			English	Article							NEURAL CREST MIGRATION; N-CADHERIN; AXON; SYSTEM; FIBROBLASTS; PRECURSORS; EXPRESSION; PATTERNS; ADHESION; GUIDANCE	The peripheral nervous system has astonishing regenerative capabilities in that cut nerves are able to reconnect and re-establish their function. Schwann cells are important players in this process, during which they dedifferentiate to a progenitor/stem cell and promote axonal regrowth. Here, we report that fibroblasts also play a key role. Upon nerve cut, ephrin-B/EphB2 signaling between fibroblasts and Schwann cells results in cell sorting, followed by directional collective cell migration of Schwann cells out of the nerve stumps to guide regrowing axons across the wound. Mechanistically, we find that cell-sorting downstream of EphB2 is mediated by the stemness factor Sox2 through N-cadherin relocalization to Schwann cell-cell contacts. In vivo, loss of EphB2 signaling impaired organized migration of Schwann cells, resulting in misdirected axonal regrowth. Our results identify a link between Ephs and Sox proteins, providing a mechanism by which progenitor cells can translate environmental cues to orchestrate the formation of new tissue.	[Parrinello, Simona; Napoli, Ilaria; Ribeiro, Sara; Digby, Patrick Wingfield; Fedorova, Marina; Lloyd, Alison C.] UCL, MRC Lab Mol Cell Biol, London WC1E 6BT, England; [Parrinello, Simona; Napoli, Ilaria; Ribeiro, Sara; Digby, Patrick Wingfield; Fedorova, Marina; Lloyd, Alison C.] UCL, UCL Canc Inst, London WC1E 6BT, England; [Parkinson, David B.; Doddrell, Robin D. S.] Univ Plymouth, Peninsula Coll Med & Dent, Plymouth PL6 8BU, Devon, England; [Nakayama, Masanori; Adams, Ralf H.] Univ Munster, Dept Tissue Morphogenesis, Max Planck Inst Mol Biomed, D-48149 Munster, Germany; [Nakayama, Masanori; Adams, Ralf H.] Univ Munster, Fac Med, D-48149 Munster, Germany	MRC Laboratory Molecular Biology; University of London; University College London; University of London; University College London; University of Plymouth; Max Planck Society; University of Munster; University of Munster	Lloyd, AC (corresponding author), UCL, MRC Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.	alison.lloyd@ucl.ac.uk	Adams, Ralf H/AAE-9274-2019; Ribeiro, Sara/I-1615-2013	Ribeiro, Sara/0000-0002-6500-8412; Napoli, Ilaria/0000-0002-0649-1950	Cancer Research UK program; Association for International Cancer Research; Cancer Research UK [11244] Funding Source: researchfish	Cancer Research UK program(Cancer Research UK); Association for International Cancer Research; Cancer Research UK(Cancer Research UK)	S.P. is a Royal Society D.H. Research Fellow. This work was supported by a Cancer Research UK program and an Association for International Cancer Research project grant. We thank C.D. Nobes for advice and M. Raff and B. Baum for critical reading of the manuscript, M. Herlyn, J. Milbrandt, E. Battle, and D. Wilkinson for constructs and G. Parrinello, A. Mira, and J. Kriston-Vizi for statistics.	Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen YY, 2005, J NEUROPATH EXP NEUR, V64, P613, DOI 10.1097/01.jnen.0000171650.94341.46; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Crawford AT, 2008, GLIA, V56, P1637, DOI 10.1002/glia.20716; Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002; Gilmour DT, 2002, NEURON, V34, P577, DOI 10.1016/S0896-6273(02)00683-9; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Kuriyama S, 2008, PHILOS T R SOC B, V363, P1349, DOI 10.1098/rstb.2007.2252; Lackmann M, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.115re2; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; LETOURNEAU PC, 1991, J NEUROBIOL, V22, P707, DOI 10.1002/neu.480220706; Luria V, 2008, NEURON, V60, P1039, DOI 10.1016/j.neuron.2008.11.011; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; Mcdonald D, 2006, NEURON GLIA BIOL, V2, P139, DOI 10.1017/S1740925X05000347; McDonald DS, 2003, J NEUROSCI METH, V122, P171, DOI 10.1016/S0165-0270(02)00319-9; MORRIS JH, 1972, Z ZELLFORSCH MIK ANA, V124, P165, DOI 10.1007/BF00335678; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Navarro X, 2009, INT REV NEUROBIOL, V87, P483, DOI 10.1016/S0074-7742(09)87027-X; Nguyen QT, 2002, NAT NEUROSCI, V5, P861, DOI 10.1038/nn905; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Parrinello S, 2008, GENE DEV, V22, P3335, DOI 10.1101/gad.490608; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Scherer SS, 2001, AXON SCHWANN CELL IN; SCHRODER JM, 1993, CLIN NEUROL NEUROSUR, V95, P78; Sorrell JM, 2009, INT REV CEL MOL BIO, V276, P161, DOI 10.1016/S1937-6448(09)76004-6; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Von Philipsborn AC, 2006, NAT PROTOC, V1, P1322, DOI 10.1038/nprot.2006.251; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wanner IB, 2006, GLIA, V54, P439, DOI 10.1002/glia.20390; Wanner IB, 2006, GLIA, V54, P424, DOI 10.1002/glia.20389; Zochodne DW, 2008, NEUROBIOLOGY OF PERIPHERAL NERVE REGENERATION, P1, DOI 10.1017/CBO9780511541759	38	332	343	4	49	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					145	155		10.1016/j.cell.2010.08.039	http://dx.doi.org/10.1016/j.cell.2010.08.039			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20869108	Bronze, Green Accepted			2022-12-28	WOS:000282362000021
J	Holroyd, KA; Cottrell, CK; O'Donnell, FJ; Cordingley, GE; Drew, JB; Carlson, BW; Himawan, L				Holroyd, Kenneth A.; Cottrell, Constance K.; O'Donnell, Francis J.; Cordingley, Gary E.; Drew, Jana B.; Carlson, Bruce W.; Himawan, Lina			Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; LONGITUDINAL CLINICAL-TRIALS; PLACEBO-CONTROLLED TRIAL; PRIMARY-CARE; DOUBLE-BLIND; PROPHYLACTIC TREATMENT; RECURRENT HEADACHE; EARLY INTERVENTION; UNITED-STATES; PROPRANOLOL	Objective To determine if the addition of preventive drug treatment (beta blocker), brief behavioural migraine management, or their combination improves the outcome of optimised acute treatment in the management of frequent migraine. Design Randomised placebo controlled trial over 16 months from July 2001 to November 2005. Setting Two outpatient sites in Ohio, USA. Participants 232 adults (mean age 38 years; 79% female) with diagnosis of migraine with or without aura according to International Headache Society classification of headache disorders criteria, who recorded at least three migraines with disability per 30 days (mean 5.5 migraines/30 days), during an optimised run-in of acute treatment. Interventions Addition of one of four preventive treatments to optimised acute treatment: beta blocker (n=53), matched placebo (n=55), behavioural migraine management plus placebo (n=55), or behavioural migraine management plus beta blocker (n=69). Main outcome measure The primary outcome was change in migraines/30 days; secondary outcomes included change in migraine days/30 days and change in migraine specific quality of life scores. Results Mixed model analysis showed statistically significant (P <= 0.05) differences in outcomes among the four added treatments for both the primary outcome (migraines/30 days) and the two secondary outcomes (change in migraine days/30 days and change in migraine specific quality of life scores). The addition of combined beta blocker and behavioural migraine management (-3.3 migraines/30 days, 95% confidence interval -3.2 to -3.5), but not the addition of beta blocker alone (-2.1 migraines/30 days, -1.9 to -2.2) or behavioural migraine management alone (-2.2 migraines migraines/30 days, -2.0 to -2.4), improved outcomes compared with optimised acute treatment alone (-2.1 migraines/30 days, -1.9 to -2.2). For a clinically significant (>= 50% reduction) in migraines/30 days, the number needed to treat for optimised acute treatment plus combined beta blocker and behavioural migraine management was 3.1 compared with optimised acute treatment alone, 2.6 compared with optimised acute treatment plus beta blocker, and 3.1 compared with optimised acute treatment plus behavioural migraine management. Results were consistent for the two secondary outcomes, and at both month 10 ( the primary end point) and month 16. Conclusion The addition of combined beta blocker plus behavioural migraine management, but not the addition of beta blocker alone or behavioural migraine management alone, improved outcomes of optimised acute treatment. Combined beta blocker treatment and behavioural migraine management may improve outcomes in the treatment of frequent migraine.	[O'Donnell, Francis J.; Cordingley, Gary E.] Ohio Univ, Coll Osteopath Med, Athens, OH 45701 USA; [Holroyd, Kenneth A.; Cottrell, Constance K.; O'Donnell, Francis J.; Drew, Jana B.] Headache Treatment & Res, Westerville, OH 43081 USA; [O'Donnell, Francis J.] OrthoNeuro Inc, Westerville, OH 43081 USA	University System of Ohio; Ohio University	Holroyd, KA (corresponding author), 225 Porter Hall, Athens, OH 45701 USA.	holroyd@ohio.edu			National Institutes of Health [R01-NS-32374]; Merck Pharmaceuticals; GlaxoSmithKline Pharmaceuticals; National Institutes of Health (NINDS) [NS32375]; Merck; GSK; UCB Pharma; Allergan; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032374] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Merck Pharmaceuticals(Merck & Company); GlaxoSmithKline Pharmaceuticals(GlaxoSmithKline); National Institutes of Health (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Merck(Merck & Company); GSK(GlaxoSmithKline); UCB Pharma(UCB Pharma SA); Allergan(AbbVieAllergan); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Grant R01-NS-32374 (awarded to KAH) from the National Institutes of Health provided primary support for this trial. Merck Pharmaceuticals and GlaxoSmithKline Pharmaceuticals donated triptans for the trial, which was their only involvement. These organisations had no role in the data collection, statistical analysis, or writing of this article or the decision to submit for publication.; KAH has consulted for ENDO Pharmaceuticals and for Takeda Pharmaceuticals North America and received an investigator initiated grant from ENDO Pharmaceuticals. He has also received support from the National Institutes of Health (NINDS; NS32375). CKC has received research funding and materials from GlaxoSmithKline Pharmaceuticals (GSK) and Merck and participates in industry sponsored research involving GSK, Merck, UCB Pharma, and Allergan. FJO'D has received research funding and materials from GSK and Merck; receives educational funding from GSK, Merck, and Allergan; participates in industry sponsored research involving GSK, Merck, UCB Pharma, and Allergan; and has consulted for and received honorariums from GSK. GEC owns stock in Johnson and Johnson, Novartis, and Wyeth Pharmaceuticals.	Adelman JU, 1998, CEPHALALGIA, V18, P605, DOI 10.1046/j.1468-2982.1998.1809605.x; Adelman JU, 2002, HEADACHE, V42, P978, DOI 10.1046/j.1526-4610.2002.02227.x; Aurora SK, 2009, CEPHALALGIA, V29, P597, DOI 10.1111/j.1468-2982.2008.01811.x; Azzopardi TD, 2008, ANN PHARMACOTHER, V42, P397, DOI 10.1345/aph.1K481; Barnes SA, 2008, PHARM STAT, V7, P215, DOI 10.1002/pst.310; Beck A.T., 1993, PRINCIPLES PRACTICE, V2nd ed., P333; Bernstein D. A., 2000, NEW DIRECTIONS PROGR; Bigal ME, 2008, HEADACHE, V48, P7, DOI 10.1111/j.1526-4610.2007.00969.x; BLANCHARD EB, 1992, J CONSULT CLIN PSYCH, V60, P537, DOI 10.1037/0022-006X.60.4.537; BLANCHARD EB, 1988, BEHAV ASSESS, V10, P171; BLANCHARD EB, 1981, BEHAV THER, V12, P711, DOI 10.1016/S0005-7894(81)80142-6; Brandes JL, 2008, HEADACHE, V48, P430, DOI 10.1111/j.1526-4610.2007.01004.x; Brandes JL, 2004, JAMA-J AM MED ASSOC, V291, P965, DOI 10.1001/jama.291.8.965; CAMPBELL JK, 2000, EVIDENCE BASED GUIDE; Cevoli S, 2009, CEPHALALGIA, V29, P1285, DOI 10.1111/j.1468-2982.2009.01874.x; DAHLOF C, 1989, NEW ADV HEADACHE RES, P281; DaSilva AFM, 2007, NEUROLOGY, V69, P1990, DOI 10.1212/01.wnl.0000291618.32247.2d; DIAMOND R, 2005, AM J MED S1, V118, P185; Diener HC, 2004, J NEUROL, V251, P943, DOI 10.1007/s00415-004-0464-6; Diener HC, 2002, CEPHALALGIA, V22, P209, DOI 10.1046/j.1468-2982.2002.t01-1-00309.x; Diener HC, 1996, CEPHALALGIA, V16, P441, DOI 10.1046/j.1468-2982.1996.1606441.x; DIENER HC, 2004, NEUROLOGY, V63, P520; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; GAWEL MJ, 1992, CAN J NEUROL SCI, V19, P340, DOI 10.1017/S0317167100041962; Goadsby PJ, 2008, CEPHALALGIA, V28, P383, DOI 10.1111/j.1468-2982.2008.01546.x; Harpole LH, 2005, HEADACHE, V45, P1048, DOI 10.1111/j.1526-4610.2005.05186.x; Hazard E, 2009, VALUE HEALTH, V12, P55, DOI 10.1111/j.1524-4733.2008.00404.x; Holroyd K, 2000, BEHAV MANAGEMENT MIG; HOLROYD K, 2006, SEMINARS NEUROLOGY H, P199; HOLROYD K, 2008, WOLFFS HEADACHE OTHE, P721; Holroyd K, 2000, CEPHALALGIA, V36, P123; HOLROYD KA, 1990, PAIN, V42, P1, DOI 10.1016/0304-3959(90)91085-W; Holroyd KA, 2002, J CONSULT CLIN PSYCH, V70, P656, DOI 10.1037//0022-006X.70.3.656; Holroyd KA, 2001, JAMA-J AM MED ASSOC, V285, P2208, DOI 10.1001/jama.285.17.2208; HOLROYD KA, 1995, J CONSULT CLIN PSYCH, V63, P327, DOI 10.1037/0022-006X.63.2.327; HOLROYD KA, 1991, HEADACHE, V31, P333, DOI 10.1111/j.1526-4610.1991.hed3105333.x; Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x; JOHNSON RH, 1986, ACTA NEUROL SCAND, V73, P490, DOI 10.1111/j.1600-0404.1986.tb04591.x; KANGASNIEMI PJ, 1983, ACTA NEUROL SCAND, V68, P262, DOI 10.1111/j.1600-0404.1983.tb04836.x; Kaniecki RG, 1997, ARCH NEUROL-CHICAGO, V54, P1141, DOI 10.1001/archneur.1997.00550210071015; Kaniecki RL, 2004, STANDARDS CARE HEADA, P40; Kernick D, 2010, CEPHALALGIA, V30, P899, DOI 10.1177/0333102409361216; Kruit MC, 2009, CEPHALALGIA, V29, P351, DOI 10.1111/j.1468-2982.2008.01723.x; Kruit MC, 2006, STROKE, V37, P1109, DOI 10.1161/01.STR.0000206446.26702.e9; Lane P, 2008, PHARM STAT, V7, P93, DOI 10.1002/pst.267; Levy D, 2004, P NATL ACAD SCI USA, V101, P4274, DOI 10.1073/pnas.0306147101; LIPCHIK G, 2002, PSYCHOL APPROACHES P, P356; LIPTON R, 2006, MIGRAINE OTHER HEADA, P23; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lipton RB, 2000, JAMA-J AM MED ASSOC, V284, P2599, DOI 10.1001/jama.284.20.2599; Lipton RB, 1998, HEADACHE, V38, P87, DOI 10.1046/j.1526-4610.1998.3802087.x; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Loder E, 2005, HEADACHE, V45, pS33, DOI 10.1111/j.1526-4610.2005.4501002.x; Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194; Mallinckrodt CH, 2004, PHARM STAT, V3, P161, DOI 10.1002/pst.124; Mallinckrodt CH, 2003, BIOL PSYCHIAT, V53, P754, DOI 10.1016/S0006-3223(02)01867-X; Martin BC, 2000, HEADACHE, V40, P204, DOI 10.1046/j.1526-4610.2000.00030.x; Mathew NT, 2000, HEADACHE, V40, P464, DOI 10.1046/j.1526-4610.2000.00069.x; McCulloch C. E., 2000, GEN LINEAR MIXED MOD; MIKKELSEN B, 1986, ACTA NEUROL SCAND, V73, P423, DOI 10.1111/j.1600-0404.1986.tb03299.x; Molenberghs G, 2004, BIOSTATISTICS, V5, P445, DOI 10.1093/biostatistics/kxh001; OLERUD B, 1986, HEADACHE, V26, P490, DOI 10.1111/j.1526-4610.1986.hed2610490.x; Olesen J, 2006, CEPHALALGIA, V26, P742, DOI 10.1111/j.1468-2982.2006.01172.x; Patrick DL, 2000, HEADACHE, V40, P550, DOI 10.1046/j.1526-4610.2000.00086.x; Penzien DB, 2002, APPL PSYCHOPHYS BIOF, V27, P163, DOI 10.1023/A:1016247811416; Peveler R, 1999, BRIT MED J, V319, P612, DOI 10.1136/bmj.319.7210.612; Ramadan NM, 1997, CEPHALALGIA, V17, P73, DOI 10.1046/j.1468-2982.1997.1702073.x; RAMADAN NM, 2002, EVIDENCE BASED GUIDE; Rao BS, 2000, NEUROL INDIA, V48, P223; ROSSNAGEL K, 2004, COCHRANE DB SYST REV, V2; Sakai Y, 2008, NEUROLOGY, V70, P431, DOI 10.1212/01.wnl.0000299095.65331.6f; Saxena PR, 2006, HEADACHES; Scher AI, 2008, HEADACHE, V48, P16, DOI 10.1111/j.1526-4610.2007.00970.x; Schmitz N, 2008, HEADACHE, V48, P1044, DOI 10.1111/j.1526-4610.2008.01133.x; Silberstein SD, 2008, NEUROLOGY, V71, P114, DOI 10.1212/01.wnl.0000316800.22949.20; Silberstein SD, 2004, ARCH NEUROL-CHICAGO, V61, P490, DOI 10.1001/archneur.61.4.490; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2005, HEADACHE, V45, P1250, DOI 10.1111/j.1526-4610.2005.00250.x; Silberstein SD, 2008, WOLFFS HEADACHE OTHE, P177; Silberstein SD, 2008, WOLFFS HEADACHE OTHE, P315; SOLOMON GD, 1986, HEADACHE, V26, P325; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Steiner TJ, 2007, J HEADACHE PAIN S1, V8, P3; STEWART WF, 1994, EUR NEUROL, V34, P12, DOI 10.1159/000119527; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Terwindt GM, 2000, NEUROLOGY, V55, P624, DOI 10.1212/WNL.55.5.624; Tfelt-Hansen P, 2008, CEPHALALGIA, V28, P767, DOI 10.1111/j.1468-2982.2007.01415.x; TFELTHANSEN P, 2006, HEADACHES, P515; Von Korff M, 1998, NEUROLOGY, V50, P1741, DOI 10.1212/WNL.50.6.1741; ZIEGLER DK, 1993, ARCH NEUROL-CHICAGO, V50, P825, DOI 10.1001/archneur.1993.00540080036010; ZIEGLER DK, 1987, ARCH NEUROL-CHICAGO, V44, P486, DOI 10.1001/archneur.1987.00520170016015	91	99	101	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 29	2010	341								c4871	10.1136/bmj.c4871	http://dx.doi.org/10.1136/bmj.c4871			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659ND	20880898	Green Published, hybrid			2022-12-28	WOS:000282572400013
J	del Zoppo, GJ; Hawkins, BT				del Zoppo, Gregory J.; Hawkins, Brian T.			Throwing Out the Thromboemboli	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PLASMINOGEN-ACTIVATOR		[del Zoppo, Gregory J.; Hawkins, Brian T.] Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	del Zoppo, GJ (corresponding author), Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA.			Hawkins, Brian/0000-0001-6719-5402				Hosomi N, 2001, STROKE, V32, P1341, DOI 10.1161/01.STR.32.6.1341; Lam CK, 2010, NATURE, V465, P478, DOI 10.1038/nature09001; LEVIN EG, 1994, AM J PATHOL, V144, P855; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637	5	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1282	1284		10.1056/NEJMcibr1006572	http://dx.doi.org/10.1056/NEJMcibr1006572			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860513				2022-12-28	WOS:000282050000016
J	Kerry, VB; Auld, S; Farmer, P				Kerry, Vanessa Bradford; Auld, Sara; Farmer, Paul			GLOBAL HEALTH An International Service Corps for Health - An Unconventional Prescription for Diplomacy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kerry, Vanessa Bradford; Farmer, Paul] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02215 USA; [Farmer, Paul] Brigham & Womens Hosp, Dept Global Hlth & Social Equ, Boston, MA 02115 USA; [Kerry, Vanessa Bradford; Auld, Sara] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Kerry, VB (corresponding author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02215 USA.							Farmer P, 2010, LANCET; Farmer Paul E, 2004, Lancet, V363, P1832, DOI 10.1016/S0140-6736(04)16325-3; *MED ED COOP CUB, 2010, CUB GLOB HLTH; WHO, 2006, WORK TOG HLTH WORLD; Woodward, 2003, GLOBAL PUBLIC GOODS, P3	5	27	27	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1199	1201						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652ZA	20860500				2022-12-28	WOS:000282050000003
J	Currier, J; Bridge, DA; Hagins, D; Zorrilla, CD; Feinberg, J; Ryan, R; Falcon, R; Tennenberg, A; Mrus, J; Squires, K				Currier, Judith; Bridge, Dawn Averitt; Hagins, Debbie; Zorrilla, Carmen D.; Feinberg, Judith; Ryan, Robert; Falcon, Ron; Tennenberg, Alan; Mrus, Joseph; Squires, Kathleen		GRACE Study Grp	Sex-Based Outcomes of Darunavir-Ritonavir Therapy A Single-Group Trial	ANNALS OF INTERNAL MEDICINE			English	Article							TREATMENT-EXPERIENCED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; CLINICAL-TRIALS; GENDER-DIFFERENCES; EFFICACY; SAFETY; HIV; WOMEN; LOPINAVIR/RITONAVIR; REPRESENTATION	Background: Women account for an increasing proportion of patients with HIV-1 but remain underrepresented in antiretroviral clinical trials. Objective: To evaluate sex-based differences in efficacy and adverse events in treatment-experienced, HIV-positive women and men receiving darunavir-ritonavir therapy over 48 weeks. Design: Multicenter, open-label, phase 3b study designed to enroll a high proportion of women, with sample size determined on the basis of a noninferiority design with a maximum allowable difference of 15% in virologic response favoring men. (ClinicalTrials.gov registration number: NCT00381303) Setting: 65 sites in the United States, Puerto Rico, and Canada. Patients: 287 women and 142 men. Intervention: Patients received darunavir-ritonavir, 600/100 mg twice daily, plus an investigator-selected optimized background regimen. Measurements: Virologic response (HIV RNA <50 copies/mL using a time-to-loss of virologic response [TLOVR] algorithm) and adverse events were assessed over 48 weeks. Results: 67% of patients were women; 84% of patients were black or Hispanic. A higher proportion of women discontinued treatment than men (32.8% vs. 23.2%; P = 0.042); more women than men discontinued treatment for reasons other than virologic failure. Response rates in women and men at week 48 were 50.9% and 58.5%, respectively (intention-to-treat TLOVR), and 73.0% and 73.5%, respectively (TLOVR censored for patients who withdrew for reasons other than virologic failure). The absolute difference in response, based on logistic regression and adjusted for baseline log(10) viral load and CD4(+) cell count, was -9.6 percentage points (95% CI, -19.9 to 0.7 percentage points; P = 0.067) for intention-to-treat TLOVR and -3.9 percentage points (CI, -13.9 to 6.0 percentage points; P = 0.438) for TLOVR population that censored patients who withdrew for reasons other than virologic failure. Adverse events were similar between the sexes. The most common grade 2 to 4 adverse events that were considered at least possibly treatment related in women and men were nausea (5.2% and 2.8%, respectively), diarrhea (4.5% and 4.9%, respectively), and rash (2.1% and 2.8%, respectively). Limitation: Baseline characteristics differed between sexes. Conclusion: Nonsignificant, sex-based differences in response were found during the 48-week study; however, these differences were probably due to higher discontinuation rates in women, suggesting that additional efforts are needed to retain women in clinical trials.	[Bridge, Dawn Averitt] Well Project, Nellysford, VA 22958 USA; [Hagins, Debbie] Chatham Cty Hlth Dept, Savannah, GA 31401 USA; [Zorrilla, Carmen D.] Maternal Infant Studies Ctr CEMI, Rio Piedras, PR 00935 USA; [Squires, Kathleen] Div Infect Dis, Philadelphia, PA 19107 USA		Currier, J (corresponding author), Univ Calif Los Angeles, CARE Ctr, 9911 W Pico Blvd,Suite 980, Los Angeles, CA 90035 USA.				Tibotec Therapeutics; National Institute of Allergy and Infectious Diseases, National Institutes of Health [K24 AI56933]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI056933] Funding Source: NIH RePORTER	Tibotec Therapeutics; National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study and editorial assistance were funded by Tibotec Therapeutics. Dr. Currier is supported in part by a grant from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (K24 AI56933).	ABSALON J, 2010, 13 INT AIDS C MEX CI; Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006; BELDEN KA, 2008, PMID, V10, P423; Campsmith M. L., 2008, Morbidity and Mortality Weekly Report, V57, P1073; Centers for Disease Control and Prevention, 2010, HIV AIDS SURV; Centers for Disease Control and Prevention (CDC), 2010, HIV AIDS; Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; Fabricatore AN, 2009, OBES REV, V10, P333, DOI 10.1111/j.1467-789X.2009.00567.x; FOURIE J, 2010, 5 IAS C HIV PATH TRE; Gathe J, 2009, JAIDS-J ACQ IMM DEF, V50, P474, DOI 10.1097/QAI.0b013e31819c2937; Harris DJ, 2000, NEW ENGL J MED, V343, P475, DOI 10.1056/NEJM200008173430706; Hunt PW, 2003, AIDS, V17, P1907, DOI 10.1097/00002030-200309050-00009; INVESTIGATIONAL NE, 1998, FED REGIST PMID, V63, P6854; Jagsi R, 2009, CANCER-AM CANCER SOC, V115, P3293, DOI 10.1002/cncr.24366; Kempf MC, 2009, JAIDS-J ACQ IMM DEF, V52, P336, DOI 10.1097/QAI.0b013e3181b628be; Kumar PN, 2006, HIV MED, V7, P85, DOI 10.1111/j.1468-1293.2006.00346.x; Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6; Melloni C, 2010, CIRC-CARDIOVASC QUAL, V3, P135, DOI 10.1161/CIRCOUTCOMES.110.868307; Molina JM, 2007, JAIDS-J ACQ IMM DEF, V46, P24; Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720; Nicastri E, 2007, J ANTIMICROB CHEMOTH, V60, P724, DOI 10.1093/jac/dkm302; Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb; PREZISTA, 2010, FULL PRESCR INF; Ramasubbu K, 2001, J WOMEN HEALTH GEN-B, V10, P757, DOI 10.1089/15246090152636514; SEKAR V, 2010, 9 INT WORKSH CLIN PH; SMITH KY, 2010, 5 INT AIDS SOC C HIV; Squires KE, 2007, GENDER MED, V4, P294, DOI 10.1016/S1550-8579(07)80060-X; Suh JJ, 2008, AM J ADDICTION, V17, P463, DOI 10.1080/10550490802409074; Toro PL, 2010, AIDS, V24, P515, DOI 10.1097/QAD.0b013e3283350ecd; Umeh OC, 2006, EXPERT OPIN DRUG MET, V2, P273, DOI 10.1517/17425255.2.2.273; *US CENS BUR, 2010, AM COM SURV; *US FDA, 2010, GUID IND ANT DRUGS U; Zorrilla CD, 2007, FUTUR HIV THER, V1, P357	34	68	69	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					349	W118		10.7326/0003-4819-153-6-201009210-00002	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855799	Green Accepted			2022-12-28	WOS:000282043100001
J	Fava, GA				Fava, Giovanni A.			Guidelines and Conflicts of Interest	ANNALS OF INTERNAL MEDICINE			English	Letter									Univ Bologna, I-40127 Bologna, Italy	University of Bologna	Fava, GA (corresponding author), Univ Bologna, I-40127 Bologna, Italy.							Fava GA, 2010, PSYCHOTHER PSYCHOSOM, V79, P203, DOI 10.1159/000313688; Guyatt G, 2010, ANN INTERN MED, V152, P738, DOI 10.7326/0003-4819-152-11-201006010-00254; Krimsky S, 1998, PSYCHOTHER PSYCHOSOM, V67, P194, DOI 10.1159/000012281; Rothman DJ, 2009, JAMA-J AM MED ASSOC, V301, P1367, DOI 10.1001/jama.2009.407; Wilkes MS, 2000, WESTERN J MED, V172, P6, DOI 10.1136/ewjm.172.1.6	5	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					421	422		10.7326/0003-4819-153-6-201009210-00021	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855814				2022-12-28	WOS:000282043100019
J	Kim, YJ; Lee, HS; Kim, ES; Bae, SS; Lim, JK; Matsumi, R; Lebedinsky, AV; Sokolova, TG; Kozhevnikova, DA; Cha, SS; Kim, SJ; Kwon, KK; Imanaka, T; Atomi, H; Bonch-Osmolovskaya, EA; Lee, JH; Kang, SG				Kim, Yun Jae; Lee, Hyun Sook; Kim, Eun Sook; Bae, Seung Seob; Lim, Jae Kyu; Matsumi, Rie; Lebedinsky, Alexander V.; Sokolova, Tatyana G.; Kozhevnikova, Darya A.; Cha, Sun-Shin; Kim, Sang-Jin; Kwon, Kae Kyoung; Imanaka, Tadayuki; Atomi, Haruyuki; Bonch-Osmolovskaya, Elizaveta A.; Lee, Jung-Hyun; Kang, Sung Gyun			Formate-driven growth coupled with H-2 production	NATURE			English	Article							SEA HYDROTHERMAL VENT; HYPERTHERMOPHILIC ARCHAEON; ESCHERICHIA-COLI; METHANOBACTERIUM-FORMICICUM; METHANOCOCCUS-MARIPALUDIS; HYDROGENLYASE SYSTEM; OPERON; HYDROGENASE-3; METABOLISM; PREDICTION	Although a common reaction in anaerobic environments, the conversion of formate and water to bicarbonate and H-2 (with a change in Gibbs free energy of Delta G degrees = + 1.3 kJ mol(-1)) has not been considered energetic enough to support growth of microorganisms. Recently, experimental evidence for growth on formate was reported for syntrophic communities of Moorella sp. strain AMP and a hydrogen-consuming Methanothermobacter species and of Desulfovibrio sp. strain G11 and Methanobrevibacter arboriphilus strain AZ(1). The basis of the sustainable growth of the formate-users is explained by H-2 consumption by the methanogens, which lowers the H-2 partial pressure, thus making the pathway exergonic(2). However, it has not been shown that a single strain can grow on formate by catalysing its conversion to bicarbonate and H-2. Here we report that several hyperthermophilic archaea belonging to the Thermococcus genus are capable of formate-oxidizing, H-2-producing growth. The actual Delta G values for the formate metabolism are calculated to range between -8 and -20 kJ mol(-1) under the physiological conditions where Thermococcus onnurineus strain NA1 are grown. Furthermore, we detected ATP synthesis in the presence of formate as a sole energy source. Gene expression profiling and disruption identified the gene cluster encoding formate hydrogen lyase, cation/proton antiporter and formate transporter, which were responsible for the growth of T. onnurineus NA1 on formate. This work shows formate-driven growth by a single microorganism with protons as the electron acceptor, and reports the biochemical basis of this ability.	[Kim, Yun Jae; Lee, Hyun Sook; Kim, Eun Sook; Bae, Seung Seob; Lim, Jae Kyu; Cha, Sun-Shin; Kim, Sang-Jin; Kwon, Kae Kyoung; Lee, Jung-Hyun; Kang, Sung Gyun] Korea Ocean Res & Dev Inst, Ansan 425600, South Korea; [Lee, Hyun Sook; Bae, Seung Seob; Lim, Jae Kyu; Cha, Sun-Shin; Kim, Sang-Jin; Kwon, Kae Kyoung; Lee, Jung-Hyun; Kang, Sung Gyun] Univ Sci & Technol, Dept Marine Biotechnol, Taejon 305333, South Korea; [Matsumi, Rie; Imanaka, Tadayuki; Atomi, Haruyuki] Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan; [Lebedinsky, Alexander V.; Sokolova, Tatyana G.; Kozhevnikova, Darya A.; Bonch-Osmolovskaya, Elizaveta A.] Russian Acad Sci, Winogradsky Inst Microbiol, Moscow 117312, Russia	Korea Institute of Ocean Science & Technology (KIOST); Kyoto University; Research Center of Biotechnology RAS; Russian Academy of Sciences	Lee, JH (corresponding author), Korea Ocean Res & Dev Inst, POB 29, Ansan 425600, South Korea.	jlee@kordi.re.kr; sgkang@kordi.re.kr	Sokolova, Tatyana/AAU-3465-2021; Sokolova, Tatyana/E-9492-2014; Lebedinsky, Alexander V/E-9075-2014; Kozhevnikova, Daria/E-2536-2014	Sokolova, Tatyana/0000-0002-3879-2993; Sokolova, Tatyana/0000-0002-3879-2993; Lebedinsky, Alexander V/0000-0002-3686-7437; LIM, JAE KYU/0000-0002-9696-9830; Atomi, Haruyuki/0000-0001-9687-6426; Kozhevnikova, Daria/0000-0002-7263-3611; Cha, Sun-Shin/0000-0002-0913-8706	KORDI [PE98513]; Marine and Extreme Genome Research Center; Ministry of Land, Transport, and Maritime Affairs, Korea; RAS; Russian Foundation of Basic Research [10-04-01180]	KORDI; Marine and Extreme Genome Research Center; Ministry of Land, Transport, and Maritime Affairs, Korea(Ministry of Land, Transport and Maritime Affairs (MLTM), Republic of Korea); RAS(Russian Academy of SciencesRegione Sardegna); Russian Foundation of Basic Research(Russian Foundation for Basic Research (RFBR))	This work was supported by the KORDI in-house programme (PE98513), the Marine and Extreme Genome Research Center programme and the Development of Biohydrogen Production Technology using Hyperthermophilic Archaea programme of the Ministry of Land, Transport, and Maritime Affairs, Korea, as well as by the Molecular and Cell Biology programme of RAS and the Russian Foundation of Basic Research (grant no. 10-04-01180). We thank J. Querellou and the crew of the French scientific vessel Pourquoi pas?, and A.-L. Reysenbach and the crew of the American scientific vessel Thomas G. Thompson for opportunities to obtain deep-sea samples. We thank W. B. Whitman and R. K. Thauer for comments on the manuscript, and S. G. Jeon, K.-B. Yi and J.-G. Na for discussions.	Amaratunga D, 2001, J AM STAT ASSOC, V96, P1161, DOI 10.1198/016214501753381814; Amend JP, 2001, FEMS MICROBIOL REV, V25, P175, DOI 10.1016/S0168-6445(00)00062-0; Andrews SC, 1997, MICROBIOL-SGM, V143, P3633, DOI 10.1099/00221287-143-11-3633; Bae SS, 2006, J MICROBIOL BIOTECHN, V16, P1826; Bagramyan K, 2002, FEBS LETT, V516, P172, DOI 10.1016/S0014-5793(02)02555-3; BARON SF, 1989, J BACTERIOL, V171, P3854, DOI 10.1128/jb.171.7.3854-3859.1989; BOHM R, 1990, MOL MICROBIOL, V4, P231, DOI 10.1111/j.1365-2958.1990.tb00590.x; Dolfing J, 2008, APPL ENVIRON MICROB, V74, P6126, DOI 10.1128/AEM.01428-08; Gardy JL, 2005, BIOINFORMATICS, V21, P617, DOI 10.1093/bioinformatics/bti057; Hedderich R, 2005, J MOL MICROB BIOTECH, V10, P92, DOI 10.1159/000091557; Holden JF, 2001, FEMS MICROBIOL ECOL, V36, P51, DOI 10.1016/S0168-6496(01)00118-0; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jenney FE, 2008, ANN NY ACAD SCI, V1125, P252, DOI 10.1196/annals.1419.013; Lee HS, 2008, J BACTERIOL, V190, P7491, DOI 10.1128/JB.00746-08; Lupa B, 2008, APPL ENVIRON MICROB, V74, P6584, DOI 10.1128/AEM.01455-08; Matsumi R, 2007, J BACTERIOL, V189, P2683, DOI 10.1128/JB.01692-06; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Sapra R, 2000, J BACTERIOL, V182, P3423, DOI 10.1128/JB.182.12.3423-3428.2000; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; SCHAUER NL, 1980, J BACTERIOL, V142, P800, DOI 10.1128/JB.142.3.800-807.1980; Schink B, 1997, MICROBIOL MOL BIOL R, V61, P262, DOI 10.1128/.61.2.262-280.1997; Sokolova TG, 2004, EXTREMOPHILES, V8, P317, DOI 10.1007/s00792-004-0389-0; Stams AJM, 2009, NAT REV MICROBIOL, V7, P568, DOI 10.1038/nrmicro2166; Takacs M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-88; THAUER RK, 1984, MICROBE 1984 2, P123; Wood GE, 2003, J BACTERIOL, V185, P2548, DOI 10.1128/JB.185.8.2548-2554.2003; Zivanovic Y, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r70	27	167	176	3	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					352	U137		10.1038/nature09375	http://dx.doi.org/10.1038/nature09375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844539				2022-12-28	WOS:000281824900044
J	Andriole, DA; Jeffe, DB				Andriole, Dorothy A.; Jeffe, Donna B.			Prematriculation Variables Associated With Suboptimal Outcomes for the 1994-1999 Cohort of US Medical School Matriculants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATIONAL-PROGRAMS; PREDICTIVE-VALIDITY; STEP 1; SCORES; MCAT	Context The relationship between increasing numbers and diversity of medical school enrollees and the US physician workforce size and composition has not been described. Objective To identify demographic and prematriculation factors associated with medical school matriculants' outcomes. Design, Setting, and Participants Retrospective study using deidentified data for the 1994-1999 national cohort of 97 445 matriculants who were followed up through March 2, 2009, and had graduated, had withdrawn, or were dismissed. Data were analyzed using multivariable logistic regression to identify factors associated with suboptimal outcomes. Main Outcome Measures Academic withdrawal or dismissal, nonacademic withdrawal or dismissal, and graduation without first-attempt passing scores on the US Medical Licensing Examination Step 1 and/or Step 2 Clinical Knowledge (CK) compared with graduation with first-attempt passing scores on both of the examinations. Results Of 84 018 matriculants (86.2%), 74 494 graduated and had first-attempt passing scores on both the Step 1 and Step 2 CK (88.7%), 6743 graduated and did not have first-attempt passing scores on the Step 1 and/or Step 2 CK (8.0%), 1049 withdrew or were dismissed for academic reasons (1.2%), and 1732 withdrew or were dismissed for nonacademic reasons (2.1%). Variables associated with greater likelihood of graduation without first-attempt passing scores on the Step 1 and/or Step 2 CK and of academic withdrawal or dismissal, respectively, were (1) Medical College Admission Test scores (scores of 18-20 [2.9% of sample] vs >29: adjusted odds ratio [AOR], 13.06 [95% confidence interval {CI}, 11.56-14.76] and AOR, 11.08 [95% CI, 8.50-14.45]; scores of 21-23 [5.6% of sample] vs >29: AOR, 7.52 [95% CI, 6.79-8.33] and AOR, 5.97 [95% CI, 4.68-7.62]; and scores of 24-26 [13.9% of sample] vs >29: AOR, 4.27 [95% CI, 3.92-4.65] and AOR, 3.56 [95% CI, 2.88-4.40]), (2) race/ethnicity (Asian or Pacific Islander [18.2% of sample] vs white: AOR, 2.15 [95% CI, 2.00-2.32] and AOR, 1.69 [95% CI, 1.37-2.09]; under-represented minority [14.9% of sample] vs white: AOR, 2.30 [95% CI, 2.13-2.48] and AOR, 2.96 [95% CI, 2.48-3.54]), and (3) premedical debt (>=$ 50 000 [1.0% of sample] vs no debt: AOR, 1.68 [95% CI, 1.35-2.08] and AOR, 2.33 [95% CI, 1.57-3.46]). Conclusions Lower scores on the Medical College Admission Test, nonwhite race/ethnicity, and premedical debt of at least $50 000 were independently associated with a greater likelihood of academic withdrawal or dismissal and graduation without first-attempt passing scores on the US Medical Licensing Examination Step l and/or Step 2 CK. JAMA. 2010;304(11):1212-1219 www.jama.com	[Andriole, Dorothy A.; Jeffe, Donna B.] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Jeffe, Donna B.] Barnes Jewish Hosp, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Siteman Cancer Center; Washington University (WUSTL)	Andriole, DA (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave,Campus Box 8210, St Louis, MO 63110 USA.	andrioled@wustl.edu	Jeffe, Donna B./AAI-3732-2020	Jeffe, Donna B./0000-0002-7642-3777	National Institute of General Medical Sciences of the National Institutes of Health [R01 GM085350-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085350] Funding Source: NIH RePORTER	National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding for the study was provided by grant R01 GM085350-01 from the National Institute of General Medical Sciences of the National Institutes of Health.	Andriole DA, 2005, ACAD MED, V80, pS21, DOI 10.1097/00001888-200510001-00009; *ASS AM MED COLL, 2009, TABL 25 MCAT GPA GRI; Association of American Medical Colleges, SAMPL MSQ; BARZANSKY B, 1995, JAMA-J AM MED ASSOC, V274, P716, DOI 10.1001/jama.274.9.716; Barzansky B, 2001, JAMA-J AM MED ASSOC, V286, P1049, DOI 10.1001/jama.286.9.1049; Barzansky B, 2009, JAMA-J AM MED ASSOC, V302, P1349, DOI 10.1001/jama.2009.1324; Carnegie Foundation for the Advancement of Teaching, BAS CLASS DESCR; Cohen JJ, 2006, JAMA-J AM MED ASSOC, V296, P1135, DOI 10.1001/jama.296.9.1135; Council on Graduate Medical Education, 2005, PHYS WORKF POL GUID; *D GEFF SCH MED UC, POL USMLE STEP 3 UPD; Donnon T, 2007, ACAD MED, V82, P100, DOI 10.1097/01.ACM.0000249878.25186.b7; *FED STAT MED BOAR, 2003 USMLE UPD; *FED STAT MED BOAR, 2009, STAT SPEC REQ IN MED; GARRISON G, MED SCH GRADUATION A; Green M, 2009, ACAD MED, V84, P362, DOI 10.1097/ACM.0b013e3181970c6b; GRUMBACH K, 2003, CALIFORNIA ENDOWMENT; HUFF KL, 1974, ACAD MED, V454, P1992; Jolly P., DIVERSITY US MED STU; Julian ER, 2005, ACAD MED, V80, P910, DOI 10.1097/00001888-200510000-00010; Kleshinski J, 2009, ADV HEALTH SCI EDUC, V14, P69, DOI 10.1007/s10459-007-9087-x; Koenig JA, 1998, ACAD MED, V73, P1095, DOI 10.1097/00001888-199810000-00021; Liaison Committee on Medical Education, 2008, FUNCT STRUCT MED SCH; Lieberman SA, 2008, ACAD MED, V83, pS49, DOI 10.1097/ACM.0b013e318183e2d0; McGrath B, 2004, MED TEACH, V26, P510, DOI 10.1080/01421590410001696407; *MED U S CAR COLL, 2009, POL USMLE STEP 3 EQ; Odom KL, 2007, ACAD MED, V82, P146, DOI 10.1097/ACM.0b013e31802d8f2c; RAETHER J, 2009, CHARTING OUTCOMES MA; SCHULMAN S, 2009, PROJECTIONS FUTURE M; Smedley BD, 2001, RIGHT THING TO DO, THE SMART THING TO DO, P1; Smedley BD, 2004, NATIONS COMPELLING I; SZENAS P, RESULTS 2008 NRMP PR; SZENAS P, CHARTING OUTCOMES MA; TERRELL C, 2008, DIVERSITY MED ED FAC; *U MINN GRAD MED E, GEN POL PROC USMLE S; *US MED LIC EX, MIN PASS SCOR USMLE; *US MED LIC EX, 2000 USMLE PERF DAT; *US MED LIC EX, USMLE APPL MAT; *US MED LIC EX, PERF 1996 USMLE EX U; *US MED LIC EX, PERF 1998 USMLE EX E; *US MED LIC EX, 2006 USMLE PERF DAT; *US MED LIC EX, 2007 USMLE PERF DAT; *US MED LIC EX, PERF 1994 USMLE EX U; YAMAGATA H, 2006, ANAL MED SCH EXPANSI	43	40	41	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1212	1219		10.1001/jama.2010.1321	http://dx.doi.org/10.1001/jama.2010.1321			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841535	Green Accepted, Bronze			2022-12-28	WOS:000281770600014
J	Kaidi, A; Weinert, BT; Choudhary, C; Jackson, SP				Kaidi, Abderrahmane; Weinert, Brian T.; Choudhary, Chunaram; Jackson, Stephen P.			RETRACTED: Human SIRT6 Promotes DNA End Resection Through CtIP Deacetylation (Publication with Expression of Concern. See vol. 364, pg. 247, 2019) (Publication with Expression of Concern. See vol. 361, pg. 1322, 2018) (Retracted article. See vol. 364, pg. 247, 2019)	SCIENCE			English	Article; Retracted Publication							GENE-EXPRESSION; DAMAGE RESPONSE; REPAIR; INSTABILITY; CHROMATIN	SIRT6 belongs to the sirtuin family of protein lysine deacetylases, which regulate aging and genome stability. We found that human SIRT6 has a role in promoting DNA end resection, a crucial step in DNA double-strand break (DSB) repair by homologous recombination. SIRT6 depletion impaired the accumulation of replication protein A and single-stranded DNA at DNA damage sites, reduced rates of homologous recombination, and sensitized cells to DSB-inducing agents. We identified the DSB resection protein CtIP [C-terminal binding protein (CtBP) interacting protein] as a SIRT6 interaction partner and showed that SIRT6-dependent CtIP deacetylation promotes resection. A nonacetylatable CtIP mutant alleviated the effect of SIRT6 depletion on resection, thus identifying CtIP as a key substrate by which SIRT6 facilitates DSB processing and homologous recombination. These findings further clarify how SIRT6 promotes genome stability.	[Kaidi, Abderrahmane; Jackson, Stephen P.] Univ Cambridge, Gurdon Inst, Cambridge CB2 1QN, England; [Kaidi, Abderrahmane; Jackson, Stephen P.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QN, England; [Weinert, Brian T.; Choudhary, Chunaram] Univ Copenhagen, Fac Hlth Sci, NNF Ctr Prot Res, DK-2200 Copenhagen, Denmark	University of Cambridge; University of Cambridge; University of Copenhagen	Jackson, SP (corresponding author), Univ Cambridge, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	s.jackson@gurdon.cam.ac.uk	Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014; Choudhary, Chunaram/E-9819-2011	Jackson, Stephen Philip/0000-0001-9317-7937; Choudhary, Chunaram/0000-0002-9863-433X; Kaidi, Abderrahmane/0000-0001-9411-8912; Weinert, Brian/0000-0002-1335-9915	Jackson laboratory; European Community; Cancer Research UK; Wellcome Trust; Herchel Smith Fellowship; Novo Nordisk Foundation; Cancer Research UK [11224] Funding Source: researchfish	Jackson laboratory; European Community(European Commission); Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Herchel Smith Fellowship; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Cancer Research UK(Cancer Research UK)	We thank all members of the Jackson laboratory for help and support; K. Miller and B. Xhemalce for advice on in vitro HDAC assays; J. Forment for help with analysis of PARP cleavage; K. Miller, R. Chapman, T. Oelschlaegel, and K. Dry for advice on the manuscript; F. Alt for Sirt6<SUP>-/-</SUP> ESCs; R. Baer for CtIP antibodies; Y. Shiloh for ATM antibody; and S. West for RAD51 antibody. Research in the Jackson laboratory is supported by the European Community and a core infrastructure provided by Cancer Research UK and the Wellcome Trust. A. K. is funded by a Herchel Smith Fellowship. The Center for Protein Research is funded by a generous grant from the Novo Nordisk Foundation.	Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chen LC, 2008, J BIOL CHEM, V283, P7713, DOI 10.1074/jbc.M710245200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Huertas P, 2010, NAT STRUCT MOL BIOL, V17, P11, DOI 10.1038/nsmb.1710; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Mimitou EP, 2009, DNA REPAIR, V8, P983, DOI 10.1016/j.dnarep.2009.04.017; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; You ZS, 2009, MOL CELL, V36, P954, DOI 10.1016/j.molcel.2009.12.002; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	23	279	298	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1348	1353		10.1126/science.1192049	http://dx.doi.org/10.1126/science.1192049			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829486	Green Accepted			2022-12-28	WOS:000281657300040
J	Moreno, M; Rosenau, M; Oncken, O				Moreno, Marcos; Rosenau, Matthias; Oncken, Onno			2010 Maule earthquake slip correlates with pre-seismic locking of Andean subduction zone	NATURE			English	Article							OFQUI FAULT ZONE; SOUTHERN ANDES; STRAIN ACCUMULATION; CENTRAL CHILE; DEFORMATION; MODEL; GAPS; PACIFIC; AMERICA; RUPTURE	The magnitude-8.8 Maule (Chile) earthquake of 27 February 2010 ruptured a segment of the Andean subduction zone megathrust that has been suspected to be of high seismic potential(1-6). It is the largest earthquake to rupture a mature seismic gap in a subduction zone that has been monitored with a dense space-geodetic network before the event. This provides an image of the pre-seismically locked state of the plate interface of unprecedentedly high resolution, allowing for an assessment of the spatial correlation of interseismic locking with coseismic slip. Pre-seismic locking might be used to anticipate future ruptures in many seismic gaps(6-12), given the fundamental assumption that locking and slip are similar. This hypothesis, however, could not be tested without the occurrence of the first gap-filling earthquake. Here we show evidence that the 2010 Maule earthquake slip distribution correlates closely with the patchwork of interseismic locking distribution as derived by inversion of global positioning system (GPS) observations during the previous decade. The earthquake nucleated in a region of high locking gradient and released most of the stresses accumulated in the area since the last major event in 1835. Two regions of high seismic slip (asperities) appeared to be nearly fully locked before the earthquake. Between these asperities, the rupture bridged a zone that was creeping interseismically with consistently low coseismic slip. The rupture stopped in areas that were highly locked before the earthquake but where pre-stress had been significantly reduced by overlapping twentieth-century earthquakes. Our work suggests that coseismic slip heterogeneity at the scale of single asperities should indicate the seismic potential of future great earthquakes, which thus might be anticipated by geodetic observations.	[Moreno, Marcos; Rosenau, Matthias; Oncken, Onno] GFZ German Res Ctr Geosci, Helmholtz Ctr Potsdam, D-14473 Potsdam, Germany	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences	Oncken, O (corresponding author), GFZ German Res Ctr Geosci, Helmholtz Ctr Potsdam, D-14473 Potsdam, Germany.	oncken@gfz-potsdam.de	Oncken, Onno/AAU-2907-2020; Moreno, Marcos/M-4632-2013; Rosenau, Matthias/I-2081-2016	Oncken, Onno/0000-0002-2894-480X; Moreno, Marcos/0000-0002-6023-7283; Rosenau, Matthias/0000-0003-1134-5381				Angermann D, 1999, EARTH PLANET SC LETT, V171, P329, DOI 10.1016/S0012-821X(99)00173-9; Barrientos SE, 1995, GEOPHYS RES LETT, V22, P3541, DOI 10.1029/95GL03316; Beck S, 1998, J S AM EARTH SCI, V11, P115, DOI 10.1016/S0895-9811(98)00005-4; Bohm M, 2002, TECTONOPHYSICS, V356, P275, DOI 10.1016/S0040-1951(02)00399-2; Brooks BA, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2003GC000505; Burgmann R, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2005JB003648; Campos J, 2002, PHYS EARTH PLANET IN, V132, P177, DOI 10.1016/S0031-9201(02)00051-1; Cembrano J, 1996, TECTONOPHYSICS, V259, P55, DOI 10.1016/0040-1951(95)00066-6; Chlieh M, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB004981; Christensen NI, 1996, J GEOPHYS RES-SOL EA, V101, P3139, DOI 10.1029/95JB03446; CIFUENTES IL, 1989, J GEOPHYS RES-SOLID, V94, P665, DOI 10.1029/JB094iB01p00665; CLOOS M, 1992, GEOLOGY, V20, P601, DOI 10.1130/0091-7613(1992)020<0601:TTSZEA>2.3.CO;2; Darwin C, 1839, J REMARKS 1832 1836, V3, P370; Fedotov S.A., 1965, T I PHYS EARTH ACAD, V36, P66; Gross K, 2008, GEOPHYS J INT, V172, P565, DOI 10.1111/j.1365-246X.2007.03680.x; Haberland C, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL028189; HANKA W, 2010, GEOFON EXTENDED VIRT; HU Y, 2004, GEOPHYS RES LETT, V109, P1; KANAMORI H, 1994, ANNU REV EARTH PL SC, V22, P207, DOI 10.1146/annurev.ea.22.050194.001231; Kaneko Y, 2010, NAT GEOSCI, V3, P363, DOI 10.1038/NGEO843; KELLEHER J, 1973, J GEOPHYS RES, V78, P2547, DOI 10.1029/JB078i014p02547; KELLEHER JA, 1972, J GEOPHYS RES, V77, P2087, DOI 10.1029/JB077i011p02087; Klotz J, 2001, EARTH PLANET SC LETT, V193, P437, DOI 10.1016/S0012-821X(01)00532-5; Klotz J, 2006, FRONT EARTH SCI SER, P65, DOI 10.1007/978-3-540-48684-8_4; Konca AO, 2008, NATURE, V456, P631, DOI 10.1038/nature07572; Lange D, 2008, TECTONOPHYSICS, V455, P14, DOI 10.1016/j.tecto.2008.04.014; Lay T, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043379; Lomnitz C, 1971, GEOFIS PANAMERICANA, V1, P151; Luth S, 2003, REV GEOL CHILE, V30, P83; Masterlark T, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002296; MCNALLY KC, 1983, ANNU REV EARTH PL SC, V11, P359, DOI 10.1146/annurev.ea.11.050183.002043; Melnick D, 2006, GEOL SOC AM BULL, V118, P1463, DOI 10.1130/B25865.1; MELOSH HJ, 1981, B SEISMOL SOC AM, V71, P1391; Mogi K., 1969, B EARTHQ RES I TOKYO, V47, P395; MORENO M, 2010, THESIS TU BERLIN; Moreno MS, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039276; Moreno MS, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2008GC002198; Murray J, 2006, B SEISMOL SOC AM, V96, pS283, DOI 10.1785/0120050820; NISHENKO SP, 1985, J GEOPHYS RES-SOLID, V90, P3589, DOI 10.1029/JB090iB05p03589; NISHENKO SP, 1991, PURE APPL GEOPHYS, V135, P169, DOI 10.1007/BF00880240; Perfettini H, 2010, NATURE, V465, P78, DOI 10.1038/nature09062; PLAFKER G, 1970, GEOL SOC AM BULL, V81, P1001, DOI 10.1130/0016-7606(1970)81[1001:MOTCEO]2.0.CO;2; Rosenau M, 2006, TECTONICS, V25, DOI 10.1029/2005TC001943; Ruegg JC, 2009, PHYS EARTH PLANET IN, V175, P78, DOI 10.1016/j.pepi.2008.02.015; SAVAGE JC, 1986, SCIENCE, V231, P585, DOI 10.1126/science.231.4738.585; SAVAGE JC, 1983, J GEOPHYS RES, V88, P4984, DOI 10.1029/JB088iB06p04984; Shao G., 2010, PRELIMINARY SLIP MOD; Smith WHF, 1997, SCIENCE, V277, P1956, DOI 10.1126/science.277.5334.1956; SYKES LR, 1971, J GEOPHYS RES, V76, P8021, DOI 10.1029/JB076i032p08021; Tassara A, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003976; VIGNY C, 2009, EARTH PLANET INTER, V175, P86; Wang K, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2007GC001721; Watts AB, 2000, GEOPHYS J INT, V142, P855, DOI 10.1046/j.1365-246x.2000.00189.x; [No title captured]; [No title captured]	55	321	334	1	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					198	U84		10.1038/nature09349	http://dx.doi.org/10.1038/nature09349			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829792				2022-12-28	WOS:000281616300032
J	Schulze, S; Koster, S; Geldmacher, U; van Scheltinga, ACT; Kuhlbrandt, W				Schulze, Sabrina; Koester, Stefan; Geldmacher, Ulrike; van Scheltinga, Anke C. Terwisscha; Kuehlbrandt, Werner			Structural basis of Na+-independent and cooperative substrate/product antiport in CaiT	NATURE			English	Article							SOLUTES GLYCINE BETAINE; CATION-PI INTERACTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CARNITINE TRANSPORTER; PROLINE BETAINE; BINDING-SITE; MECHANISM; DETERMINANTS; SYMPORTER	Transport of solutes across biological membranes is performed by specialized secondary transport proteins in the lipid bilayer(1), and is essential for life. Here we report the structures of the sodium-independent carnitine/butyrobetaine antiporter CaiT from Proteus mirabilis (PmCaiT) at 2.3-angstrom and from Escherichia coli (EcCaiT) at 3.5-angstrom resolution. CaiT belongs to the family of betaine/carnitine/choline transporters (BCCT), which are mostly Na+ or H+ dependent, whereas EcCaiT is Na+ and H+ independent(2). The three-dimensional architecture of CaiT resembles that of the Na+-dependent transporters LeuT(3) and BetP(4), but in CaiT a methionine sulphur takes the place of the Na+ ion to coordinate the substrate in the central transport site, accounting for Na+-independent transport. Both CaiT structures show the fully open, inward-facing conformation, and thus complete the set of functional states that describe the alternating access mechanism(5). EcCaiT contains two bound butyrobetaine substrate molecules, one in the central transport site, the other in an extracellular binding pocket. In the structure of PmCaiT, a tryptophan side chain occupies the transport site, and access to the extracellular site is blocked. Binding of both substrates to CaiT reconstituted into proteoliposomes is cooperative, with Hill coefficients up to 1.7, indicating that the extracellular site is regulatory. We propose a mechanism whereby the occupied regulatory site increases the binding affinity of the transport site and initiates substrate translocation.	[Schulze, Sabrina; Koester, Stefan; Geldmacher, Ulrike; van Scheltinga, Anke C. Terwisscha; Kuehlbrandt, Werner] Max Planck Inst Biophys, Dept Biol Struct, D-60438 Frankfurt, Germany	Max Planck Society	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Max von Laue Str 3, D-60438 Frankfurt, Germany.	werner.kuehlbrandt@biophys.mpg.de		Kuhlbrandt, Werner/0000-0002-2013-4810				Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barros T, 2009, EMBO J, V28, P298, DOI 10.1038/emboj.2008.276; CSAKY TZ, 1965, ANNU REV PHYSIOL, V27, P415, DOI 10.1146/annurev.ph.27.030165.002215; DeLano W.L, PYMOL MOL GRAPHICS S; Diallinas G, 2008, SCIENCE, V322, P1644, DOI 10.1126/science.1168107; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Faham S, 2008, SCIENCE, V321, P810, DOI 10.1126/science.1160406; Fang YL, 2009, NATURE, V460, P1040, DOI 10.1038/nature08201; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Gao X, 2009, SCIENCE, V324, P1565, DOI 10.1126/science.1173654; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horn C, 2006, J MOL BIOL, V357, P592, DOI 10.1016/j.jmb.2005.12.085; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung H, 2002, J BIOL CHEM, V277, P39251, DOI 10.1074/jbc.M206319200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Padgett CL, 2007, J NEUROSCI, V27, P886, DOI 10.1523/JNEUROSCI.4791-06.2007; Ressl S, 2009, NATURE, V458, P47, DOI 10.1038/nature07819; RICARD J, 1987, EUR J BIOCHEM, V166, P255, DOI 10.1111/j.1432-1033.1987.tb13510.x; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; Schiefner A, 2004, J BIOL CHEM, V279, P5588, DOI 10.1074/jbc.M309771200; Sevilla A, 2005, BIOTECHNOL PROGR, V21, P329, DOI 10.1021/bp0497583; Shaffer PL, 2009, SCIENCE, V325, P1010, DOI 10.1126/science.1176088; Shi L, 2008, MOL CELL, V30, P667, DOI 10.1016/j.molcel.2008.05.008; Tang L, 2010, NAT STRUCT MOL BIOL, V17, P492, DOI 10.1038/nsmb.1788; Terwilliger TC, 2004, ACTA CRYSTALLOGR D, V60, P2144, DOI 10.1107/S0907444904019535; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Torrice MM, 2009, P NATL ACAD SCI USA, V106, P11919, DOI 10.1073/pnas.0903260106; Vinothkumar KR, 2006, J BIOL CHEM, V281, P4795, DOI 10.1074/jbc.M508993200; Weyand S, 2008, SCIENCE, V322, P709, DOI [10.1126/science.1164440, 10.1126/science.1160058]; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	36	98	99	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					233	U129		10.1038/nature09310	http://dx.doi.org/10.1038/nature09310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829798	Green Submitted, Green Published			2022-12-28	WOS:000281616300040
J	Aithal, JK; Ulrich, M				Aithal, Jairam K.; Ulrich, Matthias			Subclavian Steal Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Aithal, Jairam K.] Royal Perth Hosp, Perth, WA, Australia; [Ulrich, Matthias] Pk Hosp Leipzig, Saxony, Germany	Royal Perth Hospital; University of Western Australia	Aithal, JK (corresponding author), Royal Perth Hosp, Perth, WA, Australia.	jairamaithal@hotmail.com							0	2	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					e15	e15		10.1056/NEJMicm1000568	http://dx.doi.org/10.1056/NEJMicm1000568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20830823				2022-12-28	WOS:000281441500010
J	Dennis, M; Cranswick, G; Deary, A; Fraser, A; Graham, C; Grant, S; Gunkel, A; Hunter, J; MacRae, A; Perry, D; Soosay, V; Williams, C; Williamson, A; Young, A; Sandercock, P; Reid, J; Murray, G; Venables, G; Rudd, A; Bowler, G; Celani, MG; Ricci, S; Lindley, R; Hautvast, M; Paterson, M; Ting, T; Baigent, C; Bamford, J; Slattery, J				Dennis, M.; Cranswick, G.; Deary, A.; Fraser, A.; Graham, C.; Grant, S.; Gunkel, A.; Hunter, J.; MacRae, A.; Perry, D.; Soosay, V.; Williams, C.; Williamson, A.; Young, A.; Sandercock, P.; Reid, J.; Murray, G.; Venables, G.; Rudd, A.; Bowler, G.; Celani, M. G.; Ricci, S.; Lindley, R.; Hautvast, M.; Paterson, M.; Ting, T.; Baigent, C.; Bamford, J.; Slattery, J.		CLOTS Trial Collaborat	Thigh-Length Versus Below-Knee Stockings for Deep Venous Thrombosis Prophylaxis After Stroke A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							GRADUATED COMPRESSION STOCKINGS; VEIN THROMBOSIS; PREVENTION; CLOTS	Background: Graduated compression stockings are widely used for deep venous thrombosis (DVT) prophylaxis. Although below-knee stockings are used more often than thigh-length stockings, no reliable evidence indicates that they are as effective as thigh-length stockings. Objective: To compare the effectiveness of thigh-length stockings with that of below-knee stockings for preventing proximal DVT in immobile, hospitalized patients with stroke. Design: Parallel-group trial with centralized randomization (minimization within centers) to ensure allocation concealment. The ultrasonographers who looked for DVT were blinded, but the patients and caregivers were not. (Controlled-trials.com registration number: ISRCTN28163533) Setting: 112 hospitals in 9 countries. Patients: 3114 immobile patients hospitalized with acute stroke between January 2002 and May 2009. Intervention: 1552 patients received thigh-length stockings and 1562 patients received below-knee stockings to wear while they were in the hospital. Measurements: Ultrasonographers performed compression duplex ultrasonography in 1406 patients (96% of survivors) in each treatment group between 7 and 10 days after enrollment. They performed a second scan in 643 patients in the thigh-length stockings group and 639 in the below-knee stockings group at about 25 to 30 days. The primary outcome was symptomatic or asymptomatic DVT in the popliteal or femoral veins, detected on either scan. Results: Patients were retained in their assigned group for all analyses. The primary outcome occurred in 98 patients (6.3%) who received thigh-length stockings and 138 (8.8%) who received below-knee stockings (absolute difference, 2.5 percentage points [95% CI, 0.7 to 4.4 percentage points]; P = 0.008), an odds reduction of 31% (CI, 9% to 47%). Seventy-five percent of patients in both groups wore the stockings for 30 days or until they were discharged, died, or regained mobility. Skin breaks occurred in 61 patients who received thigh-length stockings (3.9%) and 45 (2.9%) who received below-knee stockings. Limitation: Blinding was incomplete, 2 scans were not obtained for all enrolled patients, and the trial was stopped before the target accrual was reached. Conclusion: Proximal DVT occurs more often in patients with stroke who wear below-knee stockings than in those who wear thigh-length stockings.	[Dennis, M.] Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; Borders Gen Hosp, Melrose, Scotland; Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; St Thomas Hosp, London, England	University of Edinburgh; University of Sheffield; Guy's & St Thomas' NHS Foundation Trust	Dennis, M (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	martin.dennis@ed.ac.uk	celani, maria grazia/AAF-4143-2020; Bamford, John/ABE-6218-2021; Lindley, Richard/B-8148-2013	Lindley, Richard/0000-0002-0104-5679; Cranswick, Gina/0000-0002-4479-6034; Murray, Gordon/0000-0001-9866-4734	Chief Scientist Office of the Scottish Government [CZH/4/7]; Chest Heart and Stroke Scotland [03/01]; Medical Research Council of the UK [G0200531]; MRC [G0200531, G0800803] Funding Source: UKRI; Medical Research Council [G0800803, G0200531] Funding Source: researchfish	Chief Scientist Office of the Scottish Government; Chest Heart and Stroke Scotland; Medical Research Council of the UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	By the Chief Scientist Office of the Scottish Government (reference CZH/4/7), Chest Heart and Stroke Scotland (reference 03/01), and the Medical Research Council of the UK (reference G0200531). Dr. Marcello Naccarato, a neurologist at the Azienda Ospedaliera "Ospedali Riuniti," Trieste, Italy, performed the literature searches for trials of graduated compression stockings and prepared the resulting Cochrane Collaboration systematic review. Tyco Healthcare (Covidien) donated supplies of stockings and provided training in their use to participating centers.	Agu O, 1999, BRIT J SURG, V86, P992, DOI 10.1046/j.1365-2168.1999.01195.x; Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; Davidson BL, 1998, HAEMOSTASIS, V28, P113; Dennis M, 2009, LANCET, V373, P1958, DOI 10.1016/S0140-6736(09)60941-7; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; *HC HLTH COMM, 2005, 99 HC HLTH COMM; Kearon C, 2003, CIRCULATION, V107, pI22, DOI 10.1161/01.CIR.0000078464.82671.78; KIERKEGAARD A, 1993, EUR HEART J, V14, P1365, DOI 10.1093/eurheartj/14.10.1365; Muir KW, 2000, QJM-INT J MED, V93, P359, DOI 10.1093/qjmed/93.6.359; Naccarato M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001922.pub3; *NAT STROK FDN, 2007, CLIN GUID AC STROK M; Roderick P, 2005, HEALTH TECHNOL ASSES, V9, P1; Royal College of Physicians (Intercollegiate Stroke Working Party), 2008, NAT CLIN GUID STROK; Sajid MS, 2006, EUR J VASC ENDOVASC, V32, P730, DOI 10.1016/j.ejvs.2006.06.021; Sandercock PAG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000029.pub2; Scottish Intercollegiate Guidelines Network, 2002, MAN PAT STROK REH PR; *STROK PREV ED AW, 2007, IT GUID STROK PREV M; Thomas S, 2009, LANCET, V374, P1143, DOI 10.1016/S0140-6736(09)61732-3; WELLS PS, 1994, ARCH INTERN MED, V154, P67, DOI 10.1001/archinte.154.1.67	20	101	111	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					553	562		10.7326/0003-4819-153-9-201011020-00280	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00280			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	20855784				2022-12-28	WOS:000283667000001
J	Bisgaard, H; Hermansen, MN; Bonnelykke, K; Stokholm, J; Baty, F; Skytt, NL; Aniscenko, J; Kebadze, T; Johnston, SL				Bisgaard, Hans; Hermansen, Mette Northman; Bonnelykke, Klaus; Stokholm, Jakob; Baty, Florent; Skytt, Nanna Lassen; Aniscenko, Julia; Kebadze, Tatiana; Johnston, Sebastian L.			Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; ORAL PREDNISOLONE; VIRAL-INFECTIONS; DOUBLE-BLIND; 1ST YEAR; ASTHMA; EXACERBATIONS; INFANCY; LIFE; CLARITHROMYCIN	Objective To study the association between wheezy symptoms in young children and the presence of bacteria in the airways. Design Birth cohort study. Setting Clinical research unit in Copenhagen. Participants Children of asthmatic mothers, from age 4 weeks to 3 years, with planned visits and acute admissions to the research clinic. Main outcome measure Frequency of bacteria and virus carriage in airway aspirates during wheezy episodes and at planned visits without respiratory symptoms. Results 984 samples (361 children) were analysed for bacteria, 844 (299 children) for viruses, and 696 (277 children) for both viruses and bacteria. Wheezy episodes were associated with both bacterial infection (odds ratio 2.9, 95% confidence interval 1.9 to 4.3; P<0.001) and virus infection (2.8, 1.7 to 4.4; P<0.001). The associations of bacteria and viruses were independent of each other. Conclusion Acute wheezy episodes in young children were significantly associated with bacterial infections similar to but independent of the association with virus infections.	[Bisgaard, Hans; Hermansen, Mette Northman; Bonnelykke, Klaus; Stokholm, Jakob; Baty, Florent; Skytt, Nanna Lassen] Copenhagen Prospect Studies Asthma Childhood, DK-2820 Gentofte, Copenhagen, Denmark; [Bisgaard, Hans; Hermansen, Mette Northman; Bonnelykke, Klaus; Stokholm, Jakob; Baty, Florent; Skytt, Nanna Lassen] Univ Copenhagen, DK-2820 Gentofte, Copenhagen, Denmark; [Bisgaard, Hans; Hermansen, Mette Northman; Bonnelykke, Klaus; Stokholm, Jakob; Baty, Florent; Skytt, Nanna Lassen] Danish Pediat Asthma Ctr, DK-2820 Gentofte, Copenhagen, Denmark; [Bisgaard, Hans; Hermansen, Mette Northman; Bonnelykke, Klaus; Stokholm, Jakob; Baty, Florent; Skytt, Nanna Lassen] Copenhagen Univ Hosp, DK-2820 Gentofte, Copenhagen, Denmark; [Aniscenko, Julia; Kebadze, Tatiana; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, MRC & Asthma UK Ctr Allerg Mech Asthma, Dept Resp Med, London SW7 2AZ, England; [Aniscenko, Julia; Kebadze, Tatiana; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, London SW7 2AZ, England	University of Copenhagen; University of Copenhagen; Imperial College London; University of London; King's College London; Imperial College London	Bisgaard, H (corresponding author), Copenhagen Prospect Studies Asthma Childhood, Ledreborg Alle 34, DK-2820 Gentofte, Copenhagen, Denmark.	Bisgaard@copsac.com	Johnston, Sebastian Lennox/I-2423-2012; Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Johnston, Sebastian Lennox/0000-0003-3009-9200; Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018; Stokholm, Jakob/0000-0003-4989-9769	Copenhagen Prospective Study on Asthma in Childhood; Lundbeck Foundation; Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Centre; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Copenhagen Prospective Study on Asthma in Childhood; Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Centre; Lundbeck Foundation(Lundbeckfonden)	The Copenhagen Prospective Study on Asthma in Childhood is funded by private and public research funds (seewww.copsac.com). The study is supported by the Lundbeck Foundation, the Pharmacy Foundation of 1991, Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre. The funding agencies had no role in the study design; the conduct of the study; data collection and management; data analysis; or the preparation, review, or approval of the manuscript.	Andersen ZJ, 2008, THORAX, V63, P710, DOI 10.1136/thx.2007.085480; ANIANSSON G, 1992, J INFECT DIS, V165, pS38, DOI 10.1093/infdis/165-Supplement_1-S38; [Anonymous], 2005, NIH PUBL, V05-4772; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2007, PEDIATR PULM, V42, P723, DOI 10.1002/ppul.20644; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Fonseca-Aten M, 2006, ANN ALLERG ASTHMA IM, V97, P457, DOI 10.1016/S1081-1206(10)60935-0; Hahn DL, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010011; Harrison LM, 1999, FEMS IMMUNOL MED MIC, V25, P19, DOI 10.1111/j.1574-695X.1999.tb01323.x; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Johnston SL, 2006, J ALLERGY CLIN IMMUN, V117, P1233, DOI 10.1016/j.jaci.2006.03.035; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kocevar VS, 2004, CHEST, V125, P1680, DOI 10.1378/chest.125.5.1680; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lund B, 2001, CLIN MICROBIOL INFEC, V7, P230, DOI 10.1046/j.1469-0691.2001.00242.x; Murray P.R., 2003, MANUAL CLIN MICROBIO, V8th; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Peacock SJ, 2003, J CLIN MICROBIOL, V41, P5718, DOI 10.1128/JCM.41.12.5718-5725.2003; Tahan F, 2007, EUR RESPIR J, V29, P91, DOI 10.1183/09031936.00029206; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Watson K, 2006, PEDIATR INFECT DIS J, V25, P782, DOI 10.1097/01.inf.0000232705.49634.68	29	220	229	1	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2010	341								c4978	10.1136/bmj.c4978	http://dx.doi.org/10.1136/bmj.c4978			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663IZ	20921080	Green Published, hybrid			2022-12-28	WOS:000282878600001
J	Ghebreyesus, TA				Ghebreyesus, Tedros Adhanom			Achieving the health MDGs: country ownership in four steps	LANCET			English	Editorial Material									Minist Hlth, Addis Ababa, Ethiopia; [Ghebreyesus, Tedros Adhanom] Board Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland		Ghebreyesus, TA (corresponding author), Minist Hlth, Addis Ababa, Ethiopia.	moh.vmo@ethionet.et							0	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1127	1128		10.1016/S0140-6736(10)61465-1	http://dx.doi.org/10.1016/S0140-6736(10)61465-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663UN	20864154				2022-12-28	WOS:000282915700009
J	Klein, R				Klein, Ruediger			Cell Sorting during Regenerative Tissue Formation	CELL			English	Editorial Material									Max Planck Inst Neurobiol, Dept Mol Neurobiol, D-82152 Martinsried, Germany	Max Planck Society	Klein, R (corresponding author), Max Planck Inst Neurobiol, Dept Mol Neurobiol, Klopferspitz 18, D-82152 Martinsried, Germany.	rklein@neuro.mpg.de	Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163				Afshari FT, 2010, J NEUROSCI, V30, P4246, DOI 10.1523/JNEUROSCI.3351-09.2010; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; Klein R, 2009, NAT NEUROSCI, V12, P15, DOI 10.1038/nn.2231; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; Luria V, 2008, NEURON, V60, P1039, DOI 10.1016/j.neuron.2008.11.011; Mcdonald D, 2006, NEURON GLIA BIOL, V2, P139, DOI 10.1017/S1740925X05000347; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011	10	7	9	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					32	34		10.1016/j.cell.2010.09.018	http://dx.doi.org/10.1016/j.cell.2010.09.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887890	Bronze			2022-12-28	WOS:000282362000011
J	Robert, S; Kleine-Vehn, J; Barbez, E; Sauer, M; Paciorek, T; Baster, P; Vanneste, S; Zhang, J; Simon, S; Covanova, M; Hayashi, K; Dhonukshe, P; Yang, Z; Bednarek, SY; Jones, AM; Luschnig, C; Aniento, F; Zazimalova, E; Friml, J				Robert, Stephanie; Kleine-Vehn, Juergen; Barbez, Elke; Sauer, Michael; Paciorek, Tomasz; Baster, Pawel; Vanneste, Steffen; Zhang, Jing; Simon, Sibu; Covanova, Milada; Hayashi, Kenichiro; Dhonukshe, Pankaj; Yang, Zhenbiao; Bednarek, Sebastian Y.; Jones, Alan M.; Luschnig, Christian; Aniento, Fernando; Zazimalova, Eva; Friml, Jiri			ABP1 Mediates Auxin Inhibition of Clathrin-Dependent Endocytosis in Arabidopsis	CELL			English	Article							OF-FUNCTION MUTATION; BOX PROTEIN TIR1; BINDING PROTEIN-1; CELL EXPANSION; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; EFFLUX CARRIER; TYRPHOSTIN A23; TRANSPORT	Spatial distribution of the plant hormone auxin regulates multiple aspects of plant development. These self-regulating auxin gradients are established by the action of PIN auxin transporters, whose activity is regulated by their constitutive cycling between the plasma membrane and endosomes. Here, we show that auxin signaling by the auxin receptor AUXIN-BINDING PROTEIN 1 (ABP1) inhibits the clathrin-mediated internalization of PIN proteins. ABP1 acts as a positive factor in clathrin recruitment to the plasma membrane, thereby promoting endocytosis. Auxin binding to ABP1 interferes with this action and leads to the inhibition of clathrin-mediated endocytosis. Our study demonstrates that ABP1 mediates a nontranscriptional auxin signaling that regulates the evolutionarily conserved process of clathrin-mediated endocytosis and suggests that this signaling may be essential for the developmentally important feedback of auxin on its own transport.	[Robert, Stephanie; Kleine-Vehn, Juergen; Barbez, Elke; Sauer, Michael; Paciorek, Tomasz; Baster, Pawel; Vanneste, Steffen; Zhang, Jing; Friml, Jiri] VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; [Robert, Stephanie; Kleine-Vehn, Juergen; Barbez, Elke; Sauer, Michael; Paciorek, Tomasz; Baster, Pawel; Vanneste, Steffen; Zhang, Jing; Friml, Jiri] Univ Ghent, Dept Plant Biotechnol & Genet, B-9052 Ghent, Belgium; [Simon, Sibu; Covanova, Milada; Zazimalova, Eva] ASCR, Inst Expt Bot, Prague 16502 6, Czech Republic; [Hayashi, Kenichiro] Okayama Univ Sci, Dept Biochem, Okayama 7000005, Japan; [Dhonukshe, Pankaj] Univ Utrecht, Dept Biol, NL-3584 CH Utrecht, Netherlands; [Yang, Zhenbiao] Univ Calif Riverside, Dept Bot & Plant Sci, Riverside, CA 92521 USA; [Yang, Zhenbiao] Univ Calif Riverside, Ctr Plant Cell Biol, Inst Integrat Genome Biol, Riverside, CA 92521 USA; [Bednarek, Sebastian Y.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; [Jones, Alan M.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Jones, Alan M.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Luschnig, Christian] Univ Nat Resources & Appl Life Sci, BOKU, Inst Appl Genet & Cell Biol, A-1190 Vienna, Austria; [Aniento, Fernando] Univ Valencia, Dept Bioquim & Biol Mol, Burjassot 46100, Spain	Flanders Institute for Biotechnology (VIB); Ghent University; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; Okayama University of Science; Utrecht University; University of California System; University of California Riverside; University of California System; University of California Riverside; University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Natural Resources & Life Sciences, Vienna; University of Valencia	Friml, J (corresponding author), VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium.	jiri.friml@psb.vib-ugent.be	Sauer, Michael/G-3424-2011; Kleine-Vehn, Jürgen/C-8984-2014; Barbez, Elke/AAP-2131-2021; Sauer, Michael/F-6519-2014; Friml, Jiri/D-9511-2012; Robert, Stéphanie/K-7604-2012; Eva, Zazimalova/G-7432-2014; Company, Fernando Aniento/G-9781-2015; Covanova, Milada/F-7473-2014; Hayashi, Ken-ichiro/AAP-3513-2021; Simon, Sibu/A-2614-2012; Vanneste, Steffen/K-8353-2013	Kleine-Vehn, Jürgen/0000-0002-4354-3756; Sauer, Michael/0000-0002-4014-9825; Friml, Jiri/0000-0002-8302-7596; Robert, Stéphanie/0000-0002-0013-3239; Eva, Zazimalova/0000-0002-8325-7092; Company, Fernando Aniento/0000-0003-3553-585X; Hayashi, Ken-ichiro/0000-0002-9812-2801; Vanneste, Steffen/0000-0002-9948-9672; Luschnig, Christian/0000-0003-2099-9280; Barbez, Elke/0000-0002-5531-7916	Research Foundation Flanders; Ministry of Education of the Czech Republic [LC06034]; Ministerio de Educacion y Ciencia [BFU2005-00071]; Agency for Innovation by Science and Technology; HFSP long-term; Marie Curie IEF; National Institute of General Medical Sciences [GM65989]; Department of Energy [DE-FG02-05er15671]; National Science Foundation [MCB0718202, 0723515]; NWO-VENI;  [ATLF 142-2007]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100130, R01GM065989, R01GM081451] Funding Source: NIH RePORTER	Research Foundation Flanders(FWO); Ministry of Education of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Ministerio de Educacion y Ciencia(Spanish Government); Agency for Innovation by Science and Technology; HFSP long-term; Marie Curie IEF(European Commission); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Department of Energy(United States Department of Energy (DOE)); National Science Foundation(National Science Foundation (NSF)); NWO-VENI(Netherlands Organization for Scientific Research (NWO)); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank the anonymous reviewer for helpful comments and Martine De Cock for help in preparing the manuscript. We are very grateful to X.Y. Chen, M. Estelle, T. Gaude, N. Geldner, O. Leyser, C. Perrot-Rechen-mann, and J.W. Reed for sharing published materials and Drs. Jin-Gui Chen and Ming-Jing Wu for generating abp1 mutants. This work was supported by the Odysseus program of the Research Foundation Flanders, the Ministry of Education of the Czech Republic (project LC06034), and the Ministerio de Educacion y Ciencia (grant BFU2005-00071). E.B. is indebted to the Agency for Innovation by Science and Technology for a predoctoral fellowship and S.V. to EMBO for a long-term fellowship (ATLF 142-2007). M.S. was supported by HFSP long-term and Marie Curie IEF fellowships. A.M.J is supported by grants from The National Institute of General Medical Sciences (GM65989), The Department of Energy (DE-FG02-05er15671), and The National Science Foundation (MCB0718202, 0723515). P.D. is supported by NWO-VENI grant.	Abas L, 2006, NAT CELL BIOL, V8, P249, DOI 10.1038/ncb1369; Badescu GO, 2006, TRENDS PLANT SCI, V11, P217, DOI 10.1016/j.tplants.2006.03.001; Banbury AN, 2003, J BIOL CHEM, V278, P12022, DOI 10.1074/jbc.M211966200; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Braun N, 2008, PLANT CELL, V20, P2746, DOI 10.1105/tpc.108.059048; Chen JG, 2001, GENE DEV, V15, P902, DOI 10.1101/gad.866201; Collings DA, 2008, J EXP BOT, V59, P361, DOI 10.1093/jxb/erm324; Dharmasiri N, 2004, TRENDS PLANT SCI, V9, P302, DOI 10.1016/j.tplants.2004.04.003; Dharmasiri N, 2005, DEV CELL, V9, P109, DOI 10.1016/j.devcel.2005.05.014; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Dhonukshe P, 2008, NATURE, V456, P962, DOI 10.1038/nature07409; Dhonukshe P, 2007, CURR BIOL, V17, P520, DOI 10.1016/j.cub.2007.01.052; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Fukaki H, 2002, PLANT J, V29, P153, DOI 10.1046/j.0960-7412.2001.01201.x; Geisler M, 2005, PLANT J, V44, P179, DOI 10.1111/j.1365-313X.2005.02519.x; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Henderson J, 1997, PLANTA, V202, P313, DOI 10.1007/s004250050133; HERTEL R, 1972, PLANTA, V107, P325, DOI 10.1007/BF00386394; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542; Kepinski S, 2002, PLANT CELL, V14, pS81, DOI 10.1105/tpc.010447; Kim YW, 2001, PLANT PHYSIOL, V127, P1243, DOI 10.1104/pp.010450; Kleine-Vehn J, 2008, P NATL ACAD SCI USA, V105, P17812, DOI 10.1073/pnas.0808073105; Knox K, 2003, DEVELOPMENT, V130, P5769, DOI 10.1242/dev.00659; Konopka CA, 2008, PLANT CELL, V20, P1363, DOI 10.1105/tpc.108.059428; Lau S, 2009, TRENDS PLANT SCI, V14, P182, DOI 10.1016/j.tplants.2009.01.004; Leblanc N, 1997, PLANT MOL BIOL, V33, P679, DOI 10.1023/A:1005757815212; Leyser O, 2006, CURR BIOL, V16, pR424, DOI 10.1016/j.cub.2006.05.014; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; LOBLER M, 1985, J BIOL CHEM, V260, P9848; Michniewicz M, 2007, CELL, V130, P1044, DOI 10.1016/j.cell.2007.07.033; Napier RM, 2002, PLANT MOL BIOL, V49, P339, DOI 10.1023/A:1015259130955; Ortiz-Zapater E, 2006, PLANT J, V48, P757, DOI 10.1111/j.1365-313X.2006.02909.x; Paciorek T, 2005, NATURE, V435, P1251, DOI 10.1038/nature03633; Pan JW, 2009, PLANT CELL, V21, P568, DOI 10.1105/tpc.108.061465; Petrasek J, 2006, SCIENCE, V312, P914, DOI 10.1126/science.1123542; Petrasek J, 2009, DEVELOPMENT, V136, P2675, DOI 10.1242/dev.030353; Robinson DG, 2008, PLANT PHYSIOL, V147, P1482, DOI 10.1104/pp.108.120105; Santner A, 2009, NATURE, V459, P1071, DOI 10.1038/nature08122; Sauer M, 2006, NAT PROTOC, V1, P98, DOI 10.1038/nprot.2006.15; Schenck D, 2010, PLANT PHYSIOL, V152, P1183, DOI 10.1104/pp.109.149591; Shimomura S, 1999, PLANTA, V209, P118, DOI 10.1007/s004250050613; Sieberer T, 2000, CURR BIOL, V10, P1595, DOI 10.1016/S0960-9822(00)00861-7; Swarup K, 2008, NAT CELL BIOL, V10, P946, DOI 10.1038/ncb1754; Tan X, 2007, NATURE, V446, P640, DOI 10.1038/nature05731; TIAN HC, 1995, J BIOL CHEM, V270, P26962, DOI 10.1074/jbc.270.45.26962; Tian Q, 2002, PLANT CELL, V14, P301, DOI 10.1105/tpc.010283; TIMPTE C, 1994, GENETICS, V138, P1239; Tromas A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006648; Ueda T, 2001, EMBO J, V20, P4730, DOI 10.1093/emboj/20.17.4730; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Vanneste S, 2009, CELL, V136, P1005, DOI 10.1016/j.cell.2009.03.001; Vieten A, 2007, TRENDS PLANT SCI, V12, P160, DOI 10.1016/j.tplants.2007.03.006; Wisniewska J, 2006, SCIENCE, V312, P883, DOI 10.1126/science.1121356; Woo EJ, 2002, EMBO J, V21, P2877, DOI 10.1093/emboj/cdf291; Xu TD, 2010, CELL, V143, P99, DOI 10.1016/j.cell.2010.09.003; Yang HB, 2009, PLANT J, V59, P179, DOI 10.1111/j.1365-313X.2009.03856.x; ZAZIMALOVA E, 1985, PLANT GROWTH REGUL, V3, P15, DOI 10.1007/BF00123542	61	300	317	0	119	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	2010	143	1					111	121		10.1016/j.cell.2010.09.027	http://dx.doi.org/10.1016/j.cell.2010.09.027			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887896	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000282362000018
J	Ghonge, NP; Sahu, AK				Ghonge, Nitin P.; Sahu, Amit Kumar			Thyroid Ectopia in a Boy with Hypothyroidism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ghonge, Nitin P.; Sahu, Amit Kumar] Diwan Chand Imaging Res Ctr, New Delhi, India		Ghonge, NP (corresponding author), Diwan Chand Imaging Res Ctr, New Delhi, India.								0	1	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1351	1351		10.1056/NEJMicm0908453	http://dx.doi.org/10.1056/NEJMicm0908453			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879884				2022-12-28	WOS:000282271500010
J	Rosen, CJ; Khosla, S				Rosen, Clifford J.; Khosla, Sundeep			Placebo-Controlled Fracture Trials in Osteoporosis - Proceeding with Caution	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RISK; PREVENTION; DENSITY; WOMEN		[Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ON, Canada; [Khosla, Sundeep] Mayo Clin, Coll Med, Rochester, MN USA	Mayo Clinic	Rosen, CJ (corresponding author), Maine Med Ctr, Res Inst, Scarborough, ON, Canada.		Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027065] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR027065] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493; European Medicines Agency, 2005, GUID EV NEW MED PROD; Food and Drug Administration Division of Metabolic and Endocrine Drug Products, 1994, GUID PRECL CLIN EV A; Fost N, 2003, J BONE MINER RES, V18, P1110, DOI 10.1359/jbmr.2003.18.6.1110; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Silverman SL, 2008, J BONE MINER RES, V23, P159, DOI 10.1359/JBMR.070905	8	16	16	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1365	1367		10.1056/NEJMsb1002227	http://dx.doi.org/10.1056/NEJMsb1002227			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879887	Green Accepted			2022-12-28	WOS:000282271500014
J	Parry, J				Parry, Jane			Medicine and the Media Can media depictions of suicide influence copycat acts?	BRITISH MEDICAL JOURNAL			English	Editorial Material												jeparry@netvigator.com						FU KW, 2009, NOVA SCI, P153; Niederkrotenthaler T, 2007, AUST NZ J PSYCHIAT, V41, P419, DOI 10.1080/00048670701266680; Pirkis J., 2010, SUICIDE NEWS INFORM; Pirkis J, 2009, CRISIS, V30, P25, DOI 10.1027/0227-5910.30.1.25; Wong PWC, 2009, SUICIDE LIFE-THREAT, V39, P82, DOI 10.1521/suli.2009.39.1.82; 2009, REPORTING SUICIDE ME	6	4	4	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2010	341								c5067	10.1136/bmj.c5067	http://dx.doi.org/10.1136/bmj.c5067			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659ND	20880906				2022-12-28	WOS:000282572400007
J	Reches, Z; Lockner, DA				Reches, Ze'ev; Lockner, David A.			Fault weakening and earthquake instability by powder lubrication	NATURE			English	Article							HIGH-SPEED; FRICTION; WEAR; MECHANISM; ZONES; GOUGE	Earthquake instability has long been attributed to fault weakening during accelerated slip(1), and a central question of earthquake physics is identifying the mechanisms that control this weakening(2). Even with much experimental effort(2-12), the weakening mechanisms have remained enigmatic. Here we present evidence for dynamic weakening of experimental faults that are sheared at velocities approaching earthquake slip rates. The experimental faults, which were made of room-dry, solid granite blocks, quickly wore to form a fine-grain rock powder known as gouge. At modest slip velocities of 10-60 mm s(-1), this newly formed gouge organized itself into a thin deforming layer that reduced the fault's strength by a factor of 2-3. After slip, the gouge rapidly 'aged' and the fault regained its strength in a matter of hours to days. Therefore, only newly formed gouge can weaken the experimental faults. Dynamic gouge formation is expected to be a common and effective mechanism of earthquake instability in the brittle crust as (1) gouge always forms during fault slip(5,10,12-20); (2) fault-gouge behaves similarly to industrial powder lubricants(21); (3) dynamic gouge formation explains various significant earthquake properties; and (4) gouge lubricant can form for a wide range of fault configurations, compositions and temperatures(15).	[Reches, Ze'ev] Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73019 USA; [Lockner, David A.] US Geol Survey, Menlo Pk, CA 94025 USA	University of Oklahoma System; University of Oklahoma - Norman; United States Department of the Interior; United States Geological Survey	Reches, Z (corresponding author), Univ Oklahoma, Sch Geol & Geophys, 100 E Boyd St, Norman, OK 73019 USA.	reches@ou.edu; lockner@usgs.gov			National Science Foundation [0732715]; Directorate For Geosciences [0732715] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We thank J. Young, who built our instrument, as well as E. Eshkol, M. Hamilton, D. Moore, A. Madden, J. Chang and S. Busetti. Comments and reviews by J. Andrews, N. Beeler, C. Sammis, T.-f. Wong and J. Fineberg improved the manuscript. This study is supported by the National Science Foundation, Geosciences, Equipment and Facilities (grant number 0732715).	Beeler NM, 1996, B SEISMOL SOC AM, V86, P1130; BEELER NM, 1995, PURE APPL GEOPHYS, V144, P251, DOI 10.1007/BF00878634; Ben-Zion Y, 2003, PURE APPL GEOPHYS, V160, P677, DOI 10.1007/PL00012554; BINGGELI M, 1995, J VAC SCI TECHNOL B, V13, P1312, DOI 10.1116/1.587844; Brodsky EE, 2001, J GEOPHYS RES-SOL EA, V106, P16357, DOI 10.1029/2001JB000430; BYERLEE JD, 1967, J GEOPHYS RES, V72, P3639, DOI 10.1029/JZ072i014p03639; DI TORO G, 2004, NATURE, V427, P436; DIETERICH JH, 1981, GEOPHYS MONOGR SER, V24, P103, DOI DOI 10.1029/GM024P0103; DIETERICH JH, 1979, J GEOPHYS RES, V84; GODET M, 1984, WEAR, V100, P437, DOI 10.1016/0043-1648(84)90025-5; HESHMAT H, 1995, TRIBOL T, V38, P269, DOI 10.1080/10402009508983404; Higgs CF, 1999, J TRIBOL-T ASME, V121, P625, DOI 10.1115/1.2834113; Hiratsuka K, 2005, WEAR, V259, P467, DOI 10.1016/j.wear.2005.02.102; Hird JR, 2005, WEAR, V258, P18, DOI 10.1016/j.wear.2004.09.001; Hirose T, 2005, B SEISMOL SOC AM, V95, P1666, DOI 10.1785/0120040131; Ide S, 1997, J GEOPHYS RES-SOL EA, V102, P27379, DOI 10.1029/97JB02675; JORDAN T, 2003, LIVING ACTIVE EARTH; Lockner DA, 2009, PURE APPL GEOPHYS, V166, P1649, DOI 10.1007/s00024-009-0515-0; Mair K, 1999, J GEOPHYS RES-SOL EA, V104, P28899, DOI 10.1029/1999JB900279; Marone C, 2004, NATURE, V427, P405, DOI 10.1038/427405a; Marone C, 1998, ANNU REV EARTH PL SC, V26, P643, DOI 10.1146/annurev.earth.26.1.643; Mizoguchi K, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026980; Muhuri SK, 2003, GEOLOGY, V31, P881, DOI 10.1130/G19601.1; Paterson M.S., 2005, EXPT ROCK DEFORMATIO; RABINOWICZ E, 1955, P PHYS SOC LOND B, V68, P603, DOI 10.1088/0370-1301/68/9/304; RUINA A, 1983, J GEOPHYS RES, V88, P359, DOI 10.1029/JB088iB12p10359; Scholz C.H., 2002, MECH EARTHQUAKES FAU, DOI 10.1017/CBO9780511818516; WANG WB, 1994, J GEOPHYS RES-SOL EA, V99, P6789, DOI 10.1029/93JB02875; Wilson B, 2005, NATURE, V434, P749, DOI 10.1038/nature03433; Wornyoh EYA, 2007, J TRIBOL-T ASME, V129, P438, DOI 10.1115/1.2647859; YUNG RA, 1990, J GEOPHYS RES-SOLID, V95, P15589, DOI 10.1029/JB095iB10p15589	31	194	200	10	72	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					452	U102		10.1038/nature09348	http://dx.doi.org/10.1038/nature09348			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20865001				2022-12-28	WOS:000282090200041
J	Fleming, SM; Weil, RS; Nagy, Z; Dolan, RJ; Rees, G				Fleming, Stephen M.; Weil, Rimona S.; Nagy, Zoltan; Dolan, Raymond J.; Rees, Geraint			Relating Introspective Accuracy to Individual Differences in Brain Structure	SCIENCE			English	Article							PREFRONTAL CORTEX; CONFIDENCE; MEMORY; DISCRIMINATION; INSIGHTS; DECISION; ANATOMY; CHOICE	The ability to introspect about self-performance is key to human subjective experience, but the neuroanatomical basis of this ability is unknown. Such accurate introspection requires discriminating correct decisions from incorrect ones, a capacity that varies substantially across individuals. We dissociated variation in introspective ability from objective performance in a simple perceptual-decision task, allowing us to determine whether this interindividual variability was associated with a distinct neural basis. We show that introspective ability is correlated with gray matter volume in the anterior prefrontal cortex, a region that shows marked evolutionary development in humans. Moreover, interindividual variation in introspective ability is also correlated with white-matter microstructure connected with this area of the prefrontal cortex. Our findings point to a focal neuroanatomical substrate for introspective ability, a substrate distinct from that supporting primary perception.	[Fleming, Stephen M.; Weil, Rimona S.; Nagy, Zoltan; Dolan, Raymond J.; Rees, Geraint] UCL, Wellcome Trust Ctr Neuroimaging, London WC1N 3BG, England; [Weil, Rimona S.; Rees, Geraint] UCL, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London; University of London; University College London	Fleming, SM (corresponding author), UCL, Wellcome Trust Ctr Neuroimaging, 12 Queen Sq, London WC1N 3BG, England.	s.fleming@fil.ion.ucl.ac.uk	Nagy, Zoltan/AAI-2485-2019; Weil, Rimona S/B-6151-2009; Rees, Geraint/C-1493-2008; Fleming, Steve/A-9584-2010	Nagy, Zoltan/0000-0001-6611-6362; Rees, Geraint/0000-0002-9623-7007; Dolan, Ray/0000-0001-9356-761X; Fleming, Stephen/0000-0003-0233-4891; Weil, Rimona/0000-0002-5092-6325	Wellcome Trust; University College London; Medical Research Council; Medical Research Council [G0500743] Funding Source: researchfish; MRC [G0500743] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); University College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was funded by the Wellcome Trust (G. R., R.J.D., Z.N.), the University College London four-year Ph.D. program in neuroscience (S.M.F.), and the Medical Research Council (R. S. W.). We thank T. Sharot, G. Ridgway, and C. Frith for comments on earlier drafts of this manuscript.	Burgin GH, 2007, IEEE T EVOLUT COMPUT, V11, P290, DOI 10.1109/TEVC.2007.899730; Carreiras M, 2009, NATURE, V461, P983, DOI 10.1038/nature08461; Christoff K, 2000, PSYCHOBIOLOGY, V28, P168; Cleeremans A, 2007, NEURAL NETWORKS, V20, P1032, DOI 10.1016/j.neunet.2007.09.011; Daw ND, 2006, NATURE, V441, P876, DOI 10.1038/nature04766; DEL CUL A, 2009, BRAIN 9, V132, P2531; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Fleming SM, 2010, CONSCIOUS COGN, V19, P352, DOI 10.1016/j.concog.2009.11.002; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Fuentemilla L, 2009, J NEUROSCI, V29, P8698, DOI 10.1523/JNEUROSCI.5270-08.2009; Galvin SJ, 2003, PSYCHON B REV, V10, P843, DOI 10.3758/BF03196546; Graziano M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004909; Kepecs A, 2008, NATURE, V455, P227, DOI 10.1038/nature07200; Kiani R, 2009, SCIENCE, V324, P759, DOI 10.1126/science.1169405; Kornbrot DE, 2006, PERCEPT PSYCHOPHYS, V68, P393, DOI 10.3758/BF03193685; Kunimoto C, 2001, CONSCIOUS COGN, V10, P294, DOI 10.1006/ccog.2000.0494; Lau HC, 2008, PROG BRAIN RES, V168, P35, DOI 10.1016/S0079-6123(07)68004-2; Lau HC, 2006, P NATL ACAD SCI USA, V103, P18763, DOI 10.1073/pnas.0607716103; METCALFE J, 2008, HDB METAMEMORY MEMOR, P27; Metcalfe J, 1996, METACOGNITION KNOWIN; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Rounis E, 2010, COGN NEUROSCI-UK, V1, P165, DOI 10.1080/17588921003632529; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Shimamura AP, 2000, CONSCIOUS COGN, V9, P313, DOI 10.1006/ccog.2000.0450; Simons JS, 2010, CEREB CORTEX, V20, P479, DOI 10.1093/cercor/bhp116; Smith CD, 2007, NEUROBIOL AGING, V28, P1075, DOI 10.1016/j.neurobiolaging.2006.05.018; Szczepanowski R, 2007, J VISION, V7, DOI 10.1167/7.4.10; Titchener E. B., 1909, LECT EXPT PSYCHOL TH; Tuch DS, 2005, P NATL ACAD SCI USA, V102, P12212, DOI 10.1073/pnas.0407259102; Washburn DA, 2005, J GEN PSYCHOL, V132, P446, DOI 10.3200/GENP.132.4.446-461	31	484	487	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1541	1543		10.1126/science.1191883	http://dx.doi.org/10.1126/science.1191883			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847276	Green Accepted, Green Published			2022-12-28	WOS:000281869000047
J	McKenna, NJ; O'Malley, BW				McKenna, Neil J.; O'Malley, Bert W.			SnapShot: Nuclear Receptors II	CELL			English	Editorial Material							SYSTEM		[McKenna, Neil J.; O'Malley, Bert W.] Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	McKenna, NJ (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.			McKenna, Neil/0000-0001-6689-0104	NIDDK NIH HHS [U19-DK62434] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auwerx J, 1999, CELL, V97, P161; Benoit G, 2006, PHARMACOL REV, V58, P798, DOI 10.1124/pr.58.4.10; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009; Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003; Kim KW, 2009, MOL CELL ENDOCRINOL, V300, P132, DOI 10.1016/j.mce.2008.09.026; PEAREN MA, MOL ENDOCRINOL, DOI DOI 10.10.1210/ME.2010-0015; TREMBLAY AM, 2007, NUCL RECEPT SIGNAL, V3, pE9; Yin Lei, 2010, Nucl Recept Signal, V8, pe001, DOI 10.1621/nrs.08001	9	5	5	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					986	U155		10.1016/j.cell.2010.08.041	http://dx.doi.org/10.1016/j.cell.2010.08.041			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850017	Bronze			2022-12-28	WOS:000281855000021
J	Solomon, SD; Uno, H; Lewis, EF; Eckardt, KU; Lin, J; Burdmann, EA; de Zeeuw, D; Ivanovich, P; Levey, AS; Parfrey, P; Remuzzi, G; Singh, AK; Toto, R; Huang, F; Rossert, J; McMurray, JJV; Pfeffer, MA				Solomon, Scott D.; Uno, Hajime; Lewis, Eldrin F.; Eckardt, Kai-Uwe; Lin, Julie; Burdmann, Emmanuel A.; de Zeeuw, Dick; Ivanovich, Peter; Levey, Andrew S.; Parfrey, Patrick; Remuzzi, Giuseppe; Singh, Ajay K.; Toto, Robert; Huang, Fannie; Rossert, Jerome; McMurray, John J. V.; Pfeffer, Marc A.		Trial Reduce Cardiovasc Events Ara	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPOETIN-ALPHA; HEMODIALYSIS-PATIENTS; SECONDARY ANALYSIS; ANEMIC PATIENTS; HEMOGLOBIN; MORTALITY; TRIAL; MANAGEMENT; RISK; SURVIVAL	Background: Non-placebo-controlled trials of erythropoiesis-stimulating agents (ESAs) comparing lower and higher hemoglobin targets in patients with chronic kidney disease indicate that targeting of a lower hemoglobin range may avoid ESA-associated risks. However, target-based strategies are confounded by each patient's individual hematopoietic response. Methods: We assessed the relationship among the initial hemoglobin response to darbepoetin alfa after two weight-based doses, the hemoglobin level achieved after 4 weeks, the subsequent darbepoetin alfa dose, and outcomes in 1872 patients with chronic kidney disease and type 2 diabetes mellitus who were not receiving dialysis. We defined a poor initial response to darbepoetin alfa (which occurred in 471 patients) as the lowest quartile of percent change in hemoglobin level (<2%) after the first two standardized doses of the drug. Results: Patients who had a poor initial response to darbepoetin alfa had a lower average hemoglobin level at 12 weeks and during follow-up than did patients with a better hemoglobin response (a change in hemoglobin level ranging from 2 to 15% or more) (P<0.001 for both comparisons), despite receiving higher doses of darbepoetin alfa (median dose, 232 microg vs. 167 microg; P<0.001). Patients with a poor response, as compared with those with a better response, had higher rates of the composite cardiovascular end point (adjusted hazard ratio, 1.31; 95% confidence interval [CI], 1.09 to 1.59) or death (adjusted hazard ratio, 1.41; 95% CI, 1.12 to 1.78). Conclusions: A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels. Although the mechanism of this differential effect is not known, these findings raise concern about current target-based strategies for treating anemia in patients with chronic kidney disease. (Funded by Amgen; ClinicalTrials.gov number, NCT00093015.) N Engl J Med 2010;363:1146-55.	[Solomon, Scott D.; Uno, Hajime; Lewis, Eldrin F.; Pfeffer, Marc A.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02114 USA; [Lin, Julie; Singh, Ajay K.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; [Levey, Andrew S.] Tufts Med Ctr, Div Nephrol, Boston, MA USA; [Eckardt, Kai-Uwe] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Burdmann, Emmanuel A.] Fac Med Sao Jose do Rio Preto, Sao Paulo, Brazil; [de Zeeuw, Dick] Univ Groningen, Univ Med Ctr Groningen, Div Clin Pharmacol, NL-9713 AV Groningen, Netherlands; [Ivanovich, Peter] Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, Chicago, IL 60611 USA; [Parfrey, Patrick] Hlth Sci Ctr, Div Nephrol, St John, NF, Canada; [Remuzzi, Giuseppe] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy; [Toto, Robert] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA; [Huang, Fannie; Rossert, Jerome] Amgen Inc, Global Biostat & Epidemiol, Thousand Oaks, CA USA; [McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Huang, Fannie; Rossert, Jerome] Amgen Inc, Global Clin Dev, Thousand Oaks, CA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tufts Medical Center; University of Erlangen Nuremberg; University of Groningen; Northwestern University; Feinberg School of Medicine; Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Texas System; University of Texas Southwestern Medical Center Dallas; Amgen; University of Glasgow; Amgen	Solomon, SD (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02114 USA.	ssolomon@rics.bwh.harvard.edu	Burdmann, Emmanuel/B-7023-2009; Burdmann, Emmanuel/AAY-1966-2020; Solomon, Scott/I-5789-2013; Uno, Hajime/W-4099-2019; mcmurray, John/B-2467-2013; de Zeeuw, Dick/E-9080-2014; Singh, Ajay/AAF-4414-2020; Remuzzi, Giuseppe/V-9766-2017	Burdmann, Emmanuel/0000-0002-7644-8579; Uno, Hajime/0000-0003-0622-8471; mcmurray, John/0000-0002-6317-3975; de Zeeuw, Dick/0000-0003-3434-7777; Remuzzi, Giuseppe/0000-0002-6194-3446	Amgen	Amgen(Amgen)	Supported by Amgen.	Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Bradbury BD, 2009, CLIN J AM SOC NEPHRO, V4, P630, DOI 10.2215/CJN.03580708; Brookhart MA, 2010, JAMA-J AM MED ASSOC, V303, P857, DOI 10.1001/jama.2010.206; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; Horl WH, 2007, J AM SOC NEPHROL, V18, P382, DOI 10.1681/ASN.2006080856; Johnson DW, 2007, NEPHROLOGY, V12, P321, DOI 10.1111/j.1440-1797.2007.00810.x; Kausz AT, 2005, AM J KIDNEY DIS, V45, P136, DOI 10.1053/j.ajkd.2004.08.042; Kilpatrick RD, 2008, CLIN J AM SOC NEPHRO, V3, P1077, DOI 10.2215/CJN.04601007; Levin A, 2007, AM J KIDNEY DIS, V50, P471; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Lopez-Gomez JM, 2008, KIDNEY INT, V74, pS75, DOI 10.1038/ki.2008.523; Messana JM, 2009, AM J KIDNEY DIS, V53, P503, DOI 10.1053/j.ajkd.2008.10.047; Mix TCH, 2005, AM HEART J, V149, P408, DOI 10.1016/j.ahj.2004.09.047; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Phrommintikul A, 2007, LANCET, V369, P381, DOI 10.1016/S0140-6736(07)60194-9; *REN ASS, COMPL CKD; Rossert J, 2007, NEPHROL DIAL TRANSPL, V22, P794, DOI 10.1093/ndt/gfl716; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Streja E, 2008, AM J KIDNEY DIS, V52, P727, DOI 10.1053/j.ajkd.2008.05.029; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; Szczech LA, 2010, KIDNEY INT, V77, P239, DOI 10.1038/ki.2009.415; Unger EF, 2010, NEW ENGL J MED, V362, P189, DOI 10.1056/NEJMp0912328; Vlagopoulos PT, 2005, J AM SOC NEPHROL, V16, P3403, DOI 10.1681/ASN.2005030226	24	335	350	2	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1146	1155		10.1056/NEJMoa1005109	http://dx.doi.org/10.1056/NEJMoa1005109			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843249				2022-12-28	WOS:000281795800009
J	Djulbegovic, M; Beyth, RJ; Neuberger, MM; Stoffs, TL; Vieweg, J; Djulbegovic, B; Dahm, P				Djulbegovic, Mia; Beyth, Rebecca J.; Neuberger, Molly M.; Stoffs, Taryn L.; Vieweg, Johannes; Djulbegovic, Benjamin; Dahm, Philipp			Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; MORTALITY; OVERDIAGNOSIS; UPDATE; MEN	Objective To examine the evidence on the benefits and harms of screening for prostate cancer. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Electronic databases including Medline, Embase, CENTRAL, abstract proceedings, and reference lists up to July 2010. Review methods Included studies were randomised controlled trials comparing screening by prostate specific antigen with or without digital rectal examination versus no screening. Data abstraction and assessment of methodological quality with the GRADE approach was assessed by two independent reviewers and verified by the primary investigator. Mantel-Haenszel and inverse variance estimates were calculated and pooled under a random effects model expressing data as relative risks and 95% confidence intervals. Results Six randomised controlled trials with a total of 387 286 participants that met inclusion criteria were analysed. Screening was associated with an increased probability of receiving a diagnosis of prostate cancer (relative risk 1.46, 95% confidence interval 1.21 to 1.77; P<0.001) and stage I prostate cancer (1.95, 1.22 to 3.13; P=0.005). There was no significant effect of screening on death from prostate cancer (0.88, 0.71 to 1.09; P=0.25) or overall mortality (0.99, 0.97 to 1.01; P=0.44). All trials had one or more substantial methodological limitations. None provided data on the effects of screening on participants' quality of life. Little information was provided about potential harms associated with screening. Conclusions The existing evidence from randomised controlled trials does not support the routine use of screening for prostate cancer with prostate specific antigen with or without digital rectal examination.	[Djulbegovic, Mia; Neuberger, Molly M.; Stoffs, Taryn L.; Vieweg, Johannes; Dahm, Philipp] Univ Florida, Coll Med, Dept Urol & Prostate Dis Ctr, Gainesville, FL 32610 USA; [Beyth, Rebecca J.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA; [Djulbegovic, Benjamin] Univ S Florida, Ctr & Div Evidence Based Med & Outcomes Res, Tampa, FL 33612 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of South Florida	Dahm, P (corresponding author), Univ Florida, Coll Med, Dept Urol & Prostate Dis Ctr, PO Box 100247, Gainesville, FL 32610 USA.	p.dahm@urology.ufl.edu	Djulbegovic, Benjamin/I-3661-2012; Dahm, Philipp/I-1614-2019	Djulbegovic, Benjamin/0000-0003-0671-1447; Dahm, Philipp/0000-0003-2819-2553; Stoffs, Taryn/0000-0002-0830-8179	Department of Urology, University of Florida; American Geriatrics Society; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	Department of Urology, University of Florida(University of Florida); American Geriatrics Society; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by the Department of Urology, University of Florida, and the Dennis W Jahnigen Career Development Scholars Award through the American Geriatrics Society. The funders had no role in study design, the collection, analysis, and interpretation of data, the writing of the report, or the decision to submit the article for publication.	Albertsen PC, 2005, JAMA-J AM MED ASSOC, V293, P2095, DOI 10.1001/jama.293.17.2095; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; *AM JOINT COMM CAN, 2010, CANC STAG MAN; *AM UR ASS, 2010, AUA RESP AM CANC SOC; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Barry MJ, 2009, NEW ENGL J MED, V360, P1351, DOI 10.1056/NEJMe0901166; Boyle P, 2009, CA-CANCER J CLIN, V59, P220, DOI 10.3322/caac.20025; Brawley OW, 2010, CA-CANCER J CLIN, V60, P68, DOI 10.3322/caac.20067; Brawley OW, 2009, CA-CANCER J CLIN, V59, P264, DOI 10.3322/caac.20026; CARLSSON SC, 2010, EUR ASS UR ANN M BAR; *COCHR COLL, 2008, REV MAN REVM PROGR; Donovan J, 2003, Health Technol Assess, V7, P1; Draisma G, 2003, J NATL CANCER I, V95, P868, DOI 10.1093/jnci/95.12.868; Draisma G, 2009, JNCI-J NATL CANCER I, V101, P374, DOI 10.1093/jnci/djp001; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Esserman L, 2009, JAMA-J AM MED ASSOC, V302, P1685, DOI 10.1001/jama.2009.1498; Etzioni R, 2002, J NATL CANCER I, V94, P981; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Haynes RB, 2005, BMJ-BRIT MED J, V330, P1179, DOI 10.1136/bmj.38446.498542.8F; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hoffman RM, 2010, CURR OPIN UROL, V20, P189, DOI 10.1097/MOU.0b013e3283383b55; Hugosson J, 2010, LANCET ONCOL, V11, P725, DOI 10.1016/S1470-2045(10)70146-7; Ilic D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004720.pub2; Jegu J, 2009, PROG UROL, V19, P487, DOI 10.1016/j.purol.2009.03.001; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kawachi MH, 2010, J NATL COMPR CANC NE, V8, P240, DOI 10.6004/jnccn.2010.0016; Labrie F, 2004, PROSTATE, V59, P311, DOI 10.1002/pros.20017; Labrie F, 1999, PROSTATE, V38, P83, DOI 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B; LABRIE F, 1999, AGING MALE, V2, P33; Lin K, 2008, ANN INTERN MED, V149, P192, DOI 10.7326/0003-4819-149-3-200808050-00009; Makinen T, 2002, UROLOGY, V60, P846; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Prorok PC, 2000, CONTROL CLIN TRIALS, V21, p273S, DOI 10.1016/S0197-2456(00)00098-2; Raaijmakers R, 2002, UROLOGY, V60, P826, DOI 10.1016/S0090-4295(02)01958-1; Sandblom G, 2004, EUR UROL, V46, P717, DOI 10.1016/j.eururo.2004.08.011; Schroder FH, 2010, EUR UROL, V58, P46, DOI 10.1016/j.eururo.2010.03.033; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Sox HC, 2009, ANN INTERN MED, V151, P203, DOI 10.7326/0003-4819-151-3-200908040-00125; SUN X, 2010, BMJ-BRIT MED J, V340, DOI DOI 10.1136/BMJ.C117; US Preventive Serv Task Force, 2008, ANN INTERN MED, V149, P185, DOI 10.7326/0003-4819-149-3-200808050-00008; VARENHORST E, 1992, ACTA ONCOL, V31, P815, DOI 10.3109/02841869209089713; WELCH HG, 2010, JNCI-J NATL CANCER I, V102, P1; Wilt TJ, 2008, J NATL CANCER I, V100, P1123, DOI 10.1093/jnci/djn259; Wilt TJ, 2009, CONTEMP CLIN TRIALS, V30, P81, DOI 10.1016/j.cct.2008.08.002; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066; 2010, ISRCTN REGISTER 0317; 2010, ISRCTN REGISTER 0611	48	40	48	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	2010	341								c4543	10.1136/bmj.c4543	http://dx.doi.org/10.1136/bmj.c4543			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653LK	20843937	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000282092600013
J	de Andrade, PV; Carapinha, L				de Andrade, Paula Vale; Carapinha, Ludmila			Drug decriminalisation in Portugal	BRITISH MEDICAL JOURNAL			English	Editorial Material									[de Andrade, Paula Vale; Carapinha, Ludmila] Inst Drugs & Drug Addict, P-1700036 Lisbon, Portugal		de Andrade, PV (corresponding author), Inst Drugs & Drug Addict, P-1700036 Lisbon, Portugal.	paula.andrade@idt.min-saude.pt							0	8	8	0	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 10	2010	341								c4554	10.1136/bmj.c4554	http://dx.doi.org/10.1136/bmj.c4554			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZL	20833743				2022-12-28	WOS:000281815200004
J	Ruzek, D; Yakimenko, VV; Karan, LS; Tkachev, SE				Ruzek, Daniel; Yakimenko, Valeriy V.; Karan, Lyudmila S.; Tkachev, Sergey E.			Omsk haemorrhagic fever	LANCET			English	Article							TICK-BORNE ENCEPHALITIS; ANTIGENIC RELATIONSHIPS; CROSS-NEUTRALIZATION; VIRUS; FLAVIVIRUSES; INFECTION; IDENTIFICATION; TRANSMISSION; COMPLEX; TESTS	Omsk haemorrhagic fever is an acute viral disease prevalent in some regions of western Siberia in Russia. The symptoms of this disease include fever, headache, nausea, severe muscle pain, cough, and moderately severe haemorrhagic manifestations. A third of patients develop pneumonia, nephrosis, meningitis, or a combination of these complications. The only treatments available are for control of symptoms. No specific vaccine has been developed, although the vaccine against tick-borne encephalitis might provide a degree of protection against Omsk haemorrhagic fever virus. The virus is transmitted mainly by Dermacentor reticulatus ticks, but people are mainly infected after contact with infected muskrats (Ondatra zibethicus). Muskrats are very sensitive to Omsk haemorrhagic fever virus. The introduction of this species to Siberia in the 1930s probably led to viral emergence in this area, which had previously seemed free from the disease. Omsk haemorrhagic fever is, therefore, an example of a human disease that emerged owing to human-mediated disturbance of an ecological niche. We review the biological properties of the virus, and the epidemiological and clinical characteristics of Omsk haemorrhagic fever.	[Ruzek, Daniel] Acad Sci Czech Republ, Ctr Biol, Inst Parasitol, CZ-37005 Ceske Budejovice, Czech Republic; [Yakimenko, Valeriy V.] Omsk Res Inst Nat Foci Infect, Omsk, Russia; [Karan, Lyudmila S.] Minist Publ Hlth Russia, Cent Res Inst Epidemiol, Lab Epidemiol Zoonoses, Moscow, Russia; [Tkachev, Sergey E.] Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk, Russia	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences	Ruzek, D (corresponding author), Acad Sci Czech Republ, Ctr Biol, Inst Parasitol, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic.	ruzekd@paru.cas.cz	Karan, Luidmila/AAG-1347-2020; Tkachev, Sergey/I-7390-2013; Růžek, Daniel/G-9275-2014	Karan, Luidmila/0000-0002-5927-460X; Růžek, Daniel/0000-0003-4655-2380; Tkachev, Sergey/0000-0001-7767-380X	Ministry of Education, Youth and Sports of the Czech Republic [Z60220518]; Grant Agency of the Czech Republic [524/08/1509]; Research Centre of the Ministry of Education, Youth and Sports of the Czech Republic [LC 06009]; Ministry of Defense of the Czech Republic [OVUVZU2008002]; Siberian Branch of the Russian Academy of Sciences	Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Research Centre of the Ministry of Education, Youth and Sports of the Czech Republic; Ministry of Defense of the Czech Republic; Siberian Branch of the Russian Academy of Sciences(Russian Academy of Sciences)	We thank Marina Golovchenko for help in translating the Russian literature, and Jason Dean for corrections to the English-language writing. DR received grants from the Ministry of Education, Youth and Sports of the Czech Republic (Z60220518), the Grant Agency of the Czech Republic (524/08/1509), Research Centre of the Ministry of Education, Youth and Sports of the Czech Republic (LC 06009), and the Ministry of Defense of the Czech Republic (OVUVZU2008002). SET has received Integration interdisciplinary projects grants (numbers 6 and 63) and has grants pending (numbers 10 and 24) from the Siberian Branch of the Russian Academy of Sciences.	Akhrem-Akhremovich R.M., 1948, P OMGMI, V13, P3; Akhrem-Akhremovich RM, 1959, P OMGMI, V25, P107; [Anonymous], 1985, VIR HEM FEV, P128; AVAKIAN A. A., 1955, ZOOLOGICHESKII ZHURNAL, V34, P605; Belan AA, 1964, TICK BORNE ENCEPHALI, P228; Belov G.F., 1995, ZH MIKROBIOL EPIDEMI, V4, P88; Bogdanov LL, 1969, MED PARAZIT, V38, P415; Busygin F F, 2000, Vopr Virusol, V45, P4; Busygin FF, 1975, PROBLEMS INFECT PATH, P32; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; CASALS J, 1961, B WORLD HEALTH ORGAN, V24, P723; Chumakov M.P., 1948, VESTN AKAD MED NAUK, V2, P19; CLARKE DH, 1964, B WORLD HEALTH ORGAN, V31, P45; DEMADRID AT, 1974, J GEN VIROL, V23, P91, DOI 10.1099/0022-1317-23-1-91; Estrada-Pena A, 1999, EXP APPL ACAROL, V23, P685, DOI 10.1023/A:1006241108739; Fedorova TN, 1964, ZH MIKROBIOL, V11, P134; Fedorova TN., 1969, THESIS TOMSK U, P40; Gagarina A., 1957, P OMGMI, V4, P15; Gagarina AV, 1955, PRIROD OCHAG BOLEZN, P220; GAIDAMOVICH SY, 1995, EXOTIC VIRAL INFECT, P203; HOFMANN H, 1969, ARCH GES VIRUSFORSCH, V28, P197, DOI 10.1007/BF01249384; Holbrook MR, 2005, J INFECT DIS, V191, P100, DOI 10.1086/426397; HOOGSTRAAL H, 1985, ADV PARASIT, V24, P135, DOI 10.1016/S0065-308X(08)60563-1; Jelinkova-Skalova E, 1974, Cesk Epidemiol Mikrobiol Imunol, V23, P290; KARMYSHEVA V. Ya, 1965, VOP VIRUSOL, V10, P557; KENYON RH, 1992, MICROB PATHOGENESIS, V13, P399, DOI 10.1016/0882-4010(92)90083-Z; Kharitonova NN, 1985, OMSK HEMORAGIC FEVER, P230; Kharitonova NN, 1966, MUSKRAT W SIBERIA BI, P141; Khasnatinov MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007295; KONDRASHOVA Z N, 1970, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V39, P274; KORNILOVA E A, 1970, Voprosy Virusologii, V15, P232; Korsh PV, 1971, EPIZOOTIC CHARACTERI, P70; LABUDA M, 1993, J MED ENTOMOL, V30, P295, DOI 10.1093/jmedent/30.1.295; LaSala PR, 2010, CLIN LAB MED, V30, P221, DOI 10.1016/j.cll.2010.01.002; LEBEDEV E P, 1975, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, V11, P132; Li L, 2004, J GEN VIROL, V85, P1619, DOI 10.1099/vir.0.19766-0; Lin D, 2003, VIROLOGY, V313, P81, DOI 10.1016/S0042-6822(03)00246-0; Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9; Loginova S. Ya., 2002, Voprosy Virusologii, V47, P27; Maher-Sturgess SL, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-16; Matuschenko AA, 2004, CLIMATE CHANGES RUSS, P124; Mazbich IB., 1952, TRUD OMSK I EPIDEMIO, V1, P51; Moureau G, 2007, VECTOR-BORNE ZOONOT, V7, P467, DOI 10.1089/vbz.2007.0206; Neronov VM, 2008, INTEGR ZOOL, V3, P83, DOI 10.1111/j.1749-4877.2008.00084.x; Netesov SV, 2001, EMERG INFECT DIS, V7, P1, DOI 10.3201/eid0701.010101; Netzki GI, 1950, MED PARAZIT, V19, P545; Novitskiy VS, 1948, P OMGMI, V13, P97; Pattnaik P, 2006, REV MED VIROL, V16, P151, DOI 10.1002/rmv.495; Anonymous, 2007, Voprosy Virusologii, V52, P17; PORTERFIELD JS, 1957, NATURE, V180, P1201, DOI 10.1038/1801201b0; Ruzek D, 2009, J GEN VIROL, V90, P1649, DOI 10.1099/vir.0.010058-0; Ryba M, 1974, CAS LEK CES, V4, P101; Saksida A, 2005, J CLIN VIROL, V33, P331, DOI 10.1016/j.jcv.2004.07.014; Shestopalova N.M., 1965, VOPR VIRUS, V4, P425; SHESTOPALOVA NM, 1972, J ULTRA MOL STRUCT R, V40, P458, DOI 10.1016/S0022-5320(72)80035-2; Sizemova GA, 1957, P OMGMI, V21, P256; Stavsky EA, 2002, ANTHOLOGY BIOSAFETY, P179; STEPHENSON JR, 1988, VACCINE, V6, P471, DOI 10.1016/0264-410X(88)90095-3; Temovoi VA, 2003, EMERG INFECT DIS, V9, P743; Thiel H-J, 2005, VIRUS TAXONOMY, P981; Tigabu B, 2009, J MED VIROL, V81, P1261, DOI 10.1002/jmv.21524; Tikhomirova T., 1971, VOPR VIRUS, V2, P92; Tsai T.F., 1999, MANUAL CLIN MICROBIO, P1107; Tsybulina PP, 1964, TICK BORNE ENCEPHALI, P229; Von Lubitz DKJE, 2004, BIOTERRORISM FIELD G, P175; Yakimenko VV, 2007, MODERN SCI APPL ASPE, P143; Zaki AM, 1997, T ROY SOC TROP MED H, V91, P179, DOI 10.1016/S0035-9203(97)90215-7	67	72	75	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	2010	376	9758					2104	2113		10.1016/S0140-6736(10)61120-8	http://dx.doi.org/10.1016/S0140-6736(10)61120-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702LA	20850178				2022-12-28	WOS:000285895000028
J	Shuman, ES; Barry, JF; DeMille, D				Shuman, E. S.; Barry, J. F.; DeMille, D.			Laser cooling of a diatomic molecule	NATURE			English	Article							POLAR-MOLECULES; TEMPERATURES; MONOHALIDES; CHEMISTRY; ATOMS; FIELD; SRF	It has been roughly three decades since laser cooling techniques produced ultracold atoms(1-3), leading to rapid advances in a wide array of fields. Laser cooling has not yet been extended to molecules because of their complex internal structure. However, this complexity makes molecules potentially useful for a wide range of applications(4). For example, heteronuclear molecules possess permanent electric dipole moments that lead to long-range, tunable, anisotropic dipole-dipole interactions. The combination of the dipole-dipole interaction and the precise control over molecular degrees of freedom possible at ultracold temperatures makes ultracold molecules attractive candidates for use in quantum simulations of condensed-matter systems(5) and in quantum computation(6). Also, ultracold molecules could provide unique opportunities for studying chemical dynamics(7,8) and for tests of fundamental symmetries(9-11). Here we experimentally demonstrate laser cooling of the polar molecule strontium monofluoride (SrF). Using an optical cycling scheme requiring only three lasers(12), we have observed both Sisyphus and Doppler cooling forces that reduce the transverse temperature of a SrF molecular beam substantially, to a few millikelvin or less. At present, the only technique for producing ultracold molecules is to bind together ultracold alkali atoms through Feshbach resonance(13) or photoassociation(14). However, proposed applications for ultracold molecules require a variety of molecular energy-level structures (for example unpaired electronic spin(5,9,11,15), Omega doublets(16) and so on). Our method provides an alternative route to ultracold molecules. In particular, it bridges the gap between ultracold (submillikelvin) temperatures and the similar to 1-K temperatures attainable with directly cooled molecules (for example with cryogenic buffer-gas cooling(17) or decelerated supersonic beams(18)). Ultimately, our technique should allow the production of large samples of molecules at ultracold temperatures for species that are chemically distinct from bialkalis.	[Shuman, E. S.; Barry, J. F.; DeMille, D.] Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University	Shuman, ES (corresponding author), Yale Univ, Dept Phys, POB 208120, New Haven, CT 06520 USA.	edward.shuman@yale.edu			ARO; NSF; AFOSR [FA9550-09-1-0588]	ARO; NSF(National Science Foundation (NSF)); AFOSR(United States Department of DefenseAir Force Office of Scientific Research (AFOSR))	This material is based upon work supported by the ARO, the NSF and the AFOSR under the MURI award FA9550-09-1-0588.	ALLOUCHE AR, 1993, CHEM PHYS, V170, P11, DOI 10.1016/0301-0104(93)80087-P; Andre A, 2006, NAT PHYS, V2, P636, DOI 10.1038/nphys386; Balakrishnan N, 2001, CHEM PHYS LETT, V341, P652, DOI 10.1016/S0009-2614(01)00515-2; Berkeland DJ, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.033413; Bethlem HL, 2000, NATURE, V406, P491, DOI 10.1038/35020030; Carr LD, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/5/055049; CHILDS WJ, 1981, J MOL SPECTROSC, V87, P522, DOI 10.1016/0022-2852(81)90422-7; Chu S, 1998, REV MOD PHYS, V70, P685, DOI 10.1103/RevModPhys.70.685; Cohen-Tannoudji CN, 1998, REV MOD PHYS, V70, P707, DOI 10.1103/RevModPhys.70.707; DAGDIGIAN PJ, 1974, J CHEM PHYS, V60, P2330, DOI 10.1063/1.1681366; DeMille D, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.067901; DeMille D, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.023003; Di Rosa MD, 2004, EUR PHYS J D, V31, P395, DOI 10.1140/epjd/e2004-00167-2; EMILE O, 1993, J PHYS II, V3, P1709, DOI 10.1051/jp2:1993226; Flambaum VV, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.150801; GUPTA R, 1994, J OPT SOC AM B, V11, P537, DOI 10.1364/JOSAB.11.000537; KANDLER J, 1989, CHEM PHYS LETT, V155, P470, DOI 10.1016/0009-2614(89)87188-X; Krems RV, 2008, PHYS CHEM CHEM PHYS, V10, P4079, DOI 10.1039/b802322k; Maxwell SE, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.173201; Ni KK, 2008, SCIENCE, V322, P231, DOI 10.1126/science.1163861; Patterson D, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2717178; Phillips WD, 1998, REV MOD PHYS, V70, P721, DOI 10.1103/RevModPhys.70.721; Plimmer MD, 2005, JETP LETT+, V82, P17, DOI 10.1134/1.2045331; Pupillo G., 2009, COLD MOL THEORY EXPT; Sage JM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.203001; Shuman ES, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.223001; Stuhl BK, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.243002; Tarbutt MR, 2009, FARADAY DISCUSS, V142, P37, DOI 10.1039/b820625b; Vutha AC, 2010, J PHYS B-AT MOL OPT, V43, DOI 10.1088/0953-4075/43/7/074007; Weinstein JD, 1998, NATURE, V395, P148, DOI 10.1038/25949	30	555	560	3	178	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	2010	467	7317					820	823		10.1038/nature09443	http://dx.doi.org/10.1038/nature09443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663PB	20852614	Green Submitted			2022-12-28	WOS:000282898700062
J	Flier, JS; Maratos-Flier, E				Flier, Jeffrey S.; Maratos-Flier, Eleftheria			Lasker Lauds Leptin	CELL			English	Editorial Material							RECOMBINANT LEPTIN; OBESE GENE; MICE; RESISTANCE; MOUSE		[Flier, Jeffrey S.] Harvard Univ, Sch Med, Off Dean, Boston, MA 02215 USA; [Flier, Jeffrey S.; Maratos-Flier, Eleftheria] Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Flier, JS (corresponding author), Harvard Univ, Sch Med, Off Dean, Boston, MA 02215 USA.	jeffrey_flier@hms.harvard.edu; emaratos@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019					Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERVEY GR, 1959, J PHYSL, V145, P136; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Welt CK, 2004, NEW ENGL J MED, V351, P987, DOI 10.1056/NEJMoa040388; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	11	12	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					9	12		10.1016/j.cell.2010.09.021	http://dx.doi.org/10.1016/j.cell.2010.09.021			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887884	Bronze			2022-12-28	WOS:000282362000005
J	Yancopoulos, GD				Yancopoulos, George D.			Clinical Application of Therapies Targeting VEGF	CELL			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; DIABETIC-RETINOPATHY; TUMOR-GROWTH; ANGIOGENESIS; MITOGEN; FLUID		Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Regeneron	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	george@regeneron.com						ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Bagri A, 2010, CLIN CANCER RES, V16, P3887, DOI 10.1158/1078-0432.CCR-09-3100; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 1999, DEVELOPMENT, V126, P1149; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	15	45	51	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					13	16		10.1016/j.cell.2010.09.028	http://dx.doi.org/10.1016/j.cell.2010.09.028			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887885	Bronze			2022-12-28	WOS:000282362000006
J	Cleland, J				Cleland, John			The benefits of educating women	LANCET			English	Editorial Material							MORTALITY		London Sch Hyg & Trop Med, London WC1B 3DP, England	University of London; London School of Hygiene & Tropical Medicine	Cleland, J (corresponding author), London Sch Hyg & Trop Med, London WC1B 3DP, England.	john.cleland@lshtm.ac.uk	Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				[Anonymous], 2005, NATL FAMILY HLTH SUR; CALDWELL JC, 1979, POP STUD-J DEMOG, V33, P395, DOI 10.2307/2173888; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; CLELAND J, 1990, WHAT WE KNOW HLTH TR, P410; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Halstead S, 1985, GOOD HLTH LOW COST; Kravdal O, 2004, POP STUD-J DEMOG, V58, P177, DOI 10.1080/0032472042000213721; PRESTON SH, 1985, POP B UN, V18, P34; RYLAND S, 1998, OHS COMP STUDIES, V27	9	21	21	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	2010	376	9745					933	934		10.1016/S0140-6736(10)61417-1	http://dx.doi.org/10.1016/S0140-6736(10)61417-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20851245				2022-12-28	WOS:000282247600005
J	Glotch, TD; Lucey, PG; Bandfield, JL; Greenhagen, BT; Thomas, IR; Elphic, RC; Bowles, N; Wyatt, MB; Allen, CC; Hanna, KD; Paige, DA				Glotch, Timothy D.; Lucey, Paul G.; Bandfield, Joshua L.; Greenhagen, Benjamin T.; Thomas, Ian R.; Elphic, Richard C.; Bowles, Neil; Wyatt, Michael B.; Allen, Carlton C.; Hanna, Kerri Donaldson; Paige, David A.			Highly Silicic Compositions on the Moon	SCIENCE			English	Article							LUNAR; SEPARATION; REGION	Using data from the Diviner Lunar Radiometer Experiment, we show that four regions of the Moon previously described as "red spots" exhibit mid-infrared spectra best explained by quartz, silica-rich glass, or alkali feldspar. These lithologies are consistent with evolved rocks similar to lunar granites in the Apollo samples. The spectral character of these spots is distinct from surrounding mare and highlands material and from regions composed of pure plagioclase feldspar. The variety of landforms associated with the silicic spectral character suggests that both extrusive and intrusive silicic magmatism occurred on the Moon. Basaltic underplating is the preferred mechanism for silicic magma generation, leading to the formation of extrusive landforms. This mechanism or silicate liquid immiscibility could lead to the formation of intrusive bodies.	[Glotch, Timothy D.] SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; [Lucey, Paul G.] Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; [Bandfield, Joshua L.] Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; [Greenhagen, Benjamin T.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Thomas, Ian R.; Bowles, Neil] Univ Oxford, Dept Phys, Oxford, England; [Elphic, Richard C.; Hanna, Kerri Donaldson] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; [Wyatt, Michael B.] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Allen, Carlton C.] NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; [Paige, David A.] Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90024 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Hawaii System; University of Washington; University of Washington Seattle; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Oxford; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Brown University; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of California System; University of California Los Angeles	Glotch, TD (corresponding author), SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA.	tglotch@notes.cc.sunysb.edu	Hanna, Kerri Donaldson/AAC-9941-2020; Greenhagen, Benjamin T/C-3760-2016	Greenhagen, Benjamin T/0000-0002-8252-9922; Bandfield, Joshua/0000-0003-3571-3716; Thomas, Ian/0000-0003-3887-6668	Diviner science budget; NASA; Science and Technology Facilities Council [ST/H00243X/1] Funding Source: researchfish	Diviner science budget; NASA(National Aeronautics & Space Administration (NASA)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	This work was funded in part by the Diviner science budget. T. D. G., J.L.B., M. B. W., and R. C. E. were supported by the NASA Lunar Reconnaissance Orbiter Participating Scientist program.	BRUNO BC, 1991, P LUNAR PLANET SCI, V21, P405; Chevrel SD, 1999, J GEOPHYS RES-PLANET, V104, P16515, DOI 10.1029/1998JE900007; CONEL JE, 1969, J GEOPHYS RES, V74, P1614, DOI 10.1029/JB074i006p01614; Greenhagen BT, 2010, SCIENCE, V329, P1507, DOI 10.1126/science.1192196; Hagerty JJ, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002592; Hagerty JJ, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2008JE003262; Hawke BR, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002013; HEAD JW, 1978, SCIENCE, V199, P1433, DOI 10.1126/science.199.4336.1436; HEAD JW, 1978, LUNAR PLANET SCI, V9, P488; Jolliff BL, 2000, J GEOPHYS RES-PLANET, V105, P4197, DOI 10.1029/1999JE001103; Jolliff BL, 1998, INT GEOL REV, V40, P916, DOI 10.1080/00206819809465245; Jolliff BL, 1999, AM MINERAL, V84, P821, DOI 10.2138/am-1999-5-616; Lawrence DJ, 2000, J GEOPHYS RES-PLANET, V105, P20307, DOI 10.1029/1999JE001177; LOGAN LM, 1973, J GEOPHYS RES, V78, P4983, DOI 10.1029/JB078i023p04983; LUCEY PG, 1986, J GEOPHYS RES-SOLID, V91, pD344, DOI 10.1029/JB091iB04p0D344; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P3679, DOI 10.1029/97JE03019; LUCEY PG, 1995, SCIENCE, V268, P1150, DOI 10.1126/science.268.5214.1150; Maaloe S, 1997, J VOLCANOL GEOTH RES, V76, P111, DOI 10.1016/S0377-0273(96)00053-4; MALIN MC, 1974, EARTH PLANET SC LETT, V21, P331, DOI 10.1016/0012-821X(74)90170-8; NEAL CR, 1989, GEOCHIM COSMOCHIM AC, V53, P529, DOI 10.1016/0016-7037(89)90403-1; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; Ohtake M, 2009, NATURE, V461, P236, DOI 10.1038/nature08317; Paige DA, 2010, SPACE SCI REV, V150, P125, DOI 10.1007/s11214-009-9529-2; SALISBURY JW, 1989, J GEOPHYS RES-SOLID, V94, P9192, DOI 10.1029/JB094iB07p09192; SPUDIS PD, 1984, J GEOPHYS RES, V89, pC197, DOI 10.1029/JB089iS01p0C197; WAGNER RJ, 1996, LUNAR PLANET SCI, V27, P1367; WHITAKER EA, 1972, MOON, V4, P348, DOI DOI 10.1007/BF00562002; Wilcox BB, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2006JE002686; Wood C.A., 1975, C OR MAR BAS	29	118	121	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1510	1513		10.1126/science.1192148	http://dx.doi.org/10.1126/science.1192148			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847267				2022-12-28	WOS:000281869000037
J	Nishikawa, S; Arimoto, I; Ikezaki, K; Sugawa, M; Ueno, H; Komori, T; Iwane, AH; Yanagida, T				Nishikawa, So; Arimoto, Ikuo; Ikezaki, Keigo; Sugawa, Mitsuhiro; Ueno, Hiroshi; Komori, Tomotaka; Iwane, Atsuko H.; Yanagida, Toshio			Switch between Large Hand-Over-Hand and Small Inchworm-like Steps in Myosin VI	CELL			English	Article							LEVER ARM; ACTIN-FILAMENTS; UNIQUE INSERT; POWER STROKE; MOTOR; MECHANISM; WALKS; DIRECTIONALITY; MICROSCOPY; SIZE	Many biological motor molecules move within cells using stepsizes predictable from their structures. Myosin VI, however, has much larger and more broadly distributed stepsizes than those predicted from its short lever arms. We explain the discrepancy by monitoring Qdots and gold nanoparticles attached to the myosin-VI motor domains using high-sensitivity nanoimaging. The large stepsizes were attributed to an extended and relatively rigid lever arm; their variability to two stepsizes, one large (72 nm) and one small (44 nm). These results suggest that there exist two tilt angles during myosin-VI stepping, which correspond to the pre- and postpowerstroke states and regulate the leading head. The large steps are consistent with the previously reported hand-over-hand mechanism, while the small steps follow an inchworm-like mechanism and increase in frequency with ADP. Switching between these two mechanisms in a strain-sensitive, ADP-dependent manner allows myosin VI to fulfill its multiple cellular tasks including vesicle transport and membrane anchoring.	[Nishikawa, So; Arimoto, Ikuo; Ikezaki, Keigo; Sugawa, Mitsuhiro; Komori, Tomotaka; Iwane, Atsuko H.; Yanagida, Toshio] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Ueno, Hiroshi] Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; [Yanagida, Toshio] Osaka Univ, Immunol Frontier Res Ctr, WPI, Osaka 5670047, Japan; [Yanagida, Toshio] RIKEN, Suita, Osaka 5650871, Japan; [Yanagida, Toshio] Natl Inst Informat & Commun Technol, Koganei, Tokyo 1848795, Japan	Osaka University; Osaka University; Osaka University; RIKEN; National Institute of Information & Communications Technology (NICT) - Japan	Yanagida, T (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yanagida@phys1.med.osaka-u.ac.jp		SUGAWA, MITSUHIRO/0000-0002-3188-1547; Iwane, Atsuko/0000-0003-2641-2268	Ministry of Education, Science, Sports and Culture [20770121]	Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study is supported by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Young Scientists (B), 20770121, 2008-2009 (to S.N.), for Scientific Research on Priority Areas, 60402997, 2007-2008 (to S.N.), by the Yuragi Project of the Japanese Ministry of Education, Culture, Sports, Science and Technology (to T.Y.). We thank member of Yanagida Lab., Noji Lab. and Kinosita Lab. for valuable discussion. We especially thank M. A. Zulliger, R. Iino, K. V. Tabata, S. Sakakihara, S. Furuike; Y. Arai, T. Mimuro-Ichinose and R. Ogawa, for technical help; P. Karagiannis for helpful discussions and comments on the manuscript.	Ali MY, 2004, BIOPHYS J, V86, P3804, DOI 10.1529/biophysj.103.037416; Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Altman D, 2007, PLOS BIOL, V5, P1712, DOI 10.1371/journal.pbio.0050210; Bahloul A, 2004, P NATL ACAD SCI USA, V101, P4787, DOI 10.1073/pnas.0306892101; Balci H, 2005, BIOPHYS J, V89, P413, DOI 10.1529/biophysj.105.060608; Bryant Z, 2007, P NATL ACAD SCI USA, V104, P772, DOI 10.1073/pnas.0610144104; Churchman LS, 2005, P NATL ACAD SCI USA, V102, P1419, DOI 10.1073/pnas.0409487102; CHURCHMAN LS, 2007, COLOCALIZATION FLUOR, P73; DE LA CRUZ EM, 2001, J BIOL CHEM, V276, P32373; Dunn AR, 2007, NAT STRUCT MOL BIOL, V14, P246, DOI 10.1038/nsmb1206; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Iwaki M, 2009, NAT CHEM BIOL, V5, P403, DOI 10.1038/nchembio.171; KINOSITA K, 1991, J CELL BIOL, V115, P67, DOI 10.1083/jcb.115.1.67; Lan GH, 2006, BIOPHYS J, V91, P4002, DOI 10.1529/biophysj.106.089888; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; Menetrey J, 2008, EMBO J, V27, P244, DOI 10.1038/sj.emboj.7601937; Mukherjea M, 2009, MOL CELL, V35, P305, DOI 10.1016/j.molcel.2009.07.010; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Okten Z, 2004, NAT STRUCT MOL BIOL, V11, P884, DOI 10.1038/nsmb815; Park H, 2006, MOL CELL, V21, P331, DOI 10.1016/j.molcel.2005.12.015; Park H, 2007, P NATL ACAD SCI USA, V104, P778, DOI 10.1073/pnas.0610066104; Phichith D, 2009, P NATL ACAD SCI USA, V106, P17320, DOI 10.1073/pnas.0909748106; Reifenberger JG, 2009, P NATL ACAD SCI USA, V106, P18255, DOI 10.1073/pnas.0900005106; Rock RS, 2005, MOL CELL, V17, P603, DOI 10.1016/j.molcel.2005.01.015; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Shiroguchi K, 2007, SCIENCE, V316, P1208, DOI 10.1126/science.1140468; Sivaramakrishnan S, 2009, J CELL BIOL, V187, P53, DOI 10.1083/jcb.200906133; Spink BJ, 2008, NAT STRUCT MOL BIOL, V15, P591, DOI 10.1038/nsmb.1429; Spudich JA, 2010, NAT REV MOL CELL BIO, V11, P128, DOI 10.1038/nrm2833; Sun YJ, 2007, MOL CELL, V28, P954, DOI 10.1016/j.molcel.2007.10.029; Sweeney HL, 2007, CURR OPIN CELL BIOL, V19, P57, DOI 10.1016/j.ceb.2006.12.005; Taniguchi Y, 2005, NAT CHEM BIOL, V1, P342, DOI 10.1038/nchembio741; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Ueno H, 2010, BIOPHYS J, V98, P2014, DOI 10.1016/j.bpj.2010.01.011; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Warshaw DM, 2005, BIOPHYS J, V88, pL30, DOI 10.1529/biophysj.105.061903; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Yildiz A, 2004, J BIOL CHEM, V279, P37223, DOI 10.1074/jbc.C400252200; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	42	51	51	0	36	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					879	888		10.1016/j.cell.2010.08.033	http://dx.doi.org/10.1016/j.cell.2010.08.033			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850010	Bronze			2022-12-28	WOS:000281855000011
J	de Silva, V; Hanwella, R				de Silva, Varuni; Hanwella, Raveen			Personal View Why are we copyrighting science?	BRITISH MEDICAL JOURNAL			English	Editorial Material									[de Silva, Varuni; Hanwella, Raveen] Univ Colombo, Fac Med, Colombo, Sri Lanka	University of Colombo	de Silva, V (corresponding author), Univ Colombo, Fac Med, Colombo, Sri Lanka.	varunidesilva2@yahoo.co.uk		de Silva, Varuni/0000-0002-7299-3430					0	13	13	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4738	10.1136/bmj.c4738	http://dx.doi.org/10.1136/bmj.c4738			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653MO	20847026				2022-12-28	WOS:000282095800016
J	Dobson, A; Borner, M; Sinclair, T				Dobson, Andrew; Borner, Markus; Sinclair, Tony			Road will ruin Serengeti	NATURE			English	Editorial Material							TERRESTRIAL; TANZANIA; MAMMALS		[Dobson, Andrew] Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA; [Borner, Markus] Frankfurt Zool Soc, Africa Programme, Arusha, Tanzania; [Sinclair, Tony] Univ British Columbia, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada	Princeton University; University of British Columbia	Dobson, A (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.	dobson@Princeton.edu	Durant, Sarah M/AAB-9659-2019	Durant, Sarah M/0000-0003-0724-0878; Haydon, Daniel/0000-0002-1240-1886; Hudson, Peter/0000-0003-0468-3403; Ogutu, Joseph O/0000-0002-7379-0387				Boone Randall B., 2004, African Journal of Range & Forage Science, V21, P147, DOI 10.2989/10220110409485847; Chruszcz B, 2003, CAN J ZOOL, V81, P1378, DOI 10.1139/Z03-123; Dobson A, 2008, TRENDS ECOL EVOL, V23, P177, DOI 10.1016/j.tree.2007.08.019; Gereta E., 2009, Ecohydrology and Hydrobiology, V9, P115, DOI 10.2478/v10104-009-0035-7; Harris Grant, 2009, Endangered Species Research, V7, P55, DOI 10.3354/esr00173; Holdo RM, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000210; Homewood K, 2009, STUD HUM ECOL ADAPT, V5, P1, DOI 10.1007/978-0-387-87492-0; Laurance WF, 2009, TRENDS ECOL EVOL, V24, P659, DOI 10.1016/j.tree.2009.06.009; LEAKEY MD, 1979, NATURE, V278, P317, DOI 10.1038/278317a0; Newmark WD, 1996, AFR J ECOL, V34, P15, DOI 10.1111/j.1365-2028.1996.tb00590.x; Sinclair A.R.E., 1979, SERENGETI DYNAMICS E; Sinclair ARE., 2008, SERENGETI; SINCLAIR ARE, 1995, SERENGETI, V2; SPINAGE C A, 1992, Oryx, V26, P147; Trombulak SC, 2000, CONSERV BIOL, V14, P18, DOI 10.1046/j.1523-1739.2000.99084.x	15	72	72	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					272	273		10.1038/467272a	http://dx.doi.org/10.1038/467272a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	650CF	20844519				2022-12-28	WOS:000281824900018
J	Garcia-Cruz, A; Garcia-Doval, I				Garcia-Cruz, Aranzazu; Garcia-Doval, Ignacio			Gottron's Papules and Dermatomyositis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Garcia-Cruz, Aranzazu; Garcia-Doval, Ignacio] Complexo Hosp Pontevedra, Pontevedra, Spain	Complexo Hospitalario Universitario de Pontevedra	Garcia-Cruz, A (corresponding author), Complexo Hosp Pontevedra, Pontevedra, Spain.	arangcruz@gmail.com	Garcia-Doval, Ignacio/A-3703-2009	Garcia-Doval, Ignacio/0000-0002-6881-5260					0	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					E17	E17		10.1056/NEJMicm1002816	http://dx.doi.org/10.1056/NEJMicm1002816			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20857542				2022-12-28	WOS:000281795800012
J	Mackay, D; Haw, S; Ayres, JG; Fischbacher, C; Pell, JP				Mackay, Daniel; Haw, Sally; Ayres, Jon G.; Fischbacher, Colin; Pell, Jill P.			Smoke-free Legislation and Hospitalizations for Childhood Asthma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CROSS-SECTIONAL SURVEY; SECONDHAND SMOKE; 2ND-HAND SMOKE; EXPOSURE; SCOTLAND; IMPLEMENTATION; CHILDREN; HEALTH	Background: Previous studies have shown that after the adoption of comprehensive smoke-free legislation, there is a reduction in respiratory symptoms among workers in bars. However, it is not known whether respiratory disease is also reduced among people who do not have occupational exposure to environmental tobacco smoke. The aim of our study was to determine whether the ban on smoking in public places in Scotland, which was initiated in March 2006, influenced the rate of hospital admissions for childhood asthma. Methods: Routine hospital administrative data were used to identify all hospital admissions for asthma in Scotland from January 2000 through October 2009 among children younger than 15 years of age. A negative binomial regression model was fitted, with adjustment for age group, sex, quintile of socioeconomic status, urban or rural residence, month, and year. Tests for interactions were also performed. Results: Before the legislation was implemented, admissions for asthma were increasing at a mean rate of 5.2% per year (95% confidence interval [CI], 3.9 to 6.6). After implementation of the legislation, there was a mean reduction in the rate of admissions of 18.2% per year relative to the rate on March 26, 2006 (95% CI, 14.7 to 21.8; P<0.001). The reduction was apparent among both preschool and school-age children. There were no significant interactions between hospital admissions for asthma and age group, sex, urban or rural residence, region, or quintile of socioeconomic status. Conclusions: In Scotland, passage of smoke-free legislation in 2006 was associated with a subsequent reduction in the rate of respiratory disease in populations other than those with occupational exposure to environmental tobacco smoke. (Funded by NHS Health Scotland.) N Engl J Med 2010;363:1139-45.	[Mackay, Daniel; Pell, Jill P.] Univ Glasgow, Sect Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; [Haw, Sally] Scottish Collaborat Publ Hlth Res Policy, Edinburgh, Midlothian, Scotland; [Ayres, Jon G.] Univ Birmingham, Inst Occupat & Environm Med, Birmingham, W Midlands, England; [Fischbacher, Colin] NHS Natl Serv, Informat Serv Div, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Birmingham; NHS National Services Scotland	Pell, JP (corresponding author), Univ Glasgow, Sect Publ Hlth, Rm 305,1 Lilybank Gardens, Glasgow G12 8RZ, Lanark, Scotland.	j.pell@clinmed.gla.ac.uk		Pell, Jill/0000-0002-8898-7035; Fischbacher, Colin/0000-0003-3090-1857	NHS Health Scotland	NHS Health Scotland	Supported by a project grant from NHS Health Scotland.	Akhtar PC, 2009, TOB CONTROL, V18, P409, DOI 10.1136/tc.2009.030627; Akhtar PC, 2007, BMJ-BRIT MED J, V335, P545, DOI 10.1136/bmj.39311.550197.AE; Akhtar PC, 2010, J EPIDEMIOL COMMUN H, V64, P341, DOI 10.1136/jech.2008.084178; Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; Ashley MJ, 1998, TOB CONTROL, V7, P61, DOI 10.1136/tc.7.1.61; Ayres JG, 2009, OCCUP ENVIRON MED, V66, P339, DOI 10.1136/oem.2008.040311; Baena-Cagnani CE, 2009, CURR OPIN ALLERGY CL, V9, P136, DOI 10.1097/ACI.0b013e3283294038; Black C, 2009, SCOTTISH SCH ADOLESC; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Haw SJ, 2007, BRIT MED J, V335, P549, DOI 10.1136/bmj.39315.670208.47; HERMAN PM, 2010, AM J PUBLIC HLT 0513; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1902, DOI 10.1016/j.jacc.2009.10.004; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; *OFF ENV HLTH HAZ, 2005, HLTH EFF EXP ENV TOB; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Scottish Government, 2009, SCOTL PEOPL ANN REP; Semple S, 2007, ANN OCCUP HYG, V51, P571, DOI 10.1093/annhyg/mem044; Semple S, 2007, TOB CONTROL, V16, P127, DOI 10.1136/tc.2006.018119; Vork KL, 2007, ENVIRON HEALTH PERSP, V115, P1394, DOI 10.1289/ehp.10155	20	207	215	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1139	1145		10.1056/NEJMoa1002861	http://dx.doi.org/10.1056/NEJMoa1002861			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843248	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000281795800008
J	Sabatine, MS; Jaffer, FA; Staats, PN; Stone, JR				Sabatine, Marc S.; Jaffer, Farouc A.; Staats, Paul N.; Stone, James R.			A Woman, 3 Weeks Post Partum, with Substernal Chest Pain Postpartum coronary-artery dissection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SUDDEN-DEATH; INTRAVASCULAR ULTRASOUND; AORTIC DISSECTION; TERM PROGNOSIS; FOLLOW-UP; PREGNANCY; THERAPY; ANEURYSM; PREECLAMPSIA		[Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Sabatine, Marc S.; Jaffer, Farouc A.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; [Staats, Paul N.; Stone, James R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Sabatine, Marc S.; Jaffer, Farouc A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Staats, Paul N.; Stone, James R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Sabatine, MS (corresponding author), Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.		Sabatine, Marc/AAJ-6751-2020; Jaffer, Farouc/AAK-8803-2020	Sabatine, Marc/0000-0002-0691-3359; Jaffer, Farouc/0000-0001-7980-384X				ADES LC, 1995, BRIT HEART J, V74, P112; Aldoboni A H Sami, 2002, J Invasive Cardiol, V14, P694; Almahmeed W, 1996, CATHETER CARDIO DIAG, V37, P201, DOI 10.1002/(SICI)1097-0304(199602)37:2<201::AID-CCD21>3.0.CO;2-L; Arnold JR, 2008, CARDIOVASC ULTRASOUN, V6, DOI 10.1186/1476-7120-6-24; Basso C, 1996, HEART, V75, P451, DOI 10.1136/hrt.75.5.451; BATEMAN AC, 1995, J CLIN PATHOL, V48, P781, DOI 10.1136/jcp.48.8.781; BLACK MD, 1991, CAN J CARDIOL, V7, P34; BUYS EM, 1994, CATHETER CARDIO DIAG, V33, P157, DOI 10.1002/ccd.1810330216; Cano O, 2009, INT J CARDIOL, V133, pE18, DOI 10.1016/j.ijcard.2007.08.081; Chabrot Pascal, 2006, AJR Am J Roentgenol, V187, pW660, DOI 10.2214/AJR.06.0783; CHEUNG A, 1990, NEW ZEAL MED J, V103, P129; Cheung S, 2000, CATHETER CARDIO INTE, V51, P95, DOI 10.1002/1522-726X(200009)51:1<95::AID-CCD22>3.0.CO;2-M; Choi James W, 2002, J Invasive Cardiol, V14, P675; Chu KH, 1998, CATHETER CARDIO DIAG, V44, P320, DOI 10.1002/(SICI)1097-0304(199807)44:3<320::AID-CCD16>3.3.CO;2-B; CLAUDON DG, 1972, CIRCULATION, V45, P259, DOI 10.1161/01.CIR.45.2.259; DA GAMA MN, 1999, J INVASIVE CARDIOL, V11, P21; DEMAIO SJ, 1989, AM J CARDIOL, V64, P471, DOI 10.1016/0002-9149(89)90423-2; DOWLING GP, 1987, ARCH PATHOL LAB MED, V111, P470; GONZALEZ JI, 1989, AM J CARDIOL, V63, P885, DOI 10.1016/0002-9149(89)90068-4; Greenblatt JM, 1999, ANGIOLOGY, V50, P509, DOI 10.1177/000331979905000610; HEEFNER WA, 1973, JAMA-J AM MED ASSOC, V223, P550, DOI 10.1001/jama.223.5.550; Heit JA, 2005, ANN INTERN MED, V143, P697, DOI 10.7326/0003-4819-143-10-200511150-00006; Hering D, 1998, Z KARDIOL, V87, P961, DOI 10.1007/s003920050253; Hong MK, 1996, AM HEART J, V132, P200, DOI 10.1016/S0002-8703(96)90415-9; HUNSAKER JC, 1992, MAYO CLIN PROC, V67, P761, DOI 10.1016/S0025-6196(12)60801-5; Iyisoy A, 2010, INT J CARDIOL, V139, pE5, DOI 10.1016/j.ijcard.2008.06.077; JAFFE BD, 1994, NEW ENGL J MED, V330, P510, DOI 10.1056/NEJM199402173300719; James AH, 2006, CIRCULATION, V113, P1564, DOI 10.1161/CIRCULATIONAHA.105.576751; Kamineni Raghunandan, 2002, Cardiol Rev, V10, P279, DOI 10.1097/00045415-200209000-00004; Karumanchi SA, 2008, HYPERTENSION, V51, P991, DOI 10.1161/HYPERTENSIONAHA.107.100735; Klutstein MW, 1997, CATHETER CARDIO DIAG, V40, P372, DOI 10.1002/(SICI)1097-0304(199704)40:4<372::AID-CCD11>3.0.CO;2-P; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; Koul AK, 2001, CATHETER CARDIO INTE, V52, P88, DOI 10.1002/1522-726X(200101)52:1<88::AID-CCD1022>3.0.CO;2-P; Kurum T, 2006, J CARDIOVASC MED, V7, P68, DOI 10.2459/01.JCM.0000199791.24855.e0; Lawal Lookman, 2009, J Invasive Cardiol, V21, pE3; LIE JT, 1987, HUM PATHOL, V18, P654, DOI 10.1016/S0046-8177(87)80368-4; Maeder M, 2005, INT J CARDIOL, V101, P363, DOI 10.1016/j.ijcard.2004.03.045; Manghat NE, 2005, CLIN RADIOL, V60, P1120, DOI 10.1016/j.crad.2005.05.009; NALBANDIAN RM, 1965, AM J CLIN PATHOL, V43, P348; OSKOUI R, 1994, AM J CARDIOL, V73, P821, DOI 10.1016/0002-9149(94)90888-5; Pasalodos PJ, 1994, CATHET CARDIOVASC DI, V32, P27; Pinar H, 1996, PEDIATR PATHOL LAB M, V16, P901, DOI 10.1080/15513819609168713; Pretty HC, 1931, BMJ-BRIT MED J, V1, P667, DOI [10.1136/bmj.1.3667.667, DOI 10.1136/BMJ.1.3667.667]; Redline RW, 2004, PEDIATR DEVEL PATHOL, V7, P237, DOI 10.1007/s10024-003-8083-2; Roberts DJ, 2008, J CLIN PATHOL, V61, P1254, DOI 10.1136/jcp.2008.055236; Roth A, 2008, J AM COLL CARDIOL, V52, P171, DOI 10.1016/j.jacc.2008.03.049; Sarmento-Leite R, 2003, HEART, V89, P164, DOI 10.1136/heart.89.2.164; SAUNDERS SL, 1991, CAN J CARDIOL, V7, P138; Schnitker MA, 1944, ANN INTERN MED, V20, P486, DOI 10.7326/0003-4819-20-3-486; SHERRID MV, 1995, CHEST, V108, P284, DOI 10.1378/chest.108.1.284; Skelding Kimberly A, 2007, J Invasive Cardiol, V19, pE174; Slight Robert, 2003, N Z Med J, V116, pU585; Thompson Ellen A, 2005, J Invasive Cardiol, V17, P59; VACEK JL, 1984, NEW ENGL J MED, V310, P1187; Vale PR, 1998, CATHETER CARDIO DIAG, V45, P280, DOI 10.1002/(SICI)1097-0304(199811)45:3<280::AID-CCD14>3.0.CO;2-P; Vanzetto G, 2009, EUR J CARDIO-THORAC, V35, P250, DOI 10.1016/j.ejcts.2008.10.023; Zampieri P, 1996, HEART, V75, P206, DOI 10.1136/hrt.75.2.206; 2004, N ENGL J MED, V350, P1666	58	13	16	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1164	1173		10.1056/NEJMcpc1000966	http://dx.doi.org/10.1056/NEJMcpc1000966			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843252				2022-12-28	WOS:000281795800013
J	Thomson, SN; Brandon, MT; Tomkin, JH; Reiners, PW; Vasquez, C; Wilson, NJ				Thomson, Stuart N.; Brandon, Mark T.; Tomkin, Jonathan H.; Reiners, Peter W.; Vasquez, Cristian; Wilson, Nathaniel J.			Glaciation as a destructive and constructive control on mountain building	NATURE			English	Article							PATAGONIAN ANDES; TECTONIC EVOLUTION; CLIMATE; EROSION; UPLIFT; TRANSECT; BELTS; CHILE	Theoretical analysis predicts that enhanced erosion related to late Cenozoic global cooling can act as a first-order influence on the internal dynamics of mountain building, leading to a reduction in orogen width and height(1-3). The strongest response is predicted in orogens dominated by highly efficient alpine glacial erosion, producing a characteristic pattern of enhanced erosion on the windward flank of the orogen and maximum elevation controlled by glacier equilibriumline altitude(3,4), where long-term glacier mass gain equals mass loss. However, acquiring definitive field evidence of an active tectonic response to global climate cooling has been elusive(5). Here we present an extensive new low-temperature thermochronologic data set from the Patagonian Andes, a high-latitude active orogen with a well-documented late Cenozoic tectonic, climatic and glacial history. Data from 38 degrees S to 49 degrees S record a marked acceleration in erosion 7 to 5 Myr ago coeval with the onset of major Patagonian glaciation(6) and retreat of deformation from the easternmost thrust front(7). The highest rates and magnitudes of erosion are restricted to the glacial equilibrium line altitude on the windward western flank of the orogen, as predicted in models of glaciated critical taper orogens where erosion rate is a function of ice sliding velocity(3,8). In contrast, towards higher latitudes (49 degrees S to 56 degrees S) a transition to older bedrock cooling ages signifies much reduced late Cenozoic erosion despite dominantly glacial conditions here since the latest Miocene(6). The increased height of the orogenic divide at these latitudes (well above the equilibrium line altitude) leads us to conclude that the southernmost Patagonian Andes represent the first recognized example of regional glacial protection of an active orogen from erosion, leading to constructive growth in orogen height and width.	[Thomson, Stuart N.; Reiners, Peter W.] Univ Arizona, Dept Geosci, Tucson, AZ 85271 USA; [Thomson, Stuart N.; Brandon, Mark T.; Wilson, Nathaniel J.] Yale Univ, Dept Geol & Geophys, New Haven, CT 06511 USA; [Vasquez, Cristian] Univ Chile, Dept Geol, Santiago, Chile; [Tomkin, Jonathan H.] Univ Illinois, Dept Geol, Urbana, IL 61801 USA	University of Arizona; Yale University; Universidad de Chile; University of Illinois System; University of Illinois Urbana-Champaign	Thomson, SN (corresponding author), Univ Arizona, Dept Geosci, Tucson, AZ 85271 USA.	thomson@email.arizona.edu	Thomson, Stuart N/A-1222-2009	Thomson, Stuart N/0000-0003-4331-5654; Wilson, Nat/0000-0002-0642-0853	NSF [EAR0447140]; Chilean Fondecyt awards [1010412, 1050431, 7010412, 7060240]	NSF(National Science Foundation (NSF)); Chilean Fondecyt awards(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT)	This work was supported by the NSF Geomorphology and Land Use Dynamics and Tectonics Award EAR0447140. S. Nicolescu assisted with (U-Th)/He analysis. S.N.T. thanks F. Herve for numerous invitations to take part in boat expeditions in the Chilean fjords made possible through Chilean Fondecyt awards 1010412, 1050431, 7010412 and 7060240. Captains C. Alvarez Senior and Junior, V. Alvarez, D. Lleufo and C. Porter expertly guided us through the Chilean fjords on the boats Mama Dina, Penguin, Foam, 21 de Mayo and R/V Gondwana. We thank R. Fuenzalida and C. Mpodozis at ENAP/Sipetrol for allowing us to publish the apatite fission track data from the SP samples. H. Echtler and J. Glodny at the GFZ Potsdam, and F. Herve at the Universidad de Chile provided additional apatite sample separates. This work benefited from discussions with G. Roe and M. Kaplan.	Berger AL, 2008, NAT GEOSCI, V1, P793, DOI 10.1038/ngeo334; Blisniuk PM, 2005, EARTH PLANET SC LETT, V230, P125, DOI 10.1016/j.epsl.2004.11.015; BROECKER WS, 1990, QUATERNARY SCI REV, V9, P305, DOI 10.1016/0277-3791(90)90026-7; Brozovic N, 1997, SCIENCE, V276, P571, DOI 10.1126/science.276.5312.571; Coutand I, 1999, J S AM EARTH SCI, V12, P1, DOI 10.1016/S0895-9811(99)00002-4; DaSilva JL, 1997, MAR GEOL, V143, P103, DOI 10.1016/S0025-3227(97)00092-3; Egholm DL, 2009, NATURE, V460, P884, DOI 10.1038/nature08263; Fabel D, 2002, EARTH PLANET SC LETT, V201, P397, DOI 10.1016/S0012-821X(02)00714-8; FITZGERALD PG, 1995, J GEOPHYS RES-SOL EA, V100, P20175, DOI 10.1029/95JB02150; Flynn JJ, 2002, J S AM EARTH SCI, V15, P285, DOI 10.1016/S0895-9811(02)00043-3; FOSDICK JC, 2007, GSA ABSTR, V39, P341; HARAMBOUR SM, 2002, 15 C GEOL ARG ACT, V3, P232; Herve F, 2007, LITHOS, V97, P373, DOI 10.1016/j.lithos.2007.01.007; Hulton NRJ, 2002, QUATERNARY SCI REV, V21, P233, DOI 10.1016/S0277-3791(01)00103-2; MERCER JH, 1982, PALAEOGEOGR PALAEOCL, V38, P185, DOI 10.1016/0031-0182(82)90003-7; MOLNAR P, 1990, NATURE, V346, P29, DOI 10.1038/346029a0; Montgomery DR, 2001, GEOLOGY, V29, P579, DOI 10.1130/0091-7613(2001)029<0579:CTATMO>2.0.CO;2; PORTER SC, 1981, QUATERNARY RES, V16, P263, DOI 10.1016/0033-5894(81)90013-2; Ramos VA, 2005, TECTONOPHYSICS, V399, P73, DOI 10.1016/j.tecto.2004.12.016; Reiners PW, 2003, NATURE, V426, P645, DOI 10.1038/nature02111; REINERS PW, 2006, ANN REV EARTH PLANET, V34, P19; Stolar D, 2007, J GEOPHYS RES-EARTH, V112, DOI 10.1029/2006JF000713; Sugden D. E., 1978, J GLACIOL, V20, P367, DOI DOI 10.3189/S0022143000013915; Swift DA, 2008, GEOMORPHOLOGY, V97, P109, DOI 10.1016/j.geomorph.2007.02.048; Thomson SN, 2002, GEOL SOC AM BULL, V114, P1159; Tomkin JH, 2007, J GEOPHYS RES-EARTH, V112, DOI 10.1029/2005JF000332; Tomkin JH, 2007, EARTH PLANET SC LETT, V262, P385, DOI 10.1016/j.epsl.2007.07.040; Whipple KX, 2009, NAT GEOSCI, V2, P97, DOI 10.1038/ngeo413; Whipple KX, 2006, EARTH PLANET SC LETT, V243, P218, DOI 10.1016/j.epsl.2005.12.022; Willett SD, 1999, J GEOPHYS RES-SOL EA, V104, P28957, DOI 10.1029/1999JB900248	30	173	178	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					313	317		10.1038/nature09365	http://dx.doi.org/10.1038/nature09365			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844534				2022-12-28	WOS:000281824900036
J	Wandel, S; Juni, P; Tendal, B; Nuesch, E; Villiger, PM; Welton, NJ; Reichenbach, S; Trelle, S				Wandel, Simon; Jueni, Peter; Tendal, Britta; Nueesch, Eveline; Villiger, Peter M.; Welton, Nicky J.; Reichenbach, Stephan; Trelle, Sven			Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; SYSTEMATIC REVIEWS; CONTROLLED-TRIALS; OUTCOME MEASURES; CLINICAL-TRIALS; RELEVANT CHANGE; 6 SULFATE; PROGRESSION; QUALITY; PAIN	Objective To determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee. Design Network meta-analysis. Direct comparisons within trials were combined with indirect evidence from other trials by using a Bayesian model that allowed the synthesis of multiple time points. Main outcome measure Pain intensity. Secondary outcome was change in minimal width of joint space. The minimal clinically important difference between preparations and placebo was prespecified at -0.9 cm on a 10 cm visual analogue scale. Data sources Electronic databases and conference proceedings from inception to June 2009, expert contact, relevant websites. Eligibility criteria for selecting studies Large scale randomised controlled trials in more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head. Results 10 trials in 3803 patients were included. On a 10 cm visual analogue scale the overall difference in pain intensity compared with placebo was -0.4 cm (95% credible interval -0.7 to -0.1 cm) for glucosamine, -0.3 cm (-0.7 to 0.0 cm) for chondroitin, and -0.5 cm (-0.9 to 0.0 cm) for the combination. For none of the estimates did the 95% credible intervals cross the boundary of the minimal clinically important difference. Industry independent trials showed smaller effects than commercially funded trials (P=0.02 for interaction). The differences in changes in minimal width of joint space were all minute, with 95% credible intervals overlapping zero. Conclusions Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.	[Jueni, Peter] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland	University of Bern	Juni, P (corresponding author), Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland.	juni@ispm.unibe.ch	Trelle, Sven/D-3760-2009; Villiger, Peter/AAV-8132-2021; Juni, Peter/Q-8700-2016	Trelle, Sven/0000-0002-8162-8910; Juni, Peter/0000-0002-5985-0670; Reichenbach, Stephan/0000-0001-8098-6567; Welton, Nicky/0000-0003-2198-3205; , Simon/0000-0002-1442-597X	Swiss National Science Foundation [4053-0-104762/3, 3233-066377, PBBEB-115067]; Janggen-Poehn-Foundation; Medical Research Council [G0800800, G0802413] Funding Source: researchfish; MRC [G0800800, G0802413] Funding Source: UKRI	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Janggen-Poehn-Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study was funded by grants from the Swiss National Science Foundation's National Research Program 53 on musculoskeletal health (PJ and SR) (No 4053-0-104762/3). PJ was a senior research fellow in the Program for Social Medicine, Preventive and Epidemiological Research funded by the Swiss National Science Foundation (grant No 3233-066377). SR was a recipient of a research fellowship funded by the Swiss National Science Foundation (grant No PBBEB-115067). SW was a recipient of an individual fellowship of the Janggen-Poehn-Foundation. The study sponsor had no role in study design, data collection, data synthesis, data interpretation, writing the report, or the decision to submit the manuscript for publication. None of the authors is affiliated with or funded by any manufacturer of any of the agents evaluated in this study.	Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; Angst F, 2002, J RHEUMATOL, V29, P131; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Bruyere O, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-165; Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; CONTE A, 1995, ARZNEIMITTEL-FORSCH, V45-2, P918; Cooper NJ, 2006, ARCH INTERN MED, V166, P1269, DOI 10.1001/archinte.166.12.1269; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Eberle E, 1999, OSTEOARTHR CARTILAGE, V7, P502, DOI 10.1053/joca.1999.0246; Egger M, 2003, Health Technol Assess, V7, P1; Egger M, 2001, SYSTEMATIC REV HEALT, P23, DOI DOI 10.1002/9780470693926.CH2; Felson DT, 2007, ANN INTERN MED, V146, P611, DOI 10.7326/0003-4819-146-8-200704170-00014; Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; FORTIN PR, 1995, ARTHRITIS RHEUM, V38, P1027, DOI 10.1002/art.1780380802; FRANSEN M, 2009, LONG TERM EVALUATION; Gentelle-Bonnassies S, 2000, ARTHRIT CARE RES, V13, P280, DOI 10.1002/1529-0131(200010)13:5<280::AID-ANR6>3.0.CO;2-6; HELG AG, 2009, ANN INTERN MED; HELLER L, 2009, US GLUCOSAMINE GROWS; Herrero-Beaumont G, 2007, ARTHRITIS RHEUM-US, V56, P555, DOI 10.1002/art.22371; Juni P, 2006, BEST PRACT RES CL RH, V20, P721, DOI 10.1016/j.berh.2006.05.002; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kahan A, 2009, ARTHRITIS RHEUM-US, V60, P524, DOI 10.1002/art.24255; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Krogsboll LT, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-1; Lee YH, 2010, RHEUMATOL INT, V30, P357, DOI 10.1007/s00296-009-0969-5; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Mazieres B, 2007, ANN RHEUM DIS, V66, P639, DOI 10.1136/ard.2006.059899; McAlindon T, 2004, AM J MED, V117, P643, DOI 10.1016/j.amjmed.2004.06.023; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; Michel BA, 2005, ARTHRITIS RHEUM-US, V52, P779, DOI 10.1002/art.20867; Noack W, 1994, Osteoarthritis Cartilage, V2, P51, DOI 10.1016/S1063-4584(05)80006-8; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; Nuesch E, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3244; Pavelka K, 2002, ARCH INTERN MED, V162, P2113, DOI 10.1001/archinte.162.18.2113; Persiani S, 2007, OSTEOARTHR CARTILAGE, V15, P764, DOI 10.1016/j.joca.2007.01.019; Poolsup N, 2005, ANN PHARMACOTHER, V39, P1080, DOI 10.1345/aph.1E576; Puhan MA, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-94; Reginster JY, 2007, ARTHRITIS RHEUM-US, V56, P2105, DOI 10.1002/art.22852; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Reichenbach S, 2007, ANN INTERN MED, V146, P580, DOI 10.7326/0003-4819-146-8-200704170-00009; Ronca F, 1998, OSTEOARTHR CARTILAGE, V6, P14, DOI 10.1016/S1063-4584(98)80006-X; Rozendaal RM, 2008, ANN INTERN MED, V148, P268, DOI 10.7326/0003-4819-148-4-200802190-00005; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Sawitzke AD, 2008, ARTHRITIS RHEUM, V58, P3183, DOI 10.1002/art.23973; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stettler C, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1331; Towheed TE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002946.pub2; Vlad SC, 2007, ARTHRITIS RHEUM-US, V56, P2267, DOI 10.1002/art.22728; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; 2005, NUTR BUSINESS J, V10, P6	58	332	354	1	68	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2010	341								c4675	10.1136/bmj.c4675	http://dx.doi.org/10.1136/bmj.c4675			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847017	Green Published, hybrid			2022-12-28	WOS:000282095800004
J	Schwartz, A; Weiner, SJ; Harris, IB; Binns-Calvey, A				Schwartz, Alan; Weiner, Saul J.; Harris, Ilene B.; Binns-Calvey, Amy			An Educational Intervention for Contextualizing Patient Care and Medical Students' Abilities to Probe for Contextual Issues in Simulated Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; ERRORS	Context A contextual error occurs when a physician does not identify elements of a patient's environment or behavior, such as access to care, that must be addressed to appropriately plan care. Research has demonstrated that contextual errors can be identified using standardized patients. Objective To evaluate an educational intervention designed to increase physicians' skills in incorporating the patient's context in assessment and management of care and to thereby decrease the rate of contextual errors. Design, Setting, and Participants Quasi-randomized controlled trial, with assessments by blinded observers. Fourth-year medical students (n=124) in internal medicine subinternships at the University of Illinois at Chicago or Jesse Brown Veterans Administration Medical Center between July 2008 and April 2009 and between August 2009 and April 2010 participated and were assessed. Intervention A 4-hour course on contextualization. Main Outcome Measures Probing for contextual issues in an encounter, probing for medical issues in an encounter, and developing an appropriate treatment plan. Outcomes were assessed using 4 previously validated standardized patient encounters performed by each participant and were adjusted for subinternship site, academic year, time of year, and case scenario. Results Students who participated in the contextualization workshops were significantly more likely to probe for contextual issues in the standardized patient encounters than students who did not (90% [95% confidence interval {CI}, 87%-94%] vs 62% [95% CI, 54%-69%], respectively) and significantly more likely to develop appropriate treatment plans for standardized patients with contextual issues (69% [95% CI, 57%-81%] vs 22% [95% CI, 12%-32%]. There was no difference between the groups in the rate of probing for medical issues (80% [95% CI, 75%-85%] vs 81% [95% CI, 76%-86%]) or developing appropriate treatment plans for standardized patients with medical issues (54% [95% CI, 42%-67%] vs 66% [95% CI, 53%-79%]). Conclusion Medical students who underwent an educational intervention were more likely to contextualize care for individual standardized patients. JAMA. 2010;304(11):1191-1197 www.jama.com	[Schwartz, Alan; Harris, Ilene B.; Binns-Calvey, Amy] Univ Illinois, Dept Med Educ, Chicago, IL 60612 USA; [Weiner, Saul J.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Harris, Ilene B.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA; [Weiner, Saul J.] Jesse Brown Vet Adm Med Ctr, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Schwartz, A (corresponding author), Univ Illinois, Dept Med Educ, Mc 591,808 S Wood St,986 CME, Chicago, IL 60612 USA.	alansz@uic.edu	Schwartz, Alan/G-2814-2010	Schwartz, Alan/0000-0003-3809-6637	National Board of Medical Examiners (NBME); Medical Education Research Fund	National Board of Medical Examiners (NBME); Medical Education Research Fund	This project was funded in part by a National Board of Medical Examiners (NBME) Edward J. Stemmler, MD, Medical Education Research Fund grant. There were no other external sponsors.	BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; GRIMSHAW JM, 2001, MED CARE S2, V39, P2, DOI DOI 10.1097/00005650-200108002-00002; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021; Safford MM, 2007, J GEN INTERN MED, V22, P382, DOI 10.1007/s11606-007-0307-0; Studdert DM, 2006, NEW ENGL J MED, V354, P2024, DOI 10.1056/NEJMsa054479; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; US Office of Management and Budget, 1997, FED REGISTER, V62, P58781; Weiner SJ, 2007, MED DECIS MAKING, V27, P726, DOI 10.1177/0272989X07306113; Weiner Saul J, 2004, ACP J Club, V141, pA11; Weiner SJ, 2010, ANN INTERN MED, V153, P69, DOI 10.7326/0003-4819-153-2-201007200-00002; Weiner SJ, 2004, J GEN INTERN MED, V19, P281, DOI 10.1111/j.1525-1497.2004.30261.x; WEINER SJ, 2008, ENCY MED DECISION MA, P198; Yudkowsky R, 2009, MED EDUC, V43, P729, DOI 10.1111/j.1365-2923.2009.03379.x; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	32	32	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1191	1197		10.1001/jama.2010.1297	http://dx.doi.org/10.1001/jama.2010.1297			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841532	Bronze			2022-12-28	WOS:000281770600011
J	MacLeod, N; Benfield, M; Culverhouse, P				MacLeod, Norman; Benfield, Mark; Culverhouse, Phil			Time to automate identification	NATURE			English	Editorial Material							EXPERTS		[MacLeod, Norman] Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; [Benfield, Mark] Louisiana State Univ, Sch Coast & Environm, Dept Oceanog & Coastal Sci, Baton Rouge, LA 70803 USA; [Culverhouse, Phil] Univ Plymouth, Ctr Robot Neural Syst, Plymouth PL4 8AA, Devon, England	Natural History Museum London; Louisiana State University System; Louisiana State University; University of Plymouth	MacLeod, N (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.	n.macleod@nhm.ac.uk; mbenfie@lsu.edu; pculverhouse@plymouth.ac.uk		Culverhouse, Phil/0000-0002-7586-6496				Colquhoun W. P., 1959, ERGONOMICS, V2, P367, DOI 10.1080/00140135908930451; Culverhouse PF, 2003, MAR ECOL PROG SER, V247, P17, DOI 10.3354/meps247017; Culverhouse PF, 2007, SYST ASSOC SPEC VOL, V74, P25; Gauld I.D., 2000, P303; Ginsburg RN, 1997, MAR MICROPALEONTOL, V29, P67, DOI 10.1016/S0377-8398(96)00038-2; Gobalet KW, 2001, J ARCHAEOL SCI, V28, P377, DOI 10.1006/jasc.2000.0564; Kelly MG, 2001, WATER RES, V35, P2784, DOI 10.1016/S0043-1354(00)00554-6; SIMPSON R, 1991, IEEE CONFERENCE ON NEURAL NETWORKS FOR OCEAN ENGINEERING, P223, DOI 10.1109/ICNN.1991.163354; Zachariasse W. J., 1978, UTRECHT MICROPALEONT, V17, P1	9	158	166	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					154	155		10.1038/467154a	http://dx.doi.org/10.1038/467154a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829777				2022-12-28	WOS:000281616300017
J	Tehranchi, R; Woll, PS; Anderson, K; Buza-Vidas, N; Mizukami, T; Mead, AJ; Astrand-Grundstrom, I; Strombeck, B; Horvat, A; Ferry, H; Dhanda, RS; Hast, R; Ryden, T; Vyas, P; Gohring, G; Schlegelberger, B; Johansson, B; Hellstrom-Lindberg, E; List, A; Nilsson, L; Jacobsen, SEW				Tehranchi, Ramin; Woll, Petter S.; Anderson, Kristina; Buza-Vidas, Natalija; Mizukami, Takuo; Mead, Adam J.; Astrand-Grundstrom, Ingbritt; Strombeck, Bodil; Horvat, Andrea; Ferry, Helen; Dhanda, Rakesh Singh; Hast, Robert; Ryden, Tobias; Vyas, Paresh; Gohring, Gudrun; Schlegelberger, Brigitte; Johansson, Bertil; Hellstrom-Lindberg, Eva; List, Alan; Nilsson, Lars; Jacobsen, Sten Eirik W.			Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN HEMATOPOIETIC-CELLS; RECEPTOR-ALPHA CHAIN; SELF-RENEWAL; MARROW-CELLS; LENALIDOMIDE; LEUKEMIA; 5Q; DELETION; MDS; PROLIFERATION	BACKGROUND The in vivo clinical significance of malignant stem cells remains unclear. METHODS Patients who have the 5q deletion (del[5q]) myelodysplastic syndrome (interstitial deletions involving the long arm of chromosome 5) have complete clinical and cytogenetic remissions in response to lenalidomide treatment, but they often have relapse. To determine whether the persistence of rare but distinct malignant stem cells accounts for such relapses, we examined bone marrow specimens obtained from seven patients with the del(5q) myelodysplastic syndrome who became transfusion-independent while receiving lenalidomide treatment and entered cytogenetic remission. RESULTS Virtually all CD34+, CD38+ progenitor cells and stem cells that were positive for CD34 and CD90, with undetectable or low CD38 (CD38-/low), had the 5q deletion before treatment. Although lenalidomide efficiently reduced these progenitors in patients in complete remission, a larger fraction of the minor, quiescent, CD34+, CD38-/low, CD90+ del(5q) stem cells as well as functionally defined del(5q) stem cells remained distinctly resistant to lenalidomide. Over time, lenalidomide resistance developed in most of the patients in partial and complete remission, with recurrence or expansion of the del(5q) clone and clinical and cytogenetic progression. CONCLUSIONS In these patients with the del(5q) myelodysplastic syndrome, we identified rare and phenotypically distinct del(5q) myelodysplastic syndrome stem cells that were also selectively resistant to therapeutic targeting at the time of complete clinical and cytogenetic remission. (Funded by the EuroCancerStemCell Consortium and others.)	[Woll, Petter S.; Buza-Vidas, Natalija; Mizukami, Takuo; Mead, Adam J.; Ferry, Helen; Jacobsen, Sten Eirik W.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Haematopoiet Stem Cell Lab, Oxford OX3 9DS, England; [Vyas, Paresh; Jacobsen, Sten Eirik W.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Haematol Unit, Oxford OX3 9DS, England; [Tehranchi, Ramin; Anderson, Kristina; Astrand-Grundstrom, Ingbritt; Dhanda, Rakesh Singh; Nilsson, Lars; Jacobsen, Sten Eirik W.] Lund Univ, Lund Stem Cell Ctr, Hematopoiet Stem Cell Lab, Lund, Sweden; [Strombeck, Bodil; Horvat, Andrea; Johansson, Bertil] Lund Univ, Skane Univ Hosp, Univ & Reg Labs, Dept Clin Genet, Lund, Sweden; [Ryden, Tobias] Lund Univ, Dept Math Stat, Lund, Sweden; [Hast, Robert] Karolinska Univ Hosp, Hematol Ctr, Stockholm, Sweden; [Hellstrom-Lindberg, Eva] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden; [Gohring, Gudrun; Schlegelberger, Brigitte] Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; [List, Alan] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	University of Oxford; University of Oxford; Lund University; Lund University; Skane University Hospital; Lund University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Hannover Medical School; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Jacobsen, SEW (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Haematopoiet Stem Cell Lab, Oxford OX3 9DS, England.	sten.jacobsen@imm.ox.ac.uk	Jacobsen, Sten Eirik W/D-3974-2018; Mead, Adam/A-8796-2012; Mizukami, Takuo/F-9248-2016; Vyas, Paresh/B-5708-2009	Jacobsen, Sten Eirik W/0000-0002-1362-3659; Mead, Adam/0000-0001-8522-1002; Mizukami, Takuo/0000-0001-6105-6049; Vyas, Paresh/0000-0003-3931-0914; Woll, Petter S./0000-0002-2340-2526; LIST, ALAN/0000-0002-1647-2972	EuroCancerStemCell Consortium; Swedish Cancer Society; Swedish Research Council; Avtal om Lakerutbildning och Forskning; Region Skane; Goran Gustafsson Foundation; Hemato-Linne (Swedish Research Council); Torsten and Ragnar Soderbergs Foundation; Cluster of Excellence in the Area of Regenerative Biology and Reconstructive Therapies; Medical Research Council (MRC) United Kingdom; Swedish Research Council (Vetenskapsradet); MRC; MRC Molecular Haematology Unit; Oxford Partnership Comprehensive Biomedical Research Centre; Leukemia and Lymphoma Society; Leukaemia and Lymphoma Research Senior Bennett Fellowship; Astellas Foundation; Celgene; Medical Research Council [G84/6443, G1000801c, G1000729] Funding Source: researchfish; MRC [G84/6443, G1000729] Funding Source: UKRI	EuroCancerStemCell Consortium; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Avtal om Lakerutbildning och Forskning; Region Skane; Goran Gustafsson Foundation; Hemato-Linne (Swedish Research Council)(Swedish Research Council); Torsten and Ragnar Soderbergs Foundation; Cluster of Excellence in the Area of Regenerative Biology and Reconstructive Therapies; Medical Research Council (MRC) United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swedish Research Council (Vetenskapsradet)(Swedish Research Council); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Molecular Haematology Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Oxford Partnership Comprehensive Biomedical Research Centre; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Leukaemia and Lymphoma Research Senior Bennett Fellowship; Astellas Foundation(Astellas Pharmaceuticals); Celgene(Bristol-Myers SquibbCelgene Corporation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants from the EuroCancerStemCell Consortium (a sixth framework European Union integrated project), the Swedish Cancer Society, the Swedish Research Council, Avtal om Lakerutbildning och Forskning (a government public health grant), Region Skane, the Goran Gustafsson Foundation, Hemato-Linne (Swedish Research Council), the Torsten and Ragnar Soderbergs Foundation, and the Cluster of Excellence in the Area of Regenerative Biology and Reconstructive Therapies; a grant from the Medical Research Council (MRC) United Kingdom (to Dr. Jacobsen); a postdoctoral fellowship from the Swedish Research Council (Vetenskapsradet) (to Dr. Tehranchi); an MRC Disease Team Award and grants from the MRC Molecular Haematology Unit and the Oxford Partnership Comprehensive Biomedical Research Centre (to Dr. Vyas); a Career Development Program fellowship from the Leukemia and Lymphoma Society (to Dr. Woll); a Leukaemia and Lymphoma Research Senior Bennett Fellowship (to Dr. Mead); and an Astellas Foundation for Research on Metabolic Disorders fellowship (to Dr. Mizukami).; Dr. Gohring reports receiving consulting fees from Celgene; and Dr. Nilsson, honoraria and fees for the development of educational presentations from Celgene. No other potential conflict of interest relevant to this article was reported.	Abramovich C, 2005, ANN NY ACAD SCI, V1044, P109, DOI 10.1196/annals.1349.014; Ades L, 2009, BLOOD, V113, P3947, DOI 10.1182/blood-2008-08-175778; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Akala OO, 2006, CURR OPIN GENET DEV, V16, P496, DOI 10.1016/j.gde.2006.08.011; Benveniste P, 2010, CELL STEM CELL, V6, P48, DOI 10.1016/j.stem.2009.11.014; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eclache V, 2008, HAEMATOLOGICA, V93, P315, DOI [10.3324/haematol.11917, 10.3324/haematol.12059]; Gandhi AK, 2006, LEUKEMIA RES, V30, P849, DOI 10.1016/j.leukres.2006.01.010; Glimm H, 1999, BLOOD, V94, P2161, DOI 10.1182/blood.V94.7.2161.419k32_2161_2168; Gohring G, 2010, ANN HEMATOL, V89, P365, DOI 10.1007/s00277-009-0846-z; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; Jadersten M, 2009, HAEMATOL-HEMATOL J, V94, P1762, DOI 10.3324/haematol.2009.011528; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022; Misaghian N, 2009, LEUKEMIA, V23, P25, DOI 10.1038/leu.2008.246; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Nilsson L, 2007, BLOOD, V110, P3005, DOI 10.1182/blood-2007-03-079368; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Parseval LAM, 2008, J CLIN INVEST, V118, P248, DOI 10.1172/JCI32322; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Sato T, 2009, NAT MED, V15, P696, DOI 10.1038/nm.1973; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; Verhelle D, 2007, CANCER RES, V67, P746, DOI 10.1158/0008-5472.CAN-06-2317; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106	40	187	200	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1025	1037		10.1056/NEJMoa0912228	http://dx.doi.org/10.1056/NEJMoa0912228			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825315				2022-12-28	WOS:000281609700006
J	Cassidy, J				Cassidy, Jane			Health White Paper Commissioners doing it for themselves	BRITISH MEDICAL JOURNAL			English	Editorial Material												janecassi2@googlemail.com						Department of Health, 2010, LIB NHS COMM PAT CON	1	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 7	2010	341								c4488	10.1136/bmj.c4488	http://dx.doi.org/10.1136/bmj.c4488			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZI	20823013				2022-12-28	WOS:000281814900006
J	Vergote, I; Trope, CG; Amant, F; Kristensen, GB; Ehlen, T; Johnson, N; Verheijen, RHM; van der Burg, MEL; Lacave, AJ; Panici, PB; Kenter, GG; Casado, A; Mendiola, C; Coens, C; Verleye, L; Stuart, GCE; Pecorelli, S; Reed, NS				Vergote, Ignace; Trope, Claes G.; Amant, Frederic; Kristensen, Gunnar B.; Ehlen, Tom; Johnson, Nick; Verheijen, Rene H. M.; van der Burg, Maria E. L.; Lacave, Angel J.; Panici, Pierluigi Benedetti; Kenter, Gemma G.; Casado, Antonio; Mendiola, Cesar; Coens, Corneel; Verleye, Leen; Stuart, Gavin C. E.; Pecorelli, Sergio; Reed, Nick S.		European Org Res Treatment Can; NCIC Clinical Trials Grp	Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPITHELIAL OVARIAN; CYTOREDUCTIVE SURGERY; DEBULKING SURGERY; SURGICAL CYTOREDUCTION; OPEN LAPAROSCOPY; CARCINOMA; SURVIVAL; MANAGEMENT; METAANALYSIS; EVALUATE	BACKGROUND Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer. METHODS We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, fallopian-tube carcinoma, or primary peritoneal carcinoma to primary debulking surgery followed by platinum-based chemotherapy or to neoadjuvant platinum-based chemotherapy followed by debulking surgery (so-called interval debulking surgery). RESULTS Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible and started the treatment. The majority of these patients had extensive stage IIIC or IV disease at primary debulking surgery (metastatic lesions that were larger than 5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%). The largest residual tumor was 1 cm or less in diameter in 41.6% of patients after primary debulking and in 80.6% of patients after interval debulking. Postoperative rates of adverse effects and mortality tended to be higher after primary debulking than after interval debulking. The hazard ratio for death (intention-to-treat analysis) in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking surgery followed by chemotherapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P = 0.01 for non-inferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15). Complete resection of all macroscopic disease (at primary or interval surgery) was the strongest independent variable in predicting overall survival. CONCLUSIONS Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study. Complete resection of all macroscopic disease, whether performed as primary treatment or after neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery is performed.	[Vergote, Ignace] Katholieke Univ Leuven, Univ Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, B-3000 Louvain, Belgium; [Trope, Claes G.; Verleye, Leen] European Org Res & Treatment Canc Headquarters, Brussels, Belgium; [Trope, Claes G.; Kristensen, Gunnar B.] Norwegian Radium Hosp, Oslo, Norway; [Trope, Claes G.; Kristensen, Gunnar B.] Inst Med Informat, Oslo, Norway; [Ehlen, Tom; Stuart, Gavin C. E.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Johnson, Nick] Royal United Hosp, Bath BA1 3NG, Avon, England; [Reed, Nick S.] Gartnavel Royal Hosp, Glasgow, Lanark, Scotland; [Reed, Nick S.] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; [Verheijen, Rene H. M.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [van der Burg, Maria E. L.] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands; [Kenter, Gemma G.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Lacave, Angel J.] Hosp Univ Cent Asturias, Oviedo, Spain; [Panici, Pierluigi Benedetti] Univ Roma La Sapienza, Rome, Italy; [Pecorelli, Sergio] Univ Brescia, Brescia, Italy; [Mendiola, Cesar] Hosp Univ San Carlos, Madrid, Spain; [Mendiola, Cesar] Hosp Univ 12 Octubre, Madrid, Spain	KU Leuven; European Organisation for Research & Treatment of Cancer; University of Oslo; University of British Columbia; Gartnavel Royal Hospital; Beatson Oncology Centre; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Central University Hospital Asturias; Sapienza University Rome; University of Brescia; Hospital Universitario 12 de Octubre	Vergote, I (corresponding author), Katholieke Univ Leuven, Univ Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Herestr 49, B-3000 Louvain, Belgium.	ignace.vergote@uzleuven.be	Massuger, Leon F.A.G./H-8072-2014; Martín, Pluvio Coronado/AAB-3830-2019; Ottevanger, Petronella Beatrix/N-3577-2014; Amant, Frédéric/W-7436-2019; Kenter, Gemma/B-3132-2012	Martín, Pluvio Coronado/0000-0003-0357-2015; Ottevanger, Petronella Beatrix/0000-0001-8209-487X; Amant, Frédéric/0000-0002-5452-4905; Kannisto, Paivi/0000-0002-5517-1494; Kenter, Gemma/0000-0002-7284-3918; Casado Herraez, Antonio/0000-0002-8200-3306	National Cancer Institute [2U10 CA11488-28, 2U10 CA011488-36]; Vlaamse Liga Tegen Kanker (the Flemish League against Cancer); NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vlaamse Liga Tegen Kanker (the Flemish League against Cancer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants (2U10 CA11488-28 through 2U10 CA011488-36) from the National Cancer Institute and by a donation from Vlaamse Liga Tegen Kanker (the Flemish League against Cancer) to the EORTC Charitable Trust.	Aletti GD, 2006, GYNECOL ONCOL, V100, P283, DOI 10.1016/j.ygyno.2005.08.027; Angioli R, 2006, GYNECOL ONCOL, V100, P455, DOI 10.1016/j.ygyno.2005.09.060; AURE JC, 1971, OBSTET GYNECOL, V37, P1; Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248; Bristow RE, 2006, GYNECOL ONCOL, V103, P1070, DOI 10.1016/j.ygyno.2006.06.025; Brun JL, 2008, GYNECOL ONCOL, V110, P354, DOI 10.1016/j.ygyno.2008.04.042; Chi DS, 2006, GYNECOL ONCOL, V103, P559, DOI 10.1016/j.ygyno.2006.03.051; COLLETT D, 1994, MODELLING SURVIVAL D, P78; Crawford SC, 2005, J CLIN ONCOL, V23, P8802, DOI 10.1200/JCO.2005.02.1287; Crawford SC, 2005, J CLIN ONCOL, V23, P8802; du Bois A, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi961; du Bois A, 2009, CANCER-AM CANCER SOC, V115, P1234, DOI 10.1002/cncr.24149; Eisenkop SM, 1998, GYNECOL ONCOL, V69, P103, DOI 10.1006/gyno.1998.4955; Fagotti A, 2005, GYNECOL ONCOL, V96, P729, DOI 10.1016/j.ygyno.2004.11.031; GRIFFITHS CT, 1978, SURG CLIN N AM, V58, P131, DOI 10.1016/s0039-6109(16)41440-4; Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7; Kang S, 2009, ANN SURG ONCOL, V16, P2315, DOI 10.1245/s10434-009-0558-6; Marth C, 2009, INT J GYNECOL CANCER, V19, P94, DOI 10.1111/IGC.0b013e31819915cb; MEIGS JV, 1934, TUMORS PELVIC ORGANS; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; O'Malley CD, 2003, GYNECOL ONCOL, V91, P608, DOI 10.1016/j.ygyno.2003.08.010; Organization W.H, 1979, WHO HDB REP RES CANC; Risum S, 2008, GYNECOL ONCOL, V108, P265, DOI 10.1016/j.ygyno.2007.11.002; Rose PG, 2004, NEW ENGL J MED, V351, P2489, DOI 10.1056/NEJMoa041125; Schrag D, 2006, JNCI-J NATL CANCER I, V98, P163, DOI 10.1093/jnci/djj018; VANDERBURG MEL, 1995, NEW ENGL J MED, V332, P629, DOI 10.1056/NEJM199503093321002; Vergote I, 2008, INT J GYNECOL CANCER, V18, P11, DOI 10.1111/j.1525-1438.2007.01098.x; Vergote I, 2005, INT J GYNECOL CANCER, V15, P776, DOI 10.1111/j.1525-1438.2005.00135.x; Vergote I, 1998, GYNECOL ONCOL, V71, P431, DOI 10.1006/gyno.1998.5213; Vergote I, 2000, J NATL CANCER I, V92, P1534, DOI 10.1093/jnci/92.18.1534; Vernooij F, 2008, JNCI-J NATL CANCER I, V100, P399, DOI 10.1093/jnci/djn033; YEDEMA CA, 1992, TUMOR BIOL, V13, P18, DOI 10.1159/000217748; Zivanovic O, 2008, GYNECOL ONCOL, V108, P287, DOI 10.1016/j.ygyno.2007.10.001	33	1576	1656	6	70	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					943	953		10.1056/NEJMoa0908806	http://dx.doi.org/10.1056/NEJMoa0908806			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818904	Green Published, Green Accepted			2022-12-28	WOS:000281441500007
J	Hall, W; Chikritzhs, T				Hall, Wayne; Chikritzhs, Tanya			The Australian alcopops tax revisited	LANCET			English	Editorial Material							ALCOHOL PROGRAM; HEALTH; DRINKING; TAXATION; MODEL		[Hall, Wayne] Univ Queensland, UQ Ctr Clin Res, Herston, Qld 4029, Australia; [Chikritzhs, Tanya] Curtin Univ Technol, Natl Drug Res Inst, Perth, WA, Australia	University of Queensland; Curtin University	Hall, W (corresponding author), Univ Queensland, UQ Ctr Clin Res, Herston, Qld 4029, Australia.	w.hall@sph.uq.edu.au	Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096; Chikritzhs, Tanya/0000-0001-8871-3205				Australian Bureau of Statistics, 2010, APP CONS ALC AUSTR 2; Australian Bureau of Statistics, 2010, AUSTR WIN GRAP IND 2; Babor T.F., 2010, ALCHOL NO ORDINARY C, V2nd, DOI DOI 10.1093/ACPROF:OSO/9780199551149.003.002; Chikritzhs T, 2005, ADDICTION, V100, P1625, DOI 10.1111/j.1360-0443.2005.01234.x; Chikritzhs TN, 2009, MED J AUSTRALIA, V190, P294, DOI 10.5694/j.1326-5377.2009.tb02415.x; Doran CM, 2008, LANCET, V372, P701, DOI 10.1016/S0140-6736(08)61287-8; Gray D, 1999, AUST NZ J PUBL HEAL, V23, P651, DOI 10.1111/j.1467-842X.1999.tb01554.x; Gruenewald PJ, 2010, J STUD ALCOHOL DRUGS, V71, P237, DOI 10.15288/jsad.2010.71.237; Hawks D V, 1990, Drug Alcohol Rev, V9, P91, DOI 10.1080/09595239000185121; Laslett A.-M., 2010, RANGE MAGNITUDE ALCO; Purshouse RC, 2010, LANCET, V375, P1355, DOI 10.1016/S0140-6736(10)60058-X; Stockwell T, 2001, Int J Drug Policy, V12, P139, DOI 10.1016/S0955-3959(01)00079-2; Stockwell T, 2001, DRUG ALCOHOL REV, V20, P167, DOI 10.1080/09595230124886; Vandenberg B, 2008, DRUG ALCOHOL REV, V27, P579, DOI 10.1080/09595230802491600; Victorian Alcohol and Drug Association, 2010, ALC TAX; Wagenaar AC, 2009, AM J PUBLIC HEALTH, V99, P1464, DOI 10.2105/AJPH.2007.131326	16	15	15	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2011	377	9772					1136	1137		10.1016/S0140-6736(10)61420-1	http://dx.doi.org/10.1016/S0140-6736(10)61420-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	750IH	20833425				2022-12-28	WOS:000289539300010
J	Hillmen, P				Hillmen, Peter			Chronic lymphocytic leukaemia-moving towards cure?	LANCET			English	Editorial Material							FLUDARABINE PLUS CYCLOPHOSPHAMIDE; ALEMTUZUMAB; THERAPY; TRIAL		St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hillmen, P (corresponding author), St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds LS9 7TF, W Yorkshire, England.	peter.hillmen@nhs.net						Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Michos IC, 2010, DISCRETE MATH THEOR, V12, P1; Pettitt AR, 2006, LEUKEMIA, V20, P1441, DOI 10.1038/sj.leu.2404265; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245	9	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1122	1124		10.1016/S0140-6736(10)61512-7	http://dx.doi.org/10.1016/S0140-6736(10)61512-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888976				2022-12-28	WOS:000282915700006
J	Kleinert, S				Kleinert, Sabine			Singapore Statement: a global agreement on responsible research conduct	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Kleinert, S (corresponding author), The Lancet, London NW1 7BY, England.							Kleinert S, 2010, LANCET, V376, P400, DOI 10.1016/S0140-6736(10)61201-9; Singapore Statement on Research Integrity, 2010, 2 WORLD C RES INT SI	2	7	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1125	1127		10.1016/S0140-6736(10)61456-0	http://dx.doi.org/10.1016/S0140-6736(10)61456-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663UN	20864155				2022-12-28	WOS:000282915700008
J	Richards, T				Richards, Tessa			Border Crossing Who will care for us when we are old?	BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2010	341								c5341	10.1136/bmj.c5341	http://dx.doi.org/10.1136/bmj.c5341			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659ND	20880910				2022-12-28	WOS:000282572400034
J	Long, F; Su, CC; Zimmermann, MT; Boyken, SE; Rajashankar, KR; Jernigan, RL; Yu, EW				Long, Feng; Su, Chih-Chia; Zimmermann, Michael T.; Boyken, Scott E.; Rajashankar, Kanagalaghatta R.; Jernigan, Robert L.; Yu, Edward W.			Crystal structures of the CusA efflux pump suggest methionine-mediated metal transport	NATURE			English	Article							MEMBRANE-FUSION PROTEIN; MULTIDRUG EFFLUX; RECOGNITION; SYSTEM; CU(I); CRYSTALLOGRAPHY; RESISTANCE; SOFTWARE; DYNAMICS; COMPLEX	Gram-negative bacteria, such as Escherichia coli, frequently use tripartite efflux complexes in the resistance-nodulation-cell division (RND) family to expel various toxic compounds from the cell(1,2). The efflux system CusCBA is responsible for extruding biocidal Cu(I) and Ag(I) ions(3,4). No previous structural information was available for the heavy-metal efflux (HME) subfamily of the RND efflux pumps. Here we describe the crystal structures of the inner-membrane transporter CusA in the absence and presence of bound Cu(I) or Ag(I). These CusA structures provide new structural information about the HME subfamily of RND efflux pumps. The structures suggest that the metal-binding sites, formed by a three-methionine cluster, are located within the cleft region of the periplasmic domain. This cleft is closed in the apo-CusA form but open in the CusA-Cu(I) and CusA-Ag(I) structures, which directly suggests a plausible pathway for ion export. Binding of Cu(I) and Ag(I) triggers significant conformational changes in both the periplasmic and transmembrane domains. The crystal structure indicates that CusA has, in addition to the three-methionine metal-binding site, four methionine pairs-three located in the transmembrane region and one in the periplasmic domain. Genetic analysis and transport assays suggest that CusA is capable of actively picking up metal ions from the cytosol, using these methionine pairs or clusters to bind and export metal ions. These structures suggest a stepwise shuttle mechanism for transport between these sites.	[Long, Feng; Yu, Edward W.] Iowa State Univ, Mol Cellular & Dev Biol Interdept Grad Program, Ames, IA 50011 USA; [Su, Chih-Chia; Yu, Edward W.] Iowa State Univ, Dept Chem, Ames, IA 50011 USA; [Zimmermann, Michael T.; Boyken, Scott E.; Jernigan, Robert L.; Yu, Edward W.] Iowa State Univ, Bioinformat & Computat Biol Interdept Grad Progra, Ames, IA 50011 USA; [Rajashankar, Kanagalaghatta R.] Cornell Univ, Dept Chem & Chem Biol, Argonne Natl Lab, Argonne, IL 60439 USA; [Rajashankar, Kanagalaghatta R.] Cornell Univ, NE CAT, Argonne Natl Lab, Argonne, IL 60439 USA; [Jernigan, Robert L.; Yu, Edward W.] Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; [Yu, Edward W.] Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University; Cornell University; United States Department of Energy (DOE); Argonne National Laboratory; Cornell University; United States Department of Energy (DOE); Argonne National Laboratory; Iowa State University; Iowa State University	Yu, EW (corresponding author), Iowa State Univ, Mol Cellular & Dev Biol Interdept Grad Program, Ames, IA 50011 USA.	ewyu@iastate.edu	Jernigan, Robert L/A-5421-2012; Long, Feng/F-5475-2011	Jernigan, Robert L/0000-0003-0996-8360; Long, Feng/0000-0001-6313-8558; Zimmermann, Michael/0000-0001-7073-0525; Boyken, Scott/0000-0002-5378-0632	National Institutes of Health (NIH), National Center for Research Resources [RR-15301]; US Department of Energy, Office of Basic Energy Sciences [DE-AC02-06CH11357]; NIH [GM074027, GM086431, GM081680, GM072014]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086431, R01GM072014, R01GM074027, R01GM081680] Funding Source: NIH RePORTER	National Institutes of Health (NIH), National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); US Department of Energy, Office of Basic Energy Sciences(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. D. Routh for critical reading of the manuscript. This work is based on research conducted at the Northeastern Collaborative Access Team beamlines of the Advanced Photon Source, supported by National Institutes of Health (NIH) award RR-15301 from the National Center for Research Resources. Use of the Advanced Photon Source is supported by the US Department of Energy, Office of Basic Energy Sciences, under contract no. DE-AC02-06CH11357. This work was supported by NIH grants GM074027 (to E.W.Y.), GM086431 (to E.W.Y.), GM081680 (to R.L.J.) and GM072014 (to R.L.J.).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Aires JR, 2005, J BACTERIOL, V187, P1923, DOI 10.1128/JB.187.6.1923-1929.2005; Akama H, 2004, J BIOL CHEM, V279, P52816, DOI 10.1074/jbc.C400445200; Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banci L, 2006, NAT CHEM BIOL, V2, P367, DOI 10.1038/nchembio797; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Feller SE, 2000, J PHYS CHEM B, V104, P7510, DOI 10.1021/jp0007843; Franke S, 2003, J BACTERIOL, V185, P3804, DOI 10.1128/JB.185.13.3804-3812.2003; Franke S, 2001, MICROBIOL-SGM, V147, P965, DOI 10.1099/00221287-147-4-965; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Goldberg M, 1999, J BIOL CHEM, V274, P26065, DOI 10.1074/jbc.274.37.26065; Higgins MK, 2004, P NATL ACAD SCI USA, V101, P9994, DOI 10.1073/pnas.0400375101; Jiang JF, 2005, INORG CHEM, V44, P9787, DOI 10.1021/ic051180m; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Loftin IR, 2007, PROTEIN SCI, V16, P2287, DOI 10.1110/ps.073021307; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mikolosko J, 2006, STRUCTURE, V14, P577, DOI 10.1016/j.str.2005.11.015; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murakami S, 2006, NATURE, V443, P173, DOI 10.1038/nature05076; Nies DH, 2003, FEMS MICROBIOL REV, V27, P313, DOI 10.1016/S0168-6445(03)00048-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1991, CCP4 P, V80; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Seeger MA, 2006, SCIENCE, V313, P1295, DOI 10.1126/science.1131542; Sennhauser G, 2007, PLOS BIOL, V5, P106, DOI 10.1371/journal.pbio.0050007; Sennhauser G, 2009, J MOL BIOL, V389, P134, DOI 10.1016/j.jmb.2009.04.001; Su CC, 2006, J BACTERIOL, V188, P7290, DOI 10.1128/JB.00684-06; Su CC, 2009, J MOL BIOL, V393, P342, DOI 10.1016/j.jmb.2009.08.029; Symmons MF, 2009, P NATL ACAD SCI USA, V106, P7173, DOI 10.1073/pnas.0900693106; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Xue Y, 2008, NAT CHEM BIOL, V4, P107, DOI 10.1038/nchembio.2007.57; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	44	174	177	1	70	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					484	U140		10.1038/nature09395	http://dx.doi.org/10.1038/nature09395			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20865003	Green Accepted			2022-12-28	WOS:000282090200048
J	Delamothe, T; Knapton, M; Richardson, E				Delamothe, Tony; Knapton, Mike; Richardson, Eve			We're all going to die. Deal with it	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Delamothe, Tony] BMJ, London WC1H 9JR, England; [Knapton, Mike] British Heart Fdn, London NW1 7AW, England; [Richardson, Eve] Natl Council Palliat Care, London N7 9AS, England	University of London; University College London	Delamothe, T (corresponding author), BMJ, London WC1H 9JR, England.	tdelamothe@bmj.com			British Heart Foundation	British Heart Foundation(British Heart Foundation)	We are pleased to acknowledge the financial support of the British Heart Foundation in producing this Spotlight. The articles were commissioned and peer reviewed according to the BMJ's usual process. We benefited from discussions with Jane Maher, Scott Murray, Ruth Sack, and Teresa Tate.	Barclay S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4862; Bell D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3231; Boyd K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4863; Ellershaw J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4861; General Medical Council, 2010, TREATM CAR END LIF G; Grant L, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4859; Seymour JE, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4860	7	6	6	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c5028	10.1136/bmj.c5028	http://dx.doi.org/10.1136/bmj.c5028			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847024				2022-12-28	WOS:000282095800015
J	Moreno-Risueno, MA; Van Norman, JM; Moreno, A; Zhang, JY; Ahnert, SE; Benfey, PN				Moreno-Risueno, Miguel A.; Van Norman, Jaimie M.; Moreno, Antonio; Zhang, Jingyuan; Ahnert, Sebastian E.; Benfey, Philip N.			Oscillating Gene Expression Determines Competence for Periodic Arabidopsis Root Branching	SCIENCE			English	Article							PATTERN DETECTION; AUXIN TRANSPORT; INITIATION; MODEL	Plants and animals produce modular developmental units in a periodic fashion. In plants, lateral roots form as repeating units along the root primary axis; however, the developmental mechanism regulating this process is unknown. We found that cyclic expression pulses of a reporter gene mark the position of future lateral roots by establishing prebranch sites and that prebranch site production and root bending are periodic. Microarray and promoter-luciferase studies revealed two sets of genes oscillating in opposite phases at the root tip. Genetic studies show that some oscillating transcriptional regulators are required for periodicity in one or both developmental processes. This molecular mechanism has characteristics that resemble molecular clock-driven activities in animal species.	[Moreno-Risueno, Miguel A.; Van Norman, Jaimie M.; Zhang, Jingyuan; Benfey, Philip N.] Duke Univ, Dept Biol, Durham, NC 27708 USA; [Moreno-Risueno, Miguel A.; Van Norman, Jaimie M.; Zhang, Jingyuan; Benfey, Philip N.] Duke Univ, Inst Genome Sci, Durham, NC 27708 USA; [Moreno-Risueno, Miguel A.; Van Norman, Jaimie M.; Zhang, Jingyuan; Benfey, Philip N.] Duke Univ, Policy Ctr Syst Biol, Durham, NC 27708 USA; [Moreno, Antonio] CSIC, Inst Acust, Dept Acust Ambiental, E-28006 Madrid, Spain; [Ahnert, Sebastian E.] Univ Cambridge, Cavendish Lab, Condensed Matter Theory Grp, Cambridge CB3 0HE, England	Duke University; Duke University; Duke University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Acustica (IA); University of Cambridge	Benfey, PN (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	philip.benfey@duke.edu	MORENO-RISUENO, MIGUEL ANGEL/J-8832-2016	MORENO-RISUENO, MIGUEL ANGEL/0000-0002-9794-1450	Defense Advanced Research Projects Agency (DARPA) [HR0011-05-1-0057, HR0011-09-1-0055]; NIH [R01-GM043778]; Ministry of Science and Innovation (MICINN), government of Spain; Leverhulme Trust, UK; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043778] Funding Source: NIH RePORTER	Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Innovation (MICINN), government of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Leverhulme Trust, UK(Leverhulme Trust); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank H. Tsukagoshi for cloning the promoter regions of ARF7, SHP1, and ATAF1. This work was supported by grants to P.N.B. from Defense Advanced Research Projects Agency (DARPA, grants HR0011-05-1-0057 and HR0011-09-1-0055) and the NIH (R01-GM043778); a fellowship from the Ministry of Science and Innovation (MICINN), government of Spain, to M.A.M.-R.; a National Research Service Award fellowship from the NIH to J.M.V.N.; and support from the Leverhulme Trust, UK, to S.E.A. We thank W. Busch, J. Petricka, I. Rubio-Somoza, and R. Sozzani for critical reading of the manuscript. The authors would like to thank O. Pourquie for many useful discussions. The authors have declared that no competing interests exist. The National Center for Biotechnology Information Gene Expression Omnibus accession numbers for new microarrays data discussed in this manuscript are GSE21611.	Ahnert SE, 2006, BIOINFORMATICS, V22, P1471, DOI 10.1093/bioinformatics/btl121; Brady SM, 2007, SCIENCE, V318, P801, DOI 10.1126/science.1146265; De Smet I, 2008, SCIENCE, V322, P594, DOI 10.1126/science.1160158; De Smet I, 2007, DEVELOPMENT, V134, P681, DOI 10.1242/dev.02753; De Smet I, 2010, P NATL ACAD SCI USA, V107, P2705, DOI 10.1073/pnas.0915001107; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Dequeant ML, 2006, SCIENCE, V314, P1595, DOI 10.1126/science.1133141; Dequeant ML, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002856; Dinneny JR, 2005, BIOESSAYS, V27, P42, DOI 10.1002/bies.20165; Ditengou FA, 2008, P NATL ACAD SCI USA, V105, P18818, DOI 10.1073/pnas.0807814105; Dubrovsky JG, 2006, ANN BOT-LONDON, V97, P903, DOI 10.1093/aob/mcj604; Dubrovsky JG, 2008, P NATL ACAD SCI USA, V105, P8790, DOI 10.1073/pnas.0712307105; Dunlap JC, 2007, COLD SPRING HARB SYM, V72, P57, DOI 10.1101/sqb.2007.72.072; Fukaki H, 2002, PLANT J, V29, P153, DOI 10.1046/j.0960-7412.2001.01201.x; Fukaki H, 2007, INT REV CYTOL, V256, P111, DOI 10.1016/S0074-7696(07)56004-3; Heisler MG, 2005, CURR BIOL, V15, P1899, DOI 10.1016/j.cub.2005.09.052; Himanen K, 2004, P NATL ACAD SCI USA, V101, P5146, DOI 10.1073/pnas.0308702101; Jonsson H, 2006, P NATL ACAD SCI USA, V103, P1633, DOI 10.1073/pnas.0509839103; Kubo M, 2005, GENE DEV, V19, P1855, DOI 10.1101/gad.1331305; Laskowski M, 2008, PLOS BIOL, V6, P2721, DOI 10.1371/journal.pbio.0060307; Lu PL, 2007, PLANT MOL BIOL, V63, P289, DOI 10.1007/s11103-006-9089-8; Lucas M, 2008, J EXP BOT, V59, P55, DOI 10.1093/jxb/erm171; Lucas M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003673; Malamy JE, 1997, DEVELOPMENT, V124, P33; Malamy JE, 2001, PLANT PHYSIOL, V127, P899, DOI 10.1104/pp.010406; McGregor Alistair P., 2009, Communicative & Integrative Biology, V2, P174; McSteen P, 2005, ANNU REV PLANT BIOL, V56, P353, DOI 10.1146/annurev.arplant.56.032604.144122; Okushima Y, 2007, PLANT CELL, V19, P118, DOI 10.1105/tpc.106.047761; Peret B, 2009, TRENDS PLANT SCI, V14, P399, DOI 10.1016/j.tplants.2009.05.002; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Schroter C, 2008, DEV DYNAM, V237, P545, DOI 10.1002/dvdy.21458; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Vanneste S, 2005, PLANT CELL, V17, P3035, DOI 10.1105/tpc.105.035493; Yant L, 2009, CURR OPIN PLANT BIOL, V12, P580, DOI 10.1016/j.pbi.2009.07.006	34	402	409	2	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1306	1311		10.1126/science.1191937	http://dx.doi.org/10.1126/science.1191937			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829477	Green Accepted			2022-12-28	WOS:000281657300028
J	Ortega, F; Escaso, F; Sanz, JL				Ortega, Francisco; Escaso, Fernando; Sanz, Jose L.			A bizarre, humped Carcharodontosauria (Theropoda) from the Lower Cretaceous of Spain	NATURE			English	Article							DINOSAUR; FEATHER; PHYLOGENY; EVOLUTION	Carcharodontosaurs were the largest predatory dinosaurs, and their early evolutionary history seems to be more intricate than was previously thought. Until recently, carcharodontosaurs were restricted to a group of large theropods inhabiting the Late Cretaceous Gondwanan land masses(1,2), but in the last few years Laurasian evidence(3-5) has been causing a reevaluation of their initial diversification(6). Here we describe an almost complete and exquisitely preserved skeleton of a medium-sized (roughly six metres long) theropod from the Lower Cretaceous series (Barremian stage) Konservat-Lagerstatte of Las Hoyas(7) in Cuenca, Spain. Cladistic analysis supports the idea that the new taxon Concavenator corcovatus is a primitive member of Carcharodontosauria(6), exhibiting two unusual features: elongation of the neurapophyses of two presacral vertebrae forming a pointed, hump-like structure and a series of small bumps on the ulna. We think that these bumps are homologous to quill knobs present on some modern birds; the knobs are related to the insertion area of follicular ligaments that anchor the roots of the flight feathers (remiges) to the arm. We propose that Concavenator has integumentary follicular structures inserted on the ulna, as in modern birds. Because scales do not have follicles, we consider the structures anchored to the Concavenator arms to be non-scale skin appendages homologous to the feathers of modern birds. If this is true, then the phylogenetic bracket for the presence of non-scale skin structures homologous to feathers in theropod dinosaurs would be extended to the Neotetanurae, enlarging the scope for explaining the origin of feathers in theropods.	[Ortega, Francisco; Escaso, Fernando] Univ Nacl Educ Distancia, Fac Ciencias, Dept Fis Matemat & Fluidos, Grp Biol, E-28040 Madrid, Spain; [Escaso, Fernando; Sanz, Jose L.] Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Unidad Paleontol, E-28049 Madrid, Spain	Universidad Nacional de Educacion a Distancia (UNED); Autonomous University of Madrid	Ortega, F (corresponding author), Univ Nacl Educ Distancia, Fac Ciencias, Dept Fis Matemat & Fluidos, Grp Biol, Paseo Senda del Rey 9, E-28040 Madrid, Spain.	fortega@ccia.uned.es	Ortega, Francisco/K-3255-2015; Ortega, Francisco/B-5760-2009; Sanz, Jose Luis/O-1421-2019; Escaso, Fernando/H-9782-2015	Ortega, Francisco/0000-0002-7431-354X; Ortega, Francisco/0000-0002-7431-354X; Escaso, Fernando/0000-0001-7642-1555; Sanz, Jose Luis/0000-0002-5214-5725	Museo de las Ciencias de Castilla-La Mancha; Spanish Ministerio de Ciencia e Innovacion [CGL2005-05614]	Museo de las Ciencias de Castilla-La Mancha; Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank S. Prieto for information about the location of the specimen; C. Diaz-Romeral, R. de la Fuente, M. Garcia Oliva and N. Santamaria for participating in the field; P. Garcia, M. Llandres, P. Moyano and J. Saiz for specimen preparation; L. Chiappe (Natural History Museum of LA County) for comments on the manuscript; E. Feeman and Plan de Promocion de la Investigacion en la Universidad Nacional de Educacion a Distancia for manuscript revision; R. Martin for the flesh reconstruction of Concavenator in Fig. 2; and S. Torralba for photography. We acknowledge the Museo de las Ciencias de Castilla-La Mancha for support and funding. Part of this research was financed by project CGL2005-05614 of the Spanish Ministerio de Ciencia e Innovacion.	Alibardi L, 2008, PROG HISTOCHEM CYTO, V43, P1, DOI 10.1016/j.proghi.2008.01.001; Bailey JB, 1997, J PALEONTOL, V71, P1124, DOI 10.1017/S0022336000036076; Benson RBJ, 2010, NATURWISSENSCHAFTEN, V97, P71, DOI 10.1007/s00114-009-0614-x; Brown B, 1913, B AM MUS NAT HIST, V32, P395; Brusatte SL, 2008, J SYST PALAEONTOL, V6, P155, DOI 10.1017/S1477201907002404; Brusatte SL, 2009, NATURWISSENSCHAFTEN, V96, P1051, DOI 10.1007/s00114-009-0565-2; Brusatte Stephen L., 2008, Monograph of the Palaeontographical Society, P1; Carrano MT, 2008, J SYST PALAEONTOL, V6, P183, DOI 10.1017/S1477201907002246; Chuong CM, 2003, J EXP ZOOL PART B, V298B, P42, DOI 10.1002/jez.b.00025; Chuong CM, 2000, CURR OPIN GENET DEV, V10, P449, DOI 10.1016/S0959-437X(00)00111-8; Coria RA, 2006, GEODIVERSITAS, V28, P71; CORIA RA, 1995, NATURE, V377, P224, DOI 10.1038/377224a0; Currie Philip J., 2000, Geodiversitas, V22, P207; Holtz TR, 2004, DINOSAURIA, 2ND EDITION, P71; Holtz TR, 2004, DINOSAURIA, 2ND EDITION, P111; MADSEN JH, 1976, B UTAH GEOLOGICAL MI, V109, P1; Mayr G, 2002, NATURWISSENSCHAFTEN, V89, P361, DOI 10.1007/s00114-002-0339-6; Norman D.B., 1986, Bulletin de l'Institut Royal des Sciences Naturelles de Belgique Sciences de la Terre, V56, P281; Novas FE, 2005, NATURWISSENSCHAFTEN, V92, P226, DOI 10.1007/s00114-005-0623-3; Olshevsky G., 1991, SAN DIEGO CALIFORNIA, P1; Paul Gregory S., 2007, P69; Sanz JL, 2001, PALAEOBIOLOGY, VII, P356; Sawyer RH, 2003, J EXP ZOOL PART B, V298B, P57, DOI 10.1002/jez.b.26; Sereno PC, 2008, ACTA PALAEONTOL POL, V53, P15, DOI 10.4202/app.2008.0102; Sereno PC, 1998, SCIENCE, V282, P1298, DOI 10.1126/science.282.5392.1298; STOVALL JW, 1950, AM MIDL NAT, V43, P696, DOI 10.2307/2421859; Stromer E, 1915, ABHANDLUNGEN KONIGLI, V28, P1; TAQUET P, 1976, GEOLOGIE PALEONTOLOG; Turner AH, 2007, SCIENCE, V317, P1721, DOI 10.1126/science.1145076; Zheng XT, 2009, NATURE, V458, P333, DOI 10.1038/nature07856	30	83	89	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					203	206		10.1038/nature09181	http://dx.doi.org/10.1038/nature09181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829793				2022-12-28	WOS:000281616300033
J	van Gils, EJM; Veenhoven, RH; Hak, E; Rodenburg, GD; Keijzers, WCM; Bogaert, D; Trzcinski, K; Bruin, JP; van Alphen, L; van der Ende, A; Sanders, EAM				van Gils, Elske J. M.; Veenhoven, Reinier H.; Hak, Eelko; Rodenburg, Gerwin D.; Keijzers, Wendy C. M.; Bogaert, Debby; Trzcinski, Krzysztof; Bruin, Jacob P.; van Alphen, Loek; van der Ende, Arie; Sanders, Elisabeth A. M.			Pneumococcal Conjugate Vaccination and Nasopharyngeal Acquisition of Pneumococcal Serotype 19A Strains	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE OTITIS-MEDIA; STREPTOCOCCUS-PNEUMONIAE SEROTYPES; INVASIVE DISEASE; ANTIMICROBIAL RESISTANCE; POPULATION SNAPSHOT; TEMPORAL TRENDS; UNITED-STATES; CHILDREN; CARRIAGE; EMERGENCE	Context The rapid increase in multiresistant serotype 19A as a cause of invasive and respiratory pneumococcal disease has been associated in time with the widespread implementation of 7-valent pneumococcal conjugate vaccination (PCV-7) in several countries. Because spontaneous fluctuations in time and antibiotic selective pressure may have induced this serotype 19A increase, controlled studies are needed to assess the role of PCV-7. Objective To examine the association of PCV-7 vaccination and nasopharyngeal acquisition of serotype 19A pneumococci, their clonal distribution, and antibiotic susceptibility. Design, Setting, and Patients Post hoc per-protocol completer's analysis as part of a randomized controlled trial of nasopharyngeal Streptococcus pneumoniae carriage enrolling 1003 healthy newborns with follow-up to the age of 24 months in the Netherlands, which has low antibiotic resistance rates. The study was conducted before widespread PCV-7 implementation in infants, between July 7, 2005, and February 14, 2008. Nasopharyngeal swabs were obtained at the age of 6 weeks and at 6, 12, 18, and 24 months. Intervention Infants were randomly assigned to receive 2 doses of PCV-7 at 2 and 4 months; 2 + 1 doses of PCV-7 at 2, 4, and 11 months; or no dosage (unvaccinated control group). Main Outcome Measure Cumulative proportion of children with nasopharyngeal acquisition of a new serotype 19A strain from 6 through 24 months of age. Results Nine hundred forty-eight children completed the study. Fifty-four nasopharyngeal serotype 19A carriage isolates from 318 in the 2-dose group, 66 isolates from 327 in the 2 + 1-dose group, and 33 isolates from 303 in the unvaccinated were collected from 6 weeks through 24 months. The cumulative proportion who tested positive for new nasopharyngeal serotype 19A acquisition from 6 through 24 months of age was significantly higher in those having received the 2 + 1-dose PCV-7 schedule (16.2%; 95% confidence interval [CI], 12.6%-20.6%) vs those who were unvaccinated (9.2%; 95% CI, 6.5%-13.0%; relative risk [RR], 1.75; 95% CI, 1.14-2.70) but not after a 2-dose schedule (13.2%; 95% CI, 9.9%-17.4%; RR, 1.43; 95% CI, 0.91-2.25). There were 28 different sequence types identified, including 6 new types. The proportion of children with new 19A acquisition who had used antibiotics in the last 6 months (18.7%) did not differ among groups. Five isolates were penicillin-intermediate susceptible and another 3 were nonsusceptible to erythromycin and azithromycin, all in the vaccine groups. Conclusion A 2 + 1-dose PCV-7 schedule was associated with an increase in serotype 19A nasopharyngeal acquisition compared with unvaccinated controls.	[van Gils, Elske J. M.; Hak, Eelko; Rodenburg, Gerwin D.; Bogaert, Debby; Trzcinski, Krzysztof; Sanders, Elisabeth A. M.] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, NL-3508 AB Utrecht, Netherlands; [van Gils, Elske J. M.; Veenhoven, Reinier H.; Rodenburg, Gerwin D.] Univ Groningen, Univ Med Ctr Groningen, Spaarne Hosp Hoofddorp, Dept Pediat, Groningen, Netherlands; [Hak, Eelko] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Pharm Pharmacoepidemiol & PharmacoEcon, Groningen, Netherlands; [Hak, Eelko] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Bruin, Jacob P.] Reg Lab Publ Hlth, Haarlem, Netherlands; [van Alphen, Loek] Netherlands Vaccine Inst, Bilthoven, Netherlands; [Keijzers, Wendy C. M.; van der Ende, Arie] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Spaarne Hospital; University of Groningen; University of Groningen; University of Groningen	Sanders, EAM (corresponding author), Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, KB 03-023-3,POB 85090, NL-3508 AB Utrecht, Netherlands.	l.sanders@umcutrecht.nl	Trzcinski, Krzysztof/I-8840-2019; van der Ende, Arie/A-4346-2012	Trzcinski, Krzysztof/0000-0002-5433-8846; van der Ende, Arie/0000-0003-1298-3086; Bogaert, Debby/0000-0003-2651-7000	GlaxoSmithKline; Wyeth/Pfizer; Baxter; Novartis; Dutch Ministry of Health; Wellcome Trust	GlaxoSmithKline(GlaxoSmithKline); Wyeth/Pfizer(WyethPfizer); Baxter; Novartis(Novartis); Dutch Ministry of Health; Wellcome Trust(Wellcome TrustEuropean Commission)	Dr Veenhoven reported receiving grant support from GlaxoSmithKline and Wyeth/Pfizer for vaccine studies and consulting fees for GlaxoSmithKline. Dr Sanders reported receiving unrestricted grants from Wyeth/Pfizer and Baxter for research, consulting fees for Wyeth/Pfizer and GlaxoSmithKline, lecturing fees from Wyeth/Pfizer, and grant support from Wyeth/Pfizer and GlaxoSmithKline for vaccine studies. Dr Van der Ende reports receiving unrestricted grants from Wyeth/Pfizer and Novartis. For all other authors no potential conflicts were reported.; This work was supported by the Dutch Ministry of Health.; We thank the participating children and their families for their time and effort. We also thank the members of the research team for their invaluable dedicated work and support. We thank all cooperating organizations for their support. We acknowledge the use of the pneumococcal MLST database, which is located at Imperial College London and is funded by Wellcome Trust.	Aguiar SI, 2008, CLIN MICROBIOL INFEC, V14, P835, DOI 10.1111/j.1469-0691.2008.02031.x; Aguiar SI, 2010, J CLIN MICROBIOL, V48, P101, DOI 10.1128/JCM.00665-09; [Anonymous], 2008, M100S18 CLIN LAB STA; Ardanuy C, 2009, J ANTIMICROB CHEMOTH, V64, P507, DOI 10.1093/jac/dkp210; Beall B, 2006, J CLIN MICROBIOL, V44, P999, DOI 10.1128/JCM.44.3.999-1017.2006; Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5; Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168; Choi EH, 2008, EMERG INFECT DIS, V14, P275, DOI 10.3201/eid1402.070807; Dagan R, 2009, J INFECT DIS, V199, P776, DOI 10.1086/597044; Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049; Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004; Fenoll A, 2009, J CLIN MICROBIOL, V47, P1012, DOI 10.1128/JCM.01454-08; FILIUS PMG, 2008, NETHMAP 2008 CONSUMP; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Harboe ZB, 2010, CLIN INFECT DIS, V50, P329, DOI 10.1086/649872; Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081; Huang SS, 2009, PEDIATRICS, V124, pE1, DOI 10.1542/peds.2008-3099; JACOBS MR, 1992, DIAGN MICR INFEC DIS, V15, P473, DOI 10.1016/0732-8893(92)90093-9; Kaplan SL, 2010, PEDIATRICS, V125, P429, DOI 10.1542/peds.2008-1702; Linares J, 2010, CLIN MICROBIOL INFEC, V16, P402, DOI 10.1111/j.1469-0691.2010.03182.x; Lipsitch M, 2007, J INFECT DIS, V196, P1221, DOI 10.1086/521831; Mahjoub-Messai F, 2008, ARCH PEDIATRIE, V15, P1713, DOI 10.1016/j.arcped.2008.09.003; Mahjoub-Messai F, 2009, J CLIN MICROBIOL, V47, P837, DOI 10.1128/JCM.01547-08; McNeil JC, 2009, PEDIATR INFECT DIS J, V28, P766, DOI 10.1097/INF.0b013e3181a24557; Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996; O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI [10.1097/00006454-200302000-00009, 10.1097/00006454-200302000-00010]; Pai R, 2005, J INFECT DIS, V192, P1988, DOI 10.1086/498043; Pelton SI, 2007, PEDIATR INFECT DIS J, V26, P468, DOI 10.1097/INF.0b013e31803df9ca; Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772; Reingold A., 2008, Morbidity and Mortality Weekly Report, V57, P144; Robinson DA, 2001, J INFECT DIS, V183, P1501, DOI 10.1086/320194; Shouval DS, 2006, PEDIATR INFECT DIS J, V25, P602, DOI 10.1097/01.inf.0000220231.79968.f6; Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784; Techasaensiri C, 2010, PEDIATR INFECT DIS J, V29, P294, DOI 10.1097/INF.0b013e3181c2a229; van Gils EJM, 2009, JAMA-J AM MED ASSOC, V302, P159, DOI 10.1001/jama.2009.975; VANOOSTEN M, 2006, EUROSURVEILLANCE, V11; Veenhoven RH, 2004, CLIN INFECT DIS, V39, P911, DOI 10.1086/422651; Weinberger DM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000476	38	53	53	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1099	1106		10.1001/jama.2010.1290	http://dx.doi.org/10.1001/jama.2010.1290			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823436	Green Published			2022-12-28	WOS:000281559800020
J	Neeley, M; Bialczak, RC; Lenander, M; Lucero, E; Mariantoni, M; O'Connell, AD; Sank, D; Wang, H; Weides, M; Wenner, J; Yin, Y; Yamamoto, T; Cleland, AN; Martinis, JM				Neeley, Matthew; Bialczak, Radoslaw C.; Lenander, M.; Lucero, E.; Mariantoni, Matteo; O'Connell, A. D.; Sank, D.; Wang, H.; Weides, M.; Wenner, J.; Yin, Y.; Yamamoto, T.; Cleland, A. N.; Martinis, John M.			Generation of three-qubit entangled states using superconducting phase qubits	NATURE			English	Article								Entanglement is one of the key resources required for quantum computation(1), so the experimental creation and measurement of entangled states is of crucial importance for various physical implementations of quantum computers(2). In superconducting devices(3), two-qubit entangled states have been demonstrated and used to show violations of Bell's inequality(4) and to implement simple quantum algorithms(5). Unlike the two-qubit case, where all maximally entangled two-qubit states are equivalent up to local changes of basis, three qubits can be entangled in two fundamentally different ways(6). These are typified by the states vertical bar GHZ > = (vertical bar 000 > vertical bar 111 >)/root 2 and vertical bar W > = (vertical bar 001 > + vertical bar 010 > + vertical bar 100 >)/root 3. Here we demonstrate the operation of three coupled superconducting phase qubits(7) and use them to create and measure vertical bar GHZ > and vertical bar W > states. The states are fully characterized using quantum state tomography(8) and are shown to satisfy entanglement witnesses(9), confirming that they are indeed examples of three-qubit entanglement and are not separable into mixtures of two-qubit entanglement.	[Neeley, Matthew; Bialczak, Radoslaw C.; Lenander, M.; Lucero, E.; Mariantoni, Matteo; O'Connell, A. D.; Sank, D.; Wang, H.; Weides, M.; Wenner, J.; Yin, Y.; Yamamoto, T.; Cleland, A. N.; Martinis, John M.] Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; [Yamamoto, T.] NEC Corp Ltd, Green Innovat Res Labs, Tsukuba, Ibaraki 3058501, Japan	University of California System; University of California Santa Barbara; NEC Corporation	Martinis, JM (corresponding author), Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA.	martinis@physics.ucsb.edu	Wenner, James/G-3777-2014; Cleland, Andrew/AAG-7581-2019; Weides, Martin/C-1470-2009; Wang, Haohua/G-8875-2011	Wenner, James/0000-0001-7107-4734; Weides, Martin/0000-0002-2718-6795; Wang, Haohua/0000-0001-5380-4297	NSF; IARPA [W911NF-04-1-0204]; Elings Fellowship	NSF(National Science Foundation (NSF)); IARPA; Elings Fellowship	Devices were made at the UCSB Nanofabrication Facility, a part of the NSF-funded National Nanotechnology Infrastructure Network. This work was supported by IARPA under grant W911NF-04-1-0204. M.M. acknowledges support from an Elings Fellowship.	Acin A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.040401; Ansmann M, 2009, NATURE, V461, P504, DOI 10.1038/nature08363; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; Clarke J, 2008, NATURE, V453, P1031, DOI 10.1038/nature07128; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; DiCarlo L, 2009, NATURE, V460, P240, DOI 10.1038/nature08121; Dur W, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.062314; Galiautdinov A, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.010305; Hofheinz M, 2009, NATURE, V459, P546, DOI 10.1038/nature08005; Ladd TD, 2010, NATURE, V464, P45, DOI 10.1038/nature08812; Lanyon BP, 2009, NAT PHYS, V5, P134, DOI 10.1038/NPHYS1150; Lucero E, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.247001; Matsuo S, 2007, J PHYS SOC JPN, V76, DOI 10.1143/JPSJ.76.054802; McDermott R, 2005, SCIENCE, V307, P1299, DOI 10.1126/science.1107572; MERMIN ND, 1990, PHYS REV LETT, V65, P1838, DOI 10.1103/PhysRevLett.65.1838; Monz T, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.040501; Neeley M, 2009, SCIENCE, V325, P722, DOI 10.1126/science.1173440; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Schuch N, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032301; Shi YY, 2003, QUANTUM INF COMPUT, V3, P84; Steffen M, 2006, SCIENCE, V313, P1423, DOI 10.1126/science.1130886; Wei LF, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.246803	23	299	305	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					570	573		10.1038/nature09418	http://dx.doi.org/10.1038/nature09418			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882012	Green Submitted			2022-12-28	WOS:000282273100034
J	Janssen, BJC; Robinson, RA; Perez-Branguli, F; Bell, CH; Mitchell, KJ; Siebold, C; Jones, EY				Janssen, Bert J. C.; Robinson, Ross A.; Perez-Branguli, Francesc; Bell, Christian H.; Mitchell, Kevin J.; Siebold, Christian; Jones, E. Yvonne			Structural basis of semaphorin-plexin signalling	NATURE			English	Article							CRYSTAL-STRUCTURE; RECEPTOR; BINDING; MODEL; TRANSMEMBRANE; FAMILY; LIGAND; MET; GLYCOSYLATION; DIMERIZATION	Cell-cell signalling of semaphorin ligands through interaction with plexin receptors is important for the homeostasis and morphogenesis of many tissues and is widely studied for its role in neural connectivity, cancer, cell migration and immune responses(1). SEMA4D and Sema6A exemplify two diverse vertebrate, membrane-spanning semaphorin classes (4 and 6) that are capable of direct signalling through members of the two largest plexin classes, B and A, respectively(2,3). In the absence of any structural information on the plexin ectodomain or its interaction with semaphorins the extracellular specificity and mechanism controlling plexin signalling has remained unresolved. Here we present crystal structures of cognate complexes of the semaphorin-binding regions of plexins B1 and A2 with semaphorin ectodomains (human PLXNB1(1-2)-SEMA4D(ecto) and murine PlxnA2(1-4)-Sema6A(ecto)), plus unliganded structures of PlxnA2(1-4) and Sema6A(ecto). These structures, together with biophysical and cellular assays of wild-type and mutant proteins, reveal that semaphorin dimers independently bind two plexin molecules and that signalling is critically dependent on the avidity of the resulting bivalent 2: 2 complex (monomeric semaphorin binds plexin but fails to trigger signalling). In combination, our data favour a cell-cell signalling mechanism involving semaphorin-stabilized plexin dimerization, possibly followed by clustering, which is consistent with previous functional data. Furthermore, the shared generic architecture of the complexes, formed through conserved contacts of the amino-terminal seven-bladed beta-propeller (sema) domains of both semaphorin and plexin, suggests that a common mode of interaction triggers all semaphorin-plexin based signalling, while distinct insertions within or between blades of the sema domains determine binding specificity.	[Janssen, Bert J. C.; Robinson, Ross A.; Bell, Christian H.; Siebold, Christian; Jones, E. Yvonne] Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; [Perez-Branguli, Francesc; Mitchell, Kevin J.] Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland; [Perez-Branguli, Francesc; Mitchell, Kevin J.] Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland	University of Oxford; Wellcome Centre for Human Genetics; Trinity College Dublin; Trinity College Dublin	Jones, EY (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.	yvonne@strubi.ox.ac.uk	Janssen, Bert/I-3338-2016; Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Janssen, Bert/0000-0002-8101-8370; Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Robinson, Ross/0000-0002-1482-0910; Mitchell, Kevin/0000-0002-3433-4530; Siebold, Christian/0000-0002-6635-3621	Human Frontier Science Program; Science Foundation Ireland; Wellcome Trust; Cancer Research UK; MRC [G0700232, G9900061, G0900084] Funding Source: UKRI; Cancer Research UK [10976] Funding Source: researchfish; Medical Research Council [G9900061, G0700232, G0900084] Funding Source: researchfish	Human Frontier Science Program(Human Frontier Science Program); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the staff of European Synchrotron Radiation Facility beamline ID 23-1 and Diamond beamline IO3 for assistance with data collection, the Molecular Cytogenetics and Microscopy Core facility of the Wellcome Trust Centre for Human Genetics, T. S. Walter for help with crystallization, G. Sutton for help with MALS experiments, A. F. Sonnen for help with AUC experiments, W. Lu for help with tissue culture, J. M. Grimes for assistance with figures and A. R. Aricescu and D. I. Stuart for critical reading of the manuscript. This work was funded by Cancer Research UK and the UK Medical Research Council. B. J. C. J. is funded by the Human Frontier Science Program, K. J. M. by a Science Foundation Ireland grant, C. H. B. and C. S. by the Wellcome Trust and E.Y.J. by Cancer Research UK.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6; Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Chang VT, 2007, STRUCTURE, V15, P267, DOI 10.1016/j.str.2007.01.011; Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Gherardi E, 2006, P NATL ACAD SCI USA, V103, P4046, DOI 10.1073/pnas.0509040103; Gherardi E, 2004, CURR OPIN STRUC BIOL, V14, P669, DOI 10.1016/j.sbi.2004.10.010; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; He HW, 2009, P NATL ACAD SCI USA, V106, P15610, DOI 10.1073/pnas.0906923106; Kerjan G, 2005, NAT NEUROSCI, V8, P1516, DOI 10.1038/nn1555; Klostermann A, 1998, J BIOL CHEM, V273, P7326, DOI 10.1074/jbc.273.13.7326; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1997, NEURON, V19, P531, DOI 10.1016/S0896-6273(00)80369-4; Koppel AM, 1998, J BIOL CHEM, V273, P15708, DOI 10.1074/jbc.273.25.15708; Korostylev A, 2008, DEVELOPMENT, V135, P3333, DOI 10.1242/dev.019760; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Leslie A.G.W., 1992, JOINT CCP4 ESF EMACB; Liu HL, 2010, CELL, V142, P749, DOI 10.1016/j.cell.2010.07.040; Love CA, 2003, NAT STRUCT BIOL, V10, P843, DOI 10.1038/nsb977; Mayo CJ, 2005, STRUCTURE, V13, P175, DOI 10.1016/j.str.2004.12.010; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Merte J, 2010, J NEUROSCI, V30, P5767, DOI 10.1523/JNEUROSCI.5061-09.2010; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; Niemann HH, 2007, CELL, V130, P235, DOI 10.1016/j.cell.2007.05.037; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Oinuma I, 2004, J NEUROSCI, V24, P11473, DOI 10.1523/JNEUROSCI.3257-04.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Renaud J, 2008, NAT NEUROSCI, V11, P440, DOI 10.1038/nn2064; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Suto F, 2007, NEURON, V53, P535, DOI 10.1016/j.neuron.2007.01.028; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Tong YF, 2009, J BIOL CHEM, V284, P35962, DOI 10.1074/jbc.M109.056275; Toyofuku T, 2005, NAT NEUROSCI, V8, P1712, DOI 10.1038/nn1596; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Turner LJ, 2006, METHOD ENZYMOL, V406, P665, DOI 10.1016/S0076-6879(06)06052-6; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	54	160	183	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2010	467	7319					1118	U132		10.1038/nature09468	http://dx.doi.org/10.1038/nature09468			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20877282	Green Accepted			2022-12-28	WOS:000283548600050
J	Kuehne, SA; Cartman, ST; Heap, JT; Kelly, ML; Cockayne, A; Minton, NP				Kuehne, Sarah A.; Cartman, Stephen T.; Heap, John T.; Kelly, Michelle L.; Cockayne, Alan; Minton, Nigel P.			The role of toxin A and toxin B in Clostridium difficile infection	NATURE			English	Article							DIARRHEA; STRAIN; RESISTANT; GENOME	Clostridium difficile infection is the leading cause of healthcare-associated diarrhoea in Europe and North America(1,2). During infection, C. difficile produces two key virulence determinants, toxin A and toxin B. Experiments with purified toxins have indicated that toxin A alone is able to evoke the symptoms of C. difficile infection, but toxin B is unable to do so unless it is mixed with toxin A or there is prior damage to the gut mucosa(3). However, a recent study indicated that toxin B is essential for C. difficile virulence and that a strain producing toxin A alone was avirulent(4). This creates a paradox over the individual importance of toxin A and toxin B. Here we show that isogenic mutants of C. difficile producing either toxin A or toxin B alone can cause fulminant disease in the hamster model of infection. By using a gene knockout system(5,6) to inactivate the toxin genes permanently, we found that C. difficile producing either one or both toxins showed cytotoxic activity in vitro that translated directly into virulence in vivo. Furthermore, by constructing the first ever double-mutant strain of C. difficile, in which both toxin genes were inactivated, we were able to completely attenuate virulence. Our findings re-establish the importance of both toxin A and toxin B and highlight the need to continue to consider both toxins in the development of diagnostic tests and effective countermeasures against C. difficile.	[Kuehne, Sarah A.; Cartman, Stephen T.; Heap, John T.; Kelly, Michelle L.; Cockayne, Alan; Minton, Nigel P.] Univ Nottingham, NIHR Biomed Res Unit, Nottingham Digest Dis Ctr, Sch Mol Med Sci,Ctr Biomol Sci,Clostridia Res Grp, Nottingham NG7 2RD, England	University of Nottingham	Minton, NP (corresponding author), Univ Nottingham, NIHR Biomed Res Unit, Nottingham Digest Dis Ctr, Sch Mol Med Sci,Ctr Biomol Sci,Clostridia Res Grp, Nottingham NG7 2RD, England.	nigel.minton@nottingham.ac.uk	Kuehne, Sarah/AAV-3481-2021	Kuehne, Sarah/0000-0001-6790-8433; Minton, Nigel/0000-0002-9277-1261	UK Medical Research Council [G0601176]; European Union [HEALTH-F3-2008-223585]; Biotechnology and Biological Sciences Research Council (BBSRC) [BB/F003390/1]; BBSRC [BB/F003390/1] Funding Source: UKRI; MRC [G0601176] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F003390/1] Funding Source: researchfish; Medical Research Council [G0601176] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	S.A.K., S.T.C., A.C. and N.P.M. acknowledge the financial support of the UK Medical Research Council (G0601176). Support for M.L.K. was provided by the European Union (HEALTH-F3-2008-223585) and for J.T.H. by the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/F003390/1). We thank C. von-Eichel Streiber for supplying the neutralizing antibody serums and Y. Mahida for the Vero cells. We are also grateful to A. Olling and R. Gerhard for methodological advice on western blots.	Alfa MJ, 2000, J CLIN MICROBIOL, V38, P2706, DOI 10.1128/JCM.38.7.2706-2714.2000; Cartman ST, 2010, APPL ENVIRON MICROB, V76, P1103, DOI 10.1128/AEM.02525-09; Chaves-Olarte E, 2003, J BIOL CHEM, V278, P7956, DOI 10.1074/jbc.M209244200; Drudy D, 2007, INFECT CONT HOSP EP, V28, P932, DOI 10.1086/519181; Drudy D, 2007, INT J INFECT DIS, V11, P5, DOI 10.1016/j.ijid.2006.04.003; Du Tim, 2004, Can J Infect Dis, V15, P83; Elliott B, 2007, INTERN MED J, V37, P561, DOI 10.1111/j.1445-5994.2007.01403.x; HACHLER H, 1987, ANTIMICROB AGENTS CH, V31, P1039, DOI 10.1128/AAC.31.7.1039; Heap JT, 2007, J MICROBIOL METH, V70, P452, DOI 10.1016/j.mimet.2007.05.021; Heap JT, 2010, J MICROBIOL METH, V80, P49, DOI 10.1016/j.mimet.2009.10.018; Heap JT, 2009, J MICROBIOL METH, V78, P79, DOI 10.1016/j.mimet.2009.05.004; Hussain HA, 2005, J MED MICROBIOL, V54, P137, DOI 10.1099/jmm.0.45790-0; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; KIM PH, 1987, INFECT IMMUN, V55, P2984, DOI 10.1128/IAI.55.12.2984-2992.1987; LYERLY DM, 1985, INFECT IMMUN, V47, P349, DOI 10.1128/IAI.47.2.349-352.1985; Lyras D, 2009, NATURE, V458, P1176, DOI 10.1038/nature07822; O'Connor JR, 2006, MOL MICROBIOL, V61, P1335, DOI 10.1111/j.1365-2958.2006.05315.x; Poutanen SM, 2004, CAN MED ASSOC J, V171, P51, DOI 10.1503/cmaj.1031189; Sambrook J., 2001, MOL CLONING LAB MANU; Sebaihia M, 2006, NAT GENET, V38, P779, DOI 10.1038/ng1830; Sorg JA, 2008, J BACTERIOL, V190, P2505, DOI 10.1128/JB.01765-07; Stabler RA, 2008, J MED MICROBIOL, V57, P771, DOI 10.1099/jmm.0.47743-0; TORRES J, 1992, TOXICON, V30, P419, DOI 10.1016/0041-0101(92)90538-G; TORRES JF, 1991, J MED MICROBIOL, V35, P40, DOI 10.1099/00222615-35-1-40; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; WILLIAMS DR, 1990, J GEN MICROBIOL, V136, P819, DOI 10.1099/00221287-136-5-819	26	581	604	1	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	2010	467	7316					711	U97		10.1038/nature09397	http://dx.doi.org/10.1038/nature09397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20844489	Green Submitted			2022-12-28	WOS:000282572500039
J	Drake, JM; Griffen, BD				Drake, John M.; Griffen, Blaine D.			Early warning signals of extinction in deteriorating environments	NATURE			English	Article							REGIME SHIFTS; POPULATIONS; STOCHASTICITY; ECOSYSTEMS; SYSTEM; TIMES	During the decline to extinction, animal populations may present dynamical phenomena not exhibited by robust populations(1,2). Some of these phenomena, such as the scaling of demographic variance, are related to small size(3-6) whereas others result from density-dependent nonlinearities(7). Although understanding the causes of population extinction has been a central problem in theoretical biology for decades(8), the ability to anticipate extinction has remained elusive(9). Here we argue that the causes of a population's decline are central to the predictability of its extinction. Specifically, environmental degradation may cause a tipping point in population dynamics, corresponding to a bifurcation in the underlying population growth equations, beyond which decline to extinction is almost certain. In such cases, imminent extinction will be signalled by critical slowing down (CSD). We conducted an experiment with replicate laboratory populations of Daphnia magna to test this hypothesis. We show that populations crossing a transcritical bifurcation, experimentally induced by the controlled decline in environmental conditions, show statistical signatures of CSD after the onset of environmental deterioration and before the critical transition. Populations in constant environments did not have these patterns. Four statistical indicators all showed evidence of the approaching bifurcation as early as 110 days (similar to 8 generations) before the transition occurred. Two composite indices improved predictability, and comparative analysis showed that early warning signals based solely on observations in deteriorating environments without reference populations for standardization were hampered by the presence of transient dynamics before the onset of deterioration, pointing to the importance of reliable baseline data before environmental deterioration begins. The universality of bifurcations in models of population dynamics suggests that this phenomenon should be general(10-12).	[Drake, John M.] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA; [Griffen, Blaine D.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University System of Georgia; University of Georgia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Drake, JM (corresponding author), Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA.	jdrake@uga.edu	Drake, John/D-6622-2012; Griffen, Blaine/AAC-6384-2021	Drake, John/0000-0003-4646-1235	Odum School of Ecology, University of Georgia; University of South Carolina	Odum School of Ecology, University of Georgia; University of South Carolina	G. Fussman, A. Hastings, A. Kramer, R. Hall, A. Park and T. Stratmann provided comments on earlier versions of this paper. A. Silletti assisted with the preparation of the manuscript. This research was supported by funding from the Odum School of Ecology, a University of Georgia Faculty Research Grant and funding from the University of South Carolina.	BAILLIE JEM, 2004, 2004 IUCN RED LIST T, P10; Becks L, 2005, NATURE, V435, P1226, DOI 10.1038/nature03627; Biggs R, 2009, P NATL ACAD SCI USA, V106, P826, DOI 10.1073/pnas.0811729106; Brook BW, 2008, TRENDS ECOL EVOL, V23, P453, DOI 10.1016/j.tree.2008.03.011; Carpenter SR, 2006, ECOL LETT, V9, P308, DOI 10.1111/j.1461-0248.2005.00877.x; Dakos V, 2008, P NATL ACAD SCI USA, V105, P14308, DOI 10.1073/pnas.0802430105; Dakos V, 2010, THEOR ECOL-NETH, V3, P163, DOI 10.1007/s12080-009-0060-6; Drake JM, 2005, PLOS BIOL, V3, P1300, DOI 10.1371/journal.pbio.0030222; Drake JM, 2006, ECOLOGY, V87, P2215, DOI 10.1890/0012-9658(2006)87[2215:ETIEP]2.0.CO;2; Fagan WF, 2006, ECOL LETT, V9, P51, DOI 10.1111/j.1461-0248.2005.00845.x; Fussmann GF, 2000, SCIENCE, V290, P1358, DOI 10.1126/science.290.5495.1358; Guttal V, 2008, ECOL LETT, V11, P450, DOI 10.1111/j.1461-0248.2008.01160.x; HALLAM TG, 1981, J THEOR BIOL, V93, P303, DOI 10.1016/0022-5193(81)90106-5; Hastings A, 2010, ECOL LETT, V13, P464, DOI 10.1111/j.1461-0248.2010.01439.x; Jagers P, 2002, J APPL PROBAB, V39, P395, DOI 10.1017/S0021900200022609; Kefi S, 2007, NATURE, V449, P213, DOI 10.1038/nature06111; KENDALL DG, 1948, ANN MATH STAT, V19, P1, DOI 10.1214/aoms/1177730285; Lande R, 1998, OIKOS, V83, P353, DOI 10.2307/3546849; Lenton TM, 2008, P NATL ACAD SCI USA, V105, P1786, DOI 10.1073/pnas.0705414105; Ludwig D, 1996, AM NAT, V147, P506, DOI 10.1086/285863; Ludwig D, 1999, ECOLOGY, V80, P298, DOI 10.1890/0012-9658(1999)080[0298:IIMTEA]2.0.CO;2; McSharry PE, 2003, NAT MED, V9, P241, DOI 10.1038/nm0303-241; Melbourne BA, 2008, NATURE, V454, P100, DOI 10.1038/nature06922; Oborny B, 2005, OIKOS, V109, P291; Saether, 2003, STOCHASTIC POPULATIO, DOI [10.1093/acprof:oso/9780198525257.001.0001, DOI 10.1093/ACPROF:OSO/9780198525257.001.0001]; Scheffer M., 2020, CRITICAL TRANSITIONS, V16, DOI 10.2307/j.ctv173f1g1; Scheffer M, 2009, NATURE, V461, P53, DOI 10.1038/nature08227; Takimoto G, 2009, POPUL ECOL, V51, P419, DOI 10.1007/s10144-009-0148-2; VAN NES EH, 2007, AM NAT, V169, P738; WISSEL C, 1984, OECOLOGIA, V65, P101, DOI 10.1007/BF00384470	30	353	368	6	236	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					456	459		10.1038/nature09389	http://dx.doi.org/10.1038/nature09389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20827269				2022-12-28	WOS:000282090200042
J	Baltensperger, U				Baltensperger, Urs			Aerosols in Clearer Focus	SCIENCE			English	Editorial Material							POLLUTION		Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Paul Scherrer Institute	Baltensperger, U (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	urs.baltensperger@psi.ch						Andreae MO, 2007, SCIENCE, V315, P50, DOI 10.1126/science.1136529; Chow JC, 2006, J AIR WASTE MANAGE, V56, P1368, DOI 10.1080/10473289.2006.10464545; Clarke A, 2010, SCIENCE, V329, P1488, DOI 10.1126/science.1188838; Dusek U, 2006, SCIENCE, V312, P1375, DOI 10.1126/science.1125261; Findeisen W., 1938, METEOR Z, V55, P121, DOI DOI 10.1127/METZ/2015/0675; Henning S, 2002, TELLUS B, V54, P82, DOI 10.1034/j.1600-0889.2002.00299.x; McFiggans G, 2006, ATMOS CHEM PHYS, V6, P2593, DOI 10.5194/acp-6-2593-2006; Poschl U, 2010, SCIENCE, V329, P1513, DOI 10.1126/science.1191056; Rosenfeld D, 2008, SCIENCE, V321, P1309, DOI 10.1126/science.1160606; Solomon S, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P1; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2; Verheggen B, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2007JD008714; Weingartner E, 1999, J GEOPHYS RES-ATMOS, V104, P26809, DOI 10.1029/1999JD900170	13	16	20	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1474	1475		10.1126/science.1192930	http://dx.doi.org/10.1126/science.1192930			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847255				2022-12-28	WOS:000281869000025
J	Vamivakas, AN; Lu, CY; Matthiesen, C; Zhao, Y; Falt, S; Badolato, A; Atature, M				Vamivakas, A. N.; Lu, C. -Y.; Matthiesen, C.; Zhao, Y.; Falt, S.; Badolato, A.; Atatuere, M.			Observation of spin-dependent quantum jumps via quantum dot resonance fluorescence	NATURE			English	Article							SINGLE-ELECTRON SPIN; MANIPULATION; DYNAMICS	Reliable preparation, manipulation and measurement protocols are necessary to exploit a physical system as a quantum bit(1). Spins in optically active quantum dots offer one potential realization(2,3) and recent demonstrations have shown high-fidelity preparation(4,5) and ultrafast coherent manipulation(6-8). The final challenge-that is, single-shot measurement of the electron spin-has proved to be the most difficult of the three and so far only time-averaged optical measurements have been reported(9-12). The main obstacle to optical spin readout in single quantum dots is that the same laser that probes the spin state also flips the spin being measured. Here, by using a gate-controlled quantum dot molecule(13-15), we present the ability to measure the spin state of a single electron in real time via the intermittency of quantum dot resonance fluorescence(12,16). The quantum dot molecule, unlike its single quantum dot counterpart, allows separate and independent optical transitions for state preparation, manipulation and measurement, avoiding the dilemma of relying on the same transition to address the spin state of an electron.	[Vamivakas, A. N.; Lu, C. -Y.; Matthiesen, C.; Zhao, Y.; Atatuere, M.] Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; [Lu, C. -Y.] Univ Sci & Technol China, Dept Modern Phys, Hefei 230026, Peoples R China; [Lu, C. -Y.] Univ Sci & Technol China, HFNL, Hefei 230026, Peoples R China; [Zhao, Y.] Heidelberg Univ, Inst Phys, D-69120 Heidelberg, Germany; [Falt, S.] Sol Volta AB, S-22370 Lund, Sweden; [Badolato, A.] Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA	University of Cambridge; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Ruprecht Karls University Heidelberg; University of Rochester	Atature, M (corresponding author), Univ Cambridge, Cavendish Lab, JJ Thomson Ave, Cambridge CB3 0HE, England.	anv21@cam.ac.uk; ma424@cam.ac.uk	Badolato, Antonio/E-9778-2015; Atature, Mete/ABD-9297-2020; Lu, Chao-Yang/D-8481-2011; Fält, Stefan/F-8171-2010	Lu, Chao-Yang/0000-0002-8227-9177; Matthiesen, Clemens/0000-0001-7842-6536; Badolato, Antonio/0000-0001-8266-2902; Atature, Mete/0000-0003-3852-0944	University of Cambridge; EPSRC [EP/G000883/1]; QIPIRC; A. v. Humboldt Foundation; LGFG; Engineering and Physical Sciences Research Council [EP/G000883/1] Funding Source: researchfish	University of Cambridge(University of Cambridge); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); QIPIRC; A. v. Humboldt Foundation(Alexander von Humboldt Foundation); LGFG; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by grants and funds from the University of Cambridge, EPSRC Science and Innovation Awards, the QIPIRC and EPSRC grant number EP/G000883/1. Y.Z. is supported by the A. v. Humboldt Foundation and LGFG. We thank A. Imamoglu, X. Marie, T. Amand, D. Gammon and D. Steel for discussions.	Atature M, 2007, NAT PHYS, V3, P101, DOI 10.1038/nphys521; Atature M, 2006, SCIENCE, V312, P551, DOI 10.1126/science.1126074; BASCHE T, 1995, NATURE, V373, P132, DOI 10.1038/373132a0; Berezovsky J, 2008, SCIENCE, V320, P349, DOI 10.1126/science.1154798; Berezovsky J, 2006, SCIENCE, V314, P1916, DOI 10.1126/science.1133862; BERGQUIST JC, 1986, PHYS REV LETT, V57, P1699, DOI 10.1103/PhysRevLett.57.1699; DEHMELT H, 1975, B AM PHYS SOC, V20, P60; Doty MF, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.035308; Faelt S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.106401; Flagg EB, 2009, NAT PHYS, V5, P203, DOI 10.1038/NPHYS1184; de Abajo FJG, 2010, REV MOD PHYS, V82, P209, DOI 10.1103/RevModPhys.82.209; Gerardot BD, 2008, NATURE, V451, P441, DOI 10.1038/nature06472; Hanson R, 2008, NATURE, V453, P1043, DOI 10.1038/nature07129; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Imamoglu A, 2000, FORTSCHR PHYS, V48, P987, DOI 10.1002/1521-3978(200009)48:9/11<987::AID-PROP987>3.0.CO;2-F; Kim D, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.236804; Krenner HJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.057402; Kroutvar M, 2004, NATURE, V432, P81, DOI 10.1038/nature03008; Leibfried D, 2003, REV MOD PHYS, V75, P281, DOI 10.1103/RevModPhys.75.281; Lu CY, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.035332; NAGOURNEY W, 1986, PHYS REV LETT, V56, P2797, DOI 10.1103/PhysRevLett.56.2797; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Ortner G, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.157401; Pazy E, 2004, IEEE T NANOTECHNOL, V3, P10, DOI 10.1109/TNANO.2003.820516; Press D, 2008, NATURE, V456, P218, DOI 10.1038/nature07530; Robledo L, 2008, SCIENCE, V320, P772, DOI 10.1126/science.1155374; SAUTER T, 1986, PHYS REV LETT, V57, P1696, DOI 10.1103/PhysRevLett.57.1696; Stinaff EA, 2006, SCIENCE, V311, P636, DOI 10.1126/science.1121189; Uchida M, 2010, NATURE, V464, P737, DOI 10.1038/nature08904; Vamivakas AN, 2009, NAT PHYS, V5, P198, DOI 10.1038/NPHYS1182; WU Y, 2007, PHYS REV LETT, V96; Yilmaz ST, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.033601	32	117	119	2	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2010	467	7313					297	300		10.1038/nature09359	http://dx.doi.org/10.1038/nature09359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844531				2022-12-28	WOS:000281824900032
J	Lowe, AJ; Carlin, JB; Bennett, CM; Hosking, CS; Allen, KJ; Robertson, CF; Axelrad, C; Abramson, MJ; Hill, DJ; Dharmage, SC				Lowe, Adrian J.; Carlin, John B.; Bennett, Catherine M.; Hosking, Clifford S.; Allen, Katrina J.; Robertson, Colin F.; Axelrad, Christine; Abramson, Michael J.; Hill, David J.; Dharmage, Shyamali C.			Paracetamol use in early life and asthma: prospective birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUTATHIONE LEVELS; MEDICATION USE; RISK; ACETAMINOPHEN; CHILDREN; ASSOCIATION; INFECTIONS; IBUPROFEN; DISEASE; SENSITIZATION	Objective To determine if use of paracetamol in early life is an independent risk factor for childhood asthma. Design Prospective birth cohort study. Setting Melbourne Atopy Cohort Study. Participants 620 children with a family history of allergic disease, with paracetamol use prospectively documented on 18 occasions from birth to 2 years of age, followed until age 7 years. Main outcome measures The primary outcome was childhood asthma, ascertained by questionnaire at 6 and 7 years. Secondary outcomes were infantile wheeze, allergic rhinitis, eczema, and skin prick test positivity. Results Paracetamol had been used in 51% (295/575) of children by 12 weeks of age and in 97% (556/575) by 2 years. Between 6 and 7 years, 80% (495/620) were followed up; 30% (148) had current asthma. Increasing frequency of paracetamol use was weakly associated with increased risk of childhood asthma (crude odds ratio 1.18, 95% confidence interval 1.00 to 1.39, per doubling of days of use). However, after adjustment for frequency of respiratory infections, this association essentially disappeared (odds ratio 1.08, 0.91 to 1.29). Paracetamol use for non-respiratory causes was not associated with asthma (crude odds ratio 0.95, 0.81 to 1.12). Conclusions In children with a family history of allergic diseases, no association was found between early paracetamol use and risk of subsequent allergic disease after adjustment for respiratory infections or when paracetamol use was restricted to non-respiratory tract infections. These findings suggest that early paracetamol use does not increase the risk of asthma.	[Lowe, Adrian J.; Carlin, John B.; Allen, Katrina J.; Robertson, Colin F.; Axelrad, Christine; Hill, David J.; Dharmage, Shyamali C.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Lowe, Adrian J.; Carlin, John B.; Bennett, Catherine M.; Dharmage, Shyamali C.] Univ Melbourne, Sch Pop Hlth, Ctr Mol Environm Genet & Anal Epidemiol, Carlton, Vic 3053, Australia; [Hosking, Clifford S.] John Hunter Childrens Hosp New Lambton, Dept Paediat, Newcastle, NSW 2305, Australia; [Abramson, Michael J.] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Monash University	Lowe, AJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.	lowe.adrian@gmail.com	Carlin, John/AAG-4332-2020; Allen, Katrina/I-4361-2018; Abramson, Michael/AAQ-2671-2020; Carlin, John B/B-3492-2012	Carlin, John/0000-0002-2694-9463; Allen, Katrina/0000-0002-1921-4493; Abramson, Michael/0000-0002-9954-0538; Carlin, John B/0000-0002-2694-9463; Dharmage, Shyamali/0000-0001-6063-1937; Bennett, Catherine/0000-0001-9581-1612; Lowe, Adrian/0000-0002-4691-8162	Dairy Australia; CRC for Asthma; National Health and Medical Research Council; Nestec, a subsidiary of Nestle Australia; GlaxoSmithKline; Reckitt Benckiser	Dairy Australia(Dairy Australia); CRC for Asthma(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Nestec, a subsidiary of Nestle Australia(Nestle SA); GlaxoSmithKline(GlaxoSmithKline); Reckitt Benckiser	Dairy Australia, CRC for Asthma, and VicHealth supported AJL during his PhD, when the work presented in the manuscript was first developed. AJL, SCD, and KJA are supported by the National Health and Medical Research Council. Nestec, a subsidiary of Nestle Australia, provided staff funding for the first six years of the study. The funding bodies had no role in the design, analysis, conduct, or reporting of the study. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) DJH has received support from Nestec (a subsidiary of Nestle Australia) for the submitted work; (2) within the previous 3 years, SCD has received a grant from GlaxoSmithKline for unrelated work, MJA received funding from Reckitt Benckiser for an unrelated research project, CFR is on the GlaxoSmithKline Pediatric Asthma Scientific Board, and MJA is on the GlaxoSmithKline Scientific Advisory Committee for the Australian Asthma Study, and these companies might have an interest in the submitted work; (3) all authors their spouses, partners, or children have no other financial relationships that may be relevant to the submitted work; and (4) all authors have no non-financial interests that may be relevant to the submitted work.	AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; Barr RG, 2008, LANCET, V372, P1011, DOI 10.1016/S0140-6736(08)61417-8; Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Dimova S, 2005, INT J BIOCHEM CELL B, V37, P1727, DOI 10.1016/j.biocel.2005.03.005; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Farquhar H, 2009, J ALLERGY CLIN IMMUN, V124, P649, DOI 10.1016/j.jaci.2009.07.037; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lesko SM, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.4.e39; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Lowe A, 2009, LANCET, V373, P120, DOI 10.1016/S0140-6736(09)60030-1; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; Merkus PJFM, 1996, PEDIATR PULM, V21, P383, DOI 10.1002/(SICI)1099-0496(199606)21:6<383::AID-PPUL6>3.0.CO;2-M; MICHELI L, 1994, ENVIRON HEALTH PERSP, V102, P63, DOI 10.1289/ehp.94102s963; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Perzanowski MS, 2010, THORAX, V65, P118, DOI 10.1136/thx.2009.121459; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; Rockenbauer M, 2001, EPIDEMIOLOGY, V12, P461, DOI 10.1097/00001648-200107000-00017; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5	29	73	74	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 15	2010	341								c4616	10.1136/bmj.c4616	http://dx.doi.org/10.1136/bmj.c4616			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653LV	20843914	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000282093800015
J	Spence, JD				Spence, J. David			Is there a role for revascularisation in asymptomatic carotid stenosis? No	BRITISH MEDICAL JOURNAL			English	Editorial Material							ARTERY STENOSIS; RISK PATIENTS; ENDARTERECTOMY; MICROEMBOLI; TRIAL		[Spence, J. David] Univ Western Ontario, Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, London, ON N6G 2V2, Canada	Western University (University of Western Ontario)	Spence, JD (corresponding author), Univ Western Ontario, Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, 1400 Western Rd, London, ON N6G 2V2, Canada.	dspence@robarts.ca	Spence, J. David/K-6396-2013	Spence, J. David/0000-0001-7478-1098				Abbott AL, 2009, STROKE, V40, pE573, DOI 10.1161/STROKEAHA.109.556068; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Derdeyn CP, 2007, STROKE, V38, P715, DOI 10.1161/01.STR.0000249395.98417.49; Halliday A, 2004, LANCET, V363, P1491; Markus HS, 2010, LANCET NEUROL, V9, P663, DOI 10.1016/S1474-4422(10)70120-4; Marquardt L, 2010, STROKE, V41, pE11, DOI 10.1161/STROKEAHA.109.561837; Naylor AR, 2010, EUR J VASC ENDOVASC, V39, P523, DOI 10.1016/j.ejvs.2010.03.015; Rothwell PM, 2009, LANCET NEUROL, V8, P871, DOI 10.1016/S1474-4422(09)70230-3; Spence JD, 2010, NAT REV CARDIOL, V7, P426, DOI 10.1038/nrcardio.2010.100; Spence JD, 2010, VASCULAR, V18, P123, DOI 10.2310/6670.2010.00023; Spence JD, 2010, STROKE, V41, P1193, DOI 10.1161/STROKEAHA.110.577973; Spence JD, 2010, ARCH NEUROL-CHICAGO, V67, P180, DOI 10.1001/archneurol.2009.289; Spence JD, 2005, STROKE, V36, P2373, DOI 10.1161/01.STR.0000185922.49809.46; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	14	8	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 15	2010	341								c4900	10.1136/bmj.c4900	http://dx.doi.org/10.1136/bmj.c4900			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653LV	20843933				2022-12-28	WOS:000282093800007
J	Cooper, R; Kuh, D; Hardy, R				Cooper, Rachel; Kuh, Diana; Hardy, Rebecca		FALCon Study Team; HALCyon Study Team	Objectively measured physical capability levels and mortality: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALL-CAUSE MORTALITY; LOWER-BODY FUNCTION; USUAL GAIT SPEED; GRIP STRENGTH; MUSCLE STRENGTH; OLDER-ADULTS; RISK-FACTORS; DEVELOPMENTAL ORIGINS; PERFORMANCE-MEASURES; FRAILTY INDEXES	Objective To do a quantitative systematic review, including published and unpublished data, examining the associations between individual objective measures of physical capability (grip strength, walking speed, chair rising, and standing balance times) and mortality in community dwelling populations. Design Systematic review and meta-analysis. Data sources Relevant studies published by May 2009 identified through literature searches using Embase (from 1980) and Medline (from 1950) and manual searching of reference lists; unpublished results were obtained from study investigators. Study selection Eligible observational studies were those done in community dwelling people of any age that examined the association of at least one of the specified measures of physical capability (grip strength, walking speed, chair rises, or standing balance) with mortality. Data synthesis Effect estimates obtained were pooled by using random effects meta-analysis models with heterogeneity between studies investigated. Results Although heterogeneity was detected, consistent evidence was found of associations between all four measures of physical capability and mortality; those people who performed less well in these tests were found to be at higher risk of all cause mortality. For example, the summary hazard ratio for mortality comparing the weakest with the strongest quarter of grip strength (14 studies, 53 476 participants) was 1.67 (95% confidence interval 1.45 to 1.93) after adjustment for age, sex, and body size (I-2=84.0%, 95% confidence interval 74% to 90%; P from Q statistic<0.001). The summary hazard ratio for mortality comparing the slowest with the fastest quarter of walking speed (five studies, 14 692 participants) was 2.87 (2.22 to 3.72) (I-2=25.2%, 0% to 70%; P=0.25) after similar adjustments. Whereas studies of the associations of walking speed, chair rising, and standing balance with mortality have only been done in older populations (average age over 70 years), the association of grip strength with mortality was also found in younger populations (five studies had an average age under 60 years). Conclusions Objective measures of physical capability are predictors of all cause mortality in older community dwelling populations. Such measures may therefore provide useful tools for identifying older people at higher risk of death.	[Cooper, Rachel] UCL, MRC, Unit Lifelong Hlth & Ageing, London WC1B 5JU, England; UCL, Div Populat Hlth, London WC1B 5JU, England	University of London; University College London; University of London; University College London	Cooper, R (corresponding author), UCL, MRC, Unit Lifelong Hlth & Ageing, London WC1B 5JU, England.	r.cooper@nshd.mrc.ac.uk	Cooper, Rachel/ABE-3768-2021; Hardy, Rebecca/AFR-1989-2022; Rantanen, Taina/O-6579-2016	Cooper, Rachel/0000-0003-3370-5720; Gale, Catharine/0000-0002-3361-8638; Rantanen, Taina/0000-0002-1604-1945; Muniz Terrera, Graciela/0000-0002-4516-0337; Wills, Andrew/0000-0002-9751-4707; Lawlor, Debbie A/0000-0002-6793-2262; Hardy, Rebecca/0000-0001-9949-0799	UK Medical Research Council Population Health Sciences Research Network; New Dynamics of Ageing [RES-353-25-0001]; UK Medical Research Council; National Institute on Aging, NIH; National Institutes of Health [EY03083, EY016379]; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA) [AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1]; National Center for Research Resources (NCRR); NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140]; Research to Prevent Blindness, New York, NY; Economic and Social Research Council [ES/G00773X/1] Funding Source: researchfish; Medical Research Council [MC_UP_A620_1015, UD99999932, MC_U123092721, MC_U123092724, U1475000002, G0600705] Funding Source: researchfish; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024140] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY003083, R01EY016379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR045583, U01AR045647, U01AR045614, U01AR045654, U01AR045632, U01AR045580, R01AR035583, R01AR035582, R01AR035584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005407, U01AG018197, R01AG027574, U01AG027810, R01AG005394, R01AG027576] Funding Source: NIH RePORTER; ESRC [ES/G00773X/1] Funding Source: UKRI; MRC [MC_U123092724, G0600705, MC_UP_A620_1015, MC_U123092721] Funding Source: UKRI	UK Medical Research Council Population Health Sciences Research Network(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); New Dynamics of Ageing; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute on Aging, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness, New York, NY(Research to Prevent Blindness (RPB)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This project was funded by a grant from the UK Medical Research Council Population Health Sciences Research Network. RC originally received support from this grant but is now receiving support from the HALCyon programme funded by the New Dynamics of Ageing (RES-353-25-0001). DK, RH, and Andrew KWills are supported by the UK Medical Research Council. Debbie A Lawlor also works in a centre that is supported by the UK Medical Research Council. Work was also supported in part by the Intramural Research Program, National Institute on Aging, NIH. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources (NCRR), and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. The Study of Osteoporotic Fractures (SOF) is supported by National Institutes of Health funding. The National Institute on Aging (NIA) provides support under the following grant numbers: AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, and 2 R01 AG027574-22A1. This research is also supported in part by National Institutes of Health grants EY03083 and EY016379 (Barbara E K Klein) and by the Research to Prevent Blindness (B E K Klein, senior scientific investigator award), New York, NY. The study sponsors played no role in study design; the collection, analysis, and interpretation of data; the writing of the article; or the decision to submit it for publication. The researchers have independence from their funders.	Ahmad R, 2005, J GERONTOL A-BIOL, V60, P1052, DOI 10.1093/gerona/60.8.1052; Al Snih S, 2002, J AM GERIATR SOC, V50, P1250, DOI 10.1046/j.1532-5415.2002.50312.x; Anstey KJ, 2001, PSYCHOL AGING, V16, P3, DOI 10.1037//0882-7974.16.1.3; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bergman H, 2007, J GERONTOL A-BIOL, V62, P731, DOI 10.1093/gerona/62.7.731; Bohannon Richard W, 2008, J Geriatr Phys Ther, V31, P3; Cawthon PM, 2007, J AM GERIATR SOC, V55, P1216, DOI 10.1111/j.1532-5415.2007.01259.x; Cesari M, 2005, J AM GERIATR SOC, V53, P1675, DOI 10.1111/j.1532-5415.2005.53501.x; Cesari Matteo, 2008, BMC Geriatr, V8, P34, DOI 10.1186/1471-2318-8-34; Cesari M, 2009, J AM GERIATR SOC, V57, P251, DOI 10.1111/j.1532-5415.2008.02126.x; COOPER R, AGE AGEING IN PRESS; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ensrud KE, 2008, ARCH INTERN MED, V168, P382, DOI 10.1001/archinternmed.2007.113; Ensrud KE, 2009, J AM GERIATR SOC, V57, P492, DOI 10.1111/j.1532-5415.2009.02137.x; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; FUJITA Y, 1995, J CLIN EPIDEMIOL, V48, P1349, DOI 10.1016/0895-4356(95)00533-1; Gale CR, 2007, INT J EPIDEMIOL, V36, P228, DOI 10.1093/ije/dyl224; Galobardes B, 2006, ANN EPIDEMIOL, V16, P91, DOI 10.1016/j.annepidem.2005.06.053; Guralnik JM, 2006, J GERONTOL A-BIOL, V61, P694, DOI 10.1093/gerona/61.7.694; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hardy SE, 2008, J AM GERIATR SOC, V56, P1910, DOI 10.1111/j.1532-5415.2008.01957.x; Hardy SE, 2007, J AM GERIATR SOC, V55, P1727, DOI 10.1111/j.1532-5415.2007.01413.x; Harwood RH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4236; Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2008, INT J EPIDEMIOL, V37, P1158, DOI 10.1093/ije/dyn204; Ioannidis JPA, 2008, BMJ-BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117; Katzmarzyk PT, 2002, MED SCI SPORT EXER, V34, P740, DOI 10.1097/00005768-200205000-00002; Klein BEK, 2005, ARCH GERONTOL GERIAT, V41, P141, DOI 10.1016/j.archger.2005.01.002; Kuh D, 2005, J GERONTOL A-BIOL, V60, P224, DOI 10.1093/gerona/60.2.224; Kuh D, 2007, J GERONTOL A-BIOL, V62, P717, DOI 10.1093/gerona/62.7.717; Kuh D, 2006, J GERONTOL A-BIOL, V61, P702, DOI 10.1093/gerona/61.7.702; Kuh D, 2006, AM J EPIDEMIOL, V164, P110, DOI 10.1093/aje/kwj193; LAUKKANEN P, 1995, AGE AGEING, V24, P468, DOI 10.1093/ageing/24.6.468; Markides KS, 2001, J GERONTOL A-BIOL, V56, pM243, DOI 10.1093/gerona/56.4.M243; Metter EJ, 2002, J GERONTOL A-BIOL, V57, pB359, DOI 10.1093/gerona/57.10.B359; MILNE JS, 1984, AGE AGEING, V13, P42, DOI 10.1093/ageing/13.1.42; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Newman AB, 2006, J GERONTOL A-BIOL, V61, P72, DOI 10.1093/gerona/61.1.72; Ostir GV, 2007, AM J EPIDEMIOL, V166, P599, DOI 10.1093/aje/kwm121; *OTT HOSP RES I, 2009, NEWC OTT QUAL ASS SC; Penninx BWJH, 2000, J GERONTOL A-BIOL, V55, pM691, DOI 10.1093/gerona/55.11.M691; Perera S, 2005, J GERONTOL A-BIOL, V60, P894, DOI 10.1093/gerona/60.7.894; Rantanen T, 2000, J GERONTOL A-BIOL, V55, pM168, DOI 10.1093/gerona/55.3.M168; Rantanen T, 2003, SCAND J MED SCI SPOR, V13, P3, DOI 10.1034/j.1600-0838.2003.00298.x; Rolland Y, 2006, EUR J EPIDEMIOL, V21, P113, DOI 10.1007/s10654-005-5458-x; Rosano C, 2008, J AM GERIATR SOC, V56, P1618, DOI 10.1111/j.1532-5415.2008.01856.x; Rothman MD, 2008, J AM GERIATR SOC, V56, P2211, DOI 10.1111/j.1532-5415.2008.02008.x; Rucker G, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-79; Sasaki H, 2007, AM J MED, V120, P337, DOI 10.1016/j.amjmed.2006.04.018; Sayer AA, 2004, J GERONTOL A-BIOL, V59, P930, DOI 10.1093/gerona/59.9.M930; SHIBATA H, 1992, ARCH GERONTOL GERIAT, V14, P283, DOI 10.1016/0167-4943(92)90028-3; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Syddall H, 2003, AGE AGEING, V32, P650, DOI 10.1093/ageing/afg111; Takata Y, 2007, J GERONTOL A-BIOL, V62, P851, DOI 10.1093/gerona/62.8.851; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Turrell G, 2007, J EPIDEMIOL COMMUN H, V61, P723, DOI 10.1136/jech.2006.050609; van den Beld AW, 2005, J CLIN ENDOCR METAB, V90, P6403, DOI 10.1210/jc.2005-0872; Walston J, 2006, J AM GERIATR SOC, V54, P991, DOI 10.1111/j.1532-5415.2006.00745.x; Willcox BJ, 2006, JAMA-J AM MED ASSOC, V296, P2343, DOI 10.1001/jama.296.19.2343; Woo J, 1999, J AM GERIATR SOC, V47, P1257, DOI 10.1111/j.1532-5415.1999.tb05209.x	66	677	685	4	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2010	341								c4467	10.1136/bmj.c4467	http://dx.doi.org/10.1136/bmj.c4467			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZK	20829298	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000281815100001
J	Quanstrum, KH; Hayward, RA				Quanstrum, Kerianne H.; Hayward, Rodney A.			Lessons from the Mammography Wars	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BREAST-CANCER; PREVENTION		[Quanstrum, Kerianne H.; Hayward, Rodney A.] Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA; [Quanstrum, Kerianne H.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Hayward, Rodney A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Hayward, Rodney A.] VA Ann Arbor Healthcare Syst, VA Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs VA, Ann Arbor, MI USA	Robert Wood Johnson Foundation (RWJF); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Quanstrum, KH (corresponding author), Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA.							Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; BRYNER J, NEW MAMMOGRAM GUIDEL; Calonge N, 2009, ANN INTERN MED, V151, P716, DOI 10.7326/0003-4819-151-10-200911170-00008; Hayward RA, 2005, HEALTH AFFAIR, V24, P1571, DOI 10.1377/hlthaff.24.6.1571; Hayward RA, 2010, ANN INTERN MED, V152, P69, DOI 10.7326/0003-4819-152-2-201001190-00004; Lee CH, 2010, J AM COLL RADIOL, V7, P18, DOI 10.1016/j.jacr.2009.09.022; Nelson HD, 2009, ANN INTERN MED, V151, P727, DOI 10.7326/0003-4819-151-10-200911170-00009; SMITH A, 1911, WEALTH NATIONS 1, P207; Vickers AJ, 2010, SEMIN ONCOL, V37, P31, DOI 10.1053/j.seminoncol.2009.12.004; WALKER EP, USPSTF MEMBERS DEFEN; Zulman DM, 2008, MILBANK Q, V86, P557, DOI 10.1111/j.1468-0009.2008.00534.x	11	89	89	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1076	1079		10.1056/NEJMsb1002538	http://dx.doi.org/10.1056/NEJMsb1002538			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647HS	20825322				2022-12-28	WOS:000281609700014
J	Zenilman, A				Zenilman, Ariela			The Hands That Guide Me	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												azenilm1@binghamton.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1049	1049		10.1001/jama.2010.1291	http://dx.doi.org/10.1001/jama.2010.1291			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823426				2022-12-28	WOS:000281559800001
J	DiCarlo, L; Reed, MD; Sun, L; Johnson, BR; Chow, JM; Gambetta, JM; Frunzio, L; Girvin, SM; Devoret, MH; Schoelkopf, RJ				DiCarlo, L.; Reed, M. D.; Sun, L.; Johnson, B. R.; Chow, J. M.; Gambetta, J. M.; Frunzio, L.; Girvin, S. M.; Devoret, M. H.; Schoelkopf, R. J.			Preparation and measurement of three-qubit entanglement in a superconducting circuit	NATURE			English	Article							HORNE-ZEILINGER ENTANGLEMENT; QUBITS; INEQUALITY; VIOLATION; PHOTON; STATES	Traditionally, quantum entanglement has been central to foundational discussions of quantum mechanics. The measurement of correlations between entangled particles can have results at odds with classical behaviour. These discrepancies grow exponentially with the number of entangled particles(1). With the ample experimental(2-4) confirmation of quantum mechanical predictions, entanglement has evolved from a philosophical conundrum into a key resource for technologies such as quantum communication and computation(5). Although entanglement in superconducting circuits has been limited so far to two qubits(6-9), the extension of entanglement to three, eight and ten qubits has been achieved among spins(10), ions(11) and photons(12), respectively. A key question for solid-state quantum information processing is whether an engineered system could display the multi-qubit entanglement necessary for quantum error correction, which starts with tripartite entanglement. Here, using a circuit quantum electrodynamics architecture(13,14), we demonstrate deterministic production of three-qubit Greenberger-Horne-Zeilinger (GHZ) states(15) with fidelity of 88 per cent, measured with quantum state tomography. Several entanglement witnesses detect genuine three-qubit entanglement by violating biseparable bounds by 830 +/- 80 per cent. We demonstrate the first step of basic quantum error correction, namely the encoding of a logical qubit into a manifold of GHZ-like states using a repetition code. The integration of this encoding with decoding and error-correcting steps in a feedback loop will be the next step for quantum computing with integrated circuits.	[DiCarlo, L.; Reed, M. D.; Sun, L.; Johnson, B. R.; Chow, J. M.; Frunzio, L.; Girvin, S. M.; Devoret, M. H.; Schoelkopf, R. J.] Yale Univ, Dept Phys & Appl Phys, New Haven, CT 06511 USA; [Gambetta, J. M.] Univ Waterloo, Dept Phys & Astron, Waterloo, ON N2L 3G1, Canada; [Gambetta, J. M.] Univ Waterloo, Inst Quantum Comp, Waterloo, ON N2L 3G1, Canada	Yale University; University of Waterloo; University of Waterloo	DiCarlo, L (corresponding author), Yale Univ, Dept Phys & Appl Phys, New Haven, CT 06511 USA.	leonardo.dicarlo@yale.edu; robert.schoelkopf@yale.edu	DiCarlo, Leonardo/F-8714-2010; Schoelkopf, Robert J/J-8178-2012; Frunzio, Luigi/O-1573-2019	Frunzio, Luigi/0000-0002-0272-5481; Sun, Luyan/0000-0003-4419-5674	LPS/NSA [W911NF-05-1-0365]; IARPA [W911NF-09-1-0369]; NSF [DMR-0653377, DMR-0603369]; CNR-Istituto di Cibernetica, Pozzuoli, Italy; CIFAR; MITACS; MRI; NSERC	LPS/NSA(National Security Agency); IARPA; NSF(National Science Foundation (NSF)); CNR-Istituto di Cibernetica, Pozzuoli, Italy; CIFAR(Canadian Institute for Advanced Research (CIFAR)); MITACS; MRI; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	We thank M. Brink for experimental contributions, and L. S. Bishop, E. Ginossar, O. Guhne, C. Rigetti, D. I. Schuster and J. Siewert for discussions. We acknowledge support from LPS/NSA under ARO contract W911NF-05-1-0365, from IARPA under ARO contract W911NF-09-1-0369 and from the NSF under grants DMR-0653377 and DMR-0603369. Additional support was provided by CNR-Istituto di Cibernetica, Pozzuoli, Italy (L.F.), and by CIFAR, MITACS, MRI and NSERC (J.M.G.). All statements of fact, opinion or conclusions contained herein are those of the authors and should not be construed as representing the official views or policies of the US Government.	Acin A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.040401; ALTOMARE F, 2010, TRIPARTITE INTERACTI; Ansmann M, 2009, NATURE, V461, P504, DOI 10.1038/nature08363; ASPECT A, 1982, PHYS REV LETT, V49, P1804, DOI 10.1103/PhysRevLett.49.1804; Bishop LS, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.100505; Blais A, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.062320; Clarke J, 2008, NATURE, V453, P1031, DOI 10.1038/nature07128; DiCarlo L, 2009, NATURE, V460, P240, DOI 10.1038/nature08121; Filipp S, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.200402; Gao WB, 2010, NAT PHYS, V6, P331, DOI 10.1038/NPHYS1603; Haffner H, 2005, NATURE, V438, P643, DOI 10.1038/nature04279; Houck AA, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.080502; Koch J, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.042319; KWIAT PG, 1994, PHYS REV A, V49, P3209, DOI 10.1103/PhysRevA.49.3209; Majer J, 2007, NATURE, V449, P443, DOI 10.1038/nature06184; MERMIN ND, 1990, PHYS REV LETT, V65, P1838, DOI 10.1103/PhysRevLett.65.1838; Neumann P, 2008, SCIENCE, V320, P1326, DOI 10.1126/science.1157233; Nielsen Michael A., 2002, QUANTUM COMPUTATION; REED MD, 2010, PHYS REV LE IN PRESS; Schreier JA, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.180502; Schuster DI, 2007, NATURE, V445, P515, DOI 10.1038/nature05461; Steffen M, 2006, SCIENCE, V313, P1423, DOI 10.1126/science.1130886; Strauch FW, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.167005; Toth G, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.022340; Wallraff A, 2004, NATURE, V431, P162, DOI 10.1038/nature02851; Zhao Z, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.180401	29	440	451	2	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					574	578		10.1038/nature09416	http://dx.doi.org/10.1038/nature09416			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882013	Green Submitted			2022-12-28	WOS:000282273100035
J	Liao, YA; Rittner, ASC; Paprotta, T; Li, WH; Partridge, GB; Hulet, RG; Baur, SK; Mueller, EJ				Liao, Yean-an; Rittner, Ann Sophie C.; Paprotta, Tobias; Li, Wenhui; Partridge, Guthrie B.; Hulet, Randall G.; Baur, Stefan K.; Mueller, Erich J.			Spin-imbalance in a one-dimensional Fermi gas	NATURE			English	Article							DELTA-FUNCTION INTERACTION; PHASE-SEPARATION; SUPERCONDUCTIVITY	Superconductivity and magnetism generally do not coexist. Changing the relative number of up and down spin electrons disrupts the basic mechanism of superconductivity, where atoms of opposite momentum and spin form Cooper pairs. Nearly forty years ago Fulde and Ferrell(1) and Larkin and Ovchinnikov(2) (FFLO) proposed an exotic pairing mechanism in which magnetism is accommodated by the formation of pairs with finite momentum. Despite intense theoretical and experimental efforts, however, polarized superconductivity remains largely elusive(3). Unlike the three-dimensional (3D) case, theories predict that in one dimension (1D) a state with FFLO correlations occupies a major part of the phase diagram(4-12). Here we report experimental measurements of density profiles of a two-spin mixture of ultracold Li-6 atoms trapped in an array of 1D tubes (a system analogous to electrons in 1D wires). At finite spin imbalance, the system phase separates with an inverted phase profile, as compared to the 3D case. In 1D, we find a partially polarized core surrounded by wings which, depending on the degree of polarization, are composed of either a completely paired or a fully polarized Fermi gas. Our work paves the way to direct observation and characterization of FFLO pairing.	[Liao, Yean-an; Rittner, Ann Sophie C.; Paprotta, Tobias; Li, Wenhui; Partridge, Guthrie B.; Hulet, Randall G.] Rice Univ, Dept Phys & Astron, Houston, TX 77251 USA; [Liao, Yean-an; Rittner, Ann Sophie C.; Paprotta, Tobias; Li, Wenhui; Partridge, Guthrie B.; Hulet, Randall G.] Rice Univ, Rice Quantum Inst, Houston, TX 77251 USA; [Baur, Stefan K.; Mueller, Erich J.] Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; [Li, Wenhui] Natl Univ Singapore, Ctr Quantum Technol, Singapore 117543, Singapore	Rice University; Rice University; Cornell University; National University of Singapore	Hulet, RG (corresponding author), Rice Univ, Dept Phys & Astron, Houston, TX 77251 USA.	randy@rice.edu	Li, Wenhui/A-6406-2009	Li, Wenhui/0000-0001-9976-6871; Hulet, Randall/0000-0001-7045-8947; Mueller, Erich/0000-0001-5186-5889	DARPAOLE programme [W911NF-07-1-0464]; NSF; ONR; Welch Foundation [C-1133]; Keck Foundation	DARPAOLE programme; NSF(National Science Foundation (NSF)); ONR(Office of Naval Research); Welch Foundation(The Welch Foundation); Keck Foundation(W.M. Keck Foundation)	We thank S. E. Pollack for providing software to remove fringes from the images and M. Revelle for help on the experiment. E.J.M. would like to thank C. Bolech and P. Kakashvili for discussion of techniques for analysing the data. This work was supported under ARO Award W911NF-07-1-0464 with funds from the DARPAOLE programme, and by the NSF, the ONR, the Welch Foundation (grant C-1133) and the Keck Foundation.	Bartenstein M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.103201; Baur SK, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.033628; Bergeman T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.163201; Blume D, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.013601; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; Bulgac A, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.215301; Casalbuoni R, 2004, REV MOD PHYS, V76, P263, DOI 10.1103/RevModPhys.76.263; Casula M, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.033607; Feiguin AE, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.220508; Fuchs JN, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.090408; FULDE P, 1964, PHYS REV, V135, pA550, DOI 10.1103/PhysRev.135.A550; GAUDIN M, 1967, PHYS LETT A, VA 24, P55, DOI 10.1016/0375-9601(67)90193-4; Guan XW, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.085120; Heidrich-Meisner F, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.023629; Houbiers M, 1998, PHYS REV A, V57, pR1497, DOI 10.1103/PhysRevA.57.R1497; Hu H, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.070403; Kakashvili P, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.041603; Kenzelmann M, 2008, SCIENCE, V321, P1652, DOI 10.1126/science.1161818; Kinast J, 2005, SCIENCE, V307, P1296, DOI 10.1126/science.1109220; LARKIN AI, 1965, SOV PHYS JETP, V20, P762; Liu XJ, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.023601; Mizushima T, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.060404; Mora C, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.170403; Moritz H, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.210401; Nascimbene S, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.170402; Orso G, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.070402; Parish MM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.250403; Partridge GB, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.190407; Partridge GB, 2006, SCIENCE, V311, P503, DOI 10.1126/science.1122876; Radovan HA, 2003, NATURE, V425, P51, DOI 10.1038/nature01842; Sheehy DE, 2007, ANN PHYS-NEW YORK, V322, P1790, DOI 10.1016/j.aop.2006.09.009; Shin YI, 2008, NATURE, V451, P689, DOI 10.1038/nature06473; TAKAHASHI M, 1971, PROG THEOR PHYS, V46, P1388, DOI 10.1143/PTP.46.1388; Tokatly IV, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.090405; Uji S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.157001; YANG CN, 1967, PHYS REV LETT, V19, P1312, DOI 10.1103/PhysRevLett.19.1312; Yang K, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.140511; Zhao E, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.140404; Zhao E, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.063605; Zwierlein MW, 2006, SCIENCE, V311, P492, DOI 10.1126/science.1122318	40	419	423	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					567	U86		10.1038/nature09393	http://dx.doi.org/10.1038/nature09393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882011	Green Submitted			2022-12-28	WOS:000282273100033
J	Tausche, AK; Panzner, I; Aust, D; Wunderlich, C				Tausche, A. K.; Panzner, I.; Aust, D.; Wunderlich, C.			Disabling gout	LANCET			English	Editorial Material									[Tausche, A. K.] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Sect Endocrinol & Rheumatol, Dept Internal Med, D-01307 Dresden, Germany; [Panzner, I.] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Orthopaed, D-01307 Dresden, Germany; [Aust, D.] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Pathol, D-01307 Dresden, Germany; [Wunderlich, C.] Tech Univ Dresden, Univ Clin Carl Gustav Carus, Dept Cardiol, D-01307 Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Tausche, AK (corresponding author), Tech Univ Dresden, Univ Clin Carl Gustav Carus, Sect Endocrinol & Rheumatol, Dept Internal Med, Fetscherstasse 74, D-01307 Dresden, Germany.	anne-kathrin.tausche@uniklinikum-dresden.de							0	6	7	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP-OCT	2010	376	9746					1093	1093		10.1016/S0140-6736(10)60135-3	http://dx.doi.org/10.1016/S0140-6736(10)60135-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657KM	20843547				2022-12-28	WOS:000282411600036
J	Schramek, D; Leibbrandt, A; Sigl, V; Kenner, L; Pospisilik, JA; Lee, HJ; Hanada, R; Joshi, PA; Aliprantis, A; Glimcher, L; Pasparakis, M; Khokha, R; Ormandy, CJ; Widschwendter, M; Schett, G; Penninger, JM				Schramek, Daniel; Leibbrandt, Andreas; Sigl, Verena; Kenner, Lukas; Pospisilik, John A.; Lee, Heather J.; Hanada, Reiko; Joshi, Purna A.; Aliprantis, Antonios; Glimcher, Laurie; Pasparakis, Manolis; Khokha, Rama; Ormandy, Christopher J.; Widschwendter, Martin; Schett, Georg; Penninger, Josef M.			Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer	NATURE			English	Article							HORMONE-REPLACEMENT THERAPY; ESTROGEN-PLUS-PROGESTIN; STEM-CELL; POSTMENOPAUSAL WOMEN; EPITHELIAL-CELLS; MEDROXYPROGESTERONE ACETATE; OSTEOPROTEGERIN-LIGAND; RECEPTOR ACTIVATOR; GLAND DEVELOPMENT; BONE METASTASIS	Breast cancer is one of the most common cancers in humans and will on average affect up to one in eight women in their lifetime in the United States and Europe(1). The Women's Health Initiative and the Million Women Study have shown that hormone replacement therapy is associated with an increased risk of incident and fatal breast cancer(2,3). In particular, synthetic progesterone derivatives (progestins) such as medroxyprogesterone acetate (MPA), used in millions of women for hormone replacement therapy and contraceptives, markedly increase the risk of developing breast cancer. Here we show that the in vivo administration of MPA triggers massive induction of the key osteoclast differentiation factor RANKL (receptor activator of NF-kappa B ligand) in mammary-gland epithelial cells. Genetic inactivation of the RANKL receptor RANK in mammary-gland epithelial cells prevents MPA-induced epithelial proliferation, impairs expansion of the CD49f(hi) stem-cell-enriched population, and sensitizes these cells to DNA-damage-induced cell death. Deletion of RANK from the mammary epithelium results in a markedly decreased incidence and delayed onset of MPA-driven mammary cancer. These data show that the RANKL/RANK system controls the incidence and onset of progestin-driven breast cancer.	[Schramek, Daniel; Leibbrandt, Andreas; Sigl, Verena; Pospisilik, John A.; Hanada, Reiko; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria; [Kenner, Lukas] Med Univ Vienna, A-1090 Vienna, Austria; [Lee, Heather J.; Ormandy, Christopher J.] Garvan Inst Med Res, Sydney, NSW 2010, Australia; [Joshi, Purna A.; Khokha, Rama] Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; [Aliprantis, Antonios; Glimcher, Laurie] Harvard Univ, Sch Med, Dept Med, Sch Publ Hlth,Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Aliprantis, Antonios; Glimcher, Laurie] MGH MIT, Ragon Inst, Boston, MA 02115 USA; [Pasparakis, Manolis] Univ Cologne, Ctr Mol Med CMMC, Inst Genet, D-50674 Cologne, Germany; [Pasparakis, Manolis] Univ Cologne, Cologne Excellence Cluster CECAD, D-50674 Cologne, Germany; [Widschwendter, Martin] UCL, Dept Gynaecol Oncol, London WC1E 6AU, England; [Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Medical University of Vienna; Garvan Institute of Medical Research; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; University of Cologne; University of Cologne; University of London; University College London; University of Erlangen Nuremberg	Penninger, JM (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria.	josef.penninger@imba.oeaw.ac.at	Pasparakis, Manolis/N-4350-2019; Lee, Heather/M-2670-2019; Ormandy, Chris/G-4165-2014; Schramek, Daniel/J-5792-2014; Lee, Heather/B-5302-2012; Penninger, Josef M/I-6860-2013; Schramek, Daniel/AAL-1470-2020; Pasparakis, Manolis/H-9292-2017	Pasparakis, Manolis/0000-0002-9870-0966; Lee, Heather/0000-0002-6482-0337; Penninger, Josef M/0000-0002-8194-3777; Schramek, Daniel/0000-0001-9977-2104; Pasparakis, Manolis/0000-0002-9870-0966; Widschwendter, Martin/0000-0002-7778-8380; Ormandy, Christopher/0000-0002-2504-7919; Kenner, Lukas/0000-0003-2184-1338; Joshi, Purna/0000-0002-1628-9940	Burroughs Wellcome Fund; National Institutes of Health (NIH) [HD055601]; German Research Council (Deutsche Forschungsgemeinschaft (DFG)) [FOR643, SFB641, SPP1468]; Interdisciplinary Center for Clinical Sciences Erlangen; European Union (EU); National Health and Medical Research Council of Australia; Australian Cancer Research Fund; Cancer Institute New South Wales; EU InflaCare network; University College London (UCL) Hospital/UCL Comprehensive Biomedical Research Centre [152]; Department of Health National Institute for Health Research Biomedical Research Centres; Institute of Molecular Biotechnology; Austrian Ministry of Sciences; Austrian Academy of Sciences; GEN-AU (AustroMouse); European Research Council; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD055601] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Council (Deutsche Forschungsgemeinschaft (DFG))(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Sciences Erlangen; European Union (EU)(CGIAREuropean Commission); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Cancer Research Fund; Cancer Institute New South Wales; EU InflaCare network; University College London (UCL) Hospital/UCL Comprehensive Biomedical Research Centre; Department of Health National Institute for Health Research Biomedical Research Centres(National Institute for Health Research (NIHR)); Institute of Molecular Biotechnology; Austrian Ministry of Sciences; Austrian Academy of Sciences; GEN-AU (AustroMouse); European Research Council(European Research Council (ERC)European Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank all members of our laboratories for helpful discussions; G. Forni for providing NeuT transgenic mice. A.O.A. is a recipient of a Career Award for Medical Scientists from the Burroughs Wellcome Fund. L.G. is supported by National Institutes of Health (NIH) grant HD055601. G.S's work is supported by the German Research Council (Deutsche Forschungsgemeinschaft (DFG): FOR643, SFB641 and SPP1468), by the Interdisciplinary Center for Clinical Sciences Erlangen and by the focus programme SPP1468 (Immunobone) of the DFG and the Masterswitch project of the European Union (EU). C.J.O. is supported by the National Health and Medical Research Council of Australia, the Australian Cancer Research Fund and the Cancer Institute New South Wales. D.S. is supported by the EU InflaCare network. M.W. is supported by a grant from the University College London (UCL) Hospital/UCL Comprehensive Biomedical Research Centre project no. 152, and part of this work was undertaken at UCL Hospital/UCL, which received a proportion of its funding from the Department of Health National Institute for Health Research Biomedical Research Centres funding scheme. J.M.P. is supported by grants from Institute of Molecular Biotechnology, the Austrian Ministry of Sciences, the Austrian Academy of Sciences, GEN-AU (AustroMouse), an EU Marie Curie Excellence Grant, and a European Research Council Advanced Grant. Special thanks go to Limin Zhang, who provided a first idea for this manuscript and died much too early of breast cancer.	Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; ELMAHGOUB S, 1972, ACTA OBSTET GYN SCAN, V51, P251, DOI 10.3109/00016347209156855; Ewan KB, 2002, CANCER RES, V62, P5627; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gareus R, 2007, NAT CELL BIOL, V9, P461, DOI 10.1038/ncb1560; Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kim NS, 2006, MOL CELL BIOL, V26, P1002, DOI 10.1128/MCB.26.3.1002-1013.2006; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood-2005-07-2798; McTiernan A, 2005, JNCI-J NATL CANCER I, V97, P1366, DOI 10.1093/jnci/dji279; Morony S, 2001, CANCER RES, V61, P4432; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Robinson GW, 1997, DEVELOPMENT, V124, P2701; Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Srivastava S, 2003, J BIOL CHEM, V278, P46171, DOI 10.1074/jbc.M308545200; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007	41	413	437	0	55	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					98	+		10.1038/nature09387	http://dx.doi.org/10.1038/nature09387			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	20881962	Green Accepted			2022-12-28	WOS:000283786900043
J	Nogi, T; Yasui, N; Mihara, E; Matsunaga, Y; Noda, M; Yamashita, N; Toyofuku, T; Uchiyama, S; Goshima, Y; Kumanogoh, A; Takagi, J				Nogi, Terukazu; Yasui, Norihisa; Mihara, Emiko; Matsunaga, Yukiko; Noda, Masanori; Yamashita, Naoya; Toyofuku, Toshihiko; Uchiyama, Susumu; Goshima, Yoshio; Kumanogoh, Atsushi; Takagi, Junichi			Structural basis for semaphorin signalling through the plexin receptor	NATURE			English	Article							CRYSTAL-STRUCTURE; PROTEIN; BINDING; LIGAND; RESOLUTION; COMPLEX; DOMAIN; MET	Semaphorins and their receptor plexins constitute a pleiotropic cell-signalling system that is used in a wide variety of biological processes, and both protein families have been implicated in numerous human diseases(1-4). The binding of soluble or membrane-anchored semaphorins to the membrane-distal region of the plexin ecto-domain activates plexin's intrinsic GTPase-activating protein (GAP) at the cytoplasmic region, ultimately modulating cellular adhesion behaviour(5). However, the structural mechanism underlying the receptor activation remains largely unknown. Here we report the crystal structures of the semaphorin 6A (Sema6A) receptor-binding fragment and the plexin A2 (PlxnA2) ligand-binding fragment in both their pre-signalling (that is, before binding) and signalling (after complex formation) states. Before binding, the Sema6A ectodomain was in the expected 'face-to-face' homodimer arrangement, similar to that adopted by Sema3A and Sema4D, whereas PlxnA2 was in an unexpected 'head-on' homodimer arrangement. In contrast, the structure of the Sema6A-PlxnA2 signalling complex revealed a 2:2 heterotetramer in which the two PlxnA2 monomers dissociated from one another and docked onto the top face of the Sema6A homodimer using the same interface as the head-on homodimer, indicating that plexins undergo 'partner exchange'. Cell-based activity measurements using mutant ligands/receptors confirmed that the Sema6A face-to-face dimer arrangement is physiologically relevant and is maintained throughout signalling events. Thus, homodimer-to-heterodimer transitions of cell-surface plexin that result in a specific orientation of its molecular axis relative to the membrane may constitute the structural mechanism by which the ligand-binding 'signal' is transmitted to the cytoplasmic region, inducing GAP domain rearrangements and activation.	[Nogi, Terukazu; Yasui, Norihisa; Mihara, Emiko; Matsunaga, Yukiko; Takagi, Junichi] Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, Suita, Osaka 5650871, Japan; [Noda, Masanori; Uchiyama, Susumu] Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan; [Yamashita, Naoya; Goshima, Yoshio] Yokohama City Univ, Grad Sch Med, Dept Mol Pharmacol & Neurobiol, Yokohama, Kanagawa 2360004, Japan; [Toyofuku, Toshihiko; Kumanogoh, Atsushi] Osaka Univ, Microbial Dis Res Inst, Immunol Frontier Res Ctr, Dept Immunopathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Yokohama City University; Osaka University	Takagi, J (corresponding author), Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	takagi@protein.osaka-u.ac.jp	Yasui, Norihisa/V-8252-2019; UCHIYAMA, Susumu/F-9590-2017; Nogi, Terukazu/GPF-7203-2022	Yasui, Norihisa/0000-0001-7117-3070; UCHIYAMA, Susumu/0000-0002-5181-179X; Nogi, Terukazu/0000-0001-8663-3519; Matsunaga, Yukiko/0000-0002-1392-5681	Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)	Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We would like to thank Y. Yamada, N. Matsugaki and N. Igarashi of Photon Factory and Y. Kawano and N. Shimizu of SPring-8 BL-41XU for their help with the X-ray data collection; A. Rowe for discussions on the sedimentation equilibrium data analysis; C. Wu for performing the Sema6A-AP binding assay; K. Tamura-Kawakami and M. Nampo for their technical support; and M. Nakano for preparation of the manuscript. This work was supported in part by a 'Target Proteins Research Program (TPRP)' grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT).	Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Chaudhry C, 2009, EMBO J, V28, P1518, DOI 10.1038/emboj.2009.86; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goshima Y, 1997, J NEUROBIOL, V33, P316, DOI 10.1002/(SICI)1097-4695(199709)33:3<316::AID-NEU9>3.0.CO;2-4; He HW, 2009, P NATL ACAD SCI USA, V106, P15610, DOI 10.1073/pnas.0906923106; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liu HL, 2010, CELL, V142, P749, DOI 10.1016/j.cell.2010.07.040; Love CA, 2003, NAT STRUCT BIOL, V10, P843, DOI 10.1038/nsb977; Luo BH, 2006, CURR OPIN CELL BIOL, V18, P579, DOI 10.1016/j.ceb.2006.08.005; Merte J, 2010, J NEUROSCI, V30, P5767, DOI 10.1523/JNEUROSCI.5061-09.2010; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Niemann HH, 2007, CELL, V130, P235, DOI 10.1016/j.cell.2007.05.037; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasterkamp RJ, 2005, TRENDS CELL BIOL, V15, P61, DOI 10.1016/j.tcb.2004.12.005; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Renaud J, 2008, NAT NEUROSCI, V11, P440, DOI 10.1038/nn2064; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Suto F, 2005, J NEUROSCI, V25, P3628, DOI 10.1523/JNEUROSCI.4480-04.2005; Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553; Tabata S, 2010, J PROTEOMICS, V73, P1777, DOI 10.1016/j.jprot.2010.05.012; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Tong YF, 2009, J BIOL CHEM, V284, P35962, DOI 10.1074/jbc.M109.056275; Toyofuku T, 2008, DEV BIOL, V321, P251, DOI 10.1016/j.ydbio.2008.06.028; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Xu XM, 2000, J NEUROSCI, V20, P2638; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006	42	116	129	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2010	467	7319					1123	U138		10.1038/nature09473	http://dx.doi.org/10.1038/nature09473			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20881961				2022-12-28	WOS:000283548600051
J	Rosenberg, S; Elashoff, MR; Beineke, P; Daniels, SE; Wingrove, JA; Tingley, WG; Sager, PT; Sehnert, AJ; Yau, M; Kraus, WE; Newby, LK; Schwartz, RS; Voros, S; Ellis, SG; Tahirkheli, N; Waksman, R; McPherson, J; Lansky, A; Winn, ME; Schork, NJ; Topol, EJ				Rosenberg, Steven; Elashoff, Michael R.; Beineke, Philip; Daniels, Susan E.; Wingrove, James A.; Tingley, Whittemore G.; Sager, Philip T.; Sehnert, Amy J.; Yau, May; Kraus, William E.; Newby, L. Kristin; Schwartz, Robert S.; Voros, Szilard; Ellis, Stephen G.; Tahirkheli, Naeem; Waksman, Ron; McPherson, John; Lansky, Alexandra; Winn, Mary E.; Schork, Nicholas J.; Topol, Eric J.		PREDICT Investigators	Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients	ANNALS OF INTERNAL MEDICINE			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR RISK; CELL SUBTYPES; PREDICTION; RECLASSIFICATION; STATISTICS	Background: Diagnosing obstructive coronary artery disease (CAD) in at-risk patients can be challenging and typically requires both noninvasive imaging methods and coronary angiography, the gold standard. Previous studies have suggested that peripheral blood gene expression can indicate the presence of CAD. Objective: To validate a previously developed 23-gene, expression-based classification test for diagnosis of obstructive CAD in nondiabetic patients. Design: Multicenter prospective trial with blood samples obtained before coronary angiography. (ClinicalTrials.gov registration number: NCT00500617) Setting: 39 centers in the United States. Patients: An independent validation cohort of 526 nondiabetic patients with a clinical indication for coronary angiography. Measurements: Receiver-operating characteristic (ROC) analysis of classifier score measured by real-time polymerase chain reaction, additivity to clinical factors, and reclassification of patient disease likelihood versus disease status defined by quantitative coronary angiography. Obstructive CAD was defined as 50% or greater stenosis in 1 or more major coronary arteries by quantitative coronary angiography. Results: The area under the ROC curve (AUC) was 0.70 +/- 0.02 (P < 0.001); the test added to clinical variables (Diamond-Forrester method) (AUC, 0.72 with the test vs. 0.66 without; P = 0.003) and added somewhat to an expanded clinical model (AUC, 0.745 with the test vs. 0.732 without; P = 0.089). The test improved net reclassification over both the Diamond-Forrester method and the expanded clinical model (P < 0.001). At a score threshold that corresponded to a 20% likelihood of obstructive CAD (14.75), the sensitivity and specificity were 85% and 43% (yielding a negative predictive value of 83% and a positive predictive value of 46%), with 33% of patient scores below this threshold. Limitation: Patients with chronic inflammatory disorders, elevated levels of leukocytes or cardiac protein markers, or diabetes were excluded. Conclusion: A noninvasive whole-blood test based on gene expression and demographic characteristics may be useful for assessing obstructive CAD in nondiabetic patients without known CAD.	[Topol, Eric J.] Scripps Translat Sci Inst, La Jolla, CA 92037 USA; CardioDx, Palo Alto, CA USA; Duke Univ, Sch Med, Durham, NC USA; Minneapolis Heart Inst & Fdn, Minneapolis, MN USA; Piedmont Heart Inst, Atlanta, GA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Oklahoma Cardiovasc Res Grp, Oklahoma City, OK USA; Medstar Res Inst, Cardiovasc Res Inst, Washington, DC USA; Vanderbilt Heart & Vasc Inst, Nashville, TN USA; Cardiovasc Res Fdn, New York, NY USA	Scripps Research Institute; Duke University; Minneapolis Heart Institute Foundation; Piedmont Heart Institute; Cleveland Clinic Foundation; Vanderbilt University; Cardiovascular Research Foundation (CRF)	Topol, EJ (corresponding author), Scripps Translat Sci Inst, 3344 N Torrey Pines Court, La Jolla, CA 92037 USA.	etopol@scripps.edu	Winn, Mary/AAN-6495-2021	Topol, Eric/0000-0002-1478-4729; McPherson, John/0000-0003-3371-7481; Schork, Nicholas/0000-0003-0920-5013; Kraus, William E/0000-0003-1930-9684	CardioDx; Scripps Translational Science Institute [NIHUL1RR025774]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER	CardioDx; Scripps Translational Science Institute; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Grant Support: By CardioDx and also in part by a Scripps Translational Science Institute Clinical Translational Science Award (NIHUL1RR025774) (Ms. Winn and Drs. Schork and Topol).	Ardigo D, 2007, PHYSIOL GENOMICS, V31, P402, DOI 10.1152/physiolgenomics.00104.2007; Burke AP, 2004, ARTERIOSCL THROM VAS, V24, P1266, DOI 10.1161/01.ATV.0000131783.74034.97; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; Cook NR, 2009, ANN INTERN MED, V150, P795, DOI 10.7326/0003-4819-150-11-200906020-00007; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Dragu R, 2008, ATHEROSCLEROSIS, V196, P405, DOI 10.1016/j.atherosclerosis.2006.11.022; Duffy BK, 2006, AM J CARDIOL, V97, P993, DOI 10.1016/j.amjcard.2005.10.034; Gopalakrishnan P, 2009, POSTGRAD MED, V121, P60, DOI 10.3810/pgm.2009.03.1977; Hong MG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003024; Horne BD, 2005, J AM COLL CARDIOL, V45, P1638, DOI 10.1016/j.jacc.2005.02.054; Ibebuogu UN, 2009, INT J CARDIOVAS IMAG, V25, P717, DOI 10.1007/s10554-009-9483-9; KLINKMAN MS, 1994, J FAM PRACTICE, V38, P345; Lansky AJ, 1998, TXB INTERVENTIONAL C, P725; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Martina B, 1997, J GEN INTERN MED, V12, P459, DOI 10.1046/j.1525-1497.1997.00083.x; Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49, DOI 10.1001/jama.2009.943; Newson R, 2006, STATA J, V6, P309, DOI 10.1177/1536867X0600600302; Packard RRS, 2008, CLIN CHEM, V54, P24, DOI 10.1373/clinchem.2007.097360; Packard RRS, 2009, SEMIN IMMUNOPATHOL, V31, P5, DOI 10.1007/s00281-009-0153-8; Palmer C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-115; Patel MR, 2010, NEW ENGL J MED, V362, P886, DOI 10.1056/NEJMoa0907272; Paynter NP, 2009, ANN INTERN MED, V150, P65, DOI 10.7326/0003-4819-150-2-200901200-00003; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Rana JS, 2007, J INTERN MED, V262, P678, DOI 10.1111/j.1365-2796.2007.01864.x; Ridker PM, 2008, CIRCULATION, V118, P2243, DOI 10.1161/CIRCULATIONAHA.108.814251; Stangl V, 2008, EUR HEART J, V29, P707, DOI 10.1093/eurheartj/ehn047; Svavarsdottir AE, 1996, CAN FAM PHYSICIAN, V42, P1122; Tanguay JF, 2003, J AM COLL CARDIOL, V41, p404A; VanderLaan PA, 2005, J LIPID RES, V46, P829, DOI 10.1194/jlr.R500003-JLR200; Vickers AJ, 2008, AM STAT, V62, P314, DOI 10.1198/000313008X370302; Watkins NA, 2009, BLOOD, V113, pE1, DOI 10.1182/blood-2008-06-162958; Wilson PWF, 2008, CIRC-CARDIOVASC QUAL, V1, P92, DOI 10.1161/CIRCOUTCOMES.108.831198; Wingrove JA, 2008, CIRC-CARDIOVASC GENE, V1, P31, DOI 10.1161/CIRCGENETICS.108.782730; Zebrack JS, 2002, J AM COLL CARDIOL, V39, P632, DOI 10.1016/S0735-1097(01)01804-6	35	128	138	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	2010	153	7					425	+		10.7326/0003-4819-153-7-201010050-00005	http://dx.doi.org/10.7326/0003-4819-153-7-201010050-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VG	20921541	Green Accepted			2022-12-28	WOS:000282517000001
J	de Lange, G; Wang, ZH; Riste, D; Dobrovitski, VV; Hanson, R				de Lange, G.; Wang, Z. H.; Riste, D.; Dobrovitski, V. V.; Hanson, R.			Universal Dynamical Decoupling of a Single Solid-State Spin from a Spin Bath	SCIENCE			English	Article							NUCLEAR-SPIN; COHERENT DYNAMICS; COUPLED ELECTRON; QUANTUM MEMORY; DIAMOND; DOTS	Controlling the interaction of a single quantum system with its environment is a fundamental challenge in quantum science and technology. We strongly suppressed the coupling of a single spin in diamond with the surrounding spin bath by using double-axis dynamical decoupling. The coherence was preserved for arbitrary quantum states, as verified by quantum process tomography. The resulting coherence time enhancement followed a general scaling with the number of decoupling pulses. No limit was observed for the decoupling action up to 136 pulses, for which the coherence time was enhanced more than 25 times compared to that obtained with spin echo. These results uncover a new regime for experimental quantum science and allow us to overcome a major hurdle for implementing quantum information protocols.	[de Lange, G.; Riste, D.; Hanson, R.] Delft Univ Technol, Kavli Inst Nanosci Delft, NL-2600 GA Delft, Netherlands; [Wang, Z. H.; Dobrovitski, V. V.] Ames Lab, Ames, IA 50011 USA; [Wang, Z. H.; Dobrovitski, V. V.] Iowa State Univ, Ames, IA 50011 USA	Delft University of Technology; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University	Hanson, R (corresponding author), Delft Univ Technol, Kavli Inst Nanosci Delft, POB 5046, NL-2600 GA Delft, Netherlands.	r.hanson@tudelft.nl	Hanson, Ronald/B-9555-2008; de Lange, Gijs/D-6868-2012; Ristè, Diego/G-9215-2012	de Lange, Gijs/0000-0002-9437-0816; Ristè, Diego/0000-0003-1458-2585	Defense Advanced Research Projects Agency; Dutch Organization for Fundamental Research on Matter (FOM); Netherlands Organization for Scientific Research (NWO); U.S. Department of Energy Basic Energy Sciences [DE-AC02-07CH11358]	Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Dutch Organization for Fundamental Research on Matter (FOM)(FOM (The Netherlands)); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); U.S. Department of Energy Basic Energy Sciences(United States Department of Energy (DOE))	We acknowledge support from the Defense Advanced Research Projects Agency, the Dutch Organization for Fundamental Research on Matter (FOM), and the Netherlands Organization for Scientific Research (NWO). Work at the Ames Laboratory was supported by the U.S. Department of Energy Basic Energy Sciences under contract DE-AC02-07CH11358.	Biercuk MJ, 2009, NATURE, V458, P996, DOI 10.1038/nature07951; Childress L, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.070504; Childress L, 2006, SCIENCE, V314, P281, DOI 10.1126/science.1131871; Clarke J, 2008, NATURE, V453, P1031, DOI 10.1038/nature07128; Cywinski L, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.174509; Degen CL, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2943282; Du JF, 2009, NATURE, V461, P1265, DOI 10.1038/nature08470; Hanson R, 2008, SCIENCE, V320, P352, DOI 10.1126/science.1155400; Hanson R, 2007, REV MOD PHYS, V79, P1217, DOI 10.1103/RevModPhys.79.1217; Hanson R, 2008, NATURE, V453, P1043, DOI 10.1038/nature07129; Jiang L, 2009, SCIENCE, V326, P267, DOI 10.1126/science.1176496; Jones JA, 2009, SCIENCE, V324, P1166, DOI 10.1126/science.1170730; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Khodjasteh K, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.180501; KLAUDER JR, 1962, PHYS REV, V125, P912, DOI 10.1103/PhysRev.125.912; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Morton JJL, 2008, NATURE, V455, P1085, DOI 10.1038/nature07295; Neumann P, 2010, NAT PHYS, V6, P249, DOI 10.1038/NPHYS1536; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pasini S, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.012309; Taylor JM, 2008, NAT PHYS, V4, P810, DOI 10.1038/nphys1075; Uhrig GS, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.100504; Viola L, 1999, PHYS REV LETT, V82, P2417, DOI 10.1103/PhysRevLett.82.2417; Vitali D, 1999, PHYS REV A, V59, P4178, DOI 10.1103/PhysRevA.59.4178; Zurek WH, 2009, NAT PHYS, V5, P181, DOI 10.1038/NPHYS1202	27	520	531	6	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	2010	330	6000					60	63		10.1126/science.1192739	http://dx.doi.org/10.1126/science.1192739			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20829452	Green Submitted			2022-12-28	WOS:000282334500032
J	Lopez-Mosqueda, J; Maas, NL; Jonsson, ZO; DeFazio-Eli, LG; Wohlschlegel, J; Toczyski, DP				Lopez-Mosqueda, Jaime; Maas, Nancy L.; Jonsson, Zophonias O.; DeFazio-Eli, Lisa G.; Wohlschlegel, James; Toczyski, David P.			Damage-induced phosphorylation of Sld3 is important to block late origin firing	NATURE			English	Article							PROTEIN IDENTIFICATION TECHNOLOGY; S-PHASE CHECKPOINT; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; SHOTGUN PROTEOMICS; BUDDING YEAST; MEC1 KINASE; COMPLEX; INITIATION; CDC7-DBF4	Origins of replication are activated throughout the S phase of the cell cycle such that some origins fire early and others fire late to ensure that each chromosome is completely replicated in a timely fashion. However, in response to DNA damage or replication fork stalling, eukaryotic cells block activation of unfired origins. Human cells derived from patients with ataxia telangiectasia are deficient in this process due to the lack of a functional ataxia telangiectasia mutated (ATM) kinase and elicit radioresistant DNA synthesis(1-3) after gamma-irradiation(2). This effect is conserved in budding yeast, as yeast cells lacking the related kinase Mec1 (ATM and Rad3-related (ATR in humans)) also fail to inhibit DNA synthesis in the presence of DNA damage(4). This intra-S-phase checkpoint actively regulates DNA synthesis by inhibiting the firing of late replicating origins, and this inhibition requires both Mec1 and the downstream checkpoint kinase Rad53 (Chk2 in humans)(5,6). However, the Rad53 substrate(s) whose phosphorylation is required to mediate this function has remained unknown. Here we show that the replication initiation protein Sld3 is phosphorylated by Rad53, and that this phosphorylation, along with phosphorylation of the Cdc7 kinase regulatory subunit Dbf4, blocks late origin firing in Saccharomyces cerevisiae. Upon exposure to DNA-damaging agents, cells expressing non-phosphorylatable alleles of SLD3 and DBF4 (SLD3-m25 and dbf4-m25, respectively) proceed through the S phase faster than wild-type cells by inappropriately firing late origins of replication. SLD3-m25 dbf4-m25 cells grow poorly in the presence of the replication inhibitor hydroxyurea and accumulate multiple Rad52 foci. Moreover, SLD3-m25 dbf4-m25 cells are delayed in recovering from transient blocks to replication and subsequently arrest at the DNA damage checkpoint. These data indicate that the intra-S-phase checkpoint functions to block late origin firing in adverse conditions to prevent genomic instability and maximize cell survival.	[Lopez-Mosqueda, Jaime; Maas, Nancy L.; DeFazio-Eli, Lisa G.; Toczyski, David P.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Jonsson, Zophonias O.; Wohlschlegel, James] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles	Toczyski, DP (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.	toczyski@cc.ucsf.edu	Jónsson, Zophonías Oddur/AAO-1354-2020; Jónsson, Zophonías/E-1960-2015	Jónsson, Zophonías Oddur/0000-0001-5798-9647; Eli, Lisa/0000-0003-3896-0966	Ford Foundation; National Institutes of Health [GM059691]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059691, R01GM089778] Funding Source: NIH RePORTER	Ford Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank members of the Toczyski, Morgan, Li and O'Farrell laboratories for discussions. We also thank D. Morgan, G. Narlikar and J. Li for intellectual contributions, J. Benanti and M. Downey for critical reading of this manuscript, and S. Makovets and M. Hoang for assistance with two-dimensional DNA gels. We thank H. Araki for strains, R. Sclafani for plasmids and J. Diffley for communicating results before publication. We are especially grateful to N. Lopez for help with GFP foci and colony quantification. Funding was provided by a Ford Foundation Pre-Doctoral Diversity Fellowship and a National Institutes of Health grant GM059691.	Alabert C, 2009, EMBO J, V28, P1131, DOI 10.1038/emboj.2009.75; Barlow JH, 2009, EMBO J, V28, P1121, DOI 10.1038/emboj.2009.43; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dohrmann PR, 1999, GENETICS, V151, P965; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Florens L, 2006, METHODS, V40, P303, DOI 10.1016/j.ymeth.2006.07.028; Francis LI, 2009, GENE DEV, V23, P643, DOI 10.1101/gad.1759609; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; Gabrielse C, 2006, GENETICS, V173, P541, DOI 10.1534/genetics.106.057521; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Labib K, 2010, GENE DEV, V24, P1208, DOI 10.1101/gad.1933010; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Paciotti V, 2001, MOL CELL BIOL, V21, P3913, DOI 10.1128/MCB.21.12.3913-3925.2001; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pike BL, 2004, J BIOL CHEM, V279, P39636, DOI 10.1074/jbc.M405080200; Sanchez-Pulido L, 2010, CURR BIOL, V20, pR509, DOI 10.1016/j.cub.2010.05.021; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sheu YJ, 2010, NATURE, V463, P113, DOI 10.1038/nature08647; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tam ATY, 2008, BIOCHEMISTRY-US, V47, P3912, DOI 10.1021/bi800027t; Tanaka S, 2007, NATURE, V445, P328, DOI 10.1038/nature05465; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Wohlschlegel James A., 2009, V497, P33, DOI 10.1007/978-1-59745-566-4_3; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; Zegerman P, 2007, NATURE, V445, P281, DOI 10.1038/nature05432; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299	39	140	142	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					479	U133		10.1038/nature09377	http://dx.doi.org/10.1038/nature09377			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20865002	Green Accepted, Green Submitted			2022-12-28	WOS:000282090200047
J	Yun, K; Lurie, N; Hyde, PS				Yun, Katherine; Lurie, Nicole; Hyde, Pamela S.			Moving Mental Health into the Disaster-Preparedness Spotlight	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Yun, Katherine] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT 06520 USA; [Hyde, Pamela S.] US Dept HHS, Subst Abuse & Mental Hlth Serv Adm, Washington, DC 20201 USA; [Lurie, Nicole] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA	Robert Wood Johnson Foundation (RWJF); Yale University	Yun, K (corresponding author), Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT 06520 USA.							Butler AS, 2003, PREPARING PSYCHOL CO; Disaster Mental Health Subcommittee of the National Biodefense Science Board, 2008, DIS MENT HLTH REC RE; Galea S, 2007, ARCH GEN PSYCHIAT, V64, P1427, DOI 10.1001/archpsyc.64.12.1427; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; PALINKAS LA, 1993, HUM ORGAN, V52, P1	5	46	46	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1193	1195		10.1056/NEJMp1008304	http://dx.doi.org/10.1056/NEJMp1008304			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652ZA	20860498	Bronze			2022-12-28	WOS:000282050000001
J	Ghosh, C				Ghosh, Chandak			A National Health Agenda for Asian Americans and Pacific Islanders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US Hlth Resources & Serv Adm, US Dept HHS, New York, NY 10278 USA	United States Health Resources & Service Administration (HRSA)	Ghosh, C (corresponding author), US Hlth Resources & Serv Adm, US Dept HHS, 26 Fed Plaza,3337, New York, NY 10278 USA.	cghosh@hrsa.gov						*CDCP, 2005, EL HLTH DISP; CHEN MS, 1995, AM J HEALTH PROMOT, V9, P261, DOI 10.4278/0890-1171-9.4.261; Ghosh C, 2003, AM J PUBLIC HEALTH, V93, P2093, DOI 10.2105/AJPH.93.12.2093; Lin-Fu Jane S., 1993, Asian Am Pac Isl J Health, V1, P20; *NYU LANG MED CTR, HIST CSAAH; President's Advisory Commission on Asian Americans and Pacific Islanders, 2003, AS AM PAC ISL ADDR H; Trinh-Shevrin C., 2009, ASIAN AM COMMUNITIES; U.S. Census Bureau, 2010, FACTS FEAT AS PAC AM; *WK KELL FDN, 2007, HLTH ACT COMM PARTN	9	38	38	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1381	1382		10.1001/jama.2010.1358	http://dx.doi.org/10.1001/jama.2010.1358			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652LK	20858884				2022-12-28	WOS:000282007900024
J	Elliott, MR; Zheng, SQ; Park, D; Woodson, RI; Reardon, MA; Juncadella, IJ; Kinchen, JM; Zhang, J; Lysiak, JJ; Ravichandran, KS				Elliott, Michael R.; Zheng, Shuqiu; Park, Daeho; Woodson, Robin I.; Reardon, Michael A.; Juncadella, Ignacio J.; Kinchen, Jason M.; Zhang, Jun; Lysiak, Jeffrey J.; Ravichandran, Kodi S.			Unexpected requirement for ELMO1 in clearance of apoptotic germ cells in vivo	NATURE			English	Article							CRKII/DOCK180/RAC PATHWAY; SCAVENGER RECEPTOR; SERTOLI-CELLS; PH DOMAIN; PHAGOCYTOSIS; ELEGANS; CORPSE; ISCHEMIA/REPERFUSION; ACTIVATION; ENGULFMENT	Apoptosis and the subsequent clearance of dying cells occurs throughout development and adult life in many tissues. Failure to promptly clear apoptotic cells has been linked to many diseases(1-3). ELMO1 is an evolutionarily conserved cytoplasmic engulfment protein that functions downstream of the phosphatidylserine receptor BAI1, and, along with DOCK1 and the GTPase RAC1, promotes internalization of the dying cells(4-7). Here we report the generation of ELMO1-deficient mice, which we found to be unexpectedly viable and grossly normal. However, they had a striking testicular pathology, with disrupted seminiferous epithelium, multinucleated giant cells, uncleared apoptotic germ cells and decreased sperm output. Subsequent in vitro and in vivo analyses revealed a crucial role for ELMO1 in the phagocytic clearance of apoptotic germ cells by Sertoli cells lining the seminiferous epithelium. The engulfment receptor BAI1 and RAC1 (upstream and downstream of ELMO1, respectively) were also important for Sertoli-cell-mediated engulfment. Collectively, these findings uncover a selective requirement for ELMO1 in Sertoli-cell-mediated removal of apoptotic germ cells and make a compelling case for a relationship between engulfment and tissue homeostasis in vivo.	[Elliott, Michael R.; Park, Daeho; Juncadella, Ignacio J.; Ravichandran, Kodi S.] Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; [Elliott, Michael R.; Park, Daeho; Juncadella, Ignacio J.; Kinchen, Jason M.; Lysiak, Jeffrey J.; Ravichandran, Kodi S.] Univ Virginia, Ctr Cell Clearance, Charlottesville, VA 22908 USA; [Zheng, Shuqiu; Woodson, Robin I.; Reardon, Michael A.; Zhang, Jun; Lysiak, Jeffrey J.] Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA; [Kinchen, Jason M.; Ravichandran, Kodi S.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.	jl6n@virginia.edu; ravi@virginia.edu	Kinchen, Jason/ABC-5663-2021; Reardon, Michael/ABF-8880-2021	Kinchen, Jason/0000-0001-8430-2265; Elliott, Michael/0000-0002-0642-482X; Ravichandran, Kodi/0000-0001-9049-1410; Zhang, Jun/0000-0002-3339-0346	National Institutes of Health; American Cancer Society; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD057242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI055432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064709] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T. Turner, K. Tung and members of the Ravichandran and Lysiak groups for suggestions. We also thank L. Haney, A. C. Tosello-Trampont, J. Kim and S. Clugston for technical assistance. This work was supported by funding from the National Institutes of Health (to K.S.R. and J.J.L.) and the American Cancer Society (to M.R.E.). K.S.R. is a Bill Benter fellow of the American Asthma Foundation.	A-Gonzalez N, 2009, IMMUNITY, V31, P245, DOI 10.1016/j.immuni.2009.06.018; Akakura S, 2004, EXP CELL RES, V292, P403, DOI 10.1016/j.yexcr.2003.09.011; Bailey RW, 2002, BIOL REPROD, V66, P1042, DOI 10.1095/biolreprod66.4.1042; Braun RE, 1998, NAT GENET, V18, P202, DOI 10.1038/ng0398-202; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen YM, 2009, REPRODUCTION, V138, P655, DOI 10.1530/REP-09-0101; Cool J, 2009, SEMIN REPROD MED, V27, P5, DOI 10.1055/s-0028-1108005; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; Gillot I, 2005, J CELL SCI, V118, P3027, DOI 10.1242/jcs.02430; Gregory Christopher D., 2009, P271, DOI 10.1007/978-1-4020-9293-0_9; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Henson PM, 2005, NAT IMMUNOL, V6, P1179, DOI 10.1038/ni1205-1179; Holdcraft RW, 2004, DEVELOPMENT, V131, P459, DOI 10.1242/dev.00957; HOLSTEIN AF, 1986, ANDROLOGIA, V18, P5; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Loveland KL, 2005, ANN NY ACAD SCI, V1061, P173, DOI 10.1196/annals.1336.018; Lu MJ, 2004, NAT STRUCT MOL BIOL, V11, P756, DOI 10.1038/nsmb800; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lysiak JJ, 2007, CELL TISSUE RES, V328, P411, DOI 10.1007/s00441-006-0341-y; Lysiak JJ, 2000, BIOL REPROD, V63, P1465, DOI 10.1095/biolreprod63.5.1465; Lysiak JJ, 2001, BIOL REPROD, V65, P718, DOI 10.1095/biolreprod65.3.718; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Nagata S, 2010, CELL, V140, P619, DOI 10.1016/j.cell.2010.02.014; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Park SY, 2008, CELL DEATH DIFFER, V15, P192, DOI 10.1038/sj.cdd.4402242; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Shiratsuchi A, 1999, J BIOL CHEM, V274, P5901, DOI 10.1074/jbc.274.9.5901; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Xiong W, 2008, REPRODUCTION, V135, P77, DOI 10.1530/REP-07-0287; Zhou Z, 2004, CURR TOP DEV BIOL, V63, P91, DOI 10.1016/S0070-2153(04)63004-3; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	37	113	113	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2010	467	7313					333	U114		10.1038/nature09356	http://dx.doi.org/10.1038/nature09356			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844538	Green Accepted			2022-12-28	WOS:000281824900040
J	Baumgart, DC				Baumgart, Daniel C.			How many lives does an ulcerative colitis patient have?	LANCET			English	Editorial Material							INFLAMMATORY-BOWEL-DISEASE; ENDOCARDITIS; RISK		Humboldt Univ, Charite Med Ctr, Sch Med, Virchow Hosp,Dept Med,Div Hepatol & Gastroenterol, D-13344 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Baumgart, DC (corresponding author), Humboldt Univ, Charite Med Ctr, Sch Med, Virchow Hosp,Dept Med,Div Hepatol & Gastroenterol, D-13344 Berlin, Germany.	daniel.baumgart@charite.de	Baumgart, Daniel C./AAU-2930-2021	Baumgart, Daniel C./0000-0003-2146-507X				Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X; Harada A, 2008, SCAND J GASTROENTERO, V43, P423, DOI 10.1080/00365520701737229; KREUZPAINTNER G, 1992, AM J MED, V92, P391, DOI 10.1016/0002-9343(92)90269-H; Toruner M, 2008, GASTROENTEROLOGY, V134, P929, DOI 10.1053/j.gastro.2008.01.012	5	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					928	928		10.1016/S0140-6736(10)60955-5	http://dx.doi.org/10.1016/S0140-6736(10)60955-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653DW	20833304				2022-12-28	WOS:000282069100034
J	Lencucha, R				Lencucha, Raphael			Philip Morris versus Uruguay: health governance challenged	LANCET			English	Editorial Material									Univ Lethbridge, Fac Hlth Sci, Lethbridge, AB T1K 3M4, Canada	University of Lethbridge	Lencucha, R (corresponding author), Univ Lethbridge, Fac Hlth Sci, Lethbridge, AB T1K 3M4, Canada.	raphael.lencucha@uleth.ca						[Anonymous], 2010, LANCET, V375, P1580; [Anonymous], 1988, SWITZERLAND URUGUAY; Chapman S, 2003, TOB CONTROL, V12, P13; Koivusalo M, 2009, GLOBALIZATION HLTH P, P105, DOI DOI 10.1001/JAMA.2009.1694; LALIVE, 2009, WHY PLAIN PACK IS VI; Lee K, 2009, LANCET, V373, P416, DOI 10.1016/S0140-6736(08)61776-6; PETERSON LE, 2010, INVESTMENT ARBI 0302; Roemer R, 2005, AM J PUBLIC HEALTH, V95, P936, DOI 10.2105/AJPH.2003.025908; United Nations Conference on Trade and Development, 2007, INT PROP PROV INT IN; Wakefield MA, 2008, TOB CONTROL, V17, P416, DOI 10.1136/tc.2008.026732; Woo Alyssa, 2002, VANDERBILT J TRANSNA, V35, P1731; *WORLD TRAD ORG, 1986, WTO LEG TEXTS GEN AG	12	21	21	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					852	853		10.1016/S0140-6736(10)61256-1	http://dx.doi.org/10.1016/S0140-6736(10)61256-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20833287				2022-12-28	WOS:000282069100007
J	Fung, TT; van Dam, RM; Hankinson, SE; Stampfer, M; Willett, WC; Hu, FB				Fung, Teresa T.; van Dam, Rob M.; Hankinson, Susan E.; Stampfer, Meir; Willett, Walter C.; Hu, Frank B.			Low-Carbohydrate Diets and All-Cause and Cause-Specific Mortality Two Cohort Studies	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; HIGH-PROTEIN-DIET; RISK-FACTORS; WEIGHT-LOSS; MEAT CONSUMPTION; LUNG-CANCER; COLORECTAL-CANCER; FAT; METAANALYSIS; SCORE	Background: Data on the long-term association between low-carbohydrate diets and mortality are sparse. Objective: To examine the association of low-carbohydrate diets with mortality during 26 years of follow-up in women and 20 years in men. Design: Prospective cohort study of women and men who were followed from 1980 (women) or 1986 (men) until 2006. Low-carbohydrate diets, either animal-based (emphasizing animal sources of fat and protein) or vegetable-based (emphasizing vegetable sources of fat and protein), were computed from several validated food-frequency questionnaires assessed during follow-up. Setting: Nurses' Health Study and Health Professionals' Follow-up Study. Participants: 85 168 women (aged 34 to 59 years at baseline) and 44 548 men (aged 40 to 75 years at baseline) without heart disease, cancer, or diabetes. Measurements: Investigators documented 12 555 deaths (2458 cardiovascular-related and 5780 cancer-related) in women and 8678 deaths (2746 cardiovascular-related and 2960 cancer-related) in men. Results: The overall low-carbohydrate score was associated with a modest increase in overall mortality in a pooled analysis (hazard ratio [HR] comparing extreme deciles, 1.12 [95% CI, 1.01 to 1.24]; P for trend = 0.136). The animal low-carbohydrate score was associated with higher all-cause mortality (pooled HR comparing extreme deciles, 1.23 [CI, 1.11 to 1.37]; P for trend = 0.051), cardiovascular mortality (corresponding HR, 1.14 [CI, 1.01 to 1.29]; P for trend = 0.029), and cancer mortality (corresponding HR, 1.28 [CI, 1.02 to 1.60]; P for trend = 0.089). In contrast, a higher vegetable low-carbohydrate score was associated with lower all-cause mortality (HR, 0.80 [CI, 0.75 to 0.85]; P for trend <= 0.001) and cardiovascular mortality (HR, 0.77 [CI, 0.68 to 0.87]; P for trend < 0.001). Limitations: Diet and lifestyle characteristics were assessed with some degree of error. Sensitivity analyses indicated that results were probably not substantively affected by residual confounding or an unmeasured confounder. Participants were not a representative sample of the U. S. population. Conclusion: A low-carbohydrate diet based on animal sources was associated with higher all-cause mortality in both men and women, whereas a vegetable-based low-carbohydrate diet was associated with lower all-cause and cardiovascular disease mortality rates.	[Fung, Teresa T.] Harvard Univ, Sch Publ Hlth, Simmons Coll, Dept Nutr, Boston, MA 02115 USA; Natl Univ Singapore, Singapore 117548, Singapore	Harvard University; Harvard T.H. Chan School of Public Health; Simmons University; National University of Singapore	Fung, TT (corresponding author), Harvard Univ, Sch Publ Hlth, Simmons Coll, Dept Nutr, 300 Fenway, Boston, MA 02115 USA.	teresa.fung@simmons.edu	van Dam, Rob M/F-9674-2010	van Dam, Rob M/0000-0002-7354-8734	National Institutes of Health [CA87969, HL60712, CA95589]; NATIONAL CANCER INSTITUTE [R01CA095589, P01CA087969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Grant Support: By the National Institutes of Health (grants CA87969, HL60712, and CA95589).	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Benetou V, 2008, CANCER EPIDEM BIOMAR, V17, P387, DOI 10.1158/1055-9965.EPI-07-2665; Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172; CHAUNCEY KB, 2003, LOW CARB DIETING DUM; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Cross AJ, 2007, PLOS MED, V4, P1973, DOI 10.1371/journal.pmed.0040325; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; De Stefani E, 2008, LUNG CANCER, V61, P283, DOI 10.1016/j.lungcan.2008.01.004; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Halton TL, 2008, AM J CLIN NUTR, V87, P339, DOI 10.1093/ajcn/87.2.339; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Jenkins DJA, 2009, ARCH INTERN MED, V169, P1046, DOI 10.1001/archinternmed.2009.115; Kelemen LE, 2005, AM J EPIDEMIOL, V161, P239, DOI 10.1093/aje/kwi038; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Lagiou P, 2007, J INTERN MED, V261, P366, DOI 10.1111/j.1365-2796.2007.01774.x; Lam TK, 2009, CANCER RES, V69, P932, DOI 10.1158/0008-5472.CAN-08-3162; Larsson SC, 2006, INT J CANCER, V119, P2657, DOI 10.1002/ijc.22170; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; McMillan-Price J, 2006, ARCH INTERN MED, V166, P1466, DOI 10.1001/archinte.166.14.1466; Muzio F, 2007, AM J CLIN NUTR, V86, P946, DOI 10.1093/ajcn/86.4.946; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Sandhu MS, 2001, CANCER EPIDEM BIOMAR, V10, P439; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Spiegelman D, 1997, AM J CLIN NUTR, V65, P1179; Trichopoulou A, 2007, EUR J CLIN NUTR, V61, P575, DOI 10.1038/sj.ejcn.1602557; Willett W., 2012, NUTR EPIDEMIOLOGY	35	222	225	1	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2010	153	5					289	+		10.7326/0003-4819-153-5-201009070-00003	http://dx.doi.org/10.7326/0003-4819-153-5-201009070-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647GF	20820038	Green Accepted			2022-12-28	WOS:000281605500002
J	Grunwald, D; Singer, RH				Grunwald, David; Singer, Robert H.			In vivo imaging of labelled endogenous beta-actin mRNA during nucleocytoplasmic transport	NATURE			English	Article							NUCLEAR-PORE COMPLEX; CRYOELECTRON TOMOGRAPHY; AMPHIBIAN OOCYTES; SINGLE-MOLECULE; MYOSIN-V; EXPORT; TRANSLOCATION; ARCHITECTURE; ENVELOPE; PROTEIN	Export of messenger RNA occurs via nuclear pores, which are large nanomachines with diameters of roughly 120 nm that are the only link between the nucleus and cytoplasm(1). Hence, mRNA export occurs over distances smaller than the optical resolution of conventional light microscopes. There is extensive knowledge on the physical structure and composition of the nuclear pore complex(2-7), but transport selectivity and the dynamics of mRNA export at nuclear pores remain unknown(8). Here we developed a super-registration approach using fluorescence microscopy that can overcome the current limitations of co-localization by means of measuring intermolecular distances of chromatically different fluorescent molecules with nanometre precision. With this method we achieve 20-ms time-precision and at least 26-nm spatial precision, enabling the capture of highly transient interactions in living cells. Using this approach we were able to spatially resolve the kinetics of mRNA transport in mammalian cells and present a three-step model consisting of docking (80 ms), transport (5-20 ms) and release (80 ms), totalling 180 +/- 10 ms. Notably, the translocation through the channel was not the rate-limiting step, mRNAs can move bi-directionally in the pore complex and not all pores are equally active.	[Grunwald, David; Singer, Robert H.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Grunwald, David; Singer, Robert H.] Gruss Lipper Biophoton Ctr, Bronx, NY 10461 USA; [Grunwald, David] Delft Univ Technol, Dept BioNanoSci, Kavli Inst NanoSci, NL-2628 CJ Delft, Netherlands	Yeshiva University; Albert Einstein College of Medicine; Delft University of Technology	Singer, RH (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	Robert.Singer@einstein.yu.edu		Grunwald, David/0000-0001-9067-804X	DFG [3388/1]; NIH [EB2060, GM86217]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084364, R01GM086217] Funding Source: NIH RePORTER	DFG(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T. Dange, K. Czaplinski, T. Lionnet and X. Meng for help with cell lines and cloning; A. Gennerich, H. Y. Park and D. Entenberg for help on data analysis and programming; S. M. Shenoy for development of alignment software for detector pre-registration and his additional support; D. Larson, I. Lepper and U. Kubitscheck for providing fitting routines; and A. Wells for FISH and TIRF data, proof reading and discussion. Lentiviral vector was a gift from G. Mostoslavsky and R. C. Mulligan. Supported by DFG 3388/1 to D.G. Supported by NIH EB2060 and GM86217 to R.H.S. The authors express their appreciation to E. Gruss Lipper for her gift founding the Gruss Lipper Biophotonics Center that provided the equipment used in this research.	Alber F, 2007, NATURE, V450, P695, DOI 10.1038/nature06405; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bastos R, 1995, INT REV CYTOL, V162B, P257; Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808; Carmody SR, 2009, J CELL SCI, V122, P1933, DOI 10.1242/jcs.041236; Chakraborty P, 2006, METHODS, V39, P363, DOI 10.1016/j.ymeth.2006.07.002; Clemen AEM, 2005, BIOPHYS J, V88, P4402, DOI 10.1529/biophysj.104.053504; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Dange T, 2008, J CELL BIOL, V183, P77, DOI 10.1083/jcb.200806173; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P317, DOI 10.1016/S0022-5320(70)80065-X; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P288, DOI 10.1016/S0022-5320(70)80064-8; Frey S, 2007, CELL, V130, P512, DOI 10.1016/j.cell.2007.06.024; Fusco D, 2003, CURR BIOL, V13, P161, DOI 10.1016/S0960-9822(02)01436-7; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; Kiseleva E, 1998, J CELL SCI, V111, P223; Kopito RB, 2007, P NATL ACAD SCI USA, V104, P12743, DOI 10.1073/pnas.0702690104; Kubitscheck U, 2005, J CELL BIOL, V168, P233, DOI 10.1083/jcb.200411005; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lim RYH, 2007, SCIENCE, V318, P640, DOI 10.1126/science.1145980; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mor A, 2010, NAT CELL BIOL, V12, P543, DOI 10.1038/ncb2056; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Peters R, 2005, TRAFFIC, V6, P421, DOI 10.1111/j.1600-0854.2005.00287.x; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; STOCKLEY PG, 1995, NUCLEIC ACIDS RES, V23, P2512, DOI 10.1093/nar/23.13.2512; Stoffler D, 2003, J MOL BIOL, V328, P119, DOI 10.1016/S0022-2836(03)00266-3; Sun C, 2008, P NATL ACAD SCI USA, V105, P8613, DOI 10.1073/pnas.0710867105; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	31	226	229	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP	2010	467	7315					604	U128		10.1038/nature09438	http://dx.doi.org/10.1038/nature09438			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20844488	Green Accepted			2022-12-28	WOS:000282273100042
J	Johnson, J; Rogers, W; Lotz, M; Townley, C; Meyerson, D; Tomossy, G				Johnson, Jane; Rogers, Wendy; Lotz, Mianna; Townley, Cynthia; Meyerson, Denise; Tomossy, George			Ethical challenges of innovative surgery: a response to the IDEAL recommendations	LANCET			English	Editorial Material							SURGICAL INNOVATION		[Johnson, Jane; Lotz, Mianna; Townley, Cynthia] Macquarie Univ, Dept Philosophy, Sydney, NSW 2109, Australia; [Rogers, Wendy] Macquarie Univ, Dept Philosophy, Sydney, NSW 2109, Australia; [Rogers, Wendy] Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia; [Meyerson, Denise; Tomossy, George] Macquarie Univ, Macquarie Law Sch, Sydney, NSW 2109, Australia	Macquarie University; Macquarie University; Macquarie University; Macquarie University	Johnson, J (corresponding author), Macquarie Univ, Dept Philosophy, N Ryde, NSW 2109, Australia.	Jane.Johnson@mq.edu.au	Johnson, Jane/AAQ-6529-2021	Lotz, Mianna/0000-0002-9814-5675; Tomossy, George/0000-0002-1001-8795; Rogers, Wendy/0000-0001-9186-870X; Meyerson, Denise/0000-0002-6515-2406				Ahmed AS, 2005, COLUMBIA LAW REV, V105, P1529; Barkun JS, 2009, LANCET, V374, P1089, DOI 10.1016/S0140-6736(09)61083-7; Ergina PL, 2009, LANCET, V374, P1097, DOI 10.1016/S0140-6736(09)61086-2; Frader JE, 1998, SURG ETHICS, P216; Healy J, 2006, MED J AUSTRALIA, V184, pS56; Lo B, 2009, CONFLICT INTEREST ME; Mastroianni Anna C, 2006, Health Matrix Clevel, V16, P351; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; Morgenstern L, 2006, SURG INNOV, V13, P73, DOI 10.1177/155335060601300112; Morreim H, 2006, ANN THORAC SURG, V82, P1957, DOI 10.1016/j.athoracsur.2006.07.003; Strasberg SM, 2003, J AM COLL SURGEONS, V196, P938, DOI 10.1016/S1072-7515(03)00112-1	11	18	18	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1113	1115		10.1016/S0140-6736(10)61116-6	http://dx.doi.org/10.1016/S0140-6736(10)61116-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	657KM	20870102				2022-12-28	WOS:000282411600039
J	Galazka, JM; Tian, CG; Beeson, WT; Martinez, B; Glass, NL; Cate, JHD				Galazka, Jonathan M.; Tian, Chaoguang; Beeson, William T.; Martinez, Bruno; Glass, N. Louise; Cate, Jamie H. D.			Cellodextrin Transport in Yeast for Improved Biofuel Production	SCIENCE			English	Article							FUEL ETHANOL-PRODUCTION; SIMULTANEOUS SACCHARIFICATION; FERMENTATION; DEGRADATION; HYDROLYSIS; MECHANISMS; BIOMASS	Fungal degradation of plant biomass may provide insights for improving cellulosic biofuel production. We show that the model cellulolytic fungus Neurospora crassa relies on a high-affinity cellodextrin transport system for rapid growth on cellulose. Reconstitution of the N. crassa cellodextrin transport system in Saccharomyces cerevisiae promotes efficient growth of this yeast on cellodextrins. In simultaneous saccharification and fermentation experiments, the engineered yeast strains more rapidly convert cellulose to ethanol when compared with yeast lacking this system.	[Galazka, Jonathan M.; Cate, Jamie H. D.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Tian, Chaoguang; Glass, N. Louise] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Tian, Chaoguang] Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Tianjin Airport Econ Area, Tianjin 300308, Peoples R China; [Beeson, William T.; Cate, Jamie H. D.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Martinez, Bruno; Cate, Jamie H. D.] Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Chinese Academy of Sciences; Tianjin Institute of Industrial Biotechnology, CAS; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Cate, JHD (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	jcate@lbl.gov	Glass, N. Louise/ABA-7303-2021; Galazka, Jonathan Galazka/K-4847-2012	Galazka, Jonathan Galazka/0000-0002-4153-0249	Energy Biosciences Institute	Energy Biosciences Institute	We thank J. Doudna, M. Marletta, J. Taylor, T. Bruns, and C. Phillips for helpful discussions and comments on the manuscript; M. Toews for help with growth assays; S. Bauer and A. Ibanez for help with analytical methods; and C. Anderson for help with confocal microscopy. This work was supported by funding from the Energy Biosciences Institute to J. H. D. C. and N.L.G. The Regents of the University of California, the authors, and British Petroleum Technology Ventures (through the Energy Biosciences Institute) have submitted a patent for the use of cellodextrin transporters in fermenting organisms for the use of plant biomass.	Bai FW, 2008, BIOTECHNOL ADV, V26, P89, DOI 10.1016/j.biotechadv.2007.09.002; Basso LC, 2008, FEMS YEAST RES, V8, P1155, DOI 10.1111/j.1567-1364.2008.00428.x; BHAT KM, 1987, APPL ENVIRON MICROB, V53, P2175, DOI 10.1128/AEM.53.9.2175-2182.1987; Chauve M, 2010, BIOTECHNOL BIOFUELS, V3, DOI 10.1186/1754-6834-3-3; Doran-Peterson J, 2009, METHODS MOL BIOL, V581, P263, DOI 10.1007/978-1-60761-214-8_17; Drissen RET, 2009, BIOCATAL BIOTRANSFOR, V27, P27, DOI 10.1080/10242420802564358; FREER SN, 1991, APPL ENVIRON MICROB, V57, P655, DOI 10.1128/AEM.57.3.655-659.1991; Himmel ME, 2007, SCIENCE, V315, P804, DOI 10.1126/science.1137016; Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002; Martin F, 2010, NATURE, V464, P1033, DOI 10.1038/nature08867; Noguchi Y, 2009, APPL MICROBIOL BIOT, V85, P141, DOI 10.1007/s00253-009-2236-9; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; Rubin EM, 2008, NATURE, V454, P841, DOI 10.1038/nature07190; Skinner KA, 2004, J IND MICROBIOL BIOT, V31, P401, DOI 10.1007/s10295-004-0159-0; Stephanopoulos G, 2007, SCIENCE, V315, P801, DOI 10.1126/science.1139612; Sun Y, 2002, BIORESOURCE TECHNOL, V83, P1, DOI 10.1016/S0960-8524(01)00212-7; Tian CG, 2009, P NATL ACAD SCI USA, V106, P22157, DOI 10.1073/pnas.0906810106; USDA, 2006, EC FEASIBILITY ETHAN; Voutilainen SP, 2008, BIOTECHNOL BIOENG, V101, P515, DOI 10.1002/bit.21940; Wymelenberg AV, 2010, APPL ENVIRON MICROB, V76, P3599, DOI 10.1128/AEM.00058-10; XIN Z, 1993, ENZYME MICROB TECH, V15, P62, DOI 10.1016/0141-0229(93)90117-K	21	233	248	3	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	2010	330	6000					84	86		10.1126/science.1192838	http://dx.doi.org/10.1126/science.1192838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20829451				2022-12-28	WOS:000282334500039
J	Mikkelsen, TS; Xu, Z; Zhang, XL; Wang, L; Gimble, JM; Lander, ES; Rosen, ED				Mikkelsen, Tarjei S.; Xu, Zhao; Zhang, Xiaolan; Wang, Li; Gimble, Jeffrey M.; Lander, Eric S.; Rosen, Evan D.			Comparative Epigenomic Analysis of Murine and Human Adipogenesis	CELL			English	Article							TRANSCRIPTION FACTOR-BINDING; GENOME-WIDE ANALYSIS; RESPONSE ELEMENT; GENE-EXPRESSION; STEM-CELLS; CHROMOSOME CONFORMATION; HISTONE MODIFICATIONS; PPAR-GAMMA; DIFFERENTIATION; ENHANCERS	We report the generation and comparative analysis of genome-wide chromatin state maps, PPAR gamma and CTCF localization maps, and gene expression profiles from murine and human models of adipogenesis. The data provide high-resolution views of chromatin remodeling during cellular differentiation and allow identification of thousands of putative preadipocyte- and adipocyte-specific cis-regulatory elements based on dynamic chromatin signatures. We find that the specific locations of most such elements differ between the two models, including at orthologous loci with similar expression patterns. Based on sequence analysis and reporter assays, we show that these differences are determined, in part, by evolutionary turnover of transcription factor motifs in the genome sequences and that this turnover may be facilitated by the presence of multiple distal regulatory elements at adipogenesis-dependent loci. We also utilize the close relationship between open chromatin marks and transcription factor motifs to identify and validate PLZF and SRF as regulators of adipogenesis.	[Mikkelsen, Tarjei S.; Xu, Zhao; Zhang, Xiaolan; Wang, Li; Lander, Eric S.; Rosen, Evan D.] Broad Inst, Cambridge Ctr 7, Cambridge, MA 02142 USA; [Xu, Zhao; Rosen, Evan D.] Beth Israel Deaconess Med Ctr, Div Endocrinol & Metab, Boston, MA 02115 USA; [Gimble, Jeffrey M.] Louisiana Univ Syst, Pennington Biomed Res Ctr, Stem Cell Biol Lab, Baton Rouge, LA 70808 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Beth Israel Deaconess Medical Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Rosen, ED (corresponding author), Broad Inst, Cambridge Ctr 7, Cambridge, MA 02142 USA.	erosen@bidmc.harvard.edu	Mikkelsen, Tarjei S/A-1306-2007	Mikkelsen, Tarjei S/0000-0002-8133-3135	Broad Institute, NIH [DK63906]; American Diabetes Association; Pennington Biomedical Research Foundation; NORC Center [1P30 DK072476]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063906, P30DK072476] Funding Source: NIH RePORTER	Broad Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Pennington Biomedical Research Foundation; NORC Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors would like to thank the staff of the Broad Institute for assistance with data generation and Gang Yu at the Tissue Culture Core Facility, Pennington Biomedical Research Center, for isolating the hASCs. This project was supported by funds from the Broad Institute, NIH DK63906 (E.D.R.), an American Diabetes Association Career Development Award (E.D.R.), the Pennington Biomedical Research Foundation (J.M.G.), and NORC Center Grant # 1P30 DK072476 (J.M.G.). J.M.G. declares that he has consulted for companies focusing on adipose-derived adult stem cells (Toucan Capital, Cognate Bioservices, Vet-Stem) and has cofounded companies involved in developing these cells for clinical applications.	Arnone MI, 1997, DEVELOPMENT, V124, P1851; Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539; BAILEY TL, 1994, ISMB, V2, P28; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Camp HS, 2002, TRENDS MOL MED, V8, P442, DOI 10.1016/S1471-4914(02)02396-1; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dubois Severine G., 2008, V449, P69, DOI 10.1007/978-1-60327-169-1_5; Eguchi J, 2008, CELL METAB, V7, P86, DOI 10.1016/j.cmet.2007.11.002; Ghisletti S, 2010, IMMUNITY, V32, P317, DOI 10.1016/j.immuni.2010.02.008; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Hebert TL, 2009, J TISSUE ENG REGEN M, V3, P553, DOI 10.1002/term.198; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Hon GC, 2009, HUM MOL GENET, V18, pR195, DOI 10.1093/hmg/ddp409; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008; Lowe CB, 2007, P NATL ACAD SCI USA, V104, P8005, DOI 10.1073/pnas.0611223104; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mikkelsen TS, 2007, NATURE, V447, P167, DOI 10.1038/nature05805; Nielsen R, 2008, GENE DEV, V22, P2953, DOI 10.1101/gad.501108; Noer A, 2009, STEM CELLS DEV, V18, P725, DOI 10.1089/scd.2008.0189; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Odom DT, 2007, NAT GENET, V39, P730, DOI 10.1038/ng2047; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Schmidt D, 2010, SCIENCE, V328, P1036, DOI 10.1126/science.1186176; Valouev A, 2008, NAT METHODS, V5, P829, DOI 10.1038/NMETH.1246; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Weirauch MT, 2010, TRENDS GENET, V26, P66, DOI 10.1016/j.tig.2009.12.002; Xi HL, 2007, PLOS GENET, V3, P1377, DOI 10.1371/journal.pgen.0030136; Xu Z, 2008, P NATL ACAD SCI USA, V105, P2421, DOI 10.1073/pnas.0707082105; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	43	391	402	3	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	2010	143	1					156	169		10.1016/j.cell.2010.09.006	http://dx.doi.org/10.1016/j.cell.2010.09.006			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887899	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000282362000022
J	Snippert, HJ; van der Flier, LG; Sato, T; van Es, JH; van den Born, M; Kroon-Veenboer, C; Barker, N; Klein, AM; van Rheenen, J; Simons, BD; Clevers, H				Snippert, Hugo J.; van der Flier, Laurens G.; Sato, Toshiro; van Es, Johan H.; van den Born, Maaike; Kroon-Veenboer, Carla; Barker, Nick; Klein, Allon M.; van Rheenen, Jacco; Simons, Benjamin D.; Clevers, Hans			Intestinal Crypt Homeostasis Results from Neutral Competition between Symmetrically Dividing Lgr5 Stem Cells	CELL			English	Article							MOUSE SMALL-INTESTINE; SELF-RENEWAL; HAIR FOLLICLE; BETA-CATENIN; IN-VITRO; DIFFERENTIATION; DIVISION; MARKER; GENE; IDENTIFICATION	Intestinal stem cells, characterized by high Lgr5 expression, reside between Paneth cells at the small intestinal crypt base and divide every day. We have carried out fate mapping of individual stem cells by generating a multicolor Cre-reporter. As a population, Lgr5(hi) stem cells persist life-long, yet crypts drift toward clonality within a period of 1-6 months. We have collected short- and long-term clonal tracing data of individual Lgr5(hi) cells. These reveal that most Lgr5(hi) cell divisions occur symmetrically and do not support a model in which two daughter cells resulting from an Lgr5(hi) cell division adopt divergent fates (i.e., one Lgr5(hi) cell and one transit-amplifying [TA] cell per division). The cellular dynamics are consistent with a model in which the resident stem cells double their numbers each day and stochastically adopt stem or TA fates. Quantitative analysis shows that stem cell turnover follows a pattern of neutral drift dynamics.	[Snippert, Hugo J.; van der Flier, Laurens G.; Sato, Toshiro; van Es, Johan H.; van den Born, Maaike; Kroon-Veenboer, Carla; Barker, Nick; van Rheenen, Jacco; Clevers, Hans] KNAW, Hubrecht Inst, NL-3584 CT Utrecht, Netherlands; [Snippert, Hugo J.; van der Flier, Laurens G.; Sato, Toshiro; van Es, Johan H.; van den Born, Maaike; Kroon-Veenboer, Carla; Barker, Nick; van Rheenen, Jacco; Clevers, Hans] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands; [Klein, Allon M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Klein, Allon M.; Simons, Benjamin D.] Univ Cambridge, Cavendish Lab, Dept Phys, Cambridge CB3 0HE, England	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Harvard University; Harvard Medical School; University of Cambridge	Clevers, H (corresponding author), KNAW, Hubrecht Inst, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@hubrecht.eu	Simons, Benjamin/AAY-8920-2020; Sato, Toshiro/J-3522-2014; van Rheenen, Jacco/G-3655-2014; van+Es, Johan/ABD-5411-2021; Barker, Nick/AAE-9833-2021; Barker, Nick/A-5535-2011; Barker, Nick/AAS-2774-2020	Simons, Benjamin/0000-0002-3875-7071; Sato, Toshiro/0000-0001-8353-8137; Barker, Nick/0000-0003-3566-4475; 	Engineering and Physical Sciences Research Council [EP/F032773/1, EP/F043325/1] Funding Source: researchfish; EPSRC [EP/F043325/1, EP/F032773/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; BenNaim E, 1996, PHYS REV E, V53, P3078, DOI 10.1103/PhysRevE.53.3078; BRAMSON M, 1980, Z WAHRSCHEINLICHKEIT, V53, P183, DOI 10.1007/BF01013315; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669; Fuller MT, 2007, SCIENCE, V316, P402, DOI 10.1126/science.1140861; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Ireland H, 2005, DEV DYNAM, V233, P1332, DOI 10.1002/dvdy.20446; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Klein AM, 2010, CELL STEM CELL, V7, P214, DOI 10.1016/j.stem.2010.05.017; Krapivsky PL, 1997, PHYS REV E, V56, P3788, DOI 10.1103/PhysRevE.56.3788; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; LOPEZGARCIA C, 2010, SCIENCE IN PRESS; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Neumuller RA, 2009, GENE DEV, V23, P2675, DOI 10.1101/gad.1850809; POTTEN CS, 1974, CELL TISSUE KINET, V7, P271, DOI 10.1111/j.1365-2184.1974.tb00907.x; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Snippert HJ, 2009, GASTROENTEROLOGY, V136, P2187, DOI 10.1053/j.gastro.2009.03.002; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WU FY, 1982, REV MOD PHYS, V54, P235, DOI 10.1103/RevModPhys.54.235; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	40	1275	1298	6	139	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					134	144		10.1016/j.cell.2010.09.016	http://dx.doi.org/10.1016/j.cell.2010.09.016			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887898	Bronze			2022-12-28	WOS:000282362000020
J	Yu, HJ; Liao, QH; Yuan, YA; Zhou, L; Xiang, NJ; Huai, Y; Guo, XH; Zheng, YD; van Doorn, HR; Farrar, J; Gao, ZC; Feng, ZJ; Wang, Y; Yang, WZ				Yu, Hongjie; Liao, Qiaohong; Yuan, Yuan; Zhou, Lei; Xiang, Nijuan; Huai, Yang; Guo, Xiuhua; Zheng, Yingdong; van Doorn, H. Rogier; Farrar, Jeremy; Gao, Zhancheng; Feng, Zijian; Wang, Yu; Yang, Weizhong			Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEURAMINIDASE INHIBITOR OSELTAMIVIR; HOSPITALIZED-PATIENTS; RESPIRATORY-FAILURE; INFECTION; THERAPY; A(H1N1); PREVENTION; EFFICACY; SAFETY	Objective To describe the clinical features and effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A(H1N1) virus infection. Design Opportunistic retrospective review of medical charts of patients with confirmed 2009 H1N1 identified through the national surveillance system in China from May to July 2009. Setting Under coordination of the Ministry of Health, local health departments were asked to collect medical records of confirmed patients and send them to the Chinese Centre for Disease Control and Prevention on a voluntary basis as part of the public health response. Population 1291 patients with confirmed 2009 H1N1 infection and available data for chart review. Main outcome measures Demographic characteristics, comorbidities, symptoms and signs, laboratory tests, findings on chest radiography, antiviral treatment, duration of fever, and duration of viral RNA shedding. Results The median age of 1291 patients was 20 years (interquartile range 12-26); 701 (54%) were male. The most common symptoms were fever (820, 64%), cough (864, 67%), sore throat (425, 33%), sputum (239, 19%), and rhinorrhoea (228, 18%). Of 920 patients who underwent chest radiography, 110 (12%) had abnormal findings consistent with pneumonia. Some 983 (76%) patients were treated with oseltamivir from a median of the third day of symptoms (2-4). No patients required admission to the intensive care unit or mechanical ventilation. 2009 H1N1 was shed from one day before onset of symptoms to up to eight days after onset in most (91%) patients, with a median of 5 (3-6) days of shedding after onset. Treatment with oseltamivir significantly protected against subsequent development of radiographically confirmed pneumonia (odds ratio 0.12, 95% confidence interval 0.08 to 0.18), and treatment started within two days of symptom onset reduced the duration of fever and viral RNA shedding. Conclusions Chinese patients with 2009 H1N1 infection predominantly presented with features of uncomplicated, self limiting acute respiratory illness. 2009 H1N1 might be shed longer than seasonal influenza virus. Treatment with oseltamivir was associated with a significantly reduced development of radiographically confirmed pneumonia and a shorter duration of fever and viral RNA shedding. Though these patients benefited from treatment, the findings should be interpreted with caution as the study was retrospective and not all patients underwent chest radiography.	[Yu, Hongjie; Yang, Weizhong] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China	Chinese Center for Disease Control & Prevention	Yang, WZ (corresponding author), Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China.	yuhj@chinacdc.cn; yangwz@chinacdc.cn	Yu, Hongjie/GZK-5351-2022; van Doorn, H. Rogier/H-3080-2019; Farrar, Jeremy J./HGA-7610-2022	van Doorn, H. Rogier/0000-0002-9807-1821; Zhou, Lei/0000-0002-6640-0774; Farrar, Jeremy/0000-0002-2700-623X	US National Institutes of Health [U19 AI51915]; China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases; South East Asia Infectious Disease Clinical Research Network; Wellcome Trust; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051915] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases; South East Asia Infectious Disease Clinical Research Network; Wellcome Trust(Wellcome TrustEuropean Commission); Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by grants from US National Institutes of Health (Comprehensive International Program for Research on AIDS grant U19 AI51915), the China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases, South East Asia Infectious Disease Clinical Research Network, and Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. None of the funders had any role in the study design and the collection, analysis, and interpretation of data, or in the writing of the article and the decision to submit it for publication. The researchers confirm their independence from funders and sponsors. All authors had full access to all data included in the study and are jointly responsible for the integrity of the data and accuracy of data analyses.	Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; [Anonymous], 2009, GAZ BOSNIA HERZEGOVI, V43; Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; *CDCP, 2009, UPD INT REC US ANT M; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P1071; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; De Serres G, 2010, EMERG INFECT DIS, V16, P783, DOI 10.3201/eid1605.091894; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1; FRANK AL, 1981, J INFECT DIS, V144, P433, DOI 10.1093/infdis/144.5.433; HALL CB, 1975, PEDIATRICS, V55, P673; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Hanshaoworakul W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006051; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5106; KLIMOV AI, 1995, J INFECT DIS, V172, P1352, DOI 10.1093/infdis/172.5.1352; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Lee N, 2008, CLIN INFECT DIS, V46, P1323, DOI 10.1086/533477; Lee N, 2007, ANTIVIR THER, V12, P501; Leekha S, 2007, INFECT CONT HOSP EP, V28, P1071, DOI 10.1086/520101; Li IW, 2010, CHEST, V137, P759, DOI 10.1378/chest.09-3072; Ling LM, 2010, CLIN INFECT DIS, V50, P963, DOI 10.1086/651083; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584; *MIN HLTH CHIN, 2009, DISCH CRIT HUM INF P; *MIN HLTH CHIN, 2009, CLIN MAN HUM INF PAN; Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740; Nicholson K G, 1992, Semin Respir Infect, V7, P26; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Nicoll A, 2010, EUROSURVEILLANCE, V15; Ong AK, 2007, J INFECT DIS, V196, P181, DOI 10.1086/518939; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8044; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Uyeki Tim, 2009, N Engl J Med, V361, pe110, DOI 10.1056/NEJMopv0910738; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; WHO, CLIN MAN HUM INF PAN; Witkop CT, 2010, AM J PREV MED, V38, P121, DOI 10.1016/j.amepre.2009.10.005; World Health Organization, 2010, PAND H1N1 2009 UPD 1; World Health Organization, 2009, CDC PROT REALT RTPCR; 2009, N ENGL J MED, V260, P2605	43	75	80	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2010	341								c4779	10.1136/bmj.c4779	http://dx.doi.org/10.1136/bmj.c4779			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659MF	20876641	Green Published, hybrid			2022-12-28	WOS:000282569900004
J	Chitwood, DH; Timmermans, MCP				Chitwood, Daniel H.; Timmermans, Marja C. P.			Small RNAs are on the move	NATURE			English	Review							SILENCING SIGNAL; ARABIDOPSIS; GENE; INTERFERENCE; MICRORNAS; CELLS; PATHWAYS; SIRNAS; PLANTS; VIRUS	A key feature of RNA interference is its ability to spread from cell to cell. Such non-cell-autonomous gene silencing has been characterized extensively in both plants and animals, but the identity of the mobile silencing signal has remained elusive. Several recent studies now shed light on the identity of this signal in plants, and indicate that small RNA molecules-from short-interfering RNAs to microRNAs-are capable of moving between cells and through the vasculature. The movement of small, 21-24-nucleotide RNA species has implications for biological processes ranging from developmental patterning and stress responses to epigenetic inheritance.	[Timmermans, Marja C. P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Chitwood, Daniel H.] Univ Calif Davis, Sect Plant Biol, Davis, CA 95616 USA	Cold Spring Harbor Laboratory; University of California System; University of California Davis	Timmermans, MCP (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	timmerma@cshl.edu	Chitwood, Daniel/M-2841-2013	Chitwood, Daniel/0000-0003-4875-1447	NSF [IOS-0615752]	NSF(National Science Foundation (NSF))	We thank current and former members of the Timmermans laboratory for discussions. Research on small RNA mobility in the laboratory of M. C. P. T. is supported by a grant from the NSF (IOS-0615752).	Alvarez JP, 2006, PLANT CELL, V18, P1134, DOI 10.1105/tpc.105.040725; Baurle I, 2007, SCIENCE, V318, P109, DOI 10.1126/science.1146565; Borsani O, 2005, CELL, V123, P1279, DOI 10.1016/j.cell.2005.11.035; Brodersen P, 2008, SCIENCE, V320, P1185, DOI 10.1126/science.1159151; Buhtz A, 2008, PLANT J, V53, P739, DOI 10.1111/j.1365-313X.2007.03368.x; Carlsbecker A, 2010, NATURE, V465, P316, DOI 10.1038/nature08977; Chapman EJ, 2007, NAT REV GENET, V8, P884, DOI 10.1038/nrg2179; Chitwood DH, 2009, GENE DEV, V23, P549, DOI 10.1101/gad.1770009; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Deleris A, 2006, SCIENCE, V313, P68, DOI 10.1126/science.1128214; Dunoyer P, 2005, NAT GENET, V37, P1356, DOI 10.1038/ng1675; Dunoyer P, 2007, NAT GENET, V39, P848, DOI 10.1038/ng2081; Dunoyer P, 2010, EMBO J, V29, P1699, DOI 10.1038/emboj.2010.65; Dunoyer P, 2010, SCIENCE, V328, P912, DOI 10.1126/science.1185880; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Havecker ER, 2010, PLANT CELL, V22, P321, DOI 10.1105/tpc.109.072199; Himber C, 2003, EMBO J, V22, P4523, DOI 10.1093/emboj/cdg431; Kobayashi K, 2007, PLANT J, V50, P597, DOI 10.1111/j.1365-313X.2007.03073.x; Levine E, 2007, PLOS COMPUT BIOL, V3, P2356, DOI 10.1371/journal.pcbi.0030233; Liu Hong, 2008, Shengwu Jiagong Guocheng, V6, P40; Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045; Mi SJ, 2008, CELL, V133, P116, DOI 10.1016/j.cell.2008.02.034; Molnar A, 2010, SCIENCE, V328, P872, DOI 10.1126/science.1187959; Montgomery TA, 2008, CELL, V133, P128, DOI 10.1016/j.cell.2008.02.033; Mosher RA, 2009, NATURE, V460, P283, DOI 10.1038/nature08084; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Pant BD, 2008, PLANT J, V53, P731, DOI 10.1111/j.1365-313X.2007.03363.x; Parizotto EA, 2004, GENE DEV, V18, P2237, DOI 10.1101/gad.307804; Park MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI 10.1073/pnas.0405570102; Ruvkun G, 2008, NAT MED, V14, P1041, DOI 10.1038/nm1008-1041; Schwab R, 2006, PLANT CELL, V18, P1121, DOI 10.1105/tpc.105.039834; Schwach F, 2005, PLANT PHYSIOL, V138, P1842, DOI 10.1104/pp.105.063537; Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038; Smith LM, 2007, PLANT CELL, V19, P1507, DOI 10.1105/tpc.107.051540; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tretter EM, 2008, PLANT PHYSIOL, V147, P58, DOI 10.1104/pp.108.117119; Tucker MR, 2008, DEVELOPMENT, V135, P2839, DOI 10.1242/dev.023648; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vargason JM, 2003, CELL, V115, P799, DOI 10.1016/S0092-8674(03)00984-X; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Yoo BC, 2004, PLANT CELL, V16, P1979, DOI 10.1105/tpc.104.023614	42	198	216	2	69	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					415	419		10.1038/nature09351	http://dx.doi.org/10.1038/nature09351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864994				2022-12-28	WOS:000282090200033
J	Litvak, E; Pronovost, PJ				Litvak, Eugene; Pronovost, Peter J.			Rethinking Rapid Response Teams	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Litvak, Eugene] Inst Healthcare Optimizat, Newton, MA 02459 USA; [Litvak, Eugene] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Litvak, E (corresponding author), Inst Healthcare Optimizat, 7 Wells Ave, Newton, MA 02459 USA.	elitvak@ihoptimize.org						Baker DR, 2009, CRIT CARE MED, V37, P2882, DOI 10.1097/CCM.0b013e3181b01caf; Berwick DM, 2006, JAMA-J AM MED ASSOC, V295, P324, DOI 10.1001/jama.295.3.324; BUTTERFIELD S, 2007, ACP HOSP         DEC; DeVita MA, 2006, CRIT CARE MED, V34, P2463, DOI 10.1097/01.CCM.0000235743.38172.6E; Gross D., 2008, FUNDAMENTALS QUEUING; Litvak E., 2009, MANAGING PATIENT FLO; Litvak E, 2005, JT COMM J QUAL PATIE, V31, P330, DOI 10.1016/S1553-7250(05)31044-0; Organisation for Economic Co-operation and Development, OECD HLTH DAT 2010 S; Ranji SR, 2007, J HOSP MED, V2, P422, DOI 10.1002/jhm.238; Sakai T, 2009, J ANESTH, V23, P403, DOI 10.1007/s00540-009-0778-8	10	58	73	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1375	1376		10.1001/jama.2010.1385	http://dx.doi.org/10.1001/jama.2010.1385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858881				2022-12-28	WOS:000282007900021
J	Sasai, M; Linehan, MM; Iwasaki, A				Sasai, Miwa; Linehan, Melissa M.; Iwasaki, Akiko			Bifurcation of Toll-Like Receptor 9 Signaling by Adaptor Protein 3	SCIENCE			English	Article							INTERFERON-ALPHA PRODUCTION; I INTERFERON; DENDRITIC CELLS; AP-3 ADAPTER; INDUCTION; ACTIVATION; TLR9; TOLL-LIKE-RECEPTOR-9; LOCALIZATION; TRAF3	Endosomal Toll-like receptors (TLRs) 7 and 9 recognize viral pathogens and induce signals leading to the activation of nuclear factor kappa B (NF-kappa B)-dependent proinflammatory cytokines and interferon regulatory factor 7 (IRF7)-dependent type I interferons (IFNs). Recognition of viral nucleic acids by TLR9 requires its cleavage in the endolysosomal compartment. Here, we show that TLR9 signals leading to the activation of type I IFN, but not proinflammatory cytokine genes, require TLR9 trafficking from endosomes to a specialized lysosome-related organelle. Furthermore, we identify adapter protein-3 as the protein complex responsible for the trafficking of TLR9 to this subcellular compartment. Our results reveal an intracellular mechanism for bifurcation of TLR9 signals by selective receptor trafficking within the endosomal system.	[Sasai, Miwa; Linehan, Melissa M.; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA	Yale University	Iwasaki, A (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.	akiko.iwasaki@yale.edu	Iwasaki, Akiko/Z-1591-2019	Iwasaki, Akiko/0000-0002-7824-9856; Sasai, Miwa/0000-0001-6440-3958	NIH [AI054359, AI081884, AI064705]; Uehara Memorial Foundation; Gilead Sciences; Burroughs Wellcome Investigators in Pathogenesis of Infectious Disease; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054359, R01AI064705, R01AI081884] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Uehara Memorial Foundation(Uehara Memorial Foundation); Gilead Sciences(Gilead Sciences); Burroughs Wellcome Investigators in Pathogenesis of Infectious Disease(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank R. Medzhitov for critical reading of the manuscript and W. Mothes for helpful discussion. This work is supported by NIH grants to A. I. (AI054359, AI081884, and AI064705). M. S. is a Japan Society for the Promotion of Science fellow and a recipient of Uehara Memorial Foundation fellowship. A. I. acknowledges support by Gilead Sciences. A. I. is a recipient of the Burroughs Wellcome Investigators in Pathogenesis of Infectious Disease.	Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; DE MATTEIS MA, 2004, NAT CELL BIOL, V6, P487; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Ewald SE, 2008, NATURE, V456, P658, DOI 10.1038/nature07405; Gotoh K, 2010, J EXP MED, V207, P721, DOI 10.1084/jem.20091776; Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; Ikonomov OC, 2006, AM J PHYSIOL-CELL PH, V291, pC393, DOI 10.1152/ajpcell.00019.2006; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Park B, 2008, NAT IMMUNOL, V9, P1407, DOI 10.1038/ni.1669; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Shinohara ML, 2006, NAT IMMUNOL, V7, P498, DOI 10.1038/ni1327; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Watarai H, 2008, P NATL ACAD SCI USA, V105, P2993, DOI 10.1073/pnas.0710351105	29	257	260	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1530	1534		10.1126/science.1187029	http://dx.doi.org/10.1126/science.1187029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847273	Green Accepted			2022-12-28	WOS:000281869000044
J	Aguirre, A; Rubio, ME; Gallo, V				Aguirre, Adan; Rubio, Maria E.; Gallo, Vittorio			Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal	NATURE			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; GROWTH-FACTOR RECEPTOR; SUBVENTRICULAR ZONE; PROGENITOR CELLS; IN-VIVO; INTRACELLULAR DOMAIN; MAMMALIAN BRAIN; PROLIFERATION; NICHE; VISUALIZATION	Specialized cellular microenvironments, or 'niches', modulate stem cell properties, including cell number, self-renewal and fate decisions(1,2). In the adult brain, niches that maintain a source of neural stem cells (NSCs) and neural progenitor cells (NPCs) are the subventricular zone (SVZ) of the lateral ventricle and the dentate gyrus of the hippocampus(3-5). The size of the NSC population of the SVZ at any time is the result of several ongoing processes, including self-renewal, cell differentiation, and cell death. Maintaining the balance between NSCs and NPCs in the SVZ niche is critical to supply the brain with specific neural populations, both under normal conditions or after injury. A fundamental question relevant to both normal development and to cell-based repair strategies in the central nervous system is how the balance of different NSC and NPC populations is maintained in the niche. EGFR (epidermal growth factor receptor) and Notch signalling pathways have fundamental roles during development of multicellular organisms(6). In Drosophila and in Caenorhabditis elegans these pathways may have either cooperative or antagonistic functions(7-9). In the SVZ, Notch regulates NSC identity and self-renewal, whereas EGFR specifically affects NPC proliferation and migration(10-13). This suggests that interplay of these two pathways may maintain the balance between NSC and NPC numbers. Here we show that functional cell-cell interaction between NPCs and NSCs through EGFR and Notch signalling has a crucial role in maintaining the balance between these cell populations in the SVZ. Enhanced EGFR signalling in vivo results in the expansion of the NPC pool, and reduces NSC number and self-renewal. This occurs through a non-cell-autonomous mechanism involving EGFR-mediated regulation of Notch signalling. Our findings define a novel interaction between EGFR and Notch pathways in the adult SVZ, and thus provide a mechanism for NSC and NPC pool maintenance.	[Aguirre, Adan; Gallo, Vittorio] Childrens Natl Med Ctr, Neurosci Res Ctr, Washington, DC 20010 USA; [Rubio, Maria E.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15261 USA	Children's National Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gallo, V (corresponding author), Childrens Natl Med Ctr, Neurosci Res Ctr, Washington, DC 20010 USA.	vgallo@cnmcresearch.org			NIH [R01NS045702, R01NS056427, K99NS057944, ROO NS057944-03, R01DC006881]; NIH IDDRC [P30HD40677]; NSF [DBI-0420580]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K99NS057944, R01NS056427, R01NS045702, R00NS057944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006881] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH IDDRC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank N. Ratner for the Cnp-hEGFR mice. We are thankful to T. Hawley for technical advice in all FACS sorting experiments. We are grateful to J. Corbin and T. Haydar for critically reading this manuscript, and to all our colleagues at the Center for Neuroscience Research for discussion and support. We are thankful to N. Gaiano for discussion, for providing reagents and for his continuous advice on this project. We thank G. Corfas, A. Israel, C. L. Cepko, R. Kopan, R. Grosschedl, N. Gaiano and R. Kageyama for the gift of CBF-1, Hes1-GFP, Hes1-dsRED, Notch constructs, Dll-GFP, CBFRE-EGFP and Hes5-GFP, respectively. This work was supported by NIH R01NS045702 and R01NS056427 (V. G.), K99NS057944 (A. A.), ROO NS057944-03 (A. A.) and by NIH IDDRC P30HD40677 (V. G.). Electron microscopy was performed at the University of Connecticut, Department of Physiology and Neurobiology, with funding from NIH R01DC006881 to M.E.R., and from NSF DBI-0420580 for funds to purchase the Tecnai 12 Biotwin electron microscope.	Aguirre A, 2005, J NEUROSCI, V25, P11092, DOI 10.1523/JNEUROSCI.2981-05.2005; Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Aguirre A, 2007, NEURON GLIA BIOL, V3, P209, DOI 10.1017/S1740925X08000082; Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Alexson TO, 2006, DEV NEUROSCI-BASEL, V28, P34, DOI 10.1159/000090751; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Breunig JJ, 2007, P NATL ACAD SCI USA, V104, P20558, DOI 10.1073/pnas.0710156104; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chapman G, 2006, J CELL BIOL, V175, P535, DOI 10.1083/jcb.200602009; Colak D, 2008, J NEUROSCI, V28, P434, DOI 10.1523/JNEUROSCI.4374-07.2008; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1997, J NEUROSCI, V17, P5046; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Jablonska B, 2007, J CELL BIOL, V179, P1231, DOI 10.1083/jcb.200702031; Kohyama J, 2005, DEV BIOL, V286, P311, DOI 10.1016/j.ydbio.2005.08.003; Kolev V, 2005, FEBS LETT, V579, P5798, DOI 10.1016/j.febslet.2005.09.042; Kumar JP, 2001, DEVELOPMENT, V128, P2689; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lillien L, 2000, DEVELOPMENT, V127, P4993; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Mercier F, 2002, J COMP NEUROL, V451, P170, DOI 10.1002/cne.10342; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Ohtsuka T, 2006, MOL CELL NEUROSCI, V31, P109, DOI 10.1016/j.mcn.2005.09.006; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Steiner B, 2006, GLIA, V54, P805, DOI 10.1002/glia.20407; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Wehner T, 2003, J NEUROSCI, V23, P5004; Yoo AS, 2004, SCIENCE, V303, P663, DOI 10.1126/science.1091639	38	330	350	1	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					323	U101		10.1038/nature09347	http://dx.doi.org/10.1038/nature09347			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844536	Green Accepted			2022-12-28	WOS:000281824900038
J	Baratz, KH; Tosakulwong, N; Ryu, E; Brown, WL; Branham, K; Chen, W; Tran, KD; Schmid-Kubista, KE; Heckenlively, JR; Swaroop, A; Abecasis, G; Bailey, KR; Edwards, AO				Baratz, Keith H.; Tosakulwong, Nirubol; Ryu, Euijung; Brown, William L.; Branham, Kari; Chen, Wei; Tran, Khoa D.; Schmid-Kubista, Katharina E.; Heckenlively, John R.; Swaroop, Anand; Abecasis, Goncalo; Bailey, Kent R.; Edwards, Albert O.			E2-2 Protein and Fuchs's Corneal Dystrophy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SNOWFLAKE VITREORETINAL DEGENERATION; TYROSINE-PHOSPHATASE-GAMMA; ENDOTHELIAL DYSTROPHY; MACULAR DEGENERATION; TRANSCRIPTION FACTOR; MISSENSE MUTATIONS; IN-SITU; LINKAGE; FAMILY; EXPRESSION	BACKGROUND Fuchs's corneal dystrophy (FCD) is a leading cause of corneal transplantation and affects 5% of persons in the United States who are over the age of 40 years. Clinically visible deposits called guttae develop under the corneal endothelium in patients with FCD. A loss of endothelial cells and deposition of an abnormal extracellular matrix are observed microscopically. In advanced disease, the cornea swells and becomes cloudy because the remaining endothelial cells are not sufficient to keep the cornea dehydrated and clear. Although rare genetic variation that contributes to both early-onset and typical late-onset forms of FCD has been identified, to our knowledge, no common variants have been reported. METHODS We performed a genomewide association study and replicated the most significant observations in a second, independent group of subjects. RESULTS Alleles in the transcription factor 4 gene (TCF4), encoding a member of the E-protein family (E2-2), were associated with typical FCD (P = 2.3x10(-26)). The association increased the odds of having FCD by a factor of 30 for persons with two copies of the disease variants (homozygotes) and discriminated between case subjects and control subjects with about 76% accuracy. At least two regions of the TCF4 locus were associated independently with FCD. Alleles in the gene encoding protein tyrosine phosphatase receptor type G (PTPRG) were associated with FCD (P = 4.0x10(-7)), but the association did not reach genomewide significance. CONCLUSIONS Genetic variation in TCF4 contributes to the development of FCD. (Funded by the National Eye Institute and others.)	[Tran, Khoa D.; Edwards, Albert O.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; [Baratz, Keith H.; Brown, William L.; Schmid-Kubista, Katharina E.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA; [Tosakulwong, Nirubol; Ryu, Euijung; Bailey, Kent R.] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN USA; [Branham, Kari; Heckenlively, John R.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; [Chen, Wei; Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Swaroop, Anand] NEI, Bethesda, MD 20892 USA	University of Oregon; Mayo Clinic; Mayo Clinic; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Edwards, AO (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	edwardsa@uoregon.edu	Brown, William/GXN-2777-2022; Branham, Kari/AAA-8336-2022; Abecasis, Goncalo R/B-7840-2010; Chen, Wei/AAX-5994-2020	Chen, Wei/0000-0001-7196-8703; Swaroop, Anand/0000-0002-1975-1141; Abecasis, Goncalo/0000-0003-1509-1825; Branham, Kari/0000-0002-2492-254X	National Institutes of Health [EY014467, EY016862, HHSN268200782096C]; Foundation Fighting Blindness; American Health Assistance Foundation; Research to Prevent Blindness; Max Kade Foundation; NATIONAL EYE INSTITUTE [R01EY014467, ZIAEY000475, R01EY016862] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation Fighting Blindness(European Commission); American Health Assistance Foundation; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Max Kade Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported by grants from the National Institutes of Health (EY014467, EY016862, and HHSN268200782096C), the Foundation Fighting Blindness, the American Health Assistance Foundation, Research to Prevent Blindness, and the Max Kade Foundation.	Afshari NA, 2009, INVEST OPHTH VIS SCI, V50, P1093, DOI 10.1167/iovs.08-1839; Amiel J, 2007, AM J HUM GENET, V80, P988, DOI 10.1086/515582; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Beltran PJ, 2003, FRONT BIOSCI, V8, pD87, DOI 10.2741/941; Biswas S, 2001, HUM MOL GENET, V10, P2415, DOI 10.1093/hmg/10.21.2415; Bouyain S, 2010, P NATL ACAD SCI USA, V107, P2443, DOI 10.1073/pnas.0911235107; Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Engler C, 2010, AM J OPHTHALMOL, V149, P194, DOI 10.1016/j.ajo.2009.09.009; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flora A, 2007, P NATL ACAD SCI USA, V104, P15382, DOI 10.1073/pnas.0707456104; Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472; Hejtmancik JF, 2008, AM J HUM GENET, V82, P174, DOI 10.1016/j.ajhg.2007.08.002; HOGAN MJ, 1974, AM J OPHTHALMOL, V78, P363, DOI 10.1016/0002-9394(74)90224-4; Joyce NC, 1996, INVEST OPHTH VIS SCI, V37, P1566; Jurkunas UV, 2008, INVEST OPHTH VIS SCI, V49, P2956, DOI 10.1167/iovs.07-1529; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; KRACHMER JH, 1978, ARCH OPHTHALMOL-CHIC, V96, P2036, DOI 10.1001/archopht.1978.03910060424004; LAING RA, 1984, OPHTHALMOLOGY, V91, P1129; Lee MM, 2003, OPHTHALMOLOGY, V110, P2418, DOI 10.1016/S0161-6420(03)00828-5; Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242; Liu SL, 2004, ONCOGENE, V23, P1256, DOI 10.1038/sj.onc.1207235; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; LORENZETTI DW, 1967, AM J OPHTHALMOL, V64, P1155, DOI 10.1016/0002-9394(67)93073-5; McGowan SL, 2007, MOL VIS, V13, P1984; Moshirfar M, 2005, J CATARACT REFR SURG, V31, P2281, DOI 10.1016/j.jcrs.2004.05.061; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Riazuddin SA, 2010, AM J HUM GENET, V86, P45, DOI 10.1016/j.ajhg.2009.12.001; Riazuddin SA, 2009, INVEST OPHTH VIS SCI, V50, P5667, DOI 10.1167/iovs.09-3764; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Sobrado VR, 2009, J CELL SCI, V122, P1014, DOI 10.1242/jcs.028241; Sundin OH, 2006, INVEST OPHTH VIS SCI, V47, P140, DOI 10.1167/iovs.05-0578; Sundin OH, 2006, INVEST OPHTH VIS SCI, V47, P3919, DOI 10.1167/iovs.05-1619; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van Niekerk CC, 1999, CANCER LETT, V137, P61, DOI 10.1016/S0304-3835(98)00344-9; Vithana EN, 2008, HUM MOL GENET, V17, P656, DOI 10.1093/hmg/ddm337; Wang Z, 2007, OPHTHALMOLOGY, V114, P1453, DOI 10.1016/j.ophtha.2006.10.049; Zhang Cheng, 2006, Trans Am Ophthalmol Soc, V104, P85	42	193	202	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1016	1024		10.1056/NEJMoa1007064	http://dx.doi.org/10.1056/NEJMoa1007064			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825314				2022-12-28	WOS:000281609700005
J	Song, YJ; Otte, AF; Kuk, Y; Hu, YK; Torrance, DB; First, PN; de Heer, WA; Min, HK; Adam, S; Stiles, MD; MacDonald, AH; Stroscio, JA				Song, Young Jae; Otte, Alexander F.; Kuk, Young; Hu, Yike; Torrance, David B.; First, Phillip N.; de Heer, Walt A.; Min, Hongki; Adam, Shaffique; Stiles, Mark D.; MacDonald, Allan H.; Stroscio, Joseph A.			High-resolution tunnelling spectroscopy of a graphene quartet	NATURE			English	Article							ELECTRON-GAS; MASS	Electrons in a single sheet of graphene behave quite differently from those in traditional two-dimensional electron systems. Like massless relativistic particles, they have linear dispersion and chiral eigenstates. Furthermore, two sets of electrons centred at different points in reciprocal space ('valleys') have this dispersion, giving rise to valley degeneracy. The symmetry between valleys, together with spin symmetry, leads to a fourfold quartet degeneracy of the Landau levels, observed as peaks in the density of states produced by an applied magnetic field. Recent electron transport measurements have observed the lifting of the fourfold degeneracy in very large applied magnetic fields, separating the quartet into integer(1-4) and, more recently, fractional(5,6) levels. The exact nature of the broken-symmetry states that form within the Landau levels and lift these degeneracies is unclear at present and is a topic of intense theoretical debate(7-11). Here we study the detailed features of the four quantum states that make up a degenerate graphene Landau level. We use high-resolution scanning tunnelling spectroscopy at temperatures as low as 10 mK in an applied magnetic field to study the top layer of multilayer epitaxial graphene. When the Fermi level lies inside the fourfold Landau manifold, significant electron correlation effects result in an enhanced valley splitting for even filling factors, and an enhanced electron spin splitting for odd filling factors. Most unexpectedly, we observe states with Landau level filling factors of 7/2, 9/2 and 11/2, suggestive of new many-body states in graphene.	[Song, Young Jae; Otte, Alexander F.; Min, Hongki; Adam, Shaffique; Stiles, Mark D.; Stroscio, Joseph A.] NIST, Ctr Nanoscale Sci & Technol, Gaithersburg, MD 20899 USA; [Song, Young Jae; Otte, Alexander F.; Min, Hongki] Univ Maryland, Maryland NanoCtr, College Pk, MD 20742 USA; [Kuk, Young] Seoul Natl Univ, Dept Phys & Astron, Seoul 1517474, South Korea; [Hu, Yike; Torrance, David B.; First, Phillip N.; de Heer, Walt A.] Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; [MacDonald, Allan H.] Univ Texas Austin, Dept Phys, Austin, TX 78712 USA	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland College Park; Seoul National University (SNU); University System of Georgia; Georgia Institute of Technology; University of Texas System; University of Texas Austin	Stroscio, JA (corresponding author), NIST, Ctr Nanoscale Sci & Technol, Gaithersburg, MD 20899 USA.	joseph.stroscio@nist.gov	Song, Young Jae/A-5422-2013; Min, Hongki/C-3429-2009; Adam, Shaffique/B-3264-2008; MacDonald, Allan/M-9883-2019; MacDonald, Allan/GPF-8212-2022; Otte, Sander/A-4838-2013; Stiles, Mark/K-2426-2012	Song, Young Jae/0000-0001-6172-3817; Min, Hongki/0000-0001-5043-2432; Adam, Shaffique/0000-0002-3095-9920; MacDonald, Allan/0000-0003-3561-3379; Otte, Sander/0000-0003-0781-8537; Stiles, Mark/0000-0001-8238-4156	Korean Government (MOEHRD) [KRF- 2006-214-C00022]; NSF [DMR-0820382 [MRSEC], DMR-0804908, DMR-0606489]; Welch Foundation; Semiconductor Research Corporation	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); NSF(National Science Foundation (NSF)); Welch Foundation(The Welch Foundation); Semiconductor Research Corporation	We thank N. Zhitenev for discussions, S. Blankenship, A. Band and F. Hess for their technical contributions to the construction of the millikelvin scanning probe microscopy system, V. Shvarts for his advice on cryogenics and U. D. Ham for instructions on making silver probe tips. This work was supported in part by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF- 2006-214-C00022), the NSF (DMR-0820382 [MRSEC], DMR-0804908, DMR-0606489), the Welch Foundation and the Semiconductor Research Corporation (NRI-INDEX programme).	Abanin DA, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.196806; Alicea J, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.075422; ANDO T, 1974, J PHYS SOC JPN, V37, P1044, DOI 10.1143/JPSJ.37.1044; Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f; Bolotin KI, 2009, NATURE, V462, P196, DOI 10.1038/nature08582; Dial OE, 2007, NATURE, V448, P176, DOI 10.1038/nature05982; Dial OE, 2010, NATURE, V464, P566, DOI 10.1038/nature08941; Du X, 2009, NATURE, V462, P192, DOI 10.1038/nature08522; Eisenstein JP, 2004, NATURE, V432, P691, DOI 10.1038/nature03081; Gusynin VP, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.146801; Hass J, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.125504; Jiang Z, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.106802; Li GH, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.176804; Lilly MP, 1999, PHYS REV LETT, V82, P394, DOI 10.1103/PhysRevLett.82.394; Mele EJ, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.161405; Miller DL, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.125427; Miller DL, 2009, SCIENCE, V324, P924, DOI 10.1126/science.1171810; Nayak C, 2008, REV MOD PHYS, V80, P1083, DOI 10.1103/RevModPhys.80.1083; ONNES HK, 2011, COMM PHYS LAB U LE H, V120; Rezayi EH, 1999, PHYS REV LETT, V83, P1219, DOI 10.1103/PhysRevLett.83.1219; SMITH AP, 1992, PHYS REV B, V45, P8829, DOI 10.1103/PhysRevB.45.8829; VONKLITZING K, 1980, PHYS REV LETT, V45, P494, DOI 10.1103/PhysRevLett.45.494; Wang HQ, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.158001; YANG K, 2006, PHYS REV B, V74, P1; Zhang PP, 2007, ACS NANO, V1, P6, DOI 10.1021/nn7001344; Zhang Y, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.136806	30	148	149	3	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					185	189		10.1038/nature09330	http://dx.doi.org/10.1038/nature09330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829790				2022-12-28	WOS:000281616300029
J	Burke, MK; Dunham, JP; Shahrestani, P; Thornton, KR; Rose, MR; Long, AD				Burke, Molly K.; Dunham, Joseph P.; Shahrestani, Parvin; Thornton, Kevin R.; Rose, Michael R.; Long, Anthony D.			Genome-wide analysis of a long-term evolution experiment with Drosophila	NATURE			English	Article							SELECTION; ADAPTATION; GENETICS; LOCUS	Experimental evolution systems allow the genomic study of adaptation, and so far this has been done primarily in asexual systems with small genomes, such as bacteria and yeast(1-3). Here we present whole-genome resequencing data from Drosophila melanogaster populations that have experienced over 600 generations of laboratory selection for accelerated development. Flies in these selected populations develop from egg to adult similar to 20% faster than flies of ancestral control populations, and have evolved a number of other correlated phenotypes. On the basis of 688,520 intermediate-frequency, high-quality single nucleotide polymorphisms, we identify several dozen genomic regions that show strong allele frequency differentiation between a pooled sample of five replicate populations selected for accelerated development and pooled controls. On the basis of resequencing data from a single replicate population with accelerated development, as well as single nucleotide polymorphism data from individual flies from each replicate population, we infer little allele frequency differentiation between replicate populations within a selection treatment. Signatures of selection are qualitatively different than what has been observed in asexual species; in our sexual populations, adaptation is not associated with 'classic' sweeps whereby newly arising, unconditionally advantageous mutations become fixed. More parsimonious explanations include 'incomplete' sweep models, in which mutations have not had enough time to fix, and 'soft' sweep models, in which selection acts on pre-existing, common genetic variants. We conclude that, at least for life history characters such as development time, unconditionally advantageous alleles rarely arise, are associated with small net fitness gains or cannot fix because selection coefficients change over time.	[Burke, Molly K.; Shahrestani, Parvin; Thornton, Kevin R.; Rose, Michael R.; Long, Anthony D.] Univ Calif Irvine, Irvine, CA 92697 USA; [Dunham, Joseph P.] Univ So Calif, Los Angeles, CA 90098 USA	University of California System; University of California Irvine; University of Southern California	Burke, MK (corresponding author), Univ Calif Irvine, 321 Steinhaus Hall, Irvine, CA 92697 USA.	burkem@uci.edu; tdlong@uci.edu		Rose, Michael/0000-0002-7766-0731; Burke, Molly/0000-0002-4280-0247; Long, Tony/0000-0002-5007-8514; Thornton, Kevin/0000-0003-0743-4445	UCI; NSF [DEB-0614429, DGE-0638751]	UCI; NSF(National Science Foundation (NSF))	We thank K. Aeling and D. Heck at the UCI DNA and Protein Microarray Facility for help with preparation and sequencing of the ACO<INF>1</INF> library. The pooled ACO and CO libraries were sequenced at the University of Oregon High-Throughput Sequencing Facility, with advice from D. Turnbull. We are grateful to S. Nuzdhin, T. Turner and J. J. Emerson for providing suggestions during the conception of the project, and to O. Tenaillon and F. Barreto for comments on previous versions of the manuscript. We also thank A. K. Chippindale for discussion of the phenotype data. This work was supported by a UCI Faculty Research and Training Grant to M.R.R. and NSF DEB-0614429 to A.D.L. M.K.B. is supported by an NSF Graduate Fellowship in STEM K-12 Education (DGE-0638751).	Barrick JE, 2009, NATURE, V461, P1243, DOI 10.1038/nature08480; Bloom JS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-221; Chevin LM, 2008, GENETICS, V180, P1645, DOI 10.1534/genetics.108.093351; Chippindale Adam K., 2004, P413, DOI 10.1142/9789812567222_0034; Chippindale AK, 1997, EVOLUTION, V51, P1536, DOI [10.2307/2411206, 10.1111/j.1558-5646.1997.tb01477.x]; Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dunham MJ, 2002, P NATL ACAD SCI USA, V99, P16144, DOI 10.1073/pnas.242624799; Feder JL, 2003, P NATL ACAD SCI USA, V100, P10314, DOI 10.1073/pnas.1730757100; Garland Jr T., 2009, EXPT EVOLUTION CONCE; Hegreness M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-201; Hermisson J, 2005, GENETICS, V169, P2335, DOI 10.1534/genetics.104.036947; Herring CD, 2006, NAT GENET, V38, P1406, DOI 10.1038/ng1906; Hoekstra HE, 2007, EVOLUTION, V61, P995, DOI 10.1111/j.1558-5646.2007.00105.x; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; KAPLAN NL, 1989, GENETICS, V123, P887; Papadopoulos D, 1999, P NATL ACAD SCI USA, V96, P3807, DOI 10.1073/pnas.96.7.3807; Pelz HJ, 2005, GENETICS, V170, P1839, DOI 10.1534/genetics.104.040360; Przeworski M, 2005, EVOLUTION, V59, P2312, DOI 10.1554/05-273.1; Rose M.R., 2004, METHUSELAH FLIES CAS; Teotonio H, 2000, NATURE, V408, P463, DOI 10.1038/35044070; Teotonio H, 2009, NAT GENET, V41, P251, DOI 10.1038/ng.289	22	298	300	6	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					587	U111		10.1038/nature09352	http://dx.doi.org/10.1038/nature09352			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20844486				2022-12-28	WOS:000282273100038
J	de Bono, JS; Ashworth, A				de Bono, J. S.; Ashworth, Alan			Translating cancer research into targeted therapeutics	NATURE			English	Article							CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; PROGRESSION-FREE SURVIVAL; CLINICAL-TRIAL; ABIRATERONE ACETATE; PHASE-I; DRUG; GENE; IMATINIB; INHIBITION	The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects. Nevertheless, despite some successes drug development remains painfully slow. Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited. We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials. The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biology of the patient and their cancer.	[de Bono, J. S.] Inst Canc Res, Sutton SM2 5NG, Surrey, England; [de Bono, J. S.] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [Ashworth, Alan] Inst Canc Res, Breakthrough Breast Canc Ctr, London SW3 6JB, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	de Bono, JS (corresponding author), Inst Canc Res, Cotswold Rd, Sutton SM2 5NG, Surrey, England.	johann.de-bono@icr.ac.uk; alan.ashworth@icr.ac.uk		de Bono, Johann S/0000-0002-2034-595X	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Attard G, 2008, J CLIN PATHOL, V61, P891, DOI 10.1136/jcp.2008.056341; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Attard G, 2009, NAT REV UROL, V6, P473, DOI 10.1038/nrurol.2009.130; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827; Betensky RA, 2002, J CLIN ONCOL, V20, P2495, DOI 10.1200/JCO.2002.06.140; BOLLAG G, 2010, NATURE          0907, DOI DOI 10.1038/NATURE09454; Budd GT, 2006, CLIN CANCER RES, V12, P6403, DOI 10.1158/1078-0432.CCR-05-1769; Buyse M, 2000, BIOSTATISTICS, V1, P49, DOI DOI 10.1093/BIOSTATISTICS/1.1.49; Buyse M, 2007, J CLIN ONCOL, V25, P5218, DOI 10.1200/JCO.2007.11.8836; Carden CP, 2009, CLIN PHARMACOL THER, V85, P131, DOI 10.1038/clpt.2008.223; Carden CP, 2010, DRUG DISCOV TODAY, V15, P88, DOI 10.1016/j.drudis.2009.11.006; Collins I, 2006, NAT CHEM BIOL, V2, P689, DOI 10.1038/nchembio840; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; de Bono JS, 2007, CLIN CANCER RES, V13, P3611, DOI 10.1158/1078-0432.CCR-07-0268; de Bono JS, 2003, BREAST CANCER RES, V5, P154, DOI 10.1186/bcr597; De Giorgi U, 2009, J CLIN ONCOL, V27, P3303, DOI 10.1200/JCO.2008.19.4423; DiMasi JA, 2007, J CLIN ONCOL, V25, P209, DOI 10.1200/JCO.2006.09.0803; Dowsett M, 2007, JNCI-J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Goodsaid F, 2007, AAPS J, V9, pE105, DOI 10.1208/aapsj0901010; Grantab R, 2006, CANCER RES, V66, P1033, DOI 10.1158/0008-5472.CAN-05-3077; Greystoke A, 2008, ANN ONCOL, V19, P990, DOI 10.1093/annonc/mdn014; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hennessy BT, 2009, CLIN CANCER RES, V15, P417, DOI 10.1158/1078-0432.CCR-08-2620; INGLE JN, 1981, NEW ENGL J MED, V304, P16, DOI 10.1056/NEJM198101013040104; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Jordan VC, 2003, J NATL CANCER I, V95, P338, DOI 10.1093/jnci/95.5.338; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kreeger PK, 2010, CARCINOGENESIS, V31, P2, DOI 10.1093/carcin/bgp261; Kwak EL, 2009, J CLIN ONCOL, V27; Lord CJ, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-38; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mandrekar SJ, 2009, J CLIN ONCOL, V27, P4027, DOI 10.1200/JCO.2009.22.3701; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Olmos D, 2009, ANN ONCOL, V20, P27, DOI 10.1093/annonc/mdn544; Propper DJ, 2003, J CLIN ONCOL, V21, P203, DOI 10.1200/JCO.2003.02.008; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sobrero A, 2009, J CLIN ONCOL, V27, P5868, DOI 10.1200/JCO.2009.22.4162; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Taube SE, 2009, JNCI-J NATL CANCER I, V101, P1453, DOI 10.1093/jnci/djp334; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Workman P, 2008, CURR OPIN PHARMACOL, V8, P359, DOI 10.1016/j.coph.2008.07.007; Workman P, 2006, JNCI-J NATL CANCER I, V98, P580, DOI 10.1093/jnci/djj162; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004	70	242	246	2	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					543	549		10.1038/nature09339	http://dx.doi.org/10.1038/nature09339			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882008				2022-12-28	WOS:000282273100029
J	Chang, CC; Liu, KL				Chang, Chin-Chen; Liu, Kao-Lang			Bladder Diverticula	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chang, Chin-Chen; Liu, Kao-Lang] Natl Taiwan Univ Hosp, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital	Chang, CC (corresponding author), Natl Taiwan Univ Hosp, Taipei, Taiwan.			LIU, KAO-LANG/0000-0003-4100-8909; CHANG, CHIN-CHEN/0000-0002-0121-4866					0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					E13	E13		10.1056/NEJMicm0912917	http://dx.doi.org/10.1056/NEJMicm0912917			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20842786				2022-12-28	WOS:000280996600011
J	Snow, RW; Okiro, EA; Gething, PW; Atun, R; Hay, SI				Snow, Robert W.; Okiro, Emelda A.; Gething, Peter W.; Atun, Rifat; Hay, Simon I.			Equity and adequacy of international donor assistance for global malaria control:an analysis of populations at risk and external funding commitments	LANCET			English	Article							ELIMINATION		KEMRI Univ Oxford Wellcome Trust Collaborat, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford, England; Imperial Coll, Imperial Coll Business Sch, London, England; Global Fund To Fight AIDS TB & Malaria, Strategy Performance & Evaluat Cluster, Geneva, Switzerland	University of Oxford; Imperial College London	Snow, RW (corresponding author), KEMRI Univ Oxford Wellcome Trust Collaborat, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya.		Gething, Peter/ABD-2110-2020; Atun, Rifat/AAH-5537-2021; Gething, Peter/GQR-1884-2022; Hay, Simon Iain/F-8967-2015; Snow, Robert William/AFR-1436-2022	Gething, Peter/0000-0001-6759-5449; Hay, Simon Iain/0000-0002-0611-7272; Snow, Robert William/0000-0003-3725-6088; Atun, Rifat/0000-0002-1531-5983; Okiro, Emelda/0000-0001-9543-8360	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	Wellcome Trust	[Anonymous], GLOB MAL ACT PLAN MA; Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011; BALK DL, ADV PARASIT, V62, P119; *BBC, 2010, DAV 2010 W ACC IND C; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; *DON ASS COMM OECD, DAC LIST ODA REC US; Eisele TP, 2010, INT J EPIDEMIOL, V39, P88, DOI 10.1093/ije/dyq026; Feachem RGA, 2009, SHRINKING MALARIA MA, P187; GUERRA CA, 2009, PLOS NEGLECT TROP D, V4, pE744; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; International Monetary Fund, DEBT REL HEAV IND PO; Kiszewski A, 2007, B WORLD HEALTH ORGAN, V85, P623, DOI 10.2471/BLT.06.039529; Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882, DOI 10.4269/ajtmh.2009.80.882; Organization for Economic Cooperation and Development, CRED REP SYST; Presidents Malaria Initiative, 2009, PMI COUNTR PROF; *ROLL BACK MAL, MON EV REF GROUP; Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Teklehaimanot HD, 2009, AM J TROP MED HYG, V80, P133, DOI 10.4269/ajtmh.2009.80.133; The Global Fund, 2022, BMJ, DOI DOI 10.1136/BMJ.O2320; The World Bank, WORLDW GOV IND; *UN POP DIV, 2003, HUM DEV REP 2003 MIL; United Nat ions Populat ion Division, 2008, WORLD URB PROSP 2007; *WHO, WORLD MAL REP 2009; World Bank, BOOST PROGR MAL CONT; Yukich JO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-258	27	43	43	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2010	376	9750					1409	1416		10.1016/S0140-6736(10)61340-2	http://dx.doi.org/10.1016/S0140-6736(10)61340-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672ZO	20889199	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000283627500039
J	McCormack, S; Ramjee, G; Kamali, A; Rees, H; Crook, AM; Gafos, M; Jentsch, U; Pool, R; Chisembele, M; Kapiga, S; Mutemwa, R; Vallely, A; Palanee, T; Sookrajh, Y; Lacey, CJ; Darbyshire, J; Grosskurth, H; Profy, A; Nunn, A; Hayes, R; Weber, J				McCormack, Sheena; Ramjee, Gita; Kamali, Anatoli; Rees, Helen; Crook, Angela M.; Gafos, Mitzy; Jentsch, Ute; Pool, Robert; Chisembele, Maureen; Kapiga, Saidi; Mutemwa, Richard; Vallely, Andrew; Palanee, Thesla; Sookrajh, Yuki; Lacey, Charles J.; Darbyshire, Janet; Grosskurth, Heiner; Profy, Albert; Nunn, Andrew; Hayes, Richard; Weber, Jonathan			PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial	LANCET			English	Article							CANDIDATE TOPICAL MICROBICIDES; PRO 2000 GEL; VIRUS-INFECTION; PRO-2000 GEL; III TRIAL; ACCEPTABILITY; INHIBITION; EFFICACY; CONDOMS; SAFETY	Background Innovative prevention strategies for HIV-1 transmission are urgently needed. PRO2000 vaginal gel was efficacious against HIV-1 transmission in studies in macaques; we aimed to assess efficacy and safety of 2% and 0.5% PRO2000 gels against vaginal HIV-1 transmission in women in sub-Saharan Africa. Methods Microbicides Development Programme 301 was a phase 3, randomised, double-blind, parallel-group trial, undertaken at 13 clinics in South Africa, Tanzania, Uganda, and Zambia. We randomly assigned sexually active women, aged 18 years or older (>= 16 years in Tanzania and Uganda) without HIV-1 infection in a 1:1:1 ratio to 2% PRO2000, 0.5% PRO2000, or placebo gel groups for 52 weeks (up to 104 weeks in Uganda). Randomisation was done by computerised random number generator. Investigators and participants were masked to group assignment. The primary efficacy outcome was incidence of HIV-1 infection before week 52, which was censored for pregnancy and exduded participants without HIV-1 follow-up data or with HIV-1 infection at enrolment. HIV-1 status was established by rapid tests or ELISA at screening at 12 weeks, 24 weeks, 40 weeks, and 52 weeks, and confirmed in a central reference laboratory. The primary safety endpoint was an adverse event of grade 3 or worse. Use of 2% PRO2000 gel was discontinued on Feb 14,2008, on the recommendation of the Independent Data Monitoring Committee because of low probability of benefit. This trial is registered at http://isrctn.org, number ISRCTN 64716212. Findings We enrolled 9385 of 15 818 women screened. 2591 (95%) of 2734 participants enrolled to the 2% PRO2000 group, 3156 (95%) of 3326 in the 0.5% PRO2000 group, and 3112 (94%) of 3325 in the placebo group were included in the primary efficacy analysis. Mean reported gel use at last sex act was 89% (95% CI 86-91). HIV-1 incidence was much the same between groups at study end (incidence per 100 woman-years was 4.5 [95% CI 3.8-5.4] for 0.5% PRO2000 vs 4.3 [3.6-5.2] for placebo, hazard ratio 1.05 [0.82-1.34], p=0.71), and at discontinuation (4.7 [3.8-5.8] for 2% PRO2000 gel, 3.9 [3.0-4.9] for 0.5% PRO2000 gel, and 3.9 [3.1-5.0] for placebo gel). Incidence of the primary safety endpoint at study end was 4.6 per 100 woman-years (95% CI 3.9-5.4) in the 0.5% PRO2000 group and 3.9 (3.2-4.6) in the placebo group; and was 4.5 (3.7-5.5) in the 2% PRO2000 group at discontinuation. Interpretation Although safe, 0.5% PRO2000 and 2% PR02000 are not efficacious against vaginal HIV-1 transmission and are not indicated for this use.	[McCormack, Sheena; Crook, Angela M.; Darbyshire, Janet; Nunn, Andrew] MRC, Clin Trials Unit, London NW1 2DA, England; [Ramjee, Gita; Sookrajh, Yuki] MRC, HIV Prevent Res Unit, Durban, South Africa; [Kamali, Anatoli; Grosskurth, Heiner] MRC, UVRI Uganda Res Unit, Entebbe, Uganda; [Rees, Helen; Palanee, Thesla] Univ Witwatersrand, Reprod Hlth & Res Unit, Johannesburg, South Africa; [Jentsch, Ute] Univ Witwatersrand, Contract Lab Serv, Johannesburg, South Africa; [Gafos, Mitzy] Africa Ctr Hlth & Populat Studies, Mtubatuba, South Africa; [Pool, Robert] Univ Barcelona, Barcelona, Spain; [Pool, Robert] Univ Amsterdam, Amsterdam, Netherlands; [Chisembele, Maureen] Univ Teaching Hosp, Lusaka, Zambia; [Kapiga, Saidi] Mwanza Intervent Trials Unit, Mwanza, Tanzania; [Mutemwa, Richard; Vallely, Andrew; Hayes, Richard] London Sch Hyg & Trop Med, London WC1, England; [Vallely, Andrew] African Med & Res Fdn AMREF, Mwanza, Tanzania; [Lacey, Charles J.] Univ York, York YO10 5DD, N Yorkshire, England; [Profy, Albert] Endo Pharmaceut Solut, Chadds Ford, PA USA; [Weber, Jonathan] Univ London Imperial Coll Sci Technol & Med, London, England	Medical Research Council Clinical Trials Unit; University of Witwatersrand; University of Witwatersrand; University of Kwazulu Natal; University of Barcelona; University of Amsterdam; University of Zambia; University of London; London School of Hygiene & Tropical Medicine; African Medical & Research Foundation (AMREF); University of York - UK; Endo Pharmaceuticals Inc.; Imperial College London	McCormack, S (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	smc@ctu.mrc.ac.uk	Palanee-Phillips, Thesla/ABD-2449-2020	Hayes, Richard/0000-0002-1729-9892; Nunn, Andrew/0000-0002-9158-4595; Kapiga, Saidi/0000-0003-1753-4060; Vallely, Andrew/0000-0003-1558-4822; Grosskurth, Heiner/0000-0001-9960-7280; Rees, Helen/0000-0003-1442-6734; Gafos, Mitzy/0000-0002-7894-1498	Endo Pharmaceutical Solutions; UK Department for International Development; UK Medical Research Council; Medical Research Council [MC_U950080930, G0700837, G0501954, G0100137] Funding Source: researchfish; National Institute for Health Research [NF-SI-0507-10313] Funding Source: researchfish; MRC [MC_U950080930, G0100137, G0501954, G0700837] Funding Source: UKRI	Endo Pharmaceutical Solutions; UK Department for International Development; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the women who participated in the Microbicides Development Programme (MOP) 301 trial for their commitment, and the male partners who supported them; the MOP staff; the Trial Steering Committee (Anna Glasier [Chair], Mike Chirenje, Anne Johnson, Ade Lucas, Alwyn Mwinga, Angelina Wapakabulo, and Christopher Smangaliso Ntshele); the Independent Data Monitoring Committee (Alasdair Breckenridge [Chair], Catherine Hill, Isaac Malonza, and Florence Mirembe); the HIV Endpoint Committee (CIL, JW, and Adrian Purens); and Alan Stone (Chair, International Working Group on Microbicides) who facilitated international links. MOP is a partnership of African and European academic and governmental institutions with commercial organisations, and is funded by the UK Department for International Development and UK Medical Research Council. All employee institutions listed by the investigators, apart from the University of Amsterdam, contributed through provision of facilities or salary contributions. Study gels were provided by Endo Pharmaceutical Solutions.	Bourne N, 1999, J INFECT DIS, V180, P203, DOI 10.1086/314853; Cheshenko N, 2004, ANTIMICROB AGENTS CH, V48, P2025, DOI 10.1128/AAC.48.6.2025-2036.2004; Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474; Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000; Halpern V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003784; *IND PHARM 1, 2007, INV BROCH UN PLAC VE; *IND PHARM 1, 2008, INV BROCH PRO2005 5; Kamali A, 2010, SEX TRANSM INFECT, V86, P222, DOI 10.1136/sti.2009.038372; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SA, 2009, 16 C RETR OPP INF MO; Keller MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008781; Keller MJ, 2006, J INFECT DIS, V193, P27, DOI 10.1086/498533; Lacey CJN, 2006, AIDS, V20, P1027, DOI 10.1097/01.aids.0000222075.83490.ca; Mauck C, 2001, AIDS, V15, P857, DOI 10.1097/00002030-200105040-00006; Mayer KH, 2003, AIDS, V17, P321, DOI 10.1097/00002030-200302140-00005; Montgomery CM, 2008, AIDS CARE, V20, P733, DOI 10.1080/09540120701693974; Nunn A, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-99; Pool R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011600; Pool R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011632; Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234, DOI 10.1128/AAC.40.1.234; Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5; Spencer SE, 2004, J INFECT DIS, V189, P410, DOI 10.1086/381125; Tabet SR, 2003, JAIDS-J ACQ IMM DEF, V33, P476, DOI 10.1097/00126334-200308010-00008; *UN AIDS WHO, AIDS EP UPD JOINT UN; Van Damme L, 2000, SEX TRANSM INFECT, V76, P126, DOI 10.1136/sti.76.2.126; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957; Weber J, 2001, AIDS, V15, P1563, DOI 10.1097/00002030-200108170-00014	28	258	260	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1329	1337		10.1016/S0140-6736(10)61086-0	http://dx.doi.org/10.1016/S0140-6736(10)61086-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20851460	Green Published, Green Accepted			2022-12-28	WOS:000283528600035
J	Hallek, M; Fischer, K; Fingerle-Rowson, G; Fink, AM; Busch, R; Mayer, J; Hensel, M; Hopfinger, G; Hess, G; von Grunhagen, U; Bergmann, M; Catalano, J; Zinzani, PL; Caligaris-Cappio, F; Seymour, JF; Berrebi, A; Jager, U; Cazin, B; Trneny, M; Westermann, A; Wendtner, CM; Eichhorst, BF; Staib, P; Buhler, A; Winkler, D; Zenz, T; Bottcher, S; Ritgen, M; Mendila, M; Kneba, M; Dohner, H; Stilgenbauer, S				Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Gruenhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P. L.; Caligaris-Cappio, F.; Seymour, J. F.; Berrebi, A.; Jaeger, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.; Staib, P.; Buehler, A.; Winkler, D.; Zenz, T.; Boettcher, S.; Ritgen, M.; Mendila, M.; Kneba, M.; Doehner, H.; Stilgenbauer, S.		Int Grp Investigators; German Chronic Lymphocytic Leukaem	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial	LANCET			English	Article							STEM-CELL TRANSPLANTATION; PROGRESSION-FREE SURVIVAL; PLUS CYCLOPHOSPHAMIDE; CYTOKINE-RELEASE; INITIAL THERAPY; III TRIAL; CHEMOIMMUNOTHERAPY; EXPRESSION; LYMPHOMA; DELETION	Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. Methods Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on day 1 of second to sixth courses) in 190 centres in 11 countries. Investigators and patients were not masked to the computer-generated treatment assignment. The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00281918. Findings 408 patients were assigned to fludarabine, cyclophosphamide, and rituximab (chemoimmunotherapy group) and 409 to fludarabine and cyclophosphamide (chemotherapy group); all patients were analysed. At 3 years after randomisation, 65% of patients in the chemoimmunotherapy group were free of progression compared with 45% in the chemotherapy group (hazard ratio 0.56 [95% CI 0.46-0.69], p<0.0001); 87% were alive versus 83%, respectively (0.67 [0.48-0.92]; p=0.01). Chemoimmunotherapy was more frequently associated with grade 3 and 4 neutropenia (136 [34%] of 404 vs 83 [21%] of 396; p<0.0001) and leucocytopenia (97 [24%] vs 48 [12%]; p<0.0001). Other side-effects, including severe infections, were not increased. There were eight (2%) treatment-related deaths in the chemoimmunotherapy group compared with ten (3%) in the chemotherapy group. Interpretation Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia. Moreover, the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytic leukaemia.	[Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany; [Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.] Univ Cologne, Ctr Integrated Oncol, D-50924 Cologne, Germany; [Busch, R.] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany; [Mayer, J.] Univ Hosp Brno, Dept Internal Med Haematol & Oncol, Brno, Czech Republic; [Hensel, M.] Univ Heidelberg, Heidelberg, Germany; [Hopfinger, G.] Hanusch Hosp, Dept Med 3, Vienna, Austria; [Hess, G.] Johannes Gutenberg Univ Mainz, Dept Haematol & Oncol, Mainz, Germany; [von Gruenhagen, U.] Praxis Hamatol & Onkol, Cottbus, Germany; [Bergmann, M.] Univ Munich, Dept Internal Med 3, Munich, Germany; [Catalano, J.] Frankston Hosp, Haematol Dept & Dorevitch Pathol, Frankston, Vic, Australia; [Zinzani, P. L.] Univ Bologna, Dept Haematol & Oncol, Bologna, Italy; [Caligaris-Cappio, F.] Univ Sci Res Inst San Raffaele, Milan, Italy; [Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Seymour, J. F.] Univ Melbourne, Melbourne, Vic, Australia; [Berrebi, A.] Kaplan Med Ctr, Haematol Inst, Rehovot, Israel; [Jaeger, U.] Med Univ Vienna, Div Haematol & Haemostaseol, Dept Internal Med 1, Vienna, Austria; [Cazin, B.] Hop Claude Huriez, Serv Malad Sang, Lille, France; [Trneny, M.] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic; [Staib, P.] St Antonius Hosp, Klin Hamatol & Onkol, Eschweiler, Germany; [Buehler, A.; Winkler, D.; Zenz, T.; Doehner, H.; Stilgenbauer, S.] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany; [Boettcher, S.; Ritgen, M.; Kneba, M.] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany; [Mendila, M.] Hoffmann La Roche AG, Div Pharmaceut, Basel, Switzerland	University of Cologne; University of Cologne; Technical University of Munich; University Hospital Brno; Ruprecht Karls University Heidelberg; WGKK - Hanusch Hospital; Johannes Gutenberg University of Mainz; University of Munich; Frankston Hospital; University of Bologna; Peter Maccallum Cancer Center; University of Melbourne; Hebrew University of Jerusalem; Kaplan Medical Center; Medical University of Vienna; Universite de Lille - ISITE; CHU Lille; Charles University Prague; General University Hospital Prague; Saint Antonius Hospital; Ulm University; University of Kiel; Schleswig Holstein University Hospital; Roche Holding	Hallek, M (corresponding author), Univ Cologne, Dept Internal Med 1, Kerpener Str 62, D-50924 Cologne, Germany.	michael.hallek@uni-koeln.de	Stilgenbauer, Stephan/ABE-6609-2020; Hallek, Michael/Y-3191-2019; Döhner, Hartmut/C-8933-2016; Zinzani, Pier Luigi/J-9182-2016; Seymour, John/K-7326-2019; Pigeot, Iris/A-2722-2012; Mayer, Jiri/I-2377-2014	Hallek, Michael/0000-0002-7425-4455; Döhner, Hartmut/0000-0003-2116-5536; Zinzani, Pier Luigi/0000-0002-2112-2651; Seymour, John/0000-0003-2188-6835; Pigeot, Iris/0000-0001-7483-0726; Trneny, Marek/0000-0002-6952-6073; Fink, Anna Maria/0000-0002-7669-7890	F Hoffmann-La Roche	F Hoffmann-La Roche(Hoffmann-La Roche)	The trial was funded by F Hoffmann-La Roche. We thank all patients and physicians for their participation in the study; and Stephan Zurfluh and Jamie Wingate for their excellent support and cooperation during the conduct of this trial. Preliminary results were presented in part at the annual meetings of the American Society of Hematology, San Francisco, CA, USA, Dec 6-9, 2008, and New Orleans, LA, USA, Dec 5-8, 2009.	ALMASRI NM, 1992, AM J HEMATOL, V40, P259, DOI 10.1002/ajh.2830400404; Binet JL, 2006, BLOOD, V107, P859, DOI 10.1182/blood-2005-04-1677; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; Dores GAM, 2007, BRIT J HAEMATOL, V139, P809, DOI 10.1111/j.1365-2141.2007.06856.x; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Extermann M, 1998, J CLIN ONCOL, V16, P1582, DOI 10.1200/JCO.1998.16.4.1582; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Geisler C, 1999, JNCI-J NATL CANCER I, V91, P861; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Grever MR, 2007, J CLIN ONCOL, V25, P799, DOI 10.1200/JCO.2006.08.3089; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; Hallek M, 1996, LEUKEMIA LYMPHOMA, V22, P439, DOI 10.3109/10428199609054782; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HAN T, 1973, CANCER-AM CANCER SOC, V31, P502, DOI 10.1002/1097-0142(197303)31:3<502::AID-CNCR2820310303>3.0.CO;2-7; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; KEATING MJ, 1989, BLOOD, V74, P19; KNOSPE WH, 1974, CANCER, V33, P555, DOI 10.1002/1097-0142(197402)33:2<555::AID-CNCR2820330234>3.0.CO;2-I; Kunzmann V, 2001, BLOOD, V98, P1991, DOI 10.1182/blood.V98.6.1991; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; Michallet AS, 2009, BLOOD REV, V23, P11, DOI 10.1016/j.blre.2008.05.002; Moreno C, 2005, J CLIN ONCOL, V23, P3433, DOI 10.1200/JCO.2005.04.531; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Schetelig J, 2008, J CLIN ONCOL, V26, P5094, DOI 10.1200/JCO.2008.16.2982; Schlette EJ, 2009, LEUKEMIA LYMPHOMA, V50, P1597, DOI 10.1080/10428190903165241; Schulz H, 2002, BLOOD, V100, P3115, DOI 10.1182/blood-2002-03-0972; Schulz H, 2007, JNCI-J NATL CANCER I, V99, P706, DOI 10.1093/jnci/djk152; Tam CS, 2008, BLOOD, V112, P975, DOI 10.1182/blood-2008-02-140582; Tsimberidou AM, 2009, CANCER-AM CANCER SOC, V115, P373, DOI 10.1002/cncr.23993; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224	41	1453	1505	0	98	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1164	1174		10.1016/S0140-6736(10)61381-5	http://dx.doi.org/10.1016/S0140-6736(10)61381-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888994				2022-12-28	WOS:000282915700033
J	Orom, UA; Derrien, T; Beringer, M; Gumireddy, K; Gardini, A; Bussotti, G; Lai, F; Zytnicki, M; Notredame, C; Huang, QH; Guigo, R; Shiekhattar, R				Orom, Ulf Andersson; Derrien, Thomas; Beringer, Malte; Gumireddy, Kiranmai; Gardini, Alessandro; Bussotti, Giovanni; Lai, Fan; Zytnicki, Matthias; Notredame, Cedric; Huang, Qihong; Guigo, Roderic; Shiekhattar, Ramin			Long Noncoding RNAs with Enhancer-like Function in Human Cells	CELL			English	Article							TRANSCRIPTION; GENE; REVEALS; IDENTIFICATION; MECHANISMS; EXPRESSION; POSITION; ELEMENT; GENOME; REGION	While the long noncoding RNAs (ncRNAs) constitute a large portion of the mammalian transcriptome, their biological functions has remained elusive. A few long ncRNAs that have been studied in any detail silence gene expression in processes such as X-inactivation and imprinting. We used a GENCODE annotation of the human genome to characterize over a thousand long ncRNAs that are expressed in multiple cell lines. Unexpectedly, we found an enhancer-like function for a set of these long ncRNAs in human cell lines. Depletion of a number of ncRNAs led to decreased expression of their neighboring protein-coding genes, including the master regulator of hematopoiesis, SCL (also called TAL1), Snai1 and Snai2. Using heterologous transcription assays we demonstrated a requirement for the ncRNAs in activation of gene expression. These results reveal an unanticipated role for a class of long ncRNAs in activation of critical regulators of development and differentiation.	[Orom, Ulf Andersson; Beringer, Malte; Gumireddy, Kiranmai; Gardini, Alessandro; Lai, Fan; Huang, Qihong; Shiekhattar, Ramin] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Derrien, Thomas; Bussotti, Giovanni; Zytnicki, Matthias; Notredame, Cedric; Guigo, Roderic; Shiekhattar, Ramin] UPF, Ctr Genom Regulat CRG, Barcelona, Spain; [Shiekhattar, Ramin] ICREA, Barcelona, Spain	The Wistar Institute; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); ICREA	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.org	Beringer, Malte/N-3766-2015; Jha, Rajneesh/L-5606-2017; Beringer, Malte/AAC-5734-2020; lai, fan/A-9732-2011; Ørom, Ulf A/F-6727-2010; Derrien, Thomas/ABD-6197-2020; Orom, Ulf A/G-1327-2010; Lai, Fan/ABD-2862-2021; Guigo, Roderic/D-1303-2010; notredame, cedric/G-3868-2010; Bussotti, Giovanni/C-3082-2019	Beringer, Malte/0000-0003-1958-9786; Guigo, Roderic/0000-0002-5738-4477; notredame, cedric/0000-0003-1461-0988; Lai, Fan/0000-0002-0568-2616; Derrien, Thomas/0000-0002-8211-5789; Bussotti, Giovanni/0000-0002-4078-7413; Orom, Ulf/0000-0002-0643-0592	Danish Research Council; HFSPO; American Italian Cancer Foundation; Spanish ministry, GENCODE [U54 HG004555-01]; NIH [GM 079091]; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG004555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079091] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	Danish Research Council(Det Frie Forskningsrad (DFF)); HFSPO(Human Frontier Science Program); American Italian Cancer Foundation; Spanish ministry, GENCODE(Spanish Government); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ICREA(ICREA)	Thanks to the HAVANA team for use of their genome annotation. We also thank the CRG Genomic Facility and the Functional Genomics Core Facility at Wistar and UPenn for expertise in microarray analysis. We thank Dr. Ken Zaret for helpful discussions. U.A.O. is supported by a grant from the Danish Research Council; M.B. is supported by an HFSPO fellowship; A.G. was supported by a fellowship from the American Italian Cancer Foundation; R.G. was supported through Spanish ministry, GENCODE U54 HG004555-01, and NIH; and R.S. was supported by a grant from NIH, GM 079091.	BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Berezikov E, 2005, HUM MOL GENET, V14, pR183, DOI 10.1093/hmg/ddi271; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Blanco Enrique, 2007, Curr Protoc Bioinformatics, VChapter 4, DOI 10.1002/0471250953.bi0403s18; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Denoeud F, 2007, GENOME RES, V17, P746, DOI 10.1101/gr.5660607; Efroni S, 2008, CELL STEM CELL, V2, P437, DOI 10.1016/j.stem.2008.03.021; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; Fejes-Toth K, 2009, NATURE, V457, P1028, DOI 10.1038/nature07759; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Harrow J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s4; Heard E, 2006, GENE DEV, V20, P1848, DOI 10.1101/gad.1422906; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P875, DOI 10.1128/MCB.4.5.875; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; KHALIL AM, 2009, P NATL ACAD SCI US; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KIM TK, 2010, NATURE; Kong SM, 1997, MOL CELL BIOL, V17, P3955, DOI 10.1128/MCB.17.7.3955; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lecuyer E, 2004, EXP HEMATOL, V32, P11, DOI 10.1016/j.exphem.2003.10.010; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lunter G, 2006, PLOS COMPUT BIOL, V2, P2, DOI 10.1371/journal.pcbi.0020005; Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Parra G, 2000, GENOME RES, V10, P511, DOI 10.1101/gr.10.4.511; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Preker P, 2008, SCIENCE, V322, P1851, DOI 10.1126/science.1164096; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253; Shamovsky I, 2006, NATURE, V440, P556, DOI 10.1038/nature04518; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yang PK, 2007, CELL, V128, P777, DOI 10.1016/j.cell.2007.01.032	47	1396	1462	4	197	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	2010	143	1					46	58		10.1016/j.cell.2010.09.001	http://dx.doi.org/10.1016/j.cell.2010.09.001			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887892	Green Accepted, Green Submitted, Bronze, Green Published			2022-12-28	WOS:000282362000013
J	Pitt, C; Greco, G; Powell-Jackson, T; Mills, A				Pitt, Catherine; Greco, Giulia; Powell-Jackson, Timothy; Mills, Anne			Countdown to 2015: assessment of official development assistance to maternal, newborn, and child health, 2003-08	LANCET			English	Article							GLOBAL HEALTH; DEVELOPING-COUNTRIES; FOREIGN-AID; SYSTEMS	Background Achievement of high coverage of effective interventions and Millennium Development Goals (MDGs) 4 and 5A requires adequate financing. Many of the 68 priority countries in the Countdown to 2015 Initiative are dependent on official development assistance (ODA). We analysed aid flows for maternal, newborn, and child health for 2007 and 2008 and updated previous estimates for 2003-06. Methods We manually coded and analysed the complete aid activities database of the Organisation for Economic Co-operation and Development for 2007 and 2008 with methods that we previously developed to track ODA. By use of newly available data for donor disbursement and population estimates, we revised data for 2003-06. We analysed the degree to which donors target their ODA to recipients with the greatest maternal and child health needs and examined trends over the 6 years. Findings In 2007 and 2008, US$4.7 billion and $5.4 billion (constant 2008 US$), respectively, were disbursed in support of maternal, newborn, and child health activities in all developing countries. These amounts reflect a 105% increase between 2003 and 2008, but no change relative to overall ODA for health, which also increased by 105%. Countdown priority countries received $3.4 billion in 2007 and $4.1 billion in 2008, representing 71.6% and 75.6% of all maternal, newborn, and child health disbursements, respectively. Targeting of ODA to countries with high rates of maternal and child mortality improved over the 6-year period, although some of these countries persistently received far less ODA per head than did countries with much lower mortality rates and higher income levels. Funding from the GAVI Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria exceeded core funding from multilateral institutions, and bilateral funding also increased substantially between 2003 and 2008, especially from the USA and the UK. Interpretation The increases in ODA to maternal, newborn, and child health during 2003-08 are to be welcomed, as is the somewhat improved targeting of ODA to countries with greater needs. Nonetheless, these increases do not reflect increased prioritisation relative to other health areas.	[Pitt, Catherine; Greco, Giulia; Powell-Jackson, Timothy; Mills, Anne] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Hlth Econ & Financing Programme, London WC1H 9SH, England	University of London; London School of Hygiene & Tropical Medicine	Pitt, C (corresponding author), London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Hlth Econ & Financing Programme, 15-17 Tavistock Pl, London WC1H 9SH, England.	catherine.pitt@lshtm.ac.uk	Pitt, Catherine K/K-3001-2012	Pitt, Catherine K/0000-0003-4967-8966; Mills, Anne/0000-0001-9863-9950; Greco, Giulia/0000-0002-5448-9521	Partnership for Maternal, Newborn, and Child Health	Partnership for Maternal, Newborn, and Child Health	This study was undertaken as part of the Countdown to 2015 Financing Working Group's effort to track finances for maternal, newborn, and child health. The study was funded by the Partnership for Maternal, Newborn, and Child Health on behalf of the Countdown to 2015. We thank Peter Berman, Henrik Axelson, Karin Stenberg, and Giorgio Cometto for comments on an earlier version of the report, as well as several anonymous reviewers.	Alesina A, 2000, J ECON GROWTH, V5, P33, DOI 10.1023/A:1009874203400; [Anonymous], 2010, WORLD HLTH STAT 2010; [Anonymous], 2004, HUM RES HLTH OV CRIS; [Anonymous], WORLD POP PROSP 2008; Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; Cometto G, 2010, DISASTERS, V34, P885, DOI 10.1111/j.1467-7717.2010.01174.x; Easterly W, 2008, J ECON PERSPECT, V22, P29, DOI 10.1257/jep.22.2.29; Farag M, 2009, HEALTH AFFAIR, V28, P1045, DOI 10.1377/hlthaff.28.4.1045; Fryatt R, 2010, LANCET, V375, P419, DOI 10.1016/S0140-6736(09)61833-X; Greco G, 2008, LANCET, V371, P1268, DOI 10.1016/S0140-6736(08)60561-9; Lu CL, 2010, LANCET, V375, P1375, DOI 10.1016/S0140-6736(10)60233-4; OECD, 2008, ACCR AG ACT; *OECD, 2010, US GUID CRS AID ACT; *OECD, 2010, DAC LIST ODA REC US; OECD, INF NOT DAC DEFL; OECD, 2010, STAT ANN 2010 DEV CO; *OECD, 2007, REP DIR CRED REP SYS; OECD, 2005, PARIS DECLARATION AI; Patel P, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000090; Piva P, 2009, B WORLD HEALTH ORGAN, V87, P930, DOI 10.2471/BLT.08.058677; Powell-Jackson T, 2006, LANCET, V368, P1077, DOI 10.1016/S0140-6736(06)69338-0; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Schaferhoff M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000305; Shiffman J, 2006, HEALTH POLICY PLANN, V21, P411, DOI 10.1093/heapol/czl028; Sridhar D, 2008, LANCET, V372, P1185, DOI 10.1016/S0140-6736(08)61485-3; *TASKF INN INT FIN, RAIS CHANN FUNDS WOR; Taskforce on Innovative International Financing for Health Systems, 2009, CONSTR SCAL COSTS WO; The World Bank, COUNTR LEND GROUPS; United States Department of Labour, 2010, CHILD MON SIT CHILDR; *USAID, 2009, DJIB; Wagstaff A, 2004, MILLENNIUM GOALS HLT; World Health Organization, 2010, 290 WHO	33	64	65	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1485	1496		10.1016/S0140-6736(10)61302-5	http://dx.doi.org/10.1016/S0140-6736(10)61302-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	20850869				2022-12-28	WOS:000284248500031
J	Torres, EM; Dephoure, N; Panneerselvam, A; Tucker, CM; Whittaker, CA; Gygi, SP; Dunham, MJ; Amon, A				Torres, Eduardo M.; Dephoure, Noah; Panneerselvam, Amudha; Tucker, Cheryl M.; Whittaker, Charles A.; Gygi, Steven P.; Dunham, Maitreya J.; Amon, Angelika			Identification of Aneuploidy-Tolerating Mutations	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL INSTABILITY; YEAST; DEGRADATION; PROTEASOME; CELLS; DEUBIQUITINATION; DEPLETION; CODE	Aneuploidy causes a proliferative disadvantage in all normal cells analyzed to date, yet this condition is associated with a disease characterized by unabated proliferative potential, cancer. The mechanisms that allow cancer cells to tolerate the adverse effects of aneuploidy are not known. To probe this question, we identified aneuploid yeast strains with improved proliferative abilities. Their molecular characterization revealed strain-specific genetic alterations as well as mutations shared between different aneuploid strains. Among the latter, a loss-of-function mutation in the gene encoding the deubiquitinating enzyme Ubp6 improves growth rates in four different aneuploid yeast strains by attenuating the changes in intracellular protein composition caused by aneuploidy. Our results demonstrate the existence of aneuploidy-tolerating mutations that improve the fitness of multiple different aneuploidies and highlight the importance of ubiquitin-proteasomal degradation in suppressing the adverse effects of aneuploidy.	[Torres, Eduardo M.; Panneerselvam, Amudha; Whittaker, Charles A.; Amon, Angelika] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Torres, Eduardo M.; Amon, Angelika] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Dephoure, Noah; Gygi, Steven P.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Tucker, Cheryl M.] Princeton Univ, Lewis Sigler Inst, Princeton, NJ 08540 USA; [Dunham, Maitreya J.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Princeton University; University of Washington; University of Washington Seattle	Amon, A (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	angelika@mit.edu	Dephoure, Noah/N-7818-2014	Dephoure, Noah/0000-0001-5802-2657; Whittaker, Charles/0000-0002-2400-0094; Amon, Angelika/0000-0001-9837-0314; Dunham, Maitreya/0000-0001-9944-2666	National Institutes of Health [GM56800, P50 GM071508]; Charles King Trust; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508, R29GM056800, R01GM056800] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles King Trust; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Daniel Finley, Philip Hieter, and Juergen Dohmen for reagents and to Daniel Finley, John Hanna, Frank Solomon, and members of the Amon lab for suggestions and their critical reading of this manuscript. This work was supported by National Institutes of Health grant GM56800 and a Charles King Trust postdoctoral Fellowship to ET. M.J.D. and C.M.T. were supported in part by National Institutes of Health grant P50 GM071508. A.A. is also an Investigator of the Howard Hughes Medical Institute.	Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Anders KR, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-36; Ben-Aroya S, 2008, MOL CELL, V30, P248, DOI 10.1016/j.molcel.2008.02.021; Chernova TA, 2003, J BIOL CHEM, V278, P52102, DOI 10.1074/jbc.M310283200; DAVIES J, 1964, P NATL ACAD SCI USA, V51, P883, DOI 10.1073/pnas.51.5.883; DAVIES J, 1968, J BIOL CHEM, V243, P3312; Dettman JR, 2007, NATURE, V447, P585, DOI 10.1038/nature05856; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gresham D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000303; Gunjan A, 2003, CELL, V115, P537, DOI 10.1016/S0092-8674(03)00896-1; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; Peth A, 2009, MOL CELL, V36, P794, DOI 10.1016/j.molcel.2009.11.015; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Williams BR, 2009, CANCER RES, V69, P5289, DOI 10.1158/0008-5472.CAN-09-0944; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zeyl C, 2006, FEMS YEAST RES, V6, P685, DOI 10.1111/j.1567-1364.2006.00061.x	29	267	269	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	2010	143	1					71	83		10.1016/j.cell.2010.08.038	http://dx.doi.org/10.1016/j.cell.2010.08.038			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20850176	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000282362000015
J	Goldbeck-Wood, S				Goldbeck-Wood, Sandy			Commentary: Female sexual dysfunction is a real but complex problem	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Goldbeck-Wood, Sandy] Camden & Islington Mental Hlth Trust, London WC1X 9DN, England; [Goldbeck-Wood, Sandy] Ipswich Hosp Trust, Ipswich IP4 5PD, Suffolk, England	Ipswich Hospital NHS Trust; Ipswich Hospital	Goldbeck-Wood, S (corresponding author), Camden & Islington Mental Hlth Trust, London WC1X 9DN, England.	goldbeckwood@doctors.org.uk						Althof SE, 2005, J SEX MED, V2, P793, DOI 10.1111/j.1743-6109.2005.00145.x; DeRogatis LR, 2007, J SEX MED, V4, P527, DOI 10.1111/j.1743-6109.2007.00485.x; Goldbeck-Wood S, 2004, BRIT MED J, V329, P245, DOI 10.1136/bmj.329.7460.245; Goldbeck-Wood S, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2826; Greenhalgh T, 1998, BMJ; Kirkengen AL, 2010, LIVED EXPERIENCE VIO; Laumann EO, 2005, INT J IMPOT RES, V17, P39, DOI 10.1038/sj.ijir.3901250; Marwick C, 1999, JAMA-J AM MED ASSOC, V281, P2173, DOI 10.1001/jama.281.23.2173; Moynihan R., 2010, SEX LIES PHARM; Moynihan R, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c830; Skrine R, 2001, PSYCHOSEXUAL MED INT	11	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 30	2010	341								c5336	10.1136/bmj.c5336	http://dx.doi.org/10.1136/bmj.c5336			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659NI	20884703				2022-12-28	WOS:000282573000002
J	Mehanna, H; West, CML; Nutting, C; Paleri, V				Mehanna, H.; West, C. M. L.; Nutting, C.; Paleri, V.			Head and neck cancer-Part 2: Treatment and prognostic factors	BRITISH MEDICAL JOURNAL			English	Review							SQUAMOUS-CELL CARCINOMA; QUALITY-OF-LIFE; HUMAN-PAPILLOMAVIRUS; RADIOTHERAPY; CHEMOTHERAPY; RADIATION; TRIAL; FLUOROURACIL; DOCETAXEL; CISPLATIN		[Mehanna, H.] Univ Hosp Coventry, Inst Head & Neck Studies & Educ, Coventry CV2 2DX, England; [West, C. M. L.] Univ Manchester, Manchester, England; [Nutting, C.] Royal Marsden NHS Fdn Trust, Head & Neck Unit, London, England; [Paleri, V.] Newcastle upon Tyne Hosp NHS Trust, Otolaryngol Head & Neck Surg, Newcastle upon Tyne, England	University of Warwick; University of Manchester; Royal Marsden NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Mehanna, H (corresponding author), Univ Hosp Coventry, Inst Head & Neck Studies & Educ, Coventry CV2 2DX, England.	hishammehanna@aol.com	West, Catharine/J-4152-2012	West, Catharine/0000-0002-0839-3449; Paleri, Vinidh/0000-0002-7933-4585; Mehanna, Hisham/0000-0002-5544-6224	NCC-Health Technology Assessment Unit; Cancer Research UK; Macmillan Fund; Bayer	NCC-Health Technology Assessment Unit; Cancer Research UK(Cancer Research UK); Macmillan Fund; Bayer(Bayer AG)	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that they had no financial support for the submitted work; HM is the director of an institute that does contract work for GSK, which has interests in head and neck cancers; he has also received grants from NCC-Health Technology Assessment Unit, Cancer Research UK, and Macmillan Fund. CN has received three clinical trial grants from Cancer Research UK and is principal investigator on a drug trial sponsored by Bayer; all authors have no other relationships or activities that could appear to have influenced the submitted work.	Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Bhalavat RL, 2003, EUR J SURG ONCOL, V29, P750, DOI 10.1016/S0748-7983(03)00072-6; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Denis F, 2003, INT J RADIAT ONCOL, V55, P93, DOI 10.1016/S0360-3016(02)03819-1; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Langendijk JA, 2008, J CLIN ONCOL, V26, P3770, DOI 10.1200/JCO.2007.14.6647; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; List MA, 2000, J CLIN ONCOL, V18, P877, DOI 10.1200/JCO.2000.18.4.877; Mehanna HM, 2006, CLIN OTOLARYNGOL, V31, P204, DOI 10.1111/j.1749-4486.2006.01188.x; National Institute for Health and Clinical Excellence, 2004, IMPR OUTC HEAD NECK; Nuttin C, 2009, J CLIN ONCOL, V27, p18s; PALERI V, 2010, HEAD NECK IN PRESS; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Rivera F, 2009, EXPERT REV ANTICANC, V9, P1421, DOI [10.1586/era.09.113, 10.1586/ERA.09.113]; Royal College of Pathologists, 2005, STAND DAT REP CANC D; *SCOTT INT GUID NE, 2006, HEAD NECK CANC MAN; Silva P, 2007, CLIN OTOLARYNGOL, V32, P337, DOI 10.1111/j.1749-4486.2007.01544.x; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Weber RS, 2003, ARCH OTOLARYNGOL, V129, P44, DOI 10.1001/archotol.129.1.44; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	27	27	27	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 28	2010	341								c4690	10.1136/bmj.c4690	http://dx.doi.org/10.1136/bmj.c4690			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659MF	20876637				2022-12-28	WOS:000282569900005
J	Choa, R; Sharp, R; Mahtani, KR				Choa, Robert; Sharp, Robert; Mahtani, Kamal R.			10-Minute Consultation Hallux valgus	BRITISH MEDICAL JOURNAL			English	Editorial Material							ORTHOSES		[Mahtani, Kamal R.] Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England; [Choa, Robert; Sharp, Robert] Nuffield Orthopaed Ctr, Dept Foot & Ankle Surg, Oxford OX3 7LD, England	University of Oxford; Nuffield Orthopaedic Centre	Mahtani, KR (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England.	kamal.mahtani@dphpc.ox.ac.uk			National Institute for Health Research [ACF-2008-13-014] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Coughlin MJ, 2007, FOOT ANKLE INT, V28, P759, DOI 10.3113/FAI.2007.0759; Coughlin MJ, 1996, J BONE JOINT SURG AM, V78A, P932, DOI 10.2106/00004623-199606000-00018; COUGHLIN MJ, 2006, SURG FOOT ANKLE, P230; Landsman A, 2009, J AM PODIAT MED ASSN, V99, P206, DOI 10.7547/0980206; Nguyen USDT, 2010, OSTEOARTHR CARTILAGE, V18, P41, DOI 10.1016/j.joca.2009.07.008; SIMFOOK L, 1958, J BONE JOINT SURG AM, V40, P1058, DOI 10.2106/00004623-195840050-00007; Torkki M, 2003, ACTA ORTHOP SCAND, V74, P209, DOI 10.1080/00016470310013987	7	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 27	2010	341								c5130	10.1136/bmj.c5130	http://dx.doi.org/10.1136/bmj.c5130			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659LV	20876149				2022-12-28	WOS:000282568900002
J	Green, DH; Hibberson, WO; Kovacs, I; Rosenthal, A				Green, David H.; Hibberson, William O.; Kovacs, Istvan; Rosenthal, Anja			Water and its influence on the lithosphere-asthenosphere boundary	NATURE			English	Article							QUANTITATIVE-ANALYSIS; MIDOCEAN RIDGES; PHASE-RELATIONS; HIGH-PRESSURES; MANTLE; MELT; H2O; PERIDOTITE; AMPHIBOLE; OLIVINE	The Earth has distinctive convective behaviour, described by the plate tectonics model, in which lateral motion of the oceanic lithosphere of basaltic crust and peridotitic uppermost mantle is decoupled from the underlying mechanically weaker upper mantle (asthenosphere). The reason for differentiation at the lithosphere-asthenosphere boundary is currently being debated with relevant observations from geophysics (including seismology) and geo-chemistry (including experimental petrology). Water is thought to have an important effect on mantle rheology, either by weakening the crystal structure of olivine and pyroxenes by dilute solid solution(1), or by causing low-temperature partial melting(2). Here we present a novel experimental approach to clarify the role of water in the uppermost mantle at pressures up to 6 GPa, equivalent to a depth of 190 km. We found that for lherzolite in which a water-rich vapour is present, the temperature at which a silicate melt first appears (the vapour-saturated solidus) increases from a minimum of 970 degrees C at 1.5 GPa to 1,350 degrees C at 6 GPa. We have measured the water content in lherzolite to be approximately 180 parts per million, retained in nominally anhydrous minerals at 2.5 and 4 GPa at temperatures above and below the vapour-saturated solidus. The hydrous mineral pargasite is the main water-storage site in the uppermost mantle, and the instability of pargasite at pressures greater than 3 GPa (equivalent to more than about 90 km depth) causes a sharp drop in both the water-storage capacity and the solidus temperature of fertile upper-mantle lherzolite. The presence of interstitial melt in mantle with more than 180 parts per million of water at pressures greater than 3 GPa alters mantle rheology and defines the lithosphere-asthenosphere boundary. Modern asthenospheric mantle acting as the source for mid-oceanic ridge basalts has a water content of 50-200 parts per million (refs 3-5). We show that this matches the water content of residual nominally anhydrous minerals after incipient melting of lherzolite at the vapour-saturated solidus at high pressure.	[Green, David H.] Univ Tasmania, Sch Earth Sci, Hobart, Tas 7001, Australia; [Green, David H.] Univ Tasmania, Ctr Ore Deposit Studies, Hobart, Tas 7001, Australia; [Green, David H.; Hibberson, William O.; Kovacs, Istvan; Rosenthal, Anja] Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; [Kovacs, Istvan] Eotvos Lorand Geophys Inst Hungary, Dept Data Management, H-1145 Budapest, Hungary	University of Tasmania; University of Tasmania; Australian National University	Green, DH (corresponding author), Univ Tasmania, Sch Earth Sci, Hobart, Tas 7001, Australia.	David.H.Green@utas.edu.au	Rosenthal, Anja/J-9393-2014; Kovacs, Istvan/A-1267-2008; Green, David/A-5288-2008	Rosenthal, Anja/0000-0003-3912-4046; Kovacs, Istvan/0000-0002-3488-3716; Green, David/0000-0002-5290-2087	Australian Research Council; A.E. Ringwood Memorial Scholarship; Australian International Postgraduate Research Scholarship; Marie Curie International Reintegration Grant [NAMS-230937]; Australian National University	Australian Research Council(Australian Research Council); A.E. Ringwood Memorial Scholarship; Australian International Postgraduate Research Scholarship; Marie Curie International Reintegration Grant(European Commission); Australian National University(Australian National University)	We thank H. St C. O'Neill, J. Hermann and G. M. Yaxley for discussions, and F. Brink for comprehensive support at scanning electron microscopy (SEM) facilities. We appreciate the help of J. Blundy in the revision of the original manuscript. This research was supported by Australian Research Council grants to D. H. G., and to G. M. Yaxley and D. H. G. I. K. was supported by an A.E. Ringwood Memorial Scholarship, an Australian International Postgraduate Research Scholarship and a Marie Curie International Reintegration Grant (NAMS-230937). A. R. was supported by an Australian National University PhD Scholarship.	Artemieva IM, 2009, LITHOS, V109, P23, DOI 10.1016/j.lithos.2008.09.015; Asahara Y, 2001, PHYS EARTH PLANET IN, V125, P31, DOI 10.1016/S0031-9201(01)00208-4; Asimow PD, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000568; BELL DR, 1995, AM MINERAL, V80, P465; Bell DR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000679; BOWEN NL, 1949, GEOL SOC AM BULL, V60, P439, DOI 10.1130/0016-7606(1949)60[439:TSM]2.0.CO;2; BREY G, 1977, CONTRIB MINERAL PETR, V61, P141, DOI 10.1007/BF00374364; Danyushevsky LV, 2000, J PETROL, V41, P1329, DOI 10.1093/petrology/41.8.1329; Faul UH, 2001, NATURE, V410, P920, DOI 10.1038/35073556; Faul UH, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004586; Green D.H., 1998, EARTHS MANTLE COMPOS, P311, DOI DOI 10.1017/CB09780511573101.010; GREEN DH, 1973, EARTH PLANET SC LETT, V19, P37, DOI 10.1016/0012-821X(73)90176-3; GREEN DH, 1973, EARTH PLANET SC LETT, V17, P456, DOI 10.1016/0012-821X(73)90214-8; GREEN DH, 1975, GEOLOGY, V3, P11, DOI 10.1130/0091-7613(1975)3<11:EDOTEO>2.0.CO;2; GREEN DH, 1971, PHILOS TR R SOC S-A, V268, P707, DOI 10.1098/rsta.1971.0022; Grove TL, 2006, EARTH PLANET SC LETT, V249, P74, DOI 10.1016/j.epsl.2006.06.043; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Kessel R, 2005, EARTH PLANET SC LETT, V237, P873, DOI 10.1016/j.epsl.2005.06.018; Kovacs I, 2008, AM MINERAL, V93, P765, DOI 10.2138/am.2008.2656; MCKENZIE D, 1988, J PETROL, V29, P625, DOI 10.1093/petrology/29.3.625; Mibe K, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2005JB004125; MICHAEL PJ, 1995, EARTH PLANET SC LETT, V170, P215; MILHOLLEN GL, 1974, J GEOL, V82, P575; Niida K, 2006, GEOCHIM COSMOCHIM AC, V70, pA445, DOI 10.1016/j.gca.2006.06.894; Niida K, 1999, CONTRIB MINERAL PETR, V135, P18, DOI 10.1007/s004100050495; Sobolev AV, 1996, EARTH PLANET SC LETT, V137, P45, DOI 10.1016/0012-821X(95)00203-O; Tenner TJ, 2009, CHEM GEOL, V262, P42, DOI 10.1016/j.chemgeo.2008.12.006; Thybo H, 2006, TECTONOPHYSICS, V416, P53, DOI 10.1016/j.tecto.2005.11.021; WYLLIE PJ, 1978, J GEOL, V86, P687, DOI 10.1086/649737	30	246	269	4	154	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					448	U97		10.1038/nature09369	http://dx.doi.org/10.1038/nature09369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20865000				2022-12-28	WOS:000282090200040
J	Papazian, L; Forel, JM; Gacouin, A; Penot-Ragon, C; Perrin, G; Loundou, A; Jaber, S; Arnal, JM; Perez, D; Seghboyan, JM; Constantin, JM; Courant, P; Lefrant, JY; Guerin, C; Prat, G; Morange, S; Roch, A				Papazian, Laurent; Forel, Jean-Marie; Gacouin, Arnaud; Penot-Ragon, Christine; Perrin, Gilles; Loundou, Anderson; Jaber, Samir; Arnal, Jean-Michel; Perez, Didier; Seghboyan, Jean-Marie; Constantin, Jean-Michel; Courant, Pierre; Lefrant, Jean-Yves; Guerin, Claude; Prat, Gwenael; Morange, Sophie; Roch, Antoine		ACURASYS Study Investigators	Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; MECHANICAL VENTILATION; BLOCKING-AGENTS; WEAKNESS; OUTCOMES	Background: In patients undergoing mechanical ventilation for the acute respiratory distress syndrome (ARDS), neuromuscular blocking agents may improve oxygenation and decrease ventilator-induced lung injury but may also cause muscle weakness. We evaluated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in patients with early, severe ARDS. Methods: In this multicenter, double-blind trial, 340 patients presenting to the intensive care unit (ICU) with an onset of severe ARDS within the previous 48 hours were randomly assigned to receive, for 48 hours, either cisatracurium besylate (178 patients) or placebo (162 patients). Severe ARDS was defined as a ratio of the partial pressure of arterial oxygen (PaO(sub 2)) to the fraction of inspired oxygen (FIO(sub 2)) of less than 150, with a positive end-expiratory pressure of 5 cm or more of water and a tidal volume of 6 to 8 ml per kilogram of predicted body weight. The primary outcome was the proportion of patients who died either before hospital discharge or within 90 days after study enrollment (i.e., the 90-day in-hospital mortality rate), adjusted for predefined covariates and baseline differences between groups with the use of a Cox model. Results: The hazard ratio for death at 90 days in the cisatracurium group, as compared with the placebo group, was 0.68 (95% confidence interval [CI], 0.48 to 0.98; P=0.04), after adjustment for both the baseline PaO(sub 2):FIO(sub 2) and plateau pressure and the Simplified Acute Physiology II score. The crude 90-day mortality was 31.6% (95% CI, 25.2 to 38.8) in the cisatracurium group and 40.7% (95% CI, 33.5 to 48.4) in the placebo group (P=0.08). Mortality at 28 days was 23.7% (95% CI, 18.1 to 30.5) with cisatracurium and 33.3% (95% CI, 26.5 to 40.9) with placebo (P=0.05). The rate of ICU-acquired paresis did not differ significantly between the two groups. Conclusions: In patients with severe ARDS, early administration of a neuromuscular blocking agent improved the adjusted 90-day survival and increased the time off the ventilator without increasing muscle weakness. (Funded by Assistance Publique-Hopitaux de Marseille and the Programme Hospitalier de Recherche Clinique Regional 2004-26 of the French Ministry of Health; ClinicalTrials.gov number, NCT00299650.) N Engl J Med 2010;363:1107-16.	[Papazian, Laurent] Hop Nord Marseille, Serv Reanimat Med, Assistance Publ Hop Marseille, CNRS,URMITE,UMR 6236, F-13009 Marseille, France; [Loundou, Anderson] Univ Aix Marseille 2, Fac Med, F-13284 Marseille 07, France; [Penot-Ragon, Christine] Hop St Marguerite, Marseille, France; [Morange, Sophie] Assistance Publ Hop Marseille, INSERM 9502, Ctr Invest Clin, Marseille, France; [Seghboyan, Jean-Marie] Hop Ambroise Pare, Marseille, France; [Gacouin, Arnaud] Hop Pontchaillou, Rennes, France; [Jaber, Samir] Hop St Eloi, Montpellier, France; [Perez, Didier] Hop Jean Minjoz, F-25030 Besancon, France; [Arnal, Jean-Michel] Hop Font Pre, Toulon, France; [Constantin, Jean-Michel] Hop Hotel Dieu, Clermont Ferrand, France; [Courant, Pierre] Ctr Hosp, Avignon, France; [Lefrant, Jean-Yves] Hop Caremeau, Nimes, France; [Guerin, Claude] Hop Croix Rousse, F-69317 Lyon, France; [Prat, Gwenael] Hop Cavale Blanche, Brest, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; CHU Rennes; Universite de Montpellier; CHU de Montpellier; Universite de Franche-Comte; CHU Besancon; CHU Clermont Ferrand; Universite de Montpellier; CHU de Nimes; CHU Lyon; CHU Brest; Universite de Bretagne Occidentale	Papazian, L (corresponding author), Hop Nord Marseille, Serv Reanimat Med, Assistance Publ Hop Marseille, CNRS,URMITE,UMR 6236, Chemin Bourrely, F-13009 Marseille, France.	laurent.papazian@ap-hm.fr	Leone, Marc/P-4835-2016; guerin, claude/H-5692-2014	Leone, Marc/0000-0002-3097-758X; guerin, claude/0000-0003-4700-6672; Guervilly, Christophe/0000-0001-9066-6591; ALLARDET-SERVENT, Jerome/0000-0002-6464-2382	Assistance Publique-Hopitaux de Marseille; Ministere de la Sante	Assistance Publique-Hopitaux de Marseille; Ministere de la Sante	Supported by the Assistance Publique-Hopitaux de Marseille and a grant from the Ministere de la Sante (Programme Hospitalier de Recherche Clinique Regional 2004-26). GlaxoSmithKline France provided the study drugs.	*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Bernard GR, 2005, AM J RESP CRIT CARE, V172, P798, DOI 10.1164/rccm.200504-663OE; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Davis NA, 1998, CRIT CARE MED, V26, P1290, DOI 10.1097/00003246-199807000-00038; DE JONGHE B, 2002, JAMA-J AM MED ASSOC, V288, P2859; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Forel JM, 2006, CRIT CARE MED, V34, P2749, DOI 10.1097/01.CCM.0000239435.87433.0D; Gainnier M, 2004, CRIT CARE MED, V32, P113, DOI 10.1097/01.CCM.0000104114.72614.BC; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; Leatherman JW, 1996, AM J RESP CRIT CARE, V153, P1686, DOI 10.1164/ajrccm.153.5.8630621; Malhotra A, 2007, NEW ENGL J MED, V357, P1113, DOI 10.1056/NEJMct074213; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Murray MJ, 2002, CRIT CARE MED, V30, P142, DOI 10.1097/00003246-200201000-00021; MURRAY MJ, 1995, CRIT CARE MED, V23, P450, DOI 10.1097/00003246-199503000-00007; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Samuelson Karin A, 2003, Intensive Crit Care Nurs, V19, P350; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Testelmans D, 2006, CRIT CARE MED, V34, P3018, DOI 10.1097/01.CCM.0000245783.28478.AD; Vender Jeffery S, 2004, Crit Care Med, V32, pS554, DOI 10.1097/01.CCM.0000145907.86298.12; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806	25	1448	1547	1	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1107	1116		10.1056/NEJMoa1005372	http://dx.doi.org/10.1056/NEJMoa1005372			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843245				2022-12-28	WOS:000281795800005
J	Fitch, MT; Atkinson, HH; Burns, CA; Lambros, MA				Fitch, Michael T.; Atkinson, Hal H.; Burns, Cynthia A.; Lambros, M. Ann			Association of Institutional Financial Support of a Core Teaching Faculty With Educational Productivity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							US MEDICAL-SCHOOLS; ACADEMIES; TIME		[Fitch, Michael T.] Wake Forest Univ, Bowman Gray Sch Med, Dept Emergency Med, Winston Salem, NC 27109 USA; [Atkinson, Hal H.; Burns, Cynthia A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA; [Lambros, M. Ann] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Fitch, MT (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Emergency Med, Winston Salem, NC 27109 USA.	mfitch@wfubmc.edu						Barzansky B, 2010, ACAD MED, V85, P260, DOI 10.1097/ACM.0b013e3181c85b22; Dewey CM, 2005, ACAD MED, V80, P358, DOI 10.1097/00001888-200504000-00012; Griner PF, 2000, JAMA-J AM MED ASSOC, V283, P2429, DOI 10.1001/jama.283.18.2429; Searle NS, 2010, ACAD MED, V85, P48, DOI 10.1097/ACM.0b013e3181c4846b; Zibrowski EM, 2008, MED EDUC, V42, P872, DOI 10.1111/j.1365-2923.2008.03145.x	5	1	1	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1169	1170		10.1001/jama.2010.1317	http://dx.doi.org/10.1001/jama.2010.1317			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841529	Bronze			2022-12-28	WOS:000281770600008
J	Salehi-Khojin, A; Lin, KY; Field, CR; Masel, RI				Salehi-Khojin, Amin; Lin, Kevin Y.; Field, Christopher R.; Masel, Richard I.			Nonthermal Current-Stimulated Desorption of Gases from Carbon Nanotubes	SCIENCE			English	Article							ELECTRICAL-CONDUCTIVITY; TRANSPORT; PHOTODESORPTION; OXYGEN; FILMS	The desorption of gases from carbon nanotubes is usually a slow process that limits the nanotubes' utility as sensors or as memristors. Here, we demonstrate that flow in the nanotube above the Poole-Frenkel conduction threshold can stimulate adsorbates to desorb without heating the sensor substantially. The method is general: alcohols, aromatics, amines, and phosphonates were all found to desorb. We postulate that the process is analogous to electron-stimulated desorption, but with an internally conducted rather than externally applied source of electrons.	[Salehi-Khojin, Amin; Lin, Kevin Y.; Field, Christopher R.; Masel, Richard I.] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Masel, RI (corresponding author), Univ Illinois, Dept Chem & Biomol Engn, 600 S Mathews Ave, Urbana, IL 61801 USA.	r-masel@illinois.edu	Masel, Richard I/E-1957-2011	Masel, Richard I/0000-0002-7392-6299	Cbana Laboratories; Dioxide Materials	Cbana Laboratories; Dioxide Materials	This work was supported by grants from Cbana Laboratories and Dioxide Materials. C.R.F. developed the sensor fabrication method that allowed the measurements to be made. K.Y.L. took most of the data. A.S.-K. directed much of the data acquisition and worked with R. I. M. to understand how Poole-Frenkel conduction would affect nanotube sensor response. R.I.M. wondered if current stimulated could occur and asked A.S.-K. to devise experiments to see if it did occur. R.I.M. and A.S.-K. drafted the paper. The authors are submitting patents based on some aspects of the work.	Agnihotri S, 2005, CARBON, V43, P2379, DOI 10.1016/j.carbon.2005.04.020; Bass AD, 2003, LOW TEMP PHYS+, V29, P202, DOI 10.1063/1.1542441; Behnam A, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2945644; Bondavalli P, 2009, SENSOR ACTUAT B-CHEM, V140, P304, DOI 10.1016/j.snb.2009.04.025; CHANG Y, 2008, ANGEW CHEM, V47, P5018; Chen RJ, 2001, APPL PHYS LETT, V79, P2258, DOI 10.1063/1.1408274; Field CR, 2010, SENSOR ACTUAT B-CHEM, V148, P315, DOI 10.1016/j.snb.2010.05.026; Goldoni A, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/1/013001; Jombert AS, 2008, J APPL PHYS, V104, DOI 10.1063/1.3006015; Karthigeyan A, 2008, JPN J APPL PHYS, V47, P7440, DOI 10.1143/JJAP.47.7440; Kim DH, 2006, NANO LETT, V6, P2821, DOI 10.1021/nl061977q; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Kumar S, 2007, J HEAT TRANS-T ASME, V129, P500, DOI 10.1115/1.2709969; Kuroda MA, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.165417; Kuroda MA, 2009, J COMPUT THEOR NANOS, V6, P1937, DOI 10.1166/jctn.2009.1249; Lee KU, 2009, CARBON, V47, P475, DOI 10.1016/j.carbon.2008.10.021; Liu Z, 2009, J NANOSCI NANOTECHNO, V9, P1354, DOI 10.1166/jnn.2009.C155; Mabrook MF, 2009, CARBON, V47, P752, DOI 10.1016/j.carbon.2008.11.009; MADEY TE, 1971, J VAC SCI TECHNOL, V8, P525, DOI 10.1116/1.1315200; MADEY TE, 1994, SURF SCI, V299, P824, DOI 10.1016/0039-6028(94)90700-5; Menzel D, 2006, SURF INTERFACE ANAL, V38, P1702, DOI 10.1002/sia.2429; Miyamoto Y, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.233408; Nanjo D, 2009, CHEM LETT, V38, P142, DOI 10.1246/cl.2009.142; Ounaies Z, 2003, COMPOS SCI TECHNOL, V63, P1637, DOI 10.1016/S0266-3538(03)00067-8; Peng N, 2009, NANO LETT, V9, P1626, DOI 10.1021/nl803930w; PERELLO D, 2009, P SPIE, V7399; Perello DJ, 2009, J APPL PHYS, V105, DOI 10.1063/1.3151916; RAMSIER RD, 1991, SURF SCI REP, V12, P243, DOI 10.1016/0167-5729(91)90013-N; Robinson JA, 2006, NANO LETT, V6, P1747, DOI 10.1021/nl0612289; Salehi-Khojin A, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3379291; SANCHE L, 1993, IEEE T ELECTR INSUL, V28, P789, DOI 10.1109/14.237742; Shim M, 2004, MATER RES SOC SYMP P, V789, P397; Snow ES, 2005, SCIENCE, V307, P1942, DOI 10.1126/science.1109128; Suehiro J, 2006, SENSOR ACTUAT B-CHEM, V114, P943, DOI 10.1016/j.snb.2005.08.043; Venet C, 2010, COLLOID SURFACE A, V354, P113, DOI 10.1016/j.colsurfa.2009.07.037; Yamada T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2177356; Zhou ZP, 2006, J PHYS CHEM B, V110, P1206, DOI 10.1021/jp053268r	37	40	42	3	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1327	1330		10.1126/science.1194210	http://dx.doi.org/10.1126/science.1194210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829482				2022-12-28	WOS:000281657300034
J	Akella, JS; Wloga, D; Kim, J; Starostina, NG; Lyons-Abbott, S; Morrissette, NS; Dougan, ST; Kipreos, ET; Gaertig, J				Akella, Jyothi S.; Wloga, Dorota; Kim, Jihyun; Starostina, Natalia G.; Lyons-Abbott, Sally; Morrissette, Naomi S.; Dougan, Scott T.; Kipreos, Edward T.; Gaertig, Jacek			MEC-17 is an alpha-tubulin acetyltransferase	NATURE			English	Article							TOUCH RECEPTOR NEURONS; TETRAHYMENA-THERMOPHILA; CAENORHABDITIS-ELEGANS; C-ELEGANS; ACETYLATION; MICROTUBULE; CILIA; TRANSPORT; DOMAIN; IDENTIFICATION	In most eukaryotic cells, subsets of microtubules are adapted for specific functions by post-translational modifications (PTMs) of tubulin subunits. Acetylation of the epsilon-amino group of K40 on alpha-tubulin is a conserved PTM on the luminal side of microtubules(1) that was discovered in the flagella of Chlamydomonas reinhardtii(2,3). Studies on the significance of microtubule acetylation have been limited by the undefined status of the alpha-tubulin acetyltransferase. Here we show that MEC-17, a protein related to the Gcn5 histone acetyltransferases(4) and required for the function of touch receptor neurons in Caenorhabditis elegans(5,6), acts as a K40-specific acetyltransferase for alpha-tubulin. In vitro, MEC-17 exclusively acetylates K40 of alpha-tubulin. Disruption of the Tetrahymena MEC-17 gene phenocopies the K40R alpha-tubulin mutation and makes microtubules more labile. Depletion of MEC-17 in zebrafish produces phenotypes consistent with neuromuscular defects. In C. elegans, MEC-17 and its paralogue W06B11.1 are redundantly required for acetylation of MEC-12 alpha-tubulin, and contribute to the function of touch receptor neurons partly via MEC-12 acetylation and partly via another function, possibly by acetylating another protein. In summary, we identify MEC-17 as an enzyme that acetylates the K40 residue of alpha-tubulin, the only PTM known to occur on the luminal surface of microtubules.	[Akella, Jyothi S.; Wloga, Dorota; Kim, Jihyun; Starostina, Natalia G.; Dougan, Scott T.; Kipreos, Edward T.; Gaertig, Jacek] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; [Lyons-Abbott, Sally; Morrissette, Naomi S.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University System of Georgia; University of Georgia; University of California System; University of California Irvine	Gaertig, J (corresponding author), Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.	jgaertig@cb.uga.edu	Dougan, Scott/B-8416-2008; Gaertig, Jacek/F-1553-2010; Włoga, Dorota/R-4078-2016	Dougan, Scott/0000-0003-0214-4772; Włoga, Dorota/0000-0003-3314-7773; Akella, Jyothi Shilpa/0000-0003-4839-4910	National Science Foundation [MBC-033965]; American Cancer Society [RSG DDC-112979]; National Institutes of Health [R01GM074212, R01AI067981, R01GM089912]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089912, R01GM074212] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by funds from the National Science Foundation (MBC-033965 to J.G.), American Cancer Society (RSG DDC-112979 to S.T.D.), and National Institutes of Health (R01GM074212 to E. T. K., R01AI067981 to N.S.M., R01GM089912 to J.G.). S.T.D. is a Georgia Cancer Coalition Distinguished Investigator. We are grateful to M. Chalfie for the mec-12(e1607) mutant, J. Frankel for 12G10 mAb (available from the Developmental Studies Hybridoma Bank), M. Gorovsky for SG anti-tubulin antibodies, D. Allis for anti-hv1 antibodies, B. Feldman for mismatch morpholinos, and S. T. Dougan laboratory members for advice and assistance with zebrafish experiments.	Barlow SB, 2002, J CELL SCI, V115, P3469; Bounoutas A, 2009, CURR BIOL, V19, P1362, DOI 10.1016/j.cub.2009.06.036; BRENNER S, 1974, GENETICS, V77, P71; CassidyHanley D, 1997, GENETICS, V146, P135; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; Chen CC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000561; Creppe C, 2009, CELL, V136, P551, DOI 10.1016/j.cell.2008.11.043; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Fox MA, 2007, J COMP NEUROL, V503, P280, DOI 10.1002/cne.21381; Frokjaer-Jensen C, 2008, NAT GENET, V40, P1375, DOI 10.1038/ng.248; Fukushige T, 1999, J CELL SCI, V112, P395; GAERTIG J, 1995, J CELL BIOL, V129, P1301, DOI 10.1083/jcb.129.5.1301; Gaertig J, 1999, NAT BIOTECHNOL, V17, P462, DOI 10.1038/8638; Hai B, 1997, P NATL ACAD SCI USA, V94, P1310, DOI 10.1073/pnas.94.4.1310; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Jerka-Dziadosz M, 2001, PROTIST, V152, P53, DOI 10.1078/1434-4610-00043; Konishi Y, 2009, NAT NEUROSCI, V12, P559, DOI 10.1038/nn.2314; KOZMINSKI KG, 1993, CELL MOTIL CYTOSKEL, V25, P158, DOI 10.1002/cm.970250205; Kuninger D, 2007, J BIOTECHNOL, V131, P253, DOI 10.1016/j.jbiotec.2007.07.498; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LEDIZET M, 1991, METHOD ENZYMOL, V196, P264; LHERNAULT SW, 1983, J CELL BIOL, V97, P258, DOI 10.1083/jcb.97.1.258; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; Miller DM, 1995, METHOD CELL BIOL, V48, P365; Mochizuki K, 2008, GENE, V425, P79, DOI 10.1016/j.gene.2008.08.007; Nakata T, 2003, J CELL BIOL, V162, P1045, DOI 10.1083/jcb.200302175; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Ohkawa N, 2008, GENES CELLS, V13, P1171, DOI 10.1111/j.1365-2443.2008.01235.x; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Shen Q, 2009, EXP CELL RES, V315, P1653, DOI 10.1016/j.yexcr.2009.03.007; Solinger JA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000820; Steczkiewicz K, 2006, CELL CYCLE, V5, P2927, DOI 10.4161/cc.5.24.3572; Sun ZX, 2004, DEVELOPMENT, V131, P4085, DOI 10.1242/dev.01240; Verhey KJ, 2007, CELL CYCLE, V6, P2152, DOI 10.4161/cc.6.17.4633; WILSON SW, 1991, DEVELOPMENT, V112, P723; Witte H, 2008, J CELL BIOL, V180, P619, DOI 10.1083/jcb.200707042; Wloga D, 2008, EUKARYOT CELL, V7, P1362, DOI 10.1128/EC.00084-08; Wloga D, 2006, MOL BIOL CELL, V17, P2799, DOI 10.1091/mbc.E05-05-0450; Wloga D, 2009, DEV CELL, V16, P867, DOI 10.1016/j.devcel.2009.04.008; Yakovich AJ, 2006, EXP PARASITOL, V114, P289, DOI 10.1016/j.exppara.2006.04.008; Zhang Y, 2002, NATURE, V418, P331, DOI 10.1038/nature00891	44	321	337	3	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					218	U111		10.1038/nature09324	http://dx.doi.org/10.1038/nature09324			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829795	Green Accepted			2022-12-28	WOS:000281616300037
J	Kaida, D; Berg, MG; Younis, I; Kasim, M; Singh, LN; Wan, L; Dreyfuss, G				Kaida, Daisuke; Berg, Michael G.; Younis, Ihab; Kasim, Mumtaz; Singh, Larry N.; Wan, Lili; Dreyfuss, Gideon			U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation	NATURE			English	Article							DISEASE GENE-PRODUCT; MAMMALIAN-CELLS; MINOR CLASS; SPLICEOSOME; COMPLEX; SMN; TRANSCRIPTION; DEFICIENCY; INSIGHTS	In eukaryotes, U1 small nuclear ribonucleoprotein (snRNP) forms spliceosomes in equal stoichiometry with U2, U4, U5 and U6 snRNPs; however, its abundance in human far exceeds that of the other snRNPs. Here we used antisense morpholino oligonucleotide to U1 snRNA to achieve functional U1 snRNP knockdown in HeLa cells, and identified accumulated unspliced pre-mRNAs by genomic tiling microarrays. In addition to inhibiting splicing, U1 snRNP knockdown caused premature cleavage and polyadenylation in numerous pre-mRNAs at cryptic polyadenylation signals, frequently in introns near (<5 kilobases) the start of the transcript. This did not occur when splicing was inhibited with U2 snRNA antisense morpholino oligonucleotide or the U2-snRNP-inactivating drug spliceostatin A unless U1 antisense morpholino oligonucleotide was also included. We further show that U1 snRNA-pre-mRNA base pairing was required to suppress premature cleavage and polyadenylation from nearby cryptic polyadenylation signals located in introns. These findings reveal a critical splicing-independent function for U1 snRNP in protecting the transcriptome, which we propose explains its overabundance.	[Kaida, Daisuke; Berg, Michael G.; Younis, Ihab; Kasim, Mumtaz; Singh, Larry N.; Wan, Lili; Dreyfuss, Gideon] Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Singh, Larry N./AAG-6880-2021; Younis, Ihab/M-1849-2019; Dreyfuss, Gideon/D-1218-2013	Singh, Larry N./0000-0002-2478-5864; Younis, Ihab/0000-0003-3329-5979; Dreyfuss, Gideon/0000-0001-8129-8774; Kaida, Daisuke/0000-0003-4014-5231	Association Francaise Contre les Myopathies (AFM)	Association Francaise Contre les Myopathies (AFM)(Association Francaise contre les Myopathies)	We are grateful to the members of our laboratory, especially J. Yong and J. Bachorik, for discussions and comments on this manuscript. We thank M. Yoshida for providing spliceostatin A. We also thank D. A. Baldwin and H. Rodriguez at the Microarray Core Facility at the University of Pennsylvania School of Medicine for help with the tiling array. This work was supported by the Association Francaise Contre les Myopathies (AFM). G.D. is an Investigator of the Howard Hughes Medical Institute.	Baserga S., 1993, RNA WORLD, P359; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Cifuentes-Diaz Carmen, 2002, Semin Pediatr Neurol, V9, P145, DOI 10.1053/spen.2002.33801; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Fortes P, 2003, P NATL ACAD SCI USA, V100, P8264, DOI 10.1073/pnas.1332669100; Friend K, 2007, MOL CELL, V28, P240, DOI 10.1016/j.molcel.2007.09.026; Gabanella F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000921; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Gromak N, 2006, MOL CELL BIOL, V26, P3986, DOI 10.1128/MCB.26.10.3986-3996.2006; Gu MG, 2005, CURR OPIN STRUC BIOL, V15, P99, DOI 10.1016/j.sbi.2005.01.009; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; Iannaccone Susan T, 2004, Curr Neurol Neurosci Rep, V4, P74, DOI 10.1007/s11910-004-0016-6; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; Kataoka N, 2004, J BIOL CHEM, V279, P7009, DOI 10.1074/jbc.M307692200; Konig H, 2007, CELL, V131, P718, DOI 10.1016/j.cell.2007.09.043; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kramer A, 2005, BIOCHEM SOC T, V33, P439; Kyburz A, 2006, MOL CELL, V23, P195, DOI 10.1016/j.molcel.2006.05.037; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Mandel CR, 2008, CELL MOL LIFE SCI, V65, P1099, DOI 10.1007/s00018-007-7474-3; Matter N, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni041; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Millevoi S, 2010, NUCLEIC ACIDS RES, V38, P2757, DOI 10.1093/nar/gkp1176; Moore MJ, 2009, CELL, V136, P688, DOI 10.1016/j.cell.2009.02.001; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Patel AA, 2003, NAT REV MOL CELL BIO, V4, P960, DOI 10.1038/nrm1259; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Vagner S, 2000, RNA, V6, P178, DOI 10.1017/S1355838200991854; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wan LL, 2005, MOL CELL BIOL, V25, P5543, DOI 10.1128/MCB.25.13.5543-5551.2005; Zhang Z, 2008, CELL, V133, P585, DOI 10.1016/j.cell.2008.03.031	42	406	415	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2010	468	7324					664	U81		10.1038/nature09479	http://dx.doi.org/10.1038/nature09479			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688GB	20881964	Green Accepted			2022-12-28	WOS:000284836700034
J	Shiels, MS; Pfeiffer, RM; Engels, EA				Shiels, Meredith S.; Pfeiffer, Ruth M.; Engels, Eric A.			Age at Cancer Diagnosis Among Persons With AIDS in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED INDIVIDUALS; HODGKIN LYMPHOMA; CROHNS-DISEASE; HEPATOCELLULAR-CARCINOMA; GENETIC ANTICIPATION; LUNG-CANCER; RISK; PEOPLE	Background: Studies have reported young ages at cancer diagnosis in HIV-infected persons and have suggested that HIV accelerates carcinogenesis. However, these comparisons did not account for differences in population age structures. Objective: To compare ages at diagnosis for non-AIDS-defining types of cancer that occur in both the AIDS and general populations, after adjustment for differences in age and other demographic characteristics between these populations. Design: Registry linkage study. Setting: 15 HIV/AIDS and cancer registry databases in the United States. Participants: 212 055 persons with AIDS enrolled in the U. S. HIV/AIDS Cancer Match Study from 1996 to 2007. Measurements: Comparison of age-at-diagnosis distributions for various types of cancer in both the AIDS and general populations, after adjustment for age and other demographic characteristics. Results: The proportion of person-time contributed by older persons (age >= 65 years) was far smaller in the AIDS population (1.5%) than in the general population (12.5%). Reflecting this difference, the ages at diagnosis for most types of cancer were approximately 20 years younger among persons with AIDS. However, after adjustment for differences in the populations at risk, the median ages at diagnosis in the AIDS and general populations did not differ for most types of cancer (for example, colon, prostate, or breast cancer; all P > 0.100). In contrast, ages at diagnosis of lung (median, 50 vs. 54 years) and anal cancer (median, 42 vs. 45 years) were significantly younger in persons with AIDS than expected in the general population (P < 0.001), and the age at diagnosis of Hodgkin lymphoma was significantly older (median, 42 vs. 40 years; P < 0.001). Limitations: Information on other cancer risk factors, including cigarette smoking, was not available. Analysis was restricted to non-Hispanic white and black persons who had AIDS, which could limit the generalizability of the findings to other racial and ethnic groups or to persons with HIV but not AIDS. Conclusion: For most types of cancer, the age at diagnosis is similar in the AIDS and general populations, after adjustment for the ages of the populations at risk. Modest age differences remained for a few types of cancer, which may indicate either acceleration of carcinogenesis by HIV or earlier exposure to cancer risk factors.	[Shiels, Meredith S.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shiels, MS (corresponding author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH, 6120 Execut Blvd,EPS 7059, Rockville, MD 20892 USA.	shielsms@mail.nih.gov	Pfeiffer, Ruth M/F-4748-2011		National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIACP010150, Z01CP010150] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant Support: By the intramural research program of the National Cancer Institute.	Alshafie MT, 1997, BRIT J SURG, V84, P1068, DOI 10.1002/bjs.1800840808; Bhavan Kavita P, 2008, Curr HIV/AIDS Rep, V5, P150, DOI 10.1007/s11904-008-0023-3; Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109; Brau N, 2007, J HEPATOL, V47, P527, DOI 10.1016/j.jhep.2007.06.010; Brock MV, 2006, JAIDS-J ACQ IMM DEF, V43, P47, DOI 10.1097/01.qai.0000232260.95288.93; BROWN GW, 1950, P 2 BERK S MATH STAT, P159; Carbone A, 2009, CURR OPIN HIV AIDS, V4, P3, DOI 10.1097/COH.0b013e32831a722b; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; *CDCP, 2009, HIV AIDS SURV REP 20; Chapman C, 2009, CLIN COLORECTAL CANC, V8, P215, DOI 10.3816/CCC.2009.n.036; Clifford GM, 2009, BLOOD, V113, P5737, DOI 10.1182/blood-2009-02-204172; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Crum-Cianflone NF, 2010, AIDS, V24, P535, DOI 10.1097/QAD.0b013e328331f6e2; D'Souza G, 2008, J GEN INTERN MED, V23, P1452, DOI 10.1007/s11606-008-0698-6; Demopoulos BP, 2003, ARCH PATHOL LAB MED, V127, P589; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Frisch M, 1996, LANCET, V347, P1551, DOI 10.1016/S0140-6736(96)90703-5; Goedert JJ, 2006, BRIT J CANCER, V95, P642, DOI 10.1038/sj.bjc.6603282; Grandbastien B, 1998, GUT, V42, P170, DOI 10.1136/gut.42.2.170; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Horner MJ, 2009, SEER CANC STAT REV 1; Long JL, 2008, AIDS, V22, P489, DOI 10.1097/QAD.0b013e3282f47082; Mani H, 2009, CLIN LYMPHOMA MYELOM, V9, P206, DOI 10.3816/CLM.2009.n.042; Mofenson Lynne M., 2009, Morbidity and Mortality Weekly Report, V58, P1; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; Picco MF, 2001, ANN INTERN MED, V134, P1124, DOI 10.7326/0003-4819-134-12-200106190-00013; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3; Puoti M, 2004, AIDS, V18, P2285, DOI 10.1097/00002030-200411190-00009; Shiels MS, 2009, JAIDS-J ACQ IMM DEF, V52, P611, DOI 10.1097/QAI.0b013e3181b327ca; Silverberg MJ, 2006, AIDS, V20, P1531, DOI 10.1097/01.aids.0000237369.41617.0f; Silverberg MJ, 2009, AIDS, V23, P2337, DOI 10.1097/QAD.0b013e3283319184; Tobias C, 2007, AIDS PATIENT CARE ST, V21, pS3, DOI 10.1089/apc.2007.9992; U.S. Census Bureau Population Division, 2009, ANN EST RES POP SEX; World Health Organization, 2000, INT CLASS DIS ONC	39	154	157	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	2010	153	7					452	+		10.7326/0003-4819-153-7-201010050-00008	http://dx.doi.org/10.7326/0003-4819-153-7-201010050-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VG	20921544	Green Accepted			2022-12-28	WOS:000282517000004
J	McKenna, NJ; O'Malley, BW				McKenna, Neil J.; O'Malley, Bert W.			SnapShot: NR Coregulators	CELL			English	Editorial Material							REPRESSION; DISEASE		[McKenna, Neil J.; O'Malley, Bert W.] Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	McKenna, NJ (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.			McKenna, Neil/0000-0001-6689-0104	NIDDK NIH HHS [U19-DK62434] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206; Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; O'Malley BW, 2007, MOL ENDOCRINOL, V21, P1009, DOI 10.1210/me.2007-0012; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; White R, 2008, FEBS LETT, V582, P39, DOI 10.1016/j.febslet.2007.11.017	11	12	13	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					172	U176		10.1016/j.cell.2010.09.032	http://dx.doi.org/10.1016/j.cell.2010.09.032			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887900	Bronze			2022-12-28	WOS:000282362000024
J	Moresi, V; Williams, AH; Meadows, E; Flynn, JM; Potthoff, MJ; McAnally, J; Shelton, JM; Backs, J; Klein, WH; Richardson, JA; Bassel-Duby, R; Olson, EN				Moresi, Viviana; Williams, Andrew H.; Meadows, Eric; Flynn, Jesse M.; Potthoff, Matthew J.; McAnally, John; Shelton, John M.; Backs, Johannes; Klein, William H.; Richardson, James A.; Bassel-Duby, Rhonda; Olson, Eric N.			Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases	CELL			English	Article							DEPENDENT CARDIAC-HYPERTROPHY; RING FINGER 1; SKELETAL-MUSCLE; SATELLITE CELLS; SOLEUS MUSCLE; GENE; DENERVATION; EXPRESSION; RAT; PROTEIN	Maintenance of skeletal muscle structure and function requires innervation by motor neurons, such that denervation causes muscle atrophy. We show that myogenin, an essential regulator of muscle development, controls neurogenic atrophy. Myogenin is upregulated in skeletal muscle following denervation and regulates expression of the E3 ubiquitin ligases MuRF1 and atrogin-1, which promote muscle proteolysis and atrophy. Deletion of myogenin from adult mice diminishes expression of MuRF1 and atrogin-1 in denervated muscle and confers resistance to atrophy. Mice lacking histone deacetylases (HDACs) 4 and 5 in skeletal muscle fail to upregulate myogenin and also preserve muscle mass following denervation. Conversely, forced expression of myogenin in skeletal muscle of HDAC mutant mice restores muscle atrophy following denervation. Thus, myogenin plays a dual role as both a regulator of muscle development and an inducer of neurogenic atrophy. These findings reveal a specific pathway for muscle wasting and potential therapeutic targets for this disorder.	[Moresi, Viviana; Williams, Andrew H.; Potthoff, Matthew J.; McAnally, John; Backs, Johannes; Richardson, James A.; Bassel-Duby, Rhonda; Olson, Eric N.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; [Shelton, John M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Richardson, James A.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Meadows, Eric; Flynn, Jesse M.; Klein, William H.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Olson, EN (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.	eric.olson@utsouthwestern.edu	Moresi, Viviana/N-7977-2013	Potthoff, Matthew/0000-0001-9158-5128; Moresi, viviana/0000-0003-1912-0339	National Institutes of Health; Robert A. Welch Foundation [I-0025]; Muscular Dystrophy Association; Deutsche Forschungsgemeinschaft [BA 2258/1-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077439, R01HL093039, R37HL053351] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); Muscular Dystrophy Association(Muscular Dystrophy Association); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Marco Sandri for scientific input, Cheryl Nolen and Svetlana Bezprozvannaya for technical assistance, Jose Cabrera for graphics, and Jennifer Brown for editorial assistance. Work in the laboratory of E.N.O. was supported by grants from the National Institutes of Health and the Robert A. Welch Foundation (grant number I-0025). W.H.K. was supported by a grant from the Muscular Dystrophy Association and the Robert A. Welch Foundation. J.B. was supported by the Deutsche Forschungsgemeinschaft (BA 2258/1-1).	Attaix D, 2005, ESSAYS BIOCHEM, V41, P173, DOI 10.1042/EB0410173; Attaix Didier, 2008, Curr Opin Support Palliat Care, V2, P262, DOI 10.1097/SPC.0b013e3283196ac2; Backs J, 2008, MOL CELL BIOL, V28, P3437, DOI 10.1128/MCB.01611-07; Beehler BC, 2006, EXP BIOL MED, V231, P335; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cao Y, 2006, EMBO J, V25, P502, DOI 10.1038/sj.emboj.7600958; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Charrel RN, 2008, LANCET INFECT DIS, V8, P5, DOI 10.1016/S1473-3099(07)70296-7; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Cohen TJ, 2007, J BIOL CHEM, V282, P33752, DOI 10.1074/jbc.M706268200; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dona M, 2003, BIOCHEM BIOPH RES CO, V312, P1132, DOI 10.1016/j.bbrc.2003.11.032; Eley HL, 2007, J BIOL CHEM, V282, P7087, DOI 10.1074/jbc.M610378200; Glass DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471-4914(03)00138-2; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Grifone R, 2004, MOL CELL BIOL, V24, P6253, DOI 10.1128/MCB.24.14.6253-6267.2004; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; HERBISON GJ, 1979, ARCH PHYS MED REHAB, V60, P401; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Hyatt JPK, 2003, AM J PHYSIOL-CELL PH, V285, pC1161, DOI 10.1152/ajpcell.00128.2003; Ishido M, 2004, AM J PHYSIOL-CELL PH, V287, pC484, DOI 10.1152/ajpcell.00080.2004; Kardon G, 2002, DEV DYNAM, V224, P350, DOI 10.1002/dvdy.10107; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Knapp JR, 2006, DEVELOPMENT, V133, P601, DOI 10.1242/dev.02249; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Li HH, 2007, J CLIN INVEST, V117, P3211, DOI 10.1172/JCI31757; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Mercer SE, 2005, J BIOL CHEM, V280, P25788, DOI 10.1074/jbc.M413594200; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MIDRIO M, 1992, PFLUG ARCH EUR J PHY, V420, P446, DOI 10.1007/BF00374618; Moriscot AS, 2010, J STRUCT BIOL, V170, P344, DOI 10.1016/j.jsb.2010.02.001; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NWOYE L, 1982, AM J PHYSIOL, V242, pR401, DOI 10.1152/ajpregu.1982.242.3.R401; OGILVIE RW, 1990, STAIN TECHNOL, V65, P231, DOI 10.3109/10520299009105613; Patterson MF, 2006, AM J PHYSIOL-CELL PH, V291, pC518, DOI 10.1152/ajpcell.00013.2006; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Rana ZA, 2004, ACTA PHYSIOL SCAND, V181, P233, DOI 10.1111/j.1365-201X.2004.01282.x; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Sato Y, 2009, BIOSCI BIOTECH BIOCH, V73, P1748, DOI 10.1271/bbb.90085; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; Tang HB, 2006, P NATL ACAD SCI USA, V103, P16977, DOI 10.1073/pnas.0601565103; Tang HB, 2009, MOL BIOL CELL, V20, P1120, DOI 10.1091/mbc.E08-07-0759; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Waddell DS, 2008, AM J PHYSIOL-ENDOC M, V295, pE785, DOI 10.1152/ajpendo.00646.2007; Williams AH, 2009, SCIENCE, V326, P1549, DOI 10.1126/science.1181046; Willis MS, 2009, AM J PHYSIOL-HEART C, V296, pH997, DOI 10.1152/ajpheart.00660.2008	63	306	325	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	2010	143	1					35	45		10.1016/j.cell.2010.09.004	http://dx.doi.org/10.1016/j.cell.2010.09.004			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887891	Green Accepted, Bronze			2022-12-28	WOS:000282362000012
J	Koh, HK; Sebelius, KG				Koh, Howard K.; Sebelius, Kathleen G.			Promoting Prevention through the Affordable Care Act.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Koh, Howard K.; Sebelius, Kathleen G.] Dept Hlth & Human Serv, Washington, DC USA		Koh, HK (corresponding author), Dept Hlth & Human Serv, Washington, DC USA.							Koh HK, 2010, NEW ENGL J MED, V362, P1653, DOI 10.1056/NEJMp1001601; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Siegel B, 2009, NEW ENGL J MED, V361, P2401, DOI 10.1056/NEJMp0909323	3	311	312	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1296	1299		10.1056/NEJMp1008560	http://dx.doi.org/10.1056/NEJMp1008560			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655TD	20879876				2022-12-28	WOS:000282271500002
J	de la Potterie, BV				de la Potterie, Bruno van Pottelsberghe			Patent fixes for Europe	NATURE			English	Editorial Material									Univ Libre Bruxelles, B-1050 Brussels, Belgium	Universite Libre de Bruxelles	de la Potterie, BV (corresponding author), Univ Libre Bruxelles, B-1050 Brussels, Belgium.	bruno.vanpottelsberghe@ulb.ac.be	VAN POTTELSBERGHE, Bruno/AAN-4779-2020; van Pottelsberghe, Bruno/A-3073-2009	van Pottelsberghe, Bruno/0000-0001-7720-1685				Danguy J., 2009, EIB PAPERS, V14, P170; de la Potterie BV, 2010, EUR J LAW ECON, V29, P211, DOI 10.1007/s10657-009-9118-6; DEWATRIPONT M, 2010, 201006 BRUEG POL; van Pottelsberghe B, 2009, BRUEGEL BLUEPRINT, V9	4	5	5	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					395	395		10.1038/467395a	http://dx.doi.org/10.1038/467395a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	653KO	20864973	Bronze			2022-12-28	WOS:000282090200013
J	Heinig, M; Petretto, E; Wallace, C; Bottolo, L; Rotival, M; Lu, H; Li, YY; Sarwar, R; Langley, SR; Bauerfeind, A; Hummel, O; Lee, YA; Paskas, S; Rintisch, C; Saar, K; Cooper, J; Buchan, R; Gray, EE; Cyster, JG; Erdmann, J; Hengstenberg, C; Maouche, S; Ouwehand, WH; Rice, CM; Samani, NJ; Schunkert, H; Goodall, AH; Schulz, H; Roider, HG; Vingron, M; Blankenberg, S; Munzel, T; Zeller, T; Szymczak, S; Ziegler, A; Tiret, L; Smyth, DJ; Pravenec, M; Aitman, TJ; Cambien, F; Clayton, D; Todd, JA; Hubner, N; Cook, SA				Heinig, Matthias; Petretto, Enrico; Wallace, Chris; Bottolo, Leonardo; Rotival, Maxime; Lu, Han; Li, Yoyo; Sarwar, Rizwan; Langley, Sarah R.; Bauerfeind, Anja; Hummel, Oliver; Lee, Young-Ae; Paskas, Svetlana; Rintisch, Carola; Saar, Kathrin; Cooper, Jason; Buchan, Rachel; Gray, Elizabeth E.; Cyster, Jason G.; Erdmann, Jeanette; Hengstenberg, Christian; Maouche, Seraya; Ouwehand, Willem H.; Rice, Catherine M.; Samani, Nilesh J.; Schunkert, Heribert; Goodall, Alison H.; Schulz, Herbert; Roider, Helge G.; Vingron, Martin; Blankenberg, Stefan; Muenzel, Thomas; Zeller, Tanja; Szymczak, Silke; Ziegler, Andreas; Tiret, Laurence; Smyth, Deborah J.; Pravenec, Michal; Aitman, Timothy J.; Cambien, Francois; Clayton, David; Todd, John A.; Hubner, Norbert; Cook, Stuart A.		Cardiogenics Consortium	A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk	NATURE			English	Article							GENOME-WIDE ASSOCIATION; TRANSCRIPTION FACTORS; MOLECULAR NETWORKS; GENE-EXPRESSION; DISEASE; INFLAMMATION; RESPONSES; IFIH1; SNPS; RAT	Combined analyses of gene networks and DNA sequence variation can provide new insights into the aetiology of common diseases that may not be apparent from genome-wide association studies alone. Recent advances in rat genomics are facilitating systems-genetics approaches(1,2). Here we report the use of integrated genome-wide approaches across seven rat tissues to identify gene networks and the loci underlying their regulation. We defined an interferon regulatory factor 7 (IRF7(3))-driven inflammatory network (IDIN) enriched for viral response genes, which represents a molecular biomarker for macrophages and which was regulated in multiple tissues by a locus on rat chromosome 15q25. We show that Epstein-Barr virus induced gene 2 (Ebi2, also known as Gpr183), which lies at this locus and controls B lymphocyte migration(4,5), is expressed in macrophages and regulates the IDIN. The human orthologous locus on chromosome 13q32 controlled the human equivalent of the IDIN, which was conserved in monocytes. IDIN genes were more likely to associate with susceptibility to type 1 diabetes (T1D)-amacrophage-associated autoimmune disease-than randomly selected immune response genes (P = 8.85 x 10(-6)). The human locus controlling the IDIN was associated with the risk of T1D at single nucleotide polymorphism rs9585056 (P = 7.0 x 10(-10); odds ratio, 1.15), which was one of five single nucleotide polymorphisms in this region associated with EBI2 (GPR183) expression. These data implicate IRF7 network genes and their regulatory locus in the pathogenesis of T1D.	[Heinig, Matthias; Bauerfeind, Anja; Hummel, Oliver; Lee, Young-Ae; Paskas, Svetlana; Rintisch, Carola; Saar, Kathrin; Schulz, Herbert; Hubner, Norbert] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Heinig, Matthias; Roider, Helge G.; Vingron, Martin] Max Planck Inst Mol Genet, D-14195 Berlin, Germany; [Petretto, Enrico; Bottolo, Leonardo; Lu, Han; Li, Yoyo; Sarwar, Rizwan; Langley, Sarah R.; Buchan, Rachel; Aitman, Timothy J.; Cook, Stuart A.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Med Res Council,Clin Sci Ctr, London W12 0NN, England; [Petretto, Enrico; Bottolo, Leonardo] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Epidemiol & Biostat, London W2 1PG, England; [Wallace, Chris; Cooper, Jason; Smyth, Deborah J.; Clayton, David; Todd, John A.] Univ Cambridge, Cambridge Inst Med Res, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Cambridge CB2 0XY, England; [Rotival, Maxime; Maouche, Seraya; Tiret, Laurence; Cambien, Francois] Univ Paris 06, INSERM, UMRS 937, F-75013 Paris, France; [Rotival, Maxime; Maouche, Seraya; Tiret, Laurence; Cambien, Francois] Sch Med, F-75013 Paris, France; [Lee, Young-Ae] Charite, D-13353 Berlin, Germany; [Gray, Elizabeth E.; Cyster, Jason G.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; [Gray, Elizabeth E.; Cyster, Jason G.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Erdmann, Jeanette; Schunkert, Heribert] Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany; [Hengstenberg, Christian] Univ Regensburg, Klin & Poliklin Innere Med 2, D-93053 Regensburg, Germany; [Ouwehand, Willem H.] Univ Cambridge, Dept Haematol, Cambridge CB2 0PT, England; [Ouwehand, Willem H.] Natl Hlth Serv Blood & Transplant, Cambridge CB2 0PT, England; [Ouwehand, Willem H.; Rice, Catherine M.] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England; [Samani, Nilesh J.; Goodall, Alison H.] Univ Leicester, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England; [Samani, Nilesh J.; Goodall, Alison H.] Glenfield Hosp, Leicester NIHR Biomed Res Unit Cardiovasc Dis, Leicester LE3 9QP, Leics, England; [Blankenberg, Stefan; Muenzel, Thomas; Zeller, Tanja] Johannes Gutenberg Univ Mainz, Med Klin & Poliklin, D-55131 Mainz, Germany; [Szymczak, Silke; Ziegler, Andreas] Univ Lubeck, Inst Med Biometrie & Stat, Univ Klinikum Schleswig Holstein, D-23562 Lubeck, Germany; [Pravenec, Michal] Acad Sci Czech Republic, Inst Physiol, Prague 14220 4, Czech Republic; [Pravenec, Michal] Ctr Appl Genom, Prague 14220 4, Czech Republic; [Hubner, Norbert] Charite, CC4, D-10117 Berlin, Germany; [Cook, Stuart A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Imperial College London; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite de Franche-Comte; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Regensburg; University of Cambridge; NHS Blood & Transplant (NHSBT); Wellcome Trust Sanger Institute; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Johannes Gutenberg University of Mainz; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Imperial College London	Hubner, N (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	nhuebner@mdc-berlin.de; stuart.cook@csc.mrc.ac.uk	Erdmann, Jeanette/P-7513-2014; Erdmann, Jeanette/A-4417-2009; Szymczak, Silke/HGT-8202-2022; Hengstenberg, Christian/U-5485-2019; Cambien, Francois/AAP-9751-2020; Langley, Sarah R/E-4481-2019; Pravenec, Michal/B-1666-2012; Cook, Stuart/G-9567-2011; Szymczak, Silke/C-6625-2013; Munzel, Thomas/A-2912-2014; Todd, John/A-3542-2010; Ziegler, Andreas/G-4246-2012	Erdmann, Jeanette/0000-0002-4486-6231; Pravenec, Michal/0000-0001-9197-5871; Munzel, Thomas/0000-0001-5503-4150; Maouche, Seraya/0000-0001-8186-1635; Ouwehand, Willem/0000-0002-7744-1790; Schmitz, Gerd/0000-0002-1325-1007; Paskas, Svetlana/0000-0002-1206-5376; Todd, John/0000-0003-2740-8148; Zeller, Tanja/0000-0003-3379-2641; Bottolo, Leonardo/0000-0002-6381-2327; Saar, Kathrin/0000-0002-4483-1557; smyth, deborah/0000-0002-6330-2669; Szymczak, Silke/0000-0002-8897-9035; Heinig, Matthias/0000-0002-5612-1720; Buchan, Rachel/0000-0003-2490-9289; Goodall, Alison/0000-0002-7883-9645; Matvienko-Sikar, Karen/0000-0003-2777-6581; Aitman, Timothy/0000-0002-7875-4502; Cook, Stuart/0000-0001-6628-194X; Ziegler, Andreas/0000-0002-8386-5397; Rotival, Maxime/0000-0003-2519-8044; Wallace, Chris/0000-0001-9755-1703	German National Genome Research Network; Helmholtz Association Alliance on Systems Biology; EURATools [LSHG-CT-2005-019015]; European Union [LSHM-CT-2006-037593]; PHC ALLIANCE [19419PH]; UK National Institute for Health Research Biomedical Research Unit (Royal Brompton and Harefield NHS Trusts, University Hospitals of Leicester NHS Trusts); Biomedical Research Centre (Imperial College NHS Trust); British Heart Foundation; Grant Agency of the Czech Republic [P301/10/0290]; Ministry of Education of the Czech Republic [1M6837805002]; Fondation Leducq; Medical Research Council UK; Research Councils UK; Juvenile Diabetes Research Foundation International; National Institute for Health Research (UK); National Institute of Diabetes and Digestive and Kidney Diseases (USA); Wellcome Trust; European Community [HEALTH-F4-2010-241504]; Medical Research Council [MC_U120085815, MC_U120061454, MC_U120097112] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10275] Funding Source: researchfish; MRC [MC_U120061454, MC_U120085815, MC_U120097112] Funding Source: UKRI	German National Genome Research Network; Helmholtz Association Alliance on Systems Biology; EURATools; European Union(European Commission); PHC ALLIANCE; UK National Institute for Health Research Biomedical Research Unit (Royal Brompton and Harefield NHS Trusts, University Hospitals of Leicester NHS Trusts); Biomedical Research Centre (Imperial College NHS Trust); British Heart Foundation(British Heart Foundation); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Ministry of Education of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Fondation Leducq(Leducq Foundation); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Research Councils UK(UK Research & Innovation (UKRI)); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); National Institute for Health Research (UK)(National Institute for Health Research (NIHR)); National Institute of Diabetes and Digestive and Kidney Diseases (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); European Community(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge funding from the German National Genome Research Network (NGFN-Plus 'Genetics of Heart Failure'), the Helmholtz Association Alliance on Systems Biology (MSBN), EURATools (LSHG-CT-2005-019015), European Union FP6 (LSHM-CT-2006-037593), PHC ALLIANCE 2009 (19419PH), UK National Institute for Health Research Biomedical Research Unit (Royal Brompton and Harefield NHS Trusts, University Hospitals of Leicester NHS Trusts) and Biomedical Research Centre (Imperial College NHS Trust) awards, the British Heart Foundation, grant P301/10/0290 from the Grant Agency of the Czech Republic, grant 1M6837805002 from the Ministry of Education of the Czech Republic, the Fondation Leducq, the Medical Research Council UK, Research Councils UK, the Juvenile Diabetes Research Foundation International, National Institute for Health Research (UK), National Institute of Diabetes and Digestive and Kidney Diseases (USA), and the Wellcome Trust. The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. HEALTH-F4-2010-241504 (EURATRANS). O. Burren performed T1DBase analyses.	Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Atanur SS, 2010, GENOME RES, V20, P791, DOI 10.1101/gr.103499.109; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Breitling R, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000232; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Cooper JD, 2009, GENES IMMUN, V10, pS85, DOI 10.1038/gene.2009.97; Dimas AS, 2009, SCIENCE, V325, P1246, DOI 10.1126/science.1174148; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Gatto D, 2009, IMMUNITY, V31, P259, DOI 10.1016/j.immuni.2009.06.016; HOLNESS CL, 1993, BLOOD, V81, P1607; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Li Q, 2008, P NATL ACAD SCI USA, V105, P12439, DOI 10.1073/pnas.0806439105; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728; Pereira JP, 2009, NATURE, V460, P1122, DOI 10.1038/nature08226; Petretto E, 2008, NAT GENET, V40, P546, DOI 10.1038/ng.134; Petretto E, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000737; Plagnol V, 2009, BIOSTATISTICS, V10, P327, DOI 10.1093/biostatistics/kxn039; Roider HG, 2009, BIOINFORMATICS, V25, P435, DOI 10.1093/bioinformatics/btn627; Saar K, 2008, NAT GENET, V40, P560, DOI 10.1038/ng.124; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Smyth DJ, 2006, NAT GENET, V38, P617, DOI 10.1038/ng1800; VON HERRATH M, 2009, NATURE, V459, P518; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	29	213	221	0	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					460	464		10.1038/nature09386	http://dx.doi.org/10.1038/nature09386			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20827270	Green Accepted, Green Published			2022-12-28	WOS:000282090200043
J	Okada, K				Okada, Katsuya			Japan's new global health policy: 2011-2015	LANCET			English	Editorial Material							SURVIVAL; MORTALITY; NEWBORN		Minist Foreign Affairs Japan, Chiyoda Ku, Tokyo 1008919, Japan		Okada, K (corresponding author), Minist Foreign Affairs Japan, Chiyoda Ku, Tokyo 1008919, Japan.	sayako.kanamori@mofa.go.jp						Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bryce J, 2008, LANCET, V371, P510, DOI 10.1016/S0140-6736(07)61694-8; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; *GOV JAP CAB OFF, 2010, PUBL OP POLL INT COO; Institute for International Cooperation Japan International Cooperation Agency, 2005, JAP EXP PUBL HLTH ME; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1	8	6	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	2010	376	9745					938	940		10.1016/S0140-6736(10)61357-8	http://dx.doi.org/10.1016/S0140-6736(10)61357-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20851246				2022-12-28	WOS:000282247600008
J	Newman, M				Newman, Melanie			Drug Regulation Bitter pills for drug companies	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Newman, Melanie] City Univ London, Bur Invest Journalism, London EC1V 7HD, England	City University London	Newman, M (corresponding author), City Univ London, Bur Invest Journalism, London EC1V 7HD, England.	melanienewman@tbij.com						GARDINER H, 2009, NY TIMES        0902; Segal A., 2010, FEDS FOUND PFIZER TO; *US DEP HHS, KICKB PHYS SELF REF; *US DEP HHS, 2009, JUST DEP ANN LARG HL	4	10	10	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 17	2010	341								c5095	10.1136/bmj.c5095	http://dx.doi.org/10.1136/bmj.c5095			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653MT	20851842				2022-12-28	WOS:000282096300001
J	Attar, EC; Hasserjian, RP				Attar, Eyal C.; Hasserjian, Robert P.			Case 27-2010: A 73-Year-Old Woman with Chronic Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK MYELODYSPLASTIC SYNDROMES; CELL TRANSPLANTATION; DELETED REGION; 5Q; IDENTIFICATION; LENALIDOMIDE; AZACITIDINE; DELINEATION; LEUKEMIA; EFFICACY		[Attar, Eyal C.] Massachusetts Gen Hosp, Div Hematol, Boston, MA 02114 USA; [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Attar, Eyal C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Hasserjian, Robert P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Attar, EC (corresponding author), Massachusetts Gen Hosp, Div Hematol, Boston, MA 02114 USA.							Ades L, 2009, BLOOD, V113, P3947, DOI 10.1182/blood-2008-08-175778; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Brunning RD, 2008, WHO CLASSIFICATION T; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Giagounidis AAN, 2004, LEUKEMIA, V18, P113, DOI 10.1038/sj.leu.2403189; Greenberg, 1998, BLOOD, V91, P1100; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Hasserjian RP, 2008, WHO CLASSIFICATION T, P102; Jaju RJ, 1998, GENE CHROMOSOME CANC, V22, P251, DOI 10.1002/(SICI)1098-2264(199807)22:3<251::AID-GCC11>3.0.CO;2-R; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Lim Z, 2010, J CLIN ONCOL, V28, P405, DOI 10.1200/JCO.2009.21.8073; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; McClune BL, 2010, J CLIN ONCOL, V28, P1878, DOI 10.1200/JCO.2009.25.4821; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Steensma DP, 2009, J CLIN ONCOL, V27, P3842, DOI 10.1200/JCO.2008.19.6550; Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106	20	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1060	1068		10.1056/NEJMcpc1000962	http://dx.doi.org/10.1056/NEJMcpc1000962			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825319				2022-12-28	WOS:000281609700011
J	Eldar, A; Elowitz, MB				Eldar, Avigdor; Elowitz, Michael B.			Functional roles for noise in genetic circuits	NATURE			English	Review							SINGLE-MOLECULE LEVEL; TO-CELL VARIABILITY; FLUCTUATING ENVIRONMENTS; BACILLUS-SUBTILIS; SACCHAROMYCES-CEREVISIAE; PRIMITIVE ENDODERM; PROTEIN EXPRESSION; ESCHERICHIA-COLI; BACTERIAL-CELL; DIFFERENTIATION	The genetic circuits that regulate cellular functions are subject to stochastic fluctuations, or 'noise', in the levels of their components. Noise, far from just a nuisance, has begun to be appreciated for its essential role in key cellular activities. Noise functions in both microbial and eukaryotic cells, in multicellular development, and in evolution. It enables coordination of gene expression across large regulons, as well as probabilistic differentiation strategies that function across cell populations. At the longest timescales, noise may facilitate evolutionary transitions. Here we review examples and emerging principles that connect noise, the architecture of the gene circuits in which it is present, and the biological functions it enables. We further indicate some of the important challenges and opportunities going forward.	[Eldar, Avigdor; Elowitz, Michael B.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Elowitz, MB (corresponding author), CALTECH, Howard Hughes Med Inst, M-C 114-96,1200 E Calif Blvd, Pasadena, CA 91125 USA.	melowitz@caltech.edu		Eldar, Avigdor/0000-0001-8485-9370	NIH [R01GM079771, P50 GM068763]; NSF [0644463]; Packard Foundation; EMBO; International Human Frontier Science Organization; Baxter fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068763, R01GM079771] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Packard Foundation(The David & Lucile Packard Foundation); EMBO(European Molecular Biology Organization (EMBO)); International Human Frontier Science Organization; Baxter fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank G. Suel, A. Raj, F. Tan and J. Rossant for providing images. We thank N. Wingreen, D. J. Anderson, R. Kishony, J.-G. Ojalvo, G. Suel, H. Y. Kueh and members of the Elowitz laboratory for discussions. Work in M.B.E.'s laboratory was supported by NIH grants R01GM079771, P50 GM068763, NSF CAREER Award 0644463 and the Packard Foundation. A.E. was supported by EMBO, the International Human Frontier Science Organization and a Baxter fellowship.	Acar M, 2008, NAT GENET, V40, P471, DOI 10.1038/ng.110; Angert ER, 2005, NAT REV MICROBIOL, V3, P214, DOI 10.1038/nrmicro1096; Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807; Beaumont HJE, 2009, NATURE, V462, P90, DOI 10.1038/nature08504; BENZER S, 1953, BIOCHIM BIOPHYS ACTA, V11, P383, DOI 10.1016/0006-3002(53)90057-2; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Boeger H, 2008, CELL, V133, P716, DOI 10.1016/j.cell.2008.02.051; Cagatay T, 2009, CELL, V139, P512, DOI 10.1016/j.cell.2009.07.046; Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; Cai L, 2008, NATURE, V455, P485, DOI 10.1038/nature07292; Canham MA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000379; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Chazaud C, 2006, DEV CELL, V10, P615, DOI 10.1016/j.devcel.2006.02.020; Choi PJ, 2008, SCIENCE, V322, P442, DOI 10.1126/science.1161427; Cox CD, 2008, P NATL ACAD SCI USA, V105, P10809, DOI 10.1073/pnas.0804829105; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Davidson CJ, 2008, ANNU REV GENET, V42, P253, DOI 10.1146/annurev.genet.42.110807.091601; Degenhardt T, 2009, CELL, V138, P489, DOI 10.1016/j.cell.2009.05.029; Di Talia S, 2007, NATURE, V448, P947, DOI 10.1038/nature06072; Dietrich JE, 2007, DEVELOPMENT, V134, P4219, DOI 10.1242/dev.003798; Dunlop MJ, 2008, NAT GENET, V40, P1493, DOI 10.1038/ng.281; Eldar A, 2009, NATURE, V460, P510, DOI 10.1038/nature08150; Elf J, 2007, SCIENCE, V316, P1191, DOI 10.1126/science.1141967; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Friedman N, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.168302; Fujita M, 2005, GENE DEV, V19, P2236, DOI 10.1101/gad.1335705; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Golding I, 2005, CELL, V123, P1025, DOI 10.1016/j.cell.2005.09.031; Hill WG, 2004, GENET RES, V83, P121, DOI 10.1017/S0016672304006640; Ito Y, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.23; Kalmar T, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000149; Kashiwagi A, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000049; Kay RR, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001503; Kussell E, 2005, SCIENCE, V309, P2075, DOI 10.1126/science.1114383; Levine E, 2007, PLOS BIOL, V5, P1998, DOI 10.1371/journal.pbio.0050229; Locke JCW, 2009, NAT REV MICROBIOL, V7, P383, DOI 10.1038/nrmicro2056; Losick R, 2008, SCIENCE, V320, P65, DOI 10.1126/science.1147888; Maamar H, 2005, MOL MICROBIOL, V56, P615, DOI 10.1111/j.1365-2958.2005.04592.x; Maamar H, 2007, SCIENCE, V317, P526, DOI 10.1126/science.1140818; Maheshri N, 2007, ANNU REV BIOPH BIOM, V36, P413, DOI 10.1146/annurev.biophys.36.040306.132705; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Mehta P, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.58; Morris SA, 2010, P NATL ACAD SCI USA, V107, P6364, DOI 10.1073/pnas.0915063107; Nachman I, 2007, CELL, V131, P544, DOI 10.1016/j.cell.2007.09.044; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; NOVICK A, 1957, P NATL ACAD SCI USA, V43, P553, DOI 10.1073/pnas.43.7.553; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Pare A, 2009, CURR BIOL, V19, P2037, DOI 10.1016/j.cub.2009.10.028; Paulsson J, 2000, P NATL ACAD SCI USA, V97, P7148, DOI 10.1073/pnas.110057697; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050; Raj A, 2006, PLOS BIOL, V4, P1707, DOI 10.1371/journal.pbio.0040309; Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shankaran H, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.90; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Sigal A, 2006, NATURE, V444, P643, DOI 10.1038/nature05316; Singh AM, 2007, STEM CELLS, V25, P2534, DOI 10.1634/stemcells.2007-0126; Snijder B, 2009, NATURE, V461, P520, DOI 10.1038/nature08282; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; Suel GM, 2007, SCIENCE, V315, P1716, DOI 10.1126/science.1137455; Suel GM, 2006, NATURE, V440, P545, DOI 10.1038/nature04588; Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523; To TL, 2010, SCIENCE, V327, P1142, DOI 10.1126/science.1178962; Valdeolmillos M, 1996, J PHYSIOL-LONDON, V493, P9, DOI 10.1113/jphysiol.1996.sp021361; Veening JW, 2008, P NATL ACAD SCI USA, V105, P4393, DOI 10.1073/pnas.0700463105; Wolf DM, 2005, J THEOR BIOL, V234, P227, DOI 10.1016/j.jtbi.2004.11.020; Yamanaka Y, 2010, DEVELOPMENT, V137, P715, DOI 10.1242/dev.043471; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623; Zenklusen D, 2008, NAT STRUCT MOL BIOL, V15, P1263, DOI 10.1038/nsmb.1514	77	1010	1029	5	239	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					167	173		10.1038/nature09326	http://dx.doi.org/10.1038/nature09326			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829787	Green Accepted			2022-12-28	WOS:000281616300026
J	Bradfield, Y				Bradfield, Yasmin			Vision Screening to Detect Refractive Error	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDREN		Univ Wisconsin, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, Y (corresponding author), Univ Wisconsin, 2870 Univ Ave,Ste 206, Madison, WI 53705 USA.	ysbradfield@ophth.wisc.edu						Baltussen R, 2009, HEALTH POLICY, V89, P201, DOI 10.1016/j.healthpol.2008.06.003; Braverman R, 2007, CURR OPIN OPHTHALMOL, V18, P379, DOI 10.1097/ICU.0b013e328244dfed; Comm Practice Ambulatory Med Secti, 2003, OPHTHALMOLOGY, V110, P860, DOI 10.1016/S0161-6420(03)00414-7; Donahue SP, 2006, J AAPOS, V10, P44, DOI 10.1016/j.jaapos.2005.08.007; Giordano L, 2009, OPHTHALMOLOGY, V116, P739, DOI 10.1016/j.ophtha.2008.12.030; Leone JF, 2010, ARCH OPHTHALMOL-CHIC, V128, P894, DOI 10.1001/archophthalmol.2010.134; Matta NS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1591, DOI 10.1001/archophthalmol.2009.294; PADHYE AS, 2009, E AFR J OPHTHALMOL, V16, P69; Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210; Robaei D, 2006, OPHTHALMOLOGY, V113, P1567, DOI 10.1016/j.ophtha.2006.02.066	10	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1114	1115		10.1001/jama.2010.1298	http://dx.doi.org/10.1001/jama.2010.1298			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20830825				2022-12-28	WOS:000281559800022
J	Appel, LJ; Wright, JT; Greene, T; Agodoa, LY; Astor, BC; Bakris, GL; Cleveland, WH; Charleston, J; Contreras, G; Faulkner, ML; Gabbai, FB; Gassman, JJ; Hebert, LA; Jamerson, KA; Kopple, JD; Kusek, JW; Lash, JP; Lea, JP; Lewis, JB; Lipkowitz, MS; Massry, SG; Miller, ER; Norris, K; Phillips, RA; Pogue, VA; Randall, OS; Rostand, SG; Smogorzewski, MJ; Toto, RD; Wang, XL				Appel, Lawrence J.; Wright, Jackson T., Jr.; Greene, Tom; Agodoa, Lawrence Y.; Astor, Brad C.; Bakris, George L.; Cleveland, William H.; Charleston, Jeanne; Contreras, Gabriel; Faulkner, Marquetta L.; Gabbai, Francis B.; Gassman, Jennifer J.; Hebert, Lee A.; Jamerson, Kenneth A.; Kopple, Joel D.; Kusek, John W.; Lash, James P.; Lea, Janice P.; Lewis, Julia B.; Lipkowitz, Michael S.; Massry, Shaul G.; Miller, Edgar R.; Norris, Keith; Phillips, Robert A.; Pogue, Velvie A.; Randall, Otelio S.; Rostand, Stephen G.; Smogorzewski, Miroslaw J.; Toto, Robert D.; Wang, Xuelei		AASK Collaborative Res Grp	Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE RENAL-DISEASE; AFRICAN-AMERICAN; PROGRESSION; PROTEINURIA; OUTCOMES; DESIGN; DIET	BACKGROUND In observational studies, the relationship between blood pressure and end-stage renal disease (ESRD) is direct and progressive. The burden of hypertension-related chronic kidney disease and ESRD is especially high among black patients. Yet few trials have tested whether intensive blood-pressure control retards the progression of chronic kidney disease among black patients. METHODS We randomly assigned 1094 black patients with hypertensive chronic kidney disease to receive either intensive or standard blood-pressure control. After completing the trial phase, patients were invited to enroll in a cohort phase in which the blood-pressure target was less than 130/80 mm Hg. The primary clinical outcome in the cohort phase was the progression of chronic kidney disease, which was defined as a doubling of the serum creatinine level, a diagnosis of ESRD, or death. Follow-up ranged from 8.8 to 12.2 years. RESULTS During the trial phase, the mean blood pressure was 130/78 mm Hg in the intensive-control group and 141/86 mm Hg in the standard-control group. During the cohort phase, corresponding mean blood pressures were 131/78 mm Hg and 134/78 mm Hg. In both phases, there was no significant between-group difference in the risk of the primary outcome (hazard ratio in the intensive-control group, 0.91; P = 0.27). However, the effects differed according to the baseline level of proteinuria (P = 0.02 for interaction), with a potential benefit in patients with a protein-to-creatinine ratio of more than 0.22 (hazard ratio, 0.73; P = 0.01). CONCLUSIONS In overall analyses, intensive blood-pressure control had no effect on kidney disease progression. However, there may be differential effects of intensive blood-pressure control in patients with and those without baseline proteinuria.	[Appel, Lawrence J.] Johns Hopkins Univ, Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; [Wright, Jackson T., Jr.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Gassman, Jennifer J.; Wang, Xuelei] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Greene, Tom] Univ Utah, Sch Med, Div Clin Epidemiol, Salt Lake City, UT USA; [Agodoa, Lawrence Y.; Kusek, John W.] NIDDK, Div Kidney Urol & Hematol Dis, Bethesda, MD USA; [Bakris, George L.] Univ Chicago, Pritzker Sch Med, Dept Med, Hypertens Dis Unit, Chicago, IL 60637 USA; [Lash, James P.] Univ Illinois, Dept Med, Chicago, IL USA; [Cleveland, William H.] Morehouse Sch Med, Multidisciplinary Res Ctr, Atlanta, GA 30310 USA; [Lea, Janice P.] Emory Univ, Sch Med, Emory Ctr Hypertens & Renal Dis Res, Atlanta, GA USA; [Contreras, Gabriel] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Faulkner, Marquetta L.] Meharry Med Coll, Nashville, TN 37208 USA; [Lewis, Julia B.] Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37212 USA; [Gabbai, Francis B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Gabbai, Francis B.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Hebert, Lee A.] Ohio State Univ, Med Ctr, Div Nephrol, Columbus, OH 43210 USA; [Jamerson, Kenneth A.] Univ Michigan, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; [Kopple, Joel D.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA; [Kopple, Joel D.] Univ Calif Los Angeles, Los Angeles, CA USA; [Massry, Shaul G.] Los Angeles Cty Univ So Calif, Med Ctr, Los Angeles, CA USA; [Smogorzewski, Miroslaw J.] Univ So Calif, Keck Sch Med, Div Nephrol, Los Angeles, CA 90033 USA; [Norris, Keith] Charles Drew Univ Med & Sci, Dept Internal Med, Los Angeles, CA USA; [Lipkowitz, Michael S.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Pogue, Velvie A.] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Dept Med, New York, NY 10032 USA; [Pogue, Velvie A.] Columbia Univ, New York, NY USA; [Phillips, Robert A.] Univ Massachusetts, Sch Med, Cardiovasc Res Fdn, Worcester, MA USA; [Randall, Otelio S.] Howard Univ, Washington, DC 20059 USA; [Randall, Otelio S.] Howard Univ Hosp, Washington, DC USA; [Rostand, Stephen G.] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL USA; [Toto, Robert D.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA	Johns Hopkins University; Johns Hopkins Medicine; Case Western Reserve University; Cleveland Clinic Foundation; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Morehouse School of Medicine; Emory University; University of Miami; Meharry Medical College; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University System of Ohio; Ohio State University; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; Charles R. Drew University of Medicine & Science; Icahn School of Medicine at Mount Sinai; Columbia University; Columbia University; University of Massachusetts System; University of Massachusetts Worcester; Howard University; Howard University; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Southwestern Medical Center Dallas	Appel, LJ (corresponding author), Johns Hopkins Univ, Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-618, Baltimore, MD 21205 USA.	lappel@jhmi.edu	Appel, Larry/GLT-2608-2022; Toto, Robert/AAQ-3336-2021		National Institute of Diabetes and Digestive and Kidney Diseases; National Center on Minority Health and Health Disparities; National Institutes of Health [M01 RR-00080, M01 RR-00071, M0100032, P20-RR11145, M01 RR00827, M01 RR00052, 2P20 RR11104, RR029887, DK 2818-02]; King Pharmaceuticals; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827, M01RR000071, M01RR000052, P20RR011145, M01RR008084, P20RR011104, UL1RR029887, M01RR000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK045386, K24DK002818] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); King Pharmaceuticals; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants to each clinical center and the coordinating center from the National Institute of Diabetes and Digestive and Kidney Diseases; by the Office of Research in Minority Health (now the National Center on Minority Health and Health Disparities); by institutional grants from the National Institutes of Health (M01 RR-00080, M01 RR-00071, M0100032, P20-RR11145, M01 RR00827, M01 RR00052, 2P20 RR11104, RR029887, and DK 2818-02); by King Pharmaceuticals, which provided monetary support and antihypertensive medications to each clinical center; and by Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia, and Upjohn, which donated antihypertensive medications.	Agarwal R, 2009, CLIN J AM SOC NEPHRO, V4, P830, DOI 10.2215/CJN.06201208; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Appel LJ, 2008, ARCH INTERN MED, V168, P832, DOI 10.1001/archinte.168.8.832; Appel LJ, 2003, J AM SOC NEPHROL, V14, pS166, DOI 10.1097/01.ASN.0000070081.15137.C0; Arguedas JA, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004349.PUB2; CHOBANIAN AV, 2004, HYPERTENSION, V43, P1; Coresh J, 1998, J Am Soc Nephrol, V9, pS24; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; Gassman JJ, 2003, J AM SOC NEPHROL, V14, pS154, DOI 10.1097/01.ASN.0000070080.21680.CB; Jafar TH, 2003, ANN INTERN MED, V139, P244, DOI 10.7326/0003-4819-139-4-200308190-00006; Jafar TH, 2002, ANN INTERN MED, V137, P299; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Klein JP., 2003, SURVIVAL ANAL TECHNI; Kovesdy CP, 2006, NEPHROL DIAL TRANSPL, V21, P1257, DOI 10.1093/ndt/gfk057; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; Mancia G, 2007, BLOOD PRESSURE, V16, P135, DOI 10.1080/08037050701461084; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; Norris KC, 2006, J AM SOC NEPHROL, V17, P2928, DOI 10.1681/ASN.2005101101; Padwal RS, 2009, CAN J CARDIOL, V25, P279, DOI 10.1016/S0828-282X(09)70491-X; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Pogue V, 2009, HYPERTENSION, V53, P20, DOI 10.1161/HYPERTENSIONAHA.108.115154; Pohl MA, 2005, J AM SOC NEPHROL, V16, P3027, DOI 10.1681/ASN.2004110919; Sarnak MJ, 2005, ANN INTERN MED, V142, P342, DOI 10.7326/0003-4819-142-5-200503010-00009; US Renal Data System, 2008, ATL CHRON KIDN DIS E; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Wright JT, 2006, JAMA-J AM MED ASSOC, V295, P2726; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Wuhl E, 2009, NEW ENGL J MED, V361, P1639, DOI 10.1056/NEJMoa0902066	29	504	536	2	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					918	929		10.1056/NEJMoa0910975	http://dx.doi.org/10.1056/NEJMoa0910975			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818902	Green Accepted			2022-12-28	WOS:000281441500005
J	Bengtson, MH; Joazeiro, CAP				Bengtson, Mario H.; Joazeiro, Claudio A. P.			Role of a ribosome-associated E3 ubiquitin ligase in protein quality control	NATURE			English	Article							MESSENGER-RNA SURVEILLANCE; YEAST; TRANSLATION; IDENTIFICATION; PROTEASOME; ANTIBIOTICS; DEGRADATION; EXPRESSION; MECHANISM; REVEALS	Messenger RNA lacking stop codons ('non-stop mRNA') can arise from errors in gene expression, and encode aberrant proteins whose accumulation could be deleterious to cellular function(1,2). In bacteria, these 'non-stop proteins' become co-translationally tagged with a peptide encoded by ssrA/tmRNA (transfer-messenger RNA), which signals their degradation by energy-dependent proteases(1,3). How eukaryotic cells eliminate non-stop proteins has remained unknown. Here we show that the Saccharomyces cerevisiae Ltn1 RING-domain-type E3 ubiquitin ligase acts in the quality control of non-stop proteins, in a process that is mechanistically distinct but conceptually analogous to that performed by ssrA: Ltn1 is predominantly associated with ribosomes, and it marks nascent non-stop proteins with ubiquitin to signal their proteasomal degradation. Ltn1-mediated ubiquitylation of non-stop proteins seems to be triggered by their stalling in ribosomes on translation through the poly(A) tail. The biological relevance of this process is underscored by the finding that loss of Ltn1 function confers sensitivity to stress caused by increased non-stop protein production. We speculate that defective protein quality control may underlie the neurodegenerative phenotype that results from mutation of the mouse Ltn1 homologue Listerin.	[Bengtson, Mario H.; Joazeiro, Claudio A. P.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Joazeiro, CAP (corresponding author), Scripps Res Inst, Dept Cell Biol, CB168,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	joazeiro@scripps.edu			American Cancer Society [08-298-01-TBE]; National Institute of General Medical Sciences [R01GM083060]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083060] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. C. Sogayar for continued mentorship; I. Kwan for technical help; A. Bacconi for help with microscopy; T. Inada, A. van Hoof, S. Liebman and J. Frydman for reagents; the Williamson and Saez laboratories for help with sucrose-gradient fractionation and real-time PCR, respectively; E. Peters for mass spectrometry analyses; M. Smolka for help with yeast methods; and R. Deshaies, E. P. Geiduschek and T. Hunter for discussions. Work in the Joazeiro laboratory is supported by Research Scholar Grant 08-298-01-TBE from the American Cancer Society and grant R01GM083060 from the National Institute of General Medical Sciences.	Bradley ME, 2003, YEAST, V20, P625, DOI 10.1002/yea.985; Braun MA, 2007, MOL CELL BIOL, V27, P2800, DOI 10.1128/MCB.01947-06; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Chu J, 2009, P NATL ACAD SCI USA, V106, P2097, DOI 10.1073/pnas.0812819106; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dimitrova LN, 2009, J BIOL CHEM, V284, P10343, DOI 10.1074/jbc.M808840200; Doma MK, 2007, CELL, V131, P660, DOI 10.1016/j.cell.2007.10.041; Dulebohn D, 2007, BIOCHEMISTRY-US, V46, P4681, DOI 10.1021/bi6026055; Fleischer TC, 2006, GENE DEV, V20, P1294, DOI 10.1101/gad.1422006; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Inada T, 2005, EMBO J, V24, P1584, DOI 10.1038/sj.emboj.7600636; Ito-Harashima S, 2007, GENE DEV, V21, P519, DOI 10.1101/gad.1490207; Kirillov S, 1997, FEBS LETT, V406, P223, DOI 10.1016/S0014-5793(97)00261-5; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Lu JL, 2008, J MOL BIOL, V384, P73, DOI 10.1016/j.jmb.2008.08.089; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; Moore SD, 2007, ANNU REV BIOCHEM, V76, P101, DOI 10.1146/annurev.biochem.75.103004.142733; Rospert S, 2004, CURR BIOL, V14, pR386, DOI 10.1016/j.cub.2004.05.013; VAN HOOF A, 2002, SCIENCE, V295, P2262; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wilson MA, 2007, GENETICS, V177, P773, DOI 10.1534/genetics.107.073205; Zenklusen D, 2008, NAT STRUCT MOL BIOL, V15, P1263, DOI 10.1038/nsmb.1514	23	305	309	2	39	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					470	473		10.1038/nature09371	http://dx.doi.org/10.1038/nature09371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20835226	Green Accepted			2022-12-28	WOS:000282090200045
J	Polli, D; Altoe, P; Weingart, O; Spillane, KM; Manzoni, C; Brida, D; Tomasello, G; Orlandi, G; Kukura, P; Mathies, RA; Garavelli, M; Cerullo, G				Polli, Dario; Altoe, Piero; Weingart, Oliver; Spillane, Katelyn M.; Manzoni, Cristian; Brida, Daniele; Tomasello, Gaia; Orlandi, Giorgio; Kukura, Philipp; Mathies, Richard A.; Garavelli, Marco; Cerullo, Giulio			Conical intersection dynamics of the primary photoisomerization event in vision	NATURE			English	Article							INITIO MOLECULAR-DYNAMICS; EXCITED-STATE DYNAMICS; 1ST STEP; FEMTOSECOND ISOMERIZATION; PERTURBATION-THEORY; CHROMOPHORE MODELS; VISUAL PIGMENTS; ENERGY-STORAGE; RHODOPSIN; SPECTROSCOPY	Ever since the conversion of the 11-cis retinal chromophore to its all-trans form in rhodopsin was identified as the primary photochemical event in vision(1), experimentalists and theoreticians have tried to unravel the molecular details of this process. The high quantum yield of 0.65 (ref. 2), the production of the primary ground-state rhodopsin photoproduct within a mere 200 fs (refs 3-7), and the storage of considerable energy in the first stable bathorhodopsin intermediate(8) all suggest an unusually fast and efficient photoactivated one-way reaction(9). Rhodopsin's unique reactivity is generally attributed to a conical intersection between the potential energy surfaces of the ground and excited electronic states(10,11) enabling the efficient and ultrafast conversion of photon energy into chemical energy(12-16). But obtaining direct experimental evidence for the involvement of a conical intersection is challenging: the energy gap between the electronic states of the reacting molecule changes significantly over an ultrashort time-scale, which calls for observational methods that combine high temporal resolution with a broad spectral observation window. Here we show that ultrafast optical spectroscopy with sub-20-fs time resolution and spectral coverage from the visible to the near-infrared allows us to follow the dynamics leading to the conical intersection in rhodopsin isomerization. We track coherent wave-packet motion from the photoexcited Franck-Condon region to the photoproduct by monitoring the loss of reactant emission and the subsequent appearance of photoproduct absorption, and find excellent agreement between the experimental observations and molecular dynamics calculations that involve a true electronic state crossing. Taken together, these findings constitute the most compelling evidence to date for the existence and importance of conical intersections in visual photochemistry.	[Altoe, Piero; Tomasello, Gaia; Orlandi, Giorgio; Garavelli, Marco] Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy; [Polli, Dario; Manzoni, Cristian; Brida, Daniele; Cerullo, Giulio] Politecn Milan, IFN, CNR, Dipartimento Fis, I-20133 Milan, Italy; [Weingart, Oliver] Univ Duisburg Essen, Lehrstuhl Theoret Chem, D-45117 Essen, Germany; [Weingart, Oliver] Max Planck Inst Kohlenforsch, D-45470 Mulheim, Germany; [Spillane, Katelyn M.; Mathies, Richard A.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Kukura, Philipp] Univ Oxford, Dept Chem, Phys & Theoret Chem Lab, Oxford OX1 3QZ, England	University of Bologna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fotonica e Nanotecnologie (IFN-CNR); Polytechnic University of Milan; University of Duisburg Essen; Max Planck Society; University of California System; University of California Berkeley; University of Oxford	Garavelli, M (corresponding author), Univ Bologna, Dipartimento Chim G Ciamician, Via F Selmi 2, I-40126 Bologna, Italy.	marco.garavelli@unibo.it; giulio.cerullo@fisi.polimi.it	Weingart, Oliver/P-9920-2017; Brida, Daniele/A-9301-2010; Manzoni, Cristian/GPX-1379-2022; GARAVELLI, MARCO/P-5510-2015; Manzoni, Cristian/ABF-1906-2020; Polli, Dario/B-4809-2011; Brida, Daniele/AAT-6672-2020; Weingart, Oliver/O-6470-2019; Cerullo, Giulio/F-6534-2011; Manzoni, Cristian/F-6669-2011	Weingart, Oliver/0000-0001-6033-3702; Brida, Daniele/0000-0003-2060-5480; Manzoni, Cristian/0000-0002-4169-8869; GARAVELLI, MARCO/0000-0002-0796-289X; Polli, Dario/0000-0002-6960-5708; Brida, Daniele/0000-0003-2060-5480; Weingart, Oliver/0000-0001-6033-3702; Cerullo, Giulio/0000-0002-9534-2702; Manzoni, Cristian/0000-0002-4169-8869; Kukura, Philipp/0000-0003-0136-7704	DFG [FOR490]; PRIN programme [2008JKBBK4]; UK Engineering and Physical Sciences Research Council [EP/H003541/1]; EPSRC [EP/H003541/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/H003541/1] Funding Source: researchfish	DFG(German Research Foundation (DFG)); PRIN programme(Ministry of Education, Universities and Research (MIUR)); UK Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	M.G., O.W., G.O., G. T. and P. A. thank E4-Computer Engineering S. p. A. for computational time and technical assistance. Part of this study was financially supported by the DFG (FOR490) and by the PRIN programme (2008JKBBK4). P. K. is supported by a Career Acceleration Fellowship awarded by the UK Engineering and Physical Sciences Research Council (EP/H003541/1).	Altoe P, 2007, THEOR CHEM ACC, V118, P219, DOI 10.1007/s00214-007-0275-9; ANDERSSON K, 1992, J CHEM PHYS, V96, P1218, DOI 10.1063/1.462209; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Cembran A, 2004, J AM CHEM SOC, V126, P16018, DOI 10.1021/ja048782+; Chosrowjan H, 1998, J AM CHEM SOC, V120, P9706, DOI 10.1021/ja981659w; Forsberg N, 1997, CHEM PHYS LETT, V274, P196, DOI 10.1016/S0009-2614(97)00669-6; Frutos LM, 2007, P NATL ACAD SCI USA, V104, P7764, DOI 10.1073/pnas.0701732104; Garavelli M, 1997, J AM CHEM SOC, V119, P6891, DOI 10.1021/ja9610895; Gonzalez-Luque R, 2000, P NATL ACAD SCI USA, V97, P9379, DOI 10.1073/pnas.97.17.9379; Groenhof G, 2004, J AM CHEM SOC, V126, P4228, DOI 10.1021/ja039557f; Groenhof G, 2007, J AM CHEM SOC, V129, P6812, DOI 10.1021/ja069176c; Haran G, 1999, J PHYS CHEM A, V103, P2202, DOI 10.1021/jp9832847; Hayashi S, 2003, BIOPHYS J, V85, P1440, DOI 10.1016/S0006-3495(03)74576-7; Hayashi S, 2009, BIOPHYS J, V96, P403, DOI 10.1016/j.bpj.2008.09.049; Hudock HR, 2007, J PHYS CHEM A, V111, P8500, DOI 10.1021/jp0723665; Hudock HR, 2008, CHEMPHYSCHEM, V9, P2486, DOI 10.1002/cphc.200800649; Kandori H, 2001, CHEM PHYS LETT, V334, P271, DOI 10.1016/S0009-2614(00)01457-3; Karlstrom G, 2003, COMP MATER SCI, V28, P222, DOI 10.1016/S0927-0256(03)00109-5; Kim JE, 2001, BIOCHEMISTRY-US, V40, P13774, DOI 10.1021/bi0116137; KLESSINGER M, 1994, EXCITED STATES PHOTO; Kochendoerfer GG, 1996, J PHYS CHEM-US, V100, P14526, DOI 10.1021/jp960509+; Kukura P, 2005, SCIENCE, V310, P1006, DOI 10.1126/science.1118379; Levine BG, 2007, ANNU REV PHYS CHEM, V58, P613, DOI 10.1146/annurev.physchem.57.032905.104612; Lin H, 2007, THEOR CHEM ACC, V117, P185, DOI 10.1007/s00214-006-0143-z; Manzoni C, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2167128; Mathies R. A., 2000, HDB BIOL PHYSICS, P55, DOI DOI 10.1016/S1383-8121(00)80005-6; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Polli D, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2800778; Roos B.O., 1987, ADV CHEM PHYS, V69, P399, DOI DOI 10.1002/9780470142943.CH7; SCHICK GA, 1987, BIOCHEMISTRY-US, V26, P2556, DOI 10.1021/bi00383a022; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SINGH UC, 1986, J COMPUT CHEM, V7, P718, DOI 10.1002/jcc.540070604; SLOANE CS, 1977, J CHEM PHYS, V66, P1523, DOI 10.1063/1.434116; Stenta M, 2008, J PHYS CHEM B, V112, P1057, DOI 10.1021/jp7104105; Tao HL, 2009, J PHYS CHEM A, V113, P13656, DOI 10.1021/jp9063565; Tomasello G, 2009, J AM CHEM SOC, V131, P5172, DOI 10.1021/ja808424b; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680; WARSHEL A, 1982, J AM CHEM SOC, V104, P1469, DOI 10.1021/ja00370a003; WARSHEL A, 1976, NATURE, V260, P679, DOI 10.1038/260679a0; Weingart O, 2007, J AM CHEM SOC, V129, P10618, DOI 10.1021/ja071793t; Weingart O, 2007, J PHYS CHEM B, V111, P3782, DOI 10.1021/jp0683216; Werner HJ, 2008, MOLPRO VERSION 2008; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	45	637	642	5	433	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					440	U88		10.1038/nature09346	http://dx.doi.org/10.1038/nature09346			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864998				2022-12-28	WOS:000282090200038
J	Mehanna, H; Paleri, V; West, CML; Nutting, C				Mehanna, H.; Paleri, V.; West, C. M. L.; Nutting, C.			Head and neck cancer-Part 1: Epidemiology, presentation, and prevention	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POOLED ANALYSIS; INTERNATIONAL HEAD; ALCOHOL-DRINKING; CARCINOMA; RISK; MORTALITY; SMOKING; TOBACCO		[Mehanna, H.] Univ Hosp Coventry, Inst Head & Neck Studies & Educ, Coventry CV2 2DX, England; [Paleri, V.] Newcastle upon Tyne Hosp NHS Trust, Otolaryngol Head & Neck Surg, Newcastle Upon Tyne, England; [West, C. M. L.] Univ Manchester, Manchester, England; [Nutting, C.] Royal Marsden NHS Fdn Trust, Head & Neck Unit, London, England	University of Warwick; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Manchester; Royal Marsden NHS Foundation Trust	Mehanna, H (corresponding author), Univ Hosp Coventry, Inst Head & Neck Studies & Educ, Coventry CV2 2DX, England.	hishammehanna@aol.com	; West, Catharine/J-4152-2012	Paleri, Vinidh/0000-0002-7933-4585; Mehanna, Hisham/0000-0002-5544-6224; West, Catharine/0000-0002-0839-3449	NCC-Health Technology Assessment Unit; Cancer Research UK; Macmillan Research Fund; Bayer	NCC-Health Technology Assessment Unit; Cancer Research UK(Cancer Research UK); Macmillan Research Fund; Bayer(Bayer AG)	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that they had no financial support for the submitted work; HM is the director of an institute that does contract work for GSK, which has interests in head and neck cancers; he has also received grants from NCC-Health Technology Assessment Unit, Cancer Research UK, and Macmillan Research Fund. CN has received three clinical trial grants from Cancer Research UK and is principal investigator on a drug trial sponsored by Bayer; all authors have no other relationships or activities that could appear to have influenced the submitted work.	Boyle P, 2008, WORLD CANC REPORT; Conway DI, 2009, ORAL ONCOL, V45, P743, DOI 10.1016/j.oraloncology.2009.02.007; *FANC AN CLIN NETW, CLIN STAND CAR UK; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; Heck JE, 2010, INT J EPIDEMIOL, V39, P166, DOI 10.1093/ije/dyp350; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC MONOGRAPHS EVAL, V90, P1; Isles MG, 2008, CLIN OTOLARYNGOL, V33, P210, DOI 10.1111/j.1749-4486.2008.01688.x; Kim JJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3884; Kujan O, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004150.PUB2.; Marron M, 2010, INT J EPIDEMIOL, V39, P182, DOI 10.1093/ije/dyp291; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mehanna H, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1439; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; National Institute for Health and Clinical Excellence, 2004, IMPR OUTC HEAD NECK; Oxford Cancer Intelligence Unit, 2010, PROF HEAD NECK CANC; Paleri V, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2639; Purdue MP, 2009, AM J EPIDEMIOL, V169, P132, DOI 10.1093/aje/kwn306; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Singhi AD, 2010, CANCER-AM CANCER SOC, V116, P2166, DOI 10.1002/cncr.25033; VANDENBREKEL MWM, 1993, EUR ARCH OTO-RHINO-L, V250, P11, DOI 10.1007/BF00176941; World Health Organization, 2008, GLOB BURD DIS 2004 U	21	144	150	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2010	341								c4684	10.1136/bmj.c4684	http://dx.doi.org/10.1136/bmj.c4684			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TH	20855405				2022-12-28	WOS:000282271900007
J	Baudry, A; Mouillet-Richard, S; Schneider, B; Launay, JM; Kellermann, O				Baudry, Anne; Mouillet-Richard, Sophie; Schneider, Benoit; Launay, Jean-Marie; Kellermann, Odile			MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants	SCIENCE			English	Article							LOCUS-COERULEUS; RECOGNITION; RECEPTOR; CELLS; RAT	The serotonin transporter (SERT) ensures the recapture of serotonin and is the pharmacological target of selective serotonin reuptake inhibitor (SSRI) antidepressants. We show that SERT is a target of microRNA-16 (miR-16). miR-16 is expressed at higher levels in noradrenergic than in serotonergic cells; its reduction in noradrenergic neurons causes de novo SERT expression. In mice, chronic treatment with the SSRI fluoxetine (Prozac) increases miR-16 levels in serotonergic raphe nuclei, which reduces SERT expression. Further, raphe exposed to fluoxetine release the neurotrophic factor S100 beta, which acts on noradrenergic cells of the locus coeruleus. By decreasing miR-16, S100 beta turns on the expression of serotonergic functions in noradrenergic neurons. Based on pharmacological and behavioral data, we propose that miR-16 contributes to the therapeutic action of SSRI antidepressants in monoaminergic neurons.	[Launay, Jean-Marie] F Hoffmann La Roche, Pharma Res Dept, CH-4070 Basel, Switzerland; [Baudry, Anne; Mouillet-Richard, Sophie; Schneider, Benoit; Kellermann, Odile] Univ Paris 05, INSERM, U747, F-75006 Paris, France; [Launay, Jean-Marie] Hop Lariboisiere, INSERM, AP HP, U942,Serv Biochim,RTRS Sante Mentale, F-75475 Paris, France	Roche Holding; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Launay, JM (corresponding author), F Hoffmann La Roche, Pharma Res Dept, CH-4070 Basel, Switzerland.	jean-marie.launay@lrb.aphp.fr; odile.kellermann@parisdescartes.fr	Baudry, Anne/O-2624-2017; Mouillet, Sophie/E-4960-2017; Schneider, Benoit/AAF-3850-2019	Mouillet, Sophie/0000-0002-8950-1949; Schneider, Benoit/0000-0002-1377-2670; Baudry, Anne/0000-0002-7729-1753	CNRS; ANR; INSERM	CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank P. Weil-Malherbe, V. Mutel, F. d'Agostini, G. Zurcher, E. Borroni, J. L. Moreau, F. Jenck, M. Buhler, and N. Pieron for skillful methodological assistance, and S. Blanquet, M. Briley, and L. Aggerbeck for critical reading of the manuscript. O.K. is a professor at Paris XI University. This work was funded by CNRS, ANR, and INSERM.	Azmitia EC, 2007, INT REV NEUROBIOL, V77, P31, DOI 10.1016/S0074-7742(06)77002-7; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Benmansour S, 2002, J NEUROSCI, V22, P6766; Berton O, 2006, NAT REV NEUROSCI, V7, P137, DOI 10.1038/nrn1846; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; FRAZER A, 1997, J CLIN PSYCHOPHARM S, V17, P25; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Kim MA, 2004, BRAIN RES, V1026, P56, DOI 10.1016/j.brainres.2004.08.022; Launay JM, 2006, FASEB J, V20, P1843, DOI 10.1096/fj.06-5724com; Manev R, 2001, EUR J PHARMACOL, V420, pR1, DOI 10.1016/S0014-2999(01)00989-X; Martello G, 2007, NATURE, V449, P183, DOI 10.1038/nature06100; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Murphy DL, 2008, NEUROPHARMACOLOGY, V55, P932, DOI 10.1016/j.neuropharm.2008.08.034; Nestler EJ, 1999, BIOL PSYCHIAT, V46, P1131, DOI 10.1016/S0006-3223(99)00158-4; QIAN Y, 1995, J NEUROSCI, V15, P1261; Shanmugam N, 2008, J BIOL CHEM, V283, P36221, DOI 10.1074/jbc.M806322200; Surget A, 2009, NEUROPSYCHOPHARMACOL, V34, P1363, DOI 10.1038/npp.2008.76; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Willner P, 1997, PSYCHOPHARMACOLOGY, V134, P319, DOI 10.1007/s002130050456	19	347	368	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1537	1541		10.1126/science.1193692	http://dx.doi.org/10.1126/science.1193692			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847275				2022-12-28	WOS:000281869000046
J	Chou, YH; Zheng, XY; Beachy, PA; Luo, LQ				Chou, Ya-Hui; Zheng, Xiaoyan; Beachy, Philip A.; Luo, Liqun			Patterning Axon Targeting of Olfactory Receptor Neurons by Coupled Hedgehog Signaling at Two Distinct Steps	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SONIC HEDGEHOG; PRONEURAL GENE; SENSE-ORGANS; DROSOPHILA; MAP; TRANSCRIPTION; SYSTEM; ORGANIZATION; SPECIFICITY	We present evidence for a coupled two-step action of Hedgehog signaling in patterning axon targeting of Drosophila olfactory receptor neurons (ORNs). In the first step, differential Hedgehog pathway activity in peripheral sensory organ precursors creates ORN populations with different levels of the Patched receptor. Different Patched levels in ORNs then determine axonal responsiveness to target-derived Hedgehog in the brain: only ORN axons that do not express high levels of Patched are responsive to and require a second step of Hedgehog signaling for target selection. Hedgehog signaling in the imaginal sensory organ precursors thus confers differential ORN responsiveness to Hedgehog-mediated axon targeting in the brain. This mechanism contributes to the spatial coordination of ORN cell bodies in the periphery and their glomerular targets in the brain. Such coupled two-step signaling may be more generally used to coordinate other spatially and temporally segregated developmental events.	[Chou, Ya-Hui; Zheng, Xiaoyan; Beachy, Philip A.; Luo, Liqun] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Chou, Ya-Hui; Luo, Liqun] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [Zheng, Xiaoyan; Beachy, Philip A.] Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	Luo, LQ (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	lluo@stanford.edu	Zheng, Xiaoyan/AAG-1251-2020; Chou, Ya-Hui/F-3775-2014	Zheng, Xiaoyan/0000-0003-4983-5503; Chou, Ya-Hui/0000-0001-6552-8728; Luo, Liqun/0000-0001-5467-9264	NIH [R01-DC005982]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005982] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank T. Clandinin, M. Scott, K. Shen, G. Struhl, and members of the Luo lab, in particular L. Sweeney, M. Spletter, D. Berdnik, K. Miyamichi, and T. Mosca for discussion and comments on the manuscript. We are grateful to D. Luginbuhl and S. Wheaton for assistance. We thank T. Tabata, I. Salecker, C. T. Chien, G. Struhl, Y.H. Sun, T. Lee, B. Dickson, R. Holmgren, N.E. Baker, J. Jiang, M. P. Scott, P. Therond, I. Guerrero, E. Sanchez-Herrero, R. Carthew, G. W. Davis, L. A. Raftery, K. Saigo, Bloomington Stock Center, Kyoto Stock Center, GETDB (NIG), and Developmental Studies Hybridoma Bank for reagents. Supported by an NIH grant (R01-DC005982 to L. L.). L. L. and P. A. B. are HHMI investigators.	Bourikas D, 2005, NAT NEUROSCI, V8, P297, DOI 10.1038/nn1396; Briscoe J, 2001, MOL CELL, V7, P1279, DOI 10.1016/S1097-2765(01)00271-4; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Casali A, 2004, NATURE, V431, P76, DOI 10.1038/nature02835; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Cho KO, 2000, CELL, V103, P331, DOI 10.1016/S0092-8674(00)00124-0; Chotard C, 2005, NEURON, V48, P237, DOI 10.1016/j.neuron.2005.09.019; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; Endo K, 2007, NAT NEUROSCI, V10, P153, DOI 10.1038/nn1832; Eugster C, 2007, DEV CELL, V13, P57, DOI 10.1016/j.devcel.2007.04.019; Fishilevich E, 2005, CURR BIOL, V15, P1548, DOI 10.1016/j.cub.2005.07.066; Gao Q, 2000, NAT NEUROSCI, V3, P780, DOI 10.1038/77680; Goulding SE, 2000, NEURON, V25, P69, DOI 10.1016/S0896-6273(00)80872-7; Gupta BP, 1998, DEV BIOL, V203, P400, DOI 10.1006/dbio.1998.9064; Gupta BP, 1997, GENES CELLS, V2, P225, DOI 10.1046/j.1365-2443.1997.d01-312.x; Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Jefferis GSXE, 2004, DEVELOPMENT, V131, P117, DOI 10.1242/dev.00896; Jefferis GSXE, 2001, NATURE, V414, P204, DOI 10.1038/35102574; Jhaveri D, 2000, DEV BIOL, V226, P73, DOI 10.1006/dbio.2000.9855; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Komiyama T, 2004, NAT NEUROSCI, V7, P819, DOI 10.1038/nn1284; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; Miyamichi K, 2005, J NEUROSCI, V25, P3586, DOI 10.1523/JNEUROSCI.0324-05.2005; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Newsome TP, 2000, DEVELOPMENT, V127, P851; Ogden SK, 2008, NATURE, V456, P967, DOI 10.1038/nature07459; Okada A, 2006, NATURE, V444, P369, DOI 10.1038/nature05246; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Parra LM, 2010, NAT NEUROSCI, V13, P29, DOI 10.1038/nn.2457; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Stocker RF, 2001, MICROSC RES TECHNIQ, V55, P284, DOI 10.1002/jemt.1178; Sweeney LB, 2007, NEURON, V53, P185, DOI 10.1016/j.neuron.2006.12.022; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Takeuchi H, 2010, CELL, V141, P1056, DOI 10.1016/j.cell.2010.04.041; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Yam PT, 2009, NEURON, V62, P349, DOI 10.1016/j.neuron.2009.03.022; Yao SQ, 2006, CELL, V125, P343, DOI 10.1016/j.cell.2006.02.040; Zheng XY, 2010, GENE DEV, V24, P57, DOI 10.1101/gad.1870310; Zhu HT, 2006, NAT NEUROSCI, V9, P349, DOI 10.1038/nn1652; Zhu HT, 2004, NEURON, V42, P63, DOI 10.1016/S0896-6273(04)00142-4	51	32	32	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					954	966		10.1016/j.cell.2010.08.015	http://dx.doi.org/10.1016/j.cell.2010.08.015			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850015	Bronze, Green Accepted			2022-12-28	WOS:000281855000017
J	Seymour, JE; French, J; Richardson, E				Seymour, Jane E.; French, Jeff; Richardson, Eve			Spotlight: Palliative Care Beyond Cancer Dying matters: let's talk about it	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; HOSPICE CARE; ATTITUDES; DEATH; LIFE; END		[Seymour, Jane E.] Univ Nottingham, Sch Nursing Midwif & Physiother, Nottingham NG7 2HA, England; [French, Jeff] Strateg Soc Marketing, Liphook, Guildford GU30 7QW, England; [Richardson, Eve] Natl Council Palliat Care, London N7 9AS, England	University of Nottingham	Seymour, JE (corresponding author), Univ Nottingham, Sch Nursing Midwif & Physiother, Nottingham NG7 2HA, England.	jane.seymour@nottingham.ac.uk	Seymour, Jane E/C-1610-2009	Seymour, Jane E/0000-0002-9384-2551	National Council for Palliative Care	National Council for Palliative Care	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: JS had support from the National Council for Palliative Care and the National End of Life Care Programme for the submitted work; JF is a consultant to the Dying Matters coalition; no other relationships or activities that could appear to have influenced the submitted work.	Arber S, 2008, J AGING STUD, V22, P366, DOI 10.1016/j.jaging.2008.05.009; Bauman Zygmunt, 1992, MORTALITY IMMORTALIT; Berger Peter Ludwig, 1973, SOCIAL REALITY RELIG; Born Wendi, 2004, J Palliat Med, V7, P247, DOI 10.1089/109662104773709369; Burdette AM, 2005, J SCI STUD RELIG, V44, P79, DOI 10.1111/j.1468-5906.2005.00266.x; Catt S, 2005, PALLIATIVE MED, V19, P402, DOI 10.1191/0269216305pm1037oa; CLARK DA, 2007, EUR J PALLIAT CARE S; Clery E, 2007, BRIT SOCIAL ATTITUDE; Department of Health, 2008, END LIF CAR STRAT PR; *DYING MATT COAL, 2009, NATCEN SURV ATT DYIN; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; French J., 2017, SOCIAL MARKETING PUB, VSecond, DOI 10.1093/med/9780198717690.001.0001; *HLTH CAR COMM, 2009, SPOTL COMPL REP 2 ST, V9; *ICM RES END UK, 2006, HAV GOOD HLTH GEN PU; Johnson KS, 2008, J AM GERIATR SOC, V56, P1953, DOI 10.1111/j.1532-5415.2008.01919.x; Kellehear A., 2008, Critical Public Health, V18, P111, DOI 10.1080/09581590701848960; Lloyd-Williams M, 2007, J PAIN SYMPTOM MANAG, V34, P60, DOI 10.1016/j.jpainsymman.2006.09.028; *M CUR CANC CAR, 2004, VIEWS DYING HOM SURV; *NAT COUNC PALL CA, 2010, DYING MATT LETS TALK; O'Neill C, 2003, SOC SCI MED, V57, P721, DOI 10.1016/S0277-9536(02)00421-5; Rietjens JAC, 2006, PALLIATIVE MED, V20, P685, DOI 10.1177/0269216306070241; Scottish Government, 2008, LIV DYING WELL NAT A; Seymour J., 2009, PUBLIC ATTITUDES DEA; WILLIAMS R, 1990, PROTESTANT LEGACY AT	24	22	23	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4860	10.1136/bmj.c4860	http://dx.doi.org/10.1136/bmj.c4860			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653MO	20847020				2022-12-28	WOS:000282095800003
J	van Schaik, KD				van Schaik, Katherine D.			"Taking" a History	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												katherine_vanschaik@hms.harvard.edu						HUNTER K, 1991, DOCTORS STORIES NARR, P51	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1159	1160		10.1001/jama.2010.1323	http://dx.doi.org/10.1001/jama.2010.1323			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841524				2022-12-28	WOS:000281770600001
J	Bahr, R				Bahr, Roald			Can electrocardiographic screening prevent sudden death in athletes? No	BRITISH MEDICAL JOURNAL			English	Editorial Material							PHYSICAL-ACTIVITY; OF-CARDIOLOGY; CARDIAC DEATH; STATEMENT; CHILDREN; RISK		[Bahr, Roald] Norwegian Sch Sport Sci, Dept Sports Med, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway	Norwegian School of Sport Sciences	Bahr, R (corresponding author), Norwegian Sch Sport Sci, Dept Sports Med, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway.	roald.bahr@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237				Baggish AL, 2010, ANN INTERN MED, V152, P269, DOI 10.7326/0003-4819-152-5-201003020-00004; Campbell RM, 2009, BRIT J SPORT MED, V43, P336, DOI 10.1136/bjsm.2008.050534; Corrado D, 2005, EUR HEART J, V26, P516, DOI 10.1093/eurheartj/ehi108; Corrado D, 2003, J AM COLL CARDIOL, V42, P1959, DOI 10.1016/j.jacc.2003.03.002; Corrado D, 2006, JAMA-J AM MED ASSOC, V296, P1593, DOI 10.1001/jama.296.13.1593; Corrado D, 2010, EUR HEART J, V31, P243, DOI 10.1093/eurheartj/ehp473; Corrado D, 2008, J AM COLL CARDIOL, V52, P1981, DOI 10.1016/j.jacc.2008.06.053; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; Lawless CE, 2008, MED SCI SPORT EXER, V40, P787, DOI 10.1249/MSS.0b013e318164dd18; Maron BJ, 2007, CIRCULATION, V115, P1643, DOI 10.1161/CIRCULATIONAHA.107.181423; Riddoch CJ, 2004, MED SCI SPORT EXER, V36, P86, DOI 10.1249/01.MSS.0000106174.43932.92; Solberg EE, 2010, EUR J CARDIOV PREV R, V17, P337, DOI 10.1097/HJR.0b013e328332f8f7; Wilson JMG, 1968, PRINCIPLES PRACTICE	13	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 14	2010	341								c4914	10.1136/bmj.c4914	http://dx.doi.org/10.1136/bmj.c4914			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653LK	20841393				2022-12-28	WOS:000282092600004
J	Liberman, J; O'Brien, M; Hall, W; Hill, D				Liberman, Jonathan; O'Brien, Megan; Hall, Wayne; Hill, David			Ending inequities in access to effective pain relief?	LANCET			English	Editorial Material									[Liberman, Jonathan; O'Brien, Megan; Hill, David] Int Union Canc, Geneva, Switzerland; [Liberman, Jonathan] Canc Council Victoria, Canton S, Vic 3053, Australia; [O'Brien, Megan] Amer Canc Soc, Washington, DC USA; [Hall, Wayne] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia	Cancer Council Victoria; American Cancer Society; University of Queensland	Liberman, J (corresponding author), Int Union Canc, Geneva, Switzerland.	jonathan.liberman@cancervic.org.au	Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				Amon J, 2009, LANCET, V374, P1676, DOI 10.1016/S0140-6736(09)61990-5; [Anonymous], 1961, SINGL CONV NARC DRUG; [Anonymous], 2008, REP INT NARC CONTR B; Barrett D, 2009, UN DRUG POLICY HUMAN; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Taylor AL, 2007, J LAW MED ETHICS, V35, P556, DOI 10.1111/j.1748-720X.2007.00180.x; *UN EC SOC COUNC C, 2010, UN EC SOC COUNC COMM; United Nations, 2010, REP INT NARC CONTR B; United Nations, 1971, CONV PSYCH SUBST; WHO Commission on Social Determinants of Health World Health Organization, 2008, CLOS GAP GEN HLTH EQ; World Health Organization, 2009, ACC CONTR MED PROGR	11	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					856	857		10.1016/S0140-6736(10)60880-X	http://dx.doi.org/10.1016/S0140-6736(10)60880-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20833289				2022-12-28	WOS:000282069100010
J	Goel, H; Lusher, A; Boneh, A				Goel, Himanshu; Lusher, Allison; Boneh, Avihu			Pediatric Mortality Due to Inborn Errors of Metabolism in Victoria, Australia: A Population-Based Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Goel, Himanshu; Boneh, Avihu] Murdoch Childrens Res Inst, Metab Serv, Melbourne, Vic, Australia; [Lusher, Allison] Royal Childrens Hosp, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Goel, H (corresponding author), Murdoch Childrens Res Inst, Metab Serv, Melbourne, Vic, Australia.	avihu.boneh@ghsv.org.au						Applegarth DA, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.1.e10; Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00; Dionisi-Vici C, 2002, J PEDIATR-US, V140, P321, DOI 10.1067/mpd.2002.122394; Hutchesson ACJ, 1998, J MED GENET, V35, P366, DOI 10.1136/jmg.35.5.366; INTERACTIVE STAT CAL	5	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1070	1072		10.1001/jama.2010.1259	http://dx.doi.org/10.1001/jama.2010.1259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823432				2022-12-28	WOS:000281559800016
J	Klitzman, R				Klitzman, Robert			Exclusion of Genetic Information From the Medical Record Ethical and Medical Dilemmas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONFIDENTIALITY; DISCRIMINATION		[Klitzman, Robert] Columbia Univ, Div Psychiat Law & Eth, New York, NY 10032 USA; [Klitzman, Robert] Columbia Univ, HIV Ctr, New York, NY 10032 USA	Columbia University; Columbia University	Klitzman, R (corresponding author), Columbia Univ, Div Psychiat Law & Eth, 1051 Riverside Dr,Unit 15, New York, NY 10032 USA.	rlk2@columbia.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002431, P20HG005535] Funding Source: NIH RePORTER; NHGRI NIH HHS [P20 HG005535, P20HG005535-01, R01 HG002431, R01 HG002431-01, R01-HG002431-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		*AM MED ASS, COD MED ETH OP 2 135; Denbo SM, 2006, AM BUS LAW J, V43, P561, DOI 10.1111/j.1744-1714.2006.00025.x; Freeman VG, 1999, ARCH INTERN MED, V159, P2263, DOI 10.1001/archinte.159.19.2263; Geppert Cynthia M.A., 2000, SEMINARS IN MED PRAC, V3, P7; Hall MA, 2000, AM J HUM GENET, V66, P293, DOI 10.1086/302714; Klitzman R, 2007, AM J MED GENET A, V143A, P1835, DOI 10.1002/ajmg.a.31864; Klitzman R, 2010, J GENET COUNS, V19, P68, DOI 10.1007/s10897-009-9262-8; SIEGLER M, 1982, NEW ENGL J MED, V307, P1518, DOI 10.1056/NEJM198212093072411; Taylor S, 2008, CLIN GENET, V74, P20, DOI 10.1111/j.1399-0004.2008.01016.x; Wideroff L, 2003, CANCER EPIDEM BIOMAR, V12, P295	10	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1120	1121		10.1001/jama.2010.1303	http://dx.doi.org/10.1001/jama.2010.1303			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823439	Green Accepted			2022-12-28	WOS:000281559800025
J	Worcester, EM; Coe, FL				Worcester, Elaine M.; Coe, Fredric L.			Calcium Kidney Stones	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HYPERCALCIURIA; POTASSIUM CITRATE; OXALATE; PHOSPHATE; NEPHROLITHIASIS; PREVENTION; RISK; UROLITHIASIS; FORMERS; DISEASE	A 43-year-old man presents for evaluation of recurrent kidney stones. He passed his first stone 9 years earlier and has had two additional symptomatic stones. Analysis of the first and the last stones showed that they contained 80% calcium oxalate and 20% calcium phosphate. Analysis of a 24-hour urine collection while the patient was not receiving medications revealed a calcium level of 408 mg (10.2 mmol), an oxalate level of 33 mg (367 mu mol), and a volume of 1.54 liters; the urine pH was 5.6. The patient had been treated with 20 to 40 mmol of potassium citrate daily since he passed his first stone. How should he be further evaluated and treated?	[Worcester, Elaine M.; Coe, Fredric L.] Univ Chicago, Nephrol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Worcester, EM (corresponding author), Univ Chicago, Nephrol Sect, Dept Med, MC 5100,5841 S Maryland Ave, Chicago, IL 60637 USA.	eworcest@bsd.uchicago.edu	Worcester, Elaine/W-2888-2019; Worcester, Elaine/HGU-5545-2022		LabCorp.; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056788] Funding Source: NIH RePORTER	LabCorp.; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Drs. Worcester and Coe report receiving consulting fees from LabCorp. No other potential conflict of interest relevant to this article was reported.	BARCELO P, 1993, J UROLOGY, V150, P1761, DOI 10.1016/S0022-5347(17)35888-3; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; BORGHI L, 1993, J CARDIOVASC PHARM, V22, pS78; Coe FL, 2005, J CLIN INVEST, V115, P2598, DOI 10.1172/JCI26662; COE FL, 1982, AM J MED, V72, P25, DOI 10.1016/0002-9343(82)90567-8; COE FL, 1974, NEW ENGL J MED, V291, P1344; Curhan GC, 2001, KIDNEY INT, V59, P2290, DOI 10.1046/j.1523-1755.2001.0590062290.x; De Yoreo JJ, 2006, AM J PHYSIOL-RENAL, V291, pF1123, DOI 10.1152/ajprenal.00136.2006; ETTINGER B, 1988, J UROLOGY, V139, P679, DOI 10.1016/S0022-5347(17)42599-7; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; Evan AE, 2008, KIDNEY INT, V74, P223, DOI 10.1038/ki.2008.161; Evan AP, 2007, ANAT REC, V290, P1315, DOI 10.1002/ar.20580; Evan AP, 2005, KIDNEY INT, V67, P576, DOI 10.1111/j.1523-1755.2005.67114.x; Fernandez-Rodriguez A, 2006, Actas Urol Esp, V30, P305; Gambaro G, 2006, UROL RES, V34, P102, DOI 10.1007/s00240-005-0019-z; GAULT MH, 1988, NEPHRON, V48, P265, DOI 10.1159/000184940; Hamm LL, 2002, ENDOCRIN METAB CLIN, V31, P885, DOI 10.1016/S0889-8529(02)00031-2; Heilberg IP, 2006, CURR OPIN NEPHROL HY, V15, P394, DOI 10.1097/01.mnh.0000232880.58340.0c; Hiatt RA, 1996, AM J EPIDEMIOL, V144, P25, DOI 10.1093/oxfordjournals.aje.a008851; HOFBAUER J, 1994, BRIT J UROL, V73, P362, DOI 10.1111/j.1464-410X.1994.tb07597.x; Hollingsworth JM, 2006, LANCET, V368, P1171, DOI 10.1016/S0140-6736(06)69474-9; Hoppe B, 2009, KIDNEY INT, V75, P1264, DOI 10.1038/ki.2009.32; Kacker R, 2008, J UROLOGY, V180, P958, DOI 10.1016/j.juro.2008.05.031; Keeley FX, 2009, ADV CHRONIC KIDNEY D, V16, P65, DOI 10.1053/j.ackd.2008.10.011; LAERUM E, 1984, ACTA MED SCAND, V215, P383; Lauderdale DS, 2001, J BONE MINER RES, V16, P1893, DOI 10.1359/jbmr.2001.16.10.1893; Madore F, 1998, AM J HYPERTENS, V11, P46, DOI 10.1016/S0895-7061(97)00371-3; Mandel N, 2003, J UROLOGY, V169, P2026, DOI 10.1097/01.ju.0000065592.55499.4e; Miller NL, 2009, BJU INT, V103, P966, DOI 10.1111/j.1464-410X.2008.08193.x; Nouvenne A, 2010, AM J CLIN NUTR, V91, P565, DOI 10.3945/ajcn.2009.28614; Odvina CV, 2003, KIDNEY INT, V63, P240, DOI 10.1046/j.1523-1755.2003.00719.x; Parks JH, 2004, KIDNEY INT, V66, P777, DOI 10.1111/j.1523-1755.2004.00803.x; Parks JH, 2002, J UROLOGY, V167, P1607, DOI 10.1016/S0022-5347(05)65163-4; Parks JH, 2001, J UROLOGY, V166, P2057, DOI 10.1016/S0022-5347(05)65505-X; Parks JH, 2009, BJU INT, V103, P1238, DOI 10.1111/j.1464-410X.2008.08170.x; Parks JH, 2009, NEPHROL DIAL TRANSPL, V24, P130, DOI 10.1093/ndt/gfn420; Rule AD, 2009, CLIN J AM SOC NEPHRO, V4, P804, DOI 10.2215/CJN.05811108; Saigal CS, 2005, KIDNEY INT, V68, P1808, DOI 10.1111/j.1523-1755.2005.00599.x; Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x; Taylor EN, 2005, JAMA-J AM MED ASSOC, V293, P455, DOI 10.1001/jama.293.4.455; Taylor EN, 2008, CLIN J AM SOC NEPHRO, V3, P1453, DOI 10.2215/CJN.01410308; Taylor EN, 2009, J AM SOC NEPHROL, V20, P2253, DOI 10.1681/ASN.2009030276; TISELIUS HG, 1993, SCANNING MICROSCOPY, V7, P381; Voss S, 2006, J UROLOGY, V175, P1711, DOI 10.1016/S0022-5347(05)01001-3; Wignall GR, 2008, UROL CLIN N AM, V35, P441, DOI 10.1016/j.ucl.2008.05.004; Worcester EM, 2008, SEMIN NEPHROL, V28, P120, DOI 10.1016/j.semnephrol.2008.01.005; Worcester EM, 2007, AM J PHYSIOL-RENAL, V292, pF66, DOI 10.1152/ajprenal.00115.2006	48	234	249	0	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					954	963		10.1056/NEJMcp1001011	http://dx.doi.org/10.1056/NEJMcp1001011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818905	Green Accepted			2022-12-28	WOS:000281441500008
J	Kirby, T				Kirby, Tony			Profile Atul Gawande-making surgery safer worldwide	LANCET			English	Editorial Material																			0	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP-OCT	2010	376	9746					1045	1045		10.1016/S0140-6736(10)61473-0	http://dx.doi.org/10.1016/S0140-6736(10)61473-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	657KM	20870085	Bronze			2022-12-28	WOS:000282411600016
J	Mendizabal, M; Silva, MO				Mendizabal, Manuel; Silva, Marcelo O.			Asterixis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mendizabal, Manuel; Silva, Marcelo O.] Hosp Univ Austral, Pilar, Argentina	Austral University; Hospital Universitario Austral	Mendizabal, M (corresponding author), Hosp Univ Austral, Pilar, Argentina.	mmendiza@cas.austral.edu.ar							0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					E14	E14		10.1056/NEJMicm0911157	http://dx.doi.org/10.1056/NEJMicm0911157			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642HG	20842766				2022-12-28	WOS:000281196600010
J	Smets, T; Bilsen, J; Cohen, J; Rurup, ML; Mortier, F; Deliens, L				Smets, Tinne; Bilsen, Johan; Cohen, Joachim; Rurup, Mette L.; Mortier, Freddy; Deliens, Luc			Reporting of euthanasia in medical practice in Flanders, Belgium: cross sectional analysis of reported and unreported cases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE DECISIONS; PHYSICIAN-ASSISTED SUICIDE; NETHERLANDS; DEATH; LAW; NOTIFICATION	Objectives To estimate the rate of reporting of euthanasia cases to the Federal Control and Evaluation Committee and to compare the characteristics of reported and unreported cases of euthanasia. Design Cross sectional analysis. Setting Flanders, Belgium. Participants A stratified at random sample was drawn of people who died between 1 June 2007 and 30 November 2007. The certifying physician of each death was sent a questionnaire on end of life decision making in the death concerned. Main outcome measures The rate of euthanasia cases reported to the Federal Control and Evaluation Committee; physicians' reasons for not reporting cases of euthanasia; the relation between reporting and non-reporting and the characteristics of the physician and patient; the time by which life was shortened according to the physician; the labelling of the end of life decision by the physician involved; and differences in characteristics of due care between reported and unreported euthanasia cases. Results The survey response rate was 58.4% (3623/6202 eligible cases). The estimated total number of cases of euthanasia in Flanders in 2007 was 1040 (95% CI 970 to 1109), thus the incidence of euthanasia was estimated as 1.9% of all deaths (95% CI 1.6% to 2.3%). Approximately half (549/1040 (52.8%, 95% CI 43.9% to 60.5%)) of all estimated cases of euthanasia were reported to the Federal Control and Evaluation Committee. Physicians who perceived their case as euthanasia reported it in 93.1% (67/72) of cases. Cases of euthanasia were reported less often when the time by which life was shortened was less than one week compared with when the perceived life shortening was greater (37.3% v 74.1%; P<0.001). Unreported cases were generally dealt with less carefully than reported cases: a written request for euthanasia was more often absent (87.7% v 17.6% verbal request only; P<0.001), other physicians and caregivers specialised in palliative care were consulted less often (54.6% v 97.5%; 33.0% v 63.9%; P<0.001 for both), the life ending act was more often performed with opioids or sedatives (92.1% v 4.4%; P<0.001), and the drugs were more often administered by a nurse (41.3% v 0.0%; P<0.001). Conclusions One out of two euthanasia cases is reported to the Federal Control and Evaluation Committee. Most non-reporting physicians do not perceive their act as euthanasia. Countries debating legalisation of euthanasia should simultaneously consider developing a policy facilitating the due care and reporting obligations of physicians.	[Smets, Tinne; Bilsen, Johan; Cohen, Joachim; Deliens, Luc] Vrije Univ Brussel, Fac Med & Pharm, End Life Care Res Grp, B-1090 Brussels, Belgium; [Rurup, Mette L.; Deliens, Luc] Vrije Univ Amsterdam Med Ctr, Expertise Ctr Palliat Care, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Mortier, Freddy] Univ Ghent, Bioeth Inst Ghent, B-9000 Ghent, Belgium	Vrije Universiteit Brussel; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Ghent University	Smets, T (corresponding author), Vrije Univ Brussel, Fac Med & Pharm, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	tinne.smets@vub.ac.be	Smets, Tinne/G-3988-2012; Cohen, Joachim/B-6803-2008	Cohen, Joachim/0000-0002-7224-9476; Mortier, Freddy/0000-0002-5390-3508; Smets, Tinne/0000-0003-1439-316X; Deliens, Luc/0000-0002-8158-2422	Institute for the Promotion of Innovation by Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen) [050158]	Institute for the Promotion of Innovation by Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT))	This study is part of the Monitoring Quality of End of Life Care (MELC) study, a collaboration between the Vrije Universiteit Brussel, Ghent University, Antwerp University, the Scientific Institute of Public Health, all in Belgium, and VU University Medical Center Amsterdam, The Netherlands. This study is supported by a grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen; SBO IWT nr. 050158). The funders had no role in study design; in the collection, analysis and interpretation of the data; in the writing of the manuscript; or in the decision to submit for publication.	ADAMS M, 2001, REGULATING PHYS NEGO, P29; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Chambaere Kenneth, 2010, J Pain Symptom Manage, V39, pe5, DOI 10.1016/j.jpainsymman.2009.10.001; Chambaere K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-299; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DILLMAN T, 1978, MAIL TELEPHONE SURVE; Distelmans W, 2006, PSYCHO-ONCOLOGY, V15, pS226; Distelmans W, 2008, PSYCHO-ONCOL, V17, pS222; Douglas C, 2008, BIOETHICS, V22, P388, DOI 10.1111/j.1467-8519.2008.00661.x; George RJD, 2005, BMJ-BRIT MED J, V331, P684, DOI 10.1136/bmj.331.7518.684; Keown J, 2006, J MED ETHICS, V32, P29, DOI 10.1136/jme.2004.011148; Magnusson RS, 2004, J MED ETHICS, V30, P441, DOI 10.1136/jme.2003.005090; Materstvedt LJ, 2003, PALLIATIVE MED, V17, P97, DOI 10.1191/0269216303pm673oa; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Mortier F, 2000, BIOETHICS, V14, P254, DOI 10.1111/1467-8519.00195; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; Onwuteaka-Philipsen BD, 2000, SOC SCI MED, V51, P429, DOI 10.1016/S0277-9536(99)00476-1; Pollard BJ, 2001, PALLIATIVE MED, V15, P61, DOI 10.1191/026921601668201749; Rurup ML, 2008, MED CARE, V46, P1198, DOI 10.1097/MLR.0b013e31817d69e8; Smets T, 2010, MED CARE, V48, P187, DOI 10.1097/MLR.0b013e3181bd4dde; Smets T, 2009, HEALTH POLICY, V90, P181, DOI 10.1016/j.healthpol.2008.10.003; Sprung CL, 2008, CRIT CARE MED, V36, P8, DOI 10.1097/01.CCM.0000295304.99946.58; Teno Joan M, 2005, J Palliat Med, V8 Suppl 1, pS42; Van den Block L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-79; van der Heide A, 2004, LANCET, V364, P24, DOI 10.1016/S0140-6736(04)17628-9; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; Van Wesemael Y, 2009, HEALTH SERV RES, V44, P2180, DOI 10.1111/j.1475-6773.2009.01042.x; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Weide MCJV, 2005, ARCH INTERN MED, V165, P1698, DOI 10.1001/archinte.165.15.1698; Weide MCJVD, 2004, HEALTH POLICY, V69, P365, DOI 10.1016/j.healthpol.2004.04.010; Weyers H, 2006, SOCIOL HEALTH ILL, V28, P802, DOI 10.1111/j.1467-9566.2006.00543.x	33	46	46	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2010	341								c5174	10.1136/bmj.c5174	http://dx.doi.org/10.1136/bmj.c5174			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663JB	20923842	Green Published, hybrid			2022-12-28	WOS:000282879000004
J	Nathan, DG				Nathan, David G.			A Life-Long Quest to Understand and Treat Genetic Blood Disorders	CELL			English	Editorial Material							ALPHA THALASSEMIA; DELETION; DIAGNOSIS; MALARIA; ANEMIA; FORM		[Nathan, David G.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Nathan, David G.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Nathan, David G.] Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Nathan, DG (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	david_nathan@dfci.harvard.edu						Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736; Gibbons RJ, 2000, AM J MED GENET, V97, P204, DOI 10.1002/1096-8628(200023)97:3<204::AID-AJMG1038>3.0.CO;2-X; HIGGS DR, 1986, P NATL ACAD SCI USA, V83, P5165, DOI 10.1073/pnas.83.14.5165; KAN YW, 1972, NEW ENGL J MED, V287, P1, DOI 10.1056/NEJM197207062870101; O'Donnell A, 2009, P NATL ACAD SCI USA, V106, P18716, DOI 10.1073/pnas.0910142106; O'Donnell A, 2007, P NATL ACAD SCI USA, V104, P9440, DOI 10.1073/pnas.0703424104; OLD JM, 1982, LANCET, V2, P1413; ORKIN SH, 1978, NEW ENGL J MED, V299, P166, DOI 10.1056/NEJM197807272990403; OTTOLENGHI S, 1974, NATURE, V251, P389, DOI 10.1038/251389a0; OTTOLENGHI S, 1976, CELL, V9, P71, DOI 10.1016/0092-8674(76)90053-2; PIPPARD MJ, 1977, LANCET, V2, P737; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; TAYLOR JM, 1974, NATURE, V251, P392, DOI 10.1038/251392a0; WEATHERA.DJ, 1965, NATURE, V208, P1061, DOI 10.1038/2081061a0; WEATHERALL DJ, 1962, BLOOD, V20, P675, DOI 10.1182/blood.V20.6.675.675	15	0	0	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					17	20		10.1016/j.cell.2010.09.015	http://dx.doi.org/10.1016/j.cell.2010.09.015			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887886	Bronze			2022-12-28	WOS:000282362000007
J	van Peperstraten, A; Nelen, W; Grol, R; Zielhuis, G; Adang, E; Stalmeier, P; Hermens, R; Kremer, J				van Peperstraten, Arno; Nelen, Willianne; Grol, Richard; Zielhuis, Gerhard; Adang, Eddy; Stalmeier, Peep; Hermens, Rosella; Kremer, Jan			The effect of a multifaceted empowerment strategy on decision making about the number of embryos transferred in in vitro fertilisation: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BECK-DEPRESSION-INVENTORY; TWIN PREGNANCIES; SINGLE; COMMUNICATION; LEGISLATION; OUTCOMES; DOCTORS; IMPACT	Objective TO evaluate the effects of a multifaceted empowerment strategy on the actual use of single embryo transfer after in vitro fertilisation Design Randomised controlled trial Setting Five in vitro fertilisation clinics in the Netherlands Participants 308 couples (women aged <40) on the waiting list for a first in vitro fertilisation cycle Interventions The multifaceted strategy aimed to empower couples in deciding how many embryos should be transferred The strategy consisted of a decision aid, support of a nurse specialising in in vitro fertilisation, and the offer of reimbursement by way of an extra treatment cycle. The control group received standard care for in vitro fertilisation. Main outcome measures Use of single embryo transfer in the first and second treatment cycles as well as decision making variables and costs of the empowerment strategy Results After the first treatment cycle, single embryo transfer was used by 43% (65/152) of couples in the intervention group and 32% (50/156) in the control group (difference 11%, 95% confidence interval 0% to 22%, P=0.05) After the second treatment cycle, single embryo transfer was used by 26% (14/154) of couples in the intervention group compared with 16% (8/51) in the control group (difference 10%, -6% to 26%, P=0.20) Compared with couples receiving standard care, those receiving the empowerment strategy had significantly higher empowerment and knowledge levels but no differences in anxiety levels Mean total savings per couple in the intervention group were calculated to be (sic)169 75 (146 pound 77, $219.12) Conclusion A multifaceted empowerment strategy encouraged use of single embryo transfer, increased patients' knowledge, reduced costs, and had no effect on levels of anxiety or depression This strategy could therefore be an important tool to reduce the twin pregnancy rate after in vitro fertilisation This trial did not, however, demonstrate the anticipated 25% difference in use of single embryo transfer of the power calculation	[van Peperstraten, Arno; Nelen, Willianne; Kremer, Jan] Radboud Univ Nijmegen Med Ctr, Dept Obstet & Gynaecol, NL-6500 HB Nijmegen, Netherlands; [Grol, Richard; Hermens, Rosella] Radboud Univ Nijmegen Med Ctr, Sci Inst Qual Healthcare, NL-6500 HB Nijmegen, Netherlands; [Zielhuis, Gerhard; Adang, Eddy; Stalmeier, Peep] Radboud Univ Nijmegen Med Ctr, Dept Epidemiol Biostat & HTA, NL-6500 HB Nijmegen, Netherlands; [Stalmeier, Peep] Radboud Univ Nijmegen Med Ctr, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	van Peperstraten, A (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Obstet & Gynaecol, PO Box 9101, NL-6500 HB Nijmegen, Netherlands.		Hermens, Rosella P.M.G./N-3581-2014; Kremer, J.A.M./H-8063-2014; Zielhuis, Gerhard A./H-8123-2014; Adang, E.M.M./L-4169-2015; Stalmeier, P.F.M./L-4666-2015; Nelen, Willianne/N-4239-2013; Grol, Richard/C-8523-2013	Hermens, Rosella P.M.G./0000-0001-7624-7120; Kremer, J.A.M./0000-0002-0495-0201; 	Netherlands Organisation for Health Research and Development [945-16-105]	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	This study was funded by the Netherlands Organisation for Health Research and Development (grant No 945-16-105). All researches are independent from this source of funding. The study sponsor had no role in the study design, collection, analysis and interpretation of data, the writing of the article, and the decision to submit it for publication.	Andersen AN, 2008, HUM REPROD, V23, P756, DOI 10.1093/humrep/den014; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Ayme S, 2008, LANCET, V371, P2048, DOI 10.1016/S0140-6736(08)60875-2; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Coetsier T, 2001, HUM REPROD, V16, P790; De Neubourg D, 2006, EUR J OBSTET GYN R B, V124, P212, DOI 10.1016/j.ejogrb.2005.08.023; Elwyn G, 2006, BMJ-BRIT MED J, V333, P417, DOI 10.1136/bmj.38926.629329.AE; Forlani G, 2006, J ENDOCRINOL INVEST, V29, P405, DOI 10.1007/BF03344123; Gleicher N, 2006, HUM REPROD, V21, P1337, DOI 10.1093/humrep/del026; Gordts S, 2005, REPROD BIOMED ONLINE, V10, P436, DOI 10.1016/S1472-6483(10)60818-8; Harrington J, 2004, PATIENT EDUC COUNS, V52, P7, DOI 10.1016/S0738-3991(03)00017-X; Helmerhorst FM, 2004, BRIT MED J, V328, P261, DOI 10.1136/bmj.37957.560278.EE; Jain T, 2002, NEW ENGL J MED, V347, P661, DOI 10.1056/NEJMsa013491; Karlstrom PO, 2007, HUM REPROD, V22, P2202, DOI 10.1093/humrep/dem120; Kremer J A M, 2008, Ned Tijdschr Geneeskd, V152, P146; Lukassen HGM, 2005, HUM REPROD, V20, P702, DOI 10.1093/humrep/deh672; Lukassen HGM, 2004, FERTIL STERIL, V81, P1240, DOI 10.1016/j.fertnstert.2003.10.029; Luszczynska A, 2005, J PSYCHOL, V139, P439, DOI 10.3200/JRLP.139.5.439-457; Maly RC, 2008, HEALTH PSYCHOL, V27, P728, DOI 10.1037/0278-6133.27.6.728; O'Connor AM, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3, 10.1002/14651858.CD001431.pub4]; Pandian Z., 2009, COCHRANE DB SYST REV, V2; Pinborg A, 2005, HUM REPROD UPDATE, V11, P575, DOI 10.1093/humupd/dmi027; Saldeen P, 2005, HUM REPROD, V20, P4, DOI 10.1093/humrep/deh610; Stalmeier PFM, 2005, PATIENT EDUC COUNS, V57, P286, DOI 10.1016/j.pec.2004.07.010; Steer RA, 1999, GEN HOSP PSYCHIAT, V21, P106, DOI 10.1016/S0163-8343(98)00070-X; Taylor I, 2000, BRIT MED J, V320, P58, DOI 10.1136/bmj.320.7226.58; Thurin A, 2004, NEW ENGL J MED, V351, P2392, DOI 10.1056/NEJMoa041032; Tomes N, 2007, LANCET, V369, P698, DOI 10.1016/S0140-6736(07)60318-3; van der Bij Akke K, 2003, Community Genet, V6, P84, DOI 10.1159/000073003; van Montfoort APA, 2006, HUM REPROD, V21, P338, DOI 10.1093/humrep/dei359; van Peperstraten AM, 2008, HUM REPROD, V23, P2036, DOI 10.1093/humrep/den156; Van Peperstraten AM, 2008, ACTA OBSTET GYN SCAN, V87, P226, DOI 10.1080/00016340701855670; van Peperstraten AM, 2008, HUM REPROD, V23, P2718, DOI 10.1093/humrep/den327; van Peperstraten AM, 2010, PATIENT EDUC COUNS, V78, P124, DOI 10.1016/j.pec.2009.04.007; van Wely M, 2006, HUM REPROD, V21, P2736, DOI 10.1093/humrep/del249	35	44	44	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	2010	341								c2501	10.1136/bmj.c2501	http://dx.doi.org/10.1136/bmj.c2501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659NI	20884700	Green Published, hybrid			2022-12-28	WOS:000282573000012
J	Aylett, V				Aylett, Virginia			Personal View Do geriatricians need guidelines?	BRITISH MEDICAL JOURNAL			English	Editorial Material									St James Univ Hosp, Leeds, W Yorkshire, England	Saint James's University Hospital	Aylett, V (corresponding author), St James Univ Hosp, Leeds, W Yorkshire, England.	virginia.aylett@leedsth.nhs.uk							0	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2010	341								c5340	10.1136/bmj.c5340	http://dx.doi.org/10.1136/bmj.c5340			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659ND	20880909				2022-12-28	WOS:000282572400011
J	Macilwain, C				Macilwain, Colin			Save British science, again	NATURE			English	Editorial Material												cfmworldview@gmail.com						Haskel J., 2010, PUBLIC SUPPORT INNOV	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					269	269		10.1038/467269a	http://dx.doi.org/10.1038/467269a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	650CF	20844513	Bronze			2022-12-28	WOS:000281824900012
J	Coombes, R				Coombes, Rebecca			Health in Developing Countries Toiling for toilets	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmjgroup.com						[Anonymous], EARTHSCAN; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Humphrey JH, 2009, LANCET, V374, P1032, DOI 10.1016/S0140-6736(09)60950-8; Mackenbach Johan P, 2007, BMJ, V334 Suppl 1, ps17, DOI 10.1136/bmj.39044.508646.94; *WAT AID, 2010, IGN BIGG CHILD KILL; WHO, 2008, SAF WAT BETT HLTH	6	2	2	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 15	2010	341								c5027	10.1136/bmj.c5027	http://dx.doi.org/10.1136/bmj.c5027			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653LV	20843925				2022-12-28	WOS:000282093800018
J	Hoffert, MI				Hoffert, Martin I.			Farewell to Fossil Fuels?	SCIENCE			English	Editorial Material							ENERGY; STABILIZATION; EMISSIONS		NYU, New York, NY 10003 USA	New York University	Hoffert, MI (corresponding author), NYU, 550 1St Ave, New York, NY 10003 USA.	marty.hoffert@nyu.edu	chen, bo-zhang/H-2407-2015					Caldeira K, 2003, SCIENCE, V299, P2052, DOI 10.1126/science.1078938; CHU S, 2009, TSINGH U PEOPL REP C; Davis SJ, 2010, SCIENCE, V329, P1330, DOI 10.1126/science.1188566; FISHER BS, 2007, CLIMATE CHANGE 2007, P220; Gore A. L., 2006, INCONVENIENT TRUTH P; Hansen James, 2009, STORMS MY GRANDCHILD; Hoffert MI, 1998, NATURE, V395, P881, DOI 10.1038/27638; Kintisch E, 2006, SCIENCE, V311, P1702, DOI 10.1126/science.311.5768.1702; Lewis NS, 2007, ENG SCI, V2, P12; MORALES A, 2010, BLOOMBERG BUSIN 0729; Pacala S, 2004, SCIENCE, V305, P968, DOI 10.1126/science.1100103; Pielke R, 2008, NATURE, V452, P531, DOI 10.1038/452531a; Raupach MR, 2007, P NATL ACAD SCI USA, V104, P10288, DOI 10.1073/pnas.0700609104; Rogelj J, 2010, NATURE, V464, P1126, DOI 10.1038/4641126a; Smalley RE, 2005, MRS BULL, V30, P412, DOI 10.1557/mrs2005.124; Smil V., 2010, ENERGY TRANSITIONS; Socolow R., 2006, AVOID DANGER CLIM CH, P347; Zweibel K., 2005, NRELTP52038350	18	50	50	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1292	1294		10.1126/science.1195449	http://dx.doi.org/10.1126/science.1195449			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	647YR	20829473				2022-12-28	WOS:000281657300022
J	Hofmann, DC				Hofmann, Douglas C.			Shape Memory Bulk Metallic Glass Composites	SCIENCE			English	Editorial Material							MATRIX COMPOSITES; SCIENCE		CALTECH, Jet Prop Lab, Engn & Sci Directorate, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Hofmann, DC (corresponding author), CALTECH, Jet Prop Lab, Engn & Sci Directorate, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	dch@jpl.nasa.gov						Ashby MF, 2006, SCRIPTA MATER, V54, P321, DOI 10.1016/j.scriptamat.2005.09.051; Byrne CJ, 2008, SCIENCE, V321, P502, DOI 10.1126/science.1158864; GREER AL, 1995, SCIENCE, V267, P1947, DOI 10.1126/science.267.5206.1947; Hays CC, 2000, PHYS REV LETT, V84, P2901, DOI 10.1103/PhysRevLett.84.2901; Hofmann DC, 2008, NATURE, V451, P1085, DOI 10.1038/nature06598; Hofmann DC, 2008, P NATL ACAD SCI USA, V105, P20136, DOI 10.1073/pnas.0809000106; Johnson WL, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400053252; Launey ME, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3156026; Launey ME, 2009, P NATL ACAD SCI USA, V106, P4986, DOI 10.1073/pnas.0900740106; Pauly S, 2010, NAT MATER, V9, P473, DOI [10.1038/NMAT2767, 10.1038/nmat2767]; Pauly S, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3222973; PEKER A, 1993, APPL PHYS LETT, V63, P2342, DOI 10.1063/1.110520; Szuecs F, 2001, ACTA MATER, V49, P1507, DOI 10.1016/S1359-6454(01)00068-4; Wu YA, 2010, ADV MATER, V22, P2770, DOI 10.1002/adma.201000482	14	177	197	8	214	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1294	1295		10.1126/science.1193522	http://dx.doi.org/10.1126/science.1193522			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829474				2022-12-28	WOS:000281657300023
J	Spies, S; Schipper, K; Nollet, F; Abma, TA				Spies, Stefan; Schipper, Karen; Nollet, Frans; Abma, Tineke A.			A Patient's Journey Duchenne muscular dystrophy	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Spies, Stefan; Schipper, Karen] Reinaerde, NL-3502 GJ Utrecht, Netherlands; [Schipper, Karen; Abma, Tineke A.] Vrije Univ Amsterdam Med Ctr, EMGO Inst, Dept Med Humanities, NL-1007 MB Amsterdam, Netherlands; [Nollet, Frans] Univ Amsterdam, Acad Med Ctr, Dept Rehabil, NL-1100 DD Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Schipper, K (corresponding author), Reinaerde, Post Box 3364, NL-3502 GJ Utrecht, Netherlands.	k.schipper@vumc.nl; f.nollet@amc.nl	Abma, Tineke/AER-4580-2022	Abma, Tineke/0000-0002-8902-322X					0	5	5	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 7	2010	341								c4364	10.1136/bmj.c4364	http://dx.doi.org/10.1136/bmj.c4364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZI	20823012				2022-12-28	WOS:000281814900008
J	Bonati, LH; Dobson, J; Algra, A; Branchereau, A; Chatellier, G; Fraedrich, G; Mali, WP; Zeumer, H; Brown, MM; Mas, JL; Ringleb, PA				Bonati, Leo H.; Dobson, Joanna; Algra, Ale; Branchereau, Alain; Chatellier, Gilles; Fraedrich, Gustav; Mali, Willem P.; Zeumer, Hermann; Brown, Martin M.; Mas, Jean-Louis; Ringleb, Peter A.			Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIALS; ANGIOPLASTY	Background Results from randomised controlled trials have shown a higher short-term risk of stroke associated with carotid stenting than with carotid endarterectomy for the treatment of symptomatic carotid stenosis. However, these trials were underpowered for investigation of whether carotid artery stenting might be a safe alternative to endarterectomy in specific patient subgroups. We therefore did a preplanned meta-analysis of individual patient data from three randomised controlled trials. Methods Data from all 3433 patients with symptomatic carotid stenosis who were randomly assigned and analysed in the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial, the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial, and the International Carotid Stenting Study (ICSS) were pooled and analysed with fixed-effect binomial regression models adjusted for source trial. The primary outcome event was any stroke or death. The intention-to-treat (ITT) analysis included all patients and outcome events occurring between randomisation and 120 days thereafter. The per-protocol (PP) analysis was restricted to patients receiving the allocated treatment and events occurring within 30 days after treatment. Findings In the first 120 days after randomisation (ITT analysis), any stroke or death occurred significantly more often in the carotid stenting group (153 [8.9%] of 1725) than in the carotid endarterectomy group (99 [5.8%] of 1708, risk ratio [RR] 1.53, [95% CI 1.20-1.95], p=0.0006; absolute risk difference 3.2 [1.4-4.9]). Of all subgroup variables assessed, only age significantly modified the treatment effect: in patients younger than 70 years (median age), the estimated 120-day risk of stroke or death was 50 (5.8%) of 869 patients in the carotid stenting group and 48 (5.7%) of 843 in the carotid endarterectomy group (RR 1.00 [0.68-1.47]); in patients 70 years or older, the estimated risk with carotid stenting was twice that with carotid endarterectomy (103 [12.0%] of 856 vs 51 [5.9%] of 865, 2.04 [1.48-2.82], interaction p=0.0053, p=0.0014 for trend). In the PP analysis, risk estimates of stroke or death within 30 days of treatment among patients younger than 70 years were 43 (5.1%) of 851 patients in the stenting group and 37 (4.5%) of 821 in the endarterectomy group (1.11 [0.73-1.71]); in patients 70 years or older, the estimates were 87 (10.5%) of 828 patients and 36 (4.4%) of 824, respectively (2.41 [1.65-3.51]; categorical interaction p=0.0078, trend interaction p=0.0013]. Interpretation Stenting for symptomatic carotid stenosis should be avoided in older patients (age >= 70 years), but might be as safe as endarterectomy in younger patients.	[Bonati, Leo H.] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Bonati, Leo H.] Univ Basel Hosp, Stroke Unit, CH-4031 Basel, Switzerland; [Bonati, Leo H.] UCL, Inst Neurol, Dept Brain Repair & Rehabil, London, England; [Dobson, Joanna] London Sch Hyg & Trop Med, Med Stat Unit, Dept Epidemiol & Populat Hlth, London WC1, England; [Algra, Ale] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands; [Algra, Ale] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Patient Care, Utrecht, Netherlands; [Branchereau, Alain] Hop Timone Adultes, Dept Vasc Surg, Marseille, France; [Chatellier, Gilles] Univ Paris 05, Clin Res Unit, Hop Europeen Georges Pompidou, Paris, France; [Fraedrich, Gustav] Med Univ, Dept Vasc Surg, Innsbruck, Austria; [Mali, Willem P.] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands; [Zeumer, Hermann] Univ Hosp Hamburg Eppendorf, Dept Diagnost & Intervent Neuroradiol, Hamburg, Germany; [Brown, Martin M.] UCL, Inst Neurol, Dept Brain Repair & Rehabil, London WC1N 38G, England; [Mas, Jean-Louis] Univ Paris 05, INSERM, Dept Neurol, Hop St Anne,UMR894, Paris, France; [Ringleb, Peter A.] Univ Heidelberg Hosp, Dept Neurol, Heidelberg, Germany	University of Basel; University of Basel; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical University of Innsbruck; Utrecht University; Utrecht University Medical Center; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of London; University College London; GHU PARIS Psychiatrie Neurosciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg	Brown, MM (corresponding author), UCL, Inst Neurol, Natl Hosp Neurol & Neurosurg, Box 6,Queen Sq, London WC1N 38G, England.	m.brown@ion.ucl.ac.uk	Zeumer, Hermann/AAO-3524-2020; Mali, Willem PThM/I-1123-2014; Bonati, Leo/G-4058-2012; LEYS, Didier/G-2955-2016	Mali, Willem PThM/0000-0003-4391-0904; Bonati, Leo/0000-0003-1163-8133; LEYS, Didier/0000-0003-4408-4392; Ringleb, Peter/0000-0002-5473-8671; Zeumer, Hermann/0000-0003-4511-1225; Sidhu, Paul/0000-0003-1928-4077; Brown, Martin M/0000-0002-3273-1356	Stroke Association; French Ministry of Health, Assistance Publique-Hopitaux de Paris; Federal Ministry of Education and Research, Germany; German Research Foundation; German Society of Neurology; German Society of Neuroradiology (German Radiological Society); Boston Scientific; Guidant; Sanofi-Aventis; Medical Research Council; Sanofi-Synthelabo; European Union; Swiss National Science Foundation [PBBSB-116873]; University of Basel, Switzerland; Beta Lila Weston Trust for Medical Research; Department of Health's National Institute of Health Research Biomedical Research Centres; MRC [G0300411] Funding Source: UKRI; Medical Research Council [G0300411] Funding Source: researchfish; National Institute for Health Research [NF-SI-0507-10339] Funding Source: researchfish; Stroke Association [TSA2008/03] Funding Source: researchfish	Stroke Association; French Ministry of Health, Assistance Publique-Hopitaux de Paris; Federal Ministry of Education and Research, Germany(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); German Society of Neurology; German Society of Neuroradiology (German Radiological Society); Boston Scientific(Boston Scientific); Guidant; Sanofi-Aventis(Sanofi-Aventis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sanofi-Synthelabo; European Union(European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); University of Basel, Switzerland; Beta Lila Weston Trust for Medical Research; Department of Health's National Institute of Health Research Biomedical Research Centres(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Stroke Association	The meta-analysis by the CSTC was funded by a grant from The Stroke Association. The EVA-3S trial was funded by a grant from the Programme Hospitalier de Recherche Clinique of the French Ministry of Health, Assistance Publique-Hopitaux de Paris. The SPACE trial was funded by grants from the Federal Ministry of Education and Research, Germany, the German Research Foundation, the German Society of Neurology, the German Society of Neuroradiology (German Radiological Society), Boston Scientific, Guidant, and Sanofi-Aventis. ICSS was funded by grants from the Medical Research Council, The Stroke Association, Sanofi-Synthelabo, and the European Union. LHB was supported by grants from the Swiss National Science Foundation (PBBSB-116873), University of Basel, Switzerland, and The Stroke Association. MMB's Chair in Stroke Medicine at University College London is supported by the Beta Lila Weston Trust for Medical Research. Part of this work was undertaken at University College London Hospital/University College London, which received a proportion of funding from the Department of Health's National Institute of Health Research Biomedical Research Centres funding scheme.	Alberts MJ, 2001, STROKE, V32, P325; Albucher JF, 2004, CEREBROVASC DIS, V18, P62, DOI 10.1159/000078751; BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0; Bonati LH, 2009, LANCET NEUROL, V8, P908, DOI 10.1016/S1474-4422(09)70227-3; Bond R, 2005, CEREBROVASC DIS, V20, P69, DOI 10.1159/000086509; Bond R, 2002, EUR J VASC ENDOVASC, V23, P108, DOI 10.1053/ejvs.2001.1541; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; Brooks WH, 2004, NEUROSURGERY, V54, P318, DOI 10.1227/01.NEU.0000103447.30087.D3; Brooks WH, 2001, J AM COLL CARDIOL, V38, P1589, DOI 10.1016/S0735-1097(01)01595-9; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Brown MM, 2001, LANCET, V357, P1729; Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0; Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Ederle J, 2009, LANCET NEUROL, V8, P898, DOI 10.1016/S1474-4422(09)70228-5; Ederle J, 2009, STROKE, V40, P1373, DOI 10.1161/STROKEAHA.108.531228; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Featherstone RL, 2004, CEREBROVASC DIS, V18, P69, DOI 10.1159/000078753; Forsting M, 2007, LANCET NEUROL, V6, P101, DOI 10.1016/S1474-4422(07)70010-8; Hacke W, 2006, STROKE, V37, P344, DOI 10.1161/01.STR.0000199664.59711.21; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HOFFMANN A, 2006, SCHWEIZ ARCH NEUROL, V157, P191; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Naylor AR, 2007, NAT CLIN PRACT CARD, V4, P244, DOI 10.1038/ncpcardio0848; Naylor AR, 1998, J VASC SURG, V28, P326, DOI 10.1016/S0741-5214(98)70182-X; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Ringleb PA, 2004, CEREBROVASC DIS, V18, P66, DOI 10.1159/000078752; Roffi M, 2010, LANCET NEUROL, V9, P339, DOI 10.1016/S1474-4422(10)70027-2; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Touze E, 2009, STROKE, V40, pE683, DOI 10.1161/STROKEAHA.109.562041; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	33	304	316	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1062	1073		10.1016/S0140-6736(10)61009-4	http://dx.doi.org/10.1016/S0140-6736(10)61009-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657KM	20832852				2022-12-28	WOS:000282411600033
J	Winter, SE; Thiennimitr, P; Winter, MG; Butler, BP; Huseby, DL; Crawford, RW; Russell, JM; Bevins, CL; Adams, LG; Tsolis, RM; Roth, JR; Baumler, AJ				Winter, Sebastian E.; Thiennimitr, Parameth; Winter, Maria G.; Butler, Brian P.; Huseby, Douglas L.; Crawford, Robert W.; Russell, Joseph M.; Bevins, Charles L.; Adams, L. Garry; Tsolis, Renee M.; Roth, John R.; Baeumler, Andreas J.			Gut inflammation provides a respiratory electron acceptor for Salmonella	NATURE			English	Article							ENTERICA SEROVAR TYPHIMURIUM; INTESTINAL MICROBIOTA; SEROTYPE TYPHIMURIUM; VIRULENCE FACTORS; HYDROGEN-SULFIDE; HOST; METHANETHIOL; DISRUPTS; DISEASE; MUCOSA	Salmonella enterica serotype Typhimurium (S. Typhimurium) causes acute gut inflammation by using its virulence factors to invade the intestinal epithelium and survive in mucosal macrophages. The inflammatory response enhances the transmission success of S. Typhimurium by promoting its outgrowth in the gut lumen through unknown mechanisms. Here we show that reactive oxygen species generated during inflammation react with endogenous, luminal sulphur compounds (thiosulphate) to form a new respiratory electron acceptor, tetrathionate. The genes conferring the ability to use tetrathionate as an electron acceptor produce a growth advantage for S. Typhimurium over the competing microbiota in the lumen of the inflamed gut. We conclude that S. Typhimurium virulence factors induce host-driven production of a new electron acceptor that allows the pathogen to use respiration to compete with fermenting gut microbes. Thus the ability to trigger intestinal inflammation is crucial for the biology of this diarrhoeal pathogen.	[Winter, Sebastian E.; Thiennimitr, Parameth; Winter, Maria G.; Butler, Brian P.; Crawford, Robert W.; Russell, Joseph M.; Bevins, Charles L.; Tsolis, Renee M.; Baeumler, Andreas J.] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA; [Thiennimitr, Parameth] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai 50000, Thailand; [Huseby, Douglas L.; Roth, John R.] Univ Calif Davis, Dept Microbiol, Davis, CA 95616 USA; [Adams, L. Garry] Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med, College Stn, TX 77843 USA	University of California System; University of California Davis; Chiang Mai University; University of California System; University of California Davis; Texas A&M University System; Texas A&M University College Station	Baumler, AJ (corresponding author), Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.	ajbaumler@ucdavis.edu	Winter, Sebastian E/A-4118-2009; Bevins, Charles L/P-4438-2015; Thiennimitr, Parameth/AAH-1761-2019; Butler, Brian/AAF-4821-2019; Baumler, Andreas J/H-2301-2011	Winter, Sebastian E/0000-0003-1532-9178; Bevins, Charles L/0000-0003-2725-2622; Butler, Brian/0000-0002-8554-2997; Baumler, Andreas J/0000-0001-9152-7809; Huseby, Douglas/0000-0001-9974-578X; Thiennimitr, Parameth/0000-0002-6339-8744; Tsolis, Renee/0000-0001-9131-6657	Public Health Service [AI040124, AI044170, AI073120, AI076246, AI088122]; Department of Microbiology, Chiang Mai University, Thailand; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076246, R21AI088122, R21AI073120, R37AI032738, R29AI040124, R01AI044170, R01AI040124] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Department of Microbiology, Chiang Mai University, Thailand; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank H. Chu for providing real-time PCR primers, V. Tolstikov for performing the liquid chromatography-mass spectrometry analysis, M. Xavier for assistance with histopathology and V. Gerriets for technical assistance. Work in A.J.B.'s laboratory is supported by Public Health Service grants AI040124, AI044170, AI073120, AI076246 and AI088122. P. T. was supported by a stipend from the Department of Microbiology, Chiang Mai University, Thailand.	Barman M, 2008, INFECT IMMUN, V76, P907, DOI 10.1128/IAI.01432-07; Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; Furne J, 2001, BIOCHEM PHARMACOL, V62, P255, DOI 10.1016/S0006-2952(01)00657-8; HARRIS JC, 1972, ANN INTERN MED, V76, P697, DOI 10.7326/0003-4819-76-5-697; Hensel M, 1999, MOL MICROBIOL, V32, P275, DOI 10.1046/j.1365-2958.1999.01345.x; Hensel M, 1999, MOL MICROBIOL, V31, P489, DOI 10.1046/j.1365-2958.1999.01190.x; Hinsley AP, 2002, MICROBIOL-SGM, V148, P3631, DOI 10.1099/00221287-148-11-3631; Lawley TD, 2008, INFECT IMMUN, V76, P403, DOI 10.1128/IAI.01189-07; Levitt MD, 1999, J CLIN INVEST, V104, P1107, DOI 10.1172/JCI7712; Lupp C, 2007, CELL HOST MICROBE, V2, P119, DOI 10.1016/j.chom.2007.06.010; Muller L, 1923, CR SOC BIOL, V89, P434; Raffatellu M, 2009, CELL HOST MICROBE, V5, P476, DOI 10.1016/j.chom.2009.03.011; Reinders CI, 2007, SCAND J GASTROENTERO, V42, P1151, DOI 10.1080/00365520701320505; Santos RL, 2009, TRENDS MICROBIOL, V17, P498, DOI 10.1016/j.tim.2009.08.008; Sekirov I, 2008, INFECT IMMUN, V76, P4726, DOI 10.1128/IAI.00319-08; Stecher B, 2007, PLOS BIOL, V5, P2177, DOI 10.1371/journal.pbio.0050244; Thomson NR, 2006, PLOS GENET, V2, P2039, DOI 10.1371/journal.pgen.0020206; Tsolis RM, 1999, INFECT IMMUN, V67, P4879, DOI 10.1128/IAI.67.9.4879-4885.1999; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002	19	796	812	7	142	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					426	429		10.1038/nature09415	http://dx.doi.org/10.1038/nature09415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864996	Green Accepted, Green Submitted			2022-12-28	WOS:000282090200035
J	Waage, J; Banerji, R; Campbell, O; Chirwa, E; Collender, G; Dieltiens, V; Dorward, A; Godfrey-Faussett, P; Hanvoravongchai, P; Kingdon, G; Little, A; Mills, A; Mulholland, K; Mwinga, A; North, A; Patcharanarumol, W; Poulton, C; Tangcharoensathien, V; Unterhalter, E				Waage, Jeff; Banerji, Rukmini; Campbell, Oona; Chirwa, Ephraim; Collender, Guy; Dieltiens, Veerle; Dorward, Andrew; Godfrey-Faussett, Peter; Hanvoravongchai, Piya; Kingdon, Geeta; Little, Angela; Mills, Anne; Mulholland, Kim; Mwinga, Alwyn; North, Amy; Patcharanarumol, Walaiporn; Poulton, Colin; Tangcharoensathien, Viroj; Unterhalter, Elaine			The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015	LANCET			English	Review							HEALTH-CARE; CHILD-MORTALITY; POVERTY; GENDER; EQUITY; INEQUALITIES; PROGRESS; AFRICA; POLICY		[Waage, Jeff; Collender, Guy] London Int Dev Ctr, London WC1H 0PD, England; [Banerji, Rukmini] Pratham ASER Ctr, New Delhi, India; [Campbell, Oona; Godfrey-Faussett, Peter; Hanvoravongchai, Piya; Mills, Anne; Mulholland, Kim] London Sch Hyg & Trop Med, London WC1, England; [Hanvoravongchai, Piya] London Sch Hyg & Trop Med, Bangkok, Thailand; [Chirwa, Ephraim] Univ Malawi, Zomba, Malawi; [Dieltiens, Veerle] Univ Witwatersrand, Johannesburg, South Africa; [Dorward, Andrew; Poulton, Colin] Univ London, Sch Oriental & African Studies, London, England; [Kingdon, Geeta; Little, Angela; North, Amy; Unterhalter, Elaine] Univ London, Inst Educ, London WC1N 1AZ, England; [Mwinga, Alwyn] Ctr Dis Control & Prevent, Global AIDS Program, Lusaka, Zambia; [Patcharanarumol, Walaiporn; Tangcharoensathien, Viroj] Int Hlth Policy Program, Nonthaburi, Thailand	University of London; London School of Hygiene & Tropical Medicine; University of Malawi; University of Witwatersrand; University of London; University of London School Oriental & African Studies (SOAS); University of London; University College London; UCL Institute of Education	Waage, J (corresponding author), London Int Dev Ctr, 36 Gordon Sq, London WC1H 0PD, England.	jeff.waage@lidc.bloomsbury.ac.uk	Kingdon, Geeta/AAQ-2321-2021; Hanvoravongchai, Piya/A-1569-2012; North, Amy/AAS-7619-2021	Hanvoravongchai, Piya/0000-0003-4256-1271; Kingdon, Geeta/0000-0002-1583-5540; Mills, Anne/0000-0001-9863-9950; North, Amy/0000-0003-0546-2397; Unterhalter, Elaine/0000-0002-2302-6583; Campbell, Oona/0000-0002-9311-0115	Economic and Social Research Council [RES-167-25-0260]; Economic and Social Research Council [ES/E021859/1] Funding Source: researchfish; ESRC [ES/E021859/1] Funding Source: UKRI	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	EU has received a grant from the Economic and Social Research Council (award number RES-167-25-0260).	ADDISON T, 2008, CHRONIC POVERTY REPO; Anand S, 2000, WORLD DEV, V28, P2029, DOI 10.1016/S0305-750X(00)00071-1; [Anonymous], MILL DEV GOALS REP 2; [Anonymous], 2010, GLOBAL INEQUALITIES; [Anonymous], 1999, DEV FREEDOM; Barton Carol., 2005, GENDER DEV, V13, P25, DOI DOI 10.1080/13552070512331332274; Bhana D, 2009, EDUC REV, V61, P49, DOI 10.1080/00131910802684771; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bose C., 2009, GLOBAL GENDER RES TR; BOURGUIGNON F, 2009, 2015 BRUSS JUN; Brundtland Commission, 1987, OUR COMMON FUTURE, DOI DOI 10.1080/07488008808408783; CABRERA L, 2005, POLITICAL THEORY GLO; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Castello LD, 2010, ENVIRON SCI POLICY, V13, P154, DOI 10.1016/j.envsci.2009.12.001; *CENTR STAT OFF MA, 2009, ZAMB DEM HLTH SURV 2; CHEN S, 2007, ABSOLUTE POVERTY MEA; *COMM MACR HLTH, 2002, INV HLTH EC DEV; *COMM MACR HLTH, 2002, 5 WHO COMM MACR HLTH; CONWAY GR, 1985, AGR ADMIN EXT, V20, P31, DOI 10.1016/0309-586X(85)90064-0; Corbett EL, 2009, INT J TUBERC LUNG D, V13, P1231; *CSO CENTR BOARD H, 2003, ZAMB DEM HLTH SURV 2; *DAW, 2009, EXP GROUP M IMP IMPL; *DFID, 2006, CHIN COUNTR ASS PLAN; DFID, 2009, EL WORLD POV BUILD O; *DHS, 2003, ER 2002 FIN REP; Dieltiens V, 2009, PERSPECT EDUC, V27, P365; Dorward A, 2009, DEV POLICY REV, V27, P131, DOI 10.1111/j.1467-7679.2009.00439.x; Easterly W, 2009, WORLD DEV, V37, P26, DOI 10.1016/j.worlddev.2008.02.009; FISCHER AM, 2009, 2015 PROM PROP POL M; FLEISCH B, 2007, PRIMARY ED CRISIS S; FLEURBAEY M, 2008, GDP IS THERE PROGR M; Fraser Nancy, 1997, JUSTICE INTERRUPTUS; FUKUDAPARR S, 2008, 48 UN DEV PROGR INT; Glewwe P, 2002, J ECON LIT, V40, P436, DOI 10.1257/002205102320161258; GORE C, 2009, 2015 PROM PROP POL M; Gore C, 2010, IDS BULL-I DEV STUD, V41, P70, DOI 10.1111/j.1759-5436.2010.00106.x; *GOV MAL, 2008, MAL MILL DEV GOALS R; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Grubb M, 2010, CLIM POLICY, V10, P127, DOI 10.3763/cpol.2010.ED83; *GRZ, 2008, ZAMB MILL DEV GOALS; GWATICIN DR, 2000, CURRENT STATE KNOWLE; Gwatkin D. R., 2005, REACHING POOR HLTH N; Habermas Jeurgen, 1984, THEORY COMMUNICATIVE; Held D., 2005, POLITICAL PHILOS COS, P10; HILLS J, 2010, ANATOMY EC INEQUALIT; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Houweling TAJ, 2007, B WORLD HEALTH ORGAN, V85, P745, DOI 10.2471/BLT.06.038588; Hulme D., 2007, MAKING MILLENNIUM DE; HULME D, 2009, 2015 PROM PROP POL M; Jahan R., 1995, ELUSIVE AGENDA MAINS; Jewkes R, 2002, SOC SCI MED, V55, P1603, DOI 10.1016/S0277-9536(01)00294-5; Joint United Nations Programme on HIV/AIDS (UNAIDS) Zambia National HIV/AIDS/STI/TB Council, 2009, ZAMB HIV PREV RESP M; Jones N, 2010, IDS BULL-I DEV STUD, V41, P113, DOI 10.1111/j.1759-5436.2010.00112.x; KABEER N, 2008, POVERTY FOCUS, V13, P3; Kai M., 2006, 11 5 YEAR PLAN TARGE; KAKURU DM, 2008, GENDER EQUALITY HIV; KINGDON G, 2010, WPS201014 CSAE U OXF; Kingdon GG, 2006, J DEV STUD, V42, P1199, DOI 10.1080/00220380600884167; Knights F, 2010, EARLY MUSIC, V38, P1, DOI 10.1093/em/caq003; Langford M, 2010, IDS BULL-I DEV STUD, V41, P83, DOI 10.1111/j.1759-5436.2010.00108.x; Limwattananon S, 2007, B WORLD HEALTH ORGAN, V85, P600, DOI 10.2471/BLT.06.033720; Limwattananon S, 2010, B WORLD HEALTH ORGAN, V88, P420, DOI 10.2471/BLT.09.068791; Macdonald M., 2003, GENDER EQUALITY MAIN; Malawi Government, 2011, MAL GROWTH DEV STRAT; Manning, 2009, USING INDICATORS ENC; McCowan, 2009, RETHINKING CITIZENSH; *MHRD, 2006, ANN REP 2005 2006; Millennium, 2005, EC HUM WELL BEING SY; *MIN HLTH ZAMB, 2005, NAT HLTH STRAT PLAN; *MIN HLTH ZAMB, 2000, NAT HLTH STRAT PLAN; MINUJIN A, 2004, SOCIOECONOMIC INEQUA; MOLETSANE R, 2010, ENG EMP ED EQ E4 C D; MOOROSI P, 2006, THESIS U KWAZULUNATA; Morrell R., 2009, GENDER EQUALITY S AF; Moser C., 2005, GENDER DEV, V13, P11, DOI [10.1080/13552070512331332283, DOI 10.1080/13552070512331332283]; Mulholland EK, 2008, B WORLD HEALTH ORGAN, V86, P399, DOI 10.2471/BLT.07.044545; *NAC, 2008, COMPR HIV AIDS PREV; *OECD, 2008, EFF AID BETT HLTH; OECD, 1996, SHAP 21 CENT CONTR D; Office of the National Economic and Social Development Board, 2004, THAIL MILL DEV GOALS; Phillips Ann, 2007, MULTICULTURALISM CUL; Pogge Thomas, 2008, GLOBAL JUSTICE SEMIN; Prakongsai P, 2009, J INT DEV, V21, P291, DOI 10.1002/jid.1553; PRIDMORE P, 2007, CREATE PATHWAYS ACCE, V2; Prins G, 2010, HARTWELL PAPER NEW D; Reetika Khera, 2006, Economic and Political Weekly, V41, P4742; Rohde J, 2008, LANCET, V372, P950, DOI 10.1016/S0140-6736(08)61405-1; ROLLESTON C, 2009, HUMAN CAPITAL POVERT; Ruger JP, 2008, GEORGETOWN LAW J, V96, P423; Rutherford ME, 2009, B WORLD HEALTH ORGAN, V87, P216, DOI 10.2471/BLT.08.052175; Sachs J., 2005, END POVERTY WE CAN M; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Schaefer I., 2013, WORLD BANK; Schech S, 2010, SOC POLIT, V17, P111, DOI 10.1093/sp/jxp025; Sen A., 2003, READINGS HUMAN DEV, P41; Sen A., 2010, IDEA JUSTICE, DOI DOI 10.2307/J.CTVJNRV7N; SETS A, 1992, INEQUALITY REEXAMINE; SHETTY S, 2009, 2015 BRUSS JUN; Skard T, 2009, FORUM DEV STUD, V36, P155, DOI 10.1080/08039410.2009.9666429; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Stiglitz J, MEASUREMENT EC PERFO; Sumner A., 2009, BROKER, V14, P8; Sumner A, 2010, IDS BULL-I DEV STUD, V41, P1, DOI 10.1111/j.1759-5436.2010.00097.x; TANGCHAROENSATH.V, 2009, BUILDING DECENT SOC; Tangcharoensathien V, 2005, SOC POLICY DEV CONTE, P257; *TASKF INN INT FIN, 2009, 1 WHO TASKF INN INT; Tiwari M., 2009, 2015 INT DEV POLICY; Tottrup C, 2009, TROP MED INT HEALTH, V14, P653, DOI 10.1111/j.1365-3156.2009.02275.x; *UN MDG GAP TASK F, 2009, STRENGTH GLOB PARTN; *UN STAT DIV, OFF LIST MDG IND 200; *UNDG, 2005, MAK MDGS MATT COUNTR; UNDP, 2003, HUMAN DEV REPORT 200; *UNDP, MDG PLUS CAS STUD TH; UNESCO, 2010, ED ALL GLOB MON REP; *UNESCO, 2008, ED ALL GLOB MON REP; United Nation, 2001, ROAD MAP IMPL UN MIL; United Nations, 2010, MILL DEV GOALS REP 2; United Nations Development Programme (UNDP), 2007, HUMAN DEV REPORT 200; United Nations General Assembly Resolution, 2000, A55L2 UN; UNTERHALTER E, 2000, CHALLENGING DEMOCRAC; UNTERHALTER E, 2009, 1 GEND ED GLOB POV R; Unterhalter E, 2009, STUD PHILOS EDUC, V28, P415, DOI 10.1007/s11217-009-9125-7; *USAID DEL PROJ, 2009, ZAMB NAT LONG TERM F; Vandemoortele J, 2009, DEV POLICY REV, V27, P355, DOI 10.1111/j.1467-7679.2009.00451.x; Vapattanawong P, 2007, LANCET, V369, P850, DOI 10.1016/S0140-6736(07)60413-9; Victora CG, 2006, B WORLD HEALTH ORGAN, V84, P792, DOI 10.2471/BLT.06.030502; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; WHO, 2007, EV BUS STRENGTH HLTH; Wilkinson Richard, 2009, SPIRIT LEVEL WHY MOR; World Bank, 1993, INV HLTH WORLD DEV R; 2009, ASER ANN STATUS ED R; COUNTDOWN 2015 TRACK	132	196	202	0	50	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2010	376	9745					991	1023		10.1016/S0140-6736(10)61196-8	http://dx.doi.org/10.1016/S0140-6736(10)61196-8			33	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20833426	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000282247600031
J	Head, JW; Fassett, CI; Kadish, SJ; Smith, DE; Zuber, MT; Neumann, GA; Mazarico, E				Head, James W., III; Fassett, Caleb I.; Kadish, Seth J.; Smith, David E.; Zuber, Maria T.; Neumann, Gregory A.; Mazarico, Erwan			Global Distribution of Large Lunar Craters: Implications for Resurfacing and Impactor Populations	SCIENCE			English	Article							INNER SOLAR-SYSTEM; MARE BASALTS; AGES; STRATIGRAPHY; VOLCANISM	By using high-resolution altimetric measurements of the Moon, we produced a catalog of all impact craters >= 20 kilometers in diameter on the lunar surface and analyzed their distribution and population characteristics. The most-densely cratered portion of the highlands reached a state of saturation equilibrium. Large impact events, such as Orientale Basin, locally modified the prebasin crater population to similar to 2 basin radii from the basin center. Basins such as Imbrium, Orientale, and Nectaris, which are important stratigraphic markers in lunar history, are temporally distinguishable on the basis of crater statistics. The characteristics of pre- and postmare crater populations support the hypothesis that there were two populations of impactors in early solar system history and that the transition occurred near the time of the Orientale Basin event.	[Head, James W., III; Fassett, Caleb I.; Kadish, Seth J.] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Smith, David E.; Zuber, Maria T.; Mazarico, Erwan] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02129 USA; [Smith, David E.; Zuber, Maria T.; Neumann, Gregory A.; Mazarico, Erwan] NASA, Goddard Space Flight Ctr, Solar Syst Explorat Div, Greenbelt, MD 20771 USA	Brown University; Massachusetts Institute of Technology (MIT); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Head, JW (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.	james_head@brown.edu	Mazarico, Erwan/N-6034-2014; Neumann, Gregory A/I-5591-2013	Mazarico, Erwan/0000-0003-3456-427X; Neumann, Gregory A/0000-0003-0644-9944; Fassett, Caleb/0000-0001-9155-3804	NASA [NNX09AM54G]	NASA(National Aeronautics & Space Administration (NASA))	We thank the LRO and LOLA mission teams for their efforts, which made the observations in this study possible, and T. Kneissl for developing the CraterTools extension to ArcMap. Funding was provided by NASA grant NNX09AM54G for LOLA.	Cohen BA, 2000, SCIENCE, V290, P1754, DOI 10.1126/science.290.5497.1754; Fassett CI, 2008, ICARUS, V195, P61, DOI 10.1016/j.icarus.2007.12.009; GAULT DE, 1970, RADIO SCI, V5, P273, DOI 10.1029/RS005i002p00273; HARTMANN WK, 1995, METEORITICS, V30, P451, DOI 10.1111/j.1945-5100.1995.tb01152.x; HEAD JW, 1975, MOON PLANETS, V12, P299, DOI 10.1007/BF02629699; HEAD JW, 1992, GEOCHIM COSMOCHIM AC, V56, P2155, DOI 10.1016/0016-7037(92)90183-J; Hiesinger H, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001985; Hiesinger H, 2000, J GEOPHYS RES-PLANET, V105, P29239, DOI 10.1029/2000JE001244; Kneissl T, 2011, PLANET SPACE SCI, V59, P1243, DOI 10.1016/j.pss.2010.03.015; Melosh H.L, 1989, IMPACT CRATERING GEO; Neukum G, 2001, SPACE SCI REV, V96, P55, DOI 10.1023/A:1011989004263; Richardson JE, 2009, ICARUS, V204, P697, DOI 10.1016/j.icarus.2009.07.029; Smith DE, 2010, SPACE SCI REV, V150, P209, DOI 10.1007/s11214-009-9512-y; SMITH DE, GEOPHYS RES IN PRESS; Strom RG, 2005, SCIENCE, V309, P1847, DOI 10.1126/science.1113544; STROM RG, 1975, J GEOPHYS RES, V80, P2478, DOI 10.1029/JB080i017p02478; Wilhelms D., 1987, GEOLOGIC HIST MOON, DOI [10.3133/pp1348, DOI 10.3133/PP1348]; Wilhelms D. E., 1976, P LUNAR PLANET SCI C, V7, P2883; WILHELMS DE, 1978, P LUNAR PLANET SCI C, V19, P3735	19	151	157	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	2010	329	5998					1504	1507		10.1126/science.1195050	http://dx.doi.org/10.1126/science.1195050			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847265				2022-12-28	WOS:000281869000035
J	Jewkes, R				Jewkes, Rachel			Emotional abuse: a neglected dimension of partner violence	LANCET			English	Editorial Material							HEALTH; WOMEN; PREVALENCE		MRC, Gender & Hlth Res Unit, ZA-0001 Pretoria, Gauteng Prov, South Africa		Jewkes, R (corresponding author), MRC, Gender & Hlth Res Unit, ZA-0001 Pretoria, Gauteng Prov, South Africa.	rjewkes@mrc.ac.za		Jewkes, Rachel/0000-0002-4330-6267				American Congress of Obstetricians and Gynecologists, SCREEN TOOLS DOM VIO; Chowdhary N, 2008, J POSTGRAD MED, V54, P306, DOI 10.4103/0022-3859.43514; Coker AL, 2000, AM J PUBLIC HEALTH, V90, P553, DOI 10.2105/AJPH.90.4.553; Deyessa Negussie, 2009, Clin Pract Epidemiol Ment Health, V5, P8, DOI 10.1186/1745-0179-5-8; Dude AM, 2011, AIDS BEHAV, V15, P142, DOI 10.1007/s10461-009-9526-1; Dunkle KL, 2004, AM J EPIDEMIOL, V160, P230, DOI 10.1093/aje/kwh194; Le Franc E, 2008, REV PANAM SALUD PUBL, V24, P409, DOI 10.1590/S1020-49892008001200005; Ludermir AB, 2010, LANCET, V376, P903, DOI 10.1016/S0140-6736(10)60887-2; Perales MT, 2009, VIOLENCE AGAINST WOM, V15, P224, DOI 10.1177/1077801208329387; Ruiz-Perez I, 2007, EUR J PUBLIC HEALTH, V17, P437, DOI 10.1093/eurpub/ckl280; Saxena S, 2007, LANCET, V370, P878, DOI 10.1016/S0140-6736(07)61239-2; Yoshihama M, 2009, AM J PUBLIC HEALTH, V99, P647, DOI 10.2105/AJPH.2007.118976	12	55	55	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					851	852		10.1016/S0140-6736(10)61079-3	http://dx.doi.org/10.1016/S0140-6736(10)61079-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20822808				2022-12-28	WOS:000282069100006
J	Ludermir, AB; Lewis, G; Valongueiro, SA; de Araujo, TVB; Araya, R				Ludermir, Ana Bernarda; Lewis, Glyn; Valongueiro, Sandra Alves; Barreto de Araujo, Thalia Velho; Araya, Ricardo			Violence against women by their intimate partner during pregnancy and postnatal depression: a prospective cohort study	LANCET			English	Article							DOMESTIC VIOLENCE; HEALTH; MISCLASSIFICATION; PREVALENCE; MOTHERS; SCALE; ABUSE; CARE	Background Partner violence against women is common during pregnancy and might have an adverse effect on the mental health of women after delivery. We aimed to investigate the association of postnatal depression with psychological, physical, and sexual violence against women by their intimate partners during pregnancy. Methods In a prospective cohort study undertaken in Recife, northeastern Brazil, between July, 2005, and December, 2006, we enrolled pregnant women (aged 18-49 years) in their third trimester of pregnancy who were attending primary health-care clinics. The women were interviewed during pregnancy and after delivery. The form of partner violence in pregnancy was assessed with a validated questionnaire, and the Edinburgh postnatal depression scale was used to measure postnatal depression. Associations were estimated with odds ratios (ORs), adjusted for confounding factors contributing to the association between postnatal depression and intimate partner violence. Findings 1133 pregnant women were eligible for inclusion in the study, of whom 1045 had complete data for all variables and were included in the analysis. 270 women (25.8%, 95% CI 23.2-28.6) had postnatal depression. The most common form of partner violence was psychological (294 [28.1%, 25.4-31.0]). Frequency of psychological violence during pregnancy was positively associated with occurrence of postnatal depression, and although this association was attenuated after adjustment, women reporting the highest frequency of psychological violence were more likely to have postnatal depression even after adjustment (adjusted OR 2-29, 95% CI 1-15-4.57). Women who reported physical or sexual violence in pregnancy were more likely to develop postnatal depression (OR 3.28, 2.29-4.70), but this association was substantially reduced after adjustment for psychological violence and confounding factors. Interpretation Psychological violence during pregnancy by an intimate partner is strongly associated with postnatal depression, independently of physical or sexual violence. This finding has important policy implications since most social policies focus on prevention and treatment of physical violence.	[Ludermir, Ana Bernarda; Valongueiro, Sandra Alves; Barreto de Araujo, Thalia Velho] Univ Fed Pernambuco, Hosp Clin, Programa Posgrad Integrado Saude Colet, Recife, PE, Brazil; [Lewis, Glyn; Araya, Ricardo] Univ Bristol, Acad Unit Psychiat, Bristol, Avon, England	Universidade Federal de Pernambuco; University of Bristol	Ludermir, AB (corresponding author), Ave Conselheiro Rosa & Silva 377-1601, BR-52020220 Recife, PE, Brazil.	abl@ufpe.br	Lewis, Glyn/E-9944-2012; Ludermir, Ana B/A-9026-2009; Araya, Ricardo/S-3144-2019	Lewis, Glyn/0000-0001-5205-8245; Araya, Ricardo/0000-0002-0420-5148	Departamento de Ciencia e Tecnologia da Secretaria de Ciencia, Tecnologia, e Insumos Estrategicos (DECIT); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil [403060/2004-4, 473545/2004-7]	Departamento de Ciencia e Tecnologia da Secretaria de Ciencia, Tecnologia, e Insumos Estrategicos (DECIT); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	We are greatly indebted to the women of Recife who participated in the study, and without whom this research would not have been possible. This study was funded by the Departamento de Ciencia e Tecnologia da Secretaria de Ciencia, Tecnologia, e Insumos Estrategicos (DECIT), and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil (grant numbers 403060/2004-4 and 473545/2004-7).	Alvarado R, 1992, REV PSIQUIATR, V3, P1168; Bacchus L, 2004, EUR J OBSTET GYN R B, V113, P6, DOI 10.1016/S0301-2115(03)00326-9; Beusenberg M., 1994, WHOMNHPSF948; BROWN GW, 1995, PSYCHOL MED, V25, P7, DOI 10.1017/S003329170002804X; CANTILINO A, 2003, NEUROBIOLOGIA, V66, P75; COUTO MT, 2006, CIENC SAUDE COLETIVA, V11, pS1323; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Doubova SV, 2007, REV SAUDE PUBL, V41, P582, DOI 10.1590/S0034-89102007000400012; Ellsberg M, 1999, AM PSYCHOL, V54, P30, DOI 10.1037/0003-066X.54.1.30; Ellsberg M., 1997, CANDIES HELL DOMESTI; Figueira Patrícia, 2009, Rev. Saúde Pública, V43, P79, DOI 10.1590/S0034-89102009000800012; *FUND I BRAS GEOGR, 1991, CENS DEM PERN; Garcia-Moreno C, 2002, LANCET, V359, P1509, DOI 10.1016/S0140-6736(02)08417-9; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Habermas Jurgen, 1990, DISCURSO FILOSOFICO; HARDING TW, 1980, PSYCHOL MED, V10, P231, DOI 10.1017/S0033291700043993; Heise L., 2002, WORLD REPORT VIOLENC; Heise Lori L., 1994, WORLD BANK DISCUSSIO; Leung WC, 2002, INT J GYNECOL OBSTET, V79, P159, DOI 10.1016/S0020-7292(02)00236-9; Ludermir AB, 2010, PSYCHOL MED, V40, P1467, DOI 10.1017/S003329170999184X; Ludermir AB, 2005, SOC PSYCH PSYCH EPID, V40, P36, DOI 10.1007/s00127-005-0840-2; Ludermir AB, 2003, SOC PSYCH PSYCH EPID, V38, P485, DOI 10.1007/s00127-003-0658-8; Ludermir AB, 2008, SOC SCI MED, V66, P1008, DOI 10.1016/j.socscimed.2007.10.021; Lutz KF, 2005, WESTERN J NURS RES, V27, P802, DOI 10.1177/0193945905278078; MARI JD, 1986, J CHRON DIS, V39, P371; Matthey S, 2006, ARCH WOMEN MENT HLTH, V9, P309, DOI 10.1007/s00737-006-0152-x; Moraes CL, 2002, INT J GYNECOL OBSTET, V79, P269, DOI 10.1016/S0020-7292(02)00250-3; Parker B, 1999, RES NURS HEALTH, V22, P59; Patel V, 2002, AM J PSYCHIAT, V159, P43, DOI 10.1176/appi.ajp.159.1.43; Pinheiro RT, 2006, ACTA PSYCHIAT SCAND, V113, P230, DOI 10.1111/j.1600-0447.2005.00708.x; Pollock JI, 2006, J AFFECT DISORDERS, V92, P267, DOI 10.1016/j.jad.2006.02.020; *PREF CID REC, 2006, REC SAUD INCL SOC QU; Ramsay J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005043.pub2; Rojas G, 2007, LANCET, V370, P1629, DOI 10.1016/S0140-6736(07)61685-7; SANTOS MF, 2000, ESCALAS AVALIACAO CL; Schraiber LB, 2009, CAD SAUDE PUBLICA, V25, pS205, DOI 10.1590/S0102-311X2009001400003; Sharma SP, 2007, LANCET ONCOL, V8, P105, DOI 10.1016/S1470-2045(07)70024-4; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Tiwari A, 2005, BJOG-INT J OBSTET GY, V112, P1249, DOI 10.1111/j.1471-0528.2005.00709.x; VENTURI Gustavo, 2004, MULHER BRASILEIRA NO; Watts C, 2002, LANCET, V359, P1232, DOI 10.1016/S0140-6736(02)08221-1; Yost NR, 2005, OBSTET GYNECOL, V106, P61, DOI 10.1097/01.AOG.0000164468.06070.2a	43	202	215	2	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2010	376	9744					903	910		10.1016/S0140-6736(10)60887-2	http://dx.doi.org/10.1016/S0140-6736(10)60887-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20822809				2022-12-28	WOS:000282069100031
J	Bennett-Guerrero, E; Pappas, TN; Koltun, WA; Fleshman, JW; Lin, M; Garg, J; Mark, DB; Marcet, JE; Remzi, FH; George, VV; Newland, K; Corey, GR				Bennett-Guerrero, Elliott; Pappas, Theodore N.; Koltun, Walter A.; Fleshman, James W.; Lin, Min; Garg, Jyotsna; Mark, Daniel B.; Marcet, Jorge E.; Remzi, Feza H.; George, Virgilio V.; Newland, Kerstin; Corey, G. R.		SWIPE 2 Trial Grp	Gentamicin-Collagen Sponge for Infection Prophylaxis in Colorectal Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL-WOUND-INFECTION; SUPPLEMENTAL PERIOPERATIVE OXYGEN; RANDOMIZED CONTROLLED-TRIAL; SITE INFECTION; RISK; HOSPITALIZATION; REDUCE; INDEX	BACKGROUND Despite the routine use of prophylactic systemic antibiotics, surgical-site infection continues to be associated with significant morbidity and cost after colorectal surgery. The gentamicin-collagen sponge, an implantable topical antibiotic agent, is approved for surgical implantation in 54 countries. Since 1985, more than 1 million patients have been treated with the sponges. METHODS In a phase 3 trial, we randomly assigned 602 patients undergoing open or laparoscopically assisted colorectal surgery at 39 U. S. sites to undergo either the insertion of two gentamicin-collagen sponges above the fascia at the time of surgical closure (the sponge group) or no intervention (the control group). All patients received standard care, including prophylactic systemic antibiotics. The primary end point was surgical-site infection occurring within 60 days after surgery, as adjudicated by a clinical-events classification committee that was unaware of the study-group assignments. RESULTS The incidence of surgical-site infection was higher in the sponge group (90 of 300 patients [30.0%]) than in the control group (63 of 302 patients [20.9%], P = 0.01). Superficial surgical-site infection occurred in 20.3% of patients in the sponge group and 13.6% of patients in the control group (P = 0.03), and deep surgical-site infection in 8.3% and 6.0% (P = 0.26), respectively. Patients in the sponge group were more likely to visit an emergency room or surgeon's office owing to a wound-related sign or symptom (19.7%, vs. 11.0% in the control group; P = 0.004) and to be rehospitalized for surgical-site infection (7.0% vs. 4.3%, P = 0.15). The frequency of adverse events did not differ significantly between the two groups. CONCLUSIONS Our large, multicenter trial shows that the gentamicin-collagen sponge is not effective at preventing surgical-site infection in patients who undergo colorectal surgery; paradoxically, it appears to result in significantly more surgical-site infections. (Funded by Innocoll Technologies; ClinicalTrials.gov number, NCT00600925.)	[Bennett-Guerrero, Elliott; Lin, Min; Garg, Jyotsna; Mark, Daniel B.; Newland, Kerstin; Corey, G. R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA; [Pappas, Theodore N.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Koltun, Walter A.] Penn State Coll Med, Milton S Hershey Med Ctr, Hershey, PA USA; [Fleshman, James W.] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Marcet, Jorge E.] Univ S Florida, Tampa, FL USA; [Remzi, Feza H.] Cleveland Clin, Cleveland, OH USA; [George, Virgilio V.] Indiana Univ Sch Med, Indianapolis, IN USA	Duke University; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington University (WUSTL); State University System of Florida; University of South Florida; Cleveland Clinic Foundation; Indiana University System; Indiana University Bloomington	Bennett-Guerrero, E (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, Box 3094, Durham, NC 27710 USA.	elliott.bennettguerrero@duke.edu	Remzi, Feza/AAE-6584-2022	Pappas, Theodore/0000-0001-9110-4849; Mark, Daniel/0000-0001-6340-8087	Innocoll Technologies	Innocoll Technologies	Supported by Innocoll Technologies.	Belda FJ, 2005, JAMA-J AM MED ASSOC, V294, P2035, DOI 10.1001/jama.294.16.2035; Bellomo R, 2009, CRIT CARE MED, V37, P3114, DOI 10.1097/CCM.0b013e3181bc7bd5; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; Fleischmann E, 2005, LANCET, V366, P1101, DOI 10.1016/S0140-6736(05)67422-3; Friberg O, 2003, SCAND J INFECT DIS, V35, P251, DOI 10.1080/003655400310000184; Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929; Gomez GGV, 1999, WORLD J SURG, V23, P123, DOI 10.1007/PL00013171; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HALEY RW, 1985, AM J EPIDEMIOL, V121, P206, DOI 10.1093/oxfordjournals.aje.a113991; Itani KMF, 2006, NEW ENGL J MED, V355, P2640, DOI 10.1056/NEJMoa054408; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Meyhoff CS, 2009, JAMA-J AM MED ASSOC, V302, P1543, DOI 10.1001/jama.2009.1452; Nowacki MP, 2005, INT J COLORECTAL DIS, V20, P114, DOI 10.1007/s00384-004-0632-2; Pryor KO, 2004, JAMA-J AM MED ASSOC, V291, P79, DOI 10.1001/jama.291.1.79; Ruszczak Z, 2003, ADV DRUG DELIVER REV, V55, P1679, DOI 10.1016/j.addr.2003.08.007; Rutten HJT, 1997, EUR J SURG, V163, P31; Smith RL, 2004, ANN SURG, V239, P599, DOI 10.1097/01.sla.0000124292.21605.99; Tam VH, 2006, ANTIMICROB AGENTS CH, V50, P2626, DOI 10.1128/AAC.01165-05; Walz JM, 2006, ARCH SURG-CHICAGO, V141, P1014, DOI 10.1001/archsurg.141.10.1014; Wilson APR, 2004, BRIT MED J, V329, P720, DOI 10.1136/bmj.38232.646227.DE; WILSON APR, 1990, J HOSP INFECT, V16, P297, DOI 10.1016/0195-6701(90)90002-6	23	110	119	3	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1038	1049		10.1056/NEJMoa1000837	http://dx.doi.org/10.1056/NEJMoa1000837			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825316	Green Published			2022-12-28	WOS:000281609700007
J	Belongia, EA; Irving, SA; Waring, SC; Coleman, LA; Meece, JK; Vandermause, M; Lindstrom, S; Kempf, D; Shay, DK				Belongia, Edward A.; Irving, Stephanie A.; Waring, Stephen C.; Coleman, Laura A.; Meece, Jennifer K.; Vandermause, Mary; Lindstrom, Stephen; Kempf, Debra; Shay, David K.			Clinical Characteristics and 30-Day Outcomes for Influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) Infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; NASOPHARYNGEAL ASPIRATE; A(H1N1) INFECTION; NASAL SWAB; OSELTAMIVIR; AUSTRALIA; VIRUS	Context The clinical characteristics of pandemic 2009 influenza A(H1N1) infections have not been compared directly with illnesses caused by other influenza A strains. Objective To compare clinical features and outcomes for 2009 H1N1, seasonal H1N1, and H3N2 influenza in a population-based cohort. Design, Setting, and Participants Active surveillance with 30-day follow-up for influenza cases among children and adults living in a 14-zip code area in Wisconsin. Patients with subjective fever, chills, or cough of fewer than 8 days' duration were screened for eligibility during an outpatient or inpatient encounter. Consenting patients were interviewed and tested for influenza A during the 2007-2008 and 2008-2009 influenza seasons and from May to November 2009; 6874 patients (70%-86% of eligible patients) agreed to participate. Medical records were reviewed to assess outcomes. Main Outcome Measures Hospital admission, radiographically confirmed pneumonia, and clinical characteristics of influenza A by strain. Results We identified 545 2009 H1N1, 221 seasonal H1N1, and 632 H3N2 infections. The median ages of infected participants were 10, 11, and 25 years, respectively (P<.001). Hospital admission occurred within 30 days for 6 of 395 children with 2009 H1N1 (1.5%; 95% confidence interval [CI], 0.6%-3.1%), 5 of 135 with seasonal H1N1 (3.7%; 95% CI, 1.4%-8.0%), and 8 of 255 with H3N2 (3.1%; 95% CI, 1.5%-5.9%). Among adults, hospital admission occurred in 6 of 150 with 2009 H1N1 (4.0%; 95% CI, 1.6%-8.1%), 2 of 86 with seasonal H1N1 (2.3%; 95% CI, 0.3%-8.1%), and 17 of 377 with H3N2 (4.5%; 95% CI, 2.7%-7.0%). Pneumonia occurred in 10 children with 2009 H1N1 (2.5%; 95% CI, 1.3%-4.5%), 2 with seasonal H1N1 (1.5%; 95% CI, 0.2%-5.2%), and 5 with H3N2 (2.0%; 95% CI, 0.7%-4.3%). Among adults, pneumonia occurred in 6 with 2009 H1N1 (4.0%; 95% CI, 1.6%-8.1%), 2 with seasonal H1N1 (2.3%; 95% CI, 0.3%-8.1%), and 4 with H3N2 (1.1%; 95% CI, 0.3%-2.7%). Conclusions In this population, individuals with 2009 H1N1 infection were younger than those with H3N2. The risk of most serious complications was not elevated in adults or children with 2009 H1N1 compared with recent seasonal strains. JAMA. 2010; 304(10): 1091-1098	[Belongia, Edward A.] Marshfield Clin Res Fdn, Epidemiol Res Ctr ML2, Marshfield, WI 54449 USA; [Lindstrom, Stephen; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Belongia, EA (corresponding author), Marshfield Clin Res Fdn, Epidemiol Res Ctr ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA.	belongia.edward@marshfieldclinic.org	Waring, Stephen/AAR-6870-2021	Waring, Stephen/0000-0002-9674-0083; Belongia, Edward/0000-0001-7478-0415; Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820	CDC [1 U01 CI000192-01]; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID) [U01CI000192] Funding Source: NIH RePORTER	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding for this research was provided by a cooperative agreement with the CDC (grant 1 U01 CI000192-01).	Abramson Joseph H, 2004, Epidemiol Perspect Innov, V1, P6, DOI 10.1186/1742-5573-1-6; Baker MG, 2009, EUROSURVEILLANCE, V14, P6; Belongia E., 2008, Morbidity and Mortality Weekly Report, V57, P393; Belongia EA, 2009, J INFECT DIS, V199, P159, DOI 10.1086/595861; Bishop JF, 2009, NEW ENGL J MED, V361, P2591, DOI 10.1056/NEJMp0910445; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P941; Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023; Denholm JT, 2010, MED J AUSTRALIA, V192, P84, DOI 10.5694/j.1326-5377.2010.tb03424.x; DeStefano F, 1996, J CLIN EPIDEMIOL, V49, P643, DOI 10.1016/0895-4356(96)00008-X; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Greenlee Robert T, 2003, Clin Med Res, V1, P273; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Heikkinen T, 2002, J CLIN MICROBIOL, V40, P4337, DOI 10.1128/JCM.40.11.4337-4339.2002; Heikkinen T, 2001, BMJ-BRIT MED J, V322, P138, DOI 10.1136/bmj.322.7279.138; Irving SA, 2009, VACCINE, V27, P6546, DOI 10.1016/j.vaccine.2009.08.050; Jackson ML, 2008, LANCET, V372, P398, DOI 10.1016/S0140-6736(08)61160-5; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Kelly HA, 2009, MED J AUSTRALIA, V191, P146, DOI 10.5694/j.1326-5377.2009.tb02723.x; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Sato M, 2005, PEDIATR INFECT DIS J, V24, P931, DOI 10.1097/01.inf.0000180976.81055.ce; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; World Health Organization, 2009, CDC PROT REALT RTPCR	27	123	132	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1091	1098		10.1001/jama.2010.1277	http://dx.doi.org/10.1001/jama.2010.1277			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823435	Bronze			2022-12-28	WOS:000281559800019
J	Menke, J; Larsen, J				Menke, Jan; Larsen, Joerg			Meta-analysis: Accuracy of Contrast-Enhanced Magnetic Resonance Angiography for Assessing Steno-occlusions in Peripheral Arterial Disease	ANNALS OF INTERNAL MEDICINE			English	Review							LOWER-EXTREMITY ARTERIES; COMPUTED-TOMOGRAPHY ANGIOGRAPHY; SUBTRACTION MR-ANGIOGRAPHY; VASCULAR TREE STENOSES; LOWER-LIMB ARTERIES; PHASED-ARRAY COIL; DIAGNOSTIC PERFORMANCE; SYSTEMATIC REVIEWS; CT ANGIOGRAPHY; RENAL-INSUFFICIENCY	Background: Contrast-enhanced magnetic resonance angiography (MRA) is a noninvasive, radiation-free imaging method for studying peripheral arterial disease (PAD) of the lower extremities. Purpose: To summarize evidence of prospective studies about how well MRA identifies or excludes arterial steno-occlusions (50% to 100% lumen reduction) in adults with PAD symptoms. Data Sources: PubMed and 3 other databases were searched from 1998 to 2009 without language restrictions. Study Selection: Two independent reviewers selected 32 studies that compared MRA with intra-arterial digital subtraction angiography in PAD. Eligible studies were prospective and provided data to reconstruct 2 x 2 or 3 x 3 contingency tables (<50% stenosis vs. >= 50% stenosis or occlusion of arterial segments) in at least 10 patients with PAD symptoms. Data Extraction: Two reviewers independently assessed the study quality and extracted the study data, with disagreements resolved by consensus. Data Synthesis: The 32 included studies generally had high methodological quality. About 26% of the 1022 included patients had critical limb ischemia with pain at rest or tissue loss. Overall, the pooled sensitivity of MRA was 94.7% (95% CI, 92.1% to 96.4%) and the specificity was 95.6% (CI, 94.0% to 96.8%) for diagnosing segmental steno-occlusions. The pooled positive and negative likelihood ratios were 21.56 (CI, 15.70 to 29.69) and 0.056 (CI, 0.037 to 0.083), respectively. Magnetic resonance angiography correctly classified 95.3%, overstaged 3.1%, and understaged 1.6% of arterial segments. Limitation: Similar to most studies of computed tomographic angiography in PAD, the primary studies reported the diagnostic accuracy of MRA on a per-segment basis, not a per-patient basis. Conclusion: This meta-analysis of 32 prospective studies further increases the evidence that contrast-enhanced MRA has high accuracy for identifying or excluding clinically relevant arterial steno-occlusions in adults with PAD symptoms.	[Menke, Jan] Univ Hosp, D-37075 Gottingen, Germany; Evangel Krankenhaus, Gottingen, Germany	University of Gottingen	Menke, J (corresponding author), Univ Hosp, Robert Koch Str 40, D-37075 Gottingen, Germany.	Menke-J@T-Online.de						Agarwal R, 2009, NEPHROL DIAL TRANSPL, V24, P856, DOI 10.1093/ndt/gfn593; Altun E, 2009, RADIOLOGY, V253, P689, DOI 10.1148/radiol.2533090649; Andreisek G, 2007, RADIOLOGY, V242, P610, DOI 10.1148/radiol.2422051111; ARMITAGE P, 1994, STAT METHODS MED RES, P443; Aronow WS, 2009, AM J CARDIOL, V103, P130, DOI 10.1016/j.amjcard.2008.08.037; Berg F, 2008, INVEST RADIOL, V43, P642, DOI 10.1097/RLI.0b013e31817e90ba; Bezooijen R, 2004, RADIOLOGY, V231, P263, DOI 10.1148/radiol.2311020845; Bhave G, 2008, J UROLOGY, V180, P830, DOI 10.1016/j.juro.2008.05.005; Biggerstaff BJ, 2000, STAT MED, V19, P649, DOI 10.1002/(SICI)1097-0258(20000315)19:5&lt;649::AID-SIM371&gt;3.0.CO;2-H; Bipat S, 2007, ACAD RADIOL, V14, P974, DOI 10.1016/j.acra.2007.05.007; Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brau ACS, 2008, MAGN RESON MED, V59, P382, DOI 10.1002/mrm.21481; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Carriero A, 2002, CARDIOVASC INTER RAD, V25, P42, DOI 10.1007/s00270-001-0064-0; Collins R, 2007, HEALTH TECHNOL ASSES, V11, P1; COLLINS R, 2007, HEALTH TECHNOL ASSES, V11, pR9; Collins R, 2007, BMJ-BRIT MED J, V334, P1257, DOI 10.1136/bmj.39217.473275.55; Cowper SE, 2008, EUR J RADIOL, V66, P191, DOI 10.1016/j.ejrad.2008.01.016; Cronberg CN, 2003, ACTA RADIOL, V44, P59; Davenport MS, 2009, RADIOLOGY, V253, P372, DOI 10.1148/radiol.2532090465; de Vries M, 2005, INVEST RADIOL, V40, P495, DOI 10.1097/01.rli.0000163004.65460.8b; de Vries M, 2005, J MAGN RESON IMAGING, V21, P37, DOI 10.1002/jmri.20240; de Vries M, 2006, RADIOLOGY, V240, P401, DOI 10.1148/radiol.2402050223; Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016; Deeks JJ, 2004, BRIT MED J, V329, P168, DOI 10.1136/bmj.329.7458.168; Diehm N, 2007, INVEST RADIOL, V42, P467, DOI 10.1097/01.rli.0000262581.52315.ef; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El-Hajar M, 2008, AM J CARDIOL, V102, P353, DOI 10.1016/j.amjcard.2008.03.067; Fenchel M, 2009, RADIOLOGY, V250, P254, DOI 10.1148/radiol.2501080494; Gjonnaess E, 2006, EUR J VASC ENDOVASC, V31, P53, DOI 10.1016/j.ejvs.2005.09.009; HAY JW, 2008, VALUE HLTH; Heijenbrok-Kal MH, 2007, RADIOLOGY, V245, P433, DOI 10.1148/radiol.2451061280; Herts BR, 2008, RADIOLOGY, V248, P106, DOI 10.1148/radiol.2481071528; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirose K, 2009, AM J CARDIOL, V103, P1215, DOI 10.1016/j.amjcard.2009.01.033; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Ho KYJAM, 1998, RADIOLOGY, V206, P683, DOI 10.1148/radiology.206.3.9494486; Ho KYJAM, 1998, RADIOLOGY, V206, P673, DOI 10.1148/radiology.206.3.9494485; Huber A, 2000, AM J ROENTGENOL, V175, P1291, DOI 10.2214/ajr.175.5.1751291; Huber A, 2003, AM J ROENTGENOL, V180, P1365, DOI 10.2214/ajr.180.5.1801365; Hunt CH, 2009, AM J ROENTGENOL, V193, P1124, DOI 10.2214/AJR.09.2520; Janka R, 2005, RADIOLOGY, V235, P319, DOI 10.1148/radiol.2351031987; JONES A, 2009, SAS STAT 9 2 USERS G; Kelly AM, 2008, ANN INTERN MED, V148, P284, DOI 10.7326/0003-4819-148-4-200802190-00007; Kock MCJM, 2007, EUR RADIOL, V17, P3208, DOI 10.1007/s00330-007-0729-4; Koelemay MJW, 2001, JAMA-J AM MED ASSOC, V285, P1338, DOI 10.1001/jama.285.10.1338; Kramer CM, 2007, CIRCULATION, V116, P1318, DOI 10.1161/CIRCULATIONAHA.107.186849; Krause UJ, 2004, ANGIOLOGY, V55, P119, DOI 10.1177/000331970405500202; Lapeyre M, 2005, AM J ROENTGENOL, V185, P1641, DOI 10.2214/AJR.04.1111; Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008; Lenhart M, 1999, ROFO-FORTSCHR RONTG, V171, P442, DOI 10.1055/s-1999-272; Lenhart M, 2000, ROFO-FORTSCHR RONTG, V172, P992, DOI 10.1055/s-2000-9215; Lundin P, 2000, ACTA RADIOL, V41, P125, DOI 10.1080/028418500127345127; Maceneaney PM, 2000, CLIN RADIOL, V55, P227, DOI 10.1053/crad.1999.0444; Meaney JFM, 1999, RADIOLOGY, V211, P59, DOI 10.1148/radiology.211.1.r99ap1859; Menke J, 2010, METHOD INFORM MED, V49, P54, DOI 10.3414/ME09-01-0001; MENKE J, 2009, EUR J RADIOL; Menke J, 2010, METHOD INFORM MED, V49, P62, DOI DOI 10.3414/ME09-01-0001; Menke J, 2010, AM J CARDIOL, V105, P502, DOI 10.1016/j.amjcard.2009.10.018; Menke J, 2010, MAGN RESON IMAGING, V28, P87, DOI 10.1016/j.mri.2009.05.027; Menke J, 2009, EUR RADIOL, V19, P2654, DOI 10.1007/s00330-009-1448-9; Menke J, 2009, EUR RADIOL, V19, P2204, DOI 10.1007/s00330-009-1403-9; Met R, 2009, JAMA-J AM MED ASSOC, V301, P415, DOI 10.1001/jama.301.4.415; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nainani N, 2009, AM J NEPHROL, V29, P1, DOI 10.1159/000149628; Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766; Nelemans PJ, 2000, RADIOLOGY, V217, P105, DOI 10.1148/radiology.217.1.r00oc11105; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Okada T, 2009, EUR J RADIOL, V71, P486, DOI 10.1016/j.ejrad.2008.06.005; Ostchega Y, 2007, J AM GERIATR SOC, V55, P583, DOI 10.1111/j.1532-5415.2007.01123.x; Ouwendijk R, 2008, AM J ROENTGENOL, V190, P1349, DOI 10.2214/AJR.07.3359; Ouwendijk R, 2006, RADIOLOGY, V241, P603, DOI 10.1148/radiol.2412050781; Owen AR, 2009, J VASC INTERV RADIOL, V20, P165, DOI 10.1016/j.jvir.2008.10.014; Perrier E, 1998, J RADIOL, V79, P1493; Poschenrieder F, 2009, AM J ROENTGENOL, V192, P117, DOI 10.2214/AJR.08.1230; Ruehm SG, 2000, AM J ROENTGENOL, V174, P1127, DOI 10.2214/ajr.174.4.1741127; Schafer FKW, 2003, ROFO-FORTSCHR RONTG, V175, P556, DOI 10.1055/s-2003-38446; Schuetz GM, 2010, ANN INTERN MED, V152, P167, DOI 10.7326/0003-4819-152-3-201002020-00008; Steffens JC, 2003, ACTA RADIOL, V44, P185, DOI 10.1034/j.1600-0455.2003.00044.x; Sueyoshi E, 1999, RADIOLOGY, V210, P683, DOI 10.1148/radiology.210.3.r99fe22683; Sun Y, 1999, IEEE T MED IMAGING, V18, P1154, DOI 10.1109/42.819325; Sun ZH, 2006, J VASC INTERV RADIOL, V17, P1915, DOI 10.1097/01.RVI.0000248830.17550.50; Sutter R, 2007, RADIOLOGY, V245, P276, DOI 10.1148/radiol.2451062081; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thomsen HS, 2009, EUR RADIOL, V19, P891, DOI 10.1007/s00330-008-1206-4; *US FDA, 2006, INF HEALTHC PROF GAD; Visser K, 2000, RADIOLOGY, V216, P67, DOI 10.1148/radiology.216.1.r00jl0367; White C, 2007, NEW ENGL J MED, V356, P1241, DOI 10.1056/NEJMcp064483; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Willmann JK, 2003, RADIOLOGY, V226, P798, DOI 10.1148/radiol.2271020014; Wilson Jennifer Fisher, 2007, Ann Intern Med, V146, pITC3; Winterer JT, 1999, J COMPUT ASSIST TOMO, V23, P583, DOI 10.1097/00004728-199907000-00019; Wyttenbach R, 2003, RADIOLOGY, V227, P261, DOI 10.1148/radiol.2271011989; Yamashita Y, 1998, JMRI-J MAGN RESON IM, V8, P1066, DOI 10.1002/jmri.1880080510; Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31; Zwinderman AH, 2008, STAT MED, V27, P687, DOI 10.1002/sim.2992	98	92	97	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2010	153	5					325	U87		10.7326/0003-4819-153-5-201009070-00007	http://dx.doi.org/10.7326/0003-4819-153-5-201009070-00007			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647GF	20820041				2022-12-28	WOS:000281605500006
J	Cohen, D				Cohen, Deborah			Drug Regulation Rosiglitazone: what went wrong?	BRITISH MEDICAL JOURNAL			English	Editorial Material												dcohen@bmj.com						*AM DIAB ASS, FDA REV DAT 2 NEW DI; CALABRESI M, 1916, TIME            0816; Department of Health and Human Services, 2010, ADV COMM M NDA 21071; Douglas IJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000154; *EUR MED AG, 2001, EPAR AV; *EUR MED AG, AV PROC STEPS TAK SC; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Harris G., 2010, NY TIMES        0713; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Krentz AJ, 2000, BMJ-BRIT MED J, V321, P252, DOI 10.1136/bmj.321.7256.252; *MHRA DEAR DOCT CE, 2010, CURR ADV INF US ROS; MULLARD A, 2010, SCRIP           0730; MULLARD A, 2010, SCRIP           0106; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Nissen SE, 2010, EUR HEART J, V31, P773, DOI 10.1093/eurheartj/ehq016; THEPH, 1999, AV CPMP KNOCKB OV SB; US Senate Committee on Finance, 2010, STAFF REP GLAXOSMITH; 2006, SCIRPP          0922; 2007, SCRIPP          0214; 2010, GLAXOSMITHKLINE 0323; 1999, THEPHARMLETTER  0429; 1998, SCRIPP          0515; 2010, THEPHARMLETTER  0825; 1998, SCRIPP          1202; 2007, SCRIP           0801	25	73	75	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2010	341								c4848	10.1136/bmj.c4848	http://dx.doi.org/10.1136/bmj.c4848			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZH	20819889				2022-12-28	WOS:000281814700012
J	Das, G; Baglioni, P; Okosieme, O				Das, Gautam; Baglioni, Piero; Okosieme, Onyebuchi			Easily Missed? Primary HIV infection	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DIAGNOSIS		[Das, Gautam; Baglioni, Piero; Okosieme, Onyebuchi] Prince Charles Hosp, Merthyr Tydfil CF47 9DT, M Glam, Wales		Das, G (corresponding author), Prince Charles Hosp, Merthyr Tydfil CF47 9DT, M Glam, Wales.	drgdas@gmail.com						[Anonymous], UK NAT GUID HIV TEST; British Association for Sexual Health and HIV, 2010, BASHH STAT HIV WIND; Daar ES, 2001, ANN INTERN MED, V134, P25, DOI 10.7326/0003-4819-134-1-200101020-00010; Health Protection Agency, 2009, HIV UK 2009 REP 2009; Kassutto S, 2004, CLIN INFECT DIS, V38, P1452, DOI 10.1086/420745; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4; Macdonald N, 2007, SEX TRANSM INFECT, V84, P8, DOI 10.1136/sti.2007.027946; Newton PJ, 2002, BRIT MED J, V325, P1225, DOI 10.1136/bmj.325.7374.1225; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Sudarshi D, 2007, SEX TRANSM INFECT, V84, P14, DOI 10.1136/sti.2007.026963; Weintrob AC, 2003, ARCH INTERN MED, V163, P2097, DOI 10.1001/archinte.163.17.2097	12	3	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2010	341								c4583	10.1136/bmj.c4583	http://dx.doi.org/10.1136/bmj.c4583			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZH	20819875	Green Accepted			2022-12-28	WOS:000281814700009
J	Freemantle, N				Freemantle, Nick			Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?	BRITISH MEDICAL JOURNAL			English	Editorial Material							MYOCARDIAL-INFARCTION; ROSIGLITAZONE		[Freemantle, Nick] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Freemantle, N (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England.	N.Freemantle@bham.ac.uk		Freemantle, Nick/0000-0001-5807-5740				Fisher R. A., 1966, DESIGN EXPT; Freemantle N, 2008, BMJ-BRIT MED J, V336, P627, DOI 10.1136/bmj.39491.493252.80; [Guidance for Industry Center for Drug Evaluation and Research Food and Drug Administration U. S. Department of Health and Human Services], 2008, GUID IND DIAB MELL E; HIGGINS JPT, COCHRANE HDB; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; TEMPLE R, 1980, NEW ENGL J MED, V303; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6	9	7	7	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 6	2010	341								c4812	10.1136/bmj.c4812	http://dx.doi.org/10.1136/bmj.c4812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZH	20819888				2022-12-28	WOS:000281814700002
J	Bollag, G; Hirth, P; Tsai, J; Zhang, JZ; Ibrahim, PN; Cho, HN; Spevak, W; Zhang, C; Zhang, Y; Habets, G; Burton, E; Wong, B; Tsang, G; West, BL; Powell, B; Shellooe, R; Marimuthu, A; Nguyen, H; Zhang, KYJ; Artis, DR; Schlessinger, J; Su, F; Higgins, B; Iyer, R; D'Andrea, K; Koehler, A; Stumm, M; Lin, PS; Lee, RJ; Grippo, J; Puzanov, I; Kim, KB; Ribas, A; McArthur, GA; Sosman, JA; Chapman, PB; Flaherty, KT; Xu, XW; Nathanson, KL; Nolop, K				Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, ElizabethA.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith			Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma	NATURE			English	Article							HUMAN CANCER; BRAF(V600E); SORAFENIB; MUTATION; PATHWAY; KERATOACANTHOMAS; SENSITIVITY; PROGRESSION; ACTIVATION; SENESCENCE	B-RAF is the most frequently mutated protein kinase in human cancers(1). The finding that oncogenic mutations in BRAF are common in melanoma(2), followed by the demonstration that these tumours are dependent on the RAF/MEK/ERK pathway(3), offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients. Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity. Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts(4). Toxicology studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation of PLX4032 (ref. 5). In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following two weeks of treatment. This analysis revealed substantial inhibition of ERK phosphorylation, yet clinical evaluation did not show tumour regressions. At higher drug exposures afforded by a new amorphous drug formulation(4,5), greater than 80% inhibition of ERK phosphorylation in the tumours of patients correlated with clinical response. Indeed, the Phase 1 clinical data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily(5). These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.	[Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, ElizabethA.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Lin, Paul S.; Nolop, Keith] Plexxikon Inc, Berkeley, CA 94710 USA; [Schlessinger, Joseph] Yale Univ, New Haven, CT 06520 USA; [Su, Fei; Higgins, Brian; Iyer, Raman; Koehler, Astrid; Stumm, Michael; Lee, Richard J.; Grippo, Joseph] Roche Pharmaceut, Nutley, NJ 07110 USA; [D'Andrea, Kurt; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.] Univ Penn, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA; [D'Andrea, Kurt; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.] Univ Penn, Abramson Canc Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Puzanov, Igor; Sosman, Jeffrey A.] Vanderbilt Univ, Nashville, TN 37232 USA; [Kim, Kevin B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [McArthur, Grant A.] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia; [Chapman, Paul B.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA	Plexxikon; Yale University; Roche Holding; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Vanderbilt University; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; Peter Maccallum Cancer Center; Memorial Sloan Kettering Cancer Center	Bollag, G (corresponding author), Plexxikon Inc, 91 Bolivar Dr, Berkeley, CA 94710 USA.	gbollag@plexxikon.com	PUZANOV, IGOR/AAP-2966-2020; Zhang, Kam Y. J./B-3552-2012	PUZANOV, IGOR/0000-0002-9803-3497; Zhang, Kam Y. J./0000-0002-9282-8045; McArthur, Grant/0000-0001-8908-6071; West, Brian/0000-0002-5320-3691; Nathanson, Katherine/0000-0002-6740-0901	NIH; Cancer Council of Victoria; NATIONAL CANCER INSTITUTE [K24CA097588, R01CA118871, P50CA093372] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Council of Victoria(Cancer Council VictoriaCanadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank L. Andries and M. Knaapen from HistoGeneX for evaluating paired biopsies, and also our colleagues at the Molecular Imaging Research division of Charles River Labs for conducting the xenograft studies. We also thank D. Heimbrook, S. Cheng, L. Burdette and B. Lestini for helpful comments on the manuscript. This research was funded in part by NIH grants to K.L.N. G.A.M. is supported by a Weary Dunlop Fellowship of the Cancer Council of Victoria.	Arnault JP, 2009, J CLIN ONCOL, V27, pE59, DOI 10.1200/JCO.2009.23.4823; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dubauskas Z, 2009, CLIN GENITOURIN CANC, V7, P20, DOI 10.3816/CGC.2009.n.003; Esteve-Puig R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004771; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Kefford R, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.8503; Koch WH, 2004, NAT REV DRUG DISCOV, V3, P749, DOI 10.1038/nrd1496; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kong HH, 2007, J AM ACAD DERMATOL, V56, P171, DOI 10.1016/j.jaad.2006.10.032; Korn EL, 2008, J CLIN ONCOL, V26, P527, DOI 10.1200/JCO.2007.12.7837; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rubinstein JC, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-67; Schwartz GK, 2009, J CLIN ONCOL, V27; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	28	1302	1358	0	206	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					596	599		10.1038/nature09454	http://dx.doi.org/10.1038/nature09454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20823850	Green Submitted, Green Accepted			2022-12-28	WOS:000282273100040
J	Ebnet, J; Nakamura, M; Lorenz, M; Bektas, H; Krauss, JK				Ebnet, Jens; Nakamura, Makoto; Lorenz, Martin; Bektas, Hueseyin; Krauss, Joachim K.			An errant bowel	LANCET			English	Editorial Material							MARFAN-SYNDROME; DURAL ECTASIA		[Ebnet, Jens; Nakamura, Makoto; Lorenz, Martin; Krauss, Joachim K.] Hannover Med Sch, Dept Neurosurg, D-3000 Hannover, Germany; [Bektas, Hueseyin] Hannover Med Sch, Dept Visceral & Transplantat Surg, D-3000 Hannover, Germany	Hannover Medical School; Hannover Medical School	Nakamura, M (corresponding author), Hannover Med Sch, Neurol Klin, Carl Neuberg Str 1, D-30625 Hannover, Germany.	nakamura.makoto@mh-hannover.de	Nakamura, Makoto/F-2620-2014	Nakamura, Makoto/0000-0001-8597-0193				Ahn NU, 2000, SPINE, V25, P1562, DOI 10.1097/00007632-200006150-00017; PYERITZ RE, 1988, AM J HUM GENET, V43, P726; Rigante D, 2001, CLIN NEUROPATHOL, V20, P70; Sponseller PD, 2000, SPINE, V25, P2797, DOI 10.1097/00007632-200011010-00012	4	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1116	1116		10.1016/S0140-6736(10)61117-8	http://dx.doi.org/10.1016/S0140-6736(10)61117-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657KM	20870103				2022-12-28	WOS:000282411600040
J	Filion, GJ; van Bemmel, JG; Braunschweig, U; Talhout, W; Kind, J; Ward, LD; Brugman, W; de Castro, IJ; Kerkhoven, RM; Bussemaker, HJ; van Steensel, B				Filion, Guillaume J.; van Bemmel, Joke G.; Braunschweig, Ulrich; Talhout, Wendy; Kind, Jop; Ward, Lucas D.; Brugman, Wim; de Castro, Ines J.; Kerkhoven, Ron M.; Bussemaker, Harmen J.; van Steensel, Bas			Systematic Protein Location Mapping Reveals Five Principal Chromatin Types in Drosophila Cells	CELL			English	Article							B-TYPE LAMIN; HISTONE H3; DOSAGE COMPENSATION; MELANOGASTER GENOME; GENE-EXPRESSION; LINKER HISTONE; NUCLEAR LAMINA; TRANSCRIPTION; COMPLEX; HETEROCHROMATIN	Chromatin is important for the regulation of transcription and other functions, yet the diversity of chromatin composition and the distribution along chromosomes are still poorly characterized. By integrative analysis of genome-wide binding maps of 53 broadly selected chromatin components in Drosophila cells, we show that the genome is segmented into five principal chromatin types that are defined by unique yet overlapping combinations of proteins and form domains that can extend over > 100 kb. We identify a repressive chromatin type that covers about half of the genome and lacks classic heterochromatin markers. Furthermore, transcriptionally active euchromatin consists of two types that differ in molecular organization and H3K36 methylation and regulate distinct classes of genes. Finally, we provide evidence that the different chromatin types help to target DNA-binding factors to specific genomic regions. These results provide a global view of chromatin diversity and domain organization in a metazoan cell.	[Filion, Guillaume J.; van Bemmel, Joke G.; Braunschweig, Ulrich; Talhout, Wendy; Kind, Jop; de Castro, Ines J.; van Steensel, Bas] Netherlands Canc Inst, Div Gene Regulat, NL-1066 CX Amsterdam, Netherlands; [Brugman, Wim; Kerkhoven, Ron M.] Netherlands Canc Inst, Cent Microarray Facil, NL-1066 CX Amsterdam, Netherlands; [Ward, Lucas D.; Bussemaker, Harmen J.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Ward, Lucas D.; Bussemaker, Harmen J.] Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10032 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Columbia University; Columbia University	van Steensel, B (corresponding author), Netherlands Canc Inst, Div Gene Regulat, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	b.v.steensel@nki.nl	Filion, Guillaume/G-9619-2015; Braunschweig, Ulrich/I-1070-2019	Filion, Guillaume/0000-0002-3473-1632; Braunschweig, Ulrich/0000-0001-6653-0926; de Castro, Ines/0000-0001-8710-3667; Ward, Lucas/0000-0002-8017-809X	EMBO; National Institutes of Health [T32GM082797, R01HG003008, U54CA121852]; Netherlands Genomics Initiative; NWO-ALW VICI; EURYI; NATIONAL CANCER INSTITUTE [U54CA121852] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM082797] Funding Source: NIH RePORTER	EMBO(European Molecular Biology Organization (EMBO)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Netherlands Genomics Initiative; NWO-ALW VICI(Netherlands Organization for Scientific Research (NWO)); EURYI(European Science Foundation (ESF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Francesco Russo for help with vector cloning; Marja Nieuwland and Arno Velds for help with RNA tag sequencing; Dirk Schubeler's laboratory for sharing H3K36 methylation data prior to publication; and Reuven Agami, Fred van Leeuwen, Wouter Meuleman, Ludo Pagie, and Aleksey Pindyurin for helpful suggestions. Supported by an EMBO long-term fellowship to J.K.; National Institutes of Health grants T32GM082797, R01HG003008, and U54CA121852 to L. D. W. and H. J.B.; and grants from the Netherlands Genomics Initiative, NWO-ALW VICI, and an EURYI Award to B. v. S.	Babenko VN, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-318; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; Bell O, 2010, NAT STRUCT MOL BIOL, V17, P894, DOI 10.1038/nsmb.1825; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bianchi-Frias D, 2004, PLOS BIOL, V2, P975, DOI 10.1371/journal.pbio.0020178; Braunschweig U, 2009, EMBO J, V28, P3635, DOI 10.1038/emboj.2009.301; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; Collas P, 2009, METHODS MOL BIOL, V567, P1, DOI 10.1007/978-1-60327-414-2_1; Crevel G, 2001, J CELL SCI, V114, P37; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; de Wit E, 2007, PLOS GENET, V3, P346, DOI 10.1371/journal.pgen.0030038; Ebert A, 2006, CHROMOSOME RES, V14, P377, DOI 10.1007/s10577-006-1066-1; Engstrom PG, 2007, GENOME RES, V17, P1898, DOI 10.1101/gr.6669607; Fauvarque MO, 2001, GENET RES, V78, P137, DOI 10.1017/S0016672301005274; Finlan LE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000039; Foat BC, 2006, BIOINFORMATICS, V22, pE141, DOI 10.1093/bioinformatics/btl223; Gelbart ME, 2005, GENE DEV, V19, P942, DOI 10.1101/gad.1298905; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Greil F, 2007, EMBO J, V26, P741, DOI 10.1038/sj.emboj.7601527; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Kelley RL, 2003, GENETICS, V164, P565; Kind J, 2008, CELL, V133, P813, DOI 10.1016/j.cell.2008.04.036; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; Lee JS, 2007, MUTAT RES-FUND MOL M, V618, P130, DOI 10.1016/j.mrfmmm.2006.08.014; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Li B, 2007, GENE DEV, V21, P1422, DOI 10.1101/gad.1539307; Liu ZQ, 2005, MOL CELL BIOL, V25, P2819, DOI 10.1128/MCB.25.7.2819-2831.2005; Lu XW, 2009, GENE DEV, V23, P452, DOI 10.1101/gad.1749309; MacAlpine HK, 2010, GENOME RES, V20, P201, DOI 10.1101/gr.097873.109; Markstein M, 2008, NAT GENET, V40, P476, DOI 10.1038/ng.101; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Moorman C, 2006, P NATL ACAD SCI USA, V103, P12027, DOI 10.1073/pnas.0605003103; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Negre N, 2006, PLOS BIOL, V4, P917, DOI 10.1371/journal.pbio.0040170; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Pickersgill H, 2006, NAT GENET, V38, P1005, DOI 10.1038/ng1852; Pindyurin AV, 2007, J CELL SCI, V120, P2344, DOI 10.1242/jcs.006007; Rando OJ, 2009, ANNU REV BIOCHEM, V78, P245, DOI 10.1146/annurev.biochem.78.071107.134639; Reddy KL, 2008, NATURE, V452, P243, DOI 10.1038/nature06727; Schmiedeberg L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004636; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Schwaiger M, 2009, GENE DEV, V23, P589, DOI 10.1101/gad.511809; Shevelyov YY, 2009, P NATL ACAD SCI USA, V106, P3282, DOI 10.1073/pnas.0811933106; Singh RK, 2009, NAT CELL BIOL, V11, P925, DOI 10.1038/ncb1903; Smith MB, 2010, CHROMOSOMA, V119, P287, DOI 10.1007/s00412-010-0257-x; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Tie F, 2003, MOL CELL BIOL, V23, P3352, DOI 10.1128/MCB.23.9.3352-3362.2003; Tie F, 2001, DEVELOPMENT, V128, P275; Tirosh I, 2008, GENOME RES, V18, P1084, DOI 10.1101/gr.076059.108; Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792; Tomancak P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r145; Towbin BD, 2009, CURR OPIN GENET DEV, V19, P180, DOI 10.1016/j.gde.2009.01.006; van Steensel B, 2001, NAT GENET, V27, P304, DOI 10.1038/85871; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Zhang P, 2006, NUCLEIC ACIDS RES, V34, P6621, DOI 10.1093/nar/gkl989; Zhimulev IF, 2003, CHROMOSOMA, V111, P377, DOI 10.1007/s00412-002-0218-0	63	664	683	0	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2010	143	2					212	224		10.1016/j.cell.2010.09.009	http://dx.doi.org/10.1016/j.cell.2010.09.009			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	665RC	20888037	Bronze, Green Accepted			2022-12-28	WOS:000283052200011
J	Dang, SY; Sun, LF; Huang, YJ; Lu, FR; Liu, YF; Gong, HP; Wang, JW; Yan, NE				Dang, Shangyu; Sun, Linfeng; Huang, Yongjian; Lu, Feiran; Liu, Yufeng; Gong, Haipeng; Wang, Jiawei; Yan, Nieng			Structure of a fucose transporter in an outward-open conformation	NATURE			English	Article							H+ SYMPORT PROTEIN; LACTOSE PERMEASE; MECHANISM; BINDING; IDENTIFICATION; FUCP; SITE	The major facilitator superfamily (MFS) transporters are an ancient and widespread family of secondary active transporters(1). In Escherichia coli, the uptake of L-fucose, a source of carbon for microorganisms, is mediated by an MFS proton symporter, FucP(2,3). Despite intensive study of the MFS transporters, atomic structure information is only available on three proteins and the outward-open conformation has yet to be captured(4-6). Here we report the crystal structure of FucP at 3.1 angstrom resolution, which shows that it contains an outward-open, amphipathic cavity. The similarly folded amino and carboxyl domains of FucP have contrasting surface features along the transport path, with negative electrostatic potential on the N domain and hydrophobic surface on the C domain. FucP only contains two acidic residues along the transport path, Asp 46 and Glu 135, which can undergo cycles of protonation and deprotonation. Their essential role in active transport is supported by both in vivo and in vitro experiments. Structure-based biochemical analyses provide insights into energy coupling, substrate recognition and the transport mechanism of FucP.	[Wang, Jiawei] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Sch Med, Struct Biol Ctr, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University	Wang, JW (corresponding author), Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	jwwang@tsinghua.edu.cn; nyan@tsinghua.edu.cn	Wang, Jiawei/D-1144-2010; Huang, Yongjian/GPK-5986-2022	Wang, Jiawei/0000-0001-9893-8539; Huang, Yongjian/0000-0002-1168-6111; Lu, Feiran/0000-0002-1757-2895; Dang, Shangyu/0000-0001-9141-1865; Liu, Yufeng/0000-0003-0848-5113	Ministry of Science and Technology [2009CB918802]; Tsinghua University [985]; Yuyuan Foundation; Li Foundation	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Tsinghua University; Yuyuan Foundation; Li Foundation	We thank N. Shimizu and T. Kumasaka at Spring-8 beamline BL41XU in Japan, and J. He and S. Huang at the Shanghai Synchrotron Radiation Facility (SSRF) for on-site assistance. This work was supported by funds from the Ministry of Science and Technology (grant number 2009CB918802) and by Tsinghua University 985 Phase II funds. N.Y. acknowledges support from the Yuyuan Foundation and the Li Foundation.	Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; BRADLEY SA, 1987, BIOCHEM J, V248, P495, DOI 10.1042/bj2480495; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Christensen M, 2003, J BACTERIOL, V185, P6042, DOI 10.1128/JB.185.20.6042-6050.2003; COWTAN K, 1994, INT CCP4 ESF EACBM N, V31, P34; DeLano W.L., 2002, PYMOL MOL VIEWER; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Guan L, 2004, P NATL ACAD SCI USA, V101, P12148, DOI 10.1073/pnas.0404936101; Guan L, 2007, P NATL ACAD SCI USA, V104, P15294, DOI 10.1073/pnas.0707688104; Guan L, 2006, ANNU REV BIOPH BIOM, V35, P67, DOI 10.1146/annurev.biophys.35.040405.102005; GUNN FJ, 1995, MOL MICROBIOL, V15, P771, DOI 10.1111/j.1365-2958.1995.tb02384.x; GUNN FJ, 1994, MOL MICROBIOL, V12, P799, DOI 10.1111/j.1365-2958.1994.tb01066.x; Horiba N, 2003, J BIOL CHEM, V278, P14669, DOI 10.1074/jbc.M212240200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaback HR, 2005, CR BIOL, V328, P557, DOI 10.1016/j.crvi.2005.03.008; Law CJ, 2008, ANNU REV MICROBIOL, V62, P289, DOI 10.1146/annurev.micro.61.080706.093329; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mirza O, 2006, EMBO J, V25, P1177, DOI 10.1038/sj.emboj.7601028; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1998, J BACTERIOL, V180, P498, DOI 10.1128/JB.180.3.498-504.1998; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Psakis G, 2009, MOL MICROBIOL, V71, P391, DOI 10.1111/j.1365-2958.2008.06535.x; Quick M, 2009, P NATL ACAD SCI USA, V106, P5563, DOI 10.1073/pnas.0811322106; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Smirnova I, 2009, P NATL ACAD SCI USA, V106, P21561, DOI 10.1073/pnas.0911434106; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; Yin Y, 2006, SCIENCE, V312, P741, DOI 10.1126/science.1125629	33	214	222	3	129	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	2010	467	7316					734	U130		10.1038/nature09406	http://dx.doi.org/10.1038/nature09406			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20877283				2022-12-28	WOS:000282572500044
J	Wennberg, DE; Marr, A; Lang, L; O'Malley, S; Bennett, G				Wennberg, David E.; Marr, Amy; Lang, Lance; O'Malley, Stephen; Bennett, George			A Randomized Trial of a Telephone Care-Management Strategy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIABETES DISEASE MANAGEMENT; QUALITY-OF-CARE; HEALTH-CARE; REGIONAL-VARIATIONS; HEART-FAILURE; OUTCOMES; SUPPORT; COSTS; VIEW	BACKGROUND Studies have shown that telephone interventions designed to promote patients' self-management skills and improve patient-physician communication can increase patients' satisfaction and their use of preventive services. The effect of such a strategy on health care costs remains controversial. METHODS We conducted a stratified, randomized study of 174,120 subjects to assess the effect of a telephone-based care-management strategy on medical costs and resource utilization. Health coaches contacted subjects with selected medical conditions and predicted high health care costs to instruct them about shared decision making, self-care, and behavioral change. The subjects were randomly assigned to either a usual-support group or an enhanced-support group. Although the same telephone intervention was delivered to the two groups, a greater number of subjects in the enhanced-support group were made eligible for coaching through the lowering of cutoff points for predicted future costs and expansion of the number of qualifying health conditions. Primary outcome measures at 1 year were total medical costs and number of hospital admissions. RESULTS At baseline, medical costs and resource utilization were similar in the two groups. After 12 months, 10.4% of the enhanced-support group and 3.7% of the usual-support group received the telephone intervention. The average monthly medical and pharmacy costs per person in the enhanced-support group were 3.6% ($7.96) lower than those in the usual-support group ($213.82 vs. $221.78, P = 0.05); a 10.1% reduction in annual hospital admissions (P<0.001) accounted for the majority of savings. The cost of this intervention program was less than $2.00 per person per month. CONCLUSIONS A targeted telephone care-management program was successful in reducing medical costs and hospitalizations in this population-based study.	[Wennberg, David E.; Marr, Amy; Lang, Lance; O'Malley, Stephen; Bennett, George] Hlth Dialog Serv, Boston, MA USA		Wennberg, DE (corresponding author), Hlth Dialog Serv, 2 Monument Sq, Portland, ME 04101 USA.	dwennberg@healthdialog.com	Bennett, George/GXW-2488-2022		Health Dialog Services	Health Dialog Services	Supported by Health Dialog Services.	Agresti A., 1990, CATEGORICAL DATA ANA, pXV; [Anonymous], DARTMOUTH ATLAS HLTH; Bandura A., 1999, J COGN PSYCHOTHER, P158, DOI [10.1891/0889-8391.13.2.158, DOI 10.1891/0889-8391.13.2.158]; BOTEHLO RJ, 2004, MOTIVATIONAL PRACTIC; *C US CONGR BUDG O, 2008, GEOGR VAR HLTH CAR S; Casarett D, 2000, JAMA-J AM MED ASSOC, V283, P2275, DOI 10.1001/jama.283.17.2275; CATLIN A, 2008, HLTH AFF MILLWOOD, V27, P593; Catlin A, 2008, HEALTH AFFAIR, V27, P14, DOI 10.1377/hlthaff.27.1.14; Congressional Budget Office, 2004, AN LIT DIS MAN PROGR; Cromwell J, 2008, HEALTH CARE FINANC R, V30, P47; DeBusk RF, 2004, ANN INTERN MED, V141, P606, DOI 10.7326/0003-4819-141-8-200410190-00008; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; *DMAA, DEF DIS MAN; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2004, HEALTH AFFAIR, V23, pVAR19, DOI 10.1377/hlthaff.var.19; Galbreath AD, 2004, CIRCULATION, V110, P3518, DOI 10.1161/01.CIR.0000148957.62328.89; Galbreath AD, 2006, CIRCULATION, V113, pe48; Galbreath AD, 2004, CIRCULATION, V110, P3615; Goetzel RZ, 2005, HEALTH CARE FINANC R, V26, P1; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Javitt JC, 2005, AM J MANAG CARE, V11, P93; Mangione CM, 2006, ANN INTERN MED, V145, P107, DOI 10.7326/0003-4819-145-2-200607180-00008; Mattke S, 2007, AM J MANAG CARE, V13, P670; MCCALL N, 2008, EVALUATION PHASE 1 M; Meigs JB, 2003, DIABETES CARE, V26, P750, DOI 10.2337/diacare.26.3.750; Miller FG, 2008, NEW ENGL J MED, V358, P765, DOI 10.1056/NEJMp0800136; OConnor A, 2003, WORKBOOK DEV EVALUAT; OCONNOR AM, 2004, HLTH AFF MILLWOOD S, pVAR63, DOI DOI 10.1377/HLTHAFF.VAR.63; Orszag PR, 2007, NEW ENGL J MED, V357, P1885, DOI 10.1056/NEJMp078191; Orszag PR, 2007, NEW ENGL J MED, V357, P1793, DOI 10.1056/NEJMp078190; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; PHILLIPS CO, 2004, JAMA-J AM MED ASSOC, V292, P1022; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Steyerberg E., 2009, CLIN PREDICTION MODE; Stokes ME, 2000, CATEGORICAL DATA ANA; Villagra VG, 2004, HEALTH AFFAIR, V23, P255, DOI 10.1377/hlthaff.23.4.255; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; FDN INFORMED MED DEC; 1998, DARTMOUTH ATLAS HLTH	42	157	159	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1245	1255		10.1056/NEJMsa0902321	http://dx.doi.org/10.1056/NEJMsa0902321			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652ZA	20860506				2022-12-28	WOS:000282050000008
J	You, DZ; Jones, G; Hill, K; Wardlaw, T; Chopra, M				You, Danzhen; Jones, Gareth; Hill, Kenneth; Wardlaw, Tessa; Chopra, Mickey			Levels and trends in child mortality, 1990-2009	LANCET			English	Editorial Material									[You, Danzhen; Wardlaw, Tessa; Chopra, Mickey] UNICEF Headquarters, New York, NY 10017 USA; [Jones, Gareth] Adeni, Ottawa, ON, Canada; [Hill, Kenneth] Harvard Univ, Cambridge, MA 02138 USA	UNICEF; Harvard University	You, DZ (corresponding author), UNICEF Headquarters, New York, NY 10017 USA.	dyou@unicef.org						Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; UNICEF, 2010, PROGR CHILDR ACH MDG, P23; UNICEF, LEV TRENDS CHILD MOR; *UNICEF, CHILD MORT DAT CME I; You D, 2010, LANCET, V375, P100, DOI 10.1016/S0140-6736(09)61601-9	6	59	59	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	2010	376	9745					931	933		10.1016/S0140-6736(10)61429-8	http://dx.doi.org/10.1016/S0140-6736(10)61429-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20851244				2022-12-28	WOS:000282247600004
J	Ellershaw, J; Dewar, S; Murphy, D				Ellershaw, John; Dewar, Steve; Murphy, Deborah			Spotlight: Palliative Care Beyond Cancer Achieving a good death for all	BRITISH MEDICAL JOURNAL			English	Article									[Ellershaw, John; Murphy, Deborah] Univ Liverpool, Marie Curie Palliat Care Inst, Liverpool L69 3BX, England; [Dewar, Steve] Marie Curie Canc Care, London SE1 7TP, England; [Ellershaw, John; Murphy, Deborah] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool L7 8XP, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital	Ellershaw, J (corresponding author), Univ Liverpool, Marie Curie Palliat Care Inst, Liverpool L69 3BX, England.	j.e.ellershaw@liv.ac.uk		Ellershaw, John/0000-0001-9789-3180				Abel J, 2009, PALLIATIVE MED, V23, P616, DOI 10.1177/0269216309106460; Addicott R, 2008, IMPROVING CHOICE END; CANDY B, 2009, NONSTATUTORY PALLIAT; DAVIES E, 2004, WHO EUROPE BETTER PA; *DEP HLTH, 2008, ENGL END LIF CAR STR; Department of Health, 2009, END LIF CAR STRAT QU; Gambles M, 2006, INT J PALLIAT NURS, V12, P414, DOI 10.12968/ijpn.2006.12.9.21869; Gambles MA, 2009, INT J CARE COORD, V13, P51, DOI 10.1258/jicp.2009.009011; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Hockley J, 2005, J RES NURS, V10, P135, DOI 10.1177/174498710501000209; Jack Barbara A, 2003, Int J Palliat Nurs, V9, P375; *M CUR PALL CAR I, 2009, LCP GEN VERS 12 COR; *M CUR PALL CAR I, 2007, NAT CAR DYING AUD HO; Marie Curie Palliative Care Institute Liverpool and Clinical Standards Department of the Royal College of Physicians, 2009, NAT CAR DYING AUD HO; MAYLAND CR, 2009, EUR ASS PALL CAR 11; National Audit Office, 2008, END LIF CAR; National Institute for Health and Clinical Excellence, 2004, IMPR SUPP PALL CAR A; Office for National Statistics, MORT STAT DEATHS REG; ROBERTS A, 2007, PALLIATIVE NURSING I; Saunders C, 1989, TXB PAIN, P624; SMITH R, 2009, DAILY TELEGRAPH 1017; St John of God Health Care, 2019, OUR VIS; Veerbeek L, 2008, PALLIATIVE MED, V22, P145, DOI 10.1177/0269216307087164	23	15	16	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4861	10.1136/bmj.c4861	http://dx.doi.org/10.1136/bmj.c4861			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847021				2022-12-28	WOS:000282095800001
J	Grant, L; Murray, SA; Sheikh, A				Grant, Liz; Murray, Scott A.; Sheikh, Aziz			Spotlight: Palliative Care Beyond Cancer Spiritual dimensions of dying in pluralist societies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; ILLNESS; PEOPLE; NEEDS; LIFE		Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland	University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Grant, Liz/0000-0001-7248-7792	COMPASS Collaborative; National Cancer Research Institute; Office of the Scottish Government	COMPASS Collaborative; National Cancer Research Institute; Office of the Scottish Government	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; AS and SM are grantholders on the COMPASS Collaborative, a programme grant for the development and evaluation of complex interventions in end of life care, which is supported by the National Cancer Research Institute; LG, SM, and AS had support from the Chief Scientist's Office of the Scottish Government, which has informed the submitted work; no other relationships or activities that could appear to have influenced the submitted work.	Breitbart William, 2009, Palliat Support Care, V7, P139, DOI 10.1017/S1478951509000182; Bryson Kenneth A, 2004, Palliat Support Care, V2, P321; CARPENITOMOYET L, 2008, HDB NURSING DIAGNOSI, P639; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; FOWLER M, 1997, J SUPERVISION TRAINI, V18, P46; Frankl VE, 1963, MANS SEARCH MEANING; Gatrad AR, 2003, LANCET, V362, P748, DOI 10.1016/S0140-6736(03)14219-5; Gatrad AR, 2003, BRIT MED J, V327, P176, DOI 10.1136/bmj.327.7408.176; GATRAD AR, 2006, PALLIATIVE CARE S AS; *GEN MED COUNC, 2009, END LIF TREATM CAR G; Grant E, 2003, J PALLIATIVE CARE, V19, P159, DOI 10.1177/082585970301900303; Grant Elizabeth, 2004, Palliat Support Care, V2, P371; *I MED, 1997, APPR DEATH IMPR CAR; Kissane DW, 2001, J PALLIAT CARE, V17, P12, DOI 10.1177/082585970101700103; LLOYDWILLIAMS M, 2003, PSYCHOSOCIAL ISSUES; *M CUR CANC CAR, 1980, SPIR REL CAR COMP SP; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; Meador Keith G, 2004, N C Med J, V65, P226; Murray SA, 2004, PALLIATIVE MED, V18, P39, DOI 10.1191/0269216304pm837oa; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murray SA, 2003, BRIT J GEN PRACT, V53, P957; Murray SA, 2007, J PAIN SYMPTOM MANAG, V34, P393, DOI 10.1016/j.jpainsymman.2006.12.009; Narayanasamy Aru, 2002, Br J Nurs, V11, P948; National Institute for Health and Clinical Excellence, 2004, IMPR SUPP PALL CAR A; Puchalski C, 2004, CRIT CARE CLIN, V20, P487, DOI 10.1016/j.ccc.2004.03.007; Sheikh A, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a273; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Sweeney K, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2862; World Health Organization, WHO DEF PALL CAR; Worth A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b183	30	17	18	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2010	341								c4859	10.1136/bmj.c4859	http://dx.doi.org/10.1136/bmj.c4859			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847019	Green Submitted			2022-12-28	WOS:000282095800012
J	Schwenk, TL; Davis, L; Wimsatt, LA				Schwenk, Thomas L.; Davis, Lindsay; Wimsatt, Leslie A.			Depression, Stigma, and Suicidal Ideation in Medical Students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENTAL-HEALTH-CARE; SELF-STIGMA; PHQ-9; PHYSICIANS; VALIDITY; BURNOUT; SCALE; US	Context There is a concerning prevalence of depression and suicidal ideation among medical students, a group that may experience poor mental health care due to stigmatization. Objective To characterize the perceptions of depressed and nondepressed medical students regarding stigma associated with depression. Design, Setting, and Participants Cross-sectional Web-based survey conducted in September-November 2009 among all students enrolled at the University of Michigan Medical School (N=769). Main Outcome Measures Prevalence of self-reported moderate to severe depression and suicidal ideation and the association of stigma perceptions with clinical and demographic variables. Results Survey response rate was 65.7% (505 of 769). Prevalence of moderate to severe depression was 14.3% (95% confidence interval [CI], 11.3%-17.3%). Women were more likely than men to have moderate to severe depression (18.0% vs 9.0%; 95% CI for difference, -14.8% to -3.1%; P=.001). Third-and fourth-year students were more likely than first-and second-year students to report suicidal ideation (7.9% vs 1.4%; 95% CI for difference, 2.7%-10.3%; P=.001). Students with moderate to severe depression, compared with no to minimal depression, more frequently agreed that "if I were depressed, fellow medical students would respect my opinions less" (56.0% vs 23.7%; 95% CI for difference, 17.3%-47.3%; P<.001), and that faculty members would view them as being unable to handle their responsibilities (83.1% vs 55.1%; 95% CI for difference, 16.1%-39.8%; P<.001). Men agreed more commonly than women that depressed students could endanger patients (36.3% vs 20.1%; 95% CI for difference, 6.1%-26.3%; P=.002). First-and second-year students more frequently agreed than third-and fourth-year students that seeking help for depression would make them feel less intelligent (34.1% vs 22.9%; 95% CI for difference, 2.3%-20.1%; P<.01). Conclusions Depressed medical students more frequently endorsed several depression stigma attitudes than nondepressed students. Stigma perceptions also differed by sex and class year. JAMA. 2010;304(11):1181-1190 www.jama.com	[Schwenk, Thomas L.; Wimsatt, Leslie A.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA; [Schwenk, Thomas L.] Univ Michigan, Dept Med Educ, Ann Arbor, MI 48109 USA; [Schwenk, Thomas L.] Univ Michigan, Depress Ctr, Ann Arbor, MI 48109 USA; [Davis, Lindsay] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schwenk, TL (corresponding author), Univ Michigan, Dept Family Med, 1500 E Med Ctr Dr,L2003 Womens Hosp,SPC 5239, Ann Arbor, MI 48109 USA.	tschwenk@umich.edu	Wimsatt, Leslie/AAI-9558-2021	Wimsatt, Leslie/0000-0001-8380-0676	Department of Family Medicine, University of Michigan	Department of Family Medicine, University of Michigan(University of Michigan System)	The Department of Family Medicine, University of Michigan.	Adewuya AO, 2006, J AFFECT DISORDERS, V96, P89, DOI 10.1016/j.jad.2006.05.021; [Anonymous], 2000, DIAGNOSTIC STAT MANU, V4th; *ASS AM MED COLL, US MED SCH APPL STUD; BURNS DD, 2000, FEELING GOOD; Cannon DS, 2007, PSYCHOL ASSESSMENT, V19, P247, DOI 10.1037/1040-3590.19.2.247; Carson AJ, 2000, SCOT MED J, V45, P115, DOI 10.1177/003693300004500406; Center C, 2003, JAMA-J AM MED ASSOC, V289, P3161, DOI 10.1001/jama.289.23.3161; Chew-Graham CA, 2003, MED EDUC, V37, P873, DOI 10.1046/j.1365-2923.2003.01627.x; Clason D.L., 1994, J AGR ED, V35, P31, DOI DOI 10.5032/JAE.1994.04031; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Corrigan PW, 2006, J SOC CLIN PSYCHOL, V25, P875, DOI 10.1521/jscp.2006.25.8.875; Dahlin M, 2005, MED EDUC, V39, P594, DOI 10.1111/j.1365-2929.2005.02176.x; Dyrbye LN, 2008, ANN INTERN MED, V149, P334, DOI 10.7326/0003-4819-149-5-200809020-00008; Dyrbye LN, 2010, ACAD MED, V85, P94, DOI 10.1097/ACM.0b013e3181c46aad; Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009; Givens JL, 2002, ACAD MED, V77, P918, DOI 10.1097/00001888-200209000-00024; Goebert D, 2009, ACAD MED, V84, P236, DOI 10.1097/ACM.0b013e31819391bb; Golberstein E, 2008, PSYCHIAT SERV, V59, P392, DOI 10.1176/ps.2008.59.4.392; Griffiths KM, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-25; Hay LR, 1996, AM J PSYCHIAT, V153, P553; Kanter JW, 2008, J NERV MENT DIS, V196, P663, DOI 10.1097/NMD.0b013e318183f8af; King M, 2007, BRIT J PSYCHIAT, V190, P248, DOI 10.1192/bjp.bp.106.024638; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363; Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003; Rosal MC, 1997, ACAD MED, V72, P542, DOI 10.1097/00001888-199706000-00022; Rosenthal JM, 2005, NEW ENGL J MED, V353, P1085, DOI 10.1056/NEJMp058183; Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295; Schwenk TL, 2008, J CLIN PSYCHIAT, V69, P617, DOI 10.4088/JCP.v69n0414; Tjia J, 2005, J AM COLL HEALTH, V53, P219, DOI 10.3200/JACH.53.5.219-224; Tyssen R, 2001, J AFFECT DISORDERS, V64, P69, DOI 10.1016/S0165-0327(00)00205-6; Yen CF, 2005, PSYCHIAT SERV, V56, P599, DOI 10.1176/appi.ps.56.5.599	32	354	363	1	60	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1181	1190		10.1001/jama.2010.1300	http://dx.doi.org/10.1001/jama.2010.1300			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649LF	20841531	Bronze			2022-12-28	WOS:000281770600010
J	Vickers, AJ; Cronin, AM; Bjork, T; Manjer, J; Nilsson, PM; Dahlin, A; Bjartell, A; Scardino, PT; Ulmert, D; Lilja, H				Vickers, Andrew J.; Cronin, Angel M.; Bjoerk, Thomas; Manjer, Jonas; Nilsson, Peter M.; Dahlin, Anders; Bjartell, Anders; Scardino, Peter T.; Ulmert, David; Lilja, Hans			Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK; DIAGNOSIS; SERUM; REPRODUCIBILITY; PREVALENCE; MORTALITY; REGISTER; BIOPSY; SWEDEN; PLASMA	Objective To determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk. Design Case-control study with 1: 3 matching nested within a highly representative population based cohort study. Setting General population of Sweden taking part in the Malmo Preventive Project. Cancer registry at the National Board of Health and Welfare. Participants 1167 men aged 60 who provided blood samples in 1981 and were followed up to age 85. Main outcome measures Metastasis or death from prostate cancer. Results The rate of screening during the course of the study was low. There were 43 cases of metastasis and 35 deaths from prostate cancer. Concentration of prostate specific antigen at age 60 was associated with prostate cancer metastasis (area under the curve 0.86, 95% confidence interval 0.79 to 0.92; P<0.001) and death from prostate cancer (0.90, 0.84 to 0.96; P<0.001). The greater the number for the area under the curve (values from 0 to 1) the better the test. Although only a minority of the men with concentrations in the top quarter (>2 ng/ml) develop fatal prostate cancer, 90% (78% to 100%) of deaths from prostate cancer occurred in these men. Conversely, men aged 60 with concentrations at the median or lower (<= 1 ng/ml) were unlikely to have clinically relevant prostate cancer (0.5% risk of metastasis by age 85 and 0.2% risk of death from prostate cancer). Conclusions The concentration of prostate specific antigen at age 60 predicts lifetime risk of metastasis and death from prostate cancer. Though men aged 60 with concentrations below the median (<= 1 ng/ml) might harbour prostate cancer, it is unlikely to become life threatening. Such men could be exempted from further screening, which should instead focus on men with higher concentrations.	[Lilja, Hans] Mem Sloan Kettering Canc Ctr, Dept Clin Labs Surg & Med, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Lilja, H (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Clin Labs Surg & Med, New York, NY 10065 USA.	liljah@mskcc.org	Lilja, Hans/S-9703-2019	Lilja, Hans/0000-0001-5871-7846; Vickers, Andrew/0000-0003-1525-6503; Venkatasubramanian, Siddharth/0000-0002-5860-0768	National Cancer Institute [R21-CA127768-01A1, P50-CA92629]; Swedish Cancer Society [3455]; Swedish Research Council (Medicine) [20095]; Sidney Kimmel Center for Prostate and Urologic Cancers; Prostate Cancer Foundation; Fundacion Federico SA; Memorial Sloan-Kettering Cancer Center; NATIONAL CANCER INSTITUTE [R33CA127768, R21CA127768, P50CA092629] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council (Medicine)(Swedish Research Council); Sidney Kimmel Center for Prostate and Urologic Cancers; Prostate Cancer Foundation; Fundacion Federico SA; Memorial Sloan-Kettering Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute (grant numbers R21-CA127768-01A1, P50-CA92629); the Swedish Cancer Society (3455); the Swedish Research Council (Medicine) (20095); the Sidney Kimmel Center for Prostate and Urologic Cancers; David H Koch through the Prostate Cancer Foundation; and Fundacion Federico SA. The manuscript editing was paid for by internal funds at Memorial Sloan-Kettering Cancer Center. The study sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Adolfsson J, 2007, SCAND J UROL NEPHROL, V41, P456, DOI 10.1080/00365590701673625; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Catalona WJ, 2009, NEW ENGL J MED, V361, P202, DOI 10.1056/NEJMc090849; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cronin AM, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-75; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Draisma G, 2009, JNCI-J NATL CANCER I, V101, P374, DOI 10.1093/jnci/djp001; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Goetzl MA, 2006, NAT CLIN PRACT UROL, V3, P422, DOI 10.1038/ncpuro0574; Greene KL, 2009, J UROLOGY, V182, P2232, DOI 10.1016/j.juro.2009.07.093; Haas GP, 2007, JNCI-J NATL CANCER I, V99, P1484, DOI 10.1093/jnci/djm153; Hernandez J, 2004, CANCER-AM CANCER SOC, V101, P894, DOI 10.1002/cncr.20480; Holmstrom B, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3537; Hsieh K, 2003, UROL CLIN N AM, V30, P669, DOI 10.1016/S0094-0143(03)00058-2; Kramer BS, 2009, J CLIN ONCOL, V27, P1502, DOI 10.1200/JCO.2008.16.9599; Lacher David A, 2006, Adv Data, P1; Lilja H, 2007, J CLIN ONCOL, V25, P431, DOI 10.1200/JCO.2006.06.9351; Lyssenko V, 2008, NEW ENGL J MED, V359, P2220, DOI 10.1056/NEJMoa0801869; MITRUNEN K, 1995, CLIN CHEM, V41, P1115; Moskowitz CS, 2008, STAT MED, V27, P3191, DOI 10.1002/sim.3151; *NAT COMPR CANC NE, 2004, J NATL COMPR CANC NE, V2, P190; Ross LE, 2008, CANCER EPIDEM BIOMAR, V17, P636, DOI 10.1158/1055-9965.EPI-07-2709; Sandblom G, 2003, SCAND J UROL NEPHROL, V37, P112, DOI 10.1080/00365590310008839; Schroder F, 2008, EUR UROL, V54, P274, DOI 10.1016/j.eururo.2008.05.022; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; Thompson IM, 2004, NEW ENGL J MED, V350, P2239, DOI 10.1056/NEJMoa031918; Thompson IM, 2006, J NATL CANCER I, V98, P529, DOI 10.1093/jnci/djj131; Ulmert D, 2006, CLIN CHEM, V52, P235, DOI 10.1373/clinchem.2005.050641; Ulmert D, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-6; Vickers A, 2010, J CLIN ONCOL, V28, P2493, DOI 10.1200/JCO.2009.24.1968; Welch HG, 2009, J NATL CANCER I, V101, P1325, DOI 10.1093/jnci/djp278	33	142	147	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	2010	341								c4521	10.1136/bmj.c4521	http://dx.doi.org/10.1136/bmj.c4521			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653LK	20843935	hybrid, Green Published			2022-12-28	WOS:000282092600011
J	Rands, MRW; Adams, WM; Bennun, L; Butchart, SHM; Clements, A; Coomes, D; Entwistle, A; Hodge, I; Kapos, V; Scharlemann, JPW; Sutherland, WJ; Vira, B				Rands, Michael R. W.; Adams, William M.; Bennun, Leon; Butchart, Stuart H. M.; Clements, Andrew; Coomes, David; Entwistle, Abigail; Hodge, Ian; Kapos, Valerie; Scharlemann, Joern P. W.; Sutherland, William J.; Vira, Bhaskar			Biodiversity Conservation: Challenges Beyond 2010	SCIENCE			English	Review							CLIMATE-CHANGE; HABITAT FRAGMENTATION; DIRECT PAYMENTS; LAND-USE; SUSTAINABILITY; ECOLOGY; COSTS	The continued growth of human populations and of per capita consumption have resulted in unsustainable exploitation of Earth's biological diversity, exacerbated by climate change, ocean acidification, and other anthropogenic environmental impacts. We argue that effective conservation of biodiversity is essential for human survival and the maintenance of ecosystem processes. Despite some conservation successes (especially at local scales) and increasing public and government interest in living sustainably, biodiversity continues to decline. Moving beyond 2010, successful conservation approaches need to be reinforced and adequately financed. In addition, however, more radical changes are required that recognize biodiversity as a global public good, that integrate biodiversity conservation into policies and decision frameworks for resource production and consumption, and that focus on wider institutional and societal changes to enable more effective implementation of policy.	[Rands, Michael R. W.] Univ Cambridge, Judge Business Sch, Cambridge Conservat Initiat, Cambridge CB2 1AG, England; [Adams, William M.; Vira, Bhaskar] Univ Cambridge, Dept Geog, Cambridge CB2 3EN, England; [Bennun, Leon; Butchart, Stuart H. M.] BirdLife Int, Wellbrook Court, Cambridge CB3 0NA, England; [Clements, Andrew] British Trust Ornithol, Thetford IP24 2PU, Norfolk, England; [Coomes, David] Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; [Entwistle, Abigail] Fauna & Flora Int, Cambridge CB1 2JD, England; [Hodge, Ian] Univ Cambridge, Dept Land Econ, Cambridge CB3 9EP, England; [Kapos, Valerie; Scharlemann, Joern P. W.] World Conservat Monitoring Ctr, United Nations Environm Programme, Cambridge CB3 0DL, England; [Kapos, Valerie] Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; [Kapos, Valerie; Sutherland, William J.] Univ Cambridge, Dept Zool, Conservat Sci Grp, Cambridge CB2 3EJ, England	University of Cambridge; University of Cambridge; BirdLife International; British Trust for Ornithology; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Rands, MRW (corresponding author), Univ Cambridge, Judge Business Sch, Cambridge Conservat Initiat, Cambridge CB2 1AG, England.	mr494@cam.ac.uk	Kapos, Valerie/G-3136-2010; Butchart, Stuart HM/Y-2711-2018; Butchart, Stuart/AAJ-1852-2021; Coomes, David/H-5630-2011; Sutherland, William/B-1291-2013; Scharlemann, Jorn/A-4737-2008	Kapos, Valerie/0000-0002-5739-8262; Butchart, Stuart/0000-0002-1140-4049; Scharlemann, Jorn/0000-0002-2834-6367; Sutherland, William/0000-0002-6498-0437; Coomes, David/0000-0002-8261-2582				Adams W.M., 2004, EXTINCTION STORY CON, DOI 10.4324/9781849770415; Adams WM, 2004, SCIENCE, V306, P1146, DOI 10.1126/science.1097920; ADAMS WM, 2009, TRANSITION SUSTAINAB; Agrawal A, 2008, SCIENCE, V320, P1460, DOI 10.1126/science.1155369; Allsopp M., 2009, STATE WORLDS OCEANS; Andam KS, 2008, P NATL ACAD SCI USA, V105, P16089, DOI 10.1073/pnas.0800437105; [Anonymous], 2001, PANARCHY UNDERSTANDI; Balmford A, 2003, ORYX, V37, P238, DOI 10.1017/S0030605303000413; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; Balmford A, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000144; Barton J, 2010, ENVIRON SCI TECHNOL, V44, P3947, DOI 10.1021/es903183r; Baumol WJ., 1988, THEORY ENV POLICY, V2, DOI 10.1017/CBO9781139173513; *BIRDLIFE INT, 2010, MEMB BIRD CONS ORG G; BirdLife International, 2004, STAT WORLDS BIRDS 20; BRECHIN SR, 2003, PROMOTING INT BIODIV; Brooks TM, 2009, CONSERV BIOL, V23, P1448, DOI 10.1111/j.1523-1739.2009.01334.x; Bruner AG, 2004, BIOSCIENCE, V54, P1119, DOI 10.1641/0006-3568(2004)054[1119:FCASOM]2.0.CO;2; Butchart SHM, 2006, ORYX, V40, P266, DOI 10.1017/S0030605306000950; Butchart SHM, 2010, SCIENCE, V328, P1164, DOI 10.1126/science.1187512; Collen B, 2008, TROP CONSERV SCI, V1, P75, DOI 10.1177/194008290800100202; Crooks K. R., 2006, CONNECTIVITY CONSERV; Danielsen F, 2009, CONSERV BIOL, V23, P348, DOI 10.1111/j.1523-1739.2008.01096.x; Dasgupta P., 1979, EC THEORY EXHAUSTIBL; Dasgupta P, 2010, PHILOS T R SOC B, V365, P5, DOI 10.1098/rstb.2009.0231; Economics of Ecosystems and Biodiversity (TEEB), 2009, TEEB EC EC BIOD NAT; Ferraro PJ, 2002, SCIENCE, V298, P1718, DOI 10.1126/science.1078104; GADGIL M, 1993, AMBIO, V22, P151; Gallai N, 2009, ECOL ECON, V68, P810, DOI 10.1016/j.ecolecon.2008.06.014; Gaston KJ, 2008, ANNU REV ECOL EVOL S, V39, P93, DOI 10.1146/annurev.ecolsys.39.110707.173529; Salcido RPG, 2009, BIODIVERS CONSERV, V18, P1421, DOI 10.1007/s10531-008-9538-6; Gutman P., 2008, REV INNOVATIVE INT F; Haufler JB, 2005, FISH WILDLIFE BENEFI; Heaton EA, 2008, GLOBAL CHANGE BIOL, V14, P2000, DOI 10.1111/j.1365-2486.2008.01662.x; Heynen N., 2007, NEOLIBERAL ENV FALSE, DOI 10.4324/9780203946848; Hole DG, 2009, ECOL LETT, V12, P420, DOI 10.1111/j.1461-0248.2009.01297.x; Honnay O, 2002, ECOL LETT, V5, P525, DOI 10.1046/j.1461-0248.2002.00346.x; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Hughes JB, 1997, SCIENCE, V278, P689, DOI 10.1126/science.278.5338.689; Hutton JM, 2003, ORYX, V37, P215, DOI 10.1017/S0030605303000395; Jacquet J, 2010, ORYX, V44, P45, DOI 10.1017/S0030605309990470; Kleijn D, 2003, J APPL ECOL, V40, P947, DOI 10.1111/j.1365-2664.2003.00868.x; Kontoleon A, 2007, BIODIVERSITY ECONOMICS, P1, DOI 10.1017/CBO9780511551079; Larigauderie A, 2010, CURR OPIN SUST, V2, P1, DOI 10.1016/j.cosust.2010.04.001; Laurance WF, 2008, BIOL CONSERV, V141, P1731, DOI 10.1016/j.biocon.2008.05.011; LAWSON S, 2010, ILL LOGG REL TRAD IN; Layard R, 2010, SCIENCE, V327, P534, DOI 10.1126/science.1186315; Lemoine N, 2003, CONSERV BIOL, V17, P577, DOI 10.1046/j.1523-1739.2003.01389.x; Leverington F., 2008, MANAGEMENT EFFECTIVE; Maclean IMD, 2008, GLOBAL CHANGE BIOL, V14, P2489, DOI 10.1111/j.1365-2486.2008.01666.x; Marris E, 2009, NATURE, V462, P30, DOI 10.1038/462030a; Martin-Queller E, 2010, ENVIRON MONIT ASSESS, V167, P423, DOI 10.1007/s10661-009-1061-z; Mason Michael., 2005, NEW ACCOUNTABILITY E; MILES L, 2009, CARBON BIODIVERSITY; Miles L, 2008, SCIENCE, V320, P1454, DOI 10.1126/science.1155358; *MILL EC ASS COND, 2005, EC HUM WELL BEING CU; Milne S, 2009, ORYX, V43, P530, DOI 10.1017/S0030605309990330; Mittermeier R.A., 2005, TRANSBOUNDARY CONSER; Monfreda C, 2004, LAND USE POLICY, V21, P231, DOI 10.1016/j.landusepol.2003.10.009; Nelleman C., 2010, RAPID RESPONSE ASSES; O'Riordan Tim, 2002, P87, DOI 10.1017/CBO9780511492655.006; Ostrom E, 1999, SCIENCE, V284, P278, DOI 10.1126/science.284.5412.278; Ostrom E, 2009, SCIENCE, V325, P419, DOI 10.1126/science.1172133; Pearce D, 2005, WORLD ECON, V6, P57; PEARCE D, 1995, BLUEPRINT, V4; Pence GQK, 2003, BIOL CONSERV, V112, P253, DOI 10.1016/S0006-3207(02)00413-5; Phelps J, 2010, SCIENCE, V328, P312, DOI 10.1126/science.1187774; Pyle RM, 2003, ORYX, V37, P206, DOI 10.1017/S0030605303000383; Ricketts TH, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000331; Rodrigues ASL, 2004, BIOSCIENCE, V54, P1092, DOI 10.1641/0006-3568(2004)054[1092:GGAPRF]2.0.CO;2; Rodriguez JP, 2005, CONSERV BIOL, V19, P969, DOI 10.1111/j.1523-1739.2005.00555.x; Runte Alfred, 1987, NATL PARKS AM EXPERI; Sachs JD, 2009, SCIENCE, V325, P1502, DOI 10.1126/science.1175035; Sanderson EW, 2002, LANDSCAPE URBAN PLAN, V58, P41, DOI 10.1016/S0169-2046(01)00231-6; Secretariat of the Convention on Biological Diversity, 2010, GLOB BIOD OUTL 3; SETHIK R, 2009, CAMBODIAN J NAT HIST, P3; SIMPSON RD, 2010, ECOSYSTEMS HUMAN WEL, P221; Smith RJ, 2009, NATURE, V462, P280, DOI 10.1038/462280a; STIGLIZ JA, 2009, REPORT COMMISSION ME; Sukhdev P, 2009, NATURE, V462, P277, DOI 10.1038/462277a; Sutherland WJ, 2010, TRENDS ECOL EVOL, V25, P1, DOI 10.1016/j.tree.2009.10.003; Sutherland WJ, 2009, TRENDS ECOL EVOL, V24, P523, DOI 10.1016/j.tree.2009.04.008; Sutherland WJ, 2004, TRENDS ECOL EVOL, V19, P305, DOI 10.1016/j.tree.2004.03.018; The Royal Society, 2009, REAP BEN; United Nations, 2008, MILL DEV GOALS IND; Vira B, 2009, CONSERV LETT, V2, P158, DOI 10.1111/j.1755-263X.2009.00063.x; Walpole M, 2009, SCIENCE, V325, P1503, DOI 10.1126/science.1175466; WBCSD, 2005, PATHW 2050 EN CLIM C; Wolmer W, 2003, J S AFR STUD, V29, P261, DOI 10.1080/0305707032000060449; 2009, AGR CROSSROADS INT A	89	635	677	24	738	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1298	1303		10.1126/science.1189138	http://dx.doi.org/10.1126/science.1189138			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	647YR	20829476				2022-12-28	WOS:000281657300025
J	Sauvageau, G; Humphries, RK				Sauvageau, Guy; Humphries, R. Keith			The Blood Stem Cell Holy Grail?	SCIENCE			English	Editorial Material							ARYL-HYDROCARBON RECEPTOR; EXPANSION; RECONSTITUTION; VIVO		[Sauvageau, Guy] Univ Montreal, Inst Res Immunol & Canc, Mol Genet Stem Cells Lab, Montreal, PQ H3C 3J7, Canada; [Sauvageau, Guy] Maisonneuve Rosemont Hosp, Div Hematol, Montreal, PQ H1T 2M4, Canada; [Sauvageau, Guy] Maisonneuve Rosemont Hosp, Leukemia Cell Bank Quebec, Montreal, PQ H1T 2M4, Canada; [Humphries, R. Keith] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Humphries, R. Keith] Univ British Columbia, Dept Med, Vancouver, BC V6T 1W5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; British Columbia Cancer Agency; University of British Columbia	Sauvageau, G (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Mol Genet Stem Cells Lab, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266; Humphries, Richard/0000-0003-0540-7005				Benveniste P, 2010, CELL STEM CELL, V6, P48, DOI 10.1016/j.stem.2009.11.014; Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536; Casado FL, 2010, BLOOD CELL MOL DIS, V44, P199, DOI 10.1016/j.bcmd.2010.01.005; Cellot S, 2007, EXP HEMATOL, V35, P802, DOI 10.1016/j.exphem.2007.02.013; Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080; Domashenko AD, 2010, BLOOD, V116, P2676, DOI 10.1182/blood-2010-03-273441; Dykstra B, 2007, CELL STEM CELL, V1, P218, DOI 10.1016/j.stem.2007.05.015; Gratwohl A, 2010, JAMA-J AM MED ASSOC, V303, P1617, DOI 10.1001/jama.2010.491; Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119; Huang CH, 2010, TISSUE ENG PART C-ME, V16, P487, DOI [10.1089/ten.tec.2009.0163, 10.1089/ten.TEC.2009.0163]; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Ohta H, 2007, EXP HEMATOL, V35, P817, DOI 10.1016/j.exphem.2007.02.012; Singh KP, 2009, CARCINOGENESIS, V30, P11, DOI 10.1093/carcin/bgn224; Thomsen JS, 2004, MOL PHARMACOL, V65, P165, DOI 10.1124/mol.65.1.165; Zhang CC, 2006, NAT MED, V12, P240, DOI 10.1038/nm1342	15	10	10	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1291	1292		10.1126/science.1195173	http://dx.doi.org/10.1126/science.1195173			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829472				2022-12-28	WOS:000281657300021
J	Carneiro, T; Khair, L; Reis, CC; Borges, V; Moser, BA; Nakamura, TM; Ferreira, MG				Carneiro, Tiago; Khair, Lyne; Reis, Clara C.; Borges, Vanessa; Moser, Bettina A.; Nakamura, Toru M.; Ferreira, Miguel Godinho			Telomeres avoid end detection by severing the checkpoint signal transduction pathway	NATURE			English	Article							FISSION YEAST; DNA-DAMAGE; CELL-CYCLE; DYSFUNCTIONAL TELOMERES; PROTEIN CRB2; RAP1; RECRUITMENT; METHYLATION; REPAIR; BREAKS	Telomeres protect the normal ends of chromosomes from being recognized as deleterious DNA double-strand breaks. Recent studies have uncovered an apparent paradox: although DNA repair is prevented, several proteins involved in DNA damage processing and checkpoint responses are recruited to telomeres in every cell cycle and are required for end protection(1). It is currently not understood how telomeres prevent DNA damage responses from causing permanent cell cycle arrest. Here we show that fission yeast (Schizosaccharomyces pombe) cells lacking Taz1, an orthologue of human TRF1 and TRF2 (ref. 2), recruit DNA repair proteins (Rad22(RAD52) and Rhp51(RAD51), where the superscript indicates the human orthologue) and checkpoint sensors (RPA, Rad9, Rad26(ATRIP) and Cut5/Rad4(TOPBP1)) to telomeres. Despite this, telomeres fail to accumulate the checkpoint mediator Crb2(53BP1) and, consequently, do not activate Chk1-dependent cell cycle arrest. Artificially recruiting Crb2(53BP1) to taz1D telomeres results in a full checkpoint response and cell cycle arrest. Stable association of Crb2(53BP1) to DNA double-strand breaks requires two independent histone modifications: H4 dimethylation at lysine 20 (H4K20me2) and H2A carboxy-terminal phosphorylation (gamma H2A)(3-5). Whereas cH2A can be readily detected, telomeres lack H4K20me2, in contrast to internal chromosome locations. Blocking checkpoint signal transduction at telomeres requires Pot1 and Ccq1, and loss of either Pot1 or Ccq1 from telomeres leads to Crb2(53BP1) foci formation, Chk1 activation and cell cycle arrest. Thus, telomeres constitute a chromatin-privileged region of the chromosomes that lack essential epigenetic markers for DNA damage response amplification and cell cycle arrest. Because the protein kinases ATM and ATR must associate with telomeres in each S phase to recruit telomerase(6), exclusion of Crb2(53BP1) has a critical role in preventing telomeres from triggering cell cycle arrest.	[Carneiro, Tiago; Reis, Clara C.; Borges, Vanessa; Ferreira, Miguel Godinho] Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal; [Khair, Lyne; Moser, Bettina A.; Nakamura, Toru M.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	Instituto Gulbenkian de Ciencia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ferreira, MG (corresponding author), Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal.	mgferreira@igc.gulbenkian.pt	Ferreira, Miguel/HHZ-6251-2022; Nakamura, Toru M/B-2055-2008; Ferreira, Miguel Godinho/F-9290-2012	Nakamura, Toru M/0000-0001-5752-0814; Ferreira, Miguel Godinho/0000-0002-8363-7183; Borges, Vanessa/0000-0003-0223-9085; Carneiro, Tiago/0000-0001-7909-4182	NIH [GM078253]; FCT [PTDC/BIA-BCM/67261/2006]; Association for International Cancer Research [06-396]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078253] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Association for International Cancer Research; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Cooper, K. Tomita and the rest of the Telomere Biology Laboratory (Cancer Research UK, London) for support at the start of this project. We thank J. Cooper, T. Wolkow, P. Russell and A. M. Carr for strains and plasmids. We thank W. Kaufman for her initial effort in the establishment of HO strains. We are grateful to S. Grewal for sharing unpublished results and to D. Lydall for insights on the quantitative analysis of checkpoint activation. We thank K. Labib, L. Jansen, K. Xavier, R. Martinho and S. Lopes for critically reading the manuscript. T. C. and C. C. R. are supported by Fundacao para a Ciencia e a Tecnologia (FCT) postdoctoral fellowships. T.M.N. was supported by the Sidney Kimmel Scholar Program and his laboratory is supported by NIH grant GM078253. This work was supported by the FCT (PTDC/BIA-BCM/67261/2006) and the Association for International Cancer Research (06-396).	Abdallah P, 2009, NAT CELL BIOL, V11, P988, DOI 10.1038/ncb1911; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Chikashige Y, 2001, CURR BIOL, V11, P1618, DOI 10.1016/S0960-9822(01)00457-2; Churikov D, 2008, NAT STRUCT MOL BIOL, V15, P79, DOI 10.1038/nsmb1331; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Du LL, 2006, GENE DEV, V20, P1583, DOI 10.1101/gad.1422606; Ferreira MG, 2004, GENE DEV, V18, P2249, DOI 10.1101/gad.315804; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Goudsouzian LK, 2006, MOL CELL, V24, P603, DOI 10.1016/j.molcel.2006.10.005; Greeson NT, 2008, J BIOL CHEM, V283, P33168, DOI 10.1074/jbc.M806857200; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; Hirano Y, 2007, MOL BIOL CELL, V18, P2026, DOI 10.1091/mbc.E06-12-1074; Khair L, 2010, J BIOL CHEM, V285, P5327, DOI 10.1074/jbc.M109.078840; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Michelson RJ, 2005, GENE DEV, V19, P2546, DOI 10.1101/gad.1293805; Miller KM, 2006, NATURE, V440, P824, DOI 10.1038/nature04638; Miller KM, 2005, EMBO J, V24, P3128, DOI 10.1038/sj.emboj.7600779; Miyoshi T, 2008, SCIENCE, V320, P1341, DOI 10.1126/science.1154819; Mochida S, 2004, EMBO J, V23, P418, DOI 10.1038/sj.emboj.7600018; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moser BA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000622; Moser BA, 2009, EMBO J, V28, P810, DOI 10.1038/emboj.2009.31; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Negrini S, 2007, GENE DEV, V21, P292, DOI 10.1101/gad.400907; Rog O, 2009, MOL CELL, V33, P559, DOI 10.1016/j.molcel.2009.01.027; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Tomita K, 2004, MOL CELL BIOL, V24, P9557, DOI 10.1128/MCB.24.21.9557-9567.2004; Tomita K, 2008, GENE DEV, V22, P3461, DOI 10.1101/gad.498608; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wang Y, 2009, EPIGENETICS-US, V4, P273, DOI 10.4161/epi.4.5.9212	33	44	47	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					228	U124		10.1038/nature09353	http://dx.doi.org/10.1038/nature09353			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829797	Green Accepted			2022-12-28	WOS:000281616300039
J	Grady, C				Grady, Christine			Do IRBs Protect Human Research Participants?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Grady, C (corresponding author), NIH, Dept Bioeth, Ctr Clin, Bldg 10-1C118, Bethesda, MD 20892 USA.	cgrady@nih.gov						Bledsoe CH, 2007, NORTHWEST U LAW REV, V101, P593; Burman W, 2009, CLIN INFECT DIS, V49, P328, DOI 10.1086/605454; *CLIN TRANSL SCI A, CLIN RES ETH IRB QUA; Coleman Carl H, 2008, BMC Med Ethics, V9, P6, DOI 10.1186/1472-6939-9-6; Fost N, 2007, JAMA-J AM MED ASSOC, V298, P2196, DOI 10.1001/jama.298.18.2196; Gunsalus CK, 2006, SCIENCE, V312, P1441, DOI 10.1126/science.1121479; Hyman DA, 2007, NORTHWEST U LAW REV, V101, P749; McCarthy C, 2008, OXFORD TXB CLIN RES, P550; *NAT I HLTH OFF BU, APPR HIST I CTR 1938	9	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1122	1123		10.1001/jama.2010.1304	http://dx.doi.org/10.1001/jama.2010.1304			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646RM	20823440				2022-12-28	WOS:000281559800026
J	Dzhindzhev, NS; Yu, QAD; Weiskopf, K; Tzolovsky, G; Cunha-Ferreira, I; Riparbelli, M; Rodrigues-Martins, A; Bettencourt-Dias, M; Callaini, G; Glover, DM				Dzhindzhev, Nikola S.; Yu, Quan D.; Weiskopf, Kipp; Tzolovsky, George; Cunha-Ferreira, Ines; Riparbelli, Maria; Rodrigues-Martins, Ana; Bettencourt-Dias, Monica; Callaini, Giuliano; Glover, David M.			Asterless is a scaffold for the onset of centriole assembly	NATURE			English	Article							POLO-BOX DOMAIN; DROSOPHILA; DUPLICATION; PROTEINS; CYTOKINESIS; BIOGENESIS; SUFFICIENT; SUBSTRATE; EMBRYO; CELLS	Centrioles are found in the centrosome core and, as basal bodies, at the base of cilia and flagella. Centriole assembly and duplication is controlled by Polo-like-kinase 4 (Plk4): these processes fail if Plk4 is downregulated and are promoted by Plk4 overexpression(1-7). Here we show that the centriolar protein Asterless (Asl; human orthologue CEP152) provides a conserved molecular platform, the amino terminus of which interacts with the cryptic Polo box of Plk4 whereas the carboxy terminus interacts with the centriolar protein Sas-4 (CPAP in humans). Drosophila Asl and human CEP152 are required for the centrosomal loading of Plk4 in Drosophila and CPAP in human cells, respectively. Depletion of Asl or CEP152 caused failure of centrosome duplication; their overexpression led to de novo centriole formation in Drosophila eggs, duplication of free centrosomes in Drosophila embryos, and centrosome amplification in cultured Drosophila and human cells. Overexpression of a Plk4-binding-deficient mutant of Asl prevented centriole duplication in cultured cells and embryos. However, this mutant protein was able to promote microtubule organizing centre (MTOC) formation in both embryos and oocytes. Such MTOCs had pericentriolar material and the centriolar protein Sas-4, but no centrioles at their core. Formation of such acentriolar MTOCs could be phenocopied by overexpression of Sas-4 in oocytes or embryos. Our findings identify independent functions for Asl as a scaffold for Plk4 and Sas-4 that facilitates self-assembly and duplication of the centriole and organization of pericentriolar material.	[Dzhindzhev, Nikola S.; Yu, Quan D.; Weiskopf, Kipp; Tzolovsky, George; Cunha-Ferreira, Ines; Rodrigues-Martins, Ana; Glover, David M.] Univ Cambridge, Dept Genet, Canc Res UK Cell Cycle Genet Grp, Cambridge CB2 3EH, England; [Tzolovsky, George; Riparbelli, Maria; Rodrigues-Martins, Ana; Glover, David M.] Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal; [Riparbelli, Maria; Callaini, Giuliano] Univ Siena, Dipartimento Biol Evolut, I-53100 Siena, Italy	University of Cambridge; Instituto Gulbenkian de Ciencia; University of Siena	Dzhindzhev, NS (corresponding author), Univ Cambridge, Dept Genet, Canc Res UK Cell Cycle Genet Grp, Downing St, Cambridge CB2 3EH, England.	nsd23@cam.ac.uk; dmg25@cam.ac.uk	Callaini, Giuliano/T-6353-2018; Bettencourt-Dias, Monica/B-5176-2015	Callaini, Giuliano/0000-0003-2252-0309; Bettencourt-Dias, Monica/0000-0003-1987-5598; Glover, David/0000-0003-0956-0103; Dzhindzhev, Nikola/0000-0001-9866-3600	Cancer Research UK; Fundacao Calouste Gulbenkian; Fundacao para a Ciencia e Tecnologia (FCT); Royal Society; Cancer Research UK [11431] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Fundacao Calouste Gulbenkian(European Commission); Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Royal Society(Royal Society of London); Cancer Research UK(Cancer Research UK)	We thank E. Wegel for technical help. We thank P. Coelho, G. Mao, P. Gonczy, T. Megraw and J. Raff for antibodies. We thank Cancer Research UK for a Programme Grant to D.M.G. and a studentship to Q.D.Y. K.W. was a visiting scholar of the Winston Churchill Foundation of the United States. Fundacao Calouste Gulbenkian, Fundacao para a Ciencia e Tecnologia (FCT) provided support to M.B.-D. and scholarships to I.C.-F. and A.R.-M. The Royal Society provided an International Joint Project Grant for collaboration between M.B.-D. and D.M.G.	Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Blachon S, 2008, GENETICS, V180, P2081, DOI 10.1534/genetics.108.095141; Chang J, 2010, EMBO J, V29, P2395, DOI 10.1038/emboj.2010.118; Cunha-Ferreira I, 2009, CURR BIOL, V19, P43, DOI 10.1016/j.cub.2008.11.037; D'Avino PP, 2006, J CELL SCI, V119, P4402, DOI 10.1242/jcs.03210; D'Avino PP, 2009, METHODS MOL BIOL, V545, P99, DOI 10.1007/978-1-60327-993-2_6; Dobbelaere J, 2008, PLOS BIOL, V6, P1975, DOI 10.1371/journal.pbio.0060224; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fox JD, 2003, FEBS LETT, V537, P53, DOI 10.1016/S0014-5793(03)00070-X; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Lowery DM, 2007, EMBO J, V26, P2262, DOI 10.1038/sj.emboj.7601683; Mottier-Pavie V, 2009, MOL BIOL CELL, V20, P2605, DOI 10.1091/mbc.E08-11-1115; Peel N, 2007, CURR BIOL, V17, P834, DOI 10.1016/j.cub.2007.04.036; Rodrigues-Martins A, 2007, SCIENCE, V316, P1046, DOI 10.1126/science.1142950; Rodrigues-Martins A, 2007, CURR BIOL, V17, P1465, DOI 10.1016/j.cub.2007.07.034; Rogers GC, 2009, J CELL BIOL, V184, P225, DOI 10.1083/jcb.200808049; Varmark H, 2007, CURR BIOL, V17, P1735, DOI 10.1016/j.cub.2007.09.031; WARN RM, 1986, EXP CELL RES, V163, P201, DOI 10.1016/0014-4827(86)90573-2	24	217	223	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					714	U104		10.1038/nature09445	http://dx.doi.org/10.1038/nature09445			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20852615				2022-12-28	WOS:000282572500040
J	Wilper, AP; Weppner, WG; Smith, CS				Wilper, Andrew P.; Weppner, William G.; Smith, C. Scott			Changes in Idaho Primary Care Physician Clinical Work Hours, 1996-2009	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Wilper, Andrew P.; Weppner, William G.; Smith, C. Scott] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wilper, AP (corresponding author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.	andrew.wilper@va.gov						*KAIS FAM FDN, 2009, HMO PEN RAT KAIS STA; *KAIS FAM FDN, NONF PRIM CAR PHYS P; *NAT ASS RUR HLTH, CMS INT MAN HC PROGR; Staiger DO, 2010, JAMA-J AM MED ASSOC, V303, P747, DOI 10.1001/jama.2010.168; *US BUR CENS, NAT STAT POP EST ANN; *US BUR CENS, ST993 US CENS BUR; *US HLTH RES SERV, SUMM KEY HLTH CTR PR	7	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2010	304	13					1443	1445		10.1001/jama.2010.1403	http://dx.doi.org/10.1001/jama.2010.1403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658SO	20924008				2022-12-28	WOS:000282509900019
J	de Bono, JS; Oudard, S; Ozguroglu, M; Hansen, S; Machiels, JP; Kocak, I; Gravis, G; Bodrogi, I; Mackenzie, MJ; Shen, L; Roessner, M; Gupta, S; Sartor, AO				de Bono, Johann Sebastian; Oudard, Stephane; Ozguroglu, Mustafa; Hansen, Steinbjorn; Machiels, Jean-Pascal; Kocak, Ivo; Gravis, Gwenaelle; Bodrogi, Istvan; Mackenzie, Mary J.; Shen, Liji; Roessner, Martin; Gupta, Sunil; Sartor, A. Oliver		TROPIC Investigators	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial	LANCET			English	Article							EVERY 3 WEEKS; SOLID TUMORS; END-POINTS; CHEMOTHERAPY; ESTRAMUSTINE; TAXANE; PAIN	Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. Methods We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant prostate cancer who had received previous hormone therapy, but whose disease had progressed during or after treatment with a docetaxel-containing regimen. Participants were treated with 10 mg oral prednisone daily, and were randomly assigned to receive either 12 mg/m(2) mitoxantrone intravenously over 15-30 min or 25 mg/m(2) cabazitaxel intravenously over 1 h every 3 weeks. The random allocation schedule was computer-generated; patients and treating physicians were not masked to treatment allocation, but the study team was masked to the data analysis. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and safety. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, NCT00417079. Findings 755 men were allocated to treatment groups (377 mitoxantrone, 378 cabazitaxel) and were included in the intention-to-treat analysis. At the cutoff for the final analysis (Sept 25, 2009), median survival was 15.1 months (95% CI 14.1-16.3) in the cabazitaxel group and 12.7 months (11.6-13.7) in the mitoxantrone group. The hazard ratio for death of men treated with cabazitaxel compared with those taking mitoxantrone was 0.70 (95% CI 0.59-0.83, p<0.0001). Median progression-free survival was 2.8 months (95% CI 2.4-3.0) in the cabazitaxel group and 1.4 months (1.4-1.7) in the mitoxantrone group (HR 0.74, 0.64-0.86, p<0.0001). The most common clinically significant grade 3 or higher adverse events were neutropenia (cabazitaxel, 303 [82%] patients vs mitoxantrone, 215 [58%]) and diarrhoea (23 [6%] vs one [<1%]). 28 (8%) patients in the cabazitaxel group and five (1%) in the mitoxantrone group had febrile neutropenia. Interpretation Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy.	[de Bono, Johann Sebastian] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [de Bono, Johann Sebastian] Inst Canc Res, Sutton SM2 5PT, Surrey, England; [Sartor, A. Oliver] Tulane Univ, New Orleans, LA 70118 USA; [Oudard, Stephane] Hop Europeen Georges Pompidou, Paris, France; [Ozguroglu, Mustafa] Istanbul Univ, Istanbul, Turkey; [Hansen, Steinbjorn] Odense Univ Hosp, DK-5000 Odense, Denmark; [Machiels, Jean-Pascal] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium; [Kocak, Ivo] Masarykuv Onkol Ustav, Brno, Czech Republic; [Gravis, Gwenaelle] Inst Paoli Calmette Hop Jour, Marseille, France; [Bodrogi, Istvan] Orszagos Onkol Intezet, Budapest, Hungary; [Mackenzie, Mary J.] London Hlth Sci Ctr, London, ON, Canada; [Shen, Liji; Roessner, Martin; Gupta, Sunil] Sanofi Aventis, Malvern, PA USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Tulane University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Istanbul University; University of Southern Denmark; Odense University Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Masaryk Memorial Cancer Institute; UNICANCER; Institut Paoli-Calmette (IPC); London Health Sciences Centre; Sanofi-Aventis	de Bono, JS (corresponding author), Royal Marsden NHS Fdn Trust, Downs Rd, Sutton SM2 5PT, Surrey, England.	johann.de-bono@icr.ac.uk	MUSTAFA, ÖZGÜROĞLU/A-8234-2016; Gravis, Gwenaelle/CAG-3019-2022	MUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628; Gravis, Gwenaelle/0000-0002-3127-1554; OUDARD, Stephane/0000-0003-0893-285X; Hansen, Steinbjorn/0000-0001-5651-6493; de Bono, Johann S/0000-0002-2034-595X	Sanofi-Aventis	Sanofi-Aventis(Sanofi-Aventis)	Sanofi-Aventis funded this clinical trial. JSB, AOS, SO, and SH have served as paid consultants for Sanofi-Aventis. LS, MR, and SG are employees of Sanofi-Aventis.	Aller AW, 2000, P AM ASSOC CANC RES, V41, P303; American Cancer Society, GLOB CANC FACTS FIG; Attard G, 2006, PATHOL BIOL, V54, P72, DOI 10.1016/j.patbio.2005.03.003; Berry DL, 2006, J CLIN ONCOL, V24, P2828, DOI 10.1200/JCO.2005.04.8207; Bissery C, 2000, P AM ASSOC CANC RES, V41, P214; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; EISENBERGER MA, 1985, J CLIN ONCOL, V3, P827, DOI 10.1200/JCO.1985.3.6.827; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kramer G, 2006, BRIT J CANCER, V94, P1592, DOI 10.1038/sj.bjc.6603129; MedDRA, MED DICT REG ACT MED; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mita AC, 2009, CLIN CANCER RES, V15, P723, DOI 10.1158/1078-0432.CCR-08-0596; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pivot X, 2008, ANN ONCOL, V19, P1547, DOI 10.1093/annonc/mdn171; Rosenberg JE, 2007, CANCER-AM CANCER SOC, V110, P556, DOI 10.1002/cncr.22811; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205	20	2405	2445	2	150	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1147	1154		10.1016/S0140-6736(10)61389-X	http://dx.doi.org/10.1016/S0140-6736(10)61389-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888992				2022-12-28	WOS:000282915700031
J	Ruiz-Irastorza, G; Crowther, M; Branch, W; Khamashta, MA				Ruiz-Irastorza, Guillermo; Crowther, Mark; Branch, Ware; Khamashta, Munther A.			Antiphospholipid syndrome	LANCET			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; RECURRENT PREGNANCY LOSS; INTERNATIONAL CONSENSUS STATEMENT; RANDOMIZED CONTROLLED-TRIAL; MOLECULAR-WEIGHT HEPARIN; PRIMARY THROMBOSIS PREVENTION; OF-THE-LITERATURE; LOW-DOSE ASPIRIN; RISK-FACTORS; FETAL LOSS	The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency. Other clinical manifestations are cardiac valvular disease, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, and cognitive impairment. Antiphospholipid antibodies promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2. Complement activation might have a central pathogenetic role. Of the different antiphospholipid antibodies, lupus anticoagulant is the strongest predictor of features related to antiphospholipid syndrome. Therapy of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively. Primary thromboprophylaxis is recommended in patients with systemic lupus erythematosus and probably in purely obstetric antiphospholipid syndrome. Obstetric care is based on combined medical-obstetric high-risk management and treatment with aspirin and heparin. Hydroxychloroquine is a potential additional treatment for this syndrome. Possible future therapies for non-pregnant patients with antiphospholipid syndrome are statins, rituximab, and new anticoagulant drugs.	[Ruiz-Irastorza, Guillermo] Univ Basque Country, Hosp Cruces, Med Interna Serv, Bizkaia 48903, Spain; [Crowther, Mark] St Joseph Hosp, Hamilton, ON, Canada; [Crowther, Mark] McMaster Univ, Hamilton, ON, Canada; [Branch, Ware] Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Salt Lake City, UT USA; [Branch, Ware] Intermt Healthcare, Salt Lake City, UT USA; [Khamashta, Munther A.] Kings Coll London, St Thomas Hosp, Rayne Inst, Lupus Res Unit, London WC2R 2LS, England	Hospital Universitario Cruces; University of Basque Country; McMaster University; Utah System of Higher Education; University of Utah; Intermountain Healthcare; Intermountain Medical Center; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Ruiz-Irastorza, G (corresponding author), Univ Basque Country, Hosp Cruces, Med Interna Serv, Bizkaia 48903, Spain.	r.irastorza@euskalnet.net	Ruiz, Guillermo/E-1724-2012; Ruiz-Irastorza, Guillermo/P-7058-2014	Ruiz-Irastorza, Guillermo/0000-0001-7788-1043	Department of Education, Universities and Research of the Basque Government; Heart and Stroke Foundation of Canada; HA and Edna Benning Foundation at the University of Utah	Department of Education, Universities and Research of the Basque Government; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); HA and Edna Benning Foundation at the University of Utah	GR-I is supported by the Department of Education, Universities and Research of the Basque Government. MC holds a Career Investigator Award from the Heart and Stroke Foundation of Canada. WB is supported by the HA and Edna Benning Foundation at the University of Utah.	Adams RJ, 2008, STROKE, V39, P1647, DOI 10.1161/STROKEAHA.107.189063; AMIGO MC, 1992, J RHEUMATOL, V19, P1181; Asherson RA, 2003, LUPUS, V12, P530, DOI 10.1191/0961203303lu394oa; Askie LM, 2007, LANCET, V369, P1791, DOI 10.1016/S0140-6736(07)60712-0; Bates SM, 2008, CHEST, V133, p844S, DOI 10.1378/chest.08-0761; Bramham K, 2010, LUPUS, V19, P58, DOI 10.1177/0961203309347794; Branch DW, 2003, OBSTET GYNECOL, V101, P1333, DOI 10.1016/S0029-7844(03)00363-6; Branch DW, 2000, AM J OBSTET GYNECOL, V182, P122, DOI 10.1016/S0002-9378(00)70500-X; Brey RL, 2004, J THROMB HAEMOST, V2, P1556, DOI 10.1111/j.1538-7836.2004.00904.x; Bushnell CD, 2000, STROKE, V31, P3067, DOI 10.1161/01.STR.31.12.3067; Carmona F, 2001, AM J REPROD IMMUNOL, V46, P274, DOI 10.1034/j.1600-0897.2001.d01-13.x; Cervera R, 2002, ARTHRITIS RHEUM-US, V46, P1019, DOI 10.1002/art.10187; Cervera R, 2010, LUPUS, V19, P412, DOI 10.1177/0961203309361353; Clark Erin A S, 2007, Curr Rheumatol Rep, V9, P219, DOI 10.1007/s11926-007-0035-9; Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; Crowther MA, 2003, NEW ENGL J MED, V349, P1133, DOI 10.1056/NEJMoa035241; Cuadrado MJ, 2000, MEDICINE, V79, P57, DOI 10.1097/00005792-200001000-00006; Danowski A, 2009, J RHEUMATOL, V36, P1195, DOI 10.3899/jrheum.081194; De Groot PG, 2005, J THROMB HAEMOST, V3, P1854; de Laat B, 2005, BLOOD, V105, P1540, DOI 10.1182/blood-2004-09-3387; De Laat B, 2009, J THROMB HAEMOST, V7, P1767, DOI 10.1111/j.1538-7836.2009.03588.x; Di Simone N, 2005, ANN RHEUM DIS, V64, P462, DOI 10.1136/ard.2004.021444; Duckitt K, 2005, BRIT MED J, V330, P565, DOI 10.1136/bmj.38380.674340.E0; Edwards MH, 1997, CIRCULATION, V96, P4380; Empson M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002859.pub2; Erkan D, 2002, RHEUMATOLOGY, V41, P924, DOI 10.1093/rheumatology/41.8.924; Erkan D, 2001, ARTHRITIS RHEUM, V44, P1466, DOI 10.1002/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C; Erkan D, 2007, ARTHRITIS RHEUM-US, V56, P2382, DOI 10.1002/art.22663; Espinola RG, 2002, THROMB HAEMOSTASIS, V87, P518; Farquharson RG, 2002, OBSTET GYNECOL, V100, P408, DOI 10.1016/S0029-7844(02)02165-8; Ferrara DE, 2004, J THROMB HAEMOST, V2, P1558, DOI 10.1111/j.1538-7836.2004.00896.x; Ferrara DE, 2003, ARTHRITIS RHEUM-US, V48, P3272, DOI 10.1002/art.11449; Finazzi G, 2005, J THROMB HAEMOST, V3, P848, DOI 10.1111/j.1538-7836.2005.01340.x; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; Forastiero R, 2005, J THROMB HAEMOST, V3, P1231, DOI 10.1111/j.1538-7836.2005.01295.x; Frances C, 2005, ARTHRITIS RHEUM, V52, P1785, DOI 10.1002/art.21041; Galli M, 2003, BLOOD, V101, P1827, DOI 10.1182/blood-2002-02-0441; Galli M, 2003, BLOOD, V102, P2717, DOI 10.1182/blood-2002-11-3334; Galli M, 2007, BLOOD, V110, P1178, DOI 10.1182/blood-2007-01-066043; Garcia DA, 2007, BLOOD, V110, P3122, DOI 10.1182/blood-2006-10-041814; Giannakopoulos B, 2009, BLOOD, V114, P2020, DOI 10.1182/blood-2009-05-220756; Giannakopoulos B, 2009, BLOOD, V113, P985, DOI 10.1182/blood-2007-12-129627; Girardi G, 2004, NAT MED, V10, P1222, DOI 10.1038/nm1121; Giron-Gonzalez JA, 2004, J RHEUMATOL, V31, P1560; Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241; Granger KA, 1997, LUPUS, V6, P509, DOI 10.1177/096120339700600606; Halkes PHA, 2006, LANCET, V367, P1665; Hanly JG, 1999, ARTHRITIS RHEUM, V42, P728, DOI 10.1002/1529-0131(199904)42:4<728::AID-ANR16>3.0.CO;2-O; Hereng T, 2008, LUPUS, V17, P11, DOI 10.1177/0961203307084724; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; Huong DLT, 2006, RHEUMATOLOGY, V45, P332, DOI 10.1093/rheumatology/kei159; Huong DLT, 2001, J RHEUMATOL, V28, P2025; Jajoria P, 2009, ANN NY ACAD SCI, V1173, P736, DOI 10.1111/j.1749-6632.2009.04815.x; Kaiser R, 2009, ANN RHEUM DIS, V68, P238, DOI 10.1136/ard.2008.093013; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; Lackner KJ, 2006, THROMB HAEMOSTASIS, V95, P917, DOI 10.1160/TH06-03-0132; Laskin CA, 2009, J RHEUMATOL, V36, P279, DOI [10.3899/jrheum.080763), 10.3899/jrheum.080763]; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; Levine SR, 2004, JAMA-J AM MED ASSOC, V291, P576, DOI 10.1001/jama.291.5.576; Lim W, 2006, JAMA-J AM MED ASSOC, V295, P1050, DOI 10.1001/jama.295.9.1050; Lima F, 1996, CLIN EXP RHEUMATOL, V14, P131; Lockshin M, 2003, LUPUS, V12, P518, DOI 10.1191/0961203303lu391oa; Lopez-Pedrera C, 2008, ARTHRITIS RHEUM-US, V58, P2835, DOI 10.1002/art.23756; Martincz-Berriotxoa A, 2007, LUPUS, V16, P810, DOI 10.1177/0961203307083316; Martinez F, 2006, MED CLIN-BARCELONA, V127, P405, DOI 10.1157/13092765; Meis PJ, 1998, AM J OBSTET GYNECOL, V178, P562, DOI 10.1016/S0002-9378(98)70439-9; Menon S, 1999, ARTHRITIS RHEUM-US, V42, P735, DOI 10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-L; Meroni PL, 2001, ARTHRITIS RHEUM-US, V44, P2870, DOI 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Mok CC, 2005, ARTHRITIS RHEUM-US, V52, P2774, DOI 10.1002/art.21224; Montiel-Manzano G, 2007, ANN NY ACAD SCI, V1108, P540, DOI 10.1196/annals.1422.057; Mulla MJ, 2009, AM J REPROD IMMUNOL, V62, P96, DOI 10.1111/j.1600-0897.2009.00717.x; Munoz-Rodriguez FJ, 1999, SEMIN ARTHRITIS RHEU, V29, P182, DOI 10.1016/S0049-0172(99)80029-8; Noble LS, 2005, FERTIL STERIL, V83, P684, DOI 10.1016/j.fertnstert.2004.11.002; Nodler J, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-11; Opatrny L, 2006, J RHEUMATOL, V33, P2214; Oshiro BT, 1996, OBSTET GYNECOL, V87, P489, DOI 10.1016/0029-7844(95)00498-X; Ostensen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1957; Pattison NS, 2000, AM J OBSTET GYNECOL, V183, P1008, DOI 10.1067/mob.2000.106754; Paul SN, 2005, ANN RHEUM DIS, V64, P1800, DOI 10.1136/ard.2005.040279; Pengo V, 2005, THROMB HAEMOSTASIS, V93, P1147, DOI 10.1160/TH04-12-0839; Pengo V, 2010, J THROMB HAEMOST, V8, P237, DOI 10.1111/j.1538-7836.2009.03674.x; Pierangeli SS, 2008, SEMIN THROMB HEMOST, V34, P236, DOI 10.1055/s-0028-1082267; Pierangeli SS, 2006, CURR OPIN HEMATOL, V13, P366; Pierangeli SS, 2005, ARTHRITIS RHEUM, V52, P2120, DOI 10.1002/art.21157; Quenby S, 2005, HUM REPROD, V20, P1729, DOI 10.1093/humrep/deh844; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; RAI RS, 1995, HUM REPROD, V10, P2001, DOI 10.1093/oxfordjournals.humrep.a136224; Ramos-Casals M, 2008, MEDICINE, V87, P345, DOI 10.1097/MD.0b013e318190f170; Rand JH, 2010, LUPUS, V19, P460, DOI 10.1177/0961203310361485; Rand JH, 2008, BLOOD, V112, P1687, DOI 10.1182/blood-2008-03-144204; Rand JH, 2010, BLOOD, V115, P2292, DOI 10.1182/blood-2009-04-213520; Roldan V, 2009, THROMB RES, V124, P174, DOI 10.1016/j.thromres.2008.11.003; Ruffatti A, 2010, ARTHRIT CARE RES, V62, P302, DOI 10.1002/acr.20098; Ruiz-Irastorza G, 2008, LUPUS, V17, P416, DOI 10.1177/0961203308090027; Ruiz-Irastorza G, 2004, ARCH INTERN MED, V164, P77, DOI 10.1001/archinte.164.1.77; Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766; Ruiz-Irastorza G, 2001, LUPUS, V10, P241, DOI 10.1191/096120301667789546; Ruiz-Irastorza G, 2007, ARTHRIT RHEUM-ARTHR, V57, P1487, DOI 10.1002/art.23109; Sanna G, 2003, RHEUMATOLOGY, V42, P200, DOI 10.1093/rheumatology/keg080; Schulman S, 2009, NEW ENGL J MED, V361, P2342, DOI 10.1056/NEJMoa0906598; SHAMONKI JM, 2007, AM J OBSTET GYNECOL, V196; SILVER RK, 1993, AM J OBSTET GYNECOL, V169, P1411, DOI 10.1016/0002-9378(93)90410-K; Silver RM, 2007, OBSTET GYNECOL, V109, P153, DOI 10.1097/01.AOG.0000248537.89739.96; Smith GCS, 2004, JAMA-J AM MED ASSOC, V292, P2249, DOI 10.1001/jama.292.18.2249; Stephenson Mary D, 2004, J Obstet Gynaecol Can, V26, P729; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; Stone S, 2001, LUPUS, V10, P67, DOI 10.1191/096120301667486047; Tarr T, 2007, LUPUS, V16, P39, DOI 10.1177/0961203306074767; Tektonidou MG, 2006, ARCH INTERN MED, V166, P2278, DOI 10.1001/archinte.166.20.2278; Tektonidou MG, 2009, ARTHRIT RHEUM-ARTHR, V61, P29, DOI 10.1002/art.24232; Tektonidou MG, 2000, QJM-INT J MED, V93, P523, DOI 10.1093/qjmed/93.8.523; Tektonidou MG, 2004, ARTHRITIS RHEUM-US, V50, P2569, DOI 10.1002/art.20433; Triolo G, 2003, ARTHRITIS RHEUM-US, V48, P728, DOI 10.1002/art.10957; Urbanus RT, 2009, LANCET NEUROL, V8, P998, DOI 10.1016/S1474-4422(09)70239-X; Vaquero E, 2001, AM J REPROD IMMUNOL, V45, P174, DOI 10.1111/j.8755-8920.2001.450309.x; Vega-Ostertag M, 2005, ARTHRITIS RHEUM-US, V52, P1545, DOI 10.1002/art.21009; Wahl DG, 2000, ARCH INTERN MED, V160, P2042, DOI 10.1001/archinte.160.13.2042; Weitz JI, 2008, CHEST, V133, p234S, DOI 10.1378/chest.08-0673; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; Yetman DL, 1996, FERTIL STERIL, V66, P540, DOI 10.1016/S0015-0282(16)58565-3	124	518	548	0	67	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2010	376	9751					1498	1509		10.1016/S0140-6736(10)60709-X	http://dx.doi.org/10.1016/S0140-6736(10)60709-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QC	20822807				2022-12-28	WOS:000284248500033
J	Lipner, RS; Lucey, CR				Lipner, Rebecca S.; Lucey, Catherine R.			Putting the Secure Examination to the Test	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CERTIFICATION; CARE		[Lipner, Rebecca S.] Amer Board Internal Med, Philadelphia, PA 19106 USA; [Lucey, Catherine R.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA	American Board of Internal Medicine; Ohio State University	Lipner, RS (corresponding author), Amer Board Internal Med, 510 Walnut St,Ste 1700, Philadelphia, PA 19106 USA.	rlipner@abim.org						[American Educational Research Association American Psychological Association National Council on Measurement in Education], 1999, STAND ED PSYCH TEST; [Anonymous], 2006, ED MEASUREMENT; Drazen JM, 2010, NEW ENGL J MED, V362, P946, DOI 10.1056/NEJMe1000174; Eva KW, 2008, J CONTIN EDUC HEALTH, V28, P14, DOI 10.1002/chp.150; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; Graber ML, 2005, ARCH INTERN MED, V165, P1493, DOI 10.1001/archinte.165.13.1493; Hawkins R. E., 2008, PRACTICAL GUIDE EVAL, P42; Heijne-Penninga M, 2008, MED EDUC, V42, P967, DOI 10.1111/j.1365-2923.2008.03125.x; Holmboe ES, 2008, ARCH INTERN MED, V168, P1396, DOI 10.1001/archinte.168.13.1396; Turchin A, 2008, CIRCULATION, V117, P623, DOI 10.1161/CIRCULATIONAHA.107.733949	10	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1379	1380		10.1001/jama.2010.1378	http://dx.doi.org/10.1001/jama.2010.1378			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858883				2022-12-28	WOS:000282007900023
J	Ray, S; Delaney, M; Muller, AF				Ray, S.; Delaney, M.; Muller, A. F.			Lesson of the Week Proton pump inhibitors and acute interstitial nephritis	BRITISH MEDICAL JOURNAL			English	Article							SECONDARY; RISK		[Ray, S.; Muller, A. F.] E Kent Univ Hosp NHS Fdn Trust, Kent & Canterbury Hosp, Dept Gastroenterol, Canterbury CT1 3NG, England; [Delaney, M.] E Kent Univ Hosp NHS Fdn Trust, Kent & Canterbury Hosp, Renal Med, Canterbury CT1 3NG, England	University of Kent; University of Kent	Muller, AF (corresponding author), E Kent Univ Hosp NHS Fdn Trust, Kent & Canterbury Hosp, Dept Gastroenterol, Canterbury CT1 3NG, England.	andrew.muller@ekht.nhs.uk						Aseeri M, 2008, AM J GASTROENTEROL, V103, P2308, DOI 10.1111/j.1572-0241.2008.01975.x; Epstein M, 2006, NEW ENGL J MED, V355, P1834, DOI 10.1056/NEJMc066308; Geevasinga N, 2005, MED J AUSTRALIA, V182, P235, DOI 10.5694/j.1326-5377.2005.tb06675.x; Geevasinga N, 2005, NEPHROLOGY, V10, P7, DOI 10.1111/j.1440-1797.2005.00365.x; Kaye JA, 2008, PHARMACOTHERAPY, V28, P951, DOI 10.1592/phco.28.8.951; Kodner CM, 2003, AM FAM PHYSICIAN, V67, P2527; NEELAKANTAPPA K, 1993, AM J KIDNEY DIS, V22, P333, DOI 10.1016/S0272-6386(12)70327-X; Ray S, 2009, GASTROENTEROLOGY, V136, pA439; Ricketson J, 2009, CAN MED ASSOC J, V180, P535, DOI 10.1503/cmaj.080456; RUFFENACH SJ, 1992, AM J MED, V93, P472, DOI 10.1016/0002-9343(92)90181-A; Sierra F, 2007, ALIMENT PHARM THER, V26, P545, DOI 10.1111/j.1365-2036.2007.03407.x; Simpson IJ, 2006, NEPHROLOGY, V11, P381, DOI 10.1111/j.1440-1797.2006.00651.x; Torpey N, 2004, NEPHROL DIAL TRANSPL, V19, P1441, DOI 10.1093/ndt/gfh137; WEISS RA, 1994, J EXP MED, V180, P2239, DOI 10.1084/jem.180.6.2239	14	21	24	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 22	2010	341								c4412	10.1136/bmj.c4412	http://dx.doi.org/10.1136/bmj.c4412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TK	20861097				2022-12-28	WOS:000282272200021
J	Jankowski, J; Barr, H; Wang, K; Delaney, B				Jankowski, Janusz; Barr, Hugh; Wang, Ken; Delaney, Brendan			Diagnosis and management of Barrett's oesophagus	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GASTROESOPHAGEAL-REFLUX DISEASE; PHOTODYNAMIC THERAPY; ADENOCARCINOMA; SURVEILLANCE; METAPLASIA; PREVALENCE; MORTALITY; ABLATION; CANCER		[Jankowski, Janusz] Univ Oxford, Gastrointest Oncol Grp, Oxford, England; [Jankowski, Janusz] Queen Mary Univ London, Blizard Inst, Ctr Digest Dis, London, England; [Jankowski, Janusz] Univ Hosp Leicester, Digest Dis Ctr, Leicester, Leics, England; [Barr, Hugh] Cranfield Univ, Cranfield Hlth, Cranfield, Beds, England; [Wang, Ken] Mayo Clin, Adv Endoscop Grp & Esophag Neoplasia, Rochester, MN USA; [Delaney, Brendan] Kings Coll London, Dept Primary Care & Publ Hlth Sci, London, England	University of Oxford; University of London; Queen Mary University London; University Hospitals of Leicester NHS Trust; University of Leicester; Cranfield University; Mayo Clinic; University of London; King's College London	Jankowski, J (corresponding author), Univ Oxford, Gastrointest Oncol Grp, Oxford, England.	j.a.jankowski@qmul.ac.uk	Jankowski, Janusz/H-2706-2012; Barr, Hugh/G-4673-2014	Jankowski, Janusz/0000-0003-2130-9181; Barr, Hugh/0000-0002-2919-5660; Delaney, Brendan/0000-0002-3518-0131	National Institute for Health Research [05/12/01] Funding Source: researchfish; Cancer Research UK Funding Source: Medline; Wellcome Trust Funding Source: Medline; Department of Health [05/12/01] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome Trust); Department of Health		*BARR DYSPL CANC T, INT CONS MAN DYSPL B; *BRIT SOC GASTR, 2005, GUID DIAGN MAN BARR; Cook MB, 2007, CANCER EPIDEM BIOMAR, V16, P2090, DOI 10.1158/1055-9965.EPI-07-0432; Das D, 2008, AM J GASTROENTEROL, V103, P1079, DOI 10.1111/j.1572-0241.2008.01790.x; Das D, 2009, RECENT RES CANCER, V181, P161; Epstein D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2576; Gerson LB, 2009, GASTROINTEST ENDOSC, V70, P867, DOI 10.1016/j.gie.2009.04.053; Hage M, 2004, GUT, V53, P785, DOI 10.1136/gut.2003.028860; Inadomi JM, 2009, GASTROENTEROLOGY, V136, P2101, DOI 10.1053/j.gastro.2009.02.062; Jankowski JA, 1999, AM J PATHOL, V154, P965, DOI 10.1016/S0002-9440(10)65346-1; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5; Jankowski JA, 2002, GASTROENTEROLOGY, V122, P588, DOI 10.1053/gast.2002.31599; Jankowski JA, 2009, AM J GASTROENTEROL, V104, P1093, DOI 10.1038/ajg.2008.172; Leedham SJ, 2008, GUT, V57, P1041, DOI 10.1136/gut.2007.143339; Leedham S, 2007, AM J GASTROENTEROL, V102, P21, DOI 10.1111/j.1572-0241.2006.01033.x; Moayyedi P, 2008, ALIMENT PHARM THERAP, V27, P316, DOI 10.1111/j.1365-2036.2007.03582.x; Moayyedi P, 2006, LANCET, V367, P2086, DOI 10.1016/S0140-6736(06)68932-0; *NAT I HLTH CLIN E, 2005, DYSPL MAN DYSP AD PR; *NAT I HLTH CLIN E, 2010, ABL THER TREATM BARR; Obszynska JA, 2010, GUT, V59, P156, DOI 10.1136/gut.2009.186775; Overholt BF, 2007, GASTROINTEST ENDOSC, V66, P460, DOI 10.1016/j.gie.2006.12.037; Peng S, 2009, ENDOSCOPY, V41, P1011, DOI 10.1055/s-0029-1215291; Robertson EV, 2008, AM J GASTROENTEROL, V103, P443, DOI 10.1111/j.1572-0241.2007.01574.x; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Rubenstein JH, 2008, GASTROINTEST ENDOSC, V68, P849, DOI 10.1016/j.gie.2008.02.062; Shaheen NJ, 2009, NEW ENGL J MED, V360, P2277, DOI 10.1056/NEJMoa0808145; Shaheen NJ, 2009, LANCET, V373, P850, DOI 10.1016/S0140-6736(09)60487-6; Sharma P, 2004, GASTROENTEROLOGY, V127, P310, DOI 10.1053/j.gastro.2004.04.010; Sharma P, 2006, GASTROENTEROLOGY, V131, P1392, DOI 10.1053/j.gastro.2006.08.032; Spechler SJ, 2010, GASTROENTEROLOGY, V138, P854, DOI 10.1053/j.gastro.2010.01.002; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x; Wang KK, 2008, AM J GASTROENTEROL, V103, P788, DOI 10.1111/j.1572-0241.2008.01835.x; Wong T, 2010, AM J MED, V123, P462, DOI 10.1016/j.amjmed.2009.10.013; FIGHT OESOPHAGEAL RE	35	38	38	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 10	2010	341								c4551	10.1136/bmj.c4551	http://dx.doi.org/10.1136/bmj.c4551			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649ZL	20833742	Green Published			2022-12-28	WOS:000281815200002
J	Korzhnev, DM; Religa, TL; Banachewicz, W; Fersht, AR; Kay, LE				Korzhnev, Dmitry M.; Religa, Tomasz L.; Banachewicz, Wiktor; Fersht, Alan R.; Kay, Lewis E.			A Transient and Low-Populated Protein-Folding Intermediate at Atomic Resolution	SCIENCE			English	Article							DISPERSION NMR-SPECTROSCOPY; ON-PATHWAY INTERMEDIATE; TIME-SCALE DYNAMICS; RELAXATION DISPERSION; CHEMICAL-SHIFTS; FF DOMAIN; ACCURATE MEASUREMENT; STRUCTURE GENERATION; TRANSITION-STATE; EXCHANGE	Proteins can sample conformational states that are critical for function but are seldom detected directly because of their low occupancies and short lifetimes. In this work, we used chemical shifts and bond-vector orientation constraints obtained from nuclear magnetic resonance relaxation dispersion spectroscopy, in concert with a chemical shift-based method for structure elucidation, to determine an atomic-resolution structure of an "invisible" folding intermediate of a small protein module: the FF domain. The structure reveals non-native elements preventing formation of the native conformation in the carboxyl-terminal part of the protein. This is consistent with the kinetics of folding in which a well-structured intermediate forms rapidly and then rearranges slowly to the native state. The approach introduces a general strategy for structure determination of low-populated and transiently formed protein states.	[Korzhnev, Dmitry M.; Religa, Tomasz L.; Kay, Lewis E.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada; [Korzhnev, Dmitry M.; Religa, Tomasz L.; Kay, Lewis E.] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; [Korzhnev, Dmitry M.; Religa, Tomasz L.; Kay, Lewis E.] Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada; [Banachewicz, Wiktor; Fersht, Alan R.] MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Toronto; University of Toronto; University of Toronto; University of Cambridge	Kay, LE (corresponding author), Univ Toronto, Dept Mol Genet, 100 Coll St, Toronto, ON M5S 1A8, Canada.	kay@pound.med.utoronto.ca	Fersht, Alan R/B-2189-2008		European Molecular Biology Organization [ALTF 827-2006]; Canadian Institutes of Health Research (CIHR); Medical Research Council [MC_U105484373] Funding Source: researchfish; MRC [MC_U105484373] Funding Source: UKRI	European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank J. Forman-Kay (Hospital for Sick Children, Toronto) for providing laboratory space and useful discussions, P. Jemth (Uppsala Univ.) for providing plasmids for protein expression, R. Vernon (Univ. of Washington, Seattle) for valuable discussions, and R. Muhandiram (Univ. of Toronto) for NMR support. T.L.R. acknowledges the European Molecular Biology Organization (ALTF 827-2006) and the Canadian Institutes of Health Research (CIHR) for postdoctoral fellowships. L.E.K. holds a Canada Research Chair in Biochemistry. This work was supported by a grant from the CIHR to L.E.K. The structural ensembles of the WT FF domain-folding intermediate have been deposited in the Protein Data Bank (PDB; www.rcsb.org) with accession code 2KZG.	Allen M, 2002, J MOL BIOL, V323, P411, DOI 10.1016/S0022-2836(02)00968-3; Auer S, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.178104; Baldwin AJ, 2009, NAT CHEM BIOL, V5, P808, DOI 10.1038/nchembio.238; BAX A, 1994, CURR OPIN STRUC BIOL, V4, P738, DOI 10.1016/S0959-440X(94)90173-2; Berjanskii MV, 2005, J AM CHEM SOC, V127, P14970, DOI 10.1021/ja054842f; Brockwell DJ, 2007, CURR OPIN STRUC BIOL, V17, P30, DOI 10.1016/j.sbi.2007.01.003; Capaldi AP, 2002, NAT STRUCT BIOL, V9, P209, DOI 10.1038/nsb757; Cavalli A, 2007, P NATL ACAD SCI USA, V104, P9615, DOI 10.1073/pnas.0610313104; Daggett V, 2003, NAT REV MOL CELL BIO, V4, P497, DOI 10.1038/nrm1126; Das R, 2008, ANNU REV BIOCHEM, V77, P363, DOI 10.1146/annurev.biochem.77.062906.171838; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Englander SW, 2007, Q REV BIOPHYS, V40, P287, DOI 10.1017/S0033583508004654; Feng HQ, 2005, P NATL ACAD SCI USA, V102, P5026, DOI 10.1073/pnas.0501372102; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Hansen DF, 2008, J PHYS CHEM B, V112, P5898, DOI 10.1021/jp074793o; Hansen DF, 2008, J AM CHEM SOC, V130, P2667, DOI 10.1021/ja078337p; Igumenova TI, 2007, J AM CHEM SOC, V129, P13396, DOI 10.1021/ja0761636; Ishima R, 2004, J BIOMOL NMR, V29, P187, DOI 10.1023/B:JNMR.0000019249.50306.5d; Ishima R, 2003, J BIOMOL NMR, V25, P243, DOI 10.1023/A:1022851228405; Jemth P, 2005, J MOL BIOL, V350, P363, DOI 10.1016/j.jmb.2005.04.067; Jemth P, 2004, P NATL ACAD SCI USA, V101, P6450, DOI 10.1073/pnas.0401732101; Jemth P, 2008, PROTEIN ENG DES SEL, V21, P207, DOI 10.1093/protein/gzm091; Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655; Korzhnev DM, 2008, ACCOUNTS CHEM RES, V41, P442, DOI 10.1021/ar700189y; Korzhnev DM, 2007, J MOL BIOL, V372, P497, DOI 10.1016/j.jmb.2007.06.012; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; Lundstrom P, 2008, J BIOMOL NMR, V42, P35, DOI 10.1007/s10858-008-9260-4; Lundstrom P, 2009, J AM CHEM SOC, V131, P1915, DOI 10.1021/ja807796a; Lundstrom P, 2007, J BIOMOL NMR, V38, P199, DOI 10.1007/s10858-007-9158-6; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; McCully ME, 2010, BIOPHYS J, V99, P1628, DOI 10.1016/j.bpj.2010.06.040; Neudecker P, 2007, P NATL ACAD SCI USA, V104, P15717, DOI 10.1073/pnas.0705097104; Orekhov VY, 2004, J AM CHEM SOC, V126, P1886, DOI 10.1021/ja038620y; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; Raman S, 2010, SCIENCE, V327, P1014, DOI 10.1126/science.1183649; Religa TL, 2005, NATURE, V437, P1053, DOI 10.1038/nature04054; Religa TL, 2007, P NATL ACAD SCI USA, V104, P9272, DOI 10.1073/pnas.0703434104; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Shen Y, 2008, P NATL ACAD SCI USA, V105, P4685, DOI 10.1073/pnas.0800256105; Shen Y, 2007, J BIOMOL NMR, V38, P289, DOI 10.1007/s10858-007-9166-6; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; Skrynnikov NR, 2002, J AM CHEM SOC, V124, P12352, DOI 10.1021/ja0207089; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Vallurupalli P, 2008, P NATL ACAD SCI USA, V105, P11766, DOI 10.1073/pnas.0804221105; Vallurupalli P, 2007, P NATL ACAD SCI USA, V104, P18473, DOI 10.1073/pnas.0708296104; Wensley BG, 2010, NATURE, V463, P685, DOI 10.1038/nature08743; Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pW496, DOI 10.1093/nar/gkn305; Wishart DS, 2001, METHOD ENZYMOL, V338, P3	49	237	238	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1312	1316		10.1126/science.1191723	http://dx.doi.org/10.1126/science.1191723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829478				2022-12-28	WOS:000281657300029
J	Jha, AK; Orav, EJ; Epstein, AM				Jha, Ashish K.; Orav, E. John; Epstein, Arnold M.			The Effect of Financial Incentives on Hospitals That Serve Poor Patients	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; PAY-FOR-PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; SAFETY-NET HOSPITALS; HEALTH-CARE; DISPARITIES; PROGRAMS	Background: Providing financial incentives to hospitals to improve quality is increasingly common, yet its effect on hospitals that care for poor patients is largely unknown. Objective: To determine how financial incentives for quality performance affect hospitals with more poor patients compared with those with fewer poor patients. Design: Retrospective study. Setting: U. S. hospitals. Participants: 251 hospitals that participated in the Premier Hospital Quality Incentive Demonstration program and a national sample of 3017 hospitals. Measurements: The association between the disproportionate-share index, a marker of caring for poor patients, and baseline quality performance, changes in performance, and terminal performance for acute myocardial infarction, congestive heart failure, and pneumonia for hospitals in the pay-for-performance program and those in the national sample (which did not receive financial incentives). Results: Among both pay-for-performance hospitals and those in the national sample, hospitals with more poor patients had lower baseline performance than did those with fewer poor patients. A high disproportionate-share index was associated with greater improvements in performance for acute myocardial infarction and pneumonia but not for congestive heart failure, and the gains were greater among hospitals that received financial incentives than among the national sample. After 3 years, hospitals that had more poor patients and received financial incentives caught up for all 3 conditions, whereas those with more poor patients among the national sample continued to lag. Limitation: Hospitals in the Premier Hospital Quality Incentive Demonstration may be atypical, and these results may not be generalizable to all hospitals. Conclusion: No evidence indicated that financial incentives widened the gap in performance between hospitals that serve poor patients and other hospitals. Pay-for-performance programs may be a promising quality improvement strategy for hospitals that serve poor patients.	Brigham & Womens Hosp, Sch Publ Hlth, Boston, MA 02115 USA; US Dept Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Jha, AK (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	ajha@hsph.harvard.edu			Changes in Health Care Financing and Organization Initiative of the Robert Wood Johnson Foundation	Changes in Health Care Financing and Organization Initiative of the Robert Wood Johnson Foundation	Grant Support: By the Changes in Health Care Financing and Organization Initiative of the Robert Wood Johnson Foundation (grant 63743).	Casalino LP, 2007, HEALTH AFFAIR, V26, pW405, DOI 10.1377/hlthaff.26.3.w405; Chien AT, 2007, MED CARE RES REV, V64, p283S, DOI 10.1177/1077558707305426; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; Glickman SW, 2007, JAMA-J AM MED ASSOC, V297, P2373, DOI 10.1001/jama.297.21.2373; Goldman LE, 2007, MED CARE, V45, P579, DOI 10.1097/MLR.0b013e318041f723; Jha AK, 2005, NEW ENGL J MED, V353, P265, DOI 10.1056/NEJMsa051249; Jha AK, 2007, ARCH INTERN MED, V167, P1177, DOI 10.1001/archinte.167.11.1177; Kahn CN, 2006, HEALTH AFFAIR, V25, P148, DOI 10.1377/hlthaff.25.1.148; LEE JS, 2003, HLTH AFF MILLWOOD S; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Rogowski J, 2007, HEALTH SERV RES, V42, P682, DOI 10.1111/j.1475-6773.2006.00631.x; Rosenthal MB, 2006, NEW ENGL J MED, V355, P1895, DOI 10.1056/NEJMsa063682; Ross JS, 2007, HEALTH AFFAIR, V26, P238, DOI 10.1377/hlthaff.26.1.238; Werner RM, 2008, JAMA-J AM MED ASSOC, V299, P2180, DOI 10.1001/jama.299.18.2180	15	59	60	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2010	153	5					299	U47		10.7326/0003-4819-153-5-201009070-00004	http://dx.doi.org/10.7326/0003-4819-153-5-201009070-00004			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647GF	20820039				2022-12-28	WOS:000281605500003
J	Mehta, SR; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KAA; Granger, CB; Jolly, S; Joyner, CD; Rupprecht, HJ; Widimsky, P; Afzal, R; Pogue, J; Yusuf, S				Mehta, Shamir R.; Bassand, Jean-Pierre; Chrolavicius, Susan; Diaz, Rafael; Eikelboom, John W.; Fox, Keith A. A.; Granger, Christopher B.; Jolly, Sanjit; Joyner, Campbell D.; Rupprecht, Hans-Jurgen; Widimsky, Petr; Afzal, Rizwan; Pogue, Janice; Yusuf, Salim		CURRENT-OASIS 7 Investigators	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; PLATELET INHIBITION; EUROPEAN-SOCIETY; UNSTABLE ANGINA; DOUBLE-BLIND; TASK-FORCE; ST; INTERVENTION; 600-MG	BACKGROUND Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidence-based guidelines for dosing have not been established for either agent. METHODS We randomly assigned, in a 2-by-2 factorial design, 25,086 patients with an acute coronary syndrome who were referred for an invasive strategy to either double-dose clopidogrel (a 600-mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter) or standard-dose clopidogrel (a 300-mg loading dose and 75 mg daily thereafter) and either higher-dose aspirin (300 to 325 mg daily) or lower-dose aspirin (75 to 100 mg daily). The primary outcome was cardiovascular death, myocardial infarction, or stroke at 30 days. RESULTS The primary outcome occurred in 4.2% of patients assigned to double-dose clopidogrel as compared with 4.4% assigned to standard-dose clopidogrel (hazard ratio, 0.94; 95% confidence interval [CI], 0.83 to 1.06; P = 0.30). Major bleeding occurred in 2.5% of patients in the double-dose group and in 2.0% in the standard-dose group (hazard ratio, 1.24; 95% CI, 1.05 to 1.46; P = 0.01). Double-dose clopidogrel was associated with a significant reduction in the secondary outcome of stent thrombosis among the 17,263 patients who underwent PCI (1.6% vs. 2.3%; hazard ratio, 0.68; 95% CI, 0.55 to 0.85; P = 0.001). There was no significant difference between higher-dose and lower-dose aspirin with respect to the primary outcome (4.2% vs. 4.4%; hazard ratio, 0.97; 95% CI, 0.86 to 1.09; P = 0.61) or major bleeding (2.3% vs. 2.3%; hazard ratio, 0.99; 95% CI, 0.84 to 1.17; P = 0.90). CONCLUSIONS In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke.	[Mehta, Shamir R.; Chrolavicius, Susan; Eikelboom, John W.; Jolly, Sanjit; Afzal, Rizwan; Pogue, Janice; Yusuf, Salim] Hamilton Hlth Sci, Vasc & Stroke Inst, Hamilton, ON L8L 2X2, Canada; [Mehta, Shamir R.; Chrolavicius, Susan; Eikelboom, John W.; Jolly, Sanjit; Afzal, Rizwan; Pogue, Janice; Yusuf, Salim] McMaster Univ, Hamilton, ON, Canada; [Bassand, Jean-Pierre] Univ Hosp Jean Minjoz, Besancon, France; [Diaz, Rafael] Estudios Clin Latinoamer, Rosario, Santa Fe, Argentina; [Fox, Keith A. A.] Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland; [Granger, Christopher B.] Duke Clin Res Inst, Durham, NC USA; [Joyner, Campbell D.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Rupprecht, Hans-Jurgen] Second Med Clin, Russelsheim, Germany; [Widimsky, Petr] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic	McMaster University; McMaster University; Universite de Franche-Comte; CHU Besancon; Royal Infirmary of Edinburgh; University of Edinburgh; Duke University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University Hospital Vinohrady	Mehta, SR (corresponding author), Hamilton Hlth Sci, Vasc & Stroke Inst, Rm 3-119,237 Barton St E, Hamilton, ON L8L 2X2, Canada.	smehta@mcmaster.ca	Thompson, Peter L/P-1071-2014; Avanzas, Pablo/B-6811-2008; Widimsky, Petr/P-8088-2016; Granger, Christopher B/D-3458-2014; Benedek, Imre/E-7052-2017; Fox, keith A A/I-3742-2013; Kubica, Jacek/D-6906-2014; Jolly, Sanjit/O-2534-2015; Benedek, Theodora/F-6353-2016; Colquhoun, David M/F-9078-2013; Eikelboom, John/AAG-6117-2019; Fernandez-Ortiz, Antonio/B-2227-2017	Avanzas, Pablo/0000-0002-4958-6108; Widimsky, Petr/0000-0001-5686-7752; Granger, Christopher B/0000-0002-0045-3291; Benedek, Imre/0000-0003-0051-4047; Kubica, Jacek/0000-0001-8250-754X; Benedek, Theodora/0000-0001-8326-1537; Eikelboom, John/0000-0003-4126-1285; Fernandez-Ortiz, Antonio/0000-0002-3239-1910; Baumbach, Andreas/0000-0001-7707-2254; Airaksinen, Juhani/0000-0002-0193-568X; Lopez-Palop, Ramon/0000-0003-4385-7939; Naslund, Ulf/0000-0003-4100-8298; Yusuf, Salim/0000-0003-4776-5601; Fox, Keith/0000-0002-0140-2752; Lanas, Fernando/0000-0003-3595-9759	Sanofi-Aventis; Bristol-Myers Squibb	Sanofi-Aventis(Sanofi-Aventis); Bristol-Myers Squibb(Bristol-Myers Squibb)	Supported by Sanofi-Aventis and Bristol-Myers Squibb.	Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Angiolillo DJ, 2004, EUR HEART J, V25, P1903, DOI 10.1016/j.ehj.2004.07.036; Angiolillo DJ, 2007, CIRCULATION, V115, P708, DOI 10.1161/CIRCULATIONAHA.106.667741; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Bhatt DL, 2009, NEW ENGL J MED, V361, P2330, DOI 10.1056/NEJMoa0908629; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; Cuisset T, 2006, J AM COLL CARDIOL, V48, P1339, DOI 10.1016/j.jacc.2006.06.049; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Fox KAA, 2004, CIRCULATION, V110, P1202, DOI 10.1161/01.CIR.0000140675.85342.1B; Harrington RA, 2008, CHEST, V133, p670S, DOI 10.1378/chest.08-0691; Harrington RA, 2009, NEW ENGL J MED, V361, P2318, DOI 10.1056/NEJMoa0908628; Hochholzer W, 2005, CIRCULATION, V111, P2560, DOI 10.1161/01.CIR.0000160869.75810.98; King Spencer B 3rd, 2008, J Am Coll Cardiol, V51, P172, DOI 10.1016/j.jacc.2007.10.002; Lotrionte M, 2007, AM J CARDIOL, V100, P1199, DOI 10.1016/j.amjcard.2007.05.048; Mehta SR, 2008, AM HEART J, V156, P1080, DOI 10.1016/j.ahj.2008.07.026; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Montalescot G, 2006, J AM COLL CARDIOL, V48, P931, DOI 10.1016/j.jacc.2006.04.090; Muller I, 2001, HEART, V85, P92, DOI 10.1136/heart.85.1.92; Patrono C, 2005, NEW ENGL J MED, V353, P2373, DOI 10.1056/NEJMra052717; Patti G, 2005, CIRCULATION, V111, P2099, DOI 10.1161/01.CIR.0000161383.06692.D4; Peters RJG, 2003, CIRCULATION, V108, P1682, DOI 10.1161/01.CIR.0000091201.39590.CB; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Sabatine MS, 2005, JAMA-J AM MED ASSOC, V294, P1224, DOI 10.1001/jama.294.10.1224; Silber S, 2005, EUR HEART J, V26, P804, DOI 10.1093/eurheartj/ehi138; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Topol EJ, 2003, CIRCULATION, V108, P399, DOI 10.1161/01.CIR.0000084501.48570.F6; von Beckerath N, 2005, CIRCULATION, V112, P2946, DOI 10.1161/CIRCULATIONAHA.105.559088; Von Beckerath N, 2007, EUR HEART J, V28, P1814, DOI 10.1093/eurheartj/ehl489; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yusuf S, 2003, CIRCULATION, V107, P966, DOI 10.1161/01.CIR.0000051362.96946.15; Yusuf S, 2001, NEW ENGL J MED, V345, P494	33	561	587	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					930	942						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818903	Bronze			2022-12-28	WOS:000281441500006
J	Mayer, M; Depken, M; Bois, JS; Julicher, F; Grill, SW				Mayer, Mirjam; Depken, Martin; Bois, Justin S.; Juelicher, Frank; Grill, Stephan W.			Anisotropies in cortical tension reveal the physical basis of polarizing cortical flows	NATURE			English	Article							C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; EARLY EMBRYOGENESIS; PROTEINS RGA-3; CELL-DIVISION; PAR PROTEINS; GERM-LINE; CYTOKINESIS; MICROFILAMENTS; MORPHOGENESIS	Asymmetric cell divisions are essential for the development of multicellular organisms. To proceed, they require an initially symmetric cell to polarize(1). In Caenorhabditis elegans zygotes, anteroposterior polarization is facilitated by a large-scale flow of the actomyosin cortex(2-4), which directs the asymmetry of the first mitotic division. Cortical flows appear in many contexts of development(5), but their underlying forces and physical principles remain poorly understood. How actomyosin contractility and cortical tension interact to generate large-scale flow is unclear. Here we report on the subcellular distribution of cortical tension in the polarizing C. elegans zygote, which we determined using position- and direction-sensitive laser ablation. We demonstrate that cortical flow is associated with anisotropies in cortical tension and is not driven by gradients in cortical tension, which contradicts previous proposals(5). These experiments, in conjunction with a theoretical description of active cortical mechanics, identify two prerequisites for large-scale cortical flow: a gradient in actomyosin contractility to drive flow and a sufficiently large viscosity of the cortex to allow flow to be long-ranged. We thus reveal the physical requirements of large-scale intracellular cortical flow that ensure the efficient polarization of the C. elegans zygote.	[Mayer, Mirjam; Depken, Martin; Bois, Justin S.; Grill, Stephan W.] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; [Mayer, Mirjam; Depken, Martin; Bois, Justin S.; Juelicher, Frank; Grill, Stephan W.] Max Planck Inst Phys Komplexer Syst, D-01187 Dresden, Germany	Max Planck Society; Max Planck Society	Grill, SW (corresponding author), Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany.	grill@mpi-cbg.de	Julicher, Frank/B-1828-2009; Grill, Stephan/D-9427-2012	Julicher, Frank/0000-0003-4731-9185; Bois, Justin/0000-0001-7137-8746	Boehringer Ingelheim Fonds; Human Frontier Science Program	Boehringer Ingelheim Fonds(Boehringer Ingelheim); Human Frontier Science Program(Human Frontier Science Program)	We thank C. Cowan, N. Goehring, P. Gonczy, J. Howard, T. Hyman, M. Loose, F. Nedelec and K. Oegema for advice and suggestions on the manuscript. We are grateful to E. Munro for scientific advice, worm strains and discussions. M. M. is supported by a predoctoral fellowship from the Boehringer Ingelheim Fonds, and J.S.B. by a postdoctoral fellowship from the Human Frontier Science Program.	BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRENNER S, 1974, GENETICS, V77, P71; Cheeks RJ, 2004, CURR BIOL, V14, P851, DOI 10.1016/j.cub.2004.05.022; Cowan CR, 2004, NATURE, V431, P92, DOI 10.1038/nature02825; Dai JW, 1999, BIOPHYS J, V77, P1168, DOI 10.1016/S0006-3495(99)76968-7; Daniels BR, 2006, BIOPHYS J, V90, P4712, DOI 10.1529/biophysj.105.080606; Gardel ML, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.088102; Gardel ML, 2004, SCIENCE, V304, P1301, DOI 10.1126/science.1095087; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Goldstein B, 1996, DEVELOPMENT, V122, P1467; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HIRAMOTO Y, 1970, Biorheology, V6, P201; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Humphrey D, 2002, NATURE, V416, P413, DOI 10.1038/416413; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Kruse K, 2005, EUR PHYS J E, V16, P5, DOI 10.1140/epje/e2005-00002-5; Lecuit T, 2007, NAT REV MOL CELL BIO, V8, P633, DOI 10.1038/nrm2222; Lieleg O, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.108101; Mandato CA, 2001, J CELL BIOL, V154, P785, DOI 10.1083/jcb.200103105; Motegi F, 2006, DEV CELL, V10, P509, DOI 10.1016/j.devcel.2006.03.001; Motegi F, 2006, NAT CELL BIOL, V8, P978, DOI 10.1038/ncb1459; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Munro E, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003400; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Raffel M, 2007, EXP FLUID MECH, P1, DOI 10.1007/978-3-540-72308-0; Rauzi M, 2008, NAT CELL BIOL, V10, P1401, DOI 10.1038/ncb1798; Salbreux G, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.058102; Schmutz C, 2007, DEVELOPMENT, V134, P3495, DOI 10.1242/dev.000802; Schonegg S, 2007, P NATL ACAD SCI USA, V104, P14976, DOI 10.1073/pnas.0706941104; Shelton CA, 1996, DEVELOPMENT, V122, P2043; Simha RA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.058101; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1988, BIOESSAYS, V8, P145, DOI 10.1002/bies.950080504; SVEEN J, 2004, ADV COASTAL OCEAN EN, V9, pCH1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Velarde N, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-142; Wottawah F, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.098103; Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592; Zhang WD, 2005, P NATL ACAD SCI USA, V102, P7186, DOI 10.1073/pnas.0502545102; Zonies S, 2010, DEVELOPMENT, V137, P1669, DOI 10.1242/dev.045823	47	326	334	4	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP	2010	467	7315					617	U150		10.1038/nature09376	http://dx.doi.org/10.1038/nature09376			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20852613				2022-12-28	WOS:000282273100045
J	Vorosmarty, CJ; McIntyre, PB; Gessner, MO; Dudgeon, D; Prusevich, A; Green, P; Glidden, S; Bunn, SE; Sullivan, CA; Liermann, CR; Davies, PM				Voeroesmarty, C. J.; McIntyre, P. B.; Gessner, M. O.; Dudgeon, D.; Prusevich, A.; Green, P.; Glidden, S.; Bunn, S. E.; Sullivan, C. A.; Liermann, C. Reidy; Davies, P. M.			Global threats to human water security and river biodiversity	NATURE			English	Article							AMERICAN FRESH-WATER; MARINE; VULNERABILITY; INDICATORS; RESOURCES; MAP	Protecting the world's freshwater resources requires diagnosing threats over a broad range of scales, from global to local. Here we present the first worldwide synthesis to jointly consider human and biodiversity perspectives on water security using a spatial framework that quantifies multiple stressors and accounts for downstream impacts. We find that nearly 80% of the world's population is exposed to high levels of threat to water security. Massive investment in water technology enables rich nations to offset high stressor levels without remedying their underlying causes, whereas less wealthy nations remain vulnerable. A similar lack of precautionary investment jeopardizes biodiversity, with habitats associated with 65% of continental discharge classified as moderately to highly threatened. The cumulative threat framework offers a tool for prioritizing policy and management responses to this crisis, and underscores the necessity of limiting threats at their source instead of through costly remediation of symptoms in order to assure global water security for both humans and freshwater biodiversity.	[Voeroesmarty, C. J.; Green, P.] CUNY City Coll, Environm CrossRd Initiat, New York, NY 10035 USA; [McIntyre, P. B.] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA; [Gessner, M. O.] Swiss Fed Inst Technol, Eawag Swiss Fed Inst Aquat Sci & Technol, Dept Aquat Ecol, CH-8600 Dubendorf, Switzerland; [Gessner, M. O.] Swiss Fed Inst Technol, Inst Integrat Biol IBZ, CH-8600 Dubendorf, Switzerland; [Gessner, M. O.] Leibniz Inst Freshwater Ecol & Inland Fisheries I, D-16775 Stechlin, Germany; [Dudgeon, D.] Univ Hong Kong, Sch Biol Sci, Div Ecol & Biodivers, Hong Kong, Hong Kong, Peoples R China; [Prusevich, A.; Glidden, S.] Univ New Hampshire, Water Syst Anal Grp, Durham, NH 03824 USA; [Bunn, S. E.] Griffith Univ, Australian Rivers Inst, Nathan, Qld 4111, Australia; [Sullivan, C. A.] So Cross Univ, Sch Environm Sci & Management, Lismore, NSW 2480, Australia; [Liermann, C. Reidy] Univ Washington, Sch Aquat & Fishery Sci, Seattle, WA 98195 USA; [Davies, P. M.] Univ Western Australia, Ctr Excellence Nat Resource Management, Albany 6330, Australia	City University of New York (CUNY) System; City College of New York (CUNY); University of Michigan System; University of Michigan; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Leibniz Institut fur Gewasserokologie und Binnenfischerei (IGB); University of Hong Kong; University System Of New Hampshire; University of New Hampshire; Griffith University; Southern Cross University; University of Washington; University of Washington Seattle; University of Western Australia	Vorosmarty, CJ (corresponding author), CUNY City Coll, Environm CrossRd Initiat, New York, NY 10035 USA.	contact@riverthreat.net	Quinn, Patrick/B-5489-2010; Hu, Lile/E-7961-2015; Davies, Peter M/C-3518-2013; Bunn, Stuart E/B-9065-2008; Sullivan, Caroline/T-8668-2017	Bunn, Stuart E/0000-0002-6540-3586; Sullivan, Caroline/0000-0001-8486-0523; Gessner, Mark O./0000-0003-2516-7416; Prusevich, Alexander/0000-0002-9529-443X	NASA [NNX07AF28G]; NSF Division of Earth Sciences [0854957]; Global Environment Facility [UPI 00345306]; D.H. Smith Fellowship	NASA(National Aeronautics & Space Administration (NASA)); NSF Division of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Global Environment Facility; D.H. Smith Fellowship	We thank A. DeSherbinin, L. Poff, C. Revenga, J. Melillo and O. Young for comments on the manuscript; D. Allan, R. Abell, J. Bogardi, M. Meybeck, W. Wollheim, R. F. Wright, D. Boswell, R. Lacey, N. Schneider and D. Vorosmarty for advice; and D. Dube and B. Fekete for technical support. Grant support for database and tool development was from NASA Inter-Disciplinary Science Program Grant NNX07AF28G, with additional support from the NSF Division of Earth Sciences (Hydrologic Sciences Program Award #0854957) and Global Environment Facility (UPI 00345306). P.B.M. was supported by a D.H. Smith Fellowship. Financial and logistical support for expert group meetings and communications was from the Global Water System Project (Bonn), DIVERSITAS-freshwaterBIODIVERSITY (Paris), NSF BestNet, and Australian Agency for International Development (AusAID) through the Australian Water Research Facility. Conference facilities were provided by the Swiss Federal Institute of Science & Technology (Eawag) and The City College of New York/CUNY.	Abell R, 2008, BIOSCIENCE, V58, P403, DOI 10.1641/B580507; Arthington AH, 2006, ECOL APPL, V16, P1311, DOI 10.1890/1051-0761(2006)016[1311:TCOPEF]2.0.CO;2; ASHLEY R, 2006, INFRASTRUCTURE 2030, pCH5; Balian EV, 2008, HYDROBIOLOGIA, V595, P627, DOI 10.1007/s10750-007-9246-3; Brooks TM, 2006, SCIENCE, V313, P58, DOI 10.1126/science.1127609; Brown Oli, 2009, RISING TEMPERATURES; Butchart SHM, 2010, SCIENCE, V328, P1164, DOI 10.1126/science.1187512; Clausen R, 2008, SOC SCI RES, V37, P1310, DOI 10.1016/j.ssresearch.2007.10.002; *CONV BIOL DIV, 2004, TEXT CONV BIOL DIV; Dinda S, 2004, ECOL ECON, V49, P431, DOI 10.1016/j.ecolecon.2004.02.011; Dudgeon D, 2006, BIOL REV, V81, P163, DOI 10.1017/S1464793105006950; Esty D.C., 2006, PILOT ENV PERFORMANC; Esty D. C., 2005, 2005 ENV SUSTAINABIL; FAO (Food and Agriculture Organization), 2006, WAT MON MAPP EX GLOB; Fekete BM, 2001, WATER RESOUR RES, V37, P1955, DOI 10.1029/2001WR900024; Freyhof J., 2007, HDB EUROPEAN FRESHWA; Gleick PH, 2003, SCIENCE, V302, P1524, DOI 10.1126/science.1089967; *GLOB ENV FAC, 2008, FIN STEW GLOB BIOD; *GLOB WAT SYST PRO, 2004, EOS AGU T, V85, P513; Grey D., 2006, WATER GROWTH DEV THE; Halpern BS, 2008, SCIENCE, V319, P948, DOI 10.1126/science.1149345; Halpern BS, 2009, CONSERV LETT, V2, P189, DOI 10.1111/j.1755-263X.2009.00060.x; International Organization of Supreme Audit Institutions (INTOSAI), 2009, INT LAB C 98 SESS GE, P1; Jelks HL, 2008, FISHERIES, V33, P372, DOI 10.1577/1548-8446-33.8.372; Karl T. R., 2009, Global climate change impacts in the United States; MEYBECK M, 2003, PHIL T R SOC LOND B; *MIN ENV PROT, 2009, STAT ENV CHIN 2008; Palmer MA, 2009, SCIENCE, V325, P575, DOI 10.1126/science.1172976; Reid W.V, 2005, MILLENNIUM ECOSYSTEM; Ricciardi A, 1999, CONSERV BIOL, V13, P1220, DOI 10.1046/j.1523-1739.1999.98380.x; Sanderson EW, 2002, BIOSCIENCE, V52, P891, DOI 10.1641/0006-3568(2002)052[0891:THFATL]2.0.CO;2; Seitzinger SP, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2005GB002606; Steffen W, 2007, AMBIO, V36, P614, DOI 10.1579/0044-7447(2007)36[614:TAAHNO]2.0.CO;2; Strayer DL, 2010, J N AM BENTHOL SOC, V29, P344, DOI 10.1899/08-171.1; Sullivan C, 2005, WATER SCI TECHNOL, V51, P69, DOI 10.2166/wst.2005.0111; Tockner K, 2009, RIVERS OF EUROPE, 1ST EDITION, P1; *UN DEV PROGR, 2006, HDR 2006 SCARC POW P; UN Environmental Programme, 2010, UNEPIPBES33; *UNEP GEMS WAT PRO, 2008, WAT QUAL EC HUM HLTH; US-Environmental Protection Agency, 2000, EPA841R02001; VOROSMARTY C. J., 2005, MILLENNIUM ECOSYSTEM, V1, P165; Vorosmarty CJ, 2000, SCIENCE, V289, P284, DOI 10.1126/science.289.5477.284; Vorosmarty CJ, 2005, AMBIO, V34, P230, DOI 10.1639/0044-7447(2005)034[0230:GIOEWS]2.0.CO;2; Vorosmarty CJ, 2002, AQUAT SCI, V64, P328, DOI 10.1007/PL00012590; WHO UNICEF, 2010, PROGR SAN DRINK WAT; *WORLD BANK, 2010, COUNTR CLASS; World Commission on Dams, 2000, DAMS DEV NEW FRAMEWO; *WORLD CONS MON CT, 1998, WCMC BIOD SER, V8; *WORLD WAT ASS PRO, 2009, WAT CHANG WORLD; Zalasiewicz J., 2008, GSA TODAY, V18, P4, DOI [DOI 10.1130/GSAT01802A.1, 10.1130/GSAT01802A.1]	50	4003	4157	147	2499	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					555	561		10.1038/nature09440	http://dx.doi.org/10.1038/nature09440			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882010	Green Submitted, Green Accepted			2022-12-28	WOS:000282273100031
J	Antiel, RM; Thompson, SM; Reed, DA; James, KM; Tilburt, JC; Bannon, MP; Fischer, PR; Farley, DR				Antiel, Ryan M.; Thompson, Scott M.; Reed, Darcy A.; James, Katherine M.; Tilburt, Jon C.; Bannon, Michael P.; Fischer, Philip R.; Farley, David R.			ACGME Duty-Hour Recommendations - A National Survey of Residency Program Directors	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PATIENT SAFETY		[Antiel, Ryan M.; Thompson, Scott M.] Mayo Clin, Mayo Med Sch, Rochester, MN 55905 USA; [Thompson, Scott M.] Mayo Clin, Mayo Clin Med Scientist Training Program, Rochester, MN USA; [Antiel, Ryan M.; Reed, Darcy A.; James, Katherine M.; Tilburt, Jon C.; Bannon, Michael P.] Mayo Clin, Mayo Clin Professionalism & Eth Program, Rochester, MN USA; [James, Katherine M.; Tilburt, Jon C.] Mayo Clin, Mayo Clin Knowledge & Encounter Res Unit, Rochester, MN USA; [Reed, Darcy A.] Mayo Clin, Div Primary Care Internal Med, Rochester, MN USA; [Tilburt, Jon C.] Mayo Clin, Div Gen Internal Med, Rochester, MN USA; [Bannon, Michael P.; Farley, David R.] Mayo Clin, Dept Surg, Rochester, MN USA; [Fischer, Philip R.] Mayo Clin, Div Pediat & Adolescent Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Antiel, RM (corresponding author), Mayo Clin, Mayo Med Sch, Rochester, MN 55905 USA.				NCRR NIH HHS [UL1 RR024150] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024150] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Britt LD, 2009, SURGERY, V146, P398, DOI 10.1016/j.surg.2009.07.002; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; Nasca TJ, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMsb1005800; Ulmer C, 2009, RESIDENT DUTY HOURS: ENHANCING SLEEP, SUPERVISION, AND SAFETY, P1; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P975, DOI 10.1001/jama.298.9.975	5	61	61	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8								10.1056/NEJMp1008305	http://dx.doi.org/10.1056/NEJMp1008305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20842785	Green Accepted			2022-12-28	WOS:000280996600004
J	Xiang, KH; Nagaike, T; Xiang, S; Kilic, T; Beh, MM; Manley, JL; Tong, LA				Xiang, Kehui; Nagaike, Takashi; Xiang, Song; Kilic, Turgay; Beh, Maia M.; Manley, James L.; Tong, Liang			Crystal structure of the human symplekin-Ssu72-CTD phosphopeptide complex	NATURE			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; ESS1 PROLYL ISOMERASE; MESSENGER-RNA; TRANSCRIPTION TERMINATION; MACROMOLECULAR STRUCTURES; POLYADENYLATION FACTOR; ANOMALOUS DIFFRACTION; SSU72; PHOSPHATASE	Symplekin (Pta1 in yeast) is a scaffold in the large protein complex that is required for 3'-end cleavage and polyadenylation of eukaryotic messenger RNA precursors (pre-mRNAs)(1-4); it also participates in transcription initiation and termination by RNA polymerase II (Pol II)(5,6). Symplekin mediates interactions between many different proteins in this machinery(1,2,7-9), although the molecular basis for its function is not known. Here we report the crystal structure at 2.4 angstrom resolution of the amino-terminal domain (residues 30-340) of human symplekin in a ternary complex with the Pol II carboxyterminal domain (CTD) Ser 5 phosphatase Ssu72 (refs 7, 10-17) and a CTD Ser 5 phosphopeptide. The N-terminal domain of symplekin has the ARM or HEAT fold, with seven pairs of antiparallel a-helices arranged in the shape of an arc. The structure of Ssu72 has some similarity to that of low-molecular-mass phosphotyrosine protein phosphatase(18,19), although Ssu72 has a unique active-site landscape as well as extra structural features at the C terminus that are important for interaction with symplekin. Ssu72 is bound to the concave face of symplekin, and engineered mutations in this interface can abolish interactions between the two proteins. The CTD peptide is bound in the active site of Ssu72, with the pSer 5-Pro 6 peptide bond in the cis configuration, which contrasts with all other known CTD peptide conformations(20,21). Although the active site of Ssu72 is about 25 angstrom from the interface with symplekin, we found that the symplekin N-terminal domain stimulates Ssu72 CTD phosphatase activity in vitro. Furthermore, the N-terminal domain of symplekin inhibits polyadenylation in vitro, but only when coupled to transcription. Because catalytically active Ssu72 overcomes this inhibition, our results show a role for mammalian Ssu72 in transcription-coupled pre-mRNA 3'-end processing.	[Xiang, Kehui; Nagaike, Takashi; Xiang, Song; Kilic, Turgay; Beh, Maia M.; Manley, James L.; Tong, Liang] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, LA (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	ltong@columbia.edu	Xiang, Song/AAF-6422-2019; KILIC, TURGAY/O-4493-2014	Xiang, Song/0000-0001-9314-4684; KILIC, TURGAY/0000-0003-2233-950X; Xiang, Kehui/0000-0002-3770-1367; Manley, James/0000-0002-8341-1459; Tong, Liang/0000-0002-0563-6468	National Institutes of Health [GM077175, GM028983]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983, R01GM077175] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank F. Forouhar and J. Seetharaman for help with data collection; T. Auperin for initial experiments with symplekin; R. Abramowitz and J. Schwanof for setting up the X4C beamline; S. Myers for setting up the X29A beamline at the National Synchrotron Light Source; M. Heidemann and D. Eick for providing the 3E10 antibody; N. Rao and C. Logan for HeLa nuclear extract and help with in vitro assays; and J. Decatur for characterizing the phosphopeptide by NMR. This research is supported in part by grants from the National Institutes of Health to L.T. (GM077175) and J.L.M. (GM028983).	Ansari A, 2005, GENE DEV, V19, P2969, DOI 10.1101/gad.1362305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Chapman RD, 2007, SCIENCE, V318, P1780, DOI 10.1126/science.1145977; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141; Ghazy MA, 2009, MOL CELL BIOL, V29, P2296, DOI 10.1128/MCB.01514-08; Hausmann S, 2005, J BIOL CHEM, V280, P37681, DOI 10.1074/jbc.M505292200; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kennedy SA, 2009, J MOL BIOL, V392, P115, DOI 10.1016/j.jmb.2009.06.062; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Krishnamurthy S, 2009, MOL CELL BIOL, V29, P2925, DOI 10.1128/MCB.01655-08; Mandel CR, 2008, CELL MOL LIFE SCI, V65, P1099, DOI 10.1007/s00018-007-7474-3; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meinhart A, 2003, J BIOL CHEM, V278, P15917, DOI 10.1074/jbc.M301643200; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Moore MJ, 2009, CELL, V136, P688, DOI 10.1016/j.cell.2009.02.001; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nedea E, 2003, J BIOL CHEM, V278, P33000, DOI 10.1074/jbc.M304454200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reyes-Reyes M, 2007, MOL CELL BIOL, V27, P926, DOI 10.1128/MCB.01361-06; Rozenblatt-Rosen O, 2009, P NATL ACAD SCI USA, V106, P755, DOI 10.1073/pnas.0812023106; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Singh N, 2009, MOL CELL, V36, P255, DOI 10.1016/j.molcel.2009.08.018; St-Pierre B, 2005, NUCLEIC ACIDS RES, V33, P464, DOI 10.1093/nar/gki171; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang Y, 2006, MOL CELL, V24, P759, DOI 10.1016/j.molcel.2006.10.027; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao J, 1999, MOL CELL BIOL, V19, P7733	41	114	117	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					729	U124		10.1038/nature09391	http://dx.doi.org/10.1038/nature09391			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20861839	Green Accepted			2022-12-28	WOS:000282572500043
J	Brouwer, MC; Kasanmoentalib, ES; Opstelten, FWJ; van der Ende, A; van de Beek, D				Brouwer, Matthijs C.; Kasanmoentalib, Erna S.; Opstelten, Frank W. J.; van der Ende, Arie; van de Beek, Diederik			A horse bite to remember	LANCET			English	Editorial Material									[Brouwer, Matthijs C.; Kasanmoentalib, Erna S.; van de Beek, Diederik] Univ Amsterdam, Acad Med Ctr, Dept Neurol, Ctr Infect & Immun Amsterdam CINIMA, NL-1100 DD Amsterdam, Netherlands; [van der Ende, Arie] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1100 DD Amsterdam, Netherlands; [van der Ende, Arie] Univ Amsterdam, Acad Med Ctr, Netherlands Reference Lab Bacterial Meningitis, NL-1100 DD Amsterdam, Netherlands; [Opstelten, Frank W. J.] Viecuri Med Ctr, Dept Neurol, Venlo, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; VieCuri Medical Center	van de Beek, D (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Ctr Infect & Immun Amsterdam CINIMA, POB 22660, NL-1100 DD Amsterdam, Netherlands.	d.vandebeek@amc.uva.nl	van de Beek, Diederik/Y-2713-2019; van de beek, diederik/A-2935-2010; van der Ende, Arie/A-4346-2012	van de Beek, Diederik/0000-0002-4571-044X; van der Ende, Arie/0000-0003-1298-3086				BARNHAM M, 1989, EPIDEMIOL INFECT, V102, P379, DOI 10.1017/S0950268800030090; Langley R, 2009, J AGROMEDICINE, V14, P370, DOI 10.1080/10599240903058087; MINCES LR, 2010, EPIDEMIOL INFECT, V138, P1; Thomas KE, 2006, BRIT J SPORT MED, V40, P619, DOI 10.1136/bjsm.2006.025858; *ZKA CONS PLANN, 2006, EQ SPORT INV 2006 PR	5	8	8	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2010	376	9747					1194	1194		10.1016/S0140-6736(10)60965-8	http://dx.doi.org/10.1016/S0140-6736(10)60965-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888995				2022-12-28	WOS:000282915700036
J	Cock, M				Cock, Matthew			Biopiracy rules should not block biological control	NATURE			English	Editorial Material									CABI, Delemont, Switzerland			m.cock@cabi.org		Cock, Matthew/0000-0003-2484-3021					0	4	4	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					369	369		10.1038/467369a	http://dx.doi.org/10.1038/467369a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864952	Bronze			2022-12-28	WOS:000282090200050
J	Narayan, KMV; Ali, MK; Koplan, JP				Narayan, K. M. Venkat; Ali, Mohammed K.; Koplan, Jeffrey P.			GLOBAL HEALTH Global Noncommunicable Diseases - Where Worlds Meet	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Narayan, K. M. Venkat] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Emory Univ, Emory Global Hlth Inst, Atlanta, GA USA	Emory University; Rollins School Public Health; Emory University	Narayan, KMV (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.		Narayan, K.M. Venkat/J-9819-2012; Ali, Mohammed K/N-9833-2013	Narayan, K.M. Venkat/0000-0001-8621-5405; Ali, Mohammed/0000-0001-7266-2503				Daar AS, 2007, NATURE, V450, P494, DOI 10.1038/450494a; Organization WH, 2009, GLOB HLTH RISKS MORT; Schiffman M, 2009, NEW ENGL J MED, V360, P1453, DOI 10.1056/NEJMe0901167; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; Yusuf S, 2009, LANCET, V373, P1341, DOI 10.1016/S0140-6736(09)60611-5	5	193	203	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1196	1198		10.1056/NEJMp1002024	http://dx.doi.org/10.1056/NEJMp1002024			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652ZA	20860499				2022-12-28	WOS:000282050000002
J	Atun, R; Raviglione, M; Marais, B; Zumla, A				Atun, Rifat; Raviglione, Mario; Marais, Ben; Zumla, Alimuddin			Tuberculosis control is crucial to achieve the MDGs	LANCET			English	Editorial Material									[Atun, Rifat] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Business Sch, London SW7 2AZ, England; [Atun, Rifat] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland; [Raviglione, Mario] WHO, STOP TB Partnership, CH-1211 Geneva, Switzerland; [Marais, Ben] Univ Stellenbosch, Dept Paediat, ZA-7600 Stellenbosch, South Africa; [Zumla, Alimuddin] UCL, Sch Med, Dept Infect, London W1N 8AA, England	Imperial College London; World Health Organization; Stellenbosch University; University of London; University College London; UCL Medical School	Atun, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Coll Business Sch, London SW7 2AZ, England.	rifat.atun@theglobalfund.org	ZUMLA, Alimuddin/ABA-8208-2020; Atun, Rifat/AAH-5537-2021; Marais, Ben/AAX-2626-2021	ZUMLA, Alimuddin/0000-0002-5111-5735; Atun, Rifat/0000-0002-1531-5983; RAVIGLIONE, Mario/0000-0002-9331-2067				Atun R, 2010, LANCET, V375, P2169, DOI 10.1016/S0140-6736(10)60493-X; Dye C, 2009, B WORLD HEALTH ORGAN, V87, P683, DOI 10.2471/BLT.08.058453; Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009, 2009, AIDS EP UPD DEC 2009; Marais BJ, 2010, LANCET, V375, P2179, DOI 10.1016/S0140-6736(10)60554-5; Marais BJ, 2010, LANCET, V375, P2057, DOI 10.1016/S0140-6736(10)60579-X; Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X; United Nation, 2010, MILL DEV GOALS; *WHO, 2009, GLOB TUB CONTR SHORT	8	15	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	2010	376	9745					940	941		10.1016/S0140-6736(10)61428-6	http://dx.doi.org/10.1016/S0140-6736(10)61428-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20851247				2022-12-28	WOS:000282247600009
J	Nygaard, I				Nygaard, Ingrid			Idiopathic Urgency Urinary Incontinence.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVERACTIVE BLADDER; OLDER WOMEN; STRESS; SYMPTOMS	At least weekly, a 62-year-old kindergarten teacher has a strong sense of urgency to urinate that is followed by urinary leakage while she rushes to the bathroom during her lunch break. She also infrequently leaks drops of urine while exercising. Her medical history is notable for mild hypertension, for which she takes hydrochlorothiazide. On physical examination, she is found to be obese and not to have abdominal masses or clinically significant pelvic-organ prolapse. How should her case be evaluated and treated?	Univ Utah, Sch Med, Dept Obstet & Gynecol, Div Urogynecol & Reconstruct Pelv Surg, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Nygaard, I (corresponding author), Univ Utah, Sch Med, Dept Obstet & Gynecol, Div Urogynecol & Reconstruct Pelv Surg, Salt Lake City, UT 84132 USA.							Albo ME, 2007, NEW ENGL J MED, V356, P2143, DOI 10.1056/NEJMoa070416; *AM COLL OBST GYN, 2005, UR INC WOM; Arya LA, 2000, OBSTET GYNECOL, V96, P85, DOI 10.1016/S0029-7844(00)00808-5; Bradley CS, 2005, AM J OBSTET GYNECOL, V192, P66, DOI 10.1016/j.ajog.2004.07.037; Brown JS, 2006, ANN INTERN MED, V144, P715, DOI 10.7326/0003-4819-144-10-200605160-00005; Brubaker L, 2008, J UROLOGY, V180, P217, DOI 10.1016/j.juro.2008.03.028; Brubaker L, 2009, NEUROUROL URODYNAM, V28, P268, DOI 10.1002/nau.20698; Bryant Charmaine M, 2002, Br J Nurs, V11, P560; Burgio KL, 2008, ANN INTERN MED, V149, P161, DOI 10.7326/0003-4819-149-3-200808050-00005; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Cody JD, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001405.pub2; Dumoulin C, 2010, COCHRANE DB SYST REV, V1; Duthie J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005493; Emmons SL, 2005, OBSTET GYNECOL, V106, P138, DOI 10.1097/01.AOG.0000163258.57895.ec; Fitzgerald MP, 2006, J UROLOGY, V175, P989, DOI 10.1016/S0022-5347(05)00416-7; FitzGerald MP, 2002, AM J OBSTET GYNECOL, V187, P1384, DOI 10.1067/mob.2002.126865; Gameiro MO, 2010, INT UROGYNECOL J, V21, P395, DOI 10.1007/s00192-009-1059-7; Hartmann Katherine E, 2009, Evid Rep Technol Assess (Full Rep), P1; Hay-Smith EJ, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD005654; Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Herbison GP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004202.pub2; HERBISON P, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002114; Hu TW, 2003, UROLOGY, V61, P1123, DOI 10.1016/S0090-4295(03)00009-8; KEGEL AH, 1951, JAMA-J AM MED ASSOC, V146, P915, DOI 10.1001/jama.1951.03670100035008; *NAT I HLTH CLIN E, 2006, CG40 UR INC QUICK RE; Peters KM, 2010, J UROLOGY, V183, P1438, DOI 10.1016/j.juro.2009.12.036; Rosier PFWM, 2010, NEUROUROL URODYNAM, V29, P140, DOI 10.1002/nau.20764; Shamliyan Tatyana, 2007, Evid Rep Technol Assess (Full Rep), P1; Stewart WF, 2002, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4; Subak LL, 2009, NEW ENGL J MED, V360, P481, DOI 10.1056/NEJMoa0806375; Wallace SA, 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001308.PUB2; Williams KS, 2006, BJU INT, V98, P1043, DOI 10.1111/j.1464-410X.2006.06484.x; [No title captured], DOI DOI 10.1111/J.1471-0528.2008.01751.X	35	45	45	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1156	1162		10.1056/NEJMcp1003849	http://dx.doi.org/10.1056/NEJMcp1003849			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843250				2022-12-28	WOS:000281795800010
J	Sessions, SY; Detsky, AS				Sessions, Samuel Y.; Detsky, Allan S.			Incorporating Economic Reality Into Medical Education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMPACT		[Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Sessions, Samuel Y.] Harbor UCLA Med Ctr, Dept Psychiat & Biobehav Sci, Torrance, CA 90509 USA; [Sessions, Samuel Y.] Harbor UCLA Med Ctr, LABiomed, Torrance, CA 90509 USA; [Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Evaluat & Med, Toronto, ON, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 429-600 Univ Ave, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						Avorn J, 2004, POWERFUL MED BENEFIT; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; CAPUTO I, 2009, WASHINGTON POST 0818; Carragee EJ, 2010, JAMA-J AM MED ASSOC, V303, P1309, DOI 10.1001/jama.2010.402; Nathan DM, 2007, NEW ENGL J MED, V356, P437, DOI 10.1056/NEJMp068294; SINGER N, 2010, NY TIMES        0113; Truffer CJ, 2010, HEALTH AFFAIR, V29, P522, DOI 10.1377/hlthaff.2009.1074; Wells DA, 2007, JAMA-J AM MED ASSOC, V298, P2785, DOI 10.1001/jama.298.23.2785; 2008 TOP 200 BRANDED	9	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1229	1230		10.1001/jama.2010.1348	http://dx.doi.org/10.1001/jama.2010.1348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841538				2022-12-28	WOS:000281770600017
J	Loewenberg, S				Loewenberg, Samuel			Sakena Yacoobi: leader for Afghan women's health and education Profile	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Loewenberg, S (corresponding author), The Lancet, London NW1 7BY, England.								0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					865	865		10.1016/S0140-6736(10)61400-6	http://dx.doi.org/10.1016/S0140-6736(10)61400-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20833291				2022-12-28	WOS:000282069100014
J	Manel, N; Hogstad, B; Wang, YM; Levy, DE; Unutmaz, D; Littman, DR				Manel, Nicolas; Hogstad, Brandon; Wang, Yaming; Levy, David E.; Unutmaz, Derya; Littman, Dan R.			A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELLS; TRANS-ENHANCEMENT; DC-SIGN; INFECTION; REPLICATION; VECTORS; RNA; DIFFERENTIATION; TRANSDUCTION	Dendritic cells serve a key function in host defence, linking innate detection of microbes to activation of pathogen-specific adaptive immune responses(1,2). Whether there is cell-intrinsic recognition of human immunodeficiency virus (HIV) by host innate pattern-recognition receptors and subsequent coupling to antiviral T-cell responses is not yet known(3). Dendritic cells are largely resistant to infection with HIV-1(4), but facilitate infection of co-cultured T-helper cells through a process of trans-enhancement(5,6). Here we show that, when dendritic cell resistance to infection is circumvented(7,8), HIV-1 induces dendritic cell maturation, an antiviral type I interferon response and activation of T cells. This innate response is dependent on the interaction of newly synthesized HIV-1 capsid with cellular cyclophilin A (CYPA) and the subsequent activation of the transcription factor IRF3. Because the peptidylprolyl isomerase CYPA also interacts with HIV-1 capsid to promote infectivity, our results indicate that capsid conformation has evolved under opposing selective pressures for infectivity versus furtiveness. Thus, a cell-intrinsic sensor for HIV-1 exists in dendritic cells and mediates an antiviral immune response, but it is not typically engaged owing to the absence of dendritic cell infection. The virulence of HIV-1 may be related to evasion of this response, the manipulation of which may be necessary to generate an effective HIV-1 vaccine.	[Manel, Nicolas; Hogstad, Brandon; Littman, Dan R.] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med,Mol Pathogenesis Program, New York, NY 10016 USA; [Manel, Nicolas] Univ Montpellier 1 & 2, Inst Genet Mol Montpellier, CNRS, UMR5535, F-34070 Montpellier, France; [Hogstad, Brandon; Littman, Dan R.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; [Wang, Yaming; Levy, David E.; Unutmaz, Derya; Littman, Dan R.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Wang, Yaming; Levy, David E.] NYU, Sch Med, Inst Canc, New York, NY 10016 USA; [Unutmaz, Derya; Littman, Dan R.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Howard Hughes Medical Institute; New York University; New York University; New York University; New York University	Littman, DR (corresponding author), NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med,Mol Pathogenesis Program, New York, NY 10016 USA.	dan.littman@med.nyu.edu	Manel, Nicolas/E-2128-2011; Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Manel, Nicolas/0000-0002-1481-4430; Levy, David/0000-0002-7320-7788; Unutmaz, Derya/0000-0001-8898-6633	EMBO; Cancer Research Institute; Institut National de la Sante et de la Recherche Medicale; Howard Hughes Medical Institute; Helen and Martin Kimmel Center for Biology and Medicine; National Institutes of Health (NIH) [AI33856, AI28900, U54AI57168, R01AI065303]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065303, R21AI084633, U54AI057168, R01AI028900, U54AI057158, R01AI033856] Funding Source: NIH RePORTER	EMBO(European Molecular Biology Organization (EMBO)); Cancer Research Institute; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Helen and Martin Kimmel Center for Biology and Medicine; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank members of the Littman laboratory for valuable discussions and critical reading of the manuscript, and T. Egawa, E. Kurz, X. Gong and L. Kozyhaya for assistance with experiments. We thank S. Hopkins at Scynexis for the gift of the SCY compound, J. Zavadil and the genomic core facility of New York University Medical Center for performing the array studies, M. Emerman, M. Yamashita and W. Sundquist for HIV constructs and critical reading of the manuscript, B. Walker, A. Piechocka-Trocha, D. Kwon, S. M. Vine, N. Bardhwaj and E. Miller for T-cell clones and reagents, and S. Schwab and R. Medzhitov for critical reading of the manuscript. N. M. thanks M. Sitbon, N. Taylor and J.-M. Blanchard for continuous support. The work was supported sequentially by EMBO and Cancer Research Institute fellowships (N.M.), by the Institut National de la Sante et de la Recherche Medicale (N.M.), by the Howard Hughes Medical Institute (D.R.L.), the Helen and Martin Kimmel Center for Biology and Medicine (D.R.L.), and National Institutes of Health (NIH) grants AI33856 (D.R.L.), AI28900 (D.E.L.), U54AI57168 (D.E.L.) and R01AI065303 (D.U.).	Antons AK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002952; Boggiano C, 2007, J VIROL, V81, P2519, DOI 10.1128/JVI.01661-06; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Chatterji U, 2009, J BIOL CHEM, V284, P16998, DOI 10.1074/jbc.M109.007625; de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Elkon R, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-110; Fonteneau JF, 2001, J IMMUNOL METHODS, V258, P111, DOI 10.1016/S0022-1759(01)00477-X; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; Goujon C, 2006, GENE THER, V13, P991, DOI 10.1038/sj.gt.3302753; Griffin SDC, 2001, J VIROL, V75, P12058, DOI 10.1128/JVI.75.24.12058-12069.2001; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Hopkins S, 2010, ANTIMICROB AGENTS CH, V54, P660, DOI 10.1128/AAC.00660-09; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kosmrlj A, 2010, NATURE, V465, P350, DOI 10.1038/nature08997; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Langenkamp A, 2002, EUR J IMMUNOL, V32, P2046, DOI 10.1002/1521-4141(200207)32:7<2046::AID-IMMU2046>3.0.CO;2-M; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangeot PE, 2002, MOL THER, V5, P283, DOI 10.1006/mthe.2002.0541; Mangeot PE, 2000, J VIROL, V74, P8307, DOI 10.1128/JVI.74.18.8307-8315.2000; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moris A, 2006, BLOOD, V108, P1643, DOI 10.1182/blood-2006-02-006361; Morner A, 1999, J VIROL, V73, P2343; Neagu MR, 2009, J CLIN INVEST, V119, P3035, DOI 10.1172/JCI39354; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Price AJ, 2009, NAT STRUCT MOL BIOL, V16, P1036, DOI 10.1038/nsmb.1667; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Shamir R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-232; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; Yamashita M, 2007, PLOS PATHOG, V3, P1502, DOI 10.1371/journal.ppat.0030156; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhang HL, 2004, J VIROL, V78, P1718, DOI 10.1128/JVI.78.4.1718-1729.2004	39	326	339	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					214	U104		10.1038/nature09337	http://dx.doi.org/10.1038/nature09337			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829794	Green Accepted			2022-12-28	WOS:000281616300036
J	Inoue, K; Kohda, T; Sugimoto, M; Sado, T; Ogonuki, N; Matoba, S; Shiura, H; Ikeda, R; Mochida, K; Fujii, T; Sawai, K; Otte, AP; Tian, XC; Yang, XZ; Ishino, F; Abe, K; Ogura, A				Inoue, Kimiko; Kohda, Takashi; Sugimoto, Michihiko; Sado, Takashi; Ogonuki, Narumi; Matoba, Shogo; Shiura, Hirosuke; Ikeda, Rieko; Mochida, Keiji; Fujii, Takashi; Sawai, Ken; Otte, Arie P.; Tian, X. Cindy; Yang, Xiangzhong; Ishino, Fumitoshi; Abe, Kuniya; Ogura, Atsuo			Impeding Xist Expression from the Active X Chromosome Improves Mouse Somatic Cell Nuclear Transfer	SCIENCE			English	Article							INACTIVATION; CLONING; MICE	Cloning mammals by means of somatic cell nuclear transfer (SCNT) is highly inefficient because of erroneous reprogramming of the donor genome. Reprogramming errors appear to arise randomly, but the nature of nonrandom, SCNT-specific errors remains elusive. We found that Xist, a noncoding RNA that inactivates one of the two X chromosomes in females, was ectopically expressed from the active X (Xa) chromosome in cloned mouse embryos of both sexes. Deletion of Xist on Xa showed normal global gene expression and resulted in about an eight-to ninefold increase in cloning efficiency. We also identified an Xist-independent mechanism that specifically down-regulated a subset of X-linked genes through somatic-type repressive histone blocks. Thus, we have identified nonrandom reprogramming errors in mouse cloning that can be altered to improve the efficiency of SCNT methods.	[Inoue, Kimiko; Sugimoto, Michihiko; Ogonuki, Narumi; Matoba, Shogo; Shiura, Hirosuke; Ikeda, Rieko; Mochida, Keiji; Abe, Kuniya; Ogura, Atsuo] RIKEN, BioResource Ctr, Tsukuba, Ibaraki 3050024, Japan; [Inoue, Kimiko; Abe, Kuniya; Ogura, Atsuo] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Kohda, Takashi; Ishino, Fumitoshi] Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1138510, Japan; [Sado, Takashi] Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; [Fujii, Takashi; Sawai, Ken] Iwate Univ, Fac Agr, Morioka, Iwate 0208550, Japan; [Otte, Arie P.] Univ Amsterdam, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands; [Tian, X. Cindy; Yang, Xiangzhong] Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA; [Tian, X. Cindy; Yang, Xiangzhong] Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA; [Ogura, Atsuo] Univ Tokyo, Fac ofMedicine, Ctr Dis Biol & Integrat Med, Tokyo 1130033, Japan	RIKEN; University of Tsukuba; Tokyo Medical & Dental University (TMDU); Kyushu University; Iwate University; University of Amsterdam; University of Connecticut; University of Connecticut; University of Tokyo	Ogura, A (corresponding author), RIKEN, BioResource Ctr, Tsukuba, Ibaraki 3050024, Japan.	ogura@rtc.riken.go.jp	Sado, Takashi/AAI-1689-2019; MATOBA, Shogo/D-9995-2016; Ogura, Atsuo/J-3916-2014; Kohda, Takashi/C-2879-2014	MATOBA, Shogo/0000-0003-0474-232X; Ogura, Atsuo/0000-0003-0447-1988; Sado, Takashi/0000-0002-1232-0250; Shiura, Hirosuke/0000-0003-2553-6971; Kohda, Takashi/0000-0002-6856-5601	Ministry of Education, Culture, Sports, Science and Technology; NOVARTIS Foundation (Japan) for the Promotion of Science; Grants-in-Aid for Scientific Research [19061001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NOVARTIS Foundation (Japan) for the Promotion of Science(Novartis); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The mice in which Xist had been knocked out (RBRC 01260) were provided by the RIKEN BioResource Center. This research was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology and NOVARTIS Foundation (Japan) for the Promotion of Science. The H3K9me2 antibody used for chromatin immunoprecipitation on chip was a kind gift from H. Kimura. We thank M. Tachibana, Y. Shinkai, H. Koseki, T. H. Endo, and S. L. Marjani for their invaluable suggestions. The microarray data have been deposited in the Gene Expression Omnibus and given the series accession number GSE23181.	Bao SQ, 2005, EMBO REP, V6, P748, DOI 10.1038/sj.embor.7400461; Fulka J, 2004, NAT BIOTECHNOL, V22, P25, DOI 10.1038/nbt0104-25; Huynh KD, 2005, NAT REV GENET, V6, P410, DOI 10.1038/nrg1604; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; Inoue K, 2006, J CELL SCI, V119, P1985, DOI 10.1242/jcs.02913; Kishigami S, 2006, BIOCHEM BIOPH RES CO, V340, P183, DOI 10.1016/j.bbrc.2005.11.164; McDonald LE, 1998, GENOMICS, V54, P379, DOI 10.1006/geno.1998.5570; Meissner A, 2006, DEV DYNAM, V235, P2460, DOI 10.1002/dvdy.20915; Navarro P, 2008, SCIENCE, V321, P1693, DOI 10.1126/science.1160952; Nolen LD, 2005, DEV BIOL, V279, P525, DOI 10.1016/j.ydbio.2005.01.016; Ogonuki N, 2002, NAT GENET, V30, P253, DOI 10.1038/ng841; Sado T, 2005, DEV CELL, V9, P159, DOI 10.1016/j.devcel.2005.05.015; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; Sung LY, 2006, NAT GENET, V38, P1323, DOI 10.1038/ng1895; Tanaka S, 2001, BIOL REPROD, V65, P1813, DOI 10.1095/biolreprod65.6.1813; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Xue F, 2002, NAT GENET, V31, P216, DOI 10.1038/ng900; Yang XZ, 2007, NAT GENET, V39, P295, DOI 10.1038/ng1973	18	180	198	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	2010	330	6003					496	499		10.1126/science.1194174	http://dx.doi.org/10.1126/science.1194174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	669EL	20847234				2022-12-28	WOS:000283329100037
J	Allen, HL; Estrada, K; Lettre, G; Berndt, SI; Weedon, MN; Rivadeneira, F; Willer, CJ; Jackson, AU; Vedantam, S; Raychaudhuri, S; Ferreira, T; Wood, AR; Weyant, RJ; Segre, AV; Speliotes, EK; Wheeler, E; Soranzo, N; Park, JH; Yang, J; Gudbjartsson, D; Heard-Costa, NL; Randall, JC; Qi, L; Smith, AV; Magi, R; Pastinen, T; Liang, L; Heid, IM; Luan, J; Thorleifsson, G; Winkler, TW; Goddard, ME; Lo, KS; Palmer, C; Workalemahu, T; Aulchenko, YS; Johansson, A; Zillikens, MC; Feitosa, MF; Esko, T; Johnson, T; Ketkar, S; Kraft, P; Mangino, M; Prokopenko, I; Absher, D; Albrecht, E; Ernst, F; Glazer, NL; Hayward, C; Hottenga, JJ; Jacobs, KB; Knowles, JW; Kutalik, Z; Monda, KL; Polasek, O; Preuss, M; Rayner, NW; Robertson, NR; Steinthorsdottir, V; Tyrer, JP; Voight, BF; Wiklund, F; Xu, JF; Zhao, JH; Nyholt, DR; Pellikka, N; Perola, M; Perry, JRB; Surakka, I; Tammesoo, ML; Altmaier, EL; Amin, N; Aspelund, T; Bhangale, T; Boucher, G; Chasman, DI; Chen, C; Coin, L; Cooper, MN; Dixon, AL; Gibson, Q; Grundberg, E; Hao, K; Junttila, MJ; Kaplan, LM; Kettunen, J; Konig, IR; Kwan, T; Lawrence, RW; Levinson, DF; Lorentzon, M; McKnight, B; Morris, AP; Muller, M; Ngwa, JS; Purcell, S; Rafelt, S; Salem, RM; Salvi, E; Sanna, S; Shi, JX; Sovio, U; Thompson, JR; Turchin, MC; Vandenput, L; Verlaan, DJ; Vitart, V; White, CC; Ziegler, A; Almgren, P; Balmforth, AJ; Campbell, H; Citterio, L; De Grandi, A; Dominiczak, A; Duan, J; Elliott, P; Elosua, R; Eriksson, JG; Freimer, NB; Geus, EJC; Glorioso, N; Haiqing, S; Hartikainen, AL; Havulinna, AS; Hicks, AA; Hui, JN; Igl, W; Illig, T; Jula, A; Kajantie, E; Kilpelaeinen, TO; Koiranen, M; Kolcic, I; Koskinen, S; Kovacs, P; Laitinen, J; Liu, JJ; Lokki, ML; Marusic, A; Maschio, A; Meitinger, T; Mulas, A; Pare, G; Parker, AN; Peden, JF; Petersmann, A; Pichler, I; Pietilainen, KH; Pouta, A; Riddertrale, M; Rotter, JI; Sambrook, JG; Sanders, AR; Schmidt, CO; Sinisalo, J; Smit, JH; Stringham, HM; Walters, GB; Widen, E; Wild, SH; Willemsen, G; Zagato, L; Zgaga, L; Zitting, P; Alavere, H; Farrall, M; McArdle, WL; Nelis, M; Peters, MJ; Ripatti, S; Meurs, JBJ; Aben, KK; Ardlie, KG; Beckmann, JS; Beilby, JP; Bergman, RN; Bergmann, S; Collins, FS; Cusi, D; den Heijer, M; Eiriksdottir, G; Gejman, PV; Hall, AS; Hamsten, A; Huikuri, HV; Iribarren, C; Kahonen, M; Kaprio, J; Kathiresan, S; Kiemeney, L; Kocher, T; Launer, LJ; Lehtimaki, T; Melander, O; Mosley, TH; Musk, AW; Nieminen, MS; O'Donnell, CJ; Ohlsson, C; Oostra, B; Palmer, LJ; Raitakari, O; Ridker, PM; Rioux, JD; Rissanen, A; Rivolta, C; Schunkert, H; Shuldiner, AR; Siscovick, DS; Stumvoll, M; Tonjes, A; Tuomilehto, J; van Ommen, GJ; Viikari, J; Heath, AC; Martin, NG; Montgomery, GW; Province, MA; Kayser, M; Arnold, AM; Atwood, LD; Boerwinkle, E; Chanock, SJ; Deloukas, P; Gieger, C; Gronberg, H; Hall, P; Hattersley, AT; Hengstenberg, C; Hoffman, W; Lathrop, GM; Salomaa, V; Schreiber, S; Uda, M; Waterworth, D; Wright, AF; Assimes, TL; Barroso, I; Hofman, A; Mohlke, KL; Boomsma, DI; Caulfield, MJ; Cupples, LA; Erdmann, J; Fox, CS; Gudnason, V; Gyllensten, U; Harris, TB; Hayes, RB; Jarvelin, MR; Mooser, V; Munroe, PB; Ouwehand, WH; Penninx, BW; Pramstaller, PP; Quertermous, T; Rudan, I; Samani, NJ; Spector, TD; Volzke, H; Watkins, H; Wilson, JF; Groop, LC; Haritunians, T; Hu, FB; Kaplan, RC; Metspalu, A; North, KE; Schlessinger, D; Wareham, NJ; Hunter, DJ; O'Connell, JR; Strachan, DP; Schadt, HE; Thorsteinsdottir, U; Peltonen, L; Uitterlinden, AG; Visscher, PM; Chatterjee, N; Loos, RJF; Boehnke, M; McCarthy, MI; Ingelsson, E; Lindgren, CM; Abecasis, GR; Stefansson, K; Frayling, TM; Hirschhorn, JN				Allen, Hana Lango; Estrada, Karol; Lettre, Guillaume; Berndt, Sonja I.; Weedon, Michael N.; Rivadeneira, Fernando; Willer, Cristen J.; Jackson, Anne U.; Vedantam, Sailaja; Raychaudhuri, Soumya; Ferreira, Teresa; Wood, Andrew R.; Weyant, Robert J.; Segre, Ayellet V.; Speliotes, Elizabeth K.; Wheeler, Eleanor; Soranzo, Nicole; Park, Ju-Hyun; Yang, Jian; Gudbjartsson, Daniel; Heard-Costa, Nancy L.; Randall, Joshua C.; Qi, Lu; Smith, Albert Vernon; Maegi, Reedik; Pastinen, Tomi; Liang, Liming; Heid, Iris M.; Luan, Jian'an; Thorleifsson, Gudmar; Winkler, Thomas W.; Goddard, Michael E.; Lo, Ken Sin; Palmer, Cameron; Workalemahu, Tsegaselassie; Aulchenko, Yurii S.; Johansson, Asa; Zillikens, M. Carola; Feitosa, Mary F.; Esko, Tonu; Johnson, Toby; Ketkar, Shamika; Kraft, Peter; Mangino, Massimo; Prokopenko, Inga; Absher, Devin; Albrecht, Eva; Ernst, Florian; Glazer, Nicole L.; Hayward, Caroline; Hottenga, Jouke-Jan; Jacobs, Kevin B.; Knowles, Joshua W.; Kutalik, Zoltan; Monda, Keri L.; Polasek, Ozren; Preuss, Michael; Rayner, Nigel W.; Robertson, Neil R.; Steinthorsdottir, Valgerdur; Tyrer, Jonathan P.; Voight, Benjamin F.; Wiklund, Fredrik; Xu, Jianfeng; Zhao, Jing Hua; Nyholt, Dale R.; Pellikka, Niina; Perola, Markus; Perry, John R. B.; Surakka, Ida; Tammesoo, Mari-Liis; Altmaier, Elizabeth L.; Amin, Najaf; Aspelund, Thor; Bhangale, Tushar; Boucher, Gabrielle; Chasman, Daniel I.; Chen, Constance; Coin, Lachlan; Cooper, Matthew N.; Dixon, Anna L.; Gibson, Quince; Grundberg, Elin; Hao, Ke; Junttila, M. Juhani; Kaplan, Lee M.; Kettunen, Johannes; Koenig, Inke R.; Kwan, Tony; Lawrence, Robert W.; Levinson, Douglas F.; Lorentzon, Mattias; McKnight, Barbara; Morris, Andrew P.; Mueller, Martina; Ngwa, Julius Suh; Purcell, Shaun; Rafelt, Suzanne; Salem, Rany M.; Salvi, Erika; Sanna, Serena; Shi, Jianxin; Sovio, Ulla; Thompson, John R.; Turchin, Michael C.; Vandenput, Liesbeth; Verlaan, Dominique J.; Vitart, Veronique; White, Charles C.; Ziegler, Andreas; Almgren, Peter; Balmforth, Anthony J.; Campbell, Harry; Citterio, Lorena; De Grandi, Alessandro; Dominiczak, Anna; Duan, Jubao; Elliott, Paul; Elosua, Roberto; Eriksson, Johan G.; Freimer, Nelson B.; Geus, Eco J. C.; Glorioso, Nicola; Haiqing, Shen; Hartikainen, Anna-Liisa; Havulinna, Aki S.; Hicks, Andrew A.; Hui, Jennie; Igl, Wilmar; Illig, Thomas; Jula, Antti; Kajantie, Eero; Kilpelaeinen, Tuomas O.; Koiranen, Markku; Kolcic, Ivana; Koskinen, Seppo; Kovacs, Peter; Laitinen, Jaana; Liu, Jianjun; Lokki, Marja-Liisa; Marusic, Ana; Maschio, Andrea; Meitinger, Thomas; Mulas, Antonella; Pare, Guillaume; Parker, Alex N.; Peden, John F.; Petersmann, Astrid; Pichler, Irene; Pietilainen, Kirsi H.; Pouta, Anneli; Riddertrale, Martin; Rotter, Jerome I.; Sambrook, Jennifer G.; Sanders, Alan R.; Schmidt, Carsten Oliver; Sinisalo, Juha; Smit, Jan H.; Stringham, Heather M.; Walters, G. Bragi; Widen, Elisabeth; Wild, Sarah H.; Willemsen, Gonneke; Zagato, Laura; Zgaga, Lina; Zitting, Paavo; Alavere, Helene; Farrall, Martin; McArdle, Wendy L.; Nelis, Mari; Peters, Marjolein J.; Ripatti, Samuli; vVan Meurs, Joyce B. J.; Aben, Katja K.; Ardlie, Kristin G.; Beckmann, Jacques S.; Beilby, John P.; Bergman, Richard N.; Bergmann, Sven; Collins, Francis S.; Cusi, Daniele; den Heijer, Martin; Eiriksdottir, Gudny; Gejman, Pablo V.; Hall, Alistair S.; Hamsten, Anders; Huikuri, Heikki V.; Iribarren, Carlos; Kahonen, Mika; Kaprio, Jaakko; Kathiresan, Sekar; Kiemeney, Lambertus; Kocher, Thomas; Launer, Lenore J.; Lehtimaki, Terho; Melander, Olle; Mosley, Tom H., Jr.; Musk, Arthur W.; Nieminen, Markku S.; O'Donnell, Christopher J.; Ohlsson, Claes; Oostra, Ben; Palmer, Lyle J.; Raitakari, Olli; Ridker, Paul M.; Rioux, John D.; Rissanen, Aila; Rivolta, Carlo; Schunkert, Heribert; Shuldiner, Alan R.; Siscovick, David S.; Stumvoll, Michael; Toenjes, Anke; Tuomilehto, Jaakko; van Ommen, Gert-Jan; Viikari, Jorma; Heath, Andrew C.; Martin, Nicholas G.; Montgomery, Grant W.; Province, Michael A.; Kayser, Manfred; Arnold, Alice M.; Atwood, Larry D.; Boerwinkle, Eric; Chanock, Stephen J.; Deloukas, Panos; Gieger, Christian; Gronberg, Henrik; Hall, Per; Hattersley, Andrew T.; Hengstenberg, Christian; Hoffman, Wolfgang; Lathrop, G. Mark; Salomaa, Veikko; Schreiber, Stefan; Uda, Manuela; Waterworth, Dawn; Wright, Alan F.; Assimes, Themistocles L.; Barroso, Ines; Hofman, Albert; Mohlke, Karen L.; Boomsma, Dorret I.; Caulfield, Mark J.; Cupples, L. Adrienne; Erdmann, Jeanette; Fox, Caroline S.; Gudnason, Vilmundur; Gyllensten, Ulf; Harris, Tamara B.; Hayes, Richard B.; Jarvelin, Marjo-Ritta; Mooser, Vincent; Munroe, Patricia B.; Ouwehand, Willem H.; Penninx, Brenda W.; Pramstaller, Peter P.; Quertermous, Thomas; Rudan, Igor; Samani, Nilesh J.; Spector, Timothy D.; Voelzke, Henry; Watkins, Hugh; Wilson, James F.; Groop, Leif C.; Haritunians, Talin; Hu, Frank B.; Kaplan, Robert C.; Metspalu, Andres; North, Kari E.; Schlessinger, David; Wareham, Nicholas J.; Hunter, David J.; O'Connell, Jeffrey R.; Strachan, David P.; Schadt, H. -Erich; Thorsteinsdottir, Unnur; Peltonen, Leena; Uitterlinden, Andre G.; Visscher, Peter M.; Chatterjee, Nilanjan; Loos, Ruth J. F.; Boehnke, Michael; McCarthy, Mark I.; Ingelsson, Erik; Lindgren, Cecilia M.; Abecasis, Goncalo R.; Stefansson, Kari; Frayling, Timothy M.; Hirschhorn, Joel N.		Procardis Consortium	Hundreds of variants clustered in genomic loci and biological pathways affect human height	NATURE			English	Article							WIDE ASSOCIATION; COMMON VARIANTS; HERITABILITY; ADULT	Most common human traits and diseases have a polygenic pattern of inheritance: DNA sequence variants at many genetic loci influence the phenotype. Genome-wide association (GWA) studies have identified more than 600 variants associated with human traits(1), but these typically explain small fractions of phenotypic variation, raising questions about the use of further studies. Here, using 183,727 individuals, we show that hundreds of genetic variants, in at least 180 loci, influence adult height, a highly heritable and classic polygenic trait(2,3). The large number of loci reveals patterns with important implications for genetic studies of common human diseases and traits. First, the 180 loci are not random, but instead are enriched for genes that are connected in biological pathways (P = 0.016) and that underlie skeletal growth defects (P<0.001). Second, the likely causal gene is often located near the most strongly associated variant: in 13 of 21 loci containing a known skeletal growth gene, that gene was closest to the associated variant. Third, at least 19 loci have multiple independently associated variants, suggesting that allelic heterogeneity is a frequent feature of polygenic traits, that comprehensive explorations of already-discovered loci should discover additional variants and that an appreciable fraction of associated loci may have been identified. Fourth, associated variants are enriched for likely functional effects on genes, being over-represented among variants that alter amino-acid structure of proteins and expression levels of nearby genes. Our data explain approximately 10% of the phenotypic variation in height, and we estimate that unidentified common variants of similar effect sizes would increase this figure to approximately 16% of phenotypic variation (approximately 20% of heritable variation). Although additional approaches are needed to dissect the genetic architecture of polygenic human traits fully, our findings indicate that GWA studies can identify large numbers of loci that implicate biologically relevant genes and pathways.	[Allen, Hana Lango; Weedon, Michael N.; Wood, Andrew R.; Perry, John R. B.; Hattersley, Andrew T.; Frayling, Timothy M.] Univ Exeter, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England; [Estrada, Karol; Rivadeneira, Fernando; Aulchenko, Yurii S.; Amin, Najaf; vVan Meurs, Joyce B. J.; Hofman, Albert; Uitterlinden, Andre G.] Erasmus Sch Ctr, Dept Epidemiol, NL-3015 GE Rotterdam, Netherlands; [Estrada, Karol; Rivadeneira, Fernando; Zillikens, M. Carola; Peters, Marjolein J.; vVan Meurs, Joyce B. J.; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands; [Estrada, Karol; Rivadeneira, Fernando; Aulchenko, Yurii S.; Peters, Marjolein J.; vVan Meurs, Joyce B. J.; Hofman, Albert; Uitterlinden, Andre G.] NCHA, NGI, NL-42300 RC Leiden, Netherlands; [Lettre, Guillaume; Lo, Ken Sin; Boucher, Gabrielle; Rioux, John D.] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Lettre, Guillaume; Rioux, John D.] Univ Montreal, Dept Med, Montreal, PQ H3T 1J4, Canada; [Berndt, Sonja I.; Park, Ju-Hyun; Shi, Jianxin; Chatterjee, Nilanjan] Natl Canc Inst, Natl Inst Hlth, Divis Canc Epidemiol & Genet, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Willer, Cristen J.; Jackson, Anne U.; Weyant, Robert J.; Stringham, Heather M.; Boehnke, Michael; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Vedantam, Sailaja; Palmer, Cameron; Altmaier, Elizabeth L.; Salem, Rany M.; Turchin, Michael C.] Childrens Hosp, Div Genet & Endocrinol, Boston, MA 02115 USA; [Vedantam, Sailaja; Palmer, Cameron; Altmaier, Elizabeth L.; Salem, Rany M.; Turchin, Michael C.] Childrens Hosp, Program Gen, Boston, MA 02115 USA; [Vedantam, Sailaja; Palmer, Cameron; Altmaier, Elizabeth L.; Salem, Rany M.; Turchin, Michael C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Raychaudhuri, Soumya; Segre, Ayellet V.; Voight, Benjamin F.; Ardlie, Kristin G.; Kathiresan, Sekar] MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Raychaudhuri, Soumya; Segre, Ayellet V.; Voight, Benjamin F.; Ardlie, Kristin G.; Kathiresan, Sekar] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Raychaudhuri, Soumya] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; [Ferreira, Teresa; Randall, Joshua C.; Maegi, Reedik; Prokopenko, Inga; Rayner, Nigel W.; Robertson, Neil R.; Morris, Andrew P.; Peden, John F.; Farrall, Martin; Watkins, Hugh; McCarthy, Mark I.; Lindgren, Cecilia M.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Segre, Ayellet V.; Voight, Benjamin F.; Purcell, Shaun; Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Segre, Ayellet V.; Voight, Benjamin F.] Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA; [Speliotes, Elizabeth K.; Kaplan, Lee M.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Wheeler, Eleanor; Soranzo, Nicole; Grundberg, Elin; Chanock, Stephen J.; Deloukas, Panos; Barroso, Ines; Ouwehand, Willem H.; Peltonen, Leena] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Soranzo, Nicole; Mangino, Massimo; Spector, Timothy D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England; [Yang, Jian; Visscher, Peter M.] Queensland Inst Med Res, Queensland Stat Genet Lab, Queensland 4006, Australia; [Gudbjartsson, Daniel; Thorleifsson, Gudmar; Steinthorsdottir, Valgerdur; Walters, G. Bragi; Thorsteinsdottir, Unnur; Stefansson, Kari] deCODE Genet, IS-101 Reykjavik, Iceland; [Heard-Costa, Nancy L.; Atwood, Larry D.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Qi, Lu; Workalemahu, Tsegaselassie; Hu, Frank B.; Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Qi, Lu; Pietilainen, Kirsi H.; Kaprio, Jaakko; Hu, Frank B.; Hunter, David J.] Harvard Univ, Sch Med, Dept Nutr, Boston, MA 02115 USA; [Qi, Lu; Hu, Frank B.; Hunter, David J.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Smith, Albert Vernon; Aspelund, Thor; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland; [Smith, Albert Vernon; Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, IS-101 Reykjavik, Iceland; [Pastinen, Tomi; Grundberg, Elin; Kwan, Tony; Verlaan, Dominique J.] McGill Univ, Montreal, PQ H3A 1A4, Canada; [Pastinen, Tomi; Grundberg, Elin; Kwan, Tony; Verlaan, Dominique J.] Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; [Pastinen, Tomi; Grundberg, Elin; Kwan, Tony; Verlaan, Dominique J.] McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; [Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; [Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA; [Heid, Iris M.; Winkler, Thomas W.] Univ Regensburg, Med Ctr, Dept Epidemiol & Prevent Med, D-93053 Regensburg, Germany; [Heid, Iris M.; Albrecht, Eva; Mueller, Martina; Illig, Thomas; Gieger, Christian; Schadt, H. -Erich] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; [Luan, Jian'an; Zhao, Jing Hua; Kilpelaeinen, Tuomas O.; Wareham, Nicholas J.; Loos, Ruth J. F.] Addenbrookes Hosp, Inst Met Sci, MRC Epidemiol Unit, Cambridge CB2 0QQ, England; [Goddard, Michael E.] Univ Melbourne, Fac Land & Environm, Parkville, Vic 3010, Australia; [Goddard, Michael E.] Dept Primary Ind, Bundoora, Vic 3086, Australia; [Johansson, Asa; Igl, Wilmar; Gyllensten, Ulf] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden; [Johansson, Asa] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Fac Med, N-7489 Trondheim, Norway; [Feitosa, Mary F.; Ketkar, Shamika; Province, Michael A.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Esko, Tonu; Tammesoo, Mari-Liis; Alavere, Helene; Nelis, Mari] Univ Tartu, Estonian Genome Ctr, EE-50410 Tartu, Estonia; [Esko, Tonu; Nelis, Mari; Metspalu, Andres] Estonian Bioctr, EE-51010 Tartu, Estonia; [Esko, Tonu; Nelis, Mari; Metspalu, Andres] Univ Tartu, Inst Mol & Cell Biol, EE-51010 Tartu, Estonia; [Johnson, Toby; Kutalik, Zoltan; Beckmann, Jacques S.; Bergmann, Sven; Rivolta, Carlo] Univ Lausanne, Dept Med Genet, CH-1005 Lausanne, Switzerland; [Johnson, Toby; Kutalik, Zoltan; Bergmann, Sven] Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland; [Johnson, Toby] Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London EC1M 6BQ, England; [Johnson, Toby; Caulfield, Mark J.; Munroe, Patricia B.] Univ London, William Harvey Res Inst, Barts & London Genome Ctr, Barts & London Sch Med & Dent, London EC1M6BQ, England; [Kraft, Peter; Hu, Frank B.; Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Prokopenko, Inga; Rayner, Nigel W.; Robertson, Neil R.; Lindgren, Cecilia M.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England; [Absher, Devin] Hudson Alpha Inst Biotechnol, Huntsville, AL 35806 USA; [Ernst, Florian] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Gen, D-17487 Greifswald, Germany; [Glazer, Nicole L.; Wiklund, Fredrik] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; [Glazer, Nicole L.; Wiklund, Fredrik] Univ Washington, Dept Med, Seattle, WA 98101 USA; [Hayward, Caroline; Xu, Jianfeng; Vitart, Veronique; Wright, Alan F.; Rudan, Igor] Western Gen Hosp, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Hottenga, Jouke-Jan; Geus, Eco J. C.; Willemsen, Gonneke; Boomsma, Dorret I.] Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands; [Jacobs, Kevin B.] NCI Frederick, SAIC Frederick Inc, Frederick, MD 21702 USA; [Knowles, Joshua W.; Assimes, Themistocles L.; Quertermous, Thomas] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Monda, Keri L.; North, Kari E.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27514 USA; [Polasek, Ozren; Kolcic, Ivana; Zgaga, Lina] Univ Zagreb, Andrija Stampar Sch Publ Hlth, Sch Med, Zagreb 10000, Croatia; [Polasek, Ozren] Gen Info Ltd, Zagreb 10000, Croatia; [Preuss, Michael; Koenig, Inke R.] Univ Lubeck, Inst Med Biometrie & Stat, D-23562 Lubeck, Germany; [Tyrer, Jonathan P.] Univ Cambridge, Dept Oncol, Cambridge CB1 8RN, England; [Gronberg, Henrik; Hall, Per; Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostatist, S-17177 Stockholm, Sweden; [Shuldiner, Alan R.] Wake Forest Univ, Ctr Human Genome, Winston Salem, NC 27157 USA; [Nyholt, Dale R.] Queensland Inst Med Res, Neurogenet Lab, Queensland 4006, Australia; [Pellikka, Niina; Perola, Markus; Surakka, Ida; Kettunen, Johannes; Widen, Elisabeth; Ripatti, Samuli; Kaprio, Jaakko] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki 00014, Finland; [Pellikka, Niina; Perola, Markus; Surakka, Ida; Kettunen, Johannes; Ripatti, Samuli; Peltonen, Leena] Natl Inst Hlth & Welfare, Dept Chron Dis Prevent, Unit Publ Hlth Gen, FIN-00014 Helsinki, Finland; [Bhangale, Tushar] Univ Washington, Dept Gen Sci, Seattle, WA 98195 USA; [Chasman, Daniel I.; Ridker, Paul M.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; [Chasman, Daniel I.; Kaplan, Lee M.; Ridker, Paul M.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Chen, Constance] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA; [Coin, Lachlan; Sovio, Ulla; Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Fac Med, Dept Epidemiol & Biostat, London W2 1PG, England; [Cooper, Matthew N.; Lawrence, Robert W.; Hui, Jennie; Palmer, Lyle J.] Univ Western Australia, Ctr Genet Epidemiol & Biostatist, Crawley, WA 6009, Australia; [Dixon, Anna L.] Univ Bath, Bath BA1 1RL, Avon, England; [Dixon, Anna L.] Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England; [Gibson, Quince; Haiqing, Shen; Shuldiner, Alan R.; O'Connell, Jeffrey R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Hao, Ke] Rosetta Inpharmat Wholly Owned Subsidiary Merck&C, Dept Genet, Seattle, WA 98109 USA; [Junttila, M. Juhani; Huikuri, Heikki V.] Univ Oulu, Dept Internal Med, Oulu 90014, Finland; [Kaplan, Lee M.] Massachusetts Gen Hosp, MGH Weight Ctr, Boston, MA 02114 USA; [Levinson, Douglas F.] Stanford Univ, Sch ofMedicine, Stanford, CA 93405 USA; [Lorentzon, Mattias; Vandenput, Liesbeth; Ohlsson, Claes] Univ Gothenburg, Inst Med, Dept Internal Med, Sahlgrenska Acad, S-41345 Gothenburg, Sweden; [McKnight, Barbara; Arnold, Alice M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Mueller, Martina] Univ Munich, Dept Med 1, Univ Hosp Grosshadern, D-81377 Munich, Germany; [Mueller, Martina; Schadt, H. -Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Chair Epidemiol, D-81377 Munich, Germany; [Ngwa, Julius Suh; White, Charles C.; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Purcell, Shaun; Schreiber, Stefan; Peltonen, Leena] Broad Inst Harvard, Cambridge, MA 02142 USA; [Purcell, Shaun; Peltonen, Leena] MIT, Cambridge, MA 02142 USA; [Purcell, Shaun] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Rafelt, Suzanne; Samani, Nilesh J.] Univ Leicester, Glenfield Hosp, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England; [Salvi, Erika; Cusi, Daniele] Univ Milan, Dept Med Surg & Dent, I-20139 Milan, Italy; [Salvi, Erika] KOS Genet Srl, I-20123 Milan, Italy; [Sanna, Serena; Maschio, Andrea; Mulas, Antonella; Uda, Manuela] Ist Neurogenet & Neurofarmacol CNR, I-09042 Cagliari, Italy; [Thompson, John R.; Samani, Nilesh J.] Glenfield Hosp, Leicester NIHR Biomed Res Unit Cardiovasc Dis, Leicester LE3 9QP, Leics, England; [Thompson, John R.] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England; [Ziegler, Andreas] Univ Lubeck, Inst Med Biometrie & Stat, D-23562 Lubeck, Germany; [Almgren, Peter; Groop, Leif C.] Lund Univ, Ctr Diabet, Dept Clin Sci, S-20502 Malmo, Sweden; [Balmforth, Anthony J.; Hall, Alistair S.] Univ Leeds, Multidisciplinary Cardiovasc Res Ctr, Leeds Inst Genet Hlth & Therapeut, Leeds LS2 9JT, W Yorkshire, England; [Campbell, Harry; Wild, Sarah H.; Wilson, James F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Citterio, Lorena; Zagato, Laura] Univ Vita Salute San Raffaele, Div Nephrol & Dialysis, I-20132 Milan, Italy; [De Grandi, Alessandro; Dominiczak, Anna; Hicks, Andrew A.; Pichler, Irene; Pramstaller, Peter P.] European Acad Bozen Bolzano EURAC, Inst Med Genet, I-39100 Bolzano, Italy; [De Grandi, Alessandro; Dominiczak, Anna; Hicks, Andrew A.; Pichler, Irene; Pramstaller, Peter P.] Univ Lubeck, Affiliated Inst, Lubeck, Germany; [Strachan, David P.] Univ Glasgow, British Heart Fdn Glasgow Cardiovascular Res Ct, Glasgow G12 8TA, Lanark, Scotland; [Duan, Jubao; Sanders, Alan R.; Gejman, Pablo V.] Northshore Univ Healthsyst, Evanston, IL 60201 USA; [Elosua, Roberto; Eriksson, Johan G.] Inst Municipal Invest Medica & CIBER Epidemiol &, Barcelona, Spain; Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki 00014, Finland; [Eriksson, Johan G.; Kajantie, Eero] Natl Inst Hlth & Welf, Helsinki 00271, Finland; [Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki 00280, Finland; [Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki 00250, Finland; [Eriksson, Johan G.] Vasa Cent Hosp, Vaasa 65130, Finland; [Freimer, Nelson B.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Los Angeles, CA 90095 USA; [Glorioso, Nicola] Univ Sassari, Hypertens & Cardiovasc Prevent Ctr, I-07100 Sassari, Italy; [Hartikainen, Anna-Liisa; Pouta, Anneli] Univ Oulu, Dept Clin Sci Obstet & Gynecol, Oulu 90014, Finland; [Havulinna, Aki S.; Koskinen, Seppo; Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Chron Dis Epidemiol & Prevent Unit, Helsinki 00014, Finland; [Hui, Jennie; Beilby, John P.] QEII Med Ctr, PathW Lab Western Australia, Dept Mol Genet, Nedlands, WA 6009, Australia; [Hui, Jennie; Beilby, John P.; Musk, Arthur W.; Palmer, Lyle J.] Sir Charles Gairdner Hosp, Busselton Populat Med Res Fdn Inc, Nedlands, WA, Australia; [Jula, Antti] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Populat Studies Unit, Turku 20720, Finland; [Koiranen, Markku; Jarvelin, Marjo-Ritta] Univ Oulu, Inst Hlth Sci, Oulu 90014, Finland; [Kovacs, Peter] Univ Leipzig, Interdisciplinary Ctr Clin Res, D-04103 Leipzig, Germany; [Laitinen, Jaana] Finnish Inst Occupat Hlth, Oulu 90220, Finland; [Liu, Jianjun] Genome Inst Singapore, Singapore 138672, Singapore; [Lokki, Marja-Liisa] Univ Helsinki, Haartman Inst, Transplantat Lab, Helsinki 00014, Finland; [Marusic, Ana; Rudan, Igor] Univ Split, Sch Med, Croatian Ctr Global Hlth, Split 21000, Croatia; [Meitinger, Thomas] Klinikum Rechts Isar Techn Univ Mu nchen, Inst Human Genet, D-81675 Munich, Germany; [Meitinger, Thomas] Helmholtz Zentrum Munchen German Res Ctr Environm, Inst Human Genet, D-85764 Neuherberg, Germany; [Pare, Guillaume] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Parker, Alex N.] Amgen Inc, Cambridge, MA 02139 USA; [Peden, John F.; Farrall, Martin; Watkins, Hugh; Procardis Consortium] Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; [Petersmann, Astrid] Ernst Moritz Arndt Univ Greifswald, Inst Klin Chem, D-17475 Greifswald, Germany; [Petersmann, Astrid] Ernst Moritz Arndt Univ Greifswald, Lab Med, D-17475 Greifswald, Germany; [Pietilainen, Kirsi H.; Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki 00014, Finland; [Pietilainen, Kirsi H.; Rissanen, Aila] Univ Helsinki, Cent Hosp, Dept Psychiat, Obes Res unit, Helsinki, Finland; [Pouta, Anneli; Jarvelin, Marjo-Ritta] Natl Inst Hlth & Welf, Oulu 90101, Finland; [Riddertrale, Martin; Melander, Olle] Lund Univ, Dept Clin Sci, S-20502 Maimo, Sweden; [Sambrook, Jennifer G.; Ouwehand, Willem H.] Univ Cambridge, Dept Haematol, Cambridge CB2 OPT, England; [Sambrook, Jennifer G.; Ouwehand, Willem H.] Cambridge Ctr, Cambridge CB2 0PT, England; [Schmidt, Carsten Oliver; Hoffman, Wolfgang; Voelzke, Henry] Inst Community Med, D-17489 Greifswald, Germany; [Sinisalo, Juha; Nieminen, Markku S.] Univ Helsinki, Cent Hosp, Cardiovasc Lab, Div Cardiol, Helsinki 00029, Finland; [Smit, Jan H.; Penninx, Brenda W.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiatry EMGO Inst, NL-1081 BT Amsterdam, Netherlands; [Zitting, Paavo] Lapland Cent Hosp, Dept Physiat, Rovaniemi 96101, Finland; [Farrall, Martin] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [McArdle, Wendy L.] Univ Bristol, Dept Social Med, ALSPAC, Bristol BS8 2BN, Avon, England; [Aben, Katja K.; Kiemeney, Lambertus] Comprehens Canc Ctr E, NL-6501 BG Nijmegen, Netherlands; [Beckmann, Jacques S.] CHU Vaudois, Univ Hosp, Serv Med Genet, CH-1011 Lausanne, Switzerland; [Beilby, John P.] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA 6009, Australia; [Bergman, Richard N.] Univ So Calif, Keck Sch Med, Dept Phys & Biophys, Los Angeles, CA 90033 USA; [Collins, Francis S.] Natl Human Genome Res Inst, Natl Inst Hlth, Bethesda, MD 20892 USA; [den Heijer, Martin] Radboud Univ Nijmegen, Med Ctr, Dept Endocrinol, NL-6500 HB Nijmegen, Netherlands; [Hamsten, Anders] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Atherosclerosis Res Unit, S-17176 Solna, Sweden; [Iribarren, Carlos] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA; [Iribarren, Carlos] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA; [Kahonen, Mika] Univ Tampere, Dept Clin Physiol, Tampere 33520, Finland; [Kahonen, Mika] Tampere Univ Hosp, Tampere 33520, Finland; [Kaprio, Jaakko] Natl Inst Hlth & Welf, Dept Mental Hlth & Substance Abuse Serv, Unit Child & Adolescent Mental Hlth, Helsinki 00271, Finland; [Kathiresan, Sekar; McCarthy, Mark I.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Kathiresan, Sekar; McCarthy, Mark I.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; [Kathiresan, Sekar; O'Donnell, Christopher J.] Boston Univ, Framingham, MA 01702 USA; [Kathiresan, Sekar; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; [Kathiresan, Sekar] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Kiemeney, Lambertus] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostatist & HTA, NL-6500 HB Nijmegen, Netherlands; [Kiemeney, Lambertus] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6500 HB Nijmegen, Netherlands; [Kocher, Thomas] Zentrum Zahn Mund & Kieferheilkunde, D-17489 Greifswald, Germany; [Launer, Lenore J.; Harris, Tamara B.] Natl Inst Hlth, NIA, Lab Epidemiol Demog, Bethesda, MD 20892 USA; [Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, Tampere 33520, Finland; [Lehtimaki, Terho] Tampere Univ Hosp, Dept Clin Chem, Tampere 33520, Finland; [Mosley, Tom H., Jr.] Univ Mississippi, Div Geriatr, Med Ctr, Dept Med, Jackson, MS 39216 USA; [Musk, Arthur W.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [O'Donnell, Christopher J.] Natl Inst Hlth, Nat Lung & Blood Inst, Framingham, MA 01702 USA; [Oostra, Ben] Erasmus MC, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; [Raitakari, Olli] Turku Univ, Res Ctr Appl & Prevent Cardiovasc Med, Turku 20520, Finland; [Raitakari, Olli] Turku Univ Hosp, Dept Clin Physiol, Turku 20520, Finland; [Schunkert, Heribert; Erdmann, Jeanette] Univ Lubeck, Med Klin 2, D-23562 Lubeck, Germany; [Shuldiner, Alan R.] Baltimore Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21201 USA; [Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Stumvoll, Michael; Toenjes, Anke] Univ Leipzig, Dept Med, D-04103 Leipzig, Germany; [Stumvoll, Michael] Univ Leipzig, LIFE Study Ctr, Leipzig, Germany; [Toenjes, Anke] Univ Leipzig, Coordinat Ctr Clin Trials, D-04103 Leipzig, Germany; [Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki 00271, Finland; [Tuomilehto, Jaakko] Univ Helsinki, Dept Publ Hlth, Hjelt Inst, Helsinki 00014, Finland; [Tuomilehto, Jaakko] S Ostrobothnia Cent Hosp, Seinajoki 60220, Finland; [van Ommen, Gert-Jan] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZC Leiden, Netherlands; [van Ommen, Gert-Jan] Leiden Univ, Med Ctr, Ctr Med Syst Biol, NL-2333 ZC Leiden, Netherlands; [Viikari, Jorma] Univ Turku, Dept Med, Turku 20520, Finland; [Viikari, Jorma] Turku Univ Hosp, Turku 20520, Finland; [Heath, Andrew C.] Washington Univ, Sch Med, Dept Psychiat & Midwest, Res Inst Alcoholism, St Louis, MO 63108 USA; [Martin, Nicholas G.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Montgomery, Grant W.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Province, Michael A.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Kayser, Manfred] Erasmus MC, Dept Forens Mol Biol, NL-3015 GE Rotterdam, Netherlands; [Arnold, Alice M.] Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98115 USA; [Boerwinkle, Eric] Univ Texas Houston, Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77030 USA; [Boerwinkle, Eric] Univ Texas Houston, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA; [Boerwinkle, Eric] Univ Texas Houston, Hlth Sci Ctr, Div Epidemiol, Houston, TX 77030 USA; [Hengstenberg, Christian] Univ Regensburg, Klin & Poliklin Innere Med 2, D-93053 Regensburg, Germany; [Hengstenberg, Christian] Univ Regensburg, Med Ctr, Innere Med 2, D-93053 Regensburg, Germany; [Lathrop, G. Mark] Ctr Natl Genotypage, F-91057 Paris, France; [Schreiber, Stefan] Univ Kiel, Univ Hosp Schleswig Holstein, Clin Mol Biol, D-24105 Kiel, Germany; [Schreiber, Stefan] Dept Internal Med 1, D-24105 Kiel, Germany; [Waterworth, Dawn; Mooser, Vincent] GlaxoSmithKline, Div Genet, King Of Prussia, PA 19406 USA; [Barroso, Ines] Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 OQQ, England; [Fox, Caroline S.] NHLBI, Div Intramural Res, Framingham, MA 01702 USA; [Hayes, Richard B.] NYU, Med Ctr, New York, NY 10016 USA; [Jarvelin, Marjo-Ritta] Univ Oulu, Bioctr Oulu, Oulu 90014, Finland; [Penninx, Brenda W.] Leiden Univ, Med Ctr, Dept Psychiat, NL-2300 RC Leiden, Netherlands; [Penninx, Brenda W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9713 GZ Groningen, Netherlands; [Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Bolzano, Italy; [Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [North, Kari E.] Univ N Carolina, Sch Publ Hlth, Carolina Ctr Genome Sci, Chapel Hill, NC 27514 USA; [Schlessinger, David] NIA, Genet Lab, Baltimore, MD 21224 USA; [Strachan, David P.] St Georges Univ London, Div Community Hlth Sci, London SW17 0RE, England; [Schadt, H. -Erich] Klinikum Grosshadern, D-81377 Munich, Germany; [Eriksson, Johan G.] Pacific Biosci, Menlo Pk, CA 94025 USA; Sage Bionetworks, Seattle, WA 98109 USA; [Thorsteinsdottir, Unnur] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland; [Peltonen, Leena] Univ Helsinki, Dept Med Genet, Helsinki 00014, Finland; [McCarthy, Mark I.] Churchill Hosp, NIHR Oxford Biomed Res Ctr, Oxford OX3 7LJ, England; [Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	University of Exeter; University of Plymouth; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Universite de Montreal; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Oxford; Wellcome Centre for Human Genetics; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Wellcome Trust Sanger Institute; University of London; King's College London; QIMR Berghofer Medical Research Institute; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Icelandic Heart Association; University of Iceland; McGill University; McGill University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Regensburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Melbourne; Uppsala University; Norwegian University of Science & Technology (NTNU); Washington University (WUSTL); University of Tartu; Estonian Biocentre; University of Tartu; University of Lausanne; Swiss Institute of Bioinformatics; University of London; Queen Mary University London; University of London; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Oxford; Ernst Moritz Arndt Universitat Greifswald; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Edinburgh; Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; University of Zagreb; University of Lubeck; University of Cambridge; Karolinska Institutet; Wake Forest University; QIMR Berghofer Medical Research Institute; University of Helsinki; Finland National Institute for Health & Welfare; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Imperial College London; University of Western Australia; University of Bath; Royal National Hospital for Rheumatic Diseases (RNHRD); University System of Maryland; University of Maryland Baltimore; Merck & Company; University of Oulu; Harvard University; Massachusetts General Hospital; Stanford University; University of Gothenburg; University of Washington; University of Washington Seattle; University of Munich; University of Munich; Boston University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Milan; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester; University of Lubeck; Lund University; University of Leeds; University of Edinburgh; Vita-Salute San Raffaele University; European Academy of Bozen-Bolzano; University of Lubeck; University of Glasgow; NorthShore University Health System; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; Folkhalsan Research Center; Vaasa Central Hospital; University of California System; University of California Los Angeles; University of Sassari; University of Oulu; Finland National Institute for Health & Welfare; University of Western Australia; University of Western Australia; Finland National Institute for Health & Welfare; University of Oulu; Leipzig University; Finnish Institute of Occupational Health; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of Helsinki; University of Split; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; McMaster University; Amgen; University of Oxford; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; Lund University; University of Cambridge; University of Helsinki; Helsinki University Central Hospital; Vrije Universiteit Amsterdam; University of Oxford; Wellcome Centre for Human Genetics; University of Bristol; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Western Australia; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Radboud University Nijmegen; Karolinska Institutet; Karolinska University Hospital; Kaiser Permanente; University of California System; University of California San Francisco; Tampere University; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School; Radboud University Nijmegen; Radboud University Nijmegen; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Tampere University; Tampere University; Tampere University Hospital; University of Mississippi; University of Mississippi Medical Center; University of Western Australia; National Institutes of Health (NIH) - USA; Erasmus University Rotterdam; Erasmus MC; University of Turku; University of Turku; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Leipzig University; Leipzig University; Leipzig University; Finland National Institute for Health & Welfare; University of Helsinki; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Turku; University of Turku; Washington University (WUSTL); QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; Washington University (WUSTL); Erasmus University Rotterdam; Erasmus MC; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Regensburg; University of Regensburg; CEA; University of Kiel; Schleswig Holstein University Hospital; GlaxoSmithKline; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); New York University; University of Oulu; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Groningen; Krankenhaus Bozen; Yeshiva University; Albert Einstein College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); St Georges University London; University of Munich; University of Iceland; University of Helsinki; University of Oxford; Harvard University; Harvard Medical School	Allen, HL (corresponding author), Univ Exeter, Peninsula Coll Med & Dent, Exeter EX1 2LU, Devon, England.		Loos, Ruth J F/Q-2862-2016; Hengstenberg, Christian/U-5485-2019; Kaplan, Robert/A-2526-2011; Rotter, Jerome/AAY-6598-2021; Lehtimäki, Terho/AAD-1094-2022; Colaus, PsyColaus/K-6607-2013; Pare, Guillaume/T-9631-2018; Campbell, Harry/E-2959-2010; Johansson, Åsa/AAG-6799-2021; Prokopenko, Inga/H-3241-2014; Assimes, Themistocles Leonard/D-9696-2015; Mägi, Reedik/AAJ-9679-2021; Dominiczak, Anna F/P-9390-2017; Vandenput, Liesbeth/AAP-3655-2020; Wood, Andrew R/AAB-3807-2019; Hicks, Andrew Anthony/E-9518-2017; sanna, serena/H-3009-2019; Wilson, James F/A-5704-2009; de Geus, Eco J.C./M-9318-2015; Uda, Manuela/AAC-2645-2019; Spector, Tim D/F-6533-2012; Pramstaller, Peter P/C-2357-2008; Meitinger, Thomas/O-1318-2015; Montgomery, Grant W/B-7148-2008; Segre, Ayellet V/E-9800-2010; Schmidt, Carsten Oliver/AAH-2778-2019; Boomsma, Dorret I/AAX-4470-2020; Stumvoll, Michael/ABE-1121-2021; Berndt, Sonja I/J-8423-2016; Liu, Jianjun/AAK-4989-2020; Nelis, Mari/ABG-7775-2020; Aspelund, Thor/F-4826-2011; Deloukas, Panos/B-2922-2013; Ridderstråle, Martin/F-7678-2012; Kaprio, Jaakko/A-1820-2008; Mulas, Antonella/B-4231-2015; Visscher, Peter/ABB-6151-2020; Rioux, John D/A-9599-2015; Cooper, Matthew N/J-4420-2014; Hall, Alistair/K-1953-2019; Allen, Hana Lango/G-9026-2012; Feitosa, Mary F/K-8044-2012; Sovio, Ulla/H-8532-2019; Hayward, Caroline/M-8818-2016; Aben, Katja KH/G-9686-2016; Ohlsson, Claes/AGP-3544-2022; Amin, Najaf N/D-1859-2012; Lorentzon, Mattias/W-7878-2019; Coin, Lachlan JM/A-9001-2014; Johansson, Åsa/G-5270-2011; Ohlsson, Claes/HIR-6959-2022; Kiemeney, Lambertus A./D-3357-2009; Stefansson, Kari/AAE-7187-2019; Palmer, Lyle John/N-1948-2019; Kilpeläinen, Tuomas/F-8569-2012; Nyholt, Dale Robert/J-3174-2017; Polasek, Ozren/B-6002-2011; Zagato, Laura/AAC-7739-2022; Walters, G. Bragi/L-4215-2013; Voight, Benjamin/F-1775-2011; Erdmann, Jeanette/P-7513-2014; Rivadeneira, Fernando/O-5385-2015; König, Inke R/A-4544-2009; Loos, Ruth/GON-5877-2022; Beckmann, Jacques S/A-9772-2008; Salvi, Erika/C-1033-2015; Yang, Jian/A-5852-2010; Kutalik, Zoltan/HHZ-5697-2022; Müller-Nurasyid, Martina/I-8735-2018; Gudnason, Vilmundur/K-6885-2015; Mangino, Massimo/F-5134-2011; Havulinna, Aki/AAM-4769-2021; Vandenput, Liesbeth/AAI-4100-2021; Coin, Lachlan/O-4976-2019; Zgaga, Lina/Q-9415-2018; Citterio, Lorena/AAC-1589-2019; Kolcic, Ivana/E-2713-2017; Erdmann, Jeanette/A-4417-2009; Aulchenko, Yurii/M-8270-2013; Penninx, Brenda WJH/S-7627-2017; Salvi, Erika/AAA-1415-2019; Marusic, Ana/E-7683-2013; Aspelund, Thor/C-5983-2008; Palmer, Lyle John/K-3196-2014; Hui, Jennie/A-9543-2013; Rudan, Igor/I-1467-2012; Raitakari, Olli/AAQ-7389-2021; Smith, Albert Vernon/K-5150-2015; Abecasis, Goncalo R/B-7840-2010; Maschio, Andrea/AAX-8185-2020; Ripatti, Samuli/H-9446-2014; Aspelund, Thor/K-7022-2019; Gudnason, Vilmundur/AAE-7126-2019; Prokopenko, Inga/AAU-9895-2020; den Heijer, Martin/J-8036-2015; Ziegler, Andreas/G-4246-2012; McCarthy, Mark/M-3763-2015	Loos, Ruth J F/0000-0002-8532-5087; Lehtimäki, Terho/0000-0002-2555-4427; Pare, Guillaume/0000-0002-6795-4760; Campbell, Harry/0000-0002-6169-6262; Johansson, Åsa/0000-0002-2915-4498; Prokopenko, Inga/0000-0003-1624-7457; Assimes, Themistocles Leonard/0000-0003-2349-0009; Dominiczak, Anna F/0000-0003-4913-3608; Vandenput, Liesbeth/0000-0002-1712-6131; Wood, Andrew R/0000-0003-1726-948X; Hicks, Andrew Anthony/0000-0001-6320-0411; sanna, serena/0000-0002-3768-1749; Wilson, James F/0000-0001-5751-9178; de Geus, Eco J.C./0000-0001-6022-2666; Uda, Manuela/0000-0002-4890-6456; Montgomery, Grant W/0000-0002-4140-8139; Schmidt, Carsten Oliver/0000-0001-5266-9396; Stumvoll, Michael/0000-0001-6225-8240; Liu, Jianjun/0000-0002-3255-3019; Nelis, Mari/0000-0001-9748-1020; Deloukas, Panos/0000-0001-9251-070X; Kaprio, Jaakko/0000-0002-3716-2455; Visscher, Peter/0000-0002-2143-8760; Rioux, John D/0000-0001-7560-8326; Cooper, Matthew N/0000-0003-1139-3682; Allen, Hana Lango/0000-0002-7803-8688; Feitosa, Mary F/0000-0002-0933-2410; Sovio, Ulla/0000-0002-0799-1105; Hayward, Caroline/0000-0002-9405-9550; Aben, Katja KH/0000-0002-0214-2147; Ohlsson, Claes/0000-0002-9633-2805; Lorentzon, Mattias/0000-0003-0749-1431; Coin, Lachlan JM/0000-0002-4300-455X; Johansson, Åsa/0000-0002-2915-4498; Ohlsson, Claes/0000-0002-9633-2805; Kiemeney, Lambertus A./0000-0002-2368-1326; Palmer, Lyle John/0000-0002-1628-3055; Kilpeläinen, Tuomas/0000-0002-8349-3028; Nyholt, Dale Robert/0000-0001-7159-3040; Polasek, Ozren/0000-0002-5765-1862; Walters, G. Bragi/0000-0002-5415-6487; Erdmann, Jeanette/0000-0002-4486-6231; Rivadeneira, Fernando/0000-0001-9435-9441; König, Inke R/0000-0003-0504-6465; Beckmann, Jacques S/0000-0002-9741-1900; Salvi, Erika/0000-0002-2724-2291; Yang, Jian/0000-0003-2001-2474; Kutalik, Zoltan/0000-0001-8285-7523; Müller-Nurasyid, Martina/0000-0003-3793-5910; Gudnason, Vilmundur/0000-0001-5696-0084; Mangino, Massimo/0000-0002-2167-7470; Vandenput, Liesbeth/0000-0002-1712-6131; Coin, Lachlan/0000-0002-4300-455X; Zgaga, Lina/0000-0003-4089-9703; Citterio, Lorena/0000-0001-6455-2291; Kolcic, Ivana/0000-0001-7918-6052; Aulchenko, Yurii/0000-0002-7899-1575; Penninx, Brenda WJH/0000-0001-7779-9672; Salvi, Erika/0000-0002-2724-2291; Marusic, Ana/0000-0001-6272-0917; Aspelund, Thor/0000-0002-7998-5433; Palmer, Lyle John/0000-0002-1628-3055; Hui, Jennie/0000-0002-1653-2496; Rudan, Igor/0000-0001-6993-6884; Smith, Albert Vernon/0000-0003-1942-5845; Ripatti, Samuli/0000-0002-0504-1202; Aspelund, Thor/0000-0002-7998-5433; Gudnason, Vilmundur/0000-0001-5696-0084; Goddard, Michael/0000-0001-9917-7946; Meitinger, Thomas/0000-0002-8838-8403; Hall, Alistair/0000-0003-0306-7887; Workalemahu, Tsegaselassie/0000-0003-4571-9740; Watkins, Hugh/0000-0002-5287-9016; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Abecasis, Goncalo/0000-0003-1509-1825; Caulfield, Mark/0000-0001-9295-3594; Magi, Reedik/0000-0002-2964-6011; Weyant, Robert/0000-0002-5252-9120; Hattersley, Andrew/0000-0001-5620-473X; Melander, Olle/0000-0002-2581-484X; Pietilainen, Kirsi/0000-0002-8522-1288; Hayes, Richard/0000-0002-0918-661X; Bergman, Richard/0000-0003-1539-4471; Kovacs, Peter/0000-0002-0290-5423; Peters, Marjolein/0000-0003-3167-9063; Gieger, Christian/0000-0001-6986-9554; van Meurs, Joyce/0000-0001-6245-2123; Martin, Nicholas/0000-0003-4069-8020; Kahonen, Mika/0000-0002-4510-7341; Elliott, Paul/0000-0002-7511-5684; Voight, Benjamin/0000-0002-6205-9994; Shuldiner, Alan/0000-0001-9921-4305; Esko, Tonu/0000-0003-1982-6569; Steinthorsdottir, Valgerdur/0000-0003-1846-6274; Willemsen, Gonneke/0000-0003-3755-0236; Van Duijn, Cornelia/0000-0002-2374-9204; Johnson, Toby/0000-0002-5998-3270; Barroso, Ines/0000-0001-5800-4520; Weedon, Michael/0000-0002-6174-6135; Rivolta, Carlo/0000-0002-0733-9950; den Heijer, Martin/0000-0003-3620-5617; Salem, Rany/0000-0001-8816-6862; Heard-Costa, Nancy/0000-0001-9730-0306; Glazer, Nicole/0000-0002-6397-609X; Turchin, Michael/0000-0003-3569-1529; Ziegler, Andreas/0000-0002-8386-5397; Munroe, Patricia/0000-0002-4176-2947; Zagato, Laura/0000-0002-0441-2120; Gudbjartsson, Daniel/0000-0002-5222-9857; Raychaudhuri, Soumya/0000-0002-1901-8265; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Preuss, Michael/0000-0001-5266-8465; Surakka, Ida/0000-0002-6669-5541; Beilby, John/0000-0002-4915-2254; Mulas, Antonella/0000-0002-6856-1483; Sinisalo, Juha/0000-0002-0169-5137; Soranzo, Nicole/0000-0003-1095-3852; McCarthy, Mark/0000-0002-4393-0510; maschio, andrea/0000-0002-4238-9144; Ouwehand, Willem/0000-0002-7744-1790; Pichler, Irene/0000-0001-8251-0757; Cupples, L. Adrienne/0000-0003-0273-7965; Quertermous, Thomas/0000-0002-7645-9067; Lindgren, Cecilia/0000-0002-4903-9374; Willer, Cristen/0000-0001-5645-4966; Pramstaller, Peter P/0000-0002-9831-8302; Wheeler, Eleanor/0000-0002-8616-6444; Eriksson, Johan/0000-0002-2516-2060; Bergmann, Sven/0000-0002-6785-9034; Frayling, Timothy/0000-0001-8362-2603; Randall, Joshua/0000-0003-1540-203X; Amin, Najaf/0000-0002-8944-1771	Academy of Finland [104781, 117797, 120315, 121584, 126925, 129269, 129494, 129680, 213506]; Affymetrix for genotyping services [N02-HL-6-4278]; Agency for Science, Technology and Research of Singapore; ALF/LUA Gothenburg; Althingi (the Icelandic Parliament); Amgen; AstraZeneca AB; Australian National Health and Medical Research Council [241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485, 613672]; Australian Research Council [DP0770096]; Biocentrum Helsinki; Boston Obesity Nutrition Research Center [DK46200]; British Diabetes Association; British Heart Foundation [PG/02/128]; British Heart Foundation Centre for Research Excellence, Oxford; CamStrad; Cancer Research UK; Centre for Neurogenomics and Cognitive Research; Chief Scientist Office of the Scottish Government [CZB/4/279]; Council of Health of the Academy of Finland; German Network of Diabetes; Diabetes UK; Donald W. Reynolds Foundation; Emil and Vera Cornell Foundation; Erasmus MC; Estonian Government [SF0180142s08]; European Commission [201413, ECOGENE:205419, BBMRI:212111, OPENGENE:245536, ENGAGE:HEALTH-F4-2007-201413, EURODIA:LSHG-CT-2004-518153, EU/WLRT-2001-01254, HEALTH-F2-2008-ENGAGE, HEALTH-F4-2007-201550, LSH-2006-037593, LSHG-CT-2006-018947, LSHG-CT-2006-01947, Procardis:LSHM-CT-2007-037273, POLYGENE:LSHC-CT-2005, QLG1-CT-2000-01643, QLG2-CT-2002-01254]; Eve Appeal; Finnish Ministry of Education; Finnish Diabetes Research Foundation; Finnish Diabetes Research Society; Finnish Foundation for Cardiovascular Research; Finnish Medical Society; Finska Lakaresallskapet; Folkhalsan Research Foundation; Fondation LeDucq; Foundation for Life and Health in Finland; Foundation for Strategic Research; GEN-AU; Genetic Association Information Network; German Bundesministerium fuer Forschung und Technology [01 AK 803 A-H, 01 IG 07015 G]; German Federal Ministry of Education and Research [01GS0831]; German Ministry for Health, Welfare and Sports; German Ministry of Cultural Affairs; German Ministry of Education, Culture and Science; German National Genome Research Net [01GS0823, 01ZZ0103, 01ZZ0403, 01ZZ9603, 03ZIK012]; German Research Council [KFO-152]; GlaxoSmithKline; Goteborg Medical Society; Gyllenberg Foundation; Helmholtz Center Munich; Juvenile Diabetes Research Foundation International [U01 DK062418]; Karolinska Institute; Knut and Alice Wallenberg Foundation; Lundberg Foundation; March of Dimes [6-FY-09-507]; MC Health; Medical Research Council UK [G0000649, G0000934, G0500539, G0600331, G0601261, G9521010D]; Microarray Core Facility of the Interdisciplinary Centre for Clinical Research [B27]; Mid-Atlantic Nutrition and Obesity Research Center of Maryland [P30 DK072488]; Ministry of Health and Department of Educational Assistance (South Tyrol, Italy); Ministry of Science, Education and Sport of the Republic of Croatia [216-1080315-0302]; Montreal Heart Institute Foundation; Narpes Health Care Foundation; National Cancer Institute; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute for Health Research Oxford Biomedical Research Centre; National Institute for Health Research Comprehensive Biomedical Research Centre; National Institutes of Health [263-MA-410953, AA014041, AA07535, AA10248, AA13320, AA13321, AA13326, CA047988, CA49449, CA50385, CA65725, CA67262, CA87969, DA12854, DK062370, DK063491, DK072193, DK079466, DK080145, DK58845, HG002651, HG005214, HG005581, HL043851, HL084729, HL69757, HL71981, K08-AR055688]; ADA; Netherlands Genomics Initiative/Netherlands Consortium for Healthy Aging [050-060-810]; Netherlands Organisation for Scientific Research [175.010.2005.011, 911-03-012]; Netherlands Organization for the Health Research and Development [10-000-1002]; Netherlands Scientific Organization [904-61-090, 904-61-193, 480-04-004, 400-05-717, SPI 56-464-1419]; NIA; Nordic Center of Excellence in Disease Genetics; Novo Nordisk Foundation; Ollqvist Foundation; Paavo Nurmi Foundation; Perklen Foundation; Petrus and Augusta Hedlunds Foundation; Queensland Institute of Medical Research; Radboud University Nijmegen Medical Centre; Research Institute for Diseases in the Elderly [014-93-015]; Royal Swedish Academy of Science; Sahlgrenska Center for Cardiovascular and Metabolic Research [A305:188]; Siemens Healthcare, Erlangen, Germany; Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation; Social Insurance Institution of Finland; Social Ministry of the Federal State of Mecklenburg-West Pomerania; South Tyrolean Sparkasse Foundation; Stockholm County Council; Support for Science Funding programme; Susan G. Komen Breast Cancer Foundation; Swedish Cancer Society; Swedish Cultural Foundation in Finland; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; Swedish Medical Research Council; Swedish National Cancer Institute; Swedish Research Council; Swedish Society of Medicine; Swiss National Science Foundation; Torsten and Ragnar Soderberg's Foundation; Vandervell Foundation; Vastra Gotaland Foundation; Wellcome Trust [072960, 075491, 079557, 079895, 083270, 068545/Z/02, 076113/B/04/Z, 076113/C/04/Z, 077016/Z/05/Z, 081682/Z/06/Z, 084183/Z/07/Z, 085301/Z/08/Z, 086596/Z/08/Z, 091746/Z/10/Z]; Wellcome Trust; Western Australian Genetic Epidemiology Resource; Western Australian DNA Bank;  [560183];  [K2007-66X-20270-01-3];  [8691];  [33CSCO-122661]; MRC [G9521010, MC_U106188470, G0600331, G0701863, G0000934, G0601261, MC_U127561128, MC_qA137934] Funding Source: UKRI; Medical Research Council [G0000934, G0600331, G0601261, G9521010, MC_U106179471, MC_U106188470, MC_U127561128, MC_qA137934, G0701863] Funding Source: researchfish; Chief Scientist Office [CZB/4/710] Funding Source: researchfish; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC055022, N01HC085080, N01HC045133, N01HC085085, N01HC055020, N01HC085084, N01HC085079, N01HC055016, N01HC055018, N01HC055222, N01HC055015, N01HC035129, N01HC055019, N01HC025195, N01HC085082, N01HC085083, N01HC015103, N01HC085081, N01HC055021, N01HC075150] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U01CA098233, U01CA067262, R01CA065725, P01CA087969, R01CA104021, R01CA067262, R01CA050385, R01CA049449, U01CA049449, R01CA047988] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020278, M01RR000425, UL1RR025005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080295, ZIAHL006002, R01HL064278, K99HL094535, R01HL071981, R42HL055018, R01HL087647, ZIAHL006094, U01HL084729, R01HL059367, R01HL087679, R01HL117078, U01HL072515, R01HL087641, R01HL087652, R01HL088119, R41HL055018, U19HL069757, R01HL087676, R01HL043851, U01HL084756, R01HL087700, U01HL069757, R01HL086694] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG004402, ZIAHG000024, Z01HG000024, U01HG005214, RC2HG005581, U01HG004399, R01HG002651, N01HG065403, T32HG000040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR055688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK072193, R01DK091718, R01DK058845, R01DK068336, R01DK075681, K23DK080145, R01DK089256, R01DK062370, R01DK075787, R01DK073490, R56DK062370, U01DK062370, U01DK062418, P30DK063491, F32DK079466, P30DK072488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM074518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH081800, U01MH079469, R01MH067257, R01MH059586, R01MH059571, R01MH059587, R01MH059565, R01MH063706, R01MH059160, R01MH084698, R01MH059588, RL1MH083268, R01MH059566, R01MH060879, U01MH079470, R01MH061675, R01MH060870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG007380, R01AG031890, N01AG012100, Z01AG000675, ZIAAG006000, ZIAAG007380, ZIAAG000675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013321, R01AA013326, R01AA007535, K05AA017688, R01AA013320, R01AA014041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012854, R56DA012854] Funding Source: NIH RePORTER	Academy of Finland(Academy of Finland); Affymetrix for genotyping services; Agency for Science, Technology and Research of Singapore(Agency for Science Technology & Research (A*STAR)); ALF/LUA Gothenburg; Althingi (the Icelandic Parliament); Amgen(Amgen); AstraZeneca AB(AstraZeneca); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); Biocentrum Helsinki; Boston Obesity Nutrition Research Center; British Diabetes Association(Diabetes UK); British Heart Foundation(British Heart Foundation); British Heart Foundation Centre for Research Excellence, Oxford; CamStrad; Cancer Research UK(Cancer Research UK); Centre for Neurogenomics and Cognitive Research; Chief Scientist Office of the Scottish Government; Council of Health of the Academy of Finland(Academy of Finland); German Network of Diabetes; Diabetes UK(Diabetes UK); Donald W. Reynolds Foundation; Emil and Vera Cornell Foundation; Erasmus MC; Estonian Government; European Commission(European CommissionEuropean Commission Joint Research Centre); Eve Appeal; Finnish Ministry of Education; Finnish Diabetes Research Foundation; Finnish Diabetes Research Society; Finnish Foundation for Cardiovascular Research; Finnish Medical Society; Finska Lakaresallskapet; Folkhalsan Research Foundation; Fondation LeDucq(Leducq Foundation); Foundation for Life and Health in Finland; Foundation for Strategic Research; GEN-AU; Genetic Association Information Network; German Bundesministerium fuer Forschung und Technology; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Ministry for Health, Welfare and Sports; German Ministry of Cultural Affairs; German Ministry of Education, Culture and Science; German National Genome Research Net; German Research Council(German Research Foundation (DFG)); GlaxoSmithKline(GlaxoSmithKline); Goteborg Medical Society; Gyllenberg Foundation; Helmholtz Center Munich(Helmholtz Association); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); Karolinska Institute(Karolinska Institutet); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Lundberg Foundation(European Commission); March of Dimes(March of Dimes); MC Health; Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Microarray Core Facility of the Interdisciplinary Centre for Clinical Research; Mid-Atlantic Nutrition and Obesity Research Center of Maryland; Ministry of Health and Department of Educational Assistance (South Tyrol, Italy); Ministry of Science, Education and Sport of the Republic of Croatia(Ministry of Science, Education and Sports, Republic of Croatia); Montreal Heart Institute Foundation; Narpes Health Care Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); National Institute for Health Research Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); National Institute for Health Research Comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ADA(American Diabetes Association); Netherlands Genomics Initiative/Netherlands Consortium for Healthy Aging; Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for the Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Scientific Organization; NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Nordic Center of Excellence in Disease Genetics; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Ollqvist Foundation; Paavo Nurmi Foundation; Perklen Foundation; Petrus and Augusta Hedlunds Foundation; Queensland Institute of Medical Research; Radboud University Nijmegen Medical Centre; Research Institute for Diseases in the Elderly; Royal Swedish Academy of Science; Sahlgrenska Center for Cardiovascular and Metabolic Research; Siemens Healthcare, Erlangen, Germany(Siemens AG); Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Social Insurance Institution of Finland; Social Ministry of the Federal State of Mecklenburg-West Pomerania; South Tyrolean Sparkasse Foundation; Stockholm County Council(Stockholm County Council); Support for Science Funding programme; Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Swedish Cancer Society(Swedish Cancer Society); Swedish Cultural Foundation in Finland; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish National Cancer Institute; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society of Medicine; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Torsten and Ragnar Soderberg's Foundation; Vandervell Foundation; Vastra Gotaland Foundation; Wellcome Trust(Wellcome Trust); Wellcome Trust(Wellcome Trust); Western Australian Genetic Epidemiology Resource; Western Australian DNA Bank; ; ; ; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chief Scientist Office; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Several participating studies are members of the CHARGE and ENGAGE consortia. We acknowledge funding from the following organizations: the Academy of Finland (104781, 117797, 120315, 121584, 126925, 129269, 129494, 129680, 213506); Affymetrix for genotyping services (N02-HL-6-4278); Agency for Science, Technology and Research of Singapore; ALF/LUA Gothenburg; Althingi (the Icelandic Parliament); Amgen; AstraZeneca AB; Australian National Health and Medical Research Council (241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485, 613672); Australian Research Council (DP0770096); Biocentrum Helsinki; Boston Obesity Nutrition Research Center (DK46200); British Diabetes Association; British Heart Foundation (PG/02/128); British Heart Foundation Centre for Research Excellence, Oxford; CamStrad; Cancer Research UK; Centre for Neurogenomics and Cognitive Research; Chief Scientist Office of the Scottish Government (CZB/4/279); Council of Health of the Academy of Finland; DIAB Core project of the German Network of Diabetes; Diabetes UK; Donald W.; Reynolds Foundation; Emil and Vera Cornell Foundation; Erasmus MC; Estonian Government (SF0180142s08); European Commission (201413, ECOGENE:205419, BBMRI:212111, OPENGENE:245536, ENGAGE:HEALTH-F4-2007-201413, EURODIA:LSHG-CT-2004-518153, EU/WLRT-2001-01254, HEALTH-F2-2008-ENGAGE, HEALTH-F4-2007-201550, LSH-2006-037593, LSHG-CT-2006-018947, LSHG-CT-2006-01947, Procardis:LSHM-CT-2007-037273, POLYGENE:LSHC-CT-2005, QLG1-CT-2000-01643, QLG2-CT-2002-01254, DG XII, Marie Curie Intra-European Fellowship); Eve Appeal; Finnish Ministry of Education; Finnish Diabetes Research Foundation; Finnish Diabetes Research Society; Finnish Foundation for Cardiovascular Research; Finnish Medical Society; Finska Lakaresallskapet; Folkhalsan Research Foundation; Fondation LeDucq; Foundation for Life and Health in Finland; Foundation for Strategic Research; GEN-AU-Programme 'GOLD'; Genetic Association Information Network; German Bundesministerium fuer Forschung und Technology (01 AK 803 A-H, 01 IG 07015 G); German Federal Ministry of Education and Research (01GS0831); German Ministry for Health, Welfare and Sports; German Ministry of Cultural Affairs; German Ministry of Education, Culture and Science; German National Genome Research Net (01GS0823, 01ZZ0103, 01ZZ0403, 01ZZ9603, 03ZIK012); German Research Council (KFO-152); GlaxoSmithKline; Goteborg Medical Society; Gyllenberg Foundation; Helmholtz Center Munich; Juvenile Diabetes Research Foundation International (U01 DK062418); Karolinska Institute; Knut and Alice Wallenberg Foundation; Lundberg Foundation; March of Dimes (6-FY-09-507); MC Health; Medical Research Council UK (G0000649, G0000934, G0500539, G0600331, G0601261, G9521010D, PrevMetSyn); Microarray Core Facility of the Interdisciplinary Centre for Clinical Research (B27); Mid-Atlantic Nutrition and Obesity Research Center of Maryland (P30 DK072488); Ministry of Health and Department of Educational Assistance (South Tyrol, Italy); Ministry of Science, Education and Sport of the Republic of Croatia (216-1080315-0302); Montreal Heart Institute Foundation; Narpes Health Care Foundation; National Cancer Institute; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute for Health Research Oxford Biomedical Research Centre; National Institute for Health Research Comprehensive Biomedical Research Centre; National Institutes of Health (263-MA-410953, AA014041, AA07535, AA10248, AA13320, AA13321, AA13326, CA047988, CA49449, CA50385, CA65725, CA67262, CA87969, A12854, DK062370, DK063491, DK072193, DK079466, DK080145, DK58845, HG002651, HG005214, HG005581, HL043851, HL084729, HL69757, HL71981, K08-AR055688, K23-DK080145, K99-HL094535, M01-RR00425, MH084698, N01-AG12100, N01-AG12109, N01-HC15103, N01-HC25195, N01-HC35129, N01-HC45133, N01-HC55015, N01-HC55016, N01-HC55018N01-HC55022, N01-HC55222, N01-HC75150, N01-HC85079-N01-HC85086, N01-HG65403, R01-AG031890, R01 CA104021, R01-DK068336, R01-DK073490, R01-DK075681, R01-DK075787, R01-HL086694, R01-HL087641, R01-HL087647, R01-HL087652, R01-HL087676, R01-HL087679, R01-HL087700, R01-HL088119, R01-HL59367, R01-MH059160, R01-MH59565, R01-MH59566, R01-MH59571, R01-MH59586, R01-MH59587, R01-MH59588, R01-MH60870, R01-MH60879, R01-MH61675, R01-MH63706, R01-MH67257, R01-MH79469, R01-MH81800, RL1-MH083268, T32-HG00040, U01-CA098233, U01-GM074518, U01-HG004399, U01-HG004402, U01-HL080295, U01-HL084756, U01-HL72515, U01-MH79469, U01-MH79470, U54-RR020278, UL1-RR025005, Z01-AG00675, Z01-AG007380, Z01-HG000024; contract HHSN268200625226C; ADA Mentor-Based Postdoctoral Fellowship; Pew S; holarship for the Biomedical Sciences); Netherlands Genomics Initiative/Netherlands Consortium for Healthy Aging (050-060-810); Netherlands Organisation for Scientific Research (investment number 175.010.2005.011, 911-03-012); Netherlands Organization for the Health Research and Development (10-000-1002); Netherlands Scientific Organization (904-61-090, 904-61-193, 480-04-004, 400-05-717, Center for Medical Systems Biology (NOW Genomics), SPI 56-464-1419); NIA Intramural Research Program; Nordic Center of Excellence in Disease Genetics; Novo Nordisk Foundation; Ollqvist Foundation; Paavo Nurmi Foundation; Perklen Foundation; Petrus and Augusta Hedlunds Foundation; Queensland Institute of Medical Research; Radboud University Nijmegen Medical Centre; Research Institute for Diseases in the Elderly (014-93-015); Royal Swedish Academy of Science; Sahlgrenska Center for Cardiovascular and Metabolic Research (A305:188); Siemens Healthcare, Erlangen, Germany; Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation; Social Insurance Institution of Finland; Social Ministry of the Federal State of Mecklenburg-West Pomerania; South Tyrolean Sparkasse Foundation; Stockholm County Council (560183); Support for Science Funding programme; Susan G. Komen Breast Cancer Foundation; Swedish Cancer Society; Swedish Cultural Foundation in Finland; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; Swedish Medical Research Council (K2007-66X-20270-01-3, 8691); Swedish National Cancer Institute; Swedish Research Council; Swedish Society of Medicine; Swiss National Science Foundation (33CSCO-122661); Torsten and Ragnar Soderberg's Foundation; Vandervell Foundation; Vastra Gotaland Foundation; Wellcome Trust (072960, 075491, 079557, 079895, 083270, 068545/Z/02, 076113/B/04/Z, 076113/C/04/Z, 076113/C/04/Z, 077016/Z/05/Z, 081682/Z/06/Z, 084183/Z/07/Z, 085301/Z/08/Z, 086596/Z/ 08/Z, 091746/Z/10/Z; Wellcome Trust Research Career Development Fellowship); Western Australian Genetic Epidemiology Resource and the Western Australian DNA Bank (both National Health and Medical Research Council of Australia Enabling Facilities). A detailed list of acknowledgements by study is given in the Supplementary Information.	Campbell CD, 2005, NAT GENET, V37, P868, DOI 10.1038/ng1607; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294; Estrada K, 2009, HUM MOL GENET, V18, P3516, DOI 10.1093/hmg/ddp296; Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Galton F, 1885, J R ANTHR I, V5, P329; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Gudbjartsson DF, 2008, NAT GENET, V40, P609, DOI 10.1038/ng.122; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Johansson A, 2009, HUM MOL GENET, V18, P373, DOI 10.1093/hmg/ddn350; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Lettre G, 2008, NAT GENET, V40, P584, DOI 10.1038/ng.125; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Park JH, 2010, NAT GENET, V42, P570, DOI 10.1038/ng.610; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Raychaudhuri S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000534; Reich DE, 2001, GENET EPIDEMIOL, V20, P4, DOI 10.1002/1098-2272(200101)20:1<4::AID-GEPI2>3.0.CO;2-T; Sanna S, 2008, NAT GENET, V40, P198, DOI 10.1038/ng.74; Segre AV, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001058; Soranzo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000445; Superti-Furga A, 2007, AM J MED GENET A, V143A, P1, DOI 10.1002/ajmg.a.31483; Visscher PM, 2006, PLOS GENET, V2, P316, DOI 10.1371/journal.pgen.0020041; Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121; Weedon MN, 2007, NAT GENET, V39, P1245, DOI 10.1038/ng2121; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608	28	1393	1422	6	278	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	2010	467	7317					832	838		10.1038/nature09410	http://dx.doi.org/10.1038/nature09410			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663PB	20881960	Green Submitted, Green Accepted			2022-12-28	WOS:000282898700065
J	Morello, A; Pla, JJ; Zwanenburg, FA; Chan, KW; Tan, KY; Huebl, H; Mottonen, M; Nugroho, CD; Yang, CY; van Donkelaar, JA; Alves, ADC; Jamieson, DN; Escott, CC; Hollenberg, LCL; Clark, RG; Dzurak, AS				Morello, Andrea; Pla, Jarryd J.; Zwanenburg, Floris A.; Chan, Kok W.; Tan, Kuan Y.; Huebl, Hans; Mottonen, Mikko; Nugroho, Christopher D.; Yang, Changyi; van Donkelaar, Jessica A.; Alves, Andrew D. C.; Jamieson, David N.; Escott, Christopher C.; Hollenberg, Lloyd C. L.; Clark, Robert G.; Dzurak, Andrew S.			Single-shot readout of an electron spin in silicon	NATURE			English	Article							QUANTUM DOTS; NUCLEAR-SPIN; TRANSISTOR; COMPUTATION; RELAXATION; RESONANCE; DONORS	The size of silicon transistors used in microelectronic devices is shrinking to the level at which quantum effects become important(1). Although this presents a significant challenge for the further scaling of microprocessors, it provides the potential for radical innovations in the form of spin-based quantum computers(2-4) and spintronic devices(5). An electron spin in silicon can represent a well-isolated quantum bit with long coherence times(6) because of the weak spin-orbit coupling(7) and the possibility of eliminating nuclear spins from the bulk crystal(8). However, the control of single electrons in silicon has proved challenging, and so far the observation and manipulation of a single spin has been impossible. Here we report the demonstration of single-shot, time-resolved readout of an electron spin in silicon. This has been performed in a device consisting of implanted phosphorus donors(9) coupled to a metaloxide-semiconductor single-electron transistor(10,11)-compatible with current microelectronic technology. We observed a spin lifetime of similar to 6 seconds at a magnetic field of 1.5 tesla, and achieved a spin readout fidelity better than 90 per cent. High-fidelity single-shot spin readout in silicon opens the way to the development of a new generation of quantum computing and spintronic devices, built using the most important material in the semiconductor industry.	[Morello, Andrea; Pla, Jarryd J.; Zwanenburg, Floris A.; Chan, Kok W.; Tan, Kuan Y.; Huebl, Hans; Mottonen, Mikko; Nugroho, Christopher D.; Escott, Christopher C.; Clark, Robert G.; Dzurak, Andrew S.] Univ New S Wales, Sch Elect Engn & Telecommun, Australian Res Council Ctr Excellence Quantum Com, Sydney, NSW 2052, Australia; [Yang, Changyi; van Donkelaar, Jessica A.; Alves, Andrew D. C.; Jamieson, David N.; Hollenberg, Lloyd C. L.] Univ Melbourne, Sch Phys, Australian Res Council Ctr Excellence Quantum Com, Melbourne, Vic 3010, Australia; [Mottonen, Mikko] Aalto Univ, Dept Appl Phys COMP, Aalto 00076, Finland; [Mottonen, Mikko] Aalto Univ, Low Temp Lab, Aalto 00076, Finland	University of New South Wales Sydney; University of Melbourne; Aalto University; Aalto University	Morello, A (corresponding author), Univ New S Wales, Sch Elect Engn & Telecommun, Australian Res Council Ctr Excellence Quantum Com, Sydney, NSW 2052, Australia.	a.morello@unsw.edu.au	Huebl, Hans/B-2485-2017; Morello, Andrea/B-6475-2008; Chan, Kok Wai/B-5448-2018; Möttönen, Mikko/A-6929-2012; Möttönen, Mikko/AAW-6120-2021; Zwanenburg, Floris A/K-2183-2013; Hollenberg, Lloyd/B-2296-2010; Dzurak, Andrew S/C-5973-2009; Pla, Jarryd J/J-4987-2015; Tan, Kuan Yen/G-4475-2010; Jamieson, David N/G-3753-2010	Huebl, Hans/0000-0003-3023-5209; Morello, Andrea/0000-0001-7445-699X; Chan, Kok Wai/0000-0001-8804-9893; Möttönen, Mikko/0000-0001-5084-2298; Möttönen, Mikko/0000-0001-5084-2298; Dzurak, Andrew S/0000-0003-1389-5096; Pla, Jarryd J/0000-0002-7152-3453; Tan, Kuan Yen/0000-0001-5168-4914; HOLLENBERG, LLOYD/0000-0001-7672-6965; Zwanenburg, Floris/0000-0003-1713-7866; Jamieson, David/0000-0001-7733-6715; Nugroho, Christopher/0000-0002-4396-5633	Australian Research Council; Australian Government; US National Security Agency; US Army Research Office [W911NF-08-1-0527]; Academy of Finland; Emil Aaltonen foundation	Australian Research Council(Australian Research Council); Australian Government(Australian GovernmentCGIAR); US National Security Agency(National Security Agency); US Army Research Office; Academy of Finland(Academy of Finland); Emil Aaltonen foundation	We thank D. D. Awschalom, C. Tahan, J. J. L. Morton and G. Prawiroatmodjo for comments and suggestions, W. H. Lim for assistance with device fabrication, and R. P. Starrett, D. Barber, A. Cimmino and R. Szymanski for technical assistance. We acknowledge support from the Australian Research Council, the Australian Government, the US National Security Agency and the US Army Research Office under contract number W911NF-08-1-0527. M.M. acknowledges support from the Academy of Finland and the Emil Aaltonen foundation.	Ager JW, 2005, J ELECTROCHEM SOC, V152, pG448, DOI 10.1149/1.1901674; Angus SJ, 2007, NANO LETT, V7, P2051, DOI 10.1021/nl070949k; Barthel C, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.160503; CALDERON MJ, 2009, APPL PHYS LETT, V105; De Sousa R, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.245306; Devoret MH, 2000, NATURE, V406, P1039, DOI 10.1038/35023253; DiVincenzo DP, 2000, FORTSCHR PHYS, V48, P771, DOI 10.1002/1521-3978(200009)48:9/11<771::AID-PROP771>3.0.CO;2-E; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; FEHER G, 1959, PHYS REV, V114, P1245, DOI 10.1103/PhysRev.114.1245; Goswami S, 2007, NAT PHYS, V3, P41, DOI 10.1038/nphys475; Hanson R, 2007, REV MOD PHYS, V79, P1217, DOI 10.1103/RevModPhys.79.1217; Hanson R, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.196802; HASEGAWA H, 1960, PHYS REV, V118, P1523, DOI 10.1103/PhysRev.118.1523; HAYES RR, 2009, LIFETIME MEASUREMENT; Hollenberg LCL, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.045311; Huebl H, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.235318; Jamieson DN, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1925320; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Ladd TD, 2010, NATURE, V464, P45, DOI 10.1038/nature08812; Levi AFJ, 2008, P IEEE, V96, P335, DOI 10.1109/JPROC.2007.911071; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Morello A, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.081307; Morton JJL, 2008, NATURE, V455, P1085, DOI 10.1038/nature07295; SHANKAR S, 2009, SPIN RELAXATION COHE; Tan KY, 2010, NANO LETT, V10, P11, DOI [10.1021/nl901635j, 10.1021/nl901635J]; Tyryshkin AM, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.193207; Xiao M, 2004, NATURE, V430, P435, DOI 10.1038/nature02727; Xiao M, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.096801; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	30	540	545	8	216	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					687	691		10.1038/nature09392	http://dx.doi.org/10.1038/nature09392			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20877281	Green Submitted			2022-12-28	WOS:000282572500033
J	Nathan, PC; Ness, KK; Mahoney, MC; Li, ZH; Hudson, MM; Ford, JS; Landier, W; Stovall, M; Armstrong, GT; Henderson, TO; Robison, LL; Oeffinger, KC				Nathan, Paul Craig; Ness, Kirsten Kimberlie; Mahoney, Martin Christopher; Li, Zhenghong; Hudson, Melissa Maria; Ford, Jennifer Sylene; Landier, Wendy; Stovall, Marilyn; Armstrong, Gregory Thomas; Henderson, Tara Olive; Robison, Leslie L.; Oeffinger, Kevin Charles			Screening and Surveillance for Second Malignant Neoplasms in Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVORS; BREAST-CANCER; HODGKINS-DISEASE; 5-YEAR SURVIVORS; CHEST RADIATION; DELPHI PANEL; SKIN-CANCER; HEALTH-CARE; FOLLOW-UP; RISK	Background: Survivors of childhood cancer may develop a second malignant neoplasm during adulthood and therefore require regular surveillance. Objective: To examine adherence to population cancer screening guidelines by survivors at average risk for a second malignant neoplasm and adherence to cancer surveillance guidelines by survivors at high risk for a second malignant neoplasm. Design: Retrospective cohort study. Setting: The Childhood Cancer Survivor Study (CCSS), a 26-center study of long-term survivors of childhood cancer that was diagnosed between 1970 and 1986. Patients: 4329 male and 4018 female survivors of childhood cancer who completed a CCSS questionnaire assessing screening and surveillance for new cases of cancer. Measurements: Patient-reported receipt and timing of mammography, Papanicolaou smear, colonoscopy, or skin examination was categorized as adherent to the U. S. Preventive Services Task Force guidelines for survivors at average risk for breast or cervical cancer or the Children's Oncology Group guidelines for survivors at high risk for breast, colorectal, or skin cancer as a result of cancer therapy. Results: In average-risk female survivors, 2743 of 3392 (80.9%) reported having a Papanicolaou smear within the recommended period, and 140 of 209 (67.0%) reported mammography within the recommended period. In high-risk survivors, rates of recommended mammography among women were only 241 of 522 (46.2%) and the rates of colonoscopy and complete skin examinations among both sexes were 91 of 794 (11.5%) and 1290 of 4850 (26.6%), respectively. Limitations: Data were self-reported. Participants in the CCSS are a selected group of survivors, and their adherence may not be representative of all survivors of childhood cancer. Conclusion: Female survivors at average risk for a second malignant neoplasm show reasonable rates of screening for cervical and breast cancer. However, surveillance for new cases of cancer is very low in survivors at the highest risk for colon, breast, or skin cancer, suggesting that survivors and their physicians need education about their risks and recommended surveillance.	[Nathan, Paul Craig] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); St Jude Children's Research Hospital; Roswell Park Cancer Institute; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Chicago	Nathan, PC (corresponding author), Hosp Sick Children, Div Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	paul.nathan@sickkids.ca	Ness, Kirsten K/N-2550-2018; Nathan, Paul/GRR-2377-2022; Hudson, Melissa M/N-4441-2018; Robison, Leslie/N-8122-2018; Armstrong, Gregory/N-8096-2018	Ness, Kirsten K/0000-0002-2084-1507; Hudson, Melissa M/0000-0001-6984-2407; Nathan, Paul/0000-0003-0334-0871	National Cancer Institute, National Institutes of Health [U24-CA-55727]; National Cancer Institute; NATIONAL CANCER INSTITUTE [U24CA055727, R01CA134722] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant Support: By the National Cancer Institute, National Institutes of Health (grant U24-CA-55727) to Dr. Robison and by the American Lebanese Syrian Associated Charities.; The CCSS is a collaborative, multi-institutional project, funded as a resource by the National Cancer Institute. The cohort was assembled through the efforts of 26 participating clinical research centers in the United States and Canada. Information on how to access and use the CCSS resource is available at http://ccss.stjude.org.	Allison, 2001, LOGISTIC REGRESSION; Armstrong GT, 2009, J CLIN ONCOL, V27, P2328, DOI 10.1200/JCO.2008.21.1425; Begg CB, 2008, JAMA-J AM MED ASSOC, V299, P194, DOI 10.1001/jama.2007.55-a; Bhatia S, 2003, J CLIN ONCOL, V21, P4386, DOI 10.1200/JCO.2003.11.059; Caplan LS, 2003, CANCER EPIDEM BIOMAR, V12, P1182; Centers for Disease Control and Prevention, NAT HLTH INT SURV 20; *CHILDR ONC GROUP, 2010, LONG TERM FOLL UP GU; Derogatis LR, 2000, BSI 18 ADM SCORING P; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; EASTON DF, 1995, AM J HUM GENET, V56, P265; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Henderson TO, 2010, ANN INTERN MED, V152, P444, DOI 10.7326/0003-4819-152-7-201004060-00009; Hewitt M., 2005, CANC PATIENT CANC SU; Hodgson DC, 2007, J CLIN ONCOL, V25, P1489, DOI 10.1200/JCO.2006.09.0936; Horwich A, 2004, BRIT J CANCER, V90, P294, DOI 10.1038/sj.bjc.6601499; Hudson MM, 2003, JAMA-J AM MED ASSOC, V290, P1583, DOI 10.1001/jama.290.12.1583; Inskip PD, 2007, INT J CANCER, V121, P2233, DOI 10.1002/ijc.22827; Jenkinson HC, 2004, BRIT J CANCER, V91, P1905, DOI 10.1038/sj.bjc.6602226; Kadan-Lottick NS, 2002, JAMA-J AM MED ASSOC, V287, P1832, DOI 10.1001/jama.287.14.1832; Kenney LB, 2004, ANN INTERN MED, V141, P590, DOI 10.7326/0003-4819-141-8-200410190-00006; KREMER LCM, 2006, TIJDSCHRIFT KINDERGE, V6, P214; LAIDLAW J, 1989, CAN MED ASSOC J, V141, P199; Landier W, 2004, J CLIN ONCOL, V22, P4979, DOI 10.1200/JCO.2004.11.032; Lawless SCW, 2007, PEDIATR BLOOD CANCER, V48, P333, DOI 10.1002/pbc.20723; Leisenring WM, 2009, J CLIN ONCOL, V27, P2319, DOI 10.1200/JCO.2008.21.1813; Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018; Lu WL, 2009, BREAST CANCER RES TR, V114, P403, DOI 10.1007/s10549-008-0023-4; Mariotto AB, 2009, CANCER EPIDEM BIOMAR, V18, P1033, DOI 10.1158/1055-9965.EPI-08-0988; Maurice A, 2006, EUR J CANCER, V42, P1385, DOI 10.1016/j.ejca.2006.01.055; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Meadows AT, 2009, J CLIN ONCOL, V27, P2356, DOI 10.1200/JCO.2008.21.1920; Mertens AC, 2004, J CLIN EPIDEMIOL, V57, P933, DOI 10.1016/j.jclinepi.2004.01.005; Mertens AC, 2004, HEALTH POLICY, V69, P169, DOI 10.1016/j.healthpol.2003.12.008; Metayer C, 2000, J CLIN ONCOL, V18, P2435, DOI 10.1200/JCO.2000.18.12.2435; Moss S M, 1994, J Med Screen, V1, P193; Nathan PC, 2008, J CLIN ONCOL, V26, P4401, DOI 10.1200/JCO.2008.16.9607; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; Ng AK, 2002, BLOOD, V100, P1989, DOI 10.1182/blood-2002-02-0634; Oeffinger KC, 2006, J CLIN ONCOL, V24, P5117, DOI 10.1200/JCO.2006.07.0474; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Oeffinger KC, 2009, JAMA-J AM MED ASSOC, V301, P404, DOI 10.1001/jama.2008.1039; Olsen JH, 2009, JNCI-J NATL CANCER I, V101, P806, DOI 10.1093/jnci/djp104; Perkins JL, 2005, J CLIN ONCOL, V23, P3733, DOI 10.1200/JCO.2005.06.237; Robison LL, 2009, J CLIN ONCOL, V27, P2308, DOI 10.1200/JCO.2009.22.3339; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Sanna G, 2007, ANN ONCOL, V18, P288, DOI 10.1093/annonc/mdl399; Saslow D, 2007, CA-CANCER J CLIN, V57, P75, DOI 10.3322/canjclin.57.2.75; *SCOTT COLL GUID N, LONG TERM FOLL UP SU; Simone J.V., 2003, CHILDHOOD CANC SURVI; Trask PC, 2005, AM J PREV MED, V28, P351, DOI 10.1016/j.amepre.2005.01.005; United Kingdom Children's Cancer Study Group Late Effects Group, 2005, THER BAS LONG TERM F; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wolff T, 2009, ANN INTERN MED, V150, P194, DOI 10.7326/0003-4819-150-3-200902030-00009; Zebrack BJ, 2004, CANCER-AM CANCER SOC, V100, P843, DOI 10.1002/cncr.20033	54	78	78	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	2010	153	7					442	+		10.7326/0003-4819-153-7-201010050-00007	http://dx.doi.org/10.7326/0003-4819-153-7-201010050-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VG	20921543	Green Accepted			2022-12-28	WOS:000282517000003
J	Brooke, BS				Brooke, Benjamin S.			Celiprolol therapy for vascular Ehlers-Danlos syndrome	LANCET			English	Editorial Material							GROWTH-FACTOR-BETA; SYNDROME TYPE-IV; AORTIC-ANEURYSM; MARFAN-SYNDROME; PATHWAY		Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Brooke, BS (corresponding author), Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA.	bbrooke1@jhmi.edu						Brooke BS, 2010, J VASC SURG, V51, P131, DOI 10.1016/j.jvs.2009.08.019; Dietz HC, 2010, J CLIN INVEST, V120, P403, DOI 10.1172/JCI42014; Gomez D, 2009, J PATHOL, V218, P131, DOI 10.1002/path.2516; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Jones JA, 2009, J VASC RES, V46, P119, DOI 10.1159/000151766; Judge DP, 2005, LANCET, V366, P1965, DOI 10.1016/S0140-6736(05)67789-6; Kobayashi N, 2003, HYPERTENSION, V42, P1004, DOI 10.1161/01.HYP.0000097547.35570.70; Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695; Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981; Oderich GS, 2005, J VASC SURG, V42, P98, DOI 10.1016/j.jvs.2005.03.053; Ong KT, 2010, LANCET, V376, P1476, DOI 10.1016/S0140-6736(10)60960-9; Pepin M, 2000, NEW ENGL J MED, V342, P673, DOI 10.1056/NEJM200003093421001; Schoenhoff FS, 2009, CIRCULATION, V120, pS1048; Tsubokou Y, 2002, EUR J PHARMACOL, V457, P85, DOI 10.1016/S0014-2999(02)02648-1	14	12	12	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1443	1444		10.1016/S0140-6736(10)61155-5	http://dx.doi.org/10.1016/S0140-6736(10)61155-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QC	20825985				2022-12-28	WOS:000284248500006
J	Dierolf, M; Menzel, A; Thibault, P; Schneider, P; Kewish, CM; Wepf, R; Bunk, O; Pfeiffer, F				Dierolf, Martin; Menzel, Andreas; Thibault, Pierre; Schneider, Philipp; Kewish, Cameron M.; Wepf, Roger; Bunk, Oliver; Pfeiffer, Franz			Ptychographic X-ray computed tomography at the nanoscale	NATURE			English	Article							DIFFRACTION MICROSCOPY; PHASE RETRIEVAL	X-ray tomography is an invaluable tool in biomedical imaging. It can deliver the three-dimensional internal structure of entire organisms as well as that of single cells, and even gives access to quantitative information, crucially important both for medical applications and for basic research(1-4). Most frequently such information is based on X-ray attenuation. Phase contrast is sometimes used for improved visibility but remains significantly harder to quantify(5,6). Here we describe an X-ray computed tomography technique that generates quantitative high-contrast three-dimensional electron density maps from phase contrast information without reverting to assumptions of a weak phase object or negligible absorption. This method uses a ptychographic coherent imaging approach to record tomographic data sets, exploiting both the high penetration power of hard X-rays and the high sensitivity of lensless imaging(7-9). As an example, we present images of a bone sample in which structures on the 100 nm length scale such as the osteocyte lacunae and the interconnective canalicular network are clearly resolved. The recovered electron density map provides a contrast high enough to estimate nanoscale bone density variations of less than one per cent. We expect this high-resolution tomography technique to provide invaluable information for both the life and materials sciences.	[Dierolf, Martin; Thibault, Pierre; Pfeiffer, Franz] Tech Univ Munich, Dept Phys E17, D-85748 Garching, Germany; [Menzel, Andreas; Kewish, Cameron M.; Bunk, Oliver] Paul Scherrer Inst, Swiss Light Source, CH-5232 Villigen, Switzerland; [Schneider, Philipp] ETH, Inst Biomech, CH-8093 Zurich, Switzerland; [Wepf, Roger] EMEZ, CH-8093 Zurich, Switzerland	Technical University of Munich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich	Thibault, P (corresponding author), Tech Univ Munich, Dept Phys E17, D-85748 Garching, Germany.	pierre.thibault@tum.de	Kewish, Cameron/H-5103-2011; Dierolf, Martin J/B-9816-2008; Menzel, Andreas/C-4388-2012; Schneider, Philipp/AAP-6133-2021; Thibault, Pierre/B-2656-2010; Bunk, Oliver/B-7602-2013	Kewish, Cameron/0000-0001-6242-7059; Dierolf, Martin J/0000-0001-5150-2949; Menzel, Andreas/0000-0002-0489-609X; Schneider, Philipp/0000-0001-7499-3576; Thibault, Pierre/0000-0003-1278-8846; Bunk, Oliver/0000-0001-6563-4053; Wepf, Roger/0000-0003-2203-3674	DFG Cluster of Excellence "Munich-Centre for Advanced Photonics"	DFG Cluster of Excellence "Munich-Centre for Advanced Photonics"(German Research Foundation (DFG))	We acknowledge technical support by X. Donath, FIB preparation of the specimen by P. Gasser and M. Meier and the assistance of W. Gutscher during the experiments. P. T., M. D. and F. P. acknowledge support through the DFG Cluster of Excellence "Munich-Centre for Advanced Photonics''.	Chapman HN, 2006, J OPT SOC AM A, V23, P1179, DOI 10.1364/JOSAA.23.001179; Chu YS, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2857476; Cloetens P, 1996, J PHYS D APPL PHYS, V29, P133, DOI 10.1088/0022-3727/29/1/023; DAVIS TJ, 1995, NATURE, V373, P595, DOI 10.1038/373595a0; Dierolf M, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/3/035017; Faulkner HML, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.023903; Ghiglia D.C., 1998, 2 DIMENSIONAL PHASE, V1st; Giewekemeyer K, 2010, P NATL ACAD SCI USA, V107, P529, DOI 10.1073/pnas.0905846107; Guizar-Sicairos M, 2008, OPT EXPRESS, V16, P7264, DOI 10.1364/OE.16.007264; HADDAD WS, 1994, SCIENCE, V266, P1213, DOI 10.1126/science.266.5188.1213; Howells MR, 2009, J ELECTRON SPECTROSC, V170, P4, DOI 10.1016/j.elspec.2008.10.008; Hubbell JH., 1995, TABLES XRAY MASS ATT; Kamioka H, 2009, MICROSC MICROANAL, V15, P377, DOI 10.1017/S1431927609990420; Kraft P, 2009, J SYNCHROTRON RADIAT, V16, P368, DOI 10.1107/S0909049509009911; Momose A, 1996, NAT MED, V2, P473, DOI 10.1038/nm0496-473; MORRISON GR, 1983, OPTIK, V64, P1; Nishino Y, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.018101; Nugent KA, 1996, PHYS REV LETT, V77, P2961, DOI 10.1103/PhysRevLett.77.2961; Nugent KA, 2010, ADV PHYS, V59, P1, DOI 10.1080/00018730903270926; Parkinson DY, 2008, J STRUCT BIOL, V162, P380, DOI 10.1016/j.jsb.2008.02.003; Pfeiffer F, 2006, NAT PHYS, V2, P258, DOI 10.1038/nphys265; Rodenburg JM, 2008, ADV IMAG ELECT PHYS, V150, P87, DOI 10.1016/S1076-5670(07)00003-1; Rodenburg JM, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.034801; Schneider P, 2010, BONE, V47, P848, DOI 10.1016/j.bone.2010.07.026; Schropp A, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3332591; Thibault P, 2008, SCIENCE, V321, P379, DOI 10.1126/science.1158573; Thibault P, 2009, ULTRAMICROSCOPY, V109, P338, DOI 10.1016/j.ultramic.2008.12.011; Vine DJ, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.063823; Wilkins SW, 1996, NATURE, V384, P335, DOI 10.1038/384335a0; Yin GC, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2211300	30	595	624	11	267	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					436	U82		10.1038/nature09419	http://dx.doi.org/10.1038/nature09419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864997				2022-12-28	WOS:000282090200037
J	Moffatt, MF; Gut, IG; Demenais, F; Strachan, DP; Bouzigon, E; Heath, S; von Mutius, E; Farrall, M; Lathrop, M; Cookson, WOCM; Kumar, A; Burney, P; Jarvis, D; Wjst, M; Kogevinas, M; Jogi, R; Janson, C; Franklin, KA; Omenaas, E; Leynaert, B; Pin, I; Heinrich, J; Probst-Hensch, NM; Anto, JM; Sunyer, J; Maldonado, JA; Martinez-Moratalla, J; Urrutia, I; Payo, F; Kauffmann, F; Dizier, MH; Siroux, V; Boznanski, A; Braun-Fahrlander, C; Genuneit, J; Glas, J; Horak, E; Kabesch, M; Pillai, SG; Helms, PJ; Carlsen, K; Carlsen, KH; Gerritsen, J; Silverman, M; Sly, P; Tsanakas, J; Von Berg, A; Whyte, M; Blumenthal, M; Imboden, M; Rochat, T; Thun, GA; Gerbase, MW; Curjuric, I; Gaspoz, JM; Liu, LJS; Wouters, IM; Sigsgaard, T; Heederik, D; Basinas, I; Schlunssen, V; Omland, O; Cullinan, P; Vermeulen, R; Henderson, J; Granell, R; McArdle, WL; Smith, GD; James, AL; Hui, J; Palmer, LJ; Beilby, J; Musk, AW; Laprise, C; Hudson, TJ; Lemire, M; Daley, D; Becker, A; Chan-Yeung, M; Sandford, A; Kozyrskyj, AL; Pare, P; Ferguson, A; Dimich-Ward, H; Watson, WT; Freidin, MB; Bragina, EI; Deev, IA; Deeva, EV; Kobyakova, OS; Puzyrev, VP; Ogorodova, LM; Khusnutdinova, EK; Karunas, AS; Fedorova, YY; Hall, IP; Sayers, I; Tobin, MD; Wan, YI; Heaney, LG; Al-Momani, BAH; Mansur, AH; Manney, S; Thomson, NC; Chaudhuri, R; Brightling, CE; Bafadhel, M; Singapuri, A; Niven, R; Simpson, A; Holloway, JW; Howarth, PH; Polonikov, AV; Ivanov, VP; Solodilova, MA; Melen, E; Pershagen, G; Bergstrom, A; Kull, I; Nyberg, F; Wickman, M; Soderhall, C; Kere, J; Postma, DS; Kerkhof, M; Brunekreef, B; Smit, HA; de Jongste, JC; Wijga, A; Aalberse, RC; Hoekstra, MO; Koppelman, GH; Binia, A; Chung, KF; Bhavsar, P; Chow, F; Macedo, P; Menzies-Gow, A; van Stiphout, N; Bush, A; Lee, YA; Esparza-Gordillo, J; Nickel, R; Wahn, U; Lau, S; Marenholz, I; Haahtela, T; von Hertzen, L; Jousilahti, P; Laatikainen, T; Makela, MJ; Vartiainen, E; Laitinen, T; Balding, DJ; Peden, JF; Corda, E; Lechner, D; Besse, C; Zelenika, D; Boland, A; Bacq, D; Demonchy, S; Blanche, H; Kamatani, Y; von Mutius, E; Farrall, M; Lathrop, M; Cookson, WOCM				Moffatt, Miriam F.; Gut, Ivo G.; Demenais, Florence; Strachan, David P.; Bouzigon, Emmanuelle; Heath, Simon; von Mutius, Erika; Farrall, Martin; Lathrop, Mark; Cookson, William O. C. M.; Kumar, Ashish; Burney, Peter; Jarvis, Debbie; Wjst, Matthias; Kogevinas, Manolis; Jogi, Rain; Janson, Christer; Franklin, Karl A.; Omenaas, Ernst; Leynaert, Benedicte; Pin, Isabelle; Heinrich, Joachim; Probst-Hensch, Nicole M.; Anto, Josep M.; Sunyer, Jordi; Maldonado, Jose-Antonio; Martinez-Moratalla, Jesus; Urrutia, Isabel; Payo, Felix; Kauffmann, Francine; Dizier, Marie-Helene; Siroux, Valerie; Boznanski, Andrzej; Braun-Fahrlaender, Charlotte; Genuneit, Jon; Glas, Juergen; Horak, Elisabeth; Kabesch, Michael; Pillai, Sreekumar G.; Helms, Peter J.; Carlsen, Karin; Carlsen, Kai-Hakon; Gerritsen, Jorrit; Silverman, Michael; Sly, Peter; Tsanakas, John; Von Berg, Andrea; Whyte, Moira; Blumenthal, Malcolm; Imboden, Medea; Rochat, Thierry; Thun, Gian Andri; Gerbase, Margaret W.; Curjuric, Ivan; Gaspoz, Jean-Michel; Liu, Lee-Jane S.; Wouters, Inge M.; Sigsgaard, Torben; Heederik, Dick; Basinas, Ioannis; Schlunssen, Vivi; Omland, Oyvind; Cullinan, Paul; Vermeulen, Roel; Henderson, John; Granell, Raquel; McArdle, Wendy L.; Smith, George Davey; James, Alan L.; Hui, Jennie; Palmer, Lyle J.; Beilby, John; Musk, A. William; Laprise, Catherine; Hudson, Thomas J.; Lemire, Mathieu; Daley, Denise; Becker, Allan; Chan-Yeung, Moira; Sandford, Andrew; Kozyrskyj, Anita L.; Pare, Peter; Ferguson, Alexander; Dimich-Ward, Helen; Watson, Wade T.; Freidin, Maxim B.; Bragina, Elena Iu.; Deev, Ivan A.; Deeva, Eugenia V.; Kobyakova, Olga S.; Puzyrev, Valery P.; Ogorodova, Ludmila M.; Khusnutdinova, Elza K.; Karunas, Alexandra S.; Fedorova, Yuliya Y.; Hall, Ian P.; Sayers, Ian; Tobin, Martin D.; Wan, Yize I.; Heaney, Liam G.; Al-Momani, Basima A. H.; Mansur, Adel H.; Manney, Sarah; Thomson, Neil C.; Chaudhuri, Rekha; Brightling, Christopher E.; Bafadhel, Mona; Singapuri, Amisha; Niven, Robert; Simpson, Angela; Holloway, John W.; Howarth, Peter H.; Polonikov, Alexey V.; Ivanov, Vladimir P.; Solodilova, Maria A.; Melen, Erik; Pershagen, Goeran; Bergstroem, Anna; Kull, Inger; Nyberg, Fredrik; Wickman, Magnus; Soderhall, Cilla; Kere, Juha; Postma, Dirkje S.; Kerkhof, Marjan; Brunekreef, Bert; Smit, Henriette A.; de Jongste, Johan C.; Wijga, Alet; Aalberse, R. C.; Hoekstra, Maarten O.; Koppelman, Gerard H.; Binia, Aristea; Chung, Kian Fan; Bhavsar, Pankaj; Chow, Florence; Macedo, Patricia; Menzies-Gow, Andrew; van Stiphout, Nicole; Bush, Andrew; Lee, Young-Ae; Esparza-Gordillo, Jorge; Nickel, Renate; Wahn, Ulrich; Lau, Susanne; Marenholz, Ingo; Haahtela, Tari; von Hertzen, Leena; Jousilahti, Pekka; Laatikainen, Tiina; Makela, Mika J.; Vartiainen, Erkki; Laitinen, Tarja; Balding, David J.; Peden, John F.; Corda, Eve; Lechner, Doris; Besse, Celine; Zelenika, Diana; Boland, Anne; Bacq, Delphine; Demonchy, Stephanie; Blanche, Helene; Kamatani, Yoichiro; von Mutius, Erika; Farrall, Martin; Lathrop, Mark; Cookson, William O. C. M.		GABRIEL Consortium	A Large-Scale, Consortium-Based Genomewide Association Study of Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUSCEPTIBILITY GENE; POSITIONAL CLONING; IN-VIVO; VARIANTS; DISEASE; EXPRESSION; CYTOKINE; RECEPTOR; ALLERGY; TRAITS	BACKGROUND Susceptibility to asthma is influenced by genes and environment; implicated genes may indicate pathways for therapeutic intervention. Genetic risk factors may be useful in identifying subtypes of asthma and determining whether intermediate phenotypes, such as elevation of the total serum IgE level, are causally linked to disease. METHODS We carried out a genomewide association study by genotyping 10,365 persons with physician-diagnosed asthma and 16,110 unaffected persons, all of whom were matched for ancestry. We used random-effects pooled analysis to test for association in the overall study population and in subgroups of subjects with childhood-onset asthma (defined as asthma developing before 16 years of age), later-onset asthma, severe asthma, and occupational asthma. RESULTS We observed associations of genomewide significance between asthma and the following single-nucleotide polymorphisms: rs3771166 on chromosome 2, implicating IL1RL1/IL18R1 (P = 3x10(-9)); rs9273349 on chromosome 6, implicating HLA-DQ (P = 7x10(-14)); rs1342326 on chromosome 9, flanking IL33 (P = 9x10(-10)); rs744910 on chromosome 15 in SMAD3 (P = 4x10(-9)); and rs2284033 on chromosome 22 in IL2RB (P = 1.1x10(-8)). Association with the ORMDL3/GSDMB locus on chromosome 17q21 was specific to childhood-onset disease (rs2305480, P = 6x10(-23)). Only HLA-DR showed a significant genomewide association with the total serum IgE concentration, and loci strongly associated with IgE levels were not associated with asthma. CONCLUSIONS Asthma is genetically heterogeneous. A few common alleles are associated with disease risk at all ages. Implicated genes suggest a role for communication of epithelial damage to the adaptive immune system and activation of airway inflammation. Variants at the ORMDL3/GSDMB locus are associated only with childhood-onset disease. Elevation of total serum IgE levels has a minor role in the development of asthma.	[Moffatt, Miriam F.; Cookson, William O. C. M.; Burney, Peter; Jarvis, Debbie; Cullinan, Paul; Binia, Aristea; Chung, Kian Fan; Bhavsar, Pankaj; Macedo, Patricia; Menzies-Gow, Andrew; Bush, Andrew; Cookson, William O. C. M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Farrall, Martin; Peden, John F.; Farrall, Martin] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [von Mutius, Erika; von Mutius, Erika] Univ Munich, Asthma & Allergy Dept, Univ Childrens Hosp, Munich, Germany; [Demenais, Florence; Bouzigon, Emmanuelle; Dizier, Marie-Helene] Univ Paris 07, Inst Univ Hematol, Paris, France; [Demenais, Florence; Bouzigon, Emmanuelle; Lathrop, Mark; Dizier, Marie-Helene; Corda, Eve; Blanche, Helene; Kamatani, Yoichiro; Lathrop, Mark] Fdn Jean Dausset CEPH, Paris, France; [Demenais, Florence; Bouzigon, Emmanuelle; Dizier, Marie-Helene; Corda, Eve] Fdn Jean Dausset, CEPH, INSERM, U946, Paris, France; [Gut, Ivo G.; Heath, Simon; Lathrop, Mark; Lechner, Doris; Besse, Celine; Zelenika, Diana; Boland, Anne; Bacq, Delphine; Demonchy, Stephanie; Lathrop, Mark] Commissariat Energie Atom, Inst Genom, Ctr Natl Genotypage, Evry, France; [Cookson, William O. C. M.; van Stiphout, Nicole; Bush, Andrew] Royal Brompton & Harefield NHS Fdn Trust, London, England; [Strachan, David P.] Univ London, Div Community Hlth Sci, London, England; [Burney, Peter; Jarvis, Debbie] Imperial Coll, NHLI, Respiratory Epidemiol & Publ Hlth, London, England; [Wjst, Matthias] Helmholtz Zentrum, Inst Lung Biol & Dis, Munich, Germany; [Wjst, Matthias] German Res Ctr Environm Hlth GmbH, Neuherberg, Germany; [Kogevinas, Manolis; Anto, Josep M.; Sunyer, Jordi] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Kogevinas, Manolis; Anto, Josep M.; Sunyer, Jordi] Municipal Inst Med Res IMIM Hosp Mar, Barcelona, Spain; [Kogevinas, Manolis; Anto, Josep M.; Sunyer, Jordi] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain; [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece; [Jogi, Rain] Tartu Univ Hosp, Lung Clin, Tartu, Estonia; [Janson, Christer] Uppsala Univ, Resp Med & Allergol, Uppsala, Sweden; [Franklin, Karl A.] Umea Univ, Dept Surg, S-90187 Umea, Sweden; [Omenaas, Ernst] Univ Bergen, Inst Med, N-5020 Bergen, Norway; [Omenaas, Ernst] Haukeland Hosp, Ctr Clin Res, Bergen, Norway; [Leynaert, Benedicte] Inserm, Unite 700, Paris, France; [Leynaert, Benedicte] Univ Paris Diderot, Paris, France; [Pin, Isabelle] Ctr Hosp Univ, Grenoble, France; [Pin, Isabelle; Siroux, Valerie] Inserm, Unite 823, Grenoble, France; [Pin, Isabelle; Siroux, Valerie] Univ Joseph Fourier, F-38041 Grenoble, France; [Heinrich, Joachim] Helmholtz Zentrum Munich, Inst Epidemiol, Munich, Germany; [Probst-Hensch, Nicole M.; Braun-Fahrlaender, Charlotte; Imboden, Medea; Thun, Gian Andri; Curjuric, Ivan; Liu, Lee-Jane S.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Probst-Hensch, Nicole M.; Braun-Fahrlaender, Charlotte; Imboden, Medea; Thun, Gian Andri; Curjuric, Ivan; Liu, Lee-Jane S.] Univ Basel, CH-4003 Basel, Switzerland; [Probst-Hensch, Nicole M.; Imboden, Medea; Thun, Gian Andri; Curjuric, Ivan] Univ Zurich, UPF, Dept Ciencies Expt Salut, CH-8006 Zurich, Switzerland; [Maldonado, Jose-Antonio] Hosp Juan Ramon Jimenez, Serv Neumol, Huelva, Spain; [Maldonado, Jose-Antonio; Martinez-Moratalla, Jesus] Hosp Gen Univ Albacete, Serv Neumol, Albacete, Spain; [Urrutia, Isabel] Galdakao Hosp, Pneumol Serv, Galdakao, Bizkaia, Spain; [Payo, Felix] Hosp Gen Asturias, Serv Neumol, Oviedo, Asturias, Spain; [Kauffmann, Francine] Inserm, Unite 780, Villejuif, France; [Kauffmann, Francine] Univ Paris Sud, IFR69, Villejuif, France; [Boznanski, Andrzej] Wroclaw Med Univ, Dep Paediat Allergol & Cardiol 1, Wroclaw, Poland; [Genuneit, Jon] Ulm Univ, Inst Epidemiol, Ulm, Germany; [Glas, Juergen] Univ Munich, Dept Prevent Dentistry & Periodontol, Munich, Germany; [Glas, Juergen] Rhein Westfal TH Aachen, Dept Human Genet, Aachen, Germany; [Horak, Elisabeth] Innsbruck Med Univ, Dept Pediat Pediat Pulmonol, Innsbruck, Austria; [Kabesch, Michael] Hannover Med Sch, Clin Paediat Pneumol & Neonatol, Ctr Paediat Adolescent Med, Hannover, Germany; [Pillai, Sreekumar G.] GlaxoSmithKline R&D, Genet, Res Triangle Pk, NC USA; [Helms, Peter J.] Univ Aberdeen, Royal Aberdeen Childrens Hosp, Aberdeen, Scotland; [Carlsen, Karin; Carlsen, Kai-Hakon] Oslo Univ Hosp, Dept Paediat, N-0316 Oslo, Norway; [Carlsen, Karin; Carlsen, Kai-Hakon] Univ Oslo, Fac Med, Oslo, Norway; [Gerritsen, Jorrit] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; [Silverman, Michael] Univ Leicester, Div Child Hlth, Leicester, Leics, England; [Sly, Peter] Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia; [Tsanakas, John] Aristotle Univ Thessaloniki, Pediat Pulmonol, Thessaloniki, Greece; [Whyte, Moira] Univ Sheffield, Acad Unit Resp Med, Sheffield S10 2TN, S Yorkshire, England; [Blumenthal, Malcolm] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Rochat, Thierry; Gerbase, Margaret W.] Univ Hosp Geneva, Div Pulm Med, Geneva, Switzerland; [Gaspoz, Jean-Michel] Univ Hosp Geneva, Div Commun Med & Primary Care, Geneva, Switzerland; [Wouters, Inge M.; Heederik, Dick; Basinas, Ioannis; Vermeulen, Roel; Brunekreef, Bert] Univ Utrecht, IRAS, NL-3508 TC Utrecht, Netherlands; [Sigsgaard, Torben; Basinas, Ioannis; Schlunssen, Vivi; Omland, Oyvind] Univ Aarhus, Sch Publ Hlth, Dept Environm & Occupat Med, DK-8000 Aarhus, Denmark; [Omland, Oyvind] Aarhus Univ Hosp, Aalborg Hosp, Dept Occupat Hlth, DK-9000 Aalborg, Denmark; [Henderson, John] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Granell, Raquel; McArdle, Wendy L.; Smith, George Davey] Univ Bristol, Dept Med, Bristol BS8 1TH, Avon, England; [Smith, George Davey] Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol CAiTE, Bristol BS8 1TH, Avon, England; [James, Alan L.] Sir Charles Gairdner Hosp, West Australian Sleep Disorders Res Inst, Dept Pulm Physiol, Nedlands, WA, Australia; [James, Alan L.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia; [Hui, Jennie] PathWest Lab Med, Mol Genet, Nedlands, WA, Australia; [Palmer, Lyle J.] Univ Western Australia, Ctr Genet Epidemiol & Biostat, Nedlands, WA 6009, Australia; [Beilby, John] PathWest Lab Med, Biochem, Nedlands, WA, Australia; [Musk, A. William] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA, Australia; [Musk, A. William] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Laprise, Catherine] Univ Montreal, Chicoutimi Univ Hosp, Commun Genom Med Ctr, Chicoutimi, PQ, Canada; [Laprise, Catherine] Univ Quebec Chicoutimi, Chicoutimi, PQ, Canada; [Hudson, Thomas J.; Lemire, Mathieu] Ontario Inst Canc Res, Toronto, ON, Canada; [Daley, Denise; Sandford, Andrew; Pare, Peter] Univ British Columbia, James Hogg iCAPTURE Ctr, Vancouver, BC V5Z 1M9, Canada; [Becker, Allan; Kozyrskyj, Anita L.; Watson, Wade T.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Chan-Yeung, Moira; Dimich-Ward, Helen] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Univ Alberta & Sch Publ Hlth, Fac Med & Dent, Dept Pediat, Edmonton, AB T6G 2M7, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Fac Med, Dept Commun Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Ferguson, Alexander] Univ British Columbia, Dept Pediat, Div Allergy, Vancouver, BC V5Z 1M9, Canada; [Freidin, Maxim B.; Bragina, Elena Iu.; Puzyrev, Valery P.] Russian Acad Med Sci, Res Inst Med Genet Siberian Branch, Populat Genet Lab, Tomsk 634050, Russia; [Deev, Ivan A.; Deeva, Eugenia V.; Ogorodova, Ludmila M.] Siberian State Med Univ, Dept Fac Paediat, Tomsk 634050, Russia; [Kobyakova, Olga S.] Siberian State Med Univ, Gen Doctor Practice Dept, Tomsk 634050, Russia; [Khusnutdinova, Elza K.; Karunas, Alexandra S.; Fedorova, Yuliya Y.] Russian Acad Sci, UFA Sci Ctr, Inst Biochem & Genet, Ufa 450054, Russia; [Hall, Ian P.; Sayers, Ian; Wan, Yize I.] Queens Med Ctr, Nottingham Resp Biomed Res Unit, Div Therapeut & Mol Med, Nottingham, England; [Tobin, Martin D.] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England; [Heaney, Liam G.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland; [Al-Momani, Basima A. H.] Queens Univ Belfast, Sch Pharm, Belfast BT7 1NN, Antrim, North Ireland; [Mansur, Adel H.; Manney, Sarah] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Mansur, Adel H.; Manney, Sarah] Birmingham Heartlands Hosp, Resp Med, Birmingham B15 2TT, W Midlands, England; [Thomson, Neil C.; Chaudhuri, Rekha] Univ Glasgow, Div Immunol Infect & Inflammat, Resp Med Sect, Glasgow G12 8QQ, Lanark, Scotland; [Brightling, Christopher E.; Bafadhel, Mona; Singapuri, Amisha] Univ Leicester, Glenfield Hosp, Inst Lung Hlth, Leicester LE1 7RH, Leics, England; [Niven, Robert; Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Fac Resp Med, Manchester, Lancs, England; [Holloway, John W.; Howarth, Peter H.] Univ Southampton, Sch Med, Div Human Genet, Southampton SO9 5NH, Hants, England; [Holloway, John W.; Howarth, Peter H.] Univ Southampton, Sch Med, Div Infect, Southampton SO9 5NH, Hants, England; [Howarth, Peter H.] Univ Southampton, Sch Med, Southampton NIHR Resp Biomed Res Unit, Southampton SO9 5NH, Hants, England; [Polonikov, Alexey V.; Ivanov, Vladimir P.; Solodilova, Maria A.] Kursk State Med Univ, Dept Biol Med Genet & Ecol, Kursk 305041, Russia; [Melen, Erik; Pershagen, Goeran; Bergstroem, Anna; Kull, Inger; Nyberg, Fredrik; Wickman, Magnus] Karolinska Inst, Inst Environ Med, Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Nyberg, Fredrik] AstraZeneca R&D, Molndal, Sweden; [Wickman, Magnus] Sachs Childrens Hosp, Stockholm, Sweden; [Soderhall, Cilla; Kere, Juha] Karolinska Inst, Dept Biosci & Nutrit, S-10401 Stockholm, Sweden; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonology, NL-9700 AB Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiology, NL-9700 AB Groningen, Netherlands; [Brunekreef, Bert; Smit, Henriette A.] Uni Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [de Jongste, Johan C.] Sophia Childrens Univ Hosp, Erasmus Univ Med Ctr, Dept Pediat, Rotterdam, Netherlands; [Wijga, Alet] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, Bilthoven, Netherlands; [Aalberse, R. C.] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; [Hoekstra, Maarten O.] Radboud Univ Nijmegen Med Ctr, Dept Gen Paediat, Nijmegen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 AB Groningen, Netherlands; Royal Brompton & Harefield NHS Fdn Trust, Dept Paediat Resp Med, London, England; [Lee, Young-Ae; Esparza-Gordillo, Jorge; Nickel, Renate; Wahn, Ulrich; Lau, Susanne; Marenholz, Ingo] Charite Univ Med Berlin, Pediat Pneumol & Immunol, Berlin, Germany; [Lee, Young-Ae; Esparza-Gordillo, Jorge; Marenholz, Ingo] Max Delbruck Centrum MDC Mol Med, Berlin, Germany; [Haahtela, Tari; von Hertzen, Leena; Makela, Mika J.] Helsinki Univ Cent Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Jousilahti, Pekka; Laatikainen, Tiina; Vartiainen, Erkki] Natl Inst Hlth & Welfare, Helsinki, Finland; [Laitinen, Tarja] Helsinki Univ Cent Hosp, Dept Pulm Med, Helsinki, Finland; [Balding, David J.] Imperial Coll, Dept Epidemiol & Publ Hlth, London, England; Univ Munich, Univ Childrens Hosp, Asthma & Allergy Dept, D-80337 Munich, Germany	Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Royal Brompton & Harefield NHS Foundation Trust; University of London; Imperial College London; Helmholtz Association; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; National & Kapodistrian University of Athens; Uppsala University; Umea University; University of Bergen; University of Bergen; Haukeland University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Zurich; Hospital Juan Ramon Jimenez; Galdakao Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Wroclaw Medical University; Ulm University; University of Munich; RWTH Aachen University; Medical University of Innsbruck; Hannover Medical School; GlaxoSmithKline; University of Aberdeen; University of Oslo; University of Oslo; University of Groningen; University of Leicester; University of Western Australia; Aristotle University of Thessaloniki; University of Sheffield; University of Minnesota System; University of Minnesota Twin Cities; University of Geneva; University of Geneva; Utrecht University; Aarhus University; Aalborg University; Aalborg University Hospital; Aarhus University; University of Bristol; University of Bristol; University of Bristol; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; Universite de Montreal; University of Quebec; University of Quebec Chicoutimi; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of British Columbia; University of Manitoba; University of British Columbia; University of Alberta; University of Manitoba; University of British Columbia; Russian Academy of Medical Sciences; Russian Academy of Sciences; Tomsk National Research Medical Center; Research Institute of Medical Genetics - Tomsk; Siberian State Medical University; Siberian State Medical University; Institute of Biochemistry & Genetics of Ufa Science Centre of the RAS; Russian Academy of Sciences; University of Nottingham; University of Leicester; Queens University Belfast; Queens University Belfast; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; University of Glasgow; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Manchester; University of Southampton; University of Southampton; University of Southampton; Kursk State Medical University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; AstraZeneca; Karolinska Institutet; University of Groningen; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Netherlands National Institute for Public Health & the Environment; Radboud University Nijmegen; University of Groningen; Royal Brompton & Harefield NHS Foundation Trust; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; Imperial College London; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Cookson, WOCM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Royal Brompton Campus,Guy Scadding Bldg,Dovehouse, London SW3 6LY, England.	w.cookson@imperial.ac.uk	Kogevinas, Manolis/C-3918-2017; Freidin, Maxim B/A-8222-2014; Söderhäll, Cilla/E-3940-2012; Bafadhel, Mona/ABB-1170-2021; Heath, Simon C/J-4138-2012; Hui, Jennie/A-9543-2013; Kabesch, Michael/GZM-1583-2022; Sly, Peter D/F-1486-2010; Karunas, Alexandra S/E-6421-2014; Dizier, Marie-Hélène/K-8463-2018; PIN, Isabelle/N-3020-2013; Holloway, John W/B-5424-2009; Sigsgaard, Torben/AAC-1292-2020; Laatikainen, Tiina/ABD-6622-2021; Balding, David/G-9898-2011; Kobyakova, Olga/M-5287-2014; Heinrich, Joachim/N-1720-2013; Chung, Kian Fan/B-1872-2012; Pare, Peter D/C-7425-2011; Bragina, Elena/A-8049-2014; Puzyrev, Valery P/S-3144-2016; Fedorova, Yuliya/P-8808-2017; Palmer, Lyle John/K-3196-2014; Solodilova, Maria/GSJ-2104-2022; Vermeulen, Roel/F-8037-2011; Cookson, William/HHC-1790-2022; Khusnutdinova, Elza Kamilevna/A-4810-2013; Genuneit, Jon/I-9323-2012; Kere, Juha/AAX-9117-2021; Granell, Raquel/AAB-5256-2022; Kere, Juha/A-9179-2008; Palmer, Lyle John/N-1948-2019; Koppelman, Gerard/AAG-9187-2020; Freydin, Maxim/A-5603-2011; Gut, Ivo/ABF-3188-2020; Bragina, Elena/AAF-7983-2019; Anto, J M/H-2676-2014; Polonikov, Alexey/R-7537-2016; Leynaert, Benedicte/N-5251-2018; Bouzigon, Emmanuelle/L-2766-2017; Kabesch, Michael/AAB-5701-2020; Granell, Raquel/AAY-4846-2020; Sunyer, Jordi/G-6909-2014; Davey Smith, George/A-7407-2013; Puzyrev, Valery P/A-7925-2014; Demenais, Florence/G-3298-2013	Kogevinas, Manolis/0000-0002-9605-0461; Freidin, Maxim B/0000-0002-1439-6259; Söderhäll, Cilla/0000-0002-8397-3080; Heath, Simon C/0000-0002-9550-0897; Hui, Jennie/0000-0002-1653-2496; Sly, Peter D/0000-0001-6305-2201; Karunas, Alexandra S/0000-0002-2570-0789; Dizier, Marie-Hélène/0000-0001-8460-7667; Holloway, John W/0000-0001-9998-0464; Sigsgaard, Torben/0000-0002-2043-7571; Laatikainen, Tiina/0000-0002-6614-4782; Balding, David/0000-0002-1480-6115; Kobyakova, Olga/0000-0003-0098-1403; Heinrich, Joachim/0000-0002-9620-1629; Chung, Kian Fan/0000-0001-7101-1426; Bragina, Elena/0000-0002-1103-3073; Puzyrev, Valery P/0000-0002-2113-4556; Palmer, Lyle John/0000-0002-1628-3055; Solodilova, Maria/0000-0003-4607-4913; Vermeulen, Roel/0000-0003-4082-8163; Khusnutdinova, Elza Kamilevna/0000-0003-2987-3334; Genuneit, Jon/0000-0001-5764-1528; Kere, Juha/0000-0003-1974-0271; Granell, Raquel/0000-0002-4890-4012; Kere, Juha/0000-0003-1974-0271; Palmer, Lyle John/0000-0002-1628-3055; Freydin, Maxim/0000-0002-1439-6259; Gut, Ivo/0000-0001-7219-632X; Anto, J M/0000-0002-4736-8529; Polonikov, Alexey/0000-0001-6280-247X; Bouzigon, Emmanuelle/0000-0001-5756-4286; Sunyer, Jordi/0000-0002-2602-4110; Davey Smith, George/0000-0002-1407-8314; Demenais, Florence/0000-0001-8361-0936; Jarvis, Deborah/0000-0002-1753-3896; Heederik, Dick/0000-0002-4550-1437; Simpson, Angela/0000-0003-2733-6666; Niven, Robert/0000-0003-2249-960X; Fedorova, Yuliya/0000-0002-9344-828X; Schlunssen, Vivi/0000-0003-4915-1734; Koppelman, Gerard/0000-0001-8567-3252; Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771; Nyberg, Fredrik/0000-0003-0892-5668; Kumar, Ashish/0000-0002-7075-5930; Burney, Peter/0000-0001-8635-5678; Makela, Mika/0000-0002-2933-3111; Sayers, Ian/0000-0001-5601-5410; von Mutius, Erika/0000-0002-8893-4515; Franklin, Karl/0000-0002-5306-1697; Leynaert, Benedicte/0000-0001-5045-2492; Beilby, John/0000-0002-4915-2254; Basinas, Ioannis/0000-0001-7708-3017; Bafadhel, Mona/0000-0002-9993-2478; Binia, Aristea/0000-0002-8327-049X; Wouters, Inge M./0000-0001-7834-9390	European Commission [018996]; French Ministry of Research; Wellcome Trust [WT084703MA]; Asthma UK; Medical Research Council [G0501942, G9815508, G0801056B, G0902125, G0800649, G0000934, G0401540, MC_qA137934] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; MRC [G0401540, G0000934, G0800649, G0501942, G0902125, MC_qA137934] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007048] Funding Source: NIH RePORTER	European Commission(European CommissionEuropean Commission Joint Research Centre); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by a contract from the European Commission (018996) and grants from the French Ministry of Research, the Wellcome Trust (WT084703MA), and Asthma UK.	Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Anthoni M, 2007, INT J BIOL SCI, V3, P477; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Fukao T, 2000, J IMMUNOL, V164, P64, DOI 10.4049/jimmunol.164.1.64; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Konstantinidis AK, 2007, EUR RESPIR J, V30, P40, DOI 10.1183/09031936.00025706; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Letourneau S, 2009, J ALLERGY CLIN IMMUN, V123, P758, DOI 10.1016/j.jaci.2009.02.011; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1992, P 11 INT HIST WORKSH, P765; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 2001, EUR J HUM GENET, V9, P341, DOI 10.1038/sj.ejhg.5200636; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; *NAT ASTHM CAMP, 1998, ASTHM AG; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Nixon GF, 2009, BRIT J PHARMACOL, V158, P982, DOI 10.1111/j.1476-5381.2009.00281.x; Nouri-Aria Kayhan T., 2008, Inflammation & Allergy Drug Targets, V7, P237, DOI 10.2174/187152808786848405; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Taylor JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007651; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, J ALLERGY CLIN IMMUN, V122, P267, DOI 10.1016/j.jaci.2008.06.008; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; White JH, 2008, HUM MOL GENET, V17, P1890, DOI 10.1093/hmg/ddn087; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	47	1401	1443	1	204	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1211	1221		10.1056/NEJMoa0906312	http://dx.doi.org/10.1056/NEJMoa0906312			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860503	Green Accepted, Green Published			2022-12-28	WOS:000282050000005
J	Delamothe, T				Delamothe, Tony			On the Contrary How the unmanageability of the internet might play out	BRITISH MEDICAL JOURNAL			English	Editorial Material												tdelamothe@bmj.com							0	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2010	341								c5190	10.1136/bmj.c5190	http://dx.doi.org/10.1136/bmj.c5190			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655TK	20861099				2022-12-28	WOS:000282272200012
J	Rodondi, N; den Elzen, WPJ; Bauer, DC; Cappola, AR; Razvi, S; Walsh, JP; Asvold, BO; Iervasi, G; Imaizumi, M; Collet, TH; Bremner, A; Maisonneuve, P; Sgarbi, JA; Khaw, KT; Vanderpump, MPJ; Newman, AB; Cornuz, J; Franklyn, JA; Westendorp, RGJ; Vittinghoff, E; Gussekloo, J				Rodondi, Nicolas; den Elzen, Wendy P. J.; Bauer, Douglas C.; Cappola, Anne R.; Razvi, Salman; Walsh, John P.; Asvold, Bjorn O.; Iervasi, Giorgio; Imaizumi, Misa; Collet, Tinh-Hai; Bremner, Alexandra; Maisonneuve, Patrick; Sgarbi, Jose A.; Khaw, Kay-Tee; Vanderpump, Mark P. J.; Newman, Anne B.; Cornuz, Jacques; Franklyn, Jayne A.; Westendorp, Rudi G. J.; Vittinghoff, Eric; Gussekloo, Jacobijn		Thyroid Studies Collaboration	Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and Mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INDIVIDUAL PATIENT DATA; 20-YEAR FOLLOW-UP; THYROID-DYSFUNCTION; CARDIOVASCULAR RISK; ALL-CAUSE; METAANALYSIS; ASSOCIATION; THYROXINE; FAILURE; EVENTS	Context Data regarding the association between subclinical hypothyroidism and cardiovascular disease outcomes are conflicting among large prospective cohort studies. This might reflect differences in participants' age, sex, thyroid-stimulating hormone (TSH) levels, or preexisting cardiovascular disease. Objective To assess the risks of coronary heart disease (CHD) and total mortality for adults with subclinical hypothyroidism. Data Sources and Study Selection The databases of MEDLINE and EMBASE (1950 to May 31, 2010) were searched without language restrictions for prospective cohort studies with baseline thyroid function and subsequent CHD events, CHD mortality, and total mortality. The reference lists of retrieved articles also were searched. Data Extraction Individual data on 55 287 participants with 542 494 person-years of follow-up between 1972 and 2007 were supplied from 11 prospective cohorts in the United States, Europe, Australia, Brazil, and Japan. The risk of CHD events was examined in 25 977 participants from 7 cohorts with available data. Euthyroidism was defined as a TSH level of 0.50 to 4.49 mIU/L. Subclinical hypothyroidism was defined as a TSH level of 4.5 to 19.9 mIU/L with normal thyroxine concentrations. Results Among 55 287 adults, 3450 had subclinical hypothyroidism (6.2%) and 51 837 had euthyroidism. During follow-up, 9664 participants died (2168 of CHD), and 4470 participants had CHD events (among 7 studies). The risk of CHD events and CHD mortality increased with higher TSH concentrations. In age-and sex-adjusted analyses, the hazard ratio (HR) for CHD events was 1.00 (95% confidence interval [CI], 0.86-1.18) for a TSH level of 4.5 to 6.9 mIU/L (20.3 vs 20.3/1000 person-years for participants with euthyroidism), 1.17 (95% CI, 0.96-1.43) for a TSH level of 7.0 to 9.9 mIU/L (23.8/1000 person-years), and 1.89 (95% CI, 1.28-2.80) for a TSH level of 10 to 19.9 mIU/L (n=70 events/235; 38.4/1000 person-years; P<.001 for trend). The corresponding HRs for CHD mortality were 1.09 (95% CI, 0.91-1.30; 5.3 vs 4.9/1000 person-years for participants with euthyroidism), 1.42 (95% CI, 1.03-1.95; 6.9/1000 person-years), and 1.58 (95% CI, 1.10-2.27, n=28 deaths/333; 7.7/1000 person-years; P=.005 for trend). Total mortality was not increased among participants with subclinical hypothyroidism. Results were similar after further adjustment for traditional cardiovascular risk factors. Risks did not significantly differ by age, sex, or preexisting cardiovascular disease. Conclusions Subclinical hypothyroidism is associated with an increased risk of CHD events and CHD mortality in those with higher TSH levels, particularly in those with a TSH concentration of 10 mIU/L or greater. JAMA. 2010; 304(12): 1365-1374	[Rodondi, Nicolas; Collet, Tinh-Hai; Cornuz, Jacques] Univ Lausanne, Dept Ambulatory Care & Community Med, CH-1011 Lausanne, Switzerland; [den Elzen, Wendy P. J.; Gussekloo, Jacobijn] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands; [Westendorp, Rudi G. J.] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands; [Bauer, Douglas C.; Vittinghoff, Eric] Univ Calif San Francisco, Dept Med Epidemiol & Biostat, San Francisco, CA 94143 USA; [Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Cappola, Anne R.] Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; [Razvi, Salman] Gateshead Hlth Fdn NHS Trust, Dept Endocrinol, Gateshead, England; [Walsh, John P.] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA, Australia; [Walsh, John P.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia; [Bremner, Alexandra] Univ Western Australia, Sch Populat Hlth, Crawley, WA, Australia; [Asvold, Bjorn O.] Norwegian Univ Sci & Technol, Dept Publ Hlth, N-7034 Trondheim, Norway; [Iervasi, Giorgio] CNR, Inst Clin Physiol, I-56100 Pisa, Italy; [Imaizumi, Misa] Radiat Effects Res Fdn, Dept Clin Studies, Nagasaki, Japan; [Maisonneuve, Patrick] European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; [Sgarbi, Jose A.] Univ Fed Sao Paulo, Dept Med, Div Endocrinol, Sao Paulo, Brazil; [Sgarbi, Jose A.] Fac Med Marilia, Div Endocrinol, Marilia, Brazil; [Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Vanderpump, Mark P. J.] Royal Free Hosp, Dept Endocrinol, London NW3 2QG, England; [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Franklyn, Jayne A.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Westendorp, Rudi G. J.] Netherlands Consortium Healthy Ageing, Leiden, Netherlands	University of Lausanne; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania; University of Western Australia; University of Western Australia; University of Western Australia; Norwegian University of Science & Technology (NTNU); Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Radiation Effects Research Foundation - Japan; IRCCS European Institute of Oncology (IEO); Universidade Federal de Sao Paulo (UNIFESP); Faculdade de Medicina de Marilia; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Birmingham	Rodondi, N (corresponding author), Univ Lausanne, Dept Ambulatory Care & Community Med, Bugnon 44, CH-1011 Lausanne, Switzerland.	Nicolas.Rodondi@hospvd.ch	Maisonneuve, Patrick/U-9789-2018; Gussekloo, Jacobijn/ABE-3879-2021; Newman, Anne B./C-6408-2013; Collet, Tinh-Hai/I-4462-2019; Razvi, Salman/H-6118-2019; Khaw, Kay-Tee/AAZ-3209-2021	Maisonneuve, Patrick/0000-0002-5309-4704; Gussekloo, Jacobijn/0000-0001-7186-8278; Newman, Anne B./0000-0002-0106-1150; Collet, Tinh-Hai/0000-0002-3243-1222; Razvi, Salman/0000-0002-9047-1556; Walsh, John/0000-0002-1766-2612; Bremner, Alexandra/0000-0002-4068-4860; Sgarbi, Jose/0000-0001-7187-984X; Rodondi, Nicolas/0000-0001-9083-6896; den Elzen, Wendy/0000-0002-6774-4077	National Heart, Lung, and Blood Institute [N01-HC-80007, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295, R01 HL-075366]; National Institute of Neurological Disorders and Stroke; National Institute on Aging [R01 AG-15928, R01 AG-20098, AG027058, AG-032317, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, AG-023629]; University of Pittsburgh Claude. D. Pepper Older Americans Independence Center [P30-AG-024827]; American Heart Association; Dutch Ministry of Health, Welfare, and Sports; UK Department of Health; Wallac Oy (Turku, Finland); Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan; Japanese Ministry of Health, Labor and Welfare; US Department of Energy; National Academy of Sciences; Radiation Effects Research Foundation [A-10-08]; UK Medical Research Council; UK Cancer Research; Sao Paulo State Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [6/59737-9]; Netherlands Organization for Scientific Research [NGI/NWO911-03-016]; Medical Research Council [G0401527] Funding Source: researchfish; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085083, N01HC085086, N01HC075150, N01HC045133, N01HC085081, N01HC035129, N01HC085079, N01HC055222, N01HC085085, N01HC015103, N01HC085084, N01HC085082, N01HC085080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080295, R01HL075366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024827, N01AG062106, R01AG015928, R01AG023629, N01AG062101, R01AG020098, R01AG027058, R56AG023629, R01AG032317, N01AG062103] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); University of Pittsburgh Claude. D. Pepper Older Americans Independence Center; American Heart Association(American Heart Association); Dutch Ministry of Health, Welfare, and Sports; UK Department of Health; Wallac Oy (Turku, Finland); Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan; Japanese Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); US Department of Energy(United States Department of Energy (DOE)); National Academy of Sciences; Radiation Effects Research Foundation; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Cancer Research; Sao Paulo State Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Cardiovascular Health Study and the research reported in this article were supported by contract numbers N01-HC-80007, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional funding from the National Institute of Neurological Disorders and Stroke. Additional support was provided through grants R01 AG-15928, R01 AG-20098, AG027058, and AG-032317 from the National Institute on Aging, grant R01 HL-075366 from the National Heart, Lung, and Blood Institute, and grant P30-AG-024827 from the University of Pittsburgh Claude. D. Pepper Older Americans Independence Center. A full list of principal investigators and institutions of the Cardiovascular Health Study can be found at http://www.chs-nhlbi.org/pi.htm. The thyroid measurements in the Cardiovascular Health Study were supported by an American Heart Association Grant-in-Aid (to Linda Fried). The Health, Aging, and Body Composition Study is supported by National Institute on Aging contract numbers N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106, and in part by the Intramural Research Program of the National Institutes of Health. The National Institute on Aging funded the Health Aging, and Body Composition study. The Leiden 85-plus Study was partly funded by the Dutch Ministry of Health, Welfare, and Sports. The Whickham Survey was supported by the UK Department of Health. The HUNT Study was a collaborative effort of the Faculty of Medicine, Norwegian University of Science and Technology, the Norwegian Institute of Public Health, and the Nord-Trondelag County Council. The thyroid testing in the HUNT Study was financially supported by Wallac Oy (Turku, Finland). The Nagasaki Adult Health Study was supported by the Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan, a private, nonprofit foundation funded by the Japanese Ministry of Health, Labor and Welfare and the US Department of Energy, the latter in part through the National Academy of Sciences. This publication was supported by research protocol A-10-08 from the Radiation Effects Research Foundation. The EPIC-Norfolk study was supported by research grants from the UK Medical Research Council and the UK Cancer Research. The Brazilian Thyroid Study was supported by an unrestricted grant from the Sao Paulo State Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo grant 6/59737-9 to Rui Maciel). Dr Newman is supported by grant AG-023629 from the the National Institute on Aging. Dr Westendorp is supported by grant NGI/NWO911-03-016 from the Netherlands Organization for Scientific Research. Role of the Sponsor: The majority of the sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The National Institute on Aging funded the Health, Aging, and Body Composition study and reviewed the manuscript and approved its publication. The Radiation Effects Research Foundation funded the Nagasaki Adult Health Study and reviewed the manuscript and approved its publication.	Asvold BO, 2008, ARCH INTERN MED, V168, P855, DOI 10.1001/archinte.168.8.855; Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006-0043; Boekholdt SM, 2010, CLIN ENDOCRINOL, V72, P404, DOI 10.1111/j.1365-2265.2009.03640.x; Cappola AR, 2007, J CLIN ENDOCR METAB, V92, P3404, DOI 10.1210/jc.2007-1575; Cappola AR, 2006, JAMA-J AM MED ASSOC, V295, P1033, DOI 10.1001/jama.295.9.1033; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cooper DS, 2004, JAMA-J AM MED ASSOC, V292, P2651, DOI 10.1001/jama.292.21.2651; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2001, SYSTEMATIC REV HLTH; Fatourechi V, 2003, MAYO CLIN PROC, V78, P554, DOI 10.4065/78.5.554; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197; Gharib H, 2005, J CLIN ENDOCR METAB, V90, P581, DOI 10.1210/jc.2004-1231; Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Heinze G, 2001, BIOMETRICS, V57, P114, DOI 10.1111/j.0006-341X.2001.00114.x; Helfand M, 2004, ANN INTERN MED, V140, P128, DOI 10.7326/0003-4819-140-2-200401200-00015; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Iervasi G, 2007, ARCH INTERN MED, V167, P1526, DOI 10.1001/archinte.167.14.1526; Imaizumi M, 2004, J CLIN ENDOCR METAB, V89, P3365, DOI 10.1210/jc.2003-031089; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326; Ladenson PW, 2008, ANN INTERN MED, V148, P880, DOI 10.7326/0003-4819-148-11-200806030-00011; Monzani F, 2004, J CLIN ENDOCR METAB, V89, P2099, DOI 10.1210/jc.2003-031669; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553; Ochs N, 2008, ANN INTERN MED, V148, P832, DOI 10.7326/0003-4819-148-11-200806030-00225; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; Razvi S, 2008, J CLIN ENDOCR METAB, V93, P2998, DOI 10.1210/jc.2008-0167; Razvi S, 2007, J CLIN ENDOCR METAB, V92, P1715, DOI 10.1210/jc.2006-1869; Razvi S, 2010, J CLIN ENDOCR METAB, V95, P1734, DOI 10.1210/jc.2009-1749; Riley RD, 2007, J CLIN EPIDEMIOL, V60, P431, DOI 10.1016/j.jclinepi.2006.09.009; Rodondi N, 2005, ARCH INTERN MED, V165, P2460, DOI 10.1001/archinte.165.21.2460; Rodondi N, 2008, J AM COLL CARDIOL, V52, P1152, DOI 10.1016/j.jacc.2008.07.009; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Sgarbi JA, 2010, EUR J ENDOCRINOL, V162, P569, DOI 10.1530/EJE-09-0845; Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, THYROID, V6, P155; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Volzke H, 2007, J CLIN ENDOCR METAB, V92, P2421, DOI 10.1210/jc.2007-0179; Walsh JP, 2005, ARCH INTERN MED, V165, P2467, DOI 10.1001/archinte.165.21.2467	45	728	778	2	75	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1365	1374		10.1001/jama.2010.1361	http://dx.doi.org/10.1001/jama.2010.1361			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858880	Green Accepted, Green Published			2022-12-28	WOS:000282007900020
J	Rutkow, L; Teret, SP				Rutkow, Lainie; Teret, Stephen P.			Role of State Attorneys General in Health Policy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Rutkow, Lainie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Rutkow, L (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 513, Baltimore, MD 21205 USA.	hrutkow@jhsph.edu		Rutkow, Helaine/0000-0001-6423-7291				Brandt A, 2007, CIGARETTE CENTURY; MYERS E, 2007, STATE ATTORNEYS GEN, P33; *OFF VERM ATT GEN, ATT GEN OB IN; *OR DEP JUST, 2010, OR PLEDG DEF CONST N; RICHEY W, 2010, CHRISTIAN SCI M 0323; Sack Kevin, 2010, NY TIMES, pA25; Smart Choices Program, 2009, SMART CHOICES PROGRA; TIERNEY J, 2010, STATE ATTORNEYS GEN; US Department of Justice, 2004, WARN LAMB PAY 430 MI	9	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1377	1378		10.1001/jama.2010.1377	http://dx.doi.org/10.1001/jama.2010.1377			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858882				2022-12-28	WOS:000282007900022
J	Gakidou, E; Cowling, K; Lozano, R; Murray, CJL				Gakidou, Emmanuela; Cowling, Krycia; Lozano, Rafael; Murray, Christopher J. L.			Increased educational attainment and its effect on child mortality in 175 countries between 1970 and 2009: a systematic analysis	LANCET			English	Article							MATERNAL EDUCATION; PARENTAL EDUCATION; HEALTH; DETERMINANTS; SURVIVAL; LITERACY; INFANT; IMPACT	Background In addition to the inherent importance of education and its essential role in economic growth, education and health are strongly related. We updated previous systematic assessments of educational attainment, and estimated the contribution of improvements in women's education to reductions in child mortality in the past 40 years. Methods We compiled 915 censuses and nationally representative surveys, and estimated mean number of years of education by age and sex. By use of a first-differences model, we investigated the association between child mortality and women's educational attainment, controlling for income per person and HIV seroprevalence. We then computed counterfactual estimates of child mortality for every country year between 1970 and 2009. Findings The global mean number of years of education increased from 4.7 years (95% uncertainty interval 4.4-5.1) to 8.3 years (8.0-8.6) for men (aged >= 25 years) and from 3.5 years (3.2-3.9) to 7.1 years (6.7-7.5) for women (aged >= 25 years). For women of reproductive age (15-44 years) in developing countries, the years of schooling increased from 2.2 years (2.0-2.4) to 7-2 years (6.8-7.6). By 2009, in 87 countries, women (aged 25-34 years) had higher educational attainment than had men (aged 25-34 years). Of 8.2 million fewer deaths in children younger than 5 years between 1970 and 2009, we estimated that 4.2 million (51.2%) could be attributed to increased educational attainment in women of reproductive age. Interpretation The substantial increase in education, especially of women, and the reversal of the gender gap have important implications not only for health but also for the status and roles of women in society. The continued increase in educational attainment even in some of the poorest countries suggests that rapid progress in terms of Millennium Development Goal 4 might be possible.	[Gakidou, Emmanuela; Cowling, Krycia; Lozano, Rafael; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle	Gakidou, E (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.	gakidou@uw.edu	Fahimifar, Sepideh/M-5303-2019; Lozano, Rafael/T-5352-2018	Lozano, Rafael/0000-0002-7356-8823; Cowling, Krycia/0000-0003-2489-5390	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This research was supported by funding from the Bill & Melinda Gates Foundation. We thank Brent Anderson, Jennifer Berthiaume, Haley Lee, David Phillips, Ella Sanman, and Annette Tardif for research assistance; and Majid Ezzati, Dean Jamison, Marie Ng, Stephen Lim, and Shane Murphy for helpful discussions.	Al Riyami Asya, 2004, Reprod Health Matters, V12, P144, DOI 10.1016/S0968-8080(04)23113-5; Barro RJ, 2001, OXFORD ECON PAP, V53, P541, DOI 10.1093/oep/53.3.541; Basu AM, 2005, SOC SCI MED, V60, P2011, DOI 10.1016/j.socscimed.2004.08.057; BHUIYA A, 1991, POPUL STUD CAMB, V45, P1207; BICEGO GT, 1993, SOC SCI MED, V36, P1207, DOI 10.1016/0277-9536(93)90241-U; *BILL M GAT FDN, 2009, FAM PLANN STRAT OV, P1; Boyle MH, 2006, SOC SCI MED, V63, P2242, DOI 10.1016/j.socscimed.2006.04.034; CALDWELL J, 1982, HEALTH POLICY EDUC, V2, P251, DOI 10.1016/0165-2281(82)90012-1; CALDWELL JC, 1979, POP STUD-J DEMOG, V33, P395, DOI 10.2307/2173888; Chou SY, 2010, AM ECON J-APPL ECON, V2, P33, DOI 10.1257/app.2.1.33; CLELAND JG, 1988, SOC SCI MED, V27, P1357, DOI 10.1016/0277-9536(88)90201-8; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Cohen D, 2007, J ECON GROWTH, V12, P51, DOI 10.1007/s10887-007-9011-5; Council Scientific And Technical, 2006, MOR HUM STRAT US APP, P1; Cutler D. M., 2006, MAKING AM HLTH SOCIA, DOI [10.3386/w12352, DOI 10.3386/W12352]; Desai S, 1998, DEMOGRAPHY, V35, P71, DOI 10.2307/3004028; Elo IT, 2006, EUR J POPUL, V22, P179, DOI 10.1007/s10680-006-0003-5; FORTNEY JA, 1987, STUD FAMILY PLANN, V18, P109, DOI 10.2307/1966702; Hatt LE, 2006, SOC SCI MED, V62, P375, DOI 10.1016/j.socscimed.2005.06.007; Hobcraft J, 1993, Health Transit Rev, V3, P159; *I HLTH METR EV, 2010, GROSS DOM PROD GDP D; Kiros GE, 2001, INT J EPIDEMIOL, V30, P447, DOI 10.1093/ije/30.3.447; LeVine RA, 2009, J DEV BEHAV PEDIATR, V30, P340, DOI 10.1097/DBP.0b013e3181b0eeff; Lewin Keith, 2008, AFRICA HUMAN DEV SER; LIKER JK, 1985, SOC SCI RES, V14, P80, DOI 10.1016/0049-089X(85)90013-4; Lutz W., 2007, RECONSTRUCTION POPUL, P193; Lynch SM, 2003, DEMOGRAPHY, V40, P309, DOI 10.2307/3180803; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; MARTIN TC, 1995, STUD FAMILY PLANN, V26, P187, DOI 10.2307/2137845; OPERTTI R, 2009, REG EXP M REF SEC ED; Overbosch GB, 2004, J AFR ECON, V13, P277, DOI 10.1093/jae/ejh008; Ozaltin E, 2010, JAMA-J AM MED ASSOC, V303, P1507, DOI 10.1001/jama.2010.450; Plavinski SL, 2003, BRIT MED J, V326, P1240, DOI 10.1136/bmj.326.7401.1240; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Rajaratnam JK, 2010, LANCET, V375, P1704, DOI 10.1016/S0140-6736(10)60517-X; Saleem Shabana, 2005, Reprod Health, V2, P8, DOI 10.1186/1742-4755-2-8; SANDIFORD P, 1995, POP STUD-J DEMOG, V49, P5, DOI 10.1080/0032472031000148216; Shavit Y., 1993, PERSISTENT INEQUALIT; THOMAS V, 2001, 2525 WORLD BANK; Titaley CR, 2009, J EPIDEMIOL COMMUN H, V63, P827, DOI 10.1136/jech.2008.081604; TRUSSELL J, 1984, STUD FAMILY PLANN, V15, P267, DOI 10.2307/1966071; *UNAIDS, 2009, 2009 AIDS EP UPD, P1; UNESCO, 2010, ENG ISS CHALL OPP DE, P1; *UNESCO I STAT, 2010, NAT ED SYST; UNESCO Institute of Statistics, 2005, CHILDR OUT SCH MEAS; United Nations, 2010, MILL DEV GOALS REP 2; United Nations Development Programme, 2009, HUMAN DEV REPORT 200, P1; Weinberger M. B., 1987, International Family Planning Perspectives, V13, P35, DOI 10.2307/2947826; *WORLD BANK, 1980, WORLD DEV REP 1980, P1	49	930	942	3	169	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2010	376	9745					959	974		10.1016/S0140-6736(10)61257-3	http://dx.doi.org/10.1016/S0140-6736(10)61257-3			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20851260				2022-12-28	WOS:000282247600028
J	Huang, AS; Tan, CYH				Huang, Alice S.; Tan, Chris Y. H.			Achieving Scientific Eminence Within Asia	SCIENCE			English	Editorial Material									[Huang, Alice S.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Huang, Alice S.] Amer Assoc Advancement Sci, Washington, DC 20005 USA; [Tan, Chris Y. H.] Calidris Therapeut, Vancouver, BC V6S 1B2, Canada	California Institute of Technology	Huang, AS (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	alice.huang@caltech.edu						Abdulla MA, 2009, SCIENCE, V326, P1541, DOI 10.1126/science.1177074; ARAI K, 1997, GOLDEN HELIX BIG BAN; Bao L, 2009, SCIENCE, V323, P586, DOI 10.1126/science.1167740; Bhattacharjee Y, 2006, SCIENCE, V314, P1668; Chang ZY, 2009, IUBMB LIFE, V61, P555, DOI 10.1002/iub.218; CHOUCR N, 2006, MIT NEWSL, V19, P1; Fuyuno I, 2006, NATURE, V442, P493, DOI 10.1038/442493a; GUNASINGHAM A, 2009, STRAITS TIMES   0819; LaFraniere Sharon, 2010, NEW YORK TIMES  0107, pA1; LUMAN S, 2004, WIRED; MADDOX J, 1995, NATURE, V374, P403, DOI 10.1038/374403a0; National Science Board, 2010, GLOB SCI ENG RES COM; SHI Y, SCIENCE IN PRESS, V329; TOLE S, SCIENCE IN PRESS, V329; Zakaria Fareed, 2009, POSTAMERICAN WORLD R; Zhang YS, 2009, IUBMB LIFE, V61, P549, DOI 10.1002/iub.206; 2010, ECONOMIST, V24, P43	17	6	6	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1471	1472		10.1126/science.1190145	http://dx.doi.org/10.1126/science.1190145			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	650RK	20847253				2022-12-28	WOS:000281869000023
J	Orr, MT; Lanier, LL				Orr, Mark T.; Lanier, Lewis L.			Natural Killer Cell Education and Tolerance	CELL			English	Review							MHC-CLASS-I; COMPLEX CLASS-I; DEFICIENT HEMATOPOIETIC-CELLS; IMMUNOGLOBULIN-LIKE RECEPTOR; BONE-MARROW-TRANSPLANTATION; NK CELLS; T-CELLS; INHIBITORY RECEPTORS; SELF-TOLERANCE; CYTOMEGALOVIRUS-INFECTION	Natural killer (NK) cells play a key role in the immune response to certain infections and malignancies by direct cytolysis of infected or transformed cells and by secretion of potent immune mediators. NK cells express an array of activating receptors that recognize self-molecules. If not restrained by inhibitory receptors recognizing major histocompatibility complex (MHC) class I proteins on the surface of self cells, NK cells are able to kill normal, healthy cells. Not all NK cells express inhibitory receptors for self-MHC class I; thus, other tolerance mechanisms are necessary to prevent NK cell-mediated autoimmunity. Here we review the major mechanisms of NK cell education and tolerance.	[Orr, Mark T.; Lanier, Lewis L.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Orr, Mark T.; Lanier, Lewis L.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lanier, LL (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	lewis.lanier@ucsf.edu	Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952; Orr, Mark/0000-0003-2684-4722	NIH [AI068129, CA095137, AI066897]; NATIONAL CANCER INSTITUTE [R01CA095137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068129, R37AI066897] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.T.O is an Irvington Postdoctoral Fellow of the Cancer Research Institute. L.L.L. is an American Cancer Society Professor and is supported by NIH grants AI068129, CA095137, and AI066897.	Abi-Rached L, 2005, J EXP MED, V201, P1319, DOI 10.1084/jem.20042558; Andersson KE, 2007, EUR J IMMUNOL, V37, P516, DOI 10.1002/eji.200636693; Andrews DM, 2010, J EXP MED, V207, P1333, DOI 10.1084/jem.20091193; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Back J, 2009, IMMUNITY, V31, P598, DOI 10.1016/j.immuni.2009.07.007; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; Brodin P, 2009, TRENDS IMMUNOL, V30, P143, DOI 10.1016/j.it.2009.01.006; Carlyle JR, 2008, SEMIN IMMUNOL, V20, P321, DOI 10.1016/j.smim.2008.05.004; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; Chalifour A, 2009, IMMUNITY, V30, P337, DOI 10.1016/j.immuni.2008.12.019; Champsaur M, 2010, J IMMUNOL, V185, P157, DOI 10.4049/jimmunol.1000397; Champsaur M, 2010, IMMUNOL REV, V235, P267, DOI 10.1111/j.0105-2896.2010.00893.x; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Clausen J, 2007, CLIN EXP IMMUNOL, V148, P520, DOI 10.1111/j.1365-2249.2007.03360.x; Coudert JD, 2008, BLOOD, V111, P3571, DOI 10.1182/blood-2007-07-100057; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Dokun AO, 2001, NAT IMMUNOL, V2, P951, DOI 10.1038/ni714; Dong ZJ, 2009, NAT IMMUNOL, V10, P973, DOI 10.1038/ni.1763; Dorfman JR, 1997, J IMMUNOL, V159, P5219; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Feuerer M, 2009, IMMUNITY, V31, P654, DOI 10.1016/j.immuni.2009.08.023; Gasser S, 2006, IMMUNOL REV, V214, P130, DOI 10.1111/j.1600-065X.2006.00460.x; George TC, 1999, J IMMUNOL, V163, P1859; Gur C, 2010, NAT IMMUNOL, V11, P121, DOI 10.1038/ni.1834; Hanke T, 2001, EUR J IMMUNOL, V31, P3370, DOI 10.1002/1521-4141(200111)31:11<3370::AID-IMMU3370>3.0.CO;2-2; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; Held W, 1997, J EXP MED, V185, P2079, DOI 10.1084/jem.185.12.2079; Held W, 1996, EUR J IMMUNOL, V26, P2286, DOI 10.1002/eji.1830261003; Hsu KC, 2005, BLOOD, V105, P4878, DOI 10.1182/blood-2004-12-4825; Johansson MH, 1997, J EXP MED, V186, P353, DOI 10.1084/jem.186.3.353; Joncker NT, 2009, J IMMUNOL, V182, P4572, DOI 10.4049/jimmunol.0803900; Jonsson AH, 2010, J IMMUNOL, V184, P3424, DOI 10.4049/jimmunol.0904057; Jonsson AH, 2009, ADV IMMUNOL, V101, P27, DOI 10.1016/S0065-2776(08)01002-X; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kulkarni S, 2008, SEMIN IMMUNOL, V20, P343, DOI 10.1016/j.smim.2008.06.003; Kumar V, 2005, NAT REV IMMUNOL, V5, P363, DOI 10.1038/nri1603; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; Lodoen M, 2003, J EXP MED, V197, P1245, DOI 10.1084/jem.20021973; Lodoen MB, 2004, J EXP MED, V200, P1075, DOI 10.1084/jem.20040583; Long EO, 2008, IMMUNOL REV, V224, P70, DOI 10.1111/j.1600-065X.2008.00660.x; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Martin MP, 2002, J IMMUNOL, V169, P2818, DOI 10.4049/jimmunol.169.6.2818; Miller JS, 2007, BLOOD, V109, P5058, DOI 10.1182/blood-2007-01-065383; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Namekawa T, 2000, J IMMUNOL, V165, P1138, DOI 10.4049/jimmunol.165.2.1138; Ogasawara K, 2005, NAT IMMUNOL, V6, P938, DOI 10.1038/ni1236; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Orr MT, 2010, NAT IMMUNOL, V11, P321, DOI 10.1038/ni.1849; Parham P, 2008, SEMIN IMMUNOL, V20, P311, DOI 10.1016/j.smim.2008.10.002; Poirot L, 2004, P NATL ACAD SCI USA, V101, P8102, DOI 10.1073/pnas.0402065101; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Raulet DH, 1997, IMMUNOL REV, V155, P41, DOI 10.1111/j.1600-065X.1997.tb00938.x; Robbins SH, 2004, J IMMUNOL, V173, P259, DOI 10.4049/jimmunol.173.1.259; Roth C, 2000, IMMUNITY, V13, P143, DOI 10.1016/S1074-7613(00)00015-7; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Salcedo M, 1997, J IMMUNOL, V158, P3174; Scarpellino L, 2007, J IMMUNOL, V178, P1277, DOI 10.4049/jimmunol.178.3.1277; Sentman C L, 1995, Semin Immunol, V7, P109, DOI 10.1006/smim.1995.0015; Shi FD, 2000, J IMMUNOL, V165, P3099, DOI 10.4049/jimmunol.165.6.3099; Shilling HG, 2002, J IMMUNOL, V169, P239, DOI 10.4049/jimmunol.169.1.239; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Sobecks RM, 2007, BONE MARROW TRANSPL, V39, P417, DOI 10.1038/sj.bmt.1705609; Su HC, 2001, EUR J IMMUNOL, V31, P3048, DOI 10.1002/1521-4141(2001010)31:10<3048::AID-IMMU3048>3.0.CO;2-1; Sun JC, 2008, J EXP MED, V205, P1819, DOI 10.1084/jem.20072448; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Sun JC, 2008, J IMMUNOL, V181, P7453, DOI 10.4049/jimmunol.181.11.7453; SYKES M, 1993, J EXP MED, V178, P223, DOI 10.1084/jem.178.1.223; Symons HJ, 2010, BIOL BLOOD MARROW TR, V16, P533, DOI 10.1016/j.bbmt.2009.11.022; Teague RM, 2006, NAT MED, V12, P335, DOI 10.1038/nm1359; Tripathy SK, 2008, J EXP MED, V205, P1829, DOI 10.1084/jem.20072446; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3; Wang LL, 2000, J IMMUNOL, V164, P5215, DOI 10.4049/jimmunol.164.10.5215; Wiemann K, 2005, J IMMUNOL, V175, P720, DOI 10.4049/jimmunol.175.2.720; Wu MF, 1997, J IMMUNOL, V158, P1628; Yawata M, 2006, J EXP MED, V203, P633, DOI 10.1084/jem.20051884; Yawata M, 2008, BLOOD, V112, P2369, DOI 10.1182/blood-2008-03-143727; Yen JH, 2001, J EXP MED, V193, P1159, DOI 10.1084/jem.193.10.1159; Yokoyama WM, 2006, IMMUNOL REV, V214, P143, DOI 10.1111/j.1600-065X.2006.00458.x; Yokoyama WM, 2010, BIOL BLOOD MARROW TR, V16, pS97, DOI 10.1016/j.bbmt.2009.10.009; Yu JL, 2009, BLOOD, V113, P3875, DOI 10.1182/blood-2008-09-177055	87	266	273	1	43	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					847	856		10.1016/j.cell.2010.08.031	http://dx.doi.org/10.1016/j.cell.2010.08.031			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850008	Bronze, Green Accepted			2022-12-28	WOS:000281855000008
J	Dyrbye, LN; Massie, FS; Eacker, A; Harper, W; Power, D; Durning, SJ; Thomas, MR; Moutier, C; Satele, D; Sloan, J; Shanafelt, TD				Dyrbye, Liselotte N.; Massie, F. Stanford, Jr.; Eacker, Anne; Harper, William; Power, David; Durning, Steven J.; Thomas, Matthew R.; Moutier, Christine; Satele, Daniel; Sloan, Jeff; Shanafelt, Tait D.			Relationship Between Burnout and Professional Conduct and Attitudes Among US Medical Students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCHOOL; CARE; PERCEPTIONS; DISTRESS; MULTICENTER; INSTRUMENTS; DEPRESSION; EXPOSURE; EMPATHY	Context The relationship between professionalism and distress among medical students is unknown. Objective To determine the relationship between measures of professionalism and burnout among US medical students. Design, Setting, and Participants Cross-sectional survey of all medical students attending 7 US medical schools (overall response rate, 2682/4400 [61%]) in the spring of 2009. The survey included the Maslach Burnout Inventory (MBI), the PRIME-MD depression screening instrument, and the SF-8 quality of life (QOL) assessment tool, as well as items exploring students' personal engagement in unprofessional conduct, understanding of appropriate relationships with industry, and attitudes regarding physicians' responsibility to society. Main Outcome Measures Frequency of self-reported cheating/dishonest behaviors, understanding of appropriate relationships with industry as defined by American Medical Association policy, attitudes about physicians' responsibility to society, and the relationship of these dimensions of professionalism to burnout, symptoms of depression, and QOL. Results Of the students who responded to all the MBI items, 1354 of 2566 (52.8%) had burnout. Cheating/dishonest academic behaviors were rare (endorsed by < 10%) in comparison to unprofessional conduct related to patient care (endorsed by up to 43%). Only 14% (362/2531) of students had opinions on relationships with industry consistent with guidelines for 6 scenarios. Students with burnout were more likely to report engaging in 1 or more unprofessional behaviors than those without burnout (35.0% vs 21.9%; odds ratio [OR], 1.89; 95% confidence interval [CI], 1.59-2.24). Students with burnout were also less likely to report holding altruistic views regarding physicians' responsibility to society. For example, students with burnout were less likely to want to provide care for the medically underserved than those without burnout (79.3% vs 85.0%; OR, 0.68; 95% CI, 0.55-0.83). After multivariable analysis adjusting for personal and professional characteristics, burnout was the only aspect of distress independently associated with reporting 1 or more unprofessional behaviors (OR, 1.76; 95% CI, 1.45-2.13) or holding at least 1 less altruistic view regarding physicians' responsibility to society (OR, 1.65; 95% CI, 1.35-2.01). Conclusion Burnout was associated with self-reported unprofessional conduct and less altruistic professional values among medical students at 7 US schools. JAMA. 2010;304(11):1173-1180 www.jama.com	[Dyrbye, Liselotte N.; Thomas, Matthew R.; Shanafelt, Tait D.] Mayo Clin, Coll Med, Rochester, MN USA; [Satele, Daniel; Sloan, Jeff] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Massie, F. Stanford, Jr.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Eacker, Anne] Univ Washington, Sch Med, Seattle, WA USA; [Harper, William] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Power, David] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Durning, Steven J.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Moutier, Christine] Univ Calif San Diego, San Diego, CA 92103 USA	Mayo Clinic; Mayo Clinic; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; University of Chicago; University of Minnesota System; University of Minnesota Twin Cities; Uniformed Services University of the Health Sciences - USA; University of California System; University of California San Diego	Dyrbye, LN (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	dyrbye.liselotte@mayo.edu			Mayo Clinic; Mayo Clinic Department of Medicine; Division of Primary Care; Mayo Medical School Office of Educational Research	Mayo Clinic; Mayo Clinic Department of Medicine; Division of Primary Care; Mayo Medical School Office of Educational Research	This work was supported by a Professionalism Award from the Mayo Clinic; from the Mayo Clinic Department of Medicine, Division of Primary Care intramural funds; the Mayo Clinic Department of Medicine Program on Physician Well-being; and the Mayo Medical School Office of Educational Research.	*AM MED ASS, COD MED ETH OP 8 061; American Medical Association, 2001, DECL PROF RESP MED S; ANDERSON RE, 1994, ACAD MED, V69, P323, DOI 10.1097/00001888-199405000-00002; *ASS AM MED COLL, 1996, GRAD QUEST 1995 1996; *ASS AM MED COLL, 2002, ENR GRAD MD PHD DAT; Cooke M, 2006, NEW ENGL J MED, V355, P1339, DOI 10.1056/NEJMra055445; Crandall SJS, 2007, ADV HEALTH SCI EDUC, V12, P71, DOI 10.1007/s10459-005-2297-1; Crandall Sonia J. S., 1993, JAMA (Journal of the American Medical Association), V269, P2519, DOI 10.1001/jama.269.19.2519; Dans PE, 1996, ACAD MED, V71, pS70, DOI 10.1097/00001888-199601000-00046; Dyrbye LN, 2008, ANN INTERN MED, V149, P334, DOI 10.7326/0003-4819-149-5-200809020-00008; Dyrbye LN, 2010, ACAD MED, V85, P94, DOI 10.1097/ACM.0b013e3181c46aad; Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009; Dyrbye LN, 2006, ACAD MED, V81, P374, DOI 10.1097/00001888-200604000-00010; FEUDTNER C, 1994, ACAD MED, V69, P670, DOI 10.1097/00001888-199408000-00017; FirthCozens J, 1997, SOC SCI MED, V44, P1017, DOI 10.1016/S0277-9536(96)00227-4; Grande D, 2009, ARCH INTERN MED, V169, P887, DOI 10.1001/archinternmed.2009.64; Kellerman SE, 2001, AM J PREV MED, V20, P61, DOI 10.1016/S0749-3797(00)00258-0; Lo B, 2010, NEW ENGL J MED, V362, P669, DOI 10.1056/NEJMp1000213; MORIN K, 2003, AM MED ASS ETHICAL G; Norman Geoffrey R, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P581, DOI 10.1586/14737167.4.5.581; Papadakis MA, 2005, NEW ENGL J MED, V353, P2673, DOI 10.1056/NEJMsa052596; Schaufeli W.B., 1996, MASLACH BURNOUT INVE, V3rd, P22; Schaufeli WB, 2001, PSYCHOL HEALTH, V16, P565, DOI 10.1080/08870440108405527; Shanafelt TD, 2009, ANN SURG, V250, P463, DOI 10.1097/SLA.0b013e3181ac4dfd; Shanafelt TD, 2005, J GEN INTERN MED, V20, P559, DOI 10.1007/s11606-005-0102-8; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; SIERLES F, 1980, J MED EDUC, V55, P124; Sierles FS, 2005, JAMA-J AM MED ASSOC, V294, P1034, DOI 10.1001/jama.294.9.1034; SIMPSON DE, 1989, ACAD MED, V64, P221, DOI 10.1097/00001888-198904000-00013; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Thomas MR, 2007, J GEN INTERN MED, V22, P177, DOI 10.1007/s11606-006-0039-6; Thomas NK, 2004, JAMA-J AM MED ASSOC, V292, P2880, DOI 10.1001/jama.292.23.2880; Turner-Bowker DM, 2003, QUAL LIFE RES, V12, P1003, DOI 10.1023/A:1026179517081; Veloski JJ, 2005, ACAD MED, V80, P366, DOI 10.1097/00001888-200504000-00014; Ware JE Jr, 2001, SCORE INTERPRET SING; West CP, 2009, JAMA-J AM MED ASSOC, V302, P1294, DOI 10.1001/jama.2009.1389; WEST CP, 2007, BMC MED ED, V7; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x	39	500	515	3	109	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1173	1180		10.1001/jama.2010.1318	http://dx.doi.org/10.1001/jama.2010.1318			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649LF	20841530				2022-12-28	WOS:000281770600009
J	Kies, SM; Roth, V; Rowland, M				Kies, Susan M.; Roth, Valerie; Rowland, Michelle			Association of Third-Year Medical Students' First Clerkship With Overall Clerkship Performance and Examination Scores	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-BOARD; OBSTETRICS; VALIDITY; ROTATION; ORDER	Context Anecdotal experience has suggested that third-year medical students whose first clerkship is internal medicine may have superior performance throughout the academic year. Objective To determine whether the order of clerkships by specialty is associated with student performance. Design, Setting, and Participants Clerkship performance records of medical students at all 4 campuses of the University of Illinois College of Medicine who completed their third-year core clerkships from July 2000 through June 2008 (N=2236) were reviewed. Main Outcome Measures Analysis of covariance was used to test for between-group differences (by first clerkship) in mean National Board of Medical Examiners subject examination scores (range, 0-100), preceptor ratings of clerkship clinical performances (range, 12-30), total overall clerkship grades (range, 12-30), and United States Medical Licensing Examination (USMLE) Step 2 scores, adjusted for sex, campus, and USMLE Step 1 score. Results First clerkship specialty was significantly associated with mean subject examination scores (family medicine, 71.96 [95% confidence interval {CI}, 70.90-72.98], internal medicine, 73.86 [95% CI, 73.33-74.39], obstetrics/gynecology, 72.36 [95% CI, 71.64-73.04], pediatrics, 73.11 [95% CI, 72.38-73.84], psychiatry, 72.17 [95% CI, 71.52-72.81], surgery, 72.37 [95% CI, 71.73-73.02]; P<.001) and overall clerkship grades (family medicine, 24.20 [95% CI, 23.90-24.90], internal medicine, 25.33 [95% CI, 25.07-25.60], obstetrics/gynecology, 24.68 [95% CI, 24.32-25.05], pediatrics, 24.92 [95% CI, 24.59-25.27], psychiatry, 24.61 [95% CI, 24.33-25.01], surgery 24.97 [95% CI, 24.64-25.30]; P=.01). There was no significant association with preceptor ratings or USMLE Step 2 scores. Pairwise comparisons for mean total overall clerkship grades showed a significant difference for students taking internal medicine first compared with obstetrics/gynecology (mean difference, 0.65; 95% CI, 0.18-1.12), psychiatry (mean difference, 0.66; 95% CI, 0.20-1.12), and family medicine (mean difference, 0.93; 95% CI, 0.37-1.50). Conclusion Among students at 4 campuses of a US medical school, clerkship order was significantly associated with performance on clerkship subject examinations and overall grades but not with clerkship clinical performance or USMLE Step 2 scores. JAMA. 2010;304(11):1220-1226 www.jama.com	[Kies, Susan M.; Rowland, Michelle] Univ Illinois, Coll Med, Urbana, IL 61801 USA; [Roth, Valerie] So Illinois Univ, Sch Med, Springfield, IL USA	University of Illinois System; University of Illinois Urbana-Champaign; Southern Illinois University System; Southern Illinois University	Kies, SM (corresponding author), Univ Illinois, Coll Med, 255 Med Sci Bldg,M-C 714,506 S Mathews ave, Urbana, IL 61801 USA.	kies@illinois.edu						*ASS AM MED COLL, 2008, AAMC REP; BARNELL P, FAMILY MED CLERKSHIP; Corcoran J, 2009, ACAD MED, V84, pS120, DOI 10.1097/ACM.0b013e3181b37009; Edelstein RA, 2000, ACAD MED, V75, P825, DOI 10.1097/00001888-200008000-00016; Epstein RM, 2007, NEW ENGL J MED, V356, P387, DOI 10.1056/NEJMra054784; Hampton HL, 1996, J REPROD MED, V41, P337; Hemmer PA, 2002, TEACH LEARN MED, V14, P229, DOI 10.1207/S15328015TLM1404_5; Hemmer PA, 2008, TEACH LEARN MED, V20, P118, DOI 10.1080/10401330801991287; Kogan JR, 2003, ACAD MED, V78, pS33, DOI 10.1097/00001888-200310001-00011; Levine RE, 2005, ACAD PSYCHIATR, V29, P52, DOI 10.1176/appi.ap.29.1.52; Lind DS, 1999, J SURG RES, V84, P106, DOI 10.1006/jsre.1999.5624; Nahum GG, 2004, AM J OBSTET GYNECOL, V191, P1762, DOI 10.1016/j.ajog.2004.07.074; *NAT BOARD MED EX, SUBJ EX AN PROGR INF; OLIPHANT U, SURG CLERKSHIP; Park RS, 2005, ACAD PSYCHIATR, V29, P267, DOI 10.1176/appi.ap.29.3.267; Pulito AR, 2007, MED EDUC, V41, P667, DOI 10.1111/j.1365-2923.2007.02787.x; Reteguiz JA, 2002, FAM MED, V34, P604; Roman BJB, 2006, ACAD PSYCHIATR, V30, P110, DOI 10.1176/appi.ap.30.2.110; van Gessel E, 2003, MED EDUC, V37, P966, DOI 10.1046/j.1365-2923.2003.01672.x; Wagenaar A, 2003, ADV HEALTH SCI EDUC, V8, P201, DOI 10.1023/A:1026036707461; Zahn CM, 2004, AM J OBSTET GYNECOL, V190, P1388, DOI 10.1016/j.ajog.2003.12.020	21	21	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1220	1226		10.1001/jama.2010.1184	http://dx.doi.org/10.1001/jama.2010.1184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649LF	20841536	Bronze			2022-12-28	WOS:000281770600015
J	Park, JS; Karnas, E; Ohkubo, K; Chen, P; Kadish, KM; Fukuzumi, S; Bielawski, CW; Hudnall, TW; Lynch, VM; Sessler, JL				Park, Jung Su; Karnas, Elizabeth; Ohkubo, Kei; Chen, Ping; Kadish, Karl M.; Fukuzumi, Shunichi; Bielawski, Christopher W.; Hudnall, Todd W.; Lynch, Vincent M.; Sessler, Jonathan L.			Ion-Mediated Electron Transfer in a Supramolecular Donor-Acceptor Ensemble	SCIENCE			English	Article							PHOTOSYSTEM-II; ANION-BINDING; RECEPTOR	Ion binding often mediates electron transfer in biological systems as a cofactor strategy, either as a promoter or as an inhibitor. However, it has rarely, if ever, been exploited for that purpose in synthetic host-guest assemblies. We report here that strong binding of specific anions (chloride, bromide, and methylsulfate but not tetrafluoroborate or hexafluorophosphate) to a tetrathiafulvalene calix[4]pyrrole (TTF-C4P) donor enforces a host conformation that favors electron transfer to a bisimidazolium quinone (BIQ(2+)) guest acceptor. In contrast, the addition of a tetraethylammonium cation, which binds more effectively than the BIQ(2+) guest in the TTF-C4P cavity, leads to back electron transfer, restoring the initial oxidation states of the donor and acceptor pair. The products of these processes were characterized via spectroscopy and x-ray crystallography.	[Chen, Ping; Kadish, Karl M.] Univ Houston, Dept Chem, Houston, TX 77204 USA; [Park, Jung Su; Karnas, Elizabeth; Bielawski, Christopher W.; Hudnall, Todd W.; Lynch, Vincent M.; Sessler, Jonathan L.] Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78712 USA; [Ohkubo, Kei; Fukuzumi, Shunichi] Osaka Univ, Grad Sch Engn, Dept Mat & Life Sci, Suita, Osaka 5650871, Japan; [Fukuzumi, Shunichi] Ewha Womans Univ, Dept Bioinspired Sci, Seoul 120750, South Korea; [Sessler, Jonathan L.] Yonsei Univ, Dept Chem, Seoul 120749, South Korea	University of Houston System; University of Houston; University of Texas System; University of Texas Austin; Osaka University; Ewha Womans University; Yonsei University	Kadish, KM (corresponding author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77204 USA.		Sessler, Jonathan/AAY-7091-2021; Ohkubo, Kei/L-5002-2019; Ohkubo, Kei/E-5127-2012; Fukuzumi, Shunichi/E-4728-2010; Hudnall, Todd W/K-8354-2014	Ohkubo, Kei/0000-0001-8328-9249; Ohkubo, Kei/0000-0001-8328-9249; Hudnall, Todd/0000-0002-9260-2986	Ministry of Education, Culture, Sports, Science and Technology, Japan; NSF [CHE 0749571, 0741973]; R.A. Welch Foundation [F-1018, E-680, F-1621]; Korean World Class University [R32-20080-000-10217-0, R31-2008-000-10010-0];  [20108010]; Direct For Mathematical & Physical Scien [0741973] Funding Source: National Science Foundation; Grants-in-Aid for Scientific Research [20108001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NSF(National Science Foundation (NSF)); R.A. Welch Foundation(The Welch Foundation); Korean World Class University; ; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by a grant-in-aid (no. 20108010 to S.F.) and a Global Centers of Excellence program from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to S.F.); NSF (grants CHE 0749571 to J.L.S. and 0741973 for the x-ray diffractometer); and the R.A. Welch Foundation (grants F-1018, E-680, and F-1621 to J.LS., K.M.K., and C.W.B., respectively). Support to J.L.S. and S.F. under the Korean World Class University program is also acknowledged (grants R32-20080-000-10217-0 and R31-2008-000-10010-0, respectively). Crystallographic data have been deposited with the Cambridge Crystallographic Data Centre under reference numbers CCDC-775796 to 775804.	Battistuzzi G, 1996, EUR J BIOCHEM, V241, P208, DOI 10.1111/j.1432-1033.1996.0208t.x; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fukuzumi S, 2009, PROG INORG CHEM, V56, P49, DOI 10.1002/9780470440124.ch2; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; McEvoy JP, 2006, CHEM REV, V106, P4455, DOI 10.1021/cr0204294; Nielsen K. A., 2006, ANGEW CHEM, V118, P7002; Nielsen KA, 2006, J AM CHEM SOC, V128, P2444, DOI 10.1021/ja057367u; Nielsen KA, 2004, J AM CHEM SOC, V126, P16296, DOI 10.1021/ja044664a; Rosokha SV, 2007, J AM CHEM SOC, V129, P828, DOI 10.1021/ja064166x; Sessler JL, 2006, J AM CHEM SOC, V128, P12281, DOI 10.1021/ja064012h; Tennyson AG, 2010, CHEM-EUR J, V16, P304, DOI 10.1002/chem.200901883; Utschig LM, 2004, ACCOUNTS CHEM RES, V37, P439, DOI 10.1021/ar020197v; Yocum CF, 2008, COORDIN CHEM REV, V252, P296, DOI 10.1016/j.ccr.2007.08.010; Zhao X, 2005, BIOCHEMISTRY-US, V44, P6559, DOI 10.1021/bi047465c	14	151	151	4	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1324	1327		10.1126/science.1192044	http://dx.doi.org/10.1126/science.1192044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829481				2022-12-28	WOS:000281657300033
J	Traas, J; Vernoux, T				Traas, Jan; Vernoux, Teva			Oscillating Roots	SCIENCE			English	Editorial Material							ARABIDOPSIS		[Traas, Jan; Vernoux, Teva] ENS Lyon, CNRS, INRA, Lab Reprod & Dev Plantes, F-69364 Lyon, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Traas, J (corresponding author), ENS Lyon, CNRS, INRA, Lab Reprod & Dev Plantes, 46 Allee Italie, F-69364 Lyon, France.	jan.traas@ens-lyon.fr	Vernoux, Teva/J-1695-2019; Traas, Jan/AAZ-7004-2020	Vernoux, Teva/0000-0002-8257-4088; Traas, Jan/0000-0001-5107-1472				Beemster GTS, 2002, PLANT PHYSIOL, V129, P854, DOI 10.1104/pp.002923; de Reuille PB, 2006, P NATL ACAD SCI USA, V103, P1627, DOI 10.1073/pnas.0510130103; De Smet I, 2007, DEVELOPMENT, V134, P681, DOI 10.1242/dev.02753; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Lucas M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003673; Moreno-Risueno MA, 2010, SCIENCE, V329, P1306, DOI 10.1126/science.1191937; Tautz D, 2004, DEV CELL, V7, P301, DOI 10.1016/j.devcel.2004.08.008	7	17	17	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1290	1291		10.1126/science.1195572	http://dx.doi.org/10.1126/science.1195572			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829471				2022-12-28	WOS:000281657300020
J	Bonham, VL; Dover, GJ; Brody, LC				Bonham, Vence L.; Dover, George J.; Brody, Lawrence C.			Screening Student Athletes for Sickle Cell Trait - A Social and Clinical Experiment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bonham, Vence L.] NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA; [Brody, Lawrence C.] NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA; [Dover, George J.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University	Bonham, VL (corresponding author), NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200324] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		*NAT COLL ATHL ASS, 2010, M NAT COLL ATHL ASS; RUTKOW IM, 1974, AM J PUBLIC HEALTH, V64, P217, DOI 10.2105/AJPH.64.3.217; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WHITTEN CF, 1973, NEW ENGL J MED, V288, P318, DOI 10.1056/NEJM197302082880612; WILSON B, 2009, NCAA MAY FORCE SCH T	5	62	63	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					997	999		10.1056/NEJMp1007639	http://dx.doi.org/10.1056/NEJMp1007639			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647HS	20825310				2022-12-28	WOS:000281609700001
J	Iglehart, JK				Iglehart, John K.			Defining Medical Expenses - An Early Skirmish over Insurance Reforms	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ABELSON R, 2010, NY TIMES        0723; Jennings CC, 2010, NEW ENGL J MED, V363, P897, DOI 10.1056/NEJMp1007991; RASKIN JR, 2010, HLTH CARE MANAGED CA; SCHUMACHER EA, COMMUNICATION   0517; STONE PH, MONEY POLITICS AETNA	5	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					999	1001		10.1056/NEJMp1008571	http://dx.doi.org/10.1056/NEJMp1008571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647HS	20848683				2022-12-28	WOS:000281609700002
J	Jain, D; Hebden, AK; Nakamura, TM; Miller, KM; Cooper, JP				Jain, Devanshi; Hebden, Anna K.; Nakamura, Toru M.; Miller, Kyle M.; Cooper, Julia Promisel			HAATI survivors replace canonical telomeres with blocks of generic heterochromatin	NATURE			English	Article							FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; DROSOPHILA TELOMERES; EPIGENETIC CONTROL; BINDING-PROTEIN; DOMAIN PROTEIN; 2 MODES; RECOMBINATION; MAINTENANCE; CENTROMERE	The notion that telomeres are essential for chromosome linearity stems from the existence of two chief dangers: inappropriate DNA damage response (DDR) reactions that mistake natural chromosome ends for double-strand DNA breaks (DSBs), and the progressive loss of DNA from chromosomal termini due to the end replication problem. Telomeres avert the former peril by binding sequence-specific end-protection factors that control the access of DDR activities(1,2). The latter threat is tackled by recruiting telomerase, a reverse transcriptase that uses an integral RNA subunit to template the addition of telomere repeats to chromosome ends(3). Here we describe an alternative mode of linear chromosome maintenance in which canonical telomeres are superseded by blocks of heterochromatin. We show that in the absence of telomerase, Schizosaccharomyces pombe cells can survive telomere sequence loss by continually amplifying and rearranging heterochromatic sequences. Because the heterochromatin assembly machinery is required for this survival mode, we have termed it 'HAATI' (heterochromatin amplification-mediated and telomerase-independent). HAATI uses the canonical end-protection protein Pot1 (ref. 4) and its interacting partner Ccq1 (ref. 5) to preserve chromosome linearity. The data suggest a model in which Ccq1 is recruited by the amplified heterochromatin and provides an anchor for Pot1, which accomplishes its end-protection function in the absence of its cognate DNA-binding sequence. HAATI resembles the chromosome end-maintenance strategy found in Drosophila melanogaster, which lacks specific telomere sequences but nonetheless assembles terminal heterochromatin structures that recruit end-protection factors. These findings reveal a previously unrecognized mode by which cancer cells might escape the requirement for telomerase activation, and offer a tool for studying genomes that sustain unusually high levels of heterochromatinization.	[Jain, Devanshi; Cooper, Julia Promisel] Canc Res UK, London Res Inst, London WC2A 3PX, England; [Hebden, Anna K.] Univ London Imperial Coll Sci Technol & Med, Ovarian Canc Act Grp, London W12 0NN, England; [Nakamura, Toru M.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Miller, Kyle M.] Gurdon Inst, Cambridge CB2 1QN, England	Cancer Research UK; Imperial College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cooper, JP (corresponding author), Canc Res UK, London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julie.cooper@cancer.org.uk	Nakamura, Toru M/B-2055-2008	Nakamura, Toru M/0000-0001-5752-0814; cooper, julia promisel/0000-0003-2171-2587; Miller, Kyle/0000-0002-4544-0013	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank T. Cech for discussions and gratefully acknowledge that initial work by T.M.N. on reintroducing Trt1 to circular strains was performed in the Cech laboratory. We thank our current and former laboratory members for discussions and advice. This work was supported by Cancer Research UK.	Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Cenci G, 2005, CHROMOSOMA, V114, P135, DOI 10.1007/s00412-005-0005-9; Cenci G, 2003, NAT CELL BIOL, V5, P82, DOI 10.1038/ncb902; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ekwall K, 1996, J CELL SCI, V109, P2637; Ferreira MG, 2004, GENE DEV, V18, P2249, DOI 10.1101/gad.315804; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Gao GJ, 2010, EMBO J, V29, P819, DOI 10.1038/emboj.2009.394; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Ishii K, 2008, SCIENCE, V321, P1088, DOI 10.1126/science.1158699; Kanoh J, 2005, CURR BIOL, V15, P1808, DOI 10.1016/j.cub.2005.09.041; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Maringele L, 2004, GENE DEV, V18, P2663, DOI 10.1101/gad.316504; Mason JM, 2008, BIOESSAYS, V30, P25, DOI 10.1002/bies.20688; McEachern MJ, 2006, ANNU REV BIOCHEM, V75, P111, DOI 10.1146/annurev.biochem.74.082803.133234; Miller KM, 2006, NATURE, V440, P824, DOI 10.1038/nature04638; Miyoshi T, 2008, SCIENCE, V320, P1341, DOI 10.1126/science.1154819; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakamura KI, 2008, EMBO J, V27, P3036, DOI 10.1038/emboj.2008.215; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Pitt CW, 2010, NUCLEIC ACIDS RES, V38, P6968, DOI 10.1093/nar/gkq580; Rog O, 2008, CURR OPIN GENET DEV, V18, P212, DOI 10.1016/j.gde.2008.01.011; Sugawara N. F., 1988, THESIS HARVARD U; Sugiyama T, 2007, CELL, V128, P491, DOI 10.1016/j.cell.2006.12.035; Teng SC, 1999, MOL CELL BIOL, V19, P8083; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; Tomita K, 2003, MOL CELL BIOL, V23, P5186, DOI 10.1128/MCB.23.15.5186-5197.2003; Tomita K, 2007, CELL, V130, P113, DOI 10.1016/j.cell.2007.05.024; Tomita K, 2008, GENE DEV, V22, P3461, DOI 10.1101/gad.498608; Wang X, 2008, MOL CELL, V31, P463, DOI 10.1016/j.molcel.2008.05.028	37	65	65	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2010	467	7312					223	U118		10.1038/nature09374	http://dx.doi.org/10.1038/nature09374			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829796				2022-12-28	WOS:000281616300038
J	Lestas, I; Vinnicombe, G; Paulsson, J				Lestas, Ioannis; Vinnicombe, Glenn; Paulsson, Johan			Fundamental limits on the suppression of molecular fluctuations	NATURE			English	Article							PLASMID REPLICATION; FEEDBACK-CONTROL; GENE-EXPRESSION; POISSON-TYPE; SINGLE-CELL; NOISE; PERFORMANCE; INFORMATION; LIMITATIONS; ROBUSTNESS	Negative feedback is common in biological processes and can increase a system's stability to internal and external perturbations. But at the molecular level, control loops always involve signalling steps with finite rates for random births and deaths of individual molecules. Here we show, by developing mathematical tools that merge control and information theory with physical chemistry, that seemingly mild constraints on these rates place severe limits on the ability to suppress molecular fluctuations. Specifically, the minimum standard deviation in abundances decreases with the quartic root of the number of signalling events, making it extremely expensive to increase accuracy. Our results are formulated in terms of experimental observables, and existing data show that cells use brute force when noise suppression is essential; for example, regulatory genes are transcribed tens of thousands of times per cell cycle. The theory challenges conventional beliefs about biochemical accuracy and presents an approach to the rigorous analysis of poorly characterized biological systems.	[Lestas, Ioannis; Vinnicombe, Glenn] Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England; [Paulsson, Johan] Harvard Univ, Dept Syst Biol, Boston, MA 02115 USA	University of Cambridge; Harvard University	Vinnicombe, G (corresponding author), Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England.	gv@eng.cam.ac.uk; johan_paulsson@hms.harvard.edu			BBSRC [BB/C008073/1]; National Science Foundation [DMS-074876-0, 0720056]; National Institutes of Health [GM081563-02, GM068763-06]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068763, R01GM081563] Funding Source: NIH RePORTER; Division Of Mathematical Sciences [0748760] Funding Source: National Science Foundation; Biotechnology and Biological Sciences Research Council [BB/C008073/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Division Of Mathematical Sciences(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This research was supported by the BBSRC under grant BB/C008073/1, by the National Science Foundation grants DMS-074876-0 and CAREER 0720056, and by grants GM081563-02 and GM068763-06 from the National Institutes of Health.	Barkai N, 2007, MOL CELL, V28, P755, DOI 10.1016/j.molcel.2007.11.013; Bialek W, 2005, P NATL ACAD SCI USA, V102, P10040, DOI 10.1073/pnas.0504321102; Bialek W, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.258101; Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; Cover TM, 1991, ELEMENTS INFORM THEO; Das N, 2005, P NATL ACAD SCI USA, V102, P2856, DOI 10.1073/pnas.0409790102; DAVIS MHA, 1980, IEEE T INFORM THEORY, V26, P710, DOI 10.1109/TIT.1980.1056262; Doan T, 2006, SCIENCE, V313, P530, DOI 10.1126/science.1126612; Dublanche Y, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100081; El-Samad H, 2005, P NATL ACAD SCI USA, V102, P2736, DOI 10.1073/pnas.0403510102; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Golding I, 2005, CELL, V123, P1025, DOI 10.1016/j.cell.2005.09.031; Gorbunov A. K., 1973, Problems of Information Transmission, V9, P184; Gregor T, 2007, CELL, V130, P153, DOI 10.1016/j.cell.2007.05.025; KABANOV YM, 1978, THEOR PROBAB APPL+, V23, P143, DOI 10.1137/1123013; Keizer J, 1987, STAT THERMODYNAMICS; Korobkova EA, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.058105; Martins NC, 2008, IEEE T AUTOMAT CONTR, V53, P1604, DOI 10.1109/TAC.2008.929361; Martins NC, 2007, IEEE T AUTOMAT CONTR, V52, P56, DOI 10.1109/TAC.2006.887898; MAXWELL JC, 1867, P ROY SOC, V16, P270; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2001, Q REV BIOPHYS, V34, P1, DOI 10.1017/S0033583501003663; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Pedraza JM, 2008, SCIENCE, V319, P339, DOI 10.1126/science.1144331; SAVAGEAU MA, 1971, NATURE, V229, P542, DOI 10.1038/229542a0; SHANNON E, 1948, BELL SYST TECH J, V379, P623; Singh A, 2009, BIOPHYS J, V96, P4013, DOI 10.1016/j.bpj.2009.02.064; Tkacik G, 2008, P NATL ACAD SCI USA, V105, P12265, DOI 10.1073/pnas.0806077105; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; Walczak AM, 2009, P NATL ACAD SCI USA, V106, P6529, DOI 10.1073/pnas.0811999106; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649	32	286	288	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					174	178		10.1038/nature09333	http://dx.doi.org/10.1038/nature09333			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829788	Green Accepted			2022-12-28	WOS:000281616300027
J	Amarenco, P; Labreuche, J; Mazighi, M				Amarenco, Pierre; Labreuche, Julien; Mazighi, Mikael			Lessons from carotid endarterectomy and stenting trials	LANCET			English	Editorial Material							STROKE PREVENTION; MANAGEMENT; STATINS		[Amarenco, Pierre] Hop Xavier Bichat, Dept Neurol, F-75018 Paris, France; Hop Xavier Bichat, Stroke Ctr, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Amarenco, P (corresponding author), Hop Xavier Bichat, Dept Neurol, F-75018 Paris, France.	pierre.amarenco@bch.aphp.fr		Mazighi, Mikael/0000-0003-0911-8999				Amarenco P, 2004, STROKE, V35, P2902, DOI 10.1161/01.STR.0000147965.52712.fa; Amarenco P, 2009, LANCET NEUROL, V8, P453, DOI 10.1016/S1474-4422(09)70058-4; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Halliday A, 2010, LANCET, V376, P1074, DOI 10.1016/S0140-6736(10)61197-X; Markus HS, 2010, LANCET NEUROL, V9, P663, DOI 10.1016/S1474-4422(10)70120-4; U-King-Im JM, 2009, LANCET NEUROL, V8, P569, DOI 10.1016/S1474-4422(09)70092-4; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	13	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1028	1031		10.1016/S0140-6736(10)61415-8	http://dx.doi.org/10.1016/S0140-6736(10)61415-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657KM	20870079				2022-12-28	WOS:000282411600005
J	Mouquet, H; Scheid, JF; Zoller, MJ; Krogsgaard, M; Ott, RG; Shukair, S; Artyomov, MN; Pietzsch, J; Connors, M; Pereyra, F; Walker, BD; Ho, DD; Wilson, PC; Seaman, MS; Eisen, HN; Chakraborty, AK; Hope, TJ; Ravetch, JV; Wardemann, H; Nussenzweig, MC				Mouquet, Hugo; Scheid, Johannes F.; Zoller, Markus J.; Krogsgaard, Michelle; Ott, Rene G.; Shukair, Shetha; Artyomov, Maxim N.; Pietzsch, John; Connors, Mark; Pereyra, Florencia; Walker, Bruce D.; Ho, David D.; Wilson, Patrick C.; Seaman, Michael S.; Eisen, Herman N.; Chakraborty, Arup K.; Hope, Thomas J.; Ravetch, Jeffrey V.; Wardemann, Hedda; Nussenzweig, Michel C.			Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; MEMORY B-CELLS; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEIN; TYPE-1; AUTOREACTIVITY; INDIVIDUALS; MODULATION; GENERATION	During immune responses, antibodies are selected for their ability to bind to foreign antigens with high affinity, in part by their ability to undergo homotypic bivalent binding. However, this type of binding is not always possible. For example, the small number of gp140 glycoprotein spikes displayed on the surface of the human immunodeficiency virus (HIV) disfavours homotypic bivalent antibody binding(1-3). Here we show that during the human antibody response to HIV, somatic mutations that increase antibody affinity also increase breadth and neutralizing potency. Surprisingly, the responding naive and memory B cells produce polyreactive antibodies, which are capable of bivalent heteroligation between one high-affinity anti-HIV-gp140 combining site and a second low-affinity site on another molecular structure on HIV. Although cross-reactivity to self-antigens or polyreactivity is strongly selected against during B-cell development(4), it is a common serologic feature of certain infections in humans, including HIV, Epstein-Barr virus and hepatitis C virus. Seventy-five per cent of the 134 monoclonal anti-HIV-gp140 antibodies cloned from six patients(5) with high titres of neutralizing antibodies are polyreactive. Despite the low affinity of the polyreactive combining site, heteroligation demonstrably increases the apparent affinity of polyreactive antibodies to HIV.	[Mouquet, Hugo; Scheid, Johannes F.; Pietzsch, John; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA; [Scheid, Johannes F.] Charite, D-10117 Berlin, Germany; [Zoller, Markus J.; Wardemann, Hedda] Max Planck Inst Infect Biol, D-10117 Berlin, Germany; [Krogsgaard, Michelle] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Krogsgaard, Michelle] NYU, Sch Med, Inst Canc, New York, NY 10016 USA; [Ott, Rene G.; Ravetch, Jeffrey V.] Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10065 USA; [Shukair, Shetha; Hope, Thomas J.] Northwestern Univ, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Artyomov, Maxim N.; Eisen, Herman N.; Chakraborty, Arup K.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Artyomov, Maxim N.; Eisen, Herman N.; Chakraborty, Arup K.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Artyomov, Maxim N.; Eisen, Herman N.; Chakraborty, Arup K.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Artyomov, Maxim N.; Eisen, Herman N.; Chakraborty, Arup K.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Artyomov, Maxim N.; Eisen, Herman N.; Chakraborty, Arup K.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Pietzsch, John] Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany; [Connors, Mark] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; [Connors, Mark] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; [Pereyra, Florencia; Walker, Bruce D.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA; [Pereyra, Florencia; Walker, Bruce D.] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Ho, David D.] Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; [Wilson, Patrick C.] Univ Chicago, Dept Med, Rheumatol Sect, Chicago, IL 60637 USA; [Seaman, Michael S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA	Rockefeller University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; New York University; New York University; Rockefeller University; Northwestern University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Free University of Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Harvard Medical School; University of Chicago; Harvard University; Beth Israel Deaconess Medical Center; Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.	nussenzweig@rockefeller.edu	Mouquet, Hugo/M-2750-2014; Ravetch, Jeffrey/Z-1596-2019; Nussenzweig, Michel/AAE-7292-2019; Wilson, Patrick/HGC-3157-2022	Mouquet, Hugo/0000-0002-4230-610X; Ravetch, Jeffrey/0000-0003-2024-9041; Wardemann, Hedda/0000-0003-3921-5933	Rockefeller University; National Institutes of Health [NIH 1 PO1 AI081677, R01 AI047770]; International AIDS Vaccine Initiative; Bill and Melinda Gates Foundation; German Research Foundation [GRK1121]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI081677, R01AI047770, ZIAAI000855, ZIAAI001090] Funding Source: NIH RePORTER	Rockefeller University; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International AIDS Vaccine Initiative; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); German Research Foundation(German Research Foundation (DFG)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank J. R. Mascola and R. T. Wyatt for discussion and supplying gp140 and gp120 proteins. This research was supported by the Rockefeller University, the National Institutes of Health (NIH 1 PO1 AI081677), the International AIDS Vaccine Initiative and the Bill and Melinda Gates Foundation. T.J.H. was supported by the National Institutes of Health (R01 AI047770). M.J.Z. and H.W. were supported by the German Research Foundation (GRK1121). B.D.W. and M.C.N. are Howard Hughes Medical Institute investigators.	Aguilera I, 2001, IMMUNOLOGY, V102, P273, DOI 10.1046/j.1365-2567.2001.01159.x; BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hedestam GBK, 2008, NAT REV MICROBIOL, V6, P143, DOI 10.1038/nrmicro1819; ICHIYOSHI Y, 1994, J EXP MED, V180, P885, DOI 10.1084/jem.180.3.885; Jay JI, 2009, ADV FUNCT MATER, V19, P2969, DOI 10.1002/adfm.200900757; Karlsson GB, 1996, J VIROL, V70, P6136, DOI 10.1128/JVI.70.9.6136-6142.1996; Klein JS, 2009, P NATL ACAD SCI USA, V106, P7385, DOI 10.1073/pnas.0811427106; Krogsgaard M, 2005, NATURE, V434, P238, DOI 10.1038/nature03391; Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159; Mascola JR, 2007, NATURE, V449, P29, DOI 10.1038/449029a; Meffre E, 2004, J EXP MED, V199, P145, DOI 10.1084/jem.20031550; MICHAELIDES MC, 1974, J EXP MED, V140, P687, DOI 10.1084/jem.140.3.687; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08; Scheid JF, 2009, J IMMUNOL METHODS, V343, P65, DOI 10.1016/j.jim.2008.11.012; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Shen XY, 2010, P NATL ACAD SCI USA, V107, P5972, DOI 10.1073/pnas.0912381107; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tsuiji M, 2006, J EXP MED, V203, P393, DOI 10.1084/jem.20052033; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Yurasov S, 2005, J EXP MED, V201, P703, DOI 10.1084/jem.20042251; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307	31	318	333	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					591	U117		10.1038/nature09385	http://dx.doi.org/10.1038/nature09385			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882016	Green Accepted			2022-12-28	WOS:000282273100039
J	Mohrmann, R; de Wit, H; Verhage, M; Neher, E; Sorensen, JB				Mohrmann, Ralf; de Wit, Heidi; Verhage, Matthijs; Neher, Erwin; Sorensen, Jakob B.			Fast Vesicle Fusion in Living Cells Requires at Least Three SNARE Complexes	SCIENCE			English	Article							MEMBRANE-FUSION; SECRETORY VESICLES; EXOCYTOSIS; RELEASE; SYNAPSE; DOMAIN	Exocytosis requires formation of SNARE [soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor] complexes between vesicle and target membranes. Recent assessments in reduced model systems have produced divergent estimates of the number of SNARE complexes needed for fusion. Here, we used a titration approach to answer this question in intact, cultured chromaffin cells. Simultaneous expression of wild-type SNAP-25 and a mutant unable to support exocytosis progressively altered fusion kinetics and fusion-pore opening, indicating that both proteins assemble into heteromeric fusion complexes. Expressing different wild-type: mutant ratios revealed a third-power relation for fast (synchronous) fusion and a near-linear relation for overall release. Thus, fast fusion typically observed in synapses and neurosecretory cells requires at least three functional SNARE complexes, whereas slower release might occur with fewer complexes. Heterogeneity in SNARE-complex number may explain heterogeneity in vesicular release probability.	[Mohrmann, Ralf; Neher, Erwin; Sorensen, Jakob B.] Max Planck Inst Biophys Chem, Dept Membrane Biophys, Gottingen, Germany; [Mohrmann, Ralf] Univ Saarland, Dept Physiol, D-6650 Homburg, Germany; [de Wit, Heidi; Verhage, Matthijs] Vrije Univ Amsterdam, Dept Funct Genom, Ctr Neurogenom & Cognit Res, Amsterdam, Netherlands; [de Wit, Heidi; Verhage, Matthijs] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Sorensen, Jakob B.] Univ Copenhagen, Fac Hlth Sci, Dept Neurosci & Pharmacol, Copenhagen, Denmark; [Sorensen, Jakob B.] Univ Copenhagen, Lundbeck Fdn Ctr Biomembranes Nanomed, Copenhagen, Denmark	Max Planck Society; Saarland University; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Copenhagen; Lundbeckfonden; University of Copenhagen	Mohrmann, R (corresponding author), Max Planck Inst Biophys Chem, Dept Membrane Biophys, Gottingen, Germany.	Ralf.Mohrmann@uks.eu; jakobbs@sund.ku.dk	Neher, Erwin/A-2109-2013	verhage, matthijs/0000-0002-6085-7503; Sorensen, Jakob/0000-0001-5465-3769	Lundbeck Foundation; Lundbeck Foundation Center for Biomembranes in Nanomedicine; Danish Medical Research Council; Netherlands Organization for Scientific Research [Pionier/VICI900-01-001, ZonMW 903-42-095, VENI 916-36-043]; NeuroBsik Mouse Phenomics Consortium [BSIK03053]; European Union [HEALTH-F2-2009-242167]; Lundbeck Foundation [R28-2008-1976] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Lundbeck Foundation Center for Biomembranes in Nanomedicine; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); NeuroBsik Mouse Phenomics Consortium; European Union(European Commission); Lundbeck Foundation(Lundbeckfonden)	We thank I. Herfort and D. Reuter for expert technical assistance and S. Young for help with viral expression systems. This work was supported by the Lundbeck Foundation (Junior Group Leader Fellowship, J.B.S.), the Lundbeck Foundation Center for Biomembranes in Nanomedicine (J.B.S.), the Danish Medical Research Council (J.B.S.), the Netherlands Organization for Scientific Research (Pionier/VICI900-01-001 and ZonMW 903-42-095 to M.V. and VENI 916-36-043 to H.d.W.), the NeuroBsik Mouse Phenomics Consortium (BSIK03053), and the European Union Seventh Framework Programme under grant agreement no. HEALTH-F2-2009-242167 ("SynSys" project to both J.B.S. and M.V.).	Aikawa Y, 2006, MOL BIOL CELL, V17, P2113, DOI 10.1091/mbc.E06-01-0074; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; de Wit H, 2009, CELL, V138, P935, DOI 10.1016/j.cell.2009.07.027; Domanska MK, 2009, J BIOL CHEM, V284, P32158, DOI 10.1074/jbc.M109.047381; Li F, 2007, NAT STRUCT MOL BIOL, V14, P890, DOI 10.1038/nsmb1310; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Karatekin E, 2010, P NATL ACAD SCI USA, V107, P3517, DOI 10.1073/pnas.0914723107; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Liu W, 2008, BIOPHYS J, V95, P419, DOI 10.1529/biophysj.107.127886; Montecucco C, 2005, TRENDS BIOCHEM SCI, V30, P367, DOI 10.1016/j.tibs.2005.05.002; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Sorensen JB, 2009, ANNU REV CELL DEV BI, V25, P513, DOI 10.1146/annurev.cellbio.24.110707.175239; Sorensen JB, 2006, EMBO J, V25, P955, DOI 10.1038/sj.emboj.7601003; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; van den Bogaart G, 2010, NAT STRUCT MOL BIOL, V17, P358, DOI 10.1038/nsmb.1748; Walter AM, 2010, J CELL BIOL, V188, P401, DOI 10.1083/jcb.200907018; Wiederhold K, 2009, J BIOL CHEM, V284, P13143, DOI 10.1074/jbc.M900703200; Yersin A, 2003, P NATL ACAD SCI USA, V100, P8736, DOI 10.1073/pnas.1533137100	24	211	213	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	2010	330	6003					502	505		10.1126/science.1193134	http://dx.doi.org/10.1126/science.1193134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	669EL	20847232				2022-12-28	WOS:000283329100039
J	He, XA; Szewczyk, P; Karyakin, A; Evin, M; Hong, WX; Zhang, QH; Chang, G				He, Xiao; Szewczyk, Paul; Karyakin, Andrey; Evin, Mariah; Hong, Wen-Xu; Zhang, Qinghai; Chang, Geoffrey			Structure of a cation-bound multidrug and toxic compound extrusion transporter	NATURE			English	Article							ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; DIFFRACTION DATA; NMR SYSTEM; PROTEIN; DATABASE; FAMILY; MODEL; CRYSTALLOGRAPHY; SUPERFAMILY	Transporter proteins from the MATE (multidrug and toxic compound extrusion)(1) family are vital in metabolite transport in plants(2,3), directly affecting crop yields worldwide(4). MATE transporters also mediate multiple-drug resistance (MDR) in bacteria and mammals(5), modulating the efficacy of many pharmaceutical drugs used in the treatment of a variety of diseases(6-9). MATE transporters couple substrate transport to electrochemical gradients and are the only remaining class of MDR transporters whose structure has not been determined(10). Here we report the X-ray structure of the MATE transporter NorM from Vibrio cholerae determined to 3.65 angstrom, revealing an outward-facing conformation with two portals open to the outer leaflet of the membrane and a unique topology of the predicted 12 transmembrane helices distinct from any other known MDR transporter. We also report a cation-binding site in close proximity to residues previously deemed critical for transport(11). This conformation probably represents a stage of the transport cycle with high affinity for monovalent cations and low affinity for substrates.	[He, Xiao; Szewczyk, Paul; Karyakin, Andrey; Evin, Mariah; Hong, Wen-Xu; Zhang, Qinghai; Chang, Geoffrey] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Chang, G (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,CB105, La Jolla, CA 92037 USA.	gchang@scripps.edu	Hong, Wen-Xu/H-5021-2014	Hong, Wen-Xu/0000-0003-0260-1099	National Institutes of Health [GM70480, GM73197]; Beckman Foundation; Skaggs Chemical Biology Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070480, P50GM073197] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Beckman Foundation; Skaggs Chemical Biology Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Y. Yin for his contribution to initial clones of NorM. We also thank the Canadian Light Source (CLS), the Stanford Synchrotron Radiation Laboratory (SSRL), the Advanced Light Source (ALS) and the Advanced Photon Source (APS). This work was supported by grants from the National Institutes of Health (GM70480 to G.C., and GM73197 to Q.Z.), the Beckman Foundation and the Skaggs Chemical Biology Foundation.	Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Becker MSL, 2009, DIABETES, V58, P745, DOI 10.2337/db08-1028; Brown MH, 1999, MOL MICROBIOL, V31, P394, DOI 10.1046/j.1365-2958.1999.01162.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406; Chen YJ, 2007, P NATL ACAD SCI USA, V104, P18999, DOI 10.1073/pnas.0709387104; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Hvorup RN, 2003, EUR J BIOCHEM, V270, P799, DOI 10.1046/j.1432-1033.2003.03418.x; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Kaatz GW, 2005, ANTIMICROB AGENTS CH, V49, P1857, DOI 10.1128/AAC.49.5.1857-1864.2005; Law CJ, 2008, ANNU REV MICROBIOL, V62, P289, DOI 10.1146/annurev.micro.61.080706.093329; Leslie A, 1992, NEWSLETTER PROTEIN C; Li XZ, 2003, ANTIMICROB AGENTS CH, V47, P27, DOI 10.1128/AAC.47.1.27-33.2003; Magalhaes JV, 2007, NAT GENET, V39, P1156, DOI 10.1038/ng2074; McAleese F, 2005, ANTIMICROB AGENTS CH, V49, P1865, DOI 10.1128/AAC.49.5.1865-1871.2005; Morita M, 2009, P NATL ACAD SCI USA, V106, P2447, DOI 10.1073/pnas.0812512106; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Omote H, 2006, TRENDS PHARMACOL SCI, V27, P587, DOI 10.1016/j.tips.2006.09.001; Otsuka M, 2005, J BACTERIOL, V187, P1552, DOI 10.1128/JB.187.5.1552-1558.2005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Saier MH, 2006, NUCLEIC ACIDS RES, V34, pD181, DOI 10.1093/nar/gkj001; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tsuda M, 2009, MOL PHARMACOL, V75, P1280, DOI 10.1124/mol.109.056242; Ward A, 2007, P NATL ACAD SCI USA, V104, P19005, DOI 10.1073/pnas.0709388104; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wood S., 2000, PILOT ANAL GLOBAL EC, V12; Yin Y, 2006, SCIENCE, V312, P741, DOI 10.1126/science.1125629; Zhang QH, 2007, ANGEW CHEM INT EDIT, V46, P7023, DOI 10.1002/anie.200701556; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	37	205	213	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	2010	467	7318					991	U139		10.1038/nature09408	http://dx.doi.org/10.1038/nature09408			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668FT	20861838	Green Accepted			2022-12-28	WOS:000283254700044
J	Kranendijk, M; Struys, EA; van Schaftingen, E; Gibson, KM; Kanhai, WA; van der Knaap, MS; Amiel, J; Buist, NR; Das, AM; de Klerk, JB; Feigenbaum, AS; Grange, DK; Hofstede, FC; Holme, E; Kirk, EP; Korman, SH; Morava, E; Morris, A; Smeitink, J; Sukhai, RN; Vallance, H; Jakobs, C; Salomons, GS				Kranendijk, Martijn; Struys, Eduard A.; van Schaftingen, Emile; Gibson, K. Michael; Kanhai, Warsha A.; van der Knaap, Marjo S.; Amiel, Jeanne; Buist, Neil R.; Das, Anibh M.; de Klerk, Johannis B.; Feigenbaum, Annette S.; Grange, Dorothy K.; Hofstede, Floris C.; Holme, Elisabeth; Kirk, Edwin P.; Korman, Stanley H.; Morava, Eva; Morris, Andrew; Smeitink, Jan; Sukhai, Ram N.; Vallance, Hilary; Jakobs, Cornelis; Salomons, Gajja S.			IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria	SCIENCE			English	Article									[Kranendijk, Martijn; Struys, Eduard A.; Kanhai, Warsha A.; Jakobs, Cornelis; Salomons, Gajja S.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Metab Unit, NL-1081 HV Amsterdam, Netherlands; [van Schaftingen, Emile] Catholic Univ Louvain, de Duve Inst, Lab Phys Chem, Louvain, Belgium; [Gibson, K. Michael] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; [van der Knaap, Marjo S.] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Child Neurol, Amsterdam, Netherlands; [Amiel, Jeanne] Univ Paris 05, Hop Necker, Dept Genet, Paris, France; [Amiel, Jeanne] Univ Paris 05, Hop Necker, INSERM, U781, Paris, France; [Buist, Neil R.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR USA; [Buist, Neil R.] Oregon Hlth & Sci Univ, Dept Med Genet, Portland, OR USA; [Das, Anibh M.] Hannover Med Sch, Hannover, Germany; [de Klerk, Johannis B.] ErasmusMC Sophia Childrens Hosp, Dept Metab Dis, Rotterdam, Netherlands; [Feigenbaum, Annette S.] Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON, Canada; [Feigenbaum, Annette S.] Univ Toronto, Toronto, ON, Canada; [Grange, Dorothy K.] Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat,Div Genet & Genom Med, St Louis, MO USA; [Hofstede, Floris C.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Metab Dis, Utrecht, Netherlands; [Holme, Elisabeth] Univ Gothenburg, Sahlgrenska Univer Hosp, Dept Clin Chem & Transfus Med, Gothenburg, Sweden; [Kirk, Edwin P.] Sydney Childrens Hosp, Dept Med Genet, Sydney, NSW, Australia; [Korman, Stanley H.] Hadassah Hebrew Univ, Med Ctr, Dept Human Genet & Metab Dis, Jerusalem, Israel; [Morava, Eva] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; [Morris, Andrew] Children Natl Hlth Serv Trust, Great Ormond St Hosp, London, England; [Smeitink, Jan] Radboud Univ Nijmegen, Med Ctr, Inst Genet & Metab Dis, NL-6500 HB Nijmegen, Netherlands; [Sukhai, Ram N.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Vallance, Hilary] Univ British Columbia, BC Childrens Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada	Vrije Universiteit Amsterdam; Universite Catholique Louvain; Michigan Technological University; Vrije Universiteit Amsterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Oregon Health & Science University; Oregon Health & Science University; Hannover Medical School; Erasmus University Rotterdam; Erasmus MC; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; St. Louis Children's Hospital; Washington University (WUSTL); Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; University of Gothenburg; University of Sydney; Hebrew University of Jerusalem; Hadassah University Medical Center; Radboud University Nijmegen; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; BC Childrens Hospital; University of British Columbia	Jakobs, C (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Metab Unit, NL-1081 HV Amsterdam, Netherlands.	c.jakobs@vumc.nl	amiel, jeanne/H-3501-2017; amiel, jeanne/AGX-1124-2022; Morava, E./L-4529-2015; Smeitink, Jan/C-1351-2013; Van+Schaftingen, Emile/AAF-5532-2020	amiel, jeanne/0000-0001-5973-4728; Vallance, Hilary/0000-0003-1734-1445; Kirk, Edwin/0000-0002-4662-0024; Van Schaftingen, Emile/0000-0002-6199-7647				Aghili M, 2009, J NEURO-ONCOL, V91, P233, DOI 10.1007/s11060-008-9706-2; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Kranendijk M, 2010, HUM MUTAT, V31, P279, DOI 10.1002/humu.21186; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Steenweg ME, 2010, HUM MUTAT, V31, P380, DOI 10.1002/humu.21197; Struys EA, 2005, AM J HUM GENET, V76, P358, DOI 10.1086/427890; Struys EA, 2004, FEBS LETT, V557, P115, DOI 10.1016/S0014-5793(03)01459-5; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	9	145	183	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2010	330	6002					336	336		10.1126/science.1192632	http://dx.doi.org/10.1126/science.1192632			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	664TY	20847235				2022-12-28	WOS:000282986700031
J	Valentine, DL; Kessler, JD; Redmond, MC; Mendes, SD; Heintz, MB; Farwell, C; Hu, L; Kinnaman, FS; Yvon-Lewis, S; Du, MR; Chan, EW; Tigreros, FG; Villanueva, CJ				Valentine, David L.; Kessler, John D.; Redmond, Molly C.; Mendes, Stephanie D.; Heintz, Monica B.; Farwell, Christopher; Hu, Lei; Kinnaman, Franklin S.; Yvon-Lewis, Shari; Du, Mengran; Chan, Eric W.; Tigreros, Fenix Garcia; Villanueva, Christie J.			Propane Respiration Jump-Starts Microbial Response to a Deep Oil Spill	SCIENCE			English	Article							HYDROCARBON DEGRADATION; METHANE OXIDATION; GEN. NOV.; CARBON; PLUME; BACTERIUM; SEDIMENTS; MARGIN	The Deepwater Horizon event resulted in suspension of oil in the Gulf of Mexico water column because the leakage occurred at great depth. The distribution and fate of other abundant hydrocarbon constituents, such as natural gases, are also important in determining the impact of the leakage but are not yet well understood. From 11 to 21 June 2010, we investigated dissolved hydrocarbon gases at depth using chemical and isotopic surveys and on-site biodegradation studies. Propane and ethane were the primary drivers of microbial respiration, accounting for up to 70% of the observed oxygen depletion in fresh plumes. Propane and ethane trapped in the deep water may therefore promote rapid hydrocarbon respiration by low-diversity bacterial blooms, priming bacterial populations for degradation of other hydrocarbons in the aging plume.	[Valentine, David L.; Redmond, Molly C.; Mendes, Stephanie D.; Heintz, Monica B.; Farwell, Christopher; Kinnaman, Franklin S.; Villanueva, Christie J.] Univ Calif Santa Barbara, Dept Earth Sci, Santa Barbara, CA 93106 USA; [Valentine, David L.; Redmond, Molly C.; Mendes, Stephanie D.; Heintz, Monica B.; Farwell, Christopher; Kinnaman, Franklin S.; Villanueva, Christie J.] Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; [Kessler, John D.; Hu, Lei; Yvon-Lewis, Shari; Du, Mengran; Chan, Eric W.; Tigreros, Fenix Garcia] Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Texas A&M University System; Texas A&M University College Station	Valentine, DL (corresponding author), Univ Calif Santa Barbara, Dept Earth Sci, Santa Barbara, CA 93106 USA.	valentine@geol.ucsb.edu	Yvon-Lewis, Shari/E-4108-2012; Kessler, John/U-6398-2017; Valentine, David/E-5594-2012; Hu, Lei/AAZ-4423-2021; du, mengran/AAO-7295-2021	Yvon-Lewis, Shari/0000-0003-1378-8434; Kessler, John/0000-0003-1097-6800; Garcia-Tigreros, Fenix/0000-0001-8694-9046; Valentine, David/0000-0001-5914-9107; Redmond, Molly/0000-0003-4227-394X; du, meng ran/0000-0001-8862-5256	National Science Foundation [OCE 1042097, OCE 0961725, OCE 1042650, OCE 0849246]; Department of Energy [DE-NT0005667]; Direct For Education and Human Resources [0929836] Funding Source: National Science Foundation; Division Of Ocean Sciences [0849246] Funding Source: National Science Foundation; Division Of Undergraduate Education [0806926] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); Department of Energy(United States Department of Energy (DOE)); Direct For Education and Human Resources(National Science Foundation (NSF)NSF - Directorate for STEM Education (EDU)); Division Of Ocean Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Undergraduate Education(National Science Foundation (NSF)NSF - Directorate for STEM Education (EDU))	This research was supported by the National Science Foundation through awards OCE 1042097 and OCE 0961725 to D. L. V. and OCE 1042650 and OCE 0849246 to J.D.K. and by the Department of Energy through award DE-NT0005667 to D. L. V. We thank the captain and crew of the research vessel Cape Hatteras, R. Stephens Smith, R. Amon, K. Goodman S. Bagby, G. Paradis, A. Best, L. Werra, C. Hansen, L. Sanchez, H. Hill, S. Joye, and the staff at Picarro Inc. for valuable technical assistance and discussions. Sequences are available on GenBank, accession numbers HQ222989 to HQ222996.	Brakstad OG, 2008, MICROB ECOL, V55, P540, DOI 10.1007/s00248-007-9299-x; BROOKS JM, 1975, THESIS TEXAS A M U; Camilli R, 2010, SCIENCE, V330, P201, DOI 10.1126/science.1195223; Chen FH, 2004, J MARINE SYST, V45, P189, DOI 10.1016/j.jmarsys.2003.11.005; Chung WK, 2001, APPL ENVIRON MICROB, V67, P5585, DOI 10.1128/AEM.67.12.5585-5592.2001; Dasanayaka LK, 2009, J HYDRO-ENVIRON RES, V2, P243, DOI 10.1016/j.jher.2009.01.004; Department of Epidemiology I, 2010, EHES JOINT ACT PROGR, P31; DYKSTERHOUSE SE, 1995, INT J SYST BACTERIOL, V45, P116, DOI 10.1099/00207713-45-1-116; Geiselbrecht AD, 1998, APPL ENVIRON MICROB, V64, P4703; GELWICKS JT, 1994, APPL ENVIRON MICROB, V60, P467, DOI 10.1128/AEM.60.2.467-472.1994; GELWICKS JT, 1989, ORG GEOCHEM, V14, P441, DOI 10.1016/0146-6380(89)90009-0; Grant NJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001851; Hazen TC, 2010, SCIENCE, V330, P204, DOI 10.1126/science.1195979; Hedlund BP, 1999, APPL ENVIRON MICROB, V65, P251; Kinnaman FS, 2007, GEOCHIM COSMOCHIM AC, V71, P271, DOI 10.1016/j.gca.2006.09.007; Maruyama A, 2003, MICROBIAL ECOL, V46, P442, DOI 10.1007/s00248-002-3010-z; Mastalerz V, 2009, GEOCHIM COSMOCHIM AC, V73, P3849, DOI 10.1016/j.gca.2008.12.030; Mau S, 2006, MAR GEOL, V225, P129, DOI 10.1016/j.margeo.2005.09.007; Mau S, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031344; Redmond MC, 2010, APPL ENVIRON MICROB, V76, P6412, DOI 10.1128/AEM.00271-10; Reeburgh WS, 2007, CHEM REV, V107, P486, DOI 10.1021/cr050362v; Schrope M, 2010, NATURE, V465, P274, DOI 10.1038/465274a; U. S. Geological Survey, 2010, DEEPW HOR MC252 GULF; Valentine DL, 2010, NATURE, V465, P421, DOI 10.1038/465421a; Valentine DL, 2001, GEOCHIM COSMOCHIM AC, V65, P2633, DOI 10.1016/S0016-7037(01)00625-1; YAPA PD, 2008, OCEANS, V1, P109	26	320	330	7	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	2010	330	6001					208	211		10.1126/science.1196830	http://dx.doi.org/10.1126/science.1196830			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LP	20847236				2022-12-28	WOS:000282644600038
J	DeKosky, ST; Ikonomovic, MD; Gandy, S				DeKosky, Steven T.; Ikonomovic, Milos D.; Gandy, Sam			Traumatic Brain Injury -- Football, Warfare, and Long-Term Effects.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA; [Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA; [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Edu & Clin Ctr, Pittsburgh, PA USA; [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY USA; [Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA; [Gandy, Sam] James J Peters VA Med Ctr, New York, NY USA	University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	DeKosky, ST (corresponding author), Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.			DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG010491, P01 AG010491-14] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED	5	233	236	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1293	1296		10.1056/NEJMp1007051	http://dx.doi.org/10.1056/NEJMp1007051			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655TD	20879875				2022-12-28	WOS:000282271500001
J	Vadlamudi, L; Dibbens, LM; Lawrence, KM; Iona, X; McMahon, JM; Murrell, W; Mackay-Sim, A; Scheffer, IE; Berkovic, SF				Vadlamudi, Lata; Dibbens, Leanne M.; Lawrence, Kate M.; Iona, Xenia; McMahon, Jacinta M.; Murrell, Wayne; Mackay-Sim, Alan; Scheffer, Ingrid E.; Berkovic, Samuel F.			Timing of De Novo Mutagenesis - A Twin Study of Sodium-Channel Mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE MYOCLONIC EPILEPSY; MONOZYGOTIC TWINS; DRAVET-SYNDROME; SCN1A MUTATION; INFANCY; DISEASE; MOSAICISM; DIAGNOSIS	De novo mutations are a cause of sporadic disease, but little is known about the developmental timing of such mutations. We studied concordant and discordant monozygous twins with de novo mutations in the sodium channel alpha 1 subunit gene (SCN1A) causing Dravet's syndrome, a severe epileptic encephalopathy. On the basis of our findings and the literature on mosaic cases, we conclude that de novo mutations in SCN1A may occur at any time, from the premorula stage of the embryo (causing disease in the subject) to adulthood (with mutations in the germ-line cells of parents causing disease in offspring).	[Vadlamudi, Lata; Lawrence, Kate M.; McMahon, Jacinta M.; Scheffer, Ingrid E.; Berkovic, Samuel F.] Univ Melbourne, Austin Hlth, Epilepsy Res Ctr, Melbourne, Vic, Australia; [Scheffer, Ingrid E.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Vadlamudi, Lata] Univ Queensland, Brisbane, Qld, Australia; [Vadlamudi, Lata] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Murrell, Wayne; Mackay-Sim, Alan] Griffith Univ, Natl Ctr Adult Stem Cell Res, Brisbane, Qld 4111, Australia; [Dibbens, Leanne M.; Iona, Xenia] Womens & Childrens Hosp, SA Pathol, Epilepsy Res Program, Adelaide, SA, Australia; [Dibbens, Leanne M.] Univ Adelaide, Sch Pediat & Reprod Hlth, Adelaide, SA, Australia; [Murrell, Wayne] Univ Oslo, Rikshosp, Inst Surg Res, Vilhelm Magnus Ctr, N-0027 Oslo, Norway	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Children's Hospital Melbourne; University of Queensland; Royal Brisbane & Women's Hospital; Griffith University; SA Pathology; Womens & Childrens Hospital Australia; University of Adelaide; University of Oslo; National Hospital Norway	Berkovic, SF (corresponding author), Univ Melbourne, Austin Hlth, Epilepsy Res Ctr, 1st Fl,Neurosci Bldg,Repatriat Campus,Banksia St, Melbourne, Vic, Australia.	s.berkovic@unimelb.edu.au	Mackay-Sim, Alan/C-3431-2008; Scheffer, Ingrid E/G-1668-2013; Vadlamudi, Lata/F-5044-2010; jiang, yu/HGU-0029-2022	Mackay-Sim, Alan/0000-0003-4446-5371; Scheffer, Ingrid E/0000-0002-2311-2174; Vadlamudi, Lata/0000-0002-8742-0125; McMahon, Jacinta/0000-0001-8891-0049; Berkovic, Samuel/0000-0003-4580-841X; Dibbens, Leanne/0000-0002-5824-3342	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council of Australia.	Arnheim N, 2009, NAT REV GENET, V10, P478, DOI 10.1038/nrg2529; Berkovic SF, 1998, ANN NEUROL, V43, P435, DOI 10.1002/ana.410430405; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Claes LRF, 2009, HUM MUTAT, V30, pE904, DOI 10.1002/humu.21083; Depienne C, 2009, J MED GENET, V46, P183, DOI 10.1136/jmg.2008.062323; Depienne Christel, 2006, Hum Mutat, V27, P389, DOI 10.1002/humu.9419; Dravet Charlotte, 2005, Adv Neurol, V95, P71; FUJIWARA T, 1990, EPILEPSIA, V31, P281, DOI 10.1111/j.1528-1157.1990.tb05377.x; Genmaro E, 2006, BIOCHEM BIOPH RES CO, V341, P489, DOI 10.1016/j.bbrc.2005.12.209; Harkin LA, 2007, BRAIN, V130, P843, DOI 10.1093/brain/awm002; Heron SE, 2010, J MED GENET, V47, P137, DOI 10.1136/jmg.2008.065912; Jansen FE, 2006, NEUROLOGY, V67, P2224, DOI 10.1212/01.wnl.0000249312.73155.7d; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; Lupski JR, 2007, NAT GENET, V39, pS43, DOI 10.1038/ng2084; Machin G, 2009, AM J MED GENET C, V151C, P110, DOI 10.1002/ajmg.c.30212; Marini C, 2006, EPILEPSIA, V47, P1737, DOI 10.1111/j.1528-1167.2006.00675.x; Marini C, 2009, EPILEPSIA, V50, P1670, DOI 10.1111/j.1528-1167.2009.02013.x; Matigian N, 2010, DIS MODEL MECH, V3, P785, DOI 10.1242/dmm.005447; Miyama S, 2008, PEDIATR NEUROL, V39, P120, DOI 10.1016/j.pediatrneurol.2008.04.003; Morimoto M, 2006, EPILEPSIA, V47, P1732, DOI 10.1111/j.1528-1167.2006.00645.x; Reed T, 2005, TWIN RES HUM GENET, V8, P362, DOI 10.1375/1832427054936763; Reid CA, 2009, PROG NEUROBIOL, V87, P41, DOI 10.1016/j.pneurobio.2008.09.016; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Selmer KK, 2009, CLIN GENET, V76, P398, DOI 10.1111/j.1399-0004.2009.01208.x; Sugawara T, 2002, NEUROLOGY, V58, P1122, DOI 10.1212/WNL.58.7.1122	25	74	77	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1335	1340		10.1056/NEJMoa0910752	http://dx.doi.org/10.1056/NEJMoa0910752			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879882	Green Published			2022-12-28	WOS:000282271500007
J	Yu, AL; Gilman, AL; Ozkaynak, MF; London, WB; Kreissman, SG; Chen, HX; Smith, M; Anderson, B; Villablanca, JG; Matthay, KK; Shimada, H; Grupp, SA; Seeger, R; Reynolds, CP; Buxton, A; Reisfeld, RA; Gillies, SD; Cohn, SL; Maris, JM; Sondel, PM				Yu, Alice L.; Gilman, Andrew L.; Ozkaynak, M. Fevzi; London, Wendy B.; Kreissman, Susan G.; Chen, Helen X.; Smith, Malcolm; Anderson, Barry; Villablanca, Judith G.; Matthay, Katherine K.; Shimada, Hiro; Grupp, Stephan A.; Seeger, Robert; Reynolds, C. Patrick; Buxton, Allen; Reisfeld, Ralph A.; Gillies, Steven D.; Cohn, Susan L.; Maris, John M.; Sondel, Paul M.		Children's Oncology Grp	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDRENS ONCOLOGY GROUP; HIGH-RISK NEUROBLASTOMA; ANTIGANGLIOSIDE GD2 ANTIBODY; BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; C-RECEPTOR POLYMORPHISMS; PHASE-I; RECOMBINANT INTERLEUKIN-2; REFRACTORY NEUROBLASTOMA; 13-CIS-RETINOIC ACID	Background: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. Methods: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-csf and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. Results: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66+/-5% vs. 46+/-5% at 2 years, P=0.01) and overall survival (86+/-4% vs. 75+/-5% at 2 years, P=0.02 without adjustment for interim analyses). Conclusions: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.) N Engl J Med 2010;363:1324-34.	[Yu, Alice L.] Univ Calif San Diego, San Diego, CA 92103 USA; [Yu, Alice L.] Moores Canc Ctr, San Diego, CA 92103 USA; [Yu, Alice L.] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Gilman, Andrew L.] Levine Childrens Hosp, Charlotte, NC USA; [Kreissman, Susan G.] Duke Univ, Med Ctr, Durham, NC USA; [Ozkaynak, M. Fevzi] New York Med Coll, Valhalla, NY 10595 USA; [London, Wendy B.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; [London, Wendy B.] Childrens Oncol Grp Stat & Data Ctr, Boston, MA USA; [Chen, Helen X.; Smith, Malcolm; Anderson, Barry] NCI, Bethesda, MD 20892 USA; [Villablanca, Judith G.; Shimada, Hiro; Seeger, Robert] Univ So Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA; [Matthay, Katherine K.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Matthay, Katherine K.] Univ Calif San Francisco, Childrens Hosp, San Francisco, CA 94143 USA; [Grupp, Stephan A.; Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Grupp, Stephan A.; Maris, John M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79430 USA; [Buxton, Allen] Childrens Oncol Grp Stat & Data Ctr, Arcadia, CA USA; [Reisfeld, Ralph A.] Scripps Res Inst, La Jolla, CA 92037 USA; [Gillies, Steven D.] Provenance Biopharmaceut, Waltham, MA USA; [Cohn, Susan L.] Univ Chicago, Chicago, IL 60637 USA; [Sondel, Paul M.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA	University of California System; University of California San Diego; Academia Sinica - Taiwan; Duke University; New York Medical College; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Children's Oncology Group (COG); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles; University of Southern California; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Children's Oncology Group (COG); Scripps Research Institute; University of Chicago; University of Wisconsin System; University of Wisconsin Madison	Yu, AL (corresponding author), Univ Calif San Diego, 200 W Arbor Dr, San Diego, CA 92103 USA.	aliceyu@ucsd.edu	London, Wendy Beth/ABA-8948-2021; Cohn, Susan/AAB-6010-2021; London, Wendy/ABD-4624-2021	London, Wendy Beth/0000-0003-3571-6538; Cohn, Susan/0000-0001-5749-7650; yu, alice/0000-0003-2444-0505; Reynolds, C. Patrick/0000-0002-2827-8536	National Institutes of Health [U10-CA98543, U10-CA98413, U10-CA29139]; Food and Drug Administration [FD-R-002319]; FOOD AND DRUG ADMINISTRATION [R01FD002319] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U10CA098413, U10CA029139, R01CA032685, U10CA098543] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration(United States Department of Health & Human Services); FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Institutes of Health (U10-CA98543, U10-CA98413, and U10-CA29139) and the Food and Drug Administration (FD-R-002319).	Albertini MR, 1997, CLIN CANCER RES, V3, P1277; BARKER E, 1993, CANCER RES, V53, P362; BARKER E, 1991, CANCER RES, V51, P144; CHEUNG NKV, 1987, J CLIN ONCOL, V5, P1430, DOI 10.1200/JCO.1987.5.9.1430; DALLEGRI F, 1989, CLIN EXP IMMUNOL, V77, P58; Dutcher J, 2001, MED ONCOL, V18, P209, DOI 10.1385/MO:18:3:209; Frost JD, 1997, CANCER, V80, P317, DOI 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W; Garaventa A, 2009, EUR J CANCER, V45, P2835, DOI 10.1016/j.ejca.2009.06.010; GILLIES SD, 1989, J IMMUNOL METHODS, V125, P191, DOI 10.1016/0022-1759(89)90093-8; Gilman AL, 2009, J CLIN ONCOL, V27, P85, DOI 10.1200/JCO.2006.10.3564; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; HANDGRETINGER R, 1995, EUR J CANCER, V31A, P261, DOI 10.1016/0959-8049(94)00413-Y; HANK JA, 1990, CANCER RES, V50, P5234; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kendra K, 1999, J IMMUNOTHER, V22, P423, DOI 10.1097/00002371-199909000-00006; Khan KD, 2006, CLIN CANCER RES, V12, P7046, DOI 10.1158/1078-0432.CCR-06-1571; KUSHNER BH, 1992, BLOOD, V79, P1484; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Leidi M, 2009, J IMMUNOL, V182, P4415, DOI 10.4049/jimmunol.0713732; Mani A, 2009, BREAST CANCER RES TR, V117, P83, DOI 10.1007/s10549-008-0251-7; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; MUELLER BM, 1990, J IMMUNOL, V144, P1382; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Neal ZC, 2004, CLIN CANCER RES, V10, P4839, DOI 10.1158/1078-0432.CCR-03-0799; Osenga KL, 2006, CLIN CANCER RES, V12, P1750, DOI 10.1158/1078-0432.CCR-05-2000; Ozkaynak MF, 2000, J CLIN ONCOL, V18, P4077, DOI 10.1200/JCO.2000.18.24.4077; Rosenberg SA, 2009, CURR OPIN IMMUNOL, V21, P233, DOI 10.1016/j.coi.2009.03.002; SCHULZ G, 1984, CANCER RES, V44, P5914; Simon T, 2004, J CLIN ONCOL, V22, P3549, DOI 10.1200/JCO.2004.08.143; Simon T, 2009, PEDIATR BLOOD CANCER, V53, P708; Slart R, 1997, PAIN, V69, P119, DOI 10.1016/S0304-3959(96)03247-2; Surveillance Epidemiology and End Results (SEER) Program, 1969, SEER STAT MORT DAT T; SVENNERHOLM L, 1994, BBA-LIPID LIPID MET, V1214, P115, DOI 10.1016/0005-2760(94)90034-5; Taylor RJ, 2009, CANCER IMMUNOL IMMUN, V58, P997, DOI 10.1007/s00262-008-0613-3; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Xiao WH, 1997, PAIN, V69, P145, DOI 10.1016/S0304-3959(96)03280-0; Yu AL, 1998, J CLIN ONCOL, V16, P2169, DOI 10.1200/JCO.1998.16.6.2169; Yu AL, 1997, P AN M AM SOC CLIN, V6, P1846	40	1077	1160	3	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1324	1334		10.1056/NEJMoa0911123	http://dx.doi.org/10.1056/NEJMoa0911123			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879881	Green Accepted			2022-12-28	WOS:000282271500006
J	Charlot, M; Ahlehoff, O; Norgaard, ML; Jorgensen, CH; Sorensen, R; Abildstrom, SZ; Hansen, PR; Madsen, JK; Kober, L; Torp-Pedersen, C; Gislason, G				Charlot, Mette; Ahlehoff, Ole; Norgaard, Mette Lykke; Jorgensen, Casper H.; Sorensen, Rikke; Abildstrom, Steen Z.; Hansen, Peter Riis; Madsen, Jan Kyst; Kober, Lars; Torp-Pedersen, Christian; Gislason, Gunnar			Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use A Nationwide Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; MORTALITY; VALIDITY; ASPIRIN	Background: Controversy remains on whether the dual use of clopidogrel and proton-pump inhibitors (PPIs) affects clinical efficacy of clopidogrel. Objective: To examine the risk for adverse cardiovascular outcomes related to concomitant use of PPIs and clopidogrel compared with that of PPIs alone in adults hospitalized for myocardial infarction. Design: A nationwide cohort study based on linked administrative registry data. Setting: All hospitals in Denmark. Patients: All patients discharged after first-time myocardial infarction from 2000 to 2006. Measurements: The primary outcome was a composite of re-hospitalization for myocardial infarction or stroke or cardiovascular death. Patients were examined at several assembly time points, including 7, 14, 21, and 30 days after myocardial infarction. Follow-up was 1 year. Results: Of 56 406 included patients, 9137 (16.2%) were re-hospitalized for myocardial infarction or stroke or experienced cardiovascular death. Of the 24 702 patients (43.8%) who received clopidogrel, 6753 (27.3%) received concomitant PPIs. The hazard ratio for cardiovascular death or rehospitalization for myocardial infarction or stroke for concomitant use of a PPI and clopidogrel among the cohort assembled at day 30 after discharge was 1.29 (95% CI, 1.17 to 1.42). The corresponding ratio for use of a PPI in patients who did not receive clopidogrel was 1.29 (CI, 1.21 to 1.37). No statistically significant interaction occurred between a PPI and clopidogrel (P = 0.72). Limitations: Unmeasured and residual confounding, time-varying measurement errors of exposure, and biases from survival effects were possible. Conclusion: Proton-pump inhibitors seem to be associated with increased risk for adverse cardiovascular outcomes after discharge, regardless of clopidogrel use for myocardial infarction. Dual PPI and clopidogrel use was not associated with any additional risk for adverse cardiovascular events over that observed for patients prescribed a PPI alone.	[Charlot, Mette] Univ So Denmark, Copenhagen, Denmark; [Charlot, Mette] Copenhagen Univ Hosp Rigshosp, Copenhagen, Denmark	University of Southern Denmark; Rigshospitalet; University of Copenhagen	Charlot, M (corresponding author), Copenhagen Univ Hosp Gentofte, Dept Cardiol, Natl Inst Publ Hlth, Post 67,Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	mc@heart.dk	Hansen, Peter Riis/AAR-7659-2020; Torp-Pedersen, Christian/E-5931-2013; Gislason, Gunnar/B-7561-2009	Gislason, Gunnar/0000-0002-0548-402X; Hansen, Peter Riis/0000-0002-9056-535X; Sorensen, Rikke/0000-0001-9238-6681; Kober, Lars/0000-0002-6635-1466	Danish Medical Research Council [271-06-0572]; Danish Heart Foundation [10-04-R78-A2865-22586]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Heart Foundation	By the Danish Medical Research Council (grant 271-06-0572) and the Danish Heart Foundation (grant 10-04-R78-A2865-22586).	Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; BHATT DL, 2010, PROSPECTIVE RANDOMIZ; Dunn SP, 2008, CIRCULATION, V118, pS815; *EUR MED AG, 2010, PUBL STAT POSS INT; Gaist D, 1997, DAN MED BULL, V44, P445; Gilard M, 2006, J THROMB HAEMOST, V4, P2508, DOI 10.1111/j.1538-7836.2006.02162.x; Gilard M, 2008, J AM COLL CARDIOL, V51, P256, DOI 10.1016/j.jacc.2007.06.064; Gislason GH, 2006, CIRCULATION, V113, P2906, DOI 10.1161/CIRCULATIONAHA.106.616219; Hulot JS, 2006, BLOOD, V108, P2244, DOI 10.1182/blood-2006-04-013052; Ishizaki T, 1999, ALIMENT PHARM THERAP, V13, P27; JUURLINK DN, 2009, JAMA PMID, V301, P937; Krarup LH, 2007, NEUROEPIDEMIOLOGY, V28, P150, DOI 10.1159/000102143; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; O'Donoghue ML, 2009, LANCET, V374, P989, DOI 10.1016/S0140-6736(09)61525-7; Rasmussen S, 2005, MED CARE, V43, P970, DOI 10.1097/01.mlr.0000178195.07110.d3; Rassen JA, 2009, CIRCULATION, V120, P2322, DOI 10.1161/CIRCULATIONAHA.109.873497; Ray WA, 2010, ANN INTERN MED, V152, P337, DOI 10.7326/0003-4819-152-6-201003160-00003; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Sorensen R, 2008, BRIT J CLIN PHARMACO, V66, P875, DOI 10.1111/j.1365-2125.2008.03284.x; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; *US FDA, 2010, EARL COMM ONG SAF RE; Varenhorst C, 2009, EUR HEART J, V30, P1744, DOI 10.1093/eurheartj/ehp157; Yasuda H, 2009, INTERNAL MED, V48, P1725, DOI 10.2169/internalmedicine.48.2031; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Zuern CS, 2010, THROMB RES, V125, pE51, DOI 10.1016/j.thromres.2009.08.016	27	207	214	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					378	386		10.7326/0003-4819-153-6-201009210-00005	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855802				2022-12-28	WOS:000282043100004
J	Spence, D				Spence, Des			From the Frontline Increasing NHS productivity: working 9 to 5.20	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c5030	10.1136/bmj.c5030	http://dx.doi.org/10.1136/bmj.c5030			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653MO	20847028				2022-12-28	WOS:000282095800008
J	Verstovsek, S; Kantarjian, H; Mesa, RA; Pardanani, AD; Cortes-Franco, J; Thomas, DA; Estrov, Z; Fridman, JS; Bradley, EC; Erickson-Viitanen, S; Vaddi, K; Levy, R; Tefferi, A				Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew			Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL-WORKING-GROUP; QUALITY-OF-LIFE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDERS; PROGNOSTIC-FACTORS; POLYCYTHEMIA-VERA; SCORING SYSTEM; SURVIVAL; BURDEN; EXPECTANCY	Background: Myelofibrosis is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival. About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiology of the disease. INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor. Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-positive or JAK2 V617F-negative primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis. Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 months. The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as maximum tolerated doses, on the basis of reversible thrombocytopenia. A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation. We studied additional doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titration, was the most effective and safest dosing regimen. At this dose, 17 of 33 patients (52%) had a rapid objective response (greater/equal 50% reduction of splenomegaly) lasting for 12 months or more, and this therapy was associated with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients. Patients with debilitating symptoms, including weight loss, fatigue, night sweats, and pruritus, had rapid improvement. Clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis. Conclusions: INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed. (Funded by Incyte; ClinicalTrials.gov number, NCT00509899.) N Engl J Med 2010;363:1117-27.	[Verstovsek, Srdan] Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA; [Mesa, Ruben A.] Mayo Clin, Scottsdale, AZ USA; [Pardanani, Animesh D.; Tefferi, Ayalew] Mayo Clin, Rochester, MN USA; [Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard] Incyte, Wilmington, DE USA	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Incyte	Verstovsek, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Unit 428,1515 Holcombe Blvd, Houston, TX 77030 USA.	sverstov@mdanderson.org		Verstovsek, MD, PhD, Professor of Medicine, Srdan/0000-0002-6912-8569; Cortes, Jorge/0000-0002-8636-1071	Novartis; Bristol-Myers Squibb; Wyeth; Genzyme; Amgen; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Novartis(Novartis); Bristol-Myers Squibb(Bristol-Myers Squibb); Wyeth(Wyeth); Genzyme(Sanofi-AventisGenzyme Corporation); Amgen(Amgen); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs. Bradley, Vaddi, Levy, Erickson-Viitanen, and Fridman report being employees of and owning stock in Incyte; Dr. Verstovsek, receiving honoraria from Incyte for participation as an advisory board member; and Dr. Kantarjian, receiving or having pending research grants from Novartis, Bristol-Myers Squibb, Wyeth, Genzyme, and Amgen, and receiving consulting fees from Novartis. No other potential conflict of interest relevant to this article was reported.	Barosi G, 2007, BLOOD, V110, P4030, DOI 10.1182/blood-2007-07-099184; Cervantes F, 2008, LEUKEMIA, V22, P905, DOI 10.1038/leu.2008.72; Cervantes F, 2009, BLOOD, V113, P2895, DOI 10.1182/blood-2008-07-170449; Dupriez B, 1996, BLOOD, V88, P1013; Guglielmelli P, 2009, BLOOD, V114, P1477, DOI 10.1182/blood-2009-04-216044; Jaffe ES, 2001, WHO CLASSIFICATION T; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kurzrock R, 2001, CANCER, V92, P1684, DOI 10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z; MESA RA, 2009, J CLIN ONCOL S, V27, pS15; Mesa RA, 2007, CANCER-AM CANCER SOC, V109, P68, DOI 10.1002/cncr.22365; Mesa RA, 2009, LEUKEMIA RES, V33, P1199, DOI 10.1016/j.leukres.2009.01.035; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pajak B, 2008, J PHYSIOL PHARMACOL, V59, P251; Panteli KE, 2005, BRIT J HAEMATOL, V130, P709, DOI 10.1111/j.1365-2141.2005.05674.x; Passamonti F, 2004, AM J MED, V117, P755, DOI 10.1016/j.amjmed.2004.06.032; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; Tefferi A, 2008, LEUKEMIA, V22, P756, DOI 10.1038/sj.leu.2405097; Tefferi A, 2005, BRIT J HAEMATOL, V131, P320, DOI 10.1111/j.1365-2141.2005.05776.x; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; Tefferi A, 2006, CURR OPIN HEMATOL, V13, P87, DOI 10.1097/01.moh.0000208469.48614.2e; Tefferi A, 2006, BLOOD, V108, P1497, DOI 10.1182/blood-2006-03-009746; Verstovsek S, 2009, THERAPEUTIC POTENTIA; Williams DM, 2007, EXP HEMATOL, V35, P1641, DOI 10.1016/j.exphem.2007.08.010	23	861	903	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1117	1127		10.1056/NEJMoa1002028	http://dx.doi.org/10.1056/NEJMoa1002028			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843246	Green Accepted			2022-12-28	WOS:000281795800006
J	Pelliccia, A; Corrado, D				Pelliccia, Antonio; Corrado, Domenico			Can electrocardiographic screening prevent sudden death in athletes? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							CONSENSUS STATEMENT; OF-CARDIOLOGY; CARDIAC DEATH; PROGRAM		[Pelliccia, Antonio] Italian Natl Olymp Comm, Inst Sports Med & Sci, I-00197 Rome, Italy; [Corrado, Domenico] Univ Padua, Sch Med, Dept Cardiac Thorac & Vasc Sci, I-35128 Padua, Italy	University of Padua	Pelliccia, A (corresponding author), Italian Natl Olymp Comm, Inst Sports Med & Sci, Largo Piero Gabrielli, 1, I-00197 Rome, Italy.	ant.pelliccia@libero.it		CORRADO, DOMENICO/0000-0003-1487-0392				Baggish AL, 2010, ANN INTERN MED, V152, P269, DOI 10.7326/0003-4819-152-5-201003020-00004; Corrado D, 2005, EUR HEART J, V26, P516, DOI 10.1093/eurheartj/ehi108; Corrado D, 2006, JAMA-J AM MED ASSOC, V296, P1593, DOI 10.1001/jama.296.13.1593; Corrado D, 2008, J AM COLL CARDIOL, V52, P1981, DOI 10.1016/j.jacc.2008.06.053; Lawless CE, 2008, MED SCI SPORT EXER, V40, P787, DOI 10.1249/MSS.0b013e318164dd18; Ljungqvist A, 2009, BRIT J SPORT MED, V43, P631, DOI 10.1136/bjsm.2009.064394; Maron BJ, 2007, CIRCULATION, V115, P1643, DOI 10.1161/CIRCULATIONAHA.107.181423; Pelliccia A, 2007, EUR HEART J, V28, P2703, DOI 10.1093/eurheartj/ehm455; Pelliccia A, 2006, EUR HEART J, V27, P2196, DOI 10.1093/eurheartj/ehl137; Wheeler MT, 2010, ANN INTERN MED, V152, P276, DOI 10.7326/0003-4819-152-5-201003020-00005	10	17	18	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 14	2010	341								c4923	10.1136/bmj.c4923	http://dx.doi.org/10.1136/bmj.c4923			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653LK	20841394				2022-12-28	WOS:000282092600003
J	Ioannidis, JPA; Karassa, FB				Ioannidis, John P. A.; Karassa, Fotini B.			The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence	BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIAL REGISTRATION; COST-EFFECTIVENESS; CLINICAL-TRIALS; PUBLICATION; BEVACIZUMAB; EFFICACY; CANCER		[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; [Karassa, Fotini B.] Univ Ioannina, Sch Med, Dept Internal Med, Div Rheumatol, GR-45110 Ioannina, Greece	University of Ioannina; University of Ioannina	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011; Karassa, Fotini/AAG-5040-2020					*ABB, 2009 ANN REP; Barra L, 2009, J RHEUMATOL, V36, P1421, DOI 10.3899/jrheum.081122; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; *GEN INC, K 10 FORM; Hapani S, 2009, LANCET ONCOL, V10, P559, DOI 10.1016/S1470-2045(09)70112-3; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; Ioannidis John P A, 2008, Philos Ethics Humanit Med, V3, P14, DOI 10.1186/1747-5341-3-14; Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7; Ioannidis JPA, 2008, BMJ-BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117; Ioannidis JPA, 2009, CAN MED ASSOC J, V181, P488, DOI 10.1503/cmaj.081086; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Laine C, 2007, LANCET, V369, P1909, DOI 10.1016/S0140-6736(07)60894-0; Lathyris DN, 2010, EUR J CLIN INVEST, V40, P172, DOI 10.1111/j.1365-2362.2009.02240.x; RANPURA V, 2010, AM J HYPERTENS  0225; RANPURA V, 2010, ACTA ONCOL      0216; Rennie D, 2004, JAMA-J AM MED ASSOC, V292, P1359, DOI 10.1001/jama.292.11.1359; Salanti G, 2008, ANN INTERN MED, V148, P544, DOI 10.7326/0003-4819-148-7-200804010-00011; Sfikakis PP, 2010, CURR DIR AUTOIMMUN, V11, P180, DOI 10.1159/000289205; Sutton AJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-29; Tappenden P, 2007, EUR J CANCER, V43, P2487, DOI 10.1016/j.ejca.2007.08.017; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779	25	50	50	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 13	2010	341								c4875	10.1136/bmj.c4875	http://dx.doi.org/10.1136/bmj.c4875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653KH	20837576				2022-12-28	WOS:000282089500010
J	Lee, TH; Bhunia, S; Mehregany, M				Lee, Te-Hao; Bhunia, Swarup; Mehregany, Mehran			Electromechanical Computing at 500 degrees C with Silicon Carbide	SCIENCE			English	Article							LOW-POWER LOGIC; CARBON NANOTUBE	Logic circuits capable of operating at high temperatures can alleviate expensive heat-sinking and thermal-management requirements of modern electronics and are enabling for advanced propulsion systems. Replacing existing complementary metal-oxide semiconductor field-effect transistors with silicon carbide (SiC) nanoelectromechanical system (NEMS) switches is a promising approach for low-power, high-performance logic operation at temperatures higher than 300 degrees C, beyond the capability of conventional silicon technology. These switches are capable of achieving virtually zero off-state current, microwave operating frequencies, radiation hardness, and nanoscale dimensions. Here, we report a microfabricated electromechanical inverter with SiC complementary NEMS switches capable of operating at 500 degrees C with ultralow leakage current.	[Lee, Te-Hao] Case Western Reserve Univ, Dept Mat Sci & Engn, Cleveland, OH 44106 USA; [Bhunia, Swarup; Mehregany, Mehran] Case Western Reserve Univ, Dept Elect Engn & Comp Sci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Lee, TH (corresponding author), Case Western Reserve Univ, Dept Mat Sci & Engn, Cleveland, OH 44106 USA.	tehao@case.edu; swarup.bhunia@case.edu; mehran@case.edu		Mehregany, Mehran/0000-0003-0155-4235	Defense Advanced Research Projects Agency Microsystem Technology Office [N66001-07-1-2031]	Defense Advanced Research Projects Agency Microsystem Technology Office	This work was supported by the Defense Advanced Research Projects Agency Microsystem Technology Office NEMS program under grant N66001-07-1-2031.	Akarvardar K, 2008, IEEE T ELECTRON DEV, V55, P48, DOI 10.1109/TED.2007.911070; Akarvardar K, 2009, IEEE ELECTR DEVICE L, V30, P626, DOI 10.1109/LED.2009.2018289; Cha SN, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1868064; CHEN LY, 2001, MAT RES SOC S P E, V682; Chen XW, 2008, INT J DATA MIN BIOIN, V2, P145, DOI 10.1504/IJDMB.2008.019095; Feng XL, 2008, NAT NANOTECHNOL, V3, P342, DOI 10.1038/nnano.2008.125; Goetz J., 2000, Sensors, V17, P20; Huang XMH, 2003, NATURE, V421, P496, DOI 10.1038/421496a; Kaul AB, 2006, NANO LETT, V6, P942, DOI 10.1021/nl052552r; Meyyappan K, 2003, IEEE T DEVICE MAT RE, V3, P152, DOI 10.1109/TDMR.2003.821538; Moscatelli F, 2008, IEEE T ELECTRON DEV, V55, P961, DOI 10.1109/TED.2008.917107; Naik AK, 2009, NAT NANOTECHNOL, V4, P445, DOI [10.1038/NNANO.2009.152, 10.1038/nnano.2009.152]; Neudeck PG, 2002, P IEEE, V90, P1065, DOI 10.1109/JPROC.2002.1021571; Neudeck PG, 2008, IEEE ELECTR DEVICE L, V29, P456, DOI 10.1109/LED.2008.919787; PALMOUR JW, 1993, PHYSICA B, V185, P461, DOI 10.1016/0921-4526(93)90278-E; Palmour JW, 1997, DIAM RELAT MATER, V6, P1400, DOI 10.1016/S0925-9635(97)00118-0; Patil AC, 2009, J MICROELECTROMECH S, V18, P950, DOI 10.1109/JMEMS.2009.2021831; Potbhare S, 2006, J APPL PHYS, V100, DOI 10.1063/1.2335967; Rueckes T, 2000, SCIENCE, V289, P94, DOI 10.1126/science.289.5476.94; SAVRUN E, 2002, SENSORS 2002 P IEEE, V2, P1139; Yousif MYA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/28/285204; Zimmermann R, 1997, IEEE J SOLID-ST CIRC, V32, P1079, DOI 10.1109/4.597298	22	154	159	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1316	1318		10.1126/science.1192511	http://dx.doi.org/10.1126/science.1192511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829479				2022-12-28	WOS:000281657300030
J	Murphy, E; Sugarman, P				Murphy, Elaine; Sugarman, Philip			Maudsley Debate Should NHS mental health services fear the private sector? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Murphy, Elaine] House Lords, All Party Parliamentary Grp Mental Hlth, London SW1A 0PW, England; [Sugarman, Philip] St Andrews Healthcare, Northampton NN1 5DG, England		Murphy, E (corresponding author), House Lords, All Party Parliamentary Grp Mental Hlth, London SW1A 0PW, England.	murphyel@parliament.uk						Cooper Z., 2010, DOES HOSP COMPETITIO; Gaynor Martin Rodrigo Moreno-Serra, 2010, 16164 NAT BUR EC RES; HILL A, 2008, GUARDIAN        0629	3	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 4	2010	341								c5385	10.1136/bmj.c5385	http://dx.doi.org/10.1136/bmj.c5385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663IZ	20921074				2022-12-28	WOS:000282878600010
J	Xue, G; Dong, Q; Chen, CS; Lu, ZL; Mumford, JA; Poldrack, RA				Xue, Gui; Dong, Qi; Chen, Chuansheng; Lu, Zhonglin; Mumford, Jeanette A.; Poldrack, Russell A.			Greater Neural Pattern Similarity Across Repetitions Is Associated with Better Memory	SCIENCE			English	Article							BRAIN ACTIVITY; ENCODING VARIABILITY; RETRIEVAL-PROCESSES; FREE-RECALL; REACTIVATION; HIPPOCAMPUS; CORTEX; REPLAY; FACES; TASK	Repeated study improves memory, but the underlying neural mechanisms of this improvement are not well understood. Using functional magnetic resonance imaging and representational similarity analysis of brain activity, we found that, compared with forgotten items, subsequently remembered faces and words showed greater similarity in neural activation across multiple study in many brain regions, including (but not limited to) the regions whose mean activities were correlated with subsequent memory. This result addresses a longstanding debate in the study of memory by showing that successful episodic memory encoding occurs when the same neural representations are more precisely reactivated across study episodes, rather than when patterns of activation are more variable across time.	[Xue, Gui; Dong, Qi] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China; [Xue, Gui; Lu, Zhonglin] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA; [Chen, Chuansheng] Univ Calif Irvine, Dept Psychol, Irvine, CA 92697 USA; [Chen, Chuansheng] Univ Calif Irvine, Dept Social Behav, Irvine, CA 92697 USA; [Mumford, Jeanette A.; Poldrack, Russell A.] Univ Texas Austin, Dept Psychol, Austin, TX 78759 USA; [Poldrack, Russell A.] Univ Texas Austin, Imaging Res Ctr, Austin, TX 78759 USA; [Poldrack, Russell A.] Univ Texas Austin, Dept Neurobiol, Austin, TX 78759 USA	Beijing Normal University; University of Southern California; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Dong, Q (corresponding author), Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.	dongqi@bnu.edu.cn; poldrack@mail.utexas.edu	Xue, Gui/A-1762-2009	Xue, Gui/0000-0001-7891-8151; Chen, Chuansheng/0000-0002-8224-1005; Poldrack, Russell/0000-0001-6755-0259	Program for New Century Excellent Talents in University; NSF [BCS 0823624, BCS 0823495]; NIH [HD057884-01A2]; 111 Project of China [B07008]; Direct For Social, Behav & Economic Scie [0823624] Funding Source: National Science Foundation; Division Of Behavioral and Cognitive Sci [0823495] Funding Source: National Science Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057884] Funding Source: NIH RePORTER	Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 111 Project of China; Direct For Social, Behav & Economic Scie(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE)); Division Of Behavioral and Cognitive Sci(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We wish to thank C. Stark for his suggestions in implementing Experiment 3; R. A. Bjork, D. M. Schnyer, and R. Raizada for their helpful comments on an earlier version of this report; and L. Mei, F. Xue, X. Lei, X. Xiao and M. Zhang for their help in data collection. This study was supported by the Program for New Century Excellent Talents in University, NSF (BCS 0823624 and BCS 0823495), NIH (HD057884-01A2), and the 111 Project of China (B07008).	Appleton-Knapp SL, 2005, J CONSUM RES, V32, P266, DOI 10.1086/432236; Bjork R., 1975, INFORM PROCESSING CO, P396; Bower GH., 1972, CODING PROCESS HUM, V3, P85; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Cepeda NJ, 2009, EXP PSYCHOL, V56, P236, DOI 10.1027/1618-3169.56.4.236; Ebbinghaus H., 1885, MEMORY CONTRIBUTION; Foster DJ, 2006, NATURE, V440, P680, DOI 10.1038/nature04587; Gelbard-Sagiv H, 2008, SCIENCE, V322, P96, DOI 10.1126/science.1164685; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; HOERL AE, 1970, TECHNOMETRICS, V12, P69, DOI 10.2307/1267352; Howard MW, 2002, J MATH PSYCHOL, V46, P269, DOI 10.1006/jmps.2001.1388; Ji DY, 2007, NAT NEUROSCI, V10, P100, DOI 10.1038/nn1825; Kahana MJ, 1996, MEM COGNITION, V24, P103, DOI 10.3758/BF03197276; Kahn I, 2004, J NEUROSCI, V24, P4172, DOI 10.1523/JNEUROSCI.0624-04.2004; Kriegeskorte N, 2008, FRONT SYST NEUROSCI, V2, DOI 10.3389/neuro.06.004.2008; Kuhl BA, 2010, NAT NEUROSCI, V13, P501, DOI 10.1038/nn.2498; Kuskowski MA, 1999, NEUROIMAGE, V9, P599, DOI 10.1006/nimg.1999.0442; MARTIN E, 1968, PSYCHOL REV, V75, P421, DOI 10.1037/h0026301; Mei LL, 2010, NEUROIMAGE, V52, P371, DOI 10.1016/j.neuroimage.2010.03.067; MELTON AW, 1970, J VERB LEARN VERB BE, V9, P596, DOI 10.1016/S0022-5371(70)80107-4; Nyberg L, 2001, NEUROIMAGE, V14, P521, DOI 10.1006/nimg.2001.0801; Otten LJ, 2001, BRAIN, V124, P399, DOI 10.1093/brain/124.2.399; Polyn SM, 2005, SCIENCE, V310, P1963, DOI 10.1126/science.1117645; Prince SE, 2009, NEUROPSYCHOLOGIA, V47, P2282, DOI 10.1016/j.neuropsychologia.2009.01.021; Rissman J, 2004, NEUROIMAGE, V23, P752, DOI 10.1016/j.neuroimage.2004.06.035; Schurger A, 2010, SCIENCE, V327, P97, DOI 10.1126/science.1180029; Smith APR, 2004, NEUROIMAGE, V22, P868, DOI 10.1016/j.neuroimage.2004.01.049; THIOS SJ, 1976, J VERB LEARN VERB BE, V15, P529, DOI 10.1016/0022-5371(76)90047-5; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; Wheeler ME, 2003, J NEUROSCI, V23, P3869; Wheeler ME, 2000, P NATL ACAD SCI USA, V97, P11125, DOI 10.1073/pnas.97.20.11125	31	207	215	6	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	2010	330	6000					97	101		10.1126/science.1193125	http://dx.doi.org/10.1126/science.1193125			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656KW	20829453	Green Accepted, Green Submitted			2022-12-28	WOS:000282334500044
J	Powell, LH; Calvin, JE; Richardson, D; Janssen, I; de Leon, CFM; Flynn, KJ; Grady, KL; Rucker-Whitaker, CS; Eaton, C; Avery, E				Powell, Lynda H.; Calvin, James E., Jr.; Richardson, Dejuran; Janssen, Imke; de Leon, Carlos F. Mendes; Flynn, Kristin J.; Grady, Kathleen L.; Rucker-Whitaker, Cheryl S.; Eaton, Claudia; Avery, Elizabeth		HART Investigators	Self-management Counseling in Patients With Heart Failure The Heart Failure Adherence and Retention Randomized Behavioral Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; READMISSION RATES; METAANALYSIS; STRATEGIES; PROGRAM; SUPPORT	Context Motivating patients with heart failure to adhere to medical advice has not translated into clinical benefit, but past trials have had methodological limitations. Objective To determine the value of self-management counseling plus heart failure education, compared with heart failure education alone, for the primary end point of death or heart failure hospitalization. Design, Setting, and Patients The Heart Failure Adherence and Retention Trial (HART), a single-center, multiple-hospital, partially blinded behavioral efficacy randomized controlled trial involving 902 patients with mild to moderate heart failure and reduced or preserved systolic function, randomized from the Chicago metropolitan area between October 2001 and October 2004 and undergoing follow-up for 2 to 3 subsequent years. Interventions All patients were offered 18 contacts and 18 heart failure educational tip sheets during the course of 1 year. Patients randomized to the education group received tip sheets in the mail and telephone calls to check comprehension. Patients randomized to the self-management group received tip sheets in groups and were taught self-management skills to implement the advice. Main Outcome Measure Death or heart failure hospitalization during a median of 2.56 years of follow-up. Results Patients were representative of typical clinical populations (mean age, 63.6 years; 47% women, 40% racial/ethnic minority, 52% with annual family income less than $30 000, and 23% with preserved systolic function). The rate of the primary end point in the self-management group was no different from that in the education group (163 [40.1%)] vs 171 [41.2%], respectively; odds ratio, 0.95 [95% confidence interval, 0.72-1.26]). There were no significant differences on any secondary end points, including death, heart failure hospitalization, all-cause hospitalization, or quality of life. Conclusions Compared with an enhanced educational intervention alone, the addition of self-management counseling did not reduce death or heart failure hospitalization in patients with mild to moderate heart failure.	[Powell, Lynda H.; Janssen, Imke; Eaton, Claudia; Avery, Elizabeth] Rush Univ, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; [Calvin, James E., Jr.; de Leon, Carlos F. Mendes] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA; [Richardson, Dejuran] Lake Forest Coll, Dept Math, Lake Forest, IL 60045 USA; [Flynn, Kristin J.] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65211 USA; [Grady, Kathleen L.] Northwestern Univ, Bluhm Cardiovasc Inst, Div Cardiac Surg, Chicago, IL 60611 USA; [Rucker-Whitaker, Cheryl S.] Chicago Community Trust, Chicago, IL USA	Rush University; Rush University; University of Missouri System; University of Missouri Columbia; Northwestern University	Powell, LH (corresponding author), Rush Univ, Med Ctr, Dept Prevent Med, 1700 W Van Buren St, Chicago, IL 60612 USA.	lpowell@rush.edu		Janssen, Imke/0000-0003-1184-2812	Novartis; National Institutes of Health [HL065547]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065547] Funding Source: NIH RePORTER	Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Calvin reported receiving research funding from Novartis, initiated after the conclusion of this trial. No other authors reported disclosures.; Support for The HART study was provided by National Institutes of Health grant HL065547.	ANDERSON KM, 1991, BIOMETRICS, V47, P281, DOI 10.2307/2532512; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clark RA, 2007, BMJ-BRIT MED J, V334, P942, DOI 10.1136/bmj.39156.536968.55; Collett D, 2003, MODELING SURVIVAL DA; Debusk Robert F., 1996, Cardiology Clinics, V14, P143; DeWalt DA, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-30; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; Flynn Kristin J, 2005, Congest Heart Fail, V11, P297, DOI 10.1111/j.1527-5299.2005.04361.x; FRIEDMAN M, 1984, AM HEART J, V108, P237, DOI 10.1016/0002-8703(84)90606-9; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Klersy C, 2009, J AM COLL CARDIOL, V54, P1683, DOI 10.1016/j.jacc.2009.08.017; Kozak Andrea T, 2007, Congest Heart Fail, V13, P280, DOI 10.1111/j.1527-5299.2007.07236.x; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Powell LH, 2008, AM HEART J, V156, P452, DOI 10.1016/j.ahj.2008.05.011; Prasun Marilyn A, 2005, J Cardiovasc Nurs, V20, P62; RYFF CD, 1995, J PERS SOC PSYCHOL, V69, P719; Sethares KA, 2004, HEART LUNG, V33, P249, DOI 10.1016/j.hrtlng.2004.03.005; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; VAN DER WAL MHL, 2008, INT J CARDIOL, V125, P203; VON KORFF M, 1997, ANN INTERN MED, V127, P1097; Wagner EH, 2004, ANN INTERN MED, V141, P644, DOI 10.7326/0003-4819-141-8-200410190-00015; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wright SP, 2003, EUR J HEART FAIL, V5, P371, DOI 10.1016/S1388-9842(03)00039-4; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7	33	140	145	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1331	1338		10.1001/jama.2010.1362	http://dx.doi.org/10.1001/jama.2010.1362			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652LK	20858878	Green Accepted			2022-12-28	WOS:000282007900016
J	Scheinberg, P; Cooper, JN; Sloand, EM; Wu, CO; Calado, RT; Young, NS				Scheinberg, Phillip; Cooper, James N.; Sloand, Elaine M.; Wu, Colin O.; Calado, Rodrigo T.; Young, Neal S.			Association of Telomere Length of Peripheral Blood Leukocytes With Hematopoietic Relapse, Malignant Transformation, and Survival in Severe Aplastic Anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; ULCERATIVE-COLITIS; CYCLOSPORINE; CANCER; DISEASE; INSTABILITY; PROGRESSION; MUTATIONS; CARCINOMA	Context Critically short telomeres produce apoptosis, cell senescence, and chromosomal instability in tissue culture and animal models. Variations in telomere length have been reported in severe aplastic anemia but their clinical significance is unknown. Objective To investigate the relationship between telomere length and clinical outcomes in severe aplastic anemia. Design, Setting, and Patients Single institution analysis of 183 patients with severe aplastic anemia who were treated in sequential prospective protocols at the National Institutes of Health from 2000 to 2008. The pretreatment leukocyte age-adjusted telomere length of patients with severe aplastic anemia consecutively enrolled in immunosuppression protocols with antithymocyte globulin plus cyclosporine for correlation with clinical outcomes were analyzed. Main Outcome Measures Hematologic response, relapse, clonal evolution, and survival. Results There was no relationship between hematologic response and telomere length with response rates of 56.5% of 46 patients in the first, 54.3% of 46 in the second, 60% of 45 in the third, and 56.5% of 46 in the fourth quartiles. Multivariate analysis demonstrated that telomere length was associated with relapse, clonal evolution, and mortality. Evaluated as a continuous variable, telomere length inversely correlated with the probability of hematologic relapse (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.03-0.69; P=.01). The probability of clonal evolution was higher in patients in the first quartile (24.5%; 95% CI, 8.7%-37.5%) than in quartiles 2 through 4 (8.4%; 95% CI, 3.2%-13.3%; P=.009), and evolution to monosomy 7 or complex cytogenetics was more common in the first quartile (18.8%; 95% CI, 3.5%-31.6%) than in quartiles 2 through 4 (4.5%; 95% CI, 0.5%-8.2%; P=.002). Survival between these 2 groups differed, with 66% (95% CI, 52.9%-82.5%) surviving 6 years in the first quartile compared with 83.8% (95% CI, 77.3%-90.9%) in quartiles 2 through 4 (P=.008). Conclusion In a cohort of patients with severe aplastic anemia receiving immunosuppressive therapy, telomere length was unrelated to response but was associated with risk of relapse, clonal evolution, and overall survival. JAMA. 2010; 304(12): 1358-1364	[Scheinberg, Phillip; Cooper, James N.; Sloand, Elaine M.; Calado, Rodrigo T.; Young, Neal S.] NHLBI, Hematol Branch, Bethesda, MD 20892 USA; [Wu, Colin O.] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA; [Cooper, James N.] NIH, Clin Res Training Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; Pfizer	Scheinberg, P (corresponding author), NHLBI, Hematol Branch, 10 Ctr Dr,Bldg 10 CRC,Room 3-5140,MSC 1202, Bethesda, MD 20892 USA.	scheinbp@mail.nih.gov	Calado, Rodrigo T./G-2619-2011; Scheinberg, Phillip/H-5251-2012	Calado, Rodrigo T./0000-0002-7966-6029; Scheinberg, Phillip/0000-0002-9047-4538	National Institutes of Health; National Heart, Lung, and Blood Institute; Pfizer Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006089, ZIAHL002315] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Pfizer Inc(Pfizer); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported by the Intramural Research Program of the National Institutes of Health; the National Heart, Lung, and Blood Institute. Dr Cooper's research year was made possible through the Clinical Research Training Program (CRTP), a public-private partnership supported jointly by the National Institutes of Health and Pfizer Inc (via a grant to the Foundation for National Institutes of Health from Pfizer Inc).	Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Ball SE, 1998, BLOOD, V91, P3582; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Brouilette SW, 2007, LANCET, V369, P107, DOI 10.1016/S0140-6736(07)60071-3; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Calado RT, 2008, BLOOD, V111, P4446, DOI 10.1182/blood-2007-08-019729; Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; Calado RT, 2009, BLOOD, V114, P2236, DOI 10.1182/blood-2008-09-178871; Calado RT, 2009, P NATL ACAD SCI USA, V106, P1187, DOI 10.1073/pnas.0807057106; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Engelhardt M, 1997, CLIN CANCER RES, V3, P1931; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Maciejewski JP, 2002, BLOOD, V99, P3129, DOI 10.1182/blood.V99.9.3129; Meeker AK, 2002, CANCER RES, V62, P6405; Morrish TA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000357; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Risques RA, 2008, GASTROENTEROLOGY, V135, P410, DOI 10.1053/j.gastro.2008.04.008; Risques RA, 2007, CANCER EPIDEM BIOMAR, V16, P2649, DOI 10.1158/1055-9965.EPI-07-0624; Rosenfeld S, 2003, JAMA-J AM MED ASSOC, V289, P1130, DOI 10.1001/jama.289.9.1130; Rossi D, 2009, LEUKEMIA, V23, P1062, DOI 10.1038/leu.2008.399; Scheinberg P, 2006, BRIT J HAEMATOL, V133, P622, DOI 10.1111/j.1365-2141.2006.06098.x; Scheinberg P, 2006, BRIT J HAEMATOL, V133, P606, DOI 10.1111/j.1365-2141.2006.06085.x; Scheinberg P, 2009, HAEMATOL-HEMATOL J, V94, P348, DOI 10.3324/haematol.13829; Scheinberg P, 2009, BRIT J HAEMATOL, V144, P206, DOI 10.1111/j.1365-2141.2008.07450.x; Svenson U, 2009, CANCER RES, V69, P2896, DOI 10.1158/0008-5472.CAN-08-3513; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Young NS, 2006, BLOOD, V108, P2509, DOI 10.1182/blood-2006-03-010777	31	147	170	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1358	1364		10.1001/jama.2010.1376	http://dx.doi.org/10.1001/jama.2010.1376			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858879	Green Accepted			2022-12-28	WOS:000282007900019
J	Zagrosek, A; Messroghli, D; Schulz, O; Dietz, R; Schulz-Menger, J				Zagrosek, Anja; Messroghli, Daniel; Schulz, Olaf; Dietz, Rainer; Schulz-Menger, Jeanette			Effect of Binge Drinking on the Heart as Assessed by Cardiac Magnetic Resonance Imaging	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							MYOCARDITIS; ALCOHOL		[Zagrosek, Anja; Schulz-Menger, Jeanette] Humboldt Univ, Charite Campus Buch, HELIOS Clin, Clin Cardiol, D-1086 Berlin, Germany; [Messroghli, Daniel] Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects & Pediat Cardiol, Berlin, Germany; [Schulz, Olaf] Intervent Kardiol Spandau, Berlin, Germany; [Dietz, Rainer] Humboldt Univ, Charite Campus Virchow, Dept Cardiol, D-1086 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Zagrosek, A (corresponding author), Humboldt Univ, Charite Campus Buch, HELIOS Clin, Clin Cardiol, D-1086 Berlin, Germany.	anja.zagrosek@charite.de		Schulz-Menger, Jeanette/0000-0003-3100-1092				Goral J, 2008, ALCOHOL, V42, P237, DOI 10.1016/j.alcohol.2008.02.003; Jaffe A S, 2001, Cardiovasc Toxicol, V1, P87, DOI 10.1385/CT:1:2:087; Kim DJ, 2003, ALCOHOL, V31, P167, DOI 10.1016/j.alcohol.2003.09.003; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1340, DOI 10.1016/j.jacc.2005.02.011; Urbano-Marquez A, 2004, MUSCLE NERVE, V30, P689, DOI 10.1002/mus.20168; Zagrosek A, 2009, JACC-CARDIOVASC IMAG, V2, P131, DOI 10.1016/j.jcmg.2008.09.014	6	32	33	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1328	1330		10.1001/jama.2010.1343	http://dx.doi.org/10.1001/jama.2010.1343			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858877	Bronze			2022-12-28	WOS:000282007900014
J	Kind, R; Yuan, XH				Kind, Rainer; Yuan, Xiaohui			Seismic Images of the Biggest Crash on Earth	SCIENCE			English	Editorial Material							TIBETAN PLATEAU; LITHOSPHERE BENEATH; SUBDUCTION		[Kind, Rainer; Yuan, Xiaohui] Deutsch GeoForschungsZentrum, D-14473 Potsdam, Germany	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences	Kind, R (corresponding author), Deutsch GeoForschungsZentrum, D-14473 Potsdam, Germany.	kind@gfz-potsdam.de	Yuan, Xiaohui/G-5149-2010	Yuan, Xiaohui/0000-0002-2891-1354				BARAZANGI M, 1982, GEOLOGY, V10, P179, DOI 10.1130/0091-7613(1982)10<179:VAPCOP>2.0.CO;2; Bijwaard H, 2000, GEOPHYS J INT, V141, P71, DOI 10.1046/j.1365-246X.2000.00053.x; Chen WP, 2010, EARTH PLANET SC LETT, V295, P297, DOI 10.1016/j.epsl.2010.04.017; Gan WJ, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2005JB004120; Huang WC, 2000, J GEOPHYS RES-SOL EA, V105, P27979, DOI 10.1029/2000JB900339; Hung SH, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL041875; Kind R, 2002, SCIENCE, V298, P1219, DOI 10.1126/science.1078115; Kumar P, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003930; Li C, 2008, EARTH PLANET SC LETT, V274, P157, DOI 10.1016/j.epsl.2008.07.016; Nabelek J, 2009, SCIENCE, V325, P1371, DOI 10.1126/science.1167719; Nowack RL, 2010, B SEISMOL SOC AM, V100, P1743, DOI 10.1785/0120090207; Royden LH, 2008, SCIENCE, V321, P1054, DOI 10.1126/science.1155371; Tseng TL, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040457; Xu Q, 2010, CHINESE SCI BULL, V55, P607, DOI 10.1007/s11434-009-0387-9; Yuan XH, 1997, J GEOPHYS RES-SOL EA, V102, P27491, DOI 10.1029/97JB02379; Zhao JM, 2010, P NATL ACAD SCI USA, V107, P11229, DOI 10.1073/pnas.1001921107	16	64	70	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	2010	329	5998					1479	1480		10.1126/science.1191620	http://dx.doi.org/10.1126/science.1191620			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847259				2022-12-28	WOS:000281869000029
J	Singh, SK; Sabatinos, S; Forsburg, S; Bastia, D				Singh, Samarendra K.; Sabatinos, Sarah; Forsburg, Susan; Bastia, Deepak			Regulation of Replication Termination by Reb1 Protein-Mediated Action at a Distance	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; ESCHERICHIA-COLI; DNA-REPLICATION; RIBOSOMAL DNA; POLAR ARREST; FORK ARREST; GENE; ORGANIZATION; CONTRAHELICASE; MECHANISM	DNA transactions driven by long-range protein-mediated inter-and intrachromosomal interactions have been reported to influence gene expression. Here, we report that site-specific replication termination in Schizosaccharomyces pombe is modulated by protein-mediated interactions between pairs of Ter sites located either on the same or on different chromosomes. The dimeric Reb1 protein catalyzes termination and mediates interaction between Ter sites. The Reb1-dependent interactions between two antiparallel Ter sites in cis caused looping out of the intervening DNA in vitro and enhancement of fork arrest in vivo. A Ter site on chromosome 2 interacted pairwise with two Ter sites located on chromosome 1 by chromosome kissing. Mutational inactivation of the major interacting Ter site on chromosome 1 significantly reduced fork arrest at the Ter site on chromosome 2, thereby revealing a cooperative mechanism of control of replication termination.	[Singh, Samarendra K.; Bastia, Deepak] Med Univ S Carolina, Dept Mol Biol & Biochem, Charleston, SC 29425 USA; [Sabatinos, Sarah; Forsburg, Susan] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA	Medical University of South Carolina; University of Southern California	Bastia, D (corresponding author), Med Univ S Carolina, Dept Mol Biol & Biochem, Charleston, SC 29425 USA.	bastia@musc.edu		Forsburg, Susan L/0000-0002-4895-8598	 [GM 049264];  [GM 049264-17S1]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049264, R01GM059321] Funding Source: NIH RePORTER	; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the grants GM 049264 and GM 049264-17S1 to D.B. We thank Louise Pape (University of Wisconsin) for strains and S. Biswas for technical help with one of the experiments. We also thank Carlos Escalante (VCU, Richmond, VA) for performing bioinformatics analysis of Reb1 and pointing out the presence of SANT-like domains within the myb-associated domain of Reb1, Tony Carr, Robert Schleif, and Fred Winston for useful comments on our manuscript, and Pablo Hernandez for allowing us to cite his work before its publication.	ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; Bastia D., 1996, DNA REPLICATION EUKA, P177; Bastia D, 2008, P NATL ACAD SCI USA, V105, P12831, DOI 10.1073/pnas.0805898105; Bastia Deepak, 2006, V47, P155; Biswas S, 2008, MOL CELL BIOL, V28, P6844, DOI 10.1128/MCB.01235-08; Blanco MA, 2000, EMBO J, V19, P3945, DOI 10.1093/emboj/19.15.3945; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; DE LAAT W, 2007, CURR OPIN CELL BIOL, V19, P317; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; Eydmann T, 2008, GENETICS, V180, P27, DOI 10.1534/genetics.108.089243; Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916; Gondor A, 2008, NAT PROTOC, V3, P303, DOI 10.1038/nprot.2007.540; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOCHSTRASSER M, 1987, J CELL BIOL, V104, P1471, DOI 10.1083/jcb.104.6.1471; Kaplan DL, 2009, MOL MICROBIOL, V72, P279, DOI 10.1111/j.1365-2958.2009.06656.x; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Kitamura K, 1998, MOL BIOL CELL, V9, P1065, DOI 10.1091/mbc.9.5.1065; Krings G, 2005, J BIOL CHEM, V280, P39135, DOI 10.1074/jbc.M508996200; Krings G, 2004, P NATL ACAD SCI USA, V101, P14085, DOI 10.1073/pnas.0406037101; KRINGS G, 2007, THESIS MUSC CHARLEST; Krings G, 2006, MOL CELL BIOL, V26, P8061, DOI 10.1128/MCB.01102-06; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Mejia-Ramirez E, 2005, MOL CELL BIOL, V25, P8755, DOI 10.1128/MCB.25.19.8755-8761.2005; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; Mulugu S, 2001, P NATL ACAD SCI USA, V98, P9569, DOI 10.1073/pnas.171065898; Nemeth A, 2008, EMBO J, V27, P1255, DOI 10.1038/emboj.2008.57; Sanchez-Gorostiaga A, 2004, MOL CELL BIOL, V24, P398, DOI 10.1128/MCB.24.1.398-406.2004; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Tan-Wong SM, 2009, GENE DEV, V23, P2610, DOI 10.1101/gad.1823209; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; WU JR, 1995, NUCLEIC ACIDS RES, V23, P3997, DOI 10.1093/nar/23.19.3997; Zhao A, 1997, NUCLEIC ACIDS RES, V25, P904, DOI 10.1093/nar/25.4.904; Zzaman S, 2005, MOL CELL, V20, P833, DOI 10.1016/j.molcel.2005.10.037	44	23	23	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					868	878		10.1016/j.cell.2010.08.013	http://dx.doi.org/10.1016/j.cell.2010.08.013			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850009	Bronze, Green Accepted			2022-12-28	WOS:000281855000010
J	Worobey, M; Telfer, P; Souquiere, S; Hunter, M; Coleman, CA; Metzger, MJ; Reed, P; Makuwa, M; Hearn, G; Honarvar, S; Roques, P; Apetrei, C; Kazanji, M; Marx, PA				Worobey, Michael; Telfer, Paul; Souquiere, Sandrine; Hunter, Meredith; Coleman, Clint A.; Metzger, Michael J.; Reed, Patricia; Makuwa, Maria; Hearn, Gail; Honarvar, Shaya; Roques, Pierre; Apetrei, Cristian; Kazanji, Mirdad; Marx, Preston A.			Island Biogeography Reveals the Deep History of SIV	SCIENCE			English	Article							EVOLUTION		[Telfer, Paul; Hunter, Meredith; Coleman, Clint A.; Metzger, Michael J.; Reed, Patricia; Apetrei, Cristian; Marx, Preston A.] Tulane Natl Primate Res Ctr, Covington, LA 70433 USA; [Worobey, Michael] Univ Arizona, Tucson, AZ 85721 USA; [Telfer, Paul; Souquiere, Sandrine; Reed, Patricia; Makuwa, Maria; Roques, Pierre; Kazanji, Mirdad] Ctr Int Med Res, Franceville, Gabon; [Hearn, Gail; Honarvar, Shaya] Drexel Univ, Philadelphia, PA 19104 USA	Tulane University; University of Arizona; Drexel University	Marx, PA (corresponding author), Tulane Natl Primate Res Ctr, Covington, LA 70433 USA.	pmarx@tulane.edu	Roques, Pierre/M-2212-2013; Metzger, Michael/E-2242-2014; Metzger, Michael/AAA-3635-2022; Apetrei, Cristian/AAG-9032-2021	Roques, Pierre/0000-0003-1825-1054; Metzger, Michael/0000-0001-7855-1388; Metzger, Michael/0000-0001-7855-1388; Apetrei, Cristian/0000-0002-0322-7185	NIH [1RO1AI27698, 1RO1AI44596]; Tulane Phase II Enhancement Grant; ExxonMobil Foundation; David and Lucile Packard Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044596, R01AI027698] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tulane Phase II Enhancement Grant; ExxonMobil Foundation(Exxon Mobil Corporation); David and Lucile Packard Foundation(The David & Lucile Packard Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank T. M. Butynski, J. M. Esara Echube, A. Lackner, and M. Sanderson for assistance and comments and acknowledge support from NIH grants 1RO1AI27698 and 1RO1AI44596, a Tulane Phase II Enhancement Grant, the ExxonMobil Foundation, and the David and Lucile Packard Foundation. Newly reported SIV sequences have been deposited in GenBank under accession numbers HM363406 to HM363427. P. Reed and P. T. are at the Wildlife Conservation Society, Bronx, NY, USA. P. Roques is at Commissariat a l'Energie Atomique-Life Science Division, Fontenay-aux-Roses, France. C. A. is at University of Pittsburgh, PA. M. J. M. is at University of Washington, Seattle, WA. M. K. is at Institut de Bangui, Bangui, Central African Republic.	de Sousa JD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009936; Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7; Gifford RJ, 2008, P NATL ACAD SCI USA, V105, P20362, DOI 10.1073/pnas.0807873105; JONES PJ, 1994, BIODIVERS CONSERV, V3, P772, DOI 10.1007/BF00129657; Sharp PM, 2000, BIOCHEM SOC T, V28, P275, DOI 10.1042/bst0280275; Wertheim JO, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000377	6	144	146	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1487	1487		10.1126/science.1193550	http://dx.doi.org/10.1126/science.1193550			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847261				2022-12-28	WOS:000281869000031
J	Campion, EW; Miller, PW; Costello, J; Duff, E; Drazen, JM				Campion, Edward W.; Miller, Pamela W.; Costello, Jean; Duff, Ellen; Drazen, Jeffrey M.			The Journal from 1812 to 1989 at NEJM.org.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTEGRATED APPROACH; FAT TRANSPORT; LIPOPROTEINS; MECHANISMS; DISORDERS						Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890; Miller, Pamela/0000-0002-4077-3628				Bigelow HJ., 1846, BOSTON MED SURG J, V35, P309, DOI DOI 10.1056/NEJM184611180351601; DAGATI VC, 1945, NEW ENGL J MED, V232, P1, DOI 10.1056/NEJM194501042320101; DRAPER JW, 1854, BOSTON MED SURG J, V50, P49; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FREDRICK.DS, 1967, NEW ENGL J MED, V276, P148, DOI 10.1056/NEJM196701192760305; FREDRICK.DS, 1967, NEW ENGL J MED, V276, P273, DOI 10.1056/NEJM196702022760507; FREDRICKSON DONALD S., 1967, N ENGL J MED, V276, P34, DOI 10.1056/NEJM196701052760107; FREDRICKSON DS, 1967, NEW ENGL J MED, V276, P94, DOI 10.1056/NEJM196701122760206; FREDRICKSON DS, 1967, NEW ENGL J MED, V276, P215, DOI 10.1056/NEJM196701262760406; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; JACKSON JBS, 1865, BOSTON MED SURG J, V72, P209; TOWLE SK, 1876, BOSTON MED SURG J, V94, P593; TUCKERMAN J, 1837, BOSTON MED SURG J, V16, P395; TUCKERMAN J, 1837, BOSTON MED SURG J, V16, P357; TUCKERMAN J, 1837, BOSTON MED SURG J, V16, P373; Warren J., 1812, N ENGL J MED SURG, V1, P1; WELCKER ML, 1945, NEW ENGL J MED, V232, P11, DOI 10.1056/NEJM194501042320103; 1876, BOSTON MED SURG J, V94, P197; 1854, BOSTON MED SURG J, V50, P15	19	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1175	1176		10.1056/NEJMe1009367	http://dx.doi.org/10.1056/NEJMe1009367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649TD	20843253				2022-12-28	WOS:000281795800014
J	Mamede, S; van Gog, T; van den Berge, K; Rikers, RMJP; van Saase, JLCM; van Guldener, C; Schmidt, HG				Mamede, Silvia; van Gog, Tamara; van den Berge, Kees; Rikers, Remy M. J. P.; van Saase, Jan L. C. M.; van Guldener, Coen; Schmidt, Henk G.			Effect of Availability Bias and Reflective Reasoning on Diagnostic Accuracy Among Internal Medicine Residents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERROR; PERSPECTIVE; JUDGMENT	Context Diagnostic errors have been associated with bias in clinical reasoning. Empirical evidence on the cognitive mechanisms underlying biases and effectiveness of educational strategies to counteract them is lacking. Objectives To investigate whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias. Design, Setting, and Participants Experimental study conducted in 2009 at the Erasmus Medical Centre, Rotterdam, with 18 first-year and 18 second-year internal medicine residents. Participants first evaluated diagnoses of 6 clinical cases (phase 1). Subsequently, they diagnosed 8 different cases through nonanalytical reasoning, 4 of which had findings similar to previously evaluated cases but different diagnoses (phase 2). These 4 cases were subsequently diagnosed again through reflective reasoning (phase 3). Main Outcome Measures Mean diagnostic accuracy scores (perfect score, 4.0) on cases solved with or without previous exposure to similar problems through nonanalytical (phase 2) or reflective (phase 3) reasoning and frequency that a potentially biased (ie, phase 1) diagnosis was given. Results There were no main effects, but there was a significant interaction effect between "years of training" and "recent experiences with similar problems." Results consistent with an availability bias occurred for the second-year residents, who scored lower on the cases similar to those previously encountered (1.55; 95% confidence interval [CI], 1.15-1.96) than on the other cases (2.19; 95% CI, 1.73-2.66; P=.03). This pattern was not seen among the first-year residents (2.03; 95% CI, 1.55-2.51 vs 1.42; 95% CI, 0.92-1.92; P=.046). Second-year residents provided the phase 1 diagnosis more frequently for phase 2 cases they had previously encountered than for those they had not (mean frequency per resident, 1.44; 95% CI, 0.93-1.96 vs 0.72; 95% CI, 0.28-1.17; P=.04). A significant main effect of reasoning mode was found: reflection improved the diagnoses of the similar cases compared with nonanalytical reasoning for the second-year residents (2.03; 95% CI, 1.49-2.57) and the first-year residents (2.31; 95% CI, 1.89-2.73; P=.006). Conclusion When faced with cases similar to previous ones and using nonanalytic reasoning, second-year residents made errors consistent with the availability bias. Subsequent application of diagnostic reflection tended to counter this bias; it improved diagnostic accuracy in both first-and second-year residents. JAMA. 2010;304(11):1198-1203 www.jama.com	[Mamede, Silvia; van Gog, Tamara; Rikers, Remy M. J. P.; Schmidt, Henk G.] Erasmus Univ, Dept Psychol, NL-3062 PA Rotterdam, Netherlands; [van den Berge, Kees; van Saase, Jan L. C. M.] Erasmus Univ, Dept Internal Med, Erasmus Med Ctr, NL-3062 PA Rotterdam, Netherlands; [van Guldener, Coen] Amphia Hosp, Dept Internal Med, Breda, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Amphia Hospital	Mamede, S (corresponding author), Erasmus Univ, Dept Psychol, Burgemeester Oudlaan 50, NL-3062 PA Rotterdam, Netherlands.	mamede@fsw.eur.nl	Mamede, Silvia/T-4053-2019; Rikers, Remigius/AAK-1781-2021; Schmidt, Henk G/A-3410-2012	Rikers, Remigius/0000-0002-4722-1455; 				Berner Eta S, 2003, AMIA Annu Symp Proc, P76; Brezis M, 2004, ANN INTERN MED, V140, P234, DOI 10.7326/0003-4819-140-3-200402030-00024; Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003; Eva KW, 2002, ACAD MED, V77, pS1, DOI 10.1097/00001888-200210001-00002; Eva KW, 2005, MED EDUC, V39, P98, DOI 10.1111/j.1365-2929.2004.01972.x; Evans JSBT, 2008, ANNU REV PSYCHOL, V59, P255, DOI 10.1146/annurev.psych.59.103006.093629; Friedman CP, 2005, J GEN INTERN MED, V20, P334, DOI 10.1111/j.1525-1497.2005.30145.x; Graber ML, 2005, ARCH INTERN MED, V165, P1493, DOI 10.1001/archinte.165.13.1493; HEATH L, 1991, J APPL SOC PSYCHOL, V21, P1859, DOI 10.1111/j.1559-1816.1991.tb00509.x; Kahneman D, 2003, AM PSYCHOL, V58, P697, DOI 10.1037/0003-066X.58.9.697; Kahnemann Daniel, 1982, JUDGMENT UNCERTAINTY; Klein JG, 2005, BMJ-BRIT MED J, V330, P781, DOI 10.1136/bmj.330.7494.781; Kohn KT, 1999, ERR IS HUMAN BUILDIN; Mamede S, 2008, MED EDUC, V42, P468, DOI 10.1111/j.1365-2923.2008.03030.x; Mamede S, 2007, MED EDUC, V41, P1185, DOI 10.1111/j.1365-2923.2007.02921.x; Mamede S, 2008, ACAD MED, V83, P1210, DOI 10.1097/ACM.0b013e31818c71d7; Norman G, 2009, ADV HEALTH SCI EDUC, V14, P37, DOI 10.1007/s10459-009-9179-x; Norman GR, 2010, MED EDUC, V44, P94, DOI 10.1111/j.1365-2923.2009.03507.x; Peay MY, 1998, J BEHAV MED, V21, P57, DOI 10.1023/A:1018715521706; POSES RM, 1991, MED DECIS MAKING, V11, P159, DOI 10.1177/0272989X9101100303; Redelmeier DA, 2005, ANN INTERN MED, V142, P115, DOI 10.7326/0003-4819-142-2-200501180-00010; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; SCHMIDT HG, 1993, EDUC PSYCHOL REV, V5, P1	23	215	218	2	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1198	1203		10.1001/jama.2010.1276	http://dx.doi.org/10.1001/jama.2010.1276			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649LF	20841533	Bronze			2022-12-28	WOS:000281770600012
J	Ridley, DB; Sanchez, AC				Ridley, David B.; Calles Sanchez, Alfonso			Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases	LANCET			English	Review							DRUG DEVELOPMENT; SAFETY PROBLEMS; PRICE; COMMITMENTS; DEADLINES; MARKETS; COSTS	Every year 1 billion people worldwide are affected by traditionally neglected diseases, such as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burdens. Governments, foundations, and drug manufacturers have, however, started to support development of new treatments. European Union Member States have been leaders in implementing so-called push mechanisms (payment for drug development) and pull funding (reward for output), such as the advance market commitment, which creates a market for vaccines by guaranteeing prices. We propose an additional step that could be taken to encourage development of medicines for neglected diseases. A priority review voucher scheme, as is already in place in the USA, would reward a manufacturer that developed a new medicine for neglected diseases with a voucher that could be redeemed for priority review of a future medicine, probably a potential blockbuster drug. Unlike the US system a European voucher would also accelerate pricing and reimbursement decisions. This scheme would be likely to provide substantial benefits to voucher holders, society, and public health organisations.	[Ridley, David B.] Duke Univ, Fuqua Sch Business, Durham, NC 27708 USA; [Ridley, David B.; Calles Sanchez, Alfonso] Duke Univ, Ctr European Studies, Durham, NC 27708 USA; [Calles Sanchez, Alfonso] Spanish Patent Off, Madrid, Spain	Duke University; Duke University	Ridley, DB (corresponding author), Duke Univ, Fuqua Sch Business, Box 90120, Durham, NC 27708 USA.	david.ridley@duke.edu	Ridley, David B/D-7346-2011	Ridley, David B/0000-0003-0245-0702	Genentech; Sandoz; GlaxoWellcome Foundation; Duke University's Center for the Advancement of Social Entrepreneurship	Genentech(Roche HoldingGenentech); Sandoz(Novartis); GlaxoWellcome Foundation; Duke University's Center for the Advancement of Social Entrepreneurship	In the past 3 years DBR has received consultancy fees from Genentech in relation to follow-on biologics, expert testimony fees from Sandoz in relation to generic-drug pricing, and an honorarium from PhRMA for participating at a conference. AC-S declares that he has no conflicts of interest.; DBR was involved in the original research for the US voucher, which was funded by the GlaxoWellcome Foundation and Duke University's Center for the Advancement of Social Entrepreneurship. We thank Jeffrey Moe, Damon Seils, Jia Yao, Nina Yoshimura, and the reviewers and editors for helpful comments.	Berndt ER, 2007, HEALTH ECON, V16, P491, DOI 10.1002/hec.1176; Carpenter D, 2008, NEW ENGL J MED, V358, P1354, DOI 10.1056/NEJMsa0706341; Danzon PM, 2005, HEALTH ECON, V14, P269, DOI 10.1002/hec.931; *DEP CONTR NEGL TR, 2009, NEGL TROP DIS HIDD S; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; *EUR COJMM, 2008, HIGH LEV PHARM FOR 2; *EUR COMM, 2009, PAR 1434 PHARM INQ F; *EUR COMM, 1989, OFFICIAL J EUROPEA L, V40, P8; *EUR MED AG, 2009, ANN REP EUR MED AG 2; European Medicines Agency, 2007, EMEA CONCL 1 ACC ASS; Grabowski H., 2009, PRESCRIBING CULTURES; Grabowski H, 2008, J LAW ECON, V51, P377, DOI 10.1086/589934; Kesselheim AS, 2008, NEW ENGL J MED, V359, P1981, DOI 10.1056/NEJMp0806684; Matheny J, 2009, CLIN PHARMACOL THER, V85, P571, DOI 10.1038/clpt.2009.53; Moe J, 2009, NEW ENGL J MED, V360, P837, DOI 10.1056/NEJMc086492; Moran M, 2009, PLOS MED, V6, P137, DOI 10.1371/journal.pmed.1000030; Nardinelli C, 2008, NEW ENGL J MED, V359, P95, DOI 10.1056/NEJMc086158; PATIENTS WAI, 2007, INDICATOR PHASE 8 RE; *PHARM R D POL PRO, 2005, FAST TRACK OPT FUND; PINHEIRO MH, 2006, EMEA NML IMPLEM 0203; Ridley DB, 2006, HEALTH AFFAIR, V25, P313, DOI 10.1377/hlthaff.25.2.313; SANCHEZ AC, 2009, OXFORD U J INTELLECT, V4, P305; Sonderholm J, 2009, BIOETHICS, V23, P413, DOI 10.1111/j.1467-8519.2009.01753.x; Towse A, 2005, B WORLD HEALTH ORGAN, V83, P301; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7	25	15	15	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					922	927		10.1016/S0140-6736(10)60669-1	http://dx.doi.org/10.1016/S0140-6736(10)60669-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20833303	Green Submitted			2022-12-28	WOS:000282069100033
J	Sanderson, WC; Scherbov, S				Sanderson, Warren C.; Scherbov, Sergei			Remeasuring Aging	SCIENCE			English	Editorial Material							LIFE EXPECTANCY; POPULATIONS; HEALTH		[Sanderson, Warren C.] SUNY Stony Brook, Stony Brook, NY 11794 USA; [Scherbov, Sergei] Vienna Inst Demog, A-1040 Vienna, Austria; [Sanderson, Warren C.; Scherbov, Sergei] Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; International Institute for Applied Systems Analysis (IIASA)	Sanderson, WC (corresponding author), SUNY Stony Brook, Stony Brook, NY 11794 USA.	warren.sanderson@stonybrook.edu	Sanderson, Warren/R-3398-2019; Scherbov, Sergey/F-3158-2019	Scherbov, Sergey/0000-0001-5902-3790; Scherbov, Sergei/0000-0002-0881-1073; Sanderson, Warren/0000-0002-2205-948X				Bhattacharya J, 2004, NBER FR HLTH POL RES, P75; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; COTIS JP, 2003, 239 OECD; *EHEMU, 2009, DAT ACT LIM STAT INC; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; *HUM MORT, HUM MORT DAT; JACOB S, 1993, GENERATION CHANGE PR; Lafortune G, 2007, OECD HLTH WORKING PA; Lutz W, 2008, NATURE, V451, P716, DOI 10.1038/nature06516; Manton KG, 2006, P NATL ACAD SCI USA, V103, P18374, DOI 10.1073/pnas.0608483103; Manton KG, 2006, POPUL DEV REV, V32, P81, DOI 10.1111/j.1728-4457.2006.00106.x; MANTON KG, 1986, J AM STAT ASSOC, V81, P635, DOI 10.2307/2288991; *OECD, 2005, AG POP HIGH TIM ACT; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; PETERSON P, 1999, GRAY COMING AGE WAVE; RYDER NB, 1975, POPUL INDEX, V41, P3, DOI 10.2307/2734140; Sanderson W, 2008, CONVENTIONAL PROSPEC; SANDERSON W, 2008, POP B, V63, P4; Sanderson WC, 2007, DEMOGR RES, V16, P27, DOI 10.4054/DemRes.2007.16.2; Sanderson WC, 2005, NATURE, V435, P811, DOI 10.1038/nature03593; SCHULTZ G, 2008, PUTTING OUR HOUSE OR; *SOC SEC ADM, 2010, RETR BEN; *SOC SEC ADM, 2008, SOC SEC WORLD EUR; *UK, CAL YOUR STAT PENS A; *UN, 2001, WORL POP AG 1950 205; United Nations, 2009, WORLD POP AG 2009; United Nations, 2007, WORLD POP AG 2007; United Nations, 2009, WORLD POP PROSP 2008	28	166	170	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1287	1288		10.1126/science.1193647	http://dx.doi.org/10.1126/science.1193647			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	647YR	20829469				2022-12-28	WOS:000281657300018
J	Kapur, N; Clements, C; Bateman, N; Foex, B; Mackway-Jones, K; Huxtable, R; Gunnell, D; Hawton, K				Kapur, Navneet; Clements, Caroline; Bateman, Nick; Foex, Bernard; Mackway-Jones, Kevin; Huxtable, Richard; Gunnell, David; Hawton, Keith			Advance directives and suicidal behaviour	BRITISH MEDICAL JOURNAL			English	Editorial Material							ETHICAL-DEBATE; FOLLOW-UP		[Kapur, Navneet; Clements, Caroline] Univ Manchester, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England; [Bateman, Nick] Royal Infirm Edinburgh NHS Trust, Clin Toxicol Unit, Edinburgh EH16 4SA, Midlothian, Scotland; [Foex, Bernard; Mackway-Jones, Kevin] Manchester Royal Infirm, Dept Emergency Med, Manchester M13 9WL, Lancs, England; [Huxtable, Richard] Univ Bristol, Ctr Eth Med, Bristol BS8 1TH, Avon, England; [Gunnell, David] Univ Bristol, Dept Social Med, Bristol BS8 2PS, Avon, England; [Hawton, Keith] Univ Oxford, Ctr Suicide Res, Oxford OX3 7JX, England	University of Manchester; Royal Infirmary of Edinburgh; University of Edinburgh; University of Manchester; University of Bristol; University of Bristol; University of Oxford	Kapur, N (corresponding author), Univ Manchester, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England.	nav.kapur@manchester.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Clements, Caroline/0000-0003-4735-6728; Huxtable, Richard/0000-0002-5802-1870; Kapur, Nav/0000-0002-3100-3234	Economic and Social Research Council [ES/G007543/1] Funding Source: researchfish; ESRC [ES/G007543/1] Funding Source: UKRI	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		[Anonymous], 2004, SELF HARM SHORT TERM; Bania TC, 2003, ACAD EMERG MED, V10, P65; Bashir FA, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4400; Bonner S, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4667; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; Crippen D, 2001, CRIT CARE, V5, P115, DOI 10.1186/cc1010; David AS, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4489; Dyer C, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c648; KAPUR N, 2010, QJM             0804; McLean SAM, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4112; Pajonk FG, 2005, EUR PSYCHIAT, V20, P115, DOI 10.1016/j.eurpsy.2004.10.003; ROSEN DH, 1975, WESTERN J MED, V122, P289; Sontheimer D, 2008, J MED ETHICS, V34, DOI 10.1136/jme.2008.025619	13	6	6	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 7	2010	341								c4557	10.1136/bmj.c4557	http://dx.doi.org/10.1136/bmj.c4557			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649ZI	20823015				2022-12-28	WOS:000281814900002
J	Halliday, A; Harrison, M; Hayter, E; Kong, XL; Mansfield, A; Marro, J; Pan, HC; Peto, R; Potter, J; Rahimi, K; Rau, A; Robertson, S; Streifler, J; Thomas, D				Halliday, Alison; Harrison, Michael; Hayter, Elizabeth; Kong, Xiangling; Mansfield, Averil; Marro, Joanna; Pan, Hongchao; Peto, Richard; Potter, John; Rahimi, Kazem; Rau, Angela; Robertson, Steven; Streifler, Jonathan; Thomas, Dafydd		Asymptomatic Carotid Surg Trial AC	10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial	LANCET			English	Article								Background If carotid artery narrowing remains asymptomatic (ie, has caused no recent stroke or other neurological symptoms), successful carotid endarterectomy (CEA) reduces stroke incidence for some years. We assessed the long-term effects of successful CEA. Methods Between 1993 and 2003,3120 asymptomatic patients from 126 centres in 30 countries were allocated equally, by blinded minimised randomisation, to immediate CEA (median delay 1 month, IQR 0.3-2.5) or to indefinite deferral of any carotid procedure, and were followed up until death or for a median among survivors of 9 years (IQR 6-11). The primary outcomes were perioperative mortality and morbidity (death or stroke within 30 days) and non-perioperative stroke. Kaplan-Meier percentages and logrank p values are from intention-to-treat analyses. This study is registered, number ISRCTN26156392. Findings 1560 patients were allocated immediate CEA versus 1560 allocated deferral of any carotid procedure. The proportions operated on while still asymptomatic were 89.7% versus 4.8% at 1 year (and 92.1% vs 16.5% at 5 years). Perioperative risk of stroke or death within 30 days was 3.0% (95% CI 2.4-3.9; 26 non-disabling strokes plus 34 disabling or fatal perioperative events in 1979 CEAs). Excluding perioperative events and non-stroke mortality, stroke risks (immediate vs deferred CEA) were 4.1% versus 10.0% at 5 years (gain 5.9%, 95% CI 4.0-7.8) and 10.8% versus 16.9% at 10 years (gain 6.1%, 2.7-9.4); ratio of stroke incidence rates 0.54, 95% CI 0.43-0.68, p<0.0001. 62 versus 104 had a disabling or fatal stroke, and 37 versus 84 others had a non-disabling stroke. Combining perioperative events and strokes, net risks were 6.9% versus 10.9% at 5 years (gain 4.1%, 2.0-6.2) and 13.4% versus 17.9% at 10 years (gain 4.6%, 1.2-7.9). Medication was similar in both groups; throughout the study, most were on antithrombotic and antihypertensive therapy. Net benefits were significant both for those on lipid-lowering therapy and for those not, and both for men and for women up 80 75 years of age at entry (although not for older patients). Interpretation Successful CEA for asymptomatic patients younger than 75 years of age reduces 10-year stroke risks. Half this reduction is in disabling or fatal strokes. Net benefit in future patients will depend on their risks from unoperated carotid lesions (which will be reduced by medication), on future surgical risks (which might differ from those in trials), and on whether life expectancy exceeds 10 years.	[Halliday, Alison; Hayter, Elizabeth] John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford OX3 9DU, England; [Rahimi, Kazem] John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England; [Halliday, Alison; Kong, Xiangling; Pan, Hongchao; Peto, Richard; Rahimi, Kazem] Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford, England; [Halliday, Alison; Hayter, Elizabeth] St Georges Univ London, Dept Cardiac & Vasc Sci, London, England; [Harrison, Michael] UCL, Dept Neurol, London, England; [Mansfield, Averil; Thomas, Dafydd] Univ London Imperial Coll Sci Technol & Med, Dept Surg, London, England; [Marro, Joanna; Robertson, Steven] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England; [Potter, John] Univ E Anglia, Dept Med, Norwich NR4 7TJ, Norfolk, England; [Rau, Angela] Sunderland Royal Hosp, Dept Anaesthesia, Sunderland, England; [Streifler, Jonathan] Tel Aviv Univ, Dept Neurol, Petah Tiqwa, Israel	University of Oxford; University of Oxford; University of Oxford; St Georges University London; University of London; University College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; University of East Anglia; Sunderland Royal Hospital; Tel Aviv University	Halliday, A (corresponding author), John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford OX3 9DU, England.	alison.halliday@nds.ox.ac.uk	Toutounchi, Sadegh/V-6126-2018; Beyersdorf, Friedhelm/AAK-3718-2020; Cieri, Enrico/I-3581-2012; Akchurin, Renat S/B-7762-2019; Angiletta, Domenico/H-4720-2012; Mracek, Jan/D-7495-2019; Halliday, Alison/AAA-2230-2022; Leszczynski, Jerzy/V-6130-2018; Rahimi, Kazem/AAA-4250-2022; Chuen, Jason/H-2224-2017; Marti-Masso, J.F:/D-8619-2013; bonardelli, stefano/A-6961-2011; Benes, Vladimir/M-4755-2017; Hardie, Richard/L-6950-2013; Kramar, Filip/O-5860-2017; Rahimi, Kazem/Q-1279-2015	Toutounchi, Sadegh/0000-0002-6999-7561; Beyersdorf, Friedhelm/0000-0003-2975-2751; Akchurin, Renat S/0000-0002-6726-4612; Angiletta, Domenico/0000-0002-6135-836X; Mracek, Jan/0000-0002-4629-4732; Halliday, Alison/0000-0001-9828-3579; Leszczynski, Jerzy/0000-0003-3541-4011; Chuen, Jason/0000-0002-0955-5446; Marti-Masso, J.F:/0000-0001-8428-4386; Pagliariccio, Gabriele/0000-0001-9946-4574; SPEZIALE, Francesco/0000-0001-8106-2083; Rosfors, Stefan/0000-0001-9920-5791; Nagy, Zoltan/0000-0001-9756-5427; Kolvenbach, Ralf/0000-0003-4792-8044; Gray, Richard/0000-0003-4440-574X; VENTURA, Marco/0000-0003-2573-8573; Vila Coll, Ramon/0000-0003-3235-0024; Stansby, Gerard/0000-0001-5539-3049; CIERI, Enrico/0000-0003-3852-8663; Benes, Vladimir/0000-0002-6889-857X; Iborra, Elena/0000-0003-0668-5285; Weder, Bruno/0000-0002-8106-9899; Akchurin, Renat S./0000-0002-1252-283X; Norrving, Bo/0000-0002-8024-5096; Baker, Daryll/0000-0002-0098-405X; Hardie, Richard/0000-0002-4882-8822; Kaste, Markku/0000-0001-6557-6412; Kramar, Filip/0000-0003-0833-2360; Sbarigia, Enrico/0000-0002-1478-5908; SPARTERA, Carlo/0000-0003-0401-7937; Welch, Graham/0000-0003-2258-8039; Rahimi, Kazem/0000-0002-4807-4610; Andziak, Piotr/0000-0003-0041-357X; Hendriks, Jeroen/0000-0001-9145-3643	UK Medical Research Council; Stroke Association; BUPA Foundation; Medical Research Council [MC_U137686861] Funding Source: researchfish; National Institute for Health Research [06/301/233] Funding Source: researchfish; MRC [MC_U137686861] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Stroke Association; BUPA Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The principal acknowledgment is to the patients who agreed to participate, and to the many collaborating doctors and trial staff who spent much time achieving reliable long-term follow-up. Funding was from the UK Medical Research Council, Stroke Association, and BUPA Foundation. Randomisation and statistical support were provided by the Oxford Clinical Trial Service Unit (CTSU). Trial committees were reported previously.<SUP>1</SUP>	*ACC FDN NCDR, AM COLL CARD ACC FDN; *ACST 2 COLL GROUP, 2007, ACST 2 PROT VERS 4 2; Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Baigent C, 2010, OXFORD TXB MED, P31; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; *CTT COLL, LANCET IN PRESS; Dorigo W, 2009, J VASC SURG, V50, P1301, DOI 10.1016/j.jvs.2009.07.013; *DTSCH GES GEF, 2009, JB GEF 2009, P97; GRAYWEALE AC, 1988, J CARDIOVASC SURG, V29, P676; Halliday A, 2004, LANCET, V363, P1491; Halliday AW, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1847; Mathiesen EB, 2001, CIRCULATION, V103, P2171; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Reiff T, 2009, INT J STROKE, V4, P294, DOI 10.1111/j.1747-4949.2009.00290.x; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rudarakanchana N, 2009, EUR J VASC ENDOVASC, V38, P239, DOI 10.1016/j.ejvs.2009.05.010; Sidawy AN, 2009, J VASC SURG, V49, P71, DOI 10.1016/j.jvs.2008.08.039; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; White CJ, 2008, CATHETER CARDIO INTE, V71, P721, DOI 10.1002/ccd.21502	20	587	613	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1074	1084		10.1016/S0140-6736(10)61197-X	http://dx.doi.org/10.1016/S0140-6736(10)61197-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657KM	20870099	Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000282411600034
J	Xu, TD; Wen, MZ; Nagawa, S; Fu, Y; Chen, JG; Wu, MJ; Perrot-Rechenmann, C; Friml, J; Jones, AM; Yang, ZB				Xu, Tongda; Wen, Mingzhang; Nagawa, Shingo; Fu, Ying; Chen, Jin-Gui; Wu, Ming-Jing; Perrot-Rechenmann, Catherine; Friml, Jiri; Jones, Alan M.; Yang, Zhenbiao			Cell Surface- and Rho GTPase-Based Auxin Signaling Controls Cellular Interdigitation in Arabidopsis	CELL			English	Article							RESPONSIVE GENE-EXPRESSION; BOX PROTEIN TIR1; BINDING PROTEIN-1; PLANT DEVELOPMENT; PLASMA-MEMBRANE; ROP2 GTPASE; LEAF-CELLS; POLARITY; EXPANSION; GROWTH	Auxin is a multifunctional hormone essential for plant development and pattern formation. A nuclear auxin-signaling system controlling auxin-induced gene expression is well established, but cytoplasmic auxin signaling, as in its coordination of cell polarization, is unexplored. We found a cytoplasmic auxin-signaling mechanism that modulates the interdigitated growth of Arabidopsis leaf epidermal pavement cells (PCs), which develop interdigitated lobes and indentations to form a puzzle-piece shape in a two-dimensional plane. PC interdigitation is compromised in leaves deficient in either auxin biosynthesis or its export mediated by PINFORMED 1 localized at the lobe tip. Auxin coordinately activates two Rho GTPases, ROP2 and ROP6, which promote the formation of complementary lobes and indentations, respectively. Activation of these ROPs by auxin occurs within 30 s and depends on AUXIN-BINDING PROTEIN 1. These findings reveal Rho GTPase-based auxin-signaling mechanisms, which modulate the spatial coordination of cell expansion across a field of cells.	[Xu, Tongda; Wen, Mingzhang; Nagawa, Shingo; Fu, Ying; Yang, Zhenbiao] Univ Calif Riverside, Ctr Plant Cell Biol, Dept Bot & Plant Sci, Riverside, CA 92521 USA; [Chen, Jin-Gui; Wu, Ming-Jing; Jones, Alan M.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Perrot-Rechenmann, Catherine] CNRS, Inst Sci Vegetal, UPR2355, F-91198 Gif Sur Yvette, France; [Friml, Jiri] Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; [Friml, Jiri] Univ Ghent, Dept Mol Genet, B-9052 Ghent, Belgium; [Jones, Alan M.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of California System; University of California Riverside; University of North Carolina; University of North Carolina Chapel Hill; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; University of North Carolina; University of North Carolina Chapel Hill	Yang, ZB (corresponding author), Univ Calif Riverside, Ctr Plant Cell Biol, Dept Bot & Plant Sci, Riverside, CA 92521 USA.	yang@ucr.edu	Chen, Jin-Gui/A-4773-2011; Chen, Jin-Gui/AFV-6337-2022; Xu, Tongda/ABD-9589-2020; Friml, Jiri/D-9511-2012	Chen, Jin-Gui/0000-0002-1752-4201; Chen, Jin-Gui/0000-0002-1752-4201; Friml, Jiri/0000-0002-8302-7596; Xu, Tongda/0000-0003-3398-9217	U.S. National Institute of General Medical Sciences [GM081451, GM065989]; National Science Foundation [MCB-0718202]; Department of Energy [DE-FG02-05ER15671, DE-FG02-04ER15555]; Research Foundation-Flanders (Odysseus); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100130, R01GM081451, R01GM065989] Funding Source: NIH RePORTER	U.S. National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Science Foundation(National Science Foundation (NSF)); Department of Energy(United States Department of Energy (DOE)); Research Foundation-Flanders (Odysseus)(FWO); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Veronica Grieneisen, Ben Scheres, Athanasius F. M. Maree, Paulien Hogeweg, Xuemei Chen, and G. Venugopala Reddy for their stimulating discussion and critical comments on this manuscript; and to Xinping Cui for her assistance with the statistical analysis. We are grateful to Tom Guil-foyle and Yunde Zhao for their generous supply of Arabidopsis mutant lines used in this work. This work is supported by grants from the U.S. National Institute of General Medical Sciences to Z.Y. (GM081451) and to A.M.J. (GM065989), by the National Science Foundation to A.M.J. (MCB-0718202) and the Department of Energy to A.M.J. (DE-FG02-05ER15671) and to Z.Y. (DE-FG02-04ER15555) and by the Research Foundation-Flanders (Odysseus) to J.F.	Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; Altschuler SJ, 2008, NATURE, V454, P886, DOI 10.1038/nature07119; Badescu GO, 2006, TRENDS PLANT SCI, V11, P217, DOI 10.1016/j.tplants.2006.03.001; Baxter-Burrell A, 2002, SCIENCE, V296, P2026, DOI 10.1126/science.1071505; Braun N, 2008, PLANT CELL, V20, P2746, DOI 10.1105/tpc.108.059048; Chen JG, 2001, PLANT J, V28, P607, DOI 10.1046/j.1365-313x.2001.01152.x; Chen JG, 2001, GENE DEV, V15, P902, DOI 10.1101/gad.866201; Cheng YF, 2006, GENE DEV, V20, P1790, DOI 10.1101/gad.1415106; David KM, 2007, PLANT J, V50, P197, DOI 10.1111/j.1365-313X.2007.03038.x; Dharmasiri N, 2005, DEV CELL, V9, P109, DOI 10.1016/j.devcel.2005.05.014; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Dhonukshe P, 2008, NATURE, V456, P962, DOI 10.1038/nature07409; DIEKMANN W, 1995, P NATL ACAD SCI USA, V92, P3425, DOI 10.1073/pnas.92.8.3425; Fischer U, 2006, CURR BIOL, V16, P2143, DOI 10.1016/j.cub.2006.08.091; Fu Y, 2005, CELL, V120, P687, DOI 10.1016/j.cell.2004.12.026; Fu Y, 2002, PLANT CELL, V14, P777, DOI 10.1105/tpc.001537; Fu Y, 2009, CURR BIOL, V19, P1827, DOI 10.1016/j.cub.2009.08.052; Green JBA, 2007, NAT CELL BIOL, V9, P1010, DOI 10.1038/ncb438; Hagen G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117; Hazak O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000282; Heasman J, 2006, DEVELOPMENT, V133, P1205, DOI 10.1242/dev.02304; Hwang JU, 2005, MOL BIOL CELL, V16, P5385, DOI 10.1091/mbc.E05-05-0409; JONES AM, 1993, PLANT PHYSIOL, V101, P595, DOI 10.1104/pp.101.2.595; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; Jones MA, 2002, PLANT CELL, V14, P763, DOI 10.1105/tpc.010359; Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542; Leblanc N, 1999, J BIOL CHEM, V274, P28314, DOI 10.1074/jbc.274.40.28314; Leyser O, 2006, CURR BIOL, V16, pR424, DOI 10.1016/j.cub.2006.05.014; Mathur J, 1997, BIOTECHNIQUES, V22, P280, DOI 10.2144/97222bm19; Mockaitis K, 2008, ANNU REV CELL DEV BI, V24, P55, DOI 10.1146/annurev.cellbio.23.090506.123214; Paciorek T, 2005, NATURE, V435, P1251, DOI 10.1038/nature03633; Parry G, 2006, CURR OPIN CELL BIOL, V18, P152, DOI 10.1016/j.ceb.2006.02.001; Petrasek J, 2006, SCIENCE, V312, P914, DOI 10.1126/science.1123542; Robert S, 2010, CELL, V143, P111, DOI 10.1016/j.cell.2010.09.027; Sauer M, 2006, GENE DEV, V20, P2902, DOI 10.1101/gad.390806; SENN AP, 1988, PLANT PHYSIOL, V88, P131, DOI 10.1104/pp.88.1.131; Settleman J, 2005, CELL, V120, P570, DOI 10.1016/j.cell.2005.02.025; Sheen J, 2001, PLANT PHYSIOL, V127, P1466, DOI 10.1104/pp.010820; Shimomura S, 2006, PLANT MOL BIOL, V60, P663, DOI 10.1007/s11103-005-5471-1; Shishova M, 2004, J PLANT PHYSIOL, V161, P937, DOI 10.1016/j.jplph.2003.12.005; Steffens B, 2001, PLANT J, V27, P591, DOI 10.1046/j.1365-313X.2001.01103.x; Tan X, 2007, NATURE, V446, P640, DOI 10.1038/nature05731; Tao LZ, 2002, PLANT CELL, V14, P2745, DOI 10.1105/tpc.006320; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Vanneste S, 2009, CELL, V136, P1005, DOI 10.1016/j.cell.2009.03.001; Wasteneys GO, 1997, J MICROSC-OXFORD, V188, P51, DOI 10.1046/j.1365-2818.1977.2390796.x; Wisniewska J, 2006, SCIENCE, V312, P883, DOI 10.1126/science.1121356; Woo EJ, 2002, EMBO J, V21, P2877, DOI 10.1093/emboj/cdf291; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yang ZB, 2008, ANNU REV CELL DEV BI, V24, P551, DOI 10.1146/annurev.cellbio.23.090506.123233; Zhao YD, 2001, SCIENCE, V291, P306, DOI 10.1126/science.291.5502.306	52	333	360	4	103	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					99	110		10.1016/j.cell.2010.09.003	http://dx.doi.org/10.1016/j.cell.2010.09.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887895	Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000282362000017
J	Brusatte, SL; Norell, MA; Carr, TD; Erickson, GM; Hutchinson, JR; Balanoff, AM; Bever, GS; Choiniere, JN; Makovicky, PJ; Xu, X				Brusatte, Stephen L.; Norell, Mark A.; Carr, Thomas D.; Erickson, Gregory M.; Hutchinson, John R.; Balanoff, Amy M.; Bever, Gabe S.; Choiniere, Jonah N.; Makovicky, Peter J.; Xu, Xing			Tyrannosaur Paleobiology: New Research on Ancient Exemplar Organisms	SCIENCE			English	Review							NORTH-AMERICA; THEROPOD DINOSAURS; CRANIAL MECHANICS; SOFT-TISSUE; REX; CHINA; ASIA; FEATHERS; ENGLAND; GROWTH	Tyrannosaurs, the group of dinosaurian carnivores that includes Tyrannosaurus rex and its closest relatives, are icons of prehistory. They are also the most intensively studied extinct dinosaurs, and thanks to large sample sizes and an influx of new discoveries, have become ancient exemplar organisms used to study many themes in vertebrate paleontology. A phylogeny that includes recently described species shows that tyrannosaurs originated by the Middle Jurassic but remained mostly small and ecologically marginal until the latest Cretaceous. Anatomical, biomechanical, and histological studies of T. rex and other derived tyrannosaurs show that large tyrannosaurs could not run rapidly, were capable of crushing bite forces, had accelerated growth rates and keen senses, and underwent pronounced changes during ontogeny. The biology and evolutionary history of tyrannosaurs provide a foundation for comparison with other dinosaurs and living organisms.	[Brusatte, Stephen L.; Norell, Mark A.; Erickson, Gregory M.; Balanoff, Amy M.; Choiniere, Jonah N.] Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; [Brusatte, Stephen L.; Balanoff, Amy M.] Columbia Univ, Dept Earth & Environm Sci, New York, NY 10964 USA; [Carr, Thomas D.] Carthage Coll, Dept Biol, Kenosha, WI 53140 USA; [Erickson, Gregory M.] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; [Hutchinson, John R.] Univ London Royal Vet Coll, Dept Vet Basic Sci, Hatfield AL9 7TA, Herts, England; [Bever, Gabe S.] Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; [Choiniere, Jonah N.] George Washington Univ, Dept Biol Sci, Washington, DC 20052 USA; [Makovicky, Peter J.] Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; [Xu, Xing] Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China	American Museum of Natural History (AMNH); Columbia University; State University System of Florida; Florida State University; University of London; University of London Royal Veterinary College; Yale University; George Washington University; Field Museum of Natural History (Chicago); Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	Brusatte, SL (corresponding author), Amer Museum Nat Hist, Div Paleontol, Cent Pk W & 79th St, New York, NY 10024 USA.	sbrusatte@amnh.org	Hutchinson, John/AAH-1593-2020; Brusatte, Stephen/O-9663-2014	Hutchinson, John/0000-0002-6767-7038; Brusatte, Stephen/0000-0001-7525-7319; Choiniere, Jonah/0000-0002-1008-0687	NSF; American Museum of Natural History; Natural Environment Research Council; National Natural Science Foundation of China; Special Funds For Major State Basic Research Projects of China; NERC [NE/G005877/1] Funding Source: UKRI; Natural Environment Research Council [NE/G005877/1] Funding Source: researchfish	NSF(National Science Foundation (NSF)); American Museum of Natural History; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Funds For Major State Basic Research Projects of China; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	Funded by NSF Graduate Research Fellowship (S. L. B.), American Museum of Natural History (S. L. B., M.A.N.), NSF (M.A.N., G. M. E., J.R.H., P.J.M.), Natural Environment Research Council (J.R.H.), and National Natural Science Foundation of China and Special Funds For Major State Basic Research Projects of China (X.X.).	Averianov A.O., 2010, P ZOOLOGICAL I RAS, V314, P42; Benson RBJ, 2008, J VERTEBR PALEONTOL, V28, P732, DOI 10.1671/0272-4634(2008)28[732:NIOSAT]2.0.CO;2; Benson RBJ, 2010, SCIENCE, V327, P1613, DOI 10.1126/science.1187456; Brochu CA, 2000, J VERTEBR PALEONTOL, V20, P1, DOI 10.1671/0272-4634(2000)020[0001:ADREFT]2.0.CO;2; Brochu CA, 2003, J VERTEBR PALEONTOL, V22, P1, DOI [10.1080/02724634.2003.10010947, DOI 10.1080/02724634.2003.10010947, 10.2307/3889334, DOI 10.2307/3889334]; Brusatte SL, 2009, P NATL ACAD SCI USA, V106, P17261, DOI 10.1073/pnas.0906911106; Brusatte SL, 2009, NATURWISSENSCHAFTEN, V96, P1051, DOI 10.1007/s00114-009-0565-2; Carpenter K, 2000, GAIA, V15, P135; Carr TD, 2004, ZOOL J LINN SOC-LOND, V142, P479, DOI 10.1111/j.1096-3642.2004.00130.x; Carr TD, 1999, J VERTEBR PALEONTOL, V19, P497, DOI 10.1080/02724634.1999.10011161; Carr TD, 2010, J VERTEBR PALEONTOL, V30, P1, DOI 10.1080/02724630903413032; Carrano MT, 2002, J MORPHOL, V253, P207, DOI 10.1002/jmor.10018; Chin K, 1998, NATURE, V393, P680, DOI 10.1038/31461; Currie Philip J., 2003, Ichnos, V10, P1, DOI 10.1080/10420940390235071; Currie Philip J., 2000, Gaia (Lisboa), V15, P271; Currie PJ, 2003, ACTA PALAEONTOL POL, V48, P191; Currie PJ, 2003, CAN J EARTH SCI, V40, P651, DOI 10.1139/E02-083; DODSON P, 1975, J ZOOL, V175, P315; Erickson GM, 1996, J VERTEBR PALEONTOL, V16, P175, DOI 10.1080/02724634.1996.10011297; Erickson GM, 2005, ZOOLOGY, V108, P277, DOI 10.1016/j.zool.2005.08.001; Erickson GM, 2004, NATURE, V430, P772, DOI 10.1038/nature02699; Erickson GM, 1996, NATURE, V382, P706, DOI 10.1038/382706a0; ERICKSON GM, 1999, SCI AM, V9, P32; Erickson GM, 2006, SCIENCE, V313, P213, DOI 10.1126/science.1125721; Gatesy SM, 2009, J VERTEBR PALEONTOL, V29, P535, DOI 10.1671/039.029.0213; Happ John, 2008, P354; Holtz TR, 2004, DINOSAURIA, 2ND EDITION, P111; Hurum JH, 2003, ACTA PALAEONTOL POL, V48, P161; Hutchinson JR, 2002, NATURE, V415, P1018, DOI 10.1038/4151018a; Hutt S, 2001, CRETACEOUS RES, V22, P227, DOI 10.1006/cres.2001.0252; Jacobsen Aase Roland, 1998, Historical Biology, V13, P17; Ji Qiang, 2009, Dizhi Tongbao, V28, P1369; Kaye TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002808; Li DQ, 2010, P ROY SOC B-BIOL SCI, V277, P183, DOI 10.1098/rspb.2009.0249; Makovicky PJ, 2010, P ROY SOC B-BIOL SCI, V277, P191, DOI 10.1098/rspb.2009.0236; MOLNAR R E, 1991, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V217, P137; Organ CL, 2008, SCIENCE, V320, P499, DOI 10.1126/science.1154284; Osborn HF, 1905, B AM MUS NAT HIST, V21, P259; Prieto-Marquez A, 2007, J VERTEBR PALEONTOL, V27, P603, DOI 10.1671/0272-4634(2007)27[603:NEOPSA]2.0.CO;2; Rauhut OWM, 2010, ZOOL J LINN SOC-LOND, V158, P155, DOI 10.1111/j.1096-3642.2009.00591.x; Rayfield EJ, 2005, ZOOL J LINN SOC-LOND, V144, P309, DOI 10.1111/j.1096-3642.2005.00176.x; Rayfield EJ, 2004, P ROY SOC B-BIOL SCI, V271, P1451, DOI 10.1098/rspb.2004.2755; RUSSELL DA, 1970, NATL MUS NAT HIST PU, V1, P1; Schweitzer MH, 2007, SCIENCE, V316, P277, DOI 10.1126/science.1138709; Schweitzer MH, 2005, SCIENCE, V307, P1952, DOI 10.1126/science.1108397; Schweitzer MH, 2005, SCIENCE, V308, P1456, DOI 10.1126/science.1112158; Sellers WI, 2007, P ROY SOC B-BIOL SCI, V274, P2711, DOI 10.1098/rspb.2007.0846; Sereno PC, 2009, SCIENCE, V326, P418, DOI 10.1126/science.1177428; Snively E, 2003, J MORPHOL, V255, P215, DOI 10.1002/jmor.10059; Snively E, 2007, PALEOBIOLOGY, V33, P610, DOI 10.1666/06059.1; Snively E, 2006, ACTA PALAEONTOL POL, V51, P435; TANKE DH, 2000, GAIA, V15, P168; TANKE DH, 2001, NEW MEX MUS NAT HIST, V20, P1; Upchurch P, 2002, P ROY SOC B-BIOL SCI, V269, P613, DOI 10.1098/rspb.2001.1921; Varricchio DJ, 2001, J PALEONTOL, V75, P401, DOI 10.1666/0022-3360(2001)075<0401:GCFACT>2.0.CO;2; Weishampel DB, 2004, DINOSAURIA, 2ND EDITION, P517; Witmer LM, 2009, ANAT REC, V292, P1266, DOI 10.1002/ar.20983; Xu X, 2006, NATURE, V439, P715, DOI 10.1038/nature04511; Xu X, 2004, NATURE, V431, P680, DOI 10.1038/nature02855; Xu X, 2010, NATURE, V464, P1338, DOI 10.1038/nature08965; Xu X, 2009, P NATL ACAD SCI USA, V106, P832, DOI 10.1073/pnas.0810055106; Zelenitsky DK, 2009, P ROY SOC B-BIOL SCI, V276, P667, DOI 10.1098/rspb.2008.1075	62	127	137	5	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1481	1485		10.1126/science.1193304	http://dx.doi.org/10.1126/science.1193304			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847260	Green Accepted			2022-12-28	WOS:000281869000030
J	Evans, JP; Dale, DC; Fomous, C				Evans, James P.; Dale, David C.; Fomous, Cathy			Preparing for a Consumer-Driven Genomic Age.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Evans, James P.; Dale, David C.] Secretarys Advisory Comm Genet Hlth & Soc, Washington, DC USA; [Evans, James P.] Univ N Carolina, Chapel Hill, NC USA; [Dale, David C.] Univ Washington, Seattle, WA 98195 USA; [Fomous, Cathy] NIH, Off Biotechnol Act, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA	Evans, JP (corresponding author), Secretarys Advisory Comm Genet Hlth & Soc, Washington, DC USA.							ENGLE MK, 2009, COMMUNICATION   0814; National Institutes of Health (NIH), 2010, FED REGISTER, V75, P33317; 2010, FED REG, V75, P33463	3	37	39	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1099	1103		10.1056/NEJMp1006202	http://dx.doi.org/10.1056/NEJMp1006202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649TD	20843241				2022-12-28	WOS:000281795800002
J	Grandjean, P				Grandjean, Philippe			Even low-dose lead exposure is hazardous	LANCET			English	Editorial Material									[Grandjean, Philippe] Univ So Denmark, Odense, Denmark; [Grandjean, Philippe] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA	University of Southern Denmark; Harvard University; Harvard T.H. Chan School of Public Health	Grandjean, P (corresponding author), Univ So Denmark, Odense, Denmark.	pgrandjean@health.sdu.dk	Grandjean, Philippe/I-2962-2014	Grandjean, Philippe/0000-0003-4046-9658	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Centers for Disease Control and Prevention, 2005, PREV LEAD POIS YOUNG; European Food Safety Authority, 2010, EFSA J, V8, P1570, DOI [10.2903/j.efsa.2010.1570, DOI 10.2903/J.EFSA.2010.1570]; *JOINT FAO WHO EXP, 2000, EV CERT FOOD ADD CON; Lanphear BP, 2005, ENVIRON HEALTH PERSP, V113, P894, DOI 10.1289/ehp.7688; MARKOWITZ GE, 2002, DECEIT DENIAL DEADLY, P35; *SER FRAUD OFF, 2010, INN LTD PROS CORR SF	6	68	68	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2010	376	9744					855	856		10.1016/S0140-6736(10)60745-3	http://dx.doi.org/10.1016/S0140-6736(10)60745-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20833288				2022-12-28	WOS:000282069100009
J	Mu, XD; Wang, GF				Mu, Xiang-Dong; Wang, Guang-Fa			Miliary Tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mu, Xiang-Dong; Wang, Guang-Fa] Peking Univ, Hosp 1, Beijing 100871, Peoples R China	Peking University	Mu, XD (corresponding author), Peking Univ, Hosp 1, Beijing 100871, Peoples R China.	muxiangdong@medmail.com.cn							0	2	3	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1059	1059		10.1056/NEJMicm1001480	http://dx.doi.org/10.1056/NEJMicm1001480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825318				2022-12-28	WOS:000281609700009
J	Rothberg, MB; Sivalingam, SK; Ashraf, J; Visintainer, P; Joelson, J; Kleppel, R; Vallurupalli, N; Schweiger, MJ				Rothberg, Michael B.; Sivalingam, Senthil K.; Ashraf, Javed; Visintainer, Paul; Joelson, John; Kleppel, Reva; Vallurupalli, Neelima; Schweiger, Marc J.			Patients' and Cardiologists' Perceptions of the Benefits of Percutaneous Coronary Intervention for Stable Coronary Disease	ANNALS OF INTERNAL MEDICINE			English	Article							OPTIMAL MEDICAL THERAPY; ARTERY-DISEASE; AD-HOC; INFORMED-CONSENT; ANGIOPLASTY; SURGERY; RISKS; TRIAL; REVASCULARIZATION; PCI	Background: It is unclear whether patients understand that percutaneous coronary intervention (PCI) reduces only chronic stable angina and not myocardial infarction (MI) or associated mortality. Objective: To compare cardiologists' and patients' beliefs about PCI. Design: Survey. Setting: Academic center. Participants: 153 patients who consented to elective coronary catheterization and possible PCI, 10 interventional cardiologists, and 17 referring cardiologists. Measurements: Patients' and cardiologists' beliefs about benefits of PCI. All cardiologists reported beliefs about PCI for patients in hypothetical scenarios. Interventional cardiologists also reported beliefs for study patients who underwent PCI. Results: Of 153 patients, 68% had any angina, 42% had activity-limiting angina, 77% had a positive stress test result, and 29% had had previous MI. The 53 patients who underwent PCI were more likely than those who did not to have a positive stress test result, but angina was similar in both groups. Almost three quarters of patients thought that without PCI, they would probably have MI within 5 years, and 88% believed that PCI would reduce risk for MI. Patients were more likely than physicians to believe that PCI would prevent MI (prevalence ratio, 4.25 [95% CI, 2.31 to 7.79]) or fatal MI (prevalence ratio, 4.83 [CI, 2.23 to 10.46]). Patients were less likely than their physicians to report pre-PCI angina (prevalence ratio, 0.79 [CI, 0.67 to 0.92]). For the scenarios, 63% of cardiologists believed that the benefits of PCI were limited to symptom relief. Of cardiologists who identified no benefit of PCI in 2 scenarios, 43% indicated that they would still proceed with PCI in these cases. Limitation: The study was small and conducted at 1 center, and information about precatheterization counseling was limited. Conclusion: Cardiologists' beliefs about PCI reflect trial results, but patients' beliefs do not. Discussions with patients before PCI should better explain anticipated benefits.	[Rothberg, Michael B.] Baystate Med Ctr, Dept Med, Div Gen Med & Geriatr, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Baystate Medical Center; Tufts University	Rothberg, MB (corresponding author), Baystate Med Ctr, Dept Med, Div Gen Med & Geriatr, 759 Chestnut St, Springfield, MA 01199 USA.	Michael.Rothberg@bhs.org		Visintainer, Paul/0000-0002-2491-1242				APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Arnold SV, 2008, CIRC-CARDIOVASC QUAL, V1, P21, DOI 10.1161/CIRCOUTCOMES.108.791863; Blankenship JC, 2000, CATHETER CARDIO INTE, V49, P130, DOI 10.1002/(SICI)1522-726X(200002)49:2<130::AID-CCD3>3.0.CO;2-T; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Feldman DN, 2007, AM J CARDIOL, V99, P446, DOI 10.1016/j.amjcard.2006.09.093; Fleiss JL., 2003, STAT METHODS RATES P; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Habib SB, 2008, J VASC INTERV RADIOL, V19, P177, DOI 10.1016/j.jvir.2007.10.016; Holmboe ES, 2000, J GEN INTERN MED, V15, P632, DOI 10.1046/j.1525-1497.2000.90823.x; Hueb W, 2007, CIRCULATION, V115, P1082, DOI 10.1161/CIRCULATIONAHA.106.625475; Katritsis DG, 2005, CIRCULATION, V111, P2906, DOI 10.1161/CIRCULATIONAHA.104.521864; Kee F, 1997, QUAL HEALTH CARE, V6, P131, DOI 10.1136/qshc.6.3.131; Krone RJ, 2006, CATHETER CARDIO INTE, V68, P696, DOI 10.1002/ccd.20910; Larobina ME, 2007, ANZ J SURG, V77, P530, DOI 10.1111/j.1445-2197.2007.04143.x; Le Feuvre Claude, 2003, J Interv Cardiol, V16, P195, DOI 10.1034/j.1600-0854.2003.8045.x; Lin GA, 2008, J GEN INTERN MED, V23, P1458, DOI 10.1007/s11606-008-0706-x; Lin GA, 2007, ARCH INTERN MED, V167, P1604, DOI 10.1001/archinte.167.15.1604; Lucas FL, 2008, CIRCULATION, V118, P2797, DOI 10.1161/CIRCULATIONAHA.108.789446; Morgan MW, 2000, J GEN INTERN MED, V15, P685, DOI 10.1046/j.1525-1497.2000.91139.x; Pfisterer M, 2003, JAMA-J AM MED ASSOC, V289, P1117, DOI 10.1001/jama.289.9.1117; Rahilly-Tierney CR, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-28; Ravdin PM, 1998, J CLIN ONCOL, V16, P515, DOI 10.1200/JCO.1998.16.2.515; Shaw LJ, 2008, CIRCULATION, V117, P1283, DOI 10.1161/CIRCULATIONAHA.107.743963; Siegel C, 2008, INFLAMM BOWEL DIS, V14, P1, DOI 10.1002/ibd.20283; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Weintraub WS, 2008, NEW ENGL J MED, V359, P677, DOI 10.1056/NEJMoa072771; Whittle J, 2007, AM HEART J, V154, P662, DOI 10.1016/j.ahj.2007.04.065	27	134	137	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2010	153	5					307	U55		10.7326/0003-4819-153-5-201009070-00005	http://dx.doi.org/10.7326/0003-4819-153-5-201009070-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647GF	20820040				2022-12-28	WOS:000281605500004
J	Ginath, S; Golan, A				Ginath, Shimon; Golan, Abraham			Gestational Pituitary-Tumor Apoplexy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ginath, Shimon; Golan, Abraham] Wolfson Med Ctr, Holon, Israel		Ginath, S (corresponding author), Wolfson Med Ctr, Holon, Israel.	ginath@gmail.com							0	16	16	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					E10	E10		10.1056/NEJMicm0900500	http://dx.doi.org/10.1056/NEJMicm0900500			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	636TN	20842779				2022-12-28	WOS:000280764600010
J	Williams, NM; Zaharieva, I; Martin, A; Langley, K; Mantripragada, K; Fossdal, R; Stefansson, H; Stefansson, K; Magnusson, P; Gudmundsson, OO; Gustafsson, O; Holmans, P; Owen, MJ; O'Donovan, M; Thapar, A				Williams, Nigel M.; Zaharieva, Irina; Martin, Andrew; Langley, Kate; Mantripragada, Kiran; Fossdal, Ragnheidur; Stefansson, Hreinn; Stefansson, Karl; Magnusson, Pall; Gudmundsson, Olafur O.; Gustafsson, Omar; Holmans, Peter; Owen, Michael J.; O'Donovan, Michael; Thapar, Anita			Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis	LANCET			English	Article							COPY NUMBER VARIATION; AUTISM; ADHD; ASSOCIATION; MUTATIONS; VARIANTS; 16P11.2; DISC1; CHILD; NDE1	Background Large, rare chromosomal deletions and duplications known as copy number variants (CNVs) have been implicated in neurodevelopmental disorders similar to attention-deficit hyperactivity disorder (ADHD). We aimed to establish whether burden of CNVs was increased in ADHD, and to investigate whether identified CNVs were enriched for loci previously identified in autism and schizophrenia. Methods We undertook a genome-wide analysis of CNVs in 410 children with ADHD and 1156 unrelated ethnically matched controls from the 1958 British Birth Cohort. Children of white UK origin, aged 5-17 years, who met diagnostic criteria for ADHD or hyperkinetic disorder, but not schizophrenia and autism, were recruited from community child psychiatry and paediatric outpatient clinics. Single nucleotide polymorphisms (SNPs) were genotyped in the ADHD and control groups with two arrays; CNV analysis was limited to SNPs common to both arrays and included only samples with high-quality data. CNVs in the ADHD group were validated with comparative genomic hybridisation. We assessed the genome-wide burden of large (>500 kb), rare (<1% population frequency) CNVs according to the average number of CNVs per sample, with significance assessed via permutation. Locus-specific tests of association were undertaken for test regions defined for all identified CNVs and for 20 loci implicated in autism or schizophrenia. Findings were replicated in 825 Icelandic patients with ADHD and 35 243 Icelandic controls. Findings Data for full analyses were available for 366 children with ADHD and 1047 controls. 57 large, rare CNVs were identified in children with ADHD and 78 in controls, showing a significantly increased rate of CNVs in ADHD (0.156 vs 0.075; p=8.9x10(-5)). This increased rate of CNVs was particularly high in those with intellectual disability (0.424; p=2.0x10(-6)), although there was also a significant excess in cases with no such disability (0.125, p=0.0077). An excess of chromosome 16p13.11 duplications was noted in the ADHD group (p=0.0008 after correction for multiple testing), a finding that was replicated in the Icelandic sample (p=0.031). CNVs identified in our ADHD cohort were significantly enriched for loci previously reported in both autism (p=0.0095) and schizophrenia (p=0.010). Interpretation Our findings provide genetic evidence of an increased rate of large CNVs in individuals with ADHD and suggest that ADHD is not purely a social construct.	[Williams, Nigel M.; Zaharieva, Irina; Martin, Andrew; Langley, Kate; Mantripragada, Kiran; Holmans, Peter; Owen, Michael J.; O'Donovan, Michael; Thapar, Anita] Cardiff Univ, Sch Med, MRC, Ctr Neuropsychiat Genet & Genom, Cardiff CF14 4XN, S Glam, Wales; [Williams, Nigel M.; Zaharieva, Irina; Martin, Andrew; Langley, Kate; Mantripragada, Kiran; Holmans, Peter; Owen, Michael J.; O'Donovan, Michael; Thapar, Anita] Cardiff Univ, Sch Med, Dept Psychol Med & Neurol, Cardiff CF14 4XN, S Glam, Wales; [Fossdal, Ragnheidur; Stefansson, Hreinn; Stefansson, Karl; Gustafsson, Omar] deCODE Genet, Reykjavik, Iceland; [Magnusson, Pall; Gudmundsson, Olafur O.] Landspitali Univ Hosp, Reykjavik, Iceland; [Gustafsson, Omar] Oslo Univ Hosp, Dept Psychiat, Oslo, Norway	Cardiff University; Cardiff University; Landspitali National University Hospital; University of Oslo	Williams, NM (corresponding author), Cardiff Univ, Sch Med, MRC, Ctr Neuropsychiat Genet & Genom, Cardiff CF14 4XN, S Glam, Wales.	williamsnm@cf.ac.uk	Martin, Andrew/B-9896-2012; O'Donovan, Michael C/P-7005-2018; Stefansson, Kari/AAE-7187-2019; Holmans, Peter/F-4518-2015; Guðmundsson, Ólafur Ó/AAF-1882-2019; Thapar, Anita/AAH-5555-2020	Martin, Andrew/0000-0001-9445-9151; O'Donovan, Michael C/0000-0001-7073-2379; Holmans, Peter/0000-0003-0870-9412; Thapar, Anita/0000-0002-3689-737X; Stefansson, Hreinn/0000-0002-9331-6666; Newton-Bishop, Julia/0000-0001-9147-6802; Gudmundsson, Olafur/0000-0001-8466-1559; Langley, Kate/0000-0002-2033-2657	Novartis; Pfizer; Kenyan Medical Research Institute (KEMRI); Wellcome Trust [079080, 086166, 076951]; Baily Thomas Charitable Trust; UK Medical Research Council; European Union; Medical Research Council [G0801418, G0801418B] Funding Source: researchfish; MRC [G0801418] Funding Source: UKRI	Novartis(Novartis); Pfizer(Pfizer); Kenyan Medical Research Institute (KEMRI); Wellcome Trust(Wellcome TrustEuropean Commission); Baily Thomas Charitable Trust; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	RWS has received funding from Novartis for chairing meetings of national control programmes in Africa and has received a research grant from Pfizer. RA is Director of Strategy, Performance and Evaluation Cluster at the Global Fund to Fight AIDS, Tuberculosis and Malaria. All other authors declare that they have no conflicts of interest.; We thank Caroline Kabaria for help with the map production; Viola Kurui, Richard Carr, and Yoko Akachi for help with data assemblies; Mike English and Kevin Marsh for comments on an earlier draft. We also acknowledge the support of the Kenyan Medical Research Institute (KEMRI). This paper is published with the permission of the director of KEMRI. RWS is a Wellcome Trust Principal Research Fellow (#079080). EAO is a Wellcome Trust Research Training Fellow (#086166). SI H is a Wellcome Trust Senior Research Fellow (#076951). The same grant also supports PWG. This work forms part of the output of the Malaria Atlas Project, which is principally funded by the Wellcome Trust, UK.; Baily Thomas Charitable Trust; Wellcome Trust; UK Medical Research Council; European Union.	Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346; Amaral OB, 2007, AM J PSYCHIAT, V164, P1612, DOI 10.1176/appi.ajp.2007.07060942; Angold A, 2000, J AM ACAD CHILD PSY, V39, P975, DOI 10.1097/00004583-200008000-00009; [Anonymous], 2008, RUTTERS CHILD ADOLES; Bradshaw NJ, 2009, NEUROSCI LETT, V449, P228, DOI 10.1016/j.neulet.2008.10.095; Bradshaw NJ, 2008, BIOCHEM BIOPH RES CO, V377, P1091, DOI 10.1016/j.bbrc.2008.10.120; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cook EH, 2008, NATURE, V455, P919, DOI 10.1038/nature07458; Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542; Einfeld SL, 2006, JAMA-J AM MED ASSOC, V296, P1981, DOI 10.1001/jama.296.16.1981; Elia J, 2010, MOL PSYCHIATR, V15, P637, DOI 10.1038/mp.2009.57; Franke B, 2009, HUM GENET, V126, P13, DOI 10.1007/s00439-009-0663-4; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; HANNES FD, 2009, BRIT MED J, V46, P223; Holmes J, 2004, BRIT J PSYCHIAT, V184, P74, DOI 10.1192/bjp.184.1.74; INGASON A, 2009, MOL PSYCH; Itsara A, 2009, AM J HUM GENET, V84, P148, DOI 10.1016/j.ajhg.2008.12.014; Kalscheuer VM, 2007, HUM GENET, V121, P501, DOI 10.1007/s00439-006-0284-0; Kim HG, 2008, AM J HUM GENET, V82, P199, DOI 10.1016/j.ajhg.2007.09.011; Kirov G, 2009, HUM MOL GENET, V18, P1497, DOI 10.1093/hmg/ddp043; Magnusson P, 1999, SCAND J PSYCHOL, V40, P301, DOI 10.1111/1467-9450.404130; Magnusson Pall, 2006, J Atten Disord, V9, P494, DOI 10.1177/1087054705283650; McCarthy SE, 2009, NAT GENET, V41, P1223, DOI 10.1038/ng.474; Mefford HC, 2009, GENOME RES, V19, P1579, DOI 10.1101/gr.094987.109; Moessner R, 2007, AM J HUM GENET, V81, P1289, DOI 10.1086/522590; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ronald A, 2008, J CHILD PSYCHOL PSYC, V49, P535, DOI 10.1111/j.1469-7610.2007.01857.x; Roohi J, 2009, J MED GENET, V46, P176, DOI 10.1136/jmg.2008.057505; Sinzig J, 2009, J ATTEN DISORD, V13, P117, DOI 10.1177/1087054708326261; Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Thapar A, 2007, PSYCHOL MED, V37, P1681, DOI 10.1017/S0033291707000773; Timimi S, 2004, BRIT J PSYCHIAT, V184, P8, DOI 10.1192/bjp.184.1.8; Ullmann R, 2007, HUM MUTAT, V28, P674, DOI 10.1002/humu.20546; Wain LV, 2009, LANCET, V374, P340, DOI 10.1016/S0140-6736(09)60249-X; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; WECHSLER D, 2003, WISC IV ADM SCOR; Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974	38	359	365	0	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2010	376	9750					1401	1408		10.1016/S0140-6736(10)61109-9	http://dx.doi.org/10.1016/S0140-6736(10)61109-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672ZO	20888040	Green Published			2022-12-28	WOS:000283627500035
J	Rosenthal, MS				Rosenthal, Marjorie S.			Anticipatory Guidance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												marjorie.rosenthal@yale.edu							0	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2010	304	13					1421	1422		10.1001/jama.2010.1388	http://dx.doi.org/10.1001/jama.2010.1388			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658SO	20924000				2022-12-28	WOS:000282509900001
J	Stein, CM; Ray, WA				Stein, C. Michael; Ray, Wayne A.			The Ethics of Placebo in Studies with Fracture End Points in Osteoporosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW BONE-DENSITY; POSTMENOPAUSAL WOMEN; CLINICAL-TRIALS; PREVENT FRACTURES; DEVELOPING-COUNTRIES; ZOLEDRONIC ACID; UNETHICAL USE; ISSUES; RECOMMENDATIONS; DESIGN		[Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol & Rheumatol, Nashville, TN 37212 USA; [Ray, Wayne A.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University	Stein, CM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol & Rheumatol, Nashville, TN 37212 USA.							Al-Khatib SM, 2001, SCIENCE, V292, P2013, DOI 10.1126/science.1057783; Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312; Boers M, 2002, NETH J MED, V60, P310; Brody BA, 2003, J BONE MINER RES, V18, P1105, DOI 10.1359/jbmr.2003.18.6.1105; Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Cummings SR, 2008, NEW ENGL J MED, V359, P697, DOI 10.1056/NEJMoa0800743; Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692; Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493; Delmas PD, 2002, OSTEOPOROSIS INT, V13, P1, DOI 10.1007/s198-002-8331-3; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; European Medicines Agency Committee for Medicinal Products for Human Use, GUID EV MED PROD TRE; Fink HA, 2003, OSTEOPOROSIS INT, V14, P69, DOI 10.1007/s00198-002-1314-y; *FOOD DRUG ADM, 2002, CTR DRUG EV RES ART; Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003-4819-146-5-200703060-00005; Khosla S, 2009, NEW ENGL J MED, V361, P818, DOI 10.1056/NEJMe0905480; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941; MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003-4819-148-3-200802050-00198; Michels KB, 2003, BIOETHICS, V17, P188, DOI 10.1111/1467-8519.00332; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, BELM REP ETH PRINC G; Pace C, 2003, CRIT CARE MED, V31, pS121, DOI 10.1097/01.CCM.0000054907.33928.48; Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003-4819-149-6-200809160-00007; Reginster JY, 2008, ARTHRITIS RHEUM-US, V58, P1687, DOI 10.1002/art.23461; Reginster JY, 2006, OSTEOPOROSIS INT, V17, P1, DOI 10.1007/s00198-005-1984-3; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Shapiro HT, 2001, NEW ENGL J MED, V345, P139, DOI 10.1056/NEJM200107123450212; Shea B, 2004, COCHRANE DB SYST REV, V1; Silverman SL, 2008, J BONE MINER RES, V23, P159, DOI 10.1359/JBMR.070905; Stein CM, 1999, LANCET, V353, P400, DOI 10.1016/S0140-6736(98)01373-7; Stevenson M, 2005, HEALTH TECHNOL ASSES, V9, P1; Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7; Tanne JH, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1618; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; World Medical Association (WMA), WMA DECL HELS ETH PR	35	16	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1367	1370		10.1056/NEJMsb1006120	http://dx.doi.org/10.1056/NEJMsb1006120			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655TD	20879888				2022-12-28	WOS:000282271500015
J	Holzer, M				Holzer, Michael			Targeted Temperature Management for Comatose Survivors of Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL LIAISON COMMITTEE; MILD THERAPEUTIC HYPOTHERMIA; INTENSIVE-CARE-UNIT; CEREBRAL-ISCHEMIA; POSTISCHEMIC HYPOTHERMIA; BRAIN TEMPERATURE; IN-VIVO; REPERFUSION; CARDIOPULMONARY; RESUSCITATION	A 62-year-old man collapses on the street, and emergency medical personnel who are called to the scene find that he is not breathing and that he has no pulse. The first recorded cardiac rhythm is ventricular fibrillation. Advanced cardiac life-support measures, including intubation, a total dose of 2 mg of epinephrine, and six defibrillation attempts, restore spontaneous circulation 22 minutes after the onset of the event. On admission to the emergency department, his condition is hemodynamically stable and he has adequate oxygenation and ventilation, but he is still comatose. A neurologic examination reveals reactive pupils and a positive cough reflex. The core body temperature is 35.5 degrees C. A diagnosis of the post-cardiac arrest syndrome with coma is made. An intensive care specialist evaluates the patient and recommends the immediate initiation of targeted temperature management.	Med Univ Vienna, Dept Emergency Med, A-1090 Vienna, Austria	Medical University of Vienna	Holzer, M (corresponding author), Med Univ Vienna, Dept Emergency Med, Wahringer Gurtel 18-20-6D, A-1090 Vienna, Austria.	michael.holzer@meduniwien.ac.at			KCI Medical; EMCOOLS; Medivance; Life Recovery Systems; Velomedix	KCI Medical; EMCOOLS; Medivance; Life Recovery Systems; Velomedix	Dr. Holzer reports receiving fees for board membership from KCI Medical, consulting fees from EMCOOLS, and lecture fees from KCI Medical and Medivance. The Department of Emergency Medicine at the Medical University of Vienna received research grants from KCI Medical, Life Recovery Systems, and Velomedix on behalf of Dr. Holzer. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bokesch PM, 1996, ANESTHESIOLOGY, V85, P1439, DOI 10.1097/00000542-199612000-00026; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Eberspacher E, 2005, ACTA ANAESTH SCAND, V49, P477, DOI 10.1111/j.1399-6576.2005.00649.x; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; *EUR RES COUNC, 2005, RESUSCITATION, V67, pS1, DOI DOI 10.1016/J.RESUSCITATION.2005.10.001; Falkenbach P, 2009, RESUSCITATION, V80, P990, DOI 10.1016/j.resuscitation.2009.04.044; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Greer DM, 2006, SEMIN NEUROL, V26, P373, DOI 10.1055/s-2006-948317; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hachimi-Idrissi S, 2004, BRAIN RES, V1019, P217, DOI 10.1016/j.brainres.2004.06.013; Hoesch RE, 2008, CRIT CARE CLIN, V24, P25, DOI 10.1016/j.ccc.2007.11.003; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jarnum H, 2009, RESUSCITATION, V80, P425, DOI 10.1016/j.resuscitation.2009.01.004; JENNETT B, 1975, LANCET, V1, P480; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; LAPTOOK AR, 1995, PEDIATR RES, V38, P919, DOI 10.1203/00006450-199512000-00015; Laurent I, 2005, J AM COLL CARDIOL, V46, P432, DOI 10.1016/j.jacc.2005.04.039; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; Leithner C, 2010, NEUROLOGY, V74, P965, DOI 10.1212/WNL.0b013e3181d5a631; Logue ES, 2007, ACAD EMERG MED, V14, P293, DOI 10.1197/j.aem.2006.10.097; Losert H, 2008, RESUSCITATION, V76, P214, DOI 10.1016/j.resuscitation.2007.08.003; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; McCullough JN, 1999, ANN THORAC SURG, V67, P1895, DOI 10.1016/S0003-4975(99)00441-5; Merchant RM, 2009, CIRC-CARDIOVASC QUAL, V2, P421, DOI 10.1161/CIRCOUTCOMES.108.839605; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; NICHOL G, 2008, JAMA-J AM MED ASSOC, V300, P1763; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Nolan JP, 2003, RESUSCITATION, V57, P231, DOI 10.1016/S0300-9572(03)00184-9; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Rea TD, 2004, AM J CARDIOL, V93, P1455, DOI 10.1016/j.amjcard.2004.03.002; REDMOND JM, 1994, J THORAC CARDIOV SUR, V107, P776; Rundgren M, 2006, INTENS CARE MED, V32, P836, DOI 10.1007/s00134-006-0178-6; Schulman SP, 2006, NEUROL CLIN, V24, P41, DOI 10.1016/j.ncl.2005.11.002; Seder DB, 2009, CRIT CARE MED, V37, pS211, DOI 10.1097/CCM.0b013e3181aa5bad; Skulec R, 2008, ACTA ANAESTH SCAND, V52, P188, DOI 10.1111/j.1399-6576.2007.01510.x; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004; Straus SMJM, 2004, J CLIN EPIDEMIOL, V57, P98, DOI 10.1016/S0895-4356(03)00210-5; Sunde K, 2006, RESUSCITATION, V69, P29, DOI 10.1016/j.resuscitation.2005.12.003; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wong CHY, 2008, CURR MED CHEM, V15, P1; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	62	156	166	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1256	1264		10.1056/NEJMct1002402	http://dx.doi.org/10.1056/NEJMct1002402			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860507				2022-12-28	WOS:000282050000009
J	Thompson, DWJ; Wallace, JM; Kennedy, JJ; Jones, PD				Thompson, David W. J.; Wallace, John M.; Kennedy, John J.; Jones, Phil D.			An abrupt drop in Northern Hemisphere sea surface temperature around 1970	NATURE			English	Article							CLIMATE; VARIABILITY; OSCILLATION; ICOADS	The twentieth-century trend in global-mean surface temperature was not monotonic: temperatures rose from the start of the century to the 1940s, fell slightly during the middle part of the century, and rose rapidly from the mid-1970s onwards(1). The warming-cooling-warming pattern of twentieth-century temperatures is typically interpreted as the superposition of long-term warming due to increasing greenhouse gases and either cooling due to a mid-twentieth century increase of sulphate aerosols in the troposphere(2-4), or changes in the climate of the world's oceans that evolve over decades (oscillatory multidecadal variability)(2,5). Loadings of sulphate aerosol in the troposphere are thought to have had a particularly important role in the differences in temperature trends between the Northern and Southern hemispheres during the decades following the Second World War(2-4). Here we show that the hemispheric differences in temperature trends in the middle of the twentieth century stem largely from a rapid drop in Northern Hemisphere sea surface temperatures of about 0.3 degrees C between about 1968 and 1972. The timescale of the drop is shorter than that associated with either tropospheric aerosol loadings or previous characterizations of oscillatory multidecadal variability. The drop is evident in all available historical sea surface temperature data sets, is not traceable to changes in the attendant metadata, and is not linked to any known biases in surface temperature measurements. The drop is not concentrated in any discrete region of the Northern Hemisphere oceans, but its amplitude is largest over the northern North Atlantic.	[Thompson, David W. J.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; [Wallace, John M.] Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; [Kennedy, John J.] Met Off, Hadley Ctr, Exeter EX1 3PB, Devon, England; [Jones, Phil D.] Univ E Anglia, Climat Res Unit, Norwich NR4 7TJ, Norfolk, England	Colorado State University; University of Washington; University of Washington Seattle; Met Office - UK; Hadley Centre; University of East Anglia	Thompson, DWJ (corresponding author), Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA.	davet@atmos.colostate.edu	Thompson, David W J/F-9627-2012; Jones, Philip Douglas/C-8718-2009	Thompson, David W J/0000-0002-5413-4376; Jones, Philip Douglas/0000-0001-5032-5493	National Science Foundation [ATM-0132190, ATM-0613082, ATM-0812802]; Department of Energy and Climate Change and Defra (DECC/Defra) [GA01101]; Div Atmospheric & Geospace Sciences [0812802] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); Department of Energy and Climate Change and Defra (DECC/Defra)(Department for Environment, Food & Rural Affairs (DEFRA)); Div Atmospheric & Geospace Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	D.W.J.T. and J.M.W. are supported by the National Science Foundation Climate Dynamics Program under budget numbers ATM-0132190 and ATM-0613082 (D.W.J.T.) and ATM-0812802 (J.M.W.). J.J.K. is supported by the Joint Department of Energy and Climate Change and Defra Integrated Climate Programme: DECC/Defra (GA01101).	Baines PG, 2007, J CLIMATE, V20, P2721, DOI 10.1175/JCLI4177.1; Brohan P, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006548; Delworth TL, 2000, CLIM DYNAM, V16, P661, DOI 10.1007/s003820000075; DICKSON RR, 1988, PROG OCEANOGR, V20, P103, DOI 10.1016/0079-6611(88)90049-3; Dima M, 2010, J CLIMATE, V23, P5, DOI 10.1175/2009JCLI2867.1; Enfield DB, 2001, GEOPHYS RES LETT, V28, P2077, DOI 10.1029/2000GL012745; Hegerl GC, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P663; Ishii M, 2005, INT J CLIMATOL, V25, P865, DOI 10.1002/joc.1169; Jansen E, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P433; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; Kent EC, 2007, J ATMOS OCEAN TECH, V24, P214, DOI 10.1175/JTECH1949.1; Knight JR, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024233; Rayner NA, 2006, J CLIMATE, V19, P446, DOI 10.1175/JCLI3637.1; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; Smith TM, 2008, J CLIMATE, V21, P2283, DOI 10.1175/2007JCLI2100.1; Stott PA, 2006, J CLIMATE, V19, P3055, DOI 10.1175/JCLI3802.1; Sutton RT, 2005, SCIENCE, V309, P115, DOI 10.1126/science.1109496; Tett SFB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000028; Thompson DWJ, 2008, NATURE, V453, P646, DOI 10.1038/nature06982; Thompson DWJ, 2009, J CLIMATE, V22, P6120, DOI 10.1175/2009JCLI3089.1; Trenberth KE, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026894; Trenberth KE, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P235; Woodruff SD, 2011, INT J CLIMATOL, V31, P951, DOI 10.1002/joc.2103; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P1239, DOI 10.1175/1520-0477(1987)068<1239:ACOADS>2.0.CO;2; Worley SJ, 2005, INT J CLIMATOL, V25, P823, DOI 10.1002/joc.1166; Zhang R, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028683	26	95	99	0	40	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					444	447		10.1038/nature09394	http://dx.doi.org/10.1038/nature09394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864999				2022-12-28	WOS:000282090200039
J	Fleming, TR				Fleming, Thomas R.			Clinical Trials: Discerning Hype From Substance	ANNALS OF INTERNAL MEDICINE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; TO-CHILD TRANSMISSION; PUBLICATION BIAS; PREOPERATIVE IRRADIATION; RANDOMIZED-TRIAL; ADJUVANT THERAPY; RISK-FACTORS; RENAL FLARE; REGRESSION; PREVENTION	The interest in being able to interpret and report results in clinical trials as being favorable is pervasive throughout health care research. This important source of bias needs to be recognized, and approaches need to be implemented to effectively address it. The prespecified primary analyses of the primary and secondary end points of a clinical trial should be clearly specified when disseminating results in press releases and journal publications. There should be a focus on these analyses when interpreting the results. A substantial risk for biased conclusions is produced by conducting exploratory analyses with an intention to establish that the benefit-to-risk profile of the experimental intervention is favorable, rather than to determine whether it is. In exploratory analyses, P values will be misleading when the actual sampling context is not presented to allow for proper interpretation, and the effect sizes of outcomes having particularly favorable estimates are probably overestimated because of "random high" bias. Performing exploratory analyses should be viewed as generating hypotheses that usually require reassessment in prospectively conducted confirmatory trials. Awareness of these issues will meaningfully improve our ability to be guided by substance, not hype, in making evidence-based decisions about medical care.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Fleming, TR (corresponding author), Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA.	tfleming@u.washington.edu			National Institutes of Health, National Institute of Allergy and Infectious Diseases [R37 AI 29168]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029168, R01AI029168] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	By the National Institutes of Health, National Institute of Allergy and Infectious Diseases (R37 AI 29168).	Alarcon-Segovia D, 2003, ARTHRITIS RHEUM, V48, P442, DOI 10.1002/art.10763; Atkinson G, 2010, J PHYSIOL-LONDON, V588, P1023, DOI 10.1113/jphysiol.2010.187526; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; Cardiel MH, 2008, ARTHRITIS RHEUM, V58, P2470, DOI 10.1002/art.23673; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; Cummings SR, 2000, JAMA-J AM MED ASSOC, V283, P1318, DOI 10.1001/jama.283.10.1318; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DONAHUE RMJ, 2007, WILEY ENCY CLIN TRIA; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EMERSON SS, 1989, BIOMETRICS, V45, P905, DOI 10.2307/2531692; Fleming TR, 2008, CLIN TRIALS, V5, P157, DOI 10.1177/1740774508089459; FLEMING TR, 1989, J NATL CANCER I, V81, P188, DOI 10.1093/jnci/81.3.188; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hopewell S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000006.pub3; *INTERMUNE, 2002, INTERMUNE ANN PHAS 3; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1; Laine C, 2007, ANN INTERN MED, V146, P450, DOI 10.7326/0003-4819-146-6-200703200-00154; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; Morton V, 2003, BRIT MED J, V326, P1083, DOI 10.1136/bmj.326.7398.1083; Parmar MKB, 1996, J NATL CANCER I, V88, P1645, DOI 10.1093/jnci/88.22.1645; Peng RD, 2006, AM J EPIDEMIOL, V163, P783, DOI 10.1093/aje/kwj093; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; RIDER WD, 1977, CAN J SURG, V20, P335; ROSWIT B, 1975, CANCER, V35, P1597, DOI 10.1002/1097-0142(197506)35:6<1597::AID-CNCR2820350618>3.0.CO;2-S; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; SMITH AN, 1984, BRIT J SURG, V71, P21; Suissa S, 2008, EUR RESPIR J, V32, P829, DOI 10.1183/09031936.00103008; *US DEP HHS, 1998, INT C HARM EFF GUID	33	46	47	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					400	406		10.7326/0003-4819-153-6-201009210-00008	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855804	Green Accepted			2022-12-28	WOS:000282043100007
J	Rutz, C; Bluff, LA; Reed, N; Troscianko, J; Newton, J; Inger, R; Kacelnik, A; Bearhop, S				Rutz, Christian; Bluff, Lucas A.; Reed, Nicola; Troscianko, Jolyon; Newton, Jason; Inger, Richard; Kacelnik, Alex; Bearhop, Stuart			The Ecological Significance of Tool Use in New Caledonian Crows	SCIENCE			English	Article							STABLE-ISOTOPES; CORVUS-MONEDULOIDES; WILD CHIMPANZEES; NITROGEN; WOOD	Tool use is so rare in the animal kingdom that its evolutionary origins cannot be traced with comparative analyses. Valuable insights can be gained from investigating the ecological context and adaptive significance of tool use under contemporary conditions, but obtaining robust observational data is challenging. We assayed individual-level tool-use dependence in wild New Caledonian crows by analyzing stable isotope profiles of the birds' feathers, blood, and putative food sources. Bayesian diet-mixing models revealed that a substantial amount of the crows' protein and lipid intake comes from prey obtained with stick tools-wood-boring beetle larvae. Our calculations provide estimates of larva-intake rates and show that just a few larvae can satisfy a crow's daily energy requirements, highlighting the substantial rewards available to competent tool users.	[Rutz, Christian; Bluff, Lucas A.; Kacelnik, Alex] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Reed, Nicola; Inger, Richard; Bearhop, Stuart] Univ Exeter, Sch Biosci, Ctr Ecol & Conservat, Penryn TR10 9EZ, Cornwall, England; [Troscianko, Jolyon] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; [Newton, Jason] Scottish Univ Environm Res Ctr, NERC, Life Sci Mass Spectrometry Facil, E Kilbride G75 0QF, Lanark, Scotland	University of Oxford; University of Exeter; University of Birmingham; Scottish Universities Research & Reactor Center; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Rutz, C (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	christian.rutz@zoo.ox.ac.uk	Bearhop, Stuart/G-3105-2012; Newton, Jason/A-9536-2009; Inger, Richard/D-3445-2009	Bearhop, Stuart/0000-0002-5864-0129; Newton, Jason/0000-0001-7594-3693; Inger, Richard/0000-0003-1660-3706; Troscianko, Jolyon/0000-0001-9071-2594; Rutz, Christian/0000-0001-5187-7417	Biotechnology and Biological Sciences Research Council (BBSRC) [BB/C517392/1, BB/G023913/1]; Cogito Foundation [R-120/07]; NERC [NE/F021690/1]; Province Sud (New Caledonia); Rhodes Scholarship; University of Oxford; Linacre College, Oxford; Evolution and Ecology Research Centre, University of New South Wales, Sydney; BBSRC [BB/G023913/1] Funding Source: UKRI; NERC [lsmsf010002] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C517392/1, BB/G023913/1] Funding Source: researchfish; Natural Environment Research Council [NE/F021690/1, lsmsf010002] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cogito Foundation; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Province Sud (New Caledonia); Rhodes Scholarship; University of Oxford; Linacre College, Oxford; Evolution and Ecology Research Centre, University of New South Wales, Sydney; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank N. Barre, S. Blancher, and J. Paimbou-Ayouma for logistical support in New Caledonia. Fieldwork was carried out with permissions from the Centre de Recherches sur la Biologie des Populations d'Oiseaux (France) and the Province Sud (New Caledonia), and was in accordance with the University of Oxford's procedures for local ethical review. We are grateful to M. Collett, I. Owens, B. Sheldon, and three referees for comments on the manuscript. The Edward Grey Institute of Field Ornithology (Oxford) kindly allowed us to dry blood samples in one of their ovens. Supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/C517392/1 to A. K.; BB/G023913/1 to C. R.), the Cogito Foundation (R-120/07 to A. K.), NERC (NE/F021690/1 to S. B.), the Province Sud (New Caledonia; to C. R.), a Rhodes Scholarship (to L. A. B.), the University of Oxford (grant to C. R.), and a Junior Research Fellowship at Linacre College, Oxford (to C. R.). C. R. is a BBSRC David Phillips Fellow and currently holds a Visiting Fellowship at the Evolution and Ecology Research Centre, University of New South Wales, Sydney.	Bearhop S, 2002, PHYSIOL BIOCHEM ZOOL, V75, P451, DOI 10.1086/342800; Bluff LA, 2007, COMP COGN BEHAV REV, V2, P1; Bluff LA, 2010, P ROY SOC B-BIOL SCI, V277, P1377, DOI 10.1098/rspb.2009.1953; Boesch C, 2000, CHIMPANZEES TAI FORE; GOODALL J, 1964, NATURE, V201, P1264, DOI 10.1038/2011264a0; HOBSON KA, 1992, CONDOR, V94, P181, DOI 10.2307/1368807; Hunt G.R., 2006, ACTA ZOOL SINICA, V52, P622; Hunt GR, 2002, EMU, V102, P283, DOI 10.1071/MU01037; Hunt GR, 2000, EMU, V100, P109, DOI 10.1071/MU9852; Inger R, 2008, IBIS, V150, P447, DOI 10.1111/j.1474-919X.2008.00839.x; Kenward B, 2005, NATURE, V433, P121, DOI 10.1038/433121a; Mann J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003868; NISHIDA T, 1982, J HUM EVOL, V11, P73, DOI 10.1016/S0047-2484(82)80033-X; Parnell AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009672; Pearson SF, 2003, OECOLOGIA, V135, P516, DOI 10.1007/s00442-003-1221-8; Rutz C, 2007, SCIENCE, V318, P765, DOI 10.1126/science.1146788; SMITH AC, 1981, EUPHORBIACEAE FLORA, V2; Tebbich S, 2002, ECOL LETT, V5, P656, DOI 10.1046/j.1461-0248.2002.00370.x; Yamakoshi G, 1998, AM J PHYS ANTHROPOL, V106, P283, DOI 10.1002/(SICI)1096-8644(199807)106:3<283::AID-AJPA2>3.0.CO;2-O	19	60	63	0	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	2010	329	5998					1523	1526		10.1126/science.1192053	http://dx.doi.org/10.1126/science.1192053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847272				2022-12-28	WOS:000281869000042
J	Michele, TM; Pinheiro, S; Iyasu, S				Michele, Theresa M.; Pinheiro, Simone; Iyasu, Solomon			The Safety of Tiotropium -- The FDA's Conclusions.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Michele, Theresa M.] US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Pulm Allergy & Rheumatol Prod, Silver Spring, MD USA; [Pinheiro, Simone; Iyasu, Solomon] US FDA, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, Div Epidemiol, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Michele, TM (corresponding author), US FDA, Ctr Drug Evaluat & Res, Off New Drugs, Div Pulm Allergy & Rheumatol Prod, Silver Spring, MD USA.							Food and Drug Administration, 2009, EARL COMM ONG SAF RE; Singh S, 2009, JAMA-J AM MED ASSOC, V301, P1227; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; World Health Organization, WORLD HLTH REP 2008	4	80	84	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1097	1099		10.1056/NEJMp1008502	http://dx.doi.org/10.1056/NEJMp1008502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843240				2022-12-28	WOS:000281795800001
J	Ramin, B; MacPherson, P				Ramin, Brodie; MacPherson, Paul			Easily Missed? Human brucellosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Ramin, Brodie] Univ Ottawa, Ottawa Hosp, Ottawa, ON K1H 8L6, Canada; [MacPherson, Paul] Univ Ottawa, Ottawa Hlth Res Inst, Ottawa Hosp, Div Infect Dis, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Ramin, B (corresponding author), Univ Ottawa, Ottawa Hosp, Ottawa, ON K1H 8L6, Canada.	bramin@ottawahospital.on.ca						Andriopoulos P, 2007, INT J INFECT DIS, V11, P52, DOI 10.1016/j.ijid.2005.10.011; Ariza J, 2007, PLOS MED, V4, P1872, DOI 10.1371/journal.pmed.0040317; BUZGAN T, INT J INFEC IN PRESS; Centers for Disease Control and Prevention, 2007, BRUC; Franco MP, 2007, LANCET INFECT DIS, V7, P775, DOI 10.1016/S1473-3099(07)70286-4; Memish ZA, 2004, J TRAVEL MED, V11, P49, DOI 10.2310/7060.2004.13551; Nicoletti P, 2002, VET MICROBIOL, V90, P5, DOI 10.1016/S0378-1135(02)00209-2; Pappas G, 2006, LANCET INFECT DIS, V6, P91, DOI 10.1016/S1473-3099(06)70382-6; Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570; Vassalos CM, 2009, REV MED MICROBIOL, V20, P63, DOI 10.1097/MRM.0b013e3283344b5a	10	11	16	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 10	2010	341								c4545	10.1136/bmj.c4545	http://dx.doi.org/10.1136/bmj.c4545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649ZL	20833741				2022-12-28	WOS:000281815200007
J	Neoptolemos, JP; Stocken, DD; Bassi, C; Ghaneh, P; Cunningham, D; Goldstein, D; Padbury, R; Moore, MJ; Gallinger, S; Mariette, C; Wente, MN; Izbicki, JR; Friess, H; Lerch, MM; Dervenis, C; Olah, A; Butturini, G; Doi, R; Lind, PA; Smith, D; Valle, JW; Palmer, DH; Buckels, JA; Thompson, J; McKay, CJ; Rawcliffe, CL; Buchler, MW				Neoptolemos, John P.; Stocken, Deborah D.; Bassi, Claudio; Ghaneh, Paula; Cunningham, David; Goldstein, David; Padbury, Robert; Moore, Malcolm J.; Gallinger, Steven; Mariette, Christophe; Wente, Moritz N.; Izbicki, Jakob R.; Friess, Helmut; Lerch, Markus M.; Dervenis, Christos; Olah, Attila; Butturini, Giovanni; Doi, Ryuichiro; Lind, Pehr A.; Smith, David; Valle, Juan W.; Palmer, Daniel H.; Buckels, John A.; Thompson, Joyce; McKay, Colin J.; Rawcliffe, Charlotte L.; Buechler, Markus W.		European Study Grp Pancreatic Canc	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CURATIVE RESECTION; CHEMORADIATION; SURVIVAL; THERAPY; CHEMORADIOTHERAPY; CARCINOMA	Context Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer. Objective To determine whether fluorouracil or gemcitabine is superior in terms of overall survival as adjuvant treatment following resection of pancreatic cancer. Design, Setting, and Patients The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada. Included in ESPAC-3 version 2 were 1088 patients with pancreatic ductal adenocarcinoma who had undergone cancer resection; patients were randomized between July 2000 and January 2007 and underwent at least 2 years of follow-up. Interventions Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, followed by fluorouracil, 425 mg/m(2) intravenous bolus injection given 1-5 days every 28 days) (n=551) or gemcitabine (1000 mg/m2 intravenous infusion once a week for 3 of every 4 weeks) (n=537) for 6 months. Main Outcome Measures Primary outcome measure was overall survival; secondary measures were toxicity, progression-free survival, and quality of life. Results Final analysis was carried out on an intention-to-treat basis after a median of 34.2 (interquartile range, 27.1-43.4) months' follow-up after 753 deaths (69%). Median survival was 23.0 (95% confidence interval [CI], 21.1-25.0) months for patients treated with fluorouracil plus folinic acid and 23.6 (95% CI, 21.4-26.4) months for those treated with gemcitabine (chi(2)(1) = 0.7; P = .39; hazard ratio, 0.94 [95% CI, 0.81-1.08]). Seventy-seven patients (14%) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse events, compared with 40 patients (7.5%) receiving gemcitabine, who had 52 events (P<.001). There were no significant differences in either progression-free survival or global quality-of-life scores between the treatment groups. Conclusion Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival in patients with completely resected pancreatic cancer.	[Neoptolemos, John P.; Ghaneh, Paula; Rawcliffe, Charlotte L.] Univ Liverpool, Liverpool Canc Res UK Canc Trials Unit, Liverpool Canc Res UK Ctr, Liverpool L69 3GA, Merseyside, England; [Stocken, Deborah D.] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England; [Bassi, Claudio; Butturini, Giovanni] Univ Verona, Dept Surg, I-37100 Verona, Italy; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, London, England; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, Surrey, England; [Goldstein, David; Padbury, Robert] Australasian Gastrointestinal Trials Grp, Camperdown, NSW, Australia; [Moore, Malcolm J.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; [Gallinger, Steven] Univ Toronto, Fac Med, Dept Surg, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Mariette, Christophe] Univ Hosp Claude Huriez, Dept Digest & Oncol Surg, Lille, France; [Wente, Moritz N.; Buechler, Markus W.] Heidelberg Univ, Dept Surg, D-6900 Heidelberg, Germany; [Izbicki, Jakob R.] Univ Hamburg, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Friess, Helmut] Tech Univ Munich, Dept Surg, Munich, Germany; [Lerch, Markus M.] Univ Greifswald, Dept Med A, Greifswald, Germany; [Dervenis, Christos] Agia Olga Hosp, Athens, Greece; [Olah, Attila] Petz Aladar Hosp, Gyor, Hungary; [Doi, Ryuichiro] Kyoto Univ, Dept Surg, Kyoto, Japan; [Lind, Pehr A.] Karolinska Stockholm Soder Hosp, Dept Oncol, Stockholm, Sweden; [Smith, David] Clatterbridge Ctr Oncol, Bebington, Merseyside, England; [Valle, Juan W.] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England; [Palmer, Daniel H.; Buckels, John A.] Univ Hosp Birmingham Natl Hlth Serv Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England; [Thompson, Joyce] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; [McKay, Colin J.] Glasgow Royal Infirm, Lister Dept Surg, Glasgow G4 0SF, Lanark, Scotland	University of Liverpool; Cancer Research UK; University of Birmingham; University of Verona; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Universite de Lille - ISITE; CHU Lille; Ruprecht Karls University Heidelberg; University of Hamburg; Technical University of Munich; Ernst Moritz Arndt Universitat Greifswald; General Hospital of N. Ionia Agia Olga; Kyoto University; Karolinska Institutet; Karolinska University Hospital; Clatterbridge Cancer Centre; Christie NHS Foundation Trust; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; University of Glasgow	Neoptolemos, JP (corresponding author), Univ Liverpool, Liverpool Canc Res UK Canc Trials Unit, Canc Res UK Ctr, 5th Floor,UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.	j.p.neoptolemos@liverpool.ac.uk	Gallinger, Steven/E-4575-2013; Valle, Juan W/J-3571-2015; Neoptolemos, John/HGU-7742-2022; Lerch, Markus M./E-2206-2016; Butturini, Giovanni/B-5567-2017; Sutton, Robert/I-3587-2016; Vickers, Michael M/E-4095-2010; Wyld, David/B-8893-2015; Kleeff, Jorg/B-2124-2009	Valle, Juan W/0000-0002-1999-0863; Lerch, Markus M./0000-0002-9643-8263; Butturini, Giovanni/0000-0002-9172-4885; Sutton, Robert/0000-0001-6600-562X; Naredi, Peter/0000-0002-5652-0422; Segersvard, Ralf/0000-0002-5702-7971; SALVIA, Roberto/0000-0002-3514-8473; Dousset, Bertrand/0000-0003-2526-7345; Cunningham, David/0000-0001-5158-1069; Doi, Ryuichiro/0000-0002-7298-2301; Madhusudan, Srinivasan/0000-0002-5354-5480; Wyld, David/0000-0001-9523-4333; Neoptolemos, John/0000-0002-6201-7399; Katsourakis, Anastasios/0000-0002-5151-9449; Kleeff, Jorg/0000-0003-3432-6669; Stocken, Deborah/0000-0001-8031-1738; Spry, Nigel/0000-0001-8659-5065	Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales; Cancer Council of Queensland; Cancer Council of Victoria; Cancer Council of South Australia; National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital; Cancer Research UK [11883, 8968] Funding Source: researchfish; National Institute for Health Research [08/29/02, NF-SI-0507-10154] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales(Cancer Council New South Wales); Cancer Council of Queensland(Cancer Council Queensland); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council of South Australia(Cancer Council South Australia); National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital(Royal Society of New ZealandMarsden Fund (NZ)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was supported by Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria, and South Australia. Dr Cunningham's work is funded in part by the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital.	BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; Berger AC, 2008, J CLIN ONCOL, V26, P5918, DOI 10.1200/JCO.2008.18.6288; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Butturini G, 2008, ARCH SURG-CHICAGO, V143, P75, DOI 10.1001/archsurg.2007.17; Carter R, 2009, INT J CANCER, V124, P2960, DOI 10.1002/ijc.24270; COX DR, 1972, J R STAT SOC B, V187, P220; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kosuge T, 2006, JPN J CLIN ONCOL, V36, P159, DOI 10.1093/jjco/hyi234; *NAT CANC I, 1999, COMM TOX CRIT CTC VE; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Regine WF, 2008, JAMA-J AM MED ASSOC, V299, P1019, DOI 10.1001/jama.299.9.1019; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Smeenk HG, 2007, ANN SURG, V246, P734, DOI 10.1097/SLA.0b013e318156eef3; Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831; Twombly R, 2008, J NATL CANCER I, V100, P1670, DOI 10.1093/jnci/djn428; Ueno H, 2009, BRIT J CANCER, V101, P908, DOI 10.1038/sj.bjc.6605256; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484	24	958	982	0	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1073	1081		10.1001/jama.2010.1275	http://dx.doi.org/10.1001/jama.2010.1275			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823433	Bronze			2022-12-28	WOS:000281559800017
J	Deahl, M				Deahl, Martin			Service personnel move to NHS mental health inpatient care	LANCET			English	Editorial Material									S Staffordshire & Shropshire NHS Fdn Trust, Stafford ST16 3AG, England		Deahl, M (corresponding author), S Staffordshire & Shropshire NHS Fdn Trust, Stafford ST16 3AG, England.	martindeahl@doctors.org.uk						*CAR QUAL COMM, 2009, MENT HLTH SERV AC IN; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; Iversen A, 2005, BRIT J PSYCHIAT, V186, P480, DOI 10.1192/bjp.186.6.480; *MENT HLTH FDN, 2010, MIL MENT HLTH; *NAT ARCH, DEF NEWS INP ME 1118; *NHS CONF, 2009, DEAL DOWNT GREAT EV; PALMER C, 2010, 2010 MOD PATIENT SAT	7	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 20	2010	376	9754					1717	1719		10.1016/S0140-6736(10)61190-7	http://dx.doi.org/10.1016/S0140-6736(10)61190-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690EI	20850177				2022-12-28	WOS:000284984900007
J	Mills, A				Mills, Anne			International donor assistance for health	LANCET			English	Editorial Material							FOREIGN-AID; TRACKING		London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1H 9SH, England	University of London; London School of Hygiene & Tropical Medicine	Mills, A (corresponding author), London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1H 9SH, England.	anne.mills@lshtm.ac.uk		Mills, Anne/0000-0001-9863-9950				Alesina A, 2000, J ECON GROWTH, V5, P33, DOI 10.1023/A:1009874203400; Easterly W, 2008, J ECON PERSPECT, V22, P29, DOI 10.1257/jep.22.2.29; Greco G, 2008, LANCET, V371, P1268, DOI 10.1016/S0140-6736(08)60561-9; *HIGH LEV TASKF IN, 2009, WORK GROUP 1 CONSTR; LEISE BH, 2009, INT HLTH, V1, P141; Llavador HG, 2001, J DEV ECON, V64, P147, DOI 10.1016/S0304-3878(00)00128-0; Patel P, 2011, HEALTH POLICY, V100, P116, DOI 10.1016/j.healthpol.2010.08.007; Patel P, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000090; Pitt C, 2010, LANCET, V376, P1485, DOI 10.1016/S0140-6736(10)61302-5; Powell-Jackson T, 2007, HEALTH POLICY PLANN, V22, P353, DOI 10.1093/heapol/czm024; Powell-Jackson T, 2006, LANCET, V368, P1077, DOI 10.1016/S0140-6736(06)69338-0; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Snow RW, 2010, LANCET, V376, P1409, DOI 10.1016/S0140-6736(10)61340-2; Waage J, 2010, LANCET, V376, P991, DOI 10.1016/S0140-6736(10)61196-8	14	1	1	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 23	2010	376	9750					1368	1370		10.1016/S0140-6736(10)61517-6	http://dx.doi.org/10.1016/S0140-6736(10)61517-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	672ZO	20889200				2022-12-28	WOS:000283627500007
J	Mohapatra, PR; Janmeja, AK				Mohapatra, Prasanta Raghab; Janmeja, Ashok Kumar			Asymptomatic Mediastinal Lipomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mohapatra, Prasanta Raghab; Janmeja, Ashok Kumar] Govt Med Coll & Hosp, Chandigarh, India		Mohapatra, PR (corresponding author), Govt Med Coll & Hosp, Chandigarh, India.		Mohapatra, Prasanta Raghab/ABD-2894-2021	Mohapatra, Prasanta Raghab/0000-0002-6625-2417					0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1265	1265		10.1056/NEJMicm1000714	http://dx.doi.org/10.1056/NEJMicm1000714			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860508				2022-12-28	WOS:000282050000010
J	Zegerman, P; Diffley, JFX				Zegerman, Philip; Diffley, John F. X.			Checkpoint-dependent inhibition of DNA replication initiation by Sld3 and Dbf4 phosphorylation	NATURE			English	Article							S-PHASE CHECKPOINT; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; PROGRESSION; FORKS; ORIGINS; ACTIVATION; KINASES; PATHWAY; STRESS	The initiation of eukaryotic DNA replication is regulated by three protein kinase classes: cyclin-dependent kinases (CDK), Dbf4-dependent kinase (DDK) and the DNA damage checkpoint kinases(1). CDK phosphorylation of two key initiation factors, Sld2 and Sld3, promotes essential interactions with Dpb11 (refs 2-4), whereas DDK acts by phosphorylating subunits of the Mcm2-7 helicase(5). CDK has an additional role in replication by preventing the re-loading of Mcm2-7 during the S, G2 and M phases(6), thus preventing origin re-firing and re-replication. During the G1 phase, both CDK and DDK are downregulated, which allows origin licensing and prevents premature replication initiation(3). Origin firing is also inhibited during the S phase when DNA damage or replication fork stalling activates the checkpoint kinases(7-10). Here we show that, analogous to the situation in the G1 phase, the Saccharomyces cerevisiae checkpoint kinase Rad53 inhibits both CDK- and DDK-dependent pathways, which acts redundantly to block further origin firing. Rad53 acts on DDK directly by phosphorylating Dbf4, whereas the CDK pathway is blocked by Rad53-mediated phosphorylation of the downstream CDK substrate, Sld3. This allows CDK to remain active during the S phase in the presence of DNA damage, which is crucial to prevent re-loading of Mcm2-7 onto origins that have already fired(6). Our results explain how checkpoints regulate origin firing and demonstrate that the slowing of S phase by the 'intra-S checkpoint' is primarily due to the inhibition of origin firing.	[Zegerman, Philip; Diffley, John F. X.] Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Diffley, JFX (corresponding author), Canc Res UK London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	John.Diffley@cancer.org.uk		Diffley, John/0000-0001-5184-7680; Zegerman, Philip/0000-0002-5707-1083	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We are grateful to K. Bousset, M. Godinho Ferreira, D. Quintana and C. Santocanale for early contributions to this project. We thank J. Gannon and T. Hunt for providing recombinant cyclin A/Cdk2, N. O'Reilly and the Peptide Synthesis Facility at the London Research Institute for the peptide arrays, and D. Toczyski for sharing information before publication. Work was supported by Cancer Research UK.	Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Heffernan TP, 2007, J BIOL CHEM, V282, P9458, DOI 10.1074/jbc.M611292200; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kanemaki M, 2006, EMBO J, V25, P1753, DOI 10.1038/sj.emboj.7601063; Kim Y, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-18; Kumagai A, 2010, CELL, V140, P349, DOI 10.1016/j.cell.2009.12.049; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Liu PJ, 2006, J BIOL CHEM, V281, P30631, DOI 10.1074/jbc.M602982200; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Sanchez-Pulido L, 2010, CURR BIOL, V20, pR509, DOI 10.1016/j.cub.2010.05.021; Sansam CL, 2010, GENE DEV, V24, P183, DOI 10.1101/gad.1860310; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Segurado M, 2008, GENE DEV, V22, P1816, DOI 10.1101/gad.477208; Sheu YJ, 2010, NATURE, V463, P113, DOI 10.1038/nature08647; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Tanaka S, 2007, NATURE, V445, P328, DOI 10.1038/nature05465; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Zegerman P, 2007, NATURE, V445, P281, DOI 10.1038/nature05432	30	203	206	1	16	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					474	478		10.1038/nature09373	http://dx.doi.org/10.1038/nature09373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20835227	Green Accepted			2022-12-28	WOS:000282090200046
J	Parker, C; Coupland, C; Hippisley-Cox, J				Parker, Chris; Coupland, Carol; Hippisley-Cox, Julia			Antipsychotic drugs and risk of venous thromboembolism: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							DEEP-VEIN THROMBOSIS; CONTROLLED CASE SERIES; PULMONARY-EMBOLISM; ORAL-CONTRACEPTIVES; OLDER-ADULTS; VALIDATION; DIAGNOSIS; MORTALITY; DEMENTIA	Objective To determine whether antipsychotic drugs are associated with an increased risk of venous thromboembolism, and to examine risks by type of antipsychotic, potency, and dose. Design Population based nested case-control study. Setting The UK QResearch primary care database. Participants Patients (cases) with a first ever record of venous thromboembolism between 1 January 1996 and 1 July 2007; each was matched with up to four controls by age, calendar time, sex, and practice. Main outcome measures Odds ratios for venous thromboembolism associated with antipsychotic drugs adjusted for comorbidity; concomitant drug exposure. Results There were 25 532 eligible cases (15 975 with deep vein thrombosis and 9557 with pulmonary embolism) and 89 491 matched controls from a study population of 7 267 673. Individuals prescribed antipsychotic drugs in the previous 24 months had a 32% greater risk of venous thromboembolism than non-users, despite adjustment for potential risk factors (odds ratio 1.32, 95% confidence interval 1.23 to 1.42). Patients who had started a new drug in the previous three months had about twice the risk (1.97, 1.66 to 2.33). The risk was greater for individuals prescribed atypical rather than conventional drugs (adjusted odds ratio 1.73, 1.37 to 2.17, for atypical drugs; 1.28, 1.18 to 1.38, for conventional drugs). It also tended to be greater for patients prescribed low rather than high potency drugs (1.99, 1.52 to 2.62, for low potency; 1.28, 1.18 to 1.38, for high potency). The estimated number of extra cases of venous thromboembolism per 10 000 patients treated over one year was 4 (3 to 5) in patients of all ages and 10 (7 to 13) for patients aged 65 and over. Conclusions There is an association between use of antipsychotic drugs and risk of venous thromboembolism in a large primary care population. The increased risk was more marked among new users and those prescribed atypical antipsychotic drugs.	[Parker, Chris] Nottinghamshire Cty Teach Primary Care Trust, Nottingham NG15 7JE, England		Hippisley-Cox, J (corresponding author), Nottinghamshire Cty Teach Primary Care Trust, Hucknall Hlth Ctr, Nottingham NG15 7JE, England.	juliahippisleycox@gmail.com	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				Douglas IJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1227; Gill SS, 2007, ANN INTERN MED, V146, P775, DOI 10.7326/0003-4819-146-11-200706050-00006; Hagg S, 2002, CNS DRUGS, V16, P765; Hammersley V, 2002, BRIT J GEN PRACT, V52, P463; Heit JA, 2006, J THROMB THROMBOLYS, V21, P23, DOI 10.1007/s11239-006-5572-y; Heit JA, 1999, ARCH INTERN MED, V159, P445, DOI 10.1001/archinte.159.5.445; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Kyrle PA, 2005, LANCET, V365, P1163, DOI 10.1016/S0140-6736(05)71880-8; Lacut K, 2007, FUND CLIN PHARMACOL, V21, P643, DOI 10.1111/j.1472-8206.2007.00515.x; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; Liperoti R, 2005, ARCH INTERN MED, V165, P2677, DOI 10.1001/archinte.165.22.2677; Majeed Azeem, 2004, Health Stat Q, P5; Meier CR, 1998, BRIT J CLIN PHARMACO, V45, P608, DOI 10.1046/j.1365-2125.1998.00733.x; Mohr DN, 2000, MAYO CLIN PROC, V75, P1249, DOI 10.4065/75.12.1249; Motykie GD, 2000, J THROMB THROMBOLYS, V9, P253, DOI 10.1023/A:1018770712660; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Parkin L, 2003, PHARMACOEPIDEM DR S, V12, P647, DOI 10.1002/pds.841; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Ray JG, 2002, THROMB HAEMOSTASIS, V88, P205; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Rochon PA, 2008, ARCH INTERN MED, V168, P1090, DOI 10.1001/archinte.168.10.1090; Rosendaal FR, 2003, J THROMB HAEMOST, V1, P1371, DOI 10.1046/j.1538-7836.2003.00264.x; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; Walker AM, 1997, EPIDEMIOLOGY, V8, P671, DOI 10.1097/00001648-199710000-00010; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Zornberg GL, 2000, LANCET, V356, P1219, DOI 10.1016/S0140-6736(00)02784-7	29	104	110	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 21	2010	341								c4245	10.1136/bmj.c4245	http://dx.doi.org/10.1136/bmj.c4245			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TJ	20858909	hybrid			2022-12-28	WOS:000282272100003
J	Fiquet, G; Auzende, AL; Siebert, J; Corgne, A; Bureau, H; Ozawa, H; Garbarino, G				Fiquet, G.; Auzende, A. L.; Siebert, J.; Corgne, A.; Bureau, H.; Ozawa, H.; Garbarino, G.			Melting of Peridotite to 140 Gigapascals	SCIENCE			English	Article							HIGH-PRESSURE EXPERIMENTS; LOWER MANTLE; MAGMA OCEAN; BASE; PHASE; DIFFERENTIATION; TEMPERATURE; CONSTRAINTS; PEROVSKITE; BOUNDARY	Interrogating physical processes that occur within the lowermost mantle is a key to understanding Earth's evolution and present-day inner composition. Among such processes, partial melting has been proposed to explain mantle regions with ultralow seismic velocities near the core-mantle boundary, but experimental validation at the appropriate temperature and pressure regimes remains challenging. Using laser-heated diamond anvil cells, we constructed the solidus curve of a natural fertile peridotite between 36 and 140 gigapascals. Melting at core-mantle boundary pressures occurs at 4180 +/- 150 kelvin, which is a value that matches estimated mantle geotherms. Molten regions may therefore exist at the base of the present-day mantle. Melting phase relations and element partitioning data also show that these liquids could host many incompatible elements at the base of the mantle.	[Fiquet, G.; Auzende, A. L.; Siebert, J.; Bureau, H.; Ozawa, H.] Univ Paris Diderot, Univ Paris 06, Inst Mineral & Phys Milieux Condenses, Inst Phys Globe Paris,UMR 7590,CNRS, F-75015 Paris, France; [Corgne, A.] Inst Phys Globe Paris, Inst Mineral & Phys Milieux Condenses, Equipe Mineral, F-75015 Paris, France; [Corgne, A.] Observ Midi Pyrenees, CNRS, UMR 5562, F-31400 Toulouse, France; [Ozawa, H.] Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 1528551, Japan; [Garbarino, G.] European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Tokyo Institute of Technology; European Synchrotron Radiation Facility (ESRF)	Fiquet, G (corresponding author), Univ Paris Diderot, Univ Paris 06, Inst Mineral & Phys Milieux Condenses, Inst Phys Globe Paris,UMR 7590,CNRS, 140 Rue Lourmel, F-75015 Paris, France.	guillame.fiquet@impmc.upmc.fr	Tateno, Haruka/N-7018-2014; Siebert, Julien/A-8336-2014; Fiquet, Guillaume M/H-1219-2011; Garbarino, Gaston L/D-1807-2013; Corgne, Alexandre/C-6115-2009; Fiquet, Guillaume/M-6934-2014; Fiquet, Guillaume/O-7077-2019; Corgne, Alexandre/AAB-5961-2021	Tateno, Haruka/0000-0002-1173-4021; Siebert, Julien/0000-0001-9972-6239; Fiquet, Guillaume/0000-0001-8961-3281; Corgne, Alexandre/0000-0001-9640-6977; AUZENDE, Anne-Line/0000-0001-6943-5588; BUREAU, Helene/0000-0002-5506-5122	Institut National des Sciences de l'Univers (INSU); European Research Council (ERC) under the European Community [207467]; Region Ile de France [I-07-593/R]; INSU-CNRS; Institut de Physique (INP)-CNRS; University Pierre et Marie Curie-Paris 6; French National Research Agency (ANR) [ANR-07-BLAN-0124-01]	Institut National des Sciences de l'Univers (INSU); European Research Council (ERC) under the European Community(European Research Council (ERC)); Region Ile de France(Region Ile-de-France); INSU-CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut de Physique (INP)-CNRS(Centre National de la Recherche Scientifique (CNRS)); University Pierre et Marie Curie-Paris 6; French National Research Agency (ANR)(French National Research Agency (ANR))	We thank L. Hennet and G. Ona Nguema for experimental assistance. X-ray diffraction plots were made using DATLAB software developed by K. Syassen. A. L. A. acknowledges support from Institut National des Sciences de l'Univers (INSU) program "PNP, theme SEDI-TPS," and A. C. acknowledges support from the European Research Council (ERC) under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement 207467. The Focused Ion Beam (FIB) and Scanning Electron Microscope (SEM) facility of the Institut de Mineralogie et de Physique des Milieux Condenses is supported by Region Ile de France grant SESAME 2006 N<SUP>o</SUP>I-07-593/R, INSU-CNRS, Institut de Physique (INP)-CNRS, University Pierre et Marie Curie-Paris 6, and by the French National Research Agency (ANR) grant ANR-07-BLAN-0124-01.	Albarede F, 2002, PHILOS T R SOC A, V360, P2569, DOI 10.1098/rsta.2002.1081; Boehler R, 2000, REV GEOPHYS, V38, P221, DOI 10.1029/1998RG000053; Boyet M, 2005, SCIENCE, V309, P576, DOI 10.1126/science.1113634; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; Corgne A, 2005, GEOCHIM COSMOCHIM AC, V69, P485, DOI 10.1016/j.gca.2004.06.041; Dewaele A, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.144106; Frost DJ, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006302; Frost DJ, 2004, NATURE, V428, P409, DOI 10.1038/nature02413; Garnero EJ, 2008, SCIENCE, V320, P626, DOI 10.1126/science.1148028; Garnero EJ, 1998, J GEOPHYS RES-SOL EA, V103, P12495, DOI 10.1029/98JB00700; Helmberger D, 2005, P NATL ACAD SCI USA, V102, P17257, DOI 10.1073/pnas.0502504102; Hennet L, 2002, REV SCI INSTRUM, V73, P124, DOI 10.1063/1.1426228; Holland KG, 1997, SCIENCE, V275, P1623, DOI 10.1126/science.275.5306.1623; Ito E, 2004, PHYS EARTH PLANET IN, V143, P397, DOI 10.1016/j.pepi.2003.09.016; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Labrosse S, 2007, NATURE, V450, P866, DOI 10.1038/nature06356; Lay T, 2004, PHYS EARTH PLANET IN, V146, P441, DOI 10.1016/j.pepi.2004.04.004; Lee CTA, 2010, NATURE, V463, P930, DOI 10.1038/nature08824; Michaut C, 2007, EARTH PLANET SC LETT, V257, P83, DOI 10.1016/j.epsl.2007.02.019; Ono S, 2005, EARTH PLANET SC LETT, V236, P914, DOI 10.1016/j.epsl.2005.06.001; Ricolleau A, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036759; Rost S, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB004088; Stixrude L, 2009, EARTH PLANET SC LETT, V278, P226, DOI 10.1016/j.epsl.2008.12.006; Tronnes RG, 2002, EARTH PLANET SC LETT, V197, P117, DOI 10.1016/S0012-821X(02)00466-1; Wen LX, 1998, J GEOPHYS RES-SOL EA, V103, P17901, DOI 10.1029/98JB01276; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; WILLIAMS Q, 1990, J GEOPHYS RES-SOLID, V95, P19299, DOI 10.1029/JB095iB12p19299; Zerr A, 1998, SCIENCE, V281, P243, DOI 10.1126/science.281.5374.243; ZERR A, 1994, NATURE, V371, P506, DOI 10.1038/371506a0; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553; ZHANG JZ, 1994, J GEOPHYS RES-SOL EA, V99, P17729, DOI 10.1029/94JB01406	32	242	244	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1516	1518		10.1126/science.1192448	http://dx.doi.org/10.1126/science.1192448			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847269				2022-12-28	WOS:000281869000039
J	Lau, H; Maniscalco, B				Lau, Hakwan; Maniscalco, Brian			Should Confidence Be Trusted?	SCIENCE			English	Editorial Material							PREFRONTAL CORTEX		[Lau, Hakwan; Maniscalco, Brian] Columbia Univ, Dept Psychol, New York, NY 10027 USA; [Lau, Hakwan] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands	Columbia University; Radboud University Nijmegen	Lau, H (corresponding author), Columbia Univ, Dept Psychol, New York, NY 10027 USA.	hakwan@psych.columbia.edu		Maniscalco, Brian/0000-0003-3116-6188				Cleeremans A, 2007, NEURAL NETWORKS, V20, P1032, DOI 10.1016/j.neunet.2007.09.011; DEL CUL A, 2009, BRAIN 9, V132, P2531; Fleming SM, 2010, SCIENCE, V329, P1541, DOI 10.1126/science.1191883; Galvin SJ, 2003, PSYCHON B REV, V10, P843, DOI 10.3758/BF03196546; Kornell N, 2007, PSYCHOL SCI, V18, P64, DOI 10.1111/j.1467-9280.2007.01850.x; Lau H, 2011, WIRES COGN SCI, V2, P1, DOI 10.1002/wcs.93; Lau HC, 2008, PROG BRAIN RES, V168, P35, DOI 10.1016/S0079-6123(07)68004-2; Lau HC, 2006, P NATL ACAD SCI USA, V103, P18763, DOI 10.1073/pnas.0607716103; Macmillan NA., 1991, DETECTION THEORY USE; Metcalfe J, 1996, METACOGNITION KNOWIN; Pierce CS., 1885, MEMOIRS NATL ACAD SC, V3, P73; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Rounis E, 2010, COGN NEUROSCI-UK, V1, P165, DOI 10.1080/17588921003632529; Smith JD, 2009, TRENDS COGN SCI, V13, P389, DOI 10.1016/j.tics.2009.06.009; Weiskrantz L., 1997, CONSCIOUSNESS LOST F	15	9	10	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1478	1479		10.1126/science.1195983	http://dx.doi.org/10.1126/science.1195983			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	650RK	20847258				2022-12-28	WOS:000281869000028
J	Cavazzana-Calvo, M; Payen, E; Negre, O; Wang, G; Hehir, K; Fusil, F; Down, J; Denaro, M; Brady, T; Westerman, K; Cavallesco, R; Gillet-Legrand, B; Caccavelli, L; Sgarra, R; Maouche-Chretien, L; Bernaudin, F; Girot, R; Dorazio, R; Mulder, GJ; Polack, A; Bank, A; Soulier, J; Larghero, J; Kabbara, N; Dalle, B; Gourmel, B; Socie, G; Chretien, S; Cartier, N; Aubourg, P; Fischer, A; Cornetta, K; Galacteros, F; Beuzard, Y; Gluckman, E; Bushman, F; Hacein-Bey-Abina, S; Leboulch, P				Cavazzana-Calvo, Marina; Payen, Emmanuel; Negre, Olivier; Wang, Gary; Hehir, Kathleen; Fusil, Floriane; Down, Julian; Denaro, Maria; Brady, Troy; Westerman, Karen; Cavallesco, Resy; Gillet-Legrand, Beatrix; Caccavelli, Laure; Sgarra, Riccardo; Maouche-Chretien, Leila; Bernaudin, Francoise; Girot, Robert; Dorazio, Ronald; Mulder, Geert-Jan; Polack, Axel; Bank, Arthur; Soulier, Jean; Larghero, Jerome; Kabbara, Nabil; Dalle, Bruno; Gourmel, Bernard; Socie, Gerard; Chretien, Stany; Cartier, Nathalie; Aubourg, Patrick; Fischer, Alain; Cornetta, Kenneth; Galacteros, Frederic; Beuzard, Yves; Gluckman, Eliane; Bushman, Frederick; Hacein-Bey-Abina, Salima; Leboulch, Philippe			Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia	NATURE			English	Article							GLOBIN LENTIVIRAL VECTOR; HEMATOPOIETIC STEM-CELLS; LOCUS-CONTROL REGION; IN-VIVO; EXPRESSION; INSULATOR; DISEASE; SITES; LONG; LOCALIZATION	The beta-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of beta-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound beta(E)/beta(0)-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas(1,2). The beta(E)-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated beta(E)-globin with partial instability(1,2). When this is compounded with a non-functional beta(0) allele, a profound decrease in beta-globin synthesis results, and approximately half of beta(E)/beta(0)-thalassaemia patients are transfusion-dependent(1,2). The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral beta-globin gene transfer, an adult patient with severe beta(E)/beta(0)-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl(-1), of which one-third contains vector-encoded beta-globin. Most of the therapeutic benefit results from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 in erythroid cells with further increased expression of a truncated HMGA2 mRNA insensitive to degradation by let-7 microRNAs. The clonal dominance that accompanies therapeutic efficacy may be coincidental and stochastic or result froma hitherto benign cell expansion caused by dysregulation of the HMGA2 gene in stem/progenitor cells.	[Payen, Emmanuel; Negre, Olivier; Fusil, Floriane; Maouche-Chretien, Leila; Chretien, Stany; Beuzard, Yves; Leboulch, Philippe] CEA, Inst Emerging Dis & Innovat Therapies iMETI, F-92265 Fontenay Aux Roses, France; [Cavazzana-Calvo, Marina; Caccavelli, Laure; Hacein-Bey-Abina, Salima] Grp Hosp Univ Ouest, AP HP, INSERM, Clin Invest Ctr Biotherapy, F-75015 Paris, France; [Cavazzana-Calvo, Marina; Caccavelli, Laure; Fischer, Alain; Hacein-Bey-Abina, Salima] Univ Paris 05, F-75005 Paris, France; [Payen, Emmanuel; Negre, Olivier; Fusil, Floriane; Maouche-Chretien, Leila; Chretien, Stany; Beuzard, Yves; Leboulch, Philippe] Univ Paris 11, CEA, iMETI, F-92265 Fontenay Aux Roses, France; [Payen, Emmanuel; Negre, Olivier; Fusil, Floriane; Maouche-Chretien, Leila; Chretien, Stany; Beuzard, Yves; Leboulch, Philippe] INSERM, U962, F-92265 Fontenay Aux Roses, France; [Payen, Emmanuel; Negre, Olivier; Fusil, Floriane; Soulier, Jean; Larghero, Jerome; Kabbara, Nabil; Dalle, Bruno; Gourmel, Bernard; Socie, Gerard; Beuzard, Yves; Gluckman, Eliane] Univ Paris 07, Hop St Louis, Inst Hematol,AP HP, Dept Hematol Bone Marrow Transplantat & Biochem, F-75010 Paris, France; [Negre, Olivier; Gillet-Legrand, Beatrix] CEA, iMETI, F-92265 Fontenay Aux Roses, France; [Wang, Gary; Brady, Troy; Bushman, Frederick] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; [Hehir, Kathleen; Down, Julian; Denaro, Maria; Westerman, Karen; Dorazio, Ronald; Mulder, Geert-Jan; Polack, Axel] Genetix Pharmaceut, Cambridge, MA 02139 USA; [Westerman, Karen; Cavallesco, Resy; Chretien, Stany; Leboulch, Philippe] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Westerman, Karen; Cavallesco, Resy; Chretien, Stany; Leboulch, Philippe] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Sgarra, Riccardo] Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy; [Bernaudin, Francoise] Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France; [Girot, Robert] Hop Tenon, Dept Biol, F-75020 Paris, France; [Bank, Arthur] Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; [Bank, Arthur] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Cartier, Nathalie; Aubourg, Patrick] Univ Paris 05, INSERM, UMR745, F-75005 Paris, France; [Cornetta, Kenneth] Indiana Univ, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Galacteros, Frederic] Hop Henri Mondor, AP HP, F-94000 Creteil, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Trieste; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Columbia University; Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Indiana University System; Indiana University-Purdue University Indianapolis; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Leboulch, P (corresponding author), CEA, Inst Emerging Dis & Innovat Therapies iMETI, F-92265 Fontenay Aux Roses, France.	pleboulch@rics.bwh.harvard.edu	eliane, Gluckman/AAA-5024-2021; cartier, nathalie/C-3103-2012; Chretien, Stany/M-5166-2018; NEGRE, Olivier/AAA-2027-2022; maouche, leila/E-3887-2017; Payen, Emmanuel/S-5357-2018; Caccavelli, Laure/H-8880-2017	cartier, nathalie/0000-0003-2298-5261; Payen, Emmanuel/0000-0002-1329-2327; Cavazzana, Marina/0000-0002-0264-0891; Gillet-Legrand, Beatrix/0000-0002-1159-5949; Cornetta, Kenneth/0000-0003-1415-3668; Bushman, Frederic/0000-0003-4740-4056; FUSIL, Floriane/0000-0002-1619-7333; CHRETIEN, LEILA/0000-0001-5747-9719; Sgarra, Riccardo/0000-0002-4496-2856; Caccavelli, Laure/0000-0001-6324-2304	NIH [HL090921, AI52845, AI082020]; L'Association francaise contre les myopathies; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI082020, R01AI052845] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); L'Association francaise contre les myopathies(Association Francaise contre les Myopathies); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank S. Cross, C. Ballas and L. Duffy for cGMP vector manufacturing and QC testing; T. Andrieux, D. Bachir, C. Courne, A. Henri, A. Janin, A. Moindrot, M.-E. Noguera and F. Pinto for their experimental or medical contributions; F. Calvo, C. Eaves, K. Humphries, G. Manfioletti, R. Nagel, K. Sii Felice and A. Slanetz for discussions; and C. Berry for statistical analysis. This work was supported by NIH grants HL090921 to P.L. and AI52845 and AI082020 to F.B., and l'Association francaise contre les myopathies.	Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Arumugam PI, 2009, MOL THER, V17, P1929, DOI 10.1038/mt.2009.183; Bottardi S, 2007, CELL CYCLE, V6, P1035, DOI 10.4161/cc.6.9.4208; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Cassani B, 2009, BLOOD, V114, P3546, DOI 10.1182/blood-2009-02-202085; Cattaruzzi G, 2007, NUCLEIC ACIDS RES, V35, P1751, DOI 10.1093/nar/gkl1106; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Cleynen I, 2008, INT J ONCOL, V32, P289; Dykstra B, 2007, CELL STEM CELL, V1, P218, DOI 10.1016/j.stem.2007.05.015; Fucharoen S, 2000, CURR OPIN HEMATOL, V7, P106, DOI 10.1097/00062752-200003000-00006; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hanawa H, 2004, BLOOD, V104, P2281, DOI 10.1182/blood-2004-03-0863; Hanawa H, 2009, MOL THER, V17, P667, DOI 10.1038/mt.2009.1; Hargrove PW, 2008, MOL THER, V16, P525, DOI 10.1038/sj.mt.6300394; Imren S, 2002, P NATL ACAD SCI USA, V99, P14380, DOI 10.1073/pnas.212507099; Inoue N, 2006, BLOOD, V108, P4232, DOI 10.1182/blood-2006-05-025148; Kustikova OS, 2007, BLOOD, V109, P1897, DOI 10.1182/blood-2006-08-044156; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Levasseur DN, 2003, BLOOD, V102, P4312, DOI 10.1182/blood-2003-04-1251; Malik P, 2005, ANN NY ACAD SCI, V1054, P238, DOI 10.1196/annals.1345.030; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; Miccio A, 2008, P NATL ACAD SCI USA, V105, P10547, DOI 10.1073/pnas.0711666105; Olivieri NF, 2008, BRIT J HAEMATOL, V141, P388, DOI 10.1111/j.1365-2141.2008.07126.x; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Sadelain M, 2006, CURR OPIN HEMATOL, V13, P142, DOI 10.1097/01.moh.0000219658.57915.d4; Sieburg HB, 2006, BLOOD, V107, P2311, DOI 10.1182/blood-2005-07-2970; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang GP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn125; Wang GP, 2010, BLOOD, V115, P4356, DOI 10.1182/blood-2009-12-257352	32	943	998	2	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	2010	467	7313					318	U94		10.1038/nature09328	http://dx.doi.org/10.1038/nature09328			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844535	Green Accepted			2022-12-28	WOS:000281824900037
J	Verbeeck, J; Tian, H; Schattschneider, P				Verbeeck, J.; Tian, H.; Schattschneider, P.			Production and application of electron vortex beams	NATURE			English	Article							ANGULAR-MOMENTUM; LASER-BEAMS; DISLOCATIONS; DICHROISM; LIGHT	Vortex beams (also known as beams with a phase singularity) consist of spiralling wavefronts that give rise to angular momentum around the propagation direction. Vortex photon beams are widely used in applications such as optical tweezers to manipulate micrometre-sized particles and in micro-motors to provide angular momentum(1,2), improving channel capacity in optical(3) and radio-wave(4) information transfer, astrophysics(5) and so on(6). Very recently, an experimental realization of vortex beams formed of electrons was demonstrated(7). Here we describe the creation of vortex electron beams, making use of a versatile holographic reconstruction technique in a transmission electron microscope. This technique is a reproducible method of creating vortex electron beams in a conventional electron microscope. We demonstrate how they may be used in electron energy-loss spectroscopy to detect the magnetic state of materials and describe their properties. Our results show that electron vortex beams hold promise for new applications, in particular for analysing and manipulating nanomaterials, and can be easily produced.	[Verbeeck, J.; Tian, H.] Univ Antwerp, B-2020 Antwerp, Belgium; [Schattschneider, P.] Vienna Univ Technol, Inst Solid State Phys, A-1040 Vienna, Austria; [Schattschneider, P.] Vienna Univ Technol, Univ Serv Ctr Electron Microscopy, A-1040 Vienna, Austria	University of Antwerp; Technische Universitat Wien; Technische Universitat Wien	Verbeeck, J (corresponding author), Univ Antwerp, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.	jo.verbeeck@ua.ac.be	Verbeeck, Jo/B-3707-2012; Tian, He/AAS-7880-2020	Verbeeck, Jo/0000-0002-7151-8101; Schattschneider, Peter/0000-0002-1225-7554; Tian, He/0000-0003-2108-3100	European Union [026019]; FWO-Vlaanderen [G.0147.06]	European Union(European Commission); FWO-Vlaanderen(FWO)	J.V. acknowledges financial support from the European Union under the Framework 6 programme under a contract for an Integrated Infrastructure Initiative (reference 026019 ESTEEM). H.T. acknowledges the FWO-Vlaanderen for financial support under contract number G.0147.06.	ALLEN L, 1992, PHYS REV A, V45, P8185, DOI 10.1103/PhysRevA.45.8185; BABIKER M, 1994, PHYS REV LETT, V73, P1239, DOI 10.1103/PhysRevLett.73.1239; Barreiro JT, 2008, NAT PHYS, V4, P282, DOI 10.1038/nphys919; BAZHENOV VY, 1990, JETP LETT+, V52, P429; BEIJERSBERGEN MW, 1993, OPT COMMUN, V96, P123, DOI 10.1016/0030-4018(93)90535-D; Berkhout GCG, 2009, J OPT A-PURE APPL OP, V11, DOI 10.1088/1464-4258/11/9/094021; Beth RA, 1935, PHYS REV, V48, P471, DOI 10.1103/PhysRev.48.471; Bliokh KY, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.190404; Cojoc D, 2006, MICROELECTRON ENG, V83, P1360, DOI 10.1016/j.mee.2006.01.066; Findlay SD, 2007, ULTRAMICROSCOPY, V108, P58, DOI 10.1016/j.ultramic.2007.03.003; Franke-Arnold S, 2008, LASER PHOTONICS REV, V2, P299, DOI 10.1002/lpor.200810007; HE H, 1995, PHYS REV LETT, V75, P826, DOI 10.1103/PhysRevLett.75.826; HECKENBERG NR, 1992, OPT QUANT ELECTRON, V24, pS951, DOI 10.1007/BF01588597; NYE JF, 1974, P ROY SOC LOND A MAT, V336, P165, DOI 10.1098/rspa.1974.0012; O'Neil AT, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.053601; Peele AG, 2002, OPT LETT, V27, P1752, DOI 10.1364/OL.27.001752; Rubino S, 2008, J MATER RES, V23, P2582, DOI 10.1557/JMR.2008.0348; Schattschneider P, 2006, NATURE, V441, P486, DOI 10.1038/nature04778; Schattschneider P, 2010, ULTRAMICROSCOPY, V110, P1038, DOI 10.1016/j.ultramic.2009.11.020; Thide B, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.087701	20	575	594	11	508	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2010	467	7313					301	304		10.1038/nature09366	http://dx.doi.org/10.1038/nature09366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844532				2022-12-28	WOS:000281824900033
J	Chou, R; Dana, T				Chou, Roger; Dana, Tracy			Screening Adults for Bladder Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							FLEXIBLE CYSTOSCOPY; HEMATURIA; MEN; EPIDEMIOLOGY; TUMORS; RISK; MANAGEMENT; COMMUNITY; DIAGNOSIS; IMPACT	Background: Bladder cancer is 1 of the 10 most frequently diagnosed types of cancer. Screening could identify high-grade bladder cancer at earlier stages, when it may be more easily and effectively treated. Purpose: To update the 2004 U.S. Preventive Services Task Force evidence review on screening for bladder cancer in adults in primary care settings. Data Sources: MEDLINE (2002 to December 2009), the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials (through the fourth quarter of 2009), and the CancerLit subsection of PubMed (through March 2010) were searched for studies published in English. Study Selection: Randomized trials and controlled observational studies that directly evaluated screening for bladder cancer in adults, studies on the diagnostic accuracy of screening tests for bladder cancer, and randomized trials and controlled observational studies on clinical outcomes associated with treatment compared with no treatment of screen-detected or superficial bladder cancer. Data Extraction: Details were abstracted about the patient sample, study design, data analysis, follow-up, and results. Quality was assessed by using methods developed by the U.S. Preventive Services Task Force. Data Synthesis: No randomized trials or high-quality controlled observational studies evaluated clinical outcomes associated with screening compared with no screening or treatment of screen-detected bladder cancer compared with no treatment. No study evaluated the sensitivity or specificity of tests for hematuria, urinary cytology, or other urinary biomarkers for bladder cancer in asymptomatic persons without a history of bladder cancer. The positive predictive value of screening is less than 10% in asymptomatic persons, including higher-risk populations. No study evaluated harms associated with treatment of screen-detected bladder cancer compared with no treatment. Limitation: High-quality evidence was not available for any of the key questions. Conclusion: Additional research is needed to determine whether screening of adults for bladder cancer leads to better outcomes compared with no screening.	[Chou, Roger; Dana, Tracy] Oregon Hlth & Sci Univ, Portland, OR 97239 USA	Oregon Health & Science University	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Mailcode BICC,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	chour@ohsu.edu		Chou, Roger/0000-0001-9889-8610	Agency for Healthcare Research and Quality [HHSA-290-2007-10057-I-EPC3]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Grant Support: By the Agency for Healthcare Research and Quality (contract no. HHSA-290-2007-10057-I-EPC3, Task Order Number 3).	Aaronson DS, 2009, BJU INT, V104, P506, DOI 10.1111/j.1464-410X.2009.08417.x; *AM JOINT COMM CAN, 2009, WHAT IS CANC STAG; American Cancer Society, BLADD CANC DET GUID; BRITTON JP, 1989, BRIT MED J, V299, P1010, DOI 10.1136/bmj.299.6706.1010; Burke DM, 2002, BJU INT, V89, P347, DOI 10.1046/j.1464-4096.2001.01899.x; Collado A, 2000, J UROLOGY, V164, P1529, DOI 10.1016/S0022-5347(05)67021-8; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Friedman G D, 1995, J Med Screen, V2, P219; Grossman HB, 2005, JAMA-J AM MED ASSOC, V293, P810, DOI 10.1001/jama.293.7.810; Hall MC, 2007, J UROLOGY, V178, P2314, DOI 10.1016/j.juro.2007.09.003; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hedelin H, 2006, SCAND J UROL NEPHROL, V40, P26, DOI 10.1080/00365590500368807; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8; Kiemeney LALM, 2008, SCAND J UROL NEPHROL, V42, P110, DOI 10.1080/03008880802283755; Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062; Konety BR, 2007, NIH PUBLICATION, V07-5512: 223-79; Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008; Lotan Y, 2009, BJU INT, V103, P1368, DOI 10.1111/j.1464-410X.2009.08360.x; Lotan Y, 2009, J UROLOGY, V182, P52, DOI 10.1016/j.juro.2009.02.142; Madeb R, 2007, EXPERT REV ANTICANC, V7, P981, DOI 10.1586/14737140.7.7.981; Marsh GM, 2003, AM J IND MED, V43, P142, DOI 10.1002/ajim.10166; Messing EM, 2006, CANCER-AM CANCER SOC, V107, P2173, DOI 10.1002/cncr.22224; MESSING EM, 1995, UROLOGY, V45, P387, DOI 10.1016/S0090-4295(99)80006-5; *NAT CANC I, BLADD CANC TREATM GE; National Cancer Institute, SEER CANC STAT REV 1; Olfert SM, 2006, SOUTH MED J, V99, P1256, DOI 10.1097/01.smj.0000247266.10393.72; Pashos CL, 2002, CANCER PRACT, V10, P311, DOI 10.1046/j.1523-5394.2002.106011.x; Ponsky LE, 2001, J UROLOGY, V166, P75, DOI 10.1016/S0022-5347(05)66080-6; *RTI INT U N CAR E, 2004, SCREEN BLADD CANC BR; Stav K, 2004, ISR MED ASSOC J, V6, P474; Steiner H, 2008, BJU INT, V102, P291, DOI 10.1111/j.1464-410X.2008.07596.x; THERIAULT GP, 1990, J OCCUP ENVIRON MED, V32, P869; Turan H, 2006, INT J UROL, V13, P25, DOI 10.1111/j.1442-2042.2006.01219.x; US Cancer Statistics Working Group, 2009, US CANC STAT 1999 20; WHELAN P, 1993, BRIT J UROL, V72, P893, DOI 10.1111/j.1464-410X.1993.tb16292.x; Wu XF, 2008, BJU INT, V102, P1207, DOI 10.1111/j.1464-410X.2008.07961.x; Zippe C, 1999, J UROLOGY, V161, P62, DOI 10.1016/S0022-5347(01)62063-9	38	49	49	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	2010	153	7					461	+		10.7326/0003-4819-153-7-201010050-00009	http://dx.doi.org/10.7326/0003-4819-153-7-201010050-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VG	20921545				2022-12-28	WOS:000282517000005
J	Pollock, AM				Pollock, Allyson M.			Maudsley Debate Should NHS mental health services fear the private sector? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Pollock, Allyson M.] Univ Edinburgh, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Pollock, AM (corresponding author), Univ Edinburgh, Edinburgh EH8 9AG, Midlothian, Scotland.	allyson.pollock@ed.ac.uk		pollock, allyson/0000-0002-7388-3110				Busch SH, 2009, PEDIATRICS S4, V124, pS399, DOI DOI 10.1542/PEDS.2009-1255K; CAO Z, 2006, ANN M EC POP HLTH IN; Donald A, 2001, CULT MED PSYCHIAT, V25, P427, DOI 10.1023/A:1013063216716; HUTCHINS EC, 2009, J BEHAV HLTH SE 1126; Jones K, 2006, MED CARE, V44, P320, DOI 10.1097/01.mlr.0000204302.26073.13; Knapp M, 1999, POLICY POLIT, V27, P25, DOI 10.1332/030557399782019589; Levit KR, 2008, HEALTH AFFAIR, V27, pW513, DOI 10.1377/hlthaff.27.6.w513; Player S., 2001, CRIT SOC POLICY, Vs21, P231; Pollock AM, 2001, BRIT MED J, V322, P964, DOI 10.1136/bmj.322.7292.964; Sterling S, 2010, J AM ACAD CHILD PSY, V49, P637, DOI 10.1016/j.jaac.2010.03.019	10	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2010	341								c5382	10.1136/bmj.c5382	http://dx.doi.org/10.1136/bmj.c5382			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663IZ	20921073				2022-12-28	WOS:000282878600009
J	Keevil, SF; Krestin, GP				Keevil, Stephen F.; Krestin, Gabriel P.			EMF directive still poses a risk to MRI research in Europe	LANCET			English	Editorial Material							EXPOSURE; WORKERS; FUTURE		[Keevil, Stephen F.] Guys & St Thomas NHS Fdn Trust, Dept Med Phys, London SE1 7EH, England; [Keevil, Stephen F.] Kings Coll London, Div Imaging Sci, London WC2R 2LS, England; [Krestin, Gabriel P.] Erasmus MC, Univ Med Ctr, Dept Radiol, Rotterdam, Netherlands	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Erasmus University Rotterdam; Erasmus MC	Keevil, SF (corresponding author), Guys & St Thomas NHS Fdn Trust, Dept Med Phys, London SE1 7EH, England.	stephen.keevil@kcl.ac.uk						Ahlbom A, 1998, HEALTH PHYS, V74, P494; Capstick M, 2008, INVESTIGATION OCCUPA; Crozier S, 2007, J MAGN RESON IMAGING, V26, P1261, DOI 10.1002/jmri.21160; Crozier S, 2007, J MAGN RESON IMAGING, V26, P1236, DOI 10.1002/jmri.21162; *EUR PARL, 2008, OFFICIAL J EUR UNI L, V114; *EUR PARL, 2004, OFFICIAL J EUR UNI L, V159; Hill DLG, 2005, ACAD RADIOL, V12, P1135, DOI 10.1016/j.acra.2005.05.023; International Electrotechnical Commission, 2010, MEDICAL ELECT EQUIPM, V3rd; Keevil SF, 2005, BRIT J RADIOL, V78, P973, DOI 10.1259/bjr/21943393	9	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2010	376	9747					1124	+		10.1016/S0140-6736(10)61387-6	http://dx.doi.org/10.1016/S0140-6736(10)61387-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20822810				2022-12-28	WOS:000282915700007
J	Morris, RT; Monk, BJ				Morris, Robert T.; Monk, Bradley J.			Ovarian cancer: relevant therapy, not timing, is paramount	LANCET			English	Editorial Material							PEGYLATED LIPOSOMAL DOXORUBICIN; TRIAL; CARCINOMA		[Morris, Robert T.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA; [Morris, Robert T.] St John Hosp & Med Ctr, Detroit, MI USA; [Monk, Bradley J.] Creighton Univ, Sch Med, Dept Obstet & Gynecol, St Josephs Hosp & Med Ctr,Div Gynecol Oncol, Phoenix, AZ USA	Wayne State University; St. John Hospital & Medical Center; Creighton University; St. Joseph's Hospital and Medical Center	Morris, RT (corresponding author), Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA.	rmorris@med.wayne.edu						Burger RA, 2007, J CLIN ONCOL, V25, P5165, DOI 10.1200/JCO.2007.11.5345; Chi DS, 2000, GYNECOL ONCOL, V77, P227, DOI 10.1006/gyno.2000.5749; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; Monk BJ, 2010, J CLIN ONCOL, V28, P3107, DOI 10.1200/JCO.2009.25.4037; Monk BJ, 2009, INT J GYNECOL CANCER, V19, pS63, DOI 10.1111/IGC.0b013e3181c104fa; Munkarah A, 2001, GYNECOL ONCOL, V81, P237, DOI 10.1006/gyno.2001.6143; Parmar MKB, 2003, LANCET, V361, P2099; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Pujade-Lauraine E, 2010, J CLIN ONCOL, V28, P3323, DOI 10.1200/JCO.2009.25.7519; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8	10	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1120	1122		10.1016/S0140-6736(10)61515-2	http://dx.doi.org/10.1016/S0140-6736(10)61515-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888975				2022-12-28	WOS:000282915700005
J	Targher, G; Day, CP; Bonora, E				Targher, Giovanni; Day, Christopher P.; Bonora, Enzo			Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GAMMA-GLUTAMYL-TRANSFERASE; TYPE-2 DIABETIC-PATIENTS; HEPATIC INSULIN-RESISTANCE; POPULATION-BASED COHORT; INTIMA-MEDIA THICKNESS; TERM-FOLLOW-UP; METABOLIC SYNDROME; CAROTID ATHEROSCLEROSIS; MORTALITY RISK; ALANINE AMINOTRANSFERASE	Nonalcoholic fatty liver disease encompasses a spectrum of pathologic conditions, ranging from simple steatosis to nonalcoholic steatohepatitis and cirrhosis. The disease has reached epidemic proportions and is the most common cause of chronic liver disease in Western countries.(1-4) Approximately 20 to 30% of adults in the general population in Western countries have nonalcoholic fatty liver disease, and its prevalence increases to 70 to 90% among persons who are obese or have diabetes; such patients are also at increased risk for the development of advanced fibrosis and cirrhosis.(1-4) Recognition of the importance of nonalcoholic fatty liver disease and its strong association with the metabolic syndrome(1-4) has stimulated interest in its putative role in the development and progression of cardiovascular disease.(5) Accumulating evidence suggests that cardiovascular disease dictates the outcome (or outcomes) in patients with nonalcoholic fatty liver disease more frequently and to a greater extent than does the progression of liver disease.(2,4,5) This review focuses on the rapidly expanding body of clinical evidence that supports a strong association between nonalcoholic fatty liver disease and the risk of cardiovascular disease. Because of the link between the two disorders, more careful surveillance of these patients will be needed.	[Targher, Giovanni; Bonora, Enzo] Univ Verona, Dept Med, Sect Endocrinol & Metab, I-37100 Verona, Italy; [Day, Christopher P.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Verona; Newcastle University - UK	Targher, G (corresponding author), Osped Civile, Endocrinol Sect, Piazzale Aristide Stefani 1, I-37126 Verona, Italy.	giovanni.targher@univr.it; c.p.day@ncl.ac.uk	Targher, Giovanni/AAB-9008-2019; Day, Christopher/Z-3305-2019; Bonora, Enzo/AAA-5300-2022	Targher, Giovanni/0000-0002-4325-3900; BONORA, Enzo/0000-0003-1074-5164				Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Badman MK, 2007, GASTROENTEROLOGY, V132, P2103, DOI 10.1053/j.gastro.2007.03.058; Bajaj M, 2003, DIABETES, V52, P1364, DOI 10.2337/diabetes.52.6.1364; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bonora E, 2006, ANN MED, V38, P64, DOI 10.1080/07853890500401234; Brea A, 2005, ARTERIOSCL THROM VAS, V25, P1045, DOI 10.1161/01.ATV.0000160613.57985.18; Browning JD, 2006, HEPATOLOGY, V44, P466, DOI 10.1002/hep.21248; Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984; Day CP, 2006, GASTROENTEROLOGY, V130, P207, DOI 10.1053/j.gastro.2005.11.017; de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009; Dunn W, 2008, AM J GASTROENTEROL, V103, P2263, DOI 10.1111/j.1572-0241.2008.02034.x; Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327; Fracanzani AL, 2008, AM J MED, V121, P72, DOI 10.1016/j.amjmed.2007.08.041; FRASER A, 2008, ARTERIOSCLER THROMB, V28, pE14; Fraser A, 2007, ARTERIOSCL THROM VAS, V27, P2729, DOI 10.1161/ATVBAHA.107.152298; Goessling W, 2008, GASTROENTEROLOGY, V135, P1935, DOI 10.1053/j.gastro.2008.09.018; Goland S, 2006, J CLIN GASTROENTEROL, V40, P949, DOI 10.1097/01.mcg.0000225668.53673.e6; Groll DL, 2005, J CLIN EPIDEMIOL, V58, P595, DOI 10.1016/j.jclinepi.2004.10.018; Hamaguchi M, 2007, WORLD J GASTROENTERO, V13, P1579, DOI 10.3748/wjg.v13.i10.1579; Haring R, 2009, HEPATOLOGY, V50, P1403, DOI 10.1002/hep.23135; Harrison SA, 2007, GUT, V56, P1760, DOI 10.1136/gut.2006.112094; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kim HC, 2009, ATHEROSCLEROSIS, V204, P521, DOI 10.1016/j.atherosclerosis.2008.09.012; Kotronen A, 2008, ARTERIOSCL THROM VAS, V28, P27, DOI 10.1161/ATVBAHA.107.147538; Lautamaki R, 2006, AM J PHYSIOL-ENDOC M, V291, pE282, DOI 10.1152/ajpendo.00604.2005; Lee DS, 2007, ARTERIOSCL THROM VAS, V27, P127, DOI 10.1161/01.ATV.0000251993.20372.40; Lee DH, 2006, EUR HEART J, V27, P2170, DOI 10.1093/eurheartj/ehl086; Lin YC, 2005, WORLD J GASTROENTERO, V11, P4838, DOI 10.3748/wjg.v11.i31.4838; Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180; Marchesini G, 2008, J CLIN ENDOCR METAB, V93, pS74, DOI 10.1210/jc.2008-1399; Matikainen N, 2007, J CLIN ENDOCR METAB, V92, P3052, DOI 10.1210/jc.2007-0187; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; McKimmie RL, 2008, AM J GASTROENTEROL, V103, P3029, DOI 10.1111/j.1572-0241.2008.02188.x; Mirbagheri SA, 2007, LIVER INT, V27, P891, DOI 10.1111/j.1478-3231.2007.01531.x; Musso G, 2003, HEPATOLOGY, V37, P909, DOI 10.1053/jhep.2003.50132; Nissen SE, 2007, NEW ENGL J MED, V357, P100; Perseghin G, 2008, HEPATOLOGY, V47, P51, DOI 10.1002/hep.21983; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; Petersen KF, 2007, P NATL ACAD SCI USA, V104, P12587, DOI 10.1073/pnas.0705408104; Petit JM, 2009, J CLIN ENDOCR METAB, V94, P4103, DOI 10.1210/jc.2009-0541; Rafiq N, 2009, CLIN GASTROENTEROL H, V7, P234, DOI 10.1016/j.cgh.2008.11.005; Ruhl CE, 2009, GASTROENTEROLOGY, V136, P477, DOI 10.1053/j.gastro.2008.10.052; Ruttmann E, 2005, CIRCULATION, V112, P2130, DOI 10.1161/CIRCULATIONAHA.105.552547; Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794; Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Schindhelm RK, 2007, ATHEROSCLEROSIS, V191, P391, DOI 10.1016/j.atherosclerosis.2006.04.006; Schwimmer JB, 2005, HEPATOLOGY, V42, p610A; Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059; Soderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314; Sookoian S, 2008, J HEPATOL, V49, P600, DOI 10.1016/j.jhep.2008.06.012; Stefan N, 2008, ENDOCR REV, V29, P939, DOI 10.1210/er.2008-0009; Targher G, 2008, DIABETOLOGIA, V51, P1947, DOI 10.1007/s00125-008-1135-4; Targher G, 2005, DIABETES, V54, P3541, DOI 10.2337/diabetes.54.12.3541; Targher G, 2004, DIABETES CARE, V27, P2498, DOI 10.2337/diacare.27.10.2498; Targher G, 2008, OBESITY, V16, P1394, DOI 10.1038/oby.2008.64; Targher G, 2007, DIABETES CARE, V30, P2119, DOI 10.2337/dc07-0349; Targher G, 2007, J HEPATOL, V46, P1126, DOI 10.1016/j.jhep.2007.01.021; Targher G, 2007, DIABETES CARE, V30, P1212, DOI 10.2337/dc06-2247; Targher G, 2006, DIABETES CARE, V29, P1325, DOI 10.2337/dc06-0135; Targher G, 2010, J HEPATOL, V53, P713, DOI 10.1016/j.jhep.2010.04.030; Targher G, 2009, SEMIN THROMB HEMOST, V35, P277, DOI 10.1055/s-0029-1222606; Thuy S, 2008, J NUTR, V138, P1452, DOI 10.1093/jn/138.8.1452; Tilg H, 2008, TRENDS ENDOCRIN MET, V19, P371, DOI 10.1016/j.tem.2008.08.005; Villanova N, 2005, HEPATOLOGY, V42, P473, DOI 10.1002/hep.20781; Volzke H, 2005, WORLD J GASTROENTERO, V11, P1848; Wannamethee SG, 2008, ATHEROSCLEROSIS, V201, P168, DOI 10.1016/j.atherosclerosis.2008.01.019; Wieckowska A, 2008, AM J GASTROENTEROL, V103, P1372, DOI 10.1111/j.1572-0241.2007.01774.x; Yoneda M, 2007, J GASTROENTEROL, V42, P573, DOI 10.1007/s00535-007-2060-x; Yun KE, 2009, ATHEROSCLEROSIS, V205, P533, DOI 10.1016/j.atherosclerosis.2008.12.012	71	1329	1382	4	130	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1341	1350		10.1056/NEJMra0912063	http://dx.doi.org/10.1056/NEJMra0912063			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879883				2022-12-28	WOS:000282271500008
J	Weinblatt, ME; Kavanaugh, A; Genovese, MC; Musser, TK; Grossbard, EB; Magilavy, DB				Weinblatt, Michael E.; Kavanaugh, Arthur; Genovese, Mark C.; Musser, Theresa K.; Grossbard, Elliott B.; Magilavy, Daniel B.			An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATION; VALIDATION; THERAPY; TRIAL	Background: Spleen tyrosine kinase (Syk) is an important modulator of immune signaling. The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy. Methods: We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-month, double-blind, placebo-controlled trial. The primary outcome was the American College of Rheumatology (ACR) 20 response (which indicates at least a 20% reduction in the number of both tender and swollen joints and improvement in at least three of five other criteria) at month 6. Results: R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, respectively, vs. 35%; P<0.001 for the comparison of both doses with placebo). It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.007 for the comparison of the 150-mg dose with placebo) and ACR 70 (28% and 14% vs. 10%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.34 for the comparison of the 150-mg dose with placebo). A clinically significant effect was noted by the end of the first week of treatment. Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (6% vs. 1%). R788 was associated with an increase in systolic blood pressure of approximately 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy. Conclusions: In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia. Additional studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis. (Funded by Rigel; ClinicalTrials.gov number, NCT00665925.) N Engl J Med 2010;363:1303-12.	[Weinblatt, Michael E.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Weinblatt, Michael E.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Kavanaugh, Arthur] Univ Calif San Diego, Div Rheumatol, San Diego, CA 92103 USA; [Genovese, Mark C.] Stanford Univ, Div Rheumatol, Palo Alto, CA 94304 USA; [Musser, Theresa K.; Grossbard, Elliott B.; Magilavy, Daniel B.] Rigel, San Francisco, CA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Diego; Stanford University	Weinblatt, ME (corresponding author), Brigham & Womens Hosp, Div Rheumatol & Immunol, 75 Francis St, Boston, MA 02115 USA.	mweinblatt@partners.org			Amgen; Abbott; Bristol-Myers Squibb; Biogen Idec; Crescendo Bioscience; Genentech; Astellas; AstraZeneca; BioAssets Development; CalciMedica; Can-Fite; Celsion; Centocor Ortho Biotech; Cypress Bioscience; Cytokine PharmaSciences; DeNovo Pharmaceuticals; EntreMed; Ensemble Therapeutics; Genentech, GlaxoSmithKline; Hexal-Sandoz; Horizon Pharma; Idera Pharmaceuticals; Johnson Johnson; KaloBios; Lexicon Pharmaceuticals; Lycera; Lilly; Medarex; MedImmune; Merck; Novartis; Pfizer; Phytomedics; Portola Pharmaceuticals; Reata Pharmaceuticals; Rigel; Roche; Sanofi-Aventis; EMD Serono; Teva Pharmaceuticals; Third Rock Ventures; UCB; VBL Therapeutics; Wyeth; Vertex Pharmaceuticals; Xiphos Pharmaceuticals	Amgen(Amgen); Abbott(Abbott Laboratories); Bristol-Myers Squibb(Bristol-Myers Squibb); Biogen Idec(Biogen); Crescendo Bioscience; Genentech(Roche HoldingGenentech); Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); BioAssets Development; CalciMedica; Can-Fite; Celsion; Centocor Ortho Biotech; Cypress Bioscience; Cytokine PharmaSciences; DeNovo Pharmaceuticals; EntreMed; Ensemble Therapeutics; Genentech, GlaxoSmithKline(Roche HoldingGenentechGlaxoSmithKline); Hexal-Sandoz; Horizon Pharma; Idera Pharmaceuticals; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); KaloBios; Lexicon Pharmaceuticals; Lycera; Lilly(Eli Lilly); Medarex; MedImmune(AstraZenecaMedimmune); Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer); Phytomedics; Portola Pharmaceuticals; Reata Pharmaceuticals; Rigel; Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); EMD Serono; Teva Pharmaceuticals(Teva Pharmaceutical Industries); Third Rock Ventures; UCB(UCB Pharma SA); VBL Therapeutics; Wyeth(Wyeth); Vertex Pharmaceuticals(Vertex Pharmaceuticals); Xiphos Pharmaceuticals	Dr. Weinblatt reports receiving grant support from Amgen, Abbott, Bristol-Myers Squibb, Biogen Idec, Crescendo Bioscience, and Genentech, consulting fees from Abbott, Amgen, Astellas, AstraZeneca, Biogen Idec, BioAssets Development, Bristol-Myers Squibb, CalciMedica, Can-Fite, Celsion, Centocor Ortho Biotech, Crescendo Bioscience, Cypress Bioscience, Cytokine PharmaSciences, DeNovo Pharmaceuticals, EntreMed, Ensemble Therapeutics, Genentech, GlaxoSmithKline, Hexal-Sandoz, Horizon Pharma, Idera Pharmaceuticals, Johnson & Johnson, KaloBios, Lexicon Pharmaceuticals, Lycera, Lilly, Medarex, MedImmune, Merck, Novartis, Pfizer, Phytomedics, Portola Pharmaceuticals, Reata Pharmaceuticals, Rigel, Roche, Sanofi-Aventis, EMD Serono, Teva Pharmaceuticals, Third Rock Ventures, UCB, VBL Therapeutics, Wyeth, Vertex Pharmaceuticals, and Xiphos Pharmaceuticals, stock or stock options from Can-Fite, BioAssets Development, Celsion, EntreMed, VBL Therapeutics, and Ensemble Therapeutics, and honoraria for development of education materials from the Chatham Institute, Bioexpertise, and Remedica; Dr. Kavanaugh, receiving grant support from Amgen, Abbott, Bristol-Myers Squibb, Centocor Ortho Biotech, Roche-Genentech, MedImmune, Nuon, Regeneron, Sanofi-Aventis, and UCB and consulting fees from Ardea Biosciences, Roche-Genentech, Novartis, Rigel, and UCB; Dr. Genovese, receiving grant support from Bristol-Myers Squibb, Genentech, KaloBios, Lilly, Novartis, Pfizer, Rigel, and Roche, consulting fees from Amgen, Ardea Biosciences, Astellas, Biogen Idec, Bristol-Myers Squibb, Crescendo Bioscience, Genentech, Horizon Pharma, Johnson & Johnson, Lilly, Novartis, Portola Pharmaceuticals, Rigel, Roche, and Sanofi-Aventis, reimbursement for travel or accommodations from Ardea Biosciences and Lilly, and fees for the development of educational presentations including service on speakers bureaus from Bristol-Myers Squibb and Roche; and Ms. Musser, Dr. Grossbard, and Dr. Magilavy, being full-time employees of and having stock or stock options in Rigel.	ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Braselmann S, 2006, J PHARMACOL EXP THER, V319, P998, DOI 10.1124/jpet.106.109058; Cella D, 2005, J RHEUMATOL, V32, P811; Cha HS, 2006, J PHARMACOL EXP THER, V317, P571, DOI 10.1124/jpet.105.097436; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GENOVESE M, 2009, ARTHRITIS RHEUM S, V60, P3860; Pine PR, 2007, CLIN IMMUNOL, V124, P244, DOI 10.1016/j.clim.2007.03.543; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; van Heeckeren WJ, 2007, J CLIN ONCOL, V25, P2993, DOI 10.1200/JCO.2007.11.5113; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinblatt ME, 2008, ARTHRITIS RHEUM-US, V58, P3309, DOI 10.1002/art.23992	13	307	334	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1303	1312		10.1056/NEJMoa1000500	http://dx.doi.org/10.1056/NEJMoa1000500			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879879				2022-12-28	WOS:000282271500004
J	Liu, WM; Li, YY; Learn, GH; Rudicell, RS; Robertson, JD; Keele, BF; Ndjango, JBN; Sanz, CM; Morgan, DB; Locatelli, S; Gonder, MK; Kranzusch, PJ; Walsh, PD; Delaporte, E; Mpoudi-Ngole, E; Georgiev, AV; Muller, MN; Shaw, GM; Peeters, M; Sharp, PM; Rayner, JC; Hahn, BH				Liu, Weimin; Li, Yingying; Learn, Gerald H.; Rudicell, Rebecca S.; Robertson, Joel D.; Keele, Brandon F.; Ndjango, Jean-Bosco N.; Sanz, Crickette M.; Morgan, David B.; Locatelli, Sabrina; Gonder, Mary K.; Kranzusch, Philip J.; Walsh, Peter D.; Delaporte, Eric; Mpoudi-Ngole, Eitel; Georgiev, Alexander V.; Muller, Martin N.; Shaw, George M.; Peeters, Martine; Sharp, Paul M.; Rayner, Julian C.; Hahn, Beatrice H.			Origin of the human malaria parasite Plasmodium falciparum in gorillas	NATURE			English	Article							INFECTION; HIV-1; DIVERSIFICATION; EVOLUTIONARY; PHYLOGENIES; RESERVOIRS; MULTIPLE; ACID; GENE; APES	Plasmodium falciparum is the most prevalent and lethal of the malaria parasites infecting humans, yet the origin and evolutionary history of this important pathogen remain controversial. Here we develop a single-genome amplification strategy to identify and characterize Plasmodium spp. DNA sequences in faecal samples from wild-living apes. Among nearly 3,000 specimens collected from field sites throughout central Africa, we found Plasmodium infection in chimpanzees (Pan troglodytes) and western gorillas (Gorilla gorilla), but not in eastern gorillas (Gorilla beringei) or bonobos (Pan paniscus). Ape plasmodial infections were highly prevalent, widely distributed and almost always made up of mixed parasite species. Analysis of more than 1,100 mitochondrial, apicoplast and nuclear gene sequences from chimpanzees and gorillas revealed that 99% grouped within one of six host-specific lineages representing distinct Plasmodium species within the subgenus Laverania. One of these from western gorillas comprised parasites that were nearly identical to P. falciparum. In phylogenetic analyses of full-length mitochondrial sequences, human P. falciparum formed a monophyletic lineage within the gorilla parasite radiation. These findings indicate that P. falciparum is of gorilla origin and not of chimpanzee, bonobo or ancient human origin.	[Liu, Weimin; Li, Yingying; Learn, Gerald H.; Robertson, Joel D.; Keele, Brandon F.; Shaw, George M.; Rayner, Julian C.; Hahn, Beatrice H.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Rudicell, Rebecca S.; Shaw, George M.; Hahn, Beatrice H.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Ndjango, Jean-Bosco N.] Univ Kisangani, Dept Ecol & Management Plant & Anim Resources, Fac Sci, Kisangani, DEM REP CONGO; [Sanz, Crickette M.] Washington Univ, Dept Anthropol, St Louis, MO 63130 USA; [Sanz, Crickette M.; Morgan, David B.] Wildlife Conservat Soc, Congo Program, Brazzaville, Rep Congo; [Morgan, David B.] Lester E Fisher Ctr Study & Conservat Apes, Chicago, IL 60614 USA; [Locatelli, Sabrina; Gonder, Mary K.] SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; [Kranzusch, Philip J.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; [Walsh, Peter D.] VaccinApe, Bethesda, MD USA; [Delaporte, Eric; Peeters, Martine] Univ Montpellier I, F-34394 Montpellier, France; [Delaporte, Eric; Peeters, Martine] Inst Rech Dev, F-34394 Montpellier, France; [Mpoudi-Ngole, Eitel] Ctr Rech Med, Inst Rech Med & Etud Plantes Med Prevent Sida Cam, Yaounde, Cameroon; [Georgiev, Alexander V.] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA; [Muller, Martin N.] Univ New Mexico, Dept Anthropol, Albuquerque, NM 87131 USA; [Sharp, Paul M.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland; [Sharp, Paul M.] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh EH9 3JT, Midlothian, Scotland; [Rayner, Julian C.] Wellcome Trust Sanger Inst, Sanger Inst, Malaria Programme, Cambridge CB10 1SA, England	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Albany; Harvard University; Harvard Medical School; Universite de Montpellier; Institut de Recherche pour le Developpement (IRD); Harvard University; University of New Mexico; University of Edinburgh; University of Edinburgh; Wellcome Trust Sanger Institute	Hahn, BH (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.	bhahn@uab.edu	Sharp, Paul M/GPX-1497-2022; Learn, Jerry/E-3356-2012; Locatelli, Sabrina/I-5777-2019; Learn, Gerald H/B-6934-2011; Delaporte, Eric/J-5397-2018; Sharp, Paul M/F-5783-2010; Sharp, Paul/Y-3787-2019; Georgiev, Alexander/C-5061-2015	Sharp, Paul M/0000-0001-9771-543X; Locatelli, Sabrina/0000-0002-1133-0561; Learn, Gerald H/0000-0003-0434-7733; Delaporte, Eric/0000-0002-1822-9853; Sharp, Paul M/0000-0001-9771-543X; Rayner, Julian/0000-0002-9835-1014; Hahn, Beatrice/0000-0002-9400-9887; Georgiev, Alexander/0000-0001-5622-3826	National Institutes of Health [R01 AI50529, R01 AI58715, U19 AI 067854, R03 AI074778, T32 GM008111, T32 AI007245, P30 AI 27767]; BillAMP;Melinda Gates Foundation [37874]; National Science Foundation [0755823]; Agence Nationale de Recherche sur le Sida [12152/12182]; US Fish and Wildlife Service; Arthur L. Greene Fund; Wallace Global Fund; Bristol Myers Freedom to Discover Program; Wellcome Trust; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767, F32AI007767, U19AI067854, R37AI050529, T32AI007245, R01AI050529, R03AI074778, R01AI058715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BillAMP;Melinda Gates Foundation(CGIAR); National Science Foundation(National Science Foundation (NSF)); Agence Nationale de Recherche sur le Sida(ANRSFrench National Research Agency (ANR)); US Fish and Wildlife Service(US Fish & Wildlife Service); Arthur L. Greene Fund; Wallace Global Fund; Bristol Myers Freedom to Discover Program; Wellcome Trust(Wellcome TrustEuropean Commission); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank C. Neel, S. Loul, A. Mebanga, B. Yangda and F. Liegeois for field work in Cameroon; the Cameroonian Ministries of Health, Forestry and Wildlife, and Research for permission to collect samples in Cameroon; the Water and Forest Ministry for permission to collect samples in the Central African Republic; the Ministries of Science and Technology and Forest Economy for permission to collect samples in the Republic of the Congo; the Ministry of Scientific Research and Technology and the Department of Ecology and Management of Plant and Animal Resources of the University of Kisangani for permission to collect samples in the Democratic Republic of the Congo; M. Ndunda, S. Coxe, A. Lokasola, A. Todd and the staff of the World Wildlife Fund in the Central African Republic for logistical support; R. Carter for helpful discussions; M. Salazar, Y. Chen and B. Cochran for technical assistance; and J. White for artwork and manuscript preparation. This work was supported by grants from the National Institutes of Health (R01 AI50529, R01 AI58715, U19 AI 067854, R03 AI074778, T32 GM008111, T32 AI007245, P30 AI 27767), the Bill&Melinda Gates Foundation(37874), the National Science Foundation (0755823), the Agence Nationale de Recherche sur le Sida (12152/12182), the Great Ape Conservation Fund of the US Fish and Wildlife Service, the Arthur L. Greene Fund, the Wallace Global Fund, the Bristol Myers Freedom to Discover Program and the Wellcome Trust. R. S. R. was supported by a Howard Hughes Medical Institute Med-into-Grad Fellowship.	BRAY RS, 1958, AM J TROP MED HYG, V7, P20, DOI 10.4269/ajtmh.1958.7.20; Brown WM, 2004, BIOCHEMISTRY-US, V43, P6219, DOI 10.1021/bi049892w; Carter R, 2002, CLIN MICROBIOL REV, V15, P564, DOI 10.1128/CMR.15.4.564-594.2002; Coluzzi M, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P277; Duval L, 2010, P NATL ACAD SCI USA, V107, P10561, DOI 10.1073/pnas.1005435107; Duval L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005520; ESCALANTE AA, 1995, MOL BIOL EVOL, V12, P616; ESCALANTE AA, 1994, P NATL ACAD SCI USA, V91, P11373, DOI 10.1073/pnas.91.24.11373; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Guindon S, 2009, METHODS MOL BIOL, V537, P113, DOI 10.1007/978-1-59745-251-9_6; Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931; Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531; Keele BF, 2009, J EXP MED, V206, P1117, DOI 10.1084/jem.20082831; Krief S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000765; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Le SQ, 2008, MOL BIOL EVOL, V25, P1307, DOI 10.1093/molbev/msn067; Li Y., 2010, P 17 C RETR OPP INF; Liu WM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000097; Martin MJ, 2005, P NATL ACAD SCI USA, V102, P12819, DOI 10.1073/pnas.0503819102; Neel C, 2010, J VIROL, V84, P1464, DOI 10.1128/JVI.02129-09; Nwakanma DC, 2009, J INFECT DIS, V199, P1567, DOI 10.1086/598856; Ollomo B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000446; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304; Prugnolle F, 2010, P NATL ACAD SCI USA, V107, P1458, DOI 10.1073/pnas.0914440107; Rich SM, 1998, P NATL ACAD SCI USA, V95, P4425, DOI 10.1073/pnas.95.8.4425; Rich SM, 2009, P NATL ACAD SCI USA, V106, P14902, DOI 10.1073/pnas.0907740106; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Su XZ, 2003, MICROBES INFECT, V5, P891, DOI 10.1016/S1286-4579(03)00173-4; Talman AM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-140; VAN HEUVERSWYN F, 2007, VIROLOGY, V368, P155	37	367	371	1	186	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					420	+		10.1038/nature09442	http://dx.doi.org/10.1038/nature09442			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653KO	20864995	Green Accepted			2022-12-28	WOS:000282090200034
J	Clarke, A; Kapustin, V				Clarke, Antony; Kapustin, Vladimir			Hemispheric Aerosol Vertical Profiles: Anthropogenic Impacts on Optical Depth and Cloud Nuclei	SCIENCE			English	Article							CONDENSATION NUCLEI; PARTICLE-PRODUCTION; CARBON-MONOXIDE; TRANSPORT; REMOTE; POLLUTION; ATMOSPHERE; SATELLITE; SOUTHERN; OUTFLOW	Understanding the effect of anthropogenic combustion upon aerosol optical depth (AOD), clouds, and their radiative forcing requires regionally representative aerosol profiles. In this work, we examine more than 1000 vertical profiles from 11 major airborne campaigns in the Pacific hemisphere and confirm that regional enhancements in aerosol light scattering, mass, and number are associated with carbon monoxide from combustion and can exceed values in unperturbed regions by more than one order of magnitude. Related regional increases in a proxy for cloud condensation nuclei (CCN) and AOD imply that direct and indirect aerosol radiative effects are coupled issues linked globally to aged combustion. These profiles constrain the influence of combustion on regional AOD and CCN suitable for challenging climate model performance and informing satellite retrievals.	[Clarke, Antony; Kapustin, Vladimir] Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA	University of Hawaii System	Clarke, A (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA.	tclarke@soest.hawaii.edu			NSF [ATM05-11521]; NASA [657001, 652485]; NASA Earth Science Project Office	NSF(National Science Foundation (NSF)); NASA(National Aeronautics & Space Administration (NASA)); NASA Earth Science Project Office	We thank the NSF Atmospheric Chemistry Program, the NASA Global Tropospheric Experiment, and NASA Earth Science Project Office for the many years of support represented here. We also thank G. Sachse, G. Kok, T. Campos, and J. Podolske for their associated CO measurements and our colleagues S. Howell, C. McNaughton, Y. Shinozuka, J. Zhou, J. Porter, B. Lieneart, M. Litchy, K. Moore, and M. Pinkerton for their dedicated efforts in obtaining these data. This retrospective synthesis is supported under grants NASA 657001 and 652485 and NSF ATM05-11521. This is SOEST contribution number 7948.	Anderson TL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003247; Andreae MO, 2009, ATMOS CHEM PHYS, V9, P543, DOI 10.5194/acp-9-543-2009; Browell EV, 2001, J GEOPHYS RES-ATMOS, V106, P32481, DOI 10.1029/2001JD900001; Carrico CM., 2003, J GEOPHYS RES, V108; CHIN M, 2003, J GEOPHYS RES, V108; CHIN M, 2009, CLIMATE CHANGE SCI P; Clark Michael S, 2007, Psychol Health Med, V12, P18, DOI 10.1080/13548500500429338; Clarke AD, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004378; Clarke AD, 2002, J ATMOS SCI, V59, P363, DOI 10.1175/1520-0469(2002)059<0363:APASPI>2.0.CO;2; Clarke AD, 1999, J GEOPHYS RES-ATMOS, V104, P5735, DOI 10.1029/98JD02303; Clarke AD, 1998, J GEOPHYS RES-ATMOS, V103, P16397, DOI 10.1029/97JD02987; Clarke AD, 2001, J GEOPHYS RES-ATMOS, V106, P32555, DOI 10.1029/2000JD900842; CLARKE AD, 1985, ATMOS ENVIRON, V19, P2045, DOI 10.1016/0004-6981(85)90113-1; Halthore RN, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026302; Heald CL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003507; Hegg DA, 2000, J GEOPHYS RES-ATMOS, V105, P1987, DOI 10.1029/1999JD901037; HOPPEL WA, 1994, J GEOPHYS RES-ATMOS, V99, P14443, DOI 10.1029/94JD00797; Hudson JG, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028850; Hudson JG, 1998, J GEOPHYS RES-ATMOS, V103, P16609, DOI 10.1029/97JD03438; Huebert BJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003550; Jacob DJ, 2003, J GEOPHYS RES-ATMOS, V108, P1, DOI 10.1029/2002JD003276; Jaegle L, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003121; KAPUSTIN VN, 2006, J GEOPHYS RES-OCEANS, V111, P1; MA Y, 2003, J GEOPHYS RES, V108; McNaughton CS, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003528; Moore KG, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD001451; Penner JE, 2006, ATMOS CHEM PHYS, V6, P3391, DOI 10.5194/acp-6-3391-2006; Penner JE, 2002, J ATMOS SCI, V59, P441, DOI 10.1175/1520-0469(2002)059<0441:ACOMAS>2.0.CO;2; RAES F, 1995, J GEOPHYS RES-ATMOS, V100, P2893, DOI 10.1029/94JD02832; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Remer LA, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009661; RYDER ML, 1990, NATURE, V348, P22; Shinozuka Y, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004975; Shinozuka Y, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007918; Staudt AC, 2001, J GEOPHYS RES-ATMOS, V106, P32571, DOI 10.1029/2001JD900078; Stohl A, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007216; TWOMEY S, 1987, BOUND-LAY METEOROL, V41, P335, DOI 10.1007/BF00120449	37	70	73	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1488	1492		10.1126/science.1188838	http://dx.doi.org/10.1126/science.1188838			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847262				2022-12-28	WOS:000281869000032
J	Levy, D; Gozani, O				Levy, Dan; Gozani, Or			Decoding Chromatin Goes High Tech	CELL			English	Editorial Material							LYSINE-4 TRIMETHYLATION; PHD FINGER; HISTONE; RECOGNITION; DOMAIN		[Levy, Dan; Gozani, Or] Stanford Univ, Dept Biol, Stanford, CA 94305 USA	Stanford University	Gozani, O (corresponding author), Stanford Univ, Dept Biol, Stanford, CA 94305 USA.	ogozani@stanford.edu	Levy, Dan/A-3226-2013; Gozani, Or P/I-6157-2013	Levy, Dan/0000-0003-0719-0305; Gozani, Or/0000-0002-1365-4463	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079641] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM079641] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Matthews AGW, 2007, NATURE, V450, P1106, DOI 10.1038/nature06431; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Vezzoli A, 2010, NAT STRUCT MOL BIOL, V17, P617, DOI 10.1038/nsmb.1797; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815	10	6	6	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					844	846		10.1016/j.cell.2010.08.032	http://dx.doi.org/10.1016/j.cell.2010.08.032			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850007	Green Accepted, Bronze			2022-12-28	WOS:000281855000007
J	Zhang, FL; Saha, S; Shabalina, SA; Kashina, A				Zhang, Fangliang; Saha, Sougata; Shabalina, Svetlana A.; Kashina, Anna			Differential Arginylation of Actin Isoforms Is Regulated by Coding Sequence-Dependent Degradation	SCIENCE			English	Article							N-END RULE; RNA-PROTEIN TRANSFERASE; CELLS; IDENTIFICATION; TRANSLATION; RIBOSOME; PATHWAY	The mammalian cytoskeletal proteins beta- and gamma-actin are highly homologous, but only beta-actin is amino-terminally arginylated in vivo, which regulates its function. We examined the metabolic fate of exogenously expressed arginylated and nonarginylated actin isoforms. Arginylated gamma-actin, unlike beta-, was highly unstable and was selectively ubiquitinated and degraded in vivo. This instability was regulated by the differences in the nucleotide coding sequence between the two actin isoforms, which conferred different translation rates. gamma-actin was translated more slowly than beta-actin, and this slower processing resulted in the exposure of a normally hidden lysine residue for ubiquitination, leading to the preferential degradation of gamma-actin upon arginylation. This degradation mechanism, coupled to nucleotide coding sequence, may regulate protein arginylation in vivo.	[Zhang, Fangliang; Saha, Sougata; Kashina, Anna] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Shabalina, Svetlana A.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Kashina, A (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	akashina@vet.upenn.edu	Shabalina, Svetlana/N-8939-2013	Shabalina, Svetlana/0000-0003-2272-7473	NIH [5R01HL084419]; W. W. Smith Charitable Trust; Philip Morris Research Management Group; NIH, National Center for Biotechnology Information; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084419] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); W. W. Smith Charitable Trust; Philip Morris Research Management Group; NIH, National Center for Biotechnology Information(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank R. Dominguez for help with actin structure analysis and the preparation of fig. S15; D. Volgin for helpful suggestions on quantitative polymerase chain reaction; S. Fuchs, Y. Goldman, and J. M. Murray for helpful discussions; and S. Kurosaka for critical reading of the manuscript. This work was supported by NIH grant 5R01HL084419 and W. W. Smith Charitable Trust and Philip Morris Research Management Group awards to A. K. and by the Intramural Research Program of NIH, National Center for Biotechnology Information, to S.A.S.	BALZI E, 1990, J BIOL CHEM, V265, P7464; Condeelis J, 2005, BIOL CELL, V97, P97; ELIAS S, 1990, J BIOL CHEM, V265, P15511; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GROLLMAN AP, 1967, J BIOL CHEM, V242, P3226; Hofer D, 1997, J CELL SCI, V110, P765; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Komar AA, 1999, FEBS LETT, V462, P387, DOI 10.1016/S0014-5793(99)01566-5; Kramer G, 2009, NAT STRUCT MOL BIOL, V16, P589, DOI 10.1038/nsmb.1614; Kwon YT, 1999, MOL CELL BIOL, V19, P182; LOPO AC, 1989, BIOCHEM J, V258, P553, DOI 10.1042/bj2580553; OTEY CA, 1986, J CELL BIOL, V102, P1726, DOI 10.1083/jcb.102.5.1726; OTEY CA, 1987, J CELL BIOCHEM, V34, P113, DOI 10.1002/jcb.240340205; Rai R, 2005, P NATL ACAD SCI USA, V102, P10123, DOI 10.1073/pnas.0504500102; REDMAN KL, 1984, METHOD ENZYMOL, V106, P179; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; VAN DEN ENT F, 2001, NATURE, V413, P39; VANDEKERCKHOVE J, 1978, ARCH INT PHYSIOL BIO, V86, P891; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258	22	139	141	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1534	1537		10.1126/science.1191701	http://dx.doi.org/10.1126/science.1191701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847274	Green Accepted			2022-12-28	WOS:000281869000045
J	Annes, JP; Giovanni, MA; Murray, MF				Annes, Justin P.; Giovanni, Monica A.; Murray, Michael F.			Risks of Presymptomatic Direct-to-Consumer Genetic Testing.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Annes, Justin P.; Giovanni, Monica A.; Murray, Michael F.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Annes, Justin P.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University	Annes, JP (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.			Annes, Justin/0000-0001-8431-3589	NIDDK NIH HHS [K08 DK084206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK084206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andermann A, 2008, B WORLD HEALTH ORGAN, V86, P317, DOI 10.2471/BLT.07.050112; *FOOD DRUG ADM, MED DEV ROCH AMPLICH; Holtzman NA, 1999, CLIN CHEM, V45, P732; WILSON JMG, 1968, WHO CHRON, V22, P473	4	43	45	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1100	1101		10.1056/NEJMp1006029	http://dx.doi.org/10.1056/NEJMp1006029			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649TD	20843242	Green Accepted			2022-12-28	WOS:000281795800003
J	Hurst, JR; Vestbo, J; Anzueto, A; Locantore, N; Mullerova, H; Tal-Singer, R; Miller, B; Lomas, DA; Agusti, A; MacNee, W; Calverley, P; Rennard, S; Wouters, EFM; Wedzicha, JA				Hurst, John R.; Vestbo, Jorgen; Anzueto, Antonio; Locantore, Nicholas; Muellerova, Hana; Tal-Singer, Ruth; Miller, Bruce; Lomas, David A.; Agusti, Alvar; MacNee, William; Calverley, Peter; Rennard, Stephen; Wouters, Emiel F. M.; Wedzicha, Jadwiga A.		Evaluation COPD Longitudinally	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COPD EXACERBATIONS; INFLAMMATORY MARKERS; SYMPTOMS; POPULATION; DIAGNOSIS; COHORT	Background: Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. Methods: We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Results: Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Conclusions: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.) N Engl J Med 2010;363:1128-38.	[Hurst, John R.; Wedzicha, Jadwiga A.] UCL Med Sch, Acad Unit Resp Med, London, England; [Vestbo, Jorgen] Hvidovre Univ Hosp, Copenhagen, Denmark; [Vestbo, Jorgen] Univ Copenhagen, Copenhagen, Denmark; [Vestbo, Jorgen] Univ Manchester, Manchester Acad Hlth Sci Ctr, Sch Translat Med, Resp Res Grp, Manchester, Lancs, England; [Lomas, David A.] Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; [Calverley, Peter] Univ Liverpool, Sch Clin Sci, Dept Resp Med, Liverpool L69 3BX, Merseyside, England; [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Pulm Sect, San Antonio, TX 78229 USA; [Locantore, Nicholas] GlaxoSmithKline Inc, Res Triangle Pk, NC USA; [Muellerova, Hana] GlaxoSmithKline Inc, London, England; [Tal-Singer, Ruth; Miller, Bruce] GlaxoSmithKline Inc, King Of Prussia, PA USA; [Agusti, Alvar] Hosp Clin Barcelona, Inst Torax, CIBER Enfermedades Resp, Barcelona, Spain; [Agusti, Alvar] Fdn Caubet Cimera, Barcelona, Spain; [MacNee, William] Univ Edinburgh, ELEGI Colt Res Labs, Queens Med Res Inst, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Rennard, Stephen] Nebraska Med Ctr, Dept Pulm & Crit Care Med, Omaha, NE USA; [Wouters, Emiel F. M.] Maastricht Univ Med Ctr, Dept Resp Med, Maastricht, Netherlands	University of London; University College London; University of Copenhagen; University of Copenhagen; University of Manchester; University of Cambridge; University of Liverpool; University of Texas System; University of Texas Health San Antonio; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; Atencio Primaria de Menorca; University of Edinburgh; University of Nebraska System; University of Nebraska Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC)	Vestbo, J (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Cardiol & Resp Med 253, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	jorgen.vestbo@manchester.ac.uk	Garcia-Navarro, Alvar Agusti/F-4474-2015; Coxson, Harvey O/A-9861-2017; Tal-Singer, Ruth/AAQ-2925-2021; Wouters, Emiel/ABD-6200-2021; Vestbo, Jorgen/Y-2912-2019	Garcia-Navarro, Alvar Agusti/0000-0003-3271-3788; Coxson, Harvey O/0000-0001-5750-9711; Tal-Singer, Ruth/0000-0002-5275-8062; MacNee, William/0000-0002-3692-1448; Mullerova, Hana/0000-0002-0949-0101; Hurst, John/0000-0002-7246-6040; Vestbo, Jorgen/0000-0001-6355-6362	GlaxoSmithKline; Boehringer Ingelheim; Nycomed; Novartis; AstraZeneca; Chiesi; Talecris; Pfizer; Dey Pharma; Bayer Schering Pharma; Schering-Plough; Almirall; Roche; Esteve; SMB; Biomarck; Centocor; Mpex; Nabi; Otsuka; Able Associates; Adelphi Research; APT Pharma; Britnall; Aradign; CommonHealth; Consult Complete; COPD Forum; Data Monitor; Decision Resource; Defined Health; Dey; Dunn Group; Easton Associates; Equinox; Gerson; Infomed; KOL Connection; M. Pankove; MedaCorp; MDRx Financial; Oriel Therapeutics; Pennside; PharmaVentures; Pharmaxis; PriceWaterhouse; Propagate; Pulmatrix; Reckner Associates; Recruiting Resources; Schlesinger Medical; Scimed; Sudler and Hennessey; TargeGen; Theravance; UBC; Uptake Medical; VantagePoint Management; Respifor; MRC [G0800570, G0500306] Funding Source: UKRI; Medical Research Council [G0500306, G9900991B, G0800570] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); Nycomed; Novartis(Novartis); AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); Talecris; Pfizer(Pfizer); Dey Pharma; Bayer Schering Pharma(Bayer AG); Schering-Plough(Merck & CompanySchering Plough Corporation); Almirall(Almirall); Roche(Roche Holding); Esteve; SMB; Biomarck; Centocor; Mpex; Nabi; Otsuka(Otsuka Pharmaceutical); Able Associates; Adelphi Research; APT Pharma; Britnall; Aradign; CommonHealth; Consult Complete; COPD Forum; Data Monitor; Decision Resource; Defined Health; Dey; Dunn Group; Easton Associates; Equinox; Gerson; Infomed; KOL Connection; M. Pankove; MedaCorp; MDRx Financial; Oriel Therapeutics; Pennside; PharmaVentures; Pharmaxis; PriceWaterhouse; Propagate; Pulmatrix; Reckner Associates; Recruiting Resources; Schlesinger Medical; Scimed; Sudler and Hennessey; TargeGen; Theravance; UBC; Uptake Medical; VantagePoint Management; Respifor; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grants from GlaxoSmithKline (to Drs. Vestbo, Hurst, Anzueto, Lomas, Agusti, MacNee, Calverley, Rennard, Wouters, and Wedzicha).; Dr. Vestbo reports receiving consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Nycomed, Novartis, and AstraZeneca, receiving speaking fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Nycomed, and Talecris, and serving as chairman of the GOLD Scientific Committee; Dr. Hurst, receiving consulting fees from AstraZeneca, speaking fees from AstraZeneca, Chiesi, and Pfizer, and travel support from GlaxoSmithKline and AstraZeneca; Dr. Anzueto, consulting fees, speaking fees, and grants from GlaxoSmithKline and consulting fees and speaking fees from Dey Pharma, Pfizer, Boehringer Ingelheim, Bayer Schering Pharma, and Schering-Plough; Dr. Agusti, consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Nycomed, and Roche, speaking fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, GlaxoSmithKline, Novartis, and Nycomed, grants from Almirall, GlaxoSmithKline, and Nycomed, and travel support from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Nycomed; Dr. MacNee, consulting fees from Boehringer Ingelheim, SMB, GlaxoSmithKline, Pfizer, and AstraZeneca and speaking fees from GlaxoSmithKline and AstraZeneca; Dr. Calverley, receiving consulting fees from GlaxoSmithKline, AstraZeneca, Nycomed, and Boehringer Ingelheim, speaking fees from GlaxoSmithKline and Nycomed, and travel support from Boehringer Ingelheim and providing expert testimony for Forest and Nycomed; Dr. Rennard, receiving grants from AstraZeneca, Biomarck, Centocor, Mpex, Nabi, Novartis, and Otsuka, consulting or speaking fees from Able Associates, Adelphi Research, APT Pharma and Britnall, Aradign, AstraZeneca, Boehringer Ingelheim, Chiesi, CommonHealth, Consult Complete, COPD Forum, Data Monitor, Decision Resource, Defined Health, Dey, Dunn Group, Easton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL Connection, M. Pankove, MedaCorp, MDRx Financial, Mpex, Oriel Therapeutics, Otsuka, Pennside, PharmaVentures, Pharmaxis, PriceWaterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, Scimed, Sudler and Hennessey, TargeGen, Theravance, UBC, Uptake Medical, and VantagePoint Management; Dr. Wouters, consulting fees from GlaxoSmithKline and Nycomed, speaking fees from GlaxoSmithKline, Nycomed, and AstraZeneca, and grants from GlaxoSmithKline and AstraZeneca; and Dr. Wedzicha, speaking fees from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Chiesi, and Respifor, grants from GlaxoSmithKline, AstraZeneca, Chiesi, and Novartis, and travel reimbursements from Boehringer Ingelheim. Drs. Mullerova, Locantore, Miller, and Tal-Singer are employees of GlaxoSmithKline and report owning stocks and shares of GlaxoSmithKline.	Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; Burgel PR, 2009, CHEST, V135, P975, DOI 10.1378/chest.08-2062; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Cella D, 2002, CANCER-AM CANCER SOC, V94, P528, DOI 10.1002/cncr.10245; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P45; Donaldson GC, 2008, THORAX, V63, P753; Donaldson GC, 2006, THORAX, V61, P164, DOI 10.1136/thx.2005.041806; Donaldson GC, 2005, AM J RESP CRIT CARE, V171, P446, DOI 10.1164/rccm.200408-1054OC; Foreman MG, 2007, EUR RESPIR J, V30, P1124, DOI 10.1183/09031936.00009307; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN; HAN MK, 2010, AM J RESP CRIT  0602; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Langsetmo L, 2008, AM J RESP CRIT CARE, V177, P396, DOI 10.1164/rccm.200708-1290OC; Meguro M, 2007, CHEST, V132, P456, DOI 10.1378/chest.06-0702; Miravitlles M, 2000, RESPIRATION, V67, P495, DOI 10.1159/000067462; RADLOFF LS, 1977, J APPL PSYCHOL MEASU, V1, P385, DOI DOI 10.1177/014662167700100306; Rascon-Aguilar IE, 2006, CHEST, V130, P1096, DOI 10.1378/chest.130.4.1096; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Shahab L, 2006, THORAX, V61, P1043, DOI 10.1136/thx.2006.064410; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Sullivan SD, 2000, CHEST, V117, P5; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707; Wedzicha JA, 2007, LANCET, V370, P786, DOI 10.1016/S0140-6736(07)61382-8	27	1849	1941	3	149	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1128	1138		10.1056/NEJMoa0909883	http://dx.doi.org/10.1056/NEJMoa0909883			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843247	Green Submitted, Green Published			2022-12-28	WOS:000281795800007
J	Roffi, M				Roffi, Marco			Is there a role for revascularisation in asymptomatic carotid stenosis? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							ARTERY STENOSIS; ENDARTERECTOMY; STROKE; TRIAL; RISK; ANGIOPLASTY; GUIDELINES; MANAGEMENT		[Roffi, Marco] Univ Hosp Geneva, Div Cardiol, Intervent Cardiol Unit, CH-1211 Geneva, Switzerland	University of Geneva	Roffi, M (corresponding author), Univ Hosp Geneva, Div Cardiol, Intervent Cardiol Unit, Rue Micheli-du-Crest 24, CH-1211 Geneva, Switzerland.	Marco.Roffi@hcuge.ch	Spence, J. David/K-6396-2013	Spence, J. David/0000-0001-7478-1098				Aichner FT, 2009, EUR J NEUROL, V16, P902, DOI 10.1111/j.1468-1331.2009.02614.x; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Chaturvedi S, 2005, NEUROLOGY, V65, P794, DOI 10.1212/01.wnl.0000176036.07558.82; Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0; Halliday A, 2004, LANCET, V363, P1491; Hobson RW, 2008, J VASC SURG, V48, P480, DOI 10.1016/j.jvs.2008.05.036; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Kakkos SK, 2009, J VASC SURG, V49, P902, DOI 10.1016/j.jvs.2008.10.059; Liapis CD, 2009, EUR J VASC ENDOVASC, V37, pS1, DOI 10.1016/j.ejvs.2008.11.006; Markus HS, 2010, LANCET NEUROL, V9, P663, DOI 10.1016/S1474-4422(10)70120-4; Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9; Nicolaides AN, 2005, EUR J VASC ENDOVASC, V30, P275, DOI 10.1016/j.ejvs.2005.04.031; Sabeti S, 2007, STROKE, V38, P2887, DOI 10.1161/STROKEAHA.107.488387; 2008, CEREBROVASC DIS, V25, P457	14	6	7	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 15	2010	341								c4898	10.1136/bmj.c4898	http://dx.doi.org/10.1136/bmj.c4898			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653LV	20843932				2022-12-28	WOS:000282093800008
J	Shortliffe, EH				Shortliffe, Edward H.			Biomedical Informatics in the Education of Physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Shortliffe, Edward H.] Amer Med Informat Assoc, Bethesda, MD 20814 USA; [Shortliffe, Edward H.] UTHealth, Sch Biomed Informat, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston	Shortliffe, EH (corresponding author), Amer Med Informat Assoc, 4915 St Elmo Ave,Suite 401, Bethesda, MD 20814 USA.	shortliffe@amia.org	Tao, Youyou/D-2367-2014					*AM MED INF ASS, DEGR PROGR CERT PROG; Detmer DE, 2010, APPL CLIN INFORM, V1, P11, DOI 10.4338/ACI-2009-11-R-0016; GREENES R A, 1990, Journal of the American Medical Association, V263, P1114, DOI 10.1001/jama.263.8.1114; McNeil BJ, 2005, INT J MED INFORM, V74, P1021, DOI 10.1016/j.ijmedinf.2005.05.010; National Institutes of Health, CLIN TRANSL SCI AW; Patel VL, 2009, J BIOMED INFORM, V42, P176, DOI 10.1016/j.jbi.2008.12.002; Stead WW, 2011, ACAD MED, V86, P429, DOI 10.1097/ACM.0b013e3181f41e8c; *U AR COLL MED CUR, PHOEN; 1984, J MED ED 2, V59, P1; AMIA ACAD FORUM BIOM	10	28	29	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1227	1228		10.1001/jama.2010.1262	http://dx.doi.org/10.1001/jama.2010.1262			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841537				2022-12-28	WOS:000281770600016
J	Coovadia, A; Abrams, EJ; Stehlau, R; Meyers, T; Martens, L; Sherman, G; Hunt, G; Hu, CC; Tsai, WY; Morris, L; Kuhn, L				Coovadia, Ashraf; Abrams, Elaine J.; Stehlau, Renate; Meyers, Tammy; Martens, Leigh; Sherman, Gayle; Hunt, Gillian; Hu, Chih-Chi; Tsai, Wei-Yann; Morris, Lynn; Kuhn, Louise			Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor-Based Viral Suppression A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SINGLE-DOSE NEVIRAPINE; REVERSE-TRANSCRIPTASE INHIBITOR; IMMUNODEFICIENCY-VIRUS-INFECTION; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; SUBSTITUTION; METAANALYSIS; RESISTANCE; EFAVIRENZ; ADHERENCE	Context Protease inhibitor (PI)-based therapy is recommended for infants infected with human immunodeficiency virus (HIV) who were exposed to nevirapine for prevention of mother-to-child HIV transmission. However, there are limitations of continuing PI-based therapy indefinitely and reuse of nevirapine has many advantages. Objective To test whether nevirapine-exposed infants who initially achieve viral suppression with PI-based therapy can maintain viral suppression when switched to nevirapine-based therapy. Design, Setting, and Patients Randomized trial conducted between April 2005 and May 2009 at a hospital in Johannesburg, South Africa, among 195 children who achieved viral suppression less than 400 copies/mL for 3 or more months from a cohort of 323 nevirapine exposed children who initiated PI-based therapy before 24 months of age. Interventions Control group children continued to receive ritonavir-boosted lopinavir, stavudine, and lamivudine (n=99). Switch group children substituted nevirapine for ritonavir-boosted lopinavir (n=96). Main Outcome Measures Children were followed up for 52 weeks after randomization. Plasma HIV-1 RNA of greater than 50 copies/mL was the primary end point. Confirmed viremia greater than 1000 copies/mL was used as a criterion to consider regimen changes for children in either group (safety end point). Results Plasma viremia greater than 50 copies/mL occurred less frequently in the switch group (Kaplan-Meier probability, 0.438; 95% CI, 0.334-0.537) than in the control group (0.576; 95% CI, 0.470-0.668) (P=.02). Confirmed viremia greater than 1000 copies/mL occurred more frequently in the switch group (0.201; 95% CI, 0.125-0.289) than in the control group (0.022; 95% CI, 0.004-0.069) (P<.001). CD4 cell response was better in the switch group (median CD4 percentage at 52 weeks, 34.7) vs the control group (CD4 percentage, 31.3) (P=.004). Older age (relative hazard [RH], 1.71; 95% CI, 1.08-2.72) was associated with viremia greater than 50 copies/mL in the control group. Inadequate adherence (RH, 4.14; 95% CI, 1.18-14.57) and drug resistance (RH, 4.04; 95% CI, 1.40-11.65) before treatment were associated with confirmed viremia greater than 1000 copies/mL in the switch group. Conclusion Among HIV-infected children previously exposed to nevirapine, switching to nevirapine-based therapy after achieving viral suppression with a ritonavir-boosted lopinavir regimen resulted in lower rates of viremia greater than 50 copies/mL than maintaining the primary ritonavir-boosted lopinavir regimen.	[Kuhn, Louise] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Coovadia, Ashraf; Stehlau, Renate; Martens, Leigh] Univ Witwatersrand, Rahima Moosa Mother & Child Hosp, Empilweni Serv & Res Unit, Johannesburg, South Africa; [Meyers, Tammy] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Harriet Shezi Clin, Johannesburg, South Africa; [Sherman, Gayle] Univ Witwatersrand, Dept Mol Med & Haematol, Johannesburg, South Africa; [Abrams, Elaine J.] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, New York, NY 10032 USA; [Hu, Chih-Chi; Tsai, Wei-Yann] Columbia Univ, Dept Biostat, New York, NY 10032 USA; [Abrams, Elaine J.; Kuhn, Louise] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA; [Kuhn, Louise] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Sherman, Gayle] Natl Hlth Lab Serv, Johannesburg, South Africa; [Hunt, Gillian; Morris, Lynn] Natl Inst Communicable Dis, AIDS Res Unit, Johannesburg, South Africa	Columbia University; University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; Columbia University; Columbia University; Columbia University; Columbia University; National Health Laboratory Service; National Institute for Communicable Diseases (NICD)	Kuhn, L (corresponding author), Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.	lk24@columbia.edu	Morris, Lynn/V-3941-2018	Morris, Lynn/0000-0003-3961-7828	National Institute of Child Health and Human Development [HD 47177]; Secure the Future Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047177] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Secure the Future Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The study was supported by grants from the National Institute of Child Health and Human Development (HD 47177) and Secure the Future Foundation.	Arrive E, 2007, INT J EPIDEMIOL, V36, P1009, DOI 10.1093/ije/dym104; Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526; Bitnun A, 2003, AIDS, V17, P1319, DOI 10.1097/00002030-200306130-00006; Bucher HC, 2003, AIDS, V17, P2451, DOI 10.1097/00002030-200311210-00007; Chi BH, 2007, AIDS, V21, P957, DOI 10.1097/QAD.0b013e32810996b2; Collett D, 1994, MODELLING SURVIVAL D; Coovadia A, 2009, CLIN INFECT DIS, V48, P462, DOI 10.1086/596486; Davies MA, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-34; Ena J, 2008, HIV MED, V9, P747, DOI 10.1111/j.1468-1293.2008.00627.x; Farley J, 2005, JAIDS-J ACQ IMM DEF, V38, P480, DOI 10.1097/01.qai.0000139397.30612.96; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Gonzalez-Tome MI, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-144; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; HUNT G, 2009, 16 C RETR OPP INF FE; Kuhn L, 2009, JAIDS-J ACQ IMM DEF, V52, P132, DOI 10.1097/QAI.0b013e3181ab6d5e; LOCKMAN S, 2009, 16 C RETR OPP INF FE; Lockman S, 2007, NEW ENGL J MED, V356, P135, DOI 10.1056/NEJMoa062876; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; Martinson NA, 2007, JAIDS-J ACQ IMM DEF, V44, P148, DOI 10.1097/QAI.0b013e31802b920e; McComsey G, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e275; McComsey GA, 2004, AIDS, V18, P1753, DOI 10.1097/00002030-200409030-00004; MOORTHY A, 2010, 17 C RETR OPP INF FE; Murphy R L, 2002, HIV Med, V3, P146, DOI 10.1046/j.1468-1293.2002.00102.x; Negredo E, 2002, CLIN INFECT DIS, V34, P504, DOI 10.1086/324629; Negredo E, 2006, J ANTIMICROB CHEMOTH, V58, P235, DOI 10.1093/jac/dkl191; Palumbo P, 2009, 5 INT AIDS SOC C HIV; Pillay V, 2008, ANTIVIR THER, V13, P101; Raffi F, 2000, CLIN INFECT DIS, V31, P1274, DOI 10.1086/317424; Reitz C, 2010, J INFECT DIS, V201, P1121, DOI 10.1086/651454; Ren Y, 2008, JAIDS-J ACQ IMM DEF, V47, P566, DOI 10.1097/QAI.0b013e3181642257; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; *S AFR DEP HLTH, 2004, NAT ANT TREATM GUID; Simoni JM, 2007, PEDIATRICS, V119, pE1371, DOI 10.1542/peds.2006-1232; Smith K, 2009, AIDS, V23, P1097, DOI 10.1097/QAD.0b013e32832afefc; Verweel G, 2007, ANTIVIR THER, V12, P453; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Working Group on Antiretroviral Therapy and Medical Management of HIV-infected children, 2010, GUID US ANT AG PED H; World Health Organization, ANT THER HIV INF INF; . World Health Organization, CHILD GROWTH STAND W	39	67	68	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1082	1090		10.1001/jama.2010.1278	http://dx.doi.org/10.1001/jama.2010.1278			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823434	Green Accepted, Bronze			2022-12-28	WOS:000281559800018
J	Shang, XM; Zhang, MC				Shang, Xumin; Zhang, Mingchang			Body and organ donation in Wuhan, China	LANCET			English	Editorial Material									[Shang, Xumin; Zhang, Mingchang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ophthalmol, Wuhan 430022, Peoples R China; [Shang, Xumin] Hubei Prov Red Cross, Wuhan, Peoples R China	Huazhong University of Science & Technology	Zhang, MC (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ophthalmol, Wuhan 430022, Peoples R China.	mingchangzhang@hotmail.com		Zhang, Ming-Chang/0000-0003-1886-8572				[Anonymous], 2010, 10 PROVINCES CITIES; *RED CROSS SOC CHI, 2010, DOC WORK CONV 2010; *WUH CIT RED CROSS, 2007, INTR BOD DON WUH CIT; Zhang Ming-Chang, 2007, Zhonghua Yan Ke Za Zhi, V43, P289; 2010, CHANGJIANG DAIL 0131	5	30	31	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1033	1034		10.1016/S0140-6736(10)60937-3	http://dx.doi.org/10.1016/S0140-6736(10)60937-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	657KM	20870080				2022-12-28	WOS:000282411600007
J	Vossel, KA; Zhang, K; Brodbeck, J; Daub, AC; Sharma, P; Finkbeiner, S; Cui, BX; Mucke, L				Vossel, Keith A.; Zhang, Kai; Brodbeck, Jens; Daub, Aaron C.; Sharma, Punita; Finkbeiner, Steven; Cui, Bianxiao; Mucke, Lennart			Tau Reduction Prevents A beta-Induced Defects in Axonal Transport	SCIENCE			English	Article							ALZHEIMERS-DISEASE; AMYLOID-BETA; HIPPOCAMPAL-NEURONS; MOUSE MODEL; OVEREXPRESSION; TRAFFICKING; MECHANISM	Amyloid-beta (A beta) peptides, derived from the amyloid precursor protein, and the microtubule-associated protein tau are key pathogenic factors in Alzheimer's disease (AD). How exactly they impair cognitive functions is unknown. We assessed the effects of A beta and tau on axonal transport of mitochondria and the neurotrophin receptor TrkA, cargoes that are critical for neuronal function and survival and whose distributions are altered in AD. A beta oligomers rapidly inhibited axonal transport of these cargoes in wild-type neurons. Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, A beta requires tau to impair axonal transport, and tau reduction protects against A beta-induced axonal transport defects.	[Vossel, Keith A.; Brodbeck, Jens; Daub, Aaron C.; Sharma, Punita; Finkbeiner, Steven; Mucke, Lennart] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Vossel, Keith A.; Finkbeiner, Steven; Mucke, Lennart] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Zhang, Kai; Cui, Bianxiao] Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Stanford University	Vossel, KA (corresponding author), Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	kvossel@gladstone.ucsf.edu; lmucke@gladstone.ucsf.edu	Zhang, Kai/ABD-1498-2021; Zhang, Kai/G-6437-2010; Brodbeck, Jens/AAB-9275-2020	Zhang, Kai/0000-0002-6687-4558; Zhang, Kai/0000-0002-6687-4558; 	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041787, R00NS057906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011385, R37AG011385] Funding Source: NIH RePORTER; NCRR NIH HHS [C06 RR018928] Funding Source: Medline; NIA NIH HHS [AG011385, R01 AG011385, R01 AG011385-07, R37 AG011385] Funding Source: Medline; NINDS NIH HHS [R00 NS057906, NS057906, R01 NS041787-09, R00 NS057906-05, K99 NS057906, NS041787, R01 NS041787] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Dawson HN, 2010, NEUROSCIENCE, V169, P516, DOI 10.1016/j.neuroscience.2010.04.037; Decker H, 2010, J NEUROSCI, V30, P9166, DOI 10.1523/JNEUROSCI.1074-10.2010; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hiruma H, 2003, J NEUROSCI, V23, P8967; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Pigino G, 2009, P NATL ACAD SCI USA, V106, P5907, DOI 10.1073/pnas.0901229106; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rui YF, 2006, J NEUROSCI, V26, P10480, DOI 10.1523/JNEUROSCI.3231-06.2006; Schindowski K, 2008, GENES BRAIN BEHAV, V7, P43, DOI 10.1111/j.1601-183X.2007.00378.x; Yuan A, 2008, J NEUROSCI, V28, P1682, DOI 10.1523/JNEUROSCI.5242-07.2008	12	374	387	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	2010	330	6001					198	U52		10.1126/science.1194653	http://dx.doi.org/10.1126/science.1194653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LP	20829454	Green Accepted			2022-12-28	WOS:000282644600034
J	Nedeltcheva, AV; Kilkus, JM; Imperial, J; Schoeller, DA; Penev, PD				Nedeltcheva, Arlet V.; Kilkus, Jennifer M.; Imperial, Jacqueline; Schoeller, Dale A.; Penev, Plamen D.			Insufficient Sleep Undermines Dietary Efforts to Reduce Adiposity	ANNALS OF INTERNAL MEDICINE			English	Article							ENERGY-EXPENDITURE; LEPTIN LEVELS; BODY-WEIGHT; YOUNG MEN; GHRELIN; RESTRICTION; METABOLISM; GLUCOSE; DEPRIVATION; MAINTENANCE	Background: Sleep loss can modify energy intake and expenditure. Objective: To determine whether sleep restriction attenuates the effect of a reduced-calorie diet on excess adiposity. Design: Randomized, 2-period, 2-condition crossover study. Setting: University clinical research center and sleep laboratory. Patients: 10 overweight nonsmoking adults (3 women and 7 men) with a mean age of 41 years (SD, 5) and a mean body mass index of 27.4 kg/m(2) (SD, 2.0). Intervention: 14 days of moderate caloric restriction with 8.5 or 5.5 hours of nighttime sleep opportunity. Measurements: The primary measure was loss of fat and fat-free body mass. Secondary measures were changes in substrate utilization, energy expenditure, hunger, and 24-hour metabolic hormone concentrations. Results: Sleep curtailment decreased the proportion of weight lost as fat by 55% (1.4 vs. 0.6 kg with 8.5 vs. 5.5 hours of sleep opportunity, respectively; P = 0.043) and increased the loss of fat-free body mass by 60% (1.5 vs. 2.4 kg; P = 0.002). This was accompanied by markers of enhanced neuroendocrine adaptation to caloric restriction, increased hunger, and a shift in relative substrate utilization toward oxidation of less fat. Limitation: The nature of the study limited its duration and sample size. Conclusion: The amount of human sleep contributes to the maintenance of fat-free body mass at times of decreased energy intake. Lack of sufficient sleep may compromise the efficacy of typical dietary interventions for weight loss and related metabolic risk reduction.	[Penev, Plamen D.] Univ Chicago, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA; Univ Wisconsin, Madison, WI USA	University of Chicago; University of Wisconsin System; University of Wisconsin Madison	Penev, PD (corresponding author), Univ Chicago, Dept Med, Sect Endocrinol Diabet & Metab, 5841 S Maryland Ave,MC-1027, Chicago, IL 60637 USA.	ppenev@medicine.bsd.uchicago.edu	Biguzzi, Felipe A/E-4724-2015		National Institutes of Health [P01-AG11412, R01-HL089637, CTSA-RR 04999, P60-DK020595]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004999, UL1RR024999] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, P30DK020595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011412] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant Support: By the National Institutes of Health (grants P01-AG11412, R01-HL089637, CTSA-RR 04999, and P60-DK020595).	BLACK AE, 1986, HUM NUTR-CLIN NUTR, V40C, P381; BOYLE PJ, 1994, J CLIN INVEST, V93, P529, DOI 10.1172/JCI117003; Dezaki K, 2008, PHARMACOL THERAPEUT, V118, P239, DOI 10.1016/j.pharmthera.2008.02.008; EVERSON CA, 1993, AM J PHYSIOL, V264, pR376, DOI 10.1152/ajpregu.1993.264.2.R376; Everson CA, 2009, AM J PHYSIOL-REG I, V297, pR1430, DOI 10.1152/ajpregu.00230.2009; HILL AJ, 1983, J PSYCHIATR RES, V17, P203, DOI 10.1016/0022-3956(82)90023-1; Krotkiewski M, 2000, INT J OBESITY, V24, P101, DOI 10.1038/sj.ijo.0801092; Landsberg L, 2006, CELL MOL NEUROBIOL, V26, P497, DOI 10.1007/s10571-006-9010-7; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Littman AJ, 2007, INT J OBESITY, V31, P466, DOI 10.1038/sj.ijo.0803438; Nedeltcheva AV, 2009, AM J CLIN NUTR, V89, P126, DOI 10.3945/ajcn.2008.26574; Nogueiras R, 2008, ANN NY ACAD SCI, V1126, P14, DOI 10.1196/annals.1433.054; Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118; Penev P, 2005, J CLIN ENDOCR METAB, V90, P6198, DOI 10.1210/jc.2005-0415; RAVUSSIN E, 1985, AM J CLIN NUTR, V41, P753, DOI 10.1093/ajcn/41.4.753; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; Redman LM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004377; Rodriguez A, 2009, INT J OBESITY, V33, P541, DOI 10.1038/ijo.2009.40; Rosenbaum M, 2005, J CLIN INVEST, V115, P3579, DOI 10.1172/JCI25977; Schmid SM, 2009, AM J CLIN NUTR, V90, P1476, DOI 10.3945/ajcn.2009.27984; SCRIMSHAW NS, 1966, AM J CLIN NUTR, V19, P313, DOI 10.1093/ajcn/19.5.313; Shea SA, 2005, J CLIN ENDOCR METAB, V90, P2537, DOI 10.1210/jc.2004-2232; Siegel JM, 2005, NATURE, V437, P1264, DOI 10.1038/nature04285; Spiegel K, 2004, ANN INTERN MED, V141, P846, DOI 10.7326/0003-4819-141-11-200412070-00008; Spiegel K, 2004, J CLIN ENDOCR METAB, V89, P5762, DOI 10.1210/jc.2004-1003; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090	26	233	236	2	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	2010	153	7					435	+		10.7326/0003-4819-153-7-201010050-00006	http://dx.doi.org/10.7326/0003-4819-153-7-201010050-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VG	20921542	Green Accepted			2022-12-28	WOS:000282517000002
J	Shah, S; Watnick, T; Atta, MG				Shah, Sanjeev; Watnick, Terry; Atta, Mohamed G.			Not all renal cysts are created equal	LANCET			English	Editorial Material							POLYCYSTIC KIDNEY-DISEASE; NEPHROPATHY		[Shah, Sanjeev] Univ Wisconsin, Sch Med & Publ Hlth, Div Nephrol, Madison, WI USA; [Watnick, Terry; Atta, Mohamed G.] Johns Hopkins Univ Hosp, Dept Med, Div Nephrol, Baltimore, MD 21205 USA	University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Johns Hopkins Medicine	Atta, MG (corresponding author), 1830 E Monument St,Suite 416, Baltimore, MD 21205 USA.	matta1@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076017] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK076017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benzing T, 2007, J AM SOC NEPHROL, V18, P1389, DOI 10.1681/ASN.2006121355; Farres MT, 2003, RADIOLOGY, V229, P570, DOI 10.1148/radiol.2292020758; KLING MA, 1984, LAB INVEST, V50, P526; Markowitz GS, 2000, J AM SOC NEPHROL, V11, P1439, DOI 10.1681/ASN.V1181439; Torres VE, 2009, KIDNEY INT, V76, P149, DOI 10.1038/ki.2009.128	5	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2010	376	9745					1024	1024		10.1016/S0140-6736(10)60956-7	http://dx.doi.org/10.1016/S0140-6736(10)60956-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655JZ	20851261				2022-12-28	WOS:000282247600032
J	Hillery, M				Hillery, Mark			Quantum Walks Through a Waveguide Maze	SCIENCE			English	Editorial Material							ALGORITHM		CUNY Hunter Coll, Dept Phys & Astron, New York, NY 10065 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Hillery, M (corresponding author), CUNY Hunter Coll, Dept Phys & Astron, 695 Pk Ave, New York, NY 10065 USA.	mhillery@hunter.cuny.edu						Aharonov D., 2001, PROC 33 ANN ACM S TH, ppp 50; Ambainis A, 2007, SIAM J COMPUT, V37, P210, DOI 10.1137/S0097539705447311; Farhi E, 1998, PHYS REV A, V58, P915, DOI 10.1103/PhysRevA.58.915; Farhi E., 2008, THEORY COMPUTING, V4, P169, DOI DOI 10.4086/T0C.2008.V004A008; Hillery M, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.062324; Peruzzo A, 2010, SCIENCE, V329, P1500, DOI 10.1126/science.1193515; Shenvi N, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.052307	7	5	5	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1477	1478		10.1126/science.1195446	http://dx.doi.org/10.1126/science.1195446			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847257				2022-12-28	WOS:000281869000027
J	Matute, DR; Butler, IA; Turissini, DA; Coyne, JA				Matute, Daniel R.; Butler, Ian A.; Turissini, David A.; Coyne, Jerry A.			A Test of the Snowball Theory for the Rate of Evolution of Hybrid Incompatibilities	SCIENCE			English	Article							DROSOPHILA; INVIABILITY; GENETICS; MELANOGASTER; SPECIATION; STERILITY	Hybrids between species are often sterile or inviable because the long-diverged genomes of their parents cause developmental problems when they come together in a single individual. According to the Dobzhansky-Muller (DM) model, the number of genes involved in these "intrinsic postzygotic incompatibilities" should increase faster than linearly with the divergence time between species. This straightforward prediction of the DM model has remained contentious owing to a lack of explicit tests. Examining two pairs of Drosophila species, we show that the number of genes involved in postzygotic isolation increases at least as fast as the square of the number of substitutions (an index of divergence time) between species. This observation verifies a key prediction of the DM model.	[Matute, Daniel R.; Butler, Ian A.; Turissini, David A.; Coyne, Jerry A.] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Matute, DR (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	dmatute@uchicago.edu		Butler, Ian/0000-0002-1386-2430	NIH [R01GM058260]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058260] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. C. Presgraves, T. D. Price, R. Unckless, D. Kennedy, M. A. Sprigge, and M. Przeworski for discussions and reading of the manuscript; P. Andolfatto, T. Hu, and K. Thornton for sharing data; and A. Harris and J. Gladstone for technical help. Funded by NIH grant R01GM058260 (J.A.C.).	Bolnick DI, 2005, EVOLUTION, V59, P1754, DOI 10.1111/j.0014-3820.2005.tb01824.x; Brideau NJ, 2006, SCIENCE, V314, P1292, DOI 10.1126/science.1133953; Burnham K.P., 2002, MODEL SELECTION MULT, VSecond edition; Coyne J.A., 2004, SPECIATION; Coyne JA, 1998, GENETICS, V150, P1091; Dobzhansky T., 1937; Gourbiere S, 2010, EVOLUTION, V64, P1, DOI 10.1111/j.1558-5646.2009.00844.x; Johnson Norman A., 2006, P374; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Matute DR, 2009, CELL, V139, P1180, DOI 10.1016/j.cell.2009.10.033; Moyle LC, 2008, GENETICS, V179, P1437, DOI 10.1534/genetics.107.083618; Moyle LC, 2009, TRENDS ECOL EVOL, V24, P591, DOI 10.1016/j.tree.2009.05.010; Muller HJ, 1942, BIOL S, V6, P71; ORR HA, 1995, GENETICS, V139, P1805; Orr HA, 2001, EVOLUTION, V55, P1085; Phadnis N, 2009, SCIENCE, V323, P376, DOI 10.1126/science.1163934; Presgraves DC, 2007, CURR BIOL, V17, pR125, DOI 10.1016/j.cub.2006.12.030; Presgraves DC, 2003, NATURE, V423, P715, DOI 10.1038/nature01679; Presgraves DC, 2003, GENETICS, V163, P955; Tamura K, 2004, MOL BIOL EVOL, V21, P36, DOI 10.1093/molbev/msg236; Tang SW, 2009, SCIENCE, V323, P779, DOI 10.1126/science.1169123	21	130	132	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	2010	329	5998					1518	1521		10.1126/science.1193440	http://dx.doi.org/10.1126/science.1193440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847270				2022-12-28	WOS:000281869000040
J	Kaplan, MR; Schaefer, JM; Denton, GH; Barrell, DJA; Chinn, TJH; Putnam, AE; Andersen, BG; Finkel, RC; Schwartz, R; Doughty, AM				Kaplan, Michael R.; Schaefer, Joerg M.; Denton, George H.; Barrell, David J. A.; Chinn, Trevor J. H.; Putnam, Aaron E.; Andersen, Bjorn G.; Finkel, Robert C.; Schwartz, Roseanne; Doughty, Alice M.			Glacier retreat in New Zealand during the Younger Dryas stadial	NATURE			English	Article							ANTARCTIC COLD REVERSAL; ABRUPT CLIMATE-CHANGE; SOUTHERN ALPS; ATMOSPHERIC CO2; ATLANTIC; EVENT; ICE; FLUCTUATIONS; SEASONALITY; OCEAN	Millennial-scale cold reversals in the high latitudes of both hemispheres interrupted the last transition from full glacial to interglacial climate conditions. The presence of the Younger Dryas stadial (similar to 12.9 to similar to 11.7 kyr ago) is established throughout much of the Northern Hemisphere, but the global timing, nature and extent of the event are not well established. Evidence in mid to low latitudes of the Southern Hemisphere, in particular, has remained perplexing(1-6). The debate has in part focused on the behaviour of mountain glaciers in New Zealand, where previous research has found equivocal evidence for the precise timing of increased or reduced ice extent(1-3). The interhemispheric behaviour of the climate system during the Younger Dryas thus remains an open question, fundamentally limiting our ability to formulate realistic models of global climate dynamics for this time period. Here we show that New Zealand's glaciers retreated after similar to 13 kyr BP, at the onset of the Younger Dryas, and in general over the subsequent similar to 1.5-kyr period. Our evidence is based on detailed landform mapping, a high-precision Be-10 chronology(7) and reconstruction of former ice extents and snow lines from well-preserved cirque moraines. Our late-glacial glacier chronology matches climatic trends in Antarctica, Southern Ocean behaviour and variations in atmospheric CO2. The evidence points to a distinct warming of the southern mid-latitude atmosphere during the Younger Dryas and a close coupling between New Zealand's cryosphere and southern high-latitude climate. These findings support the hypothesis that extensive winter sea ice and curtailed meridional ocean overturning in the North Atlantic led to a strong interhemispheric thermal gradient(8) during late-glacial times, in turn leading to increased upwelling and CO2 release from the Southern Ocean(9), thereby triggering Southern Hemisphere warming during the northern Younger Dryas.	[Kaplan, Michael R.; Schaefer, Joerg M.; Schwartz, Roseanne] Lamont Doherty Earth Observ, Palisades, NY 10964 USA; [Schaefer, Joerg M.] Columbia Univ, Dept Earth & Environm Sci, New York, NY 10027 USA; [Denton, George H.; Putnam, Aaron E.] Univ Maine, Dept Earth Sci, Orono, ME 04469 USA; [Denton, George H.; Putnam, Aaron E.] Univ Maine, Climate Change Inst, Orono, ME 04469 USA; [Barrell, David J. A.] GNS Sci, Dunedin 9054, New Zealand; [Chinn, Trevor J. H.] Alpine & Polar Proc Consultancy, Otago 9382, New Zealand; [Andersen, Bjorn G.] Univ Oslo, Dept Geosci, N-0316 Oslo, Norway; [Finkel, Robert C.] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 95064 USA; [Finkel, Robert C.] CEREGE, F-13545 Aix En Provence 4, France; [Doughty, Alice M.] Victoria Univ Wellington, Antarctic Res Ctr, Wellington 6140, New Zealand; [Doughty, Alice M.] Victoria Univ Wellington, Sch Earth Sci, Wellington 6140, New Zealand	Columbia University; Columbia University; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; GNS Science - New Zealand; University of Oslo; University of California System; University of California Berkeley; UDICE-French Research Universities; Aix-Marseille Universite; Victoria University Wellington; Victoria University Wellington	Kaplan, MR (corresponding author), Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	mkaplan@ldeo.columbia.edu	Kaplan, Michael R/D-4720-2011	Putnam, Aaron/0000-0002-5358-1473	Gary C. Comer Science and Education Foundation; National Oceanographic and Atmospheric Administration; National Science Foundation [EAR-0745781, 0936077, 0823521]; Foundation for Research, Science and Technology [CO5X0701]; Division Of Earth Sciences [0823693] Funding Source: National Science Foundation	Gary C. Comer Science and Education Foundation; National Oceanographic and Atmospheric Administration(National Oceanic Atmospheric Admin (NOAA) - USA); National Science Foundation(National Science Foundation (NSF)); Foundation for Research, Science and Technology(New Zealand Foundation for Research, Science and Technology); Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We thank the Comer family and W. Broecker for their support of our work. We thank B. Goehring for assisting with probability plots, S. Kelley for field assistance, T. Ritchie and K. Ritchie at Lake Ruataniwha Holiday Park for hospitality and the Helicopter Line at Glentanner Park. This research is supported by the Gary C. Comer Science and Education Foundation, the National Oceanographic and Atmospheric Administration (specifically support to G.H.D. and for field work), and National Science Foundation awards EAR-0745781, 0936077 and 0823521. D.J.A.B. was supported by Foundation for Research, Science and Technology contract CO5X0701. This is LDEO contribution #7371.	Ackert RP, 2008, SCIENCE, V321, P392, DOI 10.1126/science.1157215; Alloway BV, 2007, J QUATERNARY SCI, V22, P9, DOI 10.1002/jqs.1079; Anderson B, 2006, GEOLOGY, V34, P121, DOI 10.1130/G22151.1; Anderson RF, 2009, SCIENCE, V323, P1443, DOI 10.1126/science.1167441; Augustin L, 2004, NATURE, V429, P623, DOI 10.1038/nature02599; Barrows TT, 2007, SCIENCE, V318, P86, DOI 10.1126/science.1145873; BIRKELAND PW, 1982, GEOL SOC AM BULL, V93, P433, DOI 10.1130/0016-7606(1982)93<433:SOHGDB>2.0.CO;2; Blunier T, 1997, GEOPHYS RES LETT, V24, P2683, DOI 10.1029/97GL02658; Brauer A, 2008, NAT GEOSCI, V1, P520, DOI 10.1038/ngeo263; BROECKER WS, 2007, GEOPHYS MONOGR SER, V173, P265; Carter L, 2008, PALAEOGEOGR PALAEOCL, V260, P284, DOI 10.1016/j.palaeo.2007.08.013; Chiang JCH, 2009, ANNU REV EARTH PL SC, V37, P263, DOI 10.1146/annurev.earth.031208.100217; Chinn T, 2005, GEOGR ANN A, V87A, P141, DOI 10.1111/j.0435-3676.2005.00249.x; DENTON GH, 1994, SCIENCE, V264, P1434, DOI 10.1126/science.264.5164.1434; Denton GH, 2005, QUATERNARY SCI REV, V24, P1159, DOI 10.1016/j.quascirev.2004.12.002; Hajdas I, 2006, QUATERNARY RES, V65, P340, DOI 10.1016/j.yqres.2005.08.028; Jouzel J, 2001, GEOPHYS RES LETT, V28, P3199, DOI 10.1029/2000GL012243; Lea DW, 2003, SCIENCE, V301, P1361, DOI 10.1126/science.1088470; Lemieux-Dudon B, 2010, QUATERNARY SCI REV, V29, P8, DOI 10.1016/j.quascirev.2009.11.010; Moreno PI, 2009, GEOLOGY, V37, P375, DOI 10.1130/G25399A.1; Putnam AE, 2010, QUAT GEOCHRONOL, V5, P392, DOI 10.1016/j.quageo.2009.12.001; Rasmussen SO, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006079; Schaefer JM, 2009, SCIENCE, V324, P622, DOI 10.1126/science.1169312; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Singer C, 1998, SCIENCE, V281, P812, DOI 10.1126/science.281.5378.812; Timmermann A, 2007, J CLIMATE, V20, P4899, DOI 10.1175/JCLI4283.1; Turney CSM, 2003, GEOLOGY, V31, P223, DOI 10.1130/0091-7613(2003)031<0223:ACCBNZ>2.0.CO;2; Vandergoes MJ, 2008, QUATERNARY SCI REV, V27, P589, DOI 10.1016/j.quascirev.2007.11.015; Wang XF, 2004, NATURE, V432, P740, DOI 10.1038/nature03067; Yuan DX, 2004, SCIENCE, V304, P575, DOI 10.1126/science.1091220	30	127	129	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					194	197		10.1038/nature09313	http://dx.doi.org/10.1038/nature09313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829791				2022-12-28	WOS:000281616300031
J	Nathanson, E; Nunn, P; Uplekar, M; Floyd, K; Jaramillo, E; Lonnroth, K; Weil, D; Raviglione, M				Nathanson, Eva; Nunn, Paul; Uplekar, Mukund; Floyd, Katherine; Jaramillo, Ernesto; Loennroth, Knut; Weil, Diana; Raviglione, Mario			MDR Tuberculosis - Critical Steps for Prevention and Control	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MULTIDRUG-RESISTANT TUBERCULOSIS; COMMUNITY-BASED TREATMENT; XDR-TB; RUSSIAN-FEDERATION; TREATMENT OUTCOMES; HEALTH; CARE; SYSTEMS; PRACTITIONERS; EXPERIENCE		[Nathanson, Eva; Nunn, Paul; Uplekar, Mukund; Floyd, Katherine; Jaramillo, Ernesto; Loennroth, Knut; Weil, Diana; Raviglione, Mario] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland	World Health Organization	Jaramillo, E (corresponding author), WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.	jaramilloe@who.int	alzahrani, saud hamed/C-2014-2012; Lönnroth, Knut/L-2339-2014; Lonnroth, Knut/H-5470-2017	Lönnroth, Knut/0000-0001-5054-8240; Lonnroth, Knut/0000-0001-6944-0256; RAVIGLIONE, Mario/0000-0002-9331-2067	Bill and Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Supported by a grant from the Bill and Melinda Gates Foundation.	[Anonymous], 2010, MULTIDRUG EXTENSIVEL; Basu S, 2009, P NATL ACAD SCI USA, V106, P7672, DOI 10.1073/pnas.0812472106; Birx D, 2009, AM J CLIN PATHOL, V131, P849, DOI 10.1309/AJCPGH89QDSWFONS; Blomberg B, 2003, DRUGS, V63, P535, DOI 10.2165/00003495-200363060-00002; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Cars O, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1438; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; Cheng MH, 2009, LANCET, V373, P1328, DOI 10.1016/S0140-6736(09)60757-1; Cox HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001126; Dye C, 2009, NAT REV MICROBIOL, V7, P81, DOI 10.1038/nrmicro2048; FAUCI AS, 2009, OPINION FIGHTING TB; Floyd K, 2006, B WORLD HEALTH ORGAN, V84, P43, DOI 10.2471/BLT.04.018705; Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC; Garrett L, 2009, LANCET, V374, P1294, DOI 10.1016/S0140-6736(09)61503-8; Gelmanova IY, 2007, B WORLD HEALTH ORGAN, V85, P703, DOI 10.2471/BLT.06.038331; HANSON C, 2006, TB COMPREHENSIVE INT, P1097; Heller T, 2010, INT J TUBERC LUNG D, V14, P420; Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4; International Labour Organization, 2008, SOC HLTH PROT ILO ST; Irawati SR, 2007, INT J TUBERC LUNG D, V11, P33; KOBAIDZE K, 2009, INTERDISCIP PERSPECT, P513; Lonnroth K, 2006, B WORLD HEALTH ORGAN, V84, P876; Lonnroth K, 2010, LANCET, V375, P1814, DOI 10.1016/S0140-6736(10)60483-7; Lonnroth K, 2007, HEALTH POLICY PLANN, V22, P156, DOI 10.1093/heapol/czm007; Loveday M, 2008, INT J TUBERC LUNG D, V12, P1042; Malla P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008313; Marais BJ, 2006, J CLIN MICROBIOL, V44, P3539, DOI 10.1128/JCM.01291-06; Naidoo S, 2006, INT J TUBERC LUNG D, V10, P676; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Nodieva A, 2010, INT J TUBERC LUNG D, V14, P427; Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6; Pantoja A, 2009, INT J TUBERC LUNG D, V13, P698; Paramasivan CN, 2010, INT J TUBERC LUNG D, V14, P59; Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273; Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X; Reichman LB, 2009, LANCET, V373, P28, DOI 10.1016/S0140-6736(08)61952-2; Shin S, 2004, SOC SCI MED, V59, P1529, DOI 10.1016/j.socscimed.2004.01.027; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; Skodric-Trifunovic V, 2009, INT J TUBERC LUNG D, V13, P640; Sotgiu G, 2009, EUR RESPIR J, V33, P871, DOI 10.1183/09031936.00168008; *STOP TB, PARTN GLOB PLAN STOP; *TB ALL, 2007, PATHW PAT CHART DYN; Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324; Uplekar M, 2008, INT J TUBERC LUNG D, V12, P986; VANDEUN A, 2010, AM J RESP CRIT  0504; WHO, 2015, PREQ PROGR; WHO, 2009, WHOHTMTB2009411; *WHO, GLOB TUB CONTR PAT C; World Health Organization, 2009, WHO POL TB INF CONTR; World Health Organization, 2005, SOC HLTH INS SUST HL; World Health Organization, 2008, MOL LIN PROB ASS RAP; World Health Organization, 2006, ENG ALL HLTH CAR PRO; World Health Organization, 2001, MACR HLTH INV HLTH E; World Health Organization (WHO), 2010, GUIDELINES TREATMENT, V2nd; World Health Organization (WHO), 2010, GUID PROGR MAN DRUG; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	59	137	139	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1050	1058		10.1056/NEJMra0908076	http://dx.doi.org/10.1056/NEJMra0908076			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825317	Bronze			2022-12-28	WOS:000281609700008
J	Muller, MP; Detsky, AS				Muller, Matthew P.; Detsky, Allan S.			Public Reporting of Hospital Hand Hygiene Compliance-Helpful or Harmful?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Detsky, Allan S.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Muller, Matthew P.; Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Muller, Matthew P.] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [Detsky, Allan S.] Univ Hlth Nework, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, 429-600 Univ Ave, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; GOULD DJ, 2007, COCHRANE DB SYST REV, V18; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Ontario Ministry of Health and Long-Term Care, HAND HYG; Pines JM, 2009, J EMERG MED, V37, P335, DOI 10.1016/j.jemermed.2009.06.127; Shojania KG, 2008, CAN MED ASSOC J, V179, P153, DOI 10.1503/cmaj.080010; Wachter RM, 2008, ANN INTERN MED, V149, P29, DOI 10.7326/0003-4819-149-1-200807010-00007; WHO, 2008, WHO GUID HAND HYG HL	10	31	30	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1116	1117		10.1001/jama.2010.1301	http://dx.doi.org/10.1001/jama.2010.1301			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823438				2022-12-28	WOS:000281559800023
J	Vinnard, C; Winston, CA; Wileyto, EP; MacGregor, RR; Bisson, GP				Vinnard, Christopher; Winston, Carla A.; Wileyto, E. Paul; MacGregor, Rob Roy; Bisson, Gregory P.			Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ANTITUBERCULOSIS DRUG-RESISTANCE; CEREBROSPINAL-FLUID; HIGH PREVALENCE; MISSING VALUES; IMPUTATION; ADULTS; HIV; CHEMOTHERAPY; PYRAZINAMIDE; PENETRATION	Objective To determine whether initial isoniazid resistance is associated with death during the treatment of tuberculous meningitis. Design Retrospective cohort study. Setting National Tuberculosis Surveillance System at the Centers for Disease Control in the United States. Participants Patients with a clinical diagnosis of tuberculous meningitis, reported to the National Tuberculosis Surveillance System between 1 January 1993 and 31 December 2005. Main outcome measure All cause mortality during antituberculous treatment. Results Between 1993 and 2005, 1896 patients had a clinical diagnosis of tuberculous meningitis and positive cultures from any site. In 123 (6%) of these patients, isoniazid resistance was present on initial susceptibility testing. The unadjusted association between initial isoniazid resistance and subsequent death among these 1896 patients did not reach statistical significance (odds ratio 1.38, 95% confidence interval 0.94 to 2.02). However, among 1614 patients with positive cerebrospinal fluid cultures, a significant unadjusted association was found between initial isoniazid resistance and subsequent death (odds ratio 1.61, 1.08 to 2.40). This association increased after adjustment for age, race, sex, and HIV status (odds ratio 2.07, 1.30 to 3.29). Conclusions Isoniazid resistance on initial susceptibility testing was associated with subsequent death among cases of tuberculous meningitis with positive cerebrospinal fluid cultures. Randomised controlled trials are needed to evaluate the optimal empirical regimen for treating patients with tuberculous meningitis who are at high risk for both initial isoniazid resistance and poor clinical outcomes.	[Vinnard, Christopher; MacGregor, Rob Roy; Bisson, Gregory P.] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA; [Vinnard, Christopher; Wileyto, E. Paul; Bisson, Gregory P.] Univ Penn, Sch Med, Dept Epidemiol & Biostat, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Winston, Carla A.] Ctr Dis Control, Div TB Eliminat, Surveillance Epidemiol & Outbreak Invest Branch, Atlanta, GA 30333 USA; [Wileyto, E. Paul] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Centers for Disease Control & Prevention - USA; University of Pennsylvania	Vinnard, C (corresponding author), Univ Penn, Sch Med, Dept Med, Div Infect Dis, 502 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	christopher.vinnard@uphs.upenn.edu			NIAID NIH HHS [T32 AI055435, T32 AI055435-07] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI055435] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		American Thoracic Society, 2003, MMWR Recomm Rep, V52, P1; Arnold AM, 2003, AM J EPIDEMIOL, V157, P74, DOI 10.1093/aje/kwf156; Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2; Bergemann A, 1996, QJM-MON J ASSOC PHYS, V89, P499; Curtis AB, 2001, AM J PREV MED, V20, P108, DOI 10.1016/S0749-3797(00)00284-1; Donald P R, 2003, Expert Rev Anti Infect Ther, V1, P141, DOI 10.1586/14787210.1.1.141; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; ELLARD GA, 1987, BRIT MED J, V294, P284, DOI 10.1136/bmj.294.6567.284; ELLARD GA, 1993, AM REV RESPIR DIS, V148, P650, DOI 10.1164/ajrccm/148.3.650; French CE, 2008, EUR RESPIR J, V32, P718, DOI 10.1183/09031936.00022308; GIRGIS NI, 1976, J TROP MED HYG, V79, P14; GIRGIS NI, 1978, J TROP MED HYG, V81, P246; *HONG KONG CHEST S, 1987, AM REV RESPIR DIS, V136, P1339; Hoopes AJ, 2008, ARCH INTERN MED, V168, P1984, DOI 10.1001/archinte.168.18.1984; Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC; Kalita J, 2007, EUR J NEUROL, V14, P33, DOI 10.1111/j.1468-1331.2006.01534.x; Lew W, 2008, ANN INTERN MED, V149, P123, DOI 10.7326/0003-4819-149-2-200807150-00008; Little R. J. A., 1987, STAT ANAL MISSING DA; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; Nau R, 1998, CLIN PHARMACOKINET, V35, P223, DOI 10.2165/00003088-199835030-00005; NAU R, 1992, J ANTIMICROB CHEMOTH, V29, P719, DOI 10.1093/jac/29.6.719; Palomino JC, 2009, FEMS IMMUNOL MED MIC, V56, P103, DOI 10.1111/j.1574-695X.2009.00555.x; Patel VB, 2004, CLIN INFECT DIS, V38, P851, DOI 10.1086/381973; PHUAPRADIT P, 1990, J NEUROL NEUROSUR PS, V53, P81, DOI 10.1136/jnnp.53.1.81; Rock RB, 2008, CLIN MICROBIOL REV, V21, P243, DOI 10.1128/CMR.00042-07; SHIN S-G, 1990, Journal of Korean Medical Science, V5, P39; Silber E, 1999, J NEUROL SCI, V162, P20, DOI 10.1016/S0022-510X(98)00259-7; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Thwaites GE, 2004, J CLIN MICROBIOL, V42, P996, DOI 10.1128/JCM.42.3.996-1002.2004; Thwaites GE, 2005, J INFECT DIS, V192, P79, DOI 10.1086/430616; Thwaites GE, 2005, LANCET NEUROL, V4, P160, DOI 10.1016/S1474-4422(05)01013-6; Thwaites G, 2009, J INFECTION, V59, P167, DOI 10.1016/j.jinf.2009.06.011; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; 2009, MMWR MORB MORTAL WKL, V53, P249	34	34	38	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2010	341								c4451	10.1136/bmj.c4451	http://dx.doi.org/10.1136/bmj.c4451			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649ZH	20819874	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000281814700001
J	Richards-Dinger, K; Stein, RS; Toda, S				Richards-Dinger, Keith; Stein, Ross S.; Toda, Shinji			Decay of aftershock density with distance does not indicate triggering by dynamic stress	NATURE			English	Article							LONG-VALLEY CALDERA; EARTHQUAKE CATALOGS; SEISMICITY; MAGNITUDE; CALIFORNIA; COMPLETENESS; CONSTRAINTS; LANDERS	Resolving whether static(1-3) or dynamic(4-8) stress triggers most aftershocks and subsequent mainshocks is essential to understand earthquake interaction and to forecast seismic hazard(9). Felzer and Brodsky(10) examined the distance distribution of earthquakes occurring in the first five minutes after 2 <= M < 3 and 3 <= M < 4 mainshocks and found that their magnitude M >= 2 aftershocks showed a uniform power-law decay with slope -1.35 out to 50 km from the mainshocks. From this they argued that the distance decay could be explained only by dynamic triggering. Here we propose an alternative explanation for the decay, and subject their hypothesis to a series of tests, none of which it passes. At distances more than 300 m from the 2 <= M < 3 mainshocks, the seismicity decay 5 min before the mainshocks is indistinguishable from the decay five minutes afterwards, indicating that the mainshocks have no effect at distances outside their static triggering range. Omori temporal decay, the fundamental signature of aftershocks, is absent at distances exceeding 10 km from the mainshocks. Finally, the distance decay is found among aftershocks that occur before the arrival of the seismic wave front from the mainshock, which violates causality. We argue that Felzer and Brodsky(10) implicitly assume that the first of two independent aftershocks along a fault rupture triggers the second, and that the first of two shocks in a creep-or intrusion-driven swarm triggers the second, when this need not be the case.	[Richards-Dinger, Keith] Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; [Stein, Ross S.] US Geol Survey, Menlo Pk, CA 94025 USA; [Toda, Shinji] Kyoto Univ, Disaster Prevent Res Inst, Kyoto 6110011, Japan	University of California System; University of California Riverside; United States Department of the Interior; United States Geological Survey; Kyoto University	Richards-Dinger, K (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.	keithrd@ucr.edu						Abercrombie RE, 1995, J GEOPHYS RES-SOL EA, V100, P24015, DOI 10.1029/95JB02397; Brodsky EE, 2000, GEOPHYS RES LETT, V27, P2741, DOI 10.1029/2000GL011534; Brodsky EE, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003211; Cochran ES, 2004, SCIENCE, V306, P1164, DOI 10.1126/science.1103961; Felzer KR, 2006, NATURE, V441, P735, DOI 10.1038/nature04799; Felzer KR, 2003, B SEISMOL SOC AM, V93, P1433, DOI 10.1785/0120020229; Freed AM, 2005, ANNU REV EARTH PL SC, V33, P335, DOI 10.1146/annurev.earth.33.092203.122505; Gomberg J, 2005, NATURE, V437, P830, DOI [10.1038/437830a, 10.1038/nature04167]; Hardebeck JL, 1998, J GEOPHYS RES-SOL EA, V103, P24427, DOI 10.1029/98JB00573; Helmstetter A, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003286; Helmstetter A, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001580; Hill D. P., 2007, TREATISE GEOPHYS EAR, V4, P257, DOI [10.1016/B978-044452748-6.00070-5, DOI 10.1016/B978-044452748-6.00070-5]; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; HILL DP, 1995, J GEOPHYS RES-SOL EA, V100, P12985, DOI 10.1029/95JB00860; JENNINGS PC, 1983, B SEISMOL SOC AM, V73, P265; KENDALL M, 1969, ADV THEORY STAT, V1, pCH1; Kilb D, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000678; Lohman RB, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004596; Ma KF, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003389; Marsan D, 2008, SCIENCE, V319, P1076, DOI 10.1126/science.1148783; Miyazawa M, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2006JB004890; Parsons T, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000646; PENG Z, 2009, NATURE GEOSCI, V2, DOI DOI 10.1038/NGEO1697; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Toda S, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003415; Toda S, 2002, NATURE, V419, P58, DOI 10.1038/nature00997; Velasco AA, 2008, NAT GEOSCI, V1, P375, DOI 10.1038/ngeo204; Vidale JE, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB004034; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; Wiemer S, 2000, B SEISMOL SOC AM, V90, P859, DOI 10.1785/0119990114; Woessner J, 2005, B SEISMOL SOC AM, V95, P684, DOI 10.1785/0120040007	31	81	82	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					583	U105		10.1038/nature09402	http://dx.doi.org/10.1038/nature09402			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882015				2022-12-28	WOS:000282273100037
J	Filippakopoulos, P; Qi, J; Picaud, S; Shen, Y; Smith, WB; Fedorov, O; Morse, EM; Keates, T; Hickman, TT; Felletar, I; Philpott, M; Munro, S; McKeown, MR; Wang, YC; Christie, AL; West, N; Cameron, MJ; Schwartz, B; Heightman, TD; La Thangue, N; French, CA; Wiest, O; Kung, AL; Knapp, S; Bradner, JE				Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shonagh; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher A.; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.			Selective inhibition of BET bromodomains	NATURE			English	Article							ABL TYROSINE KINASE; PROTEIN BRD4; P-TEFB; AGGRESSIVE CARCINOMA; MITOTIC CHROMOSOMES; SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; CHEMICAL PROBES; IN-VIVO; LEUKEMIA	Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.	[Filippakopoulos, Panagis; Picaud, Sarah; Fedorov, Oleg; Keates, Tracey; Felletar, Ildiko; Philpott, Martin; Heightman, Tom D.; Knapp, Stefan] Univ Oxford, Struct Genom Consortium, Dept Clin Med, Oxford OX3 7DQ, England; [Qi, Jun; Smith, William B.; Morse, Elizabeth M.; McKeown, Michael R.; West, Nathan; Bradner, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Shen, Yao; Wiest, Olaf] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Shen, Yao; Wiest, Olaf] Univ Notre Dame, Walther Canc Res Ctr, Notre Dame, IN 46556 USA; [Hickman, Tyler T.; Cameron, Michael J.; Schwartz, Brian; French, Christopher A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Munro, Shonagh; La Thangue, Nicholas; Knapp, Stefan] Univ Oxford, Dept Clin Pharmacol, Oxford OX3 7DQ, England; [McKeown, Michael R.; Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Wang, Yuchuan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA; [Christie, Amanda L.; Kung, Andrew L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA; [Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Kung, Andrew L.] Childrens Hosp, Boston, MA 02115 USA	University of Oxford; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Notre Dame; University of Notre Dame; Walther Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Oxford; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Knapp, S (corresponding author), Univ Oxford, Struct Genom Consortium, Dept Clin Med, Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.	stefan.knapp@sgc.ox.ac.uk; james_bradner@dfci.harvard.edu	Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022; Fedorov, Oleg Y./B-6412-2014; Knapp, Stefan/AAG-2347-2019	Kung, Andrew L/0000-0002-9091-488X; Fedorov, Oleg Y./0000-0001-9004-1815; Knapp, Stefan/0000-0001-5995-6494; Schwartz, Brian/0000-0002-4659-9800; Luoma, Elizabeth/0000-0001-9371-5715; Hickman, Tyler/0000-0003-2623-3251; Wang, Yuchuan/0000-0001-5111-6562; Filippakopoulos, Panagis/0000-0002-1515-1317; Philpott, Martin/0000-0003-3632-0084	Canadian Institutes for Health Research [1097737]; Canadian Foundation for Innovation; Genome Canada through the Ontario Genomics Institute; GlaxoSmithKline; Karolinska Institutet; Knut and Alice Wallenberg Foundation; Ontario Innovation Trust; Ontario Ministry for Research and Innovation; Merck Co., Inc.; Novartis Research Foundation; Swedish Agency for Innovation Systems; Swedish Foundation for Strategic Research; Wellcome Trust; University of Notre Dame; NIGMS [T32-075762]; DF/HCC; National Institutes of Health; Burroughs Wellcome Fund; Leukemia & Lymphoma Society; Medical Research Council [G0500905, G9400953] Funding Source: researchfish; MRC [G9400953, G0500905] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [K08CA128972] Funding Source: NIH RePORTER	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Genome Canada through the Ontario Genomics Institute(Genome Canada); GlaxoSmithKline(GlaxoSmithKline); Karolinska Institutet(Karolinska Institutet); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Ontario Innovation Trust; Ontario Ministry for Research and Innovation(Ministry of Research and Innovation, Ontario); Merck Co., Inc.(Merck & Company); Novartis Research Foundation; Swedish Agency for Innovation Systems(Vinnova); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Wellcome Trust(Wellcome TrustEuropean Commission); University of Notre Dame; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DF/HCC; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to U. Oppermann, S. Muller, S. Sallan, C. Lathan, P. Rahl, R. Young, K. Lee and K. Shaw for discussions and sharing unpublished information; K. Agu, S. Johnston and L. Li for analytical chemistry support; J. Daley for flow cytometry support; T. Bowman, T. Caron, C. Marvin and S. Rodig for immunohistochemistry; and A. Bass for sharing cell lines. The Structural Genomics Consortium is a registered charity (number 1097737) that receives funds from the Canadian Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska Institutet, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co., Inc., the Novartis Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research and the Wellcome Trust. This research was supported by a Graduate Fellowship from the Chemistry-Biochemistry-Biology Interface Program at the University of Notre Dame, NIGMS T32-075762 (to Y.S.), the DF/HCC (to C. A. F. and J. E. B.), the National Institutes of Health, the Burroughs Wellcome Fund, and the Leukemia & Lymphoma Society (to J.E.B.).	Abbate EA, 2006, MOL CELL, V24, P877, DOI 10.1016/j.molcel.2006.11.002; Adachi K, 2006, WPO Patent, Patent No. [WO2006129623A1, 2006129623, PCT/JP2006/310709 (WO/2006/129623)]; [Anonymous], 2009, [No title captured], Patent No. [2009084693, WO2009084693]; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Bullock AN, 2005, J MED CHEM, V48, P7604, DOI 10.1021/jm0504858; Cole PA, 2008, NAT CHEM BIOL, V4, P590, DOI 10.1038/nchembio.111; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2009, MOL BIOL CELL, V20, P4899, DOI 10.1091/mbc.E09-05-0380; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fedorov O, 2007, P NATL ACAD SCI USA, V104, P20523, DOI 10.1073/pnas.0708800104; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; Frye SV, 2010, NAT CHEM BIOL, V6, P159, DOI 10.1038/nchembio.296; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MARUSHIGE K, 1976, P NATL ACAD SCI USA, V73, P3937, DOI 10.1073/pnas.73.11.3937; Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321; Oprea TI, 2009, NAT CHEM BIOL, V5, P441, DOI 10.1038/nchembio0709-441; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Phelps MA, 2009, BLOOD, V113, P2637, DOI 10.1182/blood-2008-07-168583; Ptashne M, 2009, CURR BIOL, V19, pR234, DOI 10.1016/j.cub.2009.02.015; Quinn AM, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp899; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; SUEOKA H, 1998, THIENOTRIAZOLODIAZEP, P1; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Vollmuth F, 2009, J BIOL CHEM, V284, P36547, DOI 10.1074/jbc.M109.033712; VONVOIGTLANDER PF, 1985, DRUG DEVELOP RES, V6, P1, DOI 10.1002/ddr.430060102; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; You JX, 2006, J VIROL, V80, P8909, DOI 10.1128/JVI.00502-06; You JX, 2009, MOL CELL BIOL, V29, P5094, DOI 10.1128/MCB.00299-09; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	43	2682	2915	19	557	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	2010	468	7327					1067	1073		10.1038/nature09504	http://dx.doi.org/10.1038/nature09504			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	697XT	20871596	Green Accepted			2022-12-28	WOS:000285553800051
J	Duncan, AW; Taylor, MH; Hickey, RD; Newell, AEH; Lenzi, ML; Olson, SB; Finegold, MJ; Grompe, M				Duncan, Andrew W.; Taylor, Matthew H.; Hickey, Raymond D.; Newell, Amy E. Hanlon; Lenzi, Michelle L.; Olson, Susan B.; Finegold, Milton J.; Grompe, Markus			The ploidy conveyor of mature hepatocytes as a source of genetic variation	NATURE			English	Article							TYROSINEMIA TYPE-I; MURINE MODEL; CELL-FUSION; MOUSE MODEL; STEM-CELLS; LIVER; MICE; VIVO; FUMARYLACETOACETATE; POLYPLOIDIZATION	Mononucleated and binucleated polyploid hepatocytes (4n, 8n, 16n and higher) are found in all mammalian species, but the functional significance of this conserved phenomenon remains unknown(1-4). Polyploidization occurs through failed cytokinesis, begins at weaning in rodents and increases with age(2,5-7). Previously, we demonstrated that the opposite event, ploidy reversal, also occurs in polyploid hepatocytes generated by artificial cell fusion(8-10). This raised the possibility that somatic 'reductive mitoses' can also happen in normal hepatocytes. Here we show that multipolar mitotic spindles form frequently in mouse polyploid hepatocytes and can result in one-step ploidy reversal to generate offspring with halved chromosome content. Proliferating hepatocytes produce a highly diverse population of daughter cells with multiple numerical chromosome imbalances as well as uniparental origins. Our findings support a dynamic model of hepatocyte polyploidization, ploidy reversal and aneuploidy, a phenomenon that we term the 'ploidy conveyor'. We propose that this mechanism evolved to generate genetic diversity and permits adaptation of hepatocytes to xenobiotic or nutritional injury.	[Duncan, Andrew W.; Hickey, Raymond D.; Grompe, Markus] Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Oregon Stem Cell Ctr, Portland, OR 97239 USA; [Taylor, Matthew H.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA; [Hickey, Raymond D.; Newell, Amy E. Hanlon; Lenzi, Michelle L.; Olson, Susan B.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; [Finegold, Milton J.] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Baylor College of Medicine	Duncan, AW (corresponding author), Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Oregon Stem Cell Ctr, Portland, OR 97239 USA.	duncanan@ohsu.edu		Duncan, Andrew/0000-0003-4962-4191; Grompe, Markus/0000-0002-6616-4345	Advanced Light Microscopy Core at OHSU [S10-RR023432]; Morphology Core of the Texas Medical Center [DK56338]; National Institute of Health [R01DK067636, F32DK076232]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK076232, R01DK067636, P30DK056338] Funding Source: NIH RePORTER	Advanced Light Microscopy Core at OHSU; Morphology Core of the Texas Medical Center; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank P. Canaday (Flow Cytometry Resource at OHSU) for cell sorting; A. Snyder and S. Kaech Petrie (Advanced Light Microscopy Core at OHSU, Core grant S10-RR023432) for microscopy assistance; and the Morphology Core of the Texas Medical Center (DK56338) for histology support. We also thank L. Smith and M. Thayer for discussions. This work was supported by grants from the National Institute of Health to M.G. (R01DK067636) and A.W.D. (F32DK076232).	BARBASON H, 1974, CELL TISSUE KINET, V7, P319, DOI 10.1111/j.1365-2184.1974.tb00414.x; BAYANI J, 2004, CURR PROTOC CELL BIO, DOI DOI 10.1002/0471143030.CB2204S2322; Celton-Morizur S, 2009, J CLIN INVEST, V119, P1880, DOI 10.1172/JCI38677; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; Duncan AW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000385; FAKTOR VM, 1975, TSITOLOGIYA+, V17, P909; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gimelbrant A, 2007, SCIENCE, V318, P1136, DOI 10.1126/science.1148910; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; KUDRYAVTSEV BN, 1993, VIRCHOWS ARCH B, V64, P387, DOI 10.1007/BF02915139; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Manning K, 1999, P NATL ACAD SCI USA, V96, P11928, DOI 10.1073/pnas.96.21.11928; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; Mitchell C, 2008, NAT PROTOC, V3, P1167, DOI 10.1038/nprot.2008.80; Overturf K, 1997, HUM GENE THER, V8, P513, DOI 10.1089/hum.1997.8.5-513; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Rancati G, 2008, CELL, V135, P879, DOI 10.1016/j.cell.2008.09.039; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062; Yannoutsos N, 1996, GENES CELLS, V1, P409, DOI 10.1046/j.1365-2443.1996.d01-244.x; YIM APC, 1982, BRIT J EXP PATHOL, V63, P458	26	335	344	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					707	U93		10.1038/nature09414	http://dx.doi.org/10.1038/nature09414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20861837	Green Accepted			2022-12-28	WOS:000282572500038
J	Rustin, GJS; van der Burg, MEL; Griffin, CL; Guthrie, D; Lamont, A; Jayson, GC; Kristensen, G; Mediola, C; Coens, C; Qian, WD; Parmar, MKB; Swart, AM				Rustin, Gordon J. S.; van der Burg, Maria E. L.; Griffin, Clare L.; Guthrie, David; Lamont, Alan; Jayson, Gordon C.; Kristensen, Gunnar; Mediola, Cesar; Coens, Corneel; Qian, Wendi; Parmar, Mahesh K. B.; Swart, Ann Marie		MRC OV05 Investigator; EORTC 55955 Investigator	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial	LANCET			English	Article							FOLLOW-UP; EUROPEAN-ORGANIZATION; CA-125; PROGRESSION; IMMEDIATE; CEA	Background Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the benefits of early treatment on the basis of increased CA125 concentrations compared with delayed treatment on the basis of clinical recurrence. Methods Women with ovarian cancer in complete remission after first-line platinum-based chemotherapy and a normal CA125 concentration were registered for this randomised controlled trial. Clinical examination and CA125 measurement were done every 3 months. Patients and investigators were masked to CA125 results, which were monitored by coordinating centres. If CA125 concentration exceeded twice the upper limit of normal, patients were randomly assigned (1:1) by minimisation to early or delayed chemotherapy. Patients and clinical sites were informed of allocation to early treatment, and treatment was started as soon as possible within 28 days of the increased CA125 measurement. Patients assigned to delayed treatment continued masked CA125 measurements, with treatment commencing at clinical or symptomatic relapse. All patients were treated according to standard local practice. The primary outcome was overall survival. Analysis was by intention to treat. This study is registered, ISRCTN87786644. Findings 1442 patients were registered for the trial, of whom 529 were randomly assigned to treatment groups and were included in our analysis (265 early, 264 delayed). With a median follow-up of 56.9 months (IQR 37.4-81.8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0.98, 95% CI 0.80-1.20, p=0.85). Median survival from randomisation was 25.7 months (95% CI 23.0-27.9) for patients on early treatment and 27.1 months (22.8-30.9) for those on delayed treatment. Interpretation Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone, and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	[Griffin, Clare L.; Qian, Wendi; Swart, Ann Marie] MRC, Clin Trials Unit, London NW1 2DA, England; [Rustin, Gordon J. S.] Mt Vernon Canc Ctr, Northwood, Middx, England; [van der Burg, Maria E. L.] Erasmus MC Univ Med Ctr, Rotterdam, Netherlands; [Guthrie, David] Derbyshire Royal Infirm, Derby DE1 2QY, England; [Lamont, Alan] Colchester Hosp Univ NHS Fdn Trust, Colchester, Essex, England; [Jayson, Gordon C.] Christie Hosp, Manchester, Lancs, England; [Jayson, Gordon C.] Univ Manchester, Manchester, Lancs, England; [Kristensen, Gunnar] Norwegian Radium Hosp, Oslo Univ Hosp, Oslo, Norway; [Mediola, Cesar] Hosp Univ 12 Octubre, Madrid, Spain; [Coens, Corneel] European Org Res & Treatment Canc Headquarters, Brussels, Belgium	Medical Research Council Clinical Trials Unit; Mount Vernon Cancer Centre; Erasmus University Rotterdam; Erasmus MC; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Oslo; Hospital Universitario 12 de Octubre; European Organisation for Research & Treatment of Cancer	Swart, AM (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	ams@ctu.mrc.ac.uk	Ottevanger, Petronella Beatrix/N-3577-2014; Jayson, Gordon C/O-8224-2015; Massuger, Leon F.A.G./H-8072-2014; Sydes, Matthew/C-3373-2008; de Barros Lopes, Alberto/B-2116-2018; Rustin, Gordon J. S./J-9763-2019	Ottevanger, Petronella Beatrix/0000-0001-8209-487X; Jayson, Gordon C/0000-0002-8515-8944; Sydes, Matthew/0000-0002-9323-1371; de Barros Lopes, Alberto/0000-0002-8796-3891; Gabra, Hani/0000-0002-3322-4399; Dorum, Anne/0000-0002-6274-2398	UK Medical Research Council; National Cancer Research Network; EORTC Charitable Trust; MRC [MC_U122861379, G0601746] Funding Source: UKRI; Medical Research Council [G0601746, MC_U122861379] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Cancer Research Network; EORTC Charitable Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	OV05 was funded by the UK Medical Research Council and supported by the National Cancer Research Network. EORTC 55955 was supported by a donation from the EORTC Charitable Trust. We thank Claire Vale (Meta-analysis Group, M RC Clinical Trials Unit), who helped with the systematic review, and all women who participated in the trials.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; Bristow RE, 2009, GYNECOL ONCOL, V112, P1, DOI 10.1016/j.ygyno.2008.10.002; Falk SJ, 2002, BRIT MED J, V325, P465, DOI 10.1136/bmj.325.7362.465; GLIMELIUS B, 1992, J CLIN ONCOL, V10, P904, DOI 10.1200/JCO.1992.10.6.904; Goonewardene TI, 2007, LANCET ONCOL, V8, P813, DOI 10.1016/S1470-2045(07)70273-5; Harter P, 2006, ANN SURG ONCOL, V13, P1702, DOI 10.1245/s10434-006-9058-0; Higgins J., 2009, COCHRANE HDB SYSTEMA; Liu PY, 2007, J CLIN ONCOL, V25, P3615, DOI 10.1200/JCO.2006.09.4540; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NAIK R, 2006, COCHRANE DB SYST REV, V3; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; O'Brien MER, 2006, ANN ONCOL, V17, P270, DOI 10.1093/annonc/mdj073; Parmar MKB, 2003, LANCET, V361, P2099; Pecorelli S, 2009, J CLIN ONCOL, V27, P4642, DOI 10.1200/JCO.2009.21.9691; Rustin GJS, 2001, J CLIN ONCOL, V19, P4054, DOI 10.1200/JCO.2001.19.20.4054; Rustin GJS, 1996, ANN ONCOL, V7, P361; Schroder FH, 2009, EUR UROL, V55, P14, DOI 10.1016/j.eururo.2008.09.008; VANDERBURG MEL, 1990, ANN ONCOL, V1, P301, DOI 10.1093/oxfordjournals.annonc.a057754; Vergote I, 2000, J NATL CANCER I, V92, P1534, DOI 10.1093/jnci/92.18.1534; Wong SSL, 2006, J MED LIBR ASSOC, V94, P41	22	360	380	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2010	376	9747					1155	1163		10.1016/S0140-6736(10)61268-8	http://dx.doi.org/10.1016/S0140-6736(10)61268-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888993				2022-12-28	WOS:000282915700032
J	Kosik, KS				Kosik, Kenneth S.			MicroRNAs and Cellular Phenotypy	CELL			English	Article							NEURAL DEVELOPMENT; STEM-CELLS; MESSENGER-RNAS; EVOLUTION; GENE; BIOLOGY; GENOME; PLURIPOTENCY; CANALIZATION; DEGRADATION		Univ Calif Santa Barbara, Neurosci Res Inst, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Kosik, KS (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	kenneth.kosik@lifesci.ucsb.edu						Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; [Anonymous], 2005, PLAUSIBILITY LIFE; Banerjee S, 2009, NEURON, V64, P871, DOI 10.1016/j.neuron.2009.11.023; Caviness VS, 2003, CEREB CORTEX, V13, P592, DOI 10.1093/cercor/13.6.592; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chatterjee S, 2009, NATURE, V461, P546, DOI 10.1038/nature08349; Chi AS, 2009, SCIENCE, V323, P220, DOI 10.1126/science.1166261; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Cock JM, 2010, NATURE, V465, P617, DOI 10.1038/nature09016; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Doe CQ, 2008, DEVELOPMENT, V135, P1575, DOI 10.1242/dev.014977; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Grimson A, 2008, NATURE, V455, P1193, DOI 10.1038/nature07415; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hornstein E, 2006, NAT GENET, V38, pS20, DOI 10.1038/ng1803; Hyun S, 2009, CELL, V139, P1096, DOI 10.1016/j.cell.2009.11.020; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Izumikawa M, 2005, NAT MED, V11, P271, DOI 10.1038/nm1193; Johnston RJ, 2005, P NATL ACAD SCI USA, V102, P12449, DOI 10.1073/pnas.0505530102; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761; Kosik KS, 2009, NAT REV NEUROSCI, V10, P754, DOI 10.1038/nrn2713; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Martinez NJ, 2008, GENE DEV, V22, P2535, DOI 10.1101/gad.1678608; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Parter M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000206; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Prochnik SE, 2007, DEV GENES EVOL, V217, P73, DOI 10.1007/s00427-006-0116-1; Puzio-Kuter AM, 2009, NAT BIOTECHNOL, V27, P914, DOI 10.1038/nbt1009-914; Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781; Rouhana L, 2010, DEV BIOL, V341, P429, DOI 10.1016/j.ydbio.2010.02.037; Sakarya O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000506; Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Tsang JS, 2010, MOL CELL, V38, P140, DOI 10.1016/j.molcel.2010.03.007; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wu CI, 2009, GENOME RES, V19, P734, DOI 10.1101/gr.084640.108; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Xu JZ, 2008, RNA, V14, P1276, DOI 10.1261/rna.997708; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	48	95	104	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					21	26		10.1016/j.cell.2010.09.008	http://dx.doi.org/10.1016/j.cell.2010.09.008			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887887	Bronze			2022-12-28	WOS:000282362000008
J	Moynihan, R				Moynihan, Ray			Medicalisation Merging of marketing and medical science: female sexual dysfunction	BRITISH MEDICAL JOURNAL			English	Editorial Material							DESIRE DISORDER; WOMEN; INSTRUMENT; PREVALENCE; DISEASE		[Moynihan, Ray] Univ Newcastle, Newcastle, NSW 2300, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Newcastle, NSW 2300, Australia.		Moynihan, Ray/ABC-3010-2020					Clayton AH, 2009, J SEX MED, V6, P730, DOI 10.1111/j.1743-6109.2008.01153.x; *FOOD DRUG ADM DIV, 2004, 21769 NDA FOOD DRUG; Institute of Medicine, 2009, CONFL INT MED RES ED; Laumann EO, 2005, INT J IMPOT RES, V17, P39, DOI 10.1038/sj.ijir.3901250; Leiblum SR, 2006, MENOPAUSE, V13, P46, DOI 10.1097/01.gme.0000172596.76272.06; McHorney CA, 2004, MENOPAUSE, V11, P474, DOI 10.1097/01.GME.0000109316.11228.77; Mercer CH, 2003, BRIT MED J, V327, P426, DOI 10.1136/bmj.327.7412.426; Moynihan R, 2005, BRIT MED J, V330, P192, DOI 10.1136/bmj.330.7484.192; Moynihan R, 2003, BRIT MED J, V326, P45, DOI 10.1136/bmj.326.7379.45; Moynihan R., 2010, SEX LIES PHARM; Moynihan R, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3339; Moynihan R, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c830; Nazareth I, 2003, BRIT MED J, V327, P423, DOI 10.1136/bmj.327.7412.423; *NEW VIEW CAMP, CHALL MED SEX; Quirk FH, 2002, J WOMEN HEALTH GEN-B, V11, P277, DOI 10.1089/152460902753668475; Rosen R, 2000, J SEX MARITAL THER, V26, P191, DOI 10.1080/009262300278597; Shiften JL, 2008, OBSTET GYNECOL, V112, P970, DOI 10.1097/AOG.0b013e3181898cdb; TIEFER L, 2001, NEW VIEW WOMENS SEXU	18	16	17	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 30	2010	341								c5050	10.1136/bmj.c5050	http://dx.doi.org/10.1136/bmj.c5050			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659NI	20884702				2022-12-28	WOS:000282573000007
J	Sciurba, FC; Ernst, A; Herth, FJF; Strange, C; Criner, GJ; Marquette, CH; Kovitz, KL; Chiacchierini, RP; Goldin, J; McLennan, G				Sciurba, Frank C.; Ernst, Armin; Herth, Felix J. F.; Strange, Charlie; Criner, Gerard J.; Marquette, Charles H.; Kovitz, Kevin L.; Chiacchierini, Richard P.; Goldin, Jonathan; McLennan, Geoffrey		VENT Study Res Grp	A Randomized Study of Endobronchial Valves for Advanced Emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUNG-VOLUME-REDUCTION; COLLATERAL VENTILATION; PULMONARY-FUNCTION; SURGERY; IMPROVEMENT; THERAPY; TRIALS; RESISTANCE	BACKGROUND Endobronchial valves that allow air to escape from a pulmonary lobe but not enter it can induce a reduction in lobar volume that may thereby improve lung function and exercise tolerance in patients with pulmonary hyperinflation related to advanced emphysema. METHODS We compared the safety and efficacy of endobronchial-valve therapy in patients with heterogeneous emphysema versus standard medical care. Efficacy end points were percent changes in the forced expiratory volume in 1 second (FEV1) and the 6-minute walk test on intention-to-treat analysis. We assessed safety on the basis of the rate of a composite of six major complications. RESULTS Of 321 enrolled patients, 220 were randomly assigned to receive endobronchial valves (EBV group) and 101 to receive standard medical care (control group). At 6 months, there was an increase of 4.3% in the FEV1 in the EBV group (an increase of 1.0 percentage point in the percent of the predicted value), as compared with a decrease of 2.5% in the control group (a decrease of 0.9 percentage point in the percent of the predicted value). Thus, there was a mean between-group difference of 6.8% in the FEV1 (P = 0.005). Roughly similar between-group differences were observed for the 6-minute walk test. At 12 months, the rate of the complications composite was 10.3% in the EBV group versus 4.6% in the control group (P = 0.17). At 90 days, in the EBV group, as compared with the control group, there were increased rates of exacerbation of chronic obstructive pulmonary disease (COPD) requiring hospitalization (7.9% vs. 1.1%, P = 0.03) and hemoptysis (6.1% vs. 0%, P = 0.01). The rate of pneumonia in the target lobe in the EBV group was 4.2% at 12 months. Greater radiographic evidence of emphysema heterogeneity and fissure completeness was associated with an enhanced response to treatment. CONCLUSIONS Endobronchial-valve treatment for advanced heterogeneous emphysema induced modest improvements in lung function, exercise tolerance, and symptoms at the cost of more frequent exacerbations of COPD, pneumonia, and hemoptysis after implantation.	[Sciurba, Frank C.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [McLennan, Geoffrey] Univ Iowa, Iowa City, IA USA; [Goldin, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Chiacchierini, Richard P.] Chiacchierini & Associates, Rockville, MD USA; [Kovitz, Kevin L.] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA; [Marquette, Charles H.] Univ Hosp Nice, Nice, France; [Criner, Gerard J.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA; [Strange, Charlie] Med Univ S Carolina, Charleston, SC 29425 USA; [Herth, Felix J. F.] Heidelberg Univ, Heidelberg, Germany; [Ernst, Armin] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Tulane University; CHU Nice; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Medical University of South Carolina; Ruprecht Karls University Heidelberg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sciurba, FC (corresponding author), Univ Pittsburgh, Sch Med, 3471 5th Ave,Suite 1211,Kaufmann Bldg, Pittsburgh, PA 15213 USA.	sciurbafc@upmc.edu	Sciurba, Frank/AAZ-9339-2021; CUVELIER, Antoine/F-5965-2014; Ficker, Joachim H./A-1153-2015; Marquette, Charles Hugo/O-4084-2016; wuyam, bernard MF/M-7438-2014; christos, chouaid/R-4477-2018; Righini, Christian/E-8468-2014; Beigelman-Aubry, Catherine I/F-4305-2017; DESLEE, Gaetan/G-2625-2013	CUVELIER, Antoine/0000-0003-0263-1845; Ficker, Joachim H./0000-0002-7175-5852; Marquette, Charles Hugo/0000-0002-0846-9941; christos, chouaid/0000-0002-4290-5524; Beigelman-Aubry, Catherine I/0000-0001-7092-6448; Feller-Kopman, David/0000-0002-9008-3617; Gonzalez-Bermejo, Jesus/0000-0003-2395-4694; dutau, herve/0000-0002-7726-2274; DESLEE, Gaetan/0000-0002-4919-5916; Degano, Bruno/0000-0003-1644-7264; sciurba, frank/0000-0001-7468-2225; Goldin, Jonathan/0000-0003-3007-9947; Strange, Charlie/0000-0002-8109-8067; Vivodtzev, Isabelle/0000-0002-5201-8603	Pulmonx; National Institutes of Health [1 P50HL084948]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL084948] Funding Source: NIH RePORTER	Pulmonx; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Emphasys Medical (now Pulmonx) and a grant (1 P50HL084948, to Dr. Sciurba) from the National Institutes of Health.	Bergman RA, 2008, ILLUSTRATED ENCY HUM; Brown MS, 2007, COMPUT MED IMAG GRAP, V31, P332, DOI 10.1016/j.compmedimag.2007.02.014; Brown MS, 1998, COMPUT MED IMAG GRAP, V22, P463, DOI 10.1016/S0895-6111(98)00051-2; Brown MS, 1997, IEEE T MED IMAGING, V16, P828, DOI 10.1109/42.650879; Cetti EJ, 2006, THORAX, V61, P371, DOI 10.1136/thx.2006.060509; Choong CK, 2008, AM J RESP CRIT CARE, V178, P902, DOI 10.1164/rccm.200712-1832OC; Criner GJ, 1999, AM J RESP CRIT CARE, V160, P2018, DOI 10.1164/ajrccm.160.6.9902117; Fesslep HE, 2005, AM J RESP CRIT CARE, V171, P423, DOI 10.1164/rccm.2412005; Fessler HE, 1998, AM J RESP CRIT CARE, V157, P715, DOI 10.1164/ajrccm.157.3.9608004; Fessler Henry E, 2008, Proc Am Thorac Soc, V5, P416, DOI 10.1513/pats.200708-117ET; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; Gelb AF, 1996, AM J RESP CRIT CARE, V154, P945, DOI 10.1164/ajrccm.154.4.8887590; HOGG JC, 1969, J CLIN INVEST, V48, P421, DOI 10.1172/JCI105999; Hopkinson NS, 2005, AM J RESP CRIT CARE, V171, P453, DOI 10.1164/rccm.200407-961OC; Ingenito EP, 1998, NEW ENGL J MED, V338, P1181, DOI 10.1056/NEJM199804233381703; Kent EM, 1942, J THORAC SURG, V12, P18; LUKOSE R, 1999, BIOMEDICINE, V19, P227; MACKLEM PT, 1978, NEW ENGL J MED, V298, P49, DOI 10.1056/NEJM197801052980112; McCulloch P, 2002, BRIT MED J, V324, P1448, DOI 10.1136/bmj.324.7351.1448; McKenna RJ, 1997, J THORAC CARDIOV SUR, V114, P957, DOI 10.1016/S0022-5223(97)70010-2; McKenna RJ, 1996, J THORAC CARDIOV SUR, V112, P1331, DOI 10.1016/S0022-5223(96)70148-4; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Naunheim KS, 2007, J THORAC CARDIOV SUR, V133, P1412, DOI 10.1016/j.jtcvs.2007.01.050; Naunheim KS, 2006, J THORAC CARDIOV SUR, V131, P43, DOI 10.1016/j.jtcvs.2005.09.006; Piantadosi S, 2005, WILEY SER PROBAB ST, P9; Reilly J, 2007, CHEST, V131, P1108, DOI 10.1378/chest.06-1754; Rogers RM, 2000, CHEST, V118, P1240, DOI 10.1378/chest.118.5.1240; Salanitri J, 2005, INTERN MED J, V35, P97, DOI 10.1111/j.1445-5994.2004.00746.x; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Snell GI, 2003, CHEST, V124, P1073, DOI 10.1378/chest.124.3.1073; Strange Charlie, 2007, BMC Pulm Med, V7, P10, DOI 10.1186/1471-2466-7-10; TERRY PB, 1978, NEW ENGL J MED, V298, P10, DOI 10.1056/NEJM197801052980103; Toma TP, 2004, SEM RESP CRIT CARE M, V25, P399, DOI 10.1055/s-2004-832712; VANBELLE GFL, 2004, BIOSTATISTICS METHOD, P540; Venuta F, 2005, ANN THORAC SURG, V79, P411, DOI 10.1016/j.athoracsur.2004.07.048; Wan IYP, 2006, CHEST, V129, P518, DOI 10.1378/chest.129.3.518; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Wood DE, 2007, J THORAC CARDIOV SUR, V133, P65, DOI 10.1016/j.jtcvs.2006.06.051	39	525	562	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1233	1244		10.1056/NEJMoa0900928	http://dx.doi.org/10.1056/NEJMoa0900928			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860505	Green Published			2022-12-28	WOS:000282050000007
J	Asher, G; Reinke, H; Altmeyer, M; Gutierrez-Arcelus, M; Hottiger, MO; Schibler, U				Asher, Gad; Reinke, Hans; Altmeyer, Matthias; Gutierrez-Arcelus, Maria; Hottiger, Michael O.; Schibler, Ueli			Poly(ADP-Ribose) Polymerase 1 Participates in the Phase Entrainment of Circadian Clocks to Feeding	CELL			English	Article							GENE-EXPRESSION; DNA-BINDING; TRANSCRIPTION; FEEDBACK; PROTEIN; PARP-1; LIVER	Circadian clocks in peripheral organs are tightly coupled to cellular metabolism and are readily entrained by feeding-fasting cycles. However, the molecular mechanisms involved are largely unknown. Here we show that in liver the activity of PARP-1, an NAD(+)-dependent ADP-ribosyltransferase, oscillates in a daily manner and is regulated by feeding. We provide biochemical evidence that PARP-1 binds and poly(ADP-ribosyl)ates CLOCK at the beginning of the light phase. The loss of PARP-1 enhances the binding of CLOCK-BMAL1 to DNA and leads to a phase-shift of the interaction of CLOCK-BMAL1 with PER and CRY repressor proteins. As a consequence, CLOCK-BMAL1-dependent gene expression is altered in PARP-1-deficient mice, in particular in response to changes in feeding times. Our results show that Parp-1 knockout mice exhibit impaired food entrainment of peripheral circadian clocks and support a role for PARP-1 in connecting feeding with the mammalian timing system.	[Asher, Gad; Gutierrez-Arcelus, Maria; Schibler, Ueli] Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; [Reinke, Hans] Heinrich Heine Univ IUF, Inst Mol Prevent Med, Sch Med, Heinrich Heine Univ,Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany; [Altmeyer, Matthias; Hottiger, Michael O.] Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; [Altmeyer, Matthias] Univ Zurich, Mol Life Sci Program, Life Sci Zurich Grad Sch, CH-8057 Zurich, Switzerland	University of Geneva; Heinrich Heine University Dusseldorf; University of Zurich; University of Zurich	Asher, G (corresponding author), Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland.	gad.asher@unige.ch; ueli.schibler@unige.ch	Altmeyer, Matthias/AAE-8186-2019; Hottiger, Michael O./J-7747-2013; ASHER, GAD/K-1333-2012	Altmeyer, Matthias/0000-0003-3780-1170; Hottiger, Michael O./0000-0002-7323-2270; Asher, Gad/0000-0001-9403-7856	Swiss National Foundation [SNF 31-113565, SNF 31-128656/1]; European Research Council [ERC2009-AdG 20090506]; State of Geneva; Louis Jeantet Foundation of Medicine	Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Research Council(European Research Council (ERC)European Commission); State of Geneva; Louis Jeantet Foundation of Medicine	The work performed in the laboratory of U.S. was supported by the Swiss National Foundation (SNF 31-113565, SNF 31-128656/1, and the NCCR program grant Frontiers in Genetics), the European Research Council (ERC2009-AdG 20090506), the State of Geneva, the Louis Jeantet Foundation of Medicine, and the 6<SUP>th</SUP> European Framework Project EUCLOCK. The work conducted in the laboratory of M.O.H. was supported by the Swiss National Foundation (SNF 31-122421) and the Kanton of Zurich. G. A. received long-term fellowships from EMBO and the Human Frontier Science Program.	Altmeyer M, 2009, AGING-US, V1, P458, DOI 10.18632/aging.100052; Altmeyer M, 2009, NUCLEIC ACIDS RES, V37, P3723, DOI 10.1093/nar/gkp229; Asher G, 2008, CELL, V134, P317, DOI 10.1016/j.cell.2008.06.050; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; Dodd AN, 2007, SCIENCE, V318, P1789, DOI 10.1126/science.1146757; Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hassa PO, 2008, FRONT BIOSCI-LANDMRK, V13, P3046, DOI 10.2741/2909; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kornmann B, 2007, PLOS BIOL, V5, P179, DOI 10.1371/journal.pbio.0050034; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LE MINH N, 2001, EMBO J, V20, P7128; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; Mohammad DH, 2009, DNA REPAIR, V8, P1009, DOI 10.1016/j.dnarep.2009.04.004; Nakahata Y, 2008, CELL, V134, P329, DOI 10.1016/j.cell.2008.07.002; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Panda S, 2002, DEV CELL, V3, P51, DOI 10.1016/S1534-5807(02)00200-9; Petesch SJ, 2008, CELL, V134, P74, DOI 10.1016/j.cell.2008.05.029; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Reinke H, 2008, GENE DEV, V22, P331, DOI 10.1101/gad.453808; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Zaniolo K, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-96	37	253	266	2	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					943	953		10.1016/j.cell.2010.08.016	http://dx.doi.org/10.1016/j.cell.2010.08.016			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20832105	Bronze			2022-12-28	WOS:000281855000016
J	Gottlinger, HG				Goettlinger, Heinrich G.			Influenza Exits the Cell without an ESCRT	CELL			English	Editorial Material							MECHANISMS; MACHINERY; PROTEINS; VIRUSES		Univ Massachusetts, Sch Med, Program Mol Med, Program Gene Funct & Express, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Gottlinger, HG (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Program Gene Funct & Express, Worcester, MA 01605 USA.	heinrich.gottlinger@umassmed.edu		Gottlinger, Heinrich/0000-0003-4124-5824				Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Bruce EA, 2009, VIROLOGY, V390, P268, DOI 10.1016/j.virol.2009.05.016; Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422; Chen BJ, 2008, J VIROL, V82, P10059, DOI 10.1128/JVI.01184-08; Chen BJ, 2008, VIROLOGY, V372, P221, DOI 10.1016/j.virol.2007.11.008; Hurley JH, 2010, NAT REV MOL CELL BIO, V11, P556, DOI 10.1038/nrm2937; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; Rossman JS, 2010, CELL, V142, P902, DOI 10.1016/j.cell.2010.08.029; Saksena S, 2007, TRENDS BIOCHEM SCI, V32, P561, DOI 10.1016/j.tibs.2007.09.010	10	3	3	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					839	841		10.1016/j.cell.2010.08.036	http://dx.doi.org/10.1016/j.cell.2010.08.036			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850005	Bronze			2022-12-28	WOS:000281855000005
J	Lu, LF; Boldin, MP; Chaudhry, A; Lin, LL; Taganov, KD; Hanada, T; Yoshimura, A; Baltimore, D; Rudensky, AY				Lu, Li-Fan; Boldin, Mark P.; Chaudhry, Ashutosh; Lin, Ling-Li; Taganov, Konstantin D.; Hanada, Toshikatsu; Yoshimura, Akihiko; Baltimore, David; Rudensky, Alexander Y.			Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses	CELL			English	Article							TRANSCRIPTION FACTOR FOXP3; T-REG-CELLS; IFN-GAMMA; SIGNALING PATHWAYS; IMMUNE-RESPONSES; TARGET GENES; CD4(+); DIFFERENTIATION; CYTOKINE; SOCS1	Foxp3(+) regulatory T (Treg) cells maintain immune homeostasis by limiting different types of inflammatory responses. Here, we report that miR-146a, one of the miRNAs prevalently expressed in Treg cells, is critical for their suppressor function. The deficiency of miR-146a in Treg cells resulted in a breakdown of immunological tolerance manifested in fatal IFN gamma-dependent immune-mediated lesions in a variety of organs. This was likely due to augmented expression and activation of signal transducer and activator transcription 1 (Stat1), a direct target of miR-146a. Likewise, heightened Stat1 activation in Treg cells subjected to a selective ablation of SOCS1, a key negative regulator of Stat1 phosphorylation downstream of the IFN gamma receptor, was associated with analogous Th1-mediated pathology. Our results suggest that specific aspects of Treg suppressor function are controlled by a single miRNA and that an optimal range of Stat1 activation is important for Treg-mediated control of Th1 responses and associated autoimmunity.	[Lu, Li-Fan; Chaudhry, Ashutosh; Lin, Ling-Li; Rudensky, Alexander Y.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA; [Lu, Li-Fan; Chaudhry, Ashutosh; Lin, Ling-Li; Rudensky, Alexander Y.] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA; [Boldin, Mark P.; Taganov, Konstantin D.; Baltimore, David] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Hanada, Toshikatsu; Yoshimura, Akihiko] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjyuku Ku, Tokyo 1608582, Japan; [Hanada, Toshikatsu; Yoshimura, Akihiko] Japan Sci & Technol Agcy JST, CREST, Chiyoda Ku, Tokyo 1020075, Japan; [Baltimore, David] Regulus Therapeut, San Diego, CA 92121 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; California Institute of Technology; Keio University; Japan Science & Technology Agency (JST); Isis Pharmaceuticals Inc	Rudensky, AY (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA.	rudenska@mskcc.org	Yoshimura, Akihiko/K-5515-2013	Chaudhry, Ashutosh/0000-0003-3379-5236; Lu, Li-Fan/0000-0002-9727-0036; Boldin, Mark/0000-0003-4593-0669	NIH; Ministry of Education, Culture, Sports, Science; Technology of Japan; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034206] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education, Culture, Sports, Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Technology of Japan; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank A. Ramos for the help in key experiments, Y. Liang, P. Zarin, A. Bravo, and J. Herlihy for superb technical assistance, and all members of our laboratory for discussions. This work was supported by grants from the NIH (A. Y. R. and D. B.) and from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (A. Y.). L.-F. L. is a Leukemia and Lymphoma Society Fellow. A. C. is a Cancer Research Institute Fellow. A. Y. R. is a Howard Hughes Medical Institute investigator. D. B. is the director and M. P. B. and K. D. T. are employees of Regulus Therapeutics Inc., a company devoted to commercializing therapies directed at microRNAs.	Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024; Barbi J, 2007, BLOOD, V110, P2215, DOI 10.1182/blood-2007-03-081307; Beima KM, 2006, J BIOL CHEM, V281, P11992, DOI 10.1074/jbc.M513613200; Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723; Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Curtale G, 2010, BLOOD, V115, P265, DOI 10.1182/blood-2009-06-225987; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Horino J, 2008, INT IMMUNOL, V20, P753, DOI 10.1093/intimm/dxn033; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Huang B, 2009, EMBO REP, V10, P180, DOI 10.1038/embor.2008.224; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062; Lord GM, 2005, BLOOD, V106, P3432, DOI 10.1182/blood-2005-04-1393; Lu LF, 2009, GENE DEV, V23, P1270, DOI 10.1101/gad.1791009; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Maitra U, 2009, J IMMUNOL, V182, P5763, DOI 10.4049/jimmunol.0900124; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Monticelli S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r71; Nakajima C, 2002, EUR J IMMUNOL, V32, P1792, DOI 10.1002/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Oldenhove G, 2009, IMMUNITY, V31, P772, DOI 10.1016/j.immuni.2009.10.001; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Siebler J, 2003, HEPATOLOGY, V38, P1573, DOI 10.1016/j.hep.2003.09.020; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tanaka K, 2008, J IMMUNOL, V180, P3746, DOI 10.4049/jimmunol.180.6.3746; Tang YJ, 2009, ARTHRITIS RHEUM-US, V60, P1065, DOI 10.1002/art.24436; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Zhan YF, 2009, IMMUNOL CELL BIOL, V87, P473, DOI 10.1038/icb.2009.23; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	56	697	762	4	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					914	929		10.1016/j.cell.2010.08.012	http://dx.doi.org/10.1016/j.cell.2010.08.012			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850013	Green Accepted, Bronze			2022-12-28	WOS:000281855000014
J	Rai, K; Sarkar, S; Broadbent, TJ; Voas, M; Grossmann, KF; Nadauld, LD; Dehghanizadeh, S; Hagos, FT; Li, YM; Toth, RK; Chidester, S; Bahr, TM; Johnson, WE; Sklow, B; Burt, R; Cairns, BR; Jones, DA				Rai, Kunal; Sarkar, Sharmistha; Broadbent, Talmage J.; Voas, Matthew; Grossmann, Kenneth F.; Nadauld, Lincoln D.; Dehghanizadeh, Somaye; Hagos, Fanuel T.; Li, Yumei; Toth, Rachel K.; Chidester, Stephanie; Bahr, Timothy M.; Johnson, W. Evan; Sklow, Brad; Burt, Randall; Cairns, Bradley R.; Jones, David A.			DNA Demethylase Activity Maintains Intestinal Cells in an Undifferentiated State Following Loss of APC	CELL			English	Article							ADENOMATOUS POLYPOSIS-COLI; RETINOIC ACID; COLORECTAL-CANCER; ALDEHYDE DEHYDROGENASE; REGULATES EXPRESSION; GENE-EXPRESSION; BETA-CATENIN; ZEBRAFISH; HYPOMETHYLATION; MICE	Although genome-wide hypomethylation is a hallmark of many cancers, roles for active DNA demethylation during tumorigenesis are unknown. Here, loss of the APC tumor suppressor gene causes upregulation of a DNA demethylase system and the concomitant hypomethylation of key intestinal cell fating genes. Notably, this hypomethylation maintained zebrafish intestinal cells in an undifferentiated state that was released upon knockdown of demethylase components. Mechanistically, the demethylase genes are directly activated by Pou5f1 and Cebp beta and are indirectly repressed by retinoic acid, which antagonizes Pou5f1 and Cebp beta. Apc mutants lack retinoic acid as a result of the transcriptional repression of retinol dehydrogenase l1 via a complex that includes Lef1, Groucho2, Ctbp1, Lsd1, and Corest. Our findings imply a model wherein APC controls intestinal cell fating through a switch in DNA methylation dynamics. Wild-type APC and retinoic acid downregulate demethylase components, thereby promoting DNA methylation of key genes and helping progenitors commit to differentiation.	[Rai, Kunal; Sarkar, Sharmistha; Broadbent, Talmage J.; Voas, Matthew; Grossmann, Kenneth F.; Nadauld, Lincoln D.; Dehghanizadeh, Somaye; Hagos, Fanuel T.; Li, Yumei; Toth, Rachel K.; Chidester, Stephanie; Johnson, W. Evan; Sklow, Brad; Burt, Randall; Cairns, Bradley R.; Jones, David A.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Rai, Kunal; Grossmann, Kenneth F.; Cairns, Bradley R.] Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; [Rai, Kunal; Sarkar, Sharmistha; Broadbent, Talmage J.; Voas, Matthew; Grossmann, Kenneth F.; Dehghanizadeh, Somaye; Hagos, Fanuel T.; Toth, Rachel K.; Cairns, Bradley R.; Jones, David A.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Jones, David A.] Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; [Burt, Randall] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; [Li, Yumei; Johnson, W. Evan; Sklow, Brad] Univ Utah, Dept Surg, Salt Lake City, UT 84112 USA; [Bahr, Timothy M.] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Brigham Young University	Cairns, BR (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	brad.cairns@hci.utah.edu; david.jones@hci.utah.edu		Johnson, W. Evan/0000-0002-6247-6595; Chidester, Stephanie/0000-0003-4163-3480; Rai, Kunal/0000-0003-2321-6894	National Cancer Institute [CA073992, CA96934]; National Institute of Child Health and Development [HD058506]; Howard Hughes Medical Institute; Huntsman Cancer Foundation; Cancer Center [CA042014]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD058506] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA042014, P01CA073992, R01CA116468] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Huntsman Cancer Foundation; Cancer Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Smitha James and Adam Karpf for liquid chromatography-mass spectrometry assay, Kornelia Edes, Chad Zavala, Jennifer Swift, Abby Evans, and Erek Winett for technical help, and Richard Dorsky for reagents. This work is supported by grants from the National Cancer Institute (CA073992 and CA96934) awarded to D. A. J., the National Institute of Child Health and Development (HD058506 to B. R. C. and D. A. J), the Howard Hughes Medical Institute (to B. R. C), and the Huntsman Cancer Foundation. The work was also supported by access to technical cores supported by a Cancer Center Support Grant (CA042014).	Begemann G, 2001, DEVELOPMENT, V128, P3081; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blanc V, 2007, CANCER RES, V67, P8565, DOI 10.1158/0008-5472.CAN-07-1593; Dobbs-McAuliffe B, 2004, MECH DEVELOP, V121, P339, DOI 10.1016/j.mod.2004.02.008; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Eads CA, 2002, CANCER RES, V62, P1296; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Eisinger AL, 2007, J BIOL CHEM, V282, P29394, DOI 10.1074/jbc.M609768200; Eisinger AL, 2006, J BIOL CHEM, V281, P20474, DOI 10.1074/jbc.M602859200; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Guimond J, 2002, BBA-GENE STRUCT EXPR, V1579, P81, DOI 10.1016/S0167-4781(02)00510-9; HOLLIDAY R, 1985, CANCER SURV, V4, P557; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; Mudumana SP, 2004, DEV DYNAM, V230, P165, DOI 10.1002/dvdy.20032; Nadauld LD, 2005, J BIOL CHEM, V280, P30490, DOI 10.1074/jbc.M504973200; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; Nadauld LD, 2006, J BIOL CHEM, V281, P37828, DOI 10.1074/jbc.M602119200; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Parvin MS, 2008, DEV DYNAM, V237, P1373, DOI 10.1002/dvdy.21539; Phelps RA, 2009, CELL CYCLE, V8, P2549, DOI 10.4161/cc.8.16.9278; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; RUSSO JE, 1988, BIOCHEM PHARMACOL, V37, P1639, DOI 10.1016/0006-2952(88)90030-5; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sparks AB, 1998, CANCER RES, V58, P1130; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990	37	75	77	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 17	2010	142	6					930	942		10.1016/j.cell.2010.08.030	http://dx.doi.org/10.1016/j.cell.2010.08.030			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850014	Green Accepted, Bronze			2022-12-28	WOS:000281855000015
J	Zahn, M; von Storch, H				Zahn, Matthias; von Storch, Hans			Decreased frequency of North Atlantic polar lows associated with future climate warming	NATURE			English	Article							COLD-AIR OUTBREAKS; MODEL	Every winter, the high-latitude oceans are struck by severe storms that are considerably smaller than the weather-dominating synoptic depressions(1). Accompanied by strong winds and heavy precipitation, these often explosively developing mesoscale cyclones-termed polar lows(1)-constitute a threat to offshore activities such as shipping or oil and gas exploitation. Yet owing to their small scale, polar lows are poorly represented in the observational and global reanalysis data(2) often used for climatological investigations of atmospheric features and cannot be assessed in coarse-resolution global simulations of possible future climates. Here we show that in a future anthropogenically warmed climate, the frequency of polar lows is projected to decline. We used a series of regional climate model simulations to downscale a set of global climate change scenarios(3) from the Intergovernmental Panel of Climate Change. In this process, we first simulated the formation of polar low systems in the North Atlantic and then counted the individual cases. A previous study(4) using NCEP/NCAR re-analysis data(5) revealed that polar low frequency from 1948 to 2005 did not systematically change. Now, in projections for the end of the twenty-first century, we found a significantly lower number of polar lows and a northward shift of their mean genesis region in response to elevated atmospheric greenhouse gas concentration. This change can be related to changes in the North Atlantic sea surface temperature and mid-troposphere temperature; the latter is found to rise faster than the former so that the resulting stability is increased, hindering the formation or intensification of polar lows. Our results provide a rare example of a climate change effect in which a type of extreme weather is likely to decrease, rather than increase.	[Zahn, Matthias] Univ Reading, Environm Syst Sci Ctr, Reading RG6 6AL, Berks, England; [Zahn, Matthias; von Storch, Hans] GKSS Forschungszentrum Geesthacht GmbH, Inst Coastal Res Syst Anal & Modelling, D-21502 Geesthacht, Germany; [von Storch, Hans] Univ Hamburg, Inst Meteorol, D-20146 Hamburg, Germany	University of Reading; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung; University of Hamburg	Zahn, M (corresponding author), Univ Reading, Environm Syst Sci Ctr, 3 Earley Gate, Reading RG6 6AL, Berks, England.	matthias.zahn@gkss.de	von Storch, Hans/J-4165-2012	von Storch, Hans/0000-0002-5825-8069; Zahn, Matthias/0000-0003-0137-2853	DFG [512]; International Detection and Attribution Group (IDAG); DoE; NERC [NE/G015708/1] Funding Source: UKRI; Natural Environment Research Council [NE/G015708/1] Funding Source: researchfish	DFG(German Research Foundation (DFG)); International Detection and Attribution Group (IDAG); DoE(United States Department of Energy (DOE)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank the Max Planck Institute for Meteorology in Germany for providing access to their ECHAM5/MPI-OM climate change simulations. We acknowledge the modelling groups for making their model output available for analysis, the Program for Climate Model Diagnosis and Intercomparison (PCMDI) for collecting and archiving this data, and the WCRP's Working Group on Coupled Modelling (WGCM) for organizing the model data analysis activity. The WCRP CMIP3 multi-model data set is supported by the Office of Science, US Department of Energy. M.Z. was funded by the DFG within the special research project 512 and thanks B. Rockel, E. Zorita and K. Hodges for their help. H. v. S. was partially supported by the International Detection and Attribution Group (IDAG), funded by the DoE, and thanks H. Hinzpeter for directing his attention to the phenomenon of polar lows in the early 1980s.	Bengtsson L, 2006, J CLIMATE, V19, P3518, DOI 10.1175/JCLI3815.1; Bindoff NL, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P385; Blechschmidt AM, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL033706; Bracegirdle TJ, 2008, INT J CLIMATOL, V28, P1903, DOI 10.1002/joc.1686; Christensen JH, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P847; Condron A, 2006, MON WEATHER REV, V134, P1518, DOI 10.1175/MWR3136.1; Condron A, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004599; Emanuel K. A., 1989, Tellus, Series A (Dynamic Meteorology and Oceanography), V41A, P1, DOI 10.1111/j.1600-0870.1989.tb00362.x; Feser F, 2005, MON WEATHER REV, V133, P1774, DOI 10.1175/MWR2939.1; HARROLD TW, 1969, Q J ROY METEOR SOC, V95, P710, DOI 10.1002/qj.49709540605; Heinemann G., 1996, GLOBAL ATMOS OCEAN S, V4, P89; Jun M, 2008, J AM STAT ASSOC, V103, P934, DOI 10.1198/016214507000001265; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Klein T, 2002, METEOROL APPL, V9, P407, DOI 10.1017/S1350482702004036; Kolstad EW, 2008, CLIM DYNAM, V30, P871, DOI 10.1007/s00382-007-0331-0; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; Levitus S, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021592; Marsland SJ, 2003, OCEAN MODEL, V5, P91, DOI 10.1016/S1463-5003(02)00015-X; Meehl GA, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; Nakicenovic N., 2000, IPCC SPECIAL REPORT; RASMUSSEN E, 1979, Q J ROY METEOR SOC, V105, P531, DOI 10.1002/qj.49710544504; Rasmussen E. A., 2003, POLAR LOWS MESOSCALE; Rockel B, 2008, METEOROL Z, V17, P347, DOI 10.1127/0941-2948/2008/0309; Roeckner E., 2003, 349 MPI; Trapp RJ, 2007, P NATL ACAD SCI USA, V104, P19719, DOI 10.1073/pnas.0705494104; Vavrus S, 2006, INT J CLIMATOL, V26, P1133, DOI 10.1002/joc.1301; WILHELMSEN K, 1985, TELLUS A, V37, P451, DOI 10.1111/j.1600-0870.1985.tb00443.x; Zahn M, 2008, TELLUS A, V60, P620, DOI 10.1111/j.1600-0870.2008.00330.x; Zahn M, 2008, METEOROL Z, V17, P445, DOI 10.1127/0941-2948/2008/0317; Zahn M, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035769	30	85	89	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2010	467	7313					309	312		10.1038/nature09388	http://dx.doi.org/10.1038/nature09388			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650CF	20844533				2022-12-28	WOS:000281824900035
J	Jena, AB; Baldwin, DC; Daugherty, SR; Meltzer, DO; Arora, VM				Jena, Anupam B.; Baldwin, DeWitt C., Jr.; Daugherty, Steven R.; Meltzer, David O.; Arora, Vineet M.			Presenteeism Among Resident Physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SICK; WORK		[Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Baldwin, DeWitt C., Jr.] Accreditat Council Grad Med Educ, Chicago, IL USA; [Daugherty, Steven R.] Rush Med Coll, Dept Psychol, Chicago, IL 60612 USA; [Meltzer, David O.; Arora, Vineet M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA	Harvard University; Massachusetts General Hospital; Rush University; University of Chicago	Jena, AB (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.	varora@medicine.bsd.uchicago.edu	Meltzer, David/C-2926-2009	Meltzer, David/0000-0003-2790-7393; Arora, Vineet/0000-0002-4745-7599				Aronsson G, 2000, J EPIDEMIOL COMMUN H, V54, P502, DOI 10.1136/jech.54.7.502; Baldwin DC, 2004, SLEEP, V27, P217, DOI 10.1093/sleep/27.2.217; Bockerman P, 2010, EUR J PUBLIC HEALTH, V20, P43, DOI 10.1093/eurpub/ckp076; Centers for Disease Control and Prevention, INT GUID INF CONTR M; Dew K, 2005, SOC SCI MED, V60, P2273, DOI 10.1016/j.socscimed.2004.10.022	5	63	66	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1166	1168		10.1001/jama.2010.1315	http://dx.doi.org/10.1001/jama.2010.1315			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841527	Bronze			2022-12-28	WOS:000281770600006
J	Romero-Gomez, M; Jover, M; Del Campo, JA; Royo, JL; Hoyas, E; Galan, JJ; Montoliu, C; Baccaro, E; Guevara, M; Cordoba, J; Soriano, G; Navarro, JM; Martinez-Sierra, C; Grande, L; Galindo, A; Mira, E; Manes, S; Ruiz, A				Romero-Gomez, Manuel; Jover, Maria; Del Campo, Jose A.; Royo, Jose L.; Hoyas, Elena; Galan, Jose J.; Montoliu, Carmina; Baccaro, Eugenia; Guevara, Monica; Cordoba, Juan; Soriano, German; Navarro, Jose M.; Martinez-Sierra, Carmen; Grande, Lourdes; Galindo, Antonio; Mira, Emilia; Manes, Santos; Ruiz, Agustin			Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients With Cirrhosis A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							METABOLISM; EXPRESSION; POLYMORPHISM; ASSOCIATION; MECHANISMS; CONSENSUS; GLUTAMATE; DISEASE; AMMONIA	Background: Hepatic encephalopathy is a major complication of cirrhosis and is associated with a poor prognosis. Objective: To identify mutations in the gene sequence for glutaminase in humans that could be responsible for the development of hepatic encephalopathy in patients with cirrhosis. Design: Cohort study. Setting: Outpatient clinics in 6 Spanish hospitals. Patients: 109 consecutive patients with cirrhosis in the estimation cohort, 177 patients in the validation cohort, and 107 healthy control participants. Measurements: Patients were followed every 3 or 6 months until the development of hepatic encephalopathy or liver transplantation, death, or the end of the study. Results: The genetic analyses showed that glutaminase TACC and CACC haplotypes were linked to the risk for overt hepatic encephalopathy. Mutation scanning of the glutaminase gene identified a section in the promoter region where base pairs were repeated (a microsatellite). Over a mean follow-up of 29.6 months, hepatic encephalopathy occurred in 28 patients (25.7%) in the estimation cohort. Multivariable Cox models were used to determine the following independent predictors: Child-Turcotte-Pugh stage (hazard ratio [HR], 1.6 [95% CI, 1.29 to 1.98]; P = 0.001), minimal hepatic encephalopathy (HR, 3.17 [CI, 1.42 to 7.09]; P = 0.006), and having 2 long alleles of the microsatellite (HR, 3.12 [CI, 1.39 to 7.02]; P = 0.006). The association between 2 long alleles of the microsatellite and overt hepatic encephalopathy was confirmed in a validation cohort (HR, 2.1 [CI, 1.17 to 3.79]; P = 0.012). Functional studies showed higher luciferase activity in cells transfected with the long form of the microsatellite, which suggests that the long microsatellite enhances glutaminase transcriptional activity. Limitation: Other genes and allelic variants might be involved in the clinical expression of hepatic encephalopathy. Conclusion: This study identifies a genetic factor that is associated with development of hepatic encephalopathy in patients with cirrhosis.	[Romero-Gomez, Manuel] Univ Seville, Unit Clin Management Digest Dis, Hosp Univ Valme, Seville 41014, Spain; Neocodex, Seville, Spain; Hosp Clin Valencia, Valencia, Spain; Hosp Clin Barcelona, Barcelona, Spain; Hosp Gen Valle Hebron, Barcelona, Spain; Hosp Santa Creu & Sant Pau, Barcelona, Spain; Hosp Costa Sol, Malaga, Spain; Hosp Puerta Mar, Cadiz, Spain; Ctr Nacl Biotecnol, Madrid, Spain	Hospital Valme; University of Sevilla; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; Hospital of Santa Creu i Sant Pau; Universidad de Cadiz; Hospital Universitario Puerta del Mar; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Romero-Gomez, M (corresponding author), Univ Seville, Unit Clin Management Digest Dis, Hosp Univ Valme, Seville 41014, Spain.	mromerogomez@us.es	Montoliu, Carmina/ABB-1904-2021; MIRA, EMILIA/K-2456-2014; Guevara, Monica/GSI-9124-2022; Royo, Jose Luis/H-6935-2012; Romero-Gomez, Manuel/L-8030-2014	MIRA, EMILIA/0000-0002-4226-1829; Manes, Santos/0000-0001-8023-957X; Ruiz Laza, Agustin/0000-0003-2633-2495; Royo, Jose Luis/0000-0003-2024-4363; Romero-Gomez, Manuel/0000-0001-8494-8947	Instituto de Salud Carlos III, Spanish Ministry of Health; Spanish Ministry of Health (Instituto de Salud Carlos III) [PI040384, PI070425]	Instituto de Salud Carlos III, Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Spanish Ministry of Health (Instituto de Salud Carlos III)(Instituto de Salud Carlos IIISpanish Government)	Grant Support: By the Spanish Ministry of Health (Instituto de Salud Carlos III, grants PI040384 and PI070425).	Albrecht J, 2006, HEPATOLOGY, V44, P788, DOI 10.1002/hep.21357; Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164; Bernal W, 1998, J HEPATOL, V29, P53, DOI 10.1016/S0168-8278(98)80178-5; Bustamante J, 1999, J HEPATOL, V30, P890, DOI 10.1016/S0168-8278(99)80144-5; Campos J, 2005, ALCOHOL CLIN EXP RES, V29, P1206, DOI 10.1097/01.ALC.0000171977.25531.7A; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r170; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Damink SWMO, 2002, HEPATOLOGY, V36, P1163, DOI 10.1053/jhep.2002.36497; de Franchis R, 2000, J HEPATOL, V33, P846; Erdmann N, 2009, J NEUROCHEM, V109, P551, DOI 10.1111/j.1471-4159.2009.05989.x; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Groeneweg M, 1998, HEPATOLOGY, V28, P45, DOI 10.1002/hep.510280108; Hui AY, 2002, J CLIN GASTROENTEROL, V34, P569, DOI 10.1097/00004836-200205000-00018; HWANG JJ, 1991, BIOCHEMISTRY-US, V30, P7522, DOI 10.1021/bi00244a022; Iglesias AR, 2004, GENE, V341, P149, DOI 10.1016/j.gene.2004.06.035; Labow BI, 2001, J NUTR, V131, p2467S, DOI 10.1093/jn/131.9.2467S; MOCK B, 1989, GENOMICS, V5, P291, DOI 10.1016/0888-7543(89)90060-8; Rimola A, 2000, J HEPATOL, V32, P142, DOI 10.1016/S0168-8278(00)80201-9; Romero-Gomez M, 2005, METAB BRAIN DIS, V20, P319, DOI 10.1007/s11011-005-7913-5; Romero-Gomez M, 2004, J HEPATOL, V41, P49, DOI 10.1016/j.jhep.2004.03.021; Romero-Gomez M, 2004, HEPATOLOGY, V39, P939, DOI 10.1002/hep.20152; Romero-Gomez M, 2001, AM J GASTROENTEROL, V96, P2718, DOI 10.1016/S0002-9270(01)02692-2; Romero-Gomez M, 2007, HEPATOLOGY, V45, P879, DOI 10.1002/hep.21586; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; STRACHAN T, 1996, HUM MOL GENET, P266; Taylor L, 2001, BBA-GENE STRUCT EXPR, V1518, P132, DOI 10.1016/S0167-4781(01)00183-X; Tregouet DA, 2004, ANN HUM GENET, V68, P165, DOI 10.1046/j.1529-8817.2003.00085.x; Vergara-Gomez M, 2006, Gastroenterol Hepatol, V29, P1, DOI 10.1157/13083245; WEBER FL, 1979, GASTROENTEROLOGY, V77, P235; Wein C, 2004, HEPATOLOGY, V39, P739, DOI 10.1002/hep.20095; Weissenborn K, 2001, J HEPATOL, V34, P768, DOI 10.1016/S0168-8278(01)00026-5; Zhang BY, 2005, EUR PSYCHIAT, V20, P45, DOI 10.1016/j.eurpsy.2004.09.028	33	53	55	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2010	153	5					281	+		10.7326/0003-4819-153-5-201009070-00002	http://dx.doi.org/10.7326/0003-4819-153-5-201009070-00002			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647GF	20820037				2022-12-28	WOS:000281605500001
J	Levy, J; Lifshitz, T				Levy, Jaime; Lifshitz, Tova			Bilateral Blurred Vision in a "Healthy" Adult	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Levy, Jaime; Lifshitz, Tova] Soroka Univ, Med Ctr, Beer Sheva, Israel	Ben Gurion University; Soroka Medical Center	Levy, J (corresponding author), Soroka Univ, Med Ctr, Beer Sheva, Israel.	ljaime@bgu.ac.il							0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					964	964		10.1056/NEJMicm1001809	http://dx.doi.org/10.1056/NEJMicm1001809			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818906				2022-12-28	WOS:000281441500009
J	O'Hara, K				O'Hara, Kathryn			Canada must free scientists to talk to journalists	NATURE			English	Editorial Material									[O'Hara, Kathryn] Carleton Univ, Ottawa, ON K1S 5B6, Canada	Carleton University	O'Hara, K (corresponding author), Carleton Univ, Ottawa, ON K1S 5B6, Canada.	kathryn_ohara@carleton.ca							0	11	11	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP	2010	467	7315					501	501		10.1038/467501a	http://dx.doi.org/10.1038/467501a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	655TT	20881970	Bronze			2022-12-28	WOS:000282273100004
J	Perkins, WJ				Perkins, William J., Jr.			Combination Lipid Therapy in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center	Perkins, WJ (corresponding author), Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA.	wperkins@wfubmc.edu						Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Rubins HB, 2002, ARCH INTERN MED, V162, P2597, DOI 10.1001/archinte.162.22.2597	2	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					694	694						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20842773				2022-12-28	WOS:000280764600019
J	Cetin, B; Cleveland, DW				Cetin, Bulent; Cleveland, Don W.			How to Survive Aneuploidy	CELL			English	Editorial Material							CHROMOSOMAL INSTABILITY		[Cetin, Bulent; Cleveland, Don W.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Cetin, Bulent; Cleveland, Don W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029513] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM029513] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; BARNUN S, 1983, BIOCHIM BIOPHYS ACTA, V741, P123, DOI 10.1016/0167-4781(83)90018-0; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; HUGERAT Y, 1994, GENOMICS, V22, P108, DOI 10.1006/geno.1994.1351; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038	9	7	8	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					27	29		10.1016/j.cell.2010.09.030	http://dx.doi.org/10.1016/j.cell.2010.09.030			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887888	Bronze, Green Accepted			2022-12-28	WOS:000282362000009
J	Pavri, R; Gazumyan, A; Jankovic, M; Di Virgilio, M; Klein, I; Ansarah-Sobrinho, C; Resch, W; Yamane, A; San-Martin, BR; Barreto, V; Nieland, TJ; Root, DE; Casellas, R; Nussenzweig, MC				Pavri, Rushad; Gazumyan, Anna; Jankovic, Mila; Di Virgilio, Michela; Klein, Isaac; Ansarah-Sobrinho, Camilo; Resch, Wolfgang; Yamane, Arito; San-Martin, Bernardo Reina; Barreto, Vasco; Nieland, Thomas J.; Root, David E.; Casellas, Rafael; Nussenzweig, Michel C.			Activation-Induced Cytidine Deaminase Targets DNA at Sites of RNA Polymerase II Stalling by Interaction with Spt5	CELL			English	Article							CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; TRANSCRIPTION ELONGATION-FACTOR; ANTIBODY DIVERSIFICATION ENZYME; PROTEIN-KINASE-A; CENTER B-CELLS; SOMATIC HYPERMUTATION; C-MYC; IMMUNOGLOBULIN GENES; P-TEFB	Activation-induced cytidine deaminase (AID) initiates antibody gene diversification by creating U:G mismatches. However, AID is not specific for antibody genes; Off-target lesions can activate oncogenes or cause chromosome translocations. Despite its importance in these transactions little is known about how AID finds its targets. We performed an shRNA screen to identify factors required for class switch recombination (CSR) of antibody loci. We found that Spt5, a factor associated with stalled RNA polymerase II (Pol II) and single stranded DNA (ssDNA), is required for CSR. Spt5 interacts with AID, it facilitates association between AID and Pol II, and AID recruitment to its Ig and non-Ig targets. ChIP-seq experiments reveal that Spt5 colocalizes with AID and stalled Pol II. Further, Spt5 accumulation at sites of Pol II stalling is predictive of AID-induced mutation. We propose that AID is targeted to sites of Pol II stalling in part via its association with Spt5.	[Pavri, Rushad; Gazumyan, Anna; Jankovic, Mila; Di Virgilio, Michela; Klein, Isaac; San-Martin, Bernardo Reina; Barreto, Vasco; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA; [Gazumyan, Anna; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA; [Ansarah-Sobrinho, Camilo; Resch, Wolfgang; Yamane, Arito; Casellas, Rafael] NCI, Natl Inst Arthrit & Musculoskeletal & Skin Dis NI, Ctr Canc Res, Bethesda, MD 20892 USA; [San-Martin, Bernardo Reina] Univ Strasbourg, INSERM U964, CNRS UMR7104, IGBMC, F-67404 Illkirch Graffenstaden, France; [Barreto, Vasco] Inst Gulbenkian Ciencias, Lab Epigenet Soma, P-2780156 Oeiras, Portugal; [Nieland, Thomas J.] MIT, Broad Inst, RNAi Platform, Cambridge, MA 02142 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Instituto Gulbenkian de Ciencia; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.	casellar@mail.nih.gov; nussen@mail.rockefeller.edu	Reina-San-Martin, Bernardo/I-9484-2016; Yamane, Arito/A-2959-2013; Barreto, Vasco M./H-2306-2018; Di Virgilio, Michela/AAE-9298-2022; Nussenzweig, Michel/AAE-7292-2019; Barreto, Vasco/D-4275-2012	Reina-San-Martin, Bernardo/0000-0003-2083-6166; Barreto, Vasco M./0000-0002-0010-8607; Barreto, Vasco/0000-0002-0010-8607; Pavri, Rushad/0000-0002-6191-6333; Resch, Wolfgang/0000-0001-7594-5963; Di Virgilio, Michela/0000-0001-5189-0793	Cancer Research Institute; NIH [AI037526]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037526] Funding Source: NIH RePORTER	Cancer Research Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank members of the Nussenzweig lab for helpful discussions, Klara Velinzon for FACS sorting, and Tom Eisenreich and David Bosque for animal management. We thank Drs Jayanta Chaudhuri and Urszula Nowak for ChIP protocols and anti-AID antibody, Dr. Sohail Malik for generously providing purified recombinant DSIF and Dr. Alan Derr for assistance with informatics. M.D.V. is a fellow of the American-Italian Cancer Foundation. R.P was a recipient of The Irvington Institute Postdoctoral Fellowship of the Cancer Research Institute. The work was supported by NIH grant (AI037526) to M.C.N.M.C.N. is a Howard Hughes Medical Institute Investigator.	Amir-Zilberstein L, 2008, J BIOL CHEM, V283, P1317, DOI 10.1074/jbc.M706767200; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Bai XY, 2010, CELL, V142, P133, DOI 10.1016/j.cell.2010.05.028; Basu U, 2005, NATURE, V438, P508, DOI 10.1038/nature04255; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Conticello SG, 2008, MOL CELL, V31, P474, DOI 10.1016/j.molcel.2008.07.009; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Daniel JA, 2010, SCIENCE, V329, P917, DOI 10.1126/science.1187942; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Ding BJ, 2010, J BIOL CHEM, V285, P5317, DOI 10.1074/jbc.M109.082818; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; Gilmour DS, 2009, CHROMOSOMA, V118, P1, DOI 10.1007/s00412-008-0182-4; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Klein U, 2003, P NATL ACAD SCI USA, V100, P2639, DOI 10.1073/pnas.0437996100; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kuchen S, 2010, IMMUNITY, V32, P828, DOI 10.1016/j.immuni.2010.05.009; Lefebvre B, 2002, MOL CELL BIOL, V22, P1446, DOI 10.1128/MCB.22.5.1446-1459.2002; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Lis JT, 2007, NATURE, V450, P198, DOI 10.1038/nature06324; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; McBride KM, 2008, J EXP MED, V205, P2585, DOI 10.1084/jem.20081319; McBride KM, 2006, P NATL ACAD SCI USA, V103, P8798, DOI 10.1073/pnas.0603272103; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; Nakamura Y, 2008, CANCER GENET CYTOGEN, V182, P144, DOI 10.1016/j.cancergencyto.2008.01.013; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Nechaev S, 2010, SCIENCE, V327, P335, DOI 10.1126/science.1181421; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; Pasqualucci L, 2006, P NATL ACAD SCI USA, V103, P395, DOI 10.1073/pnas.0509969103; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; Peled JU, 2008, ANNU REV IMMUNOL, V26, P481, DOI 10.1146/annurev.immunol.26.021607.090236; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; Rajagopal D, 2009, J EXP MED, V206, P1237, DOI 10.1084/jem.20082514; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Raschke EE, 1999, J IMMUNOL, V163, P4375; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Robbiani DF, 2009, MOL CELL, V36, P631, DOI 10.1016/j.molcel.2009.11.007; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Rohwer F, 1996, J IMMUNOL, V157, P643; Ronai D, 2007, J EXP MED, V204, P181, DOI 10.1084/jem.20062032; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shen HM, 2009, J EXP MED, V206, P1057, DOI 10.1084/jem.20082678; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; Storb U, 2007, ADV EXP MED BIOL, V596, P83; SWANSON MS, 1991, MOL CELL BIOL, V11, P4286, DOI 10.1128/MCB.11.8.4286; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; Vuong BQ, 2009, NAT IMMUNOL, V10, P420, DOI 10.1038/ni.1708; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wang LL, 2009, J EXP MED, V206, P1817, DOI 10.1084/jem.20081678; Wang M, 2010, J EXP MED, V207, P141, DOI 10.1084/jem.20092238; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26	87	268	274	0	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 1	2010	143	1					122	133		10.1016/j.cell.2010.09.017	http://dx.doi.org/10.1016/j.cell.2010.09.017			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887897	Green Accepted, Bronze			2022-12-28	WOS:000282362000019
J	Vannini, A; Ringel, R; Kusser, AG; Berninghausen, O; Kassavetis, GA; Cramer, P				Vannini, Alessandro; Ringel, Rieke; Kusser, Anselm G.; Berninghausen, Otto; Kassavetis, George A.; Cramer, Patrick			Molecular Basis of RNA Polymerase III Transcription Repression by Maf1	CELL			English	Article							ELECTRON-MICROSCOPY; STRUCTURAL BIOLOGY; SUBCOMPLEX; PROTEIN; SUBUNIT; COMPLEX; TFIIF; DEPHOSPHORYLATION; TERMINATION; INITIATION	RNA polymerase III (Pol III) transcribes short RNAs required for cell growth. Under stress conditions, the conserved protein Maf1 rapidly represses Pol III transcription. We report the crystal structure of Maf1 and cryo-electron microscopic structures of Pol III, an active Pol III-DNA-RNA complex, and a repressive Pol III-Maf1 complex. Binding of DNA and RNA causes ordering of the Pol III-specific sub-complex C82/34/31 that is required for transcription initiation. Maf1 binds the Pol III clamp and rearranges C82/34/31 at the rim of the active center cleft. This impairs recruitment of Pol III to a complex of promoter DNA with the initiation factors Brf1 and TBP and thus prevents closed complex formation. Maf1 does however not impair binding of a DNA-RNA scaffold and RNA synthesis. These results explain how Maf1 specifically represses transcription initiation from Pol III promoters and indicate that Maf1 also prevents reinitiation by binding Pol III during transcription elongation.	[Vannini, Alessandro; Ringel, Rieke; Kusser, Anselm G.; Berninghausen, Otto; Cramer, Patrick] Univ Munich, Gene Ctr, D-81377 Munich, Germany; [Vannini, Alessandro; Ringel, Rieke; Kusser, Anselm G.; Berninghausen, Otto; Cramer, Patrick] Univ Munich, Dept Biochem, CIPSM, D-81377 Munich, Germany; [Kassavetis, George A.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of Munich; University of Munich; University of California System; University of California San Diego	Cramer, P (corresponding author), Univ Munich, Gene Ctr, Feodor Lynen Str 25, D-81377 Munich, Germany.	cramer@genzentrum.lmu.de	Vannini, Alessandro/N-4528-2014; Vannini, Alessandro/E-6988-2011	Vannini, Alessandro/0000-0001-7212-5425	European Molecular Biology Organization; European Union [MEIF-CT-2006-040653]; Deutsche Forschungsgemeinschaft; Nanosystems Initiative Munich; Elitenetzwerk Bayern; Jung-Stiftung;  [SFB646];  [TR5]	European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); European Union(European Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Nanosystems Initiative Munich; Elitenetzwerk Bayern; Jung-Stiftung; ; 	We thank R. Beckmann, T. Becker, C. Ungewickel, J. Burger, and T. Mielke for help with E.M. We thank A. Imhof (Zentrallabor fur Proteinanalytik) and T. Frohlich (Laboratory for Functional Genome Analysis) for mass spectrometry. We acknowledge the crystallization facility at the department of E. Conti at the Max Planck Institute of Biochemistry, Martinsried. We thank D. Deak for help with figure preparation. A.V. was supported by a European Molecular Biology Organization long-term fellowship and by the European Union training program Marie Curie (MEIF-CT-2006-040653). P.C. was supported by the Deutsche Forschungsgemeinschaft, the SFB646, the TR5, the Nanosystems Initiative Munich, the Elitenetzwerk Bayern, and the Jung-Stiftung. A.V. prepared Pol III complexes, A.V. and A.G.K. determined EM structures, R.R. prepared and crystallized Maf1, R.R. and A.V. determined the Maf1 X-ray structure, R.R. and A.V. conducted functional assays, G.A.K. advised on Pol III preparation, A.V., R.R., A.G.K., and P.C. wrote the manuscript, and P.C. designed and supervised research.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Boguta M, 1997, GENE, V185, P291, DOI 10.1016/S0378-1119(96)00669-5; Brueckner F, 2007, SCIENCE, V315, P859, DOI 10.1126/science.1135400; Brun I, 1997, EMBO J, V16, P5730, DOI 10.1093/emboj/16.18.5730; Cabart P, 2008, J BIOL CHEM, V283, P36108, DOI 10.1074/jbc.M807538200; Carter R, 2009, MOL BIOL EVOL, V26, P2515, DOI 10.1093/molbev/msp164; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chen ZA, 2010, EMBO J, V29, P717, DOI 10.1038/emboj.2009.401; Cramer P, 2008, ANNU REV BIOPHYS, V37, P337, DOI 10.1146/annurev.biophys.37.032807.130008; Damsma GE, 2009, J BIOL CHEM, V284, P31658, DOI 10.1074/jbc.M109.022764; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Desai N, 2005, J BIOL CHEM, V280, P6455, DOI 10.1074/jbc.M412375200; Eichner J, 2010, EMBO J, V29, P706, DOI 10.1038/emboj.2009.386; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P., 2007, SCALA SCALE TOGETHER; Fernandez-Tornero C, 2007, MOL CELL, V25, P813, DOI 10.1016/j.molcel.2007.02.016; Ferri ML, 2000, MOL CELL BIOL, V20, P488, DOI 10.1128/MCB.20.2.488-495.2000; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Geiduschek EP, 2006, CURR BIOL, V16, pR849, DOI 10.1016/j.cub.2006.08.071; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Geiger SR, 2010, MOL CELL, V39, P583, DOI 10.1016/j.molcel.2010.07.028; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Jasiak AJ, 2006, MOL CELL, V23, P71, DOI 10.1016/j.molcel.2006.05.013; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; Kassavetis GA, 2005, P NATL ACAD SCI USA, V102, P15406, DOI 10.1073/pnas.0507653102; Kassavetis GA, 2003, J BIOL CHEM, V278, P17912, DOI 10.1074/jbc.M300743200; Kassavetis GA, 2010, J BIOL CHEM, V285, P2695, DOI 10.1074/jbc.M109.074013; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kostrewa D, 2009, NATURE, V462, P323, DOI 10.1038/nature08548; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Landrieux E, 2006, EMBO J, V25, P118, DOI 10.1038/sj.emboj.7600915; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; Lee J, 2009, J BIOL CHEM, V284, P12604, DOI 10.1074/jbc.C900020200; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; Lorenzen K, 2007, STRUCTURE, V15, P1237, DOI 10.1016/j.str.2007.07.016; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Moir RD, 2006, P NATL ACAD SCI USA, V103, P15044, DOI 10.1073/pnas.0607129103; Oficjalska-Pham D, 2006, MOL CELL, V22, P623, DOI 10.1016/j.molcel.2006.04.008; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pluta K, 2001, MOL CELL BIOL, V21, P5031, DOI 10.1128/MCB.21.15.5031-5040.2001; Reina JH, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000134; Roberts DN, 2006, MOL CELL, V22, P633, DOI 10.1016/j.molcel.2006.04.009; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Shor B, 2010, J BIOL CHEM, V285, P15380, DOI 10.1074/jbc.M109.071639; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; Upadhya R, 2002, MOL CELL, V10, P1489, DOI 10.1016/S1097-2765(02)00787-6; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WERNER M, 1993, J BIOL CHEM, V268, P20721; WERNER M, 1992, MOL CELL BIOL, V12, P1087, DOI 10.1128/MCB.12.3.1087; Willis IM, 2004, PROG NUCLEIC ACID RE, V77, P323, DOI 10.1016/S0079-6603(04)77009-9	60	119	122	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	2010	143	1					59	70		10.1016/j.cell.2010.09.002	http://dx.doi.org/10.1016/j.cell.2010.09.002			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	656UC	20887893	Green Submitted, Bronze			2022-12-28	WOS:000282362000014
J	Baker, DL; Schmidt, ML; Cohn, SL; Maris, JM; London, WB; Buxton, A; Stram, D; Castleberry, RP; Shimada, H; Sandler, A; Shamberger, RC; Look, AT; Reynolds, CP; Seeger, RC; Matthay, KK				Baker, David L.; Schmidt, Mary L.; Cohn, Susan L.; Maris, John M.; London, Wendy B.; Buxton, Allen; Stram, Daniel; Castleberry, Robert P.; Shimada, Hiroyuki; Sandler, Anthony; Shamberger, Robert C.; Look, A. Thomas; Reynolds, C. Patrick; Seeger, Robert C.; Matthay, Katherine K.		Children's Oncology Grp	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYC GENE AMPLIFICATION; TUMOR-CELL PLOIDY; N-MYC; CHROMOSOME 1P; UNRESECTABLE NEUROBLASTOMA; LOCALIZED NEUROBLASTOMA; INFANTS; THERAPY; CLASSIFICATION; PREDICTOR	Background: The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known. Methods: We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology-based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (greater/equal 365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features. Patients who had disease with favorable histopathological features and hyperdiploidy were assigned to four cycles of chemotherapy, and those with an incomplete response or either unfavorable feature were assigned to eight cycles. Results: Between 1997 and 2005, a total of 479 eligible patients were enrolled in this trial (270 patients with stage 3 disease, 178 with stage 4 disease, and 31 with stage 4S disease). A total of 323 patients had tumors with favorable biologic features, and 141 had tumors with unfavorable biologic features. Ploidy, but not histopathological features, was significantly predictive of the outcome. Severe adverse events without disease progression occurred in 10 patients (2.1%), including secondary leukemia (in 3 patients), death from infection (in 3 patients), and death at surgery (in 4 patients). The 3-year estimate (+/-SE) of overall survival for the entire group was 96+/-1%, with an overall survival rate of 98+/-1% among patients who had tumors with favorable biologic features and 93+/-2% among patients who had tumors with unfavorable biologic features. Conclusions: A very high rate of survival among patients with intermediate-risk neuroblastoma was achieved with a biologically based treatment assignment involving a substantially reduced duration of chemotherapy and reduced doses of chemotherapeutic agents as compared with the regimens used in earlier trials. These data provide support for further reduction in chemotherapy with more refined risk stratification. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003093.) N Engl J Med 2010;363:1313-23.	[Matthay, Katherine K.] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; [Baker, David L.] Princess Margaret Hosp Children, Perth, WA, Australia; [Schmidt, Mary L.] Univ Illinois, Coll Med, Chicago, IL USA; [Cohn, Susan L.] Comer Childrens Hosp, Chicago, IL USA; [Cohn, Susan L.] Univ Chicago, Chicago, IL 60637 USA; [Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Maris, John M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [London, Wendy B.; Shamberger, Robert C.] Childrens Hosp, Boston, MA 02115 USA; [London, Wendy B.; Shamberger, Robert C.] Harvard Univ, Sch Med, Boston, MA USA; [Buxton, Allen] Childrens Oncol Grp Stat & Data Ctr, Arcadia, CA USA; [Stram, Daniel; Shimada, Hiroyuki; Seeger, Robert C.] Univ So Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA; [Castleberry, Robert P.] Univ Alabama Birmingham, Birmingham, AL USA; [Sandler, Anthony] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Sandler, Anthony] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Look, A. Thomas] St Jude Childrens Res Hosp, Memphis, TN USA; [Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA; [Matthay, Katherine K.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Western Australia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Children's Oncology Group (COG); Children's Hospital Los Angeles; University of Southern California; University of Alabama System; University of Alabama Birmingham; Children's National Health System; George Washington University; St Jude Children's Research Hospital; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of California System; University of California San Francisco	Matthay, KK (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pediat, 505 Parnassus Ave,Rm M 647, San Francisco, CA 94143 USA.	matthayk@peds.ucsf.edu	Cohn, Susan/AAB-6010-2021; Irving, Helen/J-5158-2013; London, Wendy/ABD-4624-2021; London, Wendy Beth/ABA-8948-2021; Mascarenhas, Leo/M-1801-2019	London, Wendy Beth/0000-0003-3571-6538; Mascarenhas, Leo/0000-0001-7790-0777; Cohn, Susan/0000-0001-5749-7650; Reynolds, C. Patrick/0000-0002-2827-8536; Razzouk, Bassem/0000-0003-0536-6135; Kanwar, Vikramjit/0000-0001-6054-1579; Sandler, Anthony/0000-0001-9440-2964	National Cancer Institute of the National Institutes of Health [UIO-CA98543, UIO-CA98413, UIO-CA29139]; NATIONAL CANCER INSTITUTE [U10CA098413, U10CA098543, U10CA029139, U10CA017829] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants (UIO-CA98543, UIO-CA98413, and UIO-CA29139) from the National Cancer Institute of the National Institutes of Health.	Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; ATTIYEH EF, 2007, J CLIN ONCOL S, V25, pS18; Bagatell R, 2005, J CLIN ONCOL, V23, P8819, DOI 10.1200/JCO.2004.00.2931; Bergeron C, 2005, PEDIATR BLOOD CANCER, V45, P32, DOI 10.1002/pbc.20379; Bowman LC, 1997, J NATL CANCER I, V89, P373, DOI 10.1093/jnci/89.5.373; BROCK PR, 1992, BRIT J CANCER, V66, pS36; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2002, PRINCIPLES PRACTICE, P895; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Cecchetto G, 2005, J CLIN ONCOL, V23, P8483, DOI 10.1200/JCO.2005.02.4661; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; De Bernardi B, 2009, J CLIN ONCOL, V27, P1034, DOI 10.1200/JCO.2008.17.5877; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; English MW, 1999, BRIT J CANCER, V81, P336, DOI 10.1038/sj.bjc.6690697; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Gurney JG, 2007, PEDIATRICS, V120, pE1229, DOI 10.1542/peds.2007-0178; Hero B, 2008, J CLIN ONCOL, V26, P1504, DOI 10.1200/JCO.2007.12.3349; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Katzenstein HM, 1998, J CLIN ONCOL, V16, P2007, DOI 10.1200/JCO.1998.16.6.2007; KIELY EM, 1994, J PEDIATR SURG, V29, P128, DOI 10.1016/0022-3468(94)90307-7; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2010, BRIT J CANCER, V102, P1319, DOI 10.1038/sj.bjc.6605621; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; Nickerson HJ, 2000, J CLIN ONCOL, V18, P477, DOI 10.1200/JCO.2000.18.3.477; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Paulino AC, 2002, INT J RADIAT ONCOL, V52, P1025, DOI 10.1016/S0360-3016(01)02713-4; Rubie H, 2001, MED PEDIATR ONCOL, V36, P247, DOI 10.1002/1096-911X(20010101)36:1<247::AID-MPO1061>3.0.CO;2-Z; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Shimada H, 2001, CANCER, V92, P2451, DOI 10.1002/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S; Simon T, 2008, PEDIATR BLOOD CANCER, V50, P965, DOI 10.1002/pbc.21343; SKINNER R, 1992, BRIT J CANCER, V66, pS30; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; STEINHERZ LJ, 1992, PEDIATRICS, V89, P942; Strother D, 1997, EUR J CANCER, V33, P2121, DOI 10.1016/S0959-8049(97)00293-1; STROTHER D, 1995, J PEDIAT HEMATOL ONC, V17, P254, DOI 10.1097/00043426-199508000-00007	47	185	193	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1313	1323		10.1056/NEJMoa1001527	http://dx.doi.org/10.1056/NEJMoa1001527			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879880	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000282271500005
J	Cates, W; Karim, QA; El-Sadr, W; Haffner, DW; Kalema-Zikusoka, G; Rogo, K; Petruney, T; Averill, EMD				Cates, Willard, Jr.; Karim, Quarraisha Abdool; El-Sadr, Wafaa; Haffner, Debra W.; Kalema-Zikusoka, Gladys; Rogo, Khama; Petruney, Tricia; Averill, E. Megan Davidson			Family Planning and the Millennium Development Goals	SCIENCE			English	Editorial Material									[Cates, Willard, Jr.; Petruney, Tricia; Averill, E. Megan Davidson] FHI, Res Triangle Pk, NC 27713 USA; [Karim, Quarraisha Abdool] Univ KwaZulu Natal, Nelson R Mandela Sch Med, ZA-4041 Durban, South Africa; [Karim, Quarraisha Abdool; El-Sadr, Wafaa] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Haffner, Debra W.] Religious Inst, Westport, CT 06880 USA; [Kalema-Zikusoka, Gladys] Conservat Publ Hlth, Kampala, Uganda; [Rogo, Khama] World Bank, Washington, DC 20433 USA	University of Kwazulu Natal; Columbia University; The World Bank	Averill, EMD (corresponding author), FHI, Res Triangle Pk, NC 27713 USA.	maverill@fhi.org	Abdool Karim, Quarraisha/GVS-1160-2022	Abdool Karim, Quarraisha/0000-0002-0985-477X				Abdool Karim Q, 2010, LANCET, V375, P1948, DOI 10.1016/S0140-6736(10)60747-7; African Union, 2006, AB CALL ACC ACT UN A; [Anonymous], DSD; BAN K, 2010, INVESTING OUR FUTURE; Cates W, 2010, CONTRACEPTION, V81, P460, DOI 10.1016/j.contraception.2010.01.002; Chi F, 2007, J BACTERIOL, V189, P6085, DOI 10.1128/JB.00468-07; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; *INT C POP DEV, 1994, SUMM PROGR ACT; KALEMAZIKUSOKA G, 2008, FOCUS POPUL ENV SECU, V17, P1; Lloyd CB, 2008, POP STUD-J DEMOG, V62, P1, DOI 10.1080/00324720701810840; *OGAC, 2010, IMPL GLOB HLTH IN CO; Singh S, 2009, ADDING IT COSTS BENE; Speidel JJ, 2009, MAKING CASE US INT F; *UN, 2010, UN SUMM NEW YORK 20; *UNFPA, 2008, FAM PLANN ENV; United Nations, 2010, CONTR SPORT MILL DEV; United Nations Population Fund (UNFPA), 2007, FAM PLANN POV RED BE; United Nations (UN), 2002, INT C FIN DEV MONT M; Wilcher R, 2008, SEX TRANSM INFECT, V84, pII54, DOI 10.1136/sti.2008.030098; 2010, JOINT G8 SCI ACAD ST; 2010, PANA PRESS      0727	21	42	42	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	2010	329	5999					1603	1603		10.1126/science.1197080	http://dx.doi.org/10.1126/science.1197080			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	653NK	20847233	Green Submitted			2022-12-28	WOS:000282098100022
J	Ferguson, CD; Marburger, LE				Ferguson, Charles D.; Marburger, Lindsey E.			The best way forward	NATURE			English	Editorial Material									[Ferguson, Charles D.; Marburger, Lindsey E.] Federat Amer Scientists, Washington, DC 20036 USA		Ferguson, CD (corresponding author), Federat Amer Scientists, Washington, DC 20036 USA.	cferguson@fas.org						Energy Information Administration, 2010, ANN EN OUTL 2010 PRO; OECD/NEA, 2010, PROJ COSTS GEN EL 20	2	8	8	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2010	467	7314					391	392		10.1038/467391a	http://dx.doi.org/10.1038/467391a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	653KO	20864972				2022-12-28	WOS:000282090200011
J	Kalager, M; Zelen, M; Langmark, F; Adami, HO				Kalager, Mette; Zelen, Marvin; Langmark, Froydis; Adami, Hans-Olov			Effect of Screening Mammography on Breast-Cancer Mortality in Norway	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLETENESS; REGISTRY	BACKGROUND A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment. METHODS The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups: two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups. RESULTS We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval [CI], 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P<0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths. CONCLUSIONS The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.	[Kalager, Mette; Langmark, Froydis; Adami, Hans-Olov] Canc Registry Norway, Oslo, Norway; [Kalager, Mette; Adami, Hans-Olov] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Zelen, Marvin] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Zelen, Marvin; Adami, Hans-Olov] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Zelen, Marvin; Adami, Hans-Olov] Dana Farber Canc Inst, Boston, MA 02115 USA; [Adami, Hans-Olov] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden	University of Oslo; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Karolinska Institutet	Kalager, M (corresponding author), Oslo Univ Hosp, Dept Surg, N-0310 Oslo, Norway.	mkalager@hsph.harvard.edu			Cancer Registry of Norway; Research Council of Norway	Cancer Registry of Norway; Research Council of Norway(Research Council of Norway)	Supported by the Cancer Registry of Norway and the Research Council of Norway.	[Anonymous], STAT NORWAY; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; *CONS COUNC NORW, CONS REP 4 2002; Duffy SW, 2006, CANCER EPIDEM BIOMAR, V15, P45, DOI 10.1158/1055-9965.EPI-05-0349; ERZAAS A, 2003, QUALITY ASSURANCE MA; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; Gotzsche PC, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001877.pub2; Hakama M, 1997, BRIT MED J, V314, P864; Jonsson H, 2001, J MED SCREEN, V8, P152, DOI 10.1136/jms.8.3.152; Kalager Mette, 2009, Tidsskr Nor Laegeforen, V129, P2595, DOI 10.4045/tidsskr.09.0024; Kalager M, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2331; Larsen IK, 2009, EUR J CANCER, V45, P1218, DOI 10.1016/j.ejca.2008.10.037; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1993, CMAJ, V148, P718; NYSTROM L, 1993, LANCET, V342, P1372; Nystrom L, 2000, BRIT MED J, V321, P647, DOI 10.1136/bmj.321.7262.647; Nystrom L, 2002, LANCET, V360, P724; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen AH, 2005, BMJ-BRIT MED J, V330, P220, DOI 10.1136/bmj.38313.639236.82; Otto SJ, 2003, LANCET, V361, P1411, DOI 10.1016/S0140-6736(03)13132-7; PERRY NM, 1996, EUROPEAN GUIDELINES; Tabar L, 2003, LANCET, V361, P1405, DOI 10.1016/S0140-6736(03)13143-1; Tabar L, 2002, J MED SCREEN, V9, P159, DOI 10.1136/jms.9.4.159; Tingulstad S, 2002, INT J CANCER, V98, P907, DOI 10.1002/ijc.10254; Vainio H, 2002, IARC HDB CANC PREVEN, V7; Wang H, 2001, CANCER CAUSE CONTROL, V12, P39, DOI 10.1023/A:1008999403069	29	354	362	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1203	1210		10.1056/NEJMoa1000727	http://dx.doi.org/10.1056/NEJMoa1000727			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860502				2022-12-28	WOS:000282050000004
J	Vadhan-Raj, S; Trent, J; Patel, S; Zhou, X; Johnson, MM; Araujo, D; Ludwig, JA; O'Roark, S; Gillenwater, AM; Bueso-Ramos, C; El-Naggar, AK; Benjamin, RS				Vadhan-Raj, Saroj; Trent, Jonathan; Patel, Shreyaskumar; Zhou, Xiao; Johnson, Marcella M.; Araujo, Dejka; Ludwig, Joseph A.; O'Roark, Shana; Gillenwater, Ann M.; Bueso-Ramos, Carlos; El-Naggar, Adel K.; Benjamin, Robert S.			Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							KERATINOCYTE GROWTH-FACTOR; STEM-CELL TRANSPLANTATION; COMPETING RISK; THERAPY; RADIOTHERAPY; PATHOGENESIS; PROPHYLAXIS; MANAGEMENT; INJURY; MODEL	Background: Mucositis can be a serious complication of cancer treatment. Palifermin reduces mucositis when given in multiple doses to patients undergoing hematopoietic stem-cell transplantation. Objective: To evaluate the efficacy of palifermin given as a single dose before each cycle in patients receiving multicycle chemotherapy. Design: Randomized, double-blind, placebo-controlled trial. (Clinical Trials.gov registration number: NCT00267046) Setting: The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Patients: 48 patients with sarcoma were randomly assigned in a 2: 1 ratio to receive palifermin or placebo. All patients received doxorubicin-based chemotherapy (90 mg per m(2) of body surface area over 3 days, by infusion). Intervention: Palifermin (180 mu g per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). Patients who had severe mucositis received open-label palifermin in subsequent cycles. Measurements: Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale (grades 0 to 4), with moderate to severe mucositis (grades 2 to 4) as the main outcomes; patient-reported outcome questionnaire; and daily symptom record diary. Results: A median of 6 blinded cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo group. Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs. 88%; P < 0.001; difference, -44 percentage points [95% CI, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13% vs. 51%; P = 0.002; difference, -38 percentage points [CI, -67 to -9 percentage points]). The main adverse effects were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group received open-label palifermin. None of these patients had severe mucositis in the subsequent cycles (a total of 17) with open-label palifermin. Limitations: Study limitations include smaller sample size for the control group, inclusion of only patients with sarcoma, and perceived unblinding of the treatment because of notable differences between the biologic effects of palifermin and placebo. Conclusion: A single dose of palifermin before each cycle reduced the incidence and severity of mucositis. The drug was generally well tolerated, but most patients experienced thickening of oral mucosa. Further investigation is needed to determine whether palifermin use will facilitate greater adherence to chemotherapy regimens by reducing mucositis.	[Vadhan-Raj, Saroj] Univ Texas MD Anderson Canc Ctr, Sect Cytokines & Support Oncol, Dept Sarcoma Med Oncol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center	Vadhan-Raj, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Sect Cytokines & Support Oncol, Dept Sarcoma Med Oncol, 1515 Holcombe Blvd,Unit 450,Box 301402, Houston, TX 77230 USA.	svadhanr@mdanderson.org	Trent, Jonathan/AAR-7113-2021	Trent, Jonathan/0000-0001-6169-5238; Gillenwater, Ann/0000-0002-0935-0037	Amgen	Amgen(Amgen)	By Amgen.	Bartek J, 2001, SCIENCE, V294, P66, DOI 10.1126/science.1066237; Borges L, 2006, INT J RADIAT ONCOL, V66, P254, DOI 10.1016/j.ijrobp.2006.05.025; Dorr W, 2005, INT J RADIAT BIOL, V81, P557, DOI 10.1080/09553000500196136; Epstein Joel B, 2006, Expert Opin Emerg Drugs, V11, P353, DOI 10.1517/14728214.11.2.353; Farrell CL, 1999, INT J RADIAT BIOL, V75, P609; Farrell CL, 1998, CANCER RES, V58, P933; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gray R, 2010, CMPRSK SUBDISTRIBUTI; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Keefe DM, 2007, CANCER-AM CANCER SOC, V109, P820, DOI 10.1002/cncr.22484; Lalla RV, 2006, CANCER J, V12, P348, DOI 10.1097/00130404-200609000-00004; Lee JJ, 2000, AM STAT, V54, P63, DOI 10.2307/2685614; Lewis IJ, 2007, JNCI-J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015; Mead GM, 2002, LANCET, V359, P815, DOI 10.1016/S0140-6736(02)07960-6; Meropol NJ, 2003, J CLIN ONCOL, V21, P1452, DOI 10.1200/JCO.2003.10.079; Neganova I, 2008, J ANAT, V213, P30, DOI 10.1111/j.1469-7580.2008.00931.x; Papas AS, 2003, BONE MARROW TRANSPL, V31, P705, DOI 10.1038/sj.bmt.1703870; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Potting CMJ, 2006, EUR J CANCER CARE, V15, P431, DOI 10.1111/j.1365-2354.2006.00684.x; Rosen LS, 2006, J CLIN ONCOL, V24, P5194, DOI 10.1200/JCO.2005.04.1152; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Scully C, 2003, HEAD NECK-J SCI SPEC, V25, P1057, DOI 10.1002/hed.10318; Sonis ST, 2004, CANCER-AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162; Sorensen JB, 2008, CANCER-AM CANCER SOC, V112, P1600, DOI 10.1002/cncr.23328; Spielberger R, 2004, NEW ENGL J MED, V351, P2590, DOI 10.1056/NEJMoa040125; Stiff PJ, 2006, J CLIN ONCOL, V24, P5186, DOI 10.1200/JCO.2005.02.8340; Stiff PJ, 2006, BONE MARROW TRANSPL, V37, P393, DOI 10.1038/sj.bmt.1705250; VADHANRAJ S, 1992, J CLIN ONCOL, V10, P1266, DOI 10.1200/JCO.1992.10.8.1266; Worthington HV, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub3	29	42	42	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					358	367		10.7326/0003-4819-153-6-201009210-00003	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855800				2022-12-28	WOS:000282043100002
J	Weygand-Durasevic, I; Ibba, M				Weygand-Durasevic, Ivana; Ibba, Michael			New Roles for Codon Usage	SCIENCE			English	Editorial Material							ARGINYLATION; TRANSLATION		[Weygand-Durasevic, Ivana] Univ Zagreb, Fac Sci, Dept Chem, HR-10000 Zagreb, Croatia; [Ibba, Michael] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University of Zagreb; University System of Ohio; Ohio State University	Weygand-Durasevic, I (corresponding author), Univ Zagreb, Fac Sci, Dept Chem, HR-10000 Zagreb, Croatia.	ibba.1@osu.edu			NIGMS NIH HHS [R01 GM065183, GM65183, R01 GM065183-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berndt U, 2009, P NATL ACAD SCI USA, V106, P1398, DOI 10.1073/pnas.0808584106; Cannarrozzi G, 2010, CELL, V141, P355, DOI 10.1016/j.cell.2010.02.036; KAJI A, 1963, BIOCHEM BIOPH RES CO, V10, P406, DOI 10.1016/0006-291X(63)90546-1; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Kashina AS, 2006, TRENDS CELL BIOL, V16, P610, DOI 10.1016/j.tcb.2006.10.001; Kramer G, 2009, NAT STRUCT MOL BIOL, V16, P589, DOI 10.1038/nsmb.1614; Rai R, 2008, DEVELOPMENT, V135, P3881, DOI 10.1242/dev.022723; Seppala S, 2010, SCIENCE, V328, P1698, DOI 10.1126/science.1188950; Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258; Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701	11	21	22	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1473	1474		10.1126/science.1195567	http://dx.doi.org/10.1126/science.1195567			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847254				2022-12-28	WOS:000281869000024
J	Barclay, S; Maher, J				Barclay, Stephen; Maher, Jane			Spotlight: Palliative Care Beyond Cancer Having the difficult conversations about the end of life	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; GOOD DOCTOR; DEATH; COMMUNICATION; ONCOLOGISTS; PREFERENCES; FAMILIES; ILLNESS; DIE		[Barclay, Stephen] Inst Publ Hlth, Gen Pract & Primary Care Res Unit,, Cambridge CB2 2SR, England; [Maher, Jane] Mt Vernon Canc Ctr, London, England	University of Cambridge; Mount Vernon Cancer Centre	Barclay, S (corresponding author), Inst Publ Hlth, Gen Pract & Primary Care Res Unit,, Cambridge CB2 2SR, England.	sigb2@medschl.cam.ac.uk		Barclay, Stephen/0000-0002-4505-7743				[Anonymous], 2005, MORT STAT; Barclay S, 2009, BRIT J GEN PRACT, V59, P642, DOI 10.3399/bjgp09X454052; Berry SR, 2008, J CLIN ONCOL, V26, P157, DOI 10.1200/JCO.2007.12.3224; BUCKMAN R, 1992, BREAK BAD NEWS; Christakis N A, 1998, Hosp J, V13, P71; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Cleland John G F, 2002, Heart Fail Rev, V7, P229, DOI 10.1023/A:1020024122726; Coulter A, 2002, BRIT MED J, V325, P668, DOI 10.1136/bmj.325.7366.668; Dale J, 2009, QUAL SAF HEALTH CARE, V18, P174, DOI 10.1136/qshc.2007.024836; Ellershaw JE, 2003, CARE DYING PATHWAY E; FORD S, 1994, BRIT J CANCER, V70, P767, DOI 10.1038/bjc.1994.393; Gattellari M, 2002, J CLIN ONCOL, V20, P503, DOI 10.1200/JCO.20.2.503; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Heffner JE, 2000, CHEST, V117, P1474, DOI 10.1378/chest.117.5.1474; Hurwitz B, 2002, BMJ-BRIT MED J, V325, P667, DOI 10.1136/bmj.325.7366.667; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Koedoot CG, 2004, EUR J CANCER, V40, P225, DOI 10.1016/j.ejca.2003.10.008; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; *MACM CANC SUPP, 2004, UNCL MILL; Maltoni M, 2002, HEMATOL ONCOL CLIN N, V16, P715, DOI 10.1016/S0889-8588(02)00024-2; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murtagh FEM, 2004, CLIN MED, V4, P39, DOI 10.7861/clinmedicine.4-1-39; Quirt CF, 1997, LUNG CANCER-J IASLC, V18, P1, DOI 10.1016/S0169-5002(97)00048-2; TODD CJ, 1984, SOC SCI MED, V18, P667, DOI 10.1016/0277-9536(84)90295-8; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	29	28	29	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2010	341								c4862	10.1136/bmj.c4862	http://dx.doi.org/10.1136/bmj.c4862			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847022				2022-12-28	WOS:000282095800006
J	Black, N				Black, Nick			"Liberating the NHS" - Another Attempt to Implement Market Forces in English Health Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England	University of London; London School of Hygiene & Tropical Medicine	Black, N (corresponding author), London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England.								0	18	18	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1103	1105		10.1056/NEJMp1009188	http://dx.doi.org/10.1056/NEJMp1009188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	649TD	20843243	Green Published			2022-12-28	WOS:000281795800004
J	Sondheimer, HM				Sondheimer, Henry M.			Graduating US Medical Students Who Do Not Obtain a PGY-1 Training Position	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Sondheimer, HM (corresponding author), Assoc Amer Med Coll, Washington, DC 20037 USA.	hsondheimer@aamc.org						National Resident Matching Program W DC, NAT RES MATCH PROGR; Salsberg E, 2008, JAMA-J AM MED ASSOC, V300, P1174, DOI 10.1001/jama.300.10.1174	2	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1168	1169		10.1001/jama.2010.1316	http://dx.doi.org/10.1001/jama.2010.1316			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841528				2022-12-28	WOS:000281770600007
J	Davis, SJ; Caldeira, K; Matthews, HD				Davis, Steven J.; Caldeira, Ken; Matthews, H. Damon			Future CO2 Emissions and Climate Change from Existing Energy Infrastructure	SCIENCE			English	Article							CONSUMPTION; SYSTEM; CHINA	Slowing climate change requires overcoming inertia in political, technological, and geophysical systems. Of these, only geophysical warming commitment has been quantified. We estimated the commitment to future emissions and warming represented by existing carbon dioxide-emitting devices. We calculated cumulative future emissions of 496 (282 to 701 in lower-and upper-bounding scenarios) gigatonnes of CO2 from combustion of fossil fuels by existing infrastructure between 2010 and 2060, forcing mean warming of 1.3 degrees C (1.1 degrees to 1.4 degrees C) above the pre-industrial era and atmospheric concentrations of CO2 less than 430 parts per million. Because these conditions would likely avoid many key impacts of climate change, we conclude that sources of the most threatening emissions have yet to be built. However, CO2-emitting infrastructure will expand unless extraordinary efforts are undertaken to develop alternatives.	[Davis, Steven J.; Caldeira, Ken] Carnegie Inst Sci, Dept Global Ecol, Stanford, CA 94305 USA; [Matthews, H. Damon] Concordia Univ, Dept Geog Planning & Environm, Montreal, PQ H3G 1M8, Canada	Carnegie Institution for Science; Concordia University - Canada	Davis, SJ (corresponding author), Carnegie Inst Sci, Dept Global Ecol, 260 Panama St, Stanford, CA 94305 USA.	sjdavis@carnegie.stanford.edu	Davis, Steven/Y-2838-2019; Davis, Steven J/F-9968-2010; Caldeira, Ken/E-7914-2011; Matthews, Damon/A-8965-2008; /AAD-2430-2020	Davis, Steven/0000-0002-9338-0844; Davis, Steven J/0000-0002-9338-0844; Caldeira, Ken/0000-0002-4591-643X; /0000-0003-3625-390X				*CARMA, CARMA DAT V 2 0; Dahowski RT, 2004, ENERGY, V29, P1589, DOI 10.1016/j.energy.2004.03.061; Davis SJ, 2010, P NATL ACAD SCI USA, V107, P5687, DOI 10.1073/pnas.0906974107; Eby M, 2009, J CLIMATE, V22, P2501, DOI 10.1175/2008JCLI2554.1; Friedlingstein P, 2005, P NATL ACAD SCI USA, V102, P10832, DOI 10.1073/pnas.0504755102; HaDuong M, 1997, NATURE, V390, P270, DOI 10.1038/36825; He JK, 2010, ENERGY, V35, P4494, DOI 10.1016/j.energy.2009.04.009; He KB, 2005, ENERG POLICY, V33, P1499, DOI 10.1016/j.enpol.2004.01.007; Hoffert MI, 1998, NATURE, V395, P881, DOI 10.1038/27638; IEA, 2009, CO2 EM FUEL COMB; Mann ME, 2009, P NATL ACAD SCI USA, V106, P4065, DOI 10.1073/pnas.0901303106; Matthews HD, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032388; Matthews HD, 2010, NAT GEOSCI, V3, P142, DOI 10.1038/ngeo813; Meehl GA, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; Nakicenovic N., 2000, SPECIAL REPORT EMISS; Parry ML, 2007, CLIMATE CHANGE 2007; Ramanathan V, 2008, P NATL ACAD SCI USA, V105, P14245, DOI 10.1073/pnas.0803838105; Solomon S, 2009, P NATL ACAD SCI USA, V106, P1704, DOI 10.1073/pnas.0812721106; van Vuuren D, 2003, ENERG POLICY, V31, P369, DOI 10.1016/S0301-4215(02)00070-8; Weaver AJ, 2001, ATMOS OCEAN, V39, P361, DOI 10.1080/07055900.2001.9649686; Wigley TML, 2005, SCIENCE, V307, P1766, DOI 10.1126/science.1103934; WORLD ELECT POWER PL	22	763	782	46	537	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2010	329	5997					1330	1333		10.1126/science.1188566	http://dx.doi.org/10.1126/science.1188566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829483	Green Submitted			2022-12-28	WOS:000281657300035
J	Boehme, CC; Nabeta, P; Hillemann, D; Nicol, MP; Shenai, S; Krapp, F; Allen, J; Tahirli, R; Blakemore, R; Rustomjee, R; Milovic, A; Jones, M; O'Brien, SM; Persing, DH; Ruesch-Gerdes, S; Gotuzzo, E; Rodrigues, C; Alland, D; Perkins, MD				Boehme, Catharina C.; Nabeta, Pamela; Hillemann, Doris; Nicol, Mark P.; Shenai, Shubhada; Krapp, Fiorella; Allen, Jenny; Tahirli, Rasim; Blakemore, Robert; Rustomjee, Roxana; Milovic, Ana; Jones, Martin; O'Brien, Sean M.; Persing, David H.; Ruesch-Gerdes, Sabine; Gotuzzo, Eduardo; Rodrigues, Camilla; Alland, David; Perkins, Mark D.			Rapid Molecular Detection of Tuberculosis and Rifampin Resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANCE; MDR-TB; DIAGNOSIS; HIV; TECHNOLOGY; ASSAY; ERA	BACKGROUND Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect. METHODS We assessed the performance of Xpert MTB/RIF, an automated molecular test for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF), with fully integrated sample processing in 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary tuberculosis. Eligible patients in Peru, Azerbaijan, South Africa, and India provided three sputum specimens each. Two specimens were processed with N-acetyl-l-cysteine and sodium hydroxide before microscopy, solid and liquid culture, and the MTB/RIF test, and one specimen was used for direct testing with microscopy and the MTB/RIF test. RESULTS Among culture-positive patients, a single, direct MTB/RIF test identified 551 of 561 patients with smear-positive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%). The test was specific in 604 of 609 patients without tuberculosis (99.2%). Among patients with smear-negative, culture-positive tuberculosis, the addition of a second MTB/RIF test increased sensitivity by 12.6 percentage points and a third by 5.1 percentage points, to a total of 90.2%. As compared with phenotypic drug-susceptibility testing, MTB/RIF testing correctly identified 200 of 205 patients (97.6%) with rifampin-resistant bacteria and 504 of 514 (98.1%) with rifampin-sensitive bacteria. Sequencing resolved all but two cases in favor of the MTB/RIF assay. CONCLUSIONS The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time. (Funded by the Foundation for Innovative New Diagnostics.)	[Boehme, Catharina C.; Nabeta, Pamela; Perkins, Mark D.] Fdn Innovat New Diagnost, CH-1202 Geneva, Switzerland; [Hillemann, Doris; Ruesch-Gerdes, Sabine] Forschungszentrum Borstel, Borstel, Germany; [Nicol, Mark P.; Milovic, Ana] Univ Cape Town, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa; [Nicol, Mark P.; Milovic, Ana] Natl Hlth Lab Serv, Cape Town, South Africa; [Allen, Jenny; Rustomjee, Roxana] S African MRC, Unit Clin & Biomed TB Res, Durban, South Africa; [Shenai, Shubhada; Rodrigues, Camilla] Hinduja Natl Hosp, Bombay, Maharashtra, India; [Shenai, Shubhada; Rodrigues, Camilla] Med Res Ctr Hinduja, Bombay, Maharashtra, India; [Krapp, Fiorella; Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Tahirli, Rasim] Special Treatment Inst, Baku, Azerbaijan; [Blakemore, Robert; Alland, David] Univ Med & Dent New Jersey, New Jersey Med Sch, Div Infect Dis, Newark, NJ 07103 USA; [Jones, Martin; Persing, David H.] Cepheid, Sunnyvale, CA USA; [O'Brien, Sean M.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA	Foundation For Innovative New Diagnostics; Forschungszentrum Borstel; University of Cape Town; South African Medical Research Council; Universidad Peruana Cayetano Heredia; Rutgers State University New Brunswick; Rutgers State University Medical Center; Duke University	Boehme, CC (corresponding author), Fdn Innovat New Diagnost, Ave Bude 16, CH-1202 Geneva, Switzerland.	catharina.boehme@finddiagnostics.org	Nicol, Mark/W-4149-2019; Hug, Balthasar L./G-1568-2010; Baird, Cheryl L/F-6569-2011; Krapp, Fiorella/ABG-7436-2021; O'Brien, Sean/H-6268-2013	Nicol, Mark/0000-0002-1366-4805; Krapp, Fiorella/0000-0002-8404-2827; Milovic, Ana/0000-0002-6218-0452	National Institutes of Health [AI52523]; Cepheid, and the Bill and Melinda Gates Foundation; FIND; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080653, R41AI052523, R42AI052523] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cepheid, and the Bill and Melinda Gates Foundation; FIND; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by FIND (for clinical evaluation and assay development) and grants from the National Institutes of Health (AI52523), Cepheid, and the Bill and Melinda Gates Foundation (for assay development).	Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; BANADA PP, 2010, J CLIN MICROBIO 0818; Blakemore R, 2010, J CLIN MICROBIOL, V48, P2495, DOI 10.1128/JCM.00128-10; Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1; COHN ML, 1968, AM REV RESPIR DIS, V98, P295; El-Hajj HH, 2001, J CLIN MICROBIOL, V39, P4131, DOI 10.1128/JCM.39.11.4131-4137.2001; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0; Havlir DV, 2008, JAMA-J AM MED ASSOC, V300, P423, DOI 10.1001/jama.300.4.423; Helb D, 2010, J CLIN MICROBIOL, V48, P229, DOI 10.1128/JCM.01463-09; Hillemann D, 2005, INT J TUBERC LUNG D, V9, P1409; Kent PT, 1985, GUIDE LEVEL 3 LAB; Palomino JC, 2009, FEMS IMMUNOL MED MIC, V56, P103, DOI 10.1111/j.1574-695X.2009.00555.x; Perkins MD, 2007, J INFECT DIS, V196, pS15, DOI 10.1086/518656; Piatek AS, 1998, NAT BIOTECHNOL, V16, P359, DOI 10.1038/nbt0498-359; Raja S, 2005, CLIN CHEM, V51, P882, DOI 10.1373/clinchem.2004.046474; Siddiqi SH, 2006, MGIT PROCEDURE MANUA; Stop TB Partnership (Global Drug Facility), 2022, MED CAT; Urbanczik R, 2009, INT J TUBERC LUNG D, V13, P799; Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448; Uys PW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000757; Van Rie A, 2006, LANCET, V368, P1554, DOI 10.1016/S0140-6736(06)69575-5; WHO, 2009, WHOHTMTB2009411; World Health Organization (WHO), 1998, LAB SERVICES TUBERCU; Yagui M, 2006, INT J TUBERC LUNG D, V10, P838; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	26	1564	1652	6	311	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1005	1015		10.1056/NEJMoa0907847	http://dx.doi.org/10.1056/NEJMoa0907847			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647HS	20825313	Green Accepted			2022-12-28	WOS:000281609700004
J	Lee, BH; Lee, MJ; Park, S; Oh, DC; Elsasser, S; Chen, PC; Gartner, C; Dimova, N; Hanna, J; Gygi, SP; Wilson, SM; King, RW; Finley, D				Lee, Byung-Hoon; Lee, Min Jae; Park, Soyeon; Oh, Dong-Chan; Elsasser, Suzanne; Chen, Ping-Chung; Gartner, Carlos; Dimova, Nevena; Hanna, John; Gygi, Steven P.; Wilson, Scott M.; King, Randall W.; Finley, Daniel			Enhancement of proteasome activity by a small-molecule inhibitor of USP14	NATURE			English	Article							DEUBIQUITINATING ENZYME USP14; 26S PROTEASOME; ATAXIA MICE; UBIQUITIN; DEGRADATION; PROTEINS; SUBUNIT; SURVIVAL; SYSTEM; STRESS	Proteasomes, the primary mediators of ubiquitin-protein conjugate degradation, are regulated through complex and poorly understood mechanisms. Here we show that USP14, a proteasome-associated deubiquitinating enzyme, can inhibit the degradation of ubiquitin-protein conjugates both in vitro and in cells. A catalytically inactive variant of USP14 has reduced inhibitory activity, indicating that inhibition is mediated by trimming of the ubiquitin chain on the substrate. A high-throughput screen identified a selective small-molecule inhibitor of the deubiquitinating activity of human USP14. Treatment of cultured cells with this compound enhanced degradation of several proteasome substrates that have been implicated in neurodegenerative disease. USP14 inhibition accelerated the degradation of oxidized proteins and enhanced resistance to oxidative stress. Enhancement of proteasome activity through inhibition of USP14 may offer a strategy to reduce the levels of aberrant proteins in cells under proteotoxic stress.	[Lee, Byung-Hoon; Lee, Min Jae; Park, Soyeon; Elsasser, Suzanne; Gartner, Carlos; Dimova, Nevena; Hanna, John; Gygi, Steven P.; King, Randall W.; Finley, Daniel] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Oh, Dong-Chan] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Oh, Dong-Chan] Seoul Natl Univ, Coll Pharm, Inst Nat Prod Res, Seoul 151742, South Korea; [Chen, Ping-Chung; Wilson, Scott M.] Univ Alabama, Civitan Int Res Ctr, Evelyn F McKnight Brain Inst, Dept Neurobiol, Birmingham, AL 35294 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Seoul National University (SNU); University of Alabama System; University of Alabama Birmingham	King, RW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	randy_king@hms.harvard.edu; daniel_finley@hms.harvard.edu	Lee, Min Jae/C-9814-2015	Lee, Min Jae/0000-0002-3252-6467; Lee, Byung-Hoon/0000-0002-7101-0471; King, Randall/0000-0001-7882-8180; Wilson, Scott/0000-0001-9376-9430	National Institutes of Health [DK082906, GM65592, GM66492, NS047533]; Harvard Technology Development Accelerator Fund; Merck Co.; Johnson Johnson; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK082906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065592, R01GM066492, R01GM067945, R56GM066492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047533, P30NS057098] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Technology Development Accelerator Fund; Merck Co.(Merck & Company); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank K. Gordon, J. Y. Suk and N. Bays for advice and assistance, and members of the Finley laboratory for comments on the manuscript. We thank C. Shamu and the staff of the ICCB facility at Harvard Medical School, where the HT screen was carried out. We also thank N. Hathaway for ubiquitinated cyclin B, L. Huang for the tagged proteasome cell line, R. Baker for anti-USP14 antibody, G. DeMartino for anti-UCH37 antibody, K. Wilkinson and K. Walters for DUB enzymes, as well as C. Seong, M. Kim, S. M. Lim and D. Waterman for assistance in some experiments. For plasmids, we thank K. Walters, M. Sowa, W. Harper, V. Lee, F. Baralle, H. Paulson, Y. T. Kwon, M. Masucci, M.-K. Kwak, P. Coffino and C. Kahana. This work was supported by grants from the National Institutes of Health (DK082906 to D. F., GM65592 to D. F., GM66492 to R.W.K. and NS047533 to S.M.W.); the Harvard Technology Development Accelerator Fund (D.F.); Merck & Co. (D.F. and R.W.K.); and Johnson & Johnson (D.F. and R.W.K.).	Ahmed EK, 2007, ANN NY ACAD SCI, V1119, P88, DOI 10.1196/annals.1404.020; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Anderson C, 2005, J NEUROCHEM, V95, P724, DOI 10.1111/j.1471-4159.2005.03409.x; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Catic A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000679; Chauhan D, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S1; Chen PC, 2009, J NEUROSCI, V29, P10909, DOI 10.1523/JNEUROSCI.2635-09.2009; Chernova TA, 2003, J BIOL CHEM, V278, P52102, DOI 10.1074/jbc.M310283200; Chondrogianni N, 2005, J BIOL CHEM, V280, P11840, DOI 10.1074/jbc.M413007200; Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200; Crimmins S, 2006, J NEUROSCI, V26, P11423, DOI 10.1523/JNEUROSCI.3600-06.2006; Crimmins S, 2009, DEV BIOL, V325, P33, DOI 10.1016/j.ydbio.2008.09.021; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; Elsasser S, 2005, METHOD ENZYMOL, V398, P353, DOI 10.1016/S0076-6879(05)98029-4; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hamazaki J, 2006, EMBO J, V25, P4524, DOI 10.1038/sj.emboj.7601338; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Hanna J, 2007, CELL, V129, P747, DOI 10.1016/j.cell.2007.03.042; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hinault MP, 2006, J MOL NEUROSCI, V30, P249, DOI 10.1385/JMN:30:3:249; Hoyt MA, 2005, METHOD ENZYMOL, V398, P399, DOI 10.1016/S0076-6879(05)98033-6; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Husnjak K, 2008, NATURE, V453, P481, DOI 10.1038/nature06926; Jacobson AD, 2009, J BIOL CHEM, V284, P35485, DOI 10.1074/jbc.M109.052928; JORDAN MA, 1991, CANCER RES, V51, P2212; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Kleijnen MF, 2007, NAT STRUCT MOL BIOL, V14, P1180, DOI 10.1038/nsmb1335; Kobayashi H, 2005, J BIOL CHEM, V280, P10468, DOI 10.1074/jbc.M409969200; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kusmierczyk AR, 2008, NAT STRUCT MOL BIOL, V15, P237, DOI 10.1038/nsmb.1389; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwong LK, 2008, NEUROSIGNALS, V16, P41, DOI 10.1159/000109758; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lehman NL, 2009, ACTA NEUROPATHOL, V118, P329, DOI 10.1007/s00401-009-0560-x; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; Malo N, 2006, NAT BIOTECHNOL, V24, P167, DOI 10.1038/nbt1186; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muchamuel T, 2009, NAT MED, V15, P781, DOI 10.1038/nm.1978; Park S, 2009, NATURE, V459, P866, DOI 10.1038/nature08065; Peth A, 2009, MOL CELL, V36, P794, DOI 10.1016/j.molcel.2009.11.015; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Qiu XB, 2006, EMBO J, V25, P5742, DOI 10.1038/sj.emboj.7601450; Saeki Y, 2005, METHOD ENZYMOL, V399, P215, DOI 10.1016/S0076-6879(05)99014-9; Schrader EK, 2009, NAT CHEM BIOL, V5, P815, DOI 10.1038/nchembio.250; Shabek N, 2009, P NATL ACAD SCI USA, V106, P11907, DOI 10.1073/pnas.0905746106; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Spires-Jones TL, 2009, TRENDS NEUROSCI, V32, P150, DOI 10.1016/j.tins.2008.11.007; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Todi SV, 2007, J BIOL CHEM, V282, P29348, DOI 10.1074/jbc.M704126200; Tonoki A, 2009, MOL CELL BIOL, V29, P1095, DOI 10.1128/MCB.01227-08; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang XR, 2007, BIOCHEMISTRY-US, V46, P3553, DOI 10.1021/bi061994u; Wilson SM, 2002, NAT GENET, V32, P420, DOI 10.1038/ng1006; Yao TT, 2006, NAT CELL BIOL, V8, P994, DOI 10.1038/ncb1460; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	64	681	712	5	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2010	467	7312					179	U63		10.1038/nature09299	http://dx.doi.org/10.1038/nature09299			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647KB	20829789	Green Accepted			2022-12-28	WOS:000281616300028
J	Lazzeri, M; Guazzoni, G				Lazzeri, Massimo; Guazzoni, Giorgio			Focal therapy meets prostate cancer	LANCET			English	Editorial Material							MORTALITY		[Lazzeri, Massimo; Guazzoni, Giorgio] Univ Vita Salute San Raffaele, Hosp San Raffaele, Dept Urol, I-20127 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Lazzeri, M (corresponding author), Univ Vita Salute San Raffaele, Hosp San Raffaele, Dept Urol, I-20127 Milan, Italy.	lazzeri.m@tiscali.it	Lazzeri, Massimo/K-5004-2016; Lazzeri, Massimo/AAB-6955-2021	Lazzeri, Massimo/0000-0002-4411-3715; Lazzeri, Massimo/0000-0002-4411-3715; Guazzoni, Giorgio Ferruccio/0000-0002-5713-8313				Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Barkun JS, 2009, LANCET, V374, P1089, DOI 10.1016/S0140-6736(09)61083-7; Carter HB, 2007, J UROLOGY, V178, P2359, DOI 10.1016/j.juro.2007.08.039; Ellis DS, 2007, UROLOGY, V70, P9, DOI 10.1016/j.urology.2007.07.036; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Klotz L, 2008, NAT CLIN PRACT UROL, V5, P2, DOI 10.1038/ncpuro0993; Lindner U, 2009, J UROLOGY, V182, P1371, DOI 10.1016/j.juro.2009.06.035; Loughlin KR, 2010, J UROLOGY, V183, P871, DOI 10.1016/j.juro.2009.11.011; Mulhall JP, 2009, J UROLOGY, V181, P462, DOI 10.1016/j.juro.2008.10.047; Onik G, 2008, UROL ONCOL-SEMIN ORI, V26, P500, DOI 10.1016/j.urolonc.2008.03.004; Quinn M, 2002, BJU INT, V90, P162, DOI 10.1046/j.1464-410X.2002.2822.x; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084	12	19	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1036	1037		10.1016/S0140-6736(10)60594-6	http://dx.doi.org/10.1016/S0140-6736(10)60594-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657KM	20870082				2022-12-28	WOS:000282411600009
J	Getahun, H; Raviglione, M				Getahun, Haileyesus; Raviglione, Mario			Active case-finding for TB in the community: time to act	LANCET			English	Editorial Material							TUBERCULOSIS; AIDS		[Getahun, Haileyesus; Raviglione, Mario] WHO, Stop TB Dept, CH-1211 Geneva 27, Switzerland	World Health Organization	Getahun, H (corresponding author), WHO, Stop TB Dept, CH-1211 Geneva 27, Switzerland.	getahunh@who.int	Getahun, Haileyesus/ABC-5181-2020	RAVIGLIONE, Mario/0000-0002-9331-2067				Atun R, 2010, LANCET, V375, P2169, DOI 10.1016/S0140-6736(10)60493-X; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Coggin WL, 2010, CLIN INFECT DIS, V50, pS255, DOI 10.1086/651499; Corbett EL, 2010, LANCET, V376, P1244, DOI 10.1016/S0140-6736(10)61425-0; Datiko DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005443; Dudley L, 2003, INT J TUBERC LUNG D, V7, pS48; Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0; Golub JE, 2005, INT J TUBERC LUNG D, V9, P1183; Katz I, 2010, INT J TUBERC LUNG D, V14, P1097; Lonnroth K, 2010, LANCET, V375, P1814, DOI 10.1016/S0140-6736(10)60483-7; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; *WHO, 2000, GLOB TUB CONTR SHORT	12	17	17	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 9	2010	376	9748					1205	1206		10.1016/S0140-6736(10)61503-6	http://dx.doi.org/10.1016/S0140-6736(10)61503-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZT	20923714				2022-12-28	WOS:000283003500009
J	Fujii, T; Iwane, AH; Yanagida, T; Namba, K				Fujii, Takashi; Iwane, Atsuko H.; Yanagida, Toshio; Namba, Keiichi			Direct visualization of secondary structures of F-actin by electron cryomicroscopy	NATURE			English	Article							TOBACCO-MOSAIC-VIRUS; CRYO-EM STRUCTURE; ATOMIC MODEL; MICROSCOPY; RESOLUTION; FILAMENT; COMPLEX; RECONSTRUCTION; ARRANGEMENT; CHAPERONIN	F-actin is a helical assembly of actin, which is a component of muscle fibres essential for contraction and has a crucial role in numerous cellular processes, such as the formation of lamellipodia and filopodia(1,2), as the most abundant component and regulator of cytoskeletons by dynamic assembly and disassembly (from G-actin to F-actin and vice versa). Actin is a ubiquitous protein and is involved in important biological functions, but the definitive high-resolution structure of F-actin remains unknown. Although a recent atomic model well reproduced X-ray fibre diffraction intensity data from a highly oriented liquid-crystalline sol specimen(3), its refinement without experimental phase information has certain limitations. Direct visualization of the structure by electron cryomicroscopy, however, has been difficult because it is relatively thin and flexible. Here we report the F-actin structure at 6.6 angstrom resolution, made obtainable by recent advances in electron cryomicroscopy. The density map clearly resolves all the secondary structures of G-actin, such as alpha-helices, beta-structures and loops, and makes unambiguous modelling and refinement possible. Complex domain motions that open the nucleotide-binding pocket on F-actin formation, specific D-loop and terminal conformations, and relatively tight axial but markedly loose interprotofilament interactions hydrophilic in nature are revealed in the F-actin model, and all seem to be important for dynamic functions of actin.	[Fujii, Takashi; Iwane, Atsuko H.; Yanagida, Toshio; Namba, Keiichi] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Osaka University	Namba, K (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	keiichi@fbs.osaka-u.ac.jp	Namba, Keiichi/A-9406-2016	Iwane, Atsuko/0000-0003-2641-2268	Ministry of Education, Culture, Sports, Science and Technology of Japan [16087207, 21227006]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T. Kato for setting up and managing our cryoEM and computing facilities for high-throughput, high-resolution image analysis, and I. Tokita, M. Urabe and JEOL for maintaining the electron cryomicroscope in the best conditions. We also thank E. Egelman for his help in the use of the iterative helical real-space refinement method in the early stages of this study, and F. Oosawa, S. Asakura, H. Hotani and D. L. D. Caspar for their discussions, continuous support and encouragement. T. F. was a research fellow of the Japan Society for the Promotion of Science. This work was supported in part by Grants-in-Aid for Scientific Research to K. N. (16087207 and 21227006) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	BELA N, 1965, J AM CHEM SOC, V87, P2480; Carlier MF, 2007, J BIOL CHEM, V282, P23005, DOI 10.1074/jbc.R700020200; Cong Y, 2010, P NATL ACAD SCI USA, V107, P4967, DOI 10.1073/pnas.0913774107; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Fujii T, 2009, STRUCTURE, V17, P1485, DOI 10.1016/j.str.2009.08.017; Fujiwara I, 2007, P NATL ACAD SCI USA, V104, P8827, DOI 10.1073/pnas.0702510104; Galkin VE, 2008, P NATL ACAD SCI USA, V105, P1494, DOI 10.1073/pnas.0708667105; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Iwasa M, 2008, J BIOL CHEM, V283, P21045, DOI 10.1074/jbc.M800570200; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490; Oda T, 2009, NATURE, V457, P441, DOI 10.1038/nature07685; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; Sachse C, 2007, J MOL BIOL, V371, P812, DOI 10.1016/j.jmb.2007.05.088; Sander B, 2005, J STRUCT BIOL, V151, P92, DOI [10.1016/j.jsb.2005.04.004, 10.1016/j.jsb,2005.04.004]; Schmid MF, 2004, NATURE, V431, P104, DOI 10.1038/nature02881; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; Topf M, 2008, STRUCTURE, V16, P295, DOI 10.1016/j.str.2007.11.016; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830; Yonekura K, 2006, J STRUCT BIOL, V156, P524, DOI 10.1016/j.jsb.2006.07.016; Yu XK, 2008, NATURE, V453, P415, DOI 10.1038/nature06893; Zhang JJ, 2010, NATURE, V463, P379, DOI 10.1038/nature08701; Zhang X, 2008, P NATL ACAD SCI USA, V105, P1867, DOI 10.1073/pnas.0711623105; Zhang X, 2010, CELL, V141, P472, DOI 10.1016/j.cell.2010.03.041	35	269	273	0	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	2010	467	7316					724	U117		10.1038/nature09372	http://dx.doi.org/10.1038/nature09372			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659NE	20844487				2022-12-28	WOS:000282572500042
J	Montessuit, S; Somasekharan, SP; Terrones, O; Lucken-Ardjomande, S; Herzig, S; Schwarzenbacher, R; Manstein, DJ; Bossy-Wetzel, E; Basanez, G; Meda, P; Martinou, JC				Montessuit, Sylvie; Somasekharan, Syam Prakash; Terrones, Oihana; Lucken-Ardjomande, Safa; Herzig, Sebastien; Schwarzenbacher, Robert; Manstein, Dietmar J.; Bossy-Wetzel, Ella; Basanez, Gorka; Meda, Paolo; Martinou, Jean-Claude			Membrane Remodeling Induced by the Dynamin-Related Protein Drp1 Stimulates Bax Oligomerization	CELL			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; MITOCHONDRIAL OUTER-MEMBRANE; CELL-DEATH; APOPTOTIC PROTEINS; FISSION; FUSION; PERMEABILIZATION; ACTIVATION; ASSOCIATION	In response to many apoptotic stimuli, oligomerization of Bax is essential for mitochondrial outer membrane permeabilization and the ensuing release of cytochrome c. These events are accompanied by mitochondrial fission that appears to require Drp1, a large GTPase of the dynamin superfamily. Loss of Drp1 leads to decreased cytochrome c release by a mechanism that is poorly understood. Here we show that Drp1 stimulates tBid-induced Bax oligomerization and cytochrome c release by promoting tethering and hemifusion of membranes in vitro. This function of Drp1 is independent of its GTPase activity and relies on arginine 247 and the presence of cardiolipin in membranes. In cells, overexpression of Drp1 R247A/E delays Bax oligomerization and cell death. Our findings uncover a function of Drp1 and provide insight into the mechanism of Bax oligomerization.	[Montessuit, Sylvie; Somasekharan, Syam Prakash; Terrones, Oihana; Lucken-Ardjomande, Safa; Herzig, Sebastien; Martinou, Jean-Claude] Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland; [Schwarzenbacher, Robert] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Manstein, Dietmar J.] Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany; [Bossy-Wetzel, Ella] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA; [Basanez, Gorka] Univ Pais Vasco Euskal Herriko Unibertsitatea, CSIC, Ctr Mixto, Unidad Biofis, Bilbao 48080, Spain; [Meda, Paolo] Ctr Med Univ Geneva, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva; Salzburg University; Hannover Medical School; State University System of Florida; University of Central Florida; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Geneva	Martinou, JC (corresponding author), Univ Geneva, Dept Cell Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.	jean-claude.martinou@unige.ch	Herzig, Sebastien/AAA-8853-2019; Basanez, Gorka/L-9509-2014; Terrones, Oihana/AAA-8903-2019; Manstein, Dietmar J./AAG-2640-2019; Manstein, Dietmar J. J/M-1034-2013; Terrones, Oihana/I-4023-2015	Herzig, Sebastien/0000-0002-9329-2860; Basanez, Gorka/0000-0002-7475-7861; Manstein, Dietmar J./0000-0003-0763-0147; Manstein, Dietmar J. J/0000-0003-0763-0147; Terrones, Oihana/0000-0001-7421-6486; Somasekharan, Syam/0000-0002-9006-8206; martinou, Jean-claude/0000-0002-9847-2051; Lucken Ardjomande Hasler, Safa/0000-0003-0845-3584	Swiss National Science Foundation [310000-109402]; Juvenile Diabetes Foundation International [1-2007-158]; European Union [222980]; DFG [MA 1081/7-2]; NATIONAL EYE INSTITUTE [R01EY016164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047456, R01NS055193] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Juvenile Diabetes Foundation International; European Union(European Commission); DFG(German Research Foundation (DFG)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank P. Chiesa and D. Caille for excellent technical assistance, Dr R. Cartoni for help with electron microscopy, Dr D. Tondera for some exploratory work on Bax oligomerization, Dr L. Chernomordik and Dr M. Schick for helpful discussions on the process of membrane hemifusion and fusion pore formation, Dr T. Halazonetis for help with the 3D structure of Drp1, and Dr. M. Koppen and Alexis Jourdain for careful reading of the manuscript. P. M. is supported by grants from the Swiss National Science Foundation (310000-109402), the Juvenile Diabetes Foundation International (1-2007-158), and the European Union (FP7 BETAIMAGE 222980). D.J.M. is supported by DFG grant MA 1081/7-2. E. B.-W. is supported by NIH grants RO1 EY016164, RO1 NS0474556, and RO1 NS055193 (E. B. W.) and EU grants MCEXT-033534 and MCIRG-046536 (R. S.). This work was funded by the Swiss National Science Foundation (subsidy 31003A-124968/1 to J.-C. M.), the European union (UE6-ONCODEATH-037278), OncoSuisse, and the Geneva	ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Basanez G, 1996, BIOCHEMISTRY-US, V35, P7506, DOI 10.1021/bi953084a; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Brooks C, 2007, P NATL ACAD SCI USA, V104, P11649, DOI 10.1073/pnas.0703976104; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; DeVay RM, 2009, J CELL BIOL, V186, P793, DOI 10.1083/jcb.200906098; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Etxebarria A, 2009, J BIOL CHEM, V284, P4200, DOI 10.1074/jbc.M808050200; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gallenne T, 2009, J CELL BIOL, V185, P279, DOI 10.1083/jcb.200809153; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Heymann JAW, 2009, J CELL SCI, V122, P3427, DOI 10.1242/jcs.051714; Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Kawai C, 2005, J BIOL CHEM, V280, P34709, DOI 10.1074/jbc.M412532200; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kozlovsky Y, 2003, BIOPHYS J, V85, P85, DOI 10.1016/S0006-3495(03)74457-9; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Lucken-Ardjomande S, 2008, CELL DEATH DIFFER, V15, P484, DOI 10.1038/sj.cdd.4402280; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021; Ortiz A, 1999, BIOPHYS J, V77, P2003, DOI 10.1016/S0006-3495(99)77041-4; Ott M, 2007, J BIOL CHEM, V282, P27633, DOI 10.1074/jbc.M703155200; Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Sheridan C, 2008, MOL CELL, V31, P570, DOI 10.1016/j.molcel.2008.08.002; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tan KO, 2005, P NATL ACAD SCI USA, V102, P14623, DOI 10.1073/pnas.0503524102; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Wakabayashi J, 2009, J CELL BIOL, V186, P805, DOI 10.1083/jcb.200903065; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200	51	310	320	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	2010	142	6					889	901		10.1016/j.cell.2010.08.017	http://dx.doi.org/10.1016/j.cell.2010.08.017			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	650NA	20850011	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000281855000012
J	Al-Hashimi, HM				Al-Hashimi, Hashim M.			Exciting Structures	SCIENCE			English	Editorial Material							NMR-SPECTROSCOPY; PROTEIN; DYNAMICS; CATALYSIS		Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Al-Hashimi, HM (corresponding author), Univ Michigan, Dept Chem & Biophys, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	hashimi@umich.edu			NIAID NIH HHS [R01 AI066975-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066975] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AJ, 2009, NAT CHEM BIOL, V5, P808, DOI 10.1038/nchembio.238; Boehr DD, 2006, SCIENCE, V313, P1638, DOI 10.1126/science.1130258; Briggman KB, 2003, J AM CHEM SOC, V125, P10164, DOI 10.1021/ja035904+; Cavalli A, 2007, P NATL ACAD SCI USA, V104, P9615, DOI 10.1073/pnas.0610313104; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655; Korzhnev DM, 2010, SCIENCE, V329, P1312, DOI 10.1126/science.1191723; Lange OF, 2008, SCIENCE, V320, P1471, DOI 10.1126/science.1157092; Li PL, 2008, NAT STRUCT MOL BIOL, V15, P613, DOI 10.1038/nsmb.1428; Markwick PRL, 2009, J AM CHEM SOC, V131, P16968, DOI 10.1021/ja907476w; Palmer AG, 2006, CHEM REV, V106, P1700, DOI 10.1021/cr0404287; Religa TL, 2005, NATURE, V437, P1053, DOI 10.1038/nature04054; Shen Y, 2008, P NATL ACAD SCI USA, V105, P4685, DOI 10.1073/pnas.0800256105; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111	15	3	3	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1295	1296		10.1126/science.1195571	http://dx.doi.org/10.1126/science.1195571			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829475				2022-12-28	WOS:000281657300024
J	Lee, CY; Choi, W; Han, JH; Strano, MS				Lee, Chang Young; Choi, Wonjoon; Han, Jae-Hee; Strano, Michael S.			Coherence Resonance in a Single-Walled Carbon Nanotube Ion Channel	SCIENCE			English	Article							STOCHASTIC RESONANCE; MEMBRANE PATCHES; SURFACE-CHARGE; K+ CHANNEL; NOISE; TRANSPORT; WATER; TRANSLOCATION; COORDINATION; ENHANCEMENT	Biological ion channels are able to generate coherent and oscillatory signals from intrinsically noisy and stochastic components for ultrasensitive discrimination with the use of stochastic resonance, a concept not yet demonstrated in human-made analogs. We show that a single-walled carbon nanotube demonstrates oscillations in electroosmotic current through its interior at specific ranges of electric field that are the signatures of coherence resonance. Stochastic pore blocking is observed when individual cations partition into the nanotube obstructing an otherwise stable proton current. The observed oscillations occur because of coupling between pore blocking and a proton-diffusion limitation at the pore mouth. The result illustrates how simple ionic transport can generate coherent waveforms within an inherently noisy environment and points to new types of nanoreactors, sensors, and nanofluidic channels based on this platform.	[Lee, Chang Young; Choi, Wonjoon; Han, Jae-Hee; Strano, Michael S.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Choi, Wonjoon] MIT, Dept Mech Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Strano, MS (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	strano@mit.edu	Lee, Chang Young/E-3793-2010; Han, Jae-Hee/AAI-8420-2020	Lee, Chang Young/0000-0002-2757-8019; Han, Jae-Hee/0000-0002-2676-4442	U.S. Army Research Office [W911NF-07-D-0004]; Sloan Foundation; NSF	U.S. Army Research Office; Sloan Foundation(Alfred P. Sloan Foundation); NSF(National Science Foundation (NSF))	We thank J. Brauman, J. Collins, N. Maheshri, K. Gleason, T. Swager, and C. Song for helpful discussions. We are grateful for funding from the Institute for Soldier Nanotechnology at the Massachusetts Institute of Technology supported by the U.S. Army Research Office under contract W911NF-07-D-0004 and a fellowship to M.S.S. from the Sloan Foundation. M.S.S. is grateful for an Office of Naval Research Young Investigator Award, as well as Career and PECASE Awards from the NSF.	AGMON N, 1995, CHEM PHYS LETT, V244, P456, DOI 10.1016/0009-2614(95)00905-J; Alexiadis A, 2008, CHEM REV, V108, P5014, DOI 10.1021/cr078140f; Beckstein O, 2004, J AM CHEM SOC, V126, P14694, DOI 10.1021/ja045271e; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; BEZRUKOV SM, 1995, NATURE, V378, P362, DOI 10.1038/378362a0; Carrillo-Tripp M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.168104; Carrillo-Tripp M, 2003, J CHEM PHYS, V118, P7062, DOI 10.1063/1.1559673; Chen YF, 2008, NANO LETT, V8, P42, DOI 10.1021/nl0718566; Corry B, 2008, J PHYS CHEM B, V112, P1427, DOI 10.1021/jp709845u; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; Dellago C, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.105902; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Fornasiero F, 2008, P NATL ACAD SCI USA, V105, P17250, DOI 10.1073/pnas.0710437105; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; Georgalis Y, 2000, J PHYS CHEM B, V104, P3405, DOI 10.1021/jp000132e; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanggi P, 2002, CHEMPHYSCHEM, V3, P285, DOI 10.1002/1439-7641(20020315)3:3<285::AID-CPHC285>3.0.CO;2-A; Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298; Huang SM, 2003, J AM CHEM SOC, V125, P5636, DOI 10.1021/ja034475c; Karnik R, 2005, NANO LETT, V5, P943, DOI 10.1021/nl050493b; Koga K, 2001, NATURE, V412, P802, DOI 10.1038/35090532; Li J, 2001, NATURE, V412, P166, DOI 10.1038/35084037; Liu HT, 2010, SCIENCE, V327, P64, DOI 10.1126/science.1181799; Pikovsky AS, 1997, PHYS REV LETT, V78, P775, DOI 10.1103/PhysRevLett.78.775; Powell MR, 2008, NAT NANOTECHNOL, V3, P51, DOI 10.1038/nnano.2007.420; Priplata AA, 2003, LANCET, V362, P1123, DOI 10.1016/S0140-6736(03)14470-4; Russell DF, 1999, NATURE, V402, P291, DOI 10.1038/46279; Sakmann B., 1995, SINGLE CHANNEL RECOR; Schmid G, 2007, MATH BIOSCI, V207, P235, DOI 10.1016/j.mbs.2006.08.024; Simonotto E, 1997, PHYS REV LETT, V78, P1186, DOI 10.1103/PhysRevLett.78.1186; Siwy Z, 2004, J AM CHEM SOC, V126, P10850, DOI 10.1021/ja047675c; Smeets RMM, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.088101; Smeets RMM, 2006, NANO LETT, V6, P89, DOI 10.1021/nl052107w; Varma S, 2006, BIOPHYS CHEM, V124, P192, DOI 10.1016/j.bpc.2006.07.002; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	39	206	209	5	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1320	1324		10.1126/science.1193383	http://dx.doi.org/10.1126/science.1193383			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829480				2022-12-28	WOS:000281657300032
J	Rodrigues, J; Brayner, FA; Alves, LC; Dixit, R; Barillas-Mury, C				Rodrigues, Janneth; Brayner, Fabio Andre; Alves, Luiz Carlos; Dixit, Rajnikant; Barillas-Mury, Carolina			Hemocyte Differentiation Mediates Innate Immune Memory in Anopheles gambiae Mosquitoes	SCIENCE			English	Article							RED FLOUR BEETLE; TRIBOLIUM-CASTANEUM; INSECT; DROSOPHILA; PARASITE; INVASION	Mosquito midgut invasion by ookinetes of the malaria parasite Plasmodium disrupts the barriers that normally prevent the gut microbiota from coming in direct contact with epithelial cells. This triggers a long-lived response characterized by increased abundance of granulocytes, a subpopulation of hemocytes that circulates in the insect's hemocoel, and enhanced immunity to bacteria that indirectly reduces survival of Plasmodium parasites upon reinfection. In mosquitoes, differentiation of hemocytes was necessary and sufficient to confer innate immune memory.	[Rodrigues, Janneth; Brayner, Fabio Andre; Alves, Luiz Carlos; Dixit, Rajnikant; Barillas-Mury, Carolina] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Barillas-Mury, C (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20892 USA.	cbarillas@niaid.nih.gov	Dixit, Rajnikant/D-2566-2009; Alves, Luiz/V-5314-2019	Dixit, Rajnikant/0000-0002-3536-8329; Rodrigues, Janneth/0000-0001-9693-1958	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH; Conselho Nacionale de Desenvolvimento Cientifico e Tecnologico; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazilian government agencies; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000947] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Conselho Nacionale de Desenvolvimento Cientifico e Tecnologico; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazilian government agencies; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH. We thank A. Laughinghouse and K. Lee for insectary support; C. Ortega for experimental support; L. Koo for confocal assistance; J. Ribeiro and J. Valenzuela for their comments and insight; and B. R. Marshall for editorial assistance. F. A. B. and L. C. A. were funded by the Conselho Nacionale de Desenvolvimento Cientifico e Tecnologico and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazilian government agencies, respectively.	BEIER MS, 1994, J MED ENTOMOL, V31, P561, DOI 10.1093/jmedent/31.4.561; Blandin S, 2004, CELL, V116, P661, DOI 10.1016/S0092-8674(04)00173-4; Brown MJF, 2003, PARASITOLOGY, V126, P253, DOI 10.1017/S0031182002002755; Dong YM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000423; Eleftherianos I, 2006, INSECT BIOCHEM MOLEC, V36, P517, DOI 10.1016/j.ibmb.2006.04.001; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; Little TJ, 2003, CURR BIOL, V13, P489, DOI 10.1016/S0960-9822(03)00163-5; Meister S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000542; Moret Y, 2003, P ROY SOC B-BIOL SCI, V270, P2475, DOI 10.1098/rspb.2003.2511; Pham LN, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030026; Roth O, 2009, P ROY SOC B-BIOL SCI, V276, P145, DOI 10.1098/rspb.2008.1157; Roth O, 2010, J ANIM ECOL, V79, P403, DOI 10.1111/j.1365-2656.2009.01617.x; Sadd BM, 2006, CURR BIOL, V16, P1206, DOI 10.1016/j.cub.2006.04.047; Sadd BM, 2005, BIOL LETTERS, V1, P386, DOI 10.1098/rsbl.2005.0369; Schmid-Hempel P, 2005, ANNU REV ENTOMOL, V50, P529, DOI 10.1146/annurev.ento.50.071803.130420; Vlachou D, 2005, CURR BIOL, V15, P1185, DOI 10.1016/j.cub.2005.06.044	18	314	321	4	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2010	329	5997					1353	1355		10.1126/science.1190689	http://dx.doi.org/10.1126/science.1190689			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647YR	20829487	Green Accepted			2022-12-28	WOS:000281657300041
J	Spence, D				Spence, Des			From the Frontline Vascular disease: an amateur observation	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 22	2010	341								c5196	10.1136/bmj.c5196	http://dx.doi.org/10.1136/bmj.c5196			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TK	20861115				2022-12-28	WOS:000282272200026
J	Heiden, MGV; Locasale, JW; Swanson, KD; Sharfi, H; Heffron, GJ; Amador-Noguez, D; Christofk, HR; Wagner, G; Rabinowitz, JD; Asara, JM; Cantley, LC				Heiden, Matthew G. Vander; Locasale, Jason W.; Swanson, Kenneth D.; Sharfi, Hadar; Heffron, Greg J.; Amador-Noguez, Daniel; Christofk, Heather R.; Wagner, Gerhard; Rabinowitz, Joshua D.; Asara, John M.; Cantley, Lewis C.			Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells	SCIENCE			English	Article							PYRUVATE-KINASE M2; PHOSPHOTRANSFERASE SYSTEM; RABBIT MUSCLE; PHOSPHORYLATION; PROTEIN; METABOLISM; DEPHOSPHORYLATION; IDENTIFICATION; SINGLE; GROWTH	Proliferating cells, including cancer cells, require altered metabolism to efficiently incorporate nutrients such as glucose into biomass. The M2 isoform of pyruvate kinase (PKM2) promotes the metabolism of glucose by aerobic glycolysis and contributes to anabolic metabolism. Paradoxically, decreased pyruvate kinase enzyme activity accompanies the expression of PKM2 in rapidly dividing cancer cells and tissues. We demonstrate that phosphoenolpyruvate (PEP), the substrate for pyruvate kinase in cells, can act as a phosphate donor in mammalian cells because PEP participates in the phosphorylation of the glycolytic enzyme phosphoglycerate mutase (PGAM1) in PKM2-expressing cells. We used mass spectrometry to show that the phosphate from PEP is transferred to the catalytic histidine (His11) on human PGAM1. This reaction occurred at physiological concentrations of PEP and produced pyruvate in the absence of PKM2 activity. The presence of histidine-phosphorylated PGAM1 correlated with the expression of PKM2 in cancer cell lines and tumor tissues. Thus, decreased pyruvate kinase activity in PKM2-expressing cells allows PEP-dependent histidine phosphorylation of PGAM1 and may provide an alternate glycolytic pathway that decouples adenosine triphosphate production from PEP-mediated phosphotransfer, allowing for the high rate of glycolysis to support the anabolic metabolism observed in many proliferating cells.	[Heiden, Matthew G. Vander; Locasale, Jason W.; Swanson, Kenneth D.; Sharfi, Hadar; Christofk, Heather R.; Asara, John M.; Cantley, Lewis C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; [Heiden, Matthew G. Vander; Locasale, Jason W.; Swanson, Kenneth D.; Sharfi, Hadar; Christofk, Heather R.; Asara, John M.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Heiden, Matthew G. Vander] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Heiden, Matthew G. Vander; Locasale, Jason W.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Heffron, Greg J.; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Amador-Noguez, Daniel; Rabinowitz, Joshua D.] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; [Amador-Noguez, Daniel; Rabinowitz, Joshua D.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Princeton University; Princeton University	Cantley, LC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA.	lewis_cantley@hms.harvard.edu	Rabinowitz, Joshua/GPP-4019-2022; Cantley, Lewis C/D-1800-2014; Locasale, Jason W/ABE-6505-2020	Rabinowitz, Joshua/0000-0002-1247-4727; Cantley, Lewis C/0000-0002-1298-7653; Locasale, Jason W/0000-0002-7766-3502; Christofk, Heather/0000-0002-8662-4425	Damon Runyon Cancer Research Foundation; Burroughs Wellcome Fund; American Cancer Society; Dana-Farber/Harvard Cancer Center; NIH [1K08CA136983, 5P30CA006516-43, 5 T32 CA009361-28, R21/R33 DK070299, P01GM047467, R01 AI078063, R21 CA128620, R01-GM56302, P01CA089021, 1P01CA120964-01A]; NATIONAL CANCER INSTITUTE [K08CA136983, P01CA089021, P01CA120964, T32CA009361, R21CA128620, P30CA006516, T32CA009172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070299, R33DK070299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, P01GM047467] Funding Source: NIH RePORTER	Damon Runyon Cancer Research Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Cancer Society(American Cancer Society); Dana-Farber/Harvard Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Carrecedo and P. P. Pandolfi for normal and neoplastic prostate tissue; L. Burga and G. Wulf for normal breast and breast tumor; G. Bellinger for assistance with mouse dissection; M. Sasaki for help generating constructs; V. Vyas, A. Subtelny, L. Freimark, X. Yang, L. Schmidt, and M. Balastik for technical assistance; M. Bayro and S. Hyberts for help with processing the NMR spectra; and A. Shaywitz, J. Hutti, C. Benes, D. Anastasiou, A. Couvillion, and A. Saci for helpful discussions. This work was partially supported by the Damon Runyon Cancer Research Foundation (M. V. H.), the Burroughs Wellcome Fund (M. V. H.), the American Cancer Society (J. W. L.), Dana-Farber/Harvard Cancer Center (J. M. A. and J. W. L.), and by grants from the NIH (1K08CA136983 to M. V. H., 5P30CA006516-43 to J. M. A., 5 T32 CA009361-28 to J. W. L., R21/R33 DK070299 and P01GM047467 to G. W., R01 AI078063 and R21 CA128620 to J. D. R., R01-GM56302 and P01CA089021 to L. C. C., and 1P01CA120964-01A to J. M. A. and L.C.C.).	AINSWORTH S, 1973, BIOCHEM J, V131, P223, DOI 10.1042/bj1310223; Besant PG, 2005, BBA-PROTEINS PROTEOM, V1754, P281, DOI 10.1016/j.bbapap.2005.07.026; BLATTLER WA, 1980, BIOCHEMISTRY-US, V19, P738; BURNELL JN, 1984, ARCH BIOCHEM BIOPHYS, V231, P175, DOI 10.1016/0003-9861(84)90375-8; BURNELL JN, 1986, ARCH BIOCHEM BIOPHYS, V245, P297, DOI 10.1016/0003-9861(86)90219-5; CHEUNG EC, CURR OPIN C IN PRESS; Cho J, 2008, P NATL ACAD SCI USA, V105, P5998, DOI 10.1073/pnas.0710980105; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Deutscher J, 2006, MICROBIOL MOL BIOL R, V70, P939, DOI 10.1128/MMBR.00024-06; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engel M, 2004, J BIOL CHEM, V279, P35803, DOI 10.1074/jbc.M402768200; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hohenester UM, 2010, ANAL BIOANAL CHEM, V397, P3209, DOI 10.1007/s00216-009-3372-x; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kleinnijenhuis AJ, 2007, ANAL CHEM, V79, P7450, DOI 10.1021/ac0707838; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; Kondoh H, 2005, CANCER RES, V65, P177; LAGUNAS R, 1983, EUR J BIOCHEM, V137, P479, DOI 10.1111/j.1432-1033.1983.tb07851.x; LEE ME, 1992, BIOCHEMISTRY-US, V31, P2172, DOI 10.1021/bi00122a039; Lehninger A., 1993, PRINCIPLES BIOCH; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Medzihradszky KF, 1997, PROTEIN SCI, V6, P1405, DOI 10.1002/pro.5560060704; MINAKAMI S, 1965, BIOCHEM BIOPH RES CO, V18, P345, DOI 10.1016/0006-291X(65)90711-4; Olsen JV, 2007, NAT METHODS, V4, P709, DOI 10.1038/NMETH1060; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923; Zu XL, 2007, AMINO ACIDS, V32, P347, DOI 10.1007/s00726-007-0493-4	35	474	481	3	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1492	1499		10.1126/science.1188015	http://dx.doi.org/10.1126/science.1188015			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847263	Green Accepted, Green Submitted			2022-12-28	WOS:000281869000033
J	Poschl, U; Martin, ST; Sinha, B; Chen, Q; Gunthe, SS; Huffman, JA; Borrmann, S; Farmer, DK; Garland, RM; Helas, G; Jimenez, JL; King, SM; Manzi, A; Mikhailov, E; Pauliquevis, T; Petters, MD; Prenni, AJ; Roldin, P; Rose, D; Schneider, J; Su, H; Zorn, SR; Artaxo, P; Andreae, MO				Poeschl, U.; Martin, S. T.; Sinha, B.; Chen, Q.; Gunthe, S. S.; Huffman, J. A.; Borrmann, S.; Farmer, D. K.; Garland, R. M.; Helas, G.; Jimenez, J. L.; King, S. M.; Manzi, A.; Mikhailov, E.; Pauliquevis, T.; Petters, M. D.; Prenni, A. J.; Roldin, P.; Rose, D.; Schneider, J.; Su, H.; Zorn, S. R.; Artaxo, P.; Andreae, M. O.			Rainforest Aerosols as Biogenic Nuclei of Clouds and Precipitation in the Amazon	SCIENCE			English	Article							BIOLOGICAL PARTICLES; ATMOSPHERIC AEROSOL; CONDENSATION NUCLEI; ICE NUCLEI; SIZE; CCN; ACTIVATION; ISOPRENE; IMPACT; GROWTH	The Amazon is one of the few continental regions where atmospheric aerosol particles and their effects on climate are not dominated by anthropogenic sources. During the wet season, the ambient conditions approach those of the pristine pre-industrial era. We show that the fine submicrometer particles accounting for most cloud condensation nuclei are predominantly composed of secondary organic material formed by oxidation of gaseous biogenic precursors. Supermicrometer particles, which are relevant as ice nuclei, consist mostly of primary biological material directly released from rainforest biota. The Amazon Basin appears to be a biogeochemical reactor, in which the biosphere and atmospheric photochemistry produce nuclei for clouds and precipitation sustaining the hydrological cycle. The prevailing regime of aerosol-cloud interactions in this natural environment is distinctly different from polluted regions.	[Poeschl, U.; Sinha, B.; Gunthe, S. S.; Huffman, J. A.; Borrmann, S.; Garland, R. M.; Helas, G.; Mikhailov, E.; Rose, D.; Schneider, J.; Su, H.; Zorn, S. R.; Andreae, M. O.] Max Planck Inst Chem, D-55128 Mainz, Germany; [Martin, S. T.; Chen, Q.; King, S. M.; Zorn, S. R.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Martin, S. T.; Chen, Q.; King, S. M.; Zorn, S. R.] Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; [Farmer, D. K.; Jimenez, J. L.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Farmer, D. K.; Jimenez, J. L.] Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; [Manzi, A.] Natl Inst Amazonian Res, BR-69060 Manaus, Amazonas, Brazil; [Mikhailov, E.] St Petersburg State Univ, Inst Phys, Atmospher Phys Dept, St Petersburg 198904, Russia; [Pauliquevis, T.; Artaxo, P.] Univ Sao Paulo, Inst Phys, BR-05508 Sao Paulo, Brazil; [Pauliquevis, T.] Univ Fed Sao Paulo, BR-04023 Sao Paulo, Brazil; [Petters, M. D.; Prenni, A. J.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; [Petters, M. D.] N Carolina State Univ, Raleigh, NC 27695 USA; [Roldin, P.] Lund Univ, Dept Phys, S-22100 Lund, Sweden	Max Planck Society; Harvard University; Harvard University; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Institute Nacional de Pesquisas da Amazonia; Saint Petersburg State University; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Colorado State University; University of North Carolina; North Carolina State University; Lund University	Poschl, U (corresponding author), Max Planck Inst Chem, D-55128 Mainz, Germany.	u.poschl@mpic.de; scot_martin@harvard.edu	Petters, Markus D/D-2144-2009; Garland, Rebecca/O-1808-2015; Garland, Rebecca/GMX-3400-2022; Gunthe, Sachin/A-1970-2010; Gunthe, Sachin/E-4934-2016; Borrmann, Stephan/E-3868-2010; Andreae, Meinrat O./B-1068-2008; Pauliquevis, Theotonio M/B-9408-2012; Schneider, Johannes/A-2674-2010; Artaxo, Paulo/E-8874-2010; Pöschl, Ulrich/A-6263-2010; Rose, Diana/HGE-8574-2022; Pauliquevis, Theotonio/P-4775-2019; Rose, Diana/F-3142-2010; Huffman, J. Alex/A-7449-2010; Zorn, Soeren/C-1205-2008; Martin, Scot/G-1094-2015; Mikhailov, Eugene F/F-9452-2010; Manzi, Antonio/U-3141-2019; Sinha, Baerbel/H-1250-2012; Jimenez, Jose L/A-5294-2008; Prenni, Anthony/A-6820-2011; Su, Hang/A-6226-2010	Petters, Markus D/0000-0002-4082-1693; Garland, Rebecca/0000-0002-1855-8622; Garland, Rebecca/0000-0002-1855-8622; Gunthe, Sachin/0000-0002-7903-7783; Borrmann, Stephan/0000-0002-4774-9380; Andreae, Meinrat O./0000-0003-1968-7925; Pauliquevis, Theotonio M/0000-0001-8641-3540; Schneider, Johannes/0000-0001-7169-3973; Artaxo, Paulo/0000-0001-7754-3036; Pöschl, Ulrich/0000-0003-1412-3557; Pauliquevis, Theotonio/0000-0001-8641-3540; Huffman, J. Alex/0000-0002-5363-9516; Martin, Scot/0000-0002-8996-7554; Mikhailov, Eugene F/0000-0001-5736-0996; Manzi, Antonio/0000-0002-4860-6031; Sinha, Baerbel/0000-0001-8614-7473; Jimenez, Jose L/0000-0001-6203-1847; Su, Hang/0000-0003-4889-1669; Roldin, Pontus/0000-0002-4223-4708	Div Atmospheric & Geospace Sciences [0919189] Funding Source: National Science Foundation	Div Atmospheric & Geospace Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))		Andreae MO, 2008, EARTH-SCI REV, V89, P13, DOI 10.1016/j.earscirev.2008.03.001; Andreae MO, 2007, SCIENCE, V315, P50, DOI 10.1126/science.1136529; Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; Bowers RM, 2009, APPL ENVIRON MICROB, V75, P5121, DOI 10.1128/AEM.00447-09; Chen Q, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039880; Christner BC, 2008, SCIENCE, V319, P1214, DOI 10.1126/science.1149757; Ekman AML, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034970; Elbert W, 2007, ATMOS CHEM PHYS, V7, P4569, DOI 10.5194/acp-7-4569-2007; Frohlich-Nowoisky J, 2009, P NATL ACAD SCI USA, V106, P12814, DOI 10.1073/pnas.0811003106; Gunthe SS, 2009, ATMOS CHEM PHYS, V9, P7551, DOI 10.5194/acp-9-7551-2009; Hallquist M, 2009, ATMOS CHEM PHYS, V9, P5155, DOI 10.5194/acp-9-5155-2009; Huffman JA, 2010, ATMOS CHEM PHYS, V10, P3215, DOI 10.5194/acp-10-3215-2010; Jimenez JL, 2009, SCIENCE, V326, P1525, DOI 10.1126/science.1180353; Johnson KS, 2008, ENVIRON SCI TECHNOL, V42, P6619, DOI 10.1021/es800393e; King SM, 2010, ATMOS CHEM PHYS, V10, P3953, DOI 10.5194/acp-10-3953-2010; Koren I, 2006, ENVIRON RES LETT, V1, DOI 10.1088/1748-9326/1/1/014005; Krejci R, 2005, ATMOS CHEM PHYS, V5, P1527, DOI 10.5194/acp-5-1527-2005; Kuhn U, 2007, ATMOS CHEM PHYS, V7, P2855, DOI 10.5194/acp-7-2855-2007; Kulmala M, 2004, J AEROSOL SCI, V35, P143, DOI 10.1016/j.jaerosci.2003.10.003; Lelieveld J, 2008, NATURE, V452, P737, DOI 10.1038/nature06870; Martin S.T., 2010, ATMOS CHEM PHYS DISC, V10, P18139, DOI DOI 10.5194/ACPD-10-18139-2010; Martin ST, 2010, REV GEOPHYS, V48, DOI 10.1029/2008RG000280; Merikanto J, 2009, ATMOS CHEM PHYS, V9, P8601, DOI 10.5194/acp-9-8601-2009; Mohler O, 2007, BIOGEOSCIENCES, V4, P1059; Petters MD, 2007, ATMOS CHEM PHYS, V7, P1961, DOI 10.5194/acp-7-1961-2007; Pratt KA, 2009, NAT GEOSCI, V2, P397, DOI 10.1038/NGEO521; Prenni AJ, 2009, NAT GEOSCI, V2, P401, DOI 10.1038/NGEO517; Reutter P, 2009, ATMOS CHEM PHYS, V9, P7067, DOI 10.5194/acp-9-7067-2009; Rosenfeld D, 2008, SCIENCE, V321, P1309, DOI 10.1126/science.1160606; Solomon S., 2007, 4 IPCC; Stevens B, 2009, NATURE, V461, P607, DOI 10.1038/nature08281	31	407	420	8	344	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2010	329	5998					1513	1516		10.1126/science.1191056	http://dx.doi.org/10.1126/science.1191056			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650RK	20847268				2022-12-28	WOS:000281869000038
J	Barzansky, B; Etzel, SI				Barzansky, Barbara; Etzel, Sylvia I.			Medical Schools in the United States, 2009-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Barzansky, Barbara] Amer Med Assoc, Div Undergrad Med Educ, Chicago, IL 60654 USA; Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60654 USA	American Medical Association; American Medical Association	Barzansky, B (corresponding author), Amer Med Assoc, Div Undergrad Med Educ, 515 N State St, Chicago, IL 60654 USA.	barbara.barzansky@ama-assn.org			American Medical Association	American Medical Association	This research was funded solely by the American Medical Association, which employs Dr Barzansky and Ms Etzel.		0	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2010	304	11					1247	1254		10.1001/jama.2010.1154	http://dx.doi.org/10.1001/jama.2010.1154			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649LF	20841542				2022-12-28	WOS:000281770600021
J	Paisley, AN; Buckler, HM				Paisley, A. N.; Buckler, H. M.			Rational Testing Investigating secondary hyperhidrosis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PHEOCHROMOCYTOMA; DIAGNOSIS		[Paisley, A. N.; Buckler, H. M.] Salford Royal NHS Fdn Trust, Dept Endocrinol, Salford M6 8HD, Lancs, England	Salford Royal NHS Foundation Trust	Buckler, HM (corresponding author), Salford Royal NHS Fdn Trust, Dept Endocrinol, Salford M6 8HD, Lancs, England.	helen.buckler@srft.nhs.uk						Avis N E, 1995, J Am Med Womens Assoc (1972), V50, P45; CASPER RF, 1985, CLIN ENDOCRINOL, V22, P293, DOI 10.1111/j.1365-2265.1985.tb03243.x; FELDMAN JM, 1986, CLIN CHEM, V32, P840; Kerr EA, 2005, ANN INTERN MED, V142, P154, DOI 10.7326/0003-4819-142-2-200501180-00021; Lenders JWM, 2002, JAMA-J AM MED ASSOC, V287, P1427, DOI 10.1001/jama.287.11.1427; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Sawka AM, 2003, J CLIN ENDOCR METAB, V88, P553, DOI 10.1210/jc.2002-021251; Solish Nowell, 2008, Thorac Surg Clin, V18, P133, DOI 10.1016/j.thorsurg.2008.01.002	8	2	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2010	341								c4475	10.1136/bmj.c4475	http://dx.doi.org/10.1136/bmj.c4475			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649ZK	20829299				2022-12-28	WOS:000281815100004
J	Levison, JH; Barbieri, RL; Katz, JT; Loscalzo, J				Levison, Julie H.; Barbieri, Robert L.; Katz, Joel T.; Loscalzo, Joseph			Hard to Conceive	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEMALE GENITAL TUBERCULOSIS; GENITOURINARY TUBERCULOSIS; DIAGNOSIS; INFERTILITY; INFECTION; WOMEN		[Levison, Julie H.; Katz, Joel T.; Loscalzo, Joseph] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Levison, Julie H.; Katz, Joel T.; Loscalzo, Joseph] Harvard Univ, Sch Med, Boston, MA USA; [Barbieri, Robert L.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Katz, JT (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	jkatz@partners.org	Loscalzo, Joseph/ABD-8980-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007433] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007433] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bhanu NV, 2005, J MED MICROBIOL, V54, P927, DOI 10.1099/jmm.0.45943-0; Chavhan GB, 2004, BRIT J RADIOL, V77, P164, DOI 10.1259/bjr/27379200; CHRISTENSEN WI, 1974, MEDICINE, V53, P377, DOI 10.1097/00005792-197409000-00004; Doudier B, 2008, PEDIATR INFECT DIS J, V27, P277, DOI 10.1097/INF.0b013e31815dd06a; Gurgan T, 1996, FERTIL STERIL, V65, P367, DOI 10.1016/S0015-0282(16)58101-1; KLEIN TA, 1976, OBSTET GYNECOL, V48, P99; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; Menzies D, 2007, ANN INTERN MED, V146, P688, DOI 10.7326/0003-4819-146-9-200705010-00023; Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006; RUTSTEIN SO, 2004, 9 WHODHS; Scott JR, 2003, DANFORTHS OBSTET GYN, P600; Shaheen Riffat, 2006, JPMA Journal of the Pakistan Medical Association, V56, P306; SIMON HB, 1977, AM J MED, V63, P410, DOI 10.1016/0002-9343(77)90279-0; Singh N, 2008, ARCH GYNECOL OBSTET, V278, P325, DOI 10.1007/s00404-008-0590-y; Smith S, 2003, JAMA-J AM MED ASSOC, V290, P1767, DOI 10.1001/jama.290.13.1767	15	3	3	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2010	363	10					965	970		10.1056/NEJMcps0810360	http://dx.doi.org/10.1056/NEJMcps0810360			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	645GW	20818907	Green Accepted			2022-12-28	WOS:000281441500011
J	McCulloch, P; Schuller, F				McCulloch, Peter; Schuller, Frank			Innovation or regulation: IDEAL opportunity for consensus	LANCET			English	Editorial Material							SURGICAL INNOVATION		[McCulloch, Peter] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford OX3 9DU, England; [Schuller, Frank] Trinity Coll, Inst Sci & Soc, Oxford OX1 3BH, England	University of Oxford; University of Oxford	McCulloch, P (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford OX3 9DU, England.	peter.mcculloch@nds.ox.ac.uk		McCulloch, Peter/0000-0002-3210-8273				Barkun JS, 2009, LANCET, V374, P1089, DOI 10.1016/S0140-6736(09)61083-7; Ergina PL, 2009, LANCET, V374, P1097, DOI 10.1016/S0140-6736(09)61086-2; Hill R A, 2007, Health Technol Assess, V11, pxi; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; Wang CL, 2010, PEDIATRICS, V126, P247, DOI 10.1542/peds.2010-0528	5	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2010	376	9746					1034	1036		10.1016/S0140-6736(10)61386-4	http://dx.doi.org/10.1016/S0140-6736(10)61386-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	657KM	20870081				2022-12-28	WOS:000282411600008
J	Maslove, D; Mihm, F				Maslove, David; Mihm, Frederick			Ultrasound-Guided Internal Jugular Vein Cannulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Maslove, David; Mihm, Frederick] Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Stanford University	Maslove, D (corresponding author), Stanford Univ, Med Ctr, Stanford, CA 94305 USA.	dmaslove@stanford.edu	Maslove, David M/H-4645-2019	Maslove, David M/0000-0002-0765-7158; Mihm, Fred/0000-0002-2442-9325				Augoustides JG, 2005, J CARDIOTHOR VASC AN, V19, P310, DOI 10.1053/j.jvca.2005.03.007; Ortega Rafael, 2010, N Engl J Med, V362, pe57, DOI 10.1056/NEJMvcm0810156	2	6	8	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					796	796						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20842792				2022-12-28	WOS:000280996600025
J	Singh, S; Loke, YK; Furberg, CD				Singh, Sonal; Loke, Yoon K.; Furberg, Curt D.			Outpatient Management of Severe COPD.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Singh, Sonal] Johns Hopkins Univ, Baltimore, MD 21218 USA; [Loke, Yoon K.] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; [Furberg, Curt D.] Wake Forest Univ, Winston Salem, NC 27109 USA	Johns Hopkins University; University of East Anglia; Wake Forest University	Singh, S (corresponding author), Johns Hopkins Univ, Baltimore, MD 21218 USA.	ssingh31@jhu.edu	Singh, Sonal/A-4614-2008	Singh, Sonal/0000-0003-0912-941X				Celli B, 2009, AM J RESP CRIT CARE, V180, P948, DOI 10.1164/rccm.200906-0876OC; Niewoehner DE, 2010, NEW ENGL J MED, V362, P1407, DOI 10.1056/NEJMcp0912556; Ogale SS, 2010, CHEST, V137, P13, DOI 10.1378/chest.08-2367; Singh S, 2009, ARCH INTERN MED, V169, P219, DOI 10.1001/archinternmed.2008.550	4	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					493	494						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20666630				2022-12-28	WOS:000280411300027
J	Tai-Seale, M				Tai-Seale, Ming			What's Keeping Us So Busy in Primary Care?.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Palo Alto Med Fdn Res Inst, Palo Alto, CA USA	Palo Alto Medical Foundation Research Institute	Tai-Seale, M (corresponding author), Palo Alto Med Fdn Res Inst, Palo Alto, CA USA.	tai-sealem@pamfri.org						Baron RJ, 2010, NEW ENGL J MED, V362, P1632, DOI 10.1056/NEJMon0910793	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					495	495						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830835				2022-12-28	WOS:000280411300030
J	Raphaelson, M				Raphaelson, Marc			What's Keeping Us So Busy in Primary Care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											Raphaelson, M (corresponding author), 107 Royal St, Leesburg, VA USA.							*AM MED ASS, 2010, RBRVS DAT MAN SOFTW	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					495	495						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830835				2022-12-28	WOS:000280411300031
J	Movahed, MR				Movahed, Mohammad Reza			Ultrasound-Guided Internal Jugular Vein Cannulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									So Arizona Vet Affairs Hlth Care Syst, Tucson, AZ USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	Movahed, MR (corresponding author), So Arizona Vet Affairs Hlth Care Syst, Tucson, AZ USA.	rmova@aol.com	Maslove, David M/H-4645-2019	Maslove, David M/0000-0002-0765-7158; Mihm, Fred/0000-0002-2442-9325				Blaivas M, 2009, CRIT CARE MED, V37, P2345, DOI 10.1097/CCM.0b013e3181a067d4	1	6	8	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					796	796						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20842792				2022-12-28	WOS:000280996600026
J	Schultz, MZ				Schultz, Michelle Z.			Outpatient Management of Severe COPD	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							OBSTRUCTIVE PULMONARY-DISEASE; LUNG-CANCER		St Marys Hlth Ctr, St Louis, MO USA		Schultz, MZ (corresponding author), St Marys Hlth Ctr, St Louis, MO USA.	michelle_schultz@ssmhc.com	Singh, Sonal/A-4614-2008	Singh, Sonal/0000-0003-0912-941X				Au DH, 2006, ARCH INTERN MED, V166, P326, DOI 10.1001/archinte.166.3.326; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; Connors AF, 1997, AM J RESP CRIT CARE, V155, P386; Jennings AL, 2001, COCHRANE DB SYST REV, V4	4	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					494	494						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20666630				2022-12-28	WOS:000280411300028
